{"title": "PDF", "author": "PDF", "url": "https://diposit.ub.edu/dspace/bitstream/2445/48106/1/SGR_TESIS.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "S u s a n a  G a r c i a  R ecio\nF\na\nc\nu\nl\nt\na\nd\n \nd\ne\n \nM\ne\nd\ni\nc\ni\nn\na\nB\na\nr\nc\ne\nl\no\nn\na\n,\n \n2\n0\n1\n2\n \n  \n \n \n   \nCooperaci\u00f3n oncog\u00e9nica entre la citoquina  \npro-inflamatoria SP y el receptor  \ntirosina quinasa ErbB-2/HER2 \n \nSusana Garc\u00eda Recio \n  \n \n \n \n \n \n \n \n \n \nADVERTIMENT . La consulta d\u2019aquesta tesi queda condicionada a l\u2019acceptaci\u00f3 de les s eg\u00fcents condicions d'\u00fas: La difusi\u00f3 \nd\u2019aquesta tesi per mitj\u00e0 del servei TDX ( www.tdx.cat ) i a trav\u00e9s del Dip\u00f2sit Digital de la UB ( diposit.ub.edu ) ha estat \nautoritzada pels titulars dels drets de propietat intel\u00b7lectual  \u00fanicament per a usos priv ats emmarcats en activitats \nd\u2019investigaci\u00f3 i doc\u00e8ncia. No s\u2019autoritza la seva reproducci\u00f3 amb finalitats de lucre ni la seva difusi\u00f3 i posada a disposici\u00f3 \ndes d\u2019un lloc ali\u00e8 al servei TDX ni al Di p\u00f2sit Digital de la UB. No s\u2019autoritza la  presentaci\u00f3 del seu contingut en una finestr a \no marc ali\u00e8 a TDX o al Dip\u00f2sit Digital de la UB (framing). A questa reserva de drets afecta tant al resum de presentaci\u00f3 de \nla tesi com als seus continguts. En la utilitzaci\u00f3 o cita de par ts de la tesi \u00e9s obligat indicar el nom de la persona autora. \n \n ADVERTENCIA . La consulta de esta tesis queda condicionada a la ac eptaci\u00f3n de las siguientes  condiciones de uso: La \ndifusi\u00f3n de esta tesis por medio del servicio TDR ( www.tdx.cat ) y a trav\u00e9s del Repositorio Digital de la UB \n(diposit.ub.edu ) ha sido autorizada por los titulares de los derec hos de propiedad intelectual \u00fanicamente para usos \nprivados enmarcados en actividades de inve stigaci\u00f3n y docencia. No se autoriza su reproducci\u00f3n con finalidades de lucro \nni su difusi\u00f3n y puesta a disposici\u00f3n desde un sitio ajeno al servicio TDR o al Reposit orio Digital de la UB. No se autoriza \nla presentaci\u00f3n de su contenido en una vent ana o marco ajeno a TDR o al Repositori o Digital de la UB (framing). Esta \nreserva de derechos afecta tanto al resum en de presentaci\u00f3n de la tesis como a sus contenidos. En la utilizaci\u00f3n o cita de \npartes de la tesis es obligado indicar el nombre de la persona autora. \n  \nWARNING . On having consulted this thesis y ou\u2019re accepting the following use conditi ons:  Spreading this thesis by the \nTDX ( www.tdx.cat ) service and by the UB Digital Repository ( diposit.ub.edu ) has been authorized by the titular of the \nintellectual property rights only for private uses placed in inve stigation and teaching activities . Reproduction with lucrative  \naims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital \nRepository. Introducing its content in a window or frame forei gn to the TDX service or to the UB Digital Repository is not \nauthorized (framing). Those rights affect to the presentation summary  of the thesis as well as to its contents. In the using or  \ncitation of parts of the thesis it\u2019s ob liged to indicate the name of the author.  \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nTESIS\u00a0DOCTORAL \u00a0\nPROGRAMA \u00a0DE\u00a0DOCTORADO \u00a0EN\u00a0MEDICINA \u00a0\n\u00a0\nCOOPERACI\u00d3N \u00a0ONCOG\u00c9NICA \u00a0ENTRE\u00a0LA\u00a0\u00a0\nCITOQUINA \u00a0PRO\u2010INFLAMATORIA \u00a0SP\u00a0Y\u00a0EL\u00a0\u00a0\nRECEPTOR \u00a0TIROSINA \u00a0QUINASA \u00a0ErbB\u20102/HER2\u00a0\n\u00a0\nSusana\u00a0Garcia\u00a0Recio\u00a0\n\u00a0\nTesis\u00a0realizada \u00a0bajo\u00a0la\u00a0direcci\u00f3n \u00a0de\u00a0\n\u00a0\nDra.\u00a0Vanessa\u00a0Almendro \u00a0Navarro\u00a0\nDr.\u00a0Pere\u00a0Gasc\u00f3n\u00a0Vilaplana\u00a0\n\u00a0\nFacultad\u00a0de\u00a0Medicina \u00a0\nBarcelona, \u00a02012\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nCOOPERACI\u00d3N \u00a0ONCOG\u00c9NICA \u00a0ENTRE\u00a0LA\u00a0\u00a0\nCITOQUINA \u00a0PRO\u2010INFLAMATORIA \u00a0SP\u00a0Y\u00a0EL\u00a0\u00a0\nRECEPTOR \u00a0TIROSINA \u00a0QUINASA \u00a0ErbB\u20102/HER2\u00a0\n\u00a0\nMemoria\u00a0presentada \u00a0por\u00a0Susana\u00a0Garcia\u00a0Recio\u00a0\npara\u00a0optar\u00a0al\u00a0t\u00edtulo\u00a0de\u00a0\nDoctora\u00a0por\u00a0la\u00a0Universidad \u00a0de\u00a0Barcelona \u00a0\nDoctoranda: \u00a0\nSusana\u00a0Garcia\u00a0Recio\u00a0\n\u00a0\nDirectora: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Director:\u00a0\nDra.\u00a0Vanessa\u00a0Almendro \u00a0Navarro\u00a0 \u00a0\u00a0\u00a0 Dr.\u00a0Pere\u00a0Gasc\u00f3n\u00a0Vilaplana\u00a0\n\u00a0\n\u00a0\nLa\u00a0presente\u00a0tesis\u00a0doctoral\u00a0ha\u00a0sido\u00a0realizada\u00a0bajo\u00a0la\u00a0direcci\u00f3n\u00a0de\u00a0la\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nDra.\u00a0Vanessa\u00a0Almendro \u00a0Navarro\u00a0y\u00a0el\u00a0Dr.\u00a0Pere\u00a0Gasc\u00f3n\u00a0en\u00a0el\u00a0Laboratorio \u00a0de\u00a0Oncolog\u00eda \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nMolecular \u00a0y\u00a0Traslacional \u00a0del\u00a0IDIBAPS\u00a0\u2010Fundaci\u00f3\u00a0Cl\u00ednic.\u00a0\nBarcelona, \u00a02012\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0El objetivo de la ciencia no es abrir  la puerta a la sabidur\u00eda \ninfinita, sino poner l\u00edmites al error infinito. \nBertolt brecht  \n \nNo hay m\u00e1s que un modo de dar una vez en el clavo, y es dar \ncientos de veces en la herradura.  \nMiguel de Unamuno. \n \nDesaprender la mayor parte de las cosas que nos han ense\u00f1ado es \nm\u00e1s importante que aprender.  \nEduard Punset \n \nLa fuerza no viene de la capacidad f\u00edsica, sino de una voluntad \ninflexible.  \nMahatma Gandhi \n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n \nA mi familia, \na Javi. \n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n1\u00a0\n\u00a0ABREVIATURAS \u00a0Y\u00a0ANGLICISMOS \u00a0\n\u00a0\nAC\u00a0\u00a0 Adenilato \u00a0ciclasa\u00a0\nABC\u00a0\u00a0 Complejo \u00a0avidina\u2010biotina\u00a0\nADN\u00a0\u00a0\u00e1cido\u00a0desoxirribonucleico \u00a0\nAMPc\u00a0\u00a0Adenosin \u00a0Monofosfato \u00a0Ciclico\u00a0\nARN\u00a0\u00a0\u00c1cido\u00a0ribonucleico \u00a0\nARNm\u00a0\u00a0\u00c1cido\u00a0ribonucleico \u00a0mensajero \u00a0\nBRCA\u00a0\u00a0Breast\u00a0cancer\u00a0susceptibility \u00a0\nBSA\u00a0\u00a0 Alb\u00famina \u00a0s\u00e9rica\u00a0bovina\u00a0\nADNc\u00a0\u00a0\u00c1cido\u00a0desoxiribonucleico \u00a0complementario \u00a0\u00a0\nCAD\u00a0\u00a0Desoxiribonucleasa \u00a0activada\u00a0por\u00a0caspasas\u00a0\nCDI\u00a0\u00a0 Carcinoma \u00a0ductal\u00a0invasivo\u00a0\nCDIS\u00a0\u00a0Carcinoma \u00a0ductal\u00a0in\u00a0situ\u00a0\nCLI\u00a0\u00a0 Carcinoma \u00a0lobular\u00a0\u00a0invasivo\u00a0\nCLIS\u00a0\u00a0 Carcinoma \u00a0lobular\u00a0\u00a0\u201cin\u00a0situ\u201d\u00a0\nCM\u00a0 C\u00e1ncer\u00a0de\u00a0mama\u00a0\nCREB\u00a0\u00a0CREB\u00a0(cAMP\u00a0Response \u00a0Element\u2010Binding)\u00a0\nCTL\u00a0 Citolytic\u00a0T\u00a0Lymphocyte \u00a0\nDAB\u00a0\u00a0Diaminobenzidina \u00a0\nDAPI\u00a0\u00a04,6\u2010diamidino \u20102\u2010phenylndole \u00a0\u00a0\nDAG\u00a0Diacilglicerol \u00a0\nDEPC\u00a0\u00a0Dietilpirocarbonato \u00a0\nDMEM\u00a0\u00a0Dulbecco\u2019s \u00a0Modified\u00a0Eagle\u2019s\u00a0Medium\u00a0\nDMSO\u00a0\u00a0Dimetil\u00a0sulf\u00f2xido\u00a0\nEDTA\u00a0\u00a0\u00c1cido\u00a0etilendiaminotetraac\u00e9tico \u00a0\nEGF\u00a0\u00a0 Factor\u00a0de\u00a0crecimiento \u00a0epitelial\u00a0\nELISA\u00a0\u00a0Enzyme\u2010Linked\u00a0ImmunoSorbent \u00a0Assay\u00a0\nEGFR\u00a0\u00a0Receptor\u00a0de\u00a0factor\u00a0de\u00a0crecimiento \u00a0epitelial\u00a0\nFISH\u00a0\u00a0Fluorescent \u00a0in\u00a0situ\u00a0hybriditation \u00a0\nGH\u00a0\u00a0 Grado\u00a0histol\u00f3gico \u00a0GDP\u00a0\u00a0Guanos\u00edn \u00a0difosfato\u00a0\nGM\u2010CSF\u00a0Granulocyte \u2010macrophage \u00a0colony\u00a0stimulating \u00a0\nfactor\u00a0\u00a0\nGPCR\u00a0\u00a0G\u00a0protein\u00a0Coupled\u00a0Receptor\u00a0\nGTP\u00a0\u00a0 Guanos\u00edn \u00a0trifosfato \u00a0\nGTPasa\u00a0\u00a0Actividad \u00a0de\u00a0hidrolisis\u00a0de\u00a0GTP\u00a0\nHB\u2010EGF\u00a0Factor\u00a0de\u00a0crecimiento \u00a0epid\u00e9rmido \u00a0de\u00a0uni\u00f3n\u00a0a\u00a0\nHeparina\u00a0\nHRP\u00a0\u00a0Horseradish \u00a0peroxidase \u00a0\nIF\u00a0\u00a0 Inmunofluorescencia \u00a0\u00a0\nIg\u00a0 Inmunoglobulina \u00a0\nIGF\u20101\u00a0\u00a0Insulin\u00a0grtowth\u00a0factor\u20101\u00a0\nIHQ\u00a0\u00a0 Inmunohistoqu\u00edmica \u00a0\nIL\u00a0 Interleuquina \u00a0\nIP3\u00a0 1,4,5\u2010inositol\u2010trifosfato \u00a0\nITK\u00a0 Inhibidor\u00a0tirosina\u00a0quinasa\u00a0\nmAb\u00a0Anticuerpo \u00a0monoclonal \u00a0\nmin\u00a0\u00a0 Minuto\u00a0\nml\u00a0\u00a0 Mililitro\u00a0\nmm\u00a0\u00a0 Mil\u00edmetros \u00a0\nmTOR\u00a0Mammalian \u00a0target\u00a0of\u00a0rapamycin \u00a0\nng\u00a0\u00a0 Nanogramos \u00a0\nnM\u00a0\u00a0 Nanomolar \u00a0\nM1\u00a0 Macr\u00f3fago \u00a0tipo\u00a0I\u00a0\nM2\u00a0 Macr\u00f3fago \u00a0tipo\u00a0II\u00a0\nMAPK\u00a0\u00a0Mitogen\u2010Activated \u00a0Protein\u00a0Kinase\u00a0\nMMPs\u00a0\u00a0Metaloproteasas \u00a0\nNF\u2010\u03baB\u00a0Nuclear\u00a0factor\u00a0\u03baB\u00a0\nNK\u20101R\u00a0Receptor\u00a0de\u00a0neuroquinina \u00a01\u00a0\nNK\u20102R\u00a0Receptor\u00a0de\u00a0neuroquinina \u00a02\u00a0\u00a0\n\u00a0\n2\u00a0\n\u00a0NK\u20103R\u00a0Receptor\u00a0de\u00a0neuroquinina \u00a03\u00a0\nNKA\u00a0Neuroquinina \u00a0A\u00a0\nNKB\u00a0 Neuroquinina \u00a0B\u00a0\nOMS\u00a0\u00a0Organizaci\u00f3n \u00a0mundial\u00a0de\u00a0la\u00a0salud\u00a0\nPBS\u00a0\u00a0 Phosphate \u00a0buffered\u00a0saline\u00a0\nPCR\u00a0\u00a0 Reacci\u00f3n\u00a0en\u00a0cadena\u00a0de\u00a0la\u00a0polimerasa \u00a0\nPI3K\u00a0\u00a0Phosphoinositide \u00a03\u00a0Kinase\u00a0\nPKA\u00a0\u00a0 Proteina\u00a0quinasa\u00a0A\u00a0\nPLC\u00a0\u00a0 Fosfolipasa \u00a0C\u00a0\nPKC\u00a0 Prote\u00edna\u00a0quinasa\u00a0C\u00a0\nPTX\u00a0\u00a0 Toxina\u00a0Pert\u00fasica\u00a0\nPVDF\u00a0Polyvinylidene \u00a0fluoride\u00a0\nRE\u00a0\u00a0 Receptor\u00a0de\u00a0estr\u00f3geno \u00a0\nRP\u00a0\u00a0 Receptor\u00a0de\u00a0progesterona \u00a0\nrpm\u00a0\u00a0 Revoluciones \u00a0por\u00a0minuto\u00a0\nseg\u00a0 Segundo\u00a0\nSH2\u00a0 Src\u00a0homology \u00a02\u00a0protein\u00a0domain\u00a0\nShc\u00a0 Src\u00a0Homology \u00a02\u00a0domain\u2010conatining \u00a0protein\u00a0\nRT\u2010PCR\u00a0\u00a0Reverse\u00a0transcriptase \u00a0PCR\u00a0\nqPCR\u00a0PCR\u00a0cuantitativa \u00a0\nRTK\u00a0 Receptor\u00a0tiros\u00edna\u00a0quinasa\u00a0\nSBF\u00a0\u00a0 Suero\u00a0bovino\u00a0fetal\u00a0\nSCF\u00a0\u00a0 Suero\u00a0de\u00a0caballo\u00a0fetal\u00a0\nSDF\u20101\u00a0Stromal\u00a0cell\u2010derived\u00a0factor\u20101\u00a0\nsiRNA\u00a0small\u00a0interfering \u00a0RNA\u00a0\u00a0\nSP\u00a0 Sustancia \u00a0P\u00a0\nSTAT\u00a0Transductor \u00a0de\u00a0se\u00f1ales\u00a0y\u00a0activador \u00a0de\u00a0la\u00a0\ntranscripci\u00f3n \u00a0\nTGF\u2010\u03b2\u00a0\u00a0Tumor\u00a0growth\u00a0factor\u00a0\u03b2\u00a0\nTNF\u2010\u03b1\u00a0 Tumor\u00a0necrosis\u00a0factor\u00a0alpha\u00a0\nTNM\u00a0\u00a0Tumor\u2010ganglios\u2010met\u00e1stasis \u00a0\nTK\u00a0 Tirosina\u00a0quinasa\u00a0\nTreg\u00a0C\u00e9lulas\u00a0T\u00a0reguladoras \u00a0TH\u00a0 C\u00e9lulas\u00a0T\u00a0helper\u00a0\nVEGF\u00a0\u00a0Vascular\u00a0endothelial \u00a0growth\u00a0factor\u00a0\u00a0\nvs\u00a0 versus\u00a0\nWB\u00a0\u00a0 Western\u00a0Blot\u00a0\n\u03bc\u00a0\u00a0 Micra\u00a0\n\u00b5l\u00a0\u00a0 Microlitro \u00a0\n\u00b5g\u00a0\u00a0 Microgramos \u00a0\nWT\u00a0\u00a0 Wild\u00a0type\u00a0\n\u00a0\n\u00a0\u00a0\n3\u00a0\n\u00a0\u00a0\n\u00cdNDICE\u00a0\n\u00cdNDICE\u00a0\u00a0\n\u00a0\n\u00a0\n5\u00a0\n\u00a0\u00cdNDICE\u00a0 3 \nINTRODUCCI\u00d3N \u00a0 11 \n1.\u00a0LA\u00a0GL\u00c1NDULA \u00a0MAMARIA \u00a0 13 \n1.1.\u00a0Patolog\u00eda \u00a0benigna\u00a0y\u00a0tumores\u00a0benignos \u00a0........................................................................................... \u00a014 \n2.\u00a0PATOLOG\u00cdA \u00a0MAMARIA \u00a0MALIGNA: \u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0 15 \n2.1\u00a0Par\u00e1metros \u00a0anatomopatol\u00f3gicos \u00a0.................................................................................................... \u00a016 \n2.2.\u00a0Clasificaci\u00f3n \u00a0en\u00a0estadios\u00a0................................................................................................................ \u00a022 \n2.3.\u00a0Epidemiolog\u00eda \u00a0............................................................................................................................... .\u00a025 \n2.4.\u00a0Factores\u00a0de\u00a0riesgo\u00a0.......................................................................................................................... \u00a027 \n2.4.1.\u00a0Factores\u00a0de\u00a0riesgo\u00a0no\u00a0gen\u00e9ticos \u00a0.................................................................................................. \u00a027 \n2.4.2.\u00a0Factores\u00a0de\u00a0riesgo\u00a0gen\u00e9ticos \u00a0....................................................................................................... \u00a030 \n3.\u00a0ORIGEN\u00a0Y\u00a0EVOLUCI\u00d3N \u00a0DEL\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0 31 \n3.1.\u00a0Heterogeneidad \u00a0inter\u2010tumoral\u00a0....................................................................................................... \u00a032 \n3.1.1.\u00a0Origen\u00a0de\u00a0los\u00a0subtipos\u00a0intr\u00ednsecos \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0............................................................. \u00a033 \n3.1.2.\u00a0Identificaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0los\u00a0diferentes \u00a0subtipos\u00a0moleculares \u00a0..................................................... \u00a035 \n3.2.\u00a0Heterogeneidad \u00a0intra\u2010tumoral\u00a0....................................................................................................... \u00a036 \n4.\u00a0LA\u00a0INFLAMACI\u00d3N: \u00a0NUEVO\u00a0SIGNO\u00a0DISTINTIVO \u00a0DEL\u00a0C\u00c1NCER\u00a0 39 \n4.1.\u00a0C\u00e1nceres\u00a0asociados \u00a0a\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0...................................................................................... \u00a039 \n4.2.\u00a0La\u00a0Inflamaci\u00f3n \u00a0como\u00a0inhibidora \u00a0del\u00a0c\u00e1ncer\u00a0..................................................................................... \u00a040 \n4.3.\u00a0El\u00a0sistema\u00a0inmunol\u00f3gico \u00a0y\u00a0el\u00a0c\u00e1ncer:\u00a0tipos\u00a0celulares, \u00a0v\u00edas\u00a0y\u00a0citoquinas \u00a0pro\u2010inflamatorias \u00a0\ninvolucradas \u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0tumoral\u00a0.................................................................................................. \u00a042 \n5.\u00a0TAQUIQUININAS \u00a0Y\u00a0SUS\u00a0RECEPTORES: \u00a0PAPEL\u00a0EN\u00a0LA\u00a0INFLAMACI\u00d3N \u00a0 44 \n5.1.\u00a0La\u00a0sustancia \u00a0P\u00a0............................................................................................................................... ..\u00a045 \n5.2.\u00a0Receptores \u00a0de\u00a0taquinininas: \u00a0NK\u20101,\u00a0NK\u20102\u00a0y\u00a0NK\u20103\u00a0.............................................................................. \u00a049 \n5.2.1.\u00a0Distribuci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0en\u00a0el\u00a0organismo \u00a0.............................................. \u00a052 \n5.3.\u00a0V\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0........................................................................... \u00a052 \n5.3.1\u00a0Se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0GPCRs:\u00a0Clasificaci\u00f3n \u00a0y\u00a0funci\u00f3n\u00a0de\u00a0prote\u00ednas \u00a0G\u00a0................................... \u00a052 \n6.\u00a0SISTEMA\u00a0TAQUIQUIN\u00c9RGICO: \u00a0PAPEL\u00a0QUE\u00a0JUEGA\u00a0EN\u00a0EL\u00a0C\u00c1NCER\u00a0 55 \n6.1.\u00a0Sistema\u00a0taquiquin\u00e9rgico \u00a0y\u00a0met\u00e1stasis............................................................................................. \u00a058 \n6.2.\u00a0Tumores\u00a0y\u00a0l\u00edneas\u00a0celulares\u00a0tumorales \u00a0que\u00a0expresan \u00a0el\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0la\u00a0SP\u00a0.................................. \u00a059 \n6.3.\u00a0V\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0SP\u00a0.................................................................................... \u00a061 \n6.4.\u00a0Antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0...................................................................................................... \u00a068 \n7.\u00a0TRANSACTIVACI\u00d3N \u00a0DE\u00a0RECEPTORES \u00a0TIROSINA \u00a0QUINASA \u00a0A\u00a0TRAV\u00c9S\u00a0DE\u00a0GPCRs\u00a0 69 \n7.1.\u00a0El\u00a0papel\u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0Src\u00a0en\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0................................................... \u00a071 \u00cdNDICE\u00a0\u00a0\n\u00a0\n\u00a0\n6\u00a0\n\u00a07.2.\u00a0ADAMS\u00a0y\u00a0MMPs\u00a0como\u00a0mediadores \u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0.................................................. \u00a075 \n8.\u00a0Receptores \u00a0con\u00a0actividad \u00a0tirosina\u00a0quinasa:\u00a0Familia\u00a0de\u00a0los\u00a0receptores \u00a0ErbB\u00a0 77 \n8.1.\u00a0Estructura \u00a0y\u00a0activaci\u00f3n \u00a0................................................................................................................... \u00a077 \n8.1.1.\u00a0EGFR/HER1/ErbB1 \u00a0....................................................................................................................... \u00a080 \n8.1.2.\u00a0HER2/ErbB2 \u00a0............................................................................................................................... ..\u00a081 \n8.1.3.\u00a0HER3/ErbB3 \u00a0............................................................................................................................... ..\u00a081 \n8.1.4.\u00a0HER4/ErbB4 \u00a0............................................................................................................................... ..\u00a081 \n8.2.\u00a0Terapias\u00a0anti\u2010HER2\u00a0como\u00a0tratamientos \u00a0actuales\u00a0............................................................................ \u00a083 \n8.2.1.\u00a0Anticuerpos \u00a0monoclonales: \u00a0Trastuzumab \u00a0................................................................................... \u00a083 \n8.2.2.\u00a0Inhibidores \u00a0tirosina\u00a0quinasa:\u00a0Lapatinib \u00a0....................................................................................... \u00a085 \nHIP\u00d3TESIS \u00a0Y\u00a0OBJETIVOS \u00a0 87 \nMATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0 91 \n1.\u00a0REACTIVOS \u00a0UTILIZADOS \u00a0EN\u00a0EL\u00a0ESTUDIO\u00a0 93 \n2.\u00a0EXPERIMENTOS \u00a0IN\u00a0VITRO\u00a0 94 \n2.1.\u00a0L\u00edneas\u00a0celulares\u00a0.............................................................................................................................. \u00a094 \n2.2.\u00a0Aislamiento \u00a0y\u00a0cultivo\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0a\u00a0partir\u00a0de\u00a0tumores\u00a0primarios \u00a0............................................ \u00a094 \n2.3.\u00a0Ensayos\u00a0de\u00a0tiempo\u2010respuesta \u00a0......................................................................................................... \u00a095 \n2.3.1.\u00a0En\u00a0l\u00edneas\u00a0celulares\u00a0....................................................................................................................... \u00a095 \n2.3.2.\u00a0En\u00a0cultivos\u00a0primarios \u00a0................................................................................................................... \u00a095 \n2.4.\u00a0Ensayos\u00a0de\u00a0viabilidad \u00a0celular\u00a0.......................................................................................................... \u00a096 \n2.4.1.\u00a0Ensayo\u00a0de\u00a0MTT\u00a0............................................................................................................................ \u00a096 \n2.4.2.\u00a0Tinci\u00f3n\u00a0con\u00a0anexina\u00a0V\u2010FITC\u00a0/\u00a0yoduro\u00a0de\u00a0propidio\u00a0y\u00a0DIOC 6(3).\u00a0.................................................... \u00a097 \n2.5.\u00a0Tratamiento \u00a0cr\u00f3nico\u00a0con\u00a0SP\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0en\u00a0cultivo\u00a0.............................................................. \u00a097 \n2.6.\u00a0Obtenci\u00f3n \u00a0de\u00a0una\u00a0l\u00ednea\u00a0estable\u00a0con\u00a0sobreexpresi\u00f3n \u00a0de\u00a0TACR1\u00a0....................................................... \u00a098 \n2.6.1.\u00a0Vectores\u00a0y\u00a0construcciones \u00a0........................................................................................................... \u00a098 \n2.6.2.\u00a0Transformaci\u00f3n \u00a0mediante \u00a0choque\u00a0t\u00e9rmico\u00a0................................................................................ \u00a098 \n2.6.3.\u00a0Amplificaci\u00f3n \u00a0de\u00a0vectores\u00a0y\u00a0conservaci\u00f3n \u00a0.................................................................................. \u00a098 \n2.6.4.\u00a0Criotubo\u00a0de\u00a0cultivo\u00a0celular\u00a0.......................................................................................................... \u00a098 \n2.6.5.\u00a0Transfecci\u00f3n \u00a0de\u00a0ADN\u00a0por\u00a0electroporaci\u00f3n \u00a0.................................................................................. \u00a098 \n2.7.\u00a0Inhibici\u00f3n \u00a0del\u00a0gen\u00a0TACR1\u00a0mediante \u00a0ARN\u00a0peque\u00f1o\u00a0de\u00a0interferencia \u00a0(siRNA)\u00a0.................................... \u00a099 \n2.8.\u00a0Inhibici\u00f3n \u00a0de\u00a0receptor\u00a0NK\u20101R\u00a0con\u00a0el\u00a0antagonista \u00a0L\u2010733,\u00a0060\u00a0........................................................... \u00a099 \n2.9.\u00a0Inhibici\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0............................................................................................................... \u00a099 \n2.10.\u00a0Ensayos\u00a0clonog\u00e9nicos \u00a0................................................................................................................... \u00a099 \n3.\u00a0EXPERIMENTOS \u00a0IN\u00a0VIVO\u00a0 100 \n3.1.\u00a0Modelo\u00a0ortot\u00f3pico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0y\u00a0administraci\u00f3n \u00a0de\u00a0SP\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0mini\u00a0bombas\u00a0\nosm\u00f3ticas \u00a0............................................................................................................................... ............\u00a0100 \u00cdNDICE\u00a0\u00a0\n\u00a0\n\u00a0\n7\u00a0\n\u00a03.2.\u00a0Modelo\u00a0ortot\u00f3pico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0bajo\u00a0tratamiento \u00a0con\u00a0antagonistas \u00a0................................. \u00a0100 \n3.3.\u00a0Modelo\u00a0experimental \u00a0ortot\u00f3pico \u00a0sing\u00e9nico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0en\u00a0ratones\u00a0KO\u00a0para\u00a0el\u00a0\ngen\u00a0TAC1\u00a0............................................................................................................................... .............\u00a0101 \n4.\u00a0ESTUDIO\u00a0DE\u00a0EXPRESI\u00d3N \u00a0G\u00c9NICA\u00a0 101 \n4.1.\u00a0Extracci\u00f3n \u00a0y\u00a0cuantificaci\u00f3n \u00a0de\u00a0ARN\u00a0............................................................................................... \u00a0101 \n4.2.\u00a0PCR\u00a0quantitativa \u00a0a\u00a0tiempo\u00a0real.\u00a0.................................................................................................... \u00a0101 \n4.3.\u00a0Estudio\u00a0diferencial \u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0mediante \u00a0microarrays \u00a0..................................................... \u00a0101 \n4.3.1\u00a0Normalizaci\u00f3n \u00a0............................................................................................................................ \u00a0102 \n4.3.2\u00a0An\u00e1lisis\u00a0supervisados \u00a0.................................................................................................................. \u00a0102 \n4.3.3\u00a0An\u00e1lisis\u00a0no\u00a0supervis ados............................................................................................................. \u00a0102 \n4.3.4\u00a0An\u00e1lisis\u00a0de\u00a0rutas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0................................................................................................ \u00a0102 \n5.\u00a0MEDICI\u00d3N \u00a0DE\u00a0PROTE\u00cdNA \u00a0 103 \n5.1.\u00a0Western\u00a0blot\u00a0............................................................................................................................... .\u00a0103 \n5.2.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0fluorescencia \u00a0y\u00a0enriquecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0celular\u00a0mediante \u00a0\ncitometr\u00eda \u00a0de\u00a0flujo\u00a0separador \u00a0............................................................................................................. \u00a0104 \n5.2.1.\u00a0Enriquecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0NK\u20101R\u00a0+\u00a0................................................................................. \u00a0104 \n5.2.2.\u00a0Cuantificaci\u00f3n \u00a0por\u00a0citometr\u00eda \u00a0de\u00a0flujo\u00a0de\u00a0las\u00a0poblaciones \u00a0CD44/CD24 \u00a0.................................... \u00a0104 \n5.3.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0citoquinas \u00a0mediante \u00a0ELISA\u00a0............................................................................... \u00a0104 \n5.3.1.\u00a0SP\u00a0en\u00a0plasma\u00a0de\u00a0pacientes \u00a0........................................................................................................ \u00a0104 \n5.3.2.\u00a0IL\u20106\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0.............................................................................................................. \u00a0106 \n5.4.\u00a0Inmunofluorescencia \u00a0................................................................................................................... \u00a0106 \n5.4.1.\u00a0En\u00a0l\u00edneas\u00a0celulares\u00a0..................................................................................................................... \u00a0106 \n5.4.2.\u00a0En\u00a0cultivos\u00a0primarios \u00a0................................................................................................................. \u00a0106 \n5.5.\u00a0Microscop\u00eda \u00a0de\u00a0fluorescencia \u00a0y\u00a0adquisici\u00f3n \u00a0de\u00a0im\u00e1genes \u00a0para\u00a0la\u00a0detecci\u00f3n \u00a0y/o\u00a0\nquantificaci\u00f3n \u00a0de\u00a0pHER2\u00a0..................................................................................................................... \u00a0107 \n5.6.\u00a0Inmunohistoqu\u00edmica \u00a0.................................................................................................................... \u00a0108 \n5.6.1.\u00a0Preparaci\u00f3n \u00a0de\u00a0microarrays \u00a0de\u00a0tejidos\u00a0..................................................................................... \u00a0108 \n5.6.2.\u00a0Preparaci\u00f3n \u00a0de\u00a0bloques\u00a0celulares\u00a0............................................................................................. \u00a0108 \n5.6.3.\u00a0Procedimiento \u00a0de\u00a0inmunohistoqu\u00edmica \u00a0.................................................................................... \u00a0109 \n5.6.4.\u00a0Evaluaci\u00f3n \u00a0inmunohistoqu\u00edmica \u00a0............................................................................................... \u00a0109 \n5.6.5.\u00a0Evaluaci\u00f3n \u00a0del\u00a0\u00edndice\u00a0mit\u00f3tico\u00a0.................................................................................................. \u00a0109 \n5.6.6.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\u03b1\u2010SMA\u00a0............................................................... \u00a0110 \nRESULTADOS \u00a0 111 \n1.\u00a0EL\u00a0RECEPTOR \u00a0NK\u20101\u00a0Y\u00a0LA\u00a0SP\u00a0SE\u00a0ENCUENTRAN \u00a0EXPRESADOS \u00a0EN\u00a0TUMORES \u00a0PRIMARIOS \u00a0DE\u00a0\nC\u00c1NCER\u00a0DE\u00a0MAMA\u00a0Y\u00a0SE\u00a0CORRELACIONAN \u00a0CON\u00a0EL\u00a0SUBTIPO\u00a0TUMORAL \u00a0HER2+\u00a0 113 \n2.\u00a0LOS\u00a0NIVELES\u00a0CIRCULANTES \u00a0DE\u00a0SP\u00a0EST\u00c1N\u00a0AUMENTADOS \u00a0EN\u00a0PACIENTES \u00a0CON\u00a0C\u00c1NCER\u00a0DE\u00a0\nMAMA\u00a0 113 \u00cdNDICE\u00a0\u00a0\n\u00a0\n\u00a0\n8\u00a0\n\u00a03.\u00a0LAS\u00a0TAQUIQUININAS \u00a0MODULAN \u00a0LA\u00a0ACTIVACI\u00d3N \u00a0DE\u00a0LOS\u00a0RECEPTORES \u00a0EGFR\u00a0Y\u00a0HER2\u00a0EN\u00a0\nC\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0 115 \n3.1\u00a0La\u00a0SP\u00a0transactiva \u00a0HER2\u00a0y\u00a0EGFR\u00a0....................................................................................................... \u00a0115 \n3.2\u00a0La\u00a0cin\u00e9tica\u00a0de\u00a0activaci\u00f3n \u00a0del\u00a0receptor\u00a0HER2\u00a0es\u00a0dosis\u2010dependiente \u00a0................................................. \u00a0116 \n3.3\u00a0La\u00a0transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0no\u00a0se\u00a0limita\u00a0a\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0una\u00a0sola\u00a0taquiquinina \u00a0................................ \u00a0116 \n4.\u00a0LA\u00a0SP\u00a0TRANSACTIVA \u00a0HER2\u00a0EN\u00a0C\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0HUMANO \u00a0 119 \n5.\u00a0LA\u00a0SE\u00d1ALIZACI\u00d3N \u00a0AUTOCRINA/PARACRINA \u00a0DE\u00a0LA\u00a0SP\u00a0A\u00a0TRAV\u00c9S\u00a0DEL\u00a0RECEPTOR \u00a0NK\u20101\u00a0EN\u00a0\nC\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0CONTRIBUYE \u00a0A\u00a0LA\u00a0ACTIVACI\u00d3N \u00a0BASAL\u00a0DE\u00a0RECEPTORES \u00a0\nRTKs\u00a0 123 \n5.1.\u00a0La\u00a0sobreexpresi\u00f3n \u00a0del\u00a0receptor\u00a0TACR1\u00a0causa\u00a0un\u00a0aumento \u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0\nMAPKs\u00a0............................................................................................................................... ................. \u00a0123 \n5.2.\u00a0La\u00a0inhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0o\u00a0el\u00a0silenciamiento \u00a0del\u00a0gen\u00a0TACR1\u00a0disminuyen \u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0RTKs\u00a0y\u00a0sus\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0............................................................................... \u00a0124 \n5.3.\u00a0El\u00a0bloqueo\u00a0de\u00a0la\u00a0SP\u00a0con\u00a0anticuerpos \u00a0disminuye \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0RTKs\u00a0y\u00a0sus\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0............................................................................................................................... .........\u00a0127 \n6.\u00a0LA\u00a0TRANSACTIVACI\u00d3N \u00a0DE\u00a0HER2\u00a0Y\u00a0EGFR\u00a0ES\u00a0UN\u00a0MECANISMO \u00a0DEPENDIENTE \u00a0DE\u00a0SRC\u00a0Y\u00a0\nMMPS\u00a0 127 \n7.\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0CR\u00d3NICA \u00a0DE\u00a0LA\u00a0SP\u00a0IN\u00a0VIVO\u00a0TIENE\u00a0ACTIVIDAD \u00a0MITOG\u00c9NICA \u00a0Y\u00a0AUMENTA \u00a0\nLA\u00a0ACTIVACI\u00d3N \u00a0DE\u00a0HER2\u00a0Y\u00a0EGFR\u00a0EN\u00a0UNA\u00a0L\u00cdNEA\u00a0BASAL\u00a0 130 \n8.\u00a0LA\u00a0SP\u00a0END\u00d3GENA \u00a0NO\u00a0AFECTA\u00a0A\u00a0LA\u00a0TUMORIG\u00c9NESIS \u00a0O\u00a0EL\u00a0CRECIMIENTO \u00a0TUMORAL \u00a0 131 \n9.\u00a0LA\u00a0SE\u00d1ALIZACI\u00d3N \u00a0AUTOCRINA \u00a0DE\u00a0SP\u00a0A\u00a0TRAV\u00c9S\u00a0DE\u00a0NK\u20101R\u00a0ES\u00a0IMPRESCINDIBLE \u00a0PARA\u00a0LA\u00a0\nSUPERVIVENCIA \u00a0de\u00a0C\u00c9LULAs\u00a0DE\u00a0CM\u00a0 132 \n9.1.\u00a0El\u00a0bloqueo\u00a0del\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0\u00a0induce\u00a0muerte\u00a0celular\u00a0mediada\u00a0por\u00a0apoptosis \u00a0................ \u00a0132 \n9.1.1.\u00a0El\u00a0tratamiento \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0con\u00a0un\u00a0anticuerpo \u00a0anti\u2010SP\u00a0induce\u00a0muerte\u00a0celular\u00a0\nmediada\u00a0por\u00a0apoptosis \u00a0........................................................................................................................ \u00a0132 \n9.1.2.\u00a0La\u00a0inhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0induce\u00a0muerte\u00a0celular\u00a0mediada\u00a0por\u00a0\napoptosis \u00a0............................................................................................................................... ..............\u00a0133 \n10.\u00a0EL\u00a0ANTAGONISTA \u00a0DEL\u00a0RECEPTOR \u00a0NK\u20101,\u00a0EL\u00a0L\u2010733,060\u00a0INHIBE\u00a0EL\u00a0CRECIMIENTO \u00a0TUMORAL \u00a0\nIN\u00a0VIVO\u00a0 134 \n11.\u00a0LA\u00a0COMBINACI\u00d3N \u00a0DEL\u00a0ANTAGONISTA \u00a0DE\u00a0NK\u20101R,\u00a0L\u2010733,\u00a0060,\u00a0CON\u00a0TERAPIAS \u00a0ANTI\u2010HER2\u00a0\nINHIBE\u00a0SINERG\u00cdSTICAMENTE \u00a0LA\u00a0PROLIFERACI\u00d3N \u00a0DE\u00a0C\u00c9LULAS\u00a0DE\u00a0CM\u00a0 136 \n12.\u00a0UNA\u00a0EXPOSICI\u00d3N \u00a0CONTINUA \u00a0A\u00a0LA\u00a0SP\u00a0AUMENTA \u00a0LA\u00a0AGRESIVIDAD \u00a0DE\u00a0LAS\u00a0C\u00c9LULAS\u00a0DE\u00a0\nC\u00c1NCER\u00a0DE\u00a0MAMA\u00a0 136 \n12.1.\u00a0La\u00a0exposici\u00f3n \u00a0de\u00a0SP\u00a0durante\u00a05\u00a0meses\u00a0causa\u00a0cambios\u00a0fenot\u00edpicos \u00a0en\u00a0l\u00edneas\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0\nmama\u00a0............................................................................................................................... .................. \u00a0136 \n12.1.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0aumenta\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0en\u00a0l\u00edneas\u00a0de\u00a0CM\u00a0................. \u00a0140 \u00cdNDICE\u00a0\u00a0\n\u00a0\n\u00a0\n9\u00a0\n\u00a012.2\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0aumenta\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0receptores \u00a0de\u00a0la\u00a0familia\u00a0ErbB,\u00a0\nNK\u20101R\u00a0y\u00a0altera\u00a0los\u00a0niveles\u00a0de\u00a0IL\u20106\u00a0........................................................................................................ \u00a0140 \n12.2.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0provoca\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0genes\u00a0de\u00a0la\u00a0familia\u00a0\nERBB\u00a0............................................................................................................................... ..................... \u00a0140 \n12.2.2.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0altera\u00a0las\u00a0respuestas \u00a0celulares\u00a0a\u00a0las\u00a0terapias\u00a0\ndirigidas\u00a0contra\u00a0HER2\u00a0y\u00a0EGFR\u00a0.............................................................................................................. \u00a0142 \n12.2.3.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0aumenta\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0de\u00a0\nprote\u00ednas \u00a0implicadas \u00a0en\u00a0sus\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0como\u00a0NF\u2010\u03baB\u00a0e\u00a0IL\u20106\u00a0.................................................. \u00a0143 \n12.2.4.\u00a0La\u00a0ausencia\u00a0de\u00a0SP\u00a0despu\u00e9s\u00a0de\u00a0una\u00a0exposici\u00f3n \u00a0continua\u00a0no\u00a0altera\u00a0los\u00a0niveles\u00a0de\u00a0\nexpresi\u00f3n \u00a0de\u00a0EGFR\u00a0o\u00a0HER2\u00a0adquiridos \u00a0durante\u00a0el\u00a0tratamiento \u00a0........................................................... \u00a0144 \n13.\u00a0\u00a0EFECTO\u00a0DE\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0CONTINUADA \u00a0DE\u00a0LA\u00a0SP\u00a0EN\u00a0LA\u00a0EXPRESI\u00d3N \u00a0G\u00c9NICA\u00a0 144 \n13.1.\u00a0Genes\u00a0comunes \u00a0alterados \u00a0por\u00a0el\u00a0tratamiento \u00a0............................................................................. \u00a0145 \n14.\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0CONTINUA \u00a0A\u00a0SP\u00a0CAUSA\u00a0UNA\u00a0ALTERACI\u00d3N \u00a0EN\u00a0LA\u00a0HORMONO \u2010\nDEPENDENCIA \u00a0DE\u00a0C\u00c9LULAS\u00a0RECEPTOR \u00a0DE\u00a0ESTR\u00d3GENO \u00a0POSITIVAS \u00a0 149 \n14.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0provoca\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0genes\u00a0de\u00a0la\u00a0familia\u00a0\nERBB\u00a0y\u00a0aumenta\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0en\u00a0presencia \u00a0o\u00a0ausencia\u00a0de\u00a0hormonas \u00a0en\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0MCF7\u00a0............................................................................................................................... ........\u00a0149 \n14.2.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0aumenta\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nMCF7\u00a0en\u00a0presencia \u00a0o\u00a0ausencia\u00a0de\u00a0hormonas \u00a0....................................................................................... \u00a0150 \nART\u00cdCULO \u00a01\u00a0 153 \nDISCUSI\u00d3N \u00a0 167 \nMOL\u00c9CULAS \u00a0IMPLICADAS \u00a0EN\u00a0LA\u00a0TRANSACTIVACION \u00a0DE\u00a0RTKs\u00a0A\u00a0TRAV\u00c9S\u00a0DEL\u00a0RECEPTOR \u00a0NK1\u00a0\nE\u00a0IMPLICACIONES \u00a0CL\u00cdNICAS \u00a0................................................................................................................. \u00a0169 \nLA\u00a0SP\u00a0Y\u00a0NK\u20101R\u00a0EN\u00a0PACIENTES \u00a0CON\u00a0CM\u00a0................................................................................................ \u00a0173 \nEFECTOS\u00a0CR\u00d3NICOS \u00a0DE\u00a0LA\u00a0SP\u00a0.............................................................................................................. \u00a0174 \nCONCLUSIONES \u00a0 177 \nANEXOS\u00a0 181 \nTabla\u00a0anexa\u00a01\u00a0............................................................................................................................... .......\u00a0183 \nTabla\u00a0anexa\u00a02\u00a0............................................................................................................................... .......\u00a0184 \nTabla\u00a0anexa\u00a03\u00a0............................................................................................................................... .......\u00a0187 \nTabla\u00a0anexa\u00a04\u00a0............................................................................................................................... .......\u00a0188 \nTabla\u00a0anexa\u00a05\u00a0............................................................................................................................... .......\u00a0189 \nTabla\u00a0anexa\u00a06\u00a0............................................................................................................................... .......\u00a0190 \nFigura\u00a0anexa\u00a01\u00a0............................................................................................................................... ......\u00a0192 \nFigura\u00a0anexa\u00a02\u00a0............................................................................................................................... ......\u00a0196 \nBIBLIOGRAF\u00cdA \u00a0 203 \u00a0\n11\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n13\u00a0\n\u00a01.\u00a0LA\u00a0GL\u00c1NDULA \u00a0MAMARIA \u00a0\nLa\u00a0gl\u00e1ndula\u00a0mamaria\u00a0es\u00a0un\u00a0\u00f3rgano\u00a0en\u00a0continuo\u00a0\ndesarrollo \u00a0desde\u00a0la\u00a0fase\u00a0embrionaria, \u00a0pasando\u00a0por\u00a0\nla\u00a0pubertad, \u00a0los\u00a0ciclos\u00a0menstruales \u00a0y\u00a0el\u00a0embarazo, \u00a0\nhasta\u00a0su\u00a0atrofia\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0menopausia. \u00a0Est\u00e1\u00a0\nformada\u00a0por\u00a0c\u00e9lulas\u00a0epiteliales \u00a0de\u00a0origen\u00a0\nectod\u00e9rmico \u00a0(par\u00e9nquima) \u00a0y\u00a0por\u00a0un\u00a0tejido\u00a0\nconectivo \u00a0de\u00a0origen\u00a0mesod\u00e9rmico \u00a0(estroma) \u00a0que\u00a0\nlleva\u00a0vasos\u00a0sangu\u00edneos \u00a0y\u00a0fibras\u00a0nerviosas \u00a0a\u00a0la\u00a0\ngl\u00e1ndula2.\u00a0La\u00a0gl\u00e1ndula\u00a0mamaria\u00a0presenta\u00a0una\u00a0\nmorfolog\u00eda \u00a0variable\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0desarrollo. \u00a0\u00a0\nA\u00a0modo\u00a0de\u00a0resumen, \u00a0en\u00a0el\u00a0nacimiento \u00a0ya\u00a0se\u00a0ha\u00a0\nestablecido \u00a0un\u00a0sistema\u00a0rudimentario \u00a0de\u00a0conductos \u00a0\nen\u00a0el\u00a0que\u00a0pueden\u00a0reconocerse \u00a0c\u00e9lulas\u00a0epiteliales \u00a0y\u00a0\nmioepiteliales. \u00a0En\u00a0la\u00a0pubertad, \u00a0en\u00a0respuesta \u00a0a\u00a0los\u00a0\nniveles\u00a0crecientes \u00a0de\u00a0hormonas \u00a0ov\u00e1ricas\u00a0sexuales3,\u00a0\nse\u00a0desarrolla \u00a0el\u00a0sistema\u00a0de\u00a0conductos \u00a0epiteliales \u00a0y\u00a0\nse\u00a0acumula\u00a0grasa\u00a0en\u00a0el\u00a0tejido\u00a0conectivo \u00a0entre\u00a0los\u00a0\nl\u00f3bulos\u00a0y\u00a0los\u00a0lobulillos, \u00a0aunque\u00a0las\u00a0unidades\u00a0\nsecretoras \u00a0verdaderas \u00a0no\u00a0se\u00a0formar\u00e1n \u00a0hasta\u00a0la\u00a0\ngestaci\u00f3n4,5.\u00a0Despu\u00e9s\u00a0del\u00a0desarrollo, \u00a0la\u00a0estructura \u00a0\nde\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0fluct\u00faa\u00a0de\u00a0acuerdo\u00a0con\u00a0el\u00a0\nciclo\u00a0menstrual \u00a0y\u00a0los\u00a0cambios\u00a0hormonales \u00a0hasta\u00a0\nque\u00a0se\u00a0forma\u00a0un\u00a0\u00f3rgano\u00a0lactante\u00a0completamente \u00a0\ndiferenciado \u00a0durante\u00a0el\u00a0embarazo, \u00a0una\u00a0vez\u00a0m\u00e1s\u00a0\ndebido\u00a0a\u00a0los\u00a0cambios\u00a0hormonales \u00a0producidos \u00a0\ndurante\u00a0este\u00a0periodo4,6.\u00a0Despu\u00e9s\u00a0de\u00a0la\u00a0\nmenopausia \u00a0las\u00a0estructuras \u00a0epiteliales \u00a0y\u00a0del\u00a0tejido\u00a0\nconectivo \u00a0experimentan \u00a0una\u00a0atrofia\u00a0provocada \u00a0por\u00a0la\u00a0deficiencia \u00a0hormonal3.\u00a0\u00a0\nAnat\u00f3micamente, \u00a0el\u00a0tejido\u00a0glandular \u00a0de\u00a0la\u00a0mama\u00a0\nsexualmente \u00a0madura\u00a0(en\u00a0reposo),\u00a0est\u00e1\u00a0constituido \u00a0\npor\u00a015\u00a0a\u00a020\u00a0l\u00f3bulos\u00a0dispuestos \u00a0radialmente \u00a0en\u00a0\ndirecci\u00f3n\u00a0al\u00a0pez\u00f3n.\u00a0Los\u00a0l\u00f3bulos\u00a0est\u00e1n\u00a0situados\u00a0en\u00a0\nla\u00a0regi\u00f3n\u00a0profunda \u00a0de\u00a0la\u00a0mama,\u00a0de\u00a0manera\u00a0radial\u00a0\nen\u00a0relaci\u00f3n\u00a0al\u00a0pez\u00f3n\u00a0(Fig.\u00a01).\u00a0Cada\u00a0l\u00f3bulo\u00a0contiene\u00a0\nun\u00a0canal\u00a0excretor\u00a0propio\u00a0conocido\u00a0como\u00a0\ngalact\u00f3foro \u00a0de\u00a0primer\u00a0orden,\u00a0que\u00a0se\u00a0dilata\u00a0en\u00a0su\u00a0\nporci\u00f3n\u00a0terminal\u00a0(sinus\u00a0lact\u00edfero)\u00a0y\u00a0que\u00a0se\u00a0abre\u00a0a\u00a0\nnivel\u00a0del\u00a0pez\u00f3n\u00a0por\u00a0los\u00a0poros\u00a0galact\u00f3foros. \u00a0El\u00a0\nconducto \u00a0galact\u00f3foro \u00a0de\u00a0primer\u00a0orden\u00a0se\u00a0bifurca\u00a0\ndicot\u00f3micamente \u00a0en\u00a0galact\u00f3foros \u00a0de\u00a0segundo\u00a0\norden\u00a0y\u00a0a\u00a0medida\u00a0que\u00a0profundizan \u00a0en\u00a0el\u00a0interior\u00a0se\u00a0\nvan\u00a0ramificando \u00a0progresivamente, \u00a0haci\u00e9ndose \u00a0\nm\u00e1s\u00a0peque\u00f1os, \u00a0para\u00a0acabar\u00a0en\u00a0las\u00a0unidades\u00a0\nt\u00fabulo\u2010alveolares \u00a0(ductales\u00a0y\u00a0lobulillares) \u00a0que\u00a0\nrepresentan \u00a0la\u00a0unidad\u00a0funcional \u00a0de\u00a0la\u00a0gl\u00e1ndula,\u00a0\ncon\u00a0un\u00a0potencial \u00a0secretor7.\u00a0Estas\u00a0unidades\u00a0\nterminales \u00a0del\u00a0conducto \u00a0lobular\u00a0se\u00a0denominan \u00a0\nunidades\u00a0lobulillares \u00a0ductales\u00a0terminales \u00a0(ULDTs).\u00a0\nLa\u00a0ULDT\u00a0(l\u00f3bulo),\u00a0est\u00e1\u00a0compuesto \u00a0por\u00a0un\u00a0ducto\u00a0\nterminal\u00a0y\u00a0varios\u00a0peque\u00f1os \u00a0d\u00factulos\u00a0(o\u00a0acinos).\u00a0\nLos\u00a0conductos \u00a0galact\u00f3foros \u00a0est\u00e1n\u00a0recubiertos \u00a0por\u00a0\nun\u00a0epitelio\u00a0luminal\u00a0de\u00a0c\u00e9lulas\u00a0columnares \u00a0pero\u00a0a\u00a0\nmedida\u00a0que\u00a0los\u00a0conductos \u00a0profundizan \u00a0m\u00e1s\u00a0en\u00a0la\u00a0\nmama\u00a0su\u00a0epitelio\u00a0se\u00a0hace\u00a0m\u00e1s\u00a0delgado\u00a0y\u00a0adopta\u00a0\nuna\u00a0forma\u00a0cuboidal,\u00a0con\u00a0menor\u00a0n\u00famero\u00a0de\u00a0capas\u00a0\ncelulares. \u00a0Tanto\u00a0los\u00a0ductos\u00a0como\u00a0los\u00a0l\u00f3bulos\u00a0se\u00a0\nalinean\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0dos\u00a0capas\u00a0epiteliales \u00a0\nFigura\u00a01.\u00a0Esquema\u00a0de\u00a0la\u00a0estructura \u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria (adaptado de\u00a01).\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n14\u00a0\n\u00a0formadas \u00a0por\u00a0c\u00e9lulas\u00a0glandulares \u00a0luminales \u00a0y\u00a0\nc\u00e9lulas\u00a0mioepiteliales \u00a0(Fig.\u00a02),\u00a0que\u00a0est\u00e1n\u00a0separadas \u00a0\ndel\u00a0estroma\u00a0por\u00a0una\u00a0la\u00a0membrana \u00a0basal8.\u00a0\u00a0\nUna\u00a0tercera\u00a0poblaci\u00f3n \u00a0celular\u00a0presente\u00a0en\u00a0el\u00a0\nepitelio\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0est\u00e1\u00a0formada\u00a0por\u00a0\nc\u00e9lulas\u00a0madre/progenitoras \u00a0de\u00a0las\u00a0capas\u00a0de\u00a0c\u00e9lulas\u00a0\nluminales \u00a0y\u00a0basales\u00a0ya\u00a0nombradas \u00a0(v\u00e9ase\u00a0el\u00a0\napartado\u00a03).\u00a0En\u00a0relaci\u00f3n\u00a0a\u00a0estas\u00a0c\u00e9lulas\u00a0madres\u00a0se\u00a0\nha\u00a0descrito\u00a0que\u00a0macr\u00f3fagos \u00a0que\u00a0pertenecen \u00a0al\u00a0\nestroma\u00a0glandular \u00a0podr\u00edan\u00a0influenciar \u00a0en\u00a0la\u00a0\nactividad\u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0madre9.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0Figura\u00a02.\u00a0Estructura \u00a0del\u00a0epitelio\u00a0normal\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0\nmamaria\u00a0humana\u00a0con\u00a0las\u00a0dos\u00a0capas\u00a0de\u00a0c\u00e9lulas\u00a0bien\u00a0\ncaracterizadas, \u00a0luminal\u00a0glandular \u00a0y\u00a0mioepiteliales, \u00a0y\u00a0una\u00a0\ntercera\u00a0poblaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0madre/progenitoras \u00a0de\u00a0la\u00a0\ngl\u00e1ndula\u00a0mamaria\u00a0(adaptado \u00a0de\u00a0\n10).\u00a0\nLas\u00a0c\u00e9lulas\u00a0mioepiteliales \u00a0est\u00e1n\u00a0implicadas \u00a0en\u00a0el\u00a0\nmantenimiento \u00a0estructural, \u00a0remodelaci\u00f3n \u00a0de\u00a0la\u00a0\nmatriz\u00a0extracelular, \u00a0secreci\u00f3n \u00a0de\u00a0la\u00a0leche\u00a0inducida\u00a0\npor\u00a0la\u00a0oxitocina\u00a0y\u00a0en\u00a0el\u00a0control\u00a0de\u00a0la\u00a0fisiolog\u00eda\u00a0\ncelular\u00a0luminal4,8,11\u201013.\u00a0Estas\u00a0c\u00e9lulas\u00a0forman\u00a0una\u00a0\nconexi\u00f3n\u00a0con\u00a0la\u00a0membrana \u00a0basal\u00a0subyacente \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0miofibrillas \u00a0y\u00a0hemidesmosomas4,12\u00a0y\u00a0son\u00a0\nel\u00a0\u00fanico\u00a0recurso\u00a0de\u00a0la\u00a0laminina\u20101,\u00a0una\u00a0prote\u00edna\u00a0\npresente\u00a0en\u00a0la\u00a0membrana \u00a0basal13.\u00a0La\u00a0polaridad \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0epiteliales \u00a0y\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0la\u00a0doble\u00a0\ncapa\u00a0en\u00a0conductos \u00a0y\u00a0los\u00a0lobulillos\u00a0es\u00a0esencial\u00a0para\u00a0\nla\u00a0deposici\u00f3n \u00a0de\u00a0la\u00a0membrana \u00a0basal13.\u00a0Mientras\u00a0\nque\u00a0las\u00a0c\u00e9lulas\u00a0luminales \u00a0se\u00a0dividen\u00a0y\u00a0aumentan \u00a0\nen\u00a0n\u00famero\u00a0durante\u00a0el\u00a0embarazo \u00a0y\u00a0durante\u00a0los\u00a0\nciclos\u00a0de\u00a0menstruales, \u00a0las\u00a0c\u00e9lulas\u00a0mioepiteliales \u00a0\nmuestran \u00a0una\u00a0baja\u00a0actividad\u00a0proliferativa \u00a0en\u00a0la\u00a0\ngl\u00e1ndula\u00a0mamaria\u00a0adulta14,15.\u00a0\u00a0\nEn\u00a0definitiva \u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0sufre\u00a0ciclos\u00a0de\u00a0\ndesarrollo, \u00a0diferenciaci\u00f3n \u00a0y\u00a0apoptosis \u00a0durante\u00a0la\u00a0\nvida\u00a0del\u00a0organismo. \u00a0Estos\u00a0cambios\u00a0c\u00edclicos\u00a0afectan\u00a0\nla\u00a0estructura \u00a0y\u00a0la\u00a0funci\u00f3n\u00a0del\u00a0tejido,\u00a0y\u00a0son\u00a0regulados \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0hormonas \u00a0y\u00a0factores\u00a0de\u00a0\ncrecimiento16.\u00a0Las\u00a0hormonas \u00a0esteroideas, \u00a0\nestr\u00f3geno \u00a0y\u00a0progesterona, \u00a0promueven \u00a0la\u00a0\nproliferaci\u00f3n \u00a0y\u00a0diferenciaci\u00f3n \u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0\nmamaria17.\u00a0Factores\u00a0de\u00a0crecimiento \u00a0como\u00a0el\u00a0factor\u00a0\nde\u00a0crecimiento \u00a0epid\u00e9rmico \u00a0(EGF)\u00a0y\u00a0el\u00a0factor\u00a0de\u00a0\ncrecimiento \u00a0 insul\u00ednico \u20101\u00a0 (IGF\u20101)\u00a0 act\u00faan\u00a0\nestimulando \u00a0la\u00a0supervivencia \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0\nepitelio\u00a0mamario, \u00a0mientras\u00a0que\u00a0el\u00a0factor\u00a0de\u00a0\ncrecimiento \u00a0transformante \u2010beta\u00a0(TGF\u2010\u03b2)\u00a0induce\u00a0su\u00a0\nmuerte\u00a0celular18.\u00a0\n1.1.\u00a0Patolog\u00eda \u00a0benigna\u00a0y\u00a0tumores\u00a0\nbenignos \u00a0\nNo\u00a0existe\u00a0una\u00a0definici\u00f3n \u00a0clara\u00a0de\u00a0lo\u00a0que\u00a0constituye \u00a0\nuna\u00a0enfermedad \u00a0benigna\u00a0de\u00a0la\u00a0mama,\u00a0la\u00a0mayor\u00eda\u00a0\nde\u00a0los\u00a0trastornos \u00a0pertenecen \u00a0a\u00a0un\u00a0espectro\u00a0que\u00a0va\u00a0\ndesde\u00a0lo\u00a0normal\u00a0a\u00a0la\u00a0presentaci\u00f3n \u00a0de\u00a0s\u00edntomas\u00a0\nsuficientes \u00a0para\u00a0atraer\u00a0a\u00a0la\u00a0atenci\u00f3n\u00a0del\u00a0m\u00e9dico.\u00a0\nLa\u00a0enfermedad \u00a0es\u00a0por\u00a0lo\u00a0tanto,\u00a0una\u00a0descripci\u00f3n \u00a0\ncl\u00ednico\u2010patol\u00f3gica \u00a0y\u00a0muchas\u00a0de\u00a0las\u00a0llamadas\u00a0\nenfermedades \u00a0son\u00a0asintom\u00e1ticas. \u00a0Las\u00a0lesiones\u00a0\nbenignas\u00a0de\u00a0la\u00a0mama\u00a0pueden\u00a0ser\u00a0divididas\u00a0en\u00a0\nanormalidades \u00a0cong\u00e9nitas, \u00a0aberraciones \u00a0del\u00a0\nnormal\u00a0desarrollo \u00a0e\u00a0involuci\u00f3n \u00a0de\u00a0la\u00a0mama\u00a0(ANDI)\u00a0\ny\u00a0procesos\u00a0patol\u00f3gicos \u00a0secundarios \u00a0a\u00a0factores\u00a0\nprecipitantes \u00a0externos\u00a0(NON\u2010ANDI).19\u00a0\nDentro\u00a0del\u00a0grupo\u00a0de\u00a0ANDIs\u00a0encontramos \u00a0\ndiferentes \u00a0grupos20:\u00a0\n\u00a0\n\u2022\u00a0Los\u00a0trastornos \u00a0del\u00a0desarrollo: \u00a0\n\u2010Hipertrofia \u00a0del\u00a0adolescente :\u00a0Gran\u00a0hipertrofia \u00a0del\u00a0\nestroma\u00a0durante\u00a0el\u00a0per\u00edodo\u00a0de\u00a0desarrollo. \u00a0\n\u2010Fibroadenoma :\u00a0Es\u00a0el\u00a0tumor\u00a0benigno\u00a0m\u00e1s\u00a0\nfrecuente \u00a0de\u00a0la\u00a0mama,\u00a0formado\u00a0por\u00a0la\u00a0\nproliferaci\u00f3n \u00a0de\u00a0elementos \u00a0epiteliales \u00a0y\u00a0\nmesenquimatosos \u00a0 bien\u00a0 diferenciados, \u00a0\npredominando \u00a0su\u00a0car\u00e1cter\u00a0fibroso\u00a0frente\u00a0al\u00a0\nglandular. \u00a0Hay\u00a0varios\u00a0tipos\u00a0de\u00a0fibroadenomas, \u00a0el\u00a0\nfibroadenoma \u00a0gigante\u00a0(fibroadenoma \u00a0mayor\u00a0de\u00a05\u00a0\ncm),\u00a0el\u00a0fibroadenoma \u00a0juvenil\u00a0(suele\u00a0aparecer\u00a0en\u00a0\nmujeres\u00a0m\u00e1s\u00a0j\u00f3venes\u00a0y\u00a0adolescentes \u00a0y\u00a0crece\u00a0muy\u00a0\nr\u00e1pidamente) \u00a0y\u00a0el\u00a0fibroadenoma \u00a0complejo \u00a0\n(presenta \u00a0quistes\u00a0de\u00a0m\u00e1s\u00a0de\u00a03\u00a0mm\u00a0de\u00a0di\u00e1metro, \u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n15\u00a0\n\u00a0adenosis\u00a0esclerosante, \u00a0calcificaciones \u00a0epiteliales \u00a0y\u00a0\ncambios\u00a0papilares\u00a0apocrinos). \u00a0\n\u00a0\n\u2022\u00a0Los\u00a0cambios\u00a0involutivos: \u00a0\n\u2010Quistes :\u00a0La\u00a0involuci\u00f3n \u00a0del\u00a0estroma\u00a0y\u00a0el\u00a0epitelio\u00a0\nmamario\u00a0no\u00a0siempre\u00a0tiene\u00a0lugar\u00a0de\u00a0forma\u00a0\narm\u00f3nica, \u00a0sino\u00a0que\u00a0con\u00a0frecuencia \u00a0en\u00a0algunas\u00a0\nzonas\u00a0de\u00a0la\u00a0mama\u00a0el\u00a0estroma\u00a0especializado \u00a0es\u00a0\nsustituido \u00a0por\u00a0el\u00a0estroma\u00a0fibroso\u00a0de\u00a0sost\u00e9n\u00a0sin\u00a0\natrofia\u00a0epitelial\u00a0paralela.\u00a0La\u00a0persistencia \u00a0del\u00a0\nepitelio\u00a0funcional \u00a0de\u00a0estos\u00a0acinos,\u00a0asociado\u00a0a\u00a0la\u00a0\ndistorsi\u00f3n \u00a0o\u00a0el\u00a0estrangulamiento \u00a0de\u00a0los\u00a0ductos\u00a0por\u00a0\nel\u00a0estroma\u00a0fibr\u00f3tico\u00a0condiciona \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0\nmicroquistes, \u00a0que\u00a0son\u00a0la\u00a0base\u00a0para\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0\nmacroquistes \u00a0cuando\u00a0el\u00a0funcionamiento \u00a0epitelial\u00a0\npersiste,\u00a0con\u00a0una\u00a0acentuaci\u00f3n \u00a0de\u00a0la\u00a0obstrucci\u00f3n \u00a0\nductal.\u00a0T\u00edpicamente \u00a0aparecen \u00a0entre\u00a0los\u00a035\u00a0y\u00a050\u00a0\na\u00f1os\u00a0y\u00a0pueden\u00a0ser\u00a0dolorosos \u00a0si\u00a0presentan \u00a0un\u00a0\ncrecimiento \u00a0r\u00e1pido\u00a0debido\u00a0a\u00a0la\u00a0tensi\u00f3n\u00a0del\u00a0l\u00edquido\u00a0\nque\u00a0contienen \u00a0en\u00a0su\u00a0interior.\u00a0Pueden\u00a0ser\u00a0divididos\u00a0\npor\u00a0las\u00a0caracter\u00edsticas \u00a0del\u00a0l\u00edquido\u00a0de\u00a0su\u00a0interior\u00a0en\u00a0\napocrinos \u00a0y\u00a0no\u00a0apocrinos, \u00a0sin\u00a0importancia \u00a0en\u00a0\ncuanto\u00a0a\u00a0su\u00a0significado \u00a0y\u00a0actitud\u00a0terap\u00e9utica. \u00a0\u00a0\n\u2010Adenosis \u00a0esclerosante :\u00a0La\u00a0involuci\u00f3n \u00a0del\u00a0estroma\u00a0\nmamario\u00a0puede\u00a0producir\u00a0\u00e1reas\u00a0focales\u00a0de\u00a0fibrosis.\u00a0\nEn\u00a0esta\u00a0patolog\u00eda \u00a0se\u00a0presentan \u00a0conjuntamente \u00a0\nalteraciones \u00a0proliferativas \u00a0y\u00a0degenerativas, \u00a0\nmostrando \u00a0el\u00a0cuadro\u00a0m\u00e1s\u00a0abigarrado \u00a0y\u00a0complejo \u00a0\nde\u00a0estas\u00a0alteraciones, \u00a0con\u00a0\u00e1reas\u00a0de\u00a0fibrosis\u00a0\nestr\u00f3mica, \u00a0desarrollo \u00a0epitelial,\u00a0microquistes, \u00a0\ndistorsi\u00f3n \u00a0estructural, \u00a0etc.\u00a0Se\u00a0requiere\u00a0una\u00a0biopsia\u00a0\nexcisional \u00a0de\u00a0toda\u00a0la\u00a0lesi\u00f3n\u00a0para\u00a0el\u00a0diagn\u00f3stico \u00a0\ndefinitivo \u00a0de\u00a0benignidad. \u00a0\nA\u00a0partir\u00a0de\u00a0esta\u00a0clasificaci\u00f3n \u00a0otros\u00a0autores\u00a0ya\u00a0no\u00a0\ndefinen\u00a0este\u00a0tipo\u00a0de\u00a0lesiones\u00a0benignas\u00a0como\u00a0\nANDIS\u00a0sino\u00a0como\u00a0procesos\u00a0pseudotumorales \u00a0o\u00a0\ntumores\u00a0benignos\u00a0entre\u00a0los\u00a0cuales\u00a0encontramos \u00a0la\u00a0\nectasia\u00a0ductal,\u00a0el\u00a0galactocele \u00a0y\u00a0las\u00a0hiperplasias \u00a0\nepiteliales. \u00a0Adem\u00e1s\u00a0de\u00a0los\u00a0clasificados \u00a0como\u00a0\ntumores\u00a0epiteliales, \u00a0fibroepiteliales, \u00a0mioepiteliales \u00a0\ny\u00a0mesenquimales \u00a0(Tabla\u00a01).\u00a0\nCada\u00a0vez\u00a0m\u00e1s\u00a0el\u00a0desarrollo \u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0\nest\u00e1\u00a0recibiendo \u00a0m\u00e1s\u00a0atenci\u00f3n\u00a0sobre\u00a0todo\u00a0por\u00a0su\u00a0\nimportante \u00a0v\u00ednculo\u00a0con\u00a0la\u00a0comprensi\u00f3n \u00a0del\u00a0c\u00e1ncer\u00a0\nde\u00a0mama\u00a0(CM).\u00a0La\u00a0ausencia\u00a0de\u00a0las\u00a0alteraciones \u00a0gen\u00e9ticas \u00a0frecuentemente \u00a0involucradas \u00a0en\u00a0la\u00a0\npatolog\u00eda \u00a0maligna\u00a0o\u00a0niveles\u00a0mayores\u00a0de\u00a0receptor\u00a0\nde\u00a0estr\u00f3geno \u00a0(RE)\u00a0y\u00a0receptor\u00a0de\u00a0progesterona \u00a0(PR)\u00a0\nlos\u00a0diferencian \u00a0de\u00a0las\u00a0lesiones\u00a0benignas\u00a0mamarias \u00a0\n21.\u00a0Ahora\u00a0ya\u00a0es\u00a0m\u00e1s\u00a0evidente\u00a0que\u00a0genes\u00a0\ninvolucrados, \u00a0por\u00a0ejemplo,\u00a0en\u00a0el\u00a0ciclo\u00a0celular\u00a0como\u00a0\nciclina\u00a0D1\u00a0y\u00a0p53\u00a0tienen\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0el\u00a0\ndesarrollo \u00a0mamario22.\u00a0Otros\u00a0genes\u00a0como\u00a0BRCA1\u00a0\n(breast\u00a0cancer\u00a01)\u00a0y\u00a0BRCA2\u00a0(breast\u00a0cancer\u00a02),\u00a0si\u00a0\nest\u00e1n\u00a0mutados\u00a0en\u00a0la\u00a0l\u00ednea\u00a0germinal, \u00a0predisponen \u00a0\nal\u00a0individuo \u00a0a\u00a0desarrollar \u00a0CM\u00a0y\u00a0se\u00a0expresan\u00a0en\u00a0la\u00a0\ngl\u00e1ndula\u00a0durante\u00a0su\u00a0desarrollo23.\u00a0Por\u00a0tanto\u00a0es\u00a0\nimportante \u00a0ampliar\u00a0el\u00a0conocimiento \u00a0sobre\u00a0esta\u00a0\n\u00e1rea\u00a0para\u00a0entender\u00a0y\u00a0comprender \u00a0mejor\u00a0el\u00a0origen\u00a0\nde\u00a0un\u00a0proceso\u00a0tumoral\u00a0maligno.\u00a0\n\u00a0\n2.\u00a0PATOLOG\u00cdA \u00a0MAMARIA \u00a0\nMALIGNA: \u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\n\u00a0\nDurante\u00a0todas\u00a0las\u00a0etapas\u00a0del\u00a0desarrollo \u00a0mamario\u00a0o\u00a0\nsu\u00a0involuci\u00f3n \u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0\nest\u00e1n\u00a0sometidas \u00a0a\u00a0un\u00a0continuo\u00a0flujo\u00a0de\u00a0\ninformaci\u00f3n \u00a0que\u00a0proviene\u00a0tanto\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0su\u00a0\nalrededor \u00a0como\u00a0del\u00a0microambiente \u00a0o\u00a0del\u00a0exterior\u00a0\ndel\u00a0organismo. \u00a0La\u00a0correcta\u00a0interpretaci\u00f3n \u00a0de\u00a0estas\u00a0\nse\u00f1ales\u00a0y\u00a0la\u00a0correcta\u00a0ejecuci\u00f3n \u00a0de\u00a0las\u00a0mismas\u00a0son\u00a0\nmuy\u00a0importantes \u00a0para\u00a0la\u00a0supervivencia \u00a0tanto\u00a0de\u00a0la\u00a0\npropia\u00a0c\u00e9lula\u00a0como\u00a0del\u00a0organismo \u00a0completo. \u00a0\nCuando\u00a0por\u00a0alg\u00fan\u00a0motivo\u00a0dichas\u00a0se\u00f1ales\u00a0no\u00a0son\u00a0\npropicias\u00a0para\u00a0un\u00a0correcto\u00a0mantenimiento \u00a0tanto\u00a0\nde\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0epitelio\u00a0mamario\u00a0como\u00a0de\u00a0todo\u00a0\nel\u00a0estroma\u00a0que\u00a0las\u00a0sostiene,\u00a0y\u00a0se\u00a0rompe\u00a0el\u00a0\nequilibrio \u00a0entre\u00a0el\u00a0mantenimiento \u00a0o\u00a0la\u00a0\nsupervivencia, \u00a0es\u00a0cuando\u00a0pueden\u00a0originarse \u00a0los\u00a0\ntumores\u00a0malignos\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria. \u00a0Los\u00a0\ntumores\u00a0malignos\u00a0se\u00a0originan\u00a0por\u00a0proliferaci\u00f3n \u00a0\nat\u00edpica\u00a0del\u00a0epitelio\u00a0de\u00a0los\u00a0l\u00f3bulos\u00a0o\u00a0de\u00a0los\u00a0\nconductos \u00a0galact\u00f3foros. \u00a0Esta\u00a0proliferaci\u00f3n \u00a0\nincontrolada \u00a0llena\u00a0total\u00a0o\u00a0parcialmente \u00a0la\u00a0luz\u00a0de\u00a0\nlos\u00a0conductos. \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n16\u00a0\n\u00a0Tabla\u00a01.\u00a0Clasificaci\u00f3n \u00a0histol\u00f3gica \u00a0de\u00a0los\u00a0tumores\u00a0benignos\u00a0de\u00a0\nla\u00a0mama24.\u00a0Estos\u00a0pueden\u00a0clasificarse \u00a0seg\u00fan\u00a0el\u00a0car\u00e1cter\u00a0no\u00a0\ninfiltrativo \u00a0o\u00a0invasivo\u00a0del\u00a0estroma,\u00a0por\u00a0el\u00a0lugar\u00a0de\u00a0\norigen\u00a0histol\u00f3gico \u00a0y\u00a0por\u00a0el\u00a0patr\u00f3n\u00a0estructural25,26.\u00a0\nUna\u00a0vez\u00a0se\u00a0diagnostica \u00a0un\u00a0tumor\u00a0mamario\u00a0hay\u00a0que\u00a0\nreunir\u00a0los\u00a0datos\u00a0cl\u00ednicos,\u00a0los\u00a0hallazgos\u00a0operatorios, \u00a0\nlas\u00a0biopsias,\u00a0la\u00a0valoraci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0\nhormonales \u00a0as\u00ed\u00a0como\u00a0otras\u00a0determinaciones \u00a0\nbioqu\u00edmicas \u00a0con\u00a0el\u00a0fin\u00a0de\u00a0conseguir \u00a0una\u00a0evaluaci\u00f3n \u00a0\npron\u00f3stica \u00a0completa. \u00a0\n2.1\u00a0Par\u00e1metros \u00a0anatomopatol\u00f3gicos \u00a0\nLa\u00a0anatom\u00eda \u00a0patol\u00f3gica \u00a0permite\u00a0la\u00a0confirmaci\u00f3n \u00a0\ndiagn\u00f3stica \u00a0de\u00a0un\u00a0tumor\u00a0mamario\u00a0cuando\u00a0\npreviamente \u00a0se\u00a0tiene\u00a0la\u00a0sospecha \u00a0cl\u00ednica\u00a0de\u00a0que\u00a0\nexiste\u00a0un\u00a0proceso\u00a0maligno\u00a0mediante \u00a0m\u00e9todos\u00a0de\u00a0\nexploraci\u00f3n. \u00a0Un\u00a0estudio\u00a0de\u00a0una\u00a0pieza\u00a0operatoria \u00a0\naporta\u00a0una\u00a0serie\u00a0de\u00a0datos\u00a0que\u00a0permiten \u00a0una\u00a0mejor\u00a0\nvaloraci\u00f3n \u00a0del\u00a0pron\u00f3stico \u00a0y\u00a0de\u00a0la\u00a0enfermedad \u00a0de\u00a0la\u00a0\npaciente. \u00a0\nEn\u00a0la\u00a0valoraci\u00f3n \u00a0anatomopatol\u00f3gica \u00a0se\u00a0tienen\u00a0en\u00a0\ncuenta:\u00a0la\u00a0clasificaci\u00f3n \u00a0histol\u00f3gica \u00a0(Tabla\u00a02),\u00a0el\u00a0\ngrado\u00a0histol\u00f3gico \u00a0(Tabla\u00a03),\u00a0y\u00a0el\u00a0estadio\u00a0(el\u00a0tama\u00f1o\u00a0\ntumoral\u00a0y\u00a0la\u00a0existencia \u00a0de\u00a0met\u00e1stasis \u00a0a\u00a0distancia\u00a0y\u00a0\nganglionares \u00a0(Tabla\u00a04\u00a0y\u00a05).\u00a0\n\u00a0\nEl\u00a0carcinoma \u00a0ductal\u00a0in\u00a0situ\u00a0(CDIS)\u00a0es\u00a0un\u00a0c\u00e1ncer\u00a0de\u00a0\nseno\u00a0no\u00a0invasivo.\u00a0El\u00a0t\u00e9rmino\u00a0in\u00a0situ\u00a0significa\u00a0\u201cen\u00a0el\u00a0\nsitio\u201d.\u00a0Es\u00a0aparentemente \u00a0una\u00a0proliferaci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0malignas\u00a0dentro\u00a0del\u00a0lumen\u00a0de\u00a0los\u00a0\nconductos \u00a0mamarios \u00a0que\u00a0no\u00a0han\u00a0penetrado \u00a0en\u00a0las\u00a0\nc\u00e9lulas\u00a0mioepiteliales \u00a0envueltas \u00a0por\u00a0la\u00a0membrana \u00a0\nbasal\u00a0y\u00a0por\u00a0tanto\u00a0no\u00a0ha\u00a0invadido\u00a0el\u00a0estroma\u00a0\ncircundante. \u00a0Los\u00a0conductos \u00a0que\u00a0invaden\u00a0son\u00a0los\u00a0\nresponsables \u00a0del\u00a0transporte \u00a0de\u00a0la\u00a0leche\u00a0desde\u00a0los\u00a0\nlobulillos\u00a0(donde\u00a0se\u00a0produce)\u00a0hasta\u00a0pez\u00f3n.\u00a0El\u00a0CDIS\u00a0\npuede\u00a0afectar\u00a0s\u00f3lo\u00a0un\u00a0\u00e1rea\u00a0del\u00a0conducto \u00a0(unifocal) \u00a0\no\u00a0m\u00e1s\u00a0de\u00a0un\u00a0\u00e1rea\u00a0del\u00a0conducto \u00a0(multifocal). \u00a0Es\u00a0un\u00a0\ndiagn\u00f3stico \u00a0com\u00fan\u00a0en\u00a0mujeres\u00a0que\u00a0se\u00a0realizan\u00a0\nt\u00e9cnicas\u00a0de\u00a0detecci\u00f3n \u00a0como\u00a0las\u00a0mamograf\u00edas, \u00a0y\u00a0la\u00a0\nincidencia \u00a0de\u00a0esta\u00a0patolog\u00eda \u00a0ha\u00a0aumentado \u00a0en\u00a0las\u00a0\n\u00faltimas\u00a0d\u00e9cadas\u00a0y\u00a0representa \u00a0alrededor \u00a0del\u00a020\u2010\n25%\u00a0de\u00a0los\u00a0nuevos\u00a0casos27.\u00a0\n\u00a0\n\u00a0\n\u00a0TUMORES \u00a0FIBROEPITELIALES \u00a0\u00a0\nFIBROADENOMA \u00a0\u00a0\nTUMOR\u00a0FILOIDES\u00a0\u00a0\n\u2010BENIGNO \u00a0\u00a0\n\u2010BORDERLINE \u00a0\u00a0\n\u2010MALIGNO \u00a0\u00a0\nHAMARTOMA \u00a0MAMARIO \u00a0(ADENOFIBROLIPOMA) \u00a0\nADENOLIPOMA \u00a0\u00a0\n\u2010ADENOHIBERNOMA \u00a0\u00a0\n\u2010HAMARTOMA \u00a0MIOIDE\u00a0\u00a0\n\u00a0\nTUMORES \u00a0EPITELIALES \u00a0\u00a0\nNEOPLASIAS \u00a0PAPILARES \u00a0INTRADUCTALES \u00a0\u00a0\n\u2010PAPILOMA \u00a0CENTRAL\u00a0(PAPILOMA \u00a0SOLITARIO) \u00a0\u00a0\n\u2010PAPILOMA \u00a0PERIF\u00c9RICO \u00a0(PAPILOMATOSIS \u00a0M\u00daLTIPLE \u00a0,\u00a0\u00a0\u00a0\u00a0\u00a0\nPAPILOMATOSIS \u00a0JUVENIL)\u00a0\n\u00a0\u2010PAPILOMA \u00a0AT\u00cdPICO\u00a0\u00a0\nPROLIFERACIONES \u00a0EPITELIALES \u00a0BENIGNAS \u00a0\u00a0\n\u2219\u00a0ADENOSIS \u00a0\u00a0\n\u2010ADENOSIS \u00a0ESCLEROSANTE \u00a0\u00a0\n\u2010ADENOSIS \u00a0APOCRINA \u00a0\u00a0\n\u2010ADENOSIS \u00a0DE\u00a0DUCTOS\u00a0ROMOS\u00a0\n\u2010ADENOSIS \u00a0MICROGLANDULAR \u00a0\n\u2010ADENOSIS \u00a0ADENOMIOEPITELIAL \u00a0\n\u2219\u00a0ADENOMAS \u00a0\u00a0\n\u2010ADENOMA \u00a0TUBULAR \u00a0\u00a0\n\u2010ADENOMA \u00a0DE\u00a0LA\u00a0LACTANCIA \u00a0\u00a0\n\u2010ADENOMA \u00a0APOCRINO \u00a0\u00a0\n\u2010ADENOMA \u00a0PLEOMORFICO \u00a0\u00a0\n\u2010ADENOMA \u00a0DUCTAL\u00a0\n\u00a0\u2219\u00a0CICATRIZ\u00a0RADIAL/LESION \u00a0ESCLEROSANTE \u00a0COMPLEJA \u00a0\u00a0\n\u00a0\nLESIONES \u00a0MIOEPITELIALES \u00a0\u00a0\nMIOEPITELIOSIS \u00a0\u00a0\n\u2010INTRADUCTAL \u00a0\u00a0\n\u2010PERIDUCTAL \u00a0\u00a0\nADENOSIS \u00a0ADENOMIOEPITELIAL\nADENOMIOEPITELIOMA \u00a0BENIGNO \u00a0\u00a0\n\u00a0TUMORES \u00a0MESENQUIMALES \u00a0\u00a0\nTUMORES \u00a0VASCULARES \u00a0BENIGNOS \u00a0\u00a0\n\u2010HEMANGIOMA \u00a0\u00a0\n\u2010ANGIOMATOSIS \u00a0(ANGIOMA \u00a0DIFUSO)\u00a0\u2010\nHEMANGIOPERICITOMA \u00a0\u00a0\n\u2010HIPERPLASIA \u00a0ESTROMAL \u00a0PSEUDOANGIOMATOSA \u00a0(H.E.P.A.) \u00a0\nTUMORES \u00a0DE\u00a0ESTIRPE\u00a0NEURAL\u00a0\u00a0\n\u2010NEUROFIBROMA \u00a0\u00a0\n\u2010SCHWANNOMA \u00a0(NEURILENOMA) \u00a0\u00a0\nLIPOMA\u00a0\u00a0\n\u2010ANGIOLIPOMA \u00a0\u00a0\nLEIOMIOMA \u00a0\u00a0\nMIOFIBROBLASTOMA \u00a0\u00a0\nFIBROMATOSIS \u00a0AGRESIVA \u00a0(TUMOR\u00a0DESMOIDE \u00a0\nEXTRAABDOMINAL) \u00a0\u00a0\nTUMOR\u00a0MIOFIBROBLASTICO \u00a0INFLAMATORIO \u00a0(TUMOR\u00a0DE\u00a0\nC\u00c9LULAS\u00a0PLASM\u00c1TICAS) \u00a0\u00a0\nTUMOR\u00a0DE\u00a0C\u00c9LULAS\u00a0GRANULARES \u00a0\u00a0\n\u00a0\nTUMORES \u00a0DEL\u00a0PEZ\u00d3N\u00a0\u00a0\nADENOMA \u00a0DEL\u00a0PEZ\u00d3N\u00a0\u00a0\nADENOMA \u00a0SYRINGOMATOSO \u00a0DEL\u00a0PEZ\u00d3N\u00a0\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n17\u00a0\n\u00a0Tabla\u00a02.\u00a0Clasificaci\u00f3n \u00a0histol\u00f3gica \u00a0del\u00a0carcinoma \u00a0de\u00a0mama\u00a0\n\u00a0\nLa\u00a0clasificaci\u00f3n \u00a0patol\u00f3gica \u00a0del\u00a0CDIS\u00a0se\u00a0basa\u00a0en\u00a0el\u00a0\ngrado\u00a0nuclear\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0(bajo,\u00a0\nintermedio \u00a0o\u00a0alto)\u00a0y\u00a0en\u00a0el\u00a0patr\u00f3n\u00a0arquitect\u00f3nico \u00a0\nde\u00a0crecimiento \u00a0tumoral.\u00a0En\u00a0este\u00a0segundo\u00a0caso\u00a0el\u00a0\nCDIS\u00a0se\u00a0divide\u00a0principalmente \u00a0en\u00a04\u00a0tipos28:\u00a0\u00a0\n\u2010S\u00f3lido :\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas \u00a0llenan\u00a0\ncompletamente \u00a0el\u00a0conducto. \u00a0Si\u00a0hay\u00a0una\u00a0variaci\u00f3n\u00a0\ncorrespondiente \u00a0en\u00a0los\u00a0n\u00facleos\u00a0o\u00a0evidencia \u00a0de\u00a0\nnecrosis\u00a0los\u00a0patrones\u00a0de\u00a0crecimiento \u00a0s\u00f3lidos\u00a0son\u00a0\nde\u00a0alto\u00a0grado\u00a0dentro\u00a0del\u00a0CDIS\u00a0(Fig.\u00a03.1).\u00a0\n\u2010Comedo\u00a0necrosis :\u00a0el\u00a0conducto \u00a0mamario\u00a0est\u00e1\u00a0\nrepleto\u00a0de\u00a0c\u00e9lulas\u00a0y\u00a0se\u00a0caracteriza \u00a0por\u00a0tener\u00a0una\u00a0\nmasa\u00a0central\u00a0de\u00a0c\u00e9lulas\u00a0necr\u00f3ticas. \u00a0Debido\u00a0a\u00a0un\u00a0\nr\u00e1pido\u00a0crecimiento \u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0centrales\u00a0no\u00a0\nreciben\u00a0suficiente \u00a0alimento\u00a0y\u00a0mueren.\u00a0Se\u00a0clasifican\u00a0\ncomo\u00a0CDIS\u00a0de\u00a0alto\u00a0grado\u00a0con\u00a0alto\u00a0riesgo\u00a0de\u00a0\nprogresi\u00f3n \u00a0(Fig.\u00a03.2).\u00a0\n\u2010Cribiforme :\u00a0es\u00a0s\u00f3lido\u00a0y\u00a0afecta\u00a0a\u00a0todo\u00a0el\u00a0conducto. \u00a0\nSe\u00a0caracteriza \u00a0por\u00a0tener\u00a0espacios\u00a0entre\u00a0las\u00a0c\u00e9lulas\u00a0\nque\u00a0llenan\u00a0el\u00a0ducto\u00a0con\u00a0una\u00a0apariencia \u00a0similar\u00a0a\u00a0\n\u201cagujeros\u201d. \u00a0Un\u00a0patr\u00f3n\u00a0cribiforme \u00a0es\u00a0considerado \u00a0\nde\u00a0grado\u00a0bajo\u00a0o\u00a0medio\u00a0(Fig.\u00a03.3).\u00a0\u2010Micropapilar :\u00a0en\u00a0el\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0rodean\u00a0la\u00a0\nperiferia\u00a0del\u00a0conducto \u00a0formando \u00a0peque\u00f1as \u00a0filas\u00a0de\u00a0\nc\u00e9lulas\u00a0epiteliales \u00a0sin\u00a0trama\u00a0fibrovascular. \u00a0Puede\u00a0\nmostrar\u00a0un\u00a0patr\u00f3n\u00a0de\u00a0peque\u00f1as \u00a0protuberancias \u00a0\nsimilares\u00a0a\u00a0dedos\u00a0con\u00a0los\u00a0extremos \u00a0bulbosos, \u00a0que\u00a0\npueden\u00a0formar\u00a0arcos.\u00a0La\u00a0presencia \u00a0de\u00a0este\u00a0CDIS\u00a0\nest\u00e1\u00a0relacionada \u00a0con\u00a0un\u00a0alto\u00a0grado\u00a0de\u00a0malignidad, \u00a0\ny\u00a0es\u00a0de\u00a0mayor\u00a0riesgo\u00a0(Fig.\u00a03.4).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a03.\u00a0Patr\u00f3n\u00a0arquitect\u00f3nico \u00a0del\u00a0CDIS.\u00a0El\u00a0CDIS\u00a0puede\u00a0\npresentarse \u00a0principalmente \u00a0en\u00a04\u00a0tipos\u00a0histol\u00f3gicos \u00a0distintos: \u00a0\n1.\u00a0Solido\u00a0(A:\u00a0c\u00e9lulas\u00a0tumorales, \u00a0B:\u00a0membrana \u00a0basal),\u00a02.\u00a0\nComedo\u00a0necrosis\u00a0(A:\u00a0c\u00e9lulas\u00a0tumorales, \u00a0B:\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nen\u00a0apoptosis, \u00a0C:\u00a0debris\u00a0celular\u00a0y\u00a0D:\u00a0membrana \u00a0basal),\u00a03.\u00a0\nCribiforme \u00a0(A:\u00a0c\u00e9lulas\u00a0tumorales, \u00a0\nB:\u00a0membrana \u00a0basal\u00a0y\u00a0C:\u00a0\nlumen),\u00a0y\u00a04.\u00a0Micropapilar \u00a0(A:\u00a0c\u00e9lulas\u00a0tumorales, \u00a0B:\u00a0membrana \u00a0\nbasal\u00a0y\u00a0C:\u00a0lumen).\u00a0Im\u00e1genes \u00a0de\u00a0H&E\u00a0obtenidas \u00a0de\u00a0distintas\u00a0\nfuentes28,29.\u00a0\nEsta\u00a0proliferaci\u00f3n \u00a0incontrolada \u00a0de\u00a0c\u00e9lulas\u00a0que\u00a0\nllena\u00a0total\u00a0o\u00a0parcialmente \u00a0la\u00a0luz\u00a0de\u00a0los\u00a0conductos \u00a0y\u00a0\nse\u00a0denomina \u00a0CDIS\u00a0contiene\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0\ncambios\u00a0que\u00a0se\u00a0encuentran \u00a0en\u00a0c\u00e1nceres\u00a0\navanzados, \u00a0 como\u00a0 cambios\u00a0 gen\u00e9ticos, \u00a0\nsobreexpresi\u00f3n \u00a0de\u00a0oncogenes \u00a0o\u00a0desregulaci\u00f3n \u00a0del\u00a0\nciclo\u00a0celular\u00a0(Fig.\u00a04).\u00a0\n\u00a01.\u00a0Tumores\u00a0epiteliales \u00a0malignos: \u00a0\n1.1\u00a0Carcinoma \u00a0in\u00a0situ:\u00a0\n\u00a0\u2010Carcinoma \u00a0ductal\u00a0in\u00a0situ\u00a0(CDIS):\u00a0S\u00f3lido,\u00a0comedo\u00a0\nnecrosis,\u00a0cribiforme \u00a0y\u00a0micropapilar. \u00a0\n\u00a0\u2010Carcinoma \u00a0lobular\u00a0in\u00a0situ\u00a0(CLIS).\u00a0\n1.2\u00a0Carcinoma \u00a0invasivo:\u00a0\n\u00a01.2.1\u00a0Carcinoma \u00a0ductal\u00a0invasivo\u00a0(CDI)\u00a0inespec\u00edfico \u00a0\n(Not\u00a0Otherwise \u00a0Specified\u00a0or\u00a0NOS).\u00a0\u00a0\n\u00a01.2.2\u00a0Carcinoma \u00a0ductal\u00a0invasivo\u00a0(CDI)\u00a0espec\u00edfico:\n\u2010Mucinoso \u00a0\n\u2010Tubular\u00a0\n\u2010Papilar\u00a0\n\u2010Adenoide \u00a0qu\u00edstico\u00a0\n\u2010Medular\u00a0\n\u2010Metapl\u00e1sico \u00a0\n\u2010Otros\u00a0(apocrino, \u00a0escamoso, \u00a0de\u00a0c\u00e9lulas\u00a0gigantes\u00a0\nosteoclastoides, \u00a0neuroendocrino, \u00a0entre\u00a0otros).\u00a0\n\u00a01.2.3\u00a0Carcinoma \u00a0lobular\u00a0invasivo\u00a0(CLI).\u00a0\n1.3\u00a0Formas\u00a0especiales \u00a0de\u00a0CM:\u00a0\u00a0\n\u00a0\u2010C\u00e1ncer\u00a0inflamatorio. \u00a0\n\u2010Enfermedad \u00a0de\u00a0Paget\u00a0del\u00a0pez\u00f3n.\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n18\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a04.\u00a0Eventos\u00a0patobiol\u00f3gicos \u00a0asociados \u00a0con\u00a0el\u00a0CDIS.\u00a0Los\u00a0procesos\u00a0moleculares, \u00a0celulares, \u00a0y\u00a0patol\u00f3gicos \u00a0que\u00a0ocurren\u00a0durante\u00a0\nla\u00a0transformaci\u00f3n \u00a0del\u00a0tejido\u00a0sano\u00a0hacia\u00a0las\u00a0lesiones\u00a0preinvasoras \u00a0se\u00a0muestran \u00a0en\u00a0este\u00a0diagrama: \u00a0el\u00a0proceso\u00a0desde\u00a0que\u00a0se\u00a0origina\u00a0\nun\u00a0CDIS\u00a0hasta\u00a0la\u00a0aparici\u00f3n \u00a0del\u00a0CM.\u00a0La\u00a0mayor\u00eda\u00a0de\n\u00a0los\u00a0cambios\u00a0que\u00a0dan\u00a0lugar\u00a0al\u00a0c\u00e1ncer,\u00a0incluyendo \u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0cambios\u00a0\ngen\u00e9ticos, \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0oncogenes \u00a0y\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0la\u00a0regulaci\u00f3n \u00a0normal\u00a0del\u00a0ciclo\u00a0celular,\u00a0parece\u00a0que\u00a0tienen\u00a0lugar\u00a0una\u00a0vez\u00a0que\u00a0\nse\u00a0origina\u00a0el\u00a0CDIS.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0caracter\u00edsticas \u00a0cl\u00ednicas\u00a0de\u00a0un\u00a0CM\u00a0invasivo\u00a0ya\u00a0est\u00e1n\u00a0determinadas \u00a0en\u00a0esta\u00a0etapa,\u00a0aunque\u00a0son\u00a0\nlos\u00a0eventos\u00a0adicionales, \u00a0incluyendo \u00a0la\u00a0invasi\u00f3n\u00a0de\u00a0los\u00a0tejidos\u00a0y\u00a0los\u00a0cambios\u00a0en\u00a0el\u00a0estroma\u00a0circundante, \u00a0lo\u00a0que\u00a0caracteriza \u00a0dicho\u00a0\ntumor\u00a0invasivo.\u00a0Imagen\u00a0obtenida\u00a0de27.\u00a0\nEl\u00a0carcinoma \u00a0lobulillar\u00a0in\u00a0situ\u00a0(CLIS)\u00a0es\u00a0una\u00a0lesi\u00f3n\u00a0\ninvasiva\u00a0que\u00a0se\u00a0inicia\u00a0en\u00a0los\u00a0lobulillos\u00a0y\u00a0los\u00a0\nconductos \u00a0terminales \u00a0de\u00a0mama\u00a0descrito\u00a0por\u00a0\nprimera\u00a0vez\u00a0por\u00a0Foote\u00a0y\u00a0Stewart\u00a0en\u00a0194130.\u00a0El\u00a0\nnombre\u00a0fue\u00a0elegido\u00a0para\u00a0poner\u00a0de\u00a0relieve\u00a0las\u00a0\nsimilaridades \u00a0entre\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0carcinoma \u00a0\nlobulillar\u00a0in\u00a0situ\u00a0y\u00a0las\u00a0del\u00a0carcinoma \u00a0lobular\u00a0\ninvasivo\u00a0(Fig.\u00a05).\u00a0El\u00a0CLIS\u00a0se\u00a0caracteriza \u00a0por\u00a0una\u00a0\nproliferaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0generalmente \u00a0peque\u00f1as \u00a0y\u00a0\ncon\u00a0una\u00a0ligera\u00a0cohesividad. \u00a0Se\u00a0origina\u00a0en\u00a0la\u00a0ULDT\u00a0\ncon\u00a0o\u00a0sin\u00a0afectaci\u00f3n \u00a0de\u00a0los\u00a0conductos \u00a0terminales24.\u00a0\nEl\u00a0t\u00e9rmino\u00a0hiperplasia \u00a0lobular\u00a0at\u00edpica\u00a0(HLA)\u00a0fue\u00a0\nacu\u00f1ado\u00a0para\u00a0describir\u00a0las\u00a0lesiones\u00a0que\u00a0estaban\u00a0\nmenos\u00a0desarrollados \u00a0que\u00a0el\u00a0CLIS\u00a0y\u00a0se\u00a0utiliza\u00a0\ncuando\u00a0est\u00e1n\u00a0afectadas \u00a0unidades\u00a0ducto\u2010lobulares \u00a0\nterminales \u00a0pero\u00a0\u00e9stas\u00a0no\u00a0est\u00e1n\u00a0completamente \u00a0\ndistendidas, \u00a0o\u00a0cuando\u00a0l\u00famenes\u00a0residuales \u00a0est\u00e1n\u00a0presentes. \u00a0El\u00a0t\u00e9rmino\u00a0neoplasia \u00a0lobular\u00a0es\u00a0un\u00a0\nt\u00e9rmino\u00a0gen\u00e9rico\u00a0que\u00a0engloba\u00a0estas\u00a0dos\u00a0\ncategor\u00edas31.\u00a0Si\u00a0el\u00a050%\u00a0o\u00a0m\u00e1s\u00a0de\u00a0los\u00a0acinos\u00a0se\u00a0\nexpanden \u00a0o\u00a0distorsionan \u00a0por\u00a0c\u00e9lulas\u00a0lobulares, \u00a0un\u00a0\ndiagn\u00f3stico \u00a0de\u00a0CLIS\u00a0se\u00a0ve\u00a0favorecido. \u00a0Las\u00a0lesiones\u00a0\nque\u00a0no\u00a0se\u00a0ajusten\u00a0a\u00a0estos\u00a0criterios\u00a0se\u00a0colocan\u00a0en\u00a0la\u00a0\ncategor\u00eda \u00a0de\u00a0ALH.\u00a0\nSe\u00a0ha\u00a0descrito\u00a0que\u00a0los\u00a0subtipos\u00a0de\u00a0CLIS\u00a0se\u00a0asocian\u00a0\na\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0ER\u00a0y\u00a0de\u00a0PR\u00a0(60\u201090%\u00a0de\u00a0los\u00a0casos\u00a0\npositivos). \u00a0Las\u00a0c\u00e9lulas\u00a0de\u00a0este\u00a0tipo\u00a0de\u00a0neoplasia \u00a0\nlobular\u00a0tambi\u00e9n\u00a0se\u00a0caracterizan \u00a0por\u00a0falta\u00a0de\u00a0\nexpresi\u00f3n \u00a0de\u00a0E\u2010cadherina, \u00a0una\u00a0mol\u00e9cula\u00a0de\u00a0la\u00a0\nmembrana \u00a0celular\u00a0epitelial\u00a0implicada \u00a0en\u00a0la\u00a0\nadhesi\u00f3n\u00a0c\u00e9lula\u2010c\u00e9lula.\u00a0Las\u00a0c\u00e9lulas\u00a0de\u00a0CLIS\u00a0cl\u00e1sicas\u00a0\nno\u00a0suelen\u00a0mostrar\u00a0amplificaci\u00f3n \u00a0o\u00a0expresi\u00f3n \u00a0de\u00a0\nHER2,\u00a0y\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0TP53\u00a0es\u00a0poco\u00a0frecuente32.\u00a0\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n19\u00a0\n\u00a0Figura\u00a05.\u00a0Carcinoma \u00a0lobular\u00a0in\u00a0situ.\u00a0El\u00a0CLIS\u00a0es\u00a0una\u00a0lesi\u00f3n\u00a0no\u00a0\npalpable\u00a0que\u00a0suele\u00a0ser\u00a0un\u00a0hallazgo\u00a0incidental \u00a0en\u00a0los\u00a0senos\u00a0\nremovidos \u00a0por\u00a0otras\u00a0razones.\u00a0Los\u00a0l\u00f3bulos\u00a0est\u00e1n\u00a0distendidos \u00a0\ncon\u00a0c\u00e9lulas\u00a0ovaladas\u00a0o\u00a0uniformes, \u00a0de\u00a0tama\u00f1o\u00a0mediano. \u00a0Los\u00a0\nn\u00facleos\u00a0son\u00a0uniformes \u00a0y\u00a0normocrom\u00e1ticos. \u00a0Pero\u00a0hay\u00a0que\u00a0\ndestacar\u00a0que\u00a0la\u00a0expansi\u00f3n \u00a0lobular\u00a0no\u00a0es\u00a0un\u00a0criterio\u00a0absoluto, \u00a0\nsobre\u00a0todo\u00a0en\u00a0mujeres\u00a0post\u2010menop\u00e1usicas. \u00a0Im\u00e1gen\u00a0de\u00a0H&E\u00a0\nobtenidas \u00a0de\u00a0distintas\u00a0fuentes28,29.\u00a0\nEs\u00a0raro\u00a0que\u00a0CLIS\u00a0se\u00a0convierta \u00a0en\u00a0CM,\u00a0sin\u00a0embargo, \u00a0\ns\u00ed\u00a0que\u00a0hay\u00a0un\u00a0aumento\u00a0en\u00a0el\u00a0riesgo.\u00a0En\u00a0\ncomparaci\u00f3n \u00a0con\u00a0las\u00a0mujeres\u00a0sin\u00a0CLIS,\u00a0aquellas\u00a0\nque\u00a0son\u00a0diagnosticadas \u00a0con\u00a0esta\u00a0neoplasia \u00a0tienen\u00a0\nentre\u00a0siete\u00a0y\u00a012\u00a0veces\u00a0m\u00e1s\u00a0probabilidades \u00a0de\u00a0\ndesarrollar \u00a0c\u00e1ncer\u00a0en\u00a0cualquiera \u00a0de\u00a0las\u00a0mamas33.\u00a0\nAproximadamente \u00a0de\u00a0un\u00a020%\u00a0a\u00a0un\u00a030%\u00a0de\u00a0los\u00a0\npacientes \u00a0desarrollan \u00a0carcinoma \u00a0invasivo\u00a0en\u00a0\nausencia\u00a0de\u00a0terapia.\u00a0Las\u00a0mujeres\u00a0con\u00a0CLIS\u00a0pueden\u00a0\ndesarrollar \u00a0c\u00e1ncer\u00a0lobular\u00a0invasivo\u00a0o\u00a0c\u00e1ncer\u00a0ductal\u00a0\ninvasivo\u00a0(CDI)34\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0contraer\u00a0\u00e9ste\u00a0\u00faltimo\u00a0\nes\u00a0de\u00a0aproximadamente \u00a0de\u00a0un\u00a00,5\u20101,0%\u00a0por\u00a0a\u00f1o35.\u00a0\nPor\u00a0otro\u00a0lado\u00a0encontramos \u00a0los\u00a0c\u00e1nceres\u00a0de\u00a0mama\u00a0\ninvasivos, \u00a0que\u00a0son\u00a0un\u00a0grupo\u00a0heterog\u00e9neo \u00a0de\u00a0\ntumores\u00a0que\u00a0muestran \u00a0una\u00a0amplia\u00a0variaci\u00f3n\u00a0con\u00a0\nrespecto\u00a0 a\u00a0 su\u00a0 presentaci\u00f3n \u00a0 cl\u00ednica,\u00a0\ncomportamiento, \u00a0y\u00a0espectro\u00a0morfol\u00f3gico. \u00a0Por\u00a0lo\u00a0\nmenos\u00a018\u00a0diferentes \u00a0tipos\u00a0histol\u00f3gicos \u00a0de\u00a0CM\u00a0son\u00a0\nlos\u00a0descritos\u00a0por\u00a0la\u00a0Organizaci\u00f3n \u00a0Mundial\u00a0de\u00a0la\u00a0\nSalud\u00a0(OMS)24.\u00a0El\u00a0carcinoma \u00a0ductal\u00a0invasivo\u00a0no\u00a0\nespec\u00edfico \u00a0(CDI\u00a0NOS)\u00a0representa \u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0\nde\u00a0los\u00a0c\u00e1nceres\u00a0de\u00a0mama,\u00a0es\u00a0decir\u00a0el\u00a050\u201080%.\u00a0La\u00a0\nOMS\u00a0lo\u00a0define\u00a0como\u00a0un\u00a0tumor\u00a0que\u00a0no\u00a0presenta\u00a0\nsuficientes \u00a0caracter\u00edsticas \u00a0morfol\u00f3gicas \u00a0para\u00a0ser\u00a0\nclasificado \u00a0en\u00a0uno\u00a0de\u00a0los\u00a0tipos\u00a0histol\u00f3gicos \u00a0\nespeciales24.\u00a0Aproximadamente \u00a0el\u00a025%\u00a0de\u00a0los\u00a0c\u00e1nceres\u00a0de\u00a0mama\u00a0invasivos\u00a0son\u00a0reconocidos \u00a0\ncomo\u00a0\"tipos\u00a0especiales\", \u00a0y\u00a0se\u00a0caracteriza \u00a0por\u00a0\npatrones\u00a0de\u00a0crecimiento \u00a0distintivos \u00a0y\u00a0\ncaracter\u00edsticas \u00a0citol\u00f3gicas24,36,37\u00a0(Tabla\u00a02).\u00a0Sin\u00a0\nembargo, \u00a0los\u00a0carcinomas \u00a0de\u00a0tipo\u00a0especial\u00a0a\u00a0\nmenudo\u00a0no\u00a0son\u00a0reconocidos \u00a0como\u00a0tales\u00a0en\u00a0el\u00a0\nexamen\u00a0patol\u00f3gico, \u00a0y\u00a0se\u00a0agrupan\u00a0con\u00a0los\u00a0NOS\u00a0de\u00a0\nCDI.\u00a0\u00a0\nEl\u00a0carcinoma \u00a0ductal\u00a0invasivo\u00a0no\u00a0especifico \u00a0(CDI\u00a0\nNOS)\u00a0es\u00a0el\u00a0tumor\u00a0maligno\u00a0de\u00a0mama\u00a0m\u00e1s\u00a0\nfrecuente, \u00a0y\u00a0comprende \u00a0un\u00a0grupo\u00a0de\u00a0lesiones\u00a0\nhistol\u00f3gicamente \u00a0heterog\u00e9neas. \u00a0El\u00a0CDI\u00a0comienza \u00a0\nen\u00a0los\u00a0conductos \u00a0l\u00e1cteos\u00a0de\u00a0las\u00a0mamas\u00a0e\u00a0invade\u00a0el\u00a0\ntejido\u00a0circundante \u00a0del\u00a0seno.\u00a0\u00c9ste\u00a0muestra\u00a0una\u00a0\nenorme\u00a0variaci\u00f3n\u00a0en\u00a0la\u00a0morfolog\u00eda \u00a0celular\u00a0y\u00a0en\u00a0los\u00a0\npatrones\u00a0de\u00a0proliferaci\u00f3n. \u00a0En\u00a0general\u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0\ndisponen\u00a0en\u00a0islotes,\u00a0cordones \u00a0y\u00a0formaciones \u00a0\nglandulares. \u00a0Es\u00a0sin\u00a0duda\u00a0el\u00a0m\u00e1s\u00a0com\u00fan\u00a0de\u00a0los\u00a0tipos\u00a0\nhistol\u00f3gicos \u00a0(aproximadamente \u00a0del\u00a065\u00a0al\u00a085%\u00a0de\u00a0\nlos\u00a0c\u00e1nceres\u00a0de\u00a0mama)\u00a0y\u00a0se\u00a0caracteriza \u00a0por\u00a0la\u00a0\nausencia\u00a0de\u00a0caracter\u00edsticas \u00a0histol\u00f3gicas \u00a0especiales. \u00a0\nEstos\u00a0tumores\u00a0son\u00a0duros\u00a0a\u00a0la\u00a0palpaci\u00f3n \u00a0y\u00a0\nhabitualmente \u00a0metastatizan \u00a0a\u00a0los\u00a0ganglios\u00a0\nlinf\u00e1ticos\u00a0axilares,\u00a0lo\u00a0que\u00a0implica\u00a0un\u00a0peor\u00a0\npron\u00f3stico \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0otros\u00a0tipos\u00a0\nhistol\u00f3gicos. \u00a0\n\u00a0\nEl\u00a0carcinoma \u00a0ductal\u00a0invasivo\u00a0espec\u00edfico \u00a0est\u00e1\u00a0\nenumerado \u00a0en\u00a0un\u00a0orden\u00a0aproximado \u00a0de\u00a0mejor\u00a0a\u00a0\npeor\u00a0pron\u00f3stico \u00a0en\u00a0la\u00a0Tabla\u00a02,\u00a0todos\u00a0ellos\u00a0con\u00a0\nmejor\u00a0pron\u00f3stico \u00a0que\u00a0el\u00a0ductal\u00a0invasivo\u00a0tipo\u00a0NOS,\u00a0\nya\u00a0que\u00a0al\u00a0adoptar\u00a0caracter\u00edsticas \u00a0histol\u00f3gicas \u00a0\ndeterminadas \u00a0reflejan\u00a0una\u00a0mejor\u00a0diferenciaci\u00f3n, \u00a0\nlo\u00a0que\u00a0se\u00a0acompa\u00f1a \u00a0de\u00a0un\u00a0comportamiento \u00a0\nbiol\u00f3gico\u00a0menos\u00a0agresivo38.\u00a0Adem\u00e1s,\u00a0el\u00a0tipo\u00a0\nlobulillar\u00a0invasor\u00a0presenta\u00a0mejor\u00a0pron\u00f3stico \u00a0que\u00a0el\u00a0\nductal\u00a0tipo\u00a0NOS,\u00a0pero\u00a0peor\u00a0que\u00a0el\u00a0de\u00a0los\u00a0ductales\u00a0\nespec\u00edficos. \u00a0Se\u00a0divide\u00a0principalmente \u00a0en\u00a06\u00a0tipos\u00a0\n(Fig.\u00a06):\u00a0\n\u00a0\n\u2022\u00a0Carcinoma \u00a0mucinoso \u00a0o\u00a0coloide :\u00a0Este\u00a0ocurre\u00a0\ncuando\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas \u00a0de\u00a0la\u00a0mama\u00a0\nproducen \u00a0moco,\u00a0el\u00a0cual\u00a0a\u00a0su\u00a0vez\u00a0tambi\u00e9n\u00a0contiene\u00a0\nlas\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0y\u00a0ambos\u00a0y\u00a0se\u00a0combinan \u00a0para\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n20\u00a0\n\u00a0formar\u00a0un\u00a0tumor.\u00a0El\u00a0carcinoma \u00a0mucinoso \u00a0ductal\u00a0\npuro\u00a0tiene\u00a0un\u00a0mejor\u00a0pron\u00f3stico \u00a0que\u00a0los\u00a0tipos\u00a0m\u00e1s\u00a0\ncomunes\u00a0de\u00a0CDI.\u00a0\n\u2022\u00a0Carcinoma \u00a0tubular :\u00a0Este\u00a0es\u00a0un\u00a0diagn\u00f3stico \u00a0poco\u00a0\nfrecuente \u00a0de\u00a0CDI,\u00a0lo\u00a0que\u00a0representa \u00a0s\u00f3lo\u00a02%\u00a0de\u00a0los\u00a0\ndiagn\u00f3sticos \u00a0de\u00a0CM.\u00a0El\u00a0carcinoma \u00a0ductal\u00a0tubular\u00a0\nes\u00a0m\u00e1s\u00a0com\u00fan\u00a0en\u00a0mujeres\u00a0mayores\u00a0de\u00a050\u00a0a\u00f1os,\u00a0\nson\u00a0generalmente \u00a0peque\u00f1os, \u00a0y\u00a0son\u00a0RE\u00a0positivos\u00a0\n(lo\u00a0que\u00a0significa\u00a0que\u00a0responden \u00a0a\u00a0las\u00a0terapias\u00a0\nhormonales). \u00a0Este\u00a0tipo\u00a0de\u00a0tumor\u00a0es\u00a0un\u00a0carcinoma \u00a0\ninvasor\u00a0y\u00a0bien\u00a0diferenciado. \u00a0Macrosc\u00f3picamente, \u00a0\nla\u00a0lesi\u00f3n\u00a0es\u00a0peque\u00f1a, \u00a0con\u00a0m\u00e1rgenes \u00a0infiltrativos \u00a0y\u00a0\nde\u00a0consistencia \u00a0dura.\u00a0Microsc\u00f3picamente, \u00a0est\u00e1\u00a0\ncompuesto \u00a0por\u00a0gl\u00e1ndulas \u00a0bien\u00a0definidas, \u00a0con\u00a0\ncontornos \u00a0redondeados \u00a0ovales\u00a0o\u00a0angulados, \u00a0\nlumen\u00a0abierto,\u00a0ausencia\u00a0de\u00a0capas\u00a0de\u00a0c\u00e9lulas\u00a0\nmioepiteliales \u00a0y\u00a0ausencia\u00a0tambi\u00e9n\u00a0de\u00a0necrosis\u00a0o\u00a0\nmitosis.\u00a0\n\u2022\u00a0Carcinoma \u00a0papilar :\u00a0Los\u00a0carcinomas \u00a0papilares\u00a0\nrepresentan \u00a0del\u00a01%\u00a0al\u00a02%\u00a0de\u00a0los\u00a0carcinomas \u00a0de\u00a0\nmama\u00a0en\u00a0las\u00a0mujeres.\u00a0Bajo\u00a0el\u00a0microscopio, \u00a0se\u00a0ve\u00a0\ncomo\u00a0peque\u00f1os \u00a0dedos.\u00a0S\u00f3lo\u00a0en\u00a0raras\u00a0ocasiones, \u00a0\neste\u00a0tipo\u00a0de\u00a0c\u00e1ncer\u00a0se\u00a0convierte \u00a0en\u00a0invasivo.\u00a0El\u00a0\ncarcinoma \u00a0papilar\u00a0ocurre\u00a0con\u00a0mayor\u00a0frecuencia \u00a0en\u00a0\nancianas\u00a0o\u00a0mujeres\u00a0post\u2010menop\u00e1usicas, \u00a0y\u00a0\ncom\u00fanmente \u00a0se\u00a0presenta\u00a0como\u00a0un\u00a0tumor\u00a0\nmoderado \u00a0o\u00a0de\u00a0\"grado\u00a02\"\u00a0en\u00a0t\u00e9rminos\u00a0de\u00a0\nagresividad \u00a0y\u00a0a\u00a0veces\u00a0es\u00a0tratado\u00a0como\u00a0carcinoma \u00a0\nductal\u00a0in\u00a0situ,\u00a0a\u00a0pesar\u00a0de\u00a0ser\u00a0un\u00a0c\u00e1ncer\u00a0invasivo.\u00a0\n\u2022\u00a0Carcinoma \u00a0adenoide \u00a0qu\u00edstico :\u00a0El\u00a0carcinoma \u00a0\nadenoide \u00a0qu\u00edstico\u00a0(CAQ)\u00a0es\u00a0un\u00a0tipo\u00a0de\u00a0\nadenocarcinoma \u00a0infiltrante \u00a0de\u00a0mama\u00a0muy\u00a0poco\u00a0\nfrecuente, \u00a0que\u00a0representa \u00a0alrededor \u00a0del\u00a00.1%\u00a0de\u00a0\ntodos\u00a0los\u00a0carcinomas \u00a0mamarios38.\u00a0Al\u00a0parecer\u00a0tiene\u00a0\nun\u00a0pron\u00f3stico \u00a0m\u00e1s\u00a0favorable \u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0\notras\u00a0formas\u00a0de\u00a0CM39.\u00a0\n\u2022\u00a0Carcinoma \u00a0medular :\u00a0Este\u00a0tipo\u00a0de\u00a0c\u00e1ncer\u00a0es\u00a0poco\u00a0\nfrecuente \u00a0y\u00a0s\u00f3lo\u00a0de\u00a0un\u00a03\u00a0a\u00a0un\u00a05%\u00a0de\u00a0los\u00a0CM\u00a0son\u00a0\ndiagnosticados \u00a0como\u00a0carcinoma \u00a0ductal\u00a0medular.\u00a0\nEl\u00a0tumor\u00a0suele\u00a0aparecer\u00a0en\u00a0las\u00a0mamograf\u00edas \u00a0pero\u00a0\nno\u00a0siempre\u00a0aparece\u00a0como\u00a0una\u00a0masa\u00a0o\u00a0bulto,\u00a0sino\u00a0\nque\u00a0puede\u00a0mostrarse \u00a0como\u00a0un\u00a0cambio\u00a0de\u00a0\nesponjosidad \u00a0del\u00a0tejido\u00a0mamario. \u00a0Una\u00a0caracter\u00edstica \u00a0de\u00a0este\u00a0tumor\u00a0es\u00a0que\u00a0tiene\u00a0un\u00a0\nestroma\u00a0muy\u00a0escaso.\u00a0Este\u00a0tipo\u00a0de\u00a0c\u00e1ncer\u00a0tiene\u00a0\nuna\u00a0gran\u00a0infiltraci\u00f3n \u00a0linfoidea\u00a0que\u00a0ocupa\u00a0el\u00a0\nestroma\u00a0intratumoral \u00a0y\u00a0que,\u00a0por\u00a0su\u00a0aspecto,\u00a0da\u00a0el\u00a0\nnombre\u00a0de\u00a0\u201cmedular\u201d \u00a0al\u00a0tumor.\u00a0\n\u2022\u00a0Carcinoma \u00a0metapl\u00e1sico :\u00a0Son\u00a0un\u00a0grupo\u00a0\nheterog\u00e9neo \u00a0de\u00a0lesiones\u00a0malignas\u00a0que\u00a0\ncomprenden \u00a0<5%\u00a0de\u00a0todos\u00a0los\u00a0CM\u00a0invasivos38,40,41.\u00a0\nLa\u00a0caracter\u00edstica \u00a0com\u00fan\u00a0de\u00a0estos\u00a0tumores\u00a0es\u00a0la\u00a0\npresencia \u00a0de\u00a0una\u00a0poblaci\u00f3n \u00a0celular\u00a0epitelial\u00a0o\u00a0\nmesenquimal \u00a0mezclada \u00a0con\u00a0adenocarcinoma. \u00a0Se\u00a0\ncaracteriza \u00a0por\u00a0la\u00a0presencia \u00a0de\u00a0c\u00e9lulas\u00a0escamosas \u00a0\no\u00a0fusiformes, \u00a0entre\u00a0otras.\u00a0En\u00a0comparaci\u00f3n \u00a0con\u00a0los\u00a0\ntipos\u00a0m\u00e1s\u00a0comunes\u00a0de\u00a0CM,\u00a0los\u00a0tumores\u00a0\nmetapl\u00e1sicos \u00a0tienden\u00a0a\u00a0ser\u00a0mayores,\u00a0tener\u00a0un\u00a0\ntumor\u00a0de\u00a0grado\u00a0m\u00e1s\u00a0alto\u00a0y\u00a0ser\u00a0RE\u00a0y\u00a0HER2\u00a0\nnegativos42.\u00a0\n\u2022\u00a0 Carcinoma \u00a0 apocrino :\u00a0 Representan \u00a0\naproximadamente \u00a0el\u00a00,4%\u00a0de\u00a0todos\u00a0los\u00a0CM\u00a0\ninvasivos43.\u00a0Siguen\u00a0siendo\u00a0inciertos\u00a0los\u00a0criterios\u00a0\ndefinitivos \u00a0para\u00a0el\u00a0diagn\u00f3stico \u00a0mediante \u00a0histolog\u00eda \u00a0\nde\u00a0este\u00a0tipo\u00a0de\u00a0carcinomas. \u00a0Suelen\u00a0ser\u00a0RE\u00a0y\u00a0RP\u00a0\nnegativo, \u00a0pero\u00a0positivos\u00a0para\u00a0receptores \u00a0de\u00a0\nandr\u00f3genos \u00a0(AR).\u00a0\nEl\u00a0carcinoma \u00a0lobulillar\u00a0invasivo\u00a0(CLI)\u00a0es\u00a0el\u00a0\nsegundo\u00a0tipo\u00a0m\u00e1s\u00a0com\u00fan\u00a0de\u00a0CM\u00a0invasivo,\u00a0\nrepresenta \u00a0de\u00a0un\u00a08%\u00a0a\u00a0un\u00a014%\u00a0de\u00a0los\u00a0casos\u00a0\ninvasivos\u00a0y\u00a0es\u00a0biol\u00f3gicamente \u00a0muy\u00a0distinto\u00a0del\u00a0\nCDI.\u00a0Est\u00e1\u00a0constituido \u00a0por\u00a0c\u00e9lulas\u00a0uniformes \u00a0y\u00a0\nsimilares\u00a0a\u00a0las\u00a0del\u00a0CLIS\u00a0y,\u00a0generalmente, \u00a0con\u00a0un\u00a0\n\u00edndice\u00a0mit\u00f3tico\u00a0bajo.\u00a0Se\u00a0caracterizan \u00a0por\u00a0ser\u00a0\nmultifocales \u00a0y\u00a0bilaterales44.\u00a0\nA\u00a0nivel\u00a0microsc\u00f3pico \u00a0el\u00a0CLI\u00a0est\u00e1\u00a0formado\u00a0por\u00a0\nc\u00e9lulas\u00a0peque\u00f1as \u00a0generalmente \u00a0dispuestas \u00a0en\u00a0\nhilera\u00a0y\u00a0esta\u00a0forma\u00a0de\u00a0crecimiento \u00a0se\u00a0denomina \u00a0\n\u201cfila\u00a0india\u201d,\u00a0con\u00a0tendencia \u00a0a\u00a0crecer\u00a0tambi\u00e9n\u00a0\nalrededor \u00a0de\u00a0los\u00a0conductos. \u00a0La\u00a0infiltraci\u00f3n \u00a0por\u00a0lo\u00a0\ngeneral\u00a0no\u00a0destruye\u00a0las\u00a0estructuras \u00a0anat\u00f3micas \u00a0ni\u00a0\nincita\u00a0una\u00a0respuesta \u00a0sustancial \u00a0del\u00a0tejido\u00a0\nconectivo. \u00a0\u00a0 En\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0patr\u00f3n\u00a0de\u00a0\ncrecimiento \u00a0distintivo \u00a0y\u00a0de\u00a0su\u00a0biolog\u00eda,\u00a0los\u00a0\ncarcinomas \u00a0lobulares \u00a0a\u00a0menudo\u00a0no\u00a0logranINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n21\u00a0\n\u00a0Figura\u00a06.\u00a0Tipos\u00a0histol\u00f3gicos \u00a0de\u00a0carcinoma \u00a0ductal\u00a0invasivo.\u00a0A.\u00a0Carcinoma \u00a0ductal\u00a0infiltrante, \u00a0grado\u00a0II.\u00a0Las\u00a0c\u00e9lulas\u00a0tumorales \u00a0se\u00a0\ndisponen \u00a0en\u00a0nidos\u00a0y\u00a0en\u00a0c\u00e9lulas\u00a0individuales. \u00a0B.\u00a0Carcinoma \u00a0mucinoso. \u00a0Los\u00a0grupos\u00a0de\u00a0c\u00e9lulas\u00a0pueden\u00a0ser\u00a0s\u00f3lidos\u00a0o\u00a0pueden\u00a0mostrar\u00a0\nformaciones \u00a0acinares.\u00a0C.\u00a0Carcinoma \u00a0tubular.\u00a0Esta\u00a0fotograf\u00eda \u00a0muestra\u00a0la\u00a0disposici\u00f3n \u00a0glandular, \u00a0una\u00a0capa\u00a0de\u00a0c\u00e9lulas\u00a0individuales \u00a0y\u00a0el\u00a0\nlumen\u00a0despejado. \u00a0D.\u00a0Carcinoma \u00a0papilar.\u00a0Se\u00a0observan\u00a0numerosas \u00a0estructuras \u00a0papilares. \u00a0E.\u00a0Carcinoma \u00a0adenoide \u00a0qu\u00edstico.\u00a0El\u00a0tumor\u00a0\nse\u00a0compone \u00a0de\u00a0gl\u00e1ndulas \u00a0proliferantes \u00a0(componente \u00a0adenoideo) \u00a0y\u00a0elementos \u00a0del\u00a0estroma.\u00a0F.\u00a0Carcinoma \u00a0medular.\u00a0El\u00a0tumor\u00a0tiene\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0con\u00a0aspecto\u00a0sincitial\u00a0y\u00a0est\u00e1n\u00a0rodeadas \u00a0por\u00a0un\u00a0infiltrado\u00a0linfoplasmocitario. \u00a0G:\u00a0Carcinoma \u00a0metapl\u00e1sico. \u00a0En\u00a0este\u00a0\ncaso\u00a0el\u00a0tumor\u00a0est\u00e1\u00a0compuesto \u00a0en\u00a0gran\u00a0parte\u00a0por\u00a0c\u00e9lulas\u00a0fusiformes. \u00a0H:\u00a0Carcinoma \u00a0apocrino. \u00a0Sus\u00a0c\u00e9lulas\u00a0tumorales \u00a0tienen\u00a0n\u00facleos\u00a0\nvesiculares, \u00a0nucleolos \u00a0prominentes \u00a0y\u00a0abundante \u00a0citoplasma \u00a0eosin\u00f3filico. \u00a0Im\u00e1genes \u00a0de\u00a0H&E\u00a0obtenidas \u00a0de45.\u00a0\nformar\u00a0masas\u00a0que\u00a0puedan\u00a0ser\u00a0f\u00e1cilmente \u00a0\ndiagnosticadas \u00a0por\u00a0palpaci\u00f3n \u00a0o\u00a0por\u00a0mamograf\u00eda \u00a0\n(Fig.\u00a07).\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a07.\u00a0Carcinoma \u00a0lobulillar\u00a0invasivo.\u00a0Esta\u00a0fotograf\u00eda \u00a0del\u00a0\nCLI\u00a0muestra\u00a0la\u00a0ausencia\u00a0de\u00a0unidades\u00a0s\u00f3lidas,\u00a0alveolares, \u00a0\npapilares, \u00a0o\u00a0unidades\u00a0glandulares. \u00a0Las\u00a0c\u00e9lulas\u00a0tumorales \u00a0se\u00a0\ndisponen \u00a0en\u00a0delgados\u00a0filamentos \u00a0lineales,\u00a0en\u00a0filas\u00a0de\u00a0una\u00a0o\u00a0\ndos\u00a0c\u00e9lulas\u00a0de\u00a0anchura.\u00a0\nEl\u00a0CM\u00a0inflamatorio \u00a0(CMI)\u00a0es\u00a0una\u00a0forma\u00a0rara,\u00a0pero\u00a0\nagresiva\u00a0de\u00a0CM\u00a0localmente \u00a0avanzado. \u00a0Se\u00a0llama\u00a0\nc\u00e1ncer\u00a0inflamatorio \u00a0de\u00a0mama\u00a0debido\u00a0a\u00a0que\u00a0sus\u00a0principales \u00a0s\u00edntomas\u00a0son\u00a0hinchaz\u00f3n \u00a0(inflamaci\u00f3n) \u00a0\ny\u00a0enrojecimiento \u00a0de\u00a0la\u00a0mama.\u00a0Estos\u00a0tumores\u00a0son\u00a0a\u00a0\nmenudo\u00a0RE\u00a0negativos \u00a0y\u00a0HER2\u00a0positivos. \u00a0Debido\u00a0a\u00a0\nque\u00a0estos\u00a0c\u00e1nceres\u00a0de\u00a0mama\u00a0son\u00a0agresivos, \u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0las\u00a0mujeres\u00a0con\u00a0CMI\u00a0tienen\u00a0ganglios\u00a0\nlinf\u00e1ticos\u00a0positivos\u00a0y\u00a0de\u00a0un\u00a025\u00a0a\u00a0un\u00a030%\u00a0tienen\u00a0\nmet\u00e1stasis \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0diagn\u00f3stico46.\u00a0El\u00a0\nCMI\u00a0tambi\u00e9n\u00a0tiende\u00a0a\u00a0tener\u00a0un\u00a0mayor\u00a0\u00edndice\u00a0de\u00a0\nproliferaci\u00f3n \u00a0y\u00a0una\u00a0media\u00a0de\u00a0edad\u00a0menor\u00a0que\u00a0\notros\u00a0c\u00e1nceres\u00a0de\u00a0mama46.\u00a0\u00a0\nLa\u00a0enfermedad \u00a0de\u00a0Paget\u00a0del\u00a0pez\u00f3n\u00a0se\u00a0caracteriza \u00a0\npor\u00a0c\u00e9lulas\u00a0neopl\u00e1sicas \u00a0en\u00a0la\u00a0epidermis \u00a0del\u00a0pez\u00f3n.\u00a0\nEs\u00a0un\u00a0tipo\u00a0poco\u00a0frecuente \u00a0de\u00a0CM\u00a0y\u00a0representa \u00a0\nmenos\u00a0del\u00a05%\u00a0de\u00a0todos\u00a0los\u00a0casos\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0\nseno.\u00a0Puede\u00a0presentarse \u00a0tanto\u00a0en\u00a0las\u00a0mujeres\u00a0\ncomo\u00a0en\u00a0los\u00a0hombres\u00a0y\u00a0ocurre\u00a0con\u00a0m\u00e1s\u00a0frecuencia \u00a0\nen\u00a0personas\u00a0de\u00a050\u00a0a\u00f1os\u00a0de\u00a0edad\u00a0o\u00a0m\u00e1s.\u00a0Las\u00a0\npersonas\u00a0que\u00a0tienen\u00a0la\u00a0enfermedad \u00a0de\u00a0Paget\u00a0del\u00a0\npez\u00f3n\u00a0con\u00a0frecuencia \u00a0tambi\u00e9n\u00a0tienen\u00a0c\u00e1ncer\u00a0en\u00a0\notra\u00a0parte\u00a0la\u00a0mama,\u00a0usualmente \u00a0en\u00a0los\u00a0conductos \u00a0\nmamarios. \u00a0\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n22\u00a0\n\u00a0A\u00a0parte\u00a0de\u00a0la\u00a0divisi\u00f3n\u00a0histol\u00f3gica \u00a0de\u00a0cada\u00a0tipo\u00a0de\u00a0\ncarcinoma \u00a0de\u00a0mama\u00a0tambi\u00e9n\u00a0se\u00a0define\u00a0por\u00a0el\u00a0\ngrado\u00a0histol\u00f3gico. \u00a0El\u00a0grado\u00a0histol\u00f3gico \u00a0es\u00a0un\u00a0factor\u00a0\npron\u00f3stico \u00a0importante \u00a0que\u00a0se\u00a0obtiene\u00a0del\u00a0an\u00e1lisis\u00a0\npatol\u00f3gico \u00a0del\u00a0tumor\u00a0teniendo\u00a0en\u00a0cuenta\u00a0la\u00a0\nformaci\u00f3n \u00a0de\u00a0t\u00fabulos,\u00a0la\u00a0morfolog\u00eda \u00a0nuclear\u00a0y\u00a0el\u00a0\n\u00edndice\u00a0de\u00a0mitosis.\u00a0Al\u00a0ser\u00a0una\u00a0decisi\u00f3n\u00a0subjetiva, \u00a0\npor\u00a0si\u00a0solo,\u00a0no\u00a0sirve\u00a0para\u00a0hacer\u00a0deducciones \u00a0\npron\u00f3sticas \u00a0y\u00a0hay\u00a0que\u00a0a\u00f1adirlo\u00a0a\u00a0otras\u00a0pruebas\u00a0\ncl\u00ednicas.\u00a0Las\u00a0clasificaciones \u00a0m\u00e1s\u00a0utilizadas \u00a0son\u00a0la\u00a0de\u00a0\nScarff\u2010Bloom\u2010Richardson \u00a0(SBR)47.\u00a0La\u00a0Tabla\u00a03\u00a0\nmuestra\u00a0una\u00a0peque\u00f1a\u00a0modificaci\u00f3n \u00a0de\u00a0Elston\u2010\nEllis48\u00a0del\u00a0sistema\u00a0de\u00a0calificaci\u00f3n \u00a0SBR\u00a0(sistema\u00a0de\u00a0\nclasificaci\u00f3n \u00a0de\u00a0Nottingham)49.\u00a0\n\u00a0\n2.2.\u00a0Clasificaci\u00f3n \u00a0en\u00a0estadios\u00a0\nLa\u00a0clasificaci\u00f3n \u00a0del\u00a0CM\u00a0en\u00a0estadios\u00a0consiste\u00a0en\u00a0\ndefinir\u00a0la\u00a0extensi\u00f3n \u00a0de\u00a0dicha\u00a0enfermedad. \u00a0Un\u00a0\nsistema\u00a0de\u00a0estadiaje\u00a0aceptado \u00a0universalmente, \u00a0\nsimple,\u00a0pr\u00e1ctico\u00a0y\u00a0que\u00a0refleja\u00a0adecuadamente \u00a0el\u00a0\npron\u00f3stico \u00a0de\u00a0las\u00a0pacientes \u00a0aparece\u00a0en\u00a01987.\u00a0La\u00a0\nAmerican \u00a0Joint\u00a0Comitee\u00a0on\u00a0Cancer\u00a0(AJCC)\u00a0public\u00f3,\u00a0\nconjuntamente \u00a0con\u00a0la\u00a0Union\u00a0Internationale \u00a0Contre\u00a0\nle\u00a0Cancer\u00a0(UICC)\u00a0el\u00a0sistema\u00a0de\u00a0estadiaje\u00a0AJCC\u00a0/\u00a0\nUICC50.\u00a0Este\u00a0sistema\u00a0se\u00a0ha\u00a0revisado\u00a0y\u00a0actualizado \u00a0\nposteriormente \u00a0hasta\u00a0el\u00a0definitivo \u00a0sistema\u00a0de\u00a0\nestadiaje\u00a0para\u00a0el\u00a0CM\u00a0TNM51,52\u00a0basado\u00a0en\u00a0la\u00a0\nextensi\u00f3n \u00a0del\u00a0tumor\u00a0(T),\u00a0la\u00a0implicaci\u00f3n \u00a0de\u00a0ganglios\u00a0\nlinf\u00e1ticos\u00a0(N)\u00a0y\u00a0la\u00a0presencia \u00a0de\u00a0met\u00e1stasis \u00a0(M),\u00a0que\u00a0\nincorpora \u00a0las\u00a0caracter\u00edsticas \u00a0histol\u00f3gicas \u00a0del\u00a0tumor\u00a0\nprimario\u00a0y\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0regionales \u00a0(Tablas\u00a0\n4\u00a0y\u00a05).\u00a0\nA\u00a0partir\u00a0de\u00a0la\u00a0clasificaci\u00f3n \u00a0TNM,\u00a0y\u00a0seg\u00fan\u00a0la\u00a0\ncorrelaci\u00f3n \u00a0del\u00a0tama\u00f1o\u00a0del\u00a0tumor\u00a0y\u00a0el\u00a0estado\u00a0de\u00a0\nlos\u00a0ganglios,\u00a0se\u00a0obtiene\u00a0la\u00a0clasificaci\u00f3n \u00a0por\u00a0\nestadios\u00a0de\u00a0la\u00a0enfermedad. \u00a0Los\u00a0tumores\u00a0en\u00a0\nestadio\u00a00\u00a0(Tis,\u00a0N0,\u00a0M0)\u00a0son\u00a0los\u00a0de\u00a0mejor\u00a0\npron\u00f3stico \u00a0y\u00a0con\u00a0muchas\u00a0posibilidades \u00a0de\u00a0que\u00a0la\u00a0\nenfermedad \u00a0no\u00a0progrese. \u00a0Los\u00a0c\u00e1nceres\u00a0en\u00a0estadio\u00a0\nI\u00a0se\u00a0localizan\u00a0en\u00a0la\u00a0mama\u00a0y\u00a0son\u00a0de\u00a0tama\u00f1o\u00a0\nreducido\u00a0(\u2264\u00a02\u00a0cm).\u00a0Tabla\u00a03.\u00a0Grados\u00a0histol\u00f3gicos \u00a0del\u00a0CM48,49.\u00a0\nPAR\u00c1METROS PUNTOS\nA.\u00a0Formaci\u00f3n \u00a0de\u00a0t\u00fabulos\u00a0 \u00a0\u00a0\n\u00a0\u00a0\uf0b7\uf020El\u00a075%\u00a0o\u00a0m\u00e1s\u00a0del\u00a0tumor\u00a0presenta\u00a0\nt\u00fabulos\u00a0\u00a01\u00a0\n\u00a0\u00a0\uf0b7\uf020Entre\u00a0el\u00a010\u00a0y\u00a0el\u00a075%\u00a0del\u00a0tumor\u00a0\npresenta\u00a0t\u00fabulos\u00a0\u00a02\u00a0\n\u00a0\u00a0\uf0b7\uf020Menos\u00a0del\u00a010%\u00a0del\u00a0tumor\u00a0presenta\u00a0\nt\u00fabulos\u00a0\u00a03\u00a0\nB.\u00a0Morfolog \u00eda\u00a0nuclear\u00a0 \u00a0\u00a0\n\u00a0\u00a0\uf0b7\u00a0N\u00facleo\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0peque\u00f1o, \u00a0\nuniforme \u00a0y\u00a0patr\u00f3n\u00a0de\u00a0cromatina \u00a0con\u00a0\nescasa\u00a0variaci\u00f3n\u00a01\u00a0\n\u00a0\u00a0\uf0b7\u00a0Tama\u00f1o\u00a0nuclear\u00a0moderado, \u00a0\ncromatina \u00a0en\u00a0grumos\u00a0y\u00a0nucleolo\u00a0\naparente\u00a02\u00a0\n\u00a0\u00a0\uf0b7\u00a0N\u00facleo\u00a0con\u00a0marcada\u00a0variaci\u00f3n\u00a0en\u00a0\nforma,\u00a0tama\u00f1o\u00a0y\u00a0patr\u00f3n\u00a0de\u00a0la\u00a0\ncromatina \u00a0con\u00a02\u00a0o\u00a0m\u00e1s\u00a0nucl\u00e9olos \u00a0\naparentes \u00a03\u00a0\nC.\u00a0\u00cdndice\u00a0de\u00a0mitosis \u00a0\u00a0\n\u00a0\u00a0\uf0b7\u00a0Menos\u00a0de\u00a010\u00a0mitosis\u00a0por\u00a010\u00a0\ncampos\u00a0de\u00a0gran\u00a0aumento\u00a01\u00a0\n\u00a0\u00a0\uf0b7\u00a010\u201019\u00a0mitosis\u00a0por\u00a010\u00a0campos\u00a0de\u00a0\ngran\u00a0aumento\u00a02\u00a0\n\u00a0\u00a0\uf0b7\u00a020\u00a0mitosis\u00a0o\u00a0m\u00e1s\u00a0por\u00a010\u00a0campos\u00a0de\u00a0\ngran\u00a0aumento\u00a03\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 TOTAL*\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nGRADO\u00a0HISTOL\u00d3GICO \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PUNTUACI\u00d3N\nGrado\u00a0histol\u00f3gico \u00a0I\u00a0(bien\u00a0diferenciado) \u00a0\u00a0 3\u20105\u00a0\nGrado\u00a0histol\u00f3gico \u00a0II\u00a0(moderadamente \u00a0\ndiferenciado) \u00a06\u20107\u00a0\nGrado\u00a0histol\u00f3gico \u00a0III\u00a0(indiferenciado) \u00a0\u00a0 8\u20109\u00a0\n*El\u00a0total\u00a0representa \u00a0la\u00a0suma\u00a0de\u00a0A,\u00a0B\u00a0y\u00a0C.\u00a0\n\u00a0\nEl\u00a0estadio\u00a0II\u00a0se\u00a0reserva\u00a0para\u00a0casos\u00a0con\u00a0met\u00e1stasis \u00a0\nen\u00a0ganglios\u00a0linf\u00e1ticos\u00a0regionales \u00a0y\u00a0conlleva\u00a0un\u00a0\npron\u00f3stico \u00a0peor\u00a0que\u00a0el\u00a0de\u00a0los\u00a0estadios\u00a0I\u00a0y\u00a00.\u00a0Los\u00a0\nestadios\u00a0III\u00a0o\u00a0IV,\u00a0en\u00a0que\u00a0las\u00a0met\u00e1stasis \u00a0\nganglionares \u00a0son\u00a0>2\u00a0cm,\u00a0han\u00a0infiltrado\u00a0la\u00a0c\u00e1psula\u00a0\ndel\u00a0ganglio\u00a0y\u00a0se\u00a0han\u00a0fijado\u00a0en\u00a0otras\u00a0estructuras. \u00a0\nLos\u00a0c\u00e1nceres\u00a0en\u00a0estadio\u00a0IV\u00a0generalmente \u00a0est\u00e1n\u00a0\nm\u00e1s\u00a0all\u00e1\u00a0de\u00a0la\u00a0posibilidad \u00a0de\u00a0curaci\u00f3n\u00a0debido\u00a0a\u00a0las\u00a0\nmet\u00e1stasis \u00a0a\u00a0distancia. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n23\u00a0\n\u00a0Tabla\u00a04.\u00a0Clasificaci\u00f3n \u00a0TNM\u00a0del\u00a0CM\u00a0(adaptado \u00a0de\u00a052).\u00a0\n\u00a0\nCLASIFICACI\u00d3N \u00a0CARACTER\u00cdSTICAS \u00a0\u2013\u00a0Tumor\u00a0primario\u00a0(T)\u00a0\nTX\u00a0 No\u00a0es\u00a0posible\u00a0valorar\u00a0el\u00a0tumor\u00a0primario\u00a0\nT0\u00a0 No\u00a0hay\u00a0evidencias \u00a0de\u00a0tumor\u00a0primario\u00a0\nTis\u00a0 Carcinoma \u00a0in\u00a0situ\u00a0\nTis\u00a0(DCIS)\u00a0 DCIS\u00a0\nTis\u00a0(LCIS)\u00a0 LCIS\u00a0\nTis\u00a0(Paget)\u00a0La\u00a0enfermedad \u00a0de\u00a0Paget\u00a0del\u00a0pez\u00f3n\u00a0no\u00a0est\u00e1\u00a0asociada\u00a0a\u00a0carcinoma \u00a0invasivo\u00a0y/o\u00a0carcinoma \u00a0in\u00a0situ\u00a0\n(CDIS\u00a0y\u00a0/\u00a0o\u00a0CLIS)\u00a0en\u00a0el\u00a0par\u00e9nquima \u00a0mamario\u00a0subyacente \u00a0\nT1\u00a0 Tumor\u00a0\u2264\u00a02\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT1mi\u00a0 Tumor\u00a0\u2264\u00a00,1\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT1a\u00a0 Tumor\u00a0\u2264\u00a00,5\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT1b\u00a0 Tumor\u00a0>\u00a00,5\u00a0\u2010\u00a0\u2264\u00a01\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT1c\u00a0 Tumor\u00a0>\u00a01\u00a0\u2010\u00a0\u2264\u00a02\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT2\u00a0 Tumor\u00a0>\u00a02\u00a0\u2010\u00a0\u2264\u00a05\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT3\u00a0 Tumor\u00a0>\u00a05\u00a0cm,\u00a0en\u00a0su\u00a0di\u00e1metro\u00a0m\u00e1ximo\u00a0\nT4\u00a0Tumor\u00a0de\u00a0cualquier \u00a0tama\u00f1o\u00a0con\u00a0extensi\u00f3n \u00a0directa\u00a0a\u00a0la\u00a0pared\u00a0tor\u00e1cica\u00a0o\u00a0en\u00a0la\u00a0piel\u00a0(ulceraci\u00f3n \u00a0o\u00a0\nn\u00f3dulos\u00a0en\u00a0la\u00a0piel)*\u00a0\nT4a\u00a0 Extensi\u00f3n \u00a0a\u00a0la\u00a0pared\u00a0tor\u00e1cica,\u00a0sin\u00a0incluir\u00a0s\u00f3lo\u00a0la\u00a0adherencia/invasi\u00f3n \u00a0al\u00a0m\u00fasculo\u00a0pectoral\u00a0\nT4b\u00a0 Edema\u00a0o\u00a0ulceraci\u00f3n \u00a0de\u00a0la\u00a0piel\u00a0de\u00a0la\u00a0mama\u00a0\nT4c\u00a0 Ambos\u00a0criterios\u00a0(T4a\u00a0y\u00a0T4b)\u00a0\nT4d\u00a0 Carcinoma \u00a0inflamatorio \u00a0\n*La\u00a0invasi\u00f3n\u00a0de\u00a0la\u00a0dermis\u00a0por\u00a0s\u00ed\u00a0sola\u00a0no\u00a0puede\u00a0considerarse \u00a0como\u00a0T4\u00a0\nCLASIFICACI\u00d3N \u00a0CARACTER\u00cdSTICAS \u00a0\u2013\u00a0Ganglios\u00a0linf\u00e1ticos \u00a0(N)\u00a0\nNX\u00a0 Los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0regionales \u00a0no\u00a0pueden\u00a0evaluarse \u00a0\nN0\u00a0 No\u00a0hay\u00a0met\u00e1stasis \u00a0a\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0regionales \u00a0\nN1\u00a0 Met\u00e1stasis \u00a0en\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0ipsilaterales \u00a0(m\u00f3viles\u00a0a\u00a0la\u00a0palpaci\u00f3n) \u00a0\nN2\u00a0Met\u00e1stasis \u00a0en\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0ipsilaterales, \u00a0fijos\u00a0en\u00a0entre\u00a0s\u00ed\u00a0\u00a0\nO\u00a0met\u00e1stasis \u00a0en\u00a0los\u00a0g\u00e1nglios\u00a0internos\u00a0mamarios \u00a0ipsilaterales \u00a0detectados \u00a0cl\u00ednicamente \u00a0pero\u00a0en\u00a0\nausencia\u00a0de\u00a0met\u00e1stasis \u00a0de\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0cl\u00ednicamente \u00a0evidentes* \u00a0\nN2a\u00a0Met\u00e1stasis \u00a0ipsilateral \u00a0a\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0fijos\u00a0entre\u00a0si\u00a0(apelmazados) \u00a0o\u00a0a\u00a0otras\u00a0\nestructuras \u00a0\nN2b\u00a0\u00a0Met\u00e1stasis \u00a0solamente \u00a0en\u00a0ganglios\u00a0mamarios \u00a0internos\u00a0ipsilaterales \u00a0detectados \u00a0cl\u00ednicamente \u00a0en\u00a0\nausencia\u00a0de\u00a0met\u00e1stasis \u00a0manifiestas \u00a0en\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares*\u00a0\n\u00a0N3\u00a0Met\u00e1stasis \u00a0en\u00a0ganglios\u00a0linf\u00e1ticos\u00a0infraclaviculares \u00a0ipsilaterales \u00a0con\u00a0implicaci\u00f3n \u00a0de\u00a0ganglio\u00a0linf\u00e1tico\u00a0\naxilar\u00a0\u00a0\nO\u00a0met\u00e1stasis \u00a0en\u00a0los\u00a0ganglios\u00a0internos\u00a0mamarios \u00a0ipsilaterales \u00a0cl\u00ednicamente \u00a0detectados \u00a0con\u00a0\nmet\u00e1stasis \u00a0manifiesta \u00a0en\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0\nO\u00a0met\u00e1stasis \u00a0en\u00a0ganglios\u00a0linf\u00e1ticos\u00a0supraclaviculares \u00a0ipsilaterales \u00a0con\u00a0implicaci\u00f3n \u00a0axilar\u00a0o\u00a0mamaria\u00a0\ninterna\u00a0de\u00a0ganglios\u00a0linf\u00e1ticos\u00a0o\u00a0sin\u00a0esta\u00a0\nN3a\u00a0 Met\u00e1stasis \u00a0en\u00a0los\u00a0ganglios\u00a0infraclaviculares \u00a0ipsilaterales \u00a0\nN3b\u00a0\u00a0 Met\u00e1stasis \u00a0en\u00a0ganglios\u00a0linf\u00e1ticos\u00a0mamarios \u00a0internos\u00a0ipsilaterales \u00a0y\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos\u00a0axilares\u00a0\nN3c\u00a0 Met\u00e1stasis \u00a0en\u00a0los\u00a0ganglios\u00a0supraclaviculares \u00a0ipsilaterales \u00a0\u00a0\n*\u00a0Cl\u00ednicamente \u00a0detectado \u00a0se\u00a0define\u00a0como\u00a0detecci\u00f3n \u00a0por\u00a0estudios\u00a0de\u00a0imagen\u00a0(excluyendo \u00a0linfogammagraf\u00eda) \u00a0o\u00a0mediante \u00a0el\u00a0examen\u00a0cl\u00ednico\u00a0y\u00a0que\u00a0\ntienen\u00a0caracter\u00edsticas \u00a0altamente \u00a0sospechosas \u00a0de\u00a0malignidad \u00a0o\u00a0de\u00a0macromet\u00e1stasis \u00a0patol\u00f3gica \u00a0basada\u00a0en\u00a0la\u00a0biopsia\u00a0por\u00a0aspiraci\u00f3n \u00a0con\u00a0aguja\u00a0fina\u00a0y\u00a0\ncon\u00a0el\u00a0examen\u00a0citol\u00f3gico. \u00a0\n\u00a0Contin\u00faa \u00a0en\u00a0la\u00a0siguiente \u00a0p\u00e1gina\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n24\u00a0\n\u00a0CLASIFICACI\u00d3N \u00a0CARACTER\u00cdSTICAS \u00a0\u2013\u00a0Ganglios\u00a0linf\u00e1ticos \u00a0(N)\u00a0\nMx\u00a0 No\u00a0se\u00a0puede\u00a0valorar\u00a0la\u00a0presencia \u00a0de\u00a0met\u00e1stasis \u00a0a\u00a0distancia\u00a0\nM0\u00a0No\u00a0hay\u00a0prueba\u00a0cl\u00ednica\u00a0o\u00a0radiogr\u00e1fica \u00a0de\u00a0met\u00e1stasis \u00a0a\u00a0distancia, \u00a0pero\u00a0si\u00a0detecci\u00f3n \u00a0de\u00a0dep\u00f3sitos \u00a0de\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0moleculares \u00a0o\u00a0microsc\u00f3picas \u00a0en\u00a0la\u00a0sangre\u00a0circulante, \u00a0m\u00e9dula\u00a0\u00f3sea\u00a0u\u00a0otros\u00a0\ntejidos\u00a0ganglionares \u00a0no\u00a0regionales \u00a0que\u00a0tienen\u00a0\u22640.2\u00a0mm\u00a0en\u00a0pacientes \u00a0sin\u00a0signos\u00a0o\u00a0s\u00edntomas\u00a0de\u00a0\nmet\u00e1stasis. \u00a0\nM1\u00a0Met\u00e1stasis \u00a0a\u00a0distancia\u00a0detectables \u00a0seg\u00fan\u00a0lo\u00a0determinado \u00a0por\u00a0los\u00a0medios\u00a0cl\u00ednicos\u00a0cl\u00e1sicos\u00a0\nradiol\u00f3gicos \u00a0y/o\u00a0histol\u00f3gicos \u00a0\n\u00a0\n\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 Tabla\u00a05.\u00a0Estadio\u00a0anat\u00f3mico/grupos \u00a0pron\u00f3sticos \u00a0(adaptado \u00a0de52).\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0ESTADIO\u00a0 T\u00a0 N\u00a0 M\u00a0\n0\u00a0 Tis N0 M0\nIA\u00a0 T1bN0 M0\nIB\u00a0T0 N1mi M0\nT1bN1mi M0\nIIA\u00a0T0 N1cM0\nT1bN1cM0\nT2 N0 M0\nIIB\u00a0T2 N1 M0\nT3 N0 M0\nIIIA\u00a0T0 N2 M0\nT1bN2 M0\nT2 N2 M0\nT3 N1 M0\nT3 N2 M0\nIIIB\u00a0T4 N0 M0\nT4 N1 M0\nT4 N2 M0\nIIIC\u00a0 Cualquier \u00a0T N3 M0\nIV\u00a0 Cualquier \u00a0TCualquier \u00a0N M1\nbT1\u00a0incluye\u00a0T1mi\u00a0(micromet\u00e1stasis). \u00a0\ncTumores\u00a0T0\u00a0y\u00a0T1\u00a0con\u00a0solo\u00a0micromet\u00e1stasis \u00a0nodal,\u00a0se\u00a0excluyen\u00a0del\u00a0\nestadio\u00a0IIA\u00a0y\u00a0se\u00a0clasifican \u00a0como\u00a0estadio\u00a0IB.\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n25\u00a0\n\u00a02.3.\u00a0Epidemiolog\u00eda \u00a0\nEl\u00a0CM\u00a0es\u00a0el\u00a0c\u00e1ncer\u00a0m\u00e1s\u00a0frecuente \u00a0hoy\u00a0en\u00a0d\u00eda\u00a0entre\u00a0\nlas\u00a0mujeres.\u00a0Se\u00a0estima\u00a0que\u00a0en\u00a0el\u00a02008\u00a0se\u00a0\ndiagnosticaron \u00a01,38\u00a0millones\u00a0de\u00a0nuevos\u00a0casos\u00a0\n(23%\u00a0del\u00a0total\u00a0de\u00a0todos\u00a0los\u00a0c\u00e1nceres), \u00a0y\u00a0ocupa\u00a0el\u00a0\nsegundo\u00a0lugar\u00a0del\u00a0resto\u00a0de\u00a0c\u00e1nceres\u00a0con\u00a0un\u00a010,9%\u00a0\ndel\u00a0total\u00a0(Fig.\u00a08).\u00a0\n\u00a0\nFigura\u00a08.\u00a0Incidencia \u00a0de\u00a0los\u00a0distintos\u00a0tipos\u00a0de\u00a0c\u00e1ncer\u00a0en\u00a0el\u00a0\nmundo\u00a0(2008)53.\u00a0\n\u00a0\nActualmente \u00a0es\u00a0el\u00a0c\u00e1ncer\u00a0m\u00e1s\u00a0com\u00fan\u00a0en\u00a0las\u00a0\nregiones\u00a0desarrolladas \u00a0y\u00a0en\u00a0desarrollo \u00a0con\u00a0cerca\u00a0\nde\u00a0690.000\u00a0nuevos\u00a0casos\u00a0estimados \u00a0en\u00a0cada\u00a0\nregi\u00f3n,\u00a0con\u00a0un\u00a0ratio\u00a01:4\u00a0personas. \u00a0Las\u00a0tasas\u00a0de\u00a0\nincidencia \u00a0var\u00edan\u00a0desde\u00a0el\u00a019,3\u00a0por\u00a0cada\u00a0100.000\u00a0\nmujeres\u00a0en\u00a0el\u00a0este\u00a0de\u00a0\u00c1frica\u00a0al\u00a089,7\u00a0por\u00a0cada\u00a0\n100.000\u00a0mujeres\u00a0en\u00a0Europa\u00a0Occidental, \u00a0y\u00a0son\u00a0m\u00e1s\u00a0\naltas\u00a0(m\u00e1s\u00a0de\u00a080\u00a0por\u00a0cada\u00a0100.000)\u00a0en\u00a0las\u00a0regiones\u00a0\ndesarrolladas \u00a0del\u00a0mundo\u00a0(excepto\u00a0Jap\u00f3n)\u00a0y\u00a0bajas\u00a0\n(menos\u00a0de\u00a040\u00a0por\u00a0cada\u00a0100.000)\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nlas\u00a0regiones\u00a0en\u00a0desarrollo. \u00a0Sin\u00a0embargo, \u00a0el\u00a0rango\u00a0\nde\u00a0las\u00a0tasas\u00a0de\u00a0mortalidad \u00a0es\u00a0mucho\u00a0menor\u00a0\n(aproximadamente \u00a0el\u00a019.6\u00a0por\u00a0cada\u00a0100.000)\u00a0a\u00a0\ncausa\u00a0de\u00a0una\u00a0supervivencia \u00a0m\u00e1s\u00a0favorable \u00a0de\u00a0CM\u00a0\nen\u00a0las\u00a0regiones\u00a0desarrolladas. \u00a0Como\u00a0resultado, \u00a0se\u00a0\nsit\u00faa\u00a0el\u00a0CM\u00a0como\u00a0la\u00a0quinta\u00a0causa\u00a0de\u00a0muerte\u00a0por\u00a0\nc\u00e1ncer\u00a0en\u00a0general\u00a0(458.000\u00a0muertes), \u00a0pero\u00a0sigue\u00a0\nsiendo\u00a0la\u00a0causa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0muerte\u00a0por\u00a0\nc\u00e1ncer\u00a0en\u00a0las\u00a0mujeres\u00a0tanto\u00a0en\u00a0los\u00a0pa\u00edses\u00a0\ndesarrollados \u00a0como\u00a0en\u00a0v\u00edas\u00a0de\u00a0desarrollo \u00a0(269.000\u00a0\nmuertes,\u00a0el\u00a012,7%\u00a0del\u00a0total)\u00a0donde\u00a0las\u00a0\naproximadamente \u00a0189.000\u00a0muertes\u00a0que\u00a0se\u00a0\nproducen \u00a0son\u00a0casi\u00a0iguales\u00a0al\u00a0n\u00famero\u00a0estimado \u00a0de\u00a0muertes\u00a0por\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0(188.000\u00a0\ndefunciones)53.\u00a0\nPor\u00a0lo\u00a0tanto,\u00a0la\u00a0incidencia \u00a0y\u00a0la\u00a0mortalidad \u00a0de\u00a0esta\u00a0\npatolog\u00eda \u00a0presentan \u00a0una\u00a0gran\u00a0variabilidad \u00a0\ngeogr\u00e1fica, \u00a0observ\u00e1ndose \u00a0una\u00a0mayor\u00a0incidencia \u00a0en\u00a0\nNorteam\u00e9rica, \u00a0Australia, \u00a0Pa\u00edses\u00a0N\u00f3rdicos, \u00a0Europa\u00a0\noccidental \u00a0y\u00a0Argentina53\u00a0(Fig.\u00a09).\u00a0\nEn\u00a0la\u00a0Uni\u00f3n\u00a0Europea,\u00a0seg\u00fan\u00a0datos\u00a0de\u00a02006,\u00a0se\u00a0\ndiagnosticaron \u00a0unos\u00a0430.000\u00a0casos\u00a0al\u00a0a\u00f1o\u00a0y\u00a0la\u00a0\nprobabilidad \u00a0de\u00a0desarrollar \u00a0un\u00a0CM\u00a0antes\u00a0de\u00a0los\u00a075\u00a0\na\u00f1os\u00a0era\u00a0del\u00a08%54.\u00a0Los\u00a0resultados \u00a0demuestran \u00a0que\u00a0\nel\u00a0CM\u00a0es\u00a0el\u00a0tumor\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0las\u00a0mujeres\u00a0\ntambi\u00e9n\u00a0en\u00a0Espa\u00f1a,\u00a0lo\u00a0que\u00a0es\u00a0similar\u00a0al\u00a0resto\u00a0de\u00a0\nEuropa,\u00a0y\u00a0represent\u00f3 \u00a0el\u00a028%\u00a0del\u00a0total\u00a0de\u00a0c\u00e1nceres\u00a0\ndiagnosticados \u00a0en\u00a0la\u00a0mujer.\u00a0En\u00a0Espa\u00f1a,\u00a0afecta\u00a0a\u00a0\nuna\u00a0de\u00a0cada\u00a013\u00a0mujeres\u00a0y\u00a0se\u00a0diagnostican \u00a0\nalrededor \u00a0de\u00a022.000\u00a0casos\u00a0nuevos\u00a0al\u00a0a\u00f1o,\u00a0\nocasionando \u00a0anualmente \u00a0la\u00a0muerte\u00a0de\u00a0unas\u00a06.000\u00a0\nmujeres.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos\u00a0se\u00a0diagnostican \u00a0\nentre\u00a0los\u00a035\u00a0y\u00a0los\u00a080\u00a0a\u00f1os,\u00a0con\u00a0un\u00a0m\u00e1ximo\u00a0entre\u00a0\nlos\u00a045\u00a0y\u00a0los\u00a065.\u00a0Adem\u00e1s,\u00a0es\u00a0importante \u00a0remarcar\u00a0\nque\u00a0la\u00a0tasa\u00a0ajustada\u00a0de\u00a0incidencia \u00a0ha\u00a0pasado\u00a0de\u00a0\n42,8\u00a0casos\u00a0por\u00a0100.000\u00a0mujeres\u00a0en\u00a01985\u00a0a\u00a070,9\u00a0en\u00a0\nel\u00a02002.\u00a0Esta\u00a0variaci\u00f3n\u00a0significativa \u00a0supone\u00a0un\u00a0\nincremento \u00a0anual\u00a0del\u00a02,45%\u00a0sobretodo \u00a0en\u00a0mujeres\u00a0\nm\u00e1s\u00a0mayores\u00a0mientras\u00a0que\u00a0en\u00a0mujeres\u00a0por\u00a0debajo\u00a0\nde\u00a045\u00a0a\u00f1os,\u00a0la\u00a0tendencia \u00a0es\u00a0a\u00a0mantenerse \u00a0y\u00a0incluso\u00a0\na\u00a0disminuir55,56.\u00a0Este\u00a0aumento\u00a0est\u00e1\u00a0relacionado \u00a0\nquiz\u00e1s\u00a0con\u00a0los\u00a0cambios\u00a0en\u00a0los\u00a0h\u00e1bitos\u00a0de\u00a0vida\u00a0y\u00a0\ncon\u00a0la\u00a0mejora\u00a0de\u00a0las\u00a0t\u00e9cnicas\u00a0diagn\u00f3sticas. \u00a0No\u00a0\nobstante, \u00a0no\u00a0disponemos \u00a0de\u00a0un\u00a0sistema\u00a0nacional\u00a0\nde\u00a0registro\u00a0de\u00a0tumores\u00a0para\u00a0conocer\u00a0las\u00a0cifras\u00a0\nexactas.\u00a0\nEn\u00a0relaci\u00f3n\u00a0con\u00a0Europa,\u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0\nobserva\u00a0un\u00a0ascenso\u00a0marcado\u00a0de\u00a0las\u00a0tasas\u00a0de\u00a0\nincidencia \u00a0en\u00a0Catalu\u00f1a\u00a0que\u00a0podr\u00eda\u00a0estar\u00a0\nrelacionado \u00a0con\u00a0la\u00a0modificaci\u00f3n \u00a0de\u00a0algunos\u00a0\nfactores\u00a0de\u00a0riesgo,\u00a0como\u00a0el\u00a0uso\u00a0de\u00a0tratamientos \u00a0\nhormonales \u00a0sustitutorios \u00a0en\u00a0la\u00a0menopausia \u00a0y\u00a0\ntambi\u00e9n\u00a0con\u00a0una\u00a0mejor\u00a0capacidad \u00a0diagn\u00f3stica \u00a0\nactual\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0programas \u00a0de\u00a0detecci\u00f3n \u00a0\nprecoz\u00a0con\u00a0mamograf\u00eda \u00a0de\u00a0cribado55,57.\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n26\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nFigura\u00a09.\n\u00a0Tasas\u00a0de\u00a0incidencia \u00a0de\u00a0CM\u00a0estandarizadas \u00a0por\u00a0edad\u00a0en\u00a0el\u00a0mundo:\u00a0100.000\u00a0mujeres\u00a0por\u00a0a\u00f1o53.\u00a0\n\u00a0\nPor\u00a0otro\u00a0lado\u00a0la\u00a0mortalidad \u00a0por\u00a0CM\u00a0en\u00a0Espa\u00f1a\u00a0\ncomenz\u00f3\u00a0a\u00a0descender \u00a0en\u00a0el\u00a0a\u00f1o\u00a01992,\u00a0a\u00a0un\u00a0ritmo\u00a0\ndel\u00a02%\u00a0anual.\u00a0A\u00a0esta\u00a0disminuci\u00f3n \u00a0en\u00a0la\u00a0mortalidad \u00a0\ntambi\u00e9n\u00a0se\u00a0suma\u00a0Catalu\u00f1a\u00a0donde\u00a0ha\u00a0disminuido \u00a0\nun\u00a02,7%\u00a0anual\u00a0en\u00a0el\u00a0per\u00edodo\u00a0de\u00a01995\u00a0a\u00a02009.\u00a0\nActualmente \u00a0el\u00a0CM\u00a0tiene\u00a0una\u00a0supervivencia \u00a0del\u00a0\n81%\u00a0al\u00a0cabo\u00a0de\u00a05\u00a0a\u00f1os,\u00a0una\u00a0cifra\u00a0algo\u00a0superior\u00a0a\u00a0la\u00a0\nmedia\u00a0europea\u00a0que,\u00a0en\u00a0el\u00a0mismo\u00a0periodo\u00a0\nobservado \u00a0es\u00a0del\u00a079%57.\u00a0Los\u00a0programas \u00a0de\u00a0\ndetecci\u00f3n \u00a0precoz\u00a0junto\u00a0con\u00a0los\u00a0avances\u00a0\ndiagn\u00f3sticos \u00a0y\u00a0la\u00a0mejora\u00a0en\u00a0los\u00a0tratamientos \u00a0\nactuales\u00a0se\u00a0han\u00a0traducido \u00a0en\u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0\nsupervivencia \u00a0en\u00a0este\u00a0tipo\u00a0de\u00a0enfermedad55.\u00a0\nA\u00a0nivel\u00a0internacional, \u00a0las\u00a0grandes\u00a0diferencias \u00a0\nobservadas \u00a0hace\u00a0medio\u00a0siglo\u00a0en\u00a0la\u00a0mortalidad \u00a0por\u00a0\neste\u00a0 tumor\u00a0 tienden\u00a0 a\u00a0 desaparecer, \u00a0\nproporcionando \u00a0un\u00a0patr\u00f3n\u00a0mucho\u00a0m\u00e1s\u00a0\nhomog\u00e9neo. \u00a0En\u00a0Espa\u00f1a,\u00a0no\u00a0existe\u00a0un\u00a0patr\u00f3n\u00a0\ngeogr\u00e1fico \u00a0claro,\u00a0destacando \u00a0solamente \u00a0la\u00a0\nprovincia\u00a0de\u00a0Gran\u00a0Canaria\u00a0como\u00a0\u00e1rea\u00a0de\u00a0mayor\u00a0\nmortalidad. \u00a0El\u00a0descenso \u00a0de\u00a0la\u00a0mortalidad \u00a0m\u00e1s\u00a0\nacusado\u00a0es\u00a0en\u00a0Navarra,\u00a0siendo\u00a0de\u00a0un\u00a08%\u00a0anual\u00a0a\u00a0\npartir\u00a0de\u00a01995,\u00a0seguido\u00a0de\u00a0la\u00a0Rioja\u00a0y\u00a0Castilla\u2010Le\u00f3n\u00a0\n(Fig.\u00a010).\u00a0Navarra\u00a0fue\u00a0la\u00a0primera\u00a0Comunidad \u00a0Aut\u00f3noma \u00a0que\u00a0implant\u00f3\u00a0un\u00a0programa \u00a0de\u00a0\ndiagn\u00f3stico \u00a0precoz,\u00a0en\u00a0199055.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nFigura\u00a010.\n\u00a0Distribuci\u00f3n \u00a0geogr\u00e1fica \u00a0de\u00a0la\u00a0mortalidad \u00a0por\u00a0CM\u00a0\nen\u00a0Espa\u00f1a\u00a0(1996\u20102000)55.\u00a0\n\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n27\u00a0\n\u00a02.4.\u00a0Factores\u00a0de\u00a0riesgo\u00a0\nUn\u00a0factor\u00a0de\u00a0riesgo\u00a0es\u00a0cualquier \u00a0factor\u00a0que\u00a0\naumenta\u00a0la\u00a0posibilidad \u00a0de\u00a0que\u00a0una\u00a0persona\u00a0\ndesarrolle \u00a0c\u00e1ncer.\u00a0Si\u00a0bien\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0\npueden\u00a0influir\u00a0en\u00a0el\u00a0desarrollo \u00a0del\u00a0c\u00e1ncer,\u00a0la\u00a0\nmayor\u00eda\u00a0no\u00a0es\u00a0una\u00a0causa\u00a0directa\u00a0de\u00a0esta\u00a0\nenfermedad. \u00a0El\u00a0riesgo\u00a0relativo\u00a0compara\u00a0la\u00a0\nfrecuencia \u00a0con\u00a0que\u00a0ocurre\u00a0el\u00a0da\u00f1o\u00a0entre\u00a0los\u00a0\nindividuos \u00a0que\u00a0tienen\u00a0el\u00a0factor\u00a0de\u00a0riesgo\u00a0y\u00a0los\u00a0que\u00a0\nno\u00a0lo\u00a0tienen.\u00a0Un\u00a0riesgo\u00a0relativo\u00a0de\u00a01\u00a0indica\u00a0que\u00a0no\u00a0\nhay\u00a0riesgo\u00a0mayor,\u00a0mientras\u00a0que\u00a0un\u00a0riesgo\u00a0relativo\u00a0\nde\u00a010\u00a0indica\u00a0que\u00a0hay\u00a0un\u00a0aumento\u00a0de\u00a010\u00a0veces\u00a0de\u00a0\neste\u00a0riesgo.\u00a0Diversas\u00a0investigaciones \u00a0han\u00a0\nidentificado \u00a0un\u00a0n\u00famero\u00a0de\u00a0factores\u00a0que\u00a0aumentan \u00a0\nlas\u00a0probabilidades \u00a0de\u00a0que\u00a0una\u00a0mujer\u00a0tenga\u00a0CM.\u00a0\nLos\u00a0factores\u00a0de\u00a0riesgo\u00a0no\u00a0causan\u00a0CM\u00a0de\u00a0per\u00a0se,\u00a0\npero\u00a0pueden\u00a0aumentar \u00a0las\u00a0probabilidades \u00a0de\u00a0\ntener\u00a0dicho\u00a0c\u00e1ncer.\u00a0Algunas\u00a0mujeres\u00a0tienen\u00a0\nmuchos\u00a0factores\u00a0de\u00a0riesgo\u00a0pero\u00a0nunca\u00a0lo\u00a0\ndesarrollan, \u00a0en\u00a0cambio\u00a0otras\u00a0que\u00a0no\u00a0tienen\u00a0ning\u00fan\u00a0\nfactor\u00a0contraen\u00a0la\u00a0enfermedad. \u00a0En\u00a0la\u00a0Tabla\u00a06,\u00a0se\u00a0\ndetallan\u00a0algunos\u00a0de\u00a0los\u00a0factores\u00a0descritos\u00a0hasta\u00a0el\u00a0\nmomento \u00a0y\u00a0su\u00a0riesgo\u00a0relativo58.\u00a0\n\u00a0\n2.4.1.\u00a0Factores\u00a0de\u00a0riesgo\u00a0no\u00a0gen\u00e9ticos \u00a0\n\u00a0\nEDAD,\u00a0SEXO\u00a0Y\u00a0RAZA:\u00a0El\u00a0simple\u00a0hecho\u00a0de\u00a0ser\u00a0mujer\u00a0\nes\u00a0el\u00a0principal\u00a0factor\u00a0de\u00a0riesgo\u00a0para\u00a0desarrollar \u00a0\nCM.\u00a0Los\u00a0hombres\u00a0pueden\u00a0desarrollar \u00a0CM,\u00a0pero\u00a0\nesta\u00a0enfermedad \u00a0es\u00a0aproximadamente \u00a0100\u00a0veces\u00a0\nm\u00e1s\u00a0com\u00fan\u00a0en\u00a0las\u00a0mujeres\u00a0que\u00a0en\u00a0los\u00a0hombres. \u00a0El\u00a0\nriesgo\u00a0de\u00a0desarrollar \u00a0CM\u00a0aumenta\u00a0a\u00a0medida\u00a0que\u00a0\nse\u00a0envejece. \u00a0Cerca\u00a0de\u00a01\u00a0de\u00a0cada\u00a08\u00a0c\u00e1nceres\u00a0de\u00a0\nmama\u00a0invasivos\u00a0se\u00a0encuentran \u00a0en\u00a0las\u00a0mujeres\u00a0\nmenores\u00a0de\u00a045\u00a0a\u00f1os,\u00a0mientras\u00a0que\u00a0alrededor \u00a0de\u00a02\u00a0\nde\u00a0cada\u00a03\u00a0se\u00a0encuentran \u00a0en\u00a0mujeres\u00a0mayores\u00a0de\u00a0\n55\u00a0a\u00f1os\u00a0o\u00a0m\u00e1s28.\u00a0En\u00a0general,\u00a0las\u00a0mujeres\u00a0blancas\u00a0\nson\u00a0ligeramente \u00a0m\u00e1s\u00a0propensas \u00a0a\u00a0desarrollar \u00a0CM\u00a0\nque\u00a0las\u00a0afroamericanas, \u00a0pero\u00a0en\u00a0cambio\u00a0\u00e9stas\u00a0\n\u00faltimas\u00a0son\u00a0m\u00e1s\u00a0propensas \u00a0a\u00a0morir\u00a0de\u00a0c\u00e1ncer.\u00a0Sin\u00a0\nembargo, \u00a0en\u00a0mujeres\u00a0menores\u00a0de\u00a045\u00a0a\u00f1os\u00a0de\u00a0\nedad,\u00a0el\u00a0CM\u00a0es\u00a0m\u00e1s\u00a0com\u00fan\u00a0en\u00a0mujeres\u00a0\nafroamericanas. \u00a0Las\u00a0mujeres\u00a0asi\u00e1ticas,\u00a0hispanas\u00a0e\u00a0indias\u00a0americanas \u00a0tienen\u00a0un\u00a0menor\u00a0riesgo\u00a0de\u00a0\npadecer\u00a0y\u00a0morir\u00a0de\u00a0CM.59\u00a0\nANTECEDENTES \u00a0FAMILIARES \u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0\nMAMA:\u00a0El\u00a0riesgo\u00a0de\u00a0CM\u00a0aumenta\u00a0entre\u00a0las\u00a0\nmujeres\u00a0cuyos\u00a0familiares \u00a0cercanos\u00a0tienen\u00a0esta\u00a0\nenfermedad. \u00a0Tener\u00a0un\u00a0pariente\u00a0de\u00a0primer\u00a0grado\u00a0\n(madre,\u00a0hermana\u00a0o\u00a0hija)\u00a0con\u00a0CM\u00a0\naproximadamente \u00a0duplica\u00a0el\u00a0riesgo\u00a0de\u00a0padecerlo. \u00a0\nTener\u00a02\u00a0familiares \u00a0de\u00a0primer\u00a0grado\u00a0aumenta\u00a0el\u00a0\nriesgo\u00a0alrededor \u00a0de\u00a03\u00a0veces,\u00a0aumentando \u00a0hasta\u00a09\u00a0\nveces\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0que\u00a0el\u00a0familiar\u00a0de\u00a0primer\u00a0grado\u00a0\nsea\u00a0una\u00a0mujer\u00a0pre\u2010menop\u00e1usica \u00a0con\u00a0afectaci\u00f3n \u00a0\nbilateral60.\u00a0En\u00a0total,\u00a0menos\u00a0del\u00a015%\u00a0de\u00a0las\u00a0mujeres\u00a0\ncon\u00a0CM\u00a0tienen\u00a0un\u00a0familiar\u00a0con\u00a0esta\u00a0enfermedad. \u00a0\nEsto\u00a0significa\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0(m\u00e1s\u00a0del\u00a085%)\u00a0de\u00a0las\u00a0\nmujeres\u00a0que\u00a0contraen\u00a0CM\u00a0no\u00a0tienen\u00a0antecedentes \u00a0\nfamiliares28.\u00a0\nFACTORES \u00a0HORMONALES: \u00a0Las\u00a0mujeres\u00a0que\u00a0han\u00a0\ntenido\u00a0m\u00e1s\u00a0ciclos\u00a0menstruales \u00a0debido\u00a0a\u00a0que\u00a0\ncomenzaron \u00a0a\u00a0menstruar \u00a0a\u00a0una\u00a0edad\u00a0temprana \u00a0\n(antes\u00a0de\u00a0los\u00a012)\u00a0y/o\u00a0llegan\u00a0a\u00a0la\u00a0menopausia \u00a0a\u00a0una\u00a0\nedad\u00a0m\u00e1s\u00a0tard\u00eda\u00a0(despu\u00e9s\u00a0de\u00a055\u00a0a\u00f1os\u00a0de\u00a0edad)\u00a0\ntienen\u00a0un\u00a0riesgo\u00a0ligeramente \u00a0mayor\u00a0de\u00a0desarrollar \u00a0\nCM.\u00a0El\u00a0aumento\u00a0del\u00a0riesgo\u00a0puede\u00a0deberse\u00a0a\u00a0una\u00a0\nmayor\u00a0exposici\u00f3n \u00a0a\u00a0las\u00a0hormonas \u00a0estr\u00f3geno \u00a0y\u00a0\nprogesterona. \u00a0Estas\u00a0hormonas \u00a0tienen\u00a0un\u00a0papel\u00a0\nimportante \u00a0en\u00a0el\u00a0desarrollo \u00a0tumoral\u00a0atribuido\u00a0a\u00a0la\u00a0\npromoci\u00f3n \u00a0de\u00a0la\u00a0divisi\u00f3n\u00a0celular\u00a0que\u00a0tiene\u00a0lugar\u00a0\ntras\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0estas\u00a0hormonas \u00a0a\u00a0sus\u00a0receptores. \u00a0\nLa\u00a0menopausia \u00a0tard\u00eda,\u00a0por\u00a0el\u00a0contrario, \u00a0casi\u00a0\nduplica\u00a0el\u00a0riesgo\u00a0respecto\u00a0a\u00a0la\u00a0menopausia \u00a0precoz,\u00a0\nmientras\u00a0que\u00a0la\u00a0deprivaci\u00f3n \u00a0estrog\u00e9nica \u00a0\nprematura, \u00a0como\u00a0se\u00a0ha\u00a0observado \u00a0en\u00a0mujeres\u00a0\nsometidas \u00a0a\u00a0ooferectomia \u00a0reduce\u00a0el\u00a0riesgo61.\u00a0\u00a0\nPor\u00a0otro\u00a0lado\u00a0durante\u00a0los\u00a0embarazos \u00a0la\u00a0mujer\u00a0est\u00e1\u00a0\nexpuesta\u00a0a\u00a0dosis\u00a0mucho\u00a0m\u00e1s\u00a0elevadas\u00a0de\u00a0\nestr\u00f3genos \u00a0que\u00a0en\u00a0principio\u00a0se\u00a0asociar\u00eda\u00a0con\u00a0un\u00a0\nincremento \u00a0del\u00a0riesgo\u00a0inicial,\u00a0pero\u00a0a\u00a0la\u00a0larga\u00a0\nconstituyen \u00a0un\u00a0factor\u00a0de\u00a0protecci\u00f3n \u00a0ya\u00a0que\u00a0\nfacilitan\u00a0la\u00a0diferenciaci\u00f3n \u00a0celular\u00a0y\u00a0maduraci\u00f3n \u00a0del\u00a0\ntejido\u00a0mamario, \u00a0volvi\u00e9ndose \u00a0m\u00e1s\u00a0resistente \u00a0a\u00a0los\u00a0\nest\u00edmulos \u00a0estrog\u00e9nicos. \u00a0El\u00a0embarazo \u00a0disminuye \u00a0el\u00a0\nn\u00famero\u00a0de\u00a0ciclos\u00a0menstruales \u00a0totales\u00a0en\u00a0la\u00a0vida\u00a0de\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n28\u00a0\n\u00a0Tabla\u00a06.\u00a0Magnitud \u00a0del\u00a0riesgo\u00a0relativo\u00a0de\u00a0CM\u00a0estimado \u00a0para\u00a0diferentes \u00a0factores.\u00a0Modificado \u00a0de\u00a058.\u00a0\u00a0\nFACTORES \u00a0DE\u00a0RIESGO\u00a0EN\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\nFactor\u00a0de\u00a0riesgo\u00a0 Categor\u00eda \u00a0en\u00a0riesgo\u00a0 Comparaci\u00f3n \u00a0de\u00a0categor\u00eda \u00a0Riesgo\u00a0relativo\nIngesta\u00a0de\u00a0Alcohol\u00a0 2\u00a0bebidas\u00a0al\u00a0d\u00eda\u00a0 No\u00a0ingesta\u00a0de\u00a0alcohol\u00a0\u00a0 1.2\u00a0\u00a0\n\u00cdndice\u00a0de\u00a0Masa\u00a0Corporal\u00a0 Percentil\u00a080,\u00a055\u00a0a\u00f1os\u00a0o\u00a0mayor\u00a0\u00a0Percentil\u00a020\u00a0\u00a0 1.2\u00a0\u00a0\nTerapia\u00a0hormonal \u00a0\nsustitutiva \u00a0con\u00a0estr\u00f3geno \u00a0y\u00a0\nprogesterona \u00a0\u00a0El\u00a0usuario\u00a0habitual\u00a0durante\u00a0al\u00a0\nmenos\u00a05\u00a0a\u00f1os\u00a0Nunca\u00a0utilizado\u00a0\u00a0 1.3\u00a0\u00a0\nExposici\u00f3n \u00a0a\u00a0radiaciones \u00a0\nionizantes \u00a0\u00a0Fluoroscopia \u00a0repetida\u00a0 No\u00a0expuesto\u00a0\u00a0 1.6\u00a0\u00a0\nLa\u00a0radioterapia \u00a0para\u00a0la\u00a0\nenfermedad \u00a0de\u00a0Hodgkin\u00a0No\u00a0expuesto\u00a0\u00a0 5.2\u00a0\u00a0\nMenarq\u00faia \u00a0temprana \u00a0 Antes\u00a0de\u00a0los\u00a012\u00a0a\u00f1os\u00a0 Despu\u00e9s\u00a0de\u00a0los\u00a015\u00a0a\u00f1os\u00a0\u00a0 1.3\u00a0\u00a0\nMenopausia \u00a0tard\u00eda\u00a0 Despu\u00e9s\u00a0de\u00a0los\u00a055\u00a0a\u00f1os\u00a0 Antes\u00a0de\u00a0los\u00a045\u00a0a\u00f1os\u00a0\u00a0 1.2\u20131.5\u00a0\u00a0\nEdad\u00a0del\u00a0primer\u00a0parto\u00a0Nul\u00edparas \u00a0o\u00a01r\u00a0ni\u00f1o\u00a0despu\u00e9s\u00a0de\u00a0\nlos\u00a030\u00a0a\u00f1os\u00a01r\u00a0ni\u00f1o\u00a0antes\u00a0de\u00a0los\u00a020\u00a0a\u00f1os\u00a0\u00a0 1.7\u20131.9\u00a0\u00a0\nEdad\u00a0 65\u00a0a\u00f1os\u00a0o\u00a0mayor\u00a0 Menos\u00a0de\u00a065\u00a0a\u00f1os\u00a0\u00a0 5.8\u00a0\u00a0\nAntecedentes \u00a0de\u00a0CM\u00a0\u00a0 Carcinoma \u00a0de\u00a0mama\u00a0invasivo\u00a0Sin\u00a0antecedentes \u00a0de\u00a0carcinoma \u00a0\ninvasivo\u00a0\u00a06.8\u00a0\u00a0\nOtros\u00a0hallazgos\u00a0histol\u00f3gicos \u00a0\n\u00a0\u00a0Carcinoma \u00a0lobular\u00a0invasivo\u00a0 Sin\u00a0anomal\u00edas \u00a0detectadas \u00a0\u00a0\u00a0 16.4\u00a0\u00a0\nCarcinoma \u00a0ductal\u00a0in\u00a0situ\u00a0 Sin\u00a0anomal\u00edas \u00a0detectadas \u00a0\u00a0 \u00a0 17.3\u00a0\u00a0\nBiopsia\u00a0mamaria\u00a0Hiperplasia \u00a0sin\u00a0atipia *\u00a0\u00a0 Sin\u00a0hiperplasia \u00a0\u00a0 1.9\u00a0\u00a0\nHiperplasia \u00a0sin\u00a0atipia\u00a0 Sin\u00a0hiperplasia \u00a0\u00a0 5.3\u00a0\u00a0\nHiperplasia \u00a0con\u00a0atipia\u00a0e\u00a0\nhistoria\u00a0familiar\u00a0positiva\u00a0Sin\u00a0hiperplasia, \u00a0historia\u00a0\nfamiliar\u00a0negativa\u00a0\u00a011\u00a0\u00a0\nCitolog\u00eda\u00a0(aspiraci\u00f3n \u00a0con\u00a0aguja\u00a0\nfina,\u00a0aspiraci\u00f3n \u00a0del\u00a0l\u00edquido\u00a0del\u00a0\npez\u00f3n)\u00a0Proliferaci\u00f3n \u00a0sin\u00a0atipia\u00a0*\u00a0 Sin\u00a0anomal\u00edas \u00a0detectadas \u00a0\u00a0\u00a0 2.5\u00a0\u00a0\nProliferaci\u00f3n \u00a0sin\u00a0atipia\u00a0 Sin\u00a0anomal\u00edas \u00a0detectadas \u00a0\u00a0\u00a0 4.9\u20135\u00a0\u00a0\nProliferaci\u00f3n \u00a0con\u00a0atipia\u00a0e\u00a0\nhistoria\u00a0familiar\u00a0positiva\u00a0Sin\u00a0anomal\u00edas \u00a0detectadas \u00a0\u00a0\u00a0 18.1\u00a0\u00a0\nHistoria\u00a0familiar\u00a01r\u00a0grado\u00a0relativo\u00a0a\u00a0los\u00a050\u00a0a\u00f1os\u00a0\no\u00a0m\u00e1s\u00a0con\u00a0CM\u00a0\nposmenop\u00e1usico \u00a0Sin\u00a01r\u00a0o\u00a02o\u00a0grado\u00a0relativo\u00a0con\u00a0\nCM\u00a0\u00a01.8\u00a0\u00a0\n1\u00ba\u00a0grado\u00a0relativo\u00a0con\u00a0CM\u00a0\npremenopausico \u00a0\u00a0Sin\u00a01\u00ba\u00a0o\u00a02\u00ba\u00a0grado\u00a0relativo\u00a0con\u00a0\nCM\u00a0\u00a03.3\u00a0\u00a0\n2\u00ba\u00a0grado\u00a0relativo\u00a0con\u00a0CM\u00a0\npremenopausico \u00a0\u00a0Sin\u00a01r\u00a0o\u00a02o\u00a0grado\u00a0relativo\u00a0con\u00a0\nCM\u00a0\u00a01.5\u00a0\u00a0\nDos\u00a0primeros\u00a0grados\u00a0relativos\u00a0\ncon\u00a0CM\u00a0premenopausico \u00a0\u00a0Sin\u00a01r\u00a0o\u00a02o\u00a0grado\u00a0relativo\u00a0con\u00a0\nCM\u00a0\u00a03.6\u00a0\u00a0\nMutaci\u00f3n \u00a0en\u00a0la\u00a0l\u00ednea\u00a0germinal\u00a0\u00a0Heterocigotos \u00a0para\u00a0BRCA1,\u00a0\nedad\u00a040\u00a0\u00a0No\u00a0heterocigotos \u00a0para\u00a0BRCA1,\u00a0\nedad\u00a041\u00a0\u00a0200\u2020\u00a0\u00a0\nHeterocigotos \u00a0para\u00a0BRCA1,\u00a0\nedad\u00a060\u201069\u00a0No\u00a0heterocigotos \u00a0para\u00a0BRCA1,\u00a0\nedad\u00a060\u201069\u00a0\u00a015\u2020\u00a0\u00a0\n*\u00a0Existe\u00a0controversia \u00a0sobre\u00a0si\u00a0la\u00a0hiperplasia \u00a0patol\u00f3gica \u00a0detectada \u00a0en\u00a0muestras \u00a0de\u00a0biopsia\u00a0de\u00a0mama\u00a0es\u00a0directamente \u00a0equivalente \u00a0a\u00a0la\u00a0hiperplasia \u00a0\ndel\u00a0\u00a0examen\u00a0citol\u00f3gico \u00a0en\u00a0muestras \u00a0obtenidas \u00a0mediante \u00a0PAAF\u00a0o\u00a0la\u00a0aspiraci\u00f3n \u00a0del\u00a0pez\u00f3n.\u00a0\n\u2020\u00a0Begg\u00a0ha\u00a0sugerido\u00a0que\u00a0estos\u00a0riesgos\u00a0relativos\u00a0est\u00e1n\u00a0sujetos\u00a0a\u00a0un\u00a0sesgo\u00a0de\u00a0evaluaci\u00f3n \u00a0y\u00a0puede\u00a0sobreestimar \u00a0el\u00a0riesgo\u00a0real\u00a0asociado\u00a0con\u00a0\nmutaciones \u00a0en\u00a0la\u00a0l\u00ednea\u00a0germinal\u00a0de\u00a0los\u00a0genes\u00a0BRCA.\u00a0\n\u00a0\n\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n29\u00a0\n\u00a0la\u00a0mujer,\u00a0y\u00a0esta\u00a0podr\u00eda\u00a0ser\u00a0tambi\u00e9n\u00a0una\u00a0de\u00a0las\u00a0\nrazones\u00a0de\u00a0tal\u00a0efecto.\u00a0La\u00a0protecci\u00f3n \u00a0conferida \u00a0por\u00a0\nla\u00a0maternidad \u00a0precoz\u00a0persiste\u00a0durante\u00a0toda\u00a0la\u00a0\nvida,\u00a0y\u00a0crece\u00a0al\u00a0aumentar \u00a0la\u00a0frecuencia \u00a0de\u00a0partos61.\u00a0\u00a0\nEl\u00a0uso\u00a0de\u00a0anticonceptivos \u00a0hormonales \u00a0muestra\u00a0un\u00a0\nmodesto\u00a0incremento \u00a0en\u00a0el\u00a0riesgo\u00a0para\u00a0desarrollar \u00a0\nCM,\u00a0y\u00a0no\u00a0existen\u00a0evidencias \u00a0de\u00a0que\u00a0este\u00a0exceso\u00a0en\u00a0\nel\u00a0riesgo\u00a0persista\u00a0m\u00e1s\u00a0all\u00e1\u00a0de\u00a0los\u00a010\u00a0a\u00f1os\u00a0tras\u00a0el\u00a0\ncese\u00a0de\u00a0dichos.\u00a0Sin\u00a0embargo, \u00a0el\u00a0uso\u00a0de\u00a0terapias\u00a0de\u00a0\nreemplazo \u00a0hormonal \u00a0o\u00a0terapias\u00a0hormonales \u00a0\nsustitutivas \u00a0(TRH)\u00a0en\u00a0el\u00a0periodo\u00a0de\u00a0la\u00a0menopausia \u00a0\naumenta\u00a0el\u00a0riesgo\u00a0en\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0alargamiento \u00a0\nde\u00a0dicho\u00a0tratamiento58.\u00a0\nEXPOSICI\u00d3N \u00a0A\u00a0LA\u00a0RADIACI\u00d3N: \u00a0Los\u00a0estudios\u00a0\nrealizados \u00a0por\u00a0Boice\u00a0y\u00a0colaboradores \u00a0relacionados \u00a0\ncon\u00a0los\u00a0enfermos \u00a0de\u00a0tuberculosis \u00a0han\u00a0\ndocumentado \u00a0que\u00a0m\u00faltiples \u00a0fluoroscopias \u00a0son\u00a0un\u00a0\nfactor\u00a0de\u00a0riesgo\u00a0significativo \u00a0de\u00a0padecer\u00a0CM62,63.\u00a0\nEl\u00a0riesgo\u00a0de\u00a0CM\u00a0tambi\u00e9n\u00a0se\u00a0incrementa \u00a0en\u00a0\nmujeres\u00a0que\u00a0recibieron \u00a0radioterapia \u00a0en\u00a0el\u00a0\u00e1rea\u00a0del\u00a0\npecho\u00a0para\u00a0el\u00a0tratamiento \u00a0del\u00a0linfoma\u00a0de\u00a0Hodgkin.\u00a0\nClemons\u00a0y\u00a0colaboradores64\u00a0revisaron \u00a017\u00a0estudios\u00a0\npublicados \u00a0que\u00a0analizaban \u00a0la\u00a0incidencia \u00a0de\u00a0CM\u00a0en\u00a0\nlos\u00a0pacientes \u00a0que\u00a0sobreviv\u00edan \u00a0a\u00a0la\u00a0enfermedad \u00a0de\u00a0\nHodgkin.\u00a0Se\u00a0encontr\u00f3\u00a0un\u00a0riesgo\u00a0relativo\u00a0de\u00a0media\u00a0\n5,2\u00a0en\u00a0un\u00a0per\u00edodo\u00a0de\u00a0latencia\u00a0con\u00a0un\u00a0promedio \u00a0de\u00a0\n14\u00a0a\u00f1os.\u00a0\n\u00a0\nESTILO\u00a0DE\u00a0VIDA\u00a0Y\u00a0FACTORES \u00a0AMBIENTALES: \u00a0Hay\u00a0\nun\u00a0gran\u00a0inter\u00e9s\u00a0por\u00a0parte\u00a0del\u00a0p\u00fablico\u00a0en\u00a0general\u00a0\nen\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0que\u00a0pueden\u00a0estar\u00a0bajo\u00a0el\u00a0\ncontrol\u00a0directo\u00a0de\u00a0la\u00a0persona,\u00a0como\u00a0es\u00a0el\u00a0caso\u00a0del\u00a0\ntabaquismo \u00a0y\u00a0el\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n.\u00a0Durante\u00a0\nmucho\u00a0tiempo\u00a0no\u00a0se\u00a0encontr\u00f3\u00a0ninguna\u00a0relaci\u00f3n\u00a0\nentre\u00a0el\u00a0tabaquismo \u00a0y\u00a0el\u00a0CM\u00a0pero\u00a0en\u00a0los\u00a0\u00faltimos\u00a0\na\u00f1os,\u00a0algunos\u00a0estudios\u00a0han\u00a0encontrado \u00a0que\u00a0el\u00a0\ntabaquismo \u00a0puede\u00a0aumentar \u00a0el\u00a0riesgo\u00a0de\u00a0esta\u00a0\nenfermedad. \u00a0El\u00a0aumento\u00a0del\u00a0riesgo\u00a0parece\u00a0afectar\u00a0\na\u00a0ciertos\u00a0grupos,\u00a0tales\u00a0como\u00a0mujeres\u00a0que\u00a0\ncomenzaron \u00a0a\u00a0fumar\u00a0cuando\u00a0eran\u00a0j\u00f3venes.\u00a0En\u00a0\n2009,\u00a0la\u00a0Agencia\u00a0Internacional \u00a0para\u00a0la\u00a0\nInvestigaci\u00f3n \u00a0del\u00a0C\u00e1ncer\u00a0concluy\u00f3\u00a0que\u00a0existen\u00a0\nevidencias \u00a0limitadas\u00a0de\u00a0que\u00a0el\u00a0consumo\u00a0de\u00a0tabaco\u00a0\nprovoca\u00a0CM65.\u00a0Hoy\u00a0en\u00a0d\u00eda\u00a0se\u00a0sigue\u00a0estudiando \u00a0c\u00f3mo\u00a0prevenir\u00a0el\u00a0\nc\u00e1ncer\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0modificaciones \u00a0del\u00a0\ncomportamiento \u00a0o\u00a0la\u00a0evitaci\u00f3n\u00a0de\u00a0los\u00a0agentes\u00a0\ncancer\u00edgenos. \u00a0La\u00a0asociaci\u00f3n \u00a0entre\u00a0la\u00a0dieta\u00a0con\u00a0\nelevado\u00a0contenido \u00a0en\u00a0grasas\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0CM\u00a0\nfueron\u00a0estudiados \u00a0por\u00a0algunos\u00a0grupos\u00a0y\u00a0reflejaron \u00a0\nuna\u00a0incidencia \u00a0de\u00a0CM\u00a0superior\u00a0en\u00a0los\u00a0pa\u00edses\u00a0con\u00a0\nelevado\u00a0consumo\u00a0de\u00a0grasas.\u00a0Sin\u00a0embargo\u00a0otros\u00a0\ntrabajos\u00a0similares\u00a0no\u00a0han\u00a0podido\u00a0corroborar \u00a0\ndichos\u00a0resultados \u00a059,66.\u00a0Los\u00a0estudios\u00a0con\u00a0modelos\u00a0\nanimales\u00a0demuestran \u00a0que\u00a0el\u00a0consumo\u00a0de\u00a0grasas\u00a0\npoliinsaturadas \u00a0parece\u00a0estar\u00a0asociado\u00a0a\u00a0unos\u00a0\nniveles\u00a0circulantes \u00a0de\u00a0estr\u00f3genos \u00a0y\u00a0progest\u00e1genos \u00a0\nm\u00e1s\u00a0elevados. \u00a0Pero\u00a0no\u00a0est\u00e1\u00a0claro\u00a0si\u00a0el\u00a0incremento \u00a0\ndel\u00a0riesgo\u00a0es\u00a0debido\u00a0\u00fanicamente \u00a0al\u00a0consumo\u00a0total\u00a0\nde\u00a0grasas\u00a0o\u00a0a\u00a0una\u00a0ingesta\u00a0cal\u00f3rica\u00a0excesiva59.\u00a0\nTener\u00a0sobrepeso \u00a0u\u00a0obesidad\u00a0se\u00a0ha\u00a0asociado\u00a0a\u00a0un\u00a0\nmayor\u00a0riesgo\u00a0a\u00a0desarrollar \u00a0de\u00a0CM,\u00a0especialmente \u00a0\nen\u00a0mujeres\u00a0post\u2010menop\u00e1usicas. \u00a0Antes\u00a0de\u00a0la\u00a0\nmenopausia, \u00a0los\u00a0ovarios\u00a0producen \u00a0la\u00a0mayor\u00a0parte\u00a0\ndel\u00a0estr\u00f3geno, \u00a0y\u00a0el\u00a0tejido\u00a0graso\u00a0produce\u00a0una\u00a0\nmenor\u00a0cantidad. \u00a0Por\u00a0el\u00a0contrario\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0\nmenopausia \u00a0(cuando\u00a0los\u00a0ovarios\u00a0dejan\u00a0de\u00a0producir\u00a0\nestr\u00f3genos), \u00a0la\u00a0mayor\u00a0parte\u00a0del\u00a0estr\u00f3geno \u00a0de\u00a0una\u00a0\nmujer\u00a0proviene\u00a0de\u00a0tejido\u00a0graso.\u00a0Tener\u00a0m\u00e1s\u00a0tejido\u00a0\nadiposo\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0menopausia \u00a0puede\u00a0\naumentar \u00a0la\u00a0probabilidad \u00a0de\u00a0contraer\u00a0CM\u00a0al\u00a0\naumentar \u00a0los\u00a0niveles\u00a0de\u00a0estr\u00f3geno65.\u00a0Hay\u00a0que\u00a0\ntener\u00a0en\u00a0cuenta\u00a0que\u00a0las\u00a0mujeres\u00a0con\u00a0sobrepeso \u00a0\ntienden\u00a0a\u00a0tener\u00a0niveles\u00a0m\u00e1s\u00a0altos\u00a0de\u00a0insulina\u00a0en\u00a0\nsangre\u00a0y\u00a0niveles\u00a0m\u00e1s\u00a0altos\u00a0de\u00a0insulina\u00a0tambi\u00e9n\u00a0se\u00a0\nhan\u00a0relacionado \u00a0con\u00a0algunos\u00a0tipos\u00a0de\u00a0c\u00e1ncer,\u00a0\nincluyendo \u00a0el\u00a0CM.\u00a0Del\u00a0mismo\u00a0modo,\u00a0varios\u00a0\nestudios\u00a0sugieren\u00a0que\u00a0un\u00a0\u00edndice\u00a0de\u00a0masa\u00a0corporal\u00a0\nalto\u00a0tambi\u00e9n\u00a0est\u00e1\u00a0asociado\u00a0a\u00a0mayores\u00a0niveles\u00a0de\u00a0\ninsulina\u00a0y\u00a0factores\u00a0de\u00a0crecimiento \u00a0similares\u00a0a\u00a0la\u00a0\ninsulina,\u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0\ncontraer\u00a0la\u00a0enfermedad58.\u00a0\nPor\u00a0otro\u00a0lado\u00a0el\u00a0uso\u00a0de\u00a0alcohol\u00a0est\u00e1\u00a0claramente \u00a0\nrelacionado \u00a0con\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0\nCM.\u00a0El\u00a0riesgo\u00a0aumenta\u00a0con\u00a0la\u00a0cantidad\u00a0de\u00a0alcohol\u00a0\nconsumido. \u00a0En\u00a0comparaci\u00f3n \u00a0con\u00a0las\u00a0no\u00a0bebedoras, \u00a0\nlas\u00a0mujeres\u00a0que\u00a0consumen \u00a0una\u00a0bebida\u00a0alcoh\u00f3lica \u00a0\nal\u00a0d\u00eda\u00a0tienen\u00a0un\u00a0aumento\u00a0muy\u00a0peque\u00f1o\u00a0en\u00a0el\u00a0\nriesgo.\u00a0Las\u00a0que\u00a0consumen \u00a0de\u00a02\u00a0a\u00a05\u00a0bebidas\u00a0al\u00a0d\u00eda\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n30\u00a0\n\u00a0tienen\u00a0alrededor \u00a0de\u00a01,2\u00a0veces\u00a0m\u00e1s\u00a0riesgo\u00a0que\u00a0las\u00a0\nmujeres\u00a0que\u00a0no\u00a0toman\u00a0alcohol.\u00a0El\u00a0consumo\u00a0\nexcesivo\u00a0de\u00a0alcohol\u00a0tambi\u00e9n\u00a0se\u00a0sabe\u00a0que\u00a0aumenta\u00a0\nel\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0otros\u00a0tipos\u00a0de\u00a0c\u00e1ncer65.\u00a0\u00a0\nHISTORIA \u00a0FAMILIAR \u00a0Y\u00a0PERSONAL: \u00a0Es\u00a0importante \u00a0\nconocer\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0previa\u00a0de\u00a0cada\u00a0paciente\u00a0\npara\u00a0poder\u00a0prevenir\u00a0mejor\u00a0de\u00a0cara\u00a0al\u00a0futuro\u00a0su\u00a0\nriesgo\u00a0a\u00a0desarrollar \u00a0c\u00e1ncer.\u00a0Las\u00a0personas\u00a0que\u00a0\ntienen\u00a0una\u00a0historia\u00a0previa\u00a0de\u00a0lesiones\u00a0benignas\u00a0no\u00a0\nparecen\u00a0tener\u00a0un\u00a0mayor\u00a0riesgo,\u00a0en\u00a0cambio\u00a0\npacientes \u00a0con\u00a0lesiones\u00a0proliferativas \u00a0como\u00a0la\u00a0\nhiperplasia \u00a0(at\u00edpica\u00a0o\u00a0t\u00edpica)\u00a0parecen\u00a0incrementar \u00a0\neste\u00a0riesgo.\u00a0Dupont\u00a0y\u00a0colaboradores, \u00a0compararon \u00a0\npacientes \u00a0con\u00a0hiperplasia, \u00a0con\u00a0pacientes \u00a0sanas\u00a0y\u00a0\nencontraron \u00a0que\u00a0el\u00a0riesgo\u00a0relativo\u00a0de\u00a0CM\u00a0invasivo\u00a0\nfue\u00a0de\u00a01,9\u00a0en\u00a0pacientes \u00a0con\u00a0hiperplasia \u00a0temprana, \u00a0\nde\u00a05,3\u00a0en\u00a0pacientes \u00a0con\u00a0hiperplasia \u00a0at\u00edpica,\u00a0y\u00a011\u00a0\nen\u00a0pacientes \u00a0con\u00a0hiperplasia \u00a0at\u00edpica\u00a0con\u00a0una\u00a0\nhistoria\u00a0familiar\u00a0positiva\u00a0(madre,\u00a0hermana\u00a0o\u00a0hija)\u00a0\ncon\u00a0CM67.\u00a0\nEl\u00a0CLIS\u00a0(tambi\u00e9n\u00a0llamado\u00a0neoplasia \u00a0lobular)\u00a0se\u00a0\nagrupan\u00a0a\u00a0veces\u00a0con\u00a0el\u00a0CDIS,\u00a0como\u00a0un\u00a0tipo\u00a0de\u00a0CM\u00a0\nno\u00a0invasivo,\u00a0pero\u00a0difiere\u00a0de\u00a0un\u00a0CDIS\u00a0en\u00a0que,\u00a0\naunque\u00a0est\u00e1\u00a0reconocido \u00a0que\u00a0existe\u00a0un\u00a0cierto\u00a0\nriesgo\u00a0a\u00a0desarrollar \u00a0CM\u00a0si\u00a0eres\u00a0diagnosticada \u00a0con\u00a0\nCLIS,\u00a0no\u00a0parece\u00a0ser\u00a0una\u00a0condici\u00f3n \u00a0pre\u2010invasiva.\u00a0Las\u00a0\nmujeres\u00a0con\u00a0esta\u00a0afecci\u00f3n\u00a0tienen\u00a0un\u00a0riesgo\u00a0de\u00a07\u00a0a\u00a0\n11\u00a0veces\u00a0mayor\u00a0de\u00a0desarrollar \u00a0c\u00e1ncer\u00a0invasivo\u00a0en\u00a0\ncualquiera \u00a0de\u00a0los\u00a0senos.\u00a0Por\u00a0esta\u00a0raz\u00f3n,\u00a0deben\u00a0\nasegurarse \u00a0de\u00a0que\u00a0se\u00a0realizan\u00a0mamograf\u00edas \u00a0\nperi\u00f3dicas \u00a0y\u00a0visitas\u00a0al\u00a0m\u00e9dico.\u00a0En\u00a0cambio\u00a0el\u00a0CDIS\u00a0es\u00a0\nuna\u00a0lesi\u00f3n\u00a0pre\u2010invasiva,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0es\u00a0de\u00a0\nextra\u00f1ar\u00a0que\u00a0su\u00a0diagn\u00f3stico \u00a0se\u00a0asocie\u00a0con\u00a0un\u00a0\nmayor\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0un\u00a0carcinoma \u00a0\ninvasivo.\u00a0Un\u00a0estudio\u00a0pionero\u00a0de\u00a0Page\u00a0y\u00a0\ncolaboradores68\u00a0hizo\u00a0un\u00a0seguimiento \u00a0de\u00a0mujeres\u00a0\ncon\u00a0DCIS\u00a0que\u00a0\u00fanicamente \u00a0hab\u00edan\u00a0sido\u00a0biopsiadas \u00a0y\u00a0\nencontr\u00f3\u00a0(en\u00a0un\u00a0promedio \u00a0de\u00a0seguimiento \u00a0de\u00a0\nunos\u00a015\u00a0a\u00f1os)\u00a0una\u00a0incidencia \u00a0del\u00a028%\u00a0de\u00a0\ndesarrollo \u00a0de\u00a0c\u00e1ncer\u00a0invasivo.\u00a0Esto\u00a0significa\u00a0una\u00a0\nincidencia \u00a0anual\u00a0de\u00a0un\u00a01,9%\u00a0y\u00a0un\u00a0riesgo\u00a0relativo\u00a0\ndel\u00a017.358.\u00a0En\u00a0cambio\u00a0tras\u00a0desarrollar \u00a0un\u00a0c\u00e1ncer\u00a0\ninvasivo\u00a0de\u00a0mama,\u00a0el\u00a0riesgo\u00a0de\u00a0afectaci\u00f3n \u00a0\ncontralateral \u00a0se\u00a0incrementa \u00a0hasta\u00a010\u00a0veces61.\u00a0Por\u00a0otro\u00a0lado\u00a0no\u00a0hay\u00a0que\u00a0olvidar\u00a0que\u00a0mujeres\u00a0con\u00a0\ntejido\u00a0mamario\u00a0m\u00e1s\u00a0denso\u00a0(como\u00a0se\u00a0detecta\u00a0en\u00a0la\u00a0\nmamograf\u00eda) \u00a0con\u00a0mayor\u00a0tejido\u00a0glandular \u00a0y\u00a0menos\u00a0\ntejido\u00a0graso,\u00a0tienen\u00a0tambi\u00e9n\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0\nCM.\u00a0Por\u00a0desgracia, \u00a0un\u00a0tejido\u00a0m\u00e1s\u00a0denso\u00a0de\u00a0la\u00a0\nmama\u00a0tambi\u00e9n\u00a0puede\u00a0hacer\u00a0m\u00e1s\u00a0dif\u00edcil\u00a0para\u00a0los\u00a0\nm\u00e9dicos\u00a0detectar\u00a0problemas \u00a0en\u00a0las\u00a0mamograf\u00edas. \u00a0\n2.4.2.\u00a0Factores\u00a0de\u00a0riesgo\u00a0gen\u00e9ticos \u00a0\n\u00a0\nLa\u00a0predisposici\u00f3n \u00a0gen\u00e9tica\u00a0se\u00a0refleja\u00a0en\u00a0\naproximadamente \u00a0el\u00a020%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0CM\u00a0\nque\u00a0tienen\u00a0una\u00a0historia\u00a0familiar\u00a0positiva.\u00a0\nConcretamente \u00a0se\u00a0han\u00a0identificado \u00a0de\u00a0un\u00a05%\u00a0a\u00a0un\u00a0\n10%\u00a0de\u00a0pacientes \u00a0con\u00a0una\u00a0herencia\u00a0gen\u00e9tica\u00a0\ndebida\u00a0a\u00a0una\u00a0mutaci\u00f3n \u00a0germinal\u00a0espec\u00edfica65.\u00a0La\u00a0\ncausa\u00a0m\u00e1s\u00a0com\u00fan\u00a0de\u00a0CM\u00a0hereditario \u00a0es\u00a0una\u00a0\nmutaci\u00f3n \u00a0en\u00a0los\u00a0genes\u00a0BRCA1\u00a0y\u00a0BRCA2.\u00a0En\u00a0las\u00a0\nc\u00e9lulas\u00a0normales, \u00a0estos\u00a0genes\u00a0ayudan\u00a0a\u00a0prevenir\u00a0el\u00a0\nc\u00e1ncer\u00a0mediante \u00a0la\u00a0producci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0que\u00a0\nimpiden\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0crezcan\u00a0anormalmente. \u00a0\nLas\u00a0m\u00faltiples \u00a0funciones \u00a0de\u00a0BRCA1\u00a0podr\u00edan\u00a0ser\u00a0la\u00a0\nbase\u00a0para\u00a0conocer\u00a0mejor\u00a0su\u00a0papel\u00a0en\u00a0la\u00a0\ncarcinog\u00e9nesis. \u00a0Estas\u00a0funciones \u00a0incluyen\u00a0la\u00a0\nreparaci\u00f3n \u00a0del\u00a0ADN,\u00a0puntos\u00a0de\u00a0control\u00a0del\u00a0ciclo\u00a0\ncelular,\u00a0la\u00a0ubiquitinaci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0y\u00a0la\u00a0\nremodelaci\u00f3n \u00a0de\u00a0la\u00a0cromatina. \u00a0En\u00a0cambio\u00a0BRCA2\u00a0\nest\u00e1\u00a0implicada \u00a0en\u00a0la\u00a0recombinaci\u00f3n \u00a0hom\u00f3loga, \u00a0\npero\u00a0poco\u00a0m\u00e1s\u00a0se\u00a0sabe\u00a0acerca\u00a0de\u00a0su\u00a0funci\u00f3n69.\u00a0\nTodav\u00eda\u00a0hay\u00a0controversia \u00a0sobre\u00a0qu\u00e9\u00a0m\u00e9todo\u00a0\nepidemiol\u00f3gico \u00a0es\u00a0el\u00a0mejor\u00a0para\u00a0estimar\u00a0el\u00a0riesgo\u00a0\nde\u00a0c\u00e1ncer\u00a0que\u00a0se\u00a0asocia\u00a0con\u00a0una\u00a0mutaci\u00f3n \u00a0\nparticular. \u00a0Hay\u00a0estudios\u00a0que\u00a0sostienen \u00a0que\u00a0el\u00a0\nriesgo\u00a0de\u00a0desarrollar \u00a0CM\u00a0es\u00a0alto\u00a0para\u00a0los\u00a0\nportadores \u00a0de\u00a0determinadas \u00a0mutaciones. \u00a0Este\u00a0\nenfoque\u00a0se\u00a0basa\u00a0en\u00a0estudios\u00a0de\u00a0familias\u00a0que\u00a0\ntienen\u00a0un\u00a0historial\u00a0de\u00a0CM.\u00a0Por\u00a0otro\u00a0lado\u00a0hay\u00a0\nargumentos \u00a0que\u00a0defienden \u00a0que\u00a0las\u00a0estimaciones \u00a0\nde\u00a0penetrancia \u00a0(entendida \u00a0como\u00a0el\u00a0riesgo\u00a0de\u00a0\ndesarrolar \u00a0CM\u00a0hasta\u00a0la\u00a0edad\u00a0de\u00a070\u00a0a\u00f1os)\u00a0que\u00a0se\u00a0\nderivan\u00a0del\u00a0estudio\u00a0de\u00a0familias\u00a0de\u00a0muchos\u00a0\nmiembros, \u00a0son\u00a0demasiado \u00a0altas\u00a0y\u00a0puede\u00a0generar\u00a0\nmiedo\u00a0innecesario \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0general.\u00a0Por\u00a0lo\u00a0\ntanto\u00a0se\u00a0cree\u00a0que\u00a0la\u00a0inclusi\u00f3n\u00a0de\u00a0mujeres\u00a0en\u00a0los\u00a0\nestudios\u00a0debe\u00a0ser\u00a0independiente \u00a0de\u00a0sus\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n31\u00a0\n\u00a0antecedentes \u00a0familiares. \u00a0Se\u00a0espera\u00a0que\u00a0futuros\u00a0\nestudios\u00a0prospectivos \u00a0proporcionen \u00a0un\u00a0an\u00e1lisis\u00a0\nm\u00e1s\u00a0eficaz,\u00a0aunque\u00a0estos\u00a0requieren \u00a0un\u00a0gran\u00a0\nn\u00famero\u00a0de\u00a0pacientes \u00a0y\u00a0un\u00a0seguimiento \u00a0durante\u00a0\nlargos\u00a0per\u00edodos\u00a0de\u00a0tiempo69.\u00a0\u00a0\nAmbos\u00a0genes\u00a0BRCA1\u00a0y\u00a0BRCA2\u00a0parecen\u00a0tener\u00a0\nvalores\u00a0de\u00a0penetrancia \u00a0de\u00a0un\u00a080%70.\u00a0\nConcretamente, \u00a0el\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0c\u00e1ncer\u00a0a\u00a0\nlo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0var\u00eda\u00a0desde\u00a0el\u00a056\u00a0hasta\u00a087%\u00a0\npara\u00a0las\u00a0portadoras \u00a0de\u00a0la\u00a0mutaci\u00f3n \u00a0BRCA1\u00a0y\u00a0desde\u00a0\nel\u00a028\u00a0hasta\u00a0el\u00a084%\u00a0para\u00a0aquellas\u00a0con\u00a0mutaciones \u00a0\ndel\u00a0gen\u00a0BRCA271.\u00a0Adem\u00e1s,\u00a0las\u00a0que\u00a0sobreviven \u00a0al\u00a0\nCM\u00a0con\u00a0una\u00a0mutaci\u00f3n \u00a0hereditaria \u00a0en\u00a0cualquiera \u00a0\nde\u00a0estos\u00a0genes\u00a0tienen\u00a0un\u00a0riesgo\u00a0importante \u00a0de\u00a0\ndesarrollar \u00a0un\u00a0segundo\u00a0tumor\u00a0primario.\u00a0Este\u00a0\nriesgo\u00a0se\u00a0aproxima \u00a0al\u00a020%\u00a0durante\u00a0los\u00a0siguientes \u00a05\u00a0\na\u00f1os\u00a0a\u00a0partir\u00a0del\u00a0diagn\u00f3stico \u00a0inicial\u00a0y\u00a0al\u00a064%\u00a0\ndurante\u00a0toda\u00a0la\u00a0vida\u00a0de\u00a0la\u00a0paciente. \u00a0Mutaciones \u00a0\ndel\u00a0gen\u00a0BRCA2\u00a0se\u00a0han\u00a0asociado\u00a0con\u00a0un\u00a0riesgo\u00a0del\u00a0\n12%\u00a0de\u00a0desarrollar \u00a0un\u00a0segundo\u00a0CM\u00a0durante\u00a0los\u00a05\u00a0\na\u00f1os\u00a0desde\u00a0el\u00a0diagn\u00f3stico \u00a0inicial\u00a0y\u00a0un\u00a0riesgo\u00a0del\u00a0\n52%\u00a0a\u00a0la\u00a0edad\u00a0de\u00a070\u00a0a\u00f1os.\u00a0Adem\u00e1s,\u00a0las\u00a0mujeres\u00a0\ncon\u00a0mutaciones \u00a0en\u00a0BRCA1\u00a0o\u00a0BRCA2\u00a0tienen\u00a0un\u00a0\nriesgo\u00a0significativamente \u00a0elevado\u00a0de\u00a0por\u00a0vida\u00a0de\u00a0\ndesarrollar \u00a0otros\u00a0tumores\u00a0malignos, \u00a0en\u00a0particular \u00a0\nc\u00e1ncer\u00a0de\u00a0ovario70\u201075.\u00a0\u00a0\nEn\u00a0l\u00edneas\u00a0generales, \u00a0los\u00a0genes\u00a0que\u00a0hasta\u00a0la\u00a0fecha\u00a0\nhan\u00a0sido\u00a0identificados \u00a0como\u00a0genes\u00a0asociados \u00a0con\u00a0\nc\u00e1ncer\u00a0hereditario \u00a0de\u00a0mama\u00a0son\u00a0BRCA1,\u00a0BRCA2,\u00a0\nTP53,\u00a0CHK2,\u00a0PTEN\u00a0y\u00a0ATM65,69,76.\u00a0Todos\u00a0ellos\u00a0\nforman\u00a0parta\u00a0de\u00a0la\u00a0maquinaria \u00a0celular\u00a0que\u00a0\nmantiene \u00a0la\u00a0integridad \u00a0gen\u00f3mica \u00a0y\u00a0repara\u00a0el\u00a0ADN.\u00a0\nSin\u00a0embargo, \u00a0s\u00f3lo\u00a0las\u00a0mutaciones \u00a0en\u00a0los\u00a0genes\u00a0\nBRCA\u00a0son\u00a0criterio\u00a0para\u00a0indicar\u00a0una\u00a0prueba\u00a0\ngen\u00e9tica.\u00a0El\u00a0riesgo\u00a0para\u00a0desarrollar \u00a0CM\u00a0es\u00a0\ninfluenciado \u00a0por\u00a0la\u00a0heterogeneidad \u00a0de\u00a0los\u00a0alelos,\u00a0\npor\u00a0los\u00a0genes\u00a0modificadores, \u00a0por\u00a0cofactores \u00a0\nambientales \u00a0y\u00a0hormonales \u00a0(anticonceptivos \u00a0\norales,\u00a0terapia\u00a0de\u00a0reposici\u00f3n \u00a0hormonal, \u00a0paridad\u00a0y\u00a0\nlactancia). \u00a0\n\u00a0\n\u00a03.\u00a0ORIGEN\u00a0Y\u00a0EVOLUCI\u00d3N \u00a0DEL\u00a0\nC\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\n\u00a0\nEl\u00a0CM\u00a0es\u00a0una\u00a0enfermedad \u00a0altamente \u00a0heterog\u00e9nea, \u00a0\nhecho\u00a0que\u00a0se\u00a0manifiesta \u00a0en\u00a0casi\u00a0todas\u00a0las\u00a0\ncaracter\u00edsticas \u00a0tumorales. \u00a0\u00a0\nLa\u00a0heterogeneidad \u00a0del\u00a0CM\u00a0es\u00a0uno\u00a0de\u00a0los\u00a0\nprincipales \u00a0motivos\u00a0por\u00a0lo\u00a0que\u00a0algunos\u00a0\ntratamientos \u00a0no\u00a0son\u00a0del\u00a0todo\u00a0exitosos,\u00a0y\u00a0dificulta\u00a0\nenormemente \u00a0el\u00a0camino\u00a0para\u00a0lograr\u00a0un\u00a0\ndiagn\u00f3stico \u00a0efectivo77.\u00a0Adem\u00e1s,\u00a0durante\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas \u00a0\nadquieren \u00a0alteraciones \u00a0gen\u00e9ticas \u00a0y\u00a0epigen\u00e9ticas \u00a0\nque\u00a0generan\u00a0distintas\u00a0poblaciones \u00a0celulares\u00a0e\u00a0\nincrementan \u00a0 dram\u00e1ticamente \u00a0 dicha\u00a0\nheterogeneidad. \u00a0Si\u00a0a\u00a0esto\u00a0le\u00a0sumamos \u00a0el\u00a0hecho\u00a0de\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nque,\u00a0adem\u00e1s\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0epiteliales \u00a0tumorales, \u00a0\notras\u00a0c\u00e9lulas\u00a0como\u00a0las\u00a0mioepitaliles \u00a0o\u00a0las\u00a0c\u00e9lulas\u00a0\ndel\u00a0estroma\u00a0circundante \u00a0tambi\u00e9n\u00a0tienen\u00a0un\u00a0papel\u00a0\nimportante \u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0tumoral,\u00a0encontrar \u00a0\nterapias\u00a0totalmente \u00a0efectivas\u00a0contra\u00a0las\u00a0neoplasias \u00a0\nmamarias \u00a0malignas\u00a0es\u00a0un\u00a0camino\u00a0costoso\u00a0y\u00a0que\u00a0\ntodav\u00eda\u00a0no\u00a0se\u00a0ha\u00a0logrado\u00a0alcanzar.\u00a0\u00a0\nLa\u00a0patolog\u00eda \u00a0cl\u00ednica\u00a0cl\u00e1sica\u00a0ha\u00a0dividido\u00a0los\u00a0tumores\u00a0\nde\u00a0mama\u00a0en\u00a0m\u00faltiples \u00a0categor\u00edas, \u00a0ha\u00a0definido\u00a0\nsubtipos\u00a0con\u00a0pron\u00f3sticos \u00a0globales\u00a0diferentes \u00a0y\u00a0ha\u00a0\nidentificado \u00a0tumores\u00a0susceptibles \u00a0de\u00a0tratamientos \u00a0\nanti\u2010diana.\u00a0M\u00e1s\u00a0recientemente, \u00a0la\u00a0clasificaci\u00f3n \u00a0\nbasada\u00a0principalmente \u00a0en\u00a0la\u00a0patolog\u00eda \u00a0tradicional \u00a0\nha\u00a0sido\u00a0refinada\u00a0y\u00a0en\u00a0alg\u00fan\u00a0caso\u00a0reemplazada \u00a0por\u00a0\nlas\u00a0clasificaciones \u00a0de\u00a0tipo\u00a0molecular \u00a0que\u00a0tienen\u00a0el\u00a0\npotencial \u00a0de\u00a0combinar \u00a0mecanismos \u00a0de\u00a0la\u00a0\nenfermedad \u00a0con\u00a0caracter\u00edsticas \u00a0cl\u00ednicas.\u00a0\nEl\u00a0CM\u00a0es\u00a0uno\u00a0de\u00a0los\u00a0pocos\u00a0tipos\u00a0tumorales \u00a0cuya\u00a0\nclasificaci\u00f3n \u00a0molecular \u00a0ha\u00a0sido\u00a0usada\u00a0para\u00a0el\u00a0\ndise\u00f1o\u00a0de\u00a0terapias\u00a0individualizadas, \u00a0consiguiendo \u00a0\nsignificantes \u00a0mejor\u00edas\u00a0en\u00a0la\u00a0supervivencia \u00a0\nespec\u00edfica \u00a0de\u00a0pacientes \u00a0con\u00a0esta\u00a0enfermedad78.\u00a0\nEsta\u00a0heterogeneidad \u00a0entre\u00a0tumores\u00a0distintos\u00a0\n(heterogeneidad \u00a0inter\u2010tumoral)\u00a0y\u00a0dentro\u00a0de\u00a0un\u00a0\nmismo\u00a0tumor\u00a0(heterogeneidad \u00a0intra\u2010tumoral)\u00a0ha\u00a0\nsido\u00a0tema\u00a0de\u00a0estudio\u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os.\u00a0Diversos\u00a0\nautores79\u201081\u00a0proponen \u00a0dos\u00a0interesantes \u00a0modelos\u00a0\nque\u00a0describen \u00a0el\u00a0origen\u00a0de\u00a0la\u00a0heterogeneidad \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n32\u00a0\n\u00a0intertumoral: \u00a0el\u00a0primero\u00a0propone\u00a0que\u00a0distintas\u00a0\nmutaciones \u00a0gen\u00e9ticas \u00a0o\u00a0epigen\u00e9ticas \u00a0que\u00a0ocurren\u00a0\nen\u00a0la\u00a0misma\u00a0c\u00e9lula\u00a0diana\u00a0progenitora \u00a0dan\u00a0como\u00a0\nresultado \u00a0diferentes \u00a0fenotipos \u00a0tumorales \u00a0(Fig.\u00a011);\u00a0\nel\u00a0segundo\u00a0propone\u00a0que\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0distintos\u00a0\nsubtipos\u00a0tumorales \u00a0depende\u00a0de\u00a0en\u00a0qu\u00e9\u00a0momento \u00a0\nde\u00a0la\u00a0diferenciaci\u00f3n \u00a0(en\u00a0la\u00a0jerarqu\u00eda\u00a0de\u00a0linaje)\u00a0se\u00a0\nencuentra \u00a0la\u00a0c\u00e9lula\u00a0de\u00a0origen\u00a0da\u00f1ada\u00a0(Fig.\u00a011).\u00a0Es\u00a0\nimportante \u00a0se\u00f1alar\u00a0que\u00a0estos\u00a0dos\u00a0mecanismos \u00a0no\u00a0\nson\u00a0mutuamente \u00a0excluyentes, \u00a0sino\u00a0que\u00a0pueden\u00a0\nactuar\u00a0en\u00a0conjunto\u00a0para\u00a0determinar \u00a0la\u00a0\nhistopatolog\u00eda \u00a0del\u00a0tumor\u00a0y\u00a0el\u00a0comportamiento \u00a0del\u00a0\nmismo.\u00a0Adem\u00e1s,\u00a0hay\u00a0mecanismos \u00a0extr\u00ednsecos \u00a0que\u00a0\npueden\u00a0estar\u00a0involucrados \u00a0en\u00a0la\u00a0generaci\u00f3n \u00a0de\u00a0la\u00a0\nheterogeneidad \u00a0del\u00a0tumor,\u00a0debido\u00a0a\u00a0las\u00a0\ninteracciones \u00a0entre\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0y\u00a0el\u00a0\nmicroambiente \u00a0o\u00a0estroma\u00a0tumoral.\u00a0\n3.1.\u00a0Heterogeneidad \u00a0inter\u2010tumoral\u00a0\nEn\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0la\u00a0aplicaci\u00f3n \u00a0de\u00a0las\u00a0\ntecnolog\u00edas \u00a0basadas\u00a0en\u00a0microarrays \u00a0ha\u00a0permitido \u00a0\nrealizar\u00a0grandes\u00a0avances\u00a0que\u00a0tambi\u00e9n\u00a0se\u00a0han\u00a0visto\u00a0\nreflejados \u00a0en\u00a0el\u00a0\u00e1mbito\u00a0cl\u00ednico.\u00a0A\u00a0nivel\u00a0molecular \u00a0\nestudios\u00a0gen\u00e9ticos \u00a0han\u00a0identificado \u00a0distintos\u00a0\nsubtipos\u00a0de\u00a0tumores\u00a0de\u00a0CM.\u00a0Uno\u00a0de\u00a0los\u00a0estudios\u00a0\npioneros\u00a0fue\u00a0el\u00a0realizado\u00a0por\u00a0Charles\u00a0Perou\u00a0y\u00a0m\u00e1s\u00a0\ntarde\u00a0por\u00a0Therese\u00a0Sorlie82,83\u00a0y\u00a0colaboradores, \u00a0en\u00a0\nlos\u00a0cuales\u00a0utilizando \u00a0microarrays \u00a0de\u00a0cADN\u00a0se\u00a0\nidentificaron \u00a0diferentes \u00a0tipos\u00a0de\u00a0CM\u00a0bas\u00e1ndose \u00a0en\u00a0\nel\u00a0patr\u00f3n\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0y\u00a0en\u00a0su\u00a0correlaci\u00f3n \u00a0\ncon\u00a0los\u00a0resultados \u00a0cl\u00ednicos.\u00a0Los\u00a0subtipos\u00a0\npropuestos \u00a0en\u00a0estos\u00a0estudios\u00a0son\u00a0hasta\u00a0el\u00a0\nmomento \u00a0los\u00a0utilizados \u00a0en\u00a0cl\u00ednica\u00a0y\u00a0en\u00a0ciencia\u00a0\nb\u00e1sica\u00a0con\u00a0algunos\u00a0matices.\u00a0\u00a0\nEl\u00a0primer\u00a0autor\u00a0identific\u00f3 \u00a0cuatro\u00a0subtipos\u00a0de\u00a0CM\u00a0\nen\u00a038\u00a0tumores\u00a0invasivos, \u00a01\u00a0carcinoma \u00a0in\u00a0situ,\u00a01\u00a0\nfibroadenoma \u00a0y\u00a03\u00a0tejidos\u00a0sanos83.\u00a0Un\u00a0subgrupo \u00a0de\u00a0\npacientes \u00a0expresaban \u00a0genes\u00a0relacionados \u00a0con\u00a0las\u00a0\nc\u00e9lulas\u00a0luminales \u00a0del\u00a0tejido\u00a0mamario\u00a0normal\u00a0y\u00a0adem\u00e1s\u00a0se\u00a0agrupaban \u00a0por\u00a0tener\u00a0genes\u00a0\nrelacionados \u00a0con\u00a0los\u00a0receptores \u00a0hormonales. \u00a0A\u00a0\nestos\u00a0tumores\u00a0se\u00a0los\u00a0denomin\u00f3 \u00a0ER+/Luminal \u2010Like.\u00a0\nPor\u00a0el\u00a0contrario \u00a0el\u00a0resto\u00a0de\u00a0supgrupos \u00a0eran\u00a0\nindependientes \u00a0de\u00a0los\u00a0receptores \u00a0hormonales \u00a0de\u00a0\nmanera\u00a0que\u00a0los\u00a0clasific\u00f3\u00a0como\u00a0receptores \u00a0\nhormonales \u00a0negativos. \u00a0Dentro\u00a0de\u00a0este\u00a0grupo,\u00a0se\u00a0\ndeterminaron \u00a03\u00a0patrones\u00a0distinos:\u00a0aquellos\u00a0que\u00a0\nten\u00edan\u00a0una\u00a0amplificaci\u00f3n \u00a0g\u00e9nica\u00a0del\u00a0receptor\u00a0HER2\u00a0\n(subgrupo \u00a0HER2\u00a0enriquecido \u00a0o\u00a0HER2+),\u00a0los\u00a0que\u00a0\nexpresaban \u00a0genes\u00a0de\u00a0proliferaci\u00f3n \u00a0(subgrupo \u00a0\nBasal\u2010Like)\u00a0o\u00a0un\u00a0grupo\u00a0de\u00a0genes\u00a0relacionados \u00a0con\u00a0\nc\u00e9lulas\u00a0basales\u00a0del\u00a0tejido\u00a0normal,\u00a0pero\u00a0que\u00a0no\u00a0\nexpresaban \u00a0genes\u00a0ni\u00a0relacionados \u00a0con\u00a0HER2\u00a0ni\u00a0\ngenes\u00a0de\u00a0proliferaci\u00f3n, \u00a0a\u00a0los\u00a0que\u00a0nombr\u00f3\u00a0Normal\u2010\nLike.\u00a0\nTherese\u00a0Sorlie\u00a0hizo\u00a0un\u00a0posterior\u00a0an\u00e1lisis\u00a0de\u00a0los\u00a0\nperfiles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0en\u00a078\u00a0c\u00e1nceres\u00a0de\u00a0\nmama,\u00a03\u00a0fibroadenomas \u00a0y\u00a04\u00a0tejidos\u00a0mamarios \u00a0\nnormales. \u00a0Los\u00a0resultados \u00a0de\u00a0este\u00a0estudio\u00a0suger\u00edan\u00a0\nque\u00a0el\u00a0subtipo\u00a0ER+/Luminal \u2010like\u00a0se\u00a0divid\u00eda\u00a0en\u00a0dos\u00a0\nsubgrupos: \u00a0Luminal\u00a0A\u00a0y\u00a0Luminal\u00a0B.\u00a0Los\u00a0tumores\u00a0\nLuminal\u00a0A\u00a0eran\u00a0identificados \u00a0como\u00a0tumores\u00a0con\u00a0\nexpresi\u00f3n \u00a0del\u00a0receptor\u00a0de\u00a0estr\u00f3genos \u00a0(ER),\u00a0con\u00a0\npresencia \u00a0o\u00a0ausencia\u00a0del\u00a0receptor\u00a0de\u00a0progesterona \u00a0\n(RP),\u00a0con\u00a0expresi\u00f3n \u00a0de\u00a0citoqueratinas \u00a0(CK)\u00a08/18,\u00a0\nMUC1,\u00a0CD24\u00a0y\u00a0y\u00a0sin\u00a0expresi\u00f3n \u00a0de\u00a0HER2.\u00a0En\u00a0cambio\u00a0\nel\u00a0subtipo\u00a0Luminal\u00a0B\u00a0se\u00a0diferenciaba \u00a0del\u00a0Luminal\u00a0A\u00a0\nen\u00a0la\u00a0presencia \u00a0del\u00a0gen\u00a0HER2\u00a0en\u00a0su\u00a0patr\u00f3n\u00a0de\u00a0\nexpresi\u00f3n. \u00a0El\u00a0subtipo\u00a0HER2+\u00a0se\u00a0manten\u00eda \u00a0y\u00a0era\u00a0\ncl\u00ednicamente \u00a0definido\u00a0por\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0expresi\u00f3n \u00a0\nde\u00a0ER\u00a0y\u00a0PR\u00a0y\u00a0por\u00a0la\u00a0amplificaci\u00f3n \u00a0de\u00a0la\u00a0regi\u00f3n\u00a0\ncromos\u00f3mica \u00a017q22.24 \u00a0que\u00a0codifica\u00a0para\u00a0el\u00a0gen\u00a0\nHER2\u00a0y\u00a0GRB7.\u00a0En\u00a0cambio\u00a0el\u00a0subtipo\u00a0Basal\u2010like\u00a0que\u00a0\nmanten\u00eda \u00a0la\u00a0ausencia\u00a0de\u00a0ER\u00a0y\u00a0PR,\u00a0tampoco\u00a0\nexpresaba \u00a0el\u00a0gen\u00a0HER2\u00a0y\u00a0adem\u00e1s\u00a0expresaba \u00a0el\u00a0\nreceptor\u00a0del\u00a0factor\u00a0de\u00a0crecimiento \u00a0Epid\u00e9rmico \u00a0\n(EGFR,\u00a0del\u00a0ingl\u00e9s\u00a0epidermal \u00a0growth\u00a0factor\u00a0\nreceptor ),\u00a0CK\u00a05/6,\u00a014\u00a0y\u00a017,\u00a0laminina\u00a0y\u00a0el\u00a0gen\u00a0CD44.\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n33\u00a0\n\u00a0\u00a0\nFigura\u00a011.\u00a0Dos\u00a0modelos\u00a0de\u00a0heterogeneidad \u00a0inter\u2010tumoral .\u00a0A.\u00a0En\u00a0el\u00a0modelo\u00a0de\u00a0mutaci\u00f3n \u00a0gen\u00e9tica\u00a0(y\u00a0epigen\u00e9tica), \u00a0las\u00a0mutaciones \u00a0\ntempranas \u00a0determinan \u00a0del\u00a0fenotipo\u00a0del\u00a0tumor,\u00a0y\u00a0cada\u00a0mutaci\u00f3n \u00a0genera\u00a0tumores\u00a0con\u00a0diferente \u00a0patr\u00f3n\u00a0molecular. \u00a0B.\u00a0En\u00a0el\u00a0modelo\u00a0\nque\u00a0depende\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0de\u00a0origen,\u00a0c\u00e9lulas\u00a0en\u00a0diferentes \u00a0estadios\u00a0de\u00a0diferenciaci\u00f3n \u00a0sirven\u00a0como\u00a0c\u00e9lulas\u00a0de\u00a0origen\u00a0para\u00a0los\u00a0\ndiferentes \u00a0subtipos\u00a0de\u00a0c\u00e1ncer\u00a0que\u00a0surjan\u00a0en\u00a0ese\u00a0\u00f3rgano\u00a0o\u00a0tejido.\u00a0Ilustraci\u00f3n \u00a0modificada \u00a0de79.\u00a0\n\u00a0\nPor\u00a0otra\u00a0parte\u00a0se\u00a0consider\u00f3 \u00a0que\u00a0el\u00a0subgrupo \u00a0\nNormal\u00a0Like,\u00a0podr\u00eda\u00a0ser\u00a0una\u00a0contaminaci\u00f3n \u00a0de\u00a0\ntejido\u00a0normal\u00a0mamario, \u00a0aunque\u00a0este\u00a0subgrupo \u00a0es\u00a0\ntodav\u00eda\u00a0tema\u00a0de\u00a0estudio.\u00a0Por\u00a0lo\u00a0tanto,\u00a0se\u00a0\nconsider\u00f3 \u00a0que\u00a0los\u00a0subtipos\u00a0intr\u00ednsecos \u00a0de\u00a0CM\u00a0\nserian\u00a04:\u00a0Luminal\u00a0A,\u00a0luminal\u00a0B,\u00a0HER2+,\u00a0Basal\u2010like\u00a0y\u00a0\nm\u00e1s\u00a0recientemente \u00a0el\u00a0subtipo\u00a0bajo\u00a0en\u00a0claudina84.\u00a0\nEste\u00a0\u00faltimo\u00a0subtipo\u00a0molecular, \u00a0seg\u00fan\u00a0varios\u00a0\nautores,\u00a0comparte \u00a0similitudes \u00a0con\u00a0c\u00e9lulas\u00a0madres\u00a0\no\u00a0con\u00a0firmas\u00a0gen\u00e9ticas \u00a0ligadas\u00a0a\u00a0procesos\u00a0de\u00a0\ntransici\u00f3n \u00a0epitelio\u2010mes\u00e9nquima \u00a0(TEM)85,86.\u00a0Este\u00a0\ngrupo\u00a0presenta\u00a0una\u00a0elevada\u00a0expresi\u00f3n \u00a0de\u00a0\nVimentina, \u00a0N\u2010Cadherina \u00a0y\u00a0algunos\u00a0factores\u00a0de\u00a0\ntranscripci\u00f3n \u00a0represores \u00a0de\u00a0la\u00a0E\u2010Cadherina \u00a0como\u00a0\nTWIST1,\u00a0comparado \u00a0con\u00a0otros\u00a0subtipos\u00a0como\u00a0el\u00a0\nbasal\u2010like.\u00a0Adem\u00e1s\u00a0este\u00a0subtipo\u00a0presenta\u00a0la\u00a0menor\u00a0\nexpresi\u00f3n \u00a0de\u00a0marcadores \u00a0relacionados \u00a0con\u00a0la\u00a0\ndiferenciaci\u00f3n \u00a0epitelial\u00a0como\u00a0CD24,\u00a0EpCAM\u00a0y\u00a0\nMUC1\u00a0mientras\u00a0muestra\u00a0elevada\u00a0expresi\u00f3n \u00a0de\u00a0\nCD44\u00a0y\u00a0CD49f,\u00a0comparado \u00a0con\u00a0los\u00a0tumores\u00a0\nluminales, \u00a0definidos \u00a0por\u00a0lo\u00a0tanto\u00a0por\u00a0un\u00a0fenotipo\u00a0\nantig\u00e9ncio \u00a0parecido\u00a0al\u00a0de\u00a0c\u00e9lulas\u00a0madre87\u00a0\nCD44+/CD24\u2010/bajo\u00a0y\u00a0CD49f+/EpCAM\u2010.\u00a0\nEn\u00a0un\u00a0an\u00e1lisis\u00a0posterior\u00a0se\u00a0observ\u00f3\u00a0que\u00a0estos\u00a0\nsubtipos\u00a0moleculares \u00a0reflejaban \u00a0diferencias \u00a0en\u00a0la\u00a0\nsupervivencia \u00a0global\u00a0y\u00a0supervivencia \u00a0libre\u00a0de\u00a0\nrecidiva,\u00a0siendo\u00a0m\u00e1s\u00a0favorables \u00a0para\u00a0las\u00a0pacientes \u00a0con\u00a0tumores\u00a0subtipo\u00a0Luminal\u00a0A\u00a0y\u00a0menos\u00a0\nfavorables \u00a0para\u00a0las\u00a0pacientes \u00a0con\u00a0subtipo\u00a0HER2+\u00a0y\u00a0\nlas\u00a0que\u00a0ten\u00edan\u00a0el\u00a0subtipo\u00a0Basal\u2010Like.\u00a0En\u00a0cambio,\u00a0las\u00a0\npacientes \u00a0con\u00a0subtipo\u00a0Luminal\u00a0B,\u00a0ten\u00edan\u00a0un\u00a0\npron\u00f3stico \u00a0intermedio \u00a0entre\u00a0las\u00a0Luminal\u00a0A\u00a0y\u00a0los\u00a0\notros\u00a0dos\u00a0subtipos82.\u00a0Por\u00a0otro\u00a0lado\u00a0algunos\u00a0\nautores\u00a0relacionan \u00a0el\u00a0subtipo\u00a0bajo\u00a0en\u00a0claudina\u00a0con\u00a0\nel\u00a0CM\u00a0metapl\u00e1sico85\u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0con\u00a0un\u00a0mal\u00a0\npron\u00f3stico \u00a0de\u00a0forma\u00a0similar\u00a0que\u00a0el\u00a0subtipo\u00a0Basal\u2010\nLike\u00a0o\u00a0HER2+.\u00a0\nAunque\u00a0se\u00a0han\u00a0barajado\u00a0diversas\u00a0hip\u00f3tesis\u00a0para\u00a0\nexplicar\u00a0la\u00a0heterogenidad \u00a0tumoral\u00a0y\u00a0la\u00a0etiolog\u00eda\u00a0\ndel\u00a0CM,\u00a0e\u00a0incluso\u00a0la\u00a0existencia \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0\ndistinta\u00a0naturaleza \u00a0que\u00a0podr\u00edan\u00a0dar\u00a0lugar\u00a0a\u00a0los\u00a0\ndiferentes \u00a0subtipos\u00a0descritos, \u00a0todav\u00eda\u00a0est\u00e1\u00a0por\u00a0\ndescubrir \u00a0cu\u00e1les\u00a0son\u00a0aquellas\u00a0c\u00e9lulas\u00a0o\u00a0grupo\u00a0de\u00a0\nc\u00e9lulas\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0responsables \u00a0del\u00a0\ninicio\u00a0del\u00a0CM.\u00a0\n3.1.1.\u00a0Origen\u00a0de\u00a0los\u00a0subtipos\u00a0\nintr\u00ednsecos \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0\n\u00a0\nTal\u00a0y\u00a0como\u00a0se\u00a0ha\u00a0detallado \u00a0en\u00a0el\u00a0punto\u00a0uno\u00a0de\u00a0la\u00a0\nintroducci\u00f3n, \u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0est\u00e1\u00a0compuesta \u00a0\npor\u00a0una\u00a0red\u00a0de\u00a0ductos\u00a0que\u00a0se\u00a0ramifican \u00a0en\u00a0forma\u00a0\nde\u00a0unidades\u00a0lobulillares \u00a0ductales\u00a0terminales \u00a0o\u00a0\nULDTs.\u00a0Estos\u00a0ductos\u00a0est\u00e1n\u00a0compuestos \u00a0por\u00a0dos\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n34\u00a0\n\u00a0capas\u00a0de\u00a0c\u00e9lulas:\u00a0las\u00a0c\u00e9lulas\u00a0epiteliales \u00a0secretoras \u00a0\nque\u00a0recubren\u00a0el\u00a0interior\u00a0del\u00a0ducto\u00a0y\u00a0una\u00a0capa\u00a0de\u00a0\nc\u00e9lulas\u00a0mioepiteliales \u00a0que\u00a0lo\u00a0recubren\u00a0y\u00a0tienen\u00a0\ncapacidad \u00a0contr\u00e1ctil. \u00a0Una\u00a0membrana \u00a0basal\u00a0\nenvuelve\u00a0estas\u00a0unidades\u00a0y\u00a0conecta\u00a0con\u00a0una\u00a0matriz\u00a0\nextracelular \u00a0con\u00a0el\u00a0fin\u00a0de\u00a0dar\u00a0soporte\u00a0a\u00a0la\u00a0\nestructura \u00a0en\u00a0\u00e1rbol\u00a0y\u00a0dicha\u00a0matriz\u00a0est\u00e1\u00a0compuesta \u00a0\npor\u00a0prote\u00ednas \u00a0estructurales, \u00a0fibroblastos, \u00a0\nadipocitos, \u00a0macr\u00f3fagos \u00a0y\u00a0otras\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0\nimmunitario. \u00a0Esta\u00a0gl\u00e1ndula\u00a0mamaria\u00a0es\u00a0el\u00a0\u00fanico\u00a0\n\u00f3rgano\u00a0que\u00a0padece\u00a0una\u00a0continua\u00a0remodelaci\u00f3n \u00a0y\u00a0\ndiferenciaci\u00f3n \u00a0incluso\u00a0en\u00a0adultos.\u00a0En\u00a0base\u00a0a\u00a0esta\u00a0\nobservaci\u00f3n \u00a0se\u00a0ha\u00a0propuesto \u00a0la\u00a0existencia \u00a0de\u00a0\nc\u00e9lulas\u00a0madre\u00a0epiteliales \u00a0adultas\u00a0con\u00a0capacidad \u00a0de\u00a0\nautorenovaci\u00f3n \u00a0y\u00a0de\u00a0dividirse\u00a0asim\u00e9tricamente \u00a0\naunque\u00a0todav\u00eda\u00a0no\u00a0han\u00a0sido\u00a0del\u00a0todo\u00a0\ncaracterizadas. \u00a0Se\u00a0cree\u00a0que\u00a0c\u00e9lulas\u00a0madre\u00a0\nepiteliales \u00a0mamarias \u00a0normales \u00a0dan\u00a0lugar\u00a0al\u00a0linaje\u00a0\nluminal\u00a0y\u00a0mioepitelial, \u00a0aunque\u00a0todav\u00eda\u00a0quedan\u00a0por\u00a0\ndescubrir \u00a0que\u00a0factores\u00a0regulan\u00a0exactamente \u00a0estas\u00a0\nv\u00edas\u00a0de\u00a0diferenciaci\u00f3n \u00a0celular\u00a0(Fig.\u00a012).\u00a0Lo\u00a0que\u00a0s\u00ed\u00a0\nque\u00a0se\u00a0ha\u00a0demostrado \u00a0con\u00a0numerosos \u00a0\nexperimentos \u00a0es\u00a0la\u00a0existencia \u00a0de\u00a0c\u00e9lulas\u00a0\nprogenitoras \u00a0en\u00a0todos\u00a0los\u00a0estadios\u00a0del\u00a0desarrollo \u00a0\nde\u00a0la\u00a0mama\u00a0de\u00a0rat\u00f3n\u00a0que\u00a0pueden\u00a0regenerar \u00a0una\u00a0\ngl\u00e1ndula\u00a0mamaria\u00a0completa \u00a0funcional \u00a0cuando\u00a0son\u00a0\ntransplantadas \u00a0en\u00a0tejido\u00a0adiposo\u00a0mamario\u00a0\nmurino88.\u00a0Otros\u00a0estudios\u00a0han\u00a0demostrado \u00a0que\u00a0\ntambi\u00e9n\u00a0se\u00a0puede\u00a0regenerar \u00a0la\u00a0glandula\u00a0mamaria\u00a0\nmurina\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0una\u00a0\u00fanica\u00a0sola\u00a0c\u00e9lula\u00a0purificada \u00a0\nen\u00a0base\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0marcadores \u00a0de\u00a0\nsuperficie \u00a0celular\u00a0como\u00a0Lin\u2010CD29hiCD24+\u00a089,90.\u00a0\nPor\u00a0similitud\u00a0con\u00a0c\u00e9lulas\u00a0en\u00a0diferentes \u00a0estadios\u00a0de\u00a0\nla\u00a0jerarqu\u00eda\u00a0epitelial\u00a0de\u00a0la\u00a0mama,\u00a0se\u00a0propuso\u00a0que\u00a0\nc\u00e9lulas\u00a0progenitoras \u00a0o\u00a0incluso\u00a0otras\u00a0poblaciones \u00a0\nm\u00e1s\u00a0diferenciadas \u00a0podr\u00edan\u00a0ser\u00a0susceptibles \u00a0a\u00a0la\u00a0\ntransformaci\u00f3n \u00a0celular\u00a0y\u00a0ser\u00a0iniciadoras \u00a0de\u00a0los\u00a0\ndistintos\u00a0subtipos\u00a0de\u00a0CM79,91,92.\u00a0Las\u00a0primeras\u00a0\nhip\u00f3tesis\u00a0proponian \u00a0que\u00a0tumores\u00a0luminales \u00a0que\u00a0\nexpresan\u00a0RE\u00a0podr\u00edan\u00a0originarse \u00a0a\u00a0partir\u00a0de\u00a0c\u00e9lulas\u00a0\nluminales \u00a0epiteliales, \u00a0y\u00a0tumores\u00a0basales\u00a0RE\u00a0\nnegativos \u00a0que\u00a0expresan\u00a0cytokeratinas \u00a0(CK5/6)\u00a0se\u00a0\npodr\u00edan\u00a0originar\u00a0a\u00a0partir\u00a0de\u00a0c\u00e9lulas\u00a0madre\u00a0o\u00a0con\u00a0\nfenotipo\u00a0basal79.\u00a0Sin\u00a0embargo, \u00a0investigaciones \u00a0m\u00e1s\u00a0recientes\u00a0han\u00a0realizado\u00a0comparaciones \u00a0entre\u00a0\nfirmas\u00a0gen\u00e9ticas \u00a0de\u00a0los\u00a0subtipos\u00a0moleculares \u00a0\nintr\u00ednsecos \u00a0con\u00a0perfiles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0\nc\u00e9lulas\u00a0aisladas\u00a0de\u00a0teijido\u00a0mamario\u00a0normal\u00a0(c\u00e9lulas\u00a0\nmadre,\u00a0progenitores \u00a0luminales, \u00a0poblaciones \u00a0de\u00a0\nc\u00e9lulas\u00a0epiteliales \u00a0maduras\u00a0y\u00a0c\u00e9lulas\u00a0del\u00a0estroma)\u00a0\naportando \u00a0evidencias \u00a0que\u00a0apoyan\u00a0un\u00a0modelo\u00a0\ndistinto.\u00a0Realizando \u00a0estas\u00a0comparaciones \u00a0\nmoleculares \u00a0se\u00a0ha\u00a0observado \u00a0que\u00a0el\u00a0perfil\u00a0gen\u00e9tico\u00a0\nde\u00a0las\u00a0c\u00e9lulas\u00a0madre\u00a0progenitoras \u00a0se\u00a0asocia\u00a0a\u00a0un\u00a0\nsuptipo\u00a0normal\u2010like\u00a0o\u00a0bajo\u00a0en\u00a0Claudina, \u00a0mientras\u00a0\nque\u00a0la\u00a0firma\u00a0gen\u00e9tica\u00a0que\u00a0deriva\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nprogenitoras \u00a0luminales \u00a0m\u00e1s\u00a0tempranas \u00a0muestra\u00a0\nmayor\u00a0similitud\u00a0al\u00a0subtipo\u00a0basal\u00a0de\u00a0CM.\u00a0Por\u00a0\n\u00fatlimo,\u00a0tumores\u00a0HER2+\u00a0se\u00a0asemejan \u00a0a\u00a0\nprogenitores \u00a0luminales \u00a0m\u00e1s\u00a0avanzados79,93\u00a0(Fig.\u00a0\n12).\u00a0En\u00a0cuanto\u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0mioepiteliales \u00a0todav\u00eda\u00a0\nexiste\u00a0controversia, \u00a0mientras\u00a0algunos\u00a0autores\u00a0las\u00a0\nrelacionan \u00a0con\u00a0unas\u00a0caracter\u00edsticas \u00a0u\u00a0origen\u00a0\nepitelial\u00a0otros\u00a0las\u00a0identifican \u00a0como\u00a0c\u00e9lulas\u00a0de\u00a0\nfenotipo\u00a0basal\u00a0y\u00a0con\u00a0un\u00a0progenitor \u00a0propio93\u201096.\u00a0En\u00a0\nresumen\u00a0estos\u00a0estudios\u00a0sugieren\u00a0que\u00a0los\u00a0\ndiferentes \u00a0subtipos\u00a0moleculares \u00a0de\u00a0CM\u00a0provienen \u00a0\nde\u00a0la\u00a0transformaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0que\u00a0se\u00a0encuentran \u00a0\nen\u00a0distintas\u00a0etapas\u00a0del\u00a0proceso\u00a0de\u00a0diferenciaci\u00f3n \u00a0\nepitelial\u00a0mamaria86.\u00a0De\u00a0forma\u00a0interesante, \u00a0los\u00a0\nmismos\u00a0autores\u00a0compararon \u00a0tejido\u00a0mamario\u00a0\nnormal\u00a0con\u00a0tejido\u00a0mamario\u00a0de\u00a0mujeres\u00a0portadoras \u00a0\nde\u00a0la\u00a0mutaci\u00f3n \u00a0BRCA1\u00a0en\u00a0la\u00a0l\u00ednea\u00a0germinal\u00a0y\u00a0\nobservaron \u00a0que\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\nprogenitoras \u00a0luminales \u00a0era\u00a0mucho\u00a0mayor\u00a0en\u00a0las\u00a0\nmujeres\u00a0portadoras \u00a0de\u00a0la\u00a0mutaci\u00f3n \u00a0que\u00a0en\u00a0las\u00a0no\u00a0\nportadoras. \u00a0Adem\u00e1s,\u00a0propusieron \u00a0que\u00a0estas\u00a0\nc\u00e9lulas\u00a0progenitoras \u00a0luminales \u00a0portadoras \u00a0del\u00a0gen\u00a0\nBRCA1\u00a0podr\u00edan\u00a0ser\u00a0el\u00a0origen\u00a0del\u00a0subtipo\u00a0basal\u2010like\u00a0\nde\u00a0CM93.\u00a0Otros\u00a0estudios97\u201099,\u00a0apoyaron \u00a0y\u00a0\ndesarrollaron \u00a0esta\u00a0idea\u00a0planteando \u00a0no\u00a0solo\u00a0el\u00a0\nhecho\u00a0que\u00a0tumores\u00a0portadores \u00a0del\u00a0gen\u00a0BRCA1\u00a0con\u00a0\nfenotipo\u00a0basal\u2010like\u00a0podr\u00edan\u00a0provenir\u00a0de\u00a0\nprogenitores \u00a0luminales, \u00a0sino\u00a0que\u00a0perfiles\u00a0\nmoleculares \u00a0de\u00a0CM\u00a0del\u00a0subtipo\u00a0basal\u2010like\u00a0(que\u00a0es\u00a0\njustamente \u00a0donde\u00a0se\u00a0encuentra \u00a0el\u00a0grupo\u00a0de\u00a0\ntumores\u00a0BRCA1)\u00a0podr\u00edan\u00a0tener\u00a0su\u00a0origen\u00a0en\u00a0un\u00a0\nfenotipo\u00a0de\u00a0c\u00e9lulas\u00a0progenitoras \u00a0luminales. \u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n35\u00a0\n\u00a0\u00a0\nFigura\u00a012.\u00a0Jerarqu\u00eda \u00a0del\u00a0epitelio\u00a0normal\u00a0de\u00a0la\u00a0mama\u00a0y\u00a0distintas\u00a0poblaciones \u00a0celulares\u00a0propuestas \u00a0como\u00a0origen\u00a0de\u00a0los\u00a0distintos\u00a0\nsubtipos\u00a0de\u00a0CM.\u00a0A.\u00a0Organizaci\u00f3n \u00a0celular\u00a0del\u00a0epitelio\u00a0mamario\u00a0y\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0madre.\u00a0La\u00a0gl\u00e1ndula\u00a0mamaria\u00a0se\u00a0\ncompone \u00a0de\u00a0una\u00a0red\u00a0de\u00a0ramificaci\u00f3n \u00a0de\u00a0los\u00a0conductos \u00a0y\u00a0los\u00a0lobulillos. \u00a0El\u00a0epitelio\u00a0mamario\u00a0contiene\u00a0una\u00a0capa\u00a0luminal\u00a0de\u00a0c\u00e9lulas\u00a0\nductales\u00a0o\u00a0lobulillares, \u00a0que\u00a0est\u00e1n\u00a0rodeadas \u00a0por\u00a0una\u00a0capa\u00a0de\u00a0c\u00e9lulas\u00a0mioepiteliales \u00a0contr\u00e1ctiles. \u00a0Se\u00a0ha\u00a0descrito\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0con\u00a0\npropiedades \u00a0de\u00a0c\u00e9lulas\u00a0madre\u00a0se\u00a0localizan\u00a0en\u00a0una\u00a0posici\u00f3n\u00a0supra\u2010basal.\u00a0Diferentes \u00a0linajes\u00a0de\u00a0c\u00e9lulas\u00a0progenitoras \u00a0tambi\u00e9n\u00a0existen\u00a0\nen\u00a0el\u00a0epitelio\u00a0mamario, \u00a0y\u00a0se\u00a0diferencian \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0maduras\u00a0ductales,\u00a0lobulillares \u00a0y\u00a0mioepiteliales \u00a0(flechas\u00a0negras\u00a0indican\u00a0la\u00a0\ndiferenciaci\u00f3n \u00a0celular).\u00a0Envolviendo \u00a0esta\u00a0estructura \u00a0encontramos \u00a0una\u00a0membrana \u00a0basal\u00a0y\u00a0un\u00a0estroma\u00a0rico\u00a0en\u00a0fibras\u00a0de\u00a0soporte\u00a0y\u00a0\nen\u00a0diferentes \u00a0tipos\u00a0celulares. \u00a0B.\u00a0Jerarqu\u00eda \u00a0propuesta \u00a0en\u00a0los\u00a0estadios\u00a0de\u00a0diferenciaci\u00f3n \u00a0del\u00a0epitelio\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria. \u00a0La\u00a0\ndiferenciaci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0madre\u00a0da\u00a0lugar\u00a0a\u00a0c\u00e9lulas\u00a0bipotentes \u00a0progenitoras. \u00a0\u00c9stas\u00a0acabar\u00e1n\u00a0diferenci\u00e1ndose \u00a0en\u00a0el\u00a0linaje\u00a0de\u00a0\nc\u00e9lulas\u00a0progenitoras \u00a0ductales,\u00a0lobulillares \u00a0y\u00a0mioepiteliales. \u00a0En\u00a0base\u00a0a\u00a0las\u00a0similitudes \u00a0moleculares \u00a0entre\u00a0c\u00e9lulas\u00a0normales \u00a0y\u00a0\ncancerosas, \u00a0se\u00a0ha\u00a0propuesto \u00a0que\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0gl\u00e1ndula\u00a0mamaria\u00a0del\u00a0linaje\u00a0luminal\u00a0en\u00a0las\u00a0diferentes \u00a0etapas\u00a0de\u00a0diferenciaci\u00f3n \u00a0ser\u00e1n\u00a0\nlas\u00a0c\u00e9lulas\u00a0de\u00a0origen\u00a0de\u00a0los\u00a0subtipos\u00a0de\u00a0diferentes \u00a0CM92.\u00a0\n\u00a0\nEstas\u00a0comparaciones \u00a0moleculares \u00a0asumen\u00a0que\u00a0en\u00a0\nlos\u00a0tumores\u00a0las\u00a0c\u00e9lulas\u00a0mantienen \u00a0rasgos\u00a0de\u00a0sus\u00a0\npotenciales \u00a0c\u00e9lulas\u00a0de\u00a0origen,\u00a0pero\u00a0se\u00a0omite\u00a0el\u00a0\nhecho\u00a0de\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0epiteliales \u00a0pueden\u00a0sufrir\u00a0\nplasticidad \u00a0fenot\u00edpica \u00a0y\u00a0molecular, \u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0el\u00a0\nfenotipo\u00a0podr\u00eda\u00a0ser\u00a0adquirido \u00a0y\u00a0no\u00a0derivado\u00a0de\u00a0\nesas\u00a0c\u00e9lulas\u00a0de\u00a0origen.\u00a0Un\u00a0buen\u00a0ejemplo\u00a0de\u00a0esta\u00a0\nplasticidad \u00a0y\u00a0que\u00a0est\u00e1\u00a0ampliamente \u00a0descrito\u00a0es\u00a0lo\u00a0\nque\u00a0sucede\u00a0durante\u00a0la\u00a0TEM.\u00a0\n\u00a03.1.2.\u00a0Identificaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0los\u00a0\ndiferentes \u00a0subtipos\u00a0moleculares \u00a0\n\u00a0\nEl\u00a0uso\u00a0de\u00a0los\u00a0patrones\u00a0moleculares \u00a0del\u00a0CM\u00a0es\u00a0\ntodav\u00eda\u00a0complicado \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0ya\u00a0que\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0plataformas \u00a0creadas\u00a0para\u00a0su\u00a0an\u00e1lisis\u00a0\nson\u00a0demasiado \u00a0costosas\u00a0para\u00a0poder\u00a0\nimplementarlas \u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0rutina.\u00a0Sin\u00a0\nembargo, \u00a0se\u00a0pueden\u00a0identificar \u00a0estos\u00a0subtipos\u00a0\nmoleculares \u00a0(con\u00a0cierto\u00a0margen\u00a0de\u00a0error)\u00a0en\u00a0base\u00a0\na\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0marcadores \u00a0espec\u00edficos \u00a0por\u00a0\ninmunohistoqu\u00edmica \u00a0(IHQ)100.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0\ndescriben \u00a0los\u00a0marcadores \u00a0de\u00a0IHC\u00a0que\u00a0se\u00a0utilizan\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n36\u00a0\n\u00a0para\u00a0clasificar\u00a0los\u00a0tumores\u00a0por\u00a0analog\u00eda\u00a0con\u00a0su\u00a0\npatr\u00f3n\u00a0molecular. \u00a0\nHER2\u00a0enriquecido: \u00a0En\u00a0el\u00a0esquema\u00a0propuesto \u00a0por\u00a0\nPerou\u00a0y\u00a0colaboradores \u00a0el\u00a0subtipo\u00a0molecular \u00a0HER2,\u00a0\naunque\u00a0no\u00a0perfectamente, \u00a0coincide\u00a0con\u00a0los\u00a0\ntumores\u00a0HER2+\u00a0definidos \u00a0por\u00a0IHQ83.\u00a0\nBasal\u2010like:\u00a0Este\u00a0subtipo\u00a0se\u00a0corresponde \u00a0la\u00a0mayor\u00eda\u00a0\nde\u00a0veces\u00a0con\u00a0el\u00a0patr\u00f3n\u00a0triple\u00a0negativo\u00a0(TN)\u00a0(ER\u2010\n/PR\u2010/HER2\u2010)101.\u00a0Sin\u00a0embargo, \u00a0existen\u00a0varios\u00a0\nestudios\u00a0que\u00a0demuestran \u00a0que\u00a0el\u00a0fenotipo\u00a0TN\u00a0no\u00a0es\u00a0\nun\u00a0sustituto\u00a0ideal\u00a0para\u00a0la\u00a0identificaci\u00f3n \u00a0de\u00a0los\u00a0\nsubtipos\u00a0basal\u2010like\u00a0descritos\u00a0por\u00a0Perou\u00a0y\u00a0que\u00a0se\u00a0\nnecesitan \u00a0marcadores \u00a0adicionales \u00a0para\u00a0identificar \u00a0\nde\u00a0forma\u00a0histol\u00f3gica \u00a0este\u00a0subtipo\u00a0molecular. \u00a0Por\u00a0\nejemplo,\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0marcadores \u00a0basales\u00a0\n(CK5/6,\u00a0CK14,\u00a0CK17\u00a0y/o\u00a0EGFR)\u00a0se\u00a0asocia\u00a0con\u00a0una\u00a0\nmorfolog\u00eda \u00a0espec\u00edfica \u00a0(de\u00a0mayor\u00a0grado\u00a0histol\u00f3gico) \u00a0\ny\u00a0caracter\u00edsticas \u00a0immunofenot\u00edpicas \u00a0(p.ej.\u00a0\npositividad \u00a0de\u00a0p53),\u00a0con\u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0\nBRCA1\u00a0y\u00a0con\u00a0un\u00a0mal\u00a0pron\u00f3stico \u00a0en\u00a0comparaci\u00f3n \u00a0\ncon\u00a0los\u00a0tumores\u00a0TN102\u2010105.\u00a0De\u00a0todos\u00a0modos\u00a0existe\u00a0\ncierta\u00a0controversia \u00a0sobre\u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0CKs\u00a0ya\u00a0\nque\u00a0algunos\u00a0autores\u00a0han\u00a0demostrado \u00a0la\u00a0existencia \u00a0\nde\u00a0citoqueratinas \u00a0basales\u00a0en\u00a0c\u00e9lulas\u00a0luminales \u00a0de\u00a0\nULDTs94.\u00a0\u00a0\nLuminales: \u00a0Ambos\u00a0subtipos\u00a0(luminal\u00a0A\u00a0y\u00a0B)\u00a0se\u00a0\nidentifican \u00a0en\u00a0base\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0receptores \u00a0\nhormonales, \u00a0sin\u00a0embargo\u00a0no\u00a0hay\u00a0marcadores \u00a0\ntodav\u00eda\u00a0establecidos \u00a0para\u00a0subdividir \u00a0los\u00a0A\u00a0de\u00a0los\u00a0B.\u00a0\nAunque\u00a0los\u00a0luminales \u00a0B\u00a0tienen\u00a0una\u00a0mayor\u00a0\nexpresi\u00f3n \u00a0de\u00a0genes\u00a0implicados \u00a0en\u00a0la\u00a0proliferaci\u00f3n, \u00a0\nal\u00a0contrario\u00a0que\u00a0los\u00a0luminal\u00a0A,\u00a0y\u00a0adem\u00e1s\u00a0expresan\u00a0\nel\u00a0receptor\u00a0HER2,\u00a0hay\u00a0estudios\u00a0que\u00a0discrepan \u00a0en\u00a0\neste\u00a0\u00faltimo\u00a0punto\u00a0y\u00a0describen \u00a0que\u00a0existe\u00a0la\u00a0\nposibilidad \u00a0de\u00a0encontrar \u00a0tumores\u00a0luminal\u00a0B\u00a0sin\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0HER2,\u00a0pero\u00a0de\u00a0alto\u00a0grado\u00a0\nhistol\u00f3gico106.\u00a0Estos\u00a0tipos\u00a0de\u00a0tumores\u00a0suelen\u00a0ser\u00a0\nde\u00a0peor\u00a0pron\u00f3stico, \u00a0con\u00a0un\u00a0elevado\u00a0nivel\u00a0del\u00a0\nmarcador \u00a0de\u00a0proliferaci\u00f3n \u00a0Ki67107,108\u00a0y\u00a0una\u00a0baja\u00a0\ndiferenciaci\u00f3n \u00a0celular.\u00a0En\u00a0cambio\u00a0los\u00a0luminal\u00a0A\u00a0\nsuelen\u00a0ser\u00a0de\u00a0menor\u00a0grado\u00a0histol\u00f3gico, \u00a0poco\u00a0\ndiferenciados \u00a0y\u00a0con\u00a0niveles\u00a0bajos\u00a0de\u00a0Ki67.\u00a0Sin\u00a0\nembargo\u00a0sigue\u00a0siendo\u00a0tema\u00a0de\u00a0debate\u00a0donde\u00a0\nestablecer \u00a0el\u00a0corte\u00a0entre\u00a0bajo\u00a0y\u00a0alto\u00a0grado\u00a0histol\u00f3gico \u00a0o\u00a0de\u00a0diferenciaci\u00f3n \u00a0y/o\u00a0los\u00a0niveles\u00a0de\u00a0\nKi67.\u00a0\nBajo\u00a0en\u00a0claudina: \u00a0Son\u00a0tumores\u00a0en\u00a0principio\u00a0\ndefinidos \u00a0como\u00a0HER2\u2010\u00a0y\u00a0RE\u00a0negativos \u00a0similares\u00a0al\u00a0\nsubtipo\u00a0basal.\u00a0No\u00a0deber\u00edan\u00a0contemplarse \u00a0como\u00a0TN\u00a0\nya\u00a0que\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0entre\u00a0un\u00a015\u00a0y\u00a0\nun\u00a025%\u00a0de\u00a0estos\u00a0tumores\u00a0bajos\u00a0en\u00a0claudina\u00a0son\u00a0\nreceptores \u00a0hormonales \u00a0positivos. \u00a0\nAproximadamente \u00a0un\u00a010%\u00a0de\u00a0tumores\u00a0con\u00a0\nfenotipo\u00a0basal\u00a0tambi\u00e9n\u00a0son\u00a0receptores \u00a0\nhormonales \u00a0positivos, \u00a0y\u00a0Prat\u00a0y\u00a0colaboradores \u00a0han\u00a0\ndemostrado \u00a0que\u00a0m\u00e1s\u00a0de\u00a0un\u00a030%\u00a0de\u00a0tumores\u00a0bajos\u00a0\nen\u00a0claudina\u00a0no\u00a0entran\u00a0dentro\u00a0de\u00a0la\u00a0categor\u00eda \u00a0\ncl\u00ednica\u00a0RE\u2010/HER2\u2010109.\u00a0Suelen\u00a0estar\u00a0relacionados \u00a0con\u00a0\ntumores\u00a0metapl\u00e1sicos \u00a0y\u00a0de\u00a0mal\u00a0pron\u00f3stico \u00a0o\u00a0\ntumores\u00a0apocrinos10\u00a0y\u00a0adem\u00e1s\u00a0muestran \u00a0\npositividad \u00a0por\u00a0receptores \u00a0de\u00a0andr\u00f3genos110.\u00a0\nNormal\u2010like:\u00a0Este\u00a0fenotipo\u00a0coincide\u00a0con\u00a0tejido\u00a0\nepitelial\u00a0normal\u00a0e\u00a0incluso\u00a0puede\u00a0contener\u00a0\ncantidades \u00a0de\u00a0tejido\u00a0no\u00a0tumoral\u00a0y/o\u00a0tejido\u00a0\nestromal, \u00a0sin\u00a0embargo\u00a0futuros\u00a0estudios\u00a0como\u00a0los\u00a0\nrealizados \u00a0por\u00a0el\u00a0proyecto\u00a0The\u00a0Cancer\u00a0Genome\u00a0\nAtlas\u00a0podr\u00e1n\u00a0contestar \u00a0a\u00a0las\u00a0dudas\u00a0sobre\u00a0si\u00a0existe\u00a0\no\u00a0no\u00a0un\u00a0subtipo\u00a0tumoral\u00a0normal\u2010like.109.\u00a0\n\u00a0\n3.2.\u00a0Heterogeneidad \u00a0intra\u2010tumoral\u00a0\nTal\u00a0y\u00a0como\u00a0se\u00a0ha\u00a0mencionado \u00a0anteriromente, \u00a0el\u00a0\norigen\u00a0celular\u00a0de\u00a0muchos\u00a0tumores\u00a0s\u00f3lidos\u00a0es\u00a0\ntodav\u00eda\u00a0desconocido, \u00a0pero\u00a0cada\u00a0d\u00eda\u00a0se\u00a0especula\u00a0\nm\u00e1s\u00a0que\u00a0la\u00a0existencia \u00a0de\u00a0diferentes \u00a0subtipos\u00a0es\u00a0un\u00a0\nreflejo\u00a0de\u00a0la\u00a0existencia \u00a0de\u00a0distintas\u00a0c\u00e9lulas\u00a0de\u00a0\norigen\u00a0a\u00a0partir\u00a0de\u00a0las\u00a0cuales\u00a0tiene\u00a0lugar\u00a0la\u00a0\niniciaci\u00f3n \u00a0de\u00a0un\u00a0proceso\u00a0tumoral.\u00a0Adem\u00e1s\u00a0de\u00a0esta\u00a0\nheterogeneidad \u00a0inter\u2010tumoral\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0\ncuenta\u00a0que\u00a0tambi\u00e9n\u00a0existe\u00a0diversidad \u00a0en\u00a0las\u00a0\nc\u00e9lulas\u00a0que\u00a0forman\u00a0un\u00a0mismo\u00a0tumor\u00a0\n(heterogeneidad \u00a0intra\u2010tumoral). \u00a0Existen\u00a0dos\u00a0\nhip\u00f3tesis\u00a0distintas\u00a0para\u00a0explicar\u00a0el\u00a0origen\u00a0de\u00a0esta\u00a0\nheterogeneidad: \u00a0la\u00a0selecci\u00f3n\u00a0clonal\u00a0o\u00a0modelo\u00a0de\u00a0\nevoluci\u00f3n \u00a0clonal,\u00a0y\u00a0la\u00a0hip\u00f3tesis\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nmadre\u00a0cancerosas \u00a0(CMCs),\u00a0la\u00a0cual\u00a0fue\u00a0propuesta \u00a0\nhace\u00a0m\u00e1s\u00a0de\u00a050\u00a0a\u00f1os\u00a0pero\u00a0que\u00a0fue\u00a0retomada \u00a0hace\u00a0\nun\u00a0tiempo91,111.\u00a0Aunque\u00a0ambos\u00a0modelos\u00a0est\u00e1n\u00a0de\u00a0\nacuerdo\u00a0con\u00a0que\u00a0los\u00a0tumores\u00a0se\u00a0originan\u00a0a\u00a0partir\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n37\u00a0\n\u00a0de\u00a0una\u00a0\u00fanica\u00a0c\u00e9lula\u00a0que\u00a0adquiere\u00a0m\u00faltiples \u00a0\nmutaciones, \u00a0existen\u00a0diferencias \u00a0importantes \u00a0entre\u00a0\nambos.\u00a0El\u00a0modelo\u00a0de\u00a0evoluci\u00f3n \u00a0clonal\u00a0propone\u00a0\nque\u00a0los\u00a0tumores\u00a0se\u00a0generan\u00a0por\u00a0una\u00a0sucesi\u00f3n\u00a0de\u00a0\nexpansiones \u00a0clonales\u00a0donde\u00a0cada\u00a0expansi\u00f3n \u00a0es\u00a0\nliderada\u00a0por\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0nuevas\u00a0mutaciones. \u00a0\nEstas\u00a0mutaciones \u00a0proveen\u00a0ciertos\u00a0clones\u00a0con\u00a0\nventaja\u00a0selectiva, \u00a0y\u00a0por\u00a0procesos\u00a0de\u00a0selecci\u00f3n\u00a0\nDarwiniana \u00a0y\u00a0de\u00a0competici\u00f3n \u00a0entre\u00a0los\u00a0diferentes \u00a0\nclones,\u00a0se\u00a0seleccionan \u00a0aquellos\u00a0con\u00a0mejor\u00a0ventaja\u00a0\nevolutiva. \u00a0En\u00a0este\u00a0modelo\u00a0se\u00a0describe\u00a0que\u00a0\ndeterminadas \u00a0c\u00e9lulas\u00a0han\u00a0adquirido \u00a0a\u00a0ventaja\u00a0\nevolutiva\u00a0frente\u00a0a\u00a0las\u00a0dem\u00e1s,\u00a0gracias\u00a0a\u00a0una\u00a0o\u00a0varias\u00a0\nmutaciones, \u00a0sin\u00a0especificar \u00a0ninguna\u00a0subpoblaci\u00f3n \u00a0\ncelular\u00a0en\u00a0particular. \u00a0Una\u00a0de\u00a0estas\u00a0ventajas\u00a0podr\u00eda\u00a0\nser\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0resistencia \u00a0a\u00a0f\u00e1rmacos \u00a0dando\u00a0\nlugar\u00a0a\u00a0clones\u00a0resistentes \u00a0a\u00a0diversas\u00a0terapias\u00a0con\u00a0\nla\u00a0capacidad \u00a0de\u00a0regenerar \u00a0el\u00a0crecimiento \u00a0tumoral.\u00a0\nPor\u00a0otro\u00a0lado\u00a0el\u00a0modelo\u00a0de\u00a0las\u00a0CMCs\u00a0establece \u00a0\nque\u00a0una\u00a0peque\u00f1a\u00a0fracci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0tumor\u00a0\nllamadas\u00a0CMCs\u00a0son\u00a0las\u00a0responsables \u00a0del\u00a0\nmantenimiento \u00a0y\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0Estas\u00a0\nc\u00e9lulas\u00a0presentan \u00a0capacidad \u00a0de\u00a0auto\u00a0renovarse \u00a0(a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0divisi\u00f3n\u00a0sim\u00e9trica) \u00a0y\u00a0de\u00a0diferenciarse \u00a0\n(a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0divisi\u00f3n\u00a0asim\u00e9trica), \u00a0aunque\u00a0sea\u00a0de\u00a0\nforma\u00a0aberrante. \u00a0\u00a0\nEs\u00a0importante \u00a0remarcar\u00a0que\u00a0ambos\u00a0modelos\u00a0no\u00a0\nson\u00a0mutualmente \u00a0excluyentes, \u00a0ya\u00a0que\u00a0las\u00a0CMCs\u00a0\npor\u00a0si\u00a0mismas\u00a0tambi\u00e9n\u00a0pueden\u00a0diferenciarse \u00a0y\u00a0\nestar\u00a0sometidas \u00a0a\u00a0selecci\u00f3n\u00a0clonal77,112.\u00a0Adem\u00e1s\u00a0\nuna\u00a0CMC\u00a0puede\u00a0emerger\u00a0si\u00a0una\u00a0mutaci\u00f3n \u00a0le\u00a0\nconfiere\u00a0agresividad, \u00a0propiedades \u00a0de\u00a0auto\u00a0\nrenovaci\u00f3n \u00a0y/o\u00a0de\u00a0crecimiento. \u00a0\u00a0\nLa\u00a0primera\u00a0evidencia \u00a0sobre\u00a0la\u00a0existencia \u00a0de\u00a0CMCs\u00a0\nproviene\u00a0de\u00a0un\u00a0estudio\u00a0realizado\u00a0en\u00a0leucemia\u00a0\nmieloide\u00a0aguda\u00a0donde\u00a0se\u00a0observo\u00a0que\u00a0a\u00a0partir\u00a0de\u00a0\nuna\u00a0peque\u00f1a\u00a0poblaci\u00f3n \u00a0celular\u00a0(de\u00a0un\u00a00.01%\u00a0a\u00a0un\u00a0\n1%\u00a0de\u00a0CD34+/CD38 \u2010)\u00a0se\u00a0pod\u00eda\u00a0generar\u00a0leucemia\u00a0\nen\u00a0ratones\u00a0immunosuprimidos, \u00a0y\u00a0adem\u00e1s\u00a0esta\u00a0\npoblaci\u00f3n \u00a0era\u00a0capaz\u00a0de\u00a0diferenciarse \u00a0en\u00a0blastos\u00a0\nleuc\u00e9micos. \u00a0A\u00a0partir\u00a0de\u00a0aqu\u00ed,\u00a0diversos\u00a0estudios\u00a0han\u00a0\nidentificado \u00a0c\u00e9lulas\u00a0con\u00a0propiedades \u00a0de\u00a0c\u00e9lulas\u00a0\nmadre\u00a0tumorales \u00a0en\u00a0pr\u00f3stata,\u00a0cerebro,\u00a0ri\u00f1\u00f3n,\u00a0\npulm\u00f3n\u00a0y\u00a0est\u00f3mago \u00a0entre\u00a0otros.\u00a0Adem\u00e1s\u00a0de\u00a0las\u00a0\ndos\u00a0hip\u00f3tesis\u00a0sobre\u00a0el\u00a0origen\u00a0de\u00a0la\u00a0hetereogenidad \u00a0tumoral,\u00a0es\u00a0importante \u00a0remarcar\u00a0que\u00a0la\u00a0c\u00e9lula\u00a0\noriginaria \u00a0de\u00a0un\u00a0tumor\u00a0o\u00a0la\u00a0c\u00e9lula\u00a0normal\u00a0que\u00a0\nadquiere\u00a0por\u00a0primera\u00a0vez\u00a0esa\u00a0mutaci\u00f3n/es \u00a0\ngen\u00e9tica/s \u00a0o\u00a0cambio/s \u00a0epigen\u00e9tico/s, \u00a0no\u00a0tiene\u00a0\nporque\u00a0ser\u00a0necesariamente \u00a0una\u00a0c\u00e9lula\u00a0madre\u00a0\ntumoral\u00a0y\u00a0no\u00a0tiene\u00a0porque\u00a0originarse \u00a0\nobligatoriamente \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0transformaci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0madre\u00a0normales \u00a0(Fig.\u00a013)79.\u00a0Quiz\u00e1s\u00a0estas\u00a0\nCMCs\u00a0provienen \u00a0de\u00a0progenitores \u00a0o\u00a0quiz\u00e1s\u00a0de\u00a0otras\u00a0\nc\u00e9lulas\u00a0m\u00e1s\u00a0diferenciadas \u00a0que\u00a0han\u00a0adquirido \u00a0\npropiedades \u00a0de\u00a0auto\u2010renovaci\u00f3n \u00a0y\u00a0de\u00a0resistencia \u00a0a\u00a0\nf\u00e1rmacos \u00a079.\u00a0Esta\u00a0\u00faltima\u00a0idea\u00a0se\u00a0ejemplifica \u00a0en\u00a0un\u00a0\nestudio\u00a0en\u00a0pacientes \u00a0con\u00a0leucemia\u00a0mieloide\u00a0\ncr\u00f3nica\u00a0(LMC).\u00a0Una\u00a0mutaci\u00f3n \u00a0en\u00a0la\u00a0prote\u00edna\u00a0\u03b2 \u2010\ncatenina\u00a0parece\u00a0ser\u00a0que\u00a0confiere\u00a0propiedades \u00a0de\u00a0\nauto\u2010renovaci\u00f3n \u00a0a\u00a0los\u00a0granulocitos \u2010macr\u00f3fagos \u00a0\nprogenitores113.\u00a0\u00a0\nEn\u00a0tumores\u00a0s\u00f3lidos\u00a0todav\u00eda\u00a0no\u00a0hay\u00a0marcadores \u00a0\nfenot\u00edpicos \u00a0definitivos \u00a0bien\u00a0definidos \u00a0para\u00a0\nidentificar \u00a0c\u00e9lulas\u00a0madre\u00a0tumorales \u00a0y\u00a0su\u00a0progenie. \u00a0\nLa\u00a0identificaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0madre\u00a0en\u00a0CM\u00a0fue\u00a0\npropuesta \u00a0por\u00a0primera\u00a0vez\u00a0por\u00a0Al\u2010Hajj\u00a0y\u00a0\ncolaboradores, \u00a0quienes\u00a0identificaron \u00a0un\u00a0subgrupo \u00a0\nde\u00a0c\u00e9lulas\u00a0CD44+/CD24 \u2010\u00a0con\u00a0propiedades \u00a0de\u00a0\nCMCs114.\u00a0En\u00a0este\u00a0trabajo\u00a0se\u00a0utilizaron \u00a0efusiones \u00a0\npleurales\u00a0con\u00a0avanzado \u00a0estado\u00a0metast\u00e1sico \u00a0para\u00a0\naislar,\u00a0en\u00a0base\u00a0a\u00a0los\u00a0marcadores \u00a0antig\u00e9nicos \u00a0lin\u2010\n/CD44+/CD24 \u2010,\u00a0una\u00a0subpoblaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0que\u00a0\nmostr\u00f3\u00a0tener\u00a0una\u00a0mayor\u00a0habilidad\u00a0para\u00a0generar\u00a0\ntumores\u00a0en\u00a0animales\u00a0immunosuprimidos \u00a0y\u00a0\ndiferenciarse \u00a0en\u00a0el\u00a0resto\u00a0de\u00a0c\u00e9lulas\u00a0que\u00a0formaban \u00a0\nel\u00a0tumor,\u00a0generando \u00a0el\u00a0mismo\u00a0grado\u00a0de\u00a0\nheterogeneidad \u00a0que\u00a0el\u00a0observado \u00a0en\u00a0el\u00a0tumor\u00a0del\u00a0\nque\u00a0proven\u00edan. \u00a0Posteriormente \u00a0otro\u00a0grupo\u00a0public\u00f3\u00a0\nque\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM,\u00a0las\u00a0cuales\u00a0pose\u00edan\u00a0una\u00a0\nalta\u00a0proporci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0con\u00a0este\u00a0mismo\u00a0\nfenotipo\u00a0 (CD44+/CD24 \u2010)\u00a0 presentaban \u00a0\ncaracter\u00edsticas \u00a0basales,\u00a0mioepiteliales, \u00a0o\u00a0\nmesenquimales \u00a0de\u00a0acuerdo\u00a0con\u00a0los\u00a0perfiles\u00a0de\u00a0\nexpresi\u00f3n \u00a0g\u00e9nica\u00a0y\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0ciertos\u00a0\nmarcadores115.\u00a0Este\u00a0grupo\u00a0de\u00a0investigaci\u00f3n \u00a0lleg\u00f3\u00a0a\u00a0\nla\u00a0conclusi\u00f3n \u00a0de\u00a0que\u00a0estas\u00a0c\u00e9lulas\u00a0eran\u00a0altamente \u00a0\ninvasivas\u00a0y\u00a0expresaban \u00a0con\u00a0frecuencia \u00a0CK5,\u00a0CD10\u00a0y\u00a0\nvimentina115.\u00a0Hasta\u00a0d\u00eda\u00a0de\u00a0hoy,\u00a0varios\u00a0estudios\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n38\u00a0\n\u00a0Figura\u00a013.\u00a0La\u00a0c\u00e9lula\u00a0de\u00a0origen\u00a0y\u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a0una\u00a0c\u00e9lula\u00a0madre\u00a0cancerosa .\u00a0La\u00a0jerarqu\u00eda\u00a0celular\u00a0normal\u00a0se\u00a0inicia\u00a0a\u00a0partir\u00a0de\u00a0\nc\u00e9lulas\u00a0madre\u00a0que\u00a0progresivamente \u00a0generan\u00a0c\u00e9lulas\u00a0progenitoras \u00a0comunes\u00a0dando\u00a0lugar\u00a0a\u00a0todos\u00a0los\u00a0tipos\u00a0de\u00a0c\u00e9lulas\u00a0maduras\u00a0que\u00a0\nconstituyen \u00a0un\u00a0tejido\u00a0particular. \u00a0Aunque\u00a0la\u00a0c\u00e9lula\u00a0de\u00a0origen\u00a0de\u00a0un\u00a0tumor\u00a0en\u00a0particular, \u00a0podr\u00eda\u00a0ser\u00a0un\u00a0precursor \u00a0de\u00a0c\u00e9lulas\u00a0m\u00e1s\u00a0\ntempranas \u00a0(como\u00a0un\u00a0antepasado \u00a0com\u00fan),\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0m\u00e1s\u00a0mutaciones \u00a0gen\u00e9ticas \u00a0o\u00a0epigen\u00e9ticas \u00a0por\u00a0parte\u00a0de\u00a0una\u00a0c\u00e9lula\u00a0\ndentro\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0aberrante \u00a0(en\u00a0este\u00a0caso\u00a0expandida) \u00a0durante\u00a0la\u00a0progresi\u00f3n \u00a0neopl\u00e1sica \u00a0puede\u00a0dar\u00a0lugar\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0una\u00a0\nCMC.\u00a0En\u00a0este\u00a0modelo,\u00a0s\u00f3lo\u00a0la\u00a0CMC\u00a0(y\u00a0no\u00a0otras\u00a0c\u00e9lulas\u00a0tumorales) \u00a0son\u00a0capaces\u00a0de\u00a0sostener\u00a0la\u00a0tumorog\u00e9nesis. \u00a0As\u00ed,\u00a0la\u00a0c\u00e9lula\u00a0de\u00a0\norigen,\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0cual\u00a0se\u00a0inicia\u00a0la\u00a0tumorog\u00e9nesis, \u00a0puede\u00a0ser\u00a0distinta\u00a0de\u00a0la\u00a0CMC,\u00a0responsable \u00a0de\u00a0la\u00a0propagaci\u00f3n \u00a0del\u00a0tumor.\u00a0\nIlustraci\u00f3n \u00a0modificada \u00a0de79.\u00a0\n\u00a0\nproponen \u00a0distintos\u00a0marcadores \u00a0antig\u00e9nicos \u00a0que\u00a0\npodr\u00edan\u00a0ser\u00a0\u00fatiles\u00a0para\u00a0el\u00a0enriquecimiento \u00a0de\u00a0\nCMCs,\u00a0como\u00a0es\u00a0el\u00a0caso\u00a0del\u00a0marcador \u00a0espec\u00edfico \u00a0\nantig\u00e9nico \u00a0(ESA,\u00a0del\u00a0ingl\u00e9s\u00a0epitelial\u00a0specific\u00a0\nantigen ),\u00a0EpCamhi/CD49fhi,\u00a0CD133,\u00a0CD44\u00a0y\u00a0varias\u00a0\nintegrinas \u00a0de\u00a0superficie, \u00a0sin\u00a0embargo\u00a0ninguno\u00a0de\u00a0\nellos\u00a0parece\u00a0estar\u00a0expresado \u00a0exclusivamente \u00a0en\u00a0\nlas\u00a0CMCs\u00a0del\u00a0tumor.\u00a0Adem\u00e1s\u00a0de\u00a0marcadores \u00a0\nfenot\u00edpicos, \u00a0se\u00a0han\u00a0utilizado\u00a0otras\u00a0propiedades \u00a0\ncelulares\u00a0como\u00a0la\u00a0expulsi\u00f3n \u00a0del\u00a0colorante \u00a0Hoechst\u00a0\n33342\u00a0(utilizado \u00a0para\u00a0identificar \u00a0esta\u00a0poblaci\u00f3n \u00a0\ntambi\u00e9n\u00a0conocida\u00a0como\u00a0\u201cside\u00a0population\u201d )\u00a0o\u00a0la\u00a0\ncapacidad \u00a0de\u00a0retener\u00a0el\u00a0colorante \u00a0PKH26+\u00a0para\u00a0\nidentificar \u00a0subpoblaciones \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\ncon\u00a0propiedades \u00a0de\u00a0c\u00e9lulas\u00a0madre.\u00a0Incluso\u00a0se\u00a0han\u00a0\ndescrito\u00a0actividades \u00a0enzim\u00e1ticas \u00a0espec\u00edficas, \u00a0como\u00a0\nla\u00a0actividad\u00a0de\u00a0la\u00a0enzima\u00a0ALDH1116\u2010120,\u00a0para\u00a0\nidentificar \u00a0la\u00a0fracci\u00f3n\u00a0tumorog\u00e9nica. \u00a0Otras\u00a0\ncaracter\u00edsticas \u00a0que\u00a0se\u00a0atribuyen \u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0\nmadre\u00a0tumorales \u00a0son\u00a0la\u00a0propiedad \u00a0de\u00a0generar\u00a0\nmamosferas, \u00a0o\u00a0la\u00a0capacidad \u00a0de\u00a0generar\u00a0tumores\u00a0\nheterog\u00e9neos \u00a0en\u00a0ratones\u00a0inmunosuprimidos. \u00a0Sin\u00a0\nembargo, \u00a0existe\u00a0cierta\u00a0controversia \u00a0sobre\u00a0el\u00a0\nsignificado \u00a0real\u00a0de\u00a0la\u00a0capacidad \u00a0de\u00a0crecer\u00a0en\u00a0\nratones\u00a0inmunosuprimidos \u00a0(a\u00a0veces\u00a0con\u00a0una\u00a0incompleta \u00a0inmunosupresi\u00f3n) \u00a0dado\u00a0que\u00a0esta\u00a0\ncaracter\u00edstica \u00a0podr\u00eda\u00a0simplemente \u00a0reflejar\u00a0la\u00a0\nselecci\u00f3n\u00a0de\u00a0una\u00a0poblaci\u00f3n \u00a0c\u00e9lulas\u00a0apta\u00a0para\u00a0\ncrecer\u00a0en\u00a0el\u00a0microambiente \u00a0murino\u00a0y\u00a0no\u00a0ser\u00a0una\u00a0\npropiedad \u00a0de\u00a0c\u00e9lula\u00a0madre\u00a0tumoral\u00a0per\u00a0se.\u00a0Por\u00a0\nejemplo,\u00a0en\u00a0un\u00a0modelo\u00a0de\u00a0melanoma \u00a0se\u00a0ha\u00a0\ndemostrado \u00a0que\u00a0el\u00a0porcentaje \u00a0de\u00a0c\u00e9lulas\u00a0\ntumorig\u00e9nicas \u00a0puede\u00a0aumentar \u00a0si\u00a0estas\u00a0c\u00e9lulas\u00a0\nson\u00a0inoculadas \u00a0en\u00a0otro\u00a0modelo\u00a0murino\u00a0con\u00a0un\u00a0\nmayor\u00a0grado\u00a0de\u00a0inmunosupresi\u00f3n121.\u00a0Incluso\u00a0en\u00a0\nmodelos\u00a0sing\u00e9nicos \u00a0la\u00a0implantaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0en\u00a0un\u00a0nicho\u00a0normal\u00a0no\u00a0sustituye\u00a0\nrealmente \u00a0un\u00a0microambiente \u00a0adecuado \u00a0por\u00a0s\u00ed\u00a0\nsolo.\u00a0De\u00a0hecho\u00a0es\u00a0probable\u00a0que\u00a0c\u00e9lulas\u00a0madre\u00a0de\u00a0\nun\u00a0tejido\u00a0adulto\u00a0necesiten \u00a0tener\u00a0un\u00a0nicho\u00a0\nespec\u00edfico \u00a0(es\u00a0decir\u00a0un\u00a0microambiente \u00a0adecuado) \u00a0\npara\u00a0mantener \u00a0sus\u00a0caracter\u00edsticas \u00a0de\u00a0c\u00e9lulas\u00a0\nindiferenciadas \u00a0y\u00a0su\u00a0capadicad \u00a0pluripotente \u00a0o\u00a0\n\u201cstemness\u201d .\u00a0Cambios\u00a0en\u00a0el\u00a0microambiente \u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0CD44+\u00a0(poblaci\u00f3n \u00a0enriquecida \u00a0en\u00a0tumores\u00a0\nbasales\u00a0o\u00a0c\u00e9lulas\u00a0madre)\u00a0puede\u00a0dar\u00a0lugar\u00a0a\u00a0\ndiferenciaci\u00f3n \u00a0hacia\u00a0un\u00a0fenotipo\u00a0CD24+\u00a0(poblaci\u00f3n \u00a0\nm\u00e1s\u00a0diferenciada \u00a0y\u00a0que\u00a0se\u00a0encuentra \u00a0enriquecida \u00a0\nen\u00a0tumores\u00a0luminales), \u00a0generando \u00a0una\u00a0\nheterogeneidad \u00a0fenot\u00edpica \u00a0dentro\u00a0de\u00a0un\u00a0mismo\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n39\u00a0\n\u00a0tumor.\u00a0Asi\u00a0microambientes \u00a0diferentes, \u00a0distintas\u00a0\ncomposiciones \u00a0de\u00a0citoquinas \u00a0y\u00a0\u00e1reas\u00a0de\u00a0hipoxia\u00a0en\u00a0\nel\u00a0tumor\u00a0parecen\u00a0controlar \u00a0el\u00a0fenotipo\u00a0de\u00a0estas\u00a0\nc\u00e9lulas\u00a0madre122\u2010124.\u00a0Por\u00a0lo\u00a0tanto\u00a0sigue\u00a0siendo\u00a0\nclave\u00a0encontrar \u00a0cuales\u00a0de\u00a0los\u00a0marcadores \u00a0\nidentifican \u00a0realmente \u00a0c\u00e9lulas\u00a0madre\u00a0o\u00a0c\u00e9lulas\u00a0\nprogenitoras \u00a0y\u00a0como\u00a0el\u00a0microambiente \u00a0puede\u00a0\ninfluir\u00a0en\u00a0su\u00a0plasticidad \u00a0celular,\u00a0y\u00a0en\u00a0consecuencia \u00a0\ngenerar\u00a0heterogeneidad \u00a0intra\u2010tumoral.\u00a0\n4.\u00a0LA\u00a0INFLAMACI\u00d3N: \u00a0NUEVO\u00a0\nSIGNO\u00a0DISTINTIVO \u00a0DEL\u00a0C\u00c1NCER\u00a0\n\u00a0\nLa\u00a0relaci\u00f3n\u00a0entre\u00a0inflamaci\u00f3n \u00a0y\u00a0c\u00e1ncer\u00a0viene\u00a0\nsiendo\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0aceptada\u00a0y\u00a0estudiada \u00a0por\u00a0la\u00a0\ncomunidad \u00a0cient\u00edfica. \u00a0De\u00a0hecho,\u00a0se\u00a0ha\u00a0postulado \u00a0\nque\u00a0la\u00a0inflamaci\u00f3n \u00a0podr\u00eda\u00a0constituir \u00a0un\u00a0nuevo\u00a0\nsigno\u00a0distintivo \u00a0del\u00a0c\u00e1ncer,\u00a0y\u00a0as\u00ed\u00a0lo\u00a0describen \u00a0en\u00a0la\u00a0\nnueva\u00a0revisi\u00f3n\u00a0de\u00a0Douglas\u00a0Hanahan\u00a0y\u00a0Robert\u00a0\nWeinberg \u00a0sobre\u00a0los\u00a0sellos\u00a0distintivos \u00a0del\u00a0c\u00e1ncer125.\u00a0\nRudolf\u00a0Virchow\u00a0a\u00a0mediados \u00a0del\u00a0siglo\u00a019\u00a0nos\u00a0\nproporcion\u00f3 \u00a0una\u00a0de\u00a0las\u00a0primeras\u00a0indicaciones \u00a0que\u00a0\nprobaban \u00a0este\u00a0posible\u00a0v\u00ednculo\u00a0entre\u00a0inflamaci\u00f3n \u00a0y\u00a0\nc\u00e1ncer.\u00a0Observ\u00f3\u00a0que\u00a0alguna\u00a0clase\u00a0de\u00a0irritantes\u00a0que\u00a0\nprovocaban \u00a0da\u00f1os\u00a0en\u00a0los\u00a0tejidos,\u00a0y\u00a0una\u00a0\nconsiguiente \u00a0inflamaci\u00f3n, \u00a0eran\u00a0los\u00a0causantes \u00a0del\u00a0\naumento\u00a0de\u00a0proliferaci\u00f3n \u00a0celular126,127.\u00a0Aunque\u00a0un\u00a0\naumento\u00a0en\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0no\u00a0est\u00e1\u00a0\ndirectamente \u00a0relacionado \u00a0con\u00a0el\u00a0origen\u00a0del\u00a0\nc\u00e1ncer,\u00a0una\u00a0proliferaci\u00f3n \u00a0sostenida \u00a0en\u00a0un\u00a0\nambiente \u00a0rico\u00a0en\u00a0c\u00e9lulas\u00a0inflamatorias, \u00a0factores\u00a0de\u00a0\ncrecimiento, \u00a0c\u00e9lulas\u00a0estromales \u00a0activas\u00a0y\u00a0agentes\u00a0\ncausantes \u00a0de\u00a0da\u00f1o\u00a0al\u00a0ADN\u00a0ciertamente \u00a0podr\u00edan\u00a0\npotenciar \u00a0el\u00a0riesgo\u00a0de\u00a0originar\u00a0un\u00a0proceso\u00a0\nneopl\u00e1sico. \u00a0Es\u00a0decir,\u00a0estas\u00a0c\u00e9lulas\u00a0del\u00a0tejido\u00a0\nda\u00f1ado,\u00a0que\u00a0se\u00a0encuentran \u00a0en\u00a0continuo\u00a0proceso\u00a0\nde\u00a0regeneraci\u00f3n \u00a0y\u00a0en\u00a0un\u00a0microambiente \u00a0rico\u00a0en\u00a0\nc\u00e9lulas\u00a0inflamatorias \u00a0y\u00a0agentes\u00a0responsables \u00a0de\u00a0\nda\u00f1os\u00a0en\u00a0el\u00a0ADN,\u00a0podr\u00edan\u00a0ser\u00a0el\u00a0origen\u00a0de\u00a0un\u00a0\ntumor\u00a0y\u00a0podr\u00edan\u00a0actuar\u00a0como\u00a0heridas\u00a0que\u00a0nunca\u00a0\nse\u00a0curan128.\u00a0\nAunque\u00a0es\u00a0generalmente \u00a0aceptado \u00a0que\u00a0la\u00a0\ninflamaci\u00f3n \u00a0juega\u00a0un\u00a0papel\u00a0muy\u00a0importante \u00a0en\u00a0la\u00a0\ntumorog\u00e9nesis, \u00a0y\u00a0que\u00a0ese\u00a0microambiente \u00a0inflamatorio \u00a0es\u00a0un\u00a0componente \u00a0esencial\u00a0de\u00a0todos\u00a0\nlos\u00a0tumores,\u00a0todav\u00eda\u00a0no\u00a0est\u00e1\u00a0demostrada \u00a0una\u00a0\ncausa\u00a0directa\u00a0en\u00a0el\u00a0desarrollo \u00a0de\u00a0todos\u00a0los\u00a0tipos\u00a0de\u00a0\nc\u00e1nceres, \u00a0como\u00a0es\u00a0el\u00a0ejemplo\u00a0de\u00a0CM129.\u00a0La\u00a0\nmayor\u00eda\u00a0de\u00a0tumores\u00a0(90%)\u00a0est\u00e1n\u00a0vinculados \u00a0a\u00a0\nmutaciones \u00a0som\u00e1ticas \u00a0y\u00a0factores\u00a0ambientales \u00a0y\u00a0\nsolo\u00a0una\u00a0minor\u00eda\u00a0de\u00a0todos\u00a0los\u00a0c\u00e1nceres\u00a0a\u00a0\nmutaciones \u00a0de\u00a0genes\u00a0en\u00a0la\u00a0l\u00ednea\u00a0germinal. \u00a0Muchos\u00a0\nde\u00a0los\u00a0factores\u00a0ambientales \u00a0que\u00a0aumentan \u00a0el\u00a0\nriesgo\u00a0de\u00a0desarrollar \u00a0c\u00e1ncer\u00a0est\u00e1n\u00a0asociados \u00a0a\u00a0la\u00a0\ninflamaci\u00f3n, \u00a0producto\u00a0de\u00a0infecciones \u00a0cr\u00f3nicas\u00a0\n(20%),\u00a0fumar\u00a0tabaco\u00a0o\u00a0inhalar\u00a0poluci\u00f3n\u00a0(30%)\u00a0y\u00a0de\u00a0\nfactores\u00a0de\u00a0la\u00a0dieta\u00a0(de\u00a0un\u00a035%\u00a0a\u00a0un\u00a020%\u00a0de\u00a0los\u00a0\nc\u00e1nceres\u00a0est\u00e1n\u00a0asociados \u00a0a\u00a0la\u00a0obesidad130).\u00a0\u00a0\n4.1.\u00a0C\u00e1nceres\u00a0asociados \u00a0a\u00a0\ninflamaci\u00f3n \u00a0cr\u00f3nica\u00a0\nEn\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0inflamaciones \u00a0persistentes \u00a0y\u00a0\ncr\u00f3nicas\u00a0en\u00a0un\u00a0hu\u00e9sped,\u00a0infecciones \u00a0causadas\u00a0por\u00a0\npat\u00f3genos \u00a0provocan \u00a0que\u00a0\u00e9ste\u00a0mantenga \u00a0una\u00a0\nactivaci\u00f3n \u00a0del\u00a0sistema\u00a0inmunol\u00f3gico. \u00a0Un\u00a0\nmecanismo \u00a0efectivo\u00a0por\u00a0el\u00a0cual\u00a0un\u00a0hu\u00e9sped\u00a0lucha\u00a0\ncontra\u00a0un\u00a0agente\u00a0microbiano \u00a0es\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0\nradicales\u00a0libres\u00a0como,\u00a0reactivos\u00a0de\u00a0ox\u00edgeno\u00a0\nintermedios \u00a0(ROIs),\u00a0radicales\u00a0hidroxilo\u00a0(OH\uf0b7)\u00a0y\u00a0\nsuperxido \u00a0(O2\u2010\uf0b7),\u00a0reactivos\u00a0de\u00a0nitr\u00f3geno \u00a0\nintermedios \u00a0(RNI),\u00a0\u00f3xido\u00a0n\u00edtrico\u00a0(NO\uf0b7)\u00a0y\u00a0\nperoxidonitrito \u00a0(ONOO\u2010)\u00a0liberados \u00a0por\u00a0leucocitos \u00a0y\u00a0\notras\u00a0c\u00e9lulas\u00a0fagoc\u00edticas. \u00a0Estos\u00a0radicales\u00a0libres\u00a0que\u00a0\nde\u00a0manera\u00a0inicial\u00a0son\u00a0mol\u00e9culas \u00a0anti\u2010microbianas, \u00a0\nda\u00f1an\u00a0de\u00a0manera\u00a0importante \u00a0el\u00a0ADN\u00a0a\u00a0trav\u00e9s\u00a0de,\u00a0\npor\u00a0ejemplo,\u00a0la\u00a0oxidaci\u00f3n \u00a0o\u00a0nitraci\u00f3n\u00a0de\u00a0bases\u00a0lo\u00a0\nque\u00a0incrementa \u00a0el\u00a0riesgo\u00a0de\u00a0mutaciones \u00a0en\u00a0el\u00a0\nmaterial\u00a0gen\u00e9tico131.\u00a0Por\u00a0ejemplo,\u00a0se\u00a0han\u00a0\nobservado \u00a0frecuentes \u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0TP53\u00a0\nen\u00a0enfermedades \u00a0cr\u00f3nicas\u00a0inflamatorias \u00a0como\u00a0la\u00a0\nartritis\u00a0y\u00a0la\u00a0enfermedad \u00a0inflamatoria \u00a0intestinal132\u00a0\n(EII).\u00a0Tanto\u00a0la\u00a0enfermedad \u00a0de\u00a0Chron\u00a0como\u00a0la\u00a0colitis\u00a0\nulcerativa \u00a0cr\u00f3nica\u00a0est\u00e1n\u00a0asociadas \u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0\nde\u00a0c\u00e1ncer\u00a0de\u00a0colon.\u00a0La\u00a0hepatitis\u00a0C\u00a0o\u00a0B\u00a0en\u00a0h\u00edgado\u00a0\npredispone \u00a0al\u00a0individuo \u00a0a\u00a0desarrollar \u00a0un\u00a0\nhepatocarcinoma, \u00a0y\u00a0la\u00a0esquistosomiasis \u00a0\nincrementa \u00a0el\u00a0riesgo\u00a0de\u00a0c\u00e1ncer\u00a0en\u00a0vejiga\u00a0y\u00a0colon.\u00a0\nUna\u00a0de\u00a0las\u00a0mayores\u00a0causas\u00a0reconocidas \u00a0de\u00a0c\u00e1ncer\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n40\u00a0\n\u00a0de\u00a0est\u00f3mago \u00a0es\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0por\u00a0parte\u00a0del\u00a0\nHelicobacter \u00a0pylori,\u00a0que\u00a0tambi\u00e9n\u00a0est\u00e1\u00a0asociado\u00a0al\u00a0\nlinfoma\u00a0de\u00a0MALT\u00a0(Tejido\u00a0Linfoide\u00a0Asociado\u00a0a\u00a0\nMucosas)133.\u00a0Se\u00a0cree\u00a0que\u00a0la\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0\ncausada\u00a0por\u00a0esta\u00a0bacteria\u00a0provoca\u00a0da\u00f1os\u00a0en\u00a0el\u00a0\nADN\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0potentes\u00a0citoquinas \u00a0que\u00a0\nprovienen \u00a0de\u00a0macr\u00f3fagos \u00a0y\u00a0linfocitos. \u00a0Una\u00a0de\u00a0\nestas\u00a0citoquinas \u00a0es\u00a0el\u00a0factor\u00a0migratorio \u00a0inhibidor\u00a0\n(FMI)\u00a0que\u00a0supera\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0p53\u00a0mediante \u00a0la\u00a0\nsupresi\u00f3n \u00a0de\u00a0su\u00a0actividad\u00a0transcripcional \u00a0\namplificando \u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0\npotencialmente \u00a0oncog\u00e9nicas. \u00a0Por\u00a0otro\u00a0lado,\u00a0\nagentes\u00a0v\u00edricos\u00a0infecciosos \u00a0pueden\u00a0directamente \u00a0\ntransformar \u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0los\u00a0tejidos,\u00a0insertando \u00a0\noncogenes \u00a0activos\u00a0en\u00a0el\u00a0genoma\u00a0del\u00a0hu\u00e9sped.\u00a0Es\u00a0\nel\u00a0caso\u00a0de\u00a0virus\u00a0del\u00a0papiloma \u00a0humano\u00a0o\u00a0el\u00a0virus\u00a0\nEpstein\u2010Barr,\u00a0uno\u00a0de\u00a0los\u00a0causantes \u00a0del\u00a0c\u00e1ncer\u00a0de\u00a0\ncuello\u00a0uterino\u00a0y\u00a0el\u00a0linfoma\u00a0de\u00a0Burkett,\u00a0\nrespectivamente134.\u00a0\nEn\u00a0resumen, \u00a0fisiol\u00f3gicamente \u00a0la\u00a0estrategia \u00a0de\u00a0\ndefensa\u00a0del\u00a0hu\u00e9sped,\u00a0para\u00a0reparar\u00a0tejidos\u00a0\nda\u00f1ados\u00a0frente\u00a0a\u00a0una\u00a0infecci\u00f3n, \u00a0es\u00a0proveerse \u00a0de\u00a0\nse\u00f1ales\u00a0de\u00a0supervivencia \u00a0y\u00a0de\u00a0divisi\u00f3n\u00a0celular\u00a0\nmediante \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0una\u00a0respuesta \u00a0\ninflamatoria. \u00a0Un\u00a0proceso\u00a0inflamatorio \u00a0normal\u00a0\nestar\u00eda\u00a0auto\u2010limitado\u00a0y\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0citoquinas \u00a0\nanti\u2010inflamatorias \u00a0e\u00a0ir\u00eda\u00a0a\u00a0continuaci\u00f3n \u00a0de\u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010inflamatorias. \u00a0Sin\u00a0\nembargo\u00a0un\u00a0desequilibrio \u00a0en\u00a0la\u00a0balanza\u00a0entre\u00a0la\u00a0\neliminaci\u00f3n \u00a0de\u00a0la\u00a0inflamaci\u00f3n \u00a0dependiente \u00a0del\u00a0\npat\u00f3geno \u00a0y\u00a0una\u00a0respuesta \u00a0compensatoria \u00a0excesiva\u00a0\nque\u00a0favorezca \u00a0la\u00a0proliferaci\u00f3n \u00a0y\u00a0reparaci\u00f3n \u00a0del\u00a0\ntejido\u00a0puede\u00a0llegar\u00a0a\u00a0influenciar \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0un\u00a0\nc\u00e1ncer.\u00a0\n4.2.\u00a0La\u00a0Inflamaci\u00f3n \u00a0como\u00a0inhibidora \u00a0\ndel\u00a0c\u00e1ncer\u00a0\nAunque\u00a0diversas\u00a0evidenicas \u00a0experimentales \u00a0y\u00a0\ncl\u00ednicas\u00a0sugieren\u00a0que\u00a0la\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0puede\u00a0\nejercer\u00a0una\u00a0influencia \u00a0pro\u2010tumoral,\u00a0no\u00a0todas\u00a0las\u00a0\nenfermedades \u00a0inflamatorias \u00a0incrementan \u00a0el\u00a0riesgo\u00a0\nde\u00a0padecer\u00a0c\u00e1ncer,\u00a0e\u00a0incluso\u00a0alguna\u00a0de\u00a0ellas\u00a0lo\u00a0\nreducen,\u00a0como\u00a0es\u00a0el\u00a0caso\u00a0de\u00a0la\u00a0psoriasis135.\u00a0\nWilliam\u00a0B.\u00a0Coley\u00a0a\u00a0finales\u00a0del\u00a0siglo\u00a0XIX,\u00a0observ\u00f3\u00a0que\u00a0en\u00a0situaciones \u00a0de\u00a0inflamaci\u00f3n \u00a0aguda,\u00a0\ninducidas \u00a0por\u00a0algunas\u00a0infecciones \u00a0post\u2010operatorias \u00a0\nen\u00a0el\u00a0lugar\u00a0del\u00a0tumor,\u00a0se\u00a0desencadenaban \u00a0\nregresiones \u00a0espont\u00e1neas \u00a0del\u00a0mismo.\u00a0\u00c9l\u00a0desarroll\u00f3 \u00a0\nun\u00a0cultivo\u00a0de\u00a0toxinas\u00a0que\u00a0administr\u00f3 \u00a0a\u00a0pacientes \u00a0\n(en\u00a0el\u00a0tumor\u00a0o\u00a0alrededores) \u00a0con\u00a0un\u00a0estado\u00a0\navanzado \u00a0de\u00a0c\u00e1ncer\u00a0y,\u00a0aunque\u00a0los\u00a0resultados \u00a0no\u00a0\nfueron\u00a0concluyentes, \u00a0algunos\u00a0pacientes \u00a0\nexperimentaron \u00a0marcados \u00a0cambios\u00a0de\u00a0regresi\u00f3n \u00a0\nen\u00a0el\u00a0tumor\u00a0y\u00a0aumentaron \u00a0su\u00a0supervivencia \u00a0\ndespu\u00e9s\u00a0del\u00a0tratamiento136.\u00a0\u00a0\nEl\u00a0papel\u00a0que\u00a0desempe\u00f1a \u00a0el\u00a0sistema\u00a0inmune\u00a0en\u00a0los\u00a0\ntumores\u00a0fue\u00a0propuesto \u00a0inicialmente \u00a0por\u00a0Thomas\u00a0y\u00a0\nBurnet\u00a0en\u00a01957.\u00a0Postularon \u00a0bajo\u00a0la\u00a0teor\u00eda\u00a0de\u00a0la\u00a0\n\"vigilancia \u00a0inmunol\u00f3gica \"\u00a0que\u00a0los\u00a0linfocitos\u00a0eran\u00a0\nresponsables \u00a0de\u00a0eliminar\u00a0continuamente \u00a0las\u00a0\nc\u00e9lulas\u00a0transformadas \u00a0que\u00a0se\u00a0iban\u00a0generando137\u2010\n139.\u00a0Esta\u00a0teor\u00eda\u00a0propon\u00eda\u00a0que,\u00a0aunque\u00a0dentro\u00a0de\u00a0un\u00a0\norganismo \u00a0se\u00a0est\u00e1n\u00a0generando \u00a0continuamente \u00a0\nc\u00e9lulas\u00a0malignas, \u00a0\u00e9stas\u00a0son\u00a0identificadas \u00a0y\u00a0\ndestruidas \u00a0r\u00e1pidamente \u00a0por\u00a0el\u00a0sistema\u00a0inmune.\u00a0\nEsta\u00a0teor\u00eda\u00a0ha\u00a0sido\u00a0defendida \u00a0y\u00a0atacada\u00a0a\u00a0lo\u00a0largo\u00a0\nde\u00a0los\u00a0a\u00f1os\u00a0por\u00a0defensores \u00a0y\u00a0detractores \u00a0de\u00a0sus\u00a0\nideas.\u00a0Sin\u00a0embargo\u00a0solo\u00a0recientemente, \u00a0con\u00a0el\u00a0\ndesarrollo \u00a0de\u00a0modelos\u00a0transg\u00e9nicos \u00a0mejorados \u00a0y\u00a0\nla\u00a0producci\u00f3n \u00a0de\u00a0anticuerpos \u00a0monoclonales \u00a0\nespec\u00edficos \u00a0contra\u00a0un\u00a0componente \u00a0inmunol\u00f3gico \u00a0\nparticular, \u00a0ha\u00a0sido\u00a0posible\u00a0proveer\u00a0datos\u00a0m\u00e1s\u00a0\nrelevantes \u00a0y\u00a0convincentes, \u00a0los\u00a0cuales\u00a0se\u00a0han\u00a0\nrecopilado \u00a0por\u00a0Mark\u00a0Smyth\u00a0y\u00a0Gavin\u00a0Dunn140\u2010143\u00a0en\u00a0\nextensas\u00a0revisiones \u00a0sobre\u00a0el\u00a0tema.\u00a0\u00a0\nUn\u00a0buen\u00a0ejemplo\u00a0de\u00a0esta\u00a0teor\u00eda\u00a0es\u00a0la\u00a0psoriasis. \u00a0El\u00a0\ntipo\u00a0de\u00a0inflamaci\u00f3n \u00a0hallada\u00a0en\u00a0esta\u00a0enfermedad \u00a0\nno\u00a0promueve \u00a0el\u00a0desarrollo \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0piel\u00a0ya\u00a0\nque\u00a0parece\u00a0ser\u00a0que\u00a0los\u00a0macr\u00f3fagos \u00a0encontrados \u00a0\nen\u00a0la\u00a0piel\u00a0pueden\u00a0destruir\u00a0las\u00a0posibles\u00a0c\u00e9lulas\u00a0\naberrantes \u00a0iniciadoras \u00a0de\u00a0tumor.\u00a0En\u00a0algunos\u00a0\ntumores,\u00a0la\u00a0presencia \u00a0de\u00a0c\u00e9lulas\u00a0inflamatorias \u00a0est\u00e1\u00a0\nasociada\u00a0a\u00a0un\u00a0mejor\u00a0pron\u00f3stico \u00a0(por\u00a0ejemplo\u00a0\neosin\u00f3filos \u00a0en\u00a0tumores\u00a0de\u00a0colon\u00a0y\u00a0macr\u00f3fagos \u00a0\nasociados \u00a0a\u00a0tumores\u00a0(TAM,\u00a0del\u00a0ingl\u00e9s\u00a0tumor\u2010\nassociated \u00a0macrophages )\u00a0en\u00a0un\u00a0subgrupo \u00a0de\u00a0\ntumores\u00a0de\u00a0mama\u00a0y\u00a0p\u00e1ncreas144.\u00a0Otras\u00a0evidencias \u00a0\nindican\u00a0que\u00a0el\u00a0factor\u00a0nuclear\u00a0\u03baB\u00a0(NF\u2010\u03baB)\u00a0es\u00a0\nimportante \u00a0en\u00a0determinar \u00a0el\u00a0balance\u00a0entre\u00a0las\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n41\u00a0\n\u00a0propiedades \u00a0pro\u2010tumorales \u00a0o\u00a0anti\u2010tumorales \u00a0de\u00a0\nlos\u00a0macr\u00f3fagos, \u00a0ya\u00a0que\u00a0NF\u2010\u03baB\u00a0podr\u00eda\u00a0ser\u00a0la\u00a0\nresponsable \u00a0de\u00a0\u201cre\u2010educar\u201d\u00a0a\u00a0macr\u00f3fagos \u00a0\npromotores \u00a0de\u00a0tumores\u00a0hacia\u00a0macr\u00f3fagos \u00a0con\u00a0\nfunciones \u00a0anti\u2010tumorales \u00a0y\u00a0viceversa145.\u00a0La\u00a0\npsoriasis\u00a0adem\u00e1s,\u00a0es\u00a0una\u00a0enfermedad \u00a0mediada\u00a0\npor\u00a0linfocitos\u00a0T\u00a0helper\u00a01\u00a0(TH1),\u00a0lo\u00a0que\u00a0provoca\u00a0una\u00a0\nacumulaci\u00f3n \u00a0masiva\u00a0de\u00a0neutr\u00f3filos \u00a0y\u00a0monocitos \u00a0en\u00a0\nla\u00a0piel\u00a0que\u00a0acabaran\u00a0madurando \u00a0en\u00a0macr\u00f3fagos \u00a0\ncon\u00a0un\u00a0fenotipo\u00a0M1\u00a0(macr\u00f3fagos \u00a0que\u00a0act\u00faan\u00a0como\u00a0\nc\u00e9lulas\u00a0anti\u2010tumorales). \u00a0Por\u00a0ello\u00a0ser\u00e1\u00a0importante \u00a0\nque\u00a0futuros\u00a0estudios\u00a0encuentren \u00a0el\u00a0est\u00edmulo\u00a0\n\u00f3ptimo\u00a0para\u00a0cambiar\u00a0los\u00a0promotores \u00a0del\u00a0\nmicroambiente \u00a0tumoral\u00a0(c\u00e9lulas\u00a0TH2\u00a0y\u00a0macr\u00f3fagos \u00a0\nM2)\u00a0en\u00a0inhibidores \u00a0(c\u00e9lulas\u00a0TH1\u00a0y\u00a0macr\u00f3fagos \u00a0M1)\u00a0y\u00a0\ncomprender \u00a0los\u00a0mecanismos \u00a0reales\u00a0que\u00a0est\u00e1n\u00a0\nimplicados \u00a0en\u00a0su\u00a0transformaci\u00f3n. \u00a0\nDe\u00a0acuerdo\u00a0con\u00a0la\u00a0hip\u00f3tesis\u00a0de\u00a0la\u00a0\ninmunovigilancia, \u00a0c\u00e9lulas\u00a0asesinas\u00a0o\u00a0\u201cnatural\u00a0\nkiller \u201d\u00a0(NK)\u00a0y\u00a0linfocitos\u00a0T\u00a0citot\u00f3xicos \u00a0(CTL,\u00a0por\u00a0sus\u00a0\nsiglas\u00a0en\u00a0ingl\u00e9s\u00a0Citolytic\u00a0T\u00a0Lymphocyte ),\u00a0atacan\u00a0al\u00a0\ntumor\u00a0segregando \u00a0perforina \u00a0o\u00a0granzyme \u00a0B\u00a0\n(mediante \u00a0procesos\u00a0asociados \u00a0a\u00a0necrosis\u00a0celular),\u00a0\no\u00a0mediante \u00a0mecanismos \u00a0dependientes \u00a0de\u00a0TRAIL\u00a0y\u00a0\nFAS\u2010L,\u00a0ligados\u00a0a\u00a0procesos\u00a0apopt\u00f3ticos \u00a0o\u00a0de\u00a0muerte\u00a0\ncelular\u00a0programada. \u00a0Adem\u00e1s\u00a0linfocitos\u00a0TH1\u00a0\nsecretan\u00a0interfer\u00f3n \u2010\u03b3\u00a0(IFN\u2010\u03b3)\u00a0que\u00a0ampl\u00eda\u00a0la\u00a0\nrespuesta \u00a0inmunitaria \u00a0activando \u00a0la\u00a0producci\u00f3n \u00a0de\u00a0\nquimioquinas \u00a0locales\u00a0que\u00a0reclutar\u00e1n \u00a0m\u00e1s\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmunitario \u00a0innato\u00a0hacia\u00a0el\u00a0tumor133.\u00a0\nEste\u00a0es\u00a0el\u00a0caso,\u00a0por\u00a0ejemplo,\u00a0de\u00a0los\u00a0macr\u00f3fagos \u00a0o\u00a0\nc\u00e9lulas\u00a0dentr\u00edticas \u00a0activados \u00a0por\u00a0IFN\u2010\u03b3\u00a0que\u00a0\npresentan \u00a0ant\u00edgenos \u00a0o\u00a0responden \u00a0a\u00a0se\u00f1ales\u00a0de\u00a0\npeligro\u00a0o\u00a0estr\u00e9s.\u00a0\nTodas\u00a0estas\u00a0se\u00f1ales\u00a0producto\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0\nsistema\u00a0inmune\u00a0innato,\u00a0de\u00a0la\u00a0remodelaci\u00f3n \u00a0de\u00a0la\u00a0\nmatriz\u00a0y\u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0en\u00a0degeneraci\u00f3n \u00a0o\u00a0\nnecrosis,\u00a0incluyen\u00a0citoquinas \u00a0tales\u00a0como\u00a0IL\u20101,\u00a0TNF\u2010\n\u03b1\u00a0(TNF\u2010\u03b1,\u00a0del\u00a0ingl\u00e9s\u00a0tumor\u00a0necrosis\u00a0factor\u00a0alpha ),\u00a0\nel\u00a0factor\u00a0estimulante \u00a0de\u00a0colonias\u00a0de\u00a0granulocitos \u2010\nmacr\u00f3fagos \u00a0(GM\u2010CSF,\u00a0del\u00a0ingl\u00e9s\u00a0granulocyte \u2010\nmacrophage \u00a0colony\u00a0stimulating \u00a0factor )\u00a0y\u00a0la\u00a0IL\u201012,\u00a0\nque\u00a0promueven \u00a0la\u00a0diferenciaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\ndendr\u00edticas \u00a0(CD).\u00a0Con\u00a0la\u00a0diferenciaci\u00f3n \u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0dendr\u00edticas \u00a0se\u00a0entra\u00a0la\u00a0siguiente\u00a0fase\u00a0y\u00a0se\u00a0desarrolla \u00a0la\u00a0respuesta \u00a0inmunitaria \u00a0adaptativa \u00a0\nespec\u00edfica \u00a0del\u00a0tumor.\u00a0Estas\u00a0CD\u00a0maduras\u00a0migran\u00a0a\u00a0\nlos\u00a0n\u00f3dulos\u00a0linf\u00e1ticos\u00a0y\u00a0mediante \u00a0la\u00a0presentaci\u00f3n \u00a0\nde\u00a0ant\u00edgenos \u00a0activan\u00a0a\u00a0los\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0y\u00a0\nCD8+,\u00a0as\u00ed\u00a0como\u00a0a\u00a0los\u00a0linfocitos\u00a0B.\u00a0Estos\u00a0acuden\u00a0al\u00a0\nlugar\u00a0del\u00a0tumor\u00a0y\u00a0tienen\u00a0la\u00a0capacidad \u00a0de\u00a0\neliminarlo. \u00a0Las\u00a0c\u00e9lulas\u00a0T\u00a0CD4+\u00a0mantienen \u00a0la\u00a0\nfunci\u00f3n\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0T\u00a0CD8+\u00a0mediante \u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0IL\u20102\u00a0e\u00a0IL\u201015\u00a0que\u00a0proviene\u00a0del\u00a0tumor\u00a0\n143.\u00a0La\u00a0teor\u00eda\u00a0de\u00a0la\u00a0vigilancia \u00a0inmunol\u00f3gica \u00a0se\u00a0ve\u00a0\napoyada\u00a0por\u00a0la\u00a0idea\u00a0que\u00a0algunos\u00a0pacientes \u00a0cuyos\u00a0\ntumores\u00a0presentan \u00a0un\u00a0incremento \u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0\nactivadas, \u00a0tienen\u00a0un\u00a0mejor\u00a0pron\u00f3stico141.\u00a0\nDe\u00a0todos\u00a0modos,\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0tumores\u00a0\nestablecidos, \u00a0la\u00a0presencia \u00a0de\u00a0linfocitos\u00a0es\u00a0\ninsuficiente \u00a0para\u00a0controlar \u00a0la\u00a0proliferaci\u00f3n \u00a0del\u00a0\ntumor.\u00a0Algunas\u00a0de\u00a0estas\u00a0consideraciones \u00a0han\u00a0dado\u00a0\nlugar\u00a0a\u00a0revisiones \u00a0de\u00a0la\u00a0versi\u00f3n\u00a0de\u00a0la\u00a0teor\u00eda\u00a0de\u00a0la\u00a0\nvigilancia\u00a0inmunol\u00f3gica \u00a0en\u00a0un\u00a0nuevo\u00a0concepto \u00a0\nllamado\u00a0inmunoedici\u00f3n141,143.\u00a0Este\u00a0nuevo\u00a0\nconcepto \u00a0propone\u00a0que\u00a0el\u00a0fallo\u00a0en\u00a0la\u00a0presi\u00f3n\u00a0de\u00a0la\u00a0\nrespuesta \u00a0inmune,\u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0el\u00a0fallo\u00a0en\u00a0la\u00a0fase\u00a0\nde\u00a0eliminaci\u00f3n \u00a0del\u00a0tumor,\u00a0favorecer\u00e1 \u00a0al\u00a0\ncrecimiento \u00a0tumoral\u00a0con\u00a0una\u00a0reducida\u00a0\ninmunogenicidad. \u00a0De\u00a0esta\u00a0forma\u00a0la\u00a0c\u00e9lula\u00a0tumoral\u00a0\nestar\u00e1\u00a0continuamente \u00a0modulando \u00a0la\u00a0respuesta \u00a0\ninmune\u00a0del\u00a0hu\u00e9sped\u00a0y\u00a0la\u00a0respuesta \u00a0inmune\u00a0a\u00a0su\u00a0\nvez\u00a0dar\u00e1\u00a0forma\u00a0a\u00a0la\u00a0inmunogenicidad \u00a0del\u00a0tumor\u00a0y\u00a0\na\u00a0su\u00a0selecci\u00f3n\u00a0clonal.\u00a0Antes\u00a0de\u00a0que\u00a0la\u00a0balanza\u00a0se\u00a0\ndecline\u00a0a\u00a0favor\u00a0del\u00a0tumor,\u00a0este\u00a0se\u00a0podr\u00eda\u00a0\nmantener \u00a0en\u00a0lo\u00a0que\u00a0llaman\u00a0fase\u00a0de\u00a0equilibrio \u00a0y\u00a0\npodr\u00eda\u00a0estar\u00a0as\u00ed\u00a0durante\u00a0d\u00e9cadas\u00a0(tumor\u00a0dormancy \u00a0\nen\u00a0ingl\u00e9s)146.\u00a0Una\u00a0vez\u00a0que\u00a0el\u00a0tumor\u00a0consigue\u00a0\nreformar\u00a0el\u00a0microambiente \u00a0tumoral,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nsecreci\u00f3n \u00a0de\u00a0sus\u00a0propias\u00a0citoquinas \u00a0y\u00a0del\u00a0\nremodelamiento \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune\u00a0\n(haci\u00e9ndolo \u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0inmunosupresivo) \u00a0entra\u00a0\nen\u00a0la\u00a0fase\u00a0de\u00a0escape .\u00a0En\u00a0esta\u00a0fase\u00a0consigue\u00a0\ndisminuir \u00a0sus\u00a0ant\u00edgenos \u00a0tumorales \u00a0y\u00a0evadir\u00a0la\u00a0\nregresi\u00f3n \u00a0tumoral\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0cambios\u00a0gen\u00e9ticos \u00a0y\u00a0\nepigen\u00e9ticos \u00a0adquiridos \u00a0que\u00a0le\u00a0confieren \u00a0\nresistencia \u00a0inmune,\u00a0y\u00a0es\u00a0entonces\u00a0cuando\u00a0se\u00a0hace\u00a0\ncl\u00ednicamente \u00a0detectable. \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n42\u00a0\n\u00a04.3.\u00a0El\u00a0sistema\u00a0inmunol\u00f3gico \u00a0y\u00a0el\u00a0\nc\u00e1ncer:\u00a0tipos\u00a0celulares, \u00a0v\u00edas\u00a0y\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0\ninvolucradas \u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0\ntumoral\u00a0\nEs\u00a0conocido\u00a0que\u00a0la\u00a0vigilancia \u00a0inmunol\u00f3gica \u00a0y\u00a0la\u00a0\ninflamaci\u00f3n \u00a0que\u00a0promueve \u00a0el\u00a0desarrollo \u00a0tumoral\u00a0\npueden\u00a0coexistir\u00a0en\u00a0el\u00a0mismo\u00a0tumor147\u00a0(Fig.\u00a014).\u00a0\nComo\u00a0resultado \u00a0de\u00a0las\u00a0diferentes \u00a0formas\u00a0de\u00a0\ninflamaci\u00f3n, \u00a0el\u00a0tumor\u00a0est\u00e1\u00a0rodeado\u00a0de\u00a0un\u00a0\nmicroambiente \u00a0que\u00a0contiene\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0\nimmunitario \u00a0innato\u00a0(macr\u00f3fagos, \u00a0neutrofilos, \u00a0CD\u00a0y\u00a0\nNK)\u00a0y\u00a0adaptativo \u00a0(linfocitos \u00a0T\u00a0y\u00a0B)\u00a0adem\u00e1s\u00a0de\u00a0todas\u00a0\nlas\u00a0c\u00e9lulas\u00a0del\u00a0estroma\u00a0(fibroblastos, \u00a0c\u00e9lulas\u00a0\nendotelilaes, \u00a0pericitos\u00a0y\u00a0c\u00e9lulas\u00a0mesenquimales). \u00a0\nPero\u00a0por\u00a0otro\u00a0lado\u00a0encontramos \u00a0otros\u00a0tipos\u00a0\ncelulares\u00a0vinculados \u00a0de\u00a0forma\u00a0m\u00e1s\u00a0activa\u00a0en\u00a0el\u00a0\nproceso\u00a0de\u00a0curaci\u00f3n\u00a0de\u00a0heridas\u00a0que\u00a0son\u00a0\nreclutados \u00a0y\u00a0subvertidos \u00a0m\u00e1s\u00a0tarde\u00a0para\u00a0apoyar\u00a0la\u00a0\nprogresi\u00f3n \u00a0neopl\u00e1sica. \u00a0Por\u00a0ejemplo,\u00a0encontramos \u00a0\nuna\u00a0 subclase\u00a0 de\u00a0 c\u00e9lulas\u00a0 \u201cactivadas \u00a0\nalternativamente\u201d, \u00a0como\u00a0macr\u00f3fagos \u00a0(macr\u00f3fagos \u00a0\nasociados \u00a0a\u00a0tumores,\u00a0TAM\u00a0o\u00a0M2),\u00a0neutr\u00f3filos, \u00a0\nc\u00e9lulas\u00a0T\u00a0(TH2)\u00a0y\u00a0B\u00a0de\u00a0fenotipo\u00a0y\u00a0funci\u00f3n\u00a0distinta\u00a0a\u00a0\nlas\u00a0convencionales, \u00a0adem\u00e1s\u00a0de\u00a0c\u00e9lulas\u00a0supresoras \u00a0\nderivadas \u00a0de\u00a0la\u00a0l\u00ednea\u00a0mieloide\u00a0(MDSCs\u00a0por\u00a0sus\u00a0\nsiglas\u00a0en\u00a0ingl\u00e9s\u00a0myeloid\u2010derived\u00a0suppressor \u00a0cells)\u00a0y\u00a0\nc\u00e9lulas\u00a0estromales \u00a0como\u00a0variantes\u00a0de\u00a0fibroblastos \u00a0\nderivados \u00a0de\u00a0tejido\u00a0normal\u00a0y\u00a0miofibroblastos \u00a0\nraramente \u00a0encontrados \u00a0en\u00a0tejidos\u00a0sanos\u00a0ambos\u00a0\nconocidos \u00a0como\u00a0fibroblastos \u00a0asociados \u00a0a\u00a0c\u00e1ncer\u00a0\n(CAFs,\u00a0del\u00a0ingl\u00e9s\u00a0cancer\u2010associated \u00a0fibroblast )125.\u00a0\nEn\u00a0este\u00a0punto\u00a0se\u00a0ha\u00a0mencionado \u00a0un\u00a0grupo\u00a0nuevo\u00a0\nde\u00a0c\u00e9lulas,\u00a0entre\u00a0ellas\u00a0las\u00a0MDSCs\u00a0y\u00a0los\u00a0CAF.\u00a0Las\u00a0\nMDSCs\u00a0son\u00a0c\u00e9lulas\u00a0progenitoras \u00a0mieloides \u00a0\nparcialmente \u00a0diferenciadas \u00a0y\u00a0como\u00a0sus\u00a0derivados \u00a0\nm\u00e1s\u00a0diferenciados \u00a0tienen\u00a0una\u00a0actividad\u00a0pro\u2010\ntumoral\u00a0demostrada148.\u00a0Parece\u00a0ser\u00a0que\u00a0bloquean \u00a0\nla\u00a0actividad\u00a0de\u00a0CTL\u00a0y\u00a0c\u00e9lulas\u00a0NK.\u00a0Estas\u00a0c\u00e9lulas\u00a0son\u00a0\npotentes\u00a0supresores \u00a0de\u00a0la\u00a0respuesta \u00a0innata\u00a0\nadaptativa \u00a0y\u00a0facilitan\u00a0el\u00a0proceso\u00a0de\u00a0met\u00e1stasis \u00a0\nfacilitando \u00a0la\u00a0angiog\u00e9nsis, \u00a0la\u00a0remodelaci\u00f3n \u00a0de\u00a0la\u00a0\nmatriz\u00a0extracelular \u00a0y\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor125.\u00a0Los\u00a0CAF\u00a0se\u00a0dividen\u00a0al\u00a0menos\u00a0en\u00a0dos\u00a0clases\u00a0\ndistintas:\u00a0la\u00a0primera,\u00a0c\u00e9lulas\u00a0similares\u00a0a\u00a0los\u00a0\nfibroblastos \u00a0que\u00a0forman\u00a0parte\u00a0de\u00a0las\u00a0estructuras \u00a0\nde\u00a0los\u00a0tejidos\u00a0normales, \u00a0y\u00a0la\u00a0segunda\u00a0\nmiofibroblastos, \u00a0cuyo\u00a0rol\u00a0biol\u00f3gico\u00a0y\u00a0propiedades \u00a0\ndifieren\u00a0 de\u00a0 los\u00a0 convencionales. \u00a0 Los\u00a0\nmiofibroblastos \u00a0se\u00a0encuentran \u00a0de\u00a0forma\u00a0\nabundante \u00a0en\u00a0heridas\u00a0y\u00a0en\u00a0lugares\u00a0de\u00a0inflamaci\u00f3n \u00a0\ncr\u00f3nica\u00a0y\u00a0son\u00a0f\u00e1cilmente \u00a0identificables \u00a0por\u00a0su\u00a0\nexpresi\u00f3n \u00a0de\u00a0\u03b1\u2010actina\u00a0de\u00a0musculatura \u00a0lisa\u00a0(\u03b1\u2010SMA,\u00a0\ndel\u00a0ingl\u00e9s\u00a0mooth\u00a0muscle\u00a0\u03b1 \u2010actin ).\u00a0Tambi\u00e9n\u00a0los\u00a0\nencontramos \u00a0en\u00a0el\u00a0microambiente \u00a0tumoral\u00a0ya\u00a0que\u00a0\ncontribuyen \u00a0en\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\ntumorales, \u00a0secretan\u00a0componentes \u00a0de\u00a0la\u00a0matriz\u00a0\nextracelular \u00a0(est\u00e1n\u00a0implicados \u00a0en\u00a0la\u00a0formaci\u00f3n \u00a0del\u00a0\nestroma\u00a0desmopl\u00e1stico) \u00a0y\u00a0adem\u00e1s\u00a0favorecen \u00a0la\u00a0\nangiog\u00e9nesis, \u00a0la\u00a0invasi\u00f3n\u00a0y\u00a0la\u00a0met\u00e1stasis \u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0SDF\u20101,\u00a0entre\u00a0otros.\u00a0Sus\u00a0\nactividades \u00a0pro\u2010tumorales \u00a0han\u00a0sido\u00a0ampliamente \u00a0\ndescritas\u00a0en\u00a0modelos\u00a0murinos125.\u00a0\nUna\u00a0vez\u00a0el\u00a0tumor\u00a0induce\u00a0un\u00a0estado\u00a0de\u00a0supresi\u00f3n \u00a0\ninmunol\u00f3gica \u00a0y\u00a0la\u00a0balanza\u00a0se\u00a0declina\u00a0a\u00a0favor\u00a0de\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral,\u00a0son\u00a0otros\u00a0tipos\u00a0celulares, \u00a0\nquimioquinas \u00a0y\u00a0c\u00e9lulas\u00a0del\u00a0estroma\u00a0las\u00a0que\u00a0\nabundan\u00a0en\u00a0el\u00a0microambiente \u00a0tumoral.\u00a0La\u00a0\nprogresi\u00f3n \u00a0tumoral\u00a0depende, \u00a0en\u00a0parte,\u00a0de\u00a0la\u00a0\ndensidad\u00a0de\u00a0TAMs\u00a0ya\u00a0que\u00a0existe\u00a0una\u00a0correlaci\u00f3n \u00a0\nentre\u00a0una\u00a0peor\u00a0prognosis \u00a0y\u00a0abundancia \u00a0de\u00a0este\u00a0\ntipo\u00a0celular149,\u00a0pero\u00a0no\u00a0depende\u00a0\u00fanicamente \u00a0del\u00a0\nn\u00famero\u00a0de\u00a0TAMs,\u00a0sino\u00a0tambi\u00e9n\u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0generadas \u00a0por\u00a0su\u00a0parte.\u00a0Como\u00a0se\u00a0ha\u00a0\ndescrito\u00a0anteriormente, \u00a0los\u00a0INFs\u00a0y\u00a0otras\u00a0citoquinas \u00a0\ncomo\u00a0la\u00a0IL\u201012,\u00a0IL\u201013,\u00a0GM\u2010CSF,\u00a0entre\u00a0otras,\u00a0inducen\u00a0\nla\u00a0maduraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0dendr\u00edticas \u00a0facilitando \u00a0la\u00a0\npresentaci\u00f3n \u00a0de\u00a0ant\u00edgeno\u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0T\u00a0\ncitot\u00f3xicas \u00a0y\u00a0se\u00a0promueven \u00a0as\u00ed\u00a0la\u00a0respuesta \u00a0\ninmune\u00a0adaptativa. \u00a0Por\u00a0el\u00a0contrario\u00a0los\u00a0TAMs\u00a0\nproducen \u00a0altas\u00a0concentraciones \u00a0de\u00a0IL\u20106\u00a0y\u00a0el\u00a0factor\u00a0\nestimulador \u00a0de\u00a0colonias\u00a0(CSF1,\u00a0del\u00a0ingl\u00e9s\u00a0colony\u2010\nstimulating \u00a0factor\u00a01,)\u00a0conocido\u00a0como\u00a0M\u2010CSF.\u00a0Estas\u00a0\ncitoquinas \u00a0inhiben\u00a0la\u00a0maduraci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\ndendr\u00edticas \u00a0y\u00a0junto\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB,\u00a0IL\u20101\u00a0y\u00a0\nTNF,\u00a0promueven \u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n43\u00a0\n\u00a0\u00a0\nFigura\u00a014.\u00a0Vigilancia \u00a0inmunol\u00f3gica \u00a0y\u00a0inmunidad \u00a0pro\u2010tumoral .\u00a0El\u00a0balance\u00a0entre\u00a0la\u00a0inmunovigilancia \u00a0y\u00a0la\u00a0inflamaci\u00f3n \u00a0pro\u2010tumoral\u00a0\nen\u00a0el\u00a0microambiente \u00a0del\u00a0tumor\u00a0est\u00e1\u00a0regulado\u00a0por\u00a0distintas\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmunitario \u00a0y\u00a0citoquinas \u00a0pro\u2010inflamatorias. \u00a0La\u00a0\ninmunidad \u00a0pro\u2010tumoral\u00a0amortigua \u00a0la\u00a0inmunovigilancia, \u00a0que\u00a0de\u00a0otro\u00a0modo\u00a0inhibir\u00eda\u00a0el\u00a0crecimiento \u00a0tumoral.\u00a0Fosfo\u2010STAT3\u00a0(pSTAT3)\u00a0\ninhibe\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0genes\u00a0diana\u00a0de\u00a0NF\u2010\u03baB\u00a0en\u00a0los\u00a0linfocitos\u00a0T\u00a0que\u00a0participan \u00a0en\u00a0la\u00a0inmunidad \u00a0innata\u00a0y\u00a0respuesta \u00a0inmune\u00a0\nadaptativa, \u00a0importantes \u00a0para\u00a0controlar\u00a0las\u00a0infecciones \u00a0microbianas \u00a0y\u00a0el\u00a0crecimiento \u00a0del\u00a0tumor.\u00a0Por\u00a0otro\u00a0lado\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nSTAT3\u00a0regula\u00a0la\u00a0proliferaci\u00f3n \u00a0celular,\u00a0progresi\u00f3n \u00a0del\u00a0ciclo\u00a0celular,\u00a0apoptosis, \u00a0angiog\u00e9nesis \u00a0y\u00a0la\u00a0evasi\u00f3n\u00a0del\u00a0sistema\u00a0inmune\u00a0en\u00a0\notros\u00a0tipos\u00a0celulares. \u00a0La\u00a0figura\u00a0ha\u00a0sido\u00a0realizada\u00a0utilizando \u00a0Servier\u00a0Medial\u00a0Art.\u00a0\n\u00a0\nConcretamente, \u00a0en\u00a0animales\u00a0transg\u00e9nicos \u00a0(que\u00a0\nexpresan\u00a0el\u00a0poliomavirus \u00a0medio\u00a0T\u00a0(PyMt)\u00a0bajo\u00a0el\u00a0\ncontrol\u00a0del\u00a0promotor \u00a0MMTV)\u00a0se\u00a0desarrolla \u00a0\ncarcinoma \u00a0mamario\u00a0en\u00a0aquellos\u00a0ratones\u00a0mutados\u00a0\npara\u00a0el\u00a0gen\u00a0CSF\u20101\u00a0(Csfop)150.\u00a0En\u00a0ausencia\u00a0de\u00a0CSF\u20101\u00a0\ndurante\u00a0neoplasias \u00a0tempranas \u00a0las\u00a0met\u00e1stasis \u00a0\npulmonares \u00a0se\u00a0atenuan\u00a0significativamente \u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0ratones\u00a0que\u00a0expresan\u00a0CSF\u20101\u00a0con\u00a0\nnormalidad. \u00a0La\u00a0clave\u00a0no\u00a0est\u00e1\u00a0en\u00a0la\u00a0diferencia \u00a0en\u00a0la\u00a0\nproliferaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0epiteliales \u00a0tumorales, \u00a0si\u00a0no\u00a0\nen\u00a0la\u00a0capacidad \u00a0de\u00a0este\u00a0factor\u00a0para\u00a0reclutar\u00a0\nmacr\u00f3fagos \u00a0maduros\u00a0en\u00a0tejidos\u00a0neopl\u00e1sicos. \u00a0Por\u00a0\notro\u00a0lado,\u00a0DeNardo\u00a0y\u00a0colaboradores \u00a0demostraron \u00a0\nen\u00a0el\u00a02009\u00a0que\u00a0c\u00e9lulas\u00a0Th2\u00a0CD4+\u00a0estimulaban \u00a0el\u00a0CM\u00a0y\u00a0su\u00a0met\u00e1stasis \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\u201ceducar\u201d\u00a0a\u00a0los\u00a0\nTAMs\u00a0para\u00a0producir\u00a0factores\u00a0pro\u2010angiog\u00e9ncios \u00a0y\u00a0\npro\u2010metast\u00e1sicos151.\u00a0\nLos\u00a0TAMs\u00a0generalmente \u00a0tienen\u00a0un\u00a0fenotipo\u00a0M2\u00a0el\u00a0\ncual\u00a0est\u00e1\u00a0orientado \u00a0a\u00a0la\u00a0promover \u00a0el\u00a0crecimiento \u00a0\ntumoral,\u00a0la\u00a0remodelaci\u00f3n \u00a0de\u00a0tejidos,\u00a0la\u00a0\nangiog\u00e9nesis \u00a0y\u00a0la\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0inmunidad \u00a0\nadaptativa152,153.\u00a0Se\u00f1ales\u00a0derivadas \u00a0de\u00a0una\u00a0clase\u00a0\nde\u00a0linfocitos\u00a0inmunosupresores \u00a0como\u00a0los\u00a0linfocitos\u00a0\nT\u00a0reguladores \u00a0(Treg),\u00a0TH2\u00a0o\u00a0se\u00f1ales\u00a0que\u00a0provienen \u00a0\ndirectamente \u00a0del\u00a0tumor\u00a0como\u00a0es\u00a0el\u00a0caso\u00a0de\u00a0altos\u00a0\nniveles\u00a0de\u00a0M\u2010CSF,\u00a0IL\u201010,\u00a0IL\u20106,\u00a0CCL2,\u00a0el\u00a0factor\u00a0de\u00a0\ncrecimiento \u00a0endotelial \u00a0vascular\u00a0(VEGF,\u00a0del\u00a0ingl\u00e9s\u00a0\nvascular\u00a0endothelial \u00a0growth\u00a0factor ),\u00a0o\u00a0el\u00a0factor\u00a0de\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n44\u00a0\n\u00a0crecimiento \u00a0tumoral\u00a0TGF\u2010\u03b2,\u00a0se\u00a0describen \u00a0como\u00a0\nposibles\u00a0art\u00edfices\u00a0de\u00a0la\u00a0polarizaci\u00f3n \u00a0de\u00a0los\u00a0\nmacr\u00f3fagos \u00a0hacia\u00a0un\u00a0fenotipo\u00a0M2152\u2010155.\u00a0Adem\u00e1s,\u00a0\nestas\u00a0citoquinas \u00a0tambi\u00e9n\u00a0provienen \u00a0de\u00a0los\u00a0mismos\u00a0\nTAMs144\u00a0que\u00a0pueden\u00a0acabar\u00a0inhibiendo \u00a0la\u00a0\nmaduraci\u00f3n \u00a0de\u00a0las\u00a0CD156\u00a0(y\u00a0por\u00a0tanto\u00a0el\u00a0inicio\u00a0de\u00a0la\u00a0\nrespuesta \u00a0inmunitaria \u00a0adaptativa), \u00a0juntamente \u00a0\ncon\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0NF\u2010\u03baB\u00a0o\u00a0la\u00a0v\u00eda\u00a0de\u00a0STAT3157,158.\u00a0\nConcretamente \u00a0ellos\u00a0expresan, \u00a0entre\u00a0otras,\u00a0\nquimioquinas \u00a0como\u00a0las\u00a0CCL22,\u00a0CCL17\u00a0y\u00a0CCL24,\u00a0que\u00a0\natraer\u00e1n\u00a0hacia\u00a0el\u00a0tumor\u00a0a\u00a0c\u00e9lulas\u00a0Treg,\u00a0las\u00a0c\u00e9lulas\u00a0\nTH2,\u00a0eosin\u00f3filos \u00a0y\u00a0bas\u00f3filos. \u00a0\nNF\u2010\u03baB\u00a0por\u00a0otro\u00a0lado\u00a0es\u00a0crucial\u00a0tanto\u00a0en\u00a0el\u00a0contexto\u00a0\ndel\u00a0tumor\u00a0y\u00a0c\u00e9lulas\u00a0inflamatorias \u00a0como\u00a0en\u00a0la\u00a0\npotenciaci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0ya\u00a0que\u00a0\ndesempe\u00f1a \u00a0un\u00a0papel\u00a0central\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nnumerosas \u00a0citoquinas \u00a0pro\u2010inflamatorias \u00a0en\u00a0\nm\u00faltiples \u00a0tipos\u00a0de\u00a0c\u00e9lulas,\u00a0incluyendo \u00a0macr\u00f3fagos, \u00a0\nc\u00e9lulas\u00a0T\u00a0y\u00a0c\u00e9lulas\u00a0epiteliales. \u00a0Adem\u00e1s,\u00a0una\u00a0de\u00a0las\u00a0\nfunciones \u00a0m\u00e1s\u00a0importantes \u00a0de\u00a0NF\u2010\u03baB\u00a0y\u00a0STAT3\u00a0en\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0es\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0genes\u00a0\npromotores \u00a0de\u00a0la\u00a0supervivencia \u00a0celular\u00a0y\u00a0genes\u00a0\nanti\u2010apopt\u00f3ticos, \u00a0como\u00a0es\u00a0el\u00a0caso\u00a0de\u00a0BCL2\u00a0y\u00a0\nBCL2L1\u00a0(conocido \u00a0como\u00a0Bcl\u2010X).\u00a0En\u00a0c\u00e9lulas\u00a0del\u00a0\nsistema\u00a0inmunitario \u00a0NF\u2010\u03baB\u00a0act\u00faa\u00a0corriente\u00a0abajo\u00a0\nde\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0activadas \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nreceptores \u00a0toll\u00a0(TLR,\u00a0del\u00a0ingl\u00e9s\u00a0Toll\u2010like\u00a0receptors ).\u00a0\nEstos\u00a0receptores \u00a0est\u00e1n\u00a0asociados \u00a0a\u00a0la\u00a0prote\u00edna\u00a0\nadaptadora \u00a0MyD88,\u00a0y\u00a0detectan\u00a0patrones\u00a0\nmoleculares \u00a0expresados \u00a0por\u00a0un\u00a0amplio\u00a0espectro\u00a0\nde\u00a0agentes\u00a0infecciosos. \u00a0Se\u00a0ha\u00a0descrito\u00a0\nrecientemente \u00a0que\u00a0en\u00a0ratones\u00a0podr\u00edan\u00a0jugar\u00a0un\u00a0\npapel\u00a0importante \u00a0en\u00a0el\u00a0desarrollo \u00a0tumoral\u00a0y\u00a0la\u00a0\ncarcinog\u00e9nesis \u00a0inducida\u00a0mediante \u00a0inflamaci\u00f3n159.\u00a0\nNF\u2010\u03baB\u00a0se\u00a0activa\u00a0bajo\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0distintas\u00a0\ncitoquinas \u00a0como\u00a0IL\u20106,\u00a0IL\u20101,\u00a0IL\u201011,\u00a0IL\u201017\u00a0y\u00a0IL\u201023\u00a0y\u00a0\nregula\u00a0m\u00faltiples \u00a0genes\u00a0que\u00a0codifican\u00a0para\u00a0distintas\u00a0\nprote\u00ednas \u00a0de\u00a0adhesi\u00f3n\u00a0celular,\u00a0MMPs,\u00a0serin\u00a0\nproteasas \u00a0y\u00a0quimioquinas, \u00a0todas\u00a0ellas\u00a0esenciales \u00a0\npara\u00a0la\u00a0invasi\u00f3n\u00a0y\u00a0la\u00a0met\u00e1stais134,160.\u00a0Los\u00a0TAMs,\u00a0\nbajo\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0IL\u20101\u00a0y\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0NF\u2010\u03baB,\u00a0tambi\u00e9n\u00a0\ninducen\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0\u00f3xido\u00a0n\u00edtrico\u00a0sintetasa\u00a0\ninducible\u00a0(iNOS)\u00a0y\u00a0sobreregulan \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nciclooxigenasa \u00a02\u00a0(COX2),\u00a0involucrada \u00a0en\u00a0la\u00a0s\u00edntesis\u00a0\nde\u00a0prostaglandinas. \u00a0Esta\u00a0situaci\u00f3n\u00a0provoca\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0factor\u00a0de\u00a0hipoxia\u00a0inducible\u00a01\u03b1\u00a0(HIF1\u00a0\n\u03b1,\u00a0del\u00a0ingl\u00e9s\u00a0hipoxia\u2010inducible\u00a0factor\u00a01\u00a0\u03b1),\u00a0cuyo\u00a0\nresultado \u00a0desemboca \u00a0en\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0VEGF.\u00a0Por\u00a0lo\u00a0tanto\u00a0IL\u20101\u00a0es\u00a0requerida \u00a0\nen\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0vasos\u00a0e\u00a0invasividad \u00a0celular\u00a0de\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0in\u00a0vivo161,162.\u00a0En\u00a0resumen\u00a0NF\u2010\u03baB\u00a0\nes\u00a0clave\u00a0para\u00a0la\u00a0coordinaci\u00f3n \u00a0del\u00a0sistema\u00a0\ninmunitario \u00a0innato\u00a0y\u00a0la\u00a0inflamaci\u00f3n, \u00a0emergiendo \u00a0\ncomo\u00a0uno\u00a0de\u00a0los\u00a0m\u00e1s\u00a0importantes \u00a0promotores \u00a0\ntumorales \u00a0end\u00f3genos129.\u00a0\nConcretamente \u00a0en\u00a0CM\u00a0los\u00a0TAMs\u00a0son\u00a0la\u00a0mayor\u00a0\nfuente\u00a0de\u00a0quimioquinas \u00a0como\u00a0CCL18.\u00a0Esta\u00a0\nquimioquina \u00a0est\u00e1\u00a0inducida\u00a0por\u00a0IL\u20104,\u00a0IL\u201013\u00a0y\u00a0IL\u201010\u00a0\n(repertorio \u00a0de\u00a0quimioquinas \u00a0que\u00a0forman\u00a0parte\u00a0de\u00a0\nlos\u00a0macr\u00f3fagos \u00a0polarizados \u00a0de\u00a0fenotipo\u00a0M2163)\u00a0y\u00a0es\u00a0\nresponsable \u00a0en\u00a0parte\u00a0del\u00a0desarrollo \u00a0tumoral\u00a0y\u00a0de\u00a0\nuna\u00a0posterior\u00a0met\u00e1stasis \u00a0celular151,160.\u00a0Una\u00a0alta\u00a0\nconcentraci\u00f3n \u00a0de\u00a0CCL18\u00a0se\u00a0ha\u00a0asociado\u00a0a\u00a0una\u00a0peor\u00a0\nprognosis \u00a0en\u00a0CM164.\u00a0\nParece\u00a0entonces\u00a0que\u00a0el\u00a0equilibrio \u00a0entre\u00a0una\u00a0\nrespuesta \u00a0inflamatoria \u00a0promotora \u00a0del\u00a0c\u00e1ncer\u00a0y\u00a0\notra\u00a0inhibidora \u00a0del\u00a0mismo\u00a0depende, \u00a0en\u00a0parte,\u00a0de\u00a0\nla\u00a0plasticidad \u00a0y\u00a0las\u00a0caracter\u00edsticas \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nque\u00a0orquestan \u00a0esa\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica.\u00a0Hay\u00a0\ndiversas\u00a0evidencias \u00a0que\u00a0demuestran \u00a0que\u00a0una\u00a0\nsituaci\u00f3n\u00a0de\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0puede\u00a0causar\u00a0\nc\u00e1ncer\u00a0en\u00a0ausencia\u00a0de\u00a0agentes\u00a0cancer\u00edgenos \u00a0y\u00a0que\u00a0\nel\u00a0sistema\u00a0inmunitario \u00a0cuenta\u00a0con\u00a0mecanismos \u00a0\ncapaces\u00a0de\u00a0eliminar\u00a0esas\u00a0c\u00e9lulas\u00a0iniciadoras \u00a0de\u00a0\ntumor.\u00a0La\u00a0clave\u00a0parece\u00a0estar\u00a0en\u00a0c\u00f3mo\u00a0activar\u00a0una\u00a0\ncorrecta\u00a0y\u00a0apropiada \u00a0respuesta \u00a0inmune\u00a0adaptativa \u00a0\nanti\u2010tumoral.\u00a0Lo\u00a0que\u00a0no\u00a0es\u00a0todav\u00eda\u00a0tan\u00a0sencillo\u00a0es\u00a0\ncomo\u00a0trasladar\u00a0toda\u00a0esa\u00a0informaci\u00f3n \u00a0en\u00a0una\u00a0\nprevenci\u00f3n \u00a0y\u00a0diagn\u00f3stico \u00a0efectivo\u00a0que\u00a0permita\u00a0\nencontrar \u00a0la\u00a0terapia\u00a0m\u00e1s\u00a0\u00f3ptima\u00a0para\u00a0la\u00a0\ninflamaci\u00f3n \u00a0relacionada \u00a0con\u00a0el\u00a0c\u00e1ncer.\u00a0\u00a0\n5.\u00a0TAQUIQUININAS \u00a0Y\u00a0SUS\u00a0\nRECEPTORES: \u00a0PAPEL\u00a0EN\u00a0LA\u00a0\nINFLAMACI\u00d3N \u00a0\n\u00a0\nAlgunas\u00a0de\u00a0las\u00a0prote\u00ednas \u00a0que\u00a0han\u00a0sido\u00a0el\u00a0eje\u00a0\nprincipal\u00a0de\u00a0esta\u00a0tesis\u00a0doctoral,\u00a0conocidas \u00a0por\u00a0su\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n45\u00a0\n\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0mantenimiento \u00a0de\u00a0la\u00a0inflamaci\u00f3n \u00a0\ncr\u00f3nica\u00a0y\u00a0aguda,\u00a0entre\u00a0otras\u00a0funciones, \u00a0son\u00a0las\u00a0\ntaquiquininas \u00a0y\u00a0sus\u00a0receptores. \u00a0Las\u00a0taquiquininas \u00a0y\u00a0\nsus\u00a0receptores, \u00a0en\u00a0particular \u00a0el\u00a0receptor\u00a0de\u00a0\nneuroquinina \u00a01\u00a0(NK\u20101R,\u00a0del\u00a0ingl\u00e9s\u00a0neurokinin \u20101\u00a0\nreceptor ),\u00a0y\u00a0su\u00a0ligando\u00a0preferente, \u00a0la\u00a0sustancia \u00a0P\u00a0\n(SP),\u00a0han\u00a0sido\u00a0ampliamente \u00a0descritos\u00a0por\u00a0sus\u00a0\nefectos\u00a0pro\u2010inflamatorios \u00a0o\u00a0su\u00a0estrecha\u00a0relaci\u00f3n\u00a0\ncon\u00a0el\u00a0sistema\u00a0neurol\u00f3gico, \u00a0inmunol\u00f3gico \u00a0y\u00a0\nenfermedades \u00a0inflamatorias \u00a0del\u00a0sistema\u00a0\nrespiratorio, \u00a0gastrointestinal \u00a0y\u00a0m\u00fasculo\u2010\nesquel\u00e9tico. \u00a0Concretamente \u00a0la\u00a0SP\u00a0juega\u00a0un\u00a0papel\u00a0\nimportante \u00a0en\u00a0el\u00a0eje\u00a0neuroendocrino, \u00a0sistema\u00a0\nformado\u00a0por\u00a0c\u00e9lulas\u00a0endocrinas \u00a0especializadas \u00a0y\u00a0\nnervios\u00a0peptid\u00e9rgicos \u00a0presentes \u00a0en\u00a0todos\u00a0los\u00a0\norganismos \u00a0del\u00a0cuerpo.\u00a0En\u00a0este\u00a0cap\u00edtulo\u00a0se\u00a0\ndescribir\u00e1n \u00a0con\u00a0mas\u00a0detalle\u00a0estos\u00a0p\u00e9ptidos\u00a0y\u00a0\ncu\u00e1les\u00a0son\u00a0sus\u00a0principales \u00a0funciones \u00a0en\u00a0el\u00a0\norganismo. \u00a0No\u00a0obstante, \u00a0m\u00e1s\u00a0adelante, \u00a0se\u00a0\ndescribir\u00e1 \u00a0su\u00a0relaci\u00f3n,\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0importante, \u00a0\ncon\u00a0el\u00a0c\u00e1ncer\u00a0y\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0mismo.\u00a0\n5.1.\u00a0La\u00a0sustancia \u00a0P\u00a0\nLa\u00a0SP\u00a0fue\u00a0el\u00a0primer\u00a0miembro\u00a0de\u00a0la\u00a0familia\u00a0de\u00a0las\u00a0\ntaquiquininas \u00a0que\u00a0se\u00a0descubri\u00f3, \u00a0y\u00a0es\u00a0un\u00a0p\u00e9ptido\u00a0\nend\u00f3geno \u00a0de\u00a0once\u00a0amino\u00e1cidos \u00a0presente\u00a0tanto\u00a0en\u00a0\nespecies\u00a0mam\u00edferas \u00a0como\u00a0no\u00a0mam\u00edferas. \u00a0En\u00a01931,\u00a0\nvon\u00a0Euler\u00a0y\u00a0Gaddum\u00a0descubrieron \u00a0que\u00a0la\u00a0\n\u201cpreparaci\u00f3n \u00a0P\u201d,\u00a0obtenida\u00a0de\u00a0intestino\u00a0y\u00a0cerebro\u00a0\nde\u00a0caballo\u00a0causaban \u00a0vasodilataci\u00f3n \u00a0perif\u00e9rica \u00a0y\u00a0\ncontracci\u00f3n \u00a0intestinal \u00a0en\u00a0conejos165.\u00a0Este\u00a0extracto,\u00a0\nrenombrado \u00a0sustancia \u00a0P\u00a0(P\u00a0de\u00a0prote\u00edna), \u00a0fue\u00a0\npurificado \u00a0y\u00a0caracterizado. \u00a0Se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0SP\u00a0\nten\u00eda\u00a0un\u00a0efecto\u00a0a\u00a0nivel\u00a0perif\u00e9rico, \u00a0causando \u00a0una\u00a0\ndisminuci\u00f3n \u00a0de\u00a0la\u00a0presi\u00f3n\u00a0sangu\u00ednea \u00a0y\u00a0una\u00a0\ndisminuci\u00f3n \u00a0de\u00a0la\u00a0motilidad \u00a0intestinal \u00a0en\u00a0animales\u00a0\nde\u00a0laboratorio. \u00a0A\u00a0nivel\u00a0central\u00a0se\u00a0observ\u00f3\u00a0que\u00a0\nejerc\u00eda\u00a0efectos\u00a0estimuladores \u00a0en\u00a0la\u00a0respiraci\u00f3n166.\u00a0\nSu\u00a0aislamiento, \u00a0sin\u00a0embargo, \u00a0no\u00a0fue\u00a0posible\u00a0hasta\u00a0\nque\u00a0el\u00a0grupo\u00a0de\u00a0Susan\u00a0E.\u00a0Leeman\u00a0en\u00a01970\u20101972\u00a0lo\u00a0lograran\u00a0a\u00a0partir\u00a0de\u00a0hipot\u00e1lamo \u00a0de\u00a0cerebro\u00a0\nbovino167\u00a0y\u00a0se\u00a0decidi\u00f3\u00a0llamar\u00a0a\u00a0este\u00a0conjunto\u00a0de\u00a0\np\u00e9ptidos\u00a0 taquiquininas. \u00a0 La\u00a0 estructura \u00a0\naminoac\u00eddica \u00a0no\u00a0fue\u00a0secuenciada \u00a0hasta\u00a0un\u00a0a\u00f1o\u00a0\nm\u00e1s\u00a0tarde\u00a0y\u00a0se\u00a0identific\u00f3 \u00a0un\u00a0p\u00e9ptido\u00a0de\u00a0once\u00a0\namino\u00e1cidos \u00a0con\u00a0un\u00a0peso\u00a0molecular \u00a0de\u00a01347,6\u00a0\ng/moles. \u00a0Una\u00a0d\u00e9cada\u00a0despu\u00e9s\u00a0se\u00a0identificaron \u00a0\notras\u00a0taquiquininas \u00a0de\u00a0la\u00a0misma\u00a0familia\u00a0como\u00a0la\u00a0\nneuroquinina \u00a0A\u00a0(NKA)\u00a0y\u00a0la\u00a0neuroquinina \u00a0B\u00a0(NKB),\u00a0\ncompartiendo \u00a0todas\u00a0ellas\u00a0la\u00a0misma\u00a0secuencia \u00a0\ncarboxilo\u00a0terminal,\u00a0Phe\u2010X\u2010Gly\u2010Leu\u2010Met\u2010NH2\u00a0(X\u00a0es\u00a0\nuna\u00a0Phe\u00a0o\u00a0Val)168\u00a0(Tabla\u00a07).\u00a0La\u00a0SP\u00a0mamaria\u00a0deriva\u00a0\ndel\u00a0gen\u00a0TAC1\u00a0(anteriormente \u00a0nombrado \u00a0\npreprotaquinina \u2010A\u00a0o\u00a0PPT\u2010A)\u00a0que\u00a0se\u00a0origina\u00a0de\u00a0un\u00a0\ngen\u00a0ancestro\u00a0por\u00a0duplicaci\u00f3n. \u00a0El\u00a0gen\u00a0TAC1\u00a0(de\u00a0\nacuerdo\u00a0a\u00a0la\u00a0Human\u00a0Genome\u00a0Organization \u00a0\n(HUGO)\u00a0Gene\u00a0Nomenclature \u00a0Committee \u00a0\n(www.gene.ucl.ac.uk/nomenclature) \u00a0 tambi\u00e9n\u00a0\ncodifica\u00a0para\u00a0otras\u00a0taquiquininas, \u00a0incluyendo \u00a0NKA,\u00a0\nel\u00a0neurop\u00e9ptido \u00a0K\u00a0(NPK)\u00a0y\u00a0el\u00a0neurop\u00e9ptido \u00a0\u03b3\u00a0(NP\u03b3).\u00a0\nMediante \u00a0splicing\u00a0de\u00a0ARN\u00a0alternativo \u00a0se\u00a0obtienen\u00a0\n4\u00a0ARN\u00a0mensajeros \u00a0(ARNm)\u00a0distintos: \u00a0\u03b1TAC1,\u00a0\n\u03b2TAC1,\u00a0\u03b3TAC1\u00a0y\u00a0\u03b4TAC1.\u00a0Mientras\u00a0que\u00a0la\u00a0SP,\u00a0\n(codificada \u00a0por\u00a0el\u00a0ex\u00f3n\u00a03)\u00a0est\u00e1\u00a0presente\u00a0en\u00a0todos\u00a0\nlos\u00a0tr\u00e1nscritos, \u00a0la\u00a0NKA\u00a0(codificada \u00a0por\u00a0el\u00a0ex\u00f3n\u00a06)\u00a0\nsolo\u00a0est\u00e1\u00a0presente\u00a0en\u00a0\u03b2TAC1\u00a0y\u00a0\u03b3TAC1169(Fig.\u00a015).\u00a0\nLa\u00a0secuencia \u00a0que\u00a0codifica\u00a0para\u00a0NP\u03b3\u00a0est\u00e1\u00a0contenida \u00a0\nen\u00a0los\u00a0exones\u00a03,\u00a05\u00a0y\u00a06\u00a0y\u00a0la\u00a0secuencia \u00a0que\u00a0codifica\u00a0\npara\u00a0NPK\u00a0est\u00e1\u00a0contenida \u00a0en\u00a0los\u00a0exones\u00a03,\u00a04,\u00a05\u00a0y\u00a06.\u00a0\nPor\u00a0otro\u00a0lado,\u00a0el\u00a0gen\u00a0TAC3\u00a0codifica\u00a0\u00fanicamente \u00a0\npara\u00a0NKB\u00a0(anteriormente \u00a0conocido\u00a0como\u00a0PPT\u2010B)\u00a0\n(Fig.\u00a015).\u00a0\nRecientemente \u00a0se\u00a0ha\u00a0identificado \u00a0un\u00a0tercer\u00a0gen\u00a0\nllamado\u00a0TAC4 .\u00a0Este\u00a0gen\u00a0produce\u00a0hemoquinina \u00a01\u00a0\n(HK\u20101)\u00a0y\u00a0su\u00a0derivado\u00a0m\u00e1s\u00a0corto\u00a0hemoquinina \u00a0(4\u2010\n11),\u00a0as\u00ed\u00a0como\u00a0otros\u00a04\u00a0p\u00e9ptidos\u00a0llamados\u00a0\nendoquininas \u00a0(EKs),\u00a0EKA,\u00a0EKB,\u00a0EKC\u00a0y\u00a0EKD170\u00a0(Tabla\u00a0\n8).\u00a0La\u00a0HK\u20101\u00a0est\u00e1\u00a0relacionada \u00a0con\u00a0el\u00a0sistema\u00a0\nhematopoy\u00e9tico. \u00a0Se\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0\nsecretan\u00a0c\u00e9lulas\u00a0detr\u00edticas \u00a0171\u00a0y\u00a0que\u00a0est\u00e1\u00a0\ninvolucrada \u00a0en\u00a0la\u00a0maduraci\u00f3n \u00a0de\u00a0linfocitos\u00a0B172.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n46\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nTabla\u00a08.\u00a0Informaci\u00f3n \u00a0sobre\u00a0los\u00a0genes\u00a0de\u00a0taquiquininas \u00a0humanas. \u00a0\n\u00a0\nLa\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0est\u00e1\u00a0ampliamente \u00a0distribuida \u00a0\nen\u00a0el\u00a0sistema\u00a0nervioso\u00a0central\u00a0y\u00a0perif\u00e9rico, \u00a0sobre\u00a0\ntodo\u00a0en\u00a0las\u00a0terminaciones \u00a0de\u00a0las\u00a0neuronas \u00a0\naferentes \u00a0cuando\u00a0act\u00faa\u00a0como\u00a0neurotransmisor. \u00a0En\u00a0\nel\u00a0sistema\u00a0nervioso\u00a0central\u00a0se\u00a0encuentra \u00a0\nexpresada \u00a0en\u00a0neuronas, \u00a0astrocitos, \u00a0microglia\u00a0y\u00a0\nc\u00e9lulas\u00a0endoteliales \u00a0cerebrales. \u00a0En\u00a0muchas\u00a0de\u00a0las\u00a0\nregiones\u00a0del\u00a0cerebro\u00a0existe\u00a0una\u00a0correlaci\u00f3n \u00a0\npositiva\u00a0ente\u00a0su\u00a0expresi\u00f3n \u00a0y\u00a0la\u00a0de\u00a0su\u00a0receptor. \u00a0\u00a0\nVarios\u00a0estudios\u00a0han\u00a0demostrado \u00a0su\u00a0expresi\u00f3n \u00a0en\u00a0\nel\u00a0hipocampo, \u00a0am\u00edgdala, \u00a0hipot\u00e1lamo \u00a0y\u00a0m\u00e9dula\u00a0\nespinal.\u00a0En\u00a0la\u00a0periferia\u00a0se\u00a0han\u00a0identificado \u00a0en\u00a0\nganglios\u00a0trig\u00e9minos \u00a0y\u00a0de\u00a0la\u00a0ra\u00edz\u00a0dorsal173.\u00a0Adem\u00e1s,\u00a0\nsu\u00a0expresi\u00f3n \u00a0tambi\u00e9n\u00a0est\u00e1\u00a0relacionada \u00a0con\u00a0la\u00a0\ntransmisi\u00f3n \u00a0sensorial\u00a0neuronal\u00a0asociada\u00a0al\u00a0dolor,\u00a0\ndepresi\u00f3n \u00a0y\u00a0ansiedad\u00a0as\u00ed\u00a0como\u00a0con\u00a0las\u00a0respuestas \u00a0\ncentrales\u00a0del\u00a0estr\u00e9s174.\u00a0\nAunque\u00a0la\u00a0SP\u00a0fue\u00a0descrita\u00a0como\u00a0un\u00a0p\u00e9ptido\u00a0de\u00a0\norigen\u00a0neuronal, \u00a0distintos\u00a0estudios\u00a0en\u00a0ratones\u00a0han\u00a0\npermitido \u00a0demostrar \u00a0su\u00a0producci\u00f3n \u00a0en\u00a0c\u00e9lulas\u00a0del\u00a0\nsistema\u00a0inmunitario. \u00a0El\u00a0hecho\u00a0que\u00a0la\u00a0SP\u00a0se\u00a0\nencuentre \u00a0expresada \u00a0en\u00a0el\u00a0sistema\u00a0inmunol\u00f3gico \u00a0\ntiene\u00a0efectos\u00a0biol\u00f3gicos \u00a0como\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0\nla\u00a0respuesta \u00a0inmune,\u00a0la\u00a0contracci\u00f3n \u00a0de\u00a0la\u00a0\nmusculatura \u00a0lisa\u00a0vascular,\u00a0pulmonar \u00a0y\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0secreci\u00f3n \u00a0gastrointestinal175.\u00a0En\u00a0\nparticular \u00a0la\u00a0SP\u00a0tiene\u00a0una\u00a0importante \u00a0asociaci\u00f3n \u00a0\ncon\u00a0individuos \u00a0infectados \u00a0del\u00a0virus\u00a0de\u00a0la\u00a0\ninmunodeficiencia \u00a0humana\u00a0(VIH)\u00a0y\u00a0con\u00a0las\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune\u00a0que\u00a0la\u00a0secretan.\u00a0Douglas,\u00a0Ho\u00a0y\u00a0\ncolaboradores \u00a0observaron \u00a0que\u00a0mujeres\u00a0con\u00a0VIH\u00a0\npresentaban \u00a0un\u00a0aumento\u00a0de\u00a0SP\u00a0en\u00a0sangre\u00a0\nperif\u00e9rica \u00a0comparado \u00a0con\u00a0mujeres\u00a0no\u00a0infectadas \u00a0\n176\u2010178.\u00a0M\u00e1s\u00a0tarde\u00a0demostraron \u00a0que\u00a0un\u00a0antagonista \u00a0\nno\u00a0pept\u00eddico \u00a0de\u00a0la\u00a0SP\u00a0(CP\u201096,345)\u00a0inhib\u00eda\u00a0la\u00a0\nreplicaci\u00f3n \u00a0del\u00a0virus\u00a0en\u00a0fagocitos\u00a0mononucleares \u00a0\nhumanos, \u00a0debido\u00a0al\u00a0importante \u00a0papel\u00a0que\u00a0juega\u00a0la\u00a0\nSP\u00a0en\u00a0su\u00a0replicaci\u00f3n179.\u00a0Adem\u00e1s\u00a0comprobaron \u00a0que\u00a0\nlos\u00a0efectos\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0receptor\u00a0con\u00a0un\u00a0\nantagonista \u00a0del\u00a0mismo\u00a0(Aprepitant) \u00a0ten\u00eda\u00a0incluso\u00a0\nefectos\u00a0mayores\u00a0ex\u00a0vivo180.\u00a0\u00a0\nA\u00a0parte\u00a0de\u00a0ser\u00a0secretada \u00a0por\u00a0macr\u00f3fagos \u00a0y\u00a0\nmonocitos, \u00a0la\u00a0SP\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0\ndiversas\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmunitario \u00a0\naumentando \u00a0las\u00a0respuestas \u00a0inflamatorias. \u00a0Esta\u00a0\ntaquiquinina \u00a0no\u00a0solo\u00a0se\u00a0expresa\u00a0en\u00a0macr\u00f3fagos, \u00a0\nsino\u00a0tambi\u00e9n\u00a0en\u00a0eosin\u00f3filos, \u00a0linfocitos, \u00a0c\u00e9lulas\u00a0\ndendr\u00edticas \u00a0y\u00a0c\u00e9lulas\u00a0madre\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0\nentre\u00a0otras\u00a0174,181,182.\u00a0\u00a0Tabla\u00a07.\u00a0Las\u00a0secuencias \u00a0aminoac\u00eddicas \u00a0de\u00a0taquiquininas \u00a0humanas.\u00a0\nTaquiquininas \u00a0 Secuencia \u00a0\u00a0\nSustancia \u00a0P\u00a0 Arg\u2010Pro\u2010Lys\u2010Pro\u2010Gln\u2010Gln\u2010Phe\u2010Phe\u2010Gly\u2010Leu\u2010Met\u2010NH2\u00a0\nNeurokinina \u00a0A\u00a0 His\u2010Lys\u2010Thr\u2010Asp\u2010Ser\u2010Phe\u2010Val\u2010Gly\u2010Leu\u2010Met\u2010NH2\u00a0\nNeurokinina \u00a0B\u00a0 Asp\u2010Met\u2010His\u2010Asp\u2010Phe\u2010Phe\u2010Val\u2010Gly\u2010Leu\u2010Met\u2010NH2\u00a0\nHemokinina \u20101\u00a0 Thr\u2010Gly\u2010Lys\u2010Ala\u2010Ser\u2010Gln\u2010Phe\u2010Phe\u2010Gly\u2010Leu\u2010Met\u2010NH2\u00a0\nLos\u00a0tres\u00a0residuos\u00a0comunes\u00a0a\u00a0todas\u00a0las\u00a0taquiquininas \u00a0se\u00a0muestran \u00a0en\u00a0negrita\u00a0y\u00a0azul.\u00a0\nNombre\u00a0 Gen\u00a0Nombre\u00a0\nalternativo \u00a0N\u00famero\u00a0de\u00a0acceso\u00a0\u00a0Localizaci\u00f3n \u00a0\ncromos\u00f3mica \u00a0\nSP/NKA\u00a0NPK/NP\u03b3\u00a0 TAC1\u00a0\u00a0 PPT\u2010A\u00a0or\u00a0PPT\u2010I\u00a0\u00a0NM_013996 \u00a0(isofroma \u00a0\u03b1)\u00a0\u00a0\n7q21\u00a0\u2013\u00a0q22\u00a0\u00a0NM_003182 \u00a0(isofroma \u00a0\u03b2)\u00a0\u00a0\nNM_013997 \u00a0(isofroma \u00a0\u03b3)\u00a0\u00a0\nNM_013998 \u00a0(isofroma \u00a0\u03b4)\u00a0\u00a0\n\u00a0NKB\u00a0\u00a0 \u00a0 TAC3\u00a0\u00a0 \u00a0 PPT\u2010B\u00a0or\u00a0PPT\u2010II\u00a0 NM_013251 \u00a0\u00a0 12q13\u00a0\u2013q21\u00a0\n\u00a0HK\u20101/EKA,EKB,EKC,EKD \u00a0\u00a0 \u00a0 TAC4\u00a0\u00a0 \u00a0 PPT\u2010C\u00a0\u00a0NM_170685.2 \u00a0(isofroma \u00a0\u03b1)\u00a0\u00a0\n\u00a017q21.33 \u00a0\u00a0NM_001077503.1(isofroma \u00a0\u03b2)\u00a0\u00a0\nNM_001077504.1 \u00a0(isofroma \u00a0\u03b3)\u00a0\u00a0\nNM_001077505.1 \u00a0(isofroma \u00a0\u03b4)\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n47\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a015.\u00a0Organizaci\u00f3n \u00a0de\u00a0los\u00a0exones\u00a0de\u00a0TAC1\u00a0y\u00a0TAC3\u00a0humano\u00a0mostrando \u00a0las\u00a0posiciones \u00a0de\u00a0los\u00a0p\u00e9ptidos\u00a0previstos .\u00a0A.\u00a0Este\u00a0gen\u00a0\nde\u00a07\u00a0exones\u00a0da\u00a0lugar\u00a0a\u00a0cuatro\u00a0ARNm\u00a0diferentes \u00a0por\u00a0siplicing\u00a0alternativo. \u00a0\u03b2TAC1\u00a0codifica\u00a0para\u00a0SP,\u00a0NKA\u00a0y\u00a0NPK;\u00a0\u03b3TAC1\n\u00a0codifica\u00a0para\u00a0\nSP,\u00a0NKA\u00a0y\u00a0NP\u03b3\u00a0y\u00a0\u03b1TAC1\u00a0\u00fanicamente \u00a0codifica\u00a0para\u00a0SP\u00a0al\u00a0igual\u00a0que\u00a0\u03b4TAC1.\u00a0B.\u00a0El\u00a0gen\u00a0TAC3\u00a0tambi\u00e9n\u00a0consta\u00a0de\u00a07\u00a0exones\u00a0pero\u00a0codifica\u00a0\nsolamente \u00a0para\u00a0NKB\u00a0en\u00a0humanos. \u00a0Modificado \u00a0de\u00a0169,183,184.\u00a0\n\u00a0\nLa\u00a0SP\u00a0aumenta\u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0inmunoglobulinas \u00a0\npor\u00a0parte\u00a0de\u00a0los\u00a0linfocitos, \u00a0y\u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0por\u00a0parte\u00a0de\u00a0\nlinfocitos, \u00a0monocitos, \u00a0macr\u00f3fagos \u00a0y\u00a0mastocitos185\u2010\n188.\u00a0Adem\u00e1s\u00a0la\u00a0SP\u00a0induce\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0\nmediadores \u00a0de\u00a0la\u00a0respuesta \u00a0innata\u00a0como\u00a0radicales\u00a0\nde\u00a0oxigeno,\u00a0\u00e1cido\u00a0araquid\u00f3nico \u00a0e\u00a0histamina189.\u00a0\nRecientemente \u00a0se\u00a0ha\u00a0descubierto \u00a0que\u00a0la\u00a0SP\u00a0puede\u00a0\nactuar\u00a0sist\u00e9micamente \u00a0como\u00a0un\u00a0mensajero \u00a0para\u00a0\nmovilizar\u00a0c\u00e9lulas\u00a0estromales \u00a0CD29+\u00a0de\u00a0la\u00a0periferia\u00a0\nhacia\u00a0los\u00a0sitios\u00a0lesionados \u00a0para\u00a0promover \u00a0la\u00a0\ncuraci\u00f3n182.\u00a0Inicialmente \u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0\nmaduraci\u00f3n \u00a0de\u00a0los\u00a0leucocitos \u00a0que\u00a0se\u00a0encontraban \u00a0\nen\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0estaba\u00a0influenciada \u00a0por\u00a0la\u00a0\npresencia \u00a0de\u00a0taquiquininas. \u00a0En\u00a0En\u00a01991,\u00a0Weihe\u00a0y\u00a0\ncolaboradores \u00a0detectaron \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0fibras\u00a0\nnerviosas \u00a0en\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea190\u00a0y\u00a0esto\u00a0llevo\u00a0a\u00a0\npensar\u00a0que\u00a0ciertos\u00a0neurop\u00e9ptidos \u00a0eran\u00a0\nresponsables \u00a0de\u00a0la\u00a0maduraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0sangu\u00edneas. \u00a0De\u00a0hecho,\u00a0la\u00a0Dra.\u00a0Rameshwar \u00a0y\u00a0el\u00a0Dr.\u00a0\nGasc\u00f3n\u00a0revisaron \u00a0de\u00a0nuevo\u00a0la\u00a0importancia \u00a0de\u00a0\nestos\u00a0p\u00e9ptidos\u00a0durante\u00a0la\u00a0hematopoyesis. \u00a0\nDemostraron \u00a0que\u00a0la\u00a0SP\u00a0estimulaba \u00a0a\u00a0los\u00a0\nprogenitores \u00a0de\u00a0eritrocitos \u00a0y\u00a0linajes\u00a0mieloides191\u00a0\nadem\u00e1s\u00a0de\u00a0describir\u00a0que\u00a0era\u00a0la\u00a0responsable \u00a0de\u00a0la\u00a0\ninducci\u00f3n \u00a0de\u00a0la\u00a0IL\u20101\u00a0y\u00a0del\u00a0factor\u00a0de\u00a0c\u00e9lula\u00a0madre\u00a0\n(SCF,\u00a0del\u00a0ingl\u00e9s\u00a0stem\u00a0cell\u00a0factor )\u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0\nde\u00a0ratones192.\u00a0Por\u00a0otro\u00a0lado\u00a0describieron \u00a0que\u00a0la\u00a0SP\u00a0\ntambi\u00e9n\u00a0estimulaba \u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0IL\u20103\u00a0y\u00a0GM\u2010CSF\u00a0\npor\u00a0parte\u00a0de\u00a0c\u00e9lulas\u00a0mononucleares \u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\n\u00f3sea,\u00a0y\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0su\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0los\u00a0\nfibroblastos \u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0los\u00a0cuales\u00a0tambi\u00e9n\u00a0\nproliferaban \u00a0en\u00a0respuesta \u00a0a\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0\nmisma\u00a0SP,\u00a0creandose \u00a0una\u00a0retroalimentaci\u00f3n \u00a0\npositiva193.\u00a0A\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0promoci\u00f3n \u00a0de\u00a0la\u00a0\nvasodilataci\u00f3n, \u00a0quimiotaxis, \u00a0y\u00a0favorecimiento \u00a0en\u00a0la\u00a0\nadhesi\u00f3n\u00a0de\u00a0leucocitos \u00a0y\u00a0c\u00e9lulas\u00a0endoteliales, \u00a0la\u00a0SP\u00a0\nincrementa \u00a0la\u00a0extravasaci\u00f3n \u00a0permitiendo \u00a0el\u00a0paso\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n48\u00a0\n\u00a0de\u00a0l\u00edquido,\u00a0migraci\u00f3n \u00a0y\u00a0acumulaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0\nsistema\u00a0inmune\u00a0como\u00a0los\u00a0leucocitos \u00a0en\u00a0el\u00a0sitio\u00a0\ndonde\u00a0se\u00a0ha\u00a0producido \u00a0el\u00a0da\u00f1o\u00a0tisular181\u00a0y\u00a0\npromoviendo \u00a0de\u00a0este\u00a0modo\u00a0una\u00a0inflamaci\u00f3n \u00a0\nneurog\u00e9nica. \u00a0Por\u00a0otro\u00a0lado,\u00a0adem\u00e1s\u00a0de\u00a0que\u00a0la\u00a0SP\u00a0\npuede\u00a0actuar\u00a0como\u00a0mediadora \u00a0de\u00a0la\u00a0inflamaci\u00f3n, \u00a0\nest\u00e1\u00a0implicada \u00a0tambi\u00e9n\u00a0en\u00a0su\u00a0resoluci\u00f3n \u00a0ya\u00a0que\u00a0\ntiene\u00a0efectos\u00a0proliferativos \u00a0en\u00a0una\u00a0alta\u00a0variedad\u00a0\nde\u00a0c\u00e9lulas\u00a0dado\u00a0su\u00a0papel\u00a0como\u00a0factor\u00a0mitog\u00e9nico \u00a0\nuniversal194,195,\u00a0y\u00a0tambien\u00a0estimula\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0epiteliales196.\u00a0Por\u00a0lo\u00a0tanto,\u00a0la\u00a0inducci\u00f3n \u00a0\nde\u00a0la\u00a0mitog\u00e9nesis \u00a0y\u00a0de\u00a0la\u00a0migraci\u00f3n \u00a0celular\u00a0por\u00a0\nparte\u00a0de\u00a0este\u00a0p\u00e9ptido\u00a0sugiere\u00a0que\u00a0tambi\u00e9n\u00a0podr\u00eda\u00a0\nser\u00a0beneficioso \u00a0en\u00a0la\u00a0reparaci\u00f3n \u00a0tisular\u00a0en\u00a0\nsituaciones \u00a0de\u00a0inflamaci\u00f3n. \u00a0De\u00a0hecho,\u00a0en\u00a0un\u00a0\nmodelo\u00a0de\u00a0colitis\u00a0inflamatoria \u00a0la\u00a0SP\u00a0regula\u00a0la\u00a0\nregeneraci\u00f3n \u00a0tisular\u00a0de\u00a0este\u00a0tejido\u00a0da\u00f1ado\u00a0por\u00a0la\u00a0\ninflamaci\u00f3n197,198.\u00a0Tambi\u00e9n\u00a0presenta\u00a0efectos\u00a0anti\u2010\napopt\u00f3ticos \u00a0en\u00a0algunas\u00a0patolog\u00edas \u00a0como\u00a0el\u00a0asma,\u00a0\nfibrosis\u00a0idiop\u00e1tica \u00a0pulmonar \u00a0o\u00a0da\u00f1o\u00a0pulmonar \u00a0\nagudo\u00a0as\u00ed\u00a0como\u00a0en\u00a0m\u00faltiples \u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0\ninmune\u00a0 (macr\u00f3fagos, \u00a0 neutr\u00f3filos, \u00a0 etc.)\u00a0\nprotegiendo \u00a0a\u00a0\u00e9stas\u00a0y\u00a0otras\u00a0c\u00e9lulas\u00a0epiteliales \u00a0del\u00a0\nda\u00f1o\u00a0producido \u00a0por\u00a0estas\u00a0enfermedades181.\u00a0El\u00a0\nproblema \u00a0podr\u00eda\u00a0desencadenarse \u00a0cuando\u00a0este\u00a0\nproceso\u00a0de\u00a0reparaci\u00f3n \u00a0se\u00a0convierte \u00a0en\u00a0una\u00a0\ninflamaci\u00f3n \u00a0cr\u00f3nica\u00a0sostenida \u00a0y\u00a0ser\u00eda\u00a0entonces\u00a0\ncuando\u00a0la\u00a0SP\u00a0se\u00a0relacionar\u00eda \u00a0con\u00a0enfermedades \u00a0del\u00a0\nsistema\u00a0gastrointestinal \u00a0como\u00a0la\u00a0inflamaci\u00f3n \u00a0\naguda\u00a0intestinal199\u00a0o\u00a0la\u00a0de\u00a0p\u00e1ncreas200\u2010202\u00a0y\u00a0con\u00a0\nenfermedades \u00a0de\u00a0v\u00edas\u00a0respiratorias \u00a0(induciendo \u00a0la\u00a0\nliberaci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010inflamatorias \u00a0como\u00a0\nIL\u20108,\u00a0IL\u20106,\u00a0IL\u20101\u03b2\u00a0y\u00a0TNF\u2010\u03b1)203,204.\u00a0La\u00a0regulaci\u00f3n \u00a0de\u00a0\ntodos\u00a0estos\u00a0procesos\u00a0fisiol\u00f3gicos \u00a0se\u00a0produce\u00a0por\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0diversas\u00a0cascadas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\nintracelulares \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0\nmediada\u00a0por\u00a0SP\u00a0y/o\u00a0v\u00eda\u00a0de\u00a0las\u00a0MAPKs.\u00a0Como\u00a0\nconsecuencia \u00a0se\u00a0produce\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0como\u00a0la\u00a0IL\u20101,\u00a0IL\u20106,\u00a0IL\u2010\n8,\u00a0TNF\u2010\u03b1,\u00a0y\u00a0INF\u03b3\u00a0y\u00a0una\u00a0retroalimentaci\u00f3n \u00a0positiva\u00a0\nen\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0MAPKs\u00a0y\u00a0de\u00a0la\u00a0v\u00eda\u00a0de\u00a0la\u00a0\nPI3K/Akt\u00a0entre\u00a0otras\u00a0198.\u00a0\u00a0\nEl\u00a0metabolismo \u00a0que\u00a0regula\u00a0los\u00a0niveles\u00a0de\u00a0SP,\u00a0as\u00ed\u00a0\ncomo\u00a0sus\u00a0propiedades \u00a0pro\u00a0o\u00a0anti\u2010inflamatorias \u00a0es\u00a0\nparcialmente \u00a0mediado\u00a0por\u00a0enzimas\u00a0responsables \u00a0del\u00a0clivaje\u00a0de\u00a0una\u00a0variedad\u00a0de\u00a0p\u00e9ptidos\u00a0\nfisiol\u00f3gicamente \u00a0activos.\u00a0Estas\u00a0enzimas\u00a0son\u00a0la\u00a0\nendopeptidasa \u00a0neutral\u00a0(NEP,\u00a0del\u00a0ingl\u00e9s\u00a0neutral\u00a0\nendopeptidase :\u00a0EC3.4.24.11), \u00a0la\u00a0enzima\u00a0\ndegradante \u00a0de\u00a0la\u00a0SP\u00a0(SP\u2010DE,\u00a0del\u00a0ingl\u00e9s\u00a0substance \u2010\nP\u2010degrading \u00a0enzyme :\u00a0EC.3.4.21), \u00a0la\u00a0enzima\u00a0\nconvertidora \u00a0de\u00a0angiotensina \u00a0(ACE,\u00a0del\u00a0ing\u00e9s\u00a0\nangiotensin \u00a0convertin \u00a0enzyme :\u00a0EC.3.4.15.1), \u00a0el\u00a0\ndipeptidil \u00a0aminop\u00e9ptidasa \u00a0IV\u00a0(DP\u2010IV:\u00a0EC.3.4.21.26), \u00a0\nla\u00a0endopeptidasa \u00a0post\u2010prolina\u00a0(PEP:\u00a0EC.3.4.21.26), \u00a0\nla\u00a0catepsina \u2010D\u00a0(EC.3.4.3.23)205\u00a0y\u00a0la\u00a0captesina \u2010E\u00a0\n(EC.3.4.23.34). \u00a0Aunque\u00a0todas\u00a0ellas\u00a0pueden\u00a0\nfragmentar \u00a0la\u00a0SP\u00a0in\u00a0vitro,\u00a0una\u00a0de\u00a0las\u00a0m\u00e1s\u00a0\ninvolucradas \u00a0en\u00a0su\u00a0degradaci\u00f3n \u00a0son\u00a0la\u00a0NEP\u00a0y\u00a0la\u00a0\nACE205,206.\u00a0Varios\u00a0trabajos\u00a0han\u00a0descrito\u00a0que\u00a0una\u00a0\ndisminuci\u00f3n \u00a0de\u00a0estas\u00a0enzimas,\u00a0con\u00a0el\u00a0consecuente \u00a0\naumento\u00a0de\u00a0SP,\u00a0podr\u00edan\u00a0ser\u00a0las\u00a0causantes \u00a0de\u00a0una\u00a0\ninflamaci\u00f3n \u00a0intestinal \u00a0descontrolada207\u00a0o\u00a0una\u00a0\ndesregulaci\u00f3n \u00a0en\u00a0enfermedades \u00a0inflamatorias \u00a0de\u00a0\nla\u00a0piel\u00a0como\u00a0la\u00a0dermatitis \u00a0al\u00e9rgica\u00a0por\u00a0contacto208.\u00a0\nDe\u00a0nuevo\u00a0el\u00a0equipo\u00a0de\u00a0Pranela\u00a0Rameshwar \u00a0y\u00a0el\u00a0Dr.\u00a0\nGasc\u00f3n\u00a0estudi\u00f3\u00a0el\u00a0papel\u00a0de\u00a0la\u00a0SP\u00a0y\u00a0su\u00a0relaci\u00f3n\u00a0con\u00a0\nesta\u00a0enzima\u00a0y\u00a0el\u00a0sistema\u00a0hematopoy\u00e9tico209.\u00a0\nConcretamente \u00a0estudiaron \u00a0la\u00a0relaci\u00f3n\u00a0que\u00a0ten\u00eda\u00a0\nNEP\u00a0sobre\u00a0la\u00a0retro\u2010alimentaci\u00f3n \u00a0negativa\u00a0del\u00a0SCF\u00a0\nen\u00a0la\u00a0estimulaci\u00f3n \u00a0hematopoy\u00e9tica \u00a0mediada\u00a0por\u00a0el\u00a0\nfragmento \u00a01\u20104\u00a0de\u00a0la\u00a0SP\u00a0(fragmento \u00a0de\u00a0la\u00a0SP\u00a0con\u00a0\nefecto\u00a0antagonista \u00a0sobre\u00a0NK\u20101R\u00a0generado \u00a0por\u00a0el\u00a0\nclivaje\u00a0de\u00a0la\u00a0NEP210),\u00a0encontrando \u00a0por\u00a0tanto\u00a0un\u00a0\nnuevo\u00a0mecanismo \u00a0por\u00a0el\u00a0cual\u00a0la\u00a0SP\u00a0estaba\u00a0\ninvolucrada \u00a0en\u00a0el\u00a0proceso\u00a0de\u00a0maduraci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0hematopoy\u00e9ticas209.\u00a0La\u00a0encima\u00a0NEP\u00a0es\u00a0\ncapaz\u00a0de\u00a0fragmentar \u00a0a\u00a0la\u00a0SP\u00a0por\u00a0varios\u00a0puntos\u00a0del\u00a0\np\u00e9ptido,\u00a0unos\u00a0de\u00a0los\u00a0fragmentos \u00a0que\u00a0se\u00a0obtienen\u00a0\nes\u00a0el\u00a0fragmento \u00a0antagonista \u00a0de\u00a0NK\u20101R\u00a0(SP\u00a01\u20104)\u00a0y\u00a0el\u00a0\nfragmento \u00a0con\u00a0un\u00a0efecto\u00a0similar\u00a0al\u00a0p\u00e9ptido\u00a0\u00edntegro\u00a0\n(SP\u00a05\u201011)210.\u00a0Por\u00a0otro\u00a0lado,\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0\nla\u00a0p\u00e9rdida\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0NEP\u00a0est\u00e1\u00a0relacionada \u00a0\ncon\u00a0\u00e1reas\u00a0de\u00a0alta\u00a0actividad\u00a0proliferativa \u00a0en\u00a0c\u00e1ncer\u00a0\nde\u00a0pr\u00f3stata\u00a0independiente \u00a0de\u00a0andr\u00f3geno211,\u00a0del\u00a0\nmismo\u00a0modo\u00a0que\u00a0su\u00a0sobreexpresi\u00f3n \u00a0causa\u00a0\ninhibici\u00f3n \u00a0del\u00a0crecimiento \u00a0y\u00a0tumorigenicidad \u00a0de\u00a0\nc\u00e9lulas\u00a0del\u00a0mismo\u00a0tipo212.\u00a0En\u00a0consecuencia \u00a0estas\u00a0\nenzimas\u00a0son\u00a0una\u00a0importantes \u00a0dianas\u00a0a\u00a0tener\u00a0en\u00a0\ncuenta\u00a0en\u00a0c\u00e1ncer\u00a0o\u00a0en\u00a0enfermedades \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n49\u00a0\n\u00a0inflamatorias \u00a0donde\u00a0la\u00a0SP\u00a0y\u00a0su\u00a0metabolismo \u00a0\njuegan\u00a0un\u00a0papel\u00a0fundamental. \u00a0\n5.2.\u00a0Receptores \u00a0de\u00a0taquinininas: \u00a0NK\u2010\n1,\u00a0NK\u20102\u00a0y\u00a0NK\u20103\u00a0\nLos\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0se\u00a0han\u00a0dividido\u00a0en\u00a0\ntres\u00a0tipos\u00a0distintios\u00a0seg\u00fan\u00a0sus\u00a0ligandos\u00a0de\u00a0mayor\u00a0\nafinidad:\u00a0TACR1\u00a0(receptor \u00a0NK\u20101),\u00a0TACR2\u00a0(receptor \u00a0\nNK\u20102)\u00a0y\u00a0TACR3\u00a0(receptor \u00a0NK\u20103)\u00a0(Tabla\u00a09)\u00a0quienes\u00a0\npresentan \u00a0una\u00a0afinidad\u00a0preferente \u00a0pero\u00a0no\u00a0\u00fanica\u00a0\npor\u00a0la\u00a0SP,\u00a0NKA\u00a0y\u00a0NKB,\u00a0respectivamente183,184,213.\u00a0\u00a0\nTabla\u00a09.\u00a0Genes\u00a0de\u00a0los\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0humanos.\u00a0\n\u00a0\nEl\u00a0orden\u00a0de\u00a0potencia\u00a0de\u00a0los\u00a0receptores \u00a0de\u00a0\ntaquiquininas \u00a0por\u00a0cada\u00a0taquiquinina \u00a0se\u00a0muestra\u00a0en\u00a0\nla\u00a0tabla\u00a010183,214:\u00a0\u00a0\nTabla\u00a010.\u00a0Orden\u00a0de\u00a0afinidad\u00a0de\u00a0los\u00a0distintos\u00a0receptores \u00a0de\u00a0\ntaquiquininas \u00a0por\u00a0sus\u00a0agonistas. \u00a0\n\u00a0\n\u00a0\n\u00a0\nNPK\u00a0y\u00a0NP\u03b3\u00a0se\u00a0unen\u00a0preferentemente \u00a0al\u00a0receptor\u00a0\nNK\u20102.\u00a0La\u00a0afinidad\u00a0de\u00a0la\u00a0NKA\u00a0y\u00a0la\u00a0NKB\u00a0por\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0es\u00a0de\u00a0100\u00a0a\u00a0500\u00a0veces\u00a0menor\u00a0\n,respectivamente, \u00a0que\u00a0la\u00a0SP215.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0\ndescrito\u00a0que\u00a0la\u00a0SP\u00a0interact\u00faa \u00a0con\u00a0la\u00a0fibronectina \u00a0y\u00a0\nel\u00a0factor\u00a0inducible\u00a0de\u00a0crecimiento \u00a0hematopoy\u00e9tico \u00a0\ntipo\u00a0neuroquinina \u20101\u00a0(HGFIN,\u00a0del\u00a0ingl\u00e9s\u00a0\nhematopoyetic \u00a0growth\u00a0factor\u00a0inducible\u00a0neurokinin \u2010\n1\u00a0type)216,217.\u00a0Recientemente \u00a0se\u00a0ha\u00a0descrito\u00a0la\u00a0\nexistencia \u00a0de\u00a0una\u00a0homolog\u00eda \u00a0entre\u00a0el\u00a0receptor\u00a0\u00a0\nNK1\u00a0y\u00a0HGFIN.\u00a0Este\u00a0hallazgo\u00a0podr\u00eda\u00a0ser\u00a0relevante \u00a0\ndebido\u00a0a\u00a0que\u00a0tanto\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0como\u00a0HGFIN\u00a0\nse\u00a0han\u00a0relacionado \u00a0con\u00a0la\u00a0tumorog\u00e9nesis, \u00a0\nincluyendo \u00a0el\u00a0caso\u00a0del\u00a0CM217.\u00a0Sin\u00a0embargo, \u00a0a\u00a0\ndiferencia \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0como\u00a0promotor \u00a0tumoral,\u00a0HGFIN\u00a0parece\u00a0actuar\u00a0\ncomo\u00a0supresor217.\u00a0\nLos\u00a03\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0pertenecen \u00a0a\u00a0la\u00a0\nfamilia\u00a01\u00a0(rodopsina \u2010like)\u00a0de\u00a0receptores \u00a0acoplados \u00a0\na\u00a0prote\u00ednas \u00a0G\u00a0(GPCRs,\u00a0del\u00a0ingl\u00e9s  G\u2010protein\u00a0coupled\u00a0\nreceptors )\u00a0y\u00a0est\u00e1n\u00a0codificados \u00a0por\u00a05\u00a0exones184,218.\u00a0\nSon\u00a0receptores \u00a0de\u00a07\u00a0h\u00e9lices\u2010\u03b1\u00a0transmembrana \u00a0y\u00a0\ncomparten \u00a0la\u00a0misma\u00a0unidad\u00a0estructural: \u00a0constan\u00a0\nde\u00a0tres\u00a0bucles\u00a0extracelulares \u00a0(EL1,\u00a0EL2\u00a0y\u00a0EL3)\u00a0y\u00a03\u00a0\nintracelulares \u00a0(C1,\u00a0C2\u00a0y\u00a0C3)\u00a0con\u00a0la\u00a0posibilidad \u00a0de\u00a0\nun\u00a0cuarto\u00a0debido\u00a0a\u00a0la\u00a0palmitoilaci\u00f3n \u00a0de\u00a0una\u00a0\nCiste\u00edna\u00a0(Cys),\u00a0flanqueados \u00a0por\u00a07\u00a0dominios \u00a0inter\u2010\nmembrana \u00a0(TM\u00a01\u2010VII)\u00a0un\u00a0extremo\u00a0amino\u2010terminal\u00a0\nextracelular \u00a0 y\u00a0 otro\u00a0 carboxi\u2010terminal\u00a0\ncitoplasm\u00e1tico184\u00a0(Fig.\u00a016).\u00a0El\u00a0dominio\u00a0conservado \u00a0\ncarboxi\u2013terminal \u00a0de\u00a0las\u00a0taquiquininas \u00a0(Phe\u2010X\u2010Gly\u2010\nLeu\u2010Met\u2010NH2)\u00a0interacciona \u00a0con\u00a0los\u00a0receptores \u00a0de\u00a0\ntaquiquininas, \u00a0mientras\u00a0que\u00a0la\u00a0secuencia \u00a0amino\u2010\nterminal\u00a0es\u00a0la\u00a0responsable \u00a0de\u00a0la\u00a0especificidad \u00a0\nhacia\u00a0el\u00a0receptor181.\u00a0Todas\u00a0las\u00a0taquiquininas \u00a0se\u00a0\nencuentran \u00a0amidadas \u00a0en\u00a0el\u00a0extremo\u00a0C\u2010terminal\u00a0y\u00a0\nsu\u00a0desamidaci\u00f3n \u00a0suprime\u00a0toda\u00a0la\u00a0actividad213.\u00a0El\u00a0\nsegundo\u00a0y\u00a0tercer\u00a0lazo\u00a0est\u00e1n\u00a0relacionado \u00a0con\u00a0la\u00a0\nuni\u00f3n\u00a0de\u00a0los\u00a0agonistas \u00a0o\u00a0antagonistas, \u00a0mientras\u00a0\nque\u00a0el\u00a0tercer\u00a0lazo\u00a0citoplasm\u00e1tico \u00a0es\u00a0el\u00a0responsable \u00a0\nde\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0prote\u00ednas \u00a0G.\u00a0El\u00a0extremo\u00a0C\u2010terminal\u00a0\ncontiene\u00a0residuos\u00a0serina/treonina \u00a0que\u00a0cuando\u00a0son\u00a0\nfosforilados \u00a0causan\u00a0la\u00a0desensibilizaci\u00f3n \u00a0del\u00a0\nreceptor\u00a0una\u00a0vez\u00a0es\u00a0activado\u00a0repetidas \u00a0veces\u00a0por\u00a0\nel\u00a0agonista.\u00a0La\u00a0regi\u00f3n\u00a05\u2019\u00a0del\u00a0gen\u00a0tiene\u00a0diversos\u00a0\nelementos \u00a0reguladores \u00a0de\u00a0ADN\u00a0putativos \u00a0como\u00a0el\u00a0\nelemento \u00a0responsivo \u00a0al\u00a0AMPc,\u00a0AP\u20101,\u00a0AP\u20102,\u00a0AP4,\u00a0\nNF\u2010\u03baB,\u00a0OCT\u20102\u00a0y\u00a0un\u00a0dominio\u00a0Sp\u20101181.\u00a0En\u00a0concreto\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0tiene\u00a0407\u00a0amino\u00e1cidos \u00a0y\u00a0una\u00a0masa\u00a0\nmolecular \u00a0relativa\u00a0de\u00a046\u00a0kDa219.\u00a0NK\u20102\u00a0consta\u00a0de\u00a0\n398\u00a0amino\u00e1cidos, \u00a0y\u00a0NK\u20103\u00a0de\u00a0465\u00a0siendo\u00a0el\u00a0m\u00e1s\u00a0\nlargo\u00a0de\u00a0los\u00a0tres\u00a0receptores. \u00a0El\u00a0\u00fanico\u00a0splicing\u00a0\nidentificado \u00a0hasta\u00a0el\u00a0momento \u00a0en\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0\npierde\u00a0los\u00a0\u00faltimos\u00a096\u00a0amino\u00e1cidos \u00a0en\u00a0el\u00a0extremo\u00a0\nC\u2010terminal\u00a0y\u00a0tiene\u00a0por\u00a0tanto\u00a0311\u00a0amino\u00e1cidos220\u2010222\u00a0\n(Fig.\u00a016).\u00a0Esta\u00a0isoforma\u00a0m\u00e1s\u00a0corta\u00a0o\u00a0truncada\u00a0\n(NK1\u2010Tr)\u00a0es\u00a0generada \u00a0cuando\u00a0el\u00a0intr\u00f3n\u00a0que\u00a0se\u00a0\nencuentra \u00a0entre\u00a0el\u00a0ex\u00f3n\u00a04\u00a0y\u00a05\u00a0no\u00a0es\u00a0eliminado \u00a0y\u00a0un\u00a0\ncod\u00f3n\u00a0stop\u00a0prematuro \u00a0se\u00a0identifica \u00a0antes\u00a0de\u00a0\nempezar\u00a0el\u00a0ex\u00f3n\u00a05.\u00a0Tipo\u00a0de\u00a0\nreceptor\u00a0Gen\u00a0N\u00famero\u00a0de\u00a0\nacceso\u00a0\u00a0Localizaci\u00f3n \u00a0\ncromos\u00f3mica \u00a0\n\u00a0NK\u20101\u00a0\u00a0 \u00a0 TACR1\u00a0\u00a0 \u00a0NM_001058 \u00a0\u00a0 \u00a0 2p13.1\u00a0\u2013\u00a0p12\u00a0\u00a0\n\u00a0NK\u20102\u00a0\u00a0 \u00a0 TACR2\u00a0\u00a0 \u00a0NM_001057 \u00a0\u00a0 \u00a0 10q11\u00a0\u2013\u00a0q21\u00a0\u00a0\n\u00a0NK\u20103\u00a0\u00a0 \u00a0 TACR3\u00a0\u00a0 \u00a0NM_001059 \u00a0\u00a0 \u00a0 4q25\u00a0\u00a0\nReceptor\u00a0NK\u20101:\u00a0SP>NKA>NKB \u00a0\nReceptor\u00a0NK\u20102:\u00a0NKA>NKB>SP \u00a0\nReceptor\u00a0NK\u20103:\u00a0NKB>NKA>SP \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n50\u00a0\n\u00a0Lai\u00a0y\u00a0Douglas\u00a0observaron \u00a0que\u00a0mientras\u00a0la\u00a0SP\u00a0\naumentaba \u00a0espec\u00edficamente \u00a0el\u00a0calcio\u00a0intracelular \u00a0\nen\u00a0c\u00e9lulas\u00a0embrionarias \u00a0de\u00a0ri\u00f1on\u00a0(HEK293) \u00a0\ntransfectadas \u00a0de\u00a0forma\u00a0estable\u00a0con\u00a0la\u00a0isoforma\u00a0\nlarga,\u00a0no\u00a0se\u00a0encontraba \u00a0efecto\u00a0en\u00a0aquellas\u00a0\ntransfectadas \u00a0con\u00a0la\u00a0isoforma\u00a0truncada. \u00a0De\u00a0la\u00a0\nmisma\u00a0manera\u00a0las\u00a0c\u00e9lulas\u00a0que\u00a0expresaban \u00a0la\u00a0\nforma\u00a0completa \u00a0activaban \u00a0NF\u2010\u03baB\u00a0e\u00a0IL\u20108\u00a0mientras\u00a0\nque\u00a0las\u00a0que\u00a0expresaban \u00a0la\u00a0forma\u00a0truncada\u00a0\npresentaban \u00a0una\u00a0menor\u00a0expresi\u00f3n \u00a0de\u00a0ARNm,\u00a0de\u00a0\nIL\u20108\u00a0y\u00a0no\u00a0pod\u00edan\u00a0activar\u00a0a\u00a0la\u00a0prote\u00edna\u00a0NF\u2010\u03baB.\u00a0La\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0Erk\u00a0tambi\u00e9n\u00a0se\u00a0\nve\u00eda\u00a0alterada\u00a0en\u00a0las\u00a0mismas\u00a0c\u00e9lulas:\u00a0mientras\u00a0que\u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0esta\u00a0prote\u00edna\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nisoforma\u00a0larga\u00a0era\u00a0bastante\u00a0r\u00e1pida\u00a0(de\u00a01\u00a0a\u00a02\u00a0\nminutos)\u00a0y\u00a0se\u00a0sosten\u00eda,\u00a0las\u00a0c\u00e9lulas\u00a0transfectadas \u00a0\ncon\u00a0la\u00a0isoforma\u00a0truncada\u00a0no\u00a0eran\u00a0capaces\u00a0de\u00a0\nactivar\u00a0Erk\u00a0hasta\u00a0los\u00a020\u00a0min\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0\nexposici\u00f3n \u00a0a\u00a0SP223.\u00a0Otros\u00a0estudios\u00a0vieron\u00a0que\u00a0la\u00a0SP\u00a0\nten\u00eda\u00a0una\u00a0menor\u00a0afinidad\u00a0relativa\u00a0por\u00a0la\u00a0forma\u00a0\ntruncada\u00a0del\u00a0receptor\u00a0(incluso\u00a010\u00a0veces\u00a0menos\u00a0\nque\u00a0la\u00a0forma\u00a0completa)220.\u00a0Adem\u00e1s,\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\nciertos\u00a0residuos\u00a0serina\u00a0y\u00a0treonina\u00a0de\u00a0la\u00a0zona\u00a0C\u2010\nterminal\u00a0son\u00a0importantes \u00a0para\u00a0la\u00a0interacci\u00f3n \u00a0con\u00a0\nla\u00a0quinasa\u00a0G\u00a0asociada\u00a0al\u00a0receptor\u00a0(GRK)\u00a0y\u00a0el\u00a0\nreclutamiento \u00a0de\u00a0\u03b2 \u2010arrestinas \u00a0para\u00a0su\u00a0posterior\u00a0\ninternalizaci\u00f3n224,225.\u00a0Por\u00a0tanto,\u00a0quiz\u00e1s\u00a0la\u00a0forma\u00a0\ntruncada\u00a0deber\u00eda\u00a0tener\u00a0la\u00a0capacidad \u00a0de\u00a0prolongar \u00a0\nlas\u00a0respuestas \u00a0despu\u00e9s\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0del\u00a0ligando\u00a0\nporque\u00a0su\u00a0desensibilizaci\u00f3n \u00a0e\u00a0internalizaci\u00f3n \u00a0est\u00e1n\u00a0\nafectadas. \u00a0\nAdem\u00e1s\u00a0de\u00a0las\u00a0diferencias \u00a0entre\u00a0las\u00a0dos\u00a0isoformas \u00a0\nes\u00a0conocido\u00a0otro\u00a0fen\u00f3meno \u00a0que\u00a0interviene \u00a0en\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0estos\u00a0receptores. \u00a0Tansky,\u00a0\nPothoulakis \u00a0y\u00a0Leeman\u00a0demostraron \u00a0que\u00a0el\u00a0\nextremo\u00a0amino\u00a0terminal\u00a0ten\u00eda\u00a0dos\u00a0sitios\u00a0de\u00a0Asn\u00a0\n(N\u2010)\u00a0glicosilados \u00a0y\u00a0describieron \u00a0como\u00a0pod\u00edan\u00a0influir\u00a0\nestas\u00a0glicosilaciones \u00a0de\u00a0manera\u00a0funcional \u00a0en\u00a0el\u00a0\nreceptor226.\u00a0Observaron \u00a0que\u00a0los\u00a0receptores \u00a0no\u00a0\nglicosilados \u00a0mostraban \u00a0la\u00a0mitad\u00a0de\u00a0afinidad\u00a0por\u00a0la\u00a0\nSP\u00a0que\u00a0los\u00a0glicosilados. \u00a0Y\u00a0de\u00a0la\u00a0misma\u00a0manera\u00a0que\u00a0\nexist\u00eda\u00a0una\u00a0diferencia \u00a0entre\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0\ncompleto \u00a0o\u00a0truncado, \u00a0el\u00a0receptor\u00a0NK\u20101\u00a0no\u00a0\nglicosilado \u00a0se\u00a0internalizaba \u00a0m\u00e1s\u00a0r\u00e1pido\u00a0que\u00a0el\u00a0\nglicosilado. \u00a0Esto\u00a0tambi\u00e9n\u00a0suger\u00eda\u00a0la\u00a0posibilidad \u00a0que\u00a0la\u00a0glicosilaci\u00f3n \u00a0pudiera\u00a0ser\u00a0una\u00a0caracter\u00edstica \u00a0\nm\u00e1s\u00a0para\u00a0estabilizar \u00a0el\u00a0receptor\u00a0en\u00a0la\u00a0membrana. \u00a0\nVarias\u00a0bandas\u00a0de\u00a0pesos\u00a0moleculares \u00a0distintos\u00a0han\u00a0\nsido\u00a0identificadas \u00a0debido\u00a0quiz\u00e1s\u00a0a\u00a0este\u00a0fen\u00f3meno. \u00a0\nPor\u00a0ejemplo,\u00a0en\u00a0linfocitos\u00a0se\u00a0han\u00a0descrito\u00a0unas\u00a0\nformas\u00a0del\u00a0receptor\u00a0glicosiladas \u00a0de\u00a058\u00a0kDa227,\u00a0\nmientras\u00a0que\u00a0otras\u00a0de\u00a038\u00a0y\u00a033\u00a0kDa\u00a0aparecen \u00a0en\u00a0\nlinfoblastos \u00a0IM\u20109228.\u00a0Adem\u00e1s\u00a0isoformas \u00a0que\u00a0\npresentan \u00a0bandas\u00a0de\u00a075,\u00a058,\u00a046,\u00a034\u00a0kDa\u00a0han\u00a0sido\u00a0\nidentificadas \u00a0en\u00a0varios\u00a0estudios\u00a0de\u00a0l\u00edneas\u00a0celulares\u00a0\ntumorales \u00a0de\u00a0carcinoma \u00a0pancre\u00e1tico229,230.\u00a0\u00a0\nHace\u00a0ya\u00a0casi\u00a0dos\u00a0d\u00e9cadas\u00a0se\u00a0detectaron \u00a0tambi\u00e9n\u00a0\notras\u00a0isoformas \u00a0distintas\u00a0a\u00a0las\u00a0convencionales \u00a0con\u00a0\nafinidades \u00a0diferentes \u00a0a\u00a0la\u00a0SP\u00a0que\u00a0la\u00a0isoforma\u00a0\n\u201ccl\u00e1sica\u201d.\u00a0Por\u00a0ejemplo,\u00a0en\u00a0gl\u00e1ndulas \u00a0salivares\u00a0de\u00a0\nrata\u00a0se\u00a0detect\u00f3\u00a0otra\u00a0isoforma\u00a0al\u00a0parecer\u00a0tambi\u00e9n\u00a0\ntruncada\u00a0en\u00a0el\u00a0extremo\u00a0C\u2010terminal,\u00a0con\u00a0\naproximadamente \u00a08\u00a0kDa\u00a0menos\u00a0que\u00a0la\u00a0isoforma\u00a0\nlarga231.\u00a0A\u00a0diferencia \u00a0de\u00a0lo\u00a0demostrado \u00a0por\u00a0S.\u00a0\nLeeman\u00a0con\u00a0la\u00a0isoforma\u00a0corta,\u00a0\u00e9sta\u00a0otra\u00a0parece\u00a0\ntener\u00a0una\u00a0afinidad\u00a0por\u00a0la\u00a0SP\u00a0similar\u00a0a\u00a0la\u00a0isoforma\u00a0\ncompleta. \u00a0Se\u00a0ha\u00a0sugerido\u00a0que\u00a0esta\u00a0isoforma\u00a0surge\u00a0\na\u00a0partir\u00a0de\u00a0modificaciones \u00a0post\u2010traduccionales232.\u00a0\nAdem\u00e1s\u00a0otros\u00a0estudios\u00a0muestran \u00a0que\u00a0algunas\u00a0\nformas\u00a0del\u00a0receptor\u00a0presentan \u00a0afinidades \u00a0distintas\u00a0\na\u00a0las\u00a0propuestas \u00a0como\u00a0\u201ccl\u00e1sicas\u201d \u00a0y\u00a0dividen\u00a0al\u00a0\nreceptor\u00a0de\u00a0NK\u20101\u00a0en\u00a03\u00a0clases\u00a0diferentes: \u00a01)\u00a0\nreceptor\u00a0NK\u20101\u00a0\u201ccl\u00e1sico\u201d\u00a0(que\u00a0muestra\u00a0una\u00a0mayor\u00a0\nafinidad\u00a0a\u00a0la\u00a0uni\u00f3n\u00a0del\u00a0ligando\u00a0SP),\u00a02)\u00a0receptor\u00a0NK\u2010\n1\u00a0\u201csensitivo \u00a0a\u00a0septide\u201d\u00a0(que\u00a0muestra\u00a0una\u00a0afinidad\u00a0\nmuy\u00a0parecida\u00a0tanto\u00a0por\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0SP\u00a0como\u00a0a\u00a0otras\u00a0\ntaquiquininas \u00a0como\u00a0la\u00a0NKA,\u00a0NPK,\u00a0NP\u03b3,\u00a0la\u00a0NKB\u00a0e\u00a0\nincluso\u00a0a\u00a0otros\u00a0p\u00e9ptidos\u00a0sint\u00e9ticos \u00a0como\u00a0el\u00a0\nfragmento \u00a0septide\u00a06\u201011\u00a0de\u00a0la\u00a0SP\u00a0que\u00a0le\u00a0da\u00a0nombre\u00a0\nal\u00a0receptor183,233,\u00a0y\u00a03)\u00a0m\u00e1s\u00a0recientemente \u00a0se\u00a0ha\u00a0\ndado\u00a0a\u00a0conocer\u00a0un\u00a0tercer\u00a0subtipo\u00a0de\u00a0receptor\u00a0de\u00a0\nNK\u20101\u00a0y\u00a0lo\u00a0han\u00a0denominado \u00a0como\u00a0\u201cnuevo\u00a0NK\u20101\u00a0\nsensitivo \u201d234.\u00a0Este\u00a0subtipo\u00a0tiene\u00a0una\u00a0mayor\u00a0\nafinidad\u00a0por\u00a0taquiquininas \u00a0m\u00e1s\u00a0largas\u00a0y\u00a0no\u00a0se\u00a0une\u00a0\na\u00a0septide\u00a0o\u00a0SP\u00a0(6\u201011).\u00a0Sin\u00a0embargo, \u00a0se\u00a0necesitan \u00a0\nm\u00e1s\u00a0estudios\u00a0en\u00a0el\u00a0futuro\u00a0para\u00a0conocer\u00a0las\u00a0\ndiferencias \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0y\u00a0lugar\u00a0de\u00a0expresi\u00f3n \u00a0\nde\u00a0las\u00a0diferentes \u00a0isoformas \u00a0o\u00a0formas\u00a0glicosiladas \u00a0\nde\u00a0estos\u00a0receptores. \u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n51\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a016.\u00a0Esquema \u00a0modelo\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0Arriba\u00a0isoforma\u00a0completa \u00a0de\u00a0407\u00a0amino\u00e1cidos \u00a0o\u00a0isoforma\u00a0larga\u00a0(NK1\u2010FL).\u00a0\nContiene\u00a0un\u00a0extremo\u00a0N\u2010terminal\u00a0extracelular, \u00a0siete\u00a0dominios \u00a0que\u00a0atraviesan \u00a0la\u00a0membrana, \u00a03\u00a0bucles\u00a0extracelulares \u00a0(E1,\u00a0E2\u00a0y\u00a0E3)\u00a0y\u00a0\n3\u00a0bucles\u00a0intracelulares \u00a0(C1,\u00a0C2,\u00a0C3),\u00a0un\u00a0posible\u00a0C4\u00a0debido\u00a0a\u00a0palmitoilaci\u00f3n \u00a0de\u00a0un\u00a0residuo\u00a0Cys\u00a0y\u00a0un\u00a0extremo\u00a0C\u2010terminal\u00a0intracelular. \u00a0\nAsn14\u00a0y\u00a0Asn18\u00a0se\u00a0indican\u00a0como\u00a0sitios\u00a0putativos \u00a0de\u00a0glicosilaci\u00f3n. \u00a0Abajo\u00a0isoforma\u00a0truncada\u00a0con\u00a0311\u00a0amino\u00e1cidos \u00a0y\u00a0donde\u00a0se\u00a0\nobserva\u00a0que\u00a0ha\u00a0perdido\u00a0parte\u00a0del\u00a0extremo\u00a0C\u2010terminal\u00a0intracelular \u00a0as\u00ed\u00a0como\u00a0los\u00a0residuos\u00a0Ser/Thr\u00a0intracelulares \u00a0responsables \u00a0de\u00a0la\u00a0\ninternalizaci\u00f3n. \u00a0Modificado \u00a0de174.\u00a0\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n52\u00a0\n\u00a05.2.1.\u00a0Distribuci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0\nde\u00a0taquiquininas \u00a0en\u00a0el\u00a0organismo \u00a0\n\u00a0\nComo\u00a0se\u00a0ha\u00a0mencionado \u00a0anteriormente \u00a0las\u00a0\ntaquiquininas \u00a0y\u00a0sus\u00a0receptores \u00a0est\u00e1n\u00a0ampliamente \u00a0\nexpresadas \u00a0en\u00a0distintos\u00a0sistemas\u00a0como\u00a0el\u00a0\ncardiovascular, \u00a0gl\u00e1ndulas \u00a0salivales,\u00a0piel,\u00a0m\u00fasculos, \u00a0\ntejidos\u00a0pulmonares, \u00a0en\u00a0el\u00a0tracto\u00a0gastrointestinal, \u00a0\ngenitourinario \u00a0y\u00a0en\u00a0el\u00a0sistema\u00a0inmunol\u00f3gico235.\u00a0Los\u00a0\nreceptores \u00a0de\u00a0taquiquininas \u00a0tienen\u00a0una\u00a0\ndistribuci\u00f3n \u00a0no\u00a0uniforme. \u00a0Los\u00a0receptores \u00a0NK\u20101\u00a0y\u00a0\nNK\u20103\u00a0se\u00a0encuentran \u00a0en\u00a0el\u00a0sistema\u00a0nervioso\u00a0y\u00a0en\u00a0los\u00a0\ntejidos\u00a0perif\u00e9ricos, \u00a0mientras\u00a0que\u00a0el\u00a0receptor\u00a0NK\u20102\u00a0\nse\u00a0encuentra \u00a0s\u00f3lo\u00a0en\u00a0los\u00a0tejidos\u00a0perif\u00e9ricos \u00a0\n(ri\u00f1ones,\u00a0pulmones, \u00a0placenta\u00a0y\u00a0m\u00fasculo\u00a0\nesquel\u00e9tico)187,236,237.\u00a0Concretamente \u00a0el\u00a0receptor\u00a0\nNK\u20101\u00a0participa\u00a0en\u00a0respuestas \u00a0celulares\u00a0como\u00a0la\u00a0\ntransmisi\u00f3n \u00a0del\u00a0dolor,\u00a0la\u00a0secreci\u00f3n \u00a0endocrina \u00a0y\u00a0\nparacrina, \u00a0la\u00a0vasodilataci\u00f3n \u00a0y\u00a0la\u00a0modulaci\u00f3n \u00a0de\u00a0la\u00a0\nproliferaci\u00f3n \u00a0celular,\u00a0al\u00a0igual\u00a0que\u00a0su\u00a0ligando\u00a0de\u00a0\nmayor\u00a0afinidad\u00a0SP.\u00a0Tambi\u00e9n\u00a0act\u00faa\u00a0como\u00a0\nneuromodulador \u00a0contribuyendo \u00a0a\u00a0la\u00a0homeostasis \u00a0\ndel\u00a0cerebro\u00a0y\u00a0en\u00a0la\u00a0transmisi\u00f3n \u00a0sensorial\u00a0neuronal\u00a0\nasociada\u00a0con\u00a0la\u00a0depresi\u00f3n, \u00a0el\u00a0estr\u00e9s,\u00a0la\u00a0ansiedad\u00a0y\u00a0\nla\u00a0\u00e9mesis.\u00a0Adem\u00e1s,\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0tambi\u00e9n\u00a0es\u00a0\nresponsable \u00a0de\u00a0modular\u00a0la\u00a0respuesta \u00a0inflamatoria \u00a0\na\u00a0trav\u00e9s\u00a0del\u00a0sistema\u00a0inmune.\u00a0Se\u00a0ha\u00a0identificado \u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0en\u00a0linfocitos, \u00a0monocitos, \u00a0\nmacr\u00f3fagos, \u00a0c\u00e9lulas\u00a0NK\u00a0y\u00a0microgl\u00eda. \u00a0NK\u20101R\u00a0y\u00a0NK\u20102R\u00a0\ntambi\u00e9n\u00a0se\u00a0han\u00a0encontrado \u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0\nm\u00e9dula\u00a0\u00f3sea\u00a0(c\u00e9lulas\u00a0del\u00a0linaje\u00a0mieloide\u00a0y\u00a0linfoide)\u00a0\ndonde\u00a0son\u00a0considerados \u00a0como\u00a0reguladores \u00a0\nhematopoy\u00e9ticos. \u00a0Tanto\u00a0en\u00a0tejido\u00a0normal\u00a0como\u00a0\ndurante\u00a0la\u00a0hematopoyesis, \u00a0NK\u20101\u00a0es\u00a0mediador \u00a0de\u00a0\nefectos\u00a0estimuladores \u00a0y\u00a0NK\u20102\u00a0ejerce\u00a0funciones \u00a0\nsupresoras \u00a0(cuando\u00a0NK\u20101R\u00a0est\u00e1\u00a0expresado \u00a0en\u00a0\nc\u00e9lulas\u00a0sanas\u00a0hay\u00a0una\u00a0regulaci\u00f3n \u00a0decreciente \u00a0de\u00a0\nNK\u20102R)238,239.\u00a0Incubaciones \u00a0de\u00a0macr\u00f3fagos \u00a0\nprimarios \u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0con\u00a0un\u00a0c\u00f3ctel\u00a0de\u00a0\ncitoquinas \u00a0(IFN\u2010\u03b3,\u00a0IL\u20101\u03b2\u00a0y\u00a0TNF\u2010\u03b1)\u00a0tiene\u00a0como\u00a0\nresultado \u00a0una\u00a0disminuci\u00f3n \u00a0del\u00a0ARNm\u00a0de\u00a0la\u00a0SP\u00a0y\u00a0de\u00a0\nsu\u00a0receptor\u00a0NK\u20101.\u00a0Esto\u00a0sugiere\u00a0que\u00a0tanto\u00a0el\u00a0\nligando\u00a0como\u00a0su\u00a0receptor\u00a0juegan\u00a0un\u00a0papel\u00a0fundamental \u00a0en\u00a0la\u00a0regulaci\u00f3n \u00a0del\u00a0sistema\u00a0\ninmunitario \u00a0innato.\u00a0\u00a0\nDel\u00a0mismo\u00a0modo\u00a0que\u00a0la\u00a0SP,\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0\npuede\u00a0actuar\u00a0tanto\u00a0de\u00a0mediador \u00a0de\u00a0la\u00a0\ninflamaci\u00f3n, \u00a0como\u00a0de\u00a0mediador \u00a0de\u00a0su\u00a0resoluci\u00f3n \u00a0\nya\u00a0que\u00a0act\u00faa\u00a0principalmente \u00a0como\u00a0receptor\u00a0\nasociado\u00a0a\u00a0la\u00a0proliferaci\u00f3n. \u00a0En\u00a0un\u00a0modelo\u00a0murino\u00a0\nantagonistas \u00a0de\u00a0NK\u20101\u00a0(CP\u201096,345\u00a0y\u00a0L\u2010733,060)\u00a0\npueden\u00a0proteger\u00a0al\u00a0rat\u00f3n\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0CD95\u00a0\ny\u00a0de\u00a0la\u00a0apoptosis \u00a0mediada\u00a0por\u00a0TNF\u2010\u03b1\u00a0que\u00a0causa\u00a0\nda\u00f1o\u00a0hep\u00e1tico240.\u00a0Pero\u00a0al\u00a0igual\u00a0que\u00a0su\u00a0agonista\u00a0una\u00a0\nestimulaci\u00f3n \u00a0constante \u00a0del\u00a0tejido\u00a0por\u00a0parte\u00a0de\u00a0\nfibras\u00a0nerviosas \u00a0y\u00a0c\u00e9lulas\u00a0inflamatorias \u00a0se\u00a0\nconvierte \u00a0en\u00a0una\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0sostenida \u00a0y\u00a0\nse\u00a0relaciona\u00a0con\u00a0enfermedades \u00a0inflamatorias \u00a0\ncr\u00f3nicas\u00a0como\u00a0la\u00a0pancreatits \u00a0cr\u00f3nica\u00a0o\u00a0EIIs241\u2010243.\u00a0\n5.3.\u00a0V\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0sistema\u00a0\ntaquiquin\u00e9rgico \u00a0\nLa\u00a0regulaci\u00f3n \u00a0de\u00a0todos\u00a0estos\u00a0procesos\u00a0fisiol\u00f3gicos \u00a0\nmediados \u00a0por\u00a0la\u00a0SP\u00a0u\u00a0otras\u00a0taquinininas, \u00a0se\u00a0\nproducen \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0receptores \u00a0\nacoplados \u00a0a\u00a0prote\u00ednas \u00a0G\u00a0(GPCR,\u00a0del\u00a0ingles\u00a0G\u00a0\nprotein\u2010coupled\u00a0receptor ).\u00a0Estas\u00a0prote\u00ednas \u00a0activan,\u00a0\na\u00a0trav\u00e9s\u00a0de\u00a0segundos \u00a0mensajeros, \u00a0rutas\u00a0de\u00a0\ntransducci\u00f3n \u00a0dentro\u00a0de\u00a0la\u00a0c\u00e9lula.\u00a0Las\u00a0v\u00edas\u00a0activadas \u00a0\ndependen \u00a0de\u00a0la\u00a0naturaleza \u00a0de\u00a0las\u00a0diversas\u00a0\nprote\u00ednas \u00a0G\u00a0que\u00a0hay\u00a0dentro\u00a0de\u00a0esta\u00a0larga\u00a0fam\u00edlia.\u00a0\nEntre\u00a0ellas\u00a0encontramos \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0\nmediada\u00a0por\u00a0SP,\u00a0interleuquinas \u00a0o\u00a0factores\u00a0de\u00a0\ncrecimiento \u00a0(IL\u20101,\u00a0IL\u20106,\u00a0IL\u20108,\u00a0TNF\u2010\u03b1,\u00a0y\u00a0INF\u03b3)\u00a0y\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0otras\u00a0v\u00edas\u00a0como\u00a0las\u00a0de\u00a0las\u00a0de\u00a0MAPKs\u00a0\ny\u00a0la\u00a0v\u00eda\u00a0de\u00a0la\u00a0PI3K/Akt\u00a0entre\u00a0otras198,244,245.\u00a0\u00a0\n5.3.1\u00a0Se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0GPCRs:\u00a0\nClasificaci\u00f3n \u00a0y\u00a0funci\u00f3n\u00a0de\u00a0prote\u00ednas \u00a0G\u00a0\n\u00a0\nLos\u00a0GPCRs\u00a0median\u00a0su\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nprote\u00ednas \u00a0G\u00a0heterotrim\u00e9ricas \u00a0que\u00a0transmiten \u00a0\nse\u00f1ales\u00a0de\u00a0una\u00a0gran\u00a0variedad\u00a0de\u00a0receptores \u00a0de\u00a0\nsuperficie \u00a0celular\u00a0a\u00a0enzimas\u00a0y\u00a0canales.\u00a0Este\u00a0\ncomplejo \u00a0est\u00e1\u00a0compuesto \u00a0por\u00a0tres\u00a0subunidades \u00a0\ndistintas:\u00a0la\u00a0subunidad \u00a0G\u03b1\u00a0que\u00a0une\u00a0GDP/GTP \u00a0y\u00a0las\u00a0\nsubunidades \u00a0G\u03b2\u00a0y\u00a0G\u03b3\u00a0que\u00a0forman\u00a0el\u00a0complejo \u00a0G\u03b2\u03b3\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n53\u00a0\n\u00a0\n(el\u00a0cual\u00a0presenta\u00a0fuertes\u00a0uniones\u00a0entre\u00a0ellas)246,247.\u00a0\nLa\u00a0uni\u00f3n\u00a0de\u00a0una\u00a0taquiquinina \u00a0a\u00a0su\u00a0receptor\u00a0induce\u00a0\nen\u00a0la\u00a0subunidad \u00a0G\u03b1\u00a0el\u00a0cambio\u00a0de\u00a0GDP\u00a0por\u00a0GTP\u00a0y\u00a0su\u00a0\ndisociaci\u00f3n \u00a0del\u00a0d\u00edmero\u00a0G\u03b2\u03b3.\u00a0Estas\u00a0subunidades \u00a0por\u00a0\nseparado \u00a0(la\u00a0subunidad \u00a0G\u03b1\u00a0y\u00a0la\u00a0subunidad \u00a0G\u03b2\u03b3)\u00a0\ninician\u00a0su\u00a0propia\u00a0cascada\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0y\u00a0regulan\u00a0\npositiva\u00a0o\u00a0negativamente \u00a0la\u00a0actividad\u00a0de\u00a0efectores \u00a0\nenzim\u00e1ticos \u00a0y\u00a0de\u00a0canales\u00a0i\u00f3nicos\u00a0que\u00a0son\u00a0\nespec\u00edficos \u00a0de\u00a0cada\u00a0GPCR\u00a0y\u00a0tipo\u00a0celular248,249.\u00a0La\u00a0\nhidr\u00f3lisis\u00a0del\u00a0GTP\u00a0devuelve\u00a0a\u00a0la\u00a0subunidad \u00a0G\u03b1\u00a0a\u00a0su\u00a0\nestado\u00a0inactivo\u00a0permitiendo \u00a0de\u00a0nuevo\u00a0la\u00a0\nformaci\u00f3n \u00a0del\u00a0tr\u00edmero\u00a0con\u00a0la\u00a0subunidad \u00a0G\u03b2\u03b3250.\u00a0A\u00a0\ndiferencia \u00a0de\u00a0la\u00a0G\u03b2\u03b3,\u00a0el\u00a0alcance\u00a0de\u00a0difusi\u00f3n\u00a0de\u00a0la\u00a0\nsubunidad \u00a0\u03b1\u00a0se\u00a0encuentra \u00a0limitado\u00a0debido\u00a0a\u00a0que\u00a0\ntodas\u00a0las\u00a0subunidades \u00a0\u03b1,\u00a0a\u00a0excepci\u00f3n \u00a0de\u00a0la\u00a0\nsubunidad \u00a0G\u03b1t,\u00a0poseen\u00a0una\u00a0modificaci\u00f3n \u00a0post\u2010\ntraduccional \u00a0con\u00a0un\u00a0\u00e1cido\u00a0palm\u00edtico \u00a0en\u00a0su\u00a0porci\u00f3n\u00a0\namino\u2010terminal,\u00a0que\u00a0las\u00a0mantiene \u00a0unidas\u00a0a\u00a0la\u00a0\nmembrana \u00a0plasm\u00e1tica251.\u00a0La\u00a0propia\u00a0subunidad \u00a0\u03b1\u00a0\ntiene\u00a0capacidad \u00a0GTPasa\u00a0intr\u00ednseca \u00a0y\u00a0por\u00a0tanto\u00a0\npuede\u00a0modular\u00a0su\u00a0propia\u00a0inactivaci\u00f3n. \u00a0De\u00a0todas\u00a0\nmaneras\u00a0esta\u00a0hidr\u00f3lisis\u00a0del\u00a0GTP\u00a0es\u00a0relativamente \u00a0\nbaja\u00a0si\u00a0la\u00a0comparamos \u00a0con\u00a0prote\u00ednas \u00a0accesorias \u00a0\ncitoplasm\u00e1ticas \u00a0denominadas \u00a0reguladoras \u00a0de\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0o\u00a0(RGS)252\u00a0(Fig.\u00a017).\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFig.\u00a017.\u00a0Activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0heterotr\u00edmerica \u00a0de\u00a0los\u00a0\nGPCRs\u00a0por\u00a0GTP\u00a0y\u00a0la\u00a0consecuente \u00a0separaci\u00f3n \u00a0de\u00a0las\u00a0\nsubunidades. \u00a0\nLas\u00a0prote\u00ednas \u00a0G\u00a0heterotrim\u00e9ricas \u00a0se\u00a0han\u00a0agrupado \u00a0\nen\u00a04\u00a0familias\u00a0distintas\u00a0basadas\u00a0en\u00a0la\u00a0secuencia \u00a0\nhom\u00f3loga \u00a0aminoac\u00eddica \u00a0de\u00a0la\u00a0subunidad \u00a0G\u03b1:\u00a0Gs,\u00a0Gi,\u00a0\nGq\u00a0y\u00a0G12/13\u00a0(Tabla\u00a011).\u00a0Existen\u00a0dos\u00a0rutas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0principales \u00a0\nasociadas \u00a0a\u00a0las\u00a0subunidades \u00a0G\u03b1s\u00a0y\u00a0G\u03b1q\u00a0y\u00a0son\u00a0\nprincipalmente \u00a0las\u00a0dos\u00a0v\u00edas\u00a0por\u00a0las\u00a0cuales\u00a0se\u00f1aliza\u00a0\nel\u00a0receptor\u00a0NK\u20101253\u2010255.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0\ndescriben \u00a0las\u00a0diferentes \u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\nactivadas \u00a0por\u00a0cada\u00a0subunidad. \u00a0\n\u2010Gq/11:\u00a0La\u00a0interacci\u00f3n \u00a0de\u00a0los\u00a0agonistas \u00a0con\u00a0el\u00a0\nreceptor\u00a0regulan\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Gq/11\u00a0\ny\u00a0la\u00a0consecuente \u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0fosfolipasa \u00a0C\u03b2\u00a0\n(PLC\u03b2),\u00a0la\u00a0cual\u00a0degrada\u00a0el\u00a0fosfatidilinositol \u00a04,\u00a05\u2010\nbifosfato\u00a0(PIP 2)\u00a0para\u00a0generar\u00a0dos\u00a0compuestos: \u00a0el\u00a0\ndiacilglicerol \u00a0(DAG)\u00a0y\u00a0el\u00a01,4,5\u2010inositol\u2010trifosfato \u00a0\n(IP3)\u00a0responsable \u00a0del\u00a0incremento \u00a0de\u00a0calcio\u00a0\nintracelular. \u00a0La\u00a0transducci\u00f3n \u00a0de\u00a0se\u00f1al\u00a0por\u00a0parte\u00a0\ndel\u00a0receptor\u00a0NK\u20101\u00a0fue\u00a0estudiada \u00a0en\u00a0c\u00e9lulas\u00a0\nov\u00e1ricas\u00a0transfectadas \u00a0de\u00a0h\u00e1mster\u00a0chino\u00a0(c\u00e9lulas\u00a0\nCHO)253.\u00a0En\u00a0estas\u00a0l\u00edneas\u00a0celulares\u00a0transfectadas \u00a0\nobservaron \u00a0que\u00a0de\u00a0manera\u00a0cl\u00e1sica\u00a0la\u00a0isoforma\u00a0\nlarga\u00a0de\u00a0NK\u20101R\u00a0se\u00f1alizaba \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0una\u00a0de\u00a0las\u00a0\nprote\u00ednas \u00a0trim\u00e9ricas \u00a0Gq/11.\u00a0\n\u2010Gs:\u00a0Esta\u00a0subunidad \u00a0es\u00a0responsable \u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0del\u00a0segundo\u00a0mensajero \u00a0adenilil\u00a0ciclasa\u00a0\n(AC),\u00a0que\u00a0cataliza\u00a0la\u00a0conversi\u00f3n \u00a0del\u00a0ATP\u00a0\ncitoplasm\u00e1tico \u00a0en\u00a0adenos\u00edn\u00a0monofosfato \u00a0c\u00edclico\u00a0\n(AMPc)\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0v\u00eda\u00a0que\u00a0activa\u00a0la\u00a0prote\u00edna\u00a0Gs\u00a0\n(en\u00a0cambio,\u00a0la\u00a0inhibci\u00f3n\u00a0de\u00a0la\u00a0AC,\u00a0es\u00a0llevada\u00a0a\u00a0cabo\u00a0\npor\u00a0la\u00a0prote\u00edna\u00a0Gi\u00a0sensible\u00a0a\u00a0la\u00a0toxina\u00a0pert\u00fasica \u00a0\n(PTX)\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0rata\u00a0submandibulares254).\u00a0\nOtros\u00a0estudios\u00a0han\u00a0descrito\u00a0que\u00a0esta\u00a0subunidad \u00a0Gs\u00a0\nes\u00a0sustrato\u00a0de\u00a0la\u00a0toxina\u00a0col\u00e9rica\u00a0(CTX)\u00a0producida \u00a0\npor\u00a0Vibrio\u00a0cholerae, \u00a0que\u00a0las\u00a0ribosila\u00a0con\u00a0ADP\u00a0e\u00a0\ninhibe\u00a0su\u00a0actividad\u00a0GTPasa\u00a0intr\u00ednseca252.\u00a0Por\u00a0lo\u00a0\ngeneral\u00a0se\u00a0cree\u00a0que\u00a0este\u00a0proceso\u00a0de\u00a0aumentar \u00a0el\u00a0\nAMPc\u00a0da\u00a0lugar\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nquinasa\u00a0A\u00a0(PKA).\u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PKA\u00a0fosforila\u00a0\nel\u00a0factor\u00a0de\u00a0trancripci\u00f3n \u00a0CREB\u00a0(del\u00a0ingl\u00e9s,\u00a0cAMP\u2010\nresponsive \u00a0element\u00a0CRE\u2010binding\u00a0protein ).\u00a0CREB\u00a0se\u00a0\nune\u00a0al\u00a0elemento \u00a0de\u00a0respuesta \u00a0a\u00a0cAMP\u00a0(CRE)\u00a0de\u00a0un\u00a0\ngen\u00a0diana\u00a0y\u00a0afecta\u00a0negativamente \u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0\nde\u00a0NF\u2010\u03baB256.\u00a0Sin\u00a0embargo, \u00a0pese\u00a0a\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0Gs\u00a0la\u00a0\npotencia\u00a0por\u00a0los\u00a0agonistas \u00a0de\u00a0NK\u20101R\u00a0en\u00a0generar\u00a0\nacumulaci\u00f3n \u00a0de\u00a0AMPc\u00a0es\u00a0menor\u00a0si\u00a0la\u00a0comparamos \u00a0\ncon\u00a0la\u00a0habilidad \u00a0de\u00a0inducir\u00a0IP3\u00a0y\u00a0calcio\u00a0intracelular \u00a0\nde\u00a0Gq/11\u00a0253.\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n54\u00a0\n\u00a0\u2010Gi:\u00a0La\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0miembros \u00a0de\u00a0esta\u00a0clase\u00a0es\u00a0\nmediar\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0varios\u00a0tipos\u00a0de\u00a0AC.\u00a0Se\u00a0\npueden\u00a0estudiar\u00a0sus\u00a0funciones \u00a0mediante \u00a0el\u00a0uso\u00a0de\u00a0\nla\u00a0PTX,\u00a0producida \u00a0por\u00a0Bordetella \u00a0pertussis. \u00a0A\u00a0\ndiferencia \u00a0de\u00a0la\u00a0CTX,\u00a0la\u00a0PTX\u00a0desacopla \u00a0la\u00a0prote\u00edna\u00a0\nG\u00a0de\u00a0su\u00a0receptor\u00a0y\u00a0la\u00a0mantiene \u00a0en\u00a0su\u00a0estado\u00a0\ninactivo\u00a0unida\u00a0a\u00a0GDP\u00a0257.\u00a0\n\u2010G12/13\u00a0:\u00a0Esta\u00a0subunidad \u00a0est\u00e1\u00a0expresada \u00a0de\u00a0manera\u00a0\nubicua\u00a0en\u00a0mam\u00edferos \u00a0y\u00a0est\u00e1\u00a0compuesta \u00a0por\u00a0s\u00f3lo\u00a0\ndos\u00a0prote\u00ednas, \u00a0G\u03b112\u00a0y\u00a0G\u03b113,\u00a0tambi\u00e9n\u00a0resistentes \u00a0a\u00a0\nlas\u00a0toxinas252.\u00a0Meshki\u00a0describi\u00f3\u00a0que\u00a0la\u00a0subunidad \u00a0\nG12/13\u00a0pod\u00eda\u00a0regular\u00a0los\u00a0cambios\u00a0en\u00a0la\u00a0reordenaci\u00f3n \u00a0\ndel\u00a0citoesqueleto \u00a0cuando\u00a0la\u00a0c\u00e9lula\u00a0se\u00a0preparaba \u00a0\npara\u00a0migrar.\u00a0Estos\u00a0cambios\u00a0depend\u00edan \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Rho/Rock \u00a0que\u00a0directamente \u00a0regulan\u00a0\nla\u00a0cadena\u00a0ligera\u00a0reguladora \u00a0de\u00a0la\u00a0miosina\u00a0(MLC,\u00a0\ndel\u00a0ingl\u00e9s\u00a0myosin\u00a0regulatory \u00a0light\u00a0chain ).\u00a0La\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0esta\u00a0prote\u00edna\u00a0est\u00e1\u00a0asociada\u00a0con\u00a0la\u00a0\nformaci\u00f3n \u00a0de\u00a0peque\u00f1as \u00a0evaginaciones \u00a0esf\u00e9ricas\u00a0\nsurgidas\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0membrana \u00a0conocidas \u00a0como\u00a0\nburbujas\u00a0o\u00a0\u201cblebs\u201d ,\u00a0proceso\u00a0conocido\u00a0como\u00a0\n\u201dblebbing\u201d \u00a0en\u00a0ingl\u00e9s.\u00a0Este\u00a0proceso\u00a0no\u00a0siempre\u00a0est\u00e1\u00a0\nrelacionado \u00a0con\u00a0la\u00a0apoptosis \u00a0sino\u00a0tambi\u00e9n\u00a0con\u00a0la\u00a0\ndesestructuraci\u00f3n \u00a0citoplasm\u00e1tica \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0la\u00a0\nmigraci\u00f3n \u00a0celular\u00a0y\u00a0en\u00a0este\u00a0estudio\u00a0demostraron \u00a0\ncomo\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0ten\u00eda\u00a0la\u00a0habilidad \u00a0de\u00a0\ninteraccionar \u00a0con\u00a0la\u00a0prote\u00edna\u00a0G12/13\u00a0durante\u00a0todo\u00a0\neste\u00a0proceso258.\u00a0Tabla\u00a011.\u00a0Composici\u00f3n \u00a0heterotrim\u00e9rica \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0G.\u00a0\n\u00a0\nISOFORMAS \u00a0 EFECTORES \u00a0\nFam \u00edlia\u00a0de\u00a0las\u00a0subunidades \u00a0G\u03b1\u00a0\u00a0\nG\u03b1i1\u00a0 Inhibe\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1i2\u00a0 Inhibe\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1i3\u00a0 Inhibe\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1oA,B\u00a0 Inhibe\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1z\u00a0 Inhibe\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1t1\u00a0 Activa\u00a0PDE\u00a0(vista\u2010barras)\u00a0\nG\u03b1t2\u00a0 Activa\u00a0PDE\u00a0(vista\u2010conos)\u00a0\nG\u03b1gust\u00a0 Activa\u00a0PDE\u00a0(gusto)\u00a0\nG\u03b1s\u00a0 Estimula\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1olf\u00a0 Estimula\u00a0adenilil\u00a0ciclasas\u00a0(olfativos) \u00a0\nG\u03b1sXL\u00a0 Estimula\u00a0adenilil\u00a0ciclasas\u00a0\nG\u03b1q\u00a0 Estimula\u00a0PLC\u03b2\u00a0\nG\u03b111\u00a0 Estimula\u00a0PLC\u03b2\u00a0\nG\u03b114\u201316\u00a0 Estimula\u00a0PLC\u03b2\u00a0\nG\u03b112\u00a0 Estimula\u00a0factores\u00a0Rho\u00a0\nG\u03b113\u00a0 Estimula\u00a0factores\u00a0Rho\u00a0\nSubunidades \u00a0G\u03b2\u00a0y\u00a0G\u03b3\u00a0 \u00a0\nG\u03b21\u20135\u00a0Inhibe\u00a0adenilil\u00a0ciclasas,\u00a0estimula\u00a0Ca2+\u00a0y\u00a0canales\u00a0de\u00a0K+\u00a0,\u00a0estimula\u00a0la\u00a0actividad\u00a0\nde\u00a0PI3K\u00a0y\u00a0de\u00a0Src,\u00a0recluta\u00a0GRK2\u00a0y\u00a0estimula\u00a0PLC\u03b2\u00a0\nG\u03b31\u201312\u00a0Inhibe\u00a0adenilil\u00a0ciclasas,\u00a0estimula\u00a0Ca2+\u00a0y\u00a0canales\u00a0de\u00a0K+\u00a0,\u00a0estimula\u00a0la\u00a0actividad\u00a0\nde\u00a0PI3K\u00a0y\u00a0de\u00a0Src,\u00a0recluta\u00a0GRK2\u00a0y\u00a0estimula\u00a0PLC\u03b2\u00a0\nPDE,\u00a0fosfodiesterasa; \u00a0PI3K,\u00a0fosfatidilinositol \u00a03\u2010quinasa\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n55\u00a0\n\u00a0\u2010Go:\u00a0Nishimura \u00a0proporcion\u00f3 \u00a0la\u00a0primera\u00a0evidencia \u00a0\ndel\u00a0potencial \u00a0de\u00a0NK\u20101R\u00a0para\u00a0activar\u00a0Go\u00a0en\u00a0c\u00e9lulas\u00a0\nSf9259.\u00a0Esta\u00a0subunidad \u00a0se\u00f1aliza\u00a0corriente\u00a0abajo\u00a0de\u00a0\nlos\u00a0GPCR\u00a0Frizzled\u00a0(Fz).\u00a0Para\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0estos\u00a0\nreceptores \u00a0Go\u00a0es\u00a0crucial\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0\nde\u00a0la\u00a0Wnt\u2010\u03b2\u2010catenina252.\u00a0En\u00a0el\u00a0caso\u00a0del\u00a0sistema\u00a0\nnervioso\u00a0sus\u00a0efectos\u00a0parecen\u00a0estar\u00a0mediados \u00a0\nprincipalmente \u00a0por\u00a0esta\u00a0subunidad252.\u00a0\nPor\u00a0otro\u00a0lado\u00a0la\u00a0subunidad \u00a0G\u03b2\u03b3\u00a0ha\u00a0sido\u00a0menos\u00a0\nestudiada \u00a0que\u00a0la\u00a0subunidad \u00a0G\u03b1.\u00a0El\u00a0complejo \u00a0\u03b2\u03b3\u00a0\npuede\u00a0estar\u00a0formado\u00a0por\u00a05\u00a0subunidades \u00a0\u03b2 \u00a0\ndistintas\u00a0y\u00a012\u00a0subunidades \u00a0\u03b3252.\u00a0En\u00a0un\u00a0principio\u00a0se\u00a0\npensaba\u00a0que\u00a0su\u00a0funci\u00f3n\u00a0era\u00a0meramente \u00a0pasiva\u00a0\npero\u00a0posteriormente \u00a0se\u00a0encontr\u00f3\u00a0que\u00a0formaba\u00a0\nparte\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0efectores \u00a0como\u00a0la\u00a0PLC\u03b2,\u00a0\nadenilil\u00a0ciclasas,\u00a0PI3K,\u00a0canales\u00a0i\u00f3nicos\u00a0de\u00a0K+\u00a0y\u00a0Src.\u00a0\u00a0\nA\u00a0partir\u00a0de\u00a0todas\u00a0estas\u00a0asociaciones \u00a0entre\u00a0las\u00a0\nprote\u00ednas \u00a0trim\u00e9ricas \u00a0y\u00a0sus\u00a0segundos \u00a0mensajeros \u00a0\ntiene\u00a0lugar\u00a0una\u00a0cascada\u00a0de\u00a0eventos\u00a0intracelulares \u00a0\nque\u00a0provocaran \u00a0una\u00a0u\u00a0otra\u00a0respuesta \u00a0\ndependiendo \u00a0del\u00a0tipo\u00a0celular.\u00a0\u00a0\nLos\u00a0GPCRs\u00a0constituyen \u00a0una\u00a0gran\u00a0familia\u00a0de\u00a0\nreceptores \u00a0de\u00a0superficie \u00a0celular\u00a0que\u00a0regulan\u00a0\nmuchas\u00a0funciones \u00a0celulares, \u00a0incluyendo \u00a0la\u00a0\nproliferaci\u00f3n \u00a0celular,\u00a0la\u00a0supervivencia \u00a0y\u00a0la\u00a0\nmotilidad, \u00a0y\u00a0recientemente \u00a0han\u00a0surgido\u00a0como\u00a0\nrecepores \u00a0clave\u00a0en\u00a0el\u00a0crecimiento \u00a0tumoral,\u00a0la\u00a0\nangiog\u00e9nesis \u00a0y\u00a0la\u00a0met\u00e1stasis. \u00a0Aunque\u00a0algunos\u00a0\ntumores\u00a0endocrinos \u00a0surgen\u00a0de\u00a0formas\u00a0mutantes \u00a0\nde\u00a0GPCRs\u00a0constitutivamente \u00a0activas,\u00a0la\u00a0sobre\u2010\nexpresi\u00f3n \u00a0aberrante \u00a0de\u00a0GPCRs\u00a0y\u00a0su\u00a0activaci\u00f3n \u00a0\nautocrina \u00a0y\u00a0paracrina \u00a0(mediante \u00a0agonistas \u00a0\nliberados \u00a0por\u00a0el\u00a0tumor\u00a0o\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0estroma)\u00a0\nrepresenta \u00a0la\u00a0t\u00e1ctica\u00a0m\u00e1s\u00a0frecuente \u00a0utilizada\u00a0por\u00a0\nlas\u00a0c\u00e9lulas\u00a0del\u00a0c\u00e1ncer\u00a0para\u00a0estimular \u00a0GPCRs\u00a0y\u00a0sus\u00a0\nredes\u00a0de\u00a0se\u00f1alizaci\u00f3n. \u00a0Concretamente \u00a0las\u00a0\ninteracciones \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0prote\u00edna\u00a0Gq/11\u00a0(la\u00a0\nprote\u00edna\u00a0del\u00a0receptor\u00a0NK\u20101)\u00a0ocurre\u00a0en\u00a0varios\u00a0\nsistemas\u00a0como\u00a0en\u00a0la\u00a0secreci\u00f3n \u00a0endocrina, \u00a0la\u00a0\nvasodilataci\u00f3n, \u00a0 modulaci\u00f3n \u00a0 neuroinmune, \u00a0\nactivaci\u00f3n \u00a0de\u00a0monocitos \u00a0y\u00a0como\u00a0no,\u00a0en\u00a0la\u00a0\nproliferaci\u00f3n \u00a0celular185,187,255,260,261.\u00a0Por\u00a0este\u00a0motivo\u00a0\ndurante\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0varias\u00a0evidenicas \u00a0\nexperimentales \u00a0avalan\u00a0la\u00a0idea\u00a0que\u00a0alteraciones \u00a0en\u00a0\nel\u00a0sistema\u00a0endocrino \u00a0regulado\u00a0por\u00a0la\u00a0SP\u00a0y\u00a0NK\u20101R\u00a0contribuyen \u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0diversas\u00a0patolog\u00edas \u00a0\nasociadas \u00a0al\u00a0c\u00e1ncer.\u00a0\u00a0\nUna\u00a0vez\u00a0introducidas \u00a0las\u00a0funciones \u00a0y\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0las\u00a0taquiquininas \u00a0y\u00a0sus\u00a0receptores \u00a0\ny\u00a0c\u00f3mo\u00a0influyen\u00a0en\u00a0una\u00a0situaci\u00f3n\u00a0de\u00a0inflamaci\u00f3n, \u00a0\nen\u00a0el\u00a0pr\u00f3ximo\u00a0punto\u00a0se\u00a0detallar\u00e1\u00a0qu\u00e9\u00a0relaci\u00f3n\u00a0\nexiste\u00a0entre\u00a0estos\u00a0neurop\u00e9ptidos \u00a0o\u00a0citoquinas \u00a0pro\u2010\ninflamatorias \u00a0y\u00a0el\u00a0c\u00e1ncer.\u00a0\n6.\u00a0SISTEMA\u00a0TAQUIQUIN\u00c9RGICO: \u00a0\nPAPEL\u00a0QUE\u00a0JUEGA\u00a0EN\u00a0EL\u00a0\nC\u00c1NCER\u00a0\n\u00a0\nEl\u00a0papel\u00a0que\u00a0juegan\u00a0las\u00a0taquiquininas \u00a0y\u00a0sus\u00a0\nreceptores \u00a0en\u00a0c\u00e1ncer\u00a0resulta\u00a0en\u00a0base\u00a0a\u00a0toda\u00a0la\u00a0\ninformaci\u00f3n \u00a0aportada\u00a0hasta\u00a0ahora.\u00a0La\u00a0SP\u00a0y\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0se\u00a0encuentran \u00a0ampliamente \u00a0\nexpresados \u00a0en\u00a0el\u00a0sistema\u00a0nervioso\u00a0central\u00a0y\u00a0en\u00a0\ntejidos\u00a0perif\u00e9ricos, \u00a0sobre\u00a0todo\u00a0en\u00a0las\u00a0\nterminaciones \u00a0de\u00a0las\u00a0neuronas \u00a0aferentes \u00a0donde\u00a0\nact\u00faa\u00a0como\u00a0neurotransmisor. \u00a0Sabemos\u00a0tambi\u00e9n\u00a0\nque\u00a0la\u00a0SP\u00a0no\u00a0proviene\u00a0\u00fanicamente \u00a0del\u00a0sistema\u00a0\nnervioso, \u00a0sino\u00a0que\u00a0adem\u00e1s\u00a0otros\u00a0tipos\u00a0celulares\u00a0\ncomo\u00a0c\u00e9lulas\u00a0enteroendocrinas, \u00a0c\u00e9lulas\u00a0epiteliales \u00a0\nde\u00a0la\u00a0mucosa\u00a0y\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmunitario \u00a0\nsecretan\u00a0SP.\u00a0Tambi\u00e9n\u00a0c\u00e9lulas\u00a0endoteliales \u00a0pueden\u00a0\nproveer\u00a0a\u00a0los\u00a0tejidos\u00a0de\u00a0SP.\u00a0De\u00a0hecho\u00a0la\u00a0expresi\u00f3n \u00a0\nde\u00a0NK\u20101R\u00a0en\u00a0c\u00e9lulas\u00a0endotelilaes \u00a0controlar\u00eda \u00a0el\u00a0\ntr\u00e1fico\u00a0de\u00a0leucocitos \u00a0y\u00a0la\u00a0aniog\u00e9nesis \u00a0(ya\u00a0que\u00a0se\u00a0ha\u00a0\nlocalizado \u00a0esta\u00a0taquiquinina \u00a0en\u00a0arterias,\u00a0arteriolas, \u00a0\ncapilares\u00a0y\u00a0v\u00e9nulas\u00a0post\u2010capilares)235,262.\u00a0Mediante \u00a0\nIHQ\u00a0se\u00a0ha\u00a0identificado \u00a0una\u00a0alta\u00a0y\u00a0consistente \u00a0\nexpresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0en\u00a0vasos\u00a0sangu\u00edneos \u00a0\ntumorales \u00a0y\u00a0peritumorales \u00a0en\u00a0varios\u00a0tipos\u00a0de\u00a0\ntumores230,263\u2010266.\u00a0En\u00a0conjunto\u00a0tenemos\u00a0m\u00faltiples \u00a0\nor\u00edgenes\u00a0como\u00a0fuente\u00a0inagotable \u00a0de\u00a0prote\u00edna\u00a0que\u00a0\nutilizan\u00a0a\u00a0su\u00a0favor\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0(al\u00a0igual\u00a0\nque\u00a0otros\u00a0tipos\u00a0celulares\u00a0nombrados \u00a0\nanteriormente) \u00a0para\u00a0proliferar \u00a0y\u00a0hacer\u00a0que\u00a0el\u00a0\ntumor\u00a0progrese. \u00a0Diversos\u00a0estudios\u00a0in\u00a0vitro\u00a0han\u00a0\ndescrito\u00a0que\u00a0la\u00a0SP\u00a0estimula\u00a0el\u00a0crecimiento \u00a0de\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0y\u00a0se\u00a0han\u00a0sugerido\u00a0nuevos\u00a0\nmecanismos \u00a0por\u00a0los\u00a0cuales\u00a0esta\u00a0taquiquinina \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n56\u00a0\n\u00a0puede\u00a0activar\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0cuando\u00a0\nproviene\u00a0del\u00a0sistema\u00a0inmunitario, \u00a0de\u00a0los\u00a0nervios\u00a0\nsensoriales \u00a0y\u00a0del\u00a0sistema\u00a0vascular.\u00a0\u00a0\n\u00a0\n1)\u00a0En\u00a0relaci\u00f3n\u00a0al\u00a0sistema\u00a0inmunitario \u00a0y\u00a0el\u00a0c\u00e1ncer :\u00a0\nSe\u00a0ha\u00a0descrito\u00a0una\u00a0estrecha\u00a0relaci\u00f3n\u00a0entre\u00a0\nenfermedades \u00a0inflamatorias \u00a0del\u00a0intestino\u00a0y\u00a0la\u00a0\nexpresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0y\u00a0se\u00a0ha\u00a0relacionado \u00a0\neste\u00a0v\u00ednculo\u00a0con\u00a0una\u00a0posible\u00a0transformaci\u00f3n \u00a0\nmaligna\u00a0por\u00a0parte\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0Ya\u00a0se\u00a0ha\u00a0\nmencionado \u00a0previamente \u00a0que\u00a0los\u00a0pacientes \u00a0con\u00a0\ncolitis\u00a0ulcerativa \u00a0cr\u00f3nica\u00a0tienen\u00a0un\u00a0riesgo\u00a0mayor\u00a0\nde\u00a0desarrollar \u00a0c\u00e1ncer\u00a0de\u00a0colon.\u00a0En\u00a0otro\u00a0estudio\u00a0del\u00a0\nmismo\u00a0grupo\u00a0Gillespie\u00a0y\u00a0Leeman,\u00a0realizando \u00a0micro\u00a0\ndisecci\u00f3n \u00a0con\u00a0l\u00e1ser\u00a0microsc\u00f3pico \u00a0de\u00a0tejido\u00a0\nparafinado, \u00a0compararon \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0las\u00a0dos\u00a0\nisoformas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0(completa \u00a0y\u00a0truncada) \u00a0\nen\u00a0tejidos\u00a0que\u00a0hab\u00edan\u00a0desarrollado \u00a0c\u00e1ncer\u00a0de\u00a0\ncolon\u00a0o\u00a0displasia\u00a0de\u00a0alto\u00a0grado\u00a0con\u00a0epitelio\u00a0que\u00a0no\u00a0\npresentaba \u00a0ning\u00fan\u00a0tipo\u00a0de\u00a0displasia\u00a0ni\u00a0c\u00e1ncer\u00a0pero\u00a0\nsi\u00a0evidencias \u00a0de\u00a0inflamaci\u00f3n \u00a0(colitis\u00a0quiescente). \u00a0\nSolamente \u00a0la\u00a0isoforma\u00a0truncada\u00a0estaba\u00a0\nincrementada \u00a0un\u00a080%\u00a0en\u00a0muestras \u00a0de\u00a0c\u00e1ncer\u00a0y\u00a0un\u00a0\n40%\u00a0en\u00a0muestras \u00a0con\u00a0displasia\u00a0de\u00a0alto\u00a0grado\u00a0si\u00a0las\u00a0\ncomparaban \u00a0con\u00a0la\u00a0colitis\u00a0quiescente, \u00a0por\u00a0tanto\u00a0el\u00a0\nreceptor\u00a0truncado\u00a0de\u00a0NK\u20101\u00a0parec\u00eda\u00a0jugar\u00a0un\u00a0papel\u00a0\nfuncional \u00a0en\u00a0la\u00a0transformaci\u00f3n \u00a0maligna\u00a0de\u00a0la\u00a0\ncolitis\u00a0ulcerosa\u00a0hacia\u00a0el\u00a0c\u00e1ncer\u00a0de\u00a0colon267.\u00a0\n\u00a02)\u00a0En\u00a0relaci\u00f3n\u00a0al\u00a0sistema\u00a0nervioso\u00a0y\u00a0el\u00a0c\u00e1ncer :\u00a0Es\u00a0\nconocida\u00a0la\u00a0habilidad\u00a0de\u00a0la\u00a0SP\u00a0(que\u00a0proviene\u00a0del\u00a0\nsistema\u00a0nervioso) \u00a0de\u00a0modular\u00a0a\u00a0las\u00a0propias\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmunitario \u00a0induciendo \u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0que\u00a0participan \u00a0en\u00a0el\u00a0\nproceso\u00a0de\u00a0defensa\u00a0inmune.\u00a0De\u00a0hecho\u00a0existe\u00a0una\u00a0\nalta\u00a0incidencia \u00a0de\u00a0recurrencia \u00a0de\u00a0tumoraci\u00f3n \u00a0\ndespu\u00e9s\u00a0de\u00a0cirug\u00edas\u00a0debido\u00a0a\u00a0un\u00a0posible\u00a0estado\u00a0de\u00a0\ninmunosupresi\u00f3n. \u00a0Alrededor \u00a0de\u00a0la\u00a0herida\u00a0de\u00a0\ncirug\u00eda\u00a0es\u00a0probable\u00a0que\u00a0se\u00a0creen\u00a0eritemas\u00a0y\u00a0\nedemas\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0compuestos, \u00a0\nincluidos\u00a0la\u00a0SP193,268,\u00a0ya\u00a0que\u00a0la\u00a0SP\u00a0es\u00a0un\u00a0potente\u00a0\nvasodilatador. \u00a0Ademas,\u00a0las\u00a0terminales \u00a0nerviosas \u00a0\nque\u00a0liberan\u00a0SP\u00a0se\u00a0encuentran \u00a0cerca\u00a0de\u00a0los\u00a0vasos\u00a0\nsangu\u00edneos. \u00a0La\u00a0liberaci\u00f3n \u00a0de\u00a0esta\u00a0citoquina \u00a0puede\u00a0\nproducir\u00a0muchos\u00a0cambios\u00a0fisiol\u00f3gicos \u00a0que\u00a0se\u00a0observan \u00a0durante\u00a0la\u00a0inflamaci\u00f3n \u00a0aguda.\u00a0\nConcretamente \u00a0la\u00a0SP\u00a0interviene \u00a0en\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0como\u00a0la\u00a0IL\u20106\u00a0y\u00a0la\u00a0IL\u20108\u00a0\na\u00a0nivel\u00a0sist\u00e9mico \u00a0y\u00a0otros\u00a0factores\u00a0que\u00a0intervienen \u00a0\nen\u00a0la\u00a0inmunidad \u00a0celular\u00a0observada \u00a0despu\u00e9s\u00a0de\u00a0la\u00a0\ncirug\u00eda235,269.\u00a0Sin\u00a0embargo\u00a0no\u00a0solo\u00a0la\u00a0cirug\u00eda\u00a0\ninterviene \u00a0en\u00a0esta\u00a0respuesta \u00a0si\u00a0no\u00a0que\u00a0tambi\u00e9n\u00a0\ncon\u00a0el\u00a0estr\u00e9s\u00a0y\u00a0la\u00a0ansiedad\u00a0que\u00a0provoca\u00a0una\u00a0\noperaci\u00f3n \u00a0o\u00a0cualquier \u00a0otra\u00a0situaci\u00f3n\u00a0relacionada \u00a0\ncon\u00a0el\u00a0estr\u00e9s,\u00a0se\u00a0liberan\u00a0neurop\u00e9ptidos \u00a0como\u00a0la\u00a0SP\u00a0\ny\u00a0la\u00a0magnitud \u00a0de\u00a0su\u00a0liberaci\u00f3n \u00a0es\u00a0proporcional \u00a0a\u00a0la\u00a0\nintensidad \u00a0y\u00a0frecuencia \u00a0de\u00a0estimulaci\u00f3n270.\u00a0De\u00a0\nhecho\u00a0hay\u00a0estudios\u00a0que\u00a0revelan\u00a0que\u00a0la\u00a0interacci\u00f3n \u00a0\nSP/NK\u20101R\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0la\u00a0\nregulaci\u00f3n \u00a0de\u00a0la\u00a0conducta \u00a0afectiva270.\u00a0Hay\u00a0varias\u00a0\nrevisiones \u00a0que\u00a0recogen\u00a0distintos\u00a0experimentos \u00a0\nque\u00a0relacionan \u00a0el\u00a0comportamiento \u00a0emocional \u00a0\n(sistema\u00a0l\u00edmbico)\u00a0y\u00a0el\u00a0c\u00e1ncer245,271,272.\u00a0Hay\u00a0\nevidencias \u00a0que\u00a0demuestran \u00a0que\u00a0la\u00a0ayuda\u00a0\npsicosocial \u00a0reduce\u00a0la\u00a0depresi\u00f3n, \u00a0la\u00a0ansiedad\u00a0y\u00a0el\u00a0\ndolor\u00a0y\u00a0sobretodo \u00a0que\u00a0puede\u00a0aumentar \u00a0el\u00a0tiempo\u00a0\nde\u00a0supervivencia \u00a0de\u00a0algunos\u00a0pacientes \u00a0con\u00a0c\u00e1ncer.\u00a0\nDe\u00a0hecho\u00a0diversas\u00a0formas\u00a0de\u00a0estr\u00e9s\u00a0est\u00e1n\u00a0\nasociadas \u00a0con\u00a0tumorog\u00e9nesis \u00a0mamaria. \u00a0Esta\u00a0\ncapacidad \u00a0de\u00a0lidiar\u00a0con\u00a0el\u00a0estr\u00e9s\u00a0es\u00a0de\u00a0alguna\u00a0\nforma\u00a0el\u00a0factor\u00a0que\u00a0influye\u00a0en\u00a0el\u00a0crecimiento \u00a0del\u00a0\ntumor\u00a0mamario273,274.\u00a0Concretamente \u00a0el\u00a0receptor\u00a0\nNK\u20101\u00a0y\u00a0la\u00a0SP\u00a0est\u00e1n\u00a0involucrados \u00a0en\u00a0las\u00a0respuestas \u00a0\nemocionales \u00a0del\u00a0estr\u00e9s,\u00a0lo\u00a0que\u00a0sugiere\u00a0que\u00a0una\u00a0\nalteraci\u00f3n \u00a0en\u00a0el\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0podr\u00eda\u00a0ser\u00a0\nclave\u00a0para\u00a0el\u00a0desencadenamiento \u00a0de\u00a0una\u00a0\npatog\u00e9nesis \u00a0como\u00a0la\u00a0depresi\u00f3n \u00a0(est\u00e1\u00a0demostrado \u00a0\nque\u00a0existe\u00a0un\u00a0incremento \u00a0en\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0SP\u00a0\ndurante\u00a0la\u00a0depresi\u00f3n)275.\u00a0Incluso\u00a0se\u00a0ha\u00a0\ndocumentado \u00a0que\u00a0f\u00e1rmacos \u00a0psicotr\u00f3picos \u00a0\nmodifican \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0genes\u00a0que\u00a0codifican\u00a0\nla\u00a0s\u00edntesis\u00a0de\u00a0taquiquininas \u00a0en\u00a0algunas\u00a0zonas\u00a0del\u00a0\ncerebro\u00a0de\u00a0ratas276,277.\u00a0Estos\u00a0hallazgos\u00a0sugieren\u00a0\nque\u00a0una\u00a0reducci\u00f3n \u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0SP\u00a0en\u00a0ciertas\u00a0\nregiones\u00a0del\u00a0cerebro\u00a0podr\u00eda\u00a0contribuir \u00a0a\u00a0un\u00a0efecto\u00a0\nterap\u00e9utico \u00a0com\u00fan\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0antidepresivos \u00a0\nen\u00a0trastornos \u00a0afectivos\u00a0y\u00a0en\u00a0los\u00a0relacionados \u00a0con\u00a0\nel\u00a0c\u00e1ncer.\u00a0\u00a0\nEn\u00a0una\u00a0revisi\u00f3n\u00a0muy\u00a0interesante \u00a0de\u00a0Steven\u00a0Maier\u00a0\ny\u00a0Linda\u00a0Watkins\u00a0tambi\u00e9n\u00a0se\u00a0relaciona\u00a0el\u00a0sistema\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n57\u00a0\n\u00a0inmune,\u00a0el\u00a0sistema\u00a0nervioso\u00a0central\u00a0y\u00a0la\u00a0mediaci\u00f3n \u00a0\nde\u00a0ambos\u00a0con\u00a0el\u00a0c\u00e1ncer.\u00a0Durante\u00a0el\u00a0c\u00e1ncer\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0glia\u00a0en\u00a0el\u00a0sistema\u00a0nervioso\u00a0central\u00a0\nproduce\u00a0una\u00a0respuesta \u00a0a\u00a0esta\u00a0enfermedad \u00a0con\u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010inflamatorias. \u00a0La\u00a0\nactivaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune\u00a0inicia\u00a0una\u00a0\ncomunicaci\u00f3n \u00a0con\u00a0el\u00a0cerebro\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0torrente\u00a0\nsangu\u00edneo \u00a0y\u00a0de\u00a0comunicaciones \u00a0neuronales \u00a0\nmediadas \u00a0por\u00a0esas\u00a0citoquinas, \u00a0alterando \u00a0la\u00a0\nactividad\u00a0neuronal. \u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0esta\u00a0v\u00eda\u00a0desde\u00a0\nel\u00a0sistema\u00a0inmune\u00a0hacia\u00a0el\u00a0sistema\u00a0nervioso\u00a0\ncentral,\u00a0con\u00a0la\u00a0consiguiente \u00a0producci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0en\u00a0el\u00a0sistema\u00a0nervioso\u00a0central,\u00a0pueden\u00a0\nestar\u00a0implicados \u00a0en\u00a0la\u00a0mediaci\u00f3n \u00a0de\u00a0una\u00a0serie\u00a0de\u00a0\nfen\u00f3menos \u00a0que\u00a0ocurren\u00a0durante\u00a0el\u00a0c\u00e1ncer.\u00a0\nAlteraciones \u00a0en\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0las\u00a0taquiquininas \u00a0\n(tanto\u00a0en\u00a0el\u00a0cerebro\u00a0como\u00a0en\u00a0la\u00a0periferia) \u00a0podr\u00eda\u00a0\nser\u00a0una\u00a0de\u00a0las\u00a0causas\u00a0del\u00a0\u201csickness\u00a0sindrome \u201d\u00a0\ndesarrollado \u00a0en\u00a0pacientes \u00a0con\u00a0c\u00e1ncer278.\u00a0\nUn\u00a0trabajo\u00a0curioso\u00a0publicado \u00a0por\u00a0un\u00a0\ndepartamento \u00a0 m\u00e9dico\u00a0 especialista \u00a0 en\u00a0\nanestesiolog\u00eda \u00a0se\u00a0pregunt\u00f3 \u00a0si\u00a0la\u00a0t\u00e9cnica\u00a0de\u00a0\nanest\u00e9sica \u00a0utilizada\u00a0para\u00a0la\u00a0cirug\u00eda\u00a0de\u00a0tumores\u00a0\nprimarios \u00a0de\u00a0mama\u00a0afectaba\u00a0a\u00a0la\u00a0recurrencia \u00a0o\u00a0\nmet\u00e1stasis \u00a0de\u00a0estas\u00a0pacientes. \u00a0Observaron \u00a0que\u00a0el\u00a0\nriesgo\u00a0de\u00a0recurrencia \u00a0o\u00a0met\u00e1stasis \u00a0en\u00a0pacientes \u00a0de\u00a0\nCM\u00a0se\u00a0reduc\u00eda\u00a0hasta\u00a0casi\u00a0cuatro\u00a0veces\u00a0(durante\u00a0los\u00a0\n2\u00a0o\u00a03\u00a0a\u00f1os\u00a0posteriores \u00a0de\u00a0seguimiento) \u00a0al\u00a0utilizar\u00a0\nanestesia \u00a0paravertebral \u00a0junto\u00a0con\u00a0analgesia \u00a0\ndurante\u00a0su\u00a0intervenci\u00f3n \u00a0quir\u00fargica, \u00a0si\u00a0las\u00a0\ncomparaban \u00a0con\u00a0las\u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0anestesia \u00a0\ngeneral\u00a0y\u00a0m\u00f3rficos. \u00a0En\u00a0resumen, \u00a0los\u00a0autores\u00a0\nsupusieron \u00a0que\u00a0la\u00a0anestesia \u00a0y\u00a0analgesia \u00a0regional\u00a0\npod\u00eda\u00a0ayudar\u00a0a\u00a0preservar \u00a0la\u00a0funci\u00f3n\u00a0inmunol\u00f3gica \u00a0\nmediante \u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0respuesta \u00a0al\u00a0estr\u00e9s\u00a0\nquir\u00fargico \u00a0y\u00a0disminuyendo \u00a0as\u00ed\u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0\nopioides.\u00a0En\u00a0relaci\u00f3n\u00a0a\u00a0este\u00a0estudio,\u00a0tambi\u00e9n\u00a0se\u00a0\npropuso\u00a0que\u00a0el\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0podr\u00eda\u00a0\ntener\u00a0relaci\u00f3n\u00a0en\u00a0esa\u00a0observaci\u00f3n \u00a0hecha\u00a0por\u00a0los\u00a0\nanestesi\u00f3lgos279.\u00a0Pod\u00eda\u00a0ser\u00a0que\u00a0esto\u00a0ocurriera\u00a0si\u00a0la\u00a0\nanestesia \u00a0paravertebral \u00a0estuviera \u00a0disminuyendo \u00a0la\u00a0\ntransmisi\u00f3n \u00a0del\u00a0dolor\u00a0mediada\u00a0por\u00a0la\u00a0SP\u00a0y\u00a0la\u00a0\ninflamaci\u00f3n \u00a0neurog\u00e9nica \u00a0bloqueando \u00a0de\u00a0esta\u00a0\nforma\u00a0una\u00a0posible\u00a0inducci\u00f3n \u00a0de\u00a0la\u00a0migraci\u00f3n, \u00a0invasi\u00f3n\u00a0y\u00a0met\u00e1st\u00e1stasis \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nmedidadas \u00a0por\u00a0la\u00a0SP279.\u00a0\n\u00a0\n3)\u00a0En\u00a0relaci\u00f3n\u00a0al\u00a0sistema\u00a0vascular\u00a0y\u00a0el\u00a0c\u00e1ncer :\u00a0La\u00a0\nSP\u00a0(a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101)\u00a0es\u00a0capaz\u00a0de\u00a0\ninfluenciar \u00a0la\u00a0estructura \u00a0vascular,\u00a0ya\u00a0que\u00a0aumenta\u00a0\nla\u00a0extravasaci\u00f3n \u00a0de\u00a0los\u00a0vasos\u00a0que\u00a0rodean\u00a0el\u00a0tumor\u00a0\ny\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0\nlinfocitos, \u00a0granulocitos \u00a0y\u00a0monocitos \u00a0desde\u00a0el\u00a0\ntorrente\u00a0sangu\u00edneo \u00a0hacia\u00a0las\u00a0zonas\u00a0peritumorales \u00a0\ny\u00a0tumorales. \u00a0Adem\u00e1s\u00a0de\u00a0que\u00a0esta\u00a0situaci\u00f3n\u00a0puede\u00a0\nser\u00a0beneficiosa \u00a0para\u00a0el\u00a0tumor,\u00a0le\u00a0proporcionar\u00eda \u00a0\nox\u00edgeno\u00a0y\u00a0nutrientes \u00a0suficientes \u00a0para\u00a0una\u00a0c\u00f3moda\u00a0\nexpansi\u00f3n \u00a0tumoral262,280.\u00a0En\u00a0tumores\u00a0pancre\u00e1ticos \u00a0\no\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0peque\u00f1as \u00a0an\u00e1logos\u00a0\nde\u00a0la\u00a0SP\u00a0(antagonistas \u00a0de\u00a0GPCRs\u00a0nombrados \u00a0SPA),\u00a0\ninhiben\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0y\u00a0la\u00a0angiog\u00e9nesis \u00a0\nde\u00a0estos\u00a0tumores\u00a0in\u00a0vivo281,282.\u00a0El\u00a0hecho\u00a0de\u00a0que\u00a0el\u00a0\ntumor\u00a0est\u00e9\u00a0vascularizado \u00a0no\u00a0solo\u00a0significa\u00a0que\u00a0la\u00a0\nSP\u00a0act\u00faa\u00a0como\u00a0promotora \u00a0de\u00a0la\u00a0vascularizaci\u00f3n \u00a0y\u00a0\nde\u00a0la\u00a0quimiotaxis \u00a0de\u00a0diversos\u00a0neurotransmisores \u00a0y\u00a0\ncitoquinas, \u00a0sino\u00a0que\u00a0tambi\u00e9n\u00a0favorece\u00a0la\u00a0\ndiseminaci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nlos\u00a0vasos\u00a0que\u00a0rodean\u00a0el\u00a0tumor.\u00a0En\u00a0este\u00a0sentido\u00a0se\u00a0\nha\u00a0descrito\u00a0que\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nde\u00a0CM\u00a0como\u00a0las\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0de\u00a0pr\u00f3stata\u00a0como\u00a0\nlas\u00a0PC\u20103\u00a0es\u00a0inducida\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0dopamina, \u00a0\nnoradrenalina \u00a0y\u00a0SP,\u00a0y\u00a0que\u00a0este\u00a0efecto\u00a0puede\u00a0ser\u00a0\ncontrarrestado \u00a0por\u00a0inhibidores \u00a0de\u00a0receptores \u00a0\nadren\u00e9rgicos \u00a0D2\u00a0y\u00a0antagonistas \u00a0del\u00a0receptor\u00a0NK\u2010\n1283.\u00a0De\u00a0hecho\u00a0el\u00a0estudio\u00a0de\u00a0Meshki\u00a0citado\u00a0\nanteriormente \u00a0consigui\u00f3 \u00a0bloquear\u00a0los\u00a0cambios\u00a0de\u00a0\nmorfolog\u00eda \u00a0en\u00a0la\u00a0membrana \u00a0plasm\u00e1tica \u00a0o\u00a0\n\u201cblebbing \u201d\u00a0(importantes \u00a0para\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0y\u00a0la\u00a0invasi\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0cancerosas) \u00a0con\u00a0un\u00a0\nantagonista \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0el\u00a0L\u2010733,060258,\u00a0lo\u00a0\nque\u00a0demuestra \u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u2010\n1\u00a0en\u00a0estas\u00a0c\u00e9lulas\u00a0tumorales \u00a0puede\u00a0ser\u00a0una\u00a0\ncaracter\u00edstica \u00a0importante \u00a0para\u00a0favorecer \u00a0la\u00a0\nmigraci\u00f3n \u00a0celular.\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n58\u00a0\n\u00a06.1.\u00a0Sistema\u00a0taquiquin\u00e9rgico \u00a0y\u00a0\nmet\u00e1stasis \u00a0\nEl\u00a0papel\u00a0que\u00a0juega\u00a0la\u00a0SP\u00a0en\u00a0la\u00a0met\u00e1stasis \u00a0de\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0ha\u00a0sido\u00a0descrito\u00a0en\u00a0varias\u00a0patolog\u00edas \u00a0\noncol\u00f3gicas. \u00a0Los\u00a0efectos\u00a0directos\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0\nc\u00e9lulas\u00a0endoteliales \u00a0y\u00a0sobre\u00a0la\u00a0estructura \u00a0vascular\u00a0\ngeneral\u00a0tienen\u00a0una\u00a0influencia \u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0\nc\u00e1ncer\u00a0y\u00a0facilitan\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\ncancerosas \u00a0y\u00a0la\u00a0posterior\u00a0creaci\u00f3n\u00a0de\u00a0un\u00a0nuevo\u00a0\nfoco\u00a0cancer\u00edgeno \u00a0o\u00a0met\u00e1stasico. \u00a0Una\u00a0de\u00a0las\u00a0\ncitoquinas \u00a0responsables \u00a0y\u00a0muy\u00a0estudiadas \u00a0por\u00a0su\u00a0\nrelaci\u00f3n\u00a0con\u00a0la\u00a0migraci\u00f3n \u00a0y\u00a0la\u00a0m\u00e9tastasis \u00a0es\u00a0el\u00a0\nfactor\u00a01\u2010\u03b1\u00a0derivado\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0estroma\u00a0(SDF\u2010\n1\u03b1,\u00a0del\u00a0ingl\u00e9s\u00a0stromal\u00a0cell\u2010derived\u00a0factor\u20101\u03b1)\u00a0o\u00a0\nCXCL12,\u00a0al\u00a0igual\u00a0que\u00a0su\u00a0receptor\u00a0CXCR4.\u00a0SDF\u20101\u03b1\u00a0\njuega\u00a0un\u00a0papel\u00a0fundamental \u00a0en\u00a0la\u00a0quimiotaxis \u00a0de\u00a0\nc\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune284\u00a0y\u00a0desempe\u00f1a \u00a0un\u00a0\npapel\u00a0importante \u00a0en\u00a0la\u00a0angiog\u00e9nesis \u00a0mediante \u00a0el\u00a0\nreclutamiento \u00a0 de\u00a0 c\u00e9lulas\u00a0 progenitoras \u00a0\nendoteliales \u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0\nmecanismo \u00a0dependiente \u00a0de\u00a0su\u00a0receptor\u00a0\nCXCR4285,286.\u00a0Todo\u00a0esto\u00a0hace\u00a0que\u00a0sea\u00a0un\u00a0factor\u00a0\ninvolucrado \u00a0en\u00a0la\u00a0carcinog\u00e9nesis \u00a0y\u00a0la\u00a0\nneovascularizaci\u00f3n \u00a0ligada\u00a0a\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0\ntumor.\u00a0En\u00a0CM\u00a0el\u00a0SDF\u20101\u03b1\u00a0es\u00a0un\u00a0factor\u00a0clave\u00a0para\u00a0\ncomprender \u00a0como\u00a0migran\u00a0las\u00a0c\u00e9lulas\u00a0tumorales, \u00a0\npenetran\u00a0y/o\u00a0se\u00a0integran\u00a0en\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0SDF\u20101\u00a0\nexpresado \u00a0por\u00a0c\u00e9lulas\u00a0del\u00a0estroma\u00a0medular\u00a0\ninteract\u00faa \u00a0con\u00a0CXCR4\u00a0en\u00a0la\u00a0regi\u00f3n\u00a0del\u00a0endostio. \u00a0\nEsta\u00a0interacci\u00f3n \u00a0tambi\u00e9n\u00a0ha\u00a0sido\u00a0relacionada \u00a0con\u00a0\notras\u00a0cavidades \u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0con\u00a0lo\u00a0que\u00a0\nparece\u00a0demostrar \u00a0que\u00a0son\u00a0relevantes \u00a0para\u00a0la\u00a0\nentrada\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0ya\u00a0que\u00a0\nestas\u00a0c\u00e9lulas\u00a0tambi\u00e9n\u00a0presentan \u00a0una\u00a0expresi\u00f3n \u00a0\nelevada\u00a0de\u00a0CXCR4287,288.\u00a0Parece\u00a0ser\u00a0que\u00a0\u00e9stas\u00a0\nc\u00e9lulas,\u00a0una\u00a0vez\u00a0se\u00a0implantan \u00a0en\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0\npueden\u00a0entrar\u00a0en\u00a0un\u00a0estado\u00a0de\u00a0quiescencia \u00a0y\u00a0\nprotegerse \u00a0a\u00a0s\u00ed\u00a0mismas\u00a0de\u00a0la\u00a0destrucci\u00f3n \u00a0por\u00a0parte\u00a0\nde\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0disminuyendo \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nSDF\u20101\u03b1,\u00a0permitiendo \u00a0as\u00ed\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0\nhematopoy\u00e9ticas \u00a0interact\u00faen \u00a0con\u00a0las\u00a0c\u00e9lulas\u00a0del\u00a0\nestroma\u00a0en\u00a0lugar\u00a0de\u00a0las\u00a0cancerosas289.\u00a0El\u00a0receptor\u00a0\nNK\u20101\u00a0regula\u00a0esta\u00a0interacci\u00f3n \u00a0entre\u00a0SDF\u20101\u03b1\u00a0y\u00a0CXCR4\u00a0\nas\u00ed\u00a0como\u00a0su\u00a0expresi\u00f3n290.\u00a0En\u00a0c\u00e9lulas\u00a0del\u00a0epitelio\u00a0mamario\u00a0no\u00a0tumorales \u00a0(MCF\u201012A),\u00a0mediante \u00a0un\u00a0\nensayo\u00a0de\u00a0promotor \u00a0del\u00a0gen\u00a0TAC1 ,\u00a0se\u00a0observ\u00f3\u00a0que\u00a0\nel\u00a0factor\u00a0nuclear\u00a0activado\u00a0NF\u2010\u03baB\u00a0suprime\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0TAC1\u00a0en\u00a0presencia \u00a0de\u00a0\nniveles\u00a0muy\u00a0altos\u00a0de\u00a0SDF\u20101\u03b1291.\u00a0Concretamente, \u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0la\u00a0isoforma\u00a0truncada\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0(NK1\u2010Tr),\u00a0mediada\u00a0por\u00a0NF\u2010\u03baB,\u00a0es\u00a0\npr\u00e1cticamente \u00a0indetectable \u00a0en\u00a0aquellas\u00a0c\u00e9lulas\u00a0de\u00a0\nCM\u00a0con\u00a0fenotipo\u00a0quiescente \u00a0en\u00a0contacto\u00a0con\u00a0\nestroma\u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0ya\u00a0que\u00a0la\u00a0actividad\u00a0de\u00a0\nNF\u2010\u03baB\u00a0tambi\u00e9n\u00a0disminuye292.\u00a0Por\u00a0otro\u00a0lado\u00a0para\u00a0\nintentar\u00a0buscar\u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0de\u00a0CM\u00a0y\u00a0el\u00a0estroma\u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0\nRao\u00a0y\u00a0colaboradores \u00a0demostraron \u00a0que\u00a0c\u00e9lulas\u00a0de\u00a0\nmama\u00a0no\u00a0tumorog\u00e9nicas \u00a0(derivadas \u00a0de\u00a0biopsias\u00a0\nde\u00a0mama\u00a0o\u00a0l\u00edneas\u00a0celulares\u00a0establecidas) \u00a0no\u00a0\nsobreviv\u00edan \u00a0en\u00a0co\u2010cultivo\u00a0con\u00a0estroma\u00a0de\u00a0m\u00e9dula\u00a0\n\u00f3sea\u00a0a\u00a0diferencia \u00a0de\u00a0c\u00e9lulas\u00a0tumorig\u00e9nicas \u00a0que\u00a0\ncrec\u00edan\u00a0mejor\u00a0co\u2010cultiv\u00e1ndolas \u00a0junto\u00a0con\u00a0estroma\u00a0\nde\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0Es\u00a0m\u00e1s,\u00a0la\u00a0supresi\u00f3n \u00a0de\u00a0TAC1\u00a0con\u00a0\nARN\u00a0peque\u00f1o\u00a0de\u00a0interferencia \u00a0(siRNA,\u00a0del\u00a0ingl\u00e9s\u00a0\nsmall\u00a0interfering \u00a0RNA)\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0y\u00a0en\u00a0\nc\u00e9lulas\u00a0que\u00a0proven\u00edan \u00a0de\u00a0tumores\u00a0avanzados \u00a0de\u00a0\nCM,\u00a0imped\u00eda\u00a0el\u00a0correcto\u00a0crecimiento \u00a0en\u00a0co\u2010\ncultivos\u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0y\u00a0tambi\u00e9n\u00a0imped\u00eda\u00a0la\u00a0\ncolonizaci\u00f3n \u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0en\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0en\u00a0\nratones\u00a0desnudos, \u00a0generando \u00a0el\u00a0efecto\u00a0contrario\u00a0\nen\u00a0aquellas\u00a0c\u00e9lulas\u00a0que\u00a0sobreexpresaban \u00a0el\u00a0gen293.\u00a0\nEn\u00a0resumen, \u00a0con\u00a0este\u00a0y\u00a0otros\u00a0trabajos,\u00a0se\u00a0ha\u00a0\npropuesto \u00a0que\u00a0TAC1\u00a0contribuye \u00a0a\u00a0la\u00a0met\u00e1stasis \u00a0de\u00a0\nc\u00e9lulas\u00a0de\u00a0CM\u00a0y\u00a0a\u00a0su\u00a0integraci\u00f3n \u00a0en\u00a0el\u00a0\ncompartimiento \u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea,\u00a0as\u00ed\u00a0como\u00a0en\u00a0su\u00a0\nestado\u00a0de\u00a0quiescencia \u00a0(donde\u00a0parece\u00a0ser\u00a0que\u00a0se\u00a0\nencuentra \u00a0menos\u00a0expresado). \u00a0\nOtra\u00a0citoquina \u00a0que\u00a0podr\u00eda\u00a0facilitar\u00a0el\u00a0\nestablecimiento \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0\nes\u00a0TGF\u2010\u03b2,\u00a0cuya\u00a0producci\u00f3n \u00a0se\u00a0incrementa \u00a0en\u00a0\nc\u00e9lulas\u00a0de\u00a0CM\u00a0co\u2010cultivadas \u00a0con\u00a0estroma\u00a0medular.\u00a0\nAunque\u00a0su\u00a0eficiencia \u00a0como\u00a0mediador \u00a0de\u00a0la\u00a0\nintegraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0en\u00a0el\u00a0estroma\u00a0es\u00a0\nmenor\u00a0que\u00a0TAC1 ,\u00a0esta\u00a0citoquina \u00a0regula\u00a0la\u00a0\nactivaci\u00f3n \u00a0del\u00a0gen\u00a0TAC1\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0c\u2010myc,\u00a0\nfacilitando \u00a0la\u00a0integraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0en\u00a0\nc\u00e9lulas\u00a0del\u00a0estroma\u00a0medular294.\u00a0La\u00a0preferencia \u00a0por\u00a0\nla\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0tambi\u00e9n\u00a0es\u00a0com\u00fan\u00a0en\u00a0el\u00a0c\u00e1ncer\u00a0de\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n59\u00a0\n\u00a0pulm\u00f3n,\u00a0de\u00a0pr\u00f3stata\u00a0y\u00a0en\u00a0menor\u00a0medida\u00a0de\u00a0colon.\u00a0\nDada\u00a0la\u00a0existencia \u00a0del\u00a0sistema\u00a0neuroendocrino \u00a0\ntambi\u00e9n\u00a0en\u00a0estos\u00a0tumores,\u00a0existe\u00a0la\u00a0posibilidad \u00a0de\u00a0\nque\u00a0mecanismos \u00a0similares\u00a0a\u00a0los\u00a0estudiados \u00a0en\u00a0las\u00a0\nc\u00e9lulas\u00a0de\u00a0CM\u00a0tambi\u00e9n\u00a0sean\u00a0posibles\u00a0en\u00a0estos\u00a0\ntipos\u00a0de\u00a0c\u00e1ncer.\u00a0\n\u00a0\n6.2.\u00a0Tumores\u00a0y\u00a0l\u00edneas\u00a0celulares\u00a0\ntumorales \u00a0que\u00a0expresan \u00a0el\u00a0receptor\u00a0\nNK\u20101\u00a0y\u00a0la\u00a0SP\u00a0\nEvidencias \u00a0experimentales \u00a0obtenidas \u00a0durante\u00a0\nestos\u00a0\u00faltimos\u00a0a\u00f1os\u00a0apoyan\u00a0la\u00a0idea\u00a0de\u00a0que\u00a0\nalteraciones \u00a0en\u00a0el\u00a0sistema\u00a0neuroendocrino \u00a0\npodr\u00edan\u00a0contribuir \u00a0considerablemente \u00a0en\u00a0el\u00a0\ndesarrollo \u00a0de\u00a0distintas\u00a0patolog\u00edas \u00a0cancerosas. \u00a0Las\u00a0\ntaquiquininas \u00a0act\u00faan\u00a0directamente \u00a0en\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0modulando \u00a0sus\u00a0respuestas \u00a0en\u00a0t\u00e9rminos\u00a0\nde\u00a0proliferaci\u00f3n \u00a0y\u00a0supervivencia, \u00a0pero\u00a0\nindirectamente \u00a0tambi\u00e9n\u00a0contribuyen \u00a0alterando \u00a0el\u00a0\nmicroambiente \u00a0tumoral\u00a0y\u00a0procesos\u00a0relacionados \u00a0\ncon\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0La\u00a0SP\u00a0y\u00a0su\u00a0receptor\u00a0se\u00a0\nencuentran \u00a0expresados \u00a0en\u00a0una\u00a0amplia\u00a0variedad\u00a0de\u00a0\nl\u00edneas\u00a0celulares\u00a0tumorales \u00a0y\u00a0tumores\u00a0distintos\u00a0\ncomo\u00a0astrocitomas, \u00a0gliomas,\u00a0neuroblastomas, \u00a0\nc\u00e1ncer\u00a0de\u00a0p\u00e1ncreas, \u00a0CM\u00a0y\u00a0melanomas. \u00a0\nSe\u00a0ha\u00a0identificado \u00a0un\u00a0alto\u00a0nivel\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0en\u00a0tumores\u00a0malignos\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0tejido\u00a0normal\u00a0de\u00a0cerebro\u00a0\nadyacente \u00a0o\u00a0neoplasias \u00a0benignas. \u00a0Este\u00a0receptor\u00a0\ntambi\u00e9n\u00a0se\u00a0encuentra \u00a0expresado \u00a0unas\u00a026\u00a0veces\u00a0\nm\u00e1s\u00a0en\u00a0biopsias\u00a0tumorales \u00a0de\u00a0pacientes \u00a0con\u00a0\nestadios\u00a0avanzados \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0controles \u00a0\nnormales. \u00a0Su\u00a0sus\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0se\u00a0\nencuentran \u00a0incrementados \u00a036.7\u00a0veces\u00a0en\u00a0\nmuestras \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0p\u00e1ncreas\u00a0adem\u00e1s\u00a0de\u00a0\ncorrelacionar \u00a0con\u00a0estadios\u00a0tumorales \u00a0avanzados \u00a0y\u00a0\ncon\u00a0un\u00a0peor\u00a0pron\u00f3stico230.\u00a0\nEl\u00a0n\u00famero\u00a0de\u00a0receptores \u00a0expresados \u00a0en\u00a0c\u00e9lulas\u00a0\nnormales \u00a0como\u00a0por\u00a0ejemplo,\u00a0linfocitos\u00a0T\u00a0que\u00a0\nexpresan\u00a0de\u00a07.000\u00a0a\u00a010.000\u00a0receptores/c\u00e9lula295\u00a0\nparecen\u00a0ser\u00a0relativamente \u00a0bajos\u00a0si\u00a0los\u00a0\ncomparamos \u00a0con\u00a0los\u00a040.000\u00a0receptores/c\u00e9lula \u00a0que\u00a0\nexpresan\u00a0c\u00e9lulas\u00a0de\u00a0astrocitoma245,296.\u00a0Parece\u00a0ser,\u00a0adem\u00e1s,\u00a0que\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0en\u00a0\nfenotipos \u00a0malignos\u00a0correlaciona \u00a0con\u00a0el\u00a0grado\u00a0de\u00a0\nmalignidad, \u00a0ya\u00a0que\u00a0neoplasias \u00a0cerebrales \u00a0como\u00a0\nglioblastomas \u00a0expresan\u00a0m\u00e1s\u00a0receptores \u00a0NK\u20101\u00a0que\u00a0\nastrocitomas263.\u00a0Hennig\u00a0adem\u00e1s\u00a0de\u00a0contribuir \u00a0esta\u00a0\n\u00faltima\u00a0 observaci\u00f3n \u00a0 analiz\u00f3\u00a0 mediante \u00a0\nautorradiograf\u00eda \u00a0la\u00a0presencia \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0\nbiopsias\u00a0de\u00a0varios\u00a0tipos\u00a0celulares. \u00a0Detect\u00f3\u00a0el\u00a0\nreceptor\u00a0en\u00a0el\u00a0100%\u00a0de\u00a0las\u00a0muestras \u00a0de\u00a0\nglioblastoma \u00a0(10/10),\u00a0en\u00a0el\u00a075%\u00a0de\u00a0las\u00a0muestras \u00a0\nde\u00a0astrocitoma \u00a0(9/12),\u00a0en\u00a0el\u00a083,3%\u00a0de\u00a0las\u00a0muestras \u00a0\nde\u00a0carcinoma \u00a0medular\u00a0de\u00a0la\u00a0tiroides\u00a0(10/12),\u00a0en\u00a0el\u00a0\n80%\u00a0de\u00a0muestras \u00a0de\u00a0ganglioneuroblastomas \u00a0(4/5)\u00a0\ny\u00a0el\u00a050%\u00a0de\u00a0muestras \u00a0de\u00a0carcinoma \u00a0de\u00a0mama\u00a0\n(8/16)\u00a0263.\u00a0Por\u00a0otro\u00a0lado\u00a0identific\u00f3 \u00a0menos\u00a0casos\u00a0en\u00a0\ncolon,\u00a0p\u00e1ncreas, \u00a0adenocarcinomas \u00a0y\u00a0c\u00e1ncer\u00a0de\u00a0\npulm\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0no\u00a0peque\u00f1as. \u00a0\u00a0\nAdem\u00e1s\u00a0de\u00a0biopsias\u00a0tumorales, \u00a0l\u00edneas\u00a0celulares\u00a0\ncomo\u00a0las\u00a0U373\u00a0MG\u00a0han\u00a0mostrado \u00a0tener\u00a0una\u00a0\nrespuesta \u00a0proliferativa \u00a0en\u00a0contacto\u00a0con\u00a0la\u00a0SP\u00a0as\u00ed\u00a0\ncomo\u00a0otras\u00a0l\u00edneas\u00a0celulares\u00a0(que\u00a0expresan\u00a0\ntambi\u00e9n\u00a0 el\u00a0 receptor\u00a0 NK1)\u00a0 de\u00a0\nastrocitoma/glioblastoma \u00a0(DBTRG\u201005\u00a0MG\u00a0y\u00a0\nU138MG)297.\u00a0\u00a0\nL\u00edneas\u00a0celulares\u00a0de\u00a0neuroblastoma \u00a0como\u00a0SY5Y\u00a0y\u00a0\nCHP212,\u00a0expresan\u00a0niveles\u00a0de\u00a0ARNm\u00a0y\u00a0de\u00a0prote\u00edna\u00a0\nde\u00a0los\u00a0receptores \u00a0NK\u20101\u00a0y\u00a0NK\u20102.\u00a0Incluso\u00a0el\u00a0\nsilenciamiento \u00a0del\u00a0gen\u00a0TACR1\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0siRNA\u00a0\npara\u00a0suprimir\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0ambas\u00a0isoformas \u00a0de\u00a0\nNK\u20101R\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0neuroblastoma, \u00a0provoca\u00a0que\u00a0\nestas\u00a0c\u00e9lulas\u00a0no\u00a0consigan\u00a0formar\u00a0colonias\u00a0en\u00a0\nmetil\u2010celulosa,\u00a0muestren \u00a0fenotipos \u00a0m\u00e1s\u00a0\ndiferenciados298,\u00a0y\u00a0no\u00a0consigan\u00a0metastatizar \u00a0a\u00a0\nm\u00e9dula\u00a0\u00f3sea\u00a0de\u00a0rat\u00f3n.\u00a0El\u00a0neuroblastoma \u00a0es\u00a0un\u00a0\ntumor\u00a0del\u00a0sistema\u00a0nervioso\u00a0perif\u00e9rico \u00a0y\u00a0de\u00a0manera\u00a0\npreferente, \u00a0metastatiza \u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0El\u00a0hecho\u00a0\nde\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0impida\u00a0que\u00a0\nc\u00e9lulas\u00a0de\u00a0neuroblastoma \u00a0no\u00a0proliferen \u00a0en\u00a0\ncontacto\u00a0con\u00a0el\u00a0estroma\u00a0medular,\u00a0sugiere\u00a0que\u00a0NK\u2010\n1R\u00a0es\u00a0importante \u00a0para\u00a0la\u00a0supervivencia \u00a0de\u00a0\u00e9stas\u00a0\nc\u00e9lulas\u00a0en\u00a0este\u00a0microambiente298.\u00a0\nEn\u00a0leucemia\u00a0linfobl\u00e1stica \u00a0aguda\u00a0(LLA),\u00a0\nneurop\u00e9ptidos \u00a0como\u00a0las\u00a0taquiquininas \u00a0son\u00a0\nexpresados \u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0y\u00a0participan \u00a0en\u00a0la\u00a0\nlinfopoyesis \u00a0y\u00a0mielopoyesis \u00a0de\u00a0linfocitos\u00a0T\u00a0i\u00a0B.\u00a0La\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n60\u00a0\n\u00a0SP\u00a0ha\u00a0sido\u00a0hallada\u00a0en\u00a0distintas\u00a0muestras \u00a0\nneopl\u00e1sicas \u00a0hematol\u00f3gicas. \u00a0Concretamente, \u00a0se\u00a0ha\u00a0\ndetectado \u00a0un\u00a042%\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0LLAs\u00a0comunes, \u00a0\ny\u00a0un\u00a081,2%\u00a0en\u00a0leucemias \u00a0de\u00a0c\u00e9lulas\u00a0T.\u00a0Mediante \u00a0\ncitometr\u00eda \u00a0de\u00a0flujo\u00a0se\u00a0ha\u00a0detectado \u00a0SP\u00a0en\u00a0\nlinfocitos\u00a0de\u00a0pacientes \u00a0con\u00a0LLA,\u00a0leucemia\u00a0cr\u00f3nica\u00a0\nmieloide\u00a0y\u00a0leucemia\u00a0linfobl\u00e1stica \u2010B\u00a0cr\u00f3nica\u00a0a\u00a0\ndiferencia \u00a0de\u00a0linfocitos\u00a0normales \u00a0los\u00a0cuales\u00a0eran\u00a0\ngeneralmente \u00a0negativos \u00a0o\u00a0con\u00a0positividad \u00a0baja,\u00a0\nsugiriendo \u00a0que\u00a0la\u00a0SP\u00a0puede\u00a0ser\u00a0un\u00a0indicativo \u00a0de\u00a0\nmalignidad \u00a0en\u00a0estas\u00a0enfermedades \u00a0neoplasias \u00a0\nhematol\u00f3gicas235.\u00a0\nEn\u00a0melanoma \u00a0hasta\u00a0el\u00a0momento \u00a0no\u00a0hay\u00a0\nsuficientes \u00a0indicios\u00a0que\u00a0relacionen \u00a0las\u00a0\ntaquiquininas \u00a0con\u00a0la\u00a0melanog\u00e9nesis \u00a0y\u00a0la\u00a0\nmet\u00e1stasis, \u00a0pero\u00a0si\u00a0otros\u00a0estudios\u00a0como\u00a0por\u00a0\nejemplo\u00a0los\u00a0realizados \u00a0con\u00a0el\u00a0receptor\u00a0\nmetabotr\u00f3pico \u00a0de\u00a0glutamato \u00a0del\u00a0grupo\u00a0I\u00a0han\u00a0\ndemostrado \u00a0una\u00a0estrecha\u00a0relaci\u00f3n\u00a0entre\u00a0un\u00a0GPCR\u00a0\ny\u00a0la\u00a0melanog\u00e9nesis \u00a0y\u00a0met\u00e1stasis235.\u00a0Adem\u00e1s,\u00a0otros\u00a0\ntrabajos\u00a0publicados \u00a0en\u00a0la\u00a0literatura \u00a0demuestran \u00a0\nque\u00a0la\u00a0SP\u00a0estimula\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0histamina \u00a0por\u00a0\nparte\u00a0de\u00a0los\u00a0mastocitos. \u00a0Estas\u00a0c\u00e9lulas\u00a0potencian \u00a0\nas\u00ed\u00a0la\u00a0neoangiog\u00e9nesis \u00a0y\u00a0la\u00a0fibrosis\u00a0d\u00e9rmica,\u00a0y\u00a0ya\u00a0es\u00a0\nconocida\u00a0la\u00a0relaci\u00f3n\u00a0de\u00a0los\u00a0mastocitos \u00a0con\u00a0la\u00a0\npotenciaci\u00f3n \u00a0del\u00a0crecimiento \u00a0celular\u00a0de\u00a0\nmelanoma. \u00a0Adem\u00e1s\u00a0de\u00a0todos\u00a0estos\u00a0indicios\u00a0se\u00a0ha\u00a0\ndetectado \u00a0SP\u00a0en\u00a0el\u00a068%\u00a0(17/25)\u00a0de\u00a0melanomas \u00a0\nprimarios \u00a0invasivos, \u00a0en\u00a0el\u00a040%\u00a0(2/5)\u00a0de\u00a0\nmelanomas \u00a0metast\u00e1sicos, \u00a0en\u00a0el\u00a060%\u00a0(6/10)\u00a0de\u00a0\nmelanomas \u00a0in\u00a0situ\u00a0y\u00a0en\u00a0el\u00a058%\u00a0(7/12)\u00a0de\u00a0nevos\u00a0\nat\u00edpicos\u00a0pero\u00a0no\u00a0en\u00a0ning\u00fan\u00a0nevo\u00a0melanocitico \u00a0\nbenigno\u00a0(0/11)235.\u00a0\nEn\u00a0el\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0de\u00a0c\u00e9lula\u00a0peque\u00f1a\u00a0\ntampoco\u00a0se\u00a0ha\u00a0encontrado \u00a0una\u00a0relaci\u00f3n\u00a0directa\u00a0\ncon\u00a0el\u00a0receptor\u00a0NK\u20101,\u00a0sin\u00a0embargo\u00a0la\u00a0SP\u00a0parece\u00a0\ntener\u00a0una\u00a0quimioatracci\u00f3n \u00a0por\u00a0este\u00a0tipo\u00a0de\u00a0c\u00e9lulas\u00a0\ny\u00a0parece\u00a0estar\u00a0relacionada \u00a0con\u00a0la\u00a0met\u00e1stasis \u00a0de\u00a0\neste\u00a0tipo\u00a0de\u00a0c\u00e1ncer\u00a0ya\u00a0que\u00a0este\u00a0proceso\u00a0puede\u00a0\nrevertirse \u00a0mediante \u00a0an\u00e1logos\u00a0de\u00a0la\u00a0SP.\u00a0Adem\u00e1s\u00a0un\u00a0\nan\u00e1logo\u00a0de\u00a0la\u00a0SP,\u00a0nombrado \u00a0como\u00a0\u201cp\u00e9ptido\u00a0\nantagonista \u00a0G\u201d,\u00a0se\u00a0ha\u00a0utilizado\u00a0en\u00a0un\u00a0ensayo\u00a0\ncl\u00ednico\u00a0de\u00a0fase\u00a0I\u00a0para\u00a0inhibir\u00a0los\u00a0efectos\u00a0\nvasodilatadores \u00a0de\u00a0la\u00a0SP\u00a0(en\u00a0ausencia\u00a0de\u00a0toxicidad\u00a0\nlimitada\u00a0por\u00a0dosis),\u00a0sugiriendo \u00a0que\u00a0los\u00a0efectos\u00a0terap\u00e9uticos \u00a0de\u00a0esta\u00a0droga\u00a0son\u00a0debidos\u00a0al\u00a0control\u00a0\nde\u00a0los\u00a0vasos\u00a0del\u00a0tumor\u00a0y\u00a0la\u00a0influencia \u00a0de\u00a0la\u00a0SP\u00a0\nsobre\u00a0la\u00a0angiog\u00e9nesis299.\u00a0\nOtras\u00a0l\u00edneas\u00a0celulares\u00a0tales\u00a0como\u00a0WERI\u2010Rb\u20101,\u00a0Y\u201079\u00a0\nde\u00a0retinoblastoma, \u00a0U373\u00a0MG\u00a0y\u00a0GAMG\u00a0de\u00a0glioma,\u00a0\nSNK\u2010BE(2),\u00a0Kelly\u00a0y\u00a0IMR\u201032\u00a0de\u00a0neuroblastoma, \u00a0\nCAPAN\u20101\u00a0y\u00a0PA\u2010TU\u00a08902\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0p\u00e1ncreas, \u00a0\nHep\u20102\u00a0de\u00a0c\u00e1ncer\u00a0ce\u00a0laringe,\u00a023132/87 \u00a0de\u00a0c\u00e1ncer\u00a0\ng\u00e1strico\u00a0y\u00a0SW\u2010403\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0colon\u00a0expresan\u00a0el\u00a0\nreceptor\u00a0NK\u20101300\u2010302\u00a0ampliando \u00a0el\u00a0abanico\u00a0de\u00a0\nexpresi\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0en\u00a0m\u00faltiples \u00a0l\u00edneas\u00a0\ncelulares\u00a0de\u00a0distintos\u00a0tipos\u00a0de\u00a0c\u00e1ncer.\u00a0\u00a0\nEn\u00a0cuanto\u00a0a\u00a0la\u00a0localizaci\u00f3n \u00a0subcelular \u00a0de\u00a0la\u00a0SP,\u00a0en\u00a0\nc\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0U373\u00a0MG,\u00a0la\u00a0SP\u00a0ha\u00a0sido\u00a0\nobservada \u00a0en\u00a0la\u00a0zona\u00a0peritumoral \u00a0y\u00a0en\u00a0la\u00a0masa\u00a0\ntumoral\u00a0(especialmente \u00a0en\u00a0la\u00a0periferia)297,303.\u00a0\nAdem\u00e1s\u00a0 en\u00a0 tumores\u00a0 odontog\u00e9nicos, \u00a0\nqueratoqu\u00edsticos \u00a0en\u00a0carcinoma \u00a0oral\u00a0de\u00a0c\u00e9lulas\u00a0\nescamosas \u00a0y\u00a0en\u00a0tejido\u00a0de\u00a0carcinoma \u00a0de\u00a0laringe\u00a0la\u00a0\nSP\u00a0se\u00a0ha\u00a0detectado \u00a0en\u00a0el\u00a0n\u00facleo\u00a0y\u00a0en\u00a0el\u00a0citoplasma \u00a0\nde\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0y\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0\ncasos\u00a0en\u00a0las\u00a0capas\u00a0basales\u00a0del\u00a0epitelio304,305.\u00a0\nConcretamente \u00a0la\u00a0expresi\u00f3n \u00a0en\u00a0el\u00a0citoplasma \u00a0ha\u00a0\nsido\u00a0significativamente \u00a0asociada\u00a0con\u00a0la\u00a0presencia \u00a0\nde\u00a0epitelio\u00a0displ\u00e1sico \u00a0que\u00a0expresa\u00a0el\u00a0factor\u00a0de\u00a0\nproliferaci\u00f3n \u00a0Ki67\u00a0en\u00a0capas\u00a0suprabasales306.\u00a0\nY\u00a0por\u00a0\u00faltimo\u00a0en\u00a0CM\u00a0diversos\u00a0estudios\u00a0demuestran \u00a0\nuna\u00a0relaci\u00f3n\u00a0entre\u00a0el\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0y\u00a0el\u00a0\nc\u00e1ncer.\u00a0En\u00a0este\u00a0aspecto\u00a0la\u00a0Dra.\u00a0Rameshwar \u00a0y\u00a0el\u00a0Dr.\u00a0\nGasc\u00f3n\u00a0describieron \u00a0por\u00a0primera\u00a0vez\u00a0la\u00a0relaci\u00f3n\u00a0\nentre\u00a0el\u00a0gen\u00a0TAC1\u00a0y\u00a0el\u00a0estroma\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0\nSus\u00a0estudios\u00a0respaldaban \u00a0la\u00a0idea\u00a0de\u00a0que\u00a0el\u00a0gen\u00a0\nTAC1\u00a0facilitaba\u00a0la\u00a0integraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0en\u00a0\nel\u00a0compartimiento \u00a0estromal\u00a0durante\u00a0un\u00a0periodo\u00a0\nanterior\u00a0a\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0la\u00a0enfermedad, \u00a0sin\u00a0\ninterrumpir \u00a0la\u00a0actividad\u00a0hematopoy\u00e9tica293.\u00a0En\u00a0\notro\u00a0estudio\u00a0del\u00a0mismo\u00a0grupo,\u00a0compararon \u00a0c\u00e9lulas\u00a0\nepiteliales \u00a0normales \u00a0mamarias \u00a0y\u00a0biopsias\u00a0benignas\u00a0\ncon\u00a0distintas\u00a0l\u00edneas\u00a0celulares\u00a0tumorales \u00a0de\u00a0mama\u00a0\ny\u00a0numerosas \u00a0biopsias\u00a0de\u00a0tumores\u00a0malignos. \u00a0Tanto\u00a0\nlos\u00a0tumores\u00a0como\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0mostraban \u00a0\nun\u00a0elevado\u00a0incremento \u00a0en\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0SP\u00a0y\u00a0\nNK\u20101R307.\u00a0Y\u00a0aunque\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20102\u00a0\nno\u00a0era\u00a0muy\u00a0distinta\u00a0entre\u00a0muestras \u00a0normales \u00a0y\u00a0\ntumorales, \u00a0si\u00a0que\u00a0mediaba\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n61\u00a0\n\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0y\u00a0no\u00a0de\u00a0c\u00e9lulas\u00a0normales. \u00a0\nAntagonistas \u00a0de\u00a0los\u00a0receptores \u00a0NK\u20101\u00a0y\u00a0NK\u20102,\u00a0(CP\u2010\n96,345\u00a0y\u00a0SR48968, \u00a0respectivamente) \u00a0inhib\u00edan\u00a0la\u00a0\nproliferaci\u00f3n \u00a0celular,\u00a0sugiriendo \u00a0de\u00a0esta\u00a0forma\u00a0una\u00a0\nestimulaci\u00f3n \u00a0autocrina/paracrina \u00a0por\u00a0parte\u00a0de\u00a0\np\u00e9ptidos\u00a0de\u00a0TAC1307.\u00a0\nSin\u00a0embargo, \u00a0un\u00a0cribado\u00a0m\u00e1s\u00a0amplio,\u00a0con\u00a0un\u00a0\nmayor\u00a0n\u00famero\u00a0de\u00a0pacientes, \u00a0ser\u00eda\u00a0necesario \u00a0para\u00a0\ncaracterizar \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0estos\u00a0receptores \u00a0en\u00a0\ndistintos\u00a0tipos\u00a0de\u00a0neoplasias \u00a0y\u00a0determinar \u00a0en\u00a0\ncuales\u00a0la\u00a0SP\u00a0y\u00a0su\u00a0receptor\u00a0podr\u00edan\u00a0jugar\u00a0un\u00a0papel\u00a0\nfundamental. \u00a0\u00a0\nTodos\u00a0estos\u00a0estudios\u00a0sugieren\u00a0que\u00a0no\u00a0solo\u00a0la\u00a0\nangiog\u00e9nesis \u00a0y\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0pueden\u00a0\nestar\u00a0regulados \u00a0por\u00a0el\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0\nsino\u00a0que\u00a0tambi\u00e9n\u00a0la\u00a0migraci\u00f3n, \u00a0la\u00a0met\u00e1stasis \u00a0y\u00a0la\u00a0\nimplantaci\u00f3n \u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0tumorales \u00a0en\u00a0la\u00a0\nm\u00e9dula\u00a0\u00f3sea\u00a0est\u00e1n\u00a0reguladas \u00a0por\u00a0la\u00a0SP\u00a0y\u00a0su\u00a0\nreceptor\u00a0NK\u20101.\u00a0Por\u00a0tanto\u00a0la\u00a0SP\u00a0estimula\u00a0la\u00a0\nprogresi\u00f3n \u00a0del\u00a0tumor,\u00a0activando \u00a0su\u00a0proliferaci\u00f3n \u00a0y\u00a0\nfavorece\u00a0la\u00a0migraci\u00f3n \u00a0celular\u00a0y\u00a0la\u00a0met\u00e1stasis \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0varias\u00a0formas\u00a0(Fig.\u00a018).\u00a0\n\u00a0\nLa\u00a0SP\u00a0puede\u00a0provenir\u00a0de\u00a0diversas\u00a0fuentes:\u00a0\n\u00a0\n1)\u00a0El\u00a0sistema\u00a0nervioso\u00a0perif\u00e9rico, \u00a0ya\u00a0que\u00a0la\u00a0SP\u00a0es\u00a0\nexcretada \u00a0por\u00a0neuronas \u00a0aferentes \u00a0terminales. \u00a0\n2)\u00a0El\u00a0sistema\u00a0inmunitario, \u00a0porque\u00a0la\u00a0SP\u00a0es\u00a0\nsecretada \u00a0por\u00a0m\u00faltiples \u00a0c\u00e9lulas\u00a0que\u00a0participan \u00a0en\u00a0\nla\u00a0respuesta \u00a0inflamatoria. \u00a0\n3)\u00a0El\u00a0sistema\u00a0vascular\u00a0ya\u00a0que\u00a0se\u00a0ha\u00a0localizado \u00a0SP\u00a0y\u00a0\nNK\u20101R\u00a0en\u00a0vasos\u00a0sangu\u00edneos \u00a0colindantes \u00a0al\u00a0tumor.\u00a0\u00a0\n4)\u00a0El\u00a0mismo\u00a0tumor,\u00a0de\u00a0forma\u00a0autocrina, \u00a0ya\u00a0que\u00a0es\u00a0\ncapaz\u00a0de\u00a0sintentizar \u00a0SP\u00a0y\u00a0su\u00a0propio\u00a0receptor. \u00a0\n5)\u00a0El\u00a0mismo\u00a0tumor,\u00a0de\u00a0forma\u00a0paracrina, \u00a0ya\u00a0que\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0SP\u00a0puede\u00a0amplificar \u00a0su\u00a0propia\u00a0se\u00f1al\u00a0\nal\u00a0activar\u00a0c\u00e9lulas\u00a0que\u00a0le\u00a0rodean\u00a0y\u00a0aumentar \u00a0as\u00ed\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral.\u00a0\n\u00a06)\u00a0El\u00a0estr\u00e9s\u00a0o\u00a0factores\u00a0ambientales \u00a0que\u00a0impulsan\u00a0\nque\u00a0todos\u00a0los\u00a0sistemas\u00a0act\u00faen\u00a0juntos\u00a0y\u00a0se\u00a0unan\u00a0de\u00a0\nmanera\u00a0negativa\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0tumoral.\u00a0\n\u00a0\n6.3.\u00a0V\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0y\u00a0SP\u00a0\n\u00a0\nExisten\u00a0diversos\u00a0estudios\u00a0realizados \u00a0sobretodo \u00a0en\u00a0\nl\u00edneas\u00a0celulares\u00a0de\u00a0glioblastoma \u00a0que\u00a0desciben\u00a0los\u00a0\nefectos\u00a0de\u00a0la\u00a0SP\u00a0como\u00a0factor\u00a0mitog\u00e9nico \u00a0y\u00a0cuales\u00a0\nson\u00a0las\u00a0cascadas\u00a0o\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0que\u00a0\nactivan.\u00a0La\u00a0SP\u00a0se\u00f1aliza\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0\nestimula\u00a0la\u00a0mitog\u00e9nesis \u00a0en\u00a0neuroblastoma, \u00a0\nastrocitoma, \u00a0 melanoma, \u00a0 retinoblastoma, \u00a0\ncarcinoma \u00a0de\u00a0p\u00e1ncreas, \u00a0CM\u00a0y\u00a0glioma.\u00a0En\u00a01994\u00a0Luo\u00a0\ny\u00a0colaboradores \u00a0ya\u00a0observaron \u00a0que\u00a0peque\u00f1as \u00a0\ncantidades \u00a0de\u00a0SP\u00a0eran\u00a0capaces\u00a0de\u00a0aumentar \u00a0la\u00a0\ns\u00edntesis\u00a0de\u00a0ADN\u00a0y\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0U\u2010373\u00a0MG308.\u00a0Del\u00a0mismo\u00a0modo,\u00a0otros\u00a0tipos\u00a0\ncelulares\u00a0como\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0astrocitoma, \u00a0\nglioma,\u00a0 neuroblastoma, \u00a0 retinoblastoma, \u00a0\nmelanoma, \u00a0c\u00e1ncer\u00a0de\u00a0p\u00e1ncreas, \u00a0laringe\u00a0y\u00a0colon\u00a0\nhan\u00a0mostrado \u00a0depender \u00a0parcialmente \u00a0de\u00a0la\u00a0SP\u00a0\npara\u00a0su\u00a0correcto\u00a0crecimiento \u00a0in\u00a0vitro,\u00a0ya\u00a0que\u00a0al\u00a0ser\u00a0\ntratadas\u00a0con\u00a0antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0han\u00a0\ndisminuido \u00a0su\u00a0crecimiento \u00a0y\u00a0\u00e9ste\u00a0se\u00a0ha\u00a0visto\u00a0\nrevertido \u00a0al\u00a0entrar\u00a0en\u00a0contacto\u00a0de\u00a0nuevo\u00a0con\u00a0la\u00a0\nSP297,300,301,303,309,310.\u00a0\u00a0\nLas\u00a0reacciones \u00a0bioqu\u00edmicas \u00a0que\u00a0tienen\u00a0lugar\u00a0tras\u00a0la\u00a0\nactivaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0y\u00a0las\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0que\u00a0se\u00a0desencadenan \u00a0est\u00e1n\u00a0\nrelacionadas \u00a0con\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0l\u00edneas\u00a0celulares\u00a0\nde\u00a0glioblastoma. \u00a0En\u00a0este\u00a0tipo\u00a0celular,\u00a0al\u00a0igual\u00a0que\u00a0\nmuchos\u00a0otros\u00a0tipos\u00a0de\u00a0tumores,\u00a0la\u00a0SP\u00a0activa\u00a0la\u00a0\nacumulaci\u00f3n \u00a0de\u00a0DAG\u00a0que\u00a0a\u00a0su\u00a0vez\u00a0activa\u00a0a\u00a0la\u00a0PKC.\u00a0\nEsta\u00a0prote\u00edna\u00a0fosforila\u00a0otras\u00a0prote\u00ednas \u00a0como\u00a0c\u2010Raf\u2010\n1\u00a0y\u00a0MEK,\u00a0que\u00a0fosforilan \u00a0a\u00a0las\u00a0prote\u00ednas \u00a0tirosina\u00a0\nquinasa\u00a0Erk1/Erk2 \u00a0(tambi\u00e9n\u00a0conocidas \u00a0como\u00a0p\u2010\n42/44)\u00a0de\u00a0la\u00a0familia\u00a0de\u00a0prote\u00ednas \u00a0MAPK.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n62\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nFigura\u00a018.\u00a0Origen\u00a0de\u00a0la\u00a0SP\u00a0y\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0c\u00e1ncer.\u00a0Mecanismo \u00a0postulado \u00a0de\u00a0retroalimentaci\u00f3n \u00a0positiva\u00a0por\u00a0parte\u00a0de\u00a0la\u00a0SP\u00a0y\u00a0\nsu\u00a0receptor\u00a0NK\u20101\u00a0expresados \u00a0a\u00a0partir\u00a0de\u00a0varias\u00a0fuentes.\u00a0La\u00a0SP\u00a0es\u00a0sintetizada \u00a0por\u00a0monocitos, \u00a0macr\u00f3fagos, \u00a0linfocitos, \u00a0eosin\u00f3filos, \u00a0\nc\u00e9lulas\u00a0dendr\u00edticas \u00a0y\u00a0c\u00e9lulas\u00a0madre\u00a0estromales \u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0La\u00a0SP\u00a0aumenta\u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0inmunoglobulinas \u00a0por\u00a0parte\u00a0de\u00a0\nlos\u00a0linfocitos, \u00a0y\u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010inflamatorias \u00a0por\u00a0parte\u00a0de\u00a0linfocitos, \u00a0monocitos, \u00a0macr\u00f3fagos \u00a0y\u00a0mastocitos \u00a0que\u00a0\ncontribuyen \u00a0a\u00a0la\u00a0creaci\u00f3n\u00a0de\u00a0un\u00a0microambiente \u00a0favorable \u00a0para\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0A\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0promoci\u00f3n \u00a0de\u00a0la\u00a0\nvasodilataci\u00f3n \u00a0de\u00a0vasos\u00a0sangu\u00edneos, \u00a0la\u00a0quimiotaxis \u00a0y\u00a0el\u00a0favorecimiento \u00a0en\u00a0la\u00a0adhesi\u00f3n\u00a0de\u00a0leucocitos \u00a0y\u00a0c\u00e9lulas\u00a0endoteliales, \u00a0la\u00a0SP\u00a0\nincrementa \u00a0la\u00a0extravasaci\u00f3n \u00a0(permitiendo \u00a0el\u00a0paso\u00a0de\u00a0l\u00edquido),\u00a0la\u00a0migraci\u00f3n \u00a0y\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune\u00a0en\u00a0las\u00a0\nproximidades \u00a0del\u00a0tumor\u00a0y\u00a0de\u00a0las\u00a0teminaciones \u00a0nerviosas \u00a0sensoriales. \u00a0Estas,\u00a0a\u00a0su\u00a0vez,\u00a0pueden\u00a0estimular \u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0citoquinas \u00a0\n(en\u00a0el\u00a0sitio\u00a0donde\u00a0se\u00a0ha\u00a0producido \u00a0el\u00a0da\u00f1o\u00a0tisular)\u00a0promoviendo \u00a0de\u00a0este\u00a0modo\u00a0una\u00a0inflamaci\u00f3n \u00a0neurog\u00e9nica. \u00a0La\u00a0figura\u00a0ha\u00a0sido\u00a0\nrealizada\u00a0utilizando \u00a0Servier\u00a0Medial\u00a0Art.\u00a0\n\u00a0\nPosteriormente \u00a0factores\u00a0de\u00a0transcripci\u00f3n \u00a0como\u00a0c\u2010\nfos\u00a0o\u00a0c\u2010myc\u00a0son\u00a0activados \u00a0e\u00a0inducen\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0\nADN\u00a0y\u00a0proliferaci\u00f3n \u00a0celular\u00a0(Fig.\u00a019).\u00a0Otra\u00a0prote\u00edna\u00a0\nquinasa\u00a0que\u00a0es\u00a0posiblemente \u00a0activada\u00a0por\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0es\u00a0la\u00a0PKC\u03b4.\u00a0La\u00a0regulaci\u00f3n \u00a0del\u00a0\ncrecimiento \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0esta\u00a0prote\u00edna\u00a0se\u00a0ha\u00a0\ndescrito\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0humana\u00a0de\u00a0glioma\u00a0\nU373MG311\u00a0y\u00a0se\u00a0ha\u00a0propuesto \u00a0un\u00a0nuevo\u00a0\nmecanismo \u00a0por\u00a0el\u00a0cual\u00a0esta\u00a0l\u00ednea\u00a0celular\u00a0potencia\u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0Erk1/2\u00a0gracias\u00a0a\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR,\u00a0mediada\u00a0por\u00a0la\u00a0prote\u00edna\u00a0Src312,313.\u00a0\nEstudios\u00a0anteriores \u00a0realizados \u00a0por\u00a0Della\u00a0Rocca,\u00a0en\u00a0\n1997,\u00a0revelaron \u00a0que\u00a0las\u00a0subunidades \u00a0Gq/11\u00a0(del\u00a0\nreceptor\u00a0adren\u00e9rgico \u00a0\u03b11B)\u00a0y G\u03b2\u03b3\u00a0(disociada \u00a0de\u00a0la\u00a0\nprote\u00edna\u00a0Gi\u00a0del\u00a0receptor\u00a0adren\u00e9rgico \u00a0\u03b12A)\u00a0\ndependientes \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0PLC\u00a0aumentaban \u00a0\nlos\u00a0niveles\u00a0citoplasm\u00e1ticos \u00a0de\u00a0IP3,\u00a0resultando \u00a0en\u00a0\nun\u00a0aumento\u00a0de\u00a0Ca2+\u00a0citoplasm\u00e1tico. \u00a0Las\u00a0altas\u00a0\nconcentraciones \u00a0de\u00a0calcio\u00a0intracelular, \u00a0tal\u00a0vez\u00a0a\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n63\u00a0\n\u00a0\u00a0\n\u00a0\nFigura\u00a019.\u00a0Algunas\u00a0de\u00a0las\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0propuestas \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101.\u00a01)\u00a0La\u00a0subunidad \u00a0G\u03b1s\u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0es\u00a0responsable \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0segundo\u00a0mensajero \u00a0adenilin\u00a0ciclasa\u00a0(AC)\u00a0y\u00a0el\u00a0aumento\u00a0del\u00a0adenos\u00edn\u00a0\nmonofosfato \u00a0c\u00edclico\u00a0(AMPc).\u00a0Por\u00a0lo\u00a0general\u00a0se\u00a0cree\u00a0que\u00a0este\u00a0proceso\u00a0de\u00a0aumentar \u00a0el\u00a0AMPc\u00a0da\u00a0lugar\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nquinasa\u00a0A\u00a0(PKA),\u00a0y\u00a0que\u00a0esta\u00a0fosforila\u00a0el\u00a0factor\u00a0de\u00a0trancripci\u00f3n \u00a0CREB\u00a0(del\u00a0ingl\u00e9s,\u00a0cAMP\u2010responsive \u00a0element\u00a0CRE\u2010binding\u00a0protein ).\u00a0\nCREB\u00a0se\u00a0une\u00a0al\u00a0elemento \u00a0de\u00a0respuesta \u00a0a\u00a0cAMP\u00a0(CRE)\u00a0de\u00a0un\u00a0gen\u00a0diana\u00a0y\u00a0afecta\u00a0negativamente \u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB256.\u00a02)\u00a0La\u00a0\ninhibici\u00f3n \u00a0de\u00a0la\u00a0AC,\u00a0es\u00a0llevada\u00a0a\u00a0cabo\u00a0por\u00a0la\u00a0prote\u00edna\u00a0Gi\u00a0sensible\u00a0a\u00a0la\u00a0toxina\u00a0pertusica254.\u00a0Por\u00a0otro\u00a0lado\u00a0las\u00a0subunidades \u00a0Gi\u00a0y\u00a0\u03b2\u03b3\u00a0\npotencian \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Erk1/2\u00a0gracias\u00a0a\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0mediada\u00a0por\u00a0la\u00a0prote\u00edna\u00a0Src.\u00a03)\u00a0La\u00a0SP\u00a0al\u00a0unirse\u00a0a\u00a0su\u00a0receptor\u00a0\nestimula\u00a0el\u00a0intercambio \u00a0de\u00a0GDP\u00a0por\u00a0GTP\u00a0en\u00a0la\u00a0subunidad \u00a0G\u03b1q\u00a0y\u00a0la\u00a0subsecuente \u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PLC.\u00a0Esta\u00a0enzima\u00a0cataliza\u00a0la\u00a0\nconversi\u00f3n \u00a0de\u00a0PIP2\u00a0en\u00a0los\u00a0segundos \u00a0mensajeros \u00a0IP3\u00a0y\u00a0DAG,\u00a0que\u00a0estimulan \u00a0la\u00a0movilizaci\u00f3n \u00a0de\u00a0calcio\u00a0y\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PKC,\u00a0\nrespectivamente. \u00a0La\u00a0PKC\u00a0adem\u00e1s,\u00a0posiblemente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0prote\u00ednas \u00a0quinasas\u00a0no\u00a0receptoras \u00a0como\u00a0Src\u00a0o\u00a0Pyk2,\u00a0activan\u00a0la\u00a0v\u00eda\u00a0de\u00a0\nlas\u00a0MAPK,\u00a0pero\u00a0tambi\u00e9n\u00a0podr\u00eda\u00a0activar\u00a0directamente \u00a0la\u00a0prote\u00edna\u00a0Raf.\u00a0Otro\u00a0mecanismo \u00a0paralelo\u00a0que\u00a0regula\u00a0las\u00a0MAPK\u00a0ser\u00eda\u00a0el\u00a0\nproducido \u00a0durante\u00a0la\u00a0internalizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0el\u00a0reclutamiento \u00a0de\u00a0sus\u00a0prote\u00ednas \u00a0por\u00a0parte\u00a0de\u00a0las\u00a0\u03b2\u2010arrestinas. \u00a0Aunque\u00a0\nse\u00a0desconoce \u00a0el\u00a0mecanismo, \u00a0la\u00a0prote\u00edna\u00a0Erk1/2\u00a0tambi\u00e9n\u00a0est\u00e1\u00a0involucrada \u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB.\u00a0Esta\u00a0subunidad \u00a0G\u03b1q\u00a0tambi\u00e9n\u00a0\nmedia\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0IL\u20106\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0MAPK\u00a0p38.\u00a04)\u00a0Por\u00a0\u00faltimo,\u00a0la\u00a0subunidad \u00a0G\u03b112/13,\u00a0es\u00a0la\u00a0responsable \u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0Rho/Rock \u00a0que\u00a0directamente \u00a0regulan\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0cadena\u00a0ligera\u00a0reguladora \u00a0de\u00a0la\u00a0miosina\u00a0(MLC).\u00a0La\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0esta\u00a0prote\u00edna\u00a0est\u00e1\u00a0asociada\u00a0a\u00a0la\u00a0reorganizaci\u00f3n \u00a0del\u00a0citoesqueleto \u00a0y\u00a0a\u00a0la\u00a0migraci\u00f3n \u00a0celular.\u00a0Los\u00a0d\u00edmeros\u00a0\u03b2\u03b3\u00a0activan\u00a0\nprote\u00ednas \u00a0como\u00a0por\u00a0ejemplo,\u00a0Src,\u00a0PI3K,\u00a0PLC.\u00a0La\u00a0figura\u00a0ha\u00a0sido\u00a0realizada\u00a0utilizando \u00a0Servier\u00a0Medial\u00a0Art.\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n64\u00a0\n\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0calmodulina, \u00a0conduc\u00edan \u00a0a\u00a0una\u00a0\nactivaci\u00f3n \u00a0de\u00a0una\u00a0quinasa\u00a0llamada\u00a0prolina\u2010tirosina\u00a0\nquinasa\u00a0rica\u00a02\u00a0(Pyk2,\u00a0del\u00a0ingl\u00e9s\u00a0protein\u00a0tyrosine\u00a0\nkinase\u00a02)\u00a0asociada\u00a0a\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0de\u00a0\nadhesiones \u00a0focales\u00a0(FAK).\u00a0A\u00a0su\u00a0vez\u00a0esta\u00a0Pyk2\u00a0\n(conocida \u00a0actualmente \u00a0como\u00a0PTK2B),\u00a0regulaba\u00a0la\u00a0\nactividad\u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0Src.\u00a0Prote\u00ednas \u00a0\nadaptadoras \u00a0dependientes \u00a0de\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\ntirosinas\u00a0Src,\u00a0como\u00a0Shc,\u00a0reclutan\u00a0al\u00a0complejo \u00a0Grb2\u2010\nSOS\u00a0en\u00a0la\u00a0membrana \u00a0plasm\u00e1tica \u00a0e\u00a0inician\u00a0la\u00a0\ncascada\u00a0de\u00a0fosforilaci\u00f3n \u00a0que\u00a0conduce\u00a0a\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0Erk1/2\u00a0que\u00a0desencadena \u00a0en\u00a0v\u00edas\u00a0de\u00a0\nproliferaci\u00f3n \u00a0celular314.\u00a0\u00a0\nLa\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0MAPK,\u00a0seg\u00fan\u00a0algunos\u00a0\nestudios,\u00a0no\u00a0solo\u00a0depende\u00a0de\u00a0las\u00a0prote\u00ednas \u00a0G\u00a0y\u00a0de\u00a0\nsu\u00a0v\u00eda\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0can\u00f3nica\u00a0o\u00a0cl\u00e1sica,\u00a0sino\u00a0del\u00a0\ncomplejo \u00a0de\u00a0andamiaje \u00a0multiproteico \u00a0formado\u00a0\npara\u00a0la\u00a0internalizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0u\u00a0otros\u00a0\nGPCRs.\u00a0En\u00a0algunos\u00a0modelos\u00a0como\u00a0el\u00a0del\u00a0receptor\u00a0\nactivado\u00a0por\u00a0proteasas \u00a02\u00a0(PAR2,\u00a0del\u00a0ingl\u00e9s\u00a0G\u03b1q\u2010\ncoupled\u00a0proteinase\u2013activated \u00a0receptor\u00a02),\u00a0la\u00a0\ninteracci\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0con\u00a0prote\u00ednas \u00a0de\u00a0\ninternalizaci\u00f3n \u00a0como\u00a0las\u00a0\u03b2\u2010arrestinas \u00a0origina\u00a0una\u00a0\nretenci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Raf\u20101\u00a0y\u00a0la\u00a0prote\u00edna\u00a0\nfosforilada \u00a0Erk1/2\u00a0en\u00a0el\u00a0citoplasma \u00a0provocando \u00a0\nque\u00a0no\u00a0pueda\u00a0traslocarse \u00a0al\u00a0n\u00facleo315.\u00a0En\u00a0cambio,\u00a0\notros\u00a0como\u00a0el\u00a0receptor\u00a0\u03b22\u2010adren\u00e9rgico \u00a0(\u03b22\u2010AR),\u00a0se\u00a0\ninternalizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0complejo \u00a0formado\u00a0por\u00a0\u03b2\u2010\narrestinas, \u00a0Src\u00a0y\u00a0Erk316.\u00a0En\u00a0el\u00a0caso\u00a0del\u00a0receptor\u00a0\u03b22\u2010\nAR\u00a0se\u00a0produce\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Erk1/2\u00a0que\u00a0media\u00a0\nun\u00a0conjunto\u00a0distinto\u00a0de\u00a0respuestas \u00a0celulares\u00a0que\u00a0\nlas\u00a0producidas \u00a0por\u00a0PAR2,\u00a0ya\u00a0que\u00a0Erk1/2\u00a0no\u00a0queda\u00a0\nretenido\u00a0en\u00a0el\u00a0citoplasma. \u00a0Estas\u00a0diferencias \u00a0\npodr\u00edan\u00a0a\u00a0ser\u00a0debidas\u00a0a\u00a0que\u00a0los\u00a0distintos\u00a0\ncomplejos \u00a0proteicos \u00a0de\u00a0andamiaje \u00a0serian\u00a0los\u00a0\nresponsables \u00a0de\u00a0la\u00a0distinta\u00a0localizaci\u00f3n \u00a0subcelular \u00a0\nde\u00a0las\u00a0quinasas\u00a0activadas \u00a0durante\u00a0la\u00a0\ninternalizaci\u00f3n, \u00a0y\u00a0por\u00a0tanto\u00a0gobernar\u00edan \u00a0de\u00a0una\u00a0\nforma\u00a0u\u00a0otra\u00a0el\u00a0potencial \u00a0mitog\u00e9nico \u00a0de\u00a0cada\u00a0se\u00f1al\u00a0\nen\u00a0concreto. \u00a0\nAdem\u00e1s\u00a0de\u00a0que\u00a0el\u00a0requisito\u00a0para\u00a0la\u00a0endocitosis \u00a0\ndependiente \u00a0de\u00a0\u03b2\u2010arrestinas \u00a0difiere\u00a0entre\u00a0tipos\u00a0de\u00a0\nreceptores, \u00a0esta\u00a0variaci\u00f3n\u00a0tambi\u00e9n\u00a0parece\u00a0ser\u00a0\nindependiente \u00a0del\u00a0tipo\u00a0de\u00a0c\u00e9lula\u00a0ya\u00a0que\u00a0los\u00a0dos\u00a0\nreceptores \u00a0(NK\u20101R\u00a0y\u00a0PAR2)\u00a0expresados \u00a0en\u00a0la\u00a0misma\u00a0l\u00ednea\u00a0celular\u00a0(KNRK)\u00a0inducen\u00a0la\u00a0formaci\u00f3n \u00a0\nde\u00a0complejos \u00a0de\u00a0andamiaje \u00a0proteicos \u00a0distintos224.\u00a0\nPor\u00a0lo\u00a0tanto,\u00a0son\u00a0necesarios \u00a0mejores\u00a0estudios\u00a0para\u00a0\nidentificar \u00a0la\u00a0zona\u00a0C\u2010terminal\u00a0de\u00a0los\u00a0GPCRS\u00a0\nresponsable \u00a0de\u00a0su\u00a0internalizaci\u00f3n, \u00a0ya\u00a0que\u00a0esta\u00a0cola\u00a0\ncitoplasm\u00e1tica \u00a0podr\u00eda\u00a0conferir\u00a0una\u00a0especificidad \u00a0u\u00a0\notra\u00a0dependiendo \u00a0de\u00a0c\u00f3mo\u00a0sea\u00a0y\u00a0ser\u00a0clave\u00a0para\u00a0las\u00a0\nprote\u00ednas \u00a0que\u00a0se\u00a0unan\u00a0a\u00a0ella.\u00a0En\u00a0un\u00a0estudio\u00a0\nrealizado\u00a0en\u00a0el\u00a0a\u00f1o\u00a02000\u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0\nestimulaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0(sobreexpresado \u00a0\nen\u00a0c\u00e9lulas\u00a0KNRK\u00a0o\u00a0naturalmente \u00a0expresado \u00a0en\u00a0\nc\u00e9lulas\u00a0endoteliales) \u00a0por\u00a0parte\u00a0de\u00a0agonistas \u00a0como\u00a0\nla\u00a0SP\u00a0activaba\u00a0Erk1/2\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0mecanismo \u00a0\ndependiente \u00a0de\u00a0\u03b2 \u2010arrestinas. \u00a0La\u00a0SP\u00a0induc\u00eda\u00a0la\u00a0\nformaci\u00f3n \u00a0de\u00a0un\u00a0complejo \u00a0multiproteico \u00a0formado\u00a0\ncerca\u00a0de\u00a0la\u00a0membrana \u00a0plasm\u00e1tica \u00a0y\u00a0que\u00a0conten\u00eda\u00a0\n\u03b2\u2010arrestinas, \u00a0Src\u00a0y\u00a0Erk1/2.\u00a0Una\u00a0vez\u00a0activado\u00a0\nErk1/2,\u00a0\u00e9ste\u00a0se\u00a0translocaba \u00a0a\u00a0n\u00facleo\u00a0para\u00a0inducir\u00a0\nproliferaci\u00f3n \u00a0y\u00a0efectos\u00a0anti\u2010apopt\u00f3ticos224\u00a0(Fig.\u00a0\n20).\u00a0Adem\u00e1s\u00a0observaron \u00a0que\u00a0una\u00a0isoforma\u00a0\nmutada\u00a0truncada\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0no\u00a0\ninteractuaba \u00a0con\u00a0la\u00a0\u03b2\u2010arrestina\u00a0y\u00a0esto\u00a0mostraba \u00a0un\u00a0\ndeterioro \u00a0en\u00a0la\u00a0capacidad \u00a0para\u00a0activar\u00a0Erk1/2224.\u00a0\nSin\u00a0embargo, \u00a0se\u00a0necesitan \u00a0otros\u00a0estudios\u00a0para\u00a0\nidentificar \u00a0cu\u00e1les\u00a0son\u00a0las\u00a0v\u00edas\u00a0espec\u00edficas \u00a0por\u00a0las\u00a0\ncuales\u00a0se\u00f1aliza\u00a0la\u00a0isoforma\u00a0natural\u00a0truncada\u00a0del\u00a0\nreceptor\u00a0NK\u20101,\u00a0ya\u00a0que\u00a0se\u00a0encuentra \u00a0expresada \u00a0en\u00a0\nvarios\u00a0tipos\u00a0de\u00a0tumores\u00a0y\u00a0parece\u00a0ser\u00a0que\u00a0juega\u00a0un\u00a0\npapel\u00a0fundamental \u00a0en\u00a0la\u00a0proliferaci\u00f3n, \u00a0progresi\u00f3n \u00a0\ndel\u00a0tumor\u00a0e\u00a0integraci\u00f3n \u00a0en\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea267,292,317.\u00a0\nDurante\u00a0una\u00a0correcta\u00a0internalizaci\u00f3n \u00a0del\u00a0receptor, \u00a0\neste\u00a0se\u00a0internaliza \u00a0en\u00a0endosomas \u00a0tempranos \u00a0\ndurante\u00a0los\u00a0primeros\u00a0minutos\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0\ndel\u00a0agonista.\u00a0Esta\u00a0internalizaci\u00f3n \u00a0parece\u00a0ser\u00a0\ndependiente \u00a0de\u00a0clatrina\u00a0(prote\u00edna \u00a0que\u00a0recubre\u00a0las\u00a0\nves\u00edculas\u00a0intracelulares \u00a0y\u00a0que\u00a0se\u00a0une\u00a0a\u00a0la\u00a0\u03b2 \u2010\narrestina\u00a0durante\u00a0la\u00a0internalizaci\u00f3n \u00a0de\u00a0\nreceptores). \u00a0En\u00a0las\u00a0etapas\u00a0tempranas \u00a0de\u00a0la\u00a0\ninternalizaci\u00f3n, \u00a0el\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0la\u00a0SP\u00a0parecen\u00a0\nestar\u00a0intactos,\u00a0pero\u00a0este\u00a0complejo \u00a0se\u00a0disocia\u00a0por\u00a0\nacidificaci\u00f3n \u00a0de\u00a0los\u00a0endosomas \u00a0m\u00e1s\u00a0tard\u00edos\u00a0y\u00a0la\u00a0SP\u00a0\nempieza\u00a0a\u00a0degradarse \u00a0lentamente \u00a0en\u00a0las\u00a0ves\u00edculas\u00a0\nperinucleares225,318.\u00a0En\u00a0cambio\u00a0el\u00a0receptor\u00a0NK\u20101,\u00a0es\u00a0\nun\u00a0GPCR\u00a0de\u00a0clase\u00a0B,\u00a0y\u00a0aunque\u00a0el\u00a0reciclaje\u00a0de\u00a0estos\u00a0\nreceptores \u00a0es\u00a0m\u00e1s\u00a0lento\u00a0y\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0\u03b2\u2010arrestinas \u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n65\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a020.\u00a0Internalizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0Una\u00a0vez\u00a0se\u00a0ha\u00a0unido\u00a0el\u00a0ligando\u00a0al\u00a0receptor, \u00a0se\u00a0desencadena \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nprote\u00ednas \u00a0G\u00a0y\u00a0activaci\u00f3n \u00a0de\u00a0sus\u00a0efectores. \u00a0Por\u00a0otro\u00a0lado\u00a0la\u00a0prote\u00edna\u00a0GRK\u00a0fosforila\u00a0residuos\u00a0de\u00a0la\u00a0cola\u00a0citoplasm\u00e1tica \u00a0del\u00a0receptor\u00a0\nunido\u00a0al\u00a0agonista\u00a0y\u00a0\nrecluta\u00a0a\u00a0la\u00a0\u03b2\u2010arrestina\u00a0y\u00a0forma\u00a0complejos \u00a0estables\u00a0en\u00a0los\u00a0GPCR\u00a0de\u00a0clase\u00a0B.\u00a0Las\u00a0\u03b2\u2010arrestinas \u00a0unidas\u00a0al\u00a0receptor\u00a0\nact\u00faan\u00a0como\u00a0prote\u00ednas \u00a0adaptadoras \u00a0para\u00a0otras\u00a0mol\u00e9culas \u00a0como\u00a0la\u00a0clatrina,\u00a0AP\u20102\u00a0y\u00a0dinamina \u00a0que\u00a0son\u00a0importantes \u00a0para\u00a0la\u00a0\nformaci\u00f3n \u00a0de\u00a0las\u00a0depresiones \u00a0de\u00a0membranas \u00a0revestidas \u00a0de\u00a0clatrina.\u00a0La\u00a0\u03b2\u2010arrestina\u00a0puede\u00a0reclutar\u00a0a\u00a0prote\u00ednas \u00a0como\u00a0Src,\u00a0Erk,\u00a0u\u00a0\notras\u00a0MAPK\u00a0y\u00a0desencadenar \u00a0cascadas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0intracelular. \u00a0La\u00a0figura\u00a0ha\u00a0sido\u00a0realizada\u00a0utilizando \u00a0Servier\u00a0Medial\u00a0Art.\u00a0\n\u00a0\nes\u00a0m\u00e1s\u00a0estable,\u00a0es\u00a0reciclado\u00a0de\u00a0nuevo\u00a0a\u00a0la\u00a0\nmembrana \u00a0plasm\u00e1tica \u00a0y\u00a0raramente \u00a0degradado. \u00a0\u00a0\nLa\u00a0internalizaci\u00f3n \u00a0y\u00a0reciclaje\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0\nparece\u00a0ser\u00a0el\u00a0mecanismo \u00a0para\u00a0modular\u00a0las\u00a0\nrespuestas \u00a0celulares\u00a0a\u00a0la\u00a0SP,\u00a0y\u00a0que\u00a0aunque\u00a0la\u00a0SP\u00a0\nes\u00a0degradada, \u00a0la\u00a0recuperaci\u00f3n \u00a0del\u00a0receptor\u00a0hacia\u00a0\nla\u00a0membrana \u00a0plasm\u00e1tica \u00a0no\u00a0parece\u00a0ser\u00a0\ndependiente \u00a0de\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0nueva\u00a0prote\u00edna318.\u00a0\nLa\u00a0SP,\u00a0adem\u00e1s\u00a0de\u00a0su\u00a0actividad\u00a0mitog\u00e9nica, \u00a0\ntambi\u00e9n\u00a0es\u00a0capaz\u00a0de\u00a0estimular \u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0a\u00a0partir\u00a0de\u00a0c\u00e9lulas\u00a0normales \u00a0y\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmunitario \u00a0del\u00a0microambiente \u00a0\ntumoral\u00a0para\u00a0favorecer \u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0En\u00a0c\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0la\u00a0SP\u00a0tiene\u00a0la\u00a0\ncapacidad \u00a0de\u00a0estimular \u00a0la\u00a0producci\u00f3n \u00a0de\u00a0\ncitoquinas \u00a0como\u00a0la\u00a0IL\u20101\u03b2,\u00a0IL\u20106,\u00a0IL\u20108,\u00a0y\u00a0citoquinas \u00a0\nresponsables \u00a0de\u00a0la\u00a0actividad\u00a0autocrina/paracrina \u00a0\nde\u00a0gliomas\u00a0como\u00a0el\u00a0factor\u00a0inhibidor\u00a0de\u00a0la\u00a0\nleucemia\u00a0(LIF,\u00a0del\u00a0ingl\u00e9s\u00a0leukaemia \u00a0inhibiting \u00a0\nfactor )\u00a0y\u00a0el\u00a0GM\u2010CSF\u00a0entre\u00a0otros319\u00a0(Fig.\u00a019).\u00a0La\u00a0\nregulaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0citoquinas \u00a0como\u00a0\npor\u00a0ejemplo\u00a0la\u00a0IL\u20101\u03b2\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0astrocitoma \u00a0\nest\u00e1\u00a0mediada\u00a0por\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0SP\u00a0al\u00a0receptor\u00a0NK\u20101\u00a0\nque,\u00a0una\u00a0vez\u00a0activado,\u00a0fosforila\u00a0a\u00a0p38\u00a0MAPK/JNK \u00a0\no\u00a0activa\u00a0NF\u2010\u03baB,\u00a0prote\u00edna\u00a0de\u00a0uni\u00f3n\u00a0al\u00a0ADN\u00a0\nvinculando \u00a0as\u00ed\u00a0su\u00a0funci\u00f3n\u00a0con\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n66\u00a0\n\u00a0ADN319.\u00a0El\u00a0gen\u00a0TACR1\u00a0tambi\u00e9n\u00a0tiene\u00a0dominios \u00a0\nputativos \u00a0de\u00a0uni\u00f3n\u00a0a\u00a0NF\u2010\u03baB\u00a0y\u00a0se\u00a0ha\u00a0propuesto \u00a0que\u00a0\ndado\u00a0que\u00a0tanto\u00a0la\u00a0SP\u00a0como\u00a0la\u00a0IL\u20101\u03b2,\u00a0participan \u00a0en\u00a0\nla\u00a0inducci\u00f3n \u00a0de\u00a0NF\u2010\u03baB,\u00a0estos\u00a0factores\u00a0participar\u00edan \u00a0\nen\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0del\u00a0\nreceptor\u00a0NK\u20101320.\u00a0Un\u00a0efecto\u00a0parecido\u00a0se\u00a0observ\u00f3\u00a0\nen\u00a0c\u00e9lulas\u00a0U87\u00a0MG\u00a0bajo\u00a0tratamiento \u00a0con\u00a0IL\u20101\u03b2.\u00a0\nEstas\u00a0c\u00e9lulas\u00a0presentaban \u00a0una\u00a0elevada\u00a0expresi\u00f3n \u00a0\ndel\u00a0ARNm\u00a0del\u00a0gen\u00a0TACR1321.\u00a0\u00a0\nLas\u00a0c\u00e9lulas\u00a0U373\u00a0MG\u00a0liberan\u00a0IL\u20106\u00a0adem\u00e1s\u00a0de\u00a0la\u00a0IL\u2010\n1\u03b2.\u00a0Sin\u00a0embargo, \u00a0parece\u00a0ser\u00a0que\u00a0esta\u00a0vez\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0esta\u00a0citoquina \u00a0es\u00a0independiente \u00a0de\u00a0\nNF\u2010\u03baB.\u00a0Fiebich\u00a0y\u00a0colaboradores \u00a0demostraron \u00a0que\u00a0\nen\u00a0la\u00a0l\u00ednea\u00a0U373\u00a0MG\u00a0la\u00a0SP\u00a0activa\u00a0Erk1/2\u00a0MAPK\u00a0y\u00a0\np38\u00a0MAPK/JNK, \u00a0y\u00a0que\u00a0\u00e9sta\u00a0\u00faltima\u00a0opera\u00a0\nindependientemente \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB,\u00a0\npero\u00a0que\u00a0induce\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0IL\u20106\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101/SP322\u00a0(Fig.\u00a019).\u00a0\nHay\u00a0que\u00a0remarcar\u00a0en\u00a0este\u00a0aspecto\u00a0que\u00a0la\u00a0IL\u20106\u00a0\nparticipa\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0gliomas323.\u00a0Sin\u00a0\nembargo, \u00a0el\u00a0grupo\u00a0de\u00a0Pothoulakis \u00a0demuestra \u00a0que\u00a0\nla\u00a0SP\u00a0activa\u00a0r\u00e1pida\u00a0y\u00a0persistentemente \u00a0la\u00a0PKC\u03b4\u00a0en\u00a0\nc\u00e9lulas\u00a0epiteliales \u00a0de\u00a0c\u00f3lon,\u00a0transfectadas \u00a0con\u00a0\nTACR1\u00a0promoviendo \u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0IL\u20108.\u00a0La\u00a0SP\u00a0\ninduce\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0y\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0\nIL\u20108\u00a0en\u00a0\u00e9stas\u00a0c\u00e9lulas,\u00a0pero\u00a0dependiente \u00a0de\u00a0la\u00a0v\u00eda\u00a0\nde\u00a0las\u00a0Rho\u00a0GTPasas\u00a0y\u00a0PKC\u03b4,\u00a0y\u00a0no\u00a0de\u00a0la\u00a0liberaci\u00f3n \u00a0\nde\u00a0calcio\u00a0o\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Erk\u00a0244. \nLa\u00a0participaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0mediada\u00a0por\u00a0prote\u00ednas \u00a0\nG\u00a0ocurre\u00a0en\u00a0varios\u00a0tipos\u00a0celulares. \u00a0Se\u00a0ha\u00a0\ndemostrado \u00a0que\u00a0las\u00a0taquiquininas \u00a0activan\u00a0NF\u2010\u03baB\u00a0y\u00a0\nestimulan \u00a0la\u00a0producci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010\ninflamatorias \u00a0en\u00a0una\u00a0variedad\u00a0de\u00a0tipo\u00a0celulares: \u00a0\nc\u00e9lulas\u00a0epiteliales \u00a0de\u00a0colon244,\u00a0macr\u00f3fagos324,\u00a0\nmastocitos325,\u00a0linfocitos\u00a0T326,\u00a0c\u00e9lulas\u00a0de\u00a0\nastrocitoma320\u00a0y\u00a0c\u00e9lulas\u00a0epiteliales \u00a0de\u00a0\nadenocarcinoma \u00a0de\u00a0pulm\u00f3n\u00a0(A549)260.\u00a0Sin\u00a0\nembargo\u00a0no\u00a0todos\u00a0los\u00a0mecanismos \u00a0por\u00a0los\u00a0cuales\u00a0\nse\u00a0lleva\u00a0a\u00a0cabo\u00a0esta\u00a0activaci\u00f3n \u00a0son\u00a0totalmente \u00a0\nconocidos. \u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0SP\u00a0\nen\u00a0c\u00e9lulas\u00a0de\u00a0astrocitoma \u00a0es\u00a0dependiente \u00a0de\u00a0\ncalcio,\u00a0pero\u00a0no\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0epiteliales \u00a0de\u00a0\ncolon244,324.\u00a0\u00a0\nPor\u00a0el\u00a0contrario, \u00a0y\u00a0en\u00a0relaci\u00f3n\u00a0al\u00a0c\u00e1ncer,\u00a0Williams\u00a0\ny\u00a0colaboradores \u00a0describieron \u00a0que\u00a0exist\u00eda\u00a0una\u00a0dependencia \u00a0de\u00a0calcio\u00a0y\u00a0Erk,\u00a0para\u00a0la\u00a0correcta\u00a0\nactivaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0\nc\u00e9lulas\u00a0 A549260.\u00a0 Estos\u00a0 investigadores, \u00a0\ntransfectaron \u00a0establemente \u00a0TACR1\u00a0en\u00a0este\u00a0tipo\u00a0\ncelular\u00a0observando \u00a0que\u00a0la\u00a0subunidad \u00a0Gq/11\u00a0era\u00a0la\u00a0\nmayor\u00a0responsable \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0y\u00a0\nque\u00a0en\u00a0esta\u00a0activaci\u00f3n \u00a0estaban\u00a0involucradas \u00a0la\u00a0\nPLC,\u00a0el\u00a0calcio,\u00a0la\u00a0PKC,\u00a0Ras/Raf/Erk \u00a0y\u00a0la\u00a0\ndegradaci\u00f3n \u00a0por\u00a0proteasoma \u00a0de\u00a0I\u03baB\u00a0(Fig.\u00a019).\u00a0A\u00a0\ntrav\u00e9s\u00a0de\u00a0distintos\u00a0inhibidores \u00a0farmacol\u00f3gicos \u00a0\npudieron\u00a0comprobar \u00a0que\u00a0todas\u00a0estas\u00a0prote\u00ednas \u00a0\neran\u00a0necesarias \u00a0para\u00a0la\u00a0correcta\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\n\u03baB\u00a0.\u00a0Los\u00a0eventos\u00a0por\u00a0los\u00a0cuales\u00a0Erk\u00a0activa\u00a0NF\u2010\u03baB,\u00a0\nno\u00a0se\u00a0han\u00a0caracterizado \u00a0completamente. \u00a0Hay\u00a0\nestudios\u00a0que\u00a0hipotetizan \u00a0sobre\u00a0el\u00a0hecho\u00a0que\u00a0la\u00a0\nquinasa\u00a0IK\u03b2\u00a0(IKK)\u00a0es\u00a0activada\u00a0por\u00a0Erk\u00a0\n(presumiblemente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0otras\u00a0quinasas\u00a0\nintermediarias)327\u00a0o\u00a0que\u00a0la\u00a0interacci\u00f3n \u00a0de\u00a0Erk\u00a0con\u00a0\nla\u00a0subunidad \u00a0p65\u00a0de\u00a0NF\u2010\u03baB\u00a0es\u00a0directa\u00a0328\u00a0(Fig.\u00a019).\u00a0\nPero\u00a0Williams\u00a0describe\u00a0que\u00a0su\u00a0sistema\u00a0parece\u00a0\nproceder\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0v\u00eda\u00a0cl\u00e1sica\u00a0que\u00a0implica\u00a0la\u00a0\ndegradaci\u00f3n \u00a0proteasomal \u00a0de\u00a0I\u03baB260.\u00a0Aunque\u00a0en\u00a0\nparticular, \u00a0NF\u2010\u03baB\u00a0puede\u00a0tener\u00a0tanto\u00a0efectos\u00a0anti\u2010\napopt\u00f3ticos329\u00a0como\u00a0efectos\u00a0pro\u2010apopt\u00f3ticos330\u00a0\ndependiendo \u00a0del\u00a0est\u00edmulo\u00a0y\u00a0el\u00a0contexto\u00a0celular,\u00a0\nen\u00a0este\u00a0estudio\u00a0parece\u00a0ser\u00a0importante \u00a0su\u00a0\nactivaci\u00f3n \u00a0ya\u00a0que\u00a0nos\u00a0muestra\u00a0como\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0en\u00a0c\u00e9lulas\u00a0tumorales, \u00a0se\u00a0activan\u00a0\nv\u00edas\u00a0responsables \u00a0de\u00a0la\u00a0producci\u00f3n \u00a0de\u00a0citoquinas \u00a0\npro\u2010inflamat\u00f3rias \u00a0(propagaci\u00f3n \u00a0de\u00a0la\u00a0inflamaci\u00f3n) \u00a0\ny\u00a0v\u00edas\u00a0relacionadas \u00a0con\u00a0la\u00a0proliferaci\u00f3n \u00a0y\u00a0la\u00a0\nprogresi\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0cancerosas \u00a0(Fig.\u00a019).\u00a0\nOtras\u00a0de\u00a0la\u00a0v\u00edas\u00a0descritas\u00a0por\u00a0las\u00a0cuales\u00a0puede\u00a0\nactuar\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0es\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nserina/treonina \u00a0prote\u00edna\u00a0quinasa\u00a0Akt\u00a0o\u00a0tambi\u00e9n\u00a0\nconocida\u00a0como\u00a0prote\u00edna\u00a0quinasa\u00a0B\u00a0(PKB).\u00a0La\u00a0\nfosfoinositol \u00a03\u2010kinasa\u00a0o\u00a0PI3K\u00a0es\u00a0la\u00a0responsable \u00a0de\u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0Akt.\u00a0La\u00a0ruta\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0\nPI3K\u00a0juega\u00a0un\u00a0papel\u00a0fundamental \u00a0en\u00a0el\u00a0\nmetabolismo \u00a0del\u00a0c\u00e1ncer\u00a0331,\u00a0ya\u00a0que\u00a0contribuye \u00a0a\u00a0\nla\u00a0progresi\u00f3n \u00a0del\u00a0ciclo\u00a0celular\u00a0adem\u00e1s\u00a0de\u00a0\ndisminuir \u00a0la\u00a0apoptosis \u00a0e\u00a0incrementar \u00a0las\u00a0\ncapacidades \u00a0metast\u00e1sicas \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\ntumorales332,333.\u00a0La\u00a0PI3K\u00a0puede\u00a0ser\u00a0activada\u00a0a\u00a0\npartir\u00a0de\u00a0receptores \u00a0tirosina\u00a0quinasa\u00a0(RTKs)\u00a0y\u00a0a\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n67\u00a0\n\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0por\u00a0parte\u00a0de\u00a0\nintegrinas \u00a0o\u00a0GPCRs334.\u00a0No\u00a0se\u00a0conoce\u00a0exactamente \u00a0\ncomo\u00a0las\u00a0prote\u00ednas \u00a0G\u00a0activan\u00a0la\u00a0PI3K,\u00a0pero\u00a0si\u00a0se\u00a0\nsabe\u00a0que\u00a0la\u00a0PI3K\u00a0convierte \u00a0el\u00a0PIP2\u00a0en\u00a0un\u00a0segundo\u00a0\nmensajero, \u00a0el\u00a0PIP3\u00a0capaz\u00a0de\u00a0activar\u00a0a\u00a0AKt,\u00a0y\u00a0que\u00a0\nesta\u00a0acci\u00f3n\u00a0puede\u00a0ser\u00a0revertida\u00a0por\u00a0la\u00a0prote\u00edna\u00a0\nsupresora \u00a0de\u00a0tumores\u00a0PTEN\u00a0(del\u00a0ingl\u00e9s\u00a0\nphosphatase \u00a0and\u00a0tensin\u00a0homolog ).\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0\ndescrito\u00a0el\u00a0papel\u00a0que\u00a0juega\u00a0la\u00a0subuinad\u00a0G\u03b2\u03b3\u00a0en\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0PI3K,\u00a0ya\u00a0que\u00a0se\u00a0cree\u00a0que\u00a0existe\u00a0\nuna\u00a0activaci\u00f3n \u00a0directa\u00a0por\u00a0parte\u00a0del\u00a0d\u00edmero\u00a0\u03b2\u03b3334\u00a0\nhacia\u00a0la\u00a0quinasa\u00a0(Fig.\u00a019).\u00a0Akazawa\u00a0y\u00a0\ncolaboradores \u00a0describieron \u00a0que\u00a0la\u00a0estimulaci\u00f3n \u00a0\ndel\u00a0receptor\u00a0de\u00a0Bradiquinina \u00a0(un\u00a0receptor\u00a0de\u00a0la\u00a0\nmisma\u00a0familia\u00a0que\u00a0NK\u20101)\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0subunidad \u00a0\nG\u03b1q\u00a0y\u00a0\u03b2 1\u03b32\u00a0incrementaba \u00a0la\u00a0fosforilaci\u00f3n \u00a0y\u00a0\nactividad\u00a0de\u00a0Akt\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0PI3K\u00a0y\u00a0\u00e9sta\u00a0era\u00a0\nresponsable \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB\u00a0en\u00a0c\u00e9lulas\u00a0\nHeLa\u00a0transfectadas. \u00a0En\u00a0conjunto\u00a0todos\u00a0sus\u00a0\nresultados \u00a0suger\u00edan\u00a0que\u00a0la\u00a0v\u00eda\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0que\u00a0\nconduce\u00a0al\u00a0receptor\u00a0de\u00a0bradiquinina \u00a0a\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0IKK2,\u00a0implica\u00a0la\u00a0previa\u00a0activaci\u00f3n \u00a0de\u00a0\nG\u03b1q,\u00a0\u03b21\u03b32,\u00a0PI3K\u00a0y\u00a0Akt\u00a0(Fig.\u00a019).\u00a0Sin\u00a0embargo, \u00a0\nobservaron \u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0PI3K\u00a0y\u00a0Akt\u00a0solo\u00a0\ninhib\u00eda\u00a0parcialmente \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0\ncorriente\u00a0abajo,\u00a0por\u00a0lo\u00a0que\u00a0su\u00a0estudio\u00a0no\u00a0excluir\u00eda\u00a0\notras\u00a0v\u00edas\u00a0paralelas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0como\u00a0las\u00a0que\u00a0\nse\u00a0han\u00a0mencionado \u00a0anteriormente, \u00a0como\u00a0por\u00a0\nejemplo\u00a0la\u00a0v\u00eda\u00a0de\u00a0las\u00a0MAPK.\u00a0\u00a0\nAdem\u00e1s\u00a0describen \u00a0por\u00a0primera\u00a0vez\u00a0que\u00a0la\u00a0\nisoforma\u00a0truncada\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0se\u00a0\nencuentra \u00a0constitutivamente \u00a0activa\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0\nglioblastoma \u00a0y\u00a0esto\u00a0conlleva\u00a0a\u00a0un\u00a0incremento \u00a0en\u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0Akt\u00a0y\u00a0la\u00a0consecuente \u00a0activaci\u00f3n \u00a0\nde\u00a0NF\u2010\u03baB.\u00a0En\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Akt\u00a0parecen\u00a0estar\u00a0\nimplicadas \u00a0directamente \u00a0la\u00a0PI3K\u00a0y\u00a0la\u00a0prote\u00edna\u00a0Src,\u00a0\ny\u00a0en\u00a0cambio\u00a0el\u00a0receptor\u00a0EGFR,\u00a0parece\u00a0mediar\u00a0solo\u00a0\nparcialmente \u00a0su\u00a0activaci\u00f3n \u00a0ya\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0\nsu\u00a0actividad\u00a0mediante \u00a0el\u00a0inhibidor\u00a0qu\u00edmico\u00a0\nAG1478\u00a0solo\u00a0provoca\u00a0una\u00a0peque\u00f1a\u00a0disminuci\u00f3n \u00a0\nen\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0Akt335.\u00a0Inhibidores \u00a0qu\u00edmicos\u00a0\nde\u00a0NK\u20101R\u00a0como\u00a0L\u2010733,060,\u00a0inducen\u00a0un\u00a0aumento\u00a0\nen\u00a0el\u00a0clivaje\u00a0de\u00a0la\u00a0capsasa\u20103\u00a0en\u00a0estas\u00a0c\u00e9lulas,\u00a0\nreforzando \u00a0la\u00a0idea\u00a0del\u00a0importante \u00a0papel\u00a0que\u00a0\njuega\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0la\u00a0apoptosis \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales. \u00a0Finalmente, \u00a0en\u00a0CM\u00a0tambi\u00e9n\u00a0\nhan\u00a0sido\u00a0descritas\u00a0varias\u00a0aproximaciones \u00a0que\u00a0\ndemuestran \u00a0una\u00a0implicaci\u00f3n \u00a0directa\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0y\u00a0estas\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0proliferaci\u00f3n \u00a0\ny\u00a0supervivencia. \u00a0Como\u00a0ya\u00a0se\u00a0ha\u00a0mencionado \u00a0\nanteriormente \u00a0trabajos\u00a0de\u00a0la\u00a0Dra.\u00a0Rameshwar \u00a0y\u00a0el\u00a0\nDr.\u00a0Gasc\u00f3n\u00a0revelaban \u00a0que\u00a0los\u00a0receptores \u00a0NK\u20101\u00a0y\u00a0\nNK\u20102\u00a0son\u00a0en\u00a0parte\u00a0responsables \u00a0de\u00a0la\u00a0\nproliferaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM,\u00a0y\u00a0que\u00a0las\u00a0\ntaquiquininas \u00a0y\u00a0sus\u00a0receptores \u00a0estaban\u00a0\nimplicados \u00a0en\u00a0la\u00a0integraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nmamarias \u00a0en\u00a0el\u00a0estroma\u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea307.\u00a0Otros\u00a0\ntrabajos\u00a0sin\u00a0embargo, \u00a0refuerzan \u00a0la\u00a0idea\u00a0que\u00a0el\u00a0\nfactor\u00a0nuclear\u00a0NF\u2010\u03baB\u00a0tiene\u00a0un\u00a0papel\u00a0central\u00a0en\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0la\u00a0isoforma\u00a0truncada\u00a0del\u00a0receptor\u00a0\nNK\u20101292.\u00a0A\u00a0pesar\u00a0de\u00a0que\u00a0NK1\u2010Tr\u00a0falla\u00a0en\u00a0la\u00a0\ndesensibilizaci\u00f3n \u00a0del\u00a0receptor, \u00a0esto\u00a0no\u00a0impide\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0C,\u00a0y\u00a0en\u00a0trabajos\u00a0\nanteriores \u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0esta\u00a0isoforma\u00a0\nes\u00a0capaz\u00a0de\u00a0transformar \u00a0c\u00e9lulas\u00a0no\u00a0tumorales \u00a0\nmamarias \u00a0en\u00a0c\u00e9lulas\u00a0con\u00a0un\u00a0mayor\u00a0grado\u00a0de\u00a0\nproliferaci\u00f3n \u00a0y\u00a0clonogenicidad317.\u00a0A\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\ntransfecci\u00f3n \u00a0de\u00a0un\u00a0dominante \u2010negativo\u00a0de\u00a0I\u03baB\u00a0\n(que\u00a0previene\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nsupresora \u00a0de\u00a0NF\u2010\u03baB\u00a0y\u00a0por\u00a0tanto\u00a0inhibe\u00a0su\u00a0\nactivaci\u00f3n) \u00a0s\u00f3lo\u00a0se\u00a0detectaba \u00a0expresi\u00f3n \u00a0en\u00a0NK1\u2010FL\u00a0\nen\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0En\u00a0cambio\u00a0la\u00a0transfecci\u00f3n \u00a0con\u00a0\nla\u00a0prote\u00edna\u00a0I\u03baB,\u00a0en\u00a0su\u00a0estado\u00a0natural,\u00a0promov\u00eda \u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0ambas\u00a0isoformas \u00a0del\u00a0receptor. \u00a0Estos\u00a0\nresultados \u00a0apoyaban \u00a0a\u00a0los\u00a0mencionados \u00a0\nanteriormente, \u00a0relacionando \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nNK1\u2010Tr\u00a0con\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB292.\u00a0La\u00a0\ninteracci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0y\u00a0cultivos\u00a0\nprimarios \u00a0con\u00a0el\u00a0estroma\u00a0inhib\u00eda\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nNK1\u2010Tr\u00a0y\u00a0de\u00a0la\u00a0subunidad \u00a0p65\u00a0de\u00a0NF\u2010\u03baB292.\u00a0\u00a0\nPor\u00a0lo\u00a0tanto,\u00a0todos\u00a0estos\u00a0estudios\u00a0nos\u00a0han\u00a0\naportado \u00a0evidencias \u00a0sobre\u00a0mol\u00e9culas \u00a0clave\u00a0que\u00a0\nparticipan \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0\nen\u00a0varios\u00a0tipos\u00a0celulares\u00a0no\u00a0tumorales \u00a0y\u00a0\ntumorales, \u00a0como\u00a0son\u00a0las\u00a0prote\u00ednas \u00a0p42/44\u00a0\n(MAPK),\u00a0p38\u00a0MAPK,\u00a0NF\u2010\u03baB,\u00a0PI3K,\u00a0Akt,\u00a0EGFR\u00a0y\u00a0Src\u00a0\nresponsables \u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0e\u00a0inhibici\u00f3n \u00a0\ncelular,\u00a0efectos\u00a0anti\u00a0y\u00a0pro\u2010apopt\u00f3ticos \u00a0y\u00a0\nmigraci\u00f3n \u00a0celular\u00a0y\u00a0met\u00e1stasis \u00a0(Fig.\u00a019).\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n68\u00a0\n\u00a06.4.\u00a0Antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0\nLa\u00a0modulaci\u00f3n \u00a0de\u00a0diversas\u00a0funciones \u00a0fisiol\u00f3gicas \u00a0y\u00a0\npatol\u00f3gicas \u00a0por\u00a0parte\u00a0del\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0\nha\u00a0desencadenado \u00a0la\u00a0b\u00fasqueda \u00a0de\u00a0mol\u00e9culas \u00a0\nantagonistas \u00a0contra\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0e\u00a0incluso\u00a0\ncontra\u00a0su\u00a0ligando\u00a0m\u00e1s\u00a0espec\u00edfico \u00a0(tambi\u00e9n\u00a0\nconocidos \u00a0como\u00a0antagonistas \u00a0de\u00a0receptores \u00a0\ntaquiquin\u00e9rgicos, \u00a0antagonistas \u00a0de\u00a0taquiquininas, \u00a0\nantagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0no\u00a0pept\u00eddicos, \u00a0\nantagonistas \u00a0del\u00a0receptor\u00a0de\u00a0la\u00a0SP\u00a0(SPA),\u00a0\nantagonistas \u00a0de\u00a0SP,\u00a0antagonistas \u00a0an\u00e1logos\u00a0de\u00a0la\u00a0\nSP,\u00a0o\u00a0p\u00e9ptido\u00a0antagonista \u00a0G)245,299.\u00a0Inicialmente \u00a0\nlos\u00a0antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0eran\u00a0\npept\u00eddicos, \u00a0pero\u00a0como\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0compuestos \u00a0\npept\u00eddicos, \u00a0presentaban \u00a0problemas \u00a0de\u00a0potencia, \u00a0\nsolubilidad \u00a0y\u00a0biodisponibilidad. \u00a0Desde\u00a0que\u00a0se\u00a0\ndescubri\u00f3 \u00a0el\u00a0primer\u00a0antagonista \u00a0no\u00a0pept\u00eddico \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0(CP\u201096,345),\u00a0varios\u00a0grupos\u00a0han\u00a0\nproducido \u00a0diversos\u00a0antagonistas \u00a0altamente \u00a0\nselectivos336\u00a0y\u00a0varios\u00a0antagonistas \u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0est\u00e1n\u00a0actualmente \u00a0dentro\u00a0de\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0para\u00a0el\u00a0tratamiento \u00a0de\u00a0diferentes \u00a0\nenfermedades337.\u00a0Debido\u00a0a\u00a0que\u00a0las\u00a0funciones \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0est\u00e1n\u00a0ampliamente \u00a0distribuidas \u00a0\ntanto\u00a0a\u00a0nivel\u00a0de\u00a0sistema\u00a0nervioso\u00a0central\u00a0como\u00a0\nperif\u00e9rico, \u00a0ha\u00a0sido\u00a0importante \u00a0el\u00a0hallazgo\u00a0de\u00a0estos\u00a0\ncompuestos \u00a0con\u00a0la\u00a0esperanza \u00a0de\u00a0que\u00a0puedan\u00a0\naportar\u00a0beneficios \u00a0cl\u00ednicos\u00a0como\u00a0ansiol\u00edticos, \u00a0\nanalg\u00e9sicos, \u00a0antidepresivos, \u00a0antiinflamatorios, \u00a0\nantiem\u00e9ticos, \u00a0antimigra\u00f1osos, \u00a0neuro\u00a0y\u00a0\nhepatoprotectores, \u00a0e\u00a0incluso\u00a0para\u00a0el\u00a0tratamiento \u00a0\nde\u00a0ciertas\u00a0formas\u00a0de\u00a0incontinencia \u00a0urinaria\u00a0(a\u00a0\nnivel\u00a0de\u00a0sistema\u00a0nerviosos \u00a0central).\u00a0A\u00a0nivel\u00a0de\u00a0\nsistema\u00a0nervioso\u00a0perif\u00e9rico \u00a0podr\u00eda\u00a0ser\u00a0\u00fatil\u00a0en\u00a0\ndiversas\u00a0patolog\u00edas \u00a0o\u00a0dolencias \u00a0como\u00a0\nenfermedades \u00a0inflamatorias \u00a0del\u00a0intestino, \u00a0artritis\u00a0\ny\u00a0cistitis\u00a0245,319.\u00a0\nInvestigaciones \u00a0in\u00a0vitro\u00a0e\u00a0in\u00a0vivo\u00a0indican\u00a0que\u00a0el\u00a0\nbloqueo\u00a0de\u00a0la\u00a0actividad\u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0que\u00a0\ninterviene \u00a0en\u00a0v\u00edas\u00a0relacionadas \u00a0con\u00a0la\u00a0mitog\u00e9nesis \u00a0\nen\u00a0muchos\u00a0carcinomas \u00a0humanos, \u00a0podr\u00eda\u00a0tener\u00a0\n\u00e9xito\u00a0si\u00a0se\u00a0interrumpe \u00a0su\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0\nantagonistas \u00a0selectivos. \u00a0Un\u00a0experimento \u00a0llevado\u00a0\na\u00a0cabo\u00a0con\u00a0un\u00a0modelo\u00a0murino\u00a0de\u00a0ratones\u00a0desnudos \u00a0mostr\u00f3\u00a0que\u00a0antagonistas \u00a0de\u00a0NK\u20101R\u00a0\n(MEN\u00a011467\u00a0o\u00a0MEN\u00a011149)\u00a0eran\u00a0capaces\u00a0de\u00a0\ninhibir\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0\nglioma\u00a0inoculadas \u00a0previamente \u00a0en\u00a0estos\u00a0ratones.\u00a0\nAunque\u00a0la\u00a0administraci\u00f3n \u00a0externa\u00a0de\u00a0SP\u00a0no\u00a0\nparec\u00eda\u00a0influir\u00a0en\u00a0el\u00a0crecimiento \u00a0del\u00a0tumor\u00a0en\u00a0\nestos\u00a0ratones\u00a0cuando\u00a0se\u00a0administraba \u00a0\n\u00fanicamente \u00a0para\u00a0valorar\u00a0el\u00a0crecimiento \u00a0tumoral,\u00a0\nsi\u00a0que\u00a0revert\u00eda\u00a0al\u00a0menos\u00a0parcialmente \u00a0los\u00a0efectos\u00a0\nde\u00a0los\u00a0inhibidores \u00a0si\u00a0se\u00a0administraba \u00a0una\u00a0dosis\u00a0\nalta\u00a0de\u00a0SP\u00a0(1\u00a0\u00b5mol\u00a0kg\u20131)303.\u00a0\nOtra\u00a0mol\u00e9cula\u00a0qu\u00edmica\u00a0muy\u00a0utilizada\u00a0por\u00a0su\u00a0\nactividad\u00a0anti\u2010tumoral\u00a0en\u00a0distintas\u00a0l\u00edneas\u00a0\ncelulares\u00a0es\u00a0el\u00a0antagonista \u00a0no\u2010pept\u00eddico \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0L\u2010733,060\u00a0o\u00a0((2S,3S)3\u2010[[3,5\u2010\nbis(Trifluoromethyl) \u00a0phenyl]\u20102\u2010phenylpiperidine \u00a0\nhydrochloride )).\u00a0Este\u00a0antagonista \u00a0pertenece \u00a0a\u00a0la\u00a0\nfamilia\u00a0de\u00a0las\u00a0bencileter \u00a0priperidinas \u00a0y\u00a0tiene\u00a0una\u00a0\nafinidad\u00a0estimada\u00a0por\u00a0el\u00a0receptor\u00a0de\u00a00.8\u00a0nM338.\u00a0\nEste\u00a0compuesto \u00a0se\u00a0ha\u00a0utilizado\u00a0en\u00a0trastornos \u00a0del\u00a0\nhumor,\u00a0trastornos \u00a0de\u00a0ansiedad\u00a0y\u00a0como\u00a0analg\u00e9sico \u00a0\ny\u00a0antidepresivo. \u00a0Adem\u00e1s\u00a0han\u00a0sido\u00a0comprobados \u00a0\nsus\u00a0efectos\u00a0como\u00a0inhibidor\u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0en\u00a0\nc\u00e9lulas\u00a0humanas\u00a0KELLY,\u00a0SKN\u2010BE(2)\u00a0y\u00a0IMR\u201032\u00a0de\u00a0\nneuroblastoma, \u00a0COLO\u00a0679,\u00a0COLO\u00a0858\u00a0y\u00a0MEL\u00a0HO\u00a0\nde\u00a0melanoma, \u00a0Hep\u20102\u00a0de\u00a0carcinoma \u00a0de\u00a0laringe,\u00a0\n23132/87 \u00a0y\u00a0SW\u2010403\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0colon245.\u00a0\nAdem\u00e1s\u00a0de\u00a0efectos\u00a0anti\u2010proliferativos \u00a0tambi\u00e9n\u00a0se\u00a0\nhan\u00a0comprobado \u00a0sus\u00a0propiedades \u00a0como\u00a0inhibidor\u00a0\nde\u00a0la\u00a0migraci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\n(requerimiento \u00a0crucial\u00a0para\u00a0la\u00a0met\u00e1stasis \u00a0y\u00a0la\u00a0\nprogresi\u00f3n \u00a0del\u00a0c\u00e1ncer).\u00a0Por\u00a0ejemplo\u00a0en\u00a0la\u00a0l\u00ednea\u00a0de\u00a0\nCM\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0pr\u00f3stata\u00a0PC3\u00a0el\u00a0\nefecto\u00a0migratorio \u00a0de\u00a0la\u00a0SP\u00a0se\u00a0puede\u00a0revertir\u00a0con\u00a0\nla\u00a0utilizaci\u00f3n \u00a0del\u00a0compuesto \u00a0L\u2010733,\u00a0060283.\u00a0En\u00a0otra\u00a0\nl\u00ednea\u00a0celular\u00a0de\u00a0CM,\u00a0la\u00a0MDA\u2010MB\u2010231,\u00a0los\u00a0\ncompuestos \u00a0MEN\u00a011467\u00a0y\u00a0nepadutant \u00a0(MEN\u00a0\n11420),\u00a0tambi\u00e9n\u00a0han\u00a0mostrado \u00a0efectos\u00a0\ninhibidores \u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0y\u00a0son\u00a0\ncapaces\u00a0de\u00a0bloquear\u00a0el\u00a0efecto\u00a0estimulador \u00a0de\u00a0la\u00a0\nSP\u00a0y\u00a0de\u00a0la\u00a0NKA\u00a0en\u00a0tumores\u00a0xenotransplantados \u00a0de\u00a0\nratones\u00a0desnudos339.\u00a0\u00a0\nOtro\u00a0compuesto \u00a0como\u00a0el\u00a0L\u2010732,138\u00a0(N\u2010Acetyl\u2010L\u2010\ntryptophan \u00a03,5\u2010bis(trifluoromethyl)benzyl \u00a0ester ),\u00a0\ntiene\u00a0efectos\u00a0anti\u2010tumorales \u00a0en\u00a0la\u00a0l\u00ednea\u00a0de\u00a0glioma\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n69\u00a0\n\u00a0GAMG\u00a0y\u00a0las\u00a0l\u00edneas\u00a0WERI\u2010Rb\u20101\u00a0e\u00a0Y\u201079\u00a0de\u00a0\nretinoblastoma340.\u00a0Si\u00a0comparamos \u00a0las\u00a0dosis\u00a0\nm\u00e1ximas\u00a0inhibitorias \u00a0(IC50)\u00a0de\u00a0estos\u00a0dos\u00a0\nantagonistas \u00a0se\u00a0observa\u00a0que\u00a0el\u00a0L\u2010733,060\u00a0es\u00a04\u00a0\nveces\u00a0m\u00e1s\u00a0potente\u00a0que\u00a0L\u2010732,138,\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0\nneuroblastoma, \u00a0SKN\u2010BE\u2010(2)301.\u00a0\nHasta\u00a0ahora\u00a0s\u00f3lo\u00a0un\u00a0antagonista \u00a0de\u00a0alta\u00a0afinidad\u00a0\npor\u00a0el\u00a0receptor\u00a0NK\u20101,\u00a0conocido\u00a0como\u00a0Aprepitant \u00a0\n(MK\u2010869) ,\u00a0o\u00a0su\u00a0nombre\u00a0comercial \u00a0Emend,\u00a0ha\u00a0sido\u00a0\naceptado \u00a0por\u00a0la\u00a0Food\u00a0an\u00a0Drugs\u00a0Administration ,\u00a0\ndesde\u00a0el\u00a02003341\u00a0para\u00a0su\u00a0uso\u00a0cl\u00ednico\u00a0en:\u00a0(1)\u00a0la\u00a0\nprevenci\u00f3n \u00a0de\u00a0n\u00e1useas\u00a0y\u00a0v\u00f3mitos\u00a0inducidos \u00a0por\u00a0la\u00a0\nquimioterapia \u00a0y\u00a0(2)\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0n\u00e1useas\u00a0y\u00a0\nv\u00f3mitos\u00a0postoperatorios. \u00a0Se\u00a0ha\u00a0estimado \u00a0que\u00a0\neste\u00a0antagonista \u00a0es\u00a0hasta\u00a045000\u00a0veces\u00a0m\u00e1s\u00a0\nselectivo\u00a0por\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0que\u00a0por\u00a0el\u00a0receptor\u00a0\nNK\u20102\u00a0y\u00a03000\u00a0veces\u00a0m\u00e1s\u00a0que\u00a0por\u00a0el\u00a0receptor\u00a0NK\u2010\n3342.\u00a0Este\u00a0compuesto \u00a0ha\u00a0mostrado \u00a0propiedades \u00a0\nanti\u2010proliferativas \u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0tumorales \u00a0\nde\u00a0glioma,\u00a0neuroblastoma, \u00a0retinoblastoma, \u00a0\np\u00e1ncreas, \u00a0lar\u00ednge\u00a0y\u00a0carcinoma \u00a0g\u00e1strico\u00a0y\u00a0de\u00a0colon\u00a0\ny\u00a0abarcan\u00a0unas\u00a0dosis\u00a0de\u00a0inhibici\u00f3n \u00a0desde\u00a05\u00a0a\u00a070\u00a0\n\u00b5M\u00a0con\u00a0una\u00a0IC50\u00a0distinta\u00a0dependiendo \u00a0de\u00a0la\u00a0l\u00ednea\u00a0\ncelular343.\u00a0La\u00a0seguridad \u00a0de\u00a0este\u00a0compuesto \u00a0es\u00a0\nbien\u00a0tolerada\u00a0a\u00a0una\u00a0dosis\u00a0de\u00a0300mg/d\u00eda \u00a0en\u00a0un\u00a0\nensayo\u00a0para\u00a0pacientes \u00a0con\u00a0moderada \u00a0o\u00a0severa\u00a0\ndepresi\u00f3n, \u00a0siendo\u00a0bien\u00a0tolerada\u00a0y\u00a0sin\u00a0diferencias \u00a0\nestad\u00edsticamente \u00a0significativas \u00a0respecto\u00a0a\u00a0los\u00a0\nefectos\u00a0adversos\u00a0comparados \u00a0con\u00a0pacientes \u00a0\ntratados\u00a0con\u00a0placebo275.\u00a0Adem\u00e1s\u00a0la\u00a0IC50\u00a0de\u00a0\nfibroblastos \u00a0es\u00a0aproximadamente \u00a0tres\u00a0veces\u00a0\nmayor\u00a0de\u00a0la\u00a0de\u00a0c\u00e9lulas\u00a0tumorales, \u00a0siendo\u00a0\nimportante \u00a0este\u00a0dato\u00a0ya\u00a0que\u00a0parece\u00a0ser\u00a0que\u00a0esta\u00a0\ndroga\u00a0tiene\u00a0un\u00a0amplio\u00a0espectro\u00a0de\u00a0acci\u00f3n\u00a0y\u00a0\nparece\u00a0ser\u00a0m\u00e1s\u00a0efectivas\u00a0en\u00a0aquellas\u00a0c\u00e9lulas\u00a0que\u00a0\ntienen\u00a0un\u00a0alto\u00a0\u00edndice\u00a0de\u00a0proliferaci\u00f3n343,344.\u00a0\u00a0\nEn\u00a0resumen, \u00a0antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0\ncomo\u00a0L\u2010733,060,\u00a0L\u2010732,138\u00a0y\u00a0aprepitant \u00a0(Fig.\u00a021)\u00a0\ninhiben\u00a0el\u00a0crecimiento \u00a0de\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0\nglioma303,\u00a0neuroblastoma298,\u00a0CM339,\u00a0c\u00e1ncer\u00a0de\u00a0\np\u00e1ncreas281\u00a0y\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0de\u00a0c\u00e9lula\u00a0\npeque\u00f1a345,346.\u00a0Adem\u00e1s\u00a0sus\u00a0efectos\u00a0promotores \u00a0\nde\u00a0la\u00a0apoptosis \u00a0celular\u00a0han\u00a0sido\u00a0descritos\u00a0en\u00a0\nc\u00e9lulas\u00a0de\u00a0glioblastoma335\u00a0y\u00a0c\u00e9lulas\u00a0de\u00a0CM347.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a021.\u00a0Antagonistas \u00a0del\u00a0receptor\u00a0NK1.\u00a0\n\u00a0\n7.\u00a0TRANSACTIVACI\u00d3N \u00a0DE\u00a0\nRECEPTORES \u00a0TIROSINA \u00a0\nQUINASA \u00a0A\u00a0TRAV\u00c9S\u00a0DE\u00a0GPCRs\u00a0\n\u00a0\nTal\u00a0y\u00a0como\u00a0hemos\u00a0visto,\u00a0los\u00a0GPCRs\u00a0est\u00e1n\u00a0\nrelacionados \u00a0con\u00a0una\u00a0gran\u00a0variedad\u00a0de\u00a0procesos\u00a0\nfisiol\u00f3gicos \u00a0y\u00a0biol\u00f3gicos \u00a0como\u00a0la\u00a0regulaci\u00f3n \u00a0de\u00a0la\u00a0\nneurotransmisi\u00f3n, \u00a0 el\u00a0 crecimiento, \u00a0 la\u00a0\ndiferenciaci\u00f3n \u00a0celular,\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0hormonas \u00a0y\u00a0\nneurop\u00e9ptidos, \u00a0la\u00a0respuesta \u00a0inmunitaria \u00a0y\u00a0la\u00a0\noncog\u00e9nesis, \u00a0entre\u00a0otros,\u00a0y\u00a0esto\u00a0hace\u00a0que\u00a0los\u00a0\nGPCRs\u00a0se\u00a0conviertan \u00a0en\u00a0una\u00a0diana\u00a0terap\u00e9utica \u00a0en\u00a0\nun\u00a050\u201060%\u00a0de\u00a0terapias246.\u00a0De\u00a0entre\u00a0todos\u00a0estos\u00a0\nGPCRs,\u00a0el\u00a0receptor\u00a0activado\u00a0por\u00a0proteasas \u00a0(PAR),\u00a0\nlos\u00a0receptores \u00a0de\u00a0quimioquinas, \u00a0el\u00a0receptor\u00a0LPS\u00a0\n(lipopolisac\u00e1rido), \u00a0y\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0se\u00a0\nencuentran \u00a0claramente \u00a0implicados \u00a0en\u00a0varios\u00a0tipos\u00a0\nde\u00a0c\u00e1ncer246.\u00a0Adem\u00e1s\u00a0de\u00a0regular\u00a0estos\u00a0procesos\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0sus\u00a0v\u00edas\u00a0intr\u00ednsecas \u00a0de\u00a0se\u00f1alizaci\u00f3n, \u00a0los\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n70\u00a0\n\u00a0GPCRs\u00a0se\u00f1alizan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0\notros\u00a0receptores, \u00a0como\u00a0los\u00a0receptores \u00a0tirosina\u00a0\nquinasa\u00a0o\u00a0RTKs.\u00a0Los\u00a0receptores \u00a0con\u00a0actividad\u00a0\ntirosina\u00a0quinasa\u00a0forman\u00a0una\u00a0familia\u00a0con\u00a0una\u00a0\nestructura \u00a0similar,\u00a0de\u00a0los\u00a0cuales,\u00a0los\u00a0que\u00a0\npertenecen \u00a0a\u00a0la\u00a0familia\u00a0ErbB\u00a0tienen\u00a0una\u00a0gran\u00a0\nimportancia \u00a0en\u00a0c\u00e1ncer.\u00a0La\u00a0interacci\u00f3n \u00a0de\u00a0GPCRs\u00a0y\u00a0\nRTKs\u00a0tiene\u00a0un\u00a0papel\u00a0destacado \u00a0en\u00a0diferentes \u00a0\nprocesos\u00a0fisiol\u00f3gicos \u00a0como\u00a0el\u00a0desarrollo \u00a0\nembrionario246,\u00a0la\u00a0diferenciaci\u00f3n \u00a0neuronal348\u00a0y\u00a0la\u00a0\nmaduraci\u00f3n \u00a0de\u00a0oocitos349,\u00a0pero\u00a0tambi\u00e9n\u00a0conlleva\u00a0\nuna\u00a0implicaci\u00f3n \u00a0patol\u00f3gica \u00a0relevante. \u00a0Por\u00a0lo\u00a0\ntanto,\u00a0la\u00a0interacci\u00f3n \u00a0entre\u00a0estos\u00a0receptores \u00a0no\u00a0\ns\u00f3lo\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0a\u00a0nivel\u00a0fisiol\u00f3gico, \u00a0\nsino\u00a0que\u00a0su\u00a0desregulaci\u00f3n \u00a0puede\u00a0inducir\u00a0estados\u00a0\npatol\u00f3gicos \u00a0como\u00a0el\u00a0c\u00e1ncer.\u00a0Esto\u00a0ha\u00a0hecho\u00a0que\u00a0la\u00a0\ninteracci\u00f3n \u00a0entre\u00a0estos\u00a0dos\u00a0tipos\u00a0de\u00a0receptores \u00a0\nsea\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0estudiada \u00a0y\u00a0se\u00a0empiece\u00a0a\u00a0\nconsiderar, \u00a0no\u00a0s\u00f3lo\u00a0un\u00a0mecanismo \u00a0m\u00e1s\u00a0de\u00a0\nactivaci\u00f3n \u00a0de\u00a0RTKs,\u00a0sino\u00a0una\u00a0posible\u00a0explicaci\u00f3n \u00a0a\u00a0\ndiversos\u00a0fen\u00f3menos \u00a0como\u00a0la\u00a0transformaci\u00f3n \u00a0\ncelular,\u00a0la\u00a0progresi\u00f3n \u00a0tumoral,\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0\nproceso\u00a0metast\u00e1tico, \u00a0la\u00a0falta\u00a0de\u00a0respuesta \u00a0a\u00a0\nquimioterapia \u00a0y\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0resistencia \u00a0a\u00a0\nterapias\u00a0dirigidas\u00a0contra\u00a0RTKs247.\u00a0\u00a0\nDependiendo \u00a0del\u00a0receptor\u00a0y\u00a0del\u00a0tipo\u00a0celular\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0GPCR\u00a0implicar\u00e1\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0diversos\u00a0RTKs.\u00a0Activando \u00a0diferentes \u00a0\ntipos\u00a0de\u00a0RTKs\u00a0los\u00a0GPCRs\u00a0podr\u00e1n\u00a0definir\u00a0mejor\u00a0sus\u00a0\nefectos\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0diana350,351.\u00a0De\u00a0hecho,\u00a0este\u00a0\nmecanismo \u00a0de\u00a0transactivaci\u00f3n \u00a0ha\u00a0permitido \u00a0\nexplicar\u00a0las\u00a0propiedades \u00a0mitog\u00e9nicas \u00a0de\u00a0muchos\u00a0\nligandos\u00a0de\u00a0GPCRs,\u00a0como\u00a0hormonas \u00a0y\u00a0\nneurotransmisores, \u00a0los\u00a0cuales\u00a0ejercen\u00a0algunas\u00a0de\u00a0\nsus\u00a0funciones \u00a0como\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0DNA\u00a0por\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0un\u00a0RTK\u00a0y\u00a0no\u00a0por\u00a0activaci\u00f3n \u00a0\ndirecta\u00a0de\u00a0una\u00a0v\u00eda\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0determinada. \u00a0\nAdem\u00e1s\u00a0de\u00a0quedar\u00a0clara\u00a0la\u00a0interacci\u00f3n \u00a0a\u00a0m\u00faltiples \u00a0\nniveles\u00a0entre\u00a0las\u00a0mol\u00e9culas \u00a0efectoras \u00a0de\u00a0ambos\u00a0\ntipos\u00a0de\u00a0receptores, \u00a0parece\u00a0ser\u00a0que\u00a0tambi\u00e9n\u00a0es\u00a0\nnecesaria \u00a0una\u00a0interacci\u00f3n \u00a0o,\u00a0al\u00a0menos,\u00a0una\u00a0co\u2010\nlocalizaci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0a\u00a0nivel\u00a0de\u00a0\nmembrana \u00a0plasm\u00e1tica. \u00a0Tanto\u00a0los\u00a0RTKs\u00a0como\u00a0los\u00a0\nGPCR\u00a0se\u00a0localizan\u00a0en\u00a0microdominios \u00a0de\u00a0\nmembrana \u00a0ricos\u00a0en\u00a0l\u00edpidos,\u00a0los\u00a0llamados\u00a0l\u00edpid\u00a0rafts .\u00a0Aunque\u00a0existen\u00a0pocos\u00a0trabajos\u00a0que\u00a0hayan\u00a0\ndemostrado \u00a0la\u00a0interacci\u00f3n \u00a0f\u00edsica\u00a0entre\u00a0estos\u00a0\nreceptores352,\u00a0existen\u00a0muchas\u00a0evidencias \u00a0que\u00a0\nindican\u00a0que\u00a0deben\u00a0colocalizarse \u00a0en\u00a0el\u00a0mismo\u00a0\ndominio\u00a0plasm\u00e1tico \u00a0para\u00a0que\u00a0se\u00a0produzca \u00a0una\u00a0\ntransactivaci\u00f3n \u00a0efectiva\u00a0entre\u00a0ellos247.\u00a0\nLos\u00a0RTKs\u00a0forman\u00a0una\u00a0gran\u00a0familia\u00a0d\u00f3nde\u00a0se\u00a0\nincluyen\u00a0la\u00a0mayor\u00a0parte\u00a0de\u00a0los\u00a0receptores \u00a0para\u00a0\nfactores\u00a0de\u00a0crecimiento. \u00a0Muchos\u00a0RTKs\u00a0comparten \u00a0\nlas\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n, \u00a0sin\u00a0embargo, \u00a0las\u00a0\nrespuestas \u00a0biol\u00f3gicas \u00a0espec\u00edficas \u00a0de\u00a0cada\u00a0\nreceptor\u00a0parecen\u00a0depender \u00a0m\u00e1s\u00a0del\u00a0contexto\u00a0\ncelular\u00a0que\u00a0de\u00a0ning\u00fan\u00a0otro\u00a0factor.\u00a0\u00a0La\u00a0activaci\u00f3n \u00a0\nde\u00a0un\u00a0RTK\u00a0por\u00a0su\u00a0ligando\u00a0induce\u00a0la\u00a0dimerizaci\u00f3n \u00a0\ndel\u00a0receptor\u00a0activando \u00a0su\u00a0actividad\u00a0tirosina\u00a0\nquinasa\u00a0intr\u00ednseca, \u00a0causando \u00a0la\u00a0transfosforilaci\u00f3n \u00a0\nde\u00a0los\u00a0residuos\u00a0tirosina\u00a0presentes \u00a0en\u00a0su\u00a0dominio\u00a0\ncitoplasm\u00e1tico. \u00a0 Estos\u00a0 residuos\u00a0 tirosina\u00a0\nfosforilados \u00a0pueden\u00a0ser\u00a0entonces\u00a0reconocidos \u00a0\npor\u00a0diversas\u00a0mol\u00e9culas \u00a0efectoras \u00a0que\u00a0se\u00a0\nencargar\u00e1n \u00a0de\u00a0propagar\u00a0la\u00a0se\u00f1al,\u00a0como\u00a0la\u00a0PLC\u03b3\u00a0y\u00a0\nSrc.\u00a0La\u00a0fosforilaci\u00f3n \u00a0de\u00a0estos\u00a0receptores, \u00a0como\u00a0es\u00a0\nel\u00a0caso\u00a0de\u00a0EGFR,\u00a0tambi\u00e9n\u00a0inducir\u00e1\u00a0la\u00a0fosforilaci\u00f3n \u00a0\nde\u00a0tirosinas\u00a0como\u00a0la\u00a0de\u00a0la\u00a0prote\u00edna\u00a0adaptadora \u00a0\nSHC\u00a0y\u00a0esto\u00a0provocar\u00e1 \u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0SHC\u00a0con\u00a0\nGrb2.\u00a0Grb2\u00a0est\u00e1\u00a0constitutivamente \u00a0asociada\u00a0a\u00a0\nSos1,\u00a0mol\u00e9cula\u00a0encargada \u00a0de\u00a0catalizar\u00a0el\u00a0\nintercambio \u00a0de\u00a0GDP\u00a0por\u00a0GTP\u00a0en\u00a0Ras.\u00a0Ras\u00a0es\u00a0una\u00a0\nprote\u00edna\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0GTP\u00a0que\u00a0se\u00a0encuentra \u00a0\nanclada\u00a0en\u00a0la\u00a0membrana \u00a0plasm\u00e1tica \u00a0y\u00a0que,\u00a0una\u00a0\nvez\u00a0activada\u00a0estimula\u00a0una\u00a0cascada\u00a0de\u00a0prote\u00ednas \u00a0\ncon\u00a0actividad\u00a0quinasa\u00a0en\u00a0serina\u00a0y\u00a0treonina\u00a0\nllamadas\u00a0prote\u00ednas \u00a0quinasa\u00a0activadas \u00a0por\u00a0\nmit\u00f3geno \u00a0(MAPKs).\u00a0Estas\u00a0incluyen\u00a0la\u00a0MAPKKK, \u00a0\ntambi\u00e9n\u00a0conocida\u00a0como\u00a0Raf,\u00a0la\u00a0cual\u00a0fosforila\u00a0la\u00a0\nMAPKK,\u00a0tambi\u00e9n\u00a0llamada\u00a0MEK\u00a0que\u00a0a\u00a0su\u00a0vez\u00a0\nfosforila\u00a0MAPKs.\u00a0Existen\u00a0como\u00a0m\u00ednimo\u00a0tres\u00a0\ndiferentes \u00a0MAPKs:\u00a0la\u00a0quinasa\u00a0regulada\u00a0por\u00a0\nse\u00f1ales\u00a0extracelulares \u00a0(ERKs),\u00a0la\u00a0quinasa\u00a0NH2\u00a0\nterminal\u00a0de\u00a0c\u2010Jun\u00a0(JNKs)\u00a0y\u00a0la\u00a0MAPK\u00a0p38.\u00a0Estas\u00a0\nMAPKs\u00a0finalmente \u00a0fosforilar\u00e1n \u00a0diversas\u00a0prote\u00ednas \u00a0\nreguladoras \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0influyendo \u00a0de\u00a0\nesta\u00a0manera\u00a0en\u00a0la\u00a0proliferaci\u00f3n \u00a0celular,\u00a0la\u00a0\nsupervivencia, \u00a0la\u00a0migraci\u00f3n \u00a0y\u00a0la\u00a0diferenciaci\u00f3n249.\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n71\u00a0\n\u00a0Se\u00a0ha\u00a0descrito\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0por\u00a0\nparte\u00a0de\u00a0receptores \u00a0de\u00a0distinta\u00a0naturaleza. \u00a0As\u00ed,\u00a0se\u00a0\nsabe\u00a0por\u00a0ejemplo\u00a0que\u00a0EGFR\u00a0puede\u00a0ser\u00a0\ntransactivado, \u00a0no\u00a0s\u00f3lo\u00a0por\u00a0GPCRs,\u00a0sino\u00a0por\u00a0otros\u00a0\nRTKs\u00a0como\u00a0PDGF\u00a0353,\u00a0IGF\u2010IR354\u00a0u\u00a0otros\u00a0receptores \u00a0\ncomo\u00a0el\u00a0del\u00a0TGF\u03b2\u00a0(receptor \u00a0con\u00a0actividad\u00a0\nfosfatasa\u00a0en\u00a0serina\u00a0treonina)355\u00a0e\u00a0incluso\u00a0por\u00a0el\u00a0\nreceptor\u00a0del\u00a0TNF356.\u00a0Por\u00a0lo\u00a0tanto,\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0parece\u00a0ser\u00a0un\u00a0mecanismo \u00a0mucho\u00a0\nm\u00e1s\u00a0extendido \u00a0de\u00a0lo\u00a0que\u00a0inicialmente \u00a0se\u00a0pensaba\u00a0\ny\u00a0que\u00a0sirve\u00a0para\u00a0transmitir \u00a0la\u00a0se\u00f1al\u00a0de\u00a0diversos\u00a0\nreceptores \u00a0que\u00a0necesitan \u00a0de\u00a0EGFR\u00a0para\u00a0ejercer\u00a0\nsus\u00a0efectos\u00a0biol\u00f3gicos. \u00a0\nDetr\u00e1s\u00a0de\u00a0los\u00a0mecanismos \u00a0de\u00a0transactivaci\u00f3n \u00a0sin\u00a0\nembargo, \u00a0se\u00a0esconde\u00a0una\u00a0gran\u00a0complejidad \u00a0\nmolecular, \u00a0y\u00a0se\u00a0ha\u00a0observado \u00a0que\u00a0\u00e9stos\u00a0pueden\u00a0\nverse\u00a0regulados \u00a0de\u00a0forma\u00a0diferencial \u00a0incluso\u00a0en\u00a0\nfunci\u00f3n\u00a0de\u00a0si\u00a0un\u00a0tipo\u00a0celular\u00a0est\u00e1\u00a0transformado \u00a0\n(es\u00a0tumoral)\u00a0o\u00a0no.\u00a0En\u00a0hepatocitos \u00a0por\u00a0ejemplo,\u00a0la\u00a0\nPGE2\u00a0no\u00a0induce\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR,\u00a0pero\u00a0\nsi\u00a0una\u00a0sensibilizaci\u00f3n \u00a0del\u00a0receptor\u00a0para\u00a0una\u00a0\nposterior\u00a0activaci\u00f3n. \u00a0En\u00a0cambio,\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0\nhepatoma \u00a0la\u00a0PGE2\u00a0s\u00ed\u00a0que\u00a0es\u00a0capaz\u00a0de\u00a0transactivar \u00a0\nel\u00a0receptor, \u00a0por\u00a0lo\u00a0que\u00a0parecer\u00eda \u00a0ser\u00a0que\u00a0incluso\u00a0\nen\u00a0funci\u00f3n\u00a0del\u00a0estado\u00a0de\u00a0transformaci\u00f3n \u00a0celular\u00a0\nlos\u00a0mecanismos \u00a0de\u00a0transactivaci\u00f3n \u00a0pueden\u00a0ser\u00a0\ndiferentes357.\u00a0Se\u00a0ha\u00a0observado \u00a0una\u00a0situaci\u00f3n\u00a0\nsimilar\u00a0con\u00a0TGF\u2010\u03b2,\u00a0el\u00a0cual\u00a0inhibir\u00eda\u00a0proliferaci\u00f3n \u00a0e\u00a0\ninducir\u00eda\u00a0apoptosis \u00a0en\u00a0hepatocitos, \u00a0pero\u00a0tendr\u00eda\u00a0\nun\u00a0papel\u00a0dual\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0hepatoma, \u00a0\ninduciendo \u00a0tanto\u00a0efectos\u00a0supresores \u00a0como\u00a0\ninductores \u00a0de\u00a0la\u00a0carcinog\u00e9nesis \u00a0por\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0EGFR355.\u00a0\nLos\u00a0RTKs\u00a0pueden\u00a0utilizar\u00a0diferentes \u00a0componentes \u00a0\nde\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0GPCR\u00a0como\u00a0la\u00a0\u03b2\u2010\narrestina, \u00a0las\u00a0GRKs\u00a0y\u00a0los\u00a0reguladores \u00a0de\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0para\u00a0integrar\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0las\u00a0v\u00edas358.\u00a0Por\u00a0lo\u00a0tanto,\u00a0este\u00a0\nproceso\u00a0de\u00a0transactivaci\u00f3n \u00a0entre\u00a0GPCRs\u00a0y\u00a0RTKs\u00a0\nparece\u00a0ser\u00a0rec\u00edproco, \u00a0de\u00a0manera\u00a0que\u00a0el\u00a0RTK\u00a0no\u00a0\nfunciona\u00a0solamente \u00a0como\u00a0mol\u00e9cula\u00a0efectora\u00a0del\u00a0\nGPCR,\u00a0sino\u00a0que\u00a0puede\u00a0utilizar\u00a0tambi\u00e9n\u00a0mol\u00e9culas \u00a0\nefectoras \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0GPCR\u00a0para\u00a0\ntransducir \u00a0se\u00f1al\u00a0e\u00a0incluso\u00a0los\u00a0propios\u00a0ligandos\u00a0del\u00a0\nRTK\u00a0pueden\u00a0transactivar \u00a0GPCRs359,360.\u00a0As\u00ed,\u00a0este\u00a0proceso\u00a0de\u00a0transactivaci\u00f3n \u00a0situar\u00eda\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0\ndel\u00a0GPCR\u00a0por\u00a0debajo\u00a0de\u00a0la\u00a0cascada\u00a0de\u00a0activaci\u00f3n \u00a0\ndel\u00a0RTK.\u00a0\nAdem\u00e1s,\u00a0las\u00a0consecuencias \u00a0moleculares \u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0o\u00a0transactivaci\u00f3n \u00a0de\u00a0un\u00a0RTK\u00a0pueden\u00a0\nser\u00a0distintas.\u00a0McCole\u00a0y\u00a0colaboradores \u00a0\npropusieron \u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0directa\u00a0de\u00a0EGFR\u00a0\npor\u00a0EGF\u00a0produc\u00eda\u00a0un\u00a0patr\u00f3n\u00a0de\u00a0fosforilaci\u00f3n \u00a0y\u00a0un\u00a0\nreclutamiento \u00a0de\u00a0PI3K\u00a0diferente \u00a0del\u00a0producido \u00a0\npor\u00a0activaci\u00f3n \u00a0de\u00a0GPCRs\u00a0y\u00a0transactivaci\u00f3n \u00a0de\u00a0\nEGFR\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0liberaci\u00f3n \u00a0paracrina \u00a0de\u00a0\nligandos.\u00a0Estos\u00a0efectos\u00a0diferenciales \u00a0en\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0y\u00a0su\u00a0consecuencia \u00a0depend\u00edan \u00a0de\u00a0la\u00a0\nactividad\u00a0de\u00a0la\u00a0fosfatasa\u00a01B,\u00a0la\u00a0cual\u00a0dirig\u00eda\u00a0el\u00a0\nreclutamiento \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0de\u00a0se\u00f1alizaci\u00f3n361.\u00a0\nEn\u00a0c\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0y\u00a0concretamente \u00a0en\u00a0\nrelaci\u00f3n\u00a0al\u00a0receptor\u00a0NK\u20101,\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0la\u00a0SP\u00a0\na\u00a0trav\u00e9s\u00a0de\u00a0NK\u20101\u00a0puede\u00a0transactivar \u00a0a\u00a0EGFR,\u00a0y\u00a0que\u00a0\nadem\u00e1s\u00a0este\u00a0RTK\u00a0es\u00a0un\u00a0regulador \u00a0esencial\u00a0para\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nMAPKs\u00a0importantes \u00a0para\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0U\u2010373\u00a0MG.\u00a0Otro\u00a0\nmecanismo \u00a0por\u00a0el\u00a0cual\u00a0se\u00a0demuestra \u00a0que\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0GPCRs\u00a0y\u00a0RTKs\u00a0tinen\u00a0una\u00a0estrecha\u00a0\nrelaci\u00f3n.\u00a0\nHay\u00a0varios\u00a0mecanismos \u00a0por\u00a0los\u00a0cuales\u00a0un\u00a0GPCR\u00a0\npuede\u00a0transactivar \u00a0RTKs\u00a0seg\u00fan\u00a0el\u00a0contexto\u00a0de\u00a0\ncada\u00a0tipo\u00a0celular,\u00a0pero\u00a0sin\u00a0duda,\u00a0Src\u00a0y\u00a0MMPs\u00a0son\u00a0\nlos\u00a0mecanismos \u00a0m\u00e1s\u00a0estudiados \u00a0ya\u00a0que\u00a0tanto\u00a0su\u00a0\u00a0\nse\u00f1alizaci\u00f3n \u00a0como\u00a0su\u00a0expresi\u00f3n \u00a0parecen\u00a0tener\u00a0\nuna\u00a0relevancia \u00a0cl\u00ednica\u00a0implicada \u00a0en\u00a0malignidad \u00a0y\u00a0\nresistencia \u00a0a\u00a0f\u00e1rmacos. \u00a0\n7.1.\u00a0El\u00a0papel\u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0\nSrc\u00a0en\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0\n\u00a0\nEn\u00a0diversos\u00a0tipos\u00a0celulares\u00a0se\u00a0ha\u00a0observado \u00a0que\u00a0\nSrc\u00a0juega\u00a0un\u00a0papel\u00a0muy\u00a0importante \u00a0en\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0RTKs.\u00a0Src\u00a0es\u00a0una\u00a0prote\u00edna\u00a0de\u00a0\n60kDa\u00a0compuesta \u00a0de\u00a0distintos\u00a0dominios \u00a0\nfuncionales: \u00a0(1)\u00a0La\u00a0regi\u00f3n\u00a0N\u2010terminal\u00a0que\u00a0\ncontiene\u00a0un\u00a0resto\u00a0de\u00a0\u00e1cido\u00a0mir\u00edstico\u00a0esencial\u00a0para\u00a0\nsu\u00a0localizaci\u00f3n \u00a0en\u00a0la\u00a0superficie \u00a0interior\u00a0del\u00a0la\u00a0\nmembrana \u00a0celular;\u00a0(2)\u00a0un\u00a0dominio\u00a0SH3\u00a0capaz\u00a0de\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n72\u00a0\n\u00a0unirse\u00a0a\u00a0secuencias \u00a0ricas\u00a0en\u00a0prolina\u00a0para\u00a0mediar\u00a0\nen\u00a0las\u00a0dos\u00a0interacciones \u00a0intra\u00a0e\u00a0intermoleculares; \u00a0\n(3)\u00a0un\u00a0dominio\u00a0SH2\u00a0que\u00a0puede\u00a0unirse\u00a0a\u00a0residuos\u00a0\ntirosina\u00a0fosforilados \u00a0de\u00a0la\u00a0misma\u00a0mol\u00e9cula\u00a0Src\u00a0u\u00a0\notras\u00a0prote\u00ednas \u00a0distintas;\u00a0y\u00a0(4)\u00a0el\u00a0dominio\u00a0\ncatal\u00edtico\u00a0compuesto \u00a0de\u00a0dos\u00a0l\u00f3bulos\u00a0separados \u00a0\npor\u00a0la\u00a0hendidura \u00a0catal\u00edtica\u00a0en\u00a0la\u00a0que\u00a0residen\u00a0los\u00a0\nsitios\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0ATP\u00a0(Fig.\u00a022).\u00a0Este\u00a0dominio\u00a0\npuede\u00a0regular\u00a0positivamente \u00a0la\u00a0autofosforilaci\u00f3n \u00a0\nde\u00a0la\u00a0Tyr416\u00a0(en\u00a0humanos) \u00a0importantes \u00a0para\u00a0\nalcanzar\u00a0el\u00a0m\u00e1ximo\u00a0de\u00a0actividad\u00a0de\u00a0la\u00a0quinasa.\u00a0(5)\u00a0\nLa\u00a0cola\u00a0C\u2010terminal\u00a0que\u00a0contiene\u00a0la\u00a0Tyr530\u00a0que\u00a0\nregula\u00a0negativamente \u00a0la\u00a0prote\u00edna,\u00a0cuando\u00a0se\u00a0\nfosforila,\u00a0se\u00a0puede\u00a0acoplar\u00a0al\u00a0dominio\u00a0SH2\u00a0y\u00a0\nbloquea\u00a0a\u00a0la\u00a0Tyr\u00a0416,\u00a0impidiendo \u00a0su\u00a0fosforilaci\u00f3n \u00a0\n(Fig.\u00a022).\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\nFigura\u00a022.\u00a0Representaci\u00f3n \u00a0esquem\u00e1tica \u00a0de\u00a0los\u00a0estados\u00a0de\u00a0la\u00a0\nprote\u00edna\u00a0Src\u00a0inactiva\u00a0(izquierda) \u00a0y\u00a0la\u00a0activa\u00a0(derecha). \u00a0En\u00a0la\u00a0\nconfiguraci\u00f3n \u00a0inactiva\u00a0el\u00a0dominio\u00a0SH2\u00a0se\u00a0une\u00a0a\u00a0la\u00a0tirosina\u00a0C\u2010\nterminal\u00a0Tyr530,\u00a0mientras\u00a0que\u00a0el\u00a0dominio\u00a0SH3\u00a0interact\u00faa \u00a0con\u00a0\nel\u00a0dominio\u00a0enlazador \u00a0en\u00a0el\u00a0lado\u00a0posterior\u00a0del\u00a0dominio\u00a0\ncatal\u00edtico,\n\u00a0promoviendo \u00a0as\u00ed\u00a0una\u00a0conformaci\u00f3n \u00a0cerrada\u00a0que\u00a0\nimpide\u00a0que\u00a0los\u00a0sustratos\u00a0interaccionen. \u00a0En\u00a0el\u00a0configuraci\u00f3n \u00a0\nactiva\u00a0la\u00a0Tyr530\u00a0es\u00a0desfosforilada, \u00a0y\u00a0los\u00a0dominios \u00a0SH2\u00a0y\u00a0SH3\u00a0\nse\u00a0liberan\u00a0de\u00a0las\u00a0interacciones \u00a0intramoleculares \u00a0y,\u00a0por\u00a0tanto\u00a0\npasan\u00a0a\u00a0estar\u00a0disponibles \u00a0para\u00a0unirse\u00a0a\u00a0moleculares \u00a0\nheter\u00f3logas \u00a0asociadas. \u00a0\u00c9sta\u00a0conformaci\u00f3n \u00a0abierta\u00a0permite\u00a0\ntambi\u00e9n\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0Tyr419\u00a0en\u00a0el\u00a0bucle\u00a0de\u00a0\nactivaci\u00f3n \u00a0que\u00a0mejora\u00a0la\u00a0actividad\u00a0catal\u00edtica. \u00a0Modificado \u00a0\nde362.\u00a0De\u00a0qu\u00e9\u00a0forma\u00a0los\u00a0GPCRs\u00a0activan\u00a0Src\u00a0a\u00fan\u00a0no\u00a0se\u00a0ha\u00a0\ndeterminado, \u00a0aunque\u00a0parece\u00a0ser\u00a0un\u00a0proceso\u00a0\nespec\u00edfico \u00a0de\u00a0cada\u00a0tipo\u00a0celular.\u00a0Un\u00a0ejemplo\u00a0ser\u00eda\u00a0\nel\u00a0de\u00a0los\u00a0estudios\u00a0realizados \u00a0por\u00a0Della\u00a0Rocca,\u00a0en\u00a0\n1997,\u00a0donde\u00a0revelaron \u00a0que\u00a0las\u00a0subunidades \u00a0Gq/11\u00a0\n(del\u00a0receptor\u00a0adren\u00e9rgico \u00a0\u03b11B)\u00a0y\u00a0G\u03b2\u03b3\u00a0(disociada \u00a0\nde\u00a0la\u00a0prote\u00edna\u00a0Gi\u00a0del\u00a0receptor\u00a0adren\u00e9rgico \u00a0\u03b12A)\u00a0\ndependientes \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0PLC\u00a0\naumentaban \u00a0los\u00a0niveles\u00a0citoplasm\u00e1ticos \u00a0de\u00a0IP3,\u00a0\nresultando \u00a0en\u00a0un\u00a0aumento\u00a0de\u00a0Ca2+\u00a0\ncitoplasm\u00e1tico. \u00a0Las\u00a0altas\u00a0concentraciones \u00a0de\u00a0\ncalcio\u00a0intracelular, \u00a0tal\u00a0vez\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\ncalmodulina, \u00a0conduc\u00edan \u00a0a\u00a0una\u00a0activaci\u00f3n \u00a0de\u00a0una\u00a0\nquinasa\u00a0llamada\u00a0prolina\u2010tirosina\u00a0quinasa\u00a0rica\u00a02\u00a0\n(Pyk2,\u00a0del\u00a0ingl\u00e9s\u00a0protein\u00a0tyrosine\u00a0kinase\u00a02)\u00a0\nasociada\u00a0a\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0de\u00a0adhesiones \u00a0\nfocales\u00a0(FAK).\u00a0A\u00a0su\u00a0vez\u00a0esta\u00a0Pyk2\u00a0(conocida \u00a0\nactualmente \u00a0como\u00a0PTK2B),\u00a0regulaba\u00a0la\u00a0actividad\u00a0\nde\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0Src.\u00a0Prote\u00ednas \u00a0adaptadoras \u00a0\ndependientes \u00a0de\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0tirosinas\u00a0Src,\u00a0\ncomo\u00a0Shc,\u00a0reclutan\u00a0el\u00a0complejo \u00a0Grb2\u2010SOS\u00a0en\u00a0la\u00a0\nmembrana \u00a0plasm\u00e1tica \u00a0e\u00a0inician\u00a0la\u00a0cascada\u00a0de\u00a0\nfosforilaci\u00f3n \u00a0que\u00a0conduce\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nErk1/2\u00a0que\u00a0desencadena \u00a0en\u00a0v\u00edas\u00a0de\u00a0proliferaci\u00f3n \u00a0\ncelular.\u00a0Adem\u00e1s,\u00a0Src\u00a0se\u00a0puede\u00a0unir\u00a0a\u00a0EGFR\u00a0y\u00a0\nfosforilarlo \u00a0directamente. \u00a0As\u00ed\u00a0EGFR\u00a0acaba\u00a0\nfosforilando \u00a0Shc\u2010Grb2.\u00a0En\u00a0algunos\u00a0tipos\u00a0celulares, \u00a0\ncomo\u00a0en\u00a0c\u00e9lulas\u00a0neuronales, \u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0\nEGFR\u00a0depende\u00a0de\u00a0Ca2+.\u00a0\u00a0\nPor\u00a0tanto\u00a0Src\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0v\u00edas\u00a0proliferativas \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0Grb2/Sos/Ras/Raf/MEK/MAPK \u00a0y\u00a0\nla\u00a0cascada\u00a0se\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0PI3K/Akt362.\u00a0Src\u00a0\ninteracciona \u00a0con\u00a0los\u00a0RTKs\u00a0siendo\u00a0tanto\u00a0un\u00a0\nsustrato\u00a0o\u00a0como\u00a0un\u00a0activador \u00a0de\u00a0ellos,\u00a0creando\u00a0\nun\u00a0bucle\u00a0regulador \u00a0positivo\u00a0que\u00a0contribuye \u00a0a\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0persistente \u00a0de\u00a0los\u00a0RTKs363.\u00a0La\u00a0uni\u00f3n\u00a0\nde\u00a0los\u00a0ligandos\u00a0con\u00a0sus\u00a0respectivos \u00a0RTKs\u00a0conduce\u00a0\na\u00a0la\u00a0homo\u00a0o\u00a0heterodimerizaci\u00f3n \u00a0y\u00a0\nautofosforilaci\u00f3n \u00a0de\u00a0los\u00a0residuos\u00a0tirosina\u00a0del\u00a0\ndominio\u00a0citoplasm\u00e1tico. \u00a0Los\u00a0sitios\u00a0fosforilados \u00a0\nresultantes \u00a0act\u00faan\u00a0como\u00a0puntos\u00a0de\u00a0\nreclutamiento \u00a0de\u00a0prote\u00ednas \u00a0y\u00a0entre\u00a0ellas\u00a0se\u00a0activa\u00a0\nSrc,\u00a0que\u00a0es\u00a0probablemente \u00a0la\u00a0que\u00a0active\u00a0de\u00a0nuevo\u00a0\na\u00a0los\u00a0RTKs.\u00a0Esto\u00a0por\u00a0un\u00a0lado\u00a0aumenta\u00a0la\u00a0actividad\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n73\u00a0\n\u00a0tirosina\u00a0quinasa\u00a0y\u00a0por\u00a0otro\u00a0lado\u00a0crea\u00a0m\u00e1s\u00a0sitios\u00a0de\u00a0\nuni\u00f3n\u00a0a\u00a0SH2\u00a0que\u00a0permitir\u00e1 \u00a0el\u00a0reclutamiento \u00a0de\u00a0\nGrb2/Sos \u00a0y\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Ras/MAPKs \u00a0y/o\u00a0\nPI3K/Akt. \u00a0\u00a0La\u00a0asociaci\u00f3n \u00a0de\u00a0Src\u00a0con\u00a0una\u00a0\nsobreexpresi\u00f3n \u00a0de\u00a0EGFR\u00a0causa\u00a0una\u00a0sinerg\u00edstica \u00a0\nmitogenicidad, \u00a0y\u00a0podr\u00eda\u00a0representar \u00a0un\u00a0\nmecanismo \u00a0por\u00a0el\u00a0cual\u00a0Src\u00a0contribuye \u00a0al\u00a0\ncrecimiento \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales364,365.\u00a0\nBiscardi\u00a0y\u00a0colaboradores \u00a0observaron \u00a0que\u00a0\nfibroblastos \u00a0murinos\u00a0que\u00a0sobreexpresaban \u00a0EGFR\u00a0\ny\u00a0Src\u00a0mostraban \u00a0aumentos \u00a0sin\u00e9rgicos \u00a0en:\u00a0la\u00a0\ns\u00edntesis\u00a0de\u00a0ADN,\u00a0el\u00a0crecimiento \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0en\u00a0\nagar\u00a0blando\u00a0y\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0tumores\u00a0en\u00a0\nratones\u00a0desnudos. \u00a0En\u00a0este\u00a0estudio\u00a0identificaron \u00a0\ndos\u00a0sitios\u00a0de\u00a0fosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0mediada\u00a0por\u00a0\nSrc\u00a0en\u00a0la\u00a0Tyr845\u00a0y\u00a0la\u00a0Tyr\u00a01101.\u00a0\u00a0Adem\u00e1s\u00a0\nobservaron \u00a0que\u00a0al\u00a0tratar\u00a0con\u00a0EGF\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0\ncomo\u00a0 las\u00a0 MDA\u2010MB\u2010468\u00a0 (previamente \u00a0\ntransfectadas \u00a0y\u00a0con\u00a0la\u00a0capacidad \u00a0de\u00a0\nsobreexpresar \u00a0Src),\u00a0se\u00a0induc\u00eda\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\nla\u00a0Tyr845\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0la\u00a0l\u00ednea\u00a0parental\u00a0\nsin\u00a0transfectar. \u00a0Se\u00a0describi\u00f3\u00a0por\u00a0tanto\u00a0un\u00a0posible\u00a0\nresiduo\u00a0de\u00a0fosforilaci\u00f3n \u00a0del\u00a0dominio\u00a0catal\u00edtico\u00a0\nque\u00a0pod\u00eda\u00a0ser\u00a0activado\u00a0por\u00a0la\u00a0prote\u00edna\u00a0Src364.\u00a0Este\u00a0\nresiduo\u00a0no\u00a0es\u00a0considerado \u00a0un\u00a0sitio\u00a0de\u00a0\nautofosforilaci\u00f3n \u00a0y\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0Tyr\u00a0845\u00a0depende\u00a0de\u00a0la\u00a0actividad\u00a0\ncatal\u00edtica\u00a0de\u00a0Src366\u00a0(Fig.\u00a023).\u00a0\nLa\u00a0autofosforilaci\u00f3n \u00a0en\u00a0este\u00a0sitio\u00a0est\u00e1\u00a0conservada \u00a0\nen\u00a0otros\u00a0receptores \u00a0tirosina\u00a0quinasa\u00a0y\u00a0es\u00a0\nnecesaria \u00a0para\u00a0la\u00a0actividad\u00a0catal\u00edtica\u00a0completa \u00a0y\u00a0\nbiol\u00f3gica. \u00a0En\u00a0contraste, \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0Tyr\u00a0\n845\u00a0mediada\u00a0por\u00a0Src,\u00a0y\u00a0no\u00a0por\u00a0EGFR\u00a0activado,\u00a0no\u00a0\nest\u00e1\u00a0asociada\u00a0con\u00a0la\u00a0modulaci\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0\nautoquinasa \u00a0del\u00a0receptor\u00a0o\u00a0su\u00a0capacidad \u00a0para\u00a0\nactivar\u00a0SHC\u00a0y\u00a0Erk2.\u00a0No\u00a0obstante, \u00a0la\u00a0Tyr\u00a0845\u00a0se\u00a0\nrequiere\u00a0para\u00a0la\u00a0mitog\u00e9nesis367.\u00a0En\u00a0conjunto, \u00a0\nestos\u00a0resultados \u00a0sugieren\u00a0que\u00a0la\u00a0v\u00eda\u00a0Erk2\u00a0no\u00a0es\u00a0\nsuficiente \u00a0para\u00a0la\u00a0proliferaci\u00f3n \u00a0inducida\u00a0por\u00a0EGF\u00a0y\u00a0\nque\u00a0son\u00a0necesarios \u00a0otros\u00a0efectores \u00a0corriente\u00a0\nabajo\u00a0de\u00a0pY845\u00a0367\u00a0.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a023.\u00a0Residuos\u00a0tirosina\u00a0de\u00a0EGFR .\u00a0La\u00a0Tyr\u00a0845\u00a0se\u00a0\nencuentra \u00a0en\u00a0el\u00a0dominio\u00a0catal\u00edtico\u00a0de\u00a0EGFR\u00a0en\u00a0un\u00a0\nsubdominio \u00a0altamente \u00a0conservado \u00a0que\u00a0tiene\u00a0hom\u00f3logos \u00a0\nfuncionales \u00a0en\u00a0otras\u00a0tirosina\u00a0quinasas. \u00a0Se\u00a0ha\u00a0propuesto \u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0la\u00a0Tyr\u00a0845\u00a0por\u00a0Src\n\u00a0como\u00a0un\u00a0posible\u00a0sitio\u00a0de\u00a0\nintercomunicaci\u00f3n \u00a0entre\u00a0EGFR\u00a0y\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\nactivadas \u00a0por\u00a0otros\u00a0receptores \u00a0celulares, \u00a0como\u00a0los\u00a0GPCRs\u00a0y\u00a0\nel\u00a0RE.\u00a0Modificado \u00a0de367.\u00a0\n\u00a0\n\u00a0\nStover\u00a0y\u00a0colaboradores368\u00a0demostraron \u00a0Src\u00a0\nactivado\u00a0tambi\u00e9n\u00a0pod\u00eda\u00a0fosforilar\u00a0EGFR\u00a0en\u00a0la\u00a0Tyr\u00a0\n891\u00a0y\u00a0la\u00a0Tyr\u00a0920\u00a0in\u00a0vitro,\u00a0y\u00a0que\u00a0estos\u00a0sitios\u00a0de\u00a0\nfosforilaci\u00f3n \u00a0pod\u00edan\u00a0mediar\u00a0en\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0los\u00a0\ndominios \u00a0SH2\u00a0de\u00a0la\u00a0PI3K\u00a0y\u00a0Src\u00a0en\u00a0\u00e9l\u00a0mismo.\u00a0Estos\u00a0\nsitios\u00a0de\u00a0fosforilaci\u00f3n \u00a0se\u00a0encontraron \u00a0en\u00a0varios\u00a0\ncarcinomas \u00a0colorectales \u00a0y\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0como\u00a0\nla\u00a0l\u00ednea\u00a0MCF7,\u00a0donde\u00a0Src\u00a0y\u00a0PI3K\u00a0co\u2010\ninmunoprecipitaban \u00a0con\u00a0junto\u00a0a\u00a0EGFR.\u00a0Estos\u00a0\nhallazgos\u00a0apoyaban \u00a0la\u00a0idea\u00a0de\u00a0que\u00a0las\u00a0\ninteracciones \u00a0bidireccionales \u00a0entre\u00a0Src\u00a0y\u00a0EGFR\u00a0\neran\u00a0factibles\u00a0y\u00a0que\u00a0quiz\u00e1s\u00a0para\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0RTKs\u00a0era\u00a0necesaria \u00a0la\u00a0internalizaci\u00f3n \u00a0de\u00a0los\u00a0\nreceptores. \u00a0Esto\u00a0ten\u00eda\u00a0sentido\u00a0ya\u00a0que\u00a0otros\u00a0\nsustratos\u00a0de\u00a0Src\u00a0son\u00a0la\u00a0clatrina\u00a0y\u00a0dinamina369,\u00a0dos\u00a0\nprote\u00ednas \u00a0implicadas \u00a0en\u00a0la\u00a0internalizaci\u00f3n \u00a0de\u00a0\nvarios\u00a0tipos\u00a0de\u00a0receptores \u00a0de\u00a0membrana \u00a0entre\u00a0\nellos\u00a0EGFR.\u00a0Inicialmente, \u00a0se\u00a0cre\u00eda\u00a0que\u00a0la\u00a0\ninternalizaci\u00f3n \u00a0de\u00a0los\u00a0RTKs\u00a0dependiente \u00a0de\u00a0\uf062\u2010\narresitnas \u00a0y\u00a0clatrina\u00a0era\u00a0un\u00a0mecanismo \u00a0para\u00a0\natenuar\u00a0la\u00a0se\u00f1al\u00a0del\u00a0receptor. \u00a0Posteriormente \u00a0se\u00a0\nvi\u00f3\u00a0que\u00a0adem\u00e1s\u00a0de\u00a0este\u00a0mecanismo \u00a0exist\u00edan\u00a0otras\u00a0\nv\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0importantes \u00a0dependientes \u00a0de\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n74\u00a0\n\u00a0la\u00a0internalizaci\u00f3n370,371.\u00a0Dado\u00a0que\u00a0se\u00a0ha\u00a0\ndemostrado \u00a0que\u00a0varios\u00a0tipos\u00a0de\u00a0receptores \u00a0como\u00a0\nlos\u00a0adrenoreceptores \u00a0\u03b22,\u00a0el\u00a0receptor\u00a0para\u00a0el\u00a0\u00e1cido\u00a0\nlipofosfat\u00eddico \u00a0(LPA\u20101),\u00a0receptores \u00a0muscar\u00ednicos, \u00a0\netc.,\u00a0requieren \u00a0de\u00a0la\u00a0internalizaci\u00f3n \u00a0para\u00a0activar\u00a0\nMAPKs,\u00a0surgi\u00f3\u00a0la\u00a0idea\u00a0que\u00a0la\u00a0internalizaci\u00f3n \u00a0de\u00a0\nRTKs\u00a0podr\u00eda\u00a0ser\u00a0necesaria \u00a0para\u00a0una\u00a0correcta\u00a0\ntransactivaci\u00f3n \u00a0por\u00a0parte\u00a0de\u00a0los\u00a0GPCRs.\u00a0Aunque\u00a0\nse\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0endocitosis \u00a0no\u00a0era\u00a0necesaria \u00a0\npara\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0RTKs\u00a0si\u00a0que\u00a0en\u00a0algunos\u00a0\ncasos\u00a0como\u00a0el\u00a0de\u00a0adrenorecetpores \u00a0\u03b22\u00a0era\u00a0\nimprescindible \u00a0para\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0MAPKs\u00a0\nadem\u00e1s\u00a0de\u00a0que\u00a0la\u00a0participaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0\nera\u00a0necesaria372.\u00a0Aunque\u00a0esto\u00a0no\u00a0sucede\u00a0en\u00a0todos\u00a0\nlos\u00a0GPCRs,\u00a0ya\u00a0que\u00a0el\u00a0adrenoreceptor \u00a0\u03b11\u00a0induc\u00eda\u00a0la\u00a0\ndimerizaci\u00f3n \u00a0y\u00a0autofosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0en\u00a0\npresencia \u00a0de\u00a0un\u00a0inhibidor\u00a0de\u00a0endocitosis373.\u00a0\nPor\u00a0otro\u00a0lado,\u00a0y\u00a0en\u00a0relaci\u00f3n\u00a0al\u00a0CM,\u00a0hay\u00a0varias\u00a0\npublicaciones \u00a0que\u00a0demuestran \u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0\nGPCRs\u00a0y\u00a0otro\u00a0receptor\u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0como\u00a0\nHER2.\u00a0En\u00a0varios\u00a0estudios\u00a0que\u00a0examinaron \u00a0\nconjuntamente \u00a0m\u00e1s\u00a0de\u00a0125\u00a0muestras \u00a0de\u00a0tumores\u00a0\nde\u00a0mama\u00a0humanos \u00a0y\u00a0l\u00edneas\u00a0celulares, \u00a0m\u00e1s\u00a0del\u00a0\n70%\u00a0de\u00a0las\u00a0muestras \u00a0conten\u00edan \u00a0niveles\u00a0de\u00a0Src\u00a0con\u00a0\nactividad\u00a0tirosina\u00a0quinasa\u00a0que\u00a0eran\u00a0de\u00a0dos\u00a0hasta\u00a0\n50\u00a0veces\u00a0mayor\u00a0que\u00a0las\u00a0que\u00a0se\u00a0encontraban \u00a0en\u00a0el\u00a0\nepitelio\u00a0mamario\u00a0normal\u00a0o\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0\nepiteliales \u00a0mamarias \u00a0inmortalizadas365.\u00a0Ese\u00a0fue\u00a0\nunos\u00a0de\u00a0los\u00a0motivos\u00a0que\u00a0hizo\u00a0pensar\u00a0que\u00a0esta\u00a0\nprote\u00edna\u00a0ejerc\u00eda\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0este\u00a0tipo\u00a0de\u00a0c\u00e1ncer.\u00a0\nEn\u00a0un\u00a0estudio\u00a0con\u00a0c\u00e9lulas\u00a0de\u00a0c\u00e1ncer\u00a0g\u00e1strico\u00a0se\u00a0\ndemostr\u00f3 \u00a0que\u00a0los\u00a0dos\u00a0principales \u00a0lisofosfol\u00edpidos \u00a0\nnaturales \u00a0(dos\u00a0GPCRs),\u00a0el\u00a0\u00e1cido\u00a0lisofosfat\u00eddico \u00a0\n(LPA)\u00a0y\u00a0la\u00a0esfingosina \u00a01\u2010fosfato\u00a0(S1P),\u00a0induc\u00edan\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0r\u00e1pida\u00a0y\u00a0transitoria \u00a0de\u00a0HER2\u00a0en\u00a0dos\u00a0\nl\u00edneas\u00a0humanas\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0c\u00e1ncer\u00a0g\u00e1strico374.\u00a0\nTambi\u00e9n\u00a0el\u00a0ligando\u00a0de\u00a0CXCR4\u00a0(otro\u00a0GPCR\u00a0que\u00a0\nse\u00f1aliza\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0subunidad \u00a0G\u03b1i/o),\u00a0llamado\u00a0\nSDF\u20101\u00a0o\u00a0CXCL12,\u00a0transactivaba \u00a0HER2\u00a0en\u00a0dos\u00a0l\u00edneas\u00a0\ncelulares\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0con\u00a0expresi\u00f3n \u00a0de\u00a0\nHER2\u00a0y\u00a0CXCR4\u00a0como\u00a0las\u00a0SKBR3\u00a0o\u00a0las\u00a0MDA\u2010MB\u2010362\u00a0\ny\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0no\u00a0\nreceptora \u00a0Src\u00a0tambi\u00e9n\u00a0estaba\u00a0involucrada \u00a0en\u00a0la\u00a0\ntransactivaci\u00f3n375.\u00a0En\u00a0relaci\u00f3n\u00a0a\u00a0este\u00a0tema\u00a0Yan\u00a0M.\u00a0Li\u00a0y\u00a0colaboradores \u00a0describiero, \u00a0en\u00a0un\u00a0modelo\u00a0in\u00a0\nvivo,\u00a0que\u00a0la\u00a0met\u00e1stasis \u00a0pulmonar \u00a0de\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0de\u00a0mama\u00a0mediada\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0del\u00a0receptor\u00a0HER2,\u00a0necesitaba \u00a0de\u00a0la\u00a0\nsobreexpresi\u00f3n \u00a0del\u00a0receptor\u00a0CXCR4\u00a0para\u00a0poderse\u00a0\nllevar\u00a0a\u00a0cabo,\u00a0estableciendo \u00a0de\u00a0ese\u00a0modo\u00a0un\u00a0\nv\u00ednculo\u00a0funcional \u00a0entre\u00a0HER2\u00a0y\u00a0CXCR4376.\u00a0Otro\u00a0\nreceptor\u00a0que\u00a0se\u00f1aliza\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0subunidad \u00a0\nG\u03b1i/o,\u00a0el\u00a0receptor\u00a0activado\u00a0por\u00a0proteasa\u00a0(PAR1,\u00a0\ndel\u00a0ingl\u00e9s\u00a0protease\u2010activated \u00a0receptor\u20101),\u00a0\ntrasactivaba \u00a0a\u00a0EGFR\u00a0y\u00a0HER2\u00a0promoviendo \u00a0la\u00a0\ninvasi\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM377.\u00a0\u00a0\nLa\u00a0interacci\u00f3n \u00a0de\u00a0Src\u00a0con\u00a0el\u00a0receptor\u00a0HER2\u00a0\ntambi\u00e9n\u00a0ha\u00a0sido\u00a0estudiada \u00a0y\u00a0parece\u00a0ser\u00a0que,\u00a0de\u00a0la\u00a0\nmisma\u00a0manera\u00a0que\u00a0con\u00a0EGFR,\u00a0Src\u00a0puede\u00a0se\u00f1alizar\u00a0\ncorriente\u00a0arriba\u00a0o\u00a0corriente\u00a0abajo\u00a0de\u00a0los\u00a0RTKs.\u00a0En\u00a0\nel\u00a02001,\u00a0Belsches\u00a0y\u00a0colaboradores \u00a0describieron \u00a0\nque\u00a0el\u00a0crecimiento \u00a0dependiente \u00a0de\u00a0adhesi\u00f3n\u00a0de\u00a0\nalgunas\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0\ndepend\u00eda \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0\nheregulina \u00a0(HRG),\u00a0y\u00a0esta\u00a0activaci\u00f3n \u00a0era\u00a0\ndependiente \u00a0o\u00a0independiente \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0\nen\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0estudiada378.\u00a0\u00a0\nEn\u00a02005\u00a0Harol\u00a0Kim\u00a0va\u00a0m\u00e1s\u00a0all\u00e1\u00a0y\u00a0describe\u00a0que\u00a0la\u00a0\nasociaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0con\u00a0el\u00a0receptor\u00a0\nHER2\u00a0no\u00a0\u00e9s\u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0sitios\u00a0de\u00a0\nautofosforilaci\u00f3n \u00a0de\u00a0la\u00a0zona\u00a0c\u2010terminal\u00a0sino\u00a0que\u00a0\ninteracciona \u00a0con\u00a0el\u00a0dominio\u00a0catal\u00edtico\u00a0del\u00a0\nreceptor\u00a0HER2.\u00a0Y\u00a0esta\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0\ndependiente \u00a0de\u00a0Src\u00a0inhibie\u00a0los\u00a0contactos \u00a0c\u00e9lula\u2010\nc\u00e9lula\u00a0irrumpiendo \u00a0en\u00a0la\u00a0polaridad \u00a0celular379.\u00a0Y\u00a0en\u00a0\nel\u00a02007\u00a0Ishizawar \u00a0y\u00a0colaboradores \u00a0describen \u00a0un\u00a0\nmodelo\u00a0algo\u00a0distinto\u00a0y\u00a0apuntan\u00a0que\u00a0Src\u00a0no\u00a0solo\u00a0\nse\u00f1aliza\u00a0corriente\u00a0debajo\u00a0de\u00a0los\u00a0RTKs\u00a0sino\u00a0que\u00a0\ntambi\u00e9n\u00a0juega\u00a0un\u00a0papel\u00a0importante \u00a0corriente\u00a0\narriba\u00a0en\u00a0la\u00a0modulaci\u00f3n \u00a0de\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0\nheterocomplejos \u00a0HER2/HER3 \u00a0y\u00a0de\u00a0sus\u00a0funciones \u00a0\nbiol\u00f3gicas. \u00a0Sugieren\u00a0que\u00a0el\u00a0crecimiento \u00a0\nindependiente \u00a0de\u00a0adhesi\u00f3n\u00a0por\u00a0parte\u00a0de\u00a0\nHER2/HER3 \u00a0si\u00a0es\u00a0dependiente \u00a0de\u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nSrc\u00a0de\u00a0acuerdo\u00a0con\u00a0lo\u00a0anteriormente \u00a0descrito380.\u00a0\nNo\u00a0solo\u00a0las\u00a0prote\u00ednas \u00a0G\u03b1i\u00a0son\u00a0capaces\u00a0de\u00a0\ntransactivar \u00a0RTKs,\u00a0en\u00a0algunos\u00a0estudios\u00a0y\u00a0seg\u00fan\u00a0lo\u00a0\ndescrito\u00a0en\u00a0el\u00a0apartado\u00a0de\u00a0GPCRs\u00a0en\u00a0la\u00a0\nintroducci\u00f3n, \u00a0las\u00a0subunidades \u00a0G\u03b1q\u00a0y\u00a0\u03b2 \u03b3 \u00a0 est\u00e1n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n75\u00a0\n\u00a0implicadas \u00a0en\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs.\u00a0Aunque\u00a0\nen\u00a0c\u00e9lulas\u00a0COS\u20107,\u00a0\u00a0se\u00a0describi\u00f3\u00a0que\u00a0Src\u00a0induc\u00eda\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0estimulaci\u00f3n \u00a0\nde\u00a0G\u03b1i\u00a0(LPA\u00a0y\u00a0\u03b1 2A\u2010adren\u00e9rgicos) \u00a0o\u00a0la\u00a0\nsobreexpresi\u00f3n \u00a0de\u00a0las\u00a0subunidades \u00a0G\u03b2\u03b3,\u00a0\nindependientemente \u00a0de\u00a0la\u00a0actividad\u00a0intr\u00ednseca \u00a0de\u00a0\nla\u00a0quinasa\u00a0de\u00a0EGFR381,\u00a0otros\u00a0estudios382,383\u00a0\ndemostraron \u00a0en\u00a0c\u00e9lulas\u00a0HEK\u2010293,\u00a0COS\u20107,\u00a0y\u00a0CHO),\u00a0\nque\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PKC\u00a0era\u00a0imprescindible \u00a0\npara\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0y\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nErk\u00a0a\u00a0partir\u00a0de\u00a0receptores \u00a0acoplados \u00a0a\u00a0prote\u00ednas \u00a0\nG\u03b1q\u00a0(M1\u00a0o\u00a0el\u00a0adren\u00e9rgico \u00a0\u03b11B).\u00a0De\u00a0hecho\u00a0en\u00a0estos\u00a0\nmismos\u00a0receptores, \u00a0que\u00a0se\u00f1alizan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nprote\u00ednas \u00a0G\u03b1q,\u00a0la\u00a0expresi\u00f3n \u00a0aumentada \u00a0de\u00a0\ncomplejos \u00a0G\u03b2\u03b3\u00a0incrementaba \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\nEGFR\u00a0mediada\u00a0tambi\u00e9n,\u00a0en\u00a0este\u00a0caso,\u00a0por\u00a0la\u00a0\nprote\u00edna\u00a0Src,\u00a0en\u00a0c\u00e9lulas\u00a0COS\u20107381.\u00a0Estos\u00a0datos\u00a0son\u00a0\nmuy\u00a0importantes \u00a0si\u00a0tenemos\u00a0en\u00a0cuenta\u00a0que\u00a0el\u00a0\nreceptor\u00a0NK\u20101,\u00a0es\u00a0un\u00a0GPCR\u00a0que\u00a0se\u00f1aliza\u00a0\nprincipalmente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0subunidad \u00a0G\u03b1q,\u00a0y\u00a0\npor\u00a0tanto\u00a0hay\u00a0indicios\u00a0suficientes \u00a0para\u00a0pensar\u00a0que\u00a0\neste\u00a0receptor\u00a0es\u00a0responsable \u00a0de\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0en\u00a0CM\u00a0donde\u00a0se\u00a0\nencuentra \u00a0expresado. \u00a0Por\u00a0tanto\u00a0que\u00a0subunidades \u00a0\nutiliza\u00a0cada\u00a0receptor\u00a0para\u00a0se\u00f1alizar\u00a0depende\u00a0del\u00a0\ncontexto\u00a0celular\u00a0y\u00a0de\u00a0las\u00a0m\u00f3leculas \u00a0presentes \u00a0en\u00a0\nese\u00a0momento \u00a0que\u00a0permiten \u00a0a\u00a0la\u00a0maquinaria \u00a0\ncelular\u00a0responder \u00a0de\u00a0una\u00a0forma\u00a0u\u00a0otra.\u00a0Sin\u00a0\nembargo\u00a0todav\u00eda\u00a0no\u00a0hay\u00a0bibliograf\u00eda \u00a0suficiente \u00a0\nque\u00a0demuestre \u00a0que\u00a0NK\u20101\u00a0es\u00a0capaz\u00a0de\u00a0transactivar \u00a0\nHER2,\u00a0en\u00a0este\u00a0u\u00a0otro\u00a0tipos\u00a0de\u00a0c\u00e1nceres. \u00a0\n\u00a0\n7.2.\u00a0ADAMS\u00a0y\u00a0MMPs\u00a0como\u00a0\nmediadores \u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0RTKs\u00a0\nLa\u00a0existencia \u00a0de\u00a0m\u00faltiples \u00a0niveles\u00a0de\u00a0interacci\u00f3n \u00a0\nentre\u00a0los\u00a0dos\u00a0sistemas\u00a0de\u00a0receptores \u00a0en\u00a0los\u00a0\nprimeros\u00a0pasos\u00a0del\u00a0proceso\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\npermite\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0RTK\u00a0de\u00a0forma\u00a0\nindependiente \u00a0(revisada\u00a0hasta\u00a0el\u00a0momento) \u00a0o\u00a0\ndependiente \u00a0de\u00a0ligando.\u00a0En\u00a0este\u00a0aspecto\u00a0tuvo\u00a0\nlugar\u00a0un\u00a0desubrimiento \u00a0en\u00a01999,\u00a0cuando\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0por\u00a0\nreceptores \u00a0acoplados \u00a0a\u00a0prote\u00ednas \u00a0G\u03b1q\u00a0o\u00a0G\u03b1i\u00a0\nestaba\u00a0relacionada \u00a0con\u00a0la\u00a0liberaci\u00f3n \u00a0al\u00a0medio\u00a0\nextracelular \u00a0de\u00a0un\u00a0ligando\u00a0end\u00f3geno. \u00a0Este\u00a0\nligando,\u00a0EGF\u00a0que\u00a0se\u00a0encuentra \u00a0asociado\u00a0a\u00a0la\u00a0\nheparina\u00a0(HB\u2010EGF\u00a0del\u00a0ingl\u00e9s,\u00a0heparin\u00a0binding\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor )\u00a0pod\u00eda\u00a0ser\u00a0\nhidrolizado \u00a0por\u00a0metaloproteasas, \u00a0quedando \u00a0en\u00a0\nlibertad\u00a0y\u00a0puediendo \u00a0activar\u00a0receptores \u00a0como\u00a0\nEGFR\u00a0de\u00a0forma\u00a0autocrina \u00a0(en\u00a0la\u00a0misma\u00a0c\u00e9lula)\u00a0o\u00a0\nparacrina \u00a0(en\u00a0c\u00e9lulas\u00a0vecinas)384.\u00a0Una\u00a0vez\u00a0activado\u00a0\nel\u00a0RTK\u00a0se\u00a0unen\u00a0prote\u00ednas \u00a0con\u00a0dominios \u00a0SH2\u00a0como\u00a0\nShc,\u00a0Grb2,\u00a0Gab1\u00a0y\u00a0Src.\u00a0A\u00a0partir\u00a0de\u00a0aqu\u00ed\u00a0se\u00a0activa\u00a0\nSos/Ras/Raf/MEK/MAPK \u00a0mientras\u00a0que\u00a0Gab1\u00a0\npuede\u00a0activar\u00a0a\u00a0\u00a0PI3K/Akt362\u00a0(Fig.\u00a024).\u00a0\u00a0\nHay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0\nMMPs\u00a0se\u00a0puede\u00a0producir\u00a0por\u00a0activaci\u00f3n \u00a0del\u00a0GPCR\u00a0\no\u00a0una\u00a0vez\u00a0el\u00a0RTK\u00a0ya\u00a0se\u00a0ha\u00a0activado,\u00a0lo\u00a0que\u00a0\nconllevar\u00eda \u00a0a\u00a0diferentes \u00a0picos\u00a0de\u00a0activaci\u00f3n \u00a0de\u00a0\nRTKs\u00a0por\u00a0liberaci\u00f3n \u00a0discontinua \u00a0de\u00a0sus\u00a0\nligandos247.\u00a0En\u00a0algunos\u00a0casos\u00a0se\u00a0ha\u00a0visto\u00a0que\u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0ROS\u00a0potencia\u00a0la\u00a0transactivaci\u00f3n, \u00a0\naunque\u00a0no\u00a0se\u00a0tiene\u00a0muy\u00a0claro\u00a0el\u00a0mecanismo \u00a0\nconcreto. \u00a0Una\u00a0de\u00a0las\u00a0posibilidades \u00a0ser\u00eda\u00a0que\u00a0ROS\u00a0\nfacilitara\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0MMPs,\u00a0lo\u00a0que\u00a0inducir\u00eda\u00a0un\u00a0\naumento\u00a0de\u00a0HB\u2010EGF247,385.\u00a0\u00a0\nPor\u00a0otra\u00a0parte,\u00a0tambi\u00e9n\u00a0se\u00a0ha\u00a0demostrado \u00a0la\u00a0\nimplicaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nMMPs.\u00a0Aunque\u00a0no\u00a0se\u00a0conoce\u00a0la\u00a0v\u00eda\u00a0completa, \u00a0un\u00a0\nestudio\u00a0c\u00e9lulas\u00a0COS\u20107\u00a0que\u00a0sobreexpresaban \u00a0el\u00a0\nreceptor\u00a0\u03b1 2A\u2010adren\u00e9rgico \u00a0mostr\u00f3\u00a0que\u00a0Src\u00a0se\u00a0\nactivaba\u00a0antes\u00a0de\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0y\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0G\u03b1i,\u00a0y\u00a0que\u00a0\nsu\u00a0participaci\u00f3n \u00a0era\u00a0determinante \u00a0en\u00a0la\u00a0hidr\u00f3lisis\u00a0\ndel\u00a0complejo \u00a0HB\u2010EGF,\u00a0adem\u00e1s\u00a0de\u00a0modular\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0Erk373.\u00a0Otros\u00a0estudios\u00a0han\u00a0\ndemostrado \u00a0que\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0activa\u00a0en\u00a0alg\u00fan\u00a0\npunto\u00a0de\u00a0su\u00a0ruta\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0la\u00a0tirosina\u00a0\nquinasa\u00a0Src224,311,313,\u00a0y\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0este\u00a0receptor\u00a0puede\u00a0tambi\u00e9n\u00a0estimular \u00a0\nla\u00a0s\u00edntesis\u00a0de\u00a0MMPs.\u00a0\nEsto\u00a0a\u00f1ade\u00a0una\u00a0prote\u00edna\u00a0m\u00e1s\u00a0como\u00a0responsable \u00a0\nen\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0MMPs\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0receptores \u00a0\nacoplados \u00a0a\u00a0prote\u00ednas \u00a0G\u00a0dentro\u00a0del\u00a0proceso\u00a0de\u00a0\ntransactivaci\u00f3n \u00a0ya\u00a0que\u00a0Src\u00a0parece\u00a0serINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n76\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a024.\u00a0Modelo\u00a0de\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0GPCR\u00a0en\u00a0c\u00e1ncer.\u00a0Las\u00a0flechas\u00a0negras\u00a0discont\u00ednuas \u00a0se\u00f1alan\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0del\u00a0EGFR\u00a0mediada\u00a0por\u00a0GPCR\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0mecanismos \u00a0dependientes \u00a0de\u00a0ligandos\u00a0liberados \u00a0por\u00a0las\u00a0MMPs.\u00a0Las\u00a0\nflechas\u00a0cont\u00ednuas \u00a0indican\u00a0la\u00a0transactivaci\u00f3n \u00a0del\u00a0EGFR\u00a0mediada\u00a0por\u00a0un\u00a0GPCR\u00a0independiente \u00a0de\u00a0ligando\u00a0y\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0\nmediada\u00a0por\u00a0Src.\u00a0Esta\u00a0prote\u00edna\u00a0conduce\u00a0a\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0algunos\u00a0residuos\u00a0de\u00a0tirosina\u00a0en\u00a0el\u00a0receptor\u00a0EGFR\u00a0y\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nalgunas\u00a0MMPs.\u00a0La\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0inducida\u00a0por\u00a0un\u00a0GPCR\u00a0puede\u00a0mediar\u00a0v\u00edas\u00a0como\u00a0Ras/Raf/MEK/ERK1/2 \u00a0y\u00a0PI3K/Akt. \u00a0La\u00a0\nfigura\u00a0ha\u00a0sido\u00a0dise\u00f1ada\u00a0utilizando \u00a0Servier\u00a0Medical\u00a0Art.\u00a0\n\u00a0\ndeterminante \u00a0,en\u00a0algunos\u00a0casos,\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0\nde\u00a0Erk\u00a0y\u00a0en\u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0EGF\u00a0a\u00a0partir\u00a0del\u00a0\ncomplejo \u00a0HB\u2010EGF.\u00a0Diversos\u00a0estudios\u00a0han\u00a0implicado \u00a0\ntanto\u00a0a\u00a0las\u00a0ADAMs\u00a0como\u00a0a\u00a0las\u00a0MMPs\u00a0\n(dependientes \u00a0Ca2+\u00a0o\u00a0Zn2+)\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nmiembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0por\u00a0inducir\u00a0la\u00a0\nprote\u00f3lisis \u00a0de\u00a0los\u00a0ectodominios \u00a0de\u00a0los\u00a0ligandos\u00a0de\u00a0\nEGFR.\u00a0Los\u00a0ligandos\u00a0para\u00a0los\u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0\nde\u00a0EGFR\u00a0son\u00a0EGF,\u00a0HB\u2010EGF,\u00a0TGF\u2010\u03b2,\u00a0epiregulina, \u00a0\namfiregulina, \u00a0epigen,\u00a0\u03b2 \u2010 celulina\u00a0y\u00a0cuatro\u00a0\nneuregulinas \u00a0(NRG\u20101,\u00a02,\u00a03\u00a0y\u00a04)386.\u00a0Dependiendo \u00a0del\u00a0\ntipo\u00a0celular\u00a0y\u00a0del\u00a0GPCR\u00a0activado,\u00a0se\u00a0ha\u00a0descrito\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0por\u00a0prote\u00f3lisis \u00a0de\u00a0HB\u2010\nEGF,\u00a0TGF\u2010\u03b2\u00a0y\u00a0amfiregulina \u00a0principalmente. \u00a0Sin\u00a0\nembargo, \u00a0aunque\u00a0se\u00a0ha\u00a0apuntado \u00a0al\u00a0papel\u00a0de\u00a0\ndiversas\u00a0proteasas \u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0estos\u00a0\nligandos,\u00a0no\u00a0se\u00a0ha\u00a0demostrado \u00a0si\u00a0esta\u00a0activaci\u00f3n \u00a0\nse\u00a0produce\u00a0por\u00a0efecto\u00a0directo\u00a0sobre\u00a0los\u00a0ligandos,\u00a0o\u00a0\nsi\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0ADAMs\u00a0y\u00a0MMPs\u00a0inducen\u00a0la\u00a0activaci\u00f3n \u00a0se\u00a0segundas \u00a0proteasas \u00a0implicadas \u00a0en\u00a0el\u00a0\nprocesamiento \u00a0de\u00a0los\u00a0ligandos.\u00a0En\u00a0la\u00a0Tabla\u00a012\u00a0se\u00a0\ndetallan\u00a0algunas\u00a0de\u00a0las\u00a0proteasas \u00a0que\u00a0se\u00a0han\u00a0\nrelacionado \u00a0con\u00a0procesos\u00a0de\u00a0transactivaci\u00f3n \u00a0de\u00a0\nRTKs\u00a0en\u00a0diversas\u00a0l\u00edneas\u00a0celulares\u00a0y\u00a0en\u00a0c\u00e9lulas\u00a0\ntransformadas. \u00a0\nLa\u00a0se\u00f1alizaci\u00f3n \u00a0del\u00a0EGFR\u00a0a\u00a0partir\u00a0de\u00a0EGF\u00a0de\u00a0forma\u00a0\nautocrina, \u00a0es\u00a0un\u00a0factor\u00a0importante \u00a0en\u00a0varios\u00a0tipos\u00a0\nde\u00a0c\u00e1ncer387.\u00a0Del\u00a0mismo\u00a0modo,\u00a0tanto\u00a0en\u00a0\nmam\u00edferos \u00a0como\u00a0en\u00a0otros\u00a0sistemas\u00a0de\u00a0Drosophila, \u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0Ras\u2010MAPK\u00a0induce\u00a0la\u00a0\nproducci\u00f3n \u00a0de\u00a0ligandos\u00a0del\u00a0receptor\u00a0EGFR/ErbB, \u00a0\nproveyendo \u00a0otro\u00a0mecanismo \u00a0clave\u00a0de\u00a0\nretroalimentaci\u00f3n \u00a0positiva388,389.\u00a0De\u00a0todas\u00a0formas\u00a0\nla\u00a0liberaci\u00f3n \u00a0de\u00a0ligandos\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0proceso\u00a0de\u00a0\ntransactivaci\u00f3n \u00a0parece\u00a0ser\u00a0muy\u00a0baja,\u00a0de\u00a0hecho\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0del\u00a0receptor\u00a0y\u00a0de\u00a0sus\u00a0prote\u00ednas \u00a0\nadaptadoras \u00a0es\u00a0mucho\u00a0menor\u00a0que\u00a0si\u00a0se\u00a0a\u00f1ade\u00a0EGF\u00a0\nex\u00f3ngeno390.\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n77\u00a0\n\u00a0\u00a0\nA\u00fan\u00a0as\u00ed,\u00a0la\u00a0velocidad \u00a0de\u00a0transactivaci\u00f3n \u00a0y\u00a0la\u00a0\nausencia\u00a0de\u00a0cantidades \u00a0detectables \u00a0de\u00a0EGF\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0GPCRs403,\u00a0llev\u00f3\u00a0a\u00a0la\u00a0\nconclusi\u00f3n \u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0EGFR\u00a0est\u00e1\u00a0\nexclusivamente \u00a0mediada\u00a0por\u00a0elementos \u00a0\nintracelulares404,405\u00a0y\u00a0EGF\u00a0podr\u00eda\u00a0funcionar \u00a0\nactivando \u00a0receptores \u00a0cercanos\u00a0en\u00a0los\u00a0\nmicrodominios \u00a0adyacentes390.\u00a0\n8.\u00a0RECEPTORES \u00a0CON\u00a0ACTIVIDAD \u00a0\nTIROSINA \u00a0QUINASA: \u00a0FAMILIA\u00a0\nDE\u00a0LOS\u00a0RECEPTORES \u00a0ErbB\u00a0\n8.1.\u00a0Estructura \u00a0y\u00a0activaci\u00f3n \u00a0\nLos\u00a0receptores \u00a0ErbB\u00a0pertenecen \u00a0a\u00a0la\u00a0sublcase\u00a0I\u00a0de\u00a0\nRTKs\u00a0existentes \u00a0\u00a0y\u00a0se\u00a0compone \u00a0de\u00a04\u00a0miembros \u00a0\nprincipales \u00a0EGFR\u00a0(tambi\u00e9n\u00a0conocido\u00a0como\u00a0HER1\u00a0o\u00a0ErbB1),\u00a0ErbB2\u00a0(HER2\u00a0o\u00a0c\u2010Neu),\u00a0ErbB3\u00a0(HER3)\u00a0y\u00a0\nErbB4\u00a0(HER4)406.\u00a0En\u00a0su\u00a0forma\u00a0madura\u00a0son\u00a0\nprote\u00ednas \u00a0transembrana \u00a0glicosiladas \u00a0que\u00a0\natraviesan \u00a0la\u00a0membrana \u00a0una\u00a0sola\u00a0vez.\u00a0Todos\u00a0los\u00a0\nmiembros \u00a0tienen\u00a0una\u00a0regi\u00f3n\u00a0extracelular \u00a0de\u00a0uni\u00f3n\u00a0\na\u00a0ligando,\u00a0una\u00a0regi\u00f3n\u00a0transmembrana \u00a0\u00a0y\u00a0un\u00a0\ndominio\u00a0citopl\u00e1smico \u00a0tirosina\u2010quinasa.\u00a0Estos\u00a0\nreceptores \u00a0se\u00a0expresan\u00a0en\u00a0diversos\u00a0tejidos\u00a0de\u00a0\norigen\u00a0epitelial,\u00a0mesenquimal \u00a0y\u00a0neuronal. \u00a0La\u00a0\nimportancia \u00a0de\u00a0los\u00a0receptores \u00a0ErbB\u00a0durante\u00a0el\u00a0\ndesarrollo \u00a0y\u00a0en\u00a0la\u00a0fisiolog\u00eda\u00a0normal\u00a0para\u00a0adultos\u00a0ha\u00a0\nsido\u00a0estudiada \u00a0a\u00a0partir\u00a0de\u00a0los\u00a0an\u00e1lisis\u00a0de\u00a0ratones\u00a0\ngen\u00e9ticamente \u00a0modificados \u00a0o\u00a0knock\u00a0out\u00a0para\u00a0\nestos\u00a0receptores, \u00a0ya\u00a0que\u00a0mutaciones \u00a0o\u00a0\ndelecciones \u00a0de\u00a0estos\u00a0genes\u00a0son\u00a0letales,\u00a0en\u00a0algunos\u00a0\ncasos,\u00a0durante\u00a0la\u00a0embriog\u00e9nsis \u00a0o\u00a0etapa\u00a0\npostnatal407\u2010411.\u00a0\u00a0\nSu\u00a0activaci\u00f3n \u00a0es\u00a0controlada \u00a0por\u00a0la\u00a0expresi\u00f3n \u00a0o\u00a0la\u00a0\ndisponibilidad \u00a0espacial\u00a0y\u00a0temporal\u00a0de\u00a0sus\u00a0ligandos,\u00a0Tabla\u00a012.\u00a0ADAMs\u00a0y\u00a0MMPs\u00a0implicadas \u00a0en\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR.\nPROTEASA \u00a0 AGONISTA \u00a0 RECEPTOR \u00a0 LIGANDO \u00a0 TIPO\u00a0CELULAR\u00a0 REF\u00a0\nADAM\u00a010\u00a0IL\u20108\u00a0 CXCR\u00a01\u20102\u00a0 HB\u2010EGF\u00a0KATO\u2010III,\u00a0C\u00c1NCER\u00a0\nG\u00c1STRICO \u00a0391\n\u00a0\nIL\u20101\uf062\u00a0 \u00a0 HB\u2010EGF\u00a0KATO\u2010III,\u00a0C\u00c1NCER\u00a0\nG\u00c1STRICO \u00a0391\n\u00a0\nLPA\u00a0 \u00a0 HB\u2010EGF\u00a0 ACHN,\u00a0C\u00c1NCER\u00a0DE\u00a0RI\u00d1\u00d3N\u00a0392\n\u00a0\nBOMBESINA \u00a0 REC.\u00a0BOMBESINA \u00a0 HB\u2010EGF\u00a0 PC3,\u00a0C\u00c1NCER\u00a0PR\u00d3STATA \u00a0393\n\u00a0\nFENILEFRINA \u00a0 \uf0611AR\u00a0 HB\u2010EGF\u00a0 MIOCITOS \u00a0CARD\u00cdACOS \u00a0394\n\u00a0\nADAM\u00a015\u00a0 LPA\u00a0RECEPTOR \u00a0DE\u00a0\nLPA\u00a0TGF\uf061\u00a0 TccSup,\u00a0C\u00c1NCER\u00a0DE\u00a0VEJIGA\u00a0392\nAMFIREGULINA 5637,\u00a0C\u00c1NCER\u00a0DE\u00a0BUFETA392\nADAM\u201017\u00a0\n\u00a05\u2010HT\u00a0 5\u2010HT(2A)\u00a0 HB\u2010EGF\u00a0 C\u00c9LULAS\u00a0MESANGIALES \u00a0395\n\u00a0\nANG\u00a0II\u00a0 AT1\u00a0 HB\u2010EGF\u00a0C\u00c9LULAS\u00a0MUSCULARES \u00a0DE\u00a0\nLA\u00a0VASCULATURA \u00a0LISA\u00a0396\n\u00a0\nACHN,\u00a0C\u00c1NCER\u00a0RI\u00d1\u00d3N\u00a0397\n\u00a0\nLPA\u00a0RECEPTOR \u00a0DE\u00a0\nLPA\u00a0HB\u2010EGF\u00a0CaKi2,\u00a0C\u00c1NCER\u00a0DE\u00a0RI\u00d1\u00d3N\u00a0392\n\u00a0\nA498,\u00a0C\u00c1NCER\u00a0DE\u00a0RI\u00d1\u00d3N\u00a0392\n\u00a0\nMMP\u00a01\u00a0 HISTAMINA \u00a0 H2\u00a0 HB\u2010EGF\u00a0 AGS\u00a0398\n\u00a0\nMMP\u00a02\u00a0GnRH\u00a0 GnRHR\u00a0 HB\u2010EGF\u00a0 \uf061T3\u20101\u00a0399\n\u00a0\nESTRADIOL \u00a0 ER\u00a0 HB\u2010EGF\u00a0 MCF7,\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0400\n\u00a0\nMMP7\u00a0 ADRENALINA \u00a0ADRENORECEPT\nORES\u00a0HB\u2010EGF\u00a0C\u00c9LULAS\u00a0DE\u00a0ARTERIA\u00a0\nMESENT\u00c9RICA \u00a0401\n\u00a0\nMMP\u00a08\u00a0 BRADIQUININA \u00a0 B(2)\u00a0 \u2010\u00a0 mIMCD\u20103\u00a0402\n\u00a0\nMMP\u00a09\u00a0GnRH\u00a0 GnRHR\u00a0 HB\u2010EGF\u00a0 \uf061T3\u20101\u00a0399\n\u00a0\nESTRADIOL \u00a0 ER\u00a0 HB\u2010EGF\u00a0 MCF7,\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0400\n\u00a0\nMMP\u00a013\u00a0 BRADIQUININA \u00a0 B(2)\u00a0 \u2010\u00a0 mIMCD\u20103\u00a0402\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n78\u00a0\n\u00a0que\u00a0pertenecen \u00a0a\u00a0la\u00a0familia\u00a0de\u00a0factores\u00a0de\u00a0\ncrecimiento \u00a0epid\u00e9rmico \u00a0o\u00a0EGF412.\u00a0La\u00a0uni\u00f3n\u00a0del\u00a0\nligando\u00a0a\u00a0su\u00a0receptor\u00a0comporta \u00a0un\u00a0cambio\u00a0\nconformacional \u00a0de\u00a0estos\u00a0receptores \u00a0que\u00a0favorece\u00a0\nsu\u00a0 interacci\u00f3n \u00a0 con\u00a0 ellos\u00a0 mismos\u00a0\n(homodimerizaci\u00f3n) \u00a0o\u00a0con\u00a0otros\u00a0miembros \u00a0de\u00a0la\u00a0\nfamilia\u00a0(heterodimerizaci\u00f3n). \u00a0La\u00a0interacci\u00f3n \u00a0de\u00a0los\u00a0\nreceptores \u00a0da\u00a0lugar\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0intr\u00ednseca \u00a0del\u00a0\ndominio\u00a0quinasa,\u00a0que\u00a0resulta\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0por\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0residuos\u00a0concretos \u00a0de\u00a0su\u00a0cola\u00a0\ncitoplasm\u00e1tica413.\u00a0Estos\u00a0ligandos\u00a0se\u00a0pueden\u00a0dividir\u00a0\nfundamentalmente \u00a0en\u00a03\u00a0grupos:\u00a0el\u00a0pimero\u00a0incluye\u00a0\nel\u00a0EGF,\u00a0el\u00a0TGF\u2010\u03b1\u00a0y\u00a0la\u00a0anfiregulina \u00a0(AR)\u00a0y\u00a0los\u00a0tres\u00a0se\u00a0\nunen\u00a0espec\u00edficamente \u00a0a\u00a0EGFR;\u00a0el\u00a0segundo\u00a0est\u00e1\u00a0\nformado\u00a0por\u00a0betacelulina \u00a0(BTC),\u00a0HB\u2010EGF,\u00a0\nepiregulina \u00a0(EPR)\u00a0y\u00a0epig\u00e9n\u00a0(EPG),\u00a0que\u00a0muestran \u00a0\nuna\u00a0especificidad \u00a0dual\u00a0por\u00a0EGFR\u00a0y/o\u00a0HER4;\u00a0y\u00a0el\u00a0\ntercero\u00a0est\u00e1\u00a0compuesto \u00a0por\u00a0neuregulinas \u00a0(NRGS),\u00a0\nque\u00a0a\u00a0su\u00a0vez\u00a0se\u00a0dividen\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0capacidad \u00a0\nde\u00a0uni\u00f3n\u00a0a\u00a0HER3\u00a0(NRG1)\u00a0o\u00a0a\u00a0HER4\u00a0(NRG2,\u00a0NRG3\u00a0y\u00a0\nNRG4)\u00a0(Fig.\u00a025).\u00a0Gracias\u00a0a\u00a0los\u00a0estudios\u00a0realizados \u00a0por\u00a0varios\u00a0grupos\u00a0\nsobre\u00a0la\u00a0estrucura \u00a0cristalina\u00a0de\u00a0los\u00a0receptores \u00a0\nEGFR,\u00a0HER2\u00a0y\u00a0HER3\u00a0(revisado \u00a0en\u00a0414)\u00a0se\u00a0ha\u00a0podido\u00a0\nconocer\u00a0m\u00e1s\u00a0sobre\u00a0el\u00a0proceso\u00a0de\u00a0dimerizaci\u00f3n \u00a0de\u00a0\nestos\u00a0receptores \u00a0iducidos\u00a0por\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0ligando.\u00a0\nLa\u00a0regi\u00f3n\u00a0extracelular \u00a0consta\u00a0de\u00a0cuatro\u00a0dominios \u00a0\n(I\u2010V).\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0EGFR\u00a0o\u00a0HER4,\u00a0el\u00a0brazo\u00a0de\u00a0\ndimerizaci\u00f3n \u00a0del\u00a0dominio\u00a0II\u00a0est\u00e1\u00a0bloqueado \u00a0por\u00a0\ninteracciones \u00a0intramoleculares \u00a0con\u00a0el\u00a0domino\u00a0IV,\u00a0\nen\u00a0la\u00a0conformaci\u00f3n \u00a0cerrada.\u00a0\u00a0Cuando\u00a0el\u00a0ligando\u00a0se\u00a0\nune\u00a0a\u00a0EGFR,\u00a0HER3\u00a0o\u00a0HER4415,416\u00a0se\u00a0reorganizan \u00a0los\u00a0\ndominios \u00a0y\u00a0el\u00a0dominio\u00a0I\u00a0y\u00a0III\u00a0ahora\u00a0est\u00e1n\u00a0m\u00e1s\u00a0\naccesibles \u00a0para\u00a0su\u00a0uni\u00f3n\u00a0a\u00a0ligandos\u00a0gener\u00e1ndose \u00a0\nuna\u00a0estructura \u00a0m\u00e1s\u00a0abierta\u00a0del\u00a0receptor, \u00a0donde\u00a0el\u00a0\nbrazo\u00a0de\u00a0dimerizaci\u00f3n \u00a0del\u00a0dominio\u00a0II\u00a0queda\u00a0\nexpuesto\u00a0para\u00a0poder\u00a0dimerizar414(Fig.\u00a026).\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura.\u00a025.\u00a0Ligandos\u00a0principales \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0y\u00a0se\u00f1alizaci\u00f3n \u00a0corriente \u00a0abajo\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0heterod\u00edmeros. \u00a0La\u00a0\nheterodimerizaci\u00f3n \u00a0de\u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0se\u00a0desencadena \u00a0por\u00a0la\u00a0uni\u00f3n\u00a0del\u00a0ligando\u00a0(con\u00a0la\u00a0excepci\u00f3n \u00a0de\u00a0HER2,\u00a0que\u00a0no\u00a0\ntiene\u00a0ligando\u00a0identificado \u00a0y\u00a0est\u00e1\u00a0\nsiempre\u00a0en\u00a0una\u00a0conformaci\u00f3n \u00a0abierta\u00a0que\u00a0permite\u00a0la\u00a0dimerizaci\u00f3n). \u00a0La\u00a0fosforilaci\u00f3n \u00a0de\u00a0los\u00a0\ndominios \u00a0quinasa\u00a0HER\u00a0(con\u00a0la\u00a0excepci\u00f3n \u00a0de\u00a0HER3,\u00a0que\u00a0no\u00a0tiene\u00a0un\u00a0dominio\u00a0quinasa)\u00a0inicia\u00a0una\u00a0cascada\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0corriente\u00a0\nabajo\u00a0que\u00a0resulta\u00a0en\u00a0la\u00a0transcripci\u00f3n \u00a0de\u00a0genes\u00a0involucrados \u00a0en\u00a0respuestas \u00a0implicadas \u00a0en\u00a0la\u00a0carcinog\u00e9nesis. \u00a0Abreviaturas: \u00a0AR,\u00a0\nanfiregulina; \u00a0BTC,\u00a0betacelulina; \u00a0EPG,\u00a0epigen;\u00a0EPR,\u00a0epirregulina; \u00a0HB\u2010EFG,\u00a0EGF\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0heparina; \u00a0NRG,\u00a0neuregulina. \u00a0La\u00a0figura\u00a0ha\u00a0\nsido\u00a0dise\u00f1ada\u00a0utilizando \u00a0Servier\u00a0Medical\u00a0Art.\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n79\u00a0\n\u00a0Este\u00a0brazo\u00a0de\u00a0dimerizaci\u00f3n \u00a0interacciona \u00a0con\u00a0el\u00a0\nbrazo\u00a0de\u00a0dimerizaci\u00f3n \u00a0de\u00a0otro\u00a0receptor. \u00a0Adem\u00e1s,\u00a0\notros\u00a0estudios\u00a0han\u00a0revelado\u00a0que\u00a0los\u00a0ligandos\u00a0no\u00a0\nest\u00e1n\u00a0involucrados \u00a0en\u00a0la\u00a0interacci\u00f3n \u00a0receptor\u2010\nreceptor, \u00a0\u00a0ya\u00a0que\u00a0quedan\u00a0escoltados \u00a0por\u00a0los\u00a0\ndominios \u00a0I\u00a0y\u00a0III\u00a0y\u00a0por\u00a0tanto\u00a0quedar\u00edan \u00a0lejos\u00a0un\u00a0\nligando\u00a0de\u00a0un\u00a0recptor\u00a0de\u00a0otro\u00a0sin\u00a0llegar\u00a0a\u00a0\ninteraccionar415,416\u00a0(Fig.\u00a026).\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a026.\u00a0Dimerizaci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0HER2\u00a0y\u00a0HER3\u00a0\ncompuestos \u00a0por\u00a0\u00a0cuatro\u00a0dominios \u00a0(I\u2010IV).\u00a01.\u00a0Tras\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0la\u00a0\nNRG\u00a0con\u00a0los\u00a0dominios \u00a0I\u00a0y\u00a0III\u00a0el\u00a0brazo\u00a0de\u00a0dimerizaci\u00f3n \u00a0en\u00a0el\u00a0\ndominio\u00a0II\u00a0se\u00a0expone\u00a0(2)\u00a0y\u00a0promueve \u00a0la\u00a0interacci\u00f3n \u00a0del\u00a0\ndominio\u00a0quinasa\u00a0del\u00a0receptor\u2010receptor\u00a0HER3\u00a0con\u00a0otros\u00a0\nmiembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB,\u00a0como\u00a0por\u00a0ejemplo\u00a0HER2.\u00a03.\u00a0Es\u00a0\nentonces\u00a0cuando\u00a0el\u00a0l\u00f3bulo\u00a0C\u00a0del\u00a0dominio\u00a0quinasa\u00a0interacciona \u00a0\ncon\u00a0el\u00a0l\u00f3bulo\u00a0N\u00a0del\u00a0segundo\u00a0receptor,\u00a0activando \u00a0su\u00a0dominio\u00a0\nquinasa.\u00a0Esto\u00a0provoca\u00a0la\u00a0fosforilaci\u00f3n \u00a0en\u00a0los\u00a0residuos\u00a0tirosina\u00a0\npresentes \u00a0en\u00a0la\u00a0cola\u00a0C\u2010terminal\u00a0de\u00a0HER2\u00a0(representado \u00a0como\u00a0\nesferas\u00a0rojas)\u00a0que\u00a0transfosfoilar\u00e1n \u00a0los\u00a0resudios\u00a0del\u00a0primer\u00a0\nreceptor\u00a0(HER3)\u00a0y\u00a0ambos\u00a0servir\u00e1n\u00a0como\u00a0sitios\u00a0de\u00a0anclaje\u00a0para\u00a0\nmol\u00e9culas \u00a0adaptadoras. \u00a0HER2\u00a0tiene\u00a0una\u00a0conformaci\u00f3n \u00a0fija\u00a0\nque\u00a0se\u00a0asemeja\u00a0a\u00a0la\u00a0del\u00a0estado\u00a0ligando\u2010activado\u00a0de\u00a0EGFR\u00a0y\u00a0\nHER3.\u00a0Modificado \u00a0de\u00a0406,417.\u00a0\nPor\u00a0otro\u00a0lado\u00a0la\u00a0estructura \u00a0de\u00a0la\u00a0regi\u00f3n\u00a0\nextracelular \u00a0de\u00a0HER2\u00a0es\u00a0diferente \u00a0de\u00a0los\u00a0otros\u00a0\nreceptores \u00a0de\u00a0la\u00a0familia\u00a0ErbB.\u00a0HER2\u00a0tiene\u00a0una\u00a0\nconformaci\u00f3n \u00a0fija\u00a0(similar\u00a0al\u00a0estado\u00a0activado\u00a0por\u00a0el\u00a0ligando)\u00a0o\u00a0una\u00a0conformaci\u00f3n \u00a0abierta:\u00a0la\u00a0\ninteracci\u00f3n \u00a0entre\u00a0los\u00a0dominios \u00a0II\u2010IV\u00a0est\u00e1\u00a0ausente\u00a0y\u00a0\nel\u00a0bucle\u00a0de\u00a0dimerizaci\u00f3n \u00a0en\u00a0el\u00a0dominio\u00a0II\u00a0hace\u00a0que\u00a0\neste\u00a0brazo\u00a0quede\u00a0totalmente \u00a0expuesto418,419.\u00a0Esta\u00a0\nestructura \u00a0es\u00a0consistente \u00a0con\u00a0los\u00a0datos\u00a0que\u00a0\nindican\u00a0que\u00a0el\u00a0receptor\u00a0HER2\u00a0es\u00a0el\u00a0socio\u00a0preferido \u00a0\npara\u00a0el\u00a0resto\u00a0de\u00a0recetpores \u00a0ErbBs\u00a0activados, \u00a0ya\u00a0\nque\u00a0est\u00e1\u00a0permanentemente \u00a0preparado \u00a0para\u00a0la\u00a0\ninteracci\u00f3n \u00a0con\u00a0otro\u00a0receptor\u00a0activado\u00a0por\u00a0\nligando.\u00a0Parece\u00a0que\u00a0hay\u00a0una\u00a0parte\u00a0del\u00a0dominio\u00a0II\u00a0\nde\u00a0HER2\u00a0algo\u00a0diferente \u00a0a\u00a0sus\u00a0compa\u00f1eros \u00a0de\u00a0\nse\u00f1alizaci\u00f3n, \u00a0ya\u00a0que\u00a0presenta\u00a0una\u00a0protuberancia \u00a0\nimplicada \u00a0en\u00a0la\u00a0dimerizaci\u00f3n, \u00a0algo\u00a0mayor\u00a0que\u00a0la\u00a0\ndel\u00a0resto,\u00a0y\u00a0provoca\u00a0que\u00a0este\u00a0receptor\u00a0no\u00a0dimerice\u00a0\nf\u00e1cilmente \u00a0con\u00a0el\u00a0mismo\u00a0pero\u00a0si\u00a0con\u00a0otros\u00a0\nmiembros \u00a0de\u00a0la\u00a0misma\u00a0familia420.\u00a0Sin\u00a0embargo\u00a0se\u00a0\nactiva\u00a0constitutivamente \u00a0en\u00a0tejidos\u00a0donde\u00a0se\u00a0\nsobreexpresa, \u00a0siendo\u00a0capaz\u00a0entonces\u00a0de\u00a0dimerizar \u00a0\nen\u00a0ausencia\u00a0de\u00a0ligando.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0\nque\u00a0HER2\u00a0posee\u00a0una\u00a0interacci\u00f3n \u00a0entre\u00a0los\u00a0dominio\u00a0\nI\u2010III\u00a0que\u00a0hace\u00a0que\u00a0la\u00a0uni\u00f3n\u00a0del\u00a0ligando\u00a0a\u00a0este\u00a0\nreceptor\u00a0sea\u00a0imposible, \u00a0ya\u00a0que\u00a0no\u00a0es\u00a0accesible\u00a0\npara\u00a0la\u00a0interacci\u00f3n. \u00a0Por\u00a0este\u00a0motivo\u00a0quiz\u00e1s\u00a0no\u00a0se\u00a0\nconoce\u00a0ligando\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0HER2\u00a0todav\u00eda412.\u00a0\u00a0\nA\u00a0partir\u00a0de\u00a0aqu\u00ed,\u00a0una\u00a0vez\u00a0los\u00a0receptores \u00a0han\u00a0\ndimerizado, \u00a0sus\u00a0dominios \u00a0tirosina\u00a0quinasa\u00a0entran\u00a0\nen\u00a0contacto. \u00a0En\u00a0estos\u00a0d\u00edmeros,\u00a0el\u00a0l\u00f3bulo\u00a0C\u00a0del\u00a0\ndominio\u00a0quinasa\u00a0de\u00a0un\u00a0receptor\u00a0entra\u00a0en\u00a0contacto\u00a0\ncon\u00a0el\u00a0l\u00f3bulo\u00a0N\u00a0del\u00a0dominio\u00a0quinasa\u00a0del\u00a0segundo\u00a0\nreceptor\u00a0y\u00a0lo\u00a0activa\u00a0alost\u00e9ricamente. \u00a0Para\u00a0que\u00a0\nesto\u00a0ocurra\u00a0es\u00a0necesario \u00a0un\u00a0cambio\u00a0de\u00a0\nconformaci\u00f3n \u00a0del\u00a0dominio\u00a0quinasa\u00a0del\u00a0segundo\u00a0\nreceptor, \u00a0ya\u00a0que,\u00a0una\u00a0vez\u00a0activado,\u00a0su\u00a0asa\u00a0de\u00a0\nactivaci\u00f3n \u00a0queda\u00a0expuesta\u00a0y\u00a0esto\u00a0le\u00a0permite\u00a0la\u00a0\nentrada\u00a0de\u00a0ATP\u00a0en\u00a0su\u00a0bolsillo\u00a0de\u00a0activaci\u00f3n. \u00a0Por\u00a0\n\u00faltimo,\u00a0la\u00a0cola\u00a0C\u2010terminal\u00a0del\u00a0segundo\u00a0receptor, \u00a0\nque\u00a0se\u00a0encontraba \u00a0interaccionando \u00a0con\u00a0su\u00a0\ndominio\u00a0quinasa\u00a0de\u00a0forma\u00a0autoinhibitoria, \u00a0al\u00a0\nproducirse \u00a0el\u00a0cambio\u00a0conformacional \u00a0se\u00a0libera\u00a0y\u00a0se\u00a0\nfosforilan \u00a0los\u00a0residuos\u00a0tirosina\u00a0espec\u00edficos. \u00a0\nAdem\u00e1s,\u00a0la\u00a0cola\u00a0C\u2010terminal\u00a0del\u00a0primer\u00a0receptor\u00a0\nentrar\u00e1\u00a0en\u00a0el\u00a0sitio\u00a0activo\u00a0del\u00a0segundo\u00a0receptor\u00a0\nactivado\u00a0y\u00a0ser\u00e1\u00a0tambi\u00e9n\u00a0fosforilada, \u00a0quedando \u00a0as\u00ed\u00a0\nactivados \u00a0los\u00a0dos\u00a0receptores421\u00a0(Fig.\u00a026).\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n80\u00a0\n\u00a0El\u00a0l\u00f3bulo\u00a0N\u00a0del\u00a0receptor\u00a0HER3\u00a0\u00a0presenta\u00a0cambios\u00a0\nimportantes \u00a0en\u00a0sus\u00a0residuos\u00a0aminoac\u00eddicos \u00a0y\u00a0\naunque\u00a0esto\u00a0no\u00a0impide\u00a0la\u00a0entrada\u00a0de\u00a0ATP\u00a0en\u00a0su\u00a0\nbolsillo\u00a0de\u00a0activaci\u00f3n, \u00a0su\u00a0funci\u00f3n\u00a0catal\u00edtica\u00a0es\u00a0\nmuch\u00edsimo \u00a0menor\u00a0que\u00a0el\u00a0resto\u00a0de\u00a0receptores \u00a0de\u00a0la\u00a0\nfamilia,\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0identifica \u00a0como\u00a0un\u00a0receptor\u00a0\nsin\u00a0domino\u00a0quinasa.\u00a0Sin\u00a0embargo\u00a0aunque\u00a0no\u00a0\npuede\u00a0ser\u00a0activado,\u00a0\u00e9ste\u00a0si\u00a0puede\u00a0activar\u00a0a\u00a0los\u00a0\notros\u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB417.\u00a0\nA\u00a0partir\u00a0de\u00a0aqu\u00ed\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0estos\u00a0residuos\u00a0\nde\u00a0la\u00a0cola\u00a0C\u2010terminal\u00a0proporciona \u00a0sitios\u00a0de\u00a0uni\u00f3n\u00a0\npara\u00a0prote\u00ednas \u00a0con\u00a0dominios \u00a0SH2\u00a0o\u00a0PTB\u00a0y\u00a0permiten \u00a0\nel\u00a0acoplamiento \u00a0de\u00a0mol\u00e9culas \u00a0adaptadoras \u00a0o\u00a0\ntransductoras \u00a0de\u00a0la\u00a0se\u00f1al,\u00a0como\u00a0la\u00a0Sh2,\u00a0Gbr2,\u00a0Gbr7\u00a0\no\u00a0Gab1\u00a0o\u00a0prote\u00ednas \u00a0quinasas\u00a0no\u00a0receptoras \u00a0como\u00a0\nSrc,\u00a0o\u00a0la\u00a0PI3K\u00a0(subunidad \u00a0p85\u03b1),\u00a0que\u00a0dar\u00e1n\u00a0\ncomienzo \u00a0a\u00a0m\u00faltiples \u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0celular\u00a0\ncomo\u00a0la\u00a0v\u00eda\u00a0de\u00a0MAPKs,\u00a0la\u00a0v\u00eda\u00a0de\u00a0PI3K/AKT, \u00a0o\u00a0\ntambi\u00e9n\u00a0las\u00a0rutas\u00a0de\u00a0la\u00a0PLC\u03b3406\u00a0que\u00a0regular\u00e1n \u00a0el\u00a0\nmetabolismo, \u00a0la\u00a0supervivencia, \u00a0la\u00a0diferenciaci\u00f3n \u00a0y\u00a0\nla\u00a0divisi\u00f3n\u00a0celular\u00a0dependiendo \u00a0del\u00a0contexto\u00a0\ncelular,\u00a0el\u00a0d\u00edmero\u00a0formado\u00a0y\u00a0del\u00a0ligando\u00a0que\u00a0se\u00a0\nuna.\u00a0Qu\u00e9\u00a0sitios\u00a0se\u00a0autofosforilan \u00a0y\u00a0qu\u00e9\u00a0prote\u00ednas \u00a0\nde\u00a0se\u00f1alizaci\u00f3n \u00a0est\u00e1n\u00a0involucradas \u00a0\u00a0depender\u00e1 \u00a0de\u00a0\nla\u00a0identidad \u00a0del\u00a0ligando,\u00a0as\u00ed\u00a0como\u00a0del\u00a0receptor\u00a0con\u00a0\nel\u00a0que\u00a0heterodimerice. \u00a0Por\u00a0ejemplo\u00a0Ras\u00a0y\u00a0Shc\u00a0\nactivan\u00a0la\u00a0v\u00eda\u00a0de\u00a0las\u00a0MAPKs\u00a0y\u00a0se\u00a0encuentran \u00a0\nimplicados \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0todos\u00a0los\u00a0\nmiembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB,\u00a0y\u00a0la\u00a0PI3K\u00a0activa\u00a0la\u00a0v\u00eda\u00a0\nde\u00a0Akt\u00a0que\u00a0tambi\u00e9n\u00a0sucede\u00a0corriente\u00a0abajo\u00a0en\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0d\u00edmeros.\u00a0Sin\u00a0embargo, \u00a0la\u00a0potencia\u00a0y\u00a0\ncin\u00e9tica\u00a0de\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PI3K\u00a0depende\u00a0\nprobablemente \u00a0de\u00a0que\u00a0esta\u00a0prote\u00edna\u00a0conecta\u00a0\ndirectamente \u00a0con\u00a0HER3/HER4 \u00a0e\u00a0indirectamente \u00a0\ncon\u00a0los\u00a0heterd\u00edmeros \u00a0EGFR/HER2422.\u00a0Adem\u00e1s\u00a0se\u00a0ha\u00a0\ndemostrado \u00a0 que\u00a0 combinaciones \u00a0 entre\u00a0\nhomod\u00edmeros \u00a0tienen\u00a0respuestas \u00a0mitog\u00e9nicas \u00a0\nmenores\u00a0que\u00a0las\u00a0combinaciones \u00a0entre\u00a0\nheterod\u00edmeros \u00a0que\u00a0son\u00a0las\u00a0m\u00e1s\u00a0complejas \u00a0y\u00a0\npotentes. \u00a0Quiz\u00e1s\u00a0el\u00a0mejor\u00a0ejemplo\u00a0es\u00a0el\u00a0\nheterod\u00edmero \u00a0HER2\u2010HER3,\u00a0que\u00a0aunque\u00a0ninguno\u00a0\nde\u00a0los\u00a0dos\u00a0puede\u00a0ser\u00a0activado\u00a0solo\u00a0por\u00a0ligando,\u00a0es\u00a0\nel\u00a0heterod\u00edmero \u00a0de\u00a0mayor\u00a0tranformaci\u00f3n423\u00a0y\u00a0\npotencia\u00a0mitog\u00e9nica424.\u00a0Este\u00a0heterod\u00edmero \u00a0\ntambi\u00e9n\u00a0aumenta\u00a0la\u00a0motilidad \u00a0cuando\u00a0es\u00a0estimulado \u00a0por\u00a0un\u00a0ligando425.\u00a0Ademas,\u00a0la\u00a0red\u00a0de\u00a0\nreceptores \u00a0ErbB\u00a0no\u00a0s\u00f3lo\u00a0se\u00a0activa\u00a0a\u00a0partir\u00a0de\u00a0sus\u00a0\npropios\u00a0integrantes \u00a0si\u00a0no\u00a0que\u00a0tambi\u00e9n\u00a0se\u00f1ales\u00a0\nheter\u00f3logas \u00a0que\u00a0incluyen\u00a0a\u00a0hormonas, \u00a0\nneurop\u00e9ptidos, \u00a0ciotquinas \u00a0y\u00a0se\u00f1ales\u00a0de\u00a0estr\u00e9s\u00a0\npueden\u00a0afectar\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0estos\u00a0recptores. \u00a0\nEl\u00a0mecanismo \u00a0m\u00e1s\u00a0ampliamente \u00a0estudiado \u00a0de\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0un\u00a0ErbB\u00a0es\u00a0el\u00a0que\u00a0implica\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0GPCRs\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0sus\u00a0\nligandos\u00a0preferentes412.\u00a0\n\u00a0\n8.1.1.\u00a0EGFR/HER1/ErbB1 \u00a0\nEl\u00a0receptor\u00a0EGFR\u00a0\u00a0fue\u00a0el\u00a0primer\u00a0receptor\u00a0con\u00a0\nactividad\u00a0tirosina\u00a0quinasa\u00a0descrito\u00a0426.\u00a0Se\u00a0trata\u00a0de\u00a0\nuna\u00a0una\u00a0glicoprote\u00edna \u00a0de\u00a0170\u00a0kDa\u00a0codificada \u00a0por\u00a0el\u00a0\ngen\u00a0ERBB1 ,\u00a0localizado \u00a0en\u00a0la\u00a0regi\u00f3n\u00a0cormos\u00f3mica \u00a0\n7p12.1427\u00a0y\u00a0se\u00a0\u00fane\u00a0a\u00a0m\u00faltiples \u00a0ligandos\u00a0con\u00a0la\u00a0\ncapacidad \u00a0de\u00a0formar\u00a0tres\u00a0heterod\u00edmeros \u00a0\nfuncionales. \u00a0Este\u00a0receptor\u00a0activa\u00a0directamente \u00a0\nv\u00edas\u00a0de\u00a0proliferaci\u00f3n \u00a0como\u00a0las\u00a0MAPKs\u00a0y\u00a0STAT5,\u00a0y\u00a0\naunque\u00a0no\u00a0tiene\u00a0sitios\u00a0de\u00a0uni\u00f3n\u00a0directos\u00a0con\u00a0la\u00a0\nprote\u00edna\u00a0PI3K,\u00a0se\u00a0puede\u00a0inducir\u00a0su\u00a0activaci\u00f3n \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0v\u00eda\u00a0Ras/PI3K/AKT. \u00a0La\u00a0cola\u00a0C\u2010terminal\u00a0\nde\u00a0este\u00a0receptor\u00a0tambi\u00e9n\u00a0tiene\u00a0un\u00a0sitio\u00a0de\u00a0uni\u00f3n\u00a0\npara\u00a0la\u00a0prote\u00edna\u00a0Cbl,\u00a0que\u00a0lo\u00a0regula\u00a0negativamente \u00a0\na\u00a0trav\u00e9s\u00a0de\u00a0su\u00a0internalizaci\u00f3n \u00a0y\u00a0degradaci\u00f3n428.\u00a0\nLos\u00a0niveles\u00a0elevados\u00a0del\u00a0receptor\u00a0EGFR\u00a0o\u00a0de\u00a0sus\u00a0\nligandos\u00a0m\u00e1s\u00a0afines\u00a0se\u00a0han\u00a0identificado \u00a0como\u00a0un\u00a0\ncomponente \u00a0com\u00fan\u00a0de\u00a0m\u00faltiples \u00a0tipos\u00a0de\u00a0\nc\u00e1nceres\u00a0promoviendo \u00a0el\u00a0crecimiento \u00a0de\u00a0tumores\u00a0\ns\u00f3lidos.\u00a0Aunque\u00a0es\u00a0reconocido \u00a0en\u00a0tumores\u00a0\nhumanos, \u00a0otros\u00a0estudios\u00a0sugieren\u00a0que\u00a0su\u00a0\nexpresi\u00f3n \u00a0aumenta\u00a0con\u00a0el\u00a0estadio\u00a0de\u00a0la\u00a0\nenfermedad, \u00a0haci\u00e9ndose \u00a0m\u00e1s\u00a0prominente \u00a0durante\u00a0\nla\u00a0met\u00e1stasis, \u00a0o\u00a0tras\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0la\u00a0resistencia \u00a0a\u00a0\nla\u00a0quimioterapia429,430.\u00a0Por\u00a0ejemplo,\u00a0muestras \u00a0de\u00a0\nbiopsias\u00a0de\u00a0tumores\u00a0de\u00a0colon\u00a0metast\u00e1sicos \u00a0\npresentan \u00a0cinco\u00a0veces\u00a0m\u00e1s\u00a0niveles\u00a0de\u00a0ARNm\u00a0del\u00a0\nreceptor\u00a0EGFR\u00a0que\u00a0presentan \u00a0muestras \u00a0de\u00a0\ntumores\u00a0no\u00a0metast\u00e1sicos431.\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n81\u00a0\n\u00a08.1.2.\u00a0HER2/ErbB2 \u00a0\nEl\u00a0receptor\u00a0HER2\u00a0es\u00a0una\u00a0gliocoprote\u00eda \u00a0de\u00a01255\u00a0\naminoacidos \u00a0con\u00a0un\u00a0peso\u00a0molecular \u00a0de\u00a0185\u00a0kDa.\u00a0\nEst\u00e1\u00a0codificado \u00a0por\u00a0el\u00a0gen\u00a0ERBB2\u00a0que\u00a0se\u00a0encuentra \u00a0\nen\u00a0la\u00a0regi\u00f3n\u00a0cromos\u00f3mica \u00a017\u00a0en\u00a0el\u00a0brazo\u00a0q21432.\u00a0Se\u00a0\nestima\u00a0que\u00a0la\u00a0amplificaci\u00f3n \u00a0del\u00a0gen\u00a0ERBB2\u00a0genera\u00a0\nuna\u00a0sobreexpresi\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0en\u00a0el\u00a020%\u00a0de\u00a0\nlos\u00a0pacientes \u00a0con\u00a0carcinoma \u00a0ductal\u00a0invasivo\u00a0de\u00a0\nmama433,434\u00a0(Tabla\u00a013).\u00a0Igual\u00a0que\u00a0EGFR,\u00a0HER2\u00a0\ntambi\u00e9n\u00a0posee\u00a0un\u00a0dominio\u00a0catal\u00edtico\u00a0con\u00a0actividad\u00a0\nquinasa.\u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0los\u00a0residuos\u00a0fosfotirosina \u00a0\nsirve\u00a0como\u00a0uni\u00f3n\u00a0para\u00a0prote\u00ednas \u00a0adaptadores \u00a0con\u00a0\ndominios \u00a0SH2\u00a0y\u00a0PTB\u00a0tales\u00a0como\u00a0(como\u00a0Shc,\u00a0Grb2,\u00a0\np85),\u00a0enzimas\u00a0(por\u00a0ejemplo,\u00a0la\u00a0tirosina\u00a0fosfatasa\u00a02\u00a0\no\u00a0SHP\u20102/PTP\u20102c,)\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0o\u00a0factores\u00a0de\u00a0\ntranscripci\u00f3n \u00a0como\u00a0STAT406.\u00a0Otras\u00a0mol\u00e9culas \u00a0que\u00a0\nse\u00a0unen\u00a0a\u00a0estos\u00a0sitios\u00a0principales \u00a0de\u00a0fosforilaci\u00f3n \u00a0\nson\u00a0la\u00a0familia\u00a0de\u00a0prote\u00ednas \u00a0adaptadoras \u00a0Crk,\u00a0la\u00a0\nPLC\u03b3,\u00a0as\u00ed\u00a0como\u00a0los\u00a0represores \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0\nCHK\u00a0y\u00a0Dok\u20102\u00a0(Fig.\u00a027).\u00a0La\u00a0uni\u00f3n\u00a0de\u00a0estas\u00a0prote\u00ednas \u00a0\nadaptadoras \u00a0es\u00a0el\u00a0primer\u00a0evento\u00a0de\u00a0la\u00a0\u00a0cascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0corriente\u00a0arriba,\u00a0y\u00a0que\u00a0inicia\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0una\u00a0cascada\u00a0de\u00a0prote\u00ednas \u00a0corriente\u00a0\nabajo\u00a0que\u00a0finalmente \u00a0se\u00a0unir\u00e1n\u00a0a\u00a0factores\u00a0de\u00a0\ntranscripci\u00f3n \u00a0responsables \u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0\ncelular,\u00a0diferenciaci\u00f3n, \u00a0supervivencia \u00a0y\u00a0la\u00a0\nmigraci\u00f3n. \u00a0Por\u00a0ejemplo,\u00a0HER2\u00a0se\u00a0sabe\u00a0que\u00a0activa\u00a0\nla\u00a0cascada\u00a0de\u00a0Ras/Raf/Erk \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nreclutamiento \u00a0inicial\u00a0de\u00a0Shc\u00a0y\u00a0Grb2435\u00a0(Fig.\u00a027).\u00a0\nDespu\u00e9s\u00a0de\u00a0esta\u00a0uni\u00f3n\u00a0tambi\u00e9n\u00a0se\u00a0puede\u00a0reclutar\u00a0\nal\u00a0complejo \u00a0Gab2/SHP \u20102436\u00a0que\u00a0desencadena \u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0PI3K/Akt\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0trans\u2010\nfosforilaci\u00f3n \u00a0de\u00a0residuos\u00a0tirosina\u00a0de\u00a0HER3437,\u00a0lo\u00a0\nque\u00a0en\u00a0\u00faltima\u00a0instancia, \u00a0provocar\u00e1 \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nefectores \u00a0nucleares, \u00a0tales\u00a0como\u00a0factores\u00a0de\u00a0\ntranscripci\u00f3n \u00a0y\u00a0reguladores \u00a0del\u00a0ciclo\u00a0celular.\u00a0\nDebido\u00a0a\u00a0que\u00a0este\u00a0receptor\u00a0no\u00a0tiene\u00a0ligando\u00a0\nconocido, \u00a0su\u00a0activaci\u00f3n \u00a0se\u00a0produce\u00a0mediante \u00a0la\u00a0\nhereodimerizaci\u00f3n \u00a0con\u00a0otros\u00a0receptores \u00a0o\u00a0con\u00a0\u00e9l\u00a0\nmismo\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0que\u00a0se\u00a0encuentre \u00a0\nsobreexpresado \u00a0en\u00a0la\u00a0membrana. \u00a0La\u00a0se\u00f1alizaci\u00f3n \u00a0\na\u00a0trav\u00e9s\u00a0de\u00a0HER2\u00a0tambi\u00e9n\u00a0se\u00a0asocia\u00a0con\u00a0una\u00a0\nmayor\u00a0actividad\u00a0por\u00a0parte\u00a0de\u00a0las\u00a0metaloproteasas \u00a0en\u00a0la\u00a0matriz\u00a0extracelular \u00a0y\u00a0un\u00a0mayor\u00a0potencial \u00a0\ntumorig\u00e9nico \u00a0y\u00a0metast\u00e1sico438.\u00a0\n8.1.3.\u00a0HER3/ErbB3 \u00a0\nEste\u00a0es\u00a0el\u00a0tercer\u00a0miembro\u00a0de\u00a0la\u00a0familia\u00a0I\u00a0de\u00a0RTKs\u00a0\npor\u00a0su\u00a0homolog\u00eda \u00a0a\u00a0sus\u00a0otros\u00a0dos\u00a0receptores. \u00a0Al\u00a0\nigual\u00a0que\u00a0los\u00a0otros\u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0tiene\u00a0\nvarias\u00a0isoformas \u00a0pero\u00a0la\u00a0m\u00e1s\u00a0habitual\u00a0se\u00a0detecta\u00a0\ncon\u00a0un\u00a0peso\u00a0de\u00a0185\u00a0kDa\u00a0de\u00a0forma\u00a0similar\u00a0a\u00a0los\u00a0dos\u00a0\nanteriores. \u00a0Aunque\u00a0este\u00a0receptor\u00a0carece\u00a0de\u00a0\nactividad\u00a0catal\u00edtica\u00a0en\u00a0su\u00a0dominio\u00a0quinasa,\u00a0puede\u00a0\nformar\u00a03\u00a0heterod\u00edmeros \u00a0distintos\u00a0si\u00a0se\u00a0une\u00a0a\u00a04\u00a0\nligandos\u00a0espec\u00edficos. \u00a0Es\u00a0entonces\u00a0cuando\u00a0la\u00a0cola\u00a0\ncitoplasm\u00e1tica \u00a0de\u00a0este\u00a0receptor\u00a0puede\u00a0ser\u00a0trans\u2010\nfosforilada \u00a0y\u00a0puede\u00a0reclutar\u00a0porte\u00ednas \u00a0como\u00a0la\u00a0\nPI3K\u00a0en\u00a0seis\u00a0sitios\u00a0distintos\u00a0de\u00a0uni\u00f3n\u00a0para\u00a0la\u00a0\nsubunidad \u00a0p85\u03b1\u00a0(subuindad \u00a0reguladora \u00a0de\u00a0la\u00a0PI3K)\u00a0\nconvirti\u00e9ndose \u00a0por\u00a0tanto\u00a0en\u00a0el\u00a0receptor\u00a0con\u00a0mayor\u00a0\ncapacidad \u00a0para\u00a0activar\u00a0esta\u00a0v\u00eda439\u00a0(Fig.\u00a027).\u00a0Este\u00a0\nreceptor\u00a0se\u00a0encuentra \u00a0sobreexpresado \u00a0en\u00a0CM,\u00a0\nc\u00e1ncer\u00a0de\u00a0colon,\u00a0est\u00f3mago, \u00a0pr\u00f3stata\u00a0entre\u00a0otros\u00a0\ncarcinomas \u00a0(Tabla\u00a013).\u00a0\n8.1.4.\u00a0HER4/ErbB4 \u00a0\nHER4\u00a0comparte \u00a0caracter\u00edsticas \u00a0con\u00a0EGFR.\u00a0Ambos\u00a0\nse\u00a0unen\u00a0a\u00a0un\u00a0grupo\u00a0grande\u00a0y\u00a0de\u00a0varios\u00a0ligandos,\u00a0\ncomo\u00a0BTC\u00a0y\u00a0HB\u2010EGF,\u00a0as\u00ed\u00a0como\u00a0a\u00a02\u00a0de\u00a0los\u00a0ligandos\u00a0\nde\u00a0baja\u00a0afinidad,\u00a0EPR\u00a0y\u00a0Epigen439.\u00a0Al\u00a0igual\u00a0que\u00a0\nEGFR,\u00a0HER4\u00a0recluta\u00a0a\u00a0Grb2,\u00a0Shc\u00a0y\u00a0STAT5,\u00a0mientras\u00a0\nque\u00a0una\u00a0isoforma\u00a0de\u00a0HER4\u00a0(CYT\u20101)\u00a0puede\u00a0activar\u00a0\nla\u00a0PI3K.\u00a0HER4\u00a0es\u00a0capaz\u00a0de\u00a0contactar \u00a0directamente \u00a0\ncon\u00a0la\u00a0prote\u00edna\u00a0de\u00a0ubiquitinizaci\u00f3n \u00a0Cbl,\u00a0y\u00a0por\u00a0tanto\u00a0\nla\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0regulaci\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0es\u00a0\nm\u00e1s\u00a0lenta\u00a0que\u00a0la\u00a0de\u00a0EGFR.\u00a0El\u00a0producto\u00a0de\u00a0clivaje\u00a0\nde\u00a0HER4\u00a0se\u00a0\u00a0transloca\u00a0al\u00a0n\u00facleo\u00a0y\u00a0puede\u00a0poseer\u00a0\nactividad\u00a0transcripcional439.\u00a0A\u00a0diferencia \u00a0de\u00a0los\u00a0\notros\u00a0receptores \u00a0HER4\u00a0no\u00a0se\u00a0encuentra \u00a0\nsobreexpresado \u00a0en\u00a0CM\u00a0y\u00a0de\u00a0hecho\u00a0aunque\u00a0est\u00e1\u00a0\npresente\u00a0en\u00a0casi\u00a0un\u00a012%\u00a0de\u00a0los\u00a0CM\u00a0se\u00a0correlaci\u00f3na \u00a0\ncon\u00a0un\u00a0buen\u00a0pron\u00f3stico427\u00a0(Tabla\u00a013).\u00a0\n\u00a0\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n82\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a027.\u00a0Representaci\u00f3n \u00a0esquem\u00e1tica \u00a0de\u00a0los\u00a0principales \u00a0sitios\u00a0de\u00a0autofosforilaci\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0EGFR,\u00a0HER2\u00a0y\u00a0HER3\u00a0y\u00a0de\u00a0\nlas\u00a0mol\u00e9culas \u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0asociadas \u00a0con\u00a0estos\u00a0sitios\n406.\u00a0*Sitios\u00a0de\u00a0uni\u00f3n\u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0en\u00a0el\u00a0dominio\u00a0tirosina\u00a0quinasa\u00a0y\u00a0en\u00a0\nla\u00a0cola\u00a0citoplasm\u00e1tica \u00a0de\u00a0los\u00a0receptores \u00a0EGFR\u00a0y\u00a0HER2440.\u00a0\nTabla\u00a013.\u00a0Expresi\u00f3n \u00a0de\u00a0los\u00a0distintos\u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0en\u00a0c\u00e1ncer.\u00a0Modificado \u00a0de\u00a0412.\u00a0\nRECEPTOR \u00a0NATURALEZA \u00a0DE\u00a0LA\u00a0\nDESREGULACI\u00d3N \u00a0TIPO\u00a0DE\u00a0C\u00c1NCER\u00a0 NOTAS\u00a0 REFERENCIAS \u00a0\nErbB1\u00a0Sobreexpresi\u00f3n \u00a0Cabeza\u00a0y\u00a0cuello,\u00a0mama,\u00a0\nvejiga,\u00a0pr\u00f3stata,\u00a0ri\u00f1\u00f3n,\u00a0\nc\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0de\u00a0\nc\u00e9lulas\u00a0no\u00a0peque\u00f1as \u00a0\u00a0Indicador \u00a0significativo \u00a0de\u00a0recurrencia \u00a0en\u00a0los\u00a0\ntumores\u00a0de\u00a0mama\u00a0operables, \u00a0asociado\u00a0con\u00a0una\u00a0\nmenor\u00a0supervivencia \u00a0global\u00a0libre\u00a0de\u00a0\nenfermedad \u00a0en\u00a0CM\u00a0avanzado. \u00a0Puede\u00a0servir\u00a0\ncomo\u00a0factor\u00a0pron\u00f3stico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0vejiga,\u00a0\npr\u00f3stata\u00a0y\u00a0c\u00e1ncer\u00a0de\u00a0pulm\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0no\u00a0\npeque\u00f1as \u00a0441,442\u00a0\nSobreexpresi\u00f3n \u00a0 Glioma\u00a0\u00a0\u00a0La\u00a0amplificaci\u00f3n \u00a0se\u00a0produce\u00a0en\u00a0el\u00a040%\u00a0de\u00a0los\u00a0\ngliomas,\u00a0la\u00a0sobreexpresi\u00f3n \u00a0se\u00a0correlaciona \u00a0con\u00a0\nun\u00a0mayor\u00a0grado\u00a0y\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0\nsupervivencia. \u00a0443\u00a0\nMutaci\u00f3n \u00a0Glioma,\u00a0pulm\u00f3n,\u00a0\novario,\u00a0mama\u00a0La\u00a0supresi\u00f3n \u00a0de\u00a0una\u00a0parte\u00a0del\u00a0dominio\u00a0\nextracelular \u00a0del\u00a0receptor\u00a0produce\u00a0una\u00a0\nactivaci\u00f3n \u00a0constitutiva \u00a0del\u00a0mismo.\u00a0444\u00a0\nErbB2\u00a0 Sobreexpresi\u00f3n \u00a0Mama,\u00a0pulm\u00f3n,\u00a0\np\u00e1ncreas, \u00a0colon,\u00a0\nes\u00f3fago,\u00a0endometrio, \u00a0\ncuello\u00a0uterino\u00a0Sobreexpresi\u00f3n \u00a0debida\u00a0a\u00a0la\u00a0amplificaci\u00f3n \u00a0del\u00a0\ngen\u00a0en\u00a0un\u00a015\u201030%\u00a0de\u00a0los\u00a0carcinomas \u00a0ductales\u00a0\ninvasivos\u00a0de\u00a0mama.\u00a0La\u00a0sobreexpresi\u00f3n \u00a0se\u00a0\ncorrelaciona \u00a0con\u00a0el\u00a0tama\u00f1o\u00a0del\u00a0tumor,\u00a0la\u00a0\npropagaci\u00f3n \u00a0del\u00a0tumor\u00a0a\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos, \u00a0\nun\u00a0alto\u00a0grado,\u00a0alto\u00a0porcentaje \u00a0de\u00a0c\u00e9lulas\u00a0en\u00a0\nfase\u00a0S,\u00a0aneuploid\u00eda \u00a0y\u00a0la\u00a0falta\u00a0de\u00a0receptores \u00a0\nhormonales. \u00a0445\u00a0\nErbB3\u00a0\n\u00a0Expresi\u00f3n \u00a0Mama,\u00a0colon,\u00a0\nest\u00f3mago, \u00a0pr\u00f3stata,\u00a0\notros\u00a0carcinomas \u00a0La\u00a0co\u2010expresi\u00f3n \u00a0de\u00a0ErbB2\u00a0con\u00a0ErbB1\u00a0o\u00a0ErbB3\u00a0en\u00a0\nCM\u00a0mejora\u00a0la\u00a0capacidad \u00a0de\u00a0predicci\u00f3n. \u00a0446,447\u00a0\nSobreexpresi\u00f3n \u00a0\u00a0Carcinoma \u00a0oral\u00a0de\u00a0\nc\u00e9lulas\u00a0escamosas \u00a0La\u00a0sobreexpresi\u00f3n \u00a0se\u00a0correlaciona \u00a0con\u00a0la\u00a0\nafectaci\u00f3n \u00a0ganglionar \u00a0y\u00a0supervivencia \u00a0de\u00a0los\u00a0\npacientes. \u00a0448\u00a0\nErbB4\u00a0\n\u00a0Expresi\u00f3n \u00a0reducida\u00a0\u00a0\u00a0 Mama,\u00a0pr\u00f3stata\u00a0 Se\u00a0correlaciona \u00a0con\u00a0un\u00a0fenotipo\u00a0diferenciado. \u00a0449\u00a0\nExpresi\u00f3n \u00a0Meduloblastoma \u00a0\ninflantil\u00a0\u00a0\u00a0Co\u2010expresi\u00f3n \u00a0con\u00a0ErbB2\u00a0tiene\u00a0un\u00a0valor\u00a0\npron\u00f3stico. \u00a0450\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n83\u00a0\n\u00a08.2.\u00a0Terapias\u00a0anti\u2010HER2\u00a0como\u00a0\ntratamientos \u00a0actuales\u00a0\nDado\u00a0que\u00a0la\u00a0sobreexpresi\u00f3n \u00a0de\u00a0HER2\u00a0es\u00a0altamente \u00a0\nespeci\u00edfica \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales, \u00a0las\u00a0terapias\u00a0\ndirigidas\u00a0contra\u00a0este\u00a0receptor\u00a0han\u00a0ido\u00a0ganando\u00a0\nreconocimiento \u00a0como\u00a0un\u00a0tratamiento \u00a0eficaz\u00a0\ncontra\u00a0el\u00a0desarrollo \u00a0tumoral\u00a0y\u00a0actualmente \u00a0\nsustituye\u00a0o\u00a0complementa \u00a0a\u00a0otras\u00a0terapias\u00a0que\u00a0no\u00a0\nson\u00a0anti\u2010diana.\u00a0Hay\u00a0principalmente \u00a02\u00a0enfoques \u00a0\nexperimentales \u00a0que\u00a0se\u00a0utilizan\u00a0como\u00a0estrategias \u00a0\nanti\u2010HER2:\u00a0uno\u00a0incluye\u00a0anticuerpos \u00a0antagonistas \u00a0\nde\u00a0HER2\u00a0y\u00a0el\u00a0otro\u00a0inhibidores \u00a0de\u00a0su\u00a0actividad\u00a0\ntirosina\u00a0quinasa.\u00a0Estos\u00a0tratamientos \u00a0han\u00a0\ndemostrado \u00a0que\u00a0el\u00a0bloqueo\u00a0de\u00a0la\u00a0se\u00f1al\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nHER2\u00a0conduce\u00a0a\u00a0una\u00a0regresi\u00f3n \u00a0de\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nlas\u00a0caracter\u00edsticas \u00a0pro\u2010tumorales \u00a0adquiridas \u00a0al\u00a0\nsobreexpresar \u00a0este\u00a0receptor. \u00a0Esto\u00a0identifica \u00a0a\u00a0\nHER2\u00a0como\u00a0una\u00a0mol\u00e9cula\u00a0con\u00a0un\u00a0potencial \u00a0\nterap\u00e9utico \u00a0importante451.\u00a0Existen\u00a0nuevos\u00a0\nenfoques \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0\nCM\u00a0HER2+\u00a0que\u00a0se\u00a0recogen\u00a0en\u00a0la\u00a0tabla\u00a0anexa\u00a06.\u00a0En\u00a0\neste\u00a0trabajo,\u00a0sin\u00a0embargo, \u00a0nos\u00a0centraremos \u00a0en\u00a0las\u00a0\nterapias\u00a0aprobadas \u00a0actualmente \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0CM\u00a0como\u00a0son\u00a0Lapatinib\u00a0y\u00a0\ntrastuzumab. \u00a0\n8.2.1.\u00a0Anticuerpos \u00a0monoclonales: \u00a0\nTrastuzumab \u00a0\nTrastuzumab \u00a0es\u00a0el\u00a0\u00fanico\u00a0anticuerpo \u00a0que\u00a0\nactualmente \u00a0est\u00e1\u00a0aprobado \u00a0como\u00a0tratamiento \u00a0\nadyuvante \u00a0para\u00a0pacientes \u00a0HER2+\u00a0en\u00a0estad\u00edos\u00a0\ntempranos \u00a0del\u00a0c\u00e1ncer.\u00a0Su\u00a0mecanismo \u00a0no\u00a0est\u00e1\u00a0\ncomprendido \u00a0del\u00a0todo\u00a0pero\u00a0se\u00a0sabe\u00a0que\u00a0se\u00a0une\u00a0al\u00a0\nsubdominio \u00a0IV\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0extracelular \u00a0del\u00a0\nreceptor\u00a0(Fig.28 ).\u00a0\u00a0\nLos\u00a0mecanismos \u00a0por\u00a0los\u00a0cuales\u00a0inhibe\u00a0este\u00a0\nreceptor\u00a0se\u00a0resumen\u00a0en\u00a0la\u00a0Tabla\u00a014.\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a028.\u00a0Anticuerpos \u00a0monoclonales \u00a0contra\u00a0el\u00a0receptor\u00a0\nHER2.\u00a0El\u00a0trastuzumab \u00a0se\u00a0une\u00a0subdominio \u00a0IV\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0\nextracelular, \u00a0mientras\u00a0que\u00a0el\u00a0pertuzumab \u00a0se\u00a0une\u00a0al\u00a0brazo\u00a0de\u00a0\ndimerizaci\u00f3n \u00a0del\u00a0receptor,\u00a0situado\u00a0en\u00a0el\u00a0subdominio \u00a0II\u00a0de\u00a0la\u00a0\nregi\u00f3n\u00a0extracelular \u00a0impidiendo \u00a0la\u00a0dimerizaci\u00f3n. \u00a0\n\u00a0\nTabla\u00a014.\u00a0\u00a0\u00a0Mecanismos \u00a0de\u00a0acci\u00f3n\u00a0del\u00a0trastuzumab \u00a0\nCitotoxicidad \u00a0celuar\u00a0inducida\u00a0por\u00a0anticuerpos \u00a0(ADCC)\u00a0\nInhibici\u00f3n \u00a0del\u00a0clivaje\u00a0del\u00a0receptor\u00a0HER2\u00a0(previniendo \u00a0\nla\u00a0formaci\u00f3n \u00a0de\u00a0una\u00a0isoforma\u00a0truncada\u00a0pero\u00a0\nconstitutivamente \u00a0activa\u00a0\nInternalizaci\u00f3n \u00a0y\u00a0degradaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nInducci\u00f3n \u00a0del\u00a0arresto\u00a0en\u00a0ciclo\u00a0celular\u00a0\n(indirectamente \u00a0\u00a0reduce\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0\nsecuestradoras \u00a0de\u00a0p27Kip1)\u00a0\nInhibici\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0PI3K/Akt\u00a0\nInhibici\u00f3n \u00a0de\u00a0la\u00a0angiog\u00e9nesis \u00a0\nInhibici\u00f3n \u00a0de\u00a0la\u00a0reparaci\u00f3n \u00a0del\u00a0ADN\u00a0\nInducci\u00f3n \u00a0de\u00a0la\u00a0apopt\u00f3sis \u00a0celular\u00a0\n\u00a0\nEl\u00a0trastuzumab \u00a0parece\u00a0inducir\u00a0muerte\u00a0celular\u00a0\nmediada\u00a0por\u00a0apoptosis \u00a0en\u00a0pacientes \u00a0mientras\u00a0que\u00a0\nen\u00a0cultivos\u00a0celulares\u00a0predominan \u00a0sus\u00a0efectos\u00a0\nantiproliferativos452.\u00a0\nEste\u00a0anticuerpo \u00a0como\u00a0tratamiento \u00a0adyuvante \u00a0es\u00a0\nrecomendado \u00a0por\u00a0las\u00a0directrices \u00a0del\u00a0\u201cNational\u00a0\nComprehensive \u00a0Cancer\u00a0Network\u00a0[NCCN]\u201d\u00a0y\u00a0del\u00a0\nEuropeo\u00a0(St.\u00a0Gallen)\u00a0para\u00a0su\u00a0uso\u00a0como\u00a0\nmonoterapia \u00a0despu\u00e9s\u00a0de\u00a0la\u00a0finalizaci\u00f3n \u00a0de\u00a0la\u00a0\nquimioterapia, \u00a0y\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0paclitaxel \u00a0o\u00a0\ndocetaxel \u00a0despu\u00e9s\u00a0de\u00a0la\u00a0finalizaci\u00f3n \u00a0de\u00a0la\u00a0\ndoxorrubicina \u00a0y\u00a0la\u00a0ciclofosfamida, \u00a0o\u00a0de\u00a0la\u00a0\nadministraci\u00f3n \u00a0concomitante \u00a0con\u00a0carboplatino \u00a0y\u00a0\ndocetaxel453,454.\u00a0Estas\u00a0recomendaciones \u00a0se\u00a0basan\u00a0\nen\u00a0los\u00a0resultados \u00a0de\u00a0cuatro\u00a0grandes\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0en\u00a0seguimiento, \u00a0adem\u00e1s\u00a0de\u00a0varios\u00a0ensayos\u00a0\nm\u00e1s\u00a0peque\u00f1os \u00a0(Tabla\u00a015).\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n84\u00a0\n\u00a0Tabla\u00a015.\u00a0Ensayos\u00a0en\u00a0fase\u00a0III\u00a0para\u00a0el\u00a0tratamiento \u00a0adyuvante \u00a0con\u00a0trastuzumab \u00a0en\u00a0pacientes \u00a0HER2+\u00a0en\u00a0estadios\u00a0tempranos \u00a0de\u00a0la\u00a0\nenfermedad. \u00a0Modificado \u00a0de\u00a0455.\u00a0\n\u00a0\nNOMBRE \u00a0\nDEL\u00a0\nENSAYO\u00a0PACIENTES \u00a0(n)\u00a0MEDIANA \u00a0DE\u00a0\nSEGUIMIENTO \u00a0\n(MESES)\u00a0TRATAMIENTO \u00a0 SLE*\u00a0(P\u00a0valor)\u00a0 SG*\u00a0(P\u00a0valor)\u00a0\nHERA456\u2010458\u00a0Ganglios\u00a0positivos\u00a0o\u00a0\nganglios\u00a0negativos \u00a0de\u00a0alto\u00a0\nriesgo\u00a0en\u00a0CMT\u00a0\u00a0habiendo \u00a0\ncompletado \u00a0la\u00a0\nquimioterapia \u00a0adyuvante \u00a0\nest\u00e1ndar\u00a0(5.090)\u00a048.4\u00a0Sin\u00a0terapia\u00a0adicional\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nTrastuzumab \u00a0durante\u00a01\u00a0a\u00f1o\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nTrastuzumab \u00a0durante\u00a02\u00a0a\u00f1os\u00a0\u00a078.6%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n72.2%\u00a0(P<0.0001)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nNI\u00a089.3%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n87.7%\u00a0(P=0.11)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nNI\u00a0\nNSABP\u00a0\nB.31459,460\u00a0Ganglios\u00a0positivos\u00a0en\u00a0CMT\u00a0\u00a0\n(2.101)\u00a046.8\u00a7\u00a0\u00a0\u2010Doxorubicina \u2010\nciclofosfamida \u2192paclitaxel \u25ca\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Doxorubicina \u2010ciclofosfamida \u2192\u00a0\npaclitaxel \u2010trastuzumab \u2020\u00a085.8%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n75.8%\u00a0(P<0.001)\u00a093.5%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n89.4%\u00a0(P<0.001)\u00a0\nNCCTG\u00a0\nN9831\u00a0\n460,461\u00a0Ganglios\u00a0positivos\u00a0o\u00a0\nganglios\u00a0negativos \u00a0de\u00a0alto\u00a0\nriesgo\u00a0en\u00a0CMT\u00a0(1.944)\u00a063.6\u00a0\u2010Doxorubicina \u2010\nciclofosfamida \u2192paclitaxel \u2010\ntrastuzumab\u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Doxorubicina \u2010\nciclofosfamida \u2192paclitaxel \u2010\ntrastuzumab \u2020\u00a084%\u00a0(5a\u00f1os)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n80%\u00a0(P=0.019) \u00a0NI\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nNI\u00a0\nBCIRG\u00a0\n006462,463\u00a0Ganglios\u00a0positivos\u00a0o\u00a0\nganglios\u00a0negativos \u00a0de\u00a0alto\u00a0\nriesgo\u00a0en\u00a0CMT\u00a0(3,222)\u00a065\u00a0\u2010Doxorubicina \u2010\nciclofosfamida \u2192docetaxel \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Doxorubicina \u2010\nciclofosfamida \u2192docetaxel \u2010\ntrastuzumab\u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Docetaxel \u2010carboplatino \u2010\ntrastuzumab\u2022 \u00a0\u00a0\u00a0\u00a0\u00a075%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n84%\u00a0(P<0.001\u00a0\nvs\u00a0quimioterapia) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n81%\u00a0(P=0.04\u00a0\nvs\u00a0quimioterapia) \u00a087%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n92%\u00a0(P<0.001\u00a0\nvs\u00a0quimioterapia) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n87%\u00a0(P=0.038\u00a0\nvs\u00a0quimioterapia) \u00a0\nPACS.04151 \u00a0Ganglios\u00a0positivos\u00a0\noperables \u00a0en\u00a0CMT\u00a0(528#)\u00a047\u00a0\u20105FU\u2010ciclofosfamida \u2010epirubicina \u00a0\no\u00a0epirubicina \u2010docetaxel \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n5FU\u2010ciclofosfamida \u2010epirubicina \u00a0\no\u00a0epirubicina \u2010docetaxel \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2192\u00a0trastuzumab \u2083\u00a0durante\u00a0un\u00a0\na\u00f1o\u00a078%\u00a0(3\u00a0years)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n81%\u00a0(P=0.41)\u00a096%\u00a0(3\u00a0a\u00f1os)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n95%\u00a0(P=2.38)\u00a0\nECOG\u00a0\nE2198464,465\n**\u00a0Estadio\u00a0II\u00a0de\u00a0CM\u00a0(234)\u00a0 64\u00a0\u2010Paclitaxel \u2010\ntrastuzumab \u2192doxorubicina \u2010\nciclofosfamida \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Paclitaxel \u2010\ntrastuzumab \u2192doxorubicina \u2010\nciclofosfamida \u00a0\u00a0\u00a0\n\u2192trastuzumab \u2020\u00a076%\u00a0(5\u00a0years)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n73%\u00a0(P=0.55)\u00a088%\u00a0(5\u00a0years)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n83%\u00a0(P=0.29)\u00a0\nFinHER466,467\u00a0Ganglios\u00a0positivos\u00a0o\u00a0\nganglios\u00a0negativos \u00a0de\u00a0alto\u00a0\nriesgo\u00a0en\u00a0CMT\u00a0(232#)\u00a062\u00a0\u2010Docetaxel \u00a0o\u00a0vinorelbina\n\u21925FU\u2010ciclofosfamida \u2010\nepirubicina \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Docetaxel \u00a0o\u00a0vinorelbina \u00a0\n\u21925FU\u2010ciclofosfamida \u2010\nepirubicina \u2010trastuzumab \u2020\u00a073.3%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n83%\u00a0(P=0.12)\u00a082.3%\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n91.3%\u00a0(5\u00a0a\u00f1os)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n(P=0.094)\u00a0\n*Medianas \u00a0cuando\u00a0segun\u00a0disponibilidad \u00a0(por\u00a0lo\u00a0general\u00a0no\u00a0estimable). \u00a0\u2022\u00a08\u00a0mg/kg\u00a0de\u00a0trastuzumab \u00a0inicialmente \u00a0y\u00a0luego\u00a06\u00a0mg\u00a0/kg\u00a0cada\u00a03\u00a0semanas. \u00a0\u00a0\n\u00a7\u00a0Basados\u00a0en\u00a0el\u00a0primer\u00a0an\u00e1lisis\u00a0conjunto\u00a0de\u00a0los\u00a0estudios\u00a0NSABP\u00a0B\u201031\u00a0y\u00a0NCCTG\u00a0N9831\u00a0(doxorrubicina \u2010ciclofosfamida \u2192paclitaxel \u00a0vs\u00a0a\u00a0la\u00a0\ndoxorrubicina \u2010ciclofosfamida \u2192paclitaxel \u2010trastuzumab)147. \u00a0\u25ca\u00a0Protocolo \u00a0modificado \u00a0para\u00a0permitir\u00a0el\u00a0paclitaxel \u2010trastuzumab \u00a0en\u00a0el\u00a0a\u00f1o\u00a02003.\u00a0\u2020\u00a04\u00a0\nmg/Kg\u00a0de\u00a0trastuzumab \u00a0inicialmente, \u00a0luego\u00a02\u00a0mg/kg\u00a0por\u00a0semana.\u00a0#\u00a0Subconjunto \u00a0del\u00a0estudio\u00a0principal. \u00a0**\u00a0Estudio\u00a0piloto\u00a0de\u00a0seguridad \u00a0al\u00a0azar.\u00a0\nAbreviaturas: \u00a0\u2192,\u00a0seguido\u00a0de;\u00a05\u2010FU,\u00a05\u2010fluorouracilo; \u00a0CM,\u00a0c\u00e1ncer\u00a0de\u00a0mama;\u00a0SLE,\u00a0supervivencia \u00a0libre\u00a0de\u00a0enfermedad; \u00a0CMT,\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0\ntemprano; \u00a0NI,\u00a0no\u00a0hay\u00a0informaci\u00f3n; \u00a0SG,\u00a0supervivencia \u00a0global.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n85\u00a0\n\u00a08.2.2.\u00a0Inhibidores \u00a0tirosina\u00a0quinasa:\u00a0\nLapatinib \u00a0\n\u00a0\nAunque\u00a0existen\u00a0evidencias \u00a0para\u00a0apoyar\u00a0el\u00a0uso\u00a0de\u00a0\nterapias\u00a0con\u00a0anticuerpos \u00a0monoclonales, \u00a0est\u00e1\u00a0\nsurgiendo \u00a0un\u00a0creciente \u00a0inter\u00e9s\u00a0por\u00a0utilizar\u00a0terapias\u00a0\ncon\u00a0inhibidores \u00a0tirosina\u00a0quinasa.\u00a0El\u00a0Lapatinib \u00a0\n(Tykerb\u00a0\u2122,\u00a0GSK572016, \u00a0antes\u00a0GW572016, \u00a0Glaxo\u00a0\nSmithKline, \u00a0Research\u00a0Triangle\u00a0Park,\u00a0NC,\u00a0EE.UU.)\u00a0\n(Fig.\u00a029)\u00a0es\u00a0el\u00a0\u00fanico\u00a0tratamiento, \u00a0aparte\u00a0de\u00a0\nTrastuzumab, \u00a0aprobado \u00a0por\u00a0la\u00a0FDA\u00a0en\u00a0marzo\u00a0del\u00a0\n2007\u00a0y\u00a0en\u00a0Europa\u00a0en\u00a02008\u00a0espec\u00edficamente \u00a0para\u00a0\npacientes \u00a0con\u00a0fenotipo\u00a0HER2+\u00a0en\u00a0estdio\u00a0avanzado \u00a0\nde\u00a0CM468.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Figura\u00a029.\u00a0Estructura \u00a0molecular \u00a0del\u00a0inhiibidor \u00a0reversible \u00a0de\u00a0\nla\u00a0actividad \u00a0quinasa\u00a0de\u00a0los\u00a0receptores \u00a0ErbB,\u00a0Lapatinib. \u00a0\n\u00a0\nEste\u00a0f\u00e1rmaco\u00a0inhibe\u00a0reversiblemente \u00a0la\u00a0actividad\u00a0\ntirosina\u00a0quinasa\u00a0intracelular \u00a0de\u00a0HER2\u00a0y\u00a0EGFR,\u00a0\nsuprimiendo \u00a0de\u00a0este\u00a0modo\u00a0las\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\ncomo\u00a0las\u00a0de\u00a0las\u00a0MAPK/Erk1/2 \u00a0y\u00a0PI3K/Akt469,470.\u00a0De\u00a0\nfoma\u00a0 importante \u00a0 estudios\u00a0 pre\u2010cl\u00ednicos\u00a0\ndemostraron \u00a0que\u00a0el\u00a0lapatinib\u00a0pod\u00eda\u00a0inhibir\u00a0el\u00a0\ncrecimiento \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0HER2+\u00a0resistentes \u00a0a\u00a0\ntrastuzumab \u00a0y\u00a0adem\u00e1s\u00a0pod\u00eda\u00a0potenciar \u00a0el\u00a0efecto\u00a0\nani\u2010apopt\u00f3tico \u00a0de\u00a0anticuerpos \u00a0anti\u2010HER2471,472.\u00a0\nScaltriti\u00a0y\u00a0colaboradores \u00a0demostraron \u00a0que\u00a0c\u00e9lulas\u00a0\nque\u00a0expresaban \u00a0establemente \u00a0la\u00a0isoforma\u00a0\ntruncada\u00a0del\u00a0receptor\u00a0HER2\u00a0(p95)\u00a0eran\u00a0resistentes \u00a0\na\u00a0Herceptin, \u00a0pero\u00a0segu\u00edan\u00a0siendo\u00a0sensibles\u00a0a\u00a0los\u00a0\nefectos\u00a0antiproliferativos \u00a0de\u00a0Lapatinib \u00a0tanto\u00a0in\u00a0\nvitro\u00a0como\u00a0in\u00a0vivo473.\u00a0En\u00a0los\u00a0primeros\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0este\u00a0f\u00e1rmaco\u00a0mostr\u00f3\u00a0un\u00a0resultado \u00a0cl\u00ednico\u00a0(tasas\u00a0de\u00a0respuesta \u00a0del\u00a010%)\u00a0en\u00a0pacientes \u00a0cuya\u00a0\nenfermedad \u00a0hab\u00eda\u00a0progresado \u00a0al\u00a0recibir\u00a0\ntrastuzumab474,\u00a0sin\u00a0embargo\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0los\u00a0\n2\u00a0antidiana \u00a0aprobados \u00a0(Lapatinib \u00a0y\u00a0Trastuzumab) \u00a0\nmostr\u00f3\u00a0una\u00a0eficacia\u00a0significativamente \u00a0superior\u00a0a\u00a0\nla\u00a0administraci\u00f3n \u00a0de\u00a0Lapatinib \u00a0en\u00a0monoterapia \u00a0en\u00a0\npacientes \u00a0que\u00a0ya\u00a0hab\u00edan\u00a0progresado \u00a0al\u00a0\ntratamiento \u00a0con\u00a0Trastuzumab, \u00a0mostrando \u00a0\u00a0la\u00a0alta\u00a0\neficacia\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0dual.\u00a0Lapatinib \u00a0tambi\u00e9n\u00a0\nmuestra\u00a0eficacia\u00a0a\u00a0la\u00a0progresi\u00f3n \u00a0a\u00a0Trastuzumab \u00a0en\u00a0\ncombinaci\u00f3n \u00a0con\u00a0Capecitabina \u00a0en\u00a0comparaci\u00f3n \u00a0\ncon\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0capecitabina \u00a0sola\u00a0(8,4\u00a0\nmeses\u00a0frente\u00a0a\u00a04,4,\u00a0HR\u00a00,49,\u00a0P\u00a0<0,001)\u00a0475,476.\u00a0No\u00a0\nhay\u00a0evidencias \u00a0de\u00a0ning\u00fan\u00a0aumento\u00a0grave\u00a0en\u00a0los\u00a0\nefectos\u00a0adversos\u00a0(incluyendo \u00a0cardiotoxicidad) \u00a0al\u00a0\ntratar\u00a0con\u00a0lapatinib. \u00a0La\u00a0combinaci\u00f3n \u00a0de\u00a0lapatinib\u00a0y\u00a0\ncapecitabina \u00a0ha\u00a0sido\u00a0aprobada \u00a0por\u00a0la\u00a0FDA\u00a0para\u00a0su\u00a0\nuso\u00a0en\u00a0pacientes \u00a0HER2+\u00a0tratados\u00a0previamente \u00a0con\u00a0\nuna\u00a0antraciclina, \u00a0un\u00a0taxano\u00a0y\u00a0trastuzumab. \u00a0\u00a0\nTras\u00a0los\u00a0resultados \u00a0del\u00a0estudio\u00a0de\u00a0combinaci\u00f3n \u00a0en\u00a0\npacientes \u00a0metast\u00e1sicas, \u00a0se\u00a0ha\u00a0intentado \u00a0llevar\u00a0la\u00a0\neficaz\u00a0combinaci\u00f3n \u00a0a\u00a0la\u00a0enfermedad \u00a0precoz,\u00a0con\u00a0\nvarios\u00a0ensayos\u00a0ya\u00a0con\u00a0resultados \u00a0publicados \u00a0en\u00a0\u00a0el\u00a0\ncontexto\u00a0neoadyuvante455\u00a0(Tabla\u00a016)\u00a0y\u00a0a\u00a0la\u00a0espera\u00a0\nde\u00a0confirmaci\u00f3n \u00a0de\u00a0estos\u00a0resultados \u00a0en\u00a0ensayos\u00a0\nen\u00a0el\u00a0contexto\u00a0adyuvante \u00a0com\u00a0es\u00a0el\u00a0caso\u00a0del\u00a0\nensayo\u00a0cl\u00ednico\u00a0\u00a0en\u00a0fase\u00a0\u00a0III,\u00a0ALTTO477.\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nINTRODUCCI\u00d3N \u00a0\u00a0\n\u00a0\n86\u00a0\n\u00a0Tabla\u00a016.\u00a0Algunos\u00a0de\u00a0los\u00a0ensayos\u00a0fase\u00a0III\u00a0seleccionados \u00a0para\u00a0lapatinib\u00a0en\u00a0pacientes \u00a0con\u00a0CM455.\u00a0\n\u00a0\nNOMBRE \u00a0DEL\u00a0\nENSAYO\u00a0PACIENTES \u00a0(n)\u00a0 TRATAMIENTO \u00a0PRIMER\u00a0PUNTO\u00a0\nFINAL\u00a0OTROS\u00a0RESULTADOS \u00a0\n\u00a0EGF100151475,476\u00a0\u00a0HER2+en\u00a0\u00a0CMA*\u00a0\n(399)\u00a0\u00a0Capecitabina \u00a0vs\u00a0capecitabina\u2013\nlapatinib\u00a0\u00a0Mediana\u00a0de\u00a0TPT\u00a0de\u00a0\n4.3\u00a0meses\u00a0\u00a0vs\u00a06.2\u00a0\nmeses\u00a0(P\u00a0<0.001) \u2021\u00a0\u00a0TRG\u00a0del\u00a014%\u00a0vs\u00a024%\u00a0\n(P=0.017);\u00a0mediana\u00a0de\u00a0\u00a0SG\u00a0\nde\u00a015.3\u00a0meses\u00a0\u00a0vs\u00a015.6\u00a0\nmeses\u00a0(P=0.177) \u2021\u00a0\u00a0\n\u00a0EGF30001478\u00a0CMM \u00a7\u00a0previamente \u00a0\nno\u00a0tratados\u00a0(86\u00a0\nHER2+,\u00a0493\u00a0HER2\u2013)\u00a0\u00a0Paclitaxel\u2013placebo \u00a0vs\u00a0paclitaxel\u2013\nlapatinib\u00a0\u00a0TPT\u00a0de\u00a022.9\u00a0semanas\u00a0\nvs\u00a029\u00a0semanas\u00a0\n(P=0.142)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nEn\u00a0el\u00a0subgrupo \u00a0\nHER2+\u00a0:\u00a025.1\u00a0\nsemanas\u00a0\u00a0vs\u00a036.4\u00a0\nsemanas\u00a0(P=0.005)\u00a0\u00a0TRG\u00a0del\u00a025%\u00a0vs\u00a035%\u00a0\n(P=0.008);\u00a0SLEv\u00a0o\u00a0SG\u00a0no\u00a0\nsignificativa;en \u00a0subrupo\u00a0\nHER2+:\u00a0SLEv,\u00a0TRG,\u00a0y\u00a0TBC\u00a0\nsignificativamente \u00a0mejor\u00a0con\u00a0\npaclitaxel \u2010lapatinib\u00a0\n\u00a0EGF\u00a030008479\u00a0\u00a0Mujeres\u00a0post\u2010\nmenop\u00e1usicas \u00a0con\u00a0\nRH+\u00a0y\u00a0CMA \u00a7\u00a0(219\u00a0\nHER2+,\u00a01,067\u00a0HER2\u2013)\u00a0\u00a0Letrozol\u2013placebo \u00a0vs\u00a0letrozol\u2013\nlapatinib\u00a0\u00a0En\u00a0el\u00a0subgrupo \u00a0\nHER2+\u00a0:\u00a0mediana\u00a0de\u00a0\nSLP\u00a0de\u00a03.0\u00a0meses\u00a0\u00a0vs\u00a0\n8.2\u00a0meses\u00a0(P=0.019)\u00a0\u00a0En\u00a0el\u00a0subrupo\u00a0HER2+:\u00a0TRG\u00a0\ndel\u00a015%\u00a0vs\u00a028%( P=0.021),\u00a0\nTBC\u00a0del\u00a029%\u00a0vs\u00a048%\u00a0\n(P=0.003),\u00a0SG\u00a0de\u00a032.3\u00a0meses\u00a0\u00a0\nvs\u00a033.3\u00a0meses\u00a0(P=0.113)\u00a0\u00a0\n\u00a0EGF104900480\u00a0\u00a0HER2+\u00a0en\u00a0CMM\u25ca\u00a0\u00a0\u00a0\n(296)\u00a0\u00a0Lapatinib \u00a0vs\u00a0lapatinib\u2013trastuzumab\u2022 \u00a0Median\u00a0de\u00a0SLP\u00a0de\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n8.1\u00a0semanas\u00a0\u00a0vs\u00a012.0\u00a0\nsemanas\u00a0(P=0.008)\u00a0\u00a0TBC\u00a0del\u00a012.4%\u00a0vs\u00a024.7%\u00a0\n(P=0.01),\u00a0SG\u00a0de\u00a039.0\u00a0\nsemanas\u00a0vs\u00a051.6\u00a0semanas\u00a0\n(P=0.106),\u00a0TRG\u00a06.9%\u00a0vs\u00a0\n10.3%( P=0.46)\u00a0\u00a0\n\u00a0NEOALTTO481\u00a0Tumores\u00a0HER2+\u00a0\n>2cm\u00a0(estadio\u00a0II\u2013IIIA)\u00a0\n(una\u00a0acumulaci\u00f3n \u00a0\ntotal\u00a0proyectada \u00a0de\u00a0\n455)\u00a0\u00a0\u2010Lapatinib \u2192lapatinib \u2013paclitaxel \u00a0\n\u2192cirug\u00eda\u2192FEC\u2192lapatinib\u00a0vs\u00a0\u2010\u2010\nTrastuzumab\u2022 \u2192\u00a0trastuzumab\u2022\u2013\npaclitaxel \u2192cirug\u00eda\u2192FEC\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2192trastuzumab\u2022 \u00a0\u00a0vs\u00a0\n\u2010Lapatinib\u2013trastuzumab\u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2192lapatinib\u2013trastuzumab\u2022 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\npaclitaxel \u00a0\u2192cirug\u00eda\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2192FEC\u2192lapatinib\u2013trastuzumab\u2022 \u00a0\u00a0\u00a0Tasa\u00a0de\u00a0RPC\u00a0del\u00a0\u00a0\n24.7%\u00a0vs\u00a029.5%\u00a0\u00a0vs\u00a0\n51.3%\u00a0(P=0.0001\u00a0\nque\u00a0favorece\u00a0la\u00a0\ncombinaci\u00f3n \u00a0de\u00a0\nlapatinib\u00a0y\u00a0\ntrastuzumab) \u00a0\u00a0Todav\u00eda\u00a0por\u00a0definir:\u00a0TRG,\u00a0\nporcentaje \u00a0de\u00a0ganglios\u00a0\nnegativos \u00a0en\u00a0la\u00a0cirug\u00eda,\u00a0tasa\u00a0\nde\u00a0cirug\u00eda\u00a0conservadora \u00a0de\u00a0la\u00a0\nmama,\u00a0SLE\u00a0y\u00a0SG\u00a0\u00a0\n\u00a0\nGeparQuinto#,482\u00a0\u00a0Tumor\u00a0primario\u00a0de\u00a0\nCM\u00a0HER2+\u00a0\u00a0que\u00a0\nrequiere\u00a0terapia\u00a0\nadjyuvante \u00a0(una\u00a0\nacumulaci\u00f3n \u00a0total\u00a0\nproyectada \u00a0de\u00a02.547)\u00a0\u00a0\u00a0\u2010Epirubicina\u2013ciclofosfamida \u2192\u00a0\u00a0\ndocetaxel\u2013trastuzumab \u00a0\u00a0vs\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u2010Epirubicina\u2013cyclophosphamide \u2192\u00a0\u00a0\ndocetaxel\u2013lapatinib \u00a0\u00a0Tasa\u00a0de\u00a0RPC\u00a0del\u00a0\u00a0\n31.7%\u00a0vs\u00a021.7%\u00a0\n(P<0.05)\u00a0\u00a0Todav\u00eda\u00a0por\u00a0definir:\u00a0Tasa\u00a0de\u00a0\nconservaci\u00f3n \u00a0de\u00a0la\u00a0mama,\u00a0\nSLE\u00a0cerebral,\u00a0SG\u00a0y\u00a0SLE\u00a0\u00a0\n*Avanzado \u00a0en\u00a0antraciclina, \u00a0taxano\u00a0y\u00a0trastuzumab. \u00a0\u2021Los\u00a0resultados \u00a0se\u00a0basan\u00a0en\u00a0los\u00a0datos\u00a0m\u00e1s\u00a0recientes.483\u00a0\u00a7No\u00a0seleccionado \u00a0para\u00a0HER2.\u00a0\n\u25caProgresi\u00f3n \u00a0al\u00a0trastuzumab. \u00a0\u2022\u00a0Inicialmente \u00a04\u00a0mg/kg\u00a0de\u00a0trastuzumab, \u00a0seguido\u00a0de\u00a02\u00a0mg/kg\u00a0cada\u00a0semana.\u00a0#\u00a0Parte\u00a0HER2+\u00a0(el\u00a0ensayo\u00a0incluy\u00f3\u00a0\notros\u00a0cuatro\u00a0brazos\u00a0para\u00a0los\u00a0pacientes \u00a0con\u00a0enfermedad \u00a0HER\u2010).\u00a0Abreviaturas: \u00a0\u2192,\u00a0seguido\u00a0de;\u00a0CMA,\u00a0CM\u00a0en\u00a0estadio\u00a0avanzado; \u00a0CM,\u00a0c\u00e1ncer\u00a0\nde\u00a0mama;\u00a0CMM,\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0metast\u00e1sico; \u00a0FEC,\u00a05\u2010fluorouracil\u2013epirubici na\u2013ciclofosfamida; \u00a0HER2+,\u00a0HER2\u2010positivo;\u00a0HER2\u2013,\u00a0HER2\u2010\nnegativo; \u00a0RH,\u00a0receptores \u00a0hormonales; \u00a0RPC,\u00a0respuesta \u00a0patol\u00f3gica \u00a0completa; \u00a0SG,\u00a0supervivencia \u00a0global;\u00a0SLE,\u00a0supervivencia \u00a0libre\u00a0de\u00a0\nenfermedad; \u00a0SLEv,\u00a0supervivencia \u00a0libre\u00a0de\u00a0eventos;\u00a0SLP,\u00a0supervivencia \u00a0libre\u00a0de\u00a0progresi\u00f3n; \u00a0TBC,\u00a0tasa\u00a0de\u00a0beneficio \u00a0cl\u00ednico;\u00a0TPT,tiempo \u00a0de\u00a0\nprogresi\u00f3n \u00a0tumoral;\u00a0TRG,\u00a0tasa\u00a0de\u00a0respuesta \u00a0global.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n87\u00a0\n\u00a0HIP\u00d3TESIS \u00a0Y\u00a0OBJETIVOS \u00a0\n\u00a0\nHIP\u00d3TESIS \u00a0Y\u00a0OBJETIVOS \u00a0\u00a0\n\u00a0\n89\u00a0\n\u00a0HIP\u00d3TESIS \u00a0Y\u00a0OBJETIVOS \u00a0\n\u00a0\nEstudios\u00a0previos\u00a0han\u00a0demostrado \u00a0que\u00a0los\u00a0factores\u00a0\ncelulares\u00a0y\u00a0solubles\u00a0que\u00a0componen \u00a0el\u00a0\nmicroambiente \u00a0tumoral\u00a0pueden\u00a0modular\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas \u00a0e\u00a0influir\u00a0en\u00a0\nlas\u00a0respuestas \u00a0tumorales \u00a0a\u00a0las\u00a0terapias.\u00a0Entre\u00a0los\u00a0\ncomponentes \u00a0del\u00a0microambiente \u00a0tumoral,\u00a0el\u00a0\nsistema\u00a0nervioso\u00a0y\u00a0los\u00a0neurop\u00e9ptidos \u00a0secretados \u00a0\npor\u00a0c\u00e9lulas\u00a0no\u00a0neuronales \u00a0y\u00a0neuronales \u00a0tendr\u00edan\u00a0\nun\u00a0control\u00a0directo\u00a0e\u00a0indirecto\u00a0sobre\u00a0la\u00a0progresi\u00f3n \u00a0\ndel\u00a0tumor:\u00a0(1)\u00a0actuando \u00a0sobre\u00a0los\u00a0receptores \u00a0\nneuronales \u00a0o\u00a0receptores \u00a0de\u00a0quimioquinas \u00a0\nexpresados \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas \u00a0y\u00a0(2)\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0modulaci\u00f3n \u00a0del\u00a0sistema\u00a0inmunitario \u00a0\nmediante \u00a0la\u00a0liberaci\u00f3n \u00a0de\u00a0citoquinas \u00a0pro\u2010\ninflamatorias \u00a0que\u00a0regular\u00edan \u00a0al\u00a0propio\u00a0sistema\u00a0\ninmunitario \u00a0y\u00a0al\u00a0tumor.\u00a0A\u00a0pesar\u00a0de\u00a0los\u00a0diferentes \u00a0\nneurotransmisores \u00a0y\u00a0neurop\u00e9ptidos, \u00a0como\u00a0la\u00a0\nsustancia \u00a0P\u00a0(SP),\u00a0relacionados \u00a0con\u00a0la\u00a0progresi\u00f3n \u00a0\ntumoral\u00a0hay\u00a0una\u00a0falta\u00a0de\u00a0conocimiento \u00a0de\u00a0los\u00a0\nmecanismos \u00a0precisos\u00a0que\u00a0activan\u00a0estas\u00a0mol\u00e9culas \u00a0\npara\u00a0controlar\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0y\u00a0la\u00a0\nprogresi\u00f3n \u00a0de\u00a0esta\u00a0enfermedad. \u00a0\nLa\u00a0SP\u00a0es\u00a0una\u00a0citoquina \u00a0pro\u2010inflamatoria \u00a0o\u00a0\nneurop\u00e9ptido \u00a0que\u00a0pertenece \u00a0a\u00a0la\u00a0familia\u00a0de\u00a0las\u00a0\ntaquiquininas \u00a0y\u00a0se\u00f1aliza\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0su\u00a0receptor\u00a0de\u00a0\nmayor\u00a0afinidad,\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0(NK\u20101R).\u00a0NK\u20101R\u00a0\nes\u00a0un\u00a0receptor\u00a0acoplado\u00a0a\u00a0prote\u00ednas \u00a0G\u00a0que\u00a0se\u00a0\nsobreexpresa \u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0\u00a0El\u00a0hecho\u00a0que\u00a0la\u00a0\nSP\u00a0act\u00fae\u00a0como\u00a0neurotransmisor \u00a0durante\u00a0la\u00a0\ninflamaci\u00f3n \u00a0neurog\u00e9nica, \u00a0se\u00f1alice\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nsistema\u00a0nerviososo \u00a0y\u00a0act\u00fae\u00a0como\u00a0citoquina \u00a0pro\u2010\ninflamatoria \u00a0regulando \u00a0\u00a0la\u00a0respuesta \u00a0inmune\u00a0(eje\u00a0\nneuroinmunoendocrino) \u00a0hace\u00a0que\u00a0este\u00a0p\u00e9ptido\u00a0\nest\u00e9\u00a0presente\u00a0en\u00a0m\u00faltiples \u00a0sistemas\u00a0regul\u00e1ndolos \u00a0\nde\u00a0forma\u00a0positiva\u00a0o\u00a0negativa\u00a0seg\u00fan\u00a0el\u00a0contexto. \u00a0\u00a0\nEsta\u00a0tesis\u00a0se\u00a0ha\u00a0centrado\u00a0en\u00a0estudiar\u00a0el\u00a0papel\u00a0de\u00a0la\u00a0\nSP\u00a0papel\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0tumoral\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0\nCM.\u00a0Dado\u00a0que\u00a0la\u00a0SP\u00a0se\u00f1aliza\u00a0trav\u00e9s\u00a0de\u00a0receptores \u00a0\nunidos\u00a0a\u00a0prote\u00ednas \u00a0G\u00a0como\u00a0NK\u20101R,\u00a0y\u00a0debido\u00a0al\u00a0\ncreciente \u00a0inter\u00e9s\u00a0sobre\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0\nreceptores \u00a0tirosina\u00a0quinasa\u00a0por\u00a0parte\u00a0de\u00a0GPCRs\u00a0se\u00a0\ndecidi\u00f3\u00a0investigar \u00a0la\u00a0posible\u00a0co\u2010operaci\u00f3n \u00a0oncog\u00e9nica, \u00a0principalmente, \u00a0entre\u00a0el\u00a0receptor\u00a0\ntirosina\u00a0quinasa\u00a0HER2,\u00a0importante \u00a0para\u00a0el\u00a0\ndiagn\u00f3stico \u00a0y\u00a0evoluci\u00f3n \u00a0de\u00a0la\u00a0enfermedad, \u00a0y\u00a0el\u00a0\nreceptor\u00a0de\u00a0taquiquininas \u00a0NK\u20101R.\u00a0\u00a0\nPor\u00a0tanto,\u00a0los\u00a0objetivos\u00a0principales \u00a0de\u00a0la\u00a0presente\u00a0\ntesis\u00a0fueron\u00a0los\u00a0siguientes: \u00a0\n\u00a0\n1.\u00a0Analizar\u00a0la\u00a0relevancia \u00a0cl\u00ednica\u00a0del\u00a0sistema\u00a0\ntaquiquinergico \u00a0en\u00a0CM.\u00a0\n\u00a0 1.1.\u00a0Estudiar\u00a0la\u00a0correlaci\u00f3n \u00a0entre\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0la\u00a0SP\u00a0con\u00a0diferentes \u00a0\nvariables\u00a0cl\u00ednicopatol\u00f3gicas \u00a0en\u00a0tumores\u00a0primarios \u00a0\nde\u00a0la\u00a0mama.\u00a0\n\u00a0\u00a0 1.2.\u00a0Analizar\u00a0los\u00a0niveles\u00a0circulantes \u00a0de\u00a0la\u00a0\nSP\u00a0en\u00a0pacientes \u00a0con\u00a0CM.\u00a0\n2.\u00a0Investigar \u00a0los\u00a0efectos\u00a0del\u00a0sistema\u00a0\ntaquiquin\u00e9rgico \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0\nEGFR.\u00a0\n2.1.\u00a0Investigar \u00a0la\u00a0posible\u00a0transactivaci\u00f3n \u00a0\nde\u00a0HER2\u00a0y\u00a0EGFR\u00a0por\u00a0parte\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0\nCM\u00a0obtenidas \u00a0a\u00a0partir\u00a0de\u00a0tumores\u00a0primarios \u00a0as\u00ed\u00a0\ncomo\u00a0en\u00a0algunas\u00a0l\u00edneas\u00a0celulares. \u00a0\n2.2.\u00a0Estudiar\u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0\nautocrina/paracrina \u00a0de\u00a0la\u00a0SP/NK\u20101R\u00a0en\u00a0la\u00a0\nactivaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0y\u00a0EGFR.\u00a0\n2.3.\u00a0Investigar \u00a0los\u00a0mecanismos \u00a0por\u00a0los\u00a0\ncuales\u00a0la\u00a0SP\u00a0transactiva \u00a0HER2\u00a0y\u00a0EGFR.\u00a0\n2.4.\u00a0Estudiar\u00a0si\u00a0el\u00a0proceso\u00a0de\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0HER2\u00a0o\u00a0EGFR\u00a0\u00a0se\u00a0puede\u00a0utilizar\u00a0\ncomo\u00a0una\u00a0nueva\u00a0aproximaci\u00f3n \u00a0para\u00a0mejorar\u00a0\nestrategias \u00a0terap\u00e9uticas \u00a0actuales.\u00a0\n3.\u00a0Investigar \u00a0los\u00a0efectos\u00a0cr\u00f3nicos\u00a0de\u00a0una\u00a0\nexposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0\n\u00a0\u00a0 1.1.\u00a0Crear\u00a0un\u00a0modelo\u00a0de\u00a0sobreexposici\u00f3n \u00a0a\u00a0\nSP\u00a0con\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0\n\u00a0 1.2.\u00a0Analizar\u00a0los\u00a0cambios\u00a0fenot\u00edpicos \u00a0y\u00a0\ngenot\u00edpicos \u00a0causados \u00a0por\u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0SP,\u00a0a\u00a0\nlargo\u00a0plazo,\u00a0en\u00a0l\u00edneas\u00a0de\u00a0CM.\u00a0\u00a0\n91\u00a0\n\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\n\u00a0\n\u00a0\u00a0\nMATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n93\u00a0\n\u00a01.\u00a0REACTIVOS \u00a0UTILIZADOS \u00a0EN\u00a0EL\u00a0ESTUDIO\u00a0\nEn\u00a0la\u00a0presente\u00a0tesis\u00a0doctoral\u00a0se\u00a0han\u00a0utilizado\u00a0los\u00a0anticuerpos \u00a0detallados \u00a0a\u00a0continuaci\u00f3n: \u00a0\n\u00a0\nANTICUERPOS \u00a0PRIMARIOS \u00a0CASA\u00a0\nCOMERCIAL \u00a0CATALOGO \u00a0ORIGEN\u00a0 DILUCI\u00d3N \u00a0 APLICACI\u00d3N \u00a0\npEGFR\u00a0Tyr1068\u00a0 Cell\u00a0Signaling\u00a0 2234\u00a0 Conejo\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\npEGFR\u00a0Tyr845\u00a0 Cell\u00a0Signaling\u00a0 2231\u00a0 Conejo\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\nEGFR\u00a0 Cell\u00a0Signaling\u00a0 2232\u00a0 Conejo\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\np\u2010HER2\u00a0Tyr1248\u00a0 Abcam\u00a0 ab5654\u00a0 Conejo\u00a0 1:500\u00a0 Western\u00a0blot\u00a0\nHER2\u00a0 Biogenex\u00a0 MU134\u2010UCE\u00a0Rat\u00f3n\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\np\u2010p42/44\u2010MAPK\u00a0 Cell\u00a0Signaling\u00a0 9101S\u00a0 Conejo\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\np42/44\u2010MAPK\u00a0 Cell\u00a0Signaling\u00a0 9102\u00a0 Conejo\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\np\u2010Akt\u00a0XP\u00a0 Cell\u00a0Signaling\u00a0 4060\u00a0 Conejo 1:1000\u00a0 Western\u00a0blot\u00a0\nAkt\u00a0 Cell\u00a0Signaling\u00a0 9272\u00a0 Conejo 1:1000\u00a0 Western\u00a0blot\u00a0\n\u03b1\u2010Tubulina\u00a0 Cell\u00a0Signaling\u00a0 2144\u00a0 Rat\u00f3n\u00a0 1:1000\u00a0 Western\u00a0blot\u00a0\nActina\u00a0 Sigma\u00a0Aldrich\u00a0 A2066\u00a0 Conejo 1:1000\u00a0 Western\u00a0blot y\u00a0\nNK\u20101R\u00a0 Abcam\u00a0 Ab\u2010466\u00a0 Conejo 1:1000\u00a0 Western\u00a0blot\u00a0\nNK\u20101R\u00a0 MBL\u00a0 LS\u2010A1399\u00a0 Conejo 1:100\u00a0 Inmunohistoqu\u00edmica \u00a0\nNK\u20102R\u00a0 MBL\u00a0 LS\u2010A1288\u00a0 Conejo 1:100\u00a0 Inmunohistoqu\u00edmica\nSP\u00a0 UB*\u00a0\u2010 \u00a0 Rat\u00f3n\u00a0 sobrenadante \u00a0 Inmunohistoqu\u00edmica\nSP\u00a0\u00a0 BioGenex \u00a0(AB1) AR069\u20105R Rat\u00f3n 1:100\u00a0a\u00a01:500\u00a0 Cultivos\u00a0celulares\nCOX2\u00a0 Cayman\u00a0 160112\u00a0 Rat\u00f3n 1:50\u00a0 Inmunohistoqu\u00edmica\n\u03b1\u2010Actina\u00a0de\u00a0musculatrua \u00a0lisa\u00a0 DAKO\u00a0 M0851\u00a0 Rat\u00f3n 1:100\u00a0 Inmunohistoqu\u00edmica\nEGFR\u00a0(528)\u00a0FITC\u00a0 Santa\u00a0Cruz\u00a0 sc\u2010120\u00a0FITC\u00a0 Rat\u00f3n 1:100\u00a0 Inmunofluorescencia \u00a0\nPancitoqueratina \u00a0 Santa\u00a0Cruz\u00a0 sc\u20108018\u00a0 Rat\u00f3n\u00a0 1:100\u00a0 Inmunofluorescencia\nFITC\u00a0anti\u2010human\u00a0CD44\u00a0 BD\u00a0Pharmigen \u00a0 555478\u00a0 Rat\u00f3n 1:100\u00a0 Citometr\u00eda \u00a0de\u00a0flujo\u00a0\nPE\u00a0anti\u2010human\u00a0CD24\u00a0 BD\u00a0Pharmigen \u00a0 555428\u00a0 Rat\u00f3n\u00a0 1:100\u00a0 Citometr\u00eda \u00a0de\u00a0flujo\u00a0\n*\u00a0El\u00a0anticuerpo \u00a0monoclonal \u00a0contra\u00a0la\u00a0SP\u00a0ha\u00a0sido\u00a0producido \u00a0por\u00a0el\u00a0Dr.\u00a0Pablo\u00a0Engel,\u00a0Departamento \u00a0de\u00a0Biolog\u00eda\u00a0Celular,\u00a0\nInmunolog\u00eda \u00a0y\u00a0Neurociencias \u00a0de\u00a0la\u00a0Universidad \u00a0de\u00a0Barcelona  \u00a0\n\u00a0\nANTICUERPOS \u00a0SECUNDARIOS \u00a0CASA\u00a0\nCOMERCIAL \u00a0CATALOGO \u00a0ORIGEN\u00a0DILUCI\u00d3N \u00a0 APLICACI\u00d3N \u00a0\nCabra\u00a0anti\u2010rat\u00f3n\u00a0conjugado \u00a0a\u00a0HRP\u00a0 Amersham \u00a0 NXA931\u00a0 Cabra\u00a0 1:2000\u00a0 Western\u00a0blot\u00a0\nCabra\u00a0anti\u2010rat\u00f3n\u00a0conjugado \u00a0a\u00a0HRP\u00a0 Amersham \u00a0 NA934V\u00a0 Cabra\u00a0 1:2000\u00a0 Western\u00a0blot\u00a0\nDyLight\u00a0649\u00a0F(ab\u2019) 2\u00a0cabra\u00a0anti\u2010\nconejo\u00a0IgG\u00a0Jackson\u00a0IR\u00a0111\u2010496\u2010047\u00a0Cabra\u00a0 1:250\u00a0 Citometr\u00eda \u00a0de\u00a0flujo\u00a0\nCabra\u00a0anti\u2010rat\u00f3n\u00a0conjugado \u00a0a\u00a0IgG\u00a0\nBiotinilada \u00a0Thermo\u00a0\nFisher\u00a00031820\u00a0 Cabra\u00a0 1:100\u00a0 Inmunofluorescencia \u00a0\nAlexa\u00a0Fluor\u00a0555\u00a0cabra\u00a0anti\u2010rat\u00f3n\u00a0\nIgG\u00a0Invitrogen \u00a0 A21422\u00a0 Cabra\u00a0 1:250\u00a0 Inmunofluorescencia \u00a0\nAlexa\u00a0Fluor\u00a0594\u00a0burro\u00a0anti\u2010conejo\u00a0\nIgG\u00a0Invitrogen \u00a0 A21207\u00a0 Burro\u00a0 1:250\u00a0 Inmunofluorescencia \u00a0\n\u00a0\nREACTIVOS \u00a0PARA\u00a0LA\u00a0DETECCI\u00d3N \u00a0\nDE\u00a0ANTICUERPOS \u00a0SECUNDARIOS \u00a0CASA\u00a0\nCOMERCIAL \u00a0CATALOGO \u00a0ORIGEN\u00a0DILUCI\u00d3N \u00a0 APLICACI\u00d3N \u00a0\nAlexa\u00a0Fluor\u00ae\u00a0488\u00a0Estreptavidina \u00a0 Invitrogen \u00a0 S11223\u00a0\u2010 \u00a0 1:250\u00a0 Inmunofluorescencia \u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n94\u00a0\n\u00a0Otros\u00a0reactivos\u00a0utilizados \u00a0para\u00a0los\u00a0cultivos\u00a0\ncelulares\u00a0fueron\u00a0el\u00a0factor\u00a0recombinante \u00a0de\u00a0\ncrecimiento \u00a0epitelial\u00a0(rhEGF)\u00a0(PreProtech, \u00a0Cat#\u00a0\n100\u201015),\u00a0insulina\u00a0(Sigma\u2010Aldrich,\u00a0Cat#\u00a0I\u20109278),\u00a0\nhidrocortisona \u00a0(Sigma\u2010Aldrich,\u00a0Cat#H0888) \u00a0y\u00a0\ntoxina\u00a0col\u00e9rica\u00a0(Sigma\u2010Aldrich,\u00a0Cat#\u00a0C8052).\u00a0La\u00a0SP\u00a0\n(Arg\u2010Pro\u2010Lys\u2010Pro\u2010Gln\u2010Gln\u2010Phe\u2010Phe\u2010Gly\u2010Leu\u2010Met\u2010\nNH2)\u00a0(Cat#\u00a0S1136),\u00a0NKA\u00a0(Cat#\u00a0N4267),\u00a0NKB\u00a0(Cat#\u00a0\nN4143)\u00a0y\u00a0AG1478\u00a0(Cat#\u00a0T4182),\u00a0se\u00a0obtuvieron \u00a0de\u00a0\nSigma\u2010Aldrich\u00a0y\u00a0el\u00a0inhibidor\u00a0de\u00a0qu\u00edmico\u00a0de\u00a0HER2\u00a0\nAG825\u00a0se\u00a0adquiri\u00f3\u00a0de\u00a0Gibco\u2010Invitrogen \u00a0(Cat#\u00a0\nPHZ1214). \u00a0El\u00a0antagonista \u00a0de\u00a0NK\u20101R\u00a0L\u2010733,060\u00a0se\u00a0\nobtuvo\u00a0de\u00a0Tocris\u00a0(Cat.\u00a0#\u00a01145).\u00a0GlaxoSmithKline \u00a0\nnos\u00a0suministr\u00f3 \u00a0generosamente \u00a0el\u00a0Lapatinib. \u00a0Todos\u00a0\nlos\u00a0reactivos\u00a0generales \u00a0se\u00a0adquirieron \u00a0de\u00a0Sigma\u2010\nAldrich,\u00a0Bio\u2010Rad\u00a0y\u00a0Amersham. \u00a0Todos\u00a0ellos\u00a0fueron\u00a0\npreparados \u00a0de\u00a0acuerdo\u00a0a\u00a0sus\u00a0instrucciones. \u00a0\n2.\u00a0EXPERIMENTOS \u00a0IN\u00a0VITRO\u00a0\n2.1.\u00a0L\u00edneas\u00a0celulares\u00a0\n\u00a0\nLas\u00a0siguientes \u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM\u00a0fueron\u00a0\nadquiridas \u00a0del\u00a0American \u00a0Type\u00a0Culture\u00a0Collection \u00a0\n(ATCC)\u00a0y\u00a0se\u00a0cultivaron \u00a0de\u00a0acuerdo\u00a0con\u00a0sus\u00a0\ninstrucciones: \u00a0MDA\u2010MB\u2010453,\u00a0de\u00a0carcinoma \u00a0\nmetast\u00e1sico \u00a0(efusion\u00a0pleural),\u00a0BT\u2010474\u00a0de\u00a0\ncarcinoma \u00a0ductal\u00a0invasivo,\u00a0SK\u2010BR\u20103\u00a0tambi\u00e9n\u00a0de\u00a0\norigen\u00a0metast\u00e1sico \u00a0(derrame \u00a0pleural\u00a0de\u00a0\nadenocarcinoma), \u00a0al\u00a0igual\u00a0que\u00a0MDA\u2010MB\u2010231\u00a0y\u00a0\nMCF7,\u00a0y\u00a0por\u00a0\u00faltimo\u00a0MDA\u2010MB\u2010468\u00a0de\u00a0\nadenocarcinoma \u00a0 mamario. \u00a0 Dos\u00a0 l\u00edneas\u00a0\ninmortalizadas \u00a0no\u00a0tumorales, \u00a0MCF\u00a010A\u00a0y\u00a0MCF\u00a012A,\u00a0\nque\u00a0provienen \u00a0de\u00a0un\u00a0fibroquiste \u00a0y\u00a0de\u00a0epitleio\u00a0\nmamario, \u00a0respectivamente, \u00a0fueron\u00a0adquiridas \u00a0del\u00a0\nATCC.\u00a0La\u00a0l\u00ednea\u00a0celular\u00a0de\u00a0CM\u00a0de\u00a0rat\u00f3n\u00a0EO771\u00a0fue\u00a0\namablemente \u00a0suministrada \u00a0por\u00a0el\u00a0profesor\u00a0Robert\u00a0\nSteele\u00a0(Departamento \u00a0de\u00a0Patolog\u00eda, \u00a0Universidad \u00a0\nde\u00a0Sant\u00a0Louis).\u00a0\nLas\u00a0c\u00e9lulas\u00a0se\u00a0incubaron \u00a0a\u00a037\u00b0C\u00a0en\u00a0una\u00a0atm\u00f3sfera \u00a0\nhumidificada \u00a0al\u00a05%\u00a0de\u00a0CO 2,\u00a0y\u00a0fueron\u00a0deprivadas \u00a0de\u00a0\nsuero\u00a0bovino\u00a0fetal\u00a0(SBF)\u00a0durante\u00a0la\u00a0noche\u00a0anterior\u00a0\na\u00a0los\u00a0experimentos \u00a0a\u00a0menos\u00a0que\u00a0se\u00a0especifique \u00a0lo\u00a0\ncontrario. \u00a0El\u00a0medio\u00a0de\u00a0cultivo\u00a0utilizado\u00a0en\u00a0todos\u00a0\nlos\u00a0casos\u00a0fue\u00a0DMEM\u2010F12\u00a0(Dulbecco\u2019s \u00a0Modified\u00a0Eagle\u2019s\u00a0Medium\u00a0nutrient\u00a0mixture\u2010F.12\u20131:1v/v)\u00a0\n(Gibco\u2010Invitrogen), \u00a0suplementado \u00a0con\u00a0un\u00a01%\u00a0de\u00a0L\u2010\nGlutaMAX\u2122 \u00a0200\u00a0mM\u00a0(Gibco\u2010Invitrogen), \u00a0una\u00a0\nmezcla\u00a0de\u00a0antibi\u00f3ticos \u00a0(Penicilina \u2010Estreptomicina) \u00a0\nmas\u00a0fungizona \u00a0en\u00a0un\u00a0ratio\u00a0de\u00a09:1\u00a0al\u00a01%\u00a0(Gibco\u2010\nInvitrogen) \u00a0y\u00a0por\u00a0\u00faltimo\u00a0un\u00a010\u00a0%\u00a0de\u00a0SBF\u00a0inactivado \u00a0\n(Invitrogen). \u00a0En\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0BT\u2010474\u00a0se\u00a0a\u00f1adi\u00f3\u00a010\u00a0\n\u00b5g/ml\u00a0de\u00a0insulina,\u00a0y\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0MCF7\u00a0se\u00a0\nutiliz\u00f3\u00a0D\u2010MEM\u00a0m\u00e1s\u00a0insulina\u00a0y\u00a0el\u00a0resto\u00a0de\u00a0\ncomponentes. \u00a0El\u00a0medio\u00a0de\u00a0cultivo\u00a0de\u00a0las\u00a0l\u00edneas\u00a0\ncelulares\u00a0no\u00a0tumorales \u00a0MCF\u00a010A\u00a0y\u00a0MCF\u00a012A\u00a0fue\u00a0\nsuplementado \u00a0con\u00a020\u00a0ng/ml\u00a0de\u00a0EGF,\u00a00,5\u00a0\u03bcg/ml\u00a0de\u00a0\nhidrocortisona, \u00a0100\u00a0ng/ml\u00a0de\u00a0toxina\u00a0col\u00e9rica\u00a0y\u00a0\nsuero\u00a0de\u00a0caballo\u00a0fetal\u00a0(SCF)\u00a0al\u00a05%.\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0\nEO771\u00a0se\u00a0cultivaron \u00a0en\u00a0D\u2010MEM\u00a0suplementado \u00a0con\u00a0\nSFB\u00a0al\u00a020%\u00a0m\u00e1s\u00a0antibi\u00f3ticos \u00a0y\u00a0fungizona. \u00a0La\u00a0\nautenticidad \u00a0de\u00a0todas\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0\nutilizadas \u00a0en\u00a0este\u00a0estudio\u00a0fue\u00a0validado\u00a0por\u00a0las\u00a0\nrepeticiones \u00a0cortas\u00a0en\u00a0t\u00e1ndem\u00a0(STR)\u00a0de\u00a0un\u00a0\u00fanico\u00a0\nlocus\u00a0(Bio\u2010Synthesis, \u00a0Inc.).\u00a0\n2.2.\u00a0Aislamiento \u00a0y\u00a0cultivo\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0\nCM\u00a0a\u00a0partir\u00a0de\u00a0tumores\u00a0primarios \u00a0\n\u00a0\nPara\u00a0la\u00a0preparaci\u00f3n \u00a0de\u00a0cultivos\u00a0primarios \u00a0de\u00a0\nc\u00e9lulas\u00a0de\u00a0CM,\u00a0se\u00a0obtuvieron \u00a0muestras \u00a0de\u00a0\ndiecinueve \u00a0(19)\u00a0pacientes \u00a0bajo\u00a0la\u00a0aprobaci\u00f3n \u00a0del\u00a0\nComit\u00e9\u00a0\u00c9tico\u00a0de\u00a0Investigaci\u00f3n \u00a0Cl\u00ednica\u00a0(CEIC)\u00a0del\u00a0\nHospital\u00a0Cl\u00ednic\u00a0de\u00a0Barcelona. \u00a0Estas\u00a0pacientes \u00a0se\u00a0\nsometieron \u00a0a\u00a0cirug\u00eda\u00a0para\u00a0la\u00a0extirpaci\u00f3n \u00a0\nterap\u00e9utica \u00a0del\u00a0tumor,\u00a0y\u00a0los\u00a0restos\u00a0biol\u00f3gicos \u00a0no\u00a0\nutilizados \u00a0en\u00a0diagn\u00f3stico \u00a0fueron\u00a0usados\u00a0para\u00a0el\u00a0\nprop\u00f3sito \u00a0de\u00a0este\u00a0estudio.\u00a0Cada\u00a0fragmento \u00a0\ntumoral\u00a0se\u00a0someti\u00f3\u00a0primero\u00a0a\u00a0disgregaci\u00f3n \u00a0\nmec\u00e1nica \u00a0con\u00a0un\u00a0bistur\u00ed,\u00a0y\u00a0a\u00a0los\u00a0trozos\u00a0obtenidos \u00a0\nse\u00a0le\u00a0a\u00f1adieron \u00a01\u00a0ml\u00a0de\u00a0medio\u00a0de\u00a0disgregaci\u00f3n \u00a0\n(por\u00a0cada\u00a05\u00a0ml\u00a0de\u00a0medio\u00a0de\u00a0D\u2010MEM\u2010F12\u00a0sin\u00a0\nantibi\u00f3ticos \u00a0ni\u00a0SBF,\u00a0se\u00a0a\u00f1adieron \u00a00.01\u00a0g\u00a0de\u00a0BSA,\u00a0\n0.01\u00a0g\u00a0de\u00a0colagenasa \u00a0y\u00a00.01\u00a0g\u00a0de\u00a0hialuronidasa). \u00a0El\u00a0\nmedio\u00a0de\u00a0disgregaci\u00f3n \u00a0se\u00a0filtr\u00f3\u00a0con\u00a0un\u00a0filtro\u00a0de\u00a00,2\u00a0\n\u00b5M\u00a0de\u00a0poro\u00a0antes\u00a0de\u00a0ser\u00a0utilizado.\u00a0El\u00a0tejido\u00a0\ntumoral\u00a0en\u00a0medio\u00a0de\u00a0disgregaci\u00f3n \u00a0se\u00a0dej\u00f3\u00a0en\u00a0\nagitaci\u00f3n\u00a0a\u00a037\u00b0C\u00a0durante\u00a01\u20102\u00a0h\u00a0aproximadamente \u00a0\npara\u00a0obtener\u00a0as\u00ed\u00a0c\u00e9lulas\u00a0individuales. \u00a0Una\u00a0vez\u00a0\ndisgregado, \u00a0cuando\u00a0observamos \u00a0que\u00a0todav\u00eda\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n95\u00a0\n\u00a0quedaban \u00a0algunos\u00a0organoides, \u00a0centrifugamos \u00a0las\u00a0\nc\u00e9lulas\u00a0a\u00a02000\u00a0r.p.m,\u00a0se\u00a0descart\u00f3\u00a0el\u00a0sobrenadante \u00a0\n(SN)\u00a0y\u00a0el\u00a0pellet\u00a0se\u00a0resuspendi\u00f3 \u00a0en\u00a0medio\u00a0de\u00a0\ncongelaci\u00f3n \u00a0(SFB\u00a0+\u00a010%\u00a0DMSO)\u00a0y\u00a0se\u00a0congel\u00f3\u00a0a\u00a0una\u00a0\ntemperatura \u00a0de\u00a0\u201080\u00baC\u00a0hasta\u00a0su\u00a0posterior\u00a0an\u00e1lisis.\u00a0\n2.3.\u00a0Ensayos\u00a0de\u00a0tiempo\u2010respuesta \u00a0\n2.3.1.\u00a0En\u00a0l\u00edneas\u00a0celulares\u00a0\nPara\u00a0determinar \u00a0los\u00a0efectos\u00a0del\u00a0tratamiento \u00a0de\u00a0la\u00a0\nSP,\u00a0NKA\u00a0o\u00a0NKB\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0\nHER2,\u00a0EGFR,\u00a0p42/44\u00a0MAPK\u00a0y\u00a0Akt\u00a0se\u00a0sembraron \u00a0las\u00a0\nc\u00e9lulas\u00a0en\u00a0placas\u00a0de\u00a0cultivo\u00a0de\u00a0100\u00a0mm\u00a0de\u00a0\u00d8.\u00a0\nCuando\u00a0se\u00a0alcanz\u00f3\u00a0el\u00a080%\u00a0de\u00a0confluencia, \u00a0se\u00a0\ndeprivaron \u00a0de\u00a0SBF\u00a0durante\u00a024\u00a0horas,\u00a0y\u00a0\nposteriormente \u00a0se\u00a0trataron\u00a0con\u00a0100\u00a0nM\u00a0de\u00a0SP,\u00a0\n1\u00b5M\u00a0de\u00a0NKA\u00a0y\u00a0NKB\u00a0durante\u00a0los\u00a0tiempos\u00a0indicados \u00a0\nen\u00a0cada\u00a0experimento. \u00a0Para\u00a0los\u00a0estudios\u00a0de\u00a0dosis\u2010\nrespuesta, \u00a0las\u00a0c\u00e9lulas\u00a0fueron\u00a0tratadas\u00a0con\u00a0100,\u00a0200\u00a0\ny\u00a0500\u00a0nM\u00a0de\u00a0SP.\u00a0Despu\u00e9s\u00a0de\u00a0cada\u00a0tratamiento, \u00a0las\u00a0\nc\u00e9lulas\u00a0se\u00a0lavaron\u00a0dos\u00a0veces\u00a0en\u00a0una\u00a0soluci\u00f3n\u00a0salina\u00a0\nfosfatada \u00a0fr\u00eda\u00a0(conocido \u00a0tambi\u00e9n\u00a0por\u00a0sus\u00a0siglas\u00a0en\u00a0\ningl\u00e9s,\u00a0PBS)\u00a0y\u00a0se\u00a0congelaron \u00a0r\u00e1pidamente \u00a0hasta\u00a0la\u00a0\nextracci\u00f3n \u00a0de\u00a0prote\u00edna.\u00a0Cada\u00a0experimento \u00a0se\u00a0\nrepiti\u00f3\u00a0al\u00a0menos\u00a03\u00a0veces\u00a0para\u00a0asegurar\u00a0la\u00a0\nreproducibilidad \u00a0de\u00a0los\u00a0datos.\u00a0Aunque\u00a0el\u00a0\nmomento \u00a0exacto\u00a0de\u00a0m\u00e1xima\u00a0activaci\u00f3n \u00a0no\u00a0\nsiempre\u00a0se\u00a0obtuvo\u00a0en\u00a0el\u00a0mismo\u00a0minuto,\u00a0si\u00a0que\u00a0se\u00a0\nobserv\u00f3\u00a0que\u00a0este\u00a0ocurr\u00eda\u00a0durante\u00a0la\u00a0misma\u00a0\nfracci\u00f3n\u00a0de\u00a0tiempo\u00a0(entre\u00a0los\u00a0primeros\u00a06\u00a0y\u00a010\u00a0\nmin).\u00a0Este\u00a0hecho\u00a0imposibilit\u00f3 \u00a0la\u00a0realizaci\u00f3n \u00a0del\u00a0\nan\u00e1lisis\u00a0estad\u00edstico \u00a0de\u00a0estos\u00a0experimentos. \u00a0Para\u00a0\ndeterminar \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0SP\u00a0sobre\u00a0el\u00a0\ncrecimiento \u00a0celular\u00a0en\u00a0presencia \u00a0del\u00a0inhibidor\u00a0Src,\u00a0\nse\u00a0dejaron\u00a0crecer\u00a0las\u00a0c\u00e9lulas\u00a0hasta\u00a0un\u00a080%\u00a0de\u00a0\nconfluencia \u00a0y\u00a0se\u00a0deprivaron \u00a0de\u00a0SBF\u00a0durante\u00a04\u00a0\nhoras.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0trataron\u00a0durante\u00a020\u00a0\nhoras\u00a0a\u00a0una\u00a0dosis\u00a0de\u00a01\u00a0\u03bcM\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0Src\u00a0\n(4\u2010(4\u2032\u2010Phenoxyanilino) \u20106,7\u2010dimethoxyquinazoline) \u00a0\n(Calbiochem, \u00a0Cat#\u00a0567805)\u00a0en\u00a0medio\u00a0sin\u00a0SFB\u00a0\ndurante\u00a020\u00a0horas.\u00a0Para\u00a0determinar \u00a0los\u00a0efectos\u00a0de\u00a0\nla\u00a0SP\u00a0sobre\u00a0el\u00a0crecimiento \u00a0celular\u00a0en\u00a0presencia \u00a0de\u00a0\ninhibidores \u00a0de\u00a0MMPs,\u00a0se\u00a0deprivaron \u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0\nSBF\u00a0durante\u00a020\u00a0horas\u00a0y\u00a0se\u00a0trataron\u00a0con\u00a0el\u00a0\ninhibidor\u00a0 de\u00a0 MMP\u00a0 (1,10\u2010phenantroline \u00a0monohydrate \u00a0(Sigma\u2010Aldrich,\u00a0Cat#\u00a0P9375)\u00a0a\u00a0una\u00a0\ndosis\u00a0de\u00a07\u00a0\u03bcM\u00a0durante\u00a04\u00a0horas.\u00a0Finalmente, \u00a0para\u00a0\ndeterminar \u00a0los\u00a0efectos\u00a0de\u00a0SP\u00a0en\u00a0presencia \u00a0de\u00a0\nambos\u00a0inhibidores, \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0deprivaron \u00a0de\u00a0\nSBF\u00a0durante\u00a04\u00a0horas,\u00a0y\u00a0se\u00a0trataron\u00a0con\u00a0el\u00a0inhibidor\u00a0\nde\u00a0Src\u00a0durante\u00a016\u00a0horas.\u00a0En\u00a0este\u00a0punto,\u00a0se\u00a0a\u00f1adi\u00f3\u00a0\na\u00a0las\u00a0c\u00e9lulas\u00a0el\u00a0inhibidor\u00a0de\u00a0MMPs,\u00a0y\u00a0ambos\u00a0\ninhibidores \u00a0se\u00a0incubaron \u00a0durante\u00a04\u00a0horas\u00a0\nadicionales. \u00a0El\u00a0grupo\u00a0control\u00a0sin\u00a0tratamiento \u00a0se\u00a0\ncreci\u00f3\u00a0en\u00a0paralelo\u00a0con\u00a0el\u00a0resto\u00a0de\u00a0condiciones \u00a0\ndeprivado \u00a0de\u00a0suero\u00a0tambi\u00e9n\u00a0durante\u00a024\u00a0horas.\u00a0\nDespu\u00e9s\u00a0de\u00a0cada\u00a0tratamiento, \u00a0las\u00a0c\u00e9lulas\u00a0fueron\u00a0\ntratadas\u00a0con\u00a0SP\u00a0100\u00a0nM\u00a0durante\u00a06,\u00a010\u00a0y\u00a015\u00a0min.\u00a0\nDespu\u00e9s\u00a0de\u00a0tratar\u00a0con\u00a0SP,\u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0lavaron\u00a0\ndos\u00a0veces\u00a0con\u00a0PBS\u00a0fr\u00edo,\u00a0y\u00a0se\u00a0congelaron \u00a0\nr\u00e1pidamente \u00a0hasta\u00a0su\u00a0posterior\u00a0extracci\u00f3n \u00a0de\u00a0\nprote\u00edna.\u00a0Los\u00a0experimentos \u00a0con\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0\nse\u00a0repitieron \u00a0al\u00a0menos\u00a0dos\u00a0veces\u00a0para\u00a0asegurar\u00a0la\u00a0\nreproducibilidad \u00a0de\u00a0los\u00a0datos.\u00a0\n2.3.2.\u00a0En\u00a0cultivos\u00a0primarios \u00a0\n\u00a0\nPara\u00a0determinar \u00a0los\u00a0efectos\u00a0de\u00a0SP\u00a0en\u00a0la\u00a0actividad\u00a0\nde\u00a0HER2\u00a0en\u00a0tumores\u00a0primarios \u00a0humanos \u00a0se\u00a0\nestablecieron \u00a0cultivos\u00a0a\u00a0corto\u00a0plazo.\u00a0Para\u00a0\nestablecer \u00a0cultivos\u00a0primarios \u00a0a\u00a0corto\u00a0plazo\u00a0se\u00a0\ndescongelaron \u00a0las\u00a0c\u00e9lulas\u00a0tumorales, \u00a0se\u00a0filtraron\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0una\u00a0malla\u00a0de\u00a0250\u00a0micras,\u00a0y\u00a0se\u00a0\nmantuvieron \u00a0en\u00a0medio\u00a0basal\u00a0de\u00a0epitelio\u00a0mamario\u00a0\n(MEBM\u00ae, \u00a0Lonza)\u00a0suplementado \u00a0con\u00a0extracto\u00a0de\u00a0\npituitaria\u00a0bovina,\u00a0hidrocortisona, \u00a0rhEGF,\u00a0insulina,\u00a0\ngentamicina/anfotericina \u00a0B\u00a0(MEGM\u00a0BulletKit,\u00a0\nLonza,\u00a0Cat#\u00a0CC\u20103150)\u00a0y\u00a010%\u00a0de\u00a0SFB\u00a0durante\u00a03\u00a0\nhoras\u00a0a\u00a037\u00b0C\u00a0para\u00a0permitir\u00a0as\u00ed\u00a0la\u00a0recuperaci\u00f3n \u00a0\nmetab\u00f3lica \u00a0de\u00a0las\u00a0c\u00e9lulas.\u00a0Pasado\u00a0este\u00a0tiempo\u00a0de\u00a0\nrecuperaci\u00f3n \u00a0se\u00a0deprivaron \u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0SBF\u00a0\ndurante\u00a02\u00a0horas,\u00a0y\u00a0se\u00a0dividieron \u00a0en\u00a03\u00a0grupos\u00a0\nexperimentales: \u00a0control,\u00a0tratamiento \u00a0con\u00a0SP\u00a0\ndurante\u00a06\u00a0min\u00a0y\u00a0tratamiento \u00a0con\u00a0SP\u00a0durante\u00a010\u00a0\nmin\u00a0(para\u00a0ver\u00a0una\u00a0representaci\u00f3n \u00a0gr\u00e1fica\u00a0del\u00a0\nprocedimiento \u00a0ver\u00a0fig.\u00a07\u00a0del\u00a0apartado\u00a0de\u00a0\nresultados). \u00a0Posteriormente \u00a0se\u00a0trataron\u00a0las\u00a0c\u00e9lulas\u00a0\ncon\u00a0PBS\u00a0o\u00a0SP\u00a0a\u00a037\u00b0C\u00a0durante\u00a0los\u00a0tiempos\u00a0\nindicados, \u00a0se\u00a0lavaron\u00a0con\u00a0PBS\u00a0fr\u00edo,\u00a0se\u00a0fijaron\u00a0con\u00a0\nparaformaldeh\u00eddo \u00a0al\u00a04%\u00a0(PFA\u00a04%)\u00a0durante\u00a010\u00a0min\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n96\u00a0\n\u00a0a\u00a0TA\u00a0y\u00a0se\u00a0resuspendieron \u00a0en\u00a0PBS\u00a0con\u00a0glicerol\u00a0al\u00a0\n10%\u00a0para\u00a0proporcionarles \u00a0algo\u00a0de\u00a0peso.\u00a0Estas\u00a0\nc\u00e9lulas\u00a0fueron\u00a0adheridas \u00a0a\u00a0un\u00a0portaobjetos \u00a0\nmediante \u00a0centrifugaci\u00f3n \u00a0con\u00a0citosp\u00edn\u00a0(Cytospin \u00a04,\u00a0\nThermo\u00a0Electron\u00a0Corporation) \u00a0durante\u00a010\u00a0min\u00a0a\u00a0\n1000.r.p.m, \u00a0y\u00a0se\u00a0almacenaron \u00a0a\u00a04\u00b0C\u00a0hasta\u00a0la\u00a0\nposterior\u00a0inmunodetecci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0HER2\u00a0\nfosforilada. \u00a0\n2.4.\u00a0Ensayos\u00a0de\u00a0viabilidad \u00a0celular\u00a0\n2.4.1.\u00a0Ensayo\u00a0de\u00a0MTT\u00a0\nPara\u00a0los\u00a0ensayos\u00a0de\u00a0viabilidad \u00a0celular,\u00a0las\u00a0c\u00e9lulas\u00a0\nse\u00a0sembraron \u00a0en\u00a0placas\u00a0de\u00a096\u00a0pocillos\u00a0a\u00a0una\u00a0\ndensidad\u00a0de\u00a010.000\u00a0c\u00e9lulas/pocillo \u00a0y\u00a0se\u00a0dejaron\u00a0en\u00a0\nel\u00a0incubador \u00a0durante\u00a0toda\u00a0la\u00a0noche.\u00a0Al\u00a0d\u00eda\u00a0\nsiguiente\u00a0se\u00a0trataron\u00a0las\u00a0diferentes \u00a0l\u00edneas\u00a0celulares\u00a0\ncon\u00a0el\u00a0inhibidor\u00a0del\u00a0receptor\u00a0NK\u20101R,\u00a0L\u2010733,060\u00a0(de\u00a0\n0\u00a0a\u00a040\u00a0\u03bcM),\u00a0Lapatinib \u00a0(de\u00a00\u00a0a\u00a010\u00a0\u03bcM),\u00a0AG825\u00a0(de\u00a00\u00a0\na\u00a060\u00a0\u03bcM)\u00a0o\u00a0AG1478\u00a0(de\u00a00\u00a0a\u00a0100\u00a0\u00b5M)\u00a0\nresuspendidos \u00a0en\u00a0medio\u00a0al\u00a05%\u00a0de\u00a0SFB.\u00a0Las\u00a0c\u00e9lulas\u00a0\nfueron\u00a0monitorizadas \u00a0diariamente \u00a0en\u00a0el\u00a0\nmicroscopio \u00a0y\u00a0su\u00a0viabilidad \u00a0celular\u00a0se\u00a0determin\u00f3 \u00a0\npasadas\u00a0las\u00a072\u00a0horas\u00a0con\u00a0un\u00a0kit\u00a0a\u00a0base\u00a0de\u00a0sal\u00a0de\u00a0\ntetrazolio \u00a0(96\u00a0Aqueous\u00a0One\u00a0Solution\u00a0Cell\u00a0\nProliferation \u00a0Assay\u00a0Kit\u00a0(MTS,\u00a0Promega)), \u00a0de\u00a0\nacuerdo\u00a0con\u00a0las\u00a0instrucciones \u00a0del\u00a0fabricante. \u00a0Este\u00a0\nkit\u00a0es\u00a0un\u00a0m\u00e9todo\u00a0colorim\u00e9trico \u00a0para\u00a0la\u00a0determinar \u00a0\nel\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0viables\u00a0en\u00a0los\u00a0ensayos\u00a0de\u00a0\nproliferaci\u00f3n \u00a0o\u00a0citotoxicidad \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nmedici\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0de\u00a0las\u00a0enzimas\u00a0\nmitocondriales. \u00a0A\u00a0trav\u00e9s\u00a0de\u00a0estas\u00a0enzimas\u00a0las\u00a0\nc\u00e9lulas\u00a0viables\u00a0reducen\u00a0la\u00a0sal\u00a0de\u00a0tetrazolio \u00a0o\u00a0\n(bromuro \u00a0de\u00a03\u2010(4,5\u2010Dimethylthiazol \u20102\u2010yl)\u20102,5\u2010\ndiphenyltetrazolio) \u00a0a\u00a0formaz\u00e1n. \u00a0El\u00a0formaz\u00e1n \u00a0\nadquiere\u00a0un\u00a0color\u00a0marr\u00f3n\u00a0intenso\u00a0que\u00a0se\u00a0puede\u00a0\nmedir\u00a0mediante \u00a0un\u00a0espectrofot\u00f3metro \u00a0de\u00a0placas.\u00a0\nEn\u00a0todos\u00a0los\u00a0casos,\u00a0la\u00a0dosis\u00a0correspondiente \u00a0de\u00a0\nDMSO,\u00a0disolvente \u00a0utilizado\u00a0para\u00a0algunos\u00a0de\u00a0los\u00a0\ninhibidores \u00a0(nunca\u00a0por\u00a0encima\u00a0de\u00a00,01%\u00a0v/v)\u00a0se\u00a0\na\u00f1adi\u00f3\u00a0a\u00a0los\u00a0puntos\u00a0de\u00a0control\u00a0(dosis\u00a00).\u00a0Los\u00a0\ncontroles \u00a0se\u00a0tomaron\u00a0como\u00a0referencia \u00a0del\u00a0100%\u00a0\nde\u00a0viabilidad \u00a0y\u00a0la\u00a0viabilidad \u00a0del\u00a0tratamiento \u00a0en\u00a0\ncada\u00a0punto\u00a0se\u00a0calcul\u00f3\u00a0en\u00a0relaci\u00f3n\u00a0a\u00a0los\u00a0controles \u00a0a\u00a0\npartir\u00a0de\u00a0la\u00a0f\u00f3rmula:\u00a0(Abs\u00a0490\u00a0nm\u00a0en\u00a0cada\u00a0dosis\u00a0/\u00a0Abs\u00a0490\u00a0nm\u00a0con\u00a0la\u00a0dosis\u00a00)\u00a0x\u00a0100.\u00a0Para\u00a0poder\u00a0llevar\u00a0\na\u00a0cabo\u00a0la\u00a0reacci\u00f3n\u00a0del\u00a0ensayo,\u00a0pasadas\u00a0las\u00a072\u00a0\nhoras\u00a0se\u00a0extrayeron \u00a080\u00a0\u00b5l\u00a0de\u00a0medio\u00a0de\u00a0cada\u00a0\npocillo,\u00a0se\u00a0a\u00f1adieron \u00a020\u00a0\u00b5l\u00a0de\u00a0MTS\u00a0y\u00a0se\u00a0\nmantuvieron \u00a0las\u00a0c\u00e9lulas\u00a0durante\u00a01\u00a0o\u00a02\u00a0horas\u00a0a\u00a037\u00b0C\u00a0\nen\u00a0el\u00a0incubador \u00a0hasta\u00a0su\u00a0posterior\u00a0lectura\u00a0en\u00a0el\u00a0\nespectrofot\u00f3metro \u00a0de\u00a0placas.\u00a0Se\u00a0hizo\u00a0una\u00a0lectura\u00a0\na\u00a0490\u00a0nm\u00a0(longitud\u00a0de\u00a0onda\u00a0de\u00a0ensayo)\u00a0y\u00a0se\u00a0le\u00a0\nrest\u00f3\u00a0la\u00a0realizada\u00a0a\u00a0690\u00a0nm\u00a0(referencia \u00a0de\u00a0longitud\u00a0\nde\u00a0onda\u00a0o\u00a0ruido\u00a0de\u00a0fondo).\u00a0Las\u00a0diferentes \u00a0dosis\u00a0\nfueron\u00a0evaluadas \u00a0en\u00a0sextuplicado \u00a0y\u00a0cada\u00a0\nexperimento \u00a0se\u00a0realiz\u00f3\u00a0al\u00a0menos\u00a0dos\u00a0veces.\u00a0\nLa\u00a0media\u00a0(el\u00a050%)\u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0inhibitoria \u00a0\nm\u00e1xima\u00a0(IC50),\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0ajuste\u00a0de\u00a0curvas\u00a0y\u00a0la\u00a0\nestad\u00edstica \u00a0se\u00a0realiz\u00f3\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0\nsuma\u00a0de\u00a0cuadrados \u00a0extra,\u00a0realizada\u00a0mediante \u00a0el\u00a0\nestad\u00edstico \u00a0F,\u00a0con\u00a0el\u00a0software\u00a0GraphPad \u00a0\nPrism \u00ae5.0.\u00a0Los\u00a0valores\u00a0con\u00a0una\u00a0P\u00a0<0,05\u00a0fueron\u00a0\nconsiderados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0Para\u00a0\ndeterminar \u00a0las\u00a0interacciones \u00a0aditivas,\u00a0sin\u00e9rgicas \u00a0o\u00a0\nantagonistas \u00a0de\u00a0los\u00a0tratamientos, \u00a0se\u00a0combinaron \u00a0\nensayos\u00a0est\u00e1ndar\u00a0de\u00a0MTT\u00a0para\u00a0cada\u00a0f\u00e1rmaco\u00a0con\u00a0\nla\u00a0IC50\u00a0de\u00a0un\u00a0segundo\u00a0f\u00e1rmaco.\u00a0El\u00a0efecto\u00a0de\u00a0la\u00a0\ninteracci\u00f3n \u00a0entre\u00a0los\u00a0tratamientos \u00a0se\u00a0calcularon \u00a0\nen\u00a0base\u00a0al\u00a0\u00edndice\u00a0de\u00a0combinaci\u00f3n \u00a0(IC)\u00a0del\u00a0m\u00e9todo\u00a0\ndescrito\u00a0por\u00a0Chou\u00a0y\u00a0Talalay484.\u00a0Los\u00a0valores\u00a0de\u00a0los\u00a0\ndistintos\u00a0\u00edndices\u00a0de\u00a0combinaci\u00f3n \u00a0se\u00a0calcularon \u00a0de\u00a0\nacuerdo\u00a0con\u00a0la\u00a0ecuaci\u00f3n\u00a01,\u00a0en\u00a0la\u00a0que\u00a0(D)1\u00a0y\u00a0(D)2\u00a0\nson\u00a0las\u00a0concentraciones \u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0\nf\u00e1rmacos \u00a0necesarias \u00a0para\u00a0obtener\u00a0un\u00a050%\u00a0de\u00a0\nsupervivencia; \u00a0(Dx)1\u00a0y\u00a0(Dx2)\u00a0son\u00a0las\u00a0\nconcentraciones \u00a0individuales \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0\nnecesarias \u00a0para\u00a0obtener\u00a0un\u00a050%\u00a0de\u00a0supervivencia. \u00a0\nLos\u00a0\u00edndices\u00a0de\u00a0combinaci\u00f3n \u00a0se\u00a0calcularon \u00a0\nbas\u00e1ndose \u00a0en\u00a0la\u00a0hip\u00f3tesis\u00a0conservadora \u00a0de\u00a0las\u00a0\ninteracciones \u00a0de\u00a0f\u00e1rmacos \u00a0no\u00a0mutualmente \u00a0\nexcluyentes. \u00a0\nCI \u0d4c\u123aD\u123b\u0b35\n\u123aD\u0beb\u123b\u0b35\u0d45\u123aD\u123b\u0b36\n\u123aD\u0beb\u123b\u0b36\u0d45\u123aD\u123b\u0b35\u123aD\u123b\u0b36\n\u123aD\u0beb\u123b\u0b35\u123aD\u0beb\u123b\u0b36\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0(Equaci\u00f3n\u00a01)\u00a0\nLas\u00a0interacciones \u00a0se\u00a0definen\u00a0como\u00a0se\u00a0describe\u00a0a\u00a0\ncontinuaci\u00f3n: \u00a0IC<1\u00a0significa\u00a0sinergismo, \u00a0IC=1\u00a0\nsignifica\u00a0aditividad, \u00a0y\u00a0IC>\u00a01\u00a0significa\u00a0antagonismo. \u00a0\n\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n97\u00a0\n\u00a02.4.2.\u00a0Tinci\u00f3n\u00a0con\u00a0anexina\u00a0V\u2010FITC\u00a0/\u00a0yoduro\u00a0de\u00a0\npropidio\u00a0y\u00a0DIOC 6(3).\u00a0\n\u00a0\nEn\u00a0esta\u00a0tesis\u00a0se\u00a0han\u00a0usado\u00a0diversas\u00a0t\u00e9cnicas\u00a0para\u00a0\nmedir\u00a0apotosis\u00a0celular.\u00a0\nEn\u00a0una\u00a0c\u00e9lula\u00a0viable\u00a0la\u00a0fosfatidil\u00a0serina\u00a0se\u00a0\nencuentra \u00a0en\u00a0la\u00a0parte\u00a0citos\u00f3lica \u00a0de\u00a0la\u00a0membrana \u00a0\nplasm\u00e1tica \u00a0y\u00a0durante\u00a0la\u00a0apoptosis \u00a0se\u00a0reorganizan \u00a0\nlos\u00a0fosfol\u00edpidos \u00a0de\u00a0la\u00a0membrana \u00a0y\u00a0los\u00a0residuos\u00a0de\u00a0\nfosfatidil\u00a0serina\u00a0quedan\u00a0expuestos \u00a0en\u00a0la\u00a0superficie \u00a0\nde\u00a0la\u00a0c\u00e9lula.\u00a0Esta\u00a0externalizaci\u00f3n \u00a0de\u00a0la\u00a0\nfosfatidilserina \u00a0puede\u00a0ser\u00a0detectada \u00a0por\u00a0\ncitometr\u00eda \u00a0de\u00a0flujo\u00a0gracias\u00a0al\u00a0anticuerpo \u00a0anexina\u00a0V\u00a0\nacoplado\u00a0a\u00a0fluoresce\u00edna \u00a0(FITC).\u00a0).\u00a0Para\u00a0diferenciar \u00a0\nuna\u00a0apoptosis \u00a0temprana \u00a0de\u00a0una\u00a0apoptosis \u00a0tard\u00eda\u00a0\ntambi\u00e9n\u00a0se\u00a0pueden\u00a0te\u00f1ir\u00a0las\u00a0c\u00e9lulas\u00a0con\u00a0yoduro\u00a0de\u00a0\npropidio\u00a0(un\u00a0colorante \u00a0vital\u00a0que\u00a0no\u00a0es\u00a0captado\u00a0por\u00a0\nc\u00e9lulas\u00a0viables\u00a0ya\u00a0que\u00a0se\u00a0une\u00a0al\u00a0ADN\u00a0cuando\u00a0la\u00a0\nc\u00e9lula\u00a0en\u00a0apoptosis \u00a0tard\u00eda\u00a0ha\u00a0formado\u00a0poros\u00a0en\u00a0\nsus\u00a0membranas). \u00a0La\u00a0tinci\u00f3n\u00a0con\u00a0anexina\u00a0V\u2010FITC\u00a0y\u00a0\nyoduro\u00a0de\u00a0propidio\u00a0se\u00a0llev\u00f3\u00a0a\u00a0cabo\u00a0con\u00a0un\u00a0kit\u00a0\ncomercial \u00a0(human\u00a0Annexin\u00a0V\u00a0Apoptosis \u00a0Detection \u00a0\nKit,\u00a0Bender\u00a0MedSystems). \u00a0Durante\u00a0las\u00a0primeras\u00a0\nfases\u00a0de\u00a0la\u00a0apoptosis \u00a0tambi\u00e9n\u00a0tiene\u00a0lugar\u00a0una\u00a0\ncaida\u00a0del\u00a0potencial \u00a0de\u00a0membrana \u00a0mitocondrial \u00a0\nque\u00a0se\u00a0puede\u00a0detectar\u00a0por\u00a0citometr\u00eda \u00a0de\u00a0flujo\u00a0\ndebido\u00a0la\u00a0perdida\u00a0de\u00a0marcaje\u00a0con\u00a0el\u00a0colorante \u00a0\nfluorescente \u00a0DIOC 6(3)\u00a0(Molecular \u00a0Probes\u2010\nInvitrogen, \u00a0Cat#D\u2010273).\u00a0Para\u00a0este\u00a0ensayo\u00a0se\u00a0\nsembraron \u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0a\u00a0estudiar\u00a0en\u00a0placas\u00a0\nde\u00a06\u00a0pocillos,\u00a0y\u00a0una\u00a0vez\u00a0alcanzada \u00a0la\u00a0confluencia \u00a0\ndeseada\u00a0se\u00a0deprivaron \u00a0las\u00a0c\u00e9lulas\u00a0al\u00a02%\u00a0de\u00a0SBF\u00a0\ndurante\u00a024\u00a0horas\u00a0y\u00a0se\u00a0trataron\u00a0durante\u00a072\u00a0horas\u00a0\nm\u00e1s\u00a0con\u00a0el\u00a0inhibidor\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0(L\u2010733,060\u00a0\na\u00a00,\u00a01,\u00a05,\u00a010\u00a0y\u00a020\u00a0\u00b5M)\u00a0o\u00a0con\u00a0anticuerpos \u00a0anti\u00a0SP\u00a0(SP\u00a0\nBioGenex \u00a0(AB1)\u00a0y\u00a0SP\u00a0AbDSerotec \u00a0(AB2),\u00a0ambos\u00a0a\u00a0\ndiluciones \u00a0de\u00a0trabajo\u00a0de\u00a01/100\u00a0y\u00a01/500)\u00a0seg\u00fan\u00a0el\u00a0\nexperimento \u00a0a\u00a0realizar.\u00a0Transcurrido \u00a0este\u00a0tiempo\u00a0\nse\u00a0recogi\u00f3\u00a0el\u00a0sobrenadante \u00a0(ya\u00a0que\u00a0contiene\u00a0\nc\u00e9lulas\u00a0en\u00a0apoptosis) \u00a0y\u00a0las\u00a0c\u00e9lulas\u00a0adheridas, \u00a0se\u00a0\ncentrifugaron \u00a0a\u00a01500\u00a0rpm\u00a0durante\u00a05\u00a0minutos\u00a0a\u00a04\u00b0C\u00a0\njunto\u00a0a\u00a0los\u00a0sobrenadantes \u00a0y\u00a0se\u00a0resuspendieron \u00a0en\u00a0\n400\u00a0\u00b5l\u00a0del\u00a0buffer\u00a0de\u00a0uni\u00f3n\u00a0para\u00a0la\u00a0anexina\u00a0V\u2010FITC\u00a0\ndurante\u00a015\u00a0minutos\u00a0a\u00a0TA\u00a0y\u00a0en\u00a0la\u00a0oscuridad \u00a0(2\u00a0\u00b5l\u00a0de\u00a0\nla\u00a0tinci\u00f3n\u00a0de\u00a0Anexina\u00a0por\u00a0muestra)\u00a0o\u00a020\u201030\u00a0min\u00a0a\u00a0una\u00a0concentraci\u00f3n \u00a0final\u00a0de\u00a020\u00a0nM\u00a0si\u00a0se\u00a0te\u00f1\u00eda\u00a0con\u00a0\nDIOC 6(3),\u00a0realizando \u00a0una\u00a0agitaci\u00f3n\u00a0suave\u00a0durante\u00a0\nlos\u00a0primeros\u00a05\u00a0minutos\u00a0de\u00a0incubaci\u00f3n. \u00a0A\u00a0\ncontinuaci\u00f3n, \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0lavaron\u00a0y\u00a0se\u00a0\nresuspendieron \u00a0en\u00a0yoduro\u00a0de\u00a0propidio\u00a0(1\u00a0\u00b5l\u00a0del\u00a0\nyoduro\u00a0de\u00a0propido\u00a0del\u00a0mismo\u00a0kit\u00a0comercial \u00a0por\u00a0\nmuestra)\u00a0y\u00a0se\u00a0incubaron \u00a0en\u00a0las\u00a0mismas\u00a0\ncondiciones \u00a0que\u00a0para\u00a0la\u00a0anexina\u00a0V\u2010FITC.\u00a0\nFinalmente \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0lavaron\u00a0y\u00a0resuspendieron \u00a0\nen\u00a0PBS\u00a0al\u00a02%\u00a0de\u00a0PFA.\u00a0Mediante \u00a0el\u00a0cit\u00f3metr\u00eda \u00a0de\u00a0\nflujo\u00a0(FACSCanto \u00a0II\u00a0de\u00a0Becton\u2010Dickinson, \u00a0NY)\u00a0se\u00a0\npudo\u00a0diferenciar \u00a0entre\u00a0c\u00e9lulas\u00a0viables\u00a0(negativas \u00a0\npara\u00a0anexina\u00a0V\u2010FITC\u00a0y\u00a0para\u00a0yoduro\u00a0de\u00a0propidio), \u00a0\nc\u00e9lulas\u00a0en\u00a0apoptosis \u00a0temprana \u00a0(positivas \u00a0para\u00a0\nanexina\u00a0V\u2010FITC\u00a0o\u00a0para\u00a0DIOC 6(3)\u00a0que\u00a0tambi\u00e9n\u00a0emite\u00a0\nfluorescencia \u00a0en\u00a0el\u00a0canal\u00a0verde),\u00a0c\u00e9lulas\u00a0en\u00a0\napoptosis \u00a0tard\u00eda\u00a0(positivas \u00a0para\u00a0anexina\u00a0V\u2010FITC\u00a0y\u00a0\npara\u00a0yoduro\u00a0de\u00a0propidio) \u00a0y\u00a0c\u00e9lulas\u00a0necr\u00f3ticas \u00a0\n(positivas \u00a0para\u00a0yoduro\u00a0de\u00a0propidio). \u00a0Se\u00a0analizaron \u00a0\n10.000\u00a0eventos\u00a0por\u00a0muestra\u00a0y\u00a0los\u00a0resultados \u00a0\nfueron\u00a0procesados \u00a0con\u00a0el\u00a0software\u00a0FACSDiva \u00a0\n(Becton\u2010Dickinson). \u00a0Como\u00a0la\u00a0anexina\u00a0V\u00a0y\u00a0el\u00a0DIOC\u00a0\nemitten\u00a0fluorescencia \u00a0en\u00a0rangos\u00a0parecidos \u00a0de\u00a0\nlongitud\u00a0de\u00a0onda\u00a0se\u00a0realizaron \u00a0los\u00a0experimentos \u00a0\npor\u00a0separado. \u00a0\n2.5.\u00a0Tratamiento \u00a0cr\u00f3nico\u00a0con\u00a0SP\u00a0en\u00a0l\u00edneas\u00a0\ncelulares\u00a0en\u00a0cultivo\u00a0\nPara\u00a0establecer \u00a0un\u00a0modelo\u00a0de\u00a0efecto\u00a0cr\u00f3nico\u00a0de\u00a0la\u00a0\nSP,\u00a0se\u00a0trataron\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010453,\u00a0\nMDA\u2010MB\u2010468,\u00a0MCF7,\u00a0con\u00a0SP\u00a0diariamente \u00a0durante\u00a0\n5\u00a0meses\u00a0a\u00a0una\u00a0concentraci\u00f3n \u00a0de\u00a0100\u00a0nM.\u00a0Durante\u00a0\nel\u00a0periodo\u00a0de\u00a0tratamiento \u00a0se\u00a0guardaron \u00a0algunas\u00a0\nmuestras \u00a0obtenidas \u00a0a\u00a0diferentes \u00a0tiempos\u00a0para\u00a0la\u00a0\nposterior\u00a0extracci\u00f3n \u00a0de\u00a0prote\u00edna\u00a0y\u00a0ARN\u00a0\n(concretamente \u00a0a\u00a0los\u00a02\u00a0meses\u00a0de\u00a0tratamiento). \u00a0A\u00a0\nlas\u00a0l\u00edneas\u00a0tratadas\u00a0continuamente \u00a0con\u00a0SP\u00a0se\u00a0les\u00a0\ndenomin\u00f3 \u00a0MDA\u2010MB\u2010453\u00a0SP,\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0y\u00a0\nMCF7\u00a0SP.\u00a0\n\u00a0\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n98\u00a0\n\u00a02.6.\u00a0Obtenci\u00f3n \u00a0de\u00a0una\u00a0l\u00ednea\u00a0estable\u00a0con\u00a0\nsobreexpresi\u00f3n \u00a0de\u00a0TACR1\u00a0\n2.6.1.\u00a0Vectores\u00a0y\u00a0construcciones \u00a0\u00a0\n\u00a0\nPara\u00a0la\u00a0creaci\u00f3n\u00a0de\u00a0una\u00a0l\u00ednea\u00a0estable\u00a0se\u00a0utilizaron \u00a0\nlos\u00a0vectores\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101R.\u00a0El\u00a0\npcDNA3.1(+) \u2010TACR1\u00a0se\u00a0obtuvo\u00a0del\u00a0Centro\u00a0de\u00a0\nRecursos\u00a0de\u00a0cDNA\u00a0de\u00a0la\u00a0Universidad \u00a0de\u00a0Missouri\u2010\nRolla,\u00a0y\u00a0el\u00a0vector\u00a0vac\u00edo\u00a0pcDNA3.1 \u00a0(+)\u00a0fue\u00a0generado \u00a0\npor\u00a0eliminaci\u00f3n \u00a0del\u00a0inserto\u00a0de\u00a0TACR1\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nlas\u00a0dianas\u00a0de\u00a0restricci\u00f3n \u00a0EcoRI\u00a0y\u00a0XhoI.\u00a0\n2.6.2.\u00a0Transformaci\u00f3n \u00a0mediante \u00a0choque\u00a0\nt\u00e9rmico\u00a0\n\u00a0\nEn\u00a0condiciones \u00a0est\u00e9riles\u00a0se\u00a0a\u00f1adi\u00f3\u00a0la\u00a0cantidad\u00a0\nnecesaria \u00a0de\u00a0ADN\u00a0(pcDNA3(+) \u00a0o\u00a0pcDNA3.1(+) \u2010\nTACR1 ),\u00a0a\u00a0una\u00a0concentraci\u00f3n \u00a0de\u00a01\u201010\u00a0ng\u00a0por\u00a0cada\u00a0\n50\u00a0\u00b5l\u00a0de\u00a0c\u00e9lulas\u00a0competentes \u00a0de\u00a0la\u00a0cepa\u00a0E.\u00a0coli\u00a0\nDH5\u03b1\u00a0(Invitrogen, \u00a0Cat#\u00a018265\u2010017).\u00a0El\u00a0choquen\u00a0\nt\u00e9rmico\u00a0se\u00a0realiz\u00f3\u00a0incubando \u00a0las\u00a0bacterias\u00a0a\u00a042\u00b0C\u00a0\ndurante\u00a02\u00a0min\u00a0en\u00a0un\u00a0ba\u00f1o\u00a0de\u00a0precisi\u00f3n, \u00a0para\u00a0abrir\u00a0\nporos\u00a0en\u00a0la\u00a0membrana \u00a0y\u00a0permitir\u00a0la\u00a0entrada\u00a0del\u00a0\nADN\u00a0plasm\u00eddico. \u00a0Pasado\u00a0este\u00a0tiempo\u00a0se\u00a0\nmantuvieronen \u00a0en\u00a0hielo\u00a0durante\u00a02\u00a0min\u00a0para\u00a0\npermitir\u00a0de\u00a0nuevo\u00a0el\u00a0cierre\u00a0de\u00a0los\u00a0poros\u00a0de\u00a0la\u00a0\nmembrana. \u00a0Se\u00a0le\u00a0a\u00f1adi\u00f3\u00a0950\u00a0\u03bcl\u00a0de\u00a0medio\u00a0Luria\u00a0\nBroth\u00a0LB\u00a0est\u00e9ril\u00a0\u00a0LB\u00a0(25g\u00a0en\u00a01\u00a0litro\u00a0de\u00a0agua\u00a0\ndestilada\u00a0esteril,\u00a0Sigma\u00a0Cat#\u00a0L3522)\u00a0sin\u00a0\nantibi\u00f3ticos \u00a0a\u00a037\u00b0C,\u00a0y\u00a0se\u00a0incubaron \u00a0las\u00a0c\u00e9lulas\u00a0a\u00a0\n37\u00b0C\u00a0y\u00a0en\u00a0agitaci\u00f3n\u00a0a\u00a0180\u00a0r.p.m\u00a0durante\u00a01\u00a0hora.\u00a0\nUna\u00a0vez\u00a0permitido \u00a0un\u00a0leve\u00a0crecimiento \u00a0bacteriano, \u00a0\n100\u00a0\u00b5l\u00a0del\u00a0cultivo\u00a0se\u00a0sembraron \u00a0en\u00a0una\u00a0placa\u00a0con\u00a0\nLB\u2010agar\u00a0(40g\u00a0en\u00a01\u00a0litro\u00a0de\u00a0agua\u00a0destilada\u00a0esteril,\u00a0\nSigma\u00a0Cat#\u00a0L3147)\u00a0mas\u00a0Ampicilina \u00a0(100\u00a0\u00b5g/ml)\u00a0y\u00a0\nlos\u00a0900\u00a0\u00b5l\u00a0restantes \u00a0se\u00a0centrifugaron, \u00a0se\u00a0\nresuspendieron \u00a0en\u00a0100\u00a0\u00b5l\u00a0de\u00a0LB\u00a0y\u00a0se\u00a0sembraron \u00a0en\u00a0\notra\u00a0placa\u00a0de\u00a0las\u00a0mismas\u00a0caracter\u00edsticas. \u00a0\n2.6.3.\u00a0Amplificaci\u00f3n \u00a0de\u00a0vectores\u00a0y\u00a0\nconservaci\u00f3n \u00a0\n\u00a0\nUna\u00a0vez\u00a0obtenidas \u00a0las\u00a0construcciones \u00a0de\u00a0inter\u00e9s\u00a0es\u00a0\nnecesario \u00a0amplificarlas \u00a0y\u00a0conservarlas. \u00a0Siempre\u00a0en\u00a0condiciones \u00a0de\u00a0esterilidad. \u00a0Para\u00a0ello\u00a0se\u00a0pic\u00f3\u00a0una\u00a0\ncolonia\u00a0individual \u00a0procedente \u00a0de\u00a0la\u00a0placa\u00a0de\u00a0agar\u00a0\ncon\u00a0las\u00a0colonias\u00a0transformadas, \u00a0se\u00a0puso\u00a0en\u00a0\ncontacto\u00a0con\u00a0un\u00a0cultivo\u00a0de\u00a0pocos\u00a0mililitros\u00a0(de\u00a04\u00a0a\u00a0\n5\u00a0ml)\u00a0de\u00a0medio\u00a0LB\u00a0con\u00a0Ampicilina \u00a0y\u00a0se\u00a0incubaron \u00a0\ndurante\u00a0toda\u00a0la\u00a0noche\u00a0a\u00a037\u00b0C\u00a0en\u00a0agitaci\u00f3n\u00a0a\u00a0180\u00a0\nr.p.m.\u00a0A\u00a0partir\u00a0de\u00a0este\u00a0cultivo\u00a0se\u00a0pudo\u00a0conservar \u00a0la\u00a0\nconstrucci\u00f3n \u00a0realizando \u00a0un\u00a0criotubo\u00a0celular\u00a0o\u00a0\nrecuperando \u00a0el\u00a0ADN\u00a0del\u00a0pl\u00e1smido\u00a0con\u00a0la\u00a0ayuda\u00a0de\u00a0\nkits\u00a0comerciales \u00a0como\u00a0el\u00a0kit\u00a0QIAprep\u00a0Spin\u00a0\nMiniprep\u00a0(Quiagen) \u00a0siguiendo \u00a0las\u00a0instrucciones \u00a0del\u00a0\nfabricante. \u00a0\n2.6.4.\u00a0Criotubo\u00a0de\u00a0cultivo\u00a0celular\u00a0\n\u00a0\nEn\u00a0un\u00a0microtubo \u00a0est\u00e9ril\u00a0se\u00a0depositaron \u00a00,6\u00a0ml\u00a0de\u00a0\nla\u00a0suspensi\u00f3n \u00a0de\u00a0bacterias\u00a0y\u00a0se\u00a0le\u00a0a\u00f1adi\u00f3\u00a0400\u00a0\u00b5l\u00a0de\u00a0\nglicerol\u00a0autoclavado. \u00a0Se\u00a0homogeneiz\u00f3 \u00a0la\u00a0mezcla\u00a0\nr\u00e1pidamente \u00a0con\u00a0un\u00a0v\u00f3rtex\u00a0y\u00a0se\u00a0congel\u00f3\u00a0el\u00a0\ncriotubo\u00a0por\u00a0inmersi\u00f3n \u00a0en\u00a0nitr\u00f3geno \u00a0l\u00edquido\u00a0para\u00a0\nsu\u00a0posterior\u00a0conservaci\u00f3n \u00a0a\u00a0\u201080\u00b0C.\u00a0\n2.6.5.\u00a0 Transfecci\u00f3n \u00a0 de\u00a0 ADN\u00a0 por\u00a0\nelectroporaci\u00f3n \u00a0\n\u00a0\nLos\u00a0vectores\u00a0pcDNA3.1(+) \u2010TACR1\u00a0y\u00a0pcDNA3.1(+) \u00a0se\u00a0\ntransfectaron \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010231\u00a0con\u00a0\nel\u00a0electroporador \u00a0Amaxa\u00a9\u00a0nucleofector \u00a0(Amaxa,\u00a0\nColonia,\u00a0Alemania). \u00a0A\u00a0una\u00a0suspensi\u00f3n \u00a0de\u00a0de\u00a02x106\u00a0\nc\u00e9lulas\u00a0de\u00a0MDA\u2010MB\u2010231,\u00a0se\u00a0le\u00a0a\u00f1adi\u00f3\u00a0una\u00a0soluci\u00f3n\u00a0\ncompuesta \u00a0por\u00a0100\u00a0ml\u00a0de\u00a0soluci\u00f3n\u00a0nucleofector \u00a0V\u00a0\n(Amaxa)\u00a0m\u00e1s\u00a05\u00a0\u00b5g\u00a0del\u00a0ADN\u00a0(en\u00a0nuestro\u00a0caso\u00a0de\u00a0los\u00a0\nvectores\u00a0pcDNA3.1 \u00a0(+)\u00a0o\u00a0pcDNA3.1(+) \u2010TACR1 ).\u00a0El\u00a0\npulso\u00a0el\u00e9ctrico\u00a0para\u00a0transfectar \u00a0el\u00a0ADN\u00a0se\u00a0realiz\u00f3\u00a0\nutilizando \u00a0el\u00a0programa \u00a0de\u00a0Amaxa\u00a0nucleofector \u00a0X\u2010\n13.\u00a0La\u00a0separaci\u00f3n \u00a0de\u00a0los\u00a0clones\u00a0positivos\u00a0se\u00a0realiz\u00f3\u00a0\npor\u00a0selecci\u00f3n\u00a0mediante \u00a0antibi\u00f3ticos \u00a0con\u00a0G418\u00a0\n(Invitrogen, \u00a0CA)\u00a0(1200\u00a0\u00b5g/ml)\u00a0durante\u00a0al\u00a0menos\u00a02\u00a0\nsemanas. \u00a0Adem\u00e1s\u00a0se\u00a0realiz\u00f3\u00a0un\u00a0enriquecimiento \u00a0\ncelular\u00a0adicional\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0positivas\u00a0para\u00a0el\u00a0\nreceptor\u00a0NK\u20101R\u00a0mediante \u00a0separaci\u00f3n \u00a0celular\u00a0de\u00a0\ncitometr\u00eda \u00a0de\u00a0flujo\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0fluorescencia \u00a0\ny\u00a0tama\u00f1o.\u00a0\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n99\u00a0\n\u00a02.7.\u00a0Inhibici\u00f3n \u00a0del\u00a0gen\u00a0TACR1\u00a0mediante \u00a0\nARN\u00a0peque\u00f1o\u00a0de\u00a0interferencia \u00a0(siRNA)\u00a0\n\u00a0\nLa\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0se\u00a0llev\u00f3\u00a0a\u00a0\ncabo\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0tecnolog\u00eda \u00a0de\u00a0ARN\u00a0de\u00a0\ninterferencia \u00a0(Invitrogen), \u00a0que\u00a0se\u00a0basa\u00a0en\u00a0tres\u00a0\noligonucle\u00f3tidos \u00a0modificados \u00a0qu\u00edmicamente \u00a0\ncontra\u00a0tres\u00a0regiones\u00a0distintas\u00a0del\u00a0gen\u00a0diana\u00a0que\u00a0\nqueremos \u00a0silenciar\u00a0(siRNAs\u00a0para\u00a0TACR1:\u00a0\nHSS110437, \u00a0HSS110438 \u00a0y\u00a0HSS110439). \u00a0En\u00a0primer\u00a0\nlugar,\u00a0se\u00a0obtuvieron \u00a0las\u00a0condiciones \u00a0\u00f3ptimas\u00a0de\u00a0\nsilenciamiento \u00a0de\u00a0TACR1\u00a0en\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0\nmediante \u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0diferentes \u00a0\nconcentraciones \u00a0de\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a03\u00a0\noligonucle\u00f3tidos \u00a0por\u00a0separado \u00a0y\u00a0distintas\u00a0\nconcentraciones \u00a0de\u00a0lipofectamina \u00a0(Invitrogen). \u00a0Se\u00a0\ncomprob\u00f3 \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0mediante \u00a0Real\u2010\nTime\u00a0PCR\u00a0(Applied\u00a0Biosystems) \u00a0para\u00a0escoger\u00a0el\u00a0\nsiRNA\u00a0m\u00e1s\u00a0efectivo.\u00a0Una\u00a0vez\u00a0optimizadas \u00a0las\u00a0\ncondiciones \u00a0se\u00a0realiz\u00f3\u00a0el\u00a0silenciamiento \u00a0de\u00a0NK\u20101R\u00a0\nmediante \u00a0transfecci\u00f3n \u00a0reversa.\u00a0Por\u00a0un\u00a0lado\u00a0se\u00a0\nincubaron \u00a0durante\u00a020\u00a0min,\u00a07,5\u00a0\u00b5l\u00a0de\u00a0\nLipofectamina \u00a0RNAiMAX \u00a0y\u00a030\u00a0nm\u00a0(para\u00a0las\u00a0c\u00e9lulas\u00a0\nMDA\u2010MB\u2010453\u00a0y\u00a0BT474\u00a0l\u00edneas)\u00a0o\u00a040\u00a0nm\u00a0(para\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0SKBR3)\u00a0del\u00a0oligonucle\u00f3tido \u00a0escogido. \u00a0\nPasado\u00a0este\u00a0tiempo\u00a0se\u00a0a\u00f1adi\u00f3\u00a0esta\u00a0mezcla\u00a0a\u00a0la\u00a0\nsuspensi\u00f3n \u00a0celular\u00a0(5x105\u00a0c\u00e9lulas\u00a0para\u00a0las\u00a0l\u00edneas\u00a0\nMDA\u2010MB\u2010453\u00a0y\u00a0BT474\u00a0c\u00e9lulas,\u00a0y\u00a06x105\u00a0para\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0SKBR3)\u00a0y\u00a0se\u00a0sembraron \u00a0en\u00a0placas\u00a0de\u00a0\n60\u00a0mm\u00a0de\u00a0di\u00e1metro\u00a0para\u00a0posteriormente \u00a0poder\u00a0\nextraer\u00a0una\u00a0cantidad\u00a0suficiente \u00a0de\u00a0prote\u00edna.\u00a0Como\u00a0\ncontrol\u00a0negativo\u00a0de\u00a0transfecci\u00f3n \u00a0se\u00a0utiliz\u00f3\u00a0un\u00a0\ncontrol\u00a0negativo\u00a0universal\u00a0(Invitrogen, \u00a0Cat#\u00a046\u2010\n2001).\u00a0Despu\u00e9s\u00a0de\u00a096\u00a0horas\u00a0las\u00a0c\u00e9lulas\u00a0fueron\u00a0\nlavadas\u00a0con\u00a0PBS\u00a0fr\u00edo\u00a0y\u00a0se\u00a0mantuvieron \u00a0congeladas \u00a0\nhasta\u00a0su\u00a0extracci\u00f3n \u00a0de\u00a0prote\u00edna.\u00a0Cada\u00a0\nexperimento \u00a0se\u00a0evalu\u00f3\u00a0por\u00a0duplicado \u00a0y\u00a0se\u00a0repiti\u00f3\u00a0\nal\u00a0menos\u00a0dos\u00a0veces.\u00a0Las\u00a0diferencias \u00a0de\u00a0\ncuantificaci\u00f3n \u00a0de\u00a0prote\u00edna\u00a0obtenidas \u00a0por\u00a0western\u00a0\nblot\u00a0entre\u00a0los\u00a0grupos\u00a0control\u00a0y\u00a0grupo\u00a0silenciado \u00a0se\u00a0\nevaluaron \u00a0mediante \u00a0la\u00a0prueba\u00a0t\u00a0de\u00a0Student\u00a0(test\u00a0\nde\u00a0dos\u00a0colas).\u00a0Los\u00a0valores\u00a0con\u00a0una\u00a0P\u00a0<0,05\u00a0fueron\u00a0\nconsiderados \u00a0estad\u00edsticamente \u00a0significativos. \u00a02.8.\u00a0Inhibici\u00f3n \u00a0de\u00a0receptor\u00a0NK\u20101R\u00a0con\u00a0el\u00a0\nantagonista \u00a0L\u2010733,\u00a0060\u00a0\n\u00a0\nPara\u00a0inhibir\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0se\u00a0cultivaron \u00a0\nlas\u00a0c\u00e9lulas\u00a0hasta\u00a0obtener\u00a0un\u00a070%\u00a0de\u00a0confluencia, \u00a0\nse\u00a0deprivaron \u00a0de\u00a0SBF\u00a0durante\u00a05\u00a0horas\u00a0y\u00a0se\u00a0\ntrataron\u00a0durante\u00a024\u00a0horas\u00a0con\u00a0el\u00a0antagonista \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0L\u2010733,060\u00a0a\u00a0una\u00a0dosis\u00a0de\u00a020\u00a0\u00b5M\u00a0\npara\u00a0la\u00a0l\u00ednea\u00a0SKBR3,\u00a020\u00a0\u00b5M\u00a0para\u00a0las\u00a0BT\u2010474,\u00a0y\u00a030\u00a0\n\u00b5M\u00a0para\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453.\u00a0Despu\u00e9s\u00a0\ndel\u00a0tratamiento, \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0lavaron\u00a0dos\u00a0veces\u00a0\nen\u00a0PBS\u00a0fr\u00edo,\u00a0y\u00a0se\u00a0congelaron \u00a0r\u00e1pidamente \u00a0hasta\u00a0su\u00a0\nextracci\u00f3n \u00a0de\u00a0prote\u00edna.\u00a0Los\u00a0experimentos \u00a0con\u00a0\ncada\u00a0l\u00ednea\u00a0celular\u00a0se\u00a0repitieron \u00a0al\u00a0menos\u00a0tres\u00a0\nveces\u00a0para\u00a0asegurar\u00a0la\u00a0reproducibilidad \u00a0de\u00a0los\u00a0\ndatos\u00a0y\u00a0todos\u00a0los\u00a0datos\u00a0cuantitativos \u00a0se\u00a0generaron \u00a0\na\u00a0partir\u00a0de\u00a0tres\u00a0o\u00a0m\u00e1s\u00a0repeticiones. \u00a0El\u00a0nivel\u00a0de\u00a0\nsignificaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0\nprueba\u00a0de\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0que\u00a0evalu\u00f3\u00a0las\u00a0\ndiferencias \u00a0de\u00a0cuantificaci\u00f3n \u00a0de\u00a0prote\u00edna\u00a0\nobtenidas \u00a0por\u00a0western\u00a0blot\u00a0entre\u00a0los\u00a0grupos\u00a0\ncontrol\u00a0y\u00a0grupo\u00a0tratado.\u00a0Los\u00a0valores\u00a0con\u00a0una\u00a0P\u00a0\n<0,05\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0\nsignificativos. \u00a0\n2.9.\u00a0Inhibici\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0\n\u00a0\nPara\u00a0inhibir\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0las\u00a0\nprote\u00ednas \u00a0G,\u00a0se\u00a0cultivaron \u00a0las\u00a0c\u00e9lulas\u00a0hasta\u00a0\nobtener\u00a0un\u00a080%\u00a0de\u00a0confluencia \u00a0y\u00a0se\u00a0deprivaron \u00a0de\u00a0\nSBF\u00a0durante\u00a05\u00a0horas,\u00a0y\u00a0a\u00a0continuaci\u00f3n \u00a0se\u00a0trataron\u00a0\ncon\u00a0100\u00a0ng/ml,\u00a0300\u00a0ng/ml\u00a0o\u00a0500\u00a0ng/ml\u00a0de\u00a0toxina\u00a0\npert\u00fasica \u00a0(Sigma\u2010Aldrich,\u00a0Cat#\u00a0P7208)\u00a0durante\u00a072\u00a0\nhoras.\u00a0Despu\u00e9s\u00a0del\u00a0tratamiento, \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0\nlavaron\u00a0dos\u00a0veces\u00a0en\u00a0PBS\u00a0fr\u00edo,\u00a0y\u00a0se\u00a0congelaron \u00a0\nr\u00e1pidamente \u00a0hasta\u00a0su\u00a0extracci\u00f3n \u00a0de\u00a0prote\u00edna.\u00a0Los\u00a0\nexperimentos \u00a0con\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0se\u00a0repitieron \u00a0\nal\u00a0menos\u00a0dos\u00a0veces\u00a0para\u00a0asegurar\u00a0la\u00a0\nreproducibilidad \u00a0de\u00a0los\u00a0datos.\u00a0\n2.10.\u00a0Ensayos\u00a0clonog\u00e9nicos \u00a0\n\u00a0\nPara\u00a0el\u00a0ensayo\u00a0de\u00a0formaci\u00f3n \u00a0de\u00a0colonias,\u00a0se\u00a0\nsembraron \u00a0las\u00a0c\u00e9lulas\u00a0a\u00a0una\u00a0densidad\u00a0de\u00a0500\u00a0\nc\u00e9lulas/placa \u00a0en\u00a0placas\u00a0de\u00a060\u00a0mm\u00a0de\u00a0di\u00e1metro\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n100\u00a0\n\u00a0para\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0y\u00a0\n100\u00a0c\u00e9lulas\u00a0por\u00a0placa\u00a0para\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010453\u00a0\ny\u00a0MDA\u2010MB\u2010453\u00a0SP,\u00a0y\u00a0en\u00a0todas\u00a0ellas\u00a0se\u00a0mantuvo\u00a0el\u00a0\ncrecimiento \u00a0de\u00a0las\u00a0colonias\u00a0durante\u00a028\u00a0d\u00edas.\u00a0El\u00a0\nmedio\u00a0se\u00a0cambi\u00f3\u00a0dos\u00a0veces\u00a0por\u00a0semana.\u00a0En\u00a0el\u00a0caso\u00a0\nde\u00a0las\u00a0l\u00edneas\u00a0MCF7\u00a0y\u00a0MCF7\u00a0SP,\u00a0se\u00a0sembraron \u00a0500\u00a0\nc\u00e9lulas\u00a0por\u00a0placa\u00a0y\u00a0se\u00a0establecieron \u00a02\u00a0grupos\u00a0\nexperimentales: \u00a0grupo\u00a0control\u00a0y\u00a0grupo\u00a0deprivado \u00a0\nde\u00a0hormonas \u00a0cultivado\u00a0con\u00a0medio\u00a0DMEM\u00a0sin\u00a0fenol\u00a0\nred,\u00a0(Gibco\u2010Invitrogen, \u00a0Cat#\u00a011880\u2010028)\u00a0\u00a010\u00a0\u00b5g/ml\u00a0\nde\u00a0insulina\u00a0y\u00a05%\u00a0de\u00a0SBF\u00a0deprivado \u00a0de\u00a0hormonas \u00a0\n(Charcoal\u00a0Stripped\u00a0FBS\u00a0de\u00a0Gibco\u2010Invitrogen) \u00a0(Cat#\u00a0\n12676\u2010011).\u00a0Despu\u00e9s\u00a0de\u00a03\u00a0o\u00a05\u00a0semanas\u00a0(seg\u00fan\u00a0el\u00a0\nexperimento), \u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0lavaron\u00a0con\u00a0PBS,\u00a0se\u00a0\nti\u00f1eron\u00a0con\u00a0cristal\u00a0violeta\u00a0(Sigma\u2010Aldrich,\u00a0Cat#\u00a0\nHT90132) \u00a0durante\u00a0al\u00a0menos\u00a05\u00a0min,\u00a0y\u00a0finalmente \u00a0se\u00a0\nlavaron\u00a0con\u00a0agua\u00a0destilada\u00a0hasta\u00a0la\u00a0eliminaci\u00f3n \u00a0\ndel\u00a0colorante \u00a0sobrante. \u00a0Las\u00a0placas\u00a0se\u00a0dejaron\u00a0\nsecar\u00a0a\u00a0TA\u00a0y\u00a0las\u00a0im\u00e1genes \u00a0representativas \u00a0se\u00a0\nobtuvieron \u00a0mediante \u00a0un\u00a0esc\u00e1ner\u00a0de\u00a0las\u00a0placas.\u00a0\nTodos\u00a0los\u00a0ensayos\u00a0clonog\u00e9nicos \u00a0con\u00a0las\u00a0diferentes \u00a0\nl\u00edneas\u00a0celulares\u00a0se\u00a0realizaron \u00a0por\u00a0triplicado. \u00a0\n3.\u00a0EXPERIMENTOS \u00a0IN\u00a0VIVO\u00a0\n\u00a0\nLos\u00a0experimentos \u00a0con\u00a0animales\u00a0se\u00a0realizaron \u00a0\nconforme \u00a0a\u00a0las\u00a0regulaciones \u00a0de\u00a0la\u00a0Comisi\u00f3n \u00a0\u00c9tica\u00a0\nde\u00a0nuestra\u00a0instituci\u00f3n: \u00a0 Comit\u00e9\u00e8\u00a0 \u00c8tic\u00a0\nd\u2019Experimentaci\u00f3 \u00a0animal\u00a0(CEEA),\u00a0siguiendo \u00a0las\u00a0\ndirectrices \u00a0establecidas \u00a0por\u00a0la\u00a0Generalitat \u00a0de\u00a0\nCatalu\u00f1a. \u00a0Los\u00a0ratones\u00a0fueron\u00a0criados\u00a0en\u00a0la\u00a0Unitat\u00a0\nd'Experimentaci\u00f3 \u00a0Animal\u00a0de\u00a0la\u00a0Facultat\u00a0de\u00a0\nMedicina\u00a0y/o\u00a0en\u00a0el\u00a0Servei\u00a0d\u2019Experimentaci\u00f3 \u00a0Animal\u00a0\n(SEA\u2010PCB)\u00a0del\u00a0Parc\u00a0Cient\u00edfic\u00a0Barcelona ,\u00a0y\u00a0se\u00a0\nmantuvieron \u00a0bajo\u00a0condiciones \u00a0espec\u00edficas \u00a0libres\u00a0\nde\u00a0pat\u00f3genos \u00a0a\u00a0una\u00a0TA\u00a0constante \u00a0(22\u201024\u00a0\u00baC)\u00a0y\u00a0una\u00a0\nhumedad \u00a0del\u00a0(30\u201050%).\u00a0Los\u00a0ratones\u00a0recibieron \u00a0\nalimentos \u00a0y\u00a0agua\u00a0del\u00a0grifo\u00a0esterilizados \u00a0ad\u00a0libitum.\u00a0\nDespu\u00e9s\u00a0de\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0cada\u00a0experimento, \u00a0\nlos\u00a0animales\u00a0fueron\u00a0anestesiados \u00a0y\u00a0sacrificados, \u00a0\nutilizando \u00a0los\u00a0m\u00e1s\u00a0altos\u00a0est\u00e1ndares \u00a0de\u00a0bienestar \u00a0\nanimal,\u00a0de\u00a0acuerdo\u00a0con\u00a0las\u00a0regulaciones \u00a0de\u00a0la\u00a0\nComisi\u00f3n \u00a0de\u00a0\u00c9tica\u00a0de\u00a0nuestra\u00a0instituci\u00f3n. \u00a0En\u00a0\ncualquier \u00a0caso\u00a0el\u00a0volumen\u00a0de\u00a0los\u00a0tumores\u00a0se\u00a0\ncalcularon \u00a0mediante \u00a0la\u00a0f\u00f3rmula:\u00a0Volumen\u00a0tumor\u00a0=\u00a0(largo\u00a0x\u00a0ancho2)\u00a0x\u00a0\u03c0\u00a0/\u00a06\u00a0y\u00a0el\u00a0peso\u00a0de\u00a0los\u00a0animales\u00a0y\u00a0\nel\u00a0crecimiento \u00a0tumoral\u00a0se\u00a0midieron\u00a0dos\u00a0veces\u00a0por\u00a0\nsemana\u00a0con\u00a0un\u00a0calibrador \u00a0o\u00a0pie\u00a0de\u00a0rey\u00a0digital\u00a0\ndurante\u00a0el\u00a0tiempo\u00a0que\u00a0dur\u00f3\u00a0el\u00a0experimento. \u00a0Los\u00a0\ntumores\u00a0fueron\u00a0recuperados \u00a0para\u00a0su\u00a0posterior\u00a0\nan\u00e1lisis,\u00a0se\u00a0fijaron\u00a0en\u00a0PFA\u00a0al\u00a04%\u00a0y\u00a0fueron\u00a0\nembebidos \u00a0en\u00a0parafina\u00a0siguiendo \u00a0procedimientos \u00a0\nest\u00e1ndares. \u00a0Los\u00a0cambios\u00a0de\u00a0volumen\u00a0tumoral\u00a0\nentre\u00a0los\u00a0grupos\u00a0se\u00a0analizaron \u00a0mediante \u00a0la\u00a0prueba\u00a0\nestad\u00edstica \u00a0de\u00a0Mann\u2010Whitney\u00a0(dos\u00a0colas).\u00a0Los\u00a0\nvalores\u00a0con\u00a0una\u00a0P\u00a0<0,05\u00a0fueron\u00a0considerados \u00a0\nestad\u00edsticamente \u00a0significativos. \u00a0\u00a0\n3.1.\u00a0Modelo\u00a0ortot\u00f3pico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0\nmama\u00a0y\u00a0administraci\u00f3n \u00a0de\u00a0SP\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nmini\u00a0bombas\u00a0osm\u00f3ticas \u00a0\nPara\u00a0este\u00a0in\u00a0vivo\u00a0se\u00a0utilizaron \u00a0ratones\u00a0hembra\u00a0de\u00a0\ncinco\u00a0semanas\u00a0de\u00a0edad,\u00a0CB17/IcrHarTM \u2010HSD\u2010\nPrkdcscid\u00a0(Harlan\u2010Europa).\u00a0Se\u00a0inocularon \u00a0por\u00a0\ninyecci\u00f3n \u00a0ortot\u00f3pica \u00a0en\u00a0el\u00a0tejido\u00a0graso\u00a0mamario\u00a0\nuna\u00a0mezcla\u00a0de\u00a01.6x106\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0l\u00ednea\u00a0de\u00a0CM\u00a0\nMDA\u2010MB\u2010231\u00a0en\u00a0PBS:Matrigel \u00a0(BD\u00a0Biosciences) \u00a0\n(ratio\u00a01:1)\u00a0en\u00a0un\u00a0volumen\u00a0total\u00a0de\u00a0100\u00a0\u00b5l.\u00a0Una\u00a0\nsemana\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0inoculaci\u00f3n, \u00a0cuando\u00a0los\u00a0\ntumores\u00a0eran\u00a0palpables, \u00a0se\u00a0implantaron \u00a0\nsubcut\u00e1neamente \u00a0en\u00a0el\u00a0\u00e1rea\u00a0inter\u2010escapular \u00a0de\u00a0\ncada\u00a0rat\u00f3n\u00a0mini\u2010bombas\u00a0osm\u00f3ticas \u00a0de\u00a0100\u00a0\u00b5l\u00a0de\u00a0\ncapacidad \u00a0(tasa\u00a0de\u00a0flujo\u00a0de\u00a00,11\u00a0\u00b5l/h,\u00a028\u00a0d\u00edas\u00a0de\u00a0\nbombeo)\u00a0(Modelo\u00a01004,\u00a0Alzet\u00a0Corp.,\u00a0Palo\u00a0Alto,\u00a0\nCA).\u00a0Las\u00a0bombas\u00a0osm\u00f3ticas \u00a0fueron\u00a0cargadas\u00a0para\u00a0\nsuministrar \u00a0PBS\u00a0(en\u00a0el\u00a0grupo\u00a0control)\u00a0o\u00a0500\u00a0nM\u00a0de\u00a0\nSP\u00a0(en\u00a0el\u00a0grupo\u00a0tratado)\u00a0al\u00a0d\u00eda.\u00a0La\u00a0herida\u00a0fue\u00a0\ncerrada\u00a0con\u00a0simples\u00a0suturas\u00a0quir\u00fargicas. \u00a0\u00a0\n3.2.\u00a0Modelo\u00a0ortot\u00f3pico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0\nmama\u00a0bajo\u00a0tratamiento \u00a0con\u00a0antagonistas \u00a0\n\u00a0\nPara\u00a0este\u00a0in\u00a0vivo\u00a0se\u00a0utilizaron \u00a0ratones\u00a0hembra\u00a0de\u00a0\ncinco\u00a0semanas\u00a0de\u00a0edad,\u00a0CB17/IcrHarTM \u2010HSD\u2010\nPrkdcscid\u00a0(Harlan\u2010Europa).\u00a0Se\u00a0inocularon \u00a0por\u00a0\ninyecci\u00f3n \u00a0ortot\u00f3pica \u00a0en\u00a0el\u00a0tejido\u00a0graso\u00a0mamario\u00a0\nuna\u00a0mezcla\u00a0de\u00a01.5x106\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0l\u00ednea\u00a0de\u00a0CM\u00a0\nMDA\u2010MB\u2010453\u00a0en\u00a0PBS:Matrigel \u00a0(BD\u00a0Biosciences) \u00a0\n(ratio\u00a01:1)\u00a0en\u00a0un\u00a0volumen\u00a0total\u00a0de\u00a0100\u00a0\u00b5l.\u00a0Cuando\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n101\u00a0\n\u00a0los\u00a0tumores\u00a0alcanzaron \u00a0un\u00a0volumen\u00a0promedio \u00a0de\u00a0\n100\u00a0mm3,\u00a0los\u00a0ratones\u00a0fueron\u00a0distribuidos \u00a0\nuniformemente \u00a0en\u00a0dos\u00a0grupos\u00a0en\u00a0base\u00a0al\u00a0tama\u00f1o\u00a0\ndel\u00a0tumor\u00a0(5\u00a0ratones\u00a0por\u00a0grupo).\u00a0Los\u00a0ratones\u00a0\nrecibieron \u00a0tres\u00a0veces\u00a0por\u00a0semana\u00a0una\u00a0inyecci\u00f3n \u00a0\nintraperitoneal \u00a0de\u00a0una\u00a0soluci\u00f3n\u00a0de\u00a0PBS\u00a0(grupo\u00a0\ncontrol)\u00a0o\u00a0del\u00a0antagonista \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0L\u2010\n733,060\u00a0(5\u00a0mg/Kg)\u00a0(grupo\u00a0inhibidor). \u00a0El\u00a0\ncrecimiento \u00a0tumoral\u00a0se\u00a0midi\u00f3\u00a0dos\u00a0veces\u00a0por\u00a0\nsemana,\u00a0como\u00a0se\u00a0ha\u00a0descrito\u00a0anteriormente, \u00a0\ndurante\u00a042\u00a0d\u00edas.\u00a0\u00a0\n3.3.\u00a0Modelo\u00a0experimental \u00a0ortot\u00f3pico \u00a0\nsing\u00e9nico \u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0en\u00a0ratones\u00a0\nKO\u00a0para\u00a0el\u00a0gen\u00a0TAC1\u00a0\nLos\u00a0ratones\u00a0de\u00a0la\u00a0cepa\u00a0B6.Cg\u2010Tac1tm1Bbm/J\u00a0\nhomocigotos \u00a0para\u00a0el\u00a0gen\u00a0TAC1tm1Bbm\u00a0(\u201cknock\u00a0out\u201d\u00a0\npara\u00a0el\u00a0gen\u00a0TAC1 )\u00a0se\u00a0obtuvieron \u00a0de\u00a0los\u00a0\nLaboratorios \u00a0Jackson.\u00a0Como\u00a0control\u00a0se\u00a0utilizaron \u00a0\nanimales\u00a0del\u00a0mismo\u00a0fondo\u00a0gen\u00e9tico\u00a0(C57BL/6J) \u00a0y\u00a0a\u00a0\nambos\u00a0grupos\u00a0se\u00a0les\u00a0inocularon \u00a0en\u00a0el\u00a0tejido\u00a0graso\u00a0\nmamario\u00a02x105\u00a0c\u00e9lulas/100 \u00a0\u00b5l\u00a0de\u00a0PBS,\u00a0de\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0sing\u00e9nica \u00a0de\u00a0CM\u00a0EO771.\u00a0\u00a0\n4.\u00a0ESTUDIO\u00a0DE\u00a0EXPRESI\u00d3N \u00a0\nG\u00c9NICA\u00a0\n4.1.\u00a0Extracci\u00f3n \u00a0y\u00a0cuantificaci\u00f3n \u00a0de\u00a0ARN\u00a0\nEl\u00a0ARN\u00a0total\u00a0fue\u00a0extra\u00eddo\u00a0por\u00a0un\u00a0sistema\u00a0de\u00a0\ncolumnas \u00a0(Quiagen\u00a0extraction \u00a0kit\u00a0RNA)\u00a0seg\u00fan\u00a0las\u00a0\ninstrucciones \u00a0del\u00a0fabricante. \u00a0Se\u00a0utiliz\u00f3\u00a01\u00a0\u00b5g\u00a0de\u00a0ARN\u00a0\npara\u00a0la\u00a0transcripci\u00f3n \u00a0reversa\u00a0usando\u00a0el\u00a0kit\u00a0High\u00a0\nCapacity\u00a0cADN\u00a0Reverse\u00a0Transcription \u00a0(Applied\u00a0\nBiosystems, \u00a0Foster\u00a0City,\u00a0CA)\u00a0de\u00a0acuerdo\u00a0con\u00a0las\u00a0\ninstrucciones \u00a0del\u00a0fabricante. \u00a0\n4.2.\u00a0PCR\u00a0quantitativa \u00a0a\u00a0tiempo\u00a0real.\u00a0\nPara\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0se\u00a0\nutilizaron \u00a0los\u00a0ensayos\u00a0compuestos \u00a0por\u00a0sondas\u00a06\u2010\nFAM\u00a0dye\u2010labeled\u00a0TaqMan\u00a0MGB\u00a0m\u00e1s\u00a0los\u00a0cebadores \u00a0\ncorrespondientes \u00a0no\u00a0marcados \u00a0de\u00a0Applied\u00a0\nBiosystems. \u00a0La\u00a0reacci\u00f3n\u00a0de\u00a0PCR\u00a0ten\u00eda\u00a0un\u00a0volumen\u00a0final\u00a0de\u00a010\u00a0\u00b5l\u00a0y\u00a0conten\u00eda\u00a00.5\u00a0\u00b5M\u00a0de\u00a0cada\u00a0ensayo\u00a0\n(Hs01017957_m1 \u00a0para\u00a0TACR1 ,\u00a0Hs00169052_m1 \u00a0\npara\u00a0TACR2 ,\u00a0Hs00357277_m1 \u00a0para\u00a0TACR3\u00a0\nHs01076092_m1 \u00a0para\u00a0EGFR,\u00a0Hs01001595 \u00a0para\u00a0\nERBB2 ,\u00a0Hs00176538_m1 \u00a0para\u00a0ERBB3\u00a0y\u00a0\nHs00171783_m1 \u00a0para\u00a0ERBB4m\u00a0Hs00944792_m1 \u00a0\npara\u00a0\u03b1 \u2010catenina ,\u00a0Hs001995591_m1 \u00a0para\u00a0Snail,\u00a0\nHs00169953_m1 \u00a0 para\u00a0 N\u2010Cadherina \u00a0 y\u00a0\nHs01023894_m1 \u00a0para\u00a0E\u2010Caherina), \u00a05\u00a0\u00b5l\u00a0de\u00a0master\u00a0\nmix\u00a0(TaqMAn \u00a0Universal \u00a0PCR\u00a0Master\u00a0Mix\u00a0(Applied\u00a0\nBiosystems), \u00a02.5\u00a0\u00b5l\u00a0de\u00a0cADN\u00a0y\u00a02\u00a0\u00b5l\u00a0de\u00a0H2O\u00a0DEPC\u00a0\nest\u00e9ril.\u00a0El\u00a0an\u00e1lisis\u00a0cuantitativo \u00a0de\u00a0PCR\u00a0se\u00a0realiz\u00f3\u00a0en\u00a0\nel\u00a0termociclador \u00a07900HT\u00a0Fast\u00a0Real\u2010Time\u00a0PCR\u00a0\nSystem\u00a0(Applied\u00a0Biosystems). \u00a0Los\u00a0niveles\u00a0de\u00a0\ntranscripci\u00f3n \u00a0se\u00a0normalizaron \u00a0a\u00a0partir\u00a0de\u00a0los\u00a0\nniveles\u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0beta\u2010actina\u00a0\n(Hs99999903_m1) \u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0como\u00a0control\u00a0\nend\u00f3geno. \u00a0Cada\u00a0muestra\u00a0se\u00a0analiz\u00f3\u00a0por\u00a0triplicado \u00a0\ny\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0todos\u00a0los\u00a0genes\u00a0\nfueron\u00a0calculados \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0obtenci\u00f3n \u00a0del\u00a0\nCycle\u00a0threshold \u00a0(Ct)\u00a0utilizando \u00a0el\u00a0m\u00e9todo\u00a0de\u00a0\n\u0394\u0394Ct485.\u00a0La\u00a0expresi\u00f3n \u00a0relativa\u00a0de\u00a0los\u00a0genes\u00a0de\u00a0cada\u00a0\nmuestra\u00a0fueron\u00a0descritos\u00a0como\u00a0\u201cfold\u00a0change\u00a0o\u00a0\n2\u0394\u0394Ct\u201d\u00a0(n\u00famero\u00a0de\u00a0veces\u00a0que\u00a0se\u00a0expresa\u00a0un\u00a0gen\u00a0\nrespecto\u00a0al\u00a0caso\u00a0control).\u00a0En\u00a0algunos\u00a0de\u00a0los\u00a0genes\u00a0\nestudiados \u00a0no\u00a0se\u00a0encontr\u00f3\u00a0expresi\u00f3n. \u00a0En\u00a0los\u00a0casos\u00a0\ncon\u00a0Ct>38\u00a0se\u00a0estableci\u00f3 \u00a0arbitrariamente \u00a0como\u00a0el\u00a0\nnivel\u00a0m\u00ednimo\u00a0de\u00a0expresi\u00f3n \u00a0detectable \u00a0(Ct\u00a038).\u00a0Los\u00a0\ndatos\u00a0para\u00a0estos\u00a0genes\u00a0se\u00a0interpretaron \u00a0como\u00a0el\u00a0\nm\u00ednimo\u00a0fold\u00a0change\u00a0detectado. \u00a0\n4.3.\u00a0Estudio\u00a0diferencial \u00a0de\u00a0expresi\u00f3n \u00a0\ng\u00e9nica\u00a0mediante \u00a0microarrays \u00a0\n\u00a0\nEl\u00a0ARN\u00a0obtenido\u00a0de\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010\nMB\u2010453,\u00a0MDA\u2010MB\u2010453\u00a0SP,\u00a0MDA\u2010MB\u2010468,\u00a0MDA\u2010\nMB\u2010468\u00a0SP\u00a0se\u00a0hibrid\u00f3\u00a0con\u00a0el\u00a0biochip\u00a0de\u00a0\noligonucle\u00f3tidos \u00a0Human\u00a0Genome\u00a0U133\u00a0Plus\u00a02.0\u00a0\n(Affymetrix, \u00a0USA),\u00a0que\u00a0ofrece\u00a0un\u00a0an\u00e1lisis\u00a0\nexhaustivo \u00a0de\u00a0todo\u00a0el\u00a0genoma\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0\nuna\u00a0\u00fanica\u00a0matriz.\u00a0Analiza\u00a0el\u00a0nivel\u00a0de\u00a0expresi\u00f3n \u00a0\nrelativa\u00a0de\u00a0m\u00e1s\u00a0de\u00a047.000\u00a0tr\u00e1nscritos \u00a0y\u00a0sus\u00a0\nvariantes, \u00a0incluyendo \u00a0m\u00e1s\u00a0de\u00a038.500\u00a0genes\u00a0y\u00a0uni\u2010\ngenes\u00a0bien\u00a0caracterizados. \u00a0Est\u00e1\u00a0compuesto \u00a0por\u00a0\nm\u00e1s\u00a0de\u00a054.000\u00a0sondas\u00a0de\u00a0uni\u00f3n\u00a0al\u00a0ARN\u00a0y\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n102\u00a0\n\u00a01.300.000 \u00a0caracter\u00edsiticas \u00a0de\u00a0oligonucle\u00f3tidos \u00a0\ndiferentes. \u00a0Mediante \u00a0los\u00a0pasos\u00a0siguientes, \u00a0\nrealizados \u00a0\u00edntegramente \u00a0por\u00a0el\u00a0Broad\u00a0Institute\u00a0of\u00a0\nMIT\u00a0and\u00a0Harvard\u00a0Universitiy \u00a0(Cambridge, \u00a0\nMassachusetts), \u00a0se\u00a0pudo\u00a0llevar\u00a0a\u00a0cabo\u00a0la\u00a0\nhibridaci\u00f3n \u00a0de\u00a0nuestras\u00a0muestras \u00a0con\u00a0el\u00a0biochip:\u00a0\n\u2010\u00a0Extracci\u00f3n \u00a0del\u00a0ARN\u00a0total.\u00a0\n\u2010\u00a0Purificaci\u00f3n \u00a0del\u00a0ARN.\u00a0\n\u2010\u00a0Medida\u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0y\u00a0calidad\u00a0del\u00a0ARN.\u00a0\n\u2010\u00a0S\u00edntesis\u00a0de\u00a0ADNc\u00a0a\u00a0partir\u00a0del\u00a0ARN\u00a0total.\u00a0\u00a0\n\u2010\u00a0S\u00edntesis\u00a0del\u00a0ARNc\u00a0marcado\u00a0con\u00a0un\u00a0fluorocromo \u00a0\ncon\u00a0su\u00a0posterior\u00a0purificaci\u00f3n \u00a0y\u00a0fragmentaci\u00f3n. \u00a0\n\u2010\u00a0Hibridaci\u00f3n, \u00a0tinci\u00f3n\u00a0y\u00a0lavado\u00a0del\u00a0Human\u00a0Genome\u00a0\nU133\u00a0Plus\u00a02.0\u00a0array.\u00a0\n\u2010\u00a0Scaner\u00a0de\u00a0las\u00a0intensidades \u00a0absolutas \u00a0de\u00a0cada\u00a0\nsonda.\u00a0\n\u2010\u00a0Selecci\u00f3n \u00a0de\u00a0las\u00a0sondas\u00a0con\u00a0se\u00f1ales\u00a0de\u00a0\nhibridaci\u00f3n \u00a0correctas. \u00a0\n4.3.1\u00a0Normalizaci\u00f3n \u00a0\n\u00a0\nLos\u00a0valores\u00a0crudos\u00a0de\u00a0expression \u00a0fueron\u00a0recogidos \u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0correcci\u00f3n \u00a0del\u00a0ruido\u00a0de\u00a0fondo\u00a0y\u00a0\nnormalizados \u00a0mediante \u00a0el\u00a0software\u00a0de\u00a0an\u00e1lisis\u00a0\nrobusto\u00a0de\u00a0micoarrays \u00a0(RMA,\u00a0del\u00a0ingl\u00e9s\u00a0robust\u00a0\nmultiarray \u00a0analysis )\u00a0que\u00a0se\u00a0encuentra \u00a0en\u00a0un\u00a0\npaquete\u00a0de\u00a0affy486\u00a0del\u00a0proyecto\u00a0Bioconductor487\u00a0\n(http://www.bioconductor.org). \u00a0La\u00a0normalizaci\u00f3n \u00a0\ny\u00a0el\u00a0filtrado\u00a0de\u00a0datos\u00a0para\u00a0seleccionar \u00a0aqu\u00e9llos\u00a0\nque\u00a0son\u00a0demostrativos \u00a0del\u00a0estudio\u00a0fueron\u00a0\nrealizados \u00a0en\u00a0la\u00a0plataforma \u00a0de\u00a0Bioinform\u00e1tica \u00a0del\u00a0\nIDIBAPS,\u00a0Barcelona. \u00a0\u00a0\n4.3.2\u00a0An\u00e1lisis\u00a0supervisados \u00a0\n\u00a0\nPara\u00a0verificar\u00a0la\u00a0existencia \u00a0de\u00a0diferencias \u00a0\nestad\u00edsticamente \u00a0significativas \u00a0entre\u00a0las\u00a0diferentes \u00a0\nl\u00edneas\u00a0celulares\u00a0se\u00a0hizo\u00a0una\u00a0exploraci\u00f3n \u00a0de\u00a0\nresultados \u00a0y\u00a0un\u00a0an\u00e1lisis\u00a0con\u00a0el\u00a0paquete\u00a0Rank\u00a0\nProd488\u00a0para\u00a0los\u00a0efectos\u00a0del\u00a0\u201ctratamiento \u00a0con\u00a0SP\u201d\u00a0\nsobre\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0l\u00edneas.\u00a0Se\u00a0decidi\u00f3\u00a0hacer\u00a0un\u00a0\nan\u00e1lisis\u00a0no\u00a0apareado \u00a0tomando\u00a0en\u00a0cuenta\u00a0el\u00a0\ndise\u00f1o,\u00a0y\u00a0el\u00a0ajuste\u00a0con\u00a0resultados \u00a0previos\u00a0de\u00a0\nrelevancia \u00a0biol\u00f3gica. \u00a0El\u00a0software\u00a0RankProd \u00a0se\u00a0trata\u00a0de\u00a0un\u00a0simple\u00a0m\u00e9todo\u00a0estad\u00edstico \u00a0no\u00a0param\u00e9trico \u00a0\nbasado\u00a0en\u00a0los\u00a0rangos\u00a0de\u00a0nivel\u00a0de\u00a0cambio\u00a0o\u00a0\u201cfold\u00a0\nchange \u201d\u00a0en\u00a0ingl\u00e9s\u00a0.\u00a0Este\u00a0programa \u00a0se\u00a0ejecuta\u00a0en\u00a0el\u00a0\nlenguaje\u00a0de\u00a0programaci\u00f3n \u00a0estad\u00edstica \u00a0R\u00a0\n(http://www.r \u2010project.org) \u00a0como\u00a0un\u00a0paquete\u00a0del\u00a0\nproyecto\u00a0Bioconductor: \u00a0\u00a0\n(http://www.bioconductor.org). \u00a0\u00a0\nLos\u00a0an\u00e1lisis\u00a0de\u00a0expresiones \u00a0diferenciales \u00a0fueron\u00a0\nllevados\u00a0a\u00a0cabo\u00a0mediante \u00a0este\u00a0m\u00e9todo\u00a0y\u00a0se\u00a0\nobtuvieron \u00a0los\u00a0estimados \u00a0log 2\u00a0ratios\u00a0para\u00a0cada\u00a0\ncomparaci\u00f3n \u00a0de\u00a0inter\u00e9s,\u00a0de\u00a0acuerdo\u00a0con\u00a0una\u00a0p\u00a0\nvalor\u00a0ajustada\u00a0menor\u00a0que\u00a0el\u00a00.1\u00a0(q\u00a0<0.1).\u00a0Se\u00a0le\u00a0dio\u00a0\nuna\u00a0especial\u00a0atenci\u00f3n\u00a0a\u00a0aquellos\u00a0genes\u00a0que\u00a0\nmostraban \u00a0mayores\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0(log 2\u00a0\nratio\u00a0>1.2).\u00a0\u00a0\n4.3.3\u00a0An\u00e1lisis\u00a0no\u00a0supervisados \u00a0\n\u00a0\nPara\u00a0los\u00a0an\u00e1lisis\u00a0no\u00a0supervisados \u00a0se\u00a0utiliz\u00f3\u00a0el\u00a0\nalgoritmo \u00a0requerido \u00a0para\u00a0el\u00a0agrupamiento \u00a0\njer\u00e1rquico \u00a0o\u00a0Hierarchical \u00a0clustering \u00a0en\u00a0ingl\u00e9s,\u00a0para\u00a0\nla\u00a0agrupaci\u00f3n \u00a0de\u00a0genes\u00a0que\u00a0se\u00a0aplic\u00f3\u00a0con\u00a0dos\u00a0\nprogramas \u00a0distintos: \u00a0\n\u2010\u00a0Cluster\u00a0&\u00a0TreeView. \u00a0Este\u00a0programa \u00a0es\u00a0de\u00a0acceso\u00a0\nlibre\u00a0y\u00a0se\u00a0obtiene\u00a0en\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0p\u00e1gina\u00a0web:\u00a0\nhttp://rana.lbl.gov/EisenSoftware.htm. \u00a0 Para\u00a0\naplicarlo\u00a0se\u00a0parti\u00f3\u00a0del\u00a0fichero\u00a0generado \u00a0tras\u00a0el\u00a0\nan\u00e1lisis\u00a0supervisado, \u00a0en\u00a0el\u00a0programa \u00a0cluster\u00a03.0,\u00a0se\u00a0\ncarg\u00f3\u00a0el\u00a0archivo\u00a0guardado \u00a0y\u00a0se\u00a0seleccion\u00f3 \u00a0la\u00a0\npesta\u00f1a\u00a0\u201cHierarchical \u00a0clustering\u201d. \u00a0El\u00a0programa \u00a0\ngener\u00f3\u00a0un\u00a0archivo\u00a0de\u00a0salida\u00a0con\u00a0extensi\u00f3n \u00a0.cdt\u00a0\nque\u00a0posteriormente \u00a0fue\u00a0abierto\u00a0con\u00a0la\u00a0aplicaci\u00f3n \u00a0\n\u201cTreeview\u201d \u00a0para\u00a0poder\u00a0visualizarlo. \u00a0\n\u2010\u00a0Mev4.8,\u00a0Multiexperiment \u00a0viewer:\u00a0Este\u00a0programa \u00a0\ntambi\u00e9n\u00a0es\u00a0de\u00a0acceso\u00a0libre\u00a0y\u00a0se\u00a0obtiene\u00a0a\u00a0partir\u00a0de\u00a0\nla\u00a0p\u00e1gina\u00a0web:\u00a0http://www.tm4.org/mev/. \u00a0En\u00a0este\u00a0\nprograma \u00a0se\u00a0pueden\u00a0cargar\u00a0directamente \u00a0los\u00a0\nvalores\u00a0de\u00a0expresi\u00f3n \u00a0para\u00a0poder\u00a0visualizarlos. \u00a0\n4.3.4\u00a0An\u00e1lisis\u00a0de\u00a0rutas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\n\u00a0\nA\u00a0partir\u00a0de\u00a0la\u00a0lista\u00a0obtenida\u00a0de\u00a0genes\u00a0\ndiferencialmente \u00a0expresados, \u00a0podemos \u00a0hacer\u00a0un\u00a0\nan\u00e1lisis\u00a0funcional \u00a0para\u00a0identificar \u00a0los\u00a0mecanismos \u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n103\u00a0\n\u00a0biol\u00f3gicos, \u00a0las\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0y\u00a0las\u00a0categor\u00edas \u00a0\nfuncionales \u00a0de\u00a0los\u00a0genes\u00a0gracias\u00a0a\u00a0un\u00a0software\u00a0de\u00a0\nlicencia\u00a0no\u00a0gratuita,\u00a0el\u00a0Ingenuity \u00a0Pathways \u00a0\nAnalysis\u00a0(IPA)\u00a0(Ingenuity \u00a0Systems,\u00a0Mountain \u00a0View,\u00a0\nCA,\u00a0USA),\u00a0accesible\u00a0en\u00a0formato\u00a0de\u00a0prueba\u00a0en\u00a0la\u00a0\ndirecci\u00f3n\u00a0www.ingenuity.com .\u00a0El\u00a0software\u00a0IPA\u00a0\npermite\u00a0integrar\u00a0informaci\u00f3n \u00a0sobre\u00a0el\u00a0\nconocimiento \u00a0biol\u00f3gico\u00a0y\u00a0qu\u00edmico\u00a0en\u00a0las\u00a0\nrelaciones \u00a0entre\u00a0prote\u00ednas, \u00a0genes,\u00a0metabolitos, \u00a0\ncomplejos \u00a0proteicos, \u00a0c\u00e9lulas,\u00a0\u00f3rganos,\u00a0peque\u00f1as \u00a0\nmol\u00e9culas, \u00a0fenotipos \u00a0celulares, \u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0o\u00a0rutas\u00a0metab\u00f3licas \u00a0y\u00a0procesos\u00a0de\u00a0\nalgunas\u00a0enfermedades. \u00a0En\u00a0nuestro\u00a0caso\u00a0este\u00a0\nprograma \u00a0nos\u00a0permiti\u00f3\u00a0realizar\u00a0un\u00a0an\u00e1lisis\u00a0\nfuncional \u00a0de\u00a0los\u00a0grupos\u00a0de\u00a0genes\u00a0que\u00a0manten\u00edan \u00a0\nuna\u00a0relaci\u00f3n\u00a0entre\u00a0ellos\u00a0(ya\u00a0que\u00a0se\u00a0seleccionan \u00a0\nmediante \u00a0un\u00a0an\u00e1lisis\u00a0estad\u00edstico \u00a0del\u00a0programa), \u00a0un\u00a0\nan\u00e1lisis\u00a0de\u00a0las\u00a0distintas\u00a0rutas\u00a0metab\u00f3licas \u00a0\u00a0en\u00a0las\u00a0\nque\u00a0estos\u00a0genes\u00a0tienen\u00a0una\u00a0importane \u00a0relevancia, \u00a0\ny\u00a0sus\u00a0principales \u00a0mecanismos \u00a0biol\u00f3gicos. \u00a0Adem\u00e1s\u00a0\nel\u00a0programa \u00a0relaciona\u00a0los\u00a0genes\u00a0introducidos \u00a0en\u00a0\n\u00e9l,\u00a0de\u00a0forma\u00a0que\u00a0los\u00a0sit\u00faa\u00a0en\u00a0redes\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\ninterconectadas \u00a0entre\u00a0ellas,\u00a0dando\u00a0un\u00a0color\u00a0a\u00a0los\u00a0\ngenes\u00a0sobreexpresados \u00a0y\u00a0otro\u00a0a\u00a0los\u00a0poco\u00a0\nexpresados \u00a0(rojo\u00a0y\u00a0verde,\u00a0respectivamente). \u00a0\n5.\u00a0MEDICI\u00d3N \u00a0DE\u00a0PROTE\u00cdNA \u00a0\n5.1.\u00a0Western\u00a0blot\u00a0\n\u00a0\nLa\u00a0extracci\u00f3n \u00a0de\u00a0prote\u00edna\u00a0se\u00a0realiz\u00f3\u00a0\nmec\u00e1nicamente \u00a0en\u00a0hielo\u00a0y\u00a0en\u00a0tamp\u00f3n\u00a0RIPA\u00a0\n(RadioImmunoPrecipitationAssay) \u00a0(Tris\u2010HCl\u00a050\u00a0\nmM,\u00a0pH\u00a07.4;\u00a0NP\u201040\u00a01%;\u00a00,25%\u00a0Deoxicolato \u00a0de\u00a0\nsodio,\u00a00.25%;\u00a0NaCl\u00a0150\u00a0mM;\u00a0EDTA\u00a01\u00a0mM;\u00a0PMSF\u00a01\u00a0\nmM;\u00a0inhibidores \u00a0de\u00a0proteasas; \u00a0Ortovanadato \u00a0\n(Na3VO4) \u00a01\u00a0mM\u00a0y\u00a0NaF\u00a01\u00a0mM)\u00a0y\u00a0posteriormente \u00a0se\u00a0\nsonic\u00f3\u00a0el\u00a0lisado\u00a0celular\u00a0durante\u00a010\u00a0seg.\u00a0Despu\u00e9s\u00a0\nde\u00a0centrifugar \u00a0(13000\u00a0rpm\u00a0durante\u00a05\u00a0min),\u00a0para\u00a0\nobtener\u00a0el\u00a0SN,\u00a0se\u00a0determin\u00f3 \u00a0el\u00a0contenido \u00a0proteico\u00a0\nde\u00a0cada\u00a0muestra.\u00a0La\u00a0cuantificaci\u00f3n \u00a0se\u00a0realiz\u00f3\u00a0por\u00a0\nel\u00a0m\u00e9todo\u00a0de\u00a0Lowry\u00a0utilizando \u00a0un\u00a0kit\u00a0de\u00a0reactivos\u00a0\nProtein\u00a0Assay\u00a0de\u00a0Bio\u2010Rad.\u00a0Se\u00a0prepar\u00f3\u00a0la\u00a0misma\u00a0\ncantidad\u00a0de\u00a0prote\u00edna\u00a0para\u00a0cada\u00a0muestra\u00a0y\u00a0se\u00a0le\u00a0\na\u00f1adi\u00f3\u00a0tamp\u00f3n\u00a0de\u00a0carga\u00a01X\u00a0(10%\u00a0de\u00a0glicerol,\u00a02%\u00a0SDS,\u00a00.1%\u00a0de\u00a0Bromofenol \u00a0Blue,\u00a060mM\u00a0de\u00a0Tris\u2010HCl\u00a0\na\u00a0pH\u00a06.8\u00a0y\u00a06\u00a0\u00b5l\u00a0de\u00a0\u03b2\u2010Mercaptoetanol \u00a0por\u00a0cada\u00a0ml\u00a0\nde\u00a0tamp\u00f3n). \u00a0Las\u00a0muestras \u00a0se\u00a0separaron \u00a0por\u00a0\nelectroforesis \u00a0en\u00a0un\u00a0gel\u00a0de\u00a0poliacrilamida \u00a0con\u00a0\ndodecil\u00a0sulfato\u00a0s\u00f3dico\u00a0(SDS\u2010PAGE)\u00a0y\u00a0fueron\u00a0\nelectrofor\u00e9ticamente \u00a0transferidas \u00a0a\u00a0una\u00a0\nmembrana \u00a0de\u00a0PVDF\u00a0(BioRad\u00a0Laboratories). \u00a0Una\u00a0\nvez\u00a0finalizada \u00a0la\u00a0transferencia \u00a0se\u00a0bloque\u00f3\u00a0la\u00a0\nmembrana \u00a0con\u00a0leche\u00a0en\u00a0TBS\u00a01X\u00a0(150\u00a0mM\u00a0de\u00a0NaCl,\u00a0\ny\u00a020\u00a0mM\u00a0de\u00a0Tris\u2010HCl\u00a0a\u00a0pH\u00a07.4)\u00a0al\u00a05%\u00a0(0.5\u00a0g\u00a0en\u00a05\u00a0ml)\u00a0\ndurante\u00a01\u00a0hora.\u00a0La\u00a0membrana \u00a0fue\u00a0incubada\u00a0\ndurante\u00a0toda\u00a0la\u00a0noche\u00a0a\u00a04\u00b0C\u00a0con\u00a0su\u00a0\ncorrespondiente \u00a0anticuerpo \u00a0primario,\u00a0se\u00a0lav\u00f3\u00a03\u00a0\nveces\u00a0con\u00a0TBS\u00a05\u00a0min\u00a0cada\u00a0vez\u00a0y\u00a0luego\u00a0se\u00a0volvi\u00f3\u00a0a\u00a0\nincubar\u00a0durante\u00a0una\u00a0hora\u00a0con\u00a0el\u00a0anticuerpo \u00a0\nsecundario \u00a0de\u00a0rat\u00f3n\u00a0o\u00a0conejo\u00a0unido\u00a0a\u00a0peroxidasa \u00a0\n(ECL\u00a0TM\u00a0anti\u2010rabbit/mouse \u00a0IGG\u00a0Horseradish \u00a0\nPeroxidase \u00a0linked\u00a0whole\u00a0antibody\u00a0from\u00a0donkey,\u00a0\nAmersham \u00a0Biosciences) \u00a0en\u00a0funci\u00f3n\u00a0del\u00a0anitcuerpo \u00a0\nprimario.\u00a0Despu\u00e9s\u00a0de\u00a03\u00a0nuevos\u00a0lavados\u00a0de\u00a05\u00a0min\u00a0\ncon\u00a0TBS,\u00a0la\u00a0detecci\u00f3n \u00a0del\u00a0anticuerpo \u00a0unido\u00a0a\u00a0la\u00a0\nprote\u00edna\u00a0de\u00a0inter\u00e9s\u00a0se\u00a0realiz\u00f3\u00a0con\u00a0el\u00a0equipo\u00a0de\u00a0\nreactivos\u00a0ECL\u00a0(Amersham, \u00a0Bucks,\u00a0EE.UU.),\u00a0\nreactivos\u00a0que\u00a0son\u00a0degradados \u00a0por\u00a0la\u00a0peroxidasa \u00a0\nunida\u00a0a\u00a0los\u00a0anticuerpos \u00a0secundarios, \u00a0emitiendo \u00a0\nuna\u00a0se\u00f1al\u00a0de\u00a0quimioluminiscente. \u00a0La\u00a0detecci\u00f3n \u00a0de\u00a0\nla\u00a0quimioluminiscencia \u00a0se\u00a0realiz\u00f3\u00a0con\u00a0el\u00a0m\u00f3dulo\u00a0\nde\u00a0obtenci\u00f3n \u00a0de\u00a0im\u00e1genes \u00a0LAS\u00a03000\u00a0(Fujifilm); \u00a0y\u00a0\nlas\u00a0bandas\u00a0obtenidas \u00a0se\u00a0pudieron\u00a0cuantificar \u00a0\ndensitom\u00e9tricamente \u00a0mediante \u00a0el\u00a0software\u00a0Image\u00a0\nGauge\u00a04.0\u00a0(Fujifilm). \u00a0Los\u00a0correctos \u00a0pesos\u00a0\nmoleculares \u00a0(Mr)\u00a0de\u00a0las\u00a0prote\u00ednas \u00a0fueron\u00a0\ncomparados \u00a0con\u00a0el\u00a0marcador \u00a0de\u00a0prote\u00ednas \u00a0\nPrecision\u00a0Plus\u00a0Protein\u00a0Standards, \u00a0dual\u00a0color\u00a0\n(BioRad,\u00a0Laboratories, \u00a0Hercules, \u00a0CA).\u00a0\u00a0\nPara\u00a0comprobar \u00a0que\u00a0la\u00a0carga\u00a0de\u00a0prote\u00ednas \u00a0y\u00a0su\u00a0\nconcentraci\u00f3n \u00a0era\u00a0la\u00a0m\u00e1s\u00a0similar\u00a0posible,\u00a0las\u00a0\nmembranas \u00a0se\u00a0incubaron \u00a0con\u00a0anticuerpos \u00a0anti\u00a0\u03b1\u2010\ntubulina,\u00a0anti\u2010actina\u00a0o\u00a0anticuerpos \u00a0anti\u2010GAPDH\u00a0\n(Sigma\u2010Aldrich)\u00a0como\u00a0controles \u00a0internos\u00a0de\u00a0carga\u00a0\ny\u00a0de\u00a0cuantificaci\u00f3n. \u00a0Los\u00a0cambios\u00a0entre\u00a0las\u00a0\ndiferentes \u00a0muestras \u00a0se\u00a0muestran \u00a0como\u00a0\u201cfold\u00a0\nchange\u201d\u00a0(n\u00famero\u00a0de\u00a0veces\u00a0que\u00a0se\u00a0expresa\u00a0una\u00a0\nprote\u00edna\u00a0en\u00a0una\u00a0muestra\u00a0respecto\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0\nde\u00a0la\u00a0muestra\u00a0control).\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n104\u00a0\n\u00a05.2.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0fluorescencia \u00a0y\u00a0\nenriquecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0celular\u00a0\nmediante \u00a0citometr\u00eda \u00a0de\u00a0flujo\u00a0separador \u00a0\n5.2.1.\u00a0Enriquecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0NK\u20101R\u00a0+\u00a0\n\u00a0\nLas\u00a0c\u00e9lulas\u00a0adherentes \u00a0de\u00a0CM\u00a0que\u00a0sobreexpresan \u00a0\nTACR1\u00a0se\u00a0tripsinizaron, \u00a0se\u00a0lavaron\u00a0y\u00a0se\u00a0pre\u2010\nincubaron \u00a0durante\u00a015\u00a0min\u00a0con\u00a0PBS\u00a0fr\u00edo\u00a0al\u00a01%\u00a0de\u00a0\nSBF.\u00a0A\u00a0continuaci\u00f3n, \u00a0las\u00a0c\u00e9lulas\u00a0fueron\u00a0incubadas \u00a0\nde\u00a0forma\u00a0secuencial \u00a0con\u00a0el\u00a0anticuerpo \u00a0primario\u00a0\ncontra\u00a0el\u00a0receptor\u00a0NK\u20101R\u00a0(Abcam)\u00a0a\u00a0una\u00a0diluci\u00f3n\u00a0\n1:100\u00a0en\u00a0tamp\u00f3n\u00a0de\u00a0separaci\u00f3n \u00a0(EDTA\u00a01\u00a0mM,\u00a025\u00a0\nmM\u00a0HEPES\u00a0y\u00a0FBS\u00a0al\u00a01%)\u00a0a\u00a04\u00b0C\u00a0durante\u00a030\u00a0min,\u00a0y\u00a0\ndespu\u00e9s\u00a0de\u00a0dos\u00a0lavados\u00a0con\u00a0PBS\u00a0fr\u00edo\u00a0se\u00a0incubaron \u00a0\ncon\u00a0el\u00a0anticuerpo \u00a0secundario \u00a0DyLight\u00a0649\u00a0F(ab')2\u00a0\nde\u00a0 cabra\u00a0 anti\u2010conejo\u00a0 IgG\u00a0 (Jackson\u00a0\nImmunoresearch \u00a0Laboratories \u00a0Inc,\u00a0Westgrove) \u00a0a\u00a0\nuna\u00a0diluci\u00f3n\u00a01:250\u00a0en\u00a0el\u00a0mismo\u00a0tamp\u00f3n\u00a0durante\u00a0\n30\u00a0min\u00a0a\u00a04\u00b0C\u00a0en\u00a0la\u00a0oscuridad. \u00a0Las\u00a0c\u00e9lulas\u00a0se\u00a0\nlavaron\u00a03\u00a0veces\u00a0con\u00a0PBS\u00a0fr\u00edo\u00a0al\u00a01%\u00a0de\u00a0SBF\u00a0y\u00a0se\u00a0\nresuspendieron \u00a0en\u00a0tamp\u00f3n\u00a0de\u00a0separaci\u00f3n. \u00a0La\u00a0\ndetecci\u00f3n \u00a0y\u00a0separaci\u00f3n \u00a0de\u00a0aquellas\u00a0c\u00e9lulas\u00a0que\u00a0\nexpresaban \u00a0en\u00a0su\u00a0membrana \u00a0un\u00a0n\u00famero\u00a0elevado\u00a0\nde\u00a0NK\u20101R,\u00a0se\u00a0puedo\u00a0llevar\u00a0a\u00a0cabo\u00a0mediante \u00a0un\u00a0\nseparador \u00a0de\u00a0c\u00e9lulas\u00a0o\u00a0\u201ccell\u00a0sorter \u201d\u00a0BD\u00a0Biosciences \u00a0\nFACSAria\u00a0III.\u00a0La\u00a0separaci\u00f3n \u00a0celular\u00a0por\u00a0citometr\u00eda \u00a0\nde\u00a0flujo\u00a0separa\u00a0f\u00edsicamente \u00a0las\u00a0part\u00edculas \u00a0en\u00a0base\u00a0a\u00a0\nla\u00a0expresi\u00f3n \u00a0diferencial \u00a0de\u00a0uno\u00a0o\u00a0varios\u00a0\npar\u00e1metros \u00a0analizables \u00a0ya\u00a0que\u00a0clasifica\u00a0a\u00a0las\u00a0\nc\u00e9lulas\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0tama\u00f1o,\u00a0complejidad \u00a0y\u00a0la\u00a0\nfluorescencia \u00a0que\u00a0emite,\u00a0entre\u00a0otros\u00a0par\u00e1metros. \u00a0\nA\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0receptores \u00a0en\u00a0la\u00a0membrana, \u00a0\nmayor\u00a0ser\u00e1\u00a0la\u00a0fluorescencia \u00a0emitida\u00a0por\u00a0cada\u00a0\nc\u00e9lula.\u00a0Para\u00a0determinar \u00a0la\u00a0configuraci\u00f3n \u00a0de\u00a0la\u00a0\nautofluorescencia \u00a0se\u00a0utilizaron \u00a0como\u00a0control\u00a0\nc\u00e9lulas\u00a0que\u00a0no\u00a0se\u00a0hab\u00edan\u00a0incubado \u00a0con\u00a0ning\u00fan\u00a0\nanticuerpo. \u00a0Por\u00a0otro\u00a0lado\u00a0se\u00a0utilizaron \u00a0c\u00e9lulas\u00a0\nincubadas \u00a0solamente \u00a0con\u00a0el\u00a0anticuerpo \u00a0\nsecundario \u00a0para\u00a0asegurar\u00a0la\u00a0especificidad \u00a0del\u00a0\nanticuerpo \u00a0primario\u00a0y\u00a0c\u00e9lulas\u00a0sin\u00a0marcar.\u00a0Las\u00a0\nc\u00e9lulas\u00a0vivas\u00a0fueron\u00a0clasificadas \u00a0en\u00a0base\u00a0a\u00a0la\u00a0\ndispersi\u00f3n \u00a0frontal\u00a0de\u00a0luz\u00a0(FSC,\u00a0del\u00a0ingl\u00e9s\u00a0Forward\u00a0\nScatter )\u00a0y\u00a0la\u00a0dispersi\u00f3n \u00a0lateral\u00a0de\u00a0luz\u00a0(SSC,\u00a0del\u00a0\ningl\u00e9s\u00a0Side\u00a0Scatter ),\u00a0y\u00a0las\u00a0c\u00e9lulas\u00a0individuales \u00a0que\u00a0no\u00a0formaban \u00a0agregados \u00a0fueron\u00a0clasificadas \u00a0en\u00a0\nbase\u00a0a\u00a0la\u00a0altura\u00a0de\u00a0la\u00a0dispersi\u00f3n \u00a0de\u00a0luz\u00a0frontal\u00a0\n(FSC\u2010H)\u00a0y\u00a0el\u00a0\u00e1rea\u00a0de\u00a0dispersi\u00f3n \u00a0de\u00a0luz\u00a0lateral\u00a0(FSC\u2010\nA).\u00a0La\u00a0selecci\u00f3n\u00a0final\u00a0de\u00a0las\u00a0ventanas\u00a0de\u00a0an\u00e1lisis\u00a0o\u00a0\n\u201cgates \u201d\u00a0se\u00a0determin\u00f3 \u00a0mediante \u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0\nc\u00e9lulas\u00a0marcadas \u00a0que\u00a0estuvieran \u00a0vivas\u00a0e\u00a0\nindividuales. \u00a0Las\u00a0c\u00e9lulas\u00a0separadas \u00a0se\u00a0recogieron \u00a0\nen\u00a0SFB\u00a0y\u00a0se\u00a0mantuvieron \u00a0en\u00a0hielo\u00a0hasta\u00a0su\u00a0\nposterior\u00a0sembra.\u00a0El\u00a0enriquecimiento \u00a0de\u00a0c\u00e9lulas\u00a0\nque\u00a0expresaban \u00a0el\u00a0receptor\u00a0NK\u20101\u00a0se\u00a0repiti\u00f3\u00a0varias\u00a0\nveces\u00a0y\u00a0se\u00a0obtuvo\u00a0una\u00a0poblaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0\npositivas\u00a0de\u00a0al\u00a0menos\u00a0un\u00a098%.\u00a0\n\u00a0\n5.2.2.\u00a0Cuantificaci\u00f3n \u00a0por\u00a0citometr\u00eda \u00a0de\u00a0flujo\u00a0de\u00a0\nlas\u00a0poblaciones \u00a0CD44/CD24 \u00a0\n\u00a0\nLas\u00a0c\u00e9lulas\u00a0MDA\u2010MB\u2010468/MDA \u2010MB\u2010468SP\u00a0y\u00a0MDA\u2010\nMB\u2010453/MDA \u2010MB\u2010453SP\u00a0se\u00a0tripsinizaron, \u00a0se\u00a0\nlavaron\u00a0y\u00a0se\u00a0pre\u2010incubaron \u00a0durante\u00a020\u00a0min\u00a0en\u00a0\ntamp\u00f3n\u00a0de\u00a0bloqueo\u00a0(PBS1x\u00a0+\u00a05%\u00a0BSA\u00a0+\u00a00.05%\u00a0de\u00a0\nacida\u00a0s\u00f3dica)\u00a0a\u00a04\u00b0C.\u00a0A\u00a0continuaci\u00f3n, \u00a0las\u00a0c\u00e9lulas\u00a0\nfueron\u00a0incubadas \u00a0con\u00a0el\u00a0anticuerpo \u00a0primario\u00a0\nCD44\u2010FITC\u00a0+\u00a0CD24\u2010PE\u00a0en\u00a0tamp\u00f3n\u00a0de\u00a0bloqueo\u00a0a\u00a0\nuna\u00a0diluci\u00f3n\u00a01:100\u00a0cada\u00a0uno\u00a0a\u00a04\u00b0C\u00a0durante\u00a030\u00a0min.\u00a0\nPor\u00a0otro\u00a0lado\u00a0se\u00a0incubaron \u00a0durante\u00a0el\u00a0mismo\u00a0\ntiempo\u00a0c\u00e9lulas\u00a0con\u00a0el\u00a0control\u00a0isot\u00edpico\u00a0de\u00a0cada\u00a0\nanticuerpo \u00a0primario\u00a0para\u00a0asegurar\u00a0la\u00a0especificidad \u00a0\ndel\u00a0anticuerpo \u00a0(PE\u2010IgG 2a\u03ba\u00a0de\u00a0rat\u00f3n,\u00a0Cat#\u00a0555574\u00a0y\u00a0\nFITC\u2010IgG 2b\u03ba\u00a0de\u00a0rat\u00f3n ,\u00a0Cat#\u00a0555742BD, \u00a0BD\u00a0\nBisociences) \u00a0y\u00a0c\u00e9lulas\u00a0sin\u00a0marcar\u00a0como\u00a0control\u00a0de\u00a0\nautoflorescencia. \u00a0Despu\u00e9s\u00a0del\u00a0tiempo\u00a0de\u00a0\nincubaci\u00f3n \u00a0se\u00a0lavaron\u00a0tres\u00a0veces\u00a0con\u00a0PBS\u00a0fr\u00edo\u00a0y\u00a0se\u00a0\nresuspendieron \u00a0en\u00a0300\u00a0\u00b5l\u00a0de\u00a0PBS\u00a0al\u00a02%\u00a0de\u00a0PFA\u00a0y\u00a0se\u00a0\nanalizaron \u00a0por\u00a0cit\u00f3metr\u00eda \u00a0de\u00a0flujo\u00a0(FACSCanto \u00a0II\u00a0de\u00a0\nBecton\u2010Dickinson, \u00a0NY).\u00a0\n\u00a0\n5.3.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0citoquinas \u00a0\nmediante \u00a0ELISA\u00a0\n5.3.1.\u00a0SP\u00a0en\u00a0plasma\u00a0de\u00a0pacientes \u00a0\u00a0\n\u00a0\nLos\u00a0niveles\u00a0circulantes \u00a0de\u00a0SP\u00a0se\u00a0midieron\u00a0en\u00a0139\u00a0\nsueros\u00a0de\u00a0pacientes \u00a0con\u00a0CM\u00a0y\u00a092\u00a0donantes \u00a0sanos.\u00a0\nEl\u00a0Comit\u00e9\u00a0\u00c9tico\u00a0de\u00a0Investigaci\u00f3n \u00a0Cl\u00ednica\u00a0(CEIC)\u00a0del\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n105\u00a0\n\u00a0Hospital\u00a0Cl\u00ednic\u00a0de\u00a0Barcelona \u00a0aprob\u00f3\u00a0todos\u00a0los\u00a0\nprotocolos \u00a0utilizados \u00a0en\u00a0este\u00a0estudio.\u00a0Se\u00a0tomaron\u00a0\nmuestras \u00a0de\u00a0sangre\u00a0en\u00a0tubos\u00a0est\u00e9riles\u00a0vac\u00edos\u00a0y\u00a0\nluego\u00a0se\u00a0centrifugaron \u00a0a\u00a02000\u00a0rpm\u00a0durante\u00a015\u00a0min\u00a0\na\u00a04\u00b0C.\u00a0Se\u00a0a\u00f1adi\u00f3\u00a0a\u00a0los\u00a0sueros\u00a0un\u00a0c\u00f3ctel\u00a0de\u00a0\ninhibidores \u00a0de\u00a0Proteasas \u00a0(Sigma\u2010Aldrich)\u00a0en\u00a0una\u00a0\nproporci\u00f3n \u00a0de\u00a01:50,\u00a0para\u00a0evitar\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0las\u00a0\nproteasas \u00a0y\u00a0peptidasas, \u00a0luego\u00a0se\u00a0dividieron \u00a0en\u00a0\neppendorfs \u00a0de\u00a0250\u00a0ml\u00a0y\u00a0se\u00a0congelaron \u00a0\ninmediatamente \u00a0a\u00a0\u201080\u00b0C.\u00a0La\u00a0cantidad\u00a0de\u00a0SP\u00a0\ncirculante \u00a0se\u00a0determin\u00f3 \u00a0mediante \u00a0un\u00a0ensayo\u00a0por\u00a0\ninmunoabsorci\u00f3n \u00a0ligado\u00a0a\u00a0enzimas\u00a0(ELISA\u00a0del\u00a0\ningl\u00e9s,\u00a0Enzyme\u2010Linked\u00a0ImmunoSorbent \u00a0Assay )\u00a0\ncomercial \u00a0(Substance \u00a0P\u00a0enzyme\u00a0immunoassay \u00a0kit,\u00a0\nEnzo\u00a0Life\u00a0Sciences,\u00a0Germany) \u00a0y\u00a0cada\u00a0muestra\u00a0fue\u00a0\nanalizada \u00a0por\u00a0triplicado. \u00a0Este\u00a0ELISA\u00a0es\u00a0de\u00a0tipo\u00a0\ncompetitivo \u00a0y\u00a0ya\u00a0se\u00a0suministra \u00a0con\u00a0un\u00a0anticuerpo \u00a0\nanti\u2010conejo\u00a0fijado\u00a0al\u00a0soporte.\u00a0En\u00a0primer\u00a0lugar\u00a0se\u00a0\nrealiz\u00f3\u00a0una\u00a0curva\u00a0est\u00e1ndar\u00a0con\u00a0diluciones \u00a0\ncrecientes \u00a0de\u00a0SP\u00a0y\u00a0se\u00a0a\u00f1adieron \u00a050\u00a0\u00b5l\u00a0de\u00a0cada\u00a0\ndiluci\u00f3n\u00a0por\u00a0duplicado \u00a0en\u00a0distintos\u00a0pocillos.\u00a0A\u00a0\ncontinuaci\u00f3n \u00a0se\u00a0a\u00f1adieron \u00a050\u00a0\u00b5l\u00a0de\u00a0cada\u00a0muestra\u00a0\nde\u00a0paciente\u00a0por\u00a0pocillo\u00a0y\u00a0por\u00a0triplicado, \u00a0adem\u00e1s\u00a0\nde\u00a050\u00a0\u00b5l\u00a0de\u00a0un\u00a0anticuerpo \u00a0de\u00a0conejo\u00a0anti\u2010sustancia \u00a0\nP.\u00a0Seguidamente, \u00a0se\u00a0a\u00f1adieron \u00a0a\u00a0estos\u00a0100\u00a0\u00b5l,\u00a050\u00a0\n\u00b5l\u00a0m\u00e1s\u00a0de\u00a0una\u00a0soluci\u00f3n\u00a0del\u00a0kit\u00a0que\u00a0contiene\u00a0la\u00a0\nprote\u00edna\u00a0a\u00a0estudiar\u00a0(en\u00a0este\u00a0caso\u00a0la\u00a0SP\u00a0conjugada \u00a0a\u00a0\nuna\u00a0fosfatasa\u00a0alcalina)\u00a0como\u00a0m\u00e9todo\u00a0de\u00a0\ncompetici\u00f3n \u00a0por\u00a0el\u00a0anticuerpo \u00a0de\u00a0conejo\u00a0anti\u2010SP\u00a0\nen\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0alta\u00a0o\u00a0baja\u00a0de\u00a0SP\u00a0\nde\u00a0la\u00a0muestra.\u00a0Se\u00a0incub\u00f3\u00a0la\u00a0placa\u00a0a\u00a0TA\u00a0durante\u00a02\u00a0\nhoras\u00a0y\u00a0se\u00a0mantuvo\u00a0en\u00a0agitaci\u00f3n\u00a0a\u00a0500\u00a0r.p.m.\u00a0Se\u00a0\nlavaron\u00a0las\u00a0placas\u00a02\u00a0veces\u00a0con\u00a0tamp\u00f3n\u00a0de\u00a0lavado\u00a0\npara\u00a0eliminar\u00a0los\u00a0ant\u00edgenos \u00a0que\u00a0no\u00a0se\u00a0hab\u00edan\u00a0\nunido.\u00a0Se\u00a0a\u00f1adi\u00f3\u00a0el\u00a0sustrato\u00a0de\u00a0la\u00a0fosfatasa\u00a0\nalcalina\u00a0y\u00a0se\u00a0incub\u00f3\u00a0a\u00a0TA\u00a0durante\u00a0una\u00a0hora\u00a0sin\u00a0\nagitaci\u00f3n. \u00a0Pasado\u00a0este\u00a0tiempo\u00a0se\u00a0par\u00f3\u00a0la\u00a0reacci\u00f3n\u00a0\ncon\u00a0una\u00a0soluci\u00f3n\u00a0de\u00a0parado.\u00a0La\u00a0lectura\u00a0de\u00a0la\u00a0placa\u00a0\nse\u00a0realiz\u00f3\u00a0con\u00a0un\u00a0espectrofot\u00f3metro \u00a0de\u00a0placas\u00a0a\u00a0\nuna\u00a0longitud\u00a0de\u00a0onda\u00a0de\u00a0405\u00a0nm\u00a0preferentemente \u00a0\ncon\u00a0una\u00a0correcci\u00f3n \u00a0de\u00a0ruido\u00a0de\u00a0fondo\u00a0de\u00a0570\u00a0a\u00a0\n590\u00a0nm.\u00a0La\u00a0sensibilidad \u00a0del\u00a0kit\u00a0oscila\u00a0desde\u00a010\u00a0\nhasta\u00a01000000\u00a0pg/ml\u00a0y\u00a0los\u00a0niveles\u00a0de\u00a0SP\u00a0se\u00a0\ndeterminaron \u00a0utilizando \u00a0una\u00a0curva\u00a0est\u00e1ndar\u00a0\nsigmoidea \u00a0para\u00a0encontrar \u00a0la\u00a0correspondiente \u00a0concentraci\u00f3n \u00a0de\u00a0SP\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0curva\u00a0patr\u00f3n\u00a0\ny\u00a0se\u00a0realiz\u00f3\u00a0con\u00a0el\u00a0software\u00a0GraphPad. \u00a0El\u00a0an\u00e1lisis\u00a0\nestad\u00edstico \u00a0entre\u00a0las\u00a0diferencias \u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0\nSP\u00a0de\u00a0cada\u00a0muestra\u00a0y\u00a0su\u00a0correlaci\u00f3n \u00a0con\u00a0las\u00a0\ncaracter\u00edsticas \u00a0cl\u00ednico\u2010patol\u00f3gicas \u00a0se\u00a0analizaron \u00a0\nmediante \u00a0la\u00a0prueba\u00a0estad\u00edstica \u00a0de\u00a0Mann\u2010Whitney\u00a0\npara\u00a0dos\u00a0categor\u00edas \u00a0y\u00a0Kruskal\u2010Wallis\u00a0para\u00a0m\u00e1s\u00a0de\u00a0\ndos\u00a0categor\u00edas. \u00a0El\u00a0an\u00e1lisis\u00a0se\u00a0realiz\u00f3\u00a0utilizando \u00a0el\u00a0\nsoftware\u00a0de\u00a0SAS\u00a09.2\u00a0(SAS\u00a0Institute\u00a0Inc,\u00a0Cary,\u00a0NC,\u00a0\nEE.UU.)\u00a0y\u00a0un\u00a0nivel\u00a0de\u00a00,05\u00a0(dos\u00a0colas)\u00a0fue\u00a0\nconsiderado \u00a0estad\u00edsticamente \u00a0significativo. \u00a0Las\u00a0\ncaracter\u00edsticas \u00a0cl\u00ednicas\u00a0de\u00a0los\u00a0pacientes \u00a0incluidos\u00a0\nen\u00a0este\u00a0estudio\u00a0se\u00a0resumen\u00a0en\u00a0la\u00a0Tabla\u00a0Anexa\u00a03.\u00a0\nLos\u00a0pacientes \u00a0fueron\u00a0clasificados \u00a0seg\u00fan\u00a0los\u00a0\ndiferentes \u00a0par\u00e1metros \u00a0recogidos \u00a0en\u00a0la\u00a0\ninformaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0la\u00a0siguiente\u00a0manera:\u00a0\n\u00cdndice\u00a0de\u00a0masa\u00a0\ncorporal\u00a01:\u00a0Si<18.5;\u00a02:\u00a0si\u00a018.5\u201025;\u00a03:\u00a0si\u00a025\u201030;\u00a0\n4:\u00a0si\u00a0>30.\u00a0\nCA153\u00a0\ncirculante \u00a01:\u00a0Niveles\u00a0normales \u00a0(<40\u00a0U/ml);\u00a02:\u00a0\nniveles\u00a0altos\u00a0(>40\u00a0U/ml)\u00a0\nCEA\u00a0circulante \u00a01:\u00a0Niveles\u00a0normales \u00a0(<5\u00a0ng/ml);\u00a02:\u00a0\nniveles\u00a0altos\u00a0(>5\u00a0ng/ml)\u00a0\nAmplificaci\u00f3n \u00a0\ndel\u00a0gen\u00a0HER2:\u00a01:Negativo\u00a0(en\u00a0ausencia\u00a0de\u00a0se\u00f1al),\u00a0\nbajo\u00a0(puntuaci\u00f3n \u00a0+);\u00a02:\u00a0tinci\u00f3n\u00a0\nintermedia \u00a0mediante \u00a0IHQ\u00a0y\u00a0sin\u00a0\napmlificaci\u00f3n \u00a0del\u00a017q\u00a0analizado \u00a0\nmediante \u00a0FISH\u00a0(puntuaci\u00f3n \u00a0++);\u00a03:\u00a0\ntinci\u00f3n\u00a0positiva\u00a0mediante \u00a0IHQ\u00a0\n(cuando\u00a0la\u00a0puntuaci\u00f3n \u00a0es\u00a0de\u00a0++)\u00a0\npero\u00a0hay\u00a0amplificaci\u00f3n \u00a0del\u00a017q\u00a0\nanalizado \u00a0por\u00a0FISH,\u00a0o\u00a0tinci\u00f3n\u00a0muy\u00a0\nfuerte\u00a0(puntuaci\u00f3n \u00a0+++).\u00a0\nReceptor \u00a0de\u00a0\nEstr\u00f3geno: \u00a01:\u00a0Negativo\u00a0(<10%\u00a0de\u00a0c\u00e9lulas\u00a0\npositivas); \u00a02:\u00a0positivo\u00a0(>10%\u00a0de\u00a0\nc\u00e9lulas\u00a0positivas). \u00a0\nReceptor \u00a0de\u00a0\nProgesterona: \u00a01:\u00a0Negativo\u00a0(<10%\u00a0de\u00a0c\u00e9lulas\u00a0\npositivas); \u00a02:\u00a0positivo\u00a0(>10%\u00a0de\u00a0\nc\u00e9lulas\u00a0positivas). \u00a0\nSubtipo\u00a0\ntumoral\u00a01:\u00a0Luminal\u00a0A\u00a0(ER+,\u00a0PR+/\u2010,\u00a0HER2\u2010);\u00a02:\u00a0\nLuminal\u00a0B\u00a0(ER+,\u00a0PR+/\u2010,\u00a0HER2+);\u00a03:\u00a0\nHER2\u00a0(ER\u2010,\u00a0PR\u2010,\u00a0HER2+);\u00a04:\u00a0Triple\u00a0\nnegativo\u00a0(ER\u2010,\u00a0PR\u2010,\u00a0HER2\u2010).\u00a0\u00a0\nTama\u00f1o\u00a0 del\u00a0\ntumor\u00a01:\u00a0Peque\u00f1o\u00a0(<2\u00a0cm);\u00a02:\u00a0intermedio \u00a0\n(2\u20105\u00a0cm);\u00a03:\u00a0grande\u00a0(>\u00a05\u00a0cm).\u00a0\nUICC\u00a0\u00a0TNM\u00a0Clasificaci\u00f3n \u00a0de\u00a0tumores\u00a0\nmalignos\u00a0\nPatolog\u00eda \u00a0Carcinoma \u00a0ductal\u00a0infiltrante \u00a0(CDI),\u00a0\nCarcinoma \u00a0lobular\u00a0infiltrante \u00a0(CLI),\u00a0\nCarcinoma \u00a0ductal\u00a0in\u00a0situ\u00a0(CDIS).\u00a0\nTratamiento \u00a01:\u00a0Neoadyuvancia; \u00a02:\u00a0Adyuvancia; \u00a03:\u00a0\nsolo\u00a0cirug\u00eda.\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n106\u00a0\n\u00a05.3.2.\u00a0IL\u20106\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0\u00a0\n\u00a0\nPara\u00a0detectar\u00a0los\u00a0niveles\u00a0de\u00a0IL\u20106\u00a0en\u00a0el\u00a0medio\u00a0de\u00a0\ncultivo\u00a0de\u00a0l\u00edneas\u00a0celulares, \u00a0se\u00a0sembraron \u00a012.000\u00a0\ncelulas\u00a0por\u00a0pocillo\u00a0en\u00a0una\u00a0MW\u00a0de\u00a096,\u00a0se\u00a0incubaron \u00a0\nlas\u00a0c\u00e9lulas\u00a0durante\u00a048\u00a0horas,\u00a0se\u00a0recogieron \u00a0los\u00a0\nsobrenadantes \u00a0y\u00a0se\u00a0congelaron \u00a0hasta\u00a0su\u00a0posterior\u00a0\nan\u00e1lisis.\u00a0Para\u00a0poder\u00a0corregir\u00a0los\u00a0niveles\u00a0de\u00a0IL\u20106\u00a0por\u00a0\nel\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0se\u00a0hizo\u00a0un\u00a0MTT\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nsembradas, \u00a0y\u00a0estos\u00a0valores\u00a0se\u00a0utilizaron \u00a0como\u00a0\nvalores\u00a0de\u00a0correcci\u00f3n. \u00a0La\u00a0cantidad\u00a0de\u00a0IL\u20106\u00a0se\u00a0\ndetermin\u00f3 \u00a0mediante \u00a0un\u00a0ELISA\u00a0comercial \u00a0(Human\u00a0\nIL\u20106\u00a0Elisa\u00a0Kit,\u00a0Cat#\u00a0EH2IL6,\u00a0Thermo\u00a0Scientific). \u00a0Este\u00a0\nELISA\u00a0es\u00a0de\u00a0tipo\u00a0\u201csandwich \u201d\u00a0y\u00a0tambi\u00e9n\u00a0en\u00a0este\u00a0\ncaso\u00a0el\u00a0anticuerpo \u00a0anti\u00a0IL\u20106\u00a0se\u00a0encuentra \u00a0unido\u00a0a\u00a0\nla\u00a0placa.\u00a0En\u00a0primer\u00a0lugar\u00a0se\u00a0realiz\u00f3\u00a0una\u00a0curva\u00a0\nest\u00e1ndar\u00a0con\u00a0diluciones \u00a0seriadas\u00a0de\u00a0SP\u00a0y\u00a0se\u00a0\na\u00f1adieron \u00a050\u00a0\u00b5l\u00a0de\u00a0cada\u00a0diluci\u00f3n\u00a0por\u00a0duplicado \u00a0en\u00a0\ndistintos\u00a0pocillos.\u00a0A\u00a0partir\u00a0de\u00a0aqu\u00ed\u00a0se\u00a0a\u00f1adieron \u00a050\u00a0\n\u00b5l\u00a0del\u00a0anticuerpo \u00a0anit\u2010IL\u20106\u00a0biotinilado \u00a0en\u00a0cada\u00a0\npocillo\u00a0m\u00e1s\u00a050\u00a0\u00b5l\u00a0del\u00a0sobrenadante \u00a0de\u00a0cada\u00a0l\u00ednea\u00a0\ncelular\u00a0por\u00a0triplicado. \u00a0Se\u00a0mezclaron \u00a0bien\u00a0las\u00a0dos\u00a0\nsoluciones \u00a0y\u00a0se\u00a0a\u00f1adieron \u00a050\u00a0\u00b5l\u00a0m\u00e1s\u00a0de\u00a0medio\u00a0a\u00a0\ntodos\u00a0los\u00a0pocillos\u00a0que\u00a0no\u00a0conten\u00edan \u00a0est\u00e1ndares \u00a0o\u00a0\nmuestra.\u00a0Se\u00a0tap\u00f3\u00a0la\u00a0placa\u00a0y\u00a0se\u00a0incub\u00f3\u00a0durante\u00a02\u00a0\nhoras\u00a0a\u00a020\u2010\u00a025\u00b0C.\u00a0Transcurrido \u00a0el\u00a0tiempo\u00a0de\u00a0\nincubaci\u00f3n \u00a0se\u00a0retir\u00f3\u00a0el\u00a0pl\u00e1stico\u00a0y\u00a0se\u00a0lavaron\u00a0los\u00a0\npocillos\u00a03\u00a0veces\u00a0con\u00a0soluci\u00f3n\u00a0de\u00a0lavado\u00a01X\u00a0del\u00a0kit\u00a0\ncomercial. \u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0a\u00f1adieron \u00a0100\u00a0\u00b5l\u00a0de\u00a0\nsoluci\u00f3n\u00a0Streptavidina \u2010HRP\u00a0y\u00a0se\u00a0incubi\u00f3\u00a0durante\u00a0\n30\u00a0min\u00a0m\u00e1s\u00a0para\u00a0permitir\u00a0su\u00a0uni\u00f3n\u00a0al\u00a0anticuero \u00a0\nbiotinilado \u00a0y\u00a0se\u00a0volvieron \u00a0a\u00a0realizar\u00a03\u00a0lavados.\u00a0A\u00a0\npartir\u00a0de\u00a0aqu\u00ed\u00a0se\u00a0a\u00f1adi\u00f3\u00a0el\u00a0sustrato\u00a0de\u00a0la\u00a0\nperoxidasa \u00a0y\u00a0se\u00a0incub\u00f3\u00a0a\u00a0TA\u00a0durante\u00a030\u00a0min\u00a0sin\u00a0\nagitaci\u00f3n\u00a0y\u00a0sin\u00a0luz.\u00a0Pasado\u00a0este\u00a0tiempo\u00a0se\u00a0par\u00f3\u00a0la\u00a0\nreacci\u00f3n\u00a0con\u00a0una\u00a0soluci\u00f3n\u00a0de\u00a0parado.\u00a0La\u00a0lectura\u00a0de\u00a0\nla\u00a0placa\u00a0se\u00a0realiz\u00f3\u00a0con\u00a0un\u00a0espectrofot\u00f3metro \u00a0de\u00a0\nplacas\u00a0a\u00a0una\u00a0longitud\u00a0de\u00a0onda\u00a0de\u00a0450\u00a0nm\u00a0con\u00a0una\u00a0\ncorrecci\u00f3n \u00a0de\u00a0de\u00a0ruido\u00a0de\u00a0fondo\u00a0de\u00a0550\u00a0nm.\u00a0La\u00a0\nsensibilidad \u00a0del\u00a0kit\u00a0va\u00a0desde\u00a00\u00a0hasta\u00a0400\u00a0pg/ml\u00a0y\u00a0\nlos\u00a0niveles\u00a0de\u00a0IL\u20106\u00a0se\u00a0determinaron \u00a0mediante \u00a0el\u00a0\ndesarrollo \u00a0de\u00a0una\u00a0recta\u00a0de\u00a0regresi\u00f3n \u00a0lineal\u00a0de\u00a0los\u00a0\nvalores\u00a0est\u00e1ndares \u00a0y\u00a0se\u00a0calcul\u00f3\u00a0la\u00a0correspondiente \u00a0\nconcentraci\u00f3n \u00a0de\u00a0prote\u00edna\u00a0mediante \u00a0la\u00a0f\u00f3rmula\u00a0de\u00a0\nla\u00a0pendiente \u00a0y=ax+b .\u00a05.4.\u00a0Inmunofluorescencia \u00a0\n5.4.1.\u00a0En\u00a0l\u00edneas\u00a0celulares\u00a0\n\u00a0\nPara\u00a0la\u00a0localizaci\u00f3n \u00a0de\u00a0pHER2\u00a0y\u00a0EGFR\u00a0se\u00a0\nsembraron \u00a0aproximadamente \u00a0300.000\u00a0c\u00e9lulas\u00a0en\u00a0\nplacas\u00a0de\u00a06\u00a0pocillos\u00a0donde\u00a0previamente \u00a0se\u00a0hab\u00edan\u00a0\nintroducido \u00a01\u00a0o\u00a02\u00a0laminillas \u00a0de\u00a0cubreobjetos \u00a0\ncirculares \u00a0(Marlenfeld \u00a0GMBH&CoKG, \u00a0Germany) \u00a0en\u00a0\ncada\u00a0uno.\u00a0Una\u00a0vez\u00a0alcanzado \u00a0el\u00a070\u201080%\u00a0de\u00a0\nconfluencia \u00a0se\u00a0deprivaron \u00a0de\u00a0SBF\u00a0durante\u00a024h\u00a0y\u00a0se\u00a0\ntrataron\u00a0con\u00a0SP\u00a0a\u00a0una\u00a0concentraci\u00f3n \u00a0de\u00a0100\u00a0nM\u00a0\ndurante\u00a010\u00a0min.\u00a0Posteriormente \u00a0las\u00a0c\u00e9lulas\u00a0fueron\u00a0\nlavadas\u00a0con\u00a0una\u00a0soluci\u00f3n\u00a0salina\u00a0fr\u00eda\u00a0de\u00a0HBS\u00a0(Hepes\u00a0\nBuffered\u00a0Saline :\u00a0135\u00a0mM\u00a0NaCl,\u00a010\u00a0mM\u00a0KCl,\u00a00.4\u00a0\nmM\u00a0MgCl2,\u00a01\u00a0mM\u00a0CaCl2,\u00a010\u00a0mM\u00a0Na\u2010Hepes\u00a0pH\u00a0\n7.4);\u00a0se\u00a0fijaron\u00a0durante\u00a015\u00a0min\u00a0a\u00a04\u00baC\u00a0con\u00a0una\u00a0\nsoluci\u00f3n\u00a0de\u00a0paraformaldehido \u00a0al\u00a04%\u00a0y\u00a0\nseguidamente \u00a0con\u00a0metanol\u00a0durante\u00a06\u00a0min\u00a0a\u00a0\u201020\u00b0C.\u00a0\nDespu\u00e9s\u00a0de\u00a0realizar\u00a0dos\u00a0lavados\u00a0m\u00e1s\u00a0con\u00a0HBS\u00a0de\u00a05\u00a0\nmin\u00a0cada\u00a0uno,\u00a0se\u00a0bloquearon \u00a0los\u00a0cubreobjetos \u00a0con\u00a0\nPBS\u00a0fr\u00edo\u00a0al\u00a01%\u00a0de\u00a0alb\u00famina \u00a0durante\u00a020\u00a0min.\u00a0\nDespu\u00e9s\u00a0del\u00a0bloqueo\u00a0se\u00a0se\u00a0incubaron \u00a0con\u00a0el\u00a0\nanticuerpo \u00a0primario\u00a0contra\u00a0pHER2\u00a0o\u00a0EGFR\u00a0durante\u00a0\ntoda\u00a0la\u00a0noche\u00a0a\u00a04\u00b0C.\u00a0Al\u00a0d\u00eda\u00a0siguiente, \u00a0despu\u00e9s\u00a0de\u00a0\ntres\u00a0nuevos\u00a0lavados\u00a0con\u00a0HBS,\u00a0se\u00a0incubaron \u00a0\nnuevamente \u00a0durante\u00a01\u00a0hora\u00a0a\u00a0TA\u00a0con\u00a0el\u00a0\nanticuerpo \u00a0secundario \u00a0de\u00a0conejo\u00a0unido\u00a0a\u00a0Alexa\u00a0\n594\u00a0(para\u00a0pHER2)\u00a0o\u00a0unido\u00a0a\u00a0FITC\u00a0(para\u00a0EGFR).\u00a0Por\u00a0\n\u00fatlimo\u00a0se\u00a0lavaron\u00a03\u00a0veces\u00a0con\u00a0HBS\u00a0y\u00a0se\u00a0incubaron \u00a0\ncon\u00a0una\u00a0soluci\u00f3n\u00a0de\u00a0DAPI\u00a0para\u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0los\u00a0\nn\u00facleos\u00a0(soluci\u00f3n\u00a0de\u00a0trabajo:\u00a01\u00a0\u03bcg/ml)\u00a0(Roche\u00a0\nDiagnostics, \u00a0Alemania) \u00a0durante\u00a015\u00a0min\u00a0a\u00a0TA.\u00a0Los\u00a0\ncubreobjetos \u00a0se\u00a0montaron \u00a0en\u00a0los\u00a0portaobjetos \u00a0con\u00a0\nMowiol\u00a0(Calbiochem) \u00a0y\u00a0se\u00a0analizaron \u00a0en\u00a0un\u00a0\nmicroscopio \u00a0confocal\u00a0TCS\u00a0SP5\u00a0(Leica\u00a0Microsystems \u00a0\nHeidelberg \u00a0GmbH,\u00a0Manheim, \u00a0Germany). \u00a0Los\u00a0\nexperimentos \u00a0se\u00a0realizaron \u00a0por\u00a0triplicado. \u00a0\n5.4.2.\u00a0En\u00a0cultivos\u00a0primarios \u00a0\n\u00a0\nPara\u00a0detectar\u00a0pHER2\u00a0en\u00a0tumores\u00a0primarios \u00a0los\u00a0\nportabojetos \u00a0de\u00a0c\u00e9lulas\u00a0depositadas \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\ncitosp\u00edn\u00a0se\u00a0dejaron\u00a0secar\u00a0a\u00a0TA\u00a0y\u00a0se\u00a0\npermeabilizaron \u00a0con\u00a00,25%\u00a0de\u00a0Triton\u2010X100\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n107\u00a0\n\u00a0durante\u00a02\u00a0min.\u00a0Despu\u00e9s\u00a0de\u00a0lavar\u00a0las\u00a0muestras \u00a0con\u00a0\nPBS,\u00a0se\u00a0incubaron \u00a0las\u00a0c\u00e9lulas\u00a0fijadas\u00a0durante\u00a0toda\u00a0\nla\u00a0noche\u00a0a\u00a04\u00b0C\u00a0con\u00a0los\u00a0siguientes \u00a0anticuerpos \u00a0\nprimarios: \u00a0anticuerpo \u00a0de\u00a0conejo\u00a0anti\u2010pHER2\u00a0y\u00a0\nanticuerpo \u00a0de\u00a0rat\u00f3n\u00a0anti\u2010pan\u2010citoqueratina \u00a0(CK).\u00a0\nAl\u00a0d\u00eda\u00a0siguiente, \u00a0los\u00a0portaobjetos \u00a0se\u00a0lavaron\u00a0con\u00a0\nPBS\u00a0y\u00a0se\u00a0incubaron \u00a0durante\u00a01\u00a0hora\u00a0con\u00a0los\u00a0\nanticuerpos \u00a0secundarios \u00a0de\u00a0cabra\u00a0anti\u2010IgG\u00a0de\u00a0\nconejo\u00a0biotinilado \u00a0y\u00a0el\u00a0anticuerpo \u00a0de\u00a0cabra\u00a0\nconjugado \u00a0con\u00a0Alexa\u00a0Fluor\u2010555\u00a0anti\u2010rat\u00f3n.\u00a0\nDespu\u00e9s\u00a0de\u00a0ese\u00a0tiempo\u00a0y\u00a0de\u00a03\u00a0lavados\u00a0con\u00a0PBS,\u00a0se\u00a0\nincubaron \u00a0con\u00a0Alexa\u00a0Fluor\u00a0488\u2010estreptavidina \u00a0a\u00a0TA\u00a0\ndurante\u00a01\u00a0hora.\u00a0A\u00a0continuaci\u00f3n \u00a0despu\u00e9s\u00a0de\u00a0dos\u00a0\nlavados\u00a0con\u00a0PBS,\u00a0los\u00a0portaobjetos \u00a0fueron\u00a0\ncontrate\u00f1idos \u00a0con\u00a0DAPI\u00a0como\u00a0se\u00a0ha\u00a0descrito\u00a0\nanteriormente. \u00a0Por\u00a0\u00faltimo,\u00a0se\u00a0montaron \u00a0los\u00a0\ncubreobjetos \u00a0en\u00a0los\u00a0portaobjetos \u00a0utilizando \u00a0el\u00a0\nmedio\u00a0de\u00a0montaje\u00a0Prolongue \u00ae\u00a0Gold\u00a0Antifade\u00a0\n(Invitrogen, \u00a0Molecular \u00a0Probes,\u00a0CA).\u00a0\n5.5.\u00a0Microscop\u00eda \u00a0de\u00a0fluorescencia \u00a0y\u00a0\nadquisici\u00f3n \u00a0de\u00a0im\u00e1genes \u00a0para\u00a0la\u00a0\ndetecci\u00f3n \u00a0y/o\u00a0quantificaci\u00f3n \u00a0de\u00a0pHER2\u00a0\n\u00a0\nLas\u00a0im\u00e1genes \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0fijadas\u00a0tomadas\u00a0\nmediante \u00a0microscop\u00eda \u00a0fueron\u00a0adquiridas \u00a0con\u00a0un\u00a0\nmicroscopio \u00a0confocal\u00a0l\u00e1ser\u00a0de\u00a0barrido\u00a0Leica\u00a0TCS\u00a0\nSP5,\u00a0(Leica\u00a0Microsystems \u00a0Heidelberg \u00a0GmbH,\u00a0\nMannheim, \u00a0Alemania) \u00a0equipado \u00a0con\u00a0un\u00a0\nmicroscopio \u00a0invertido\u00a0DMI6000 \u00a0y\u00a0l\u00e1seres\u00a0de\u00a0diodo\u00a0\nazul\u00a0(405\u00a0nm),\u00a0arg\u00f3n,\u00a0un\u00a0l\u00e1ser\u00a0s\u00f3lido\u00a0bombeado \u00a0\npor\u00a0diodos\u00a0(DPSS\u00a0561)\u00a0y\u00a0un\u00a0laser\u00a0de\u00a0He/Ne\u00a0633\u00a0\nnm).\u00a0Las\u00a0im\u00e1genes \u00a0de\u00a0las\u00a0tinciones\u00a0con\u00a0DAPI,\u00a0Alexa\u00a0\nFluor\u00a0488\u00a0y\u00a0Alexa\u00a0Fluor\u00a0594\u00a0de\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0\ny\u00a0las\u00a0im\u00e1genes \u00a0de\u00a0las\u00a0tinciones\u00a0con\u00a0DAPI,\u00a0Alexa\u00a0\nFluor\u00a0488\u00a0y\u00a0Alexa\u00a0Fluor\u00a0555\u00a0de\u00a0los\u00a0cultivos\u00a0\nprimarios \u00a0\u00a0fueron\u00a0obtenidas \u00a0de\u00a0forma\u00a0secuencial \u00a0\ncon\u00a0las\u00a0l\u00edneas\u00a0de\u00a0laser\u00a0405,\u00a0488\u00a0y\u00a0561,\u00a0el\u00a0divisor\u00a0de\u00a0\nhaz\u00a0acusto\u2010\u00f3ptico\u00a0AOBS\u00a0y\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0emisi\u00f3n\u00a0\nentre\u00a0los\u00a0rangos\u00a0de\u00a0415\u2010480,\u00a0500\u2010550\u00a0nm\u00a0y\u00a0571\u2010\n625,\u00a0respectivamente, \u00a0y\u00a0un\u00a0pinhole\u00a0fijado\u00a0en\u00a01.\u00a0\nTodas\u00a0las\u00a0im\u00e1genes \u00a0fueron\u00a0adquiridas \u00a0con\u00a0un\u00a0\nobjetivo\u00a0de\u00a0inmersi\u00f3n \u00a0en\u00a0aceite\u00a0APO\u00a063x\u00a0(NA\u00a01,4)\u00a0\ny\u00a0digitalizadas \u00a0en\u00a0un\u00a0formato\u00a0TIFF\u00a0de\u00a01024\u00a0\u00d7\u00a01024\u00a0\np\u00edxeles\u00a0y\u00a012\u00a0bits\u00a0de\u00a0profundidad \u00a0(4.096\u00a0niveles\u00a0de\u00a0de\u00a0informaci\u00f3n \u00a0de\u00a0intensidad \u00a0de\u00a0fluorescencia). \u00a0\nCuantificaci\u00f3n \u00a0de\u00a0pHER2\u00a0en\u00a0cultivos\u00a0primarios :\u00a0Se\u00a0\nutiliz\u00f3\u00a0un\u00a0zoom\u00a0(3X)\u00a0electr\u00f3nico \u00a0para\u00a0obtener\u00a0as\u00ed\u00a0\nuna\u00a0mayor\u00a0ampliaci\u00f3n \u00a0y\u00a0una\u00a0mejor\u00a0resoluci\u00f3n \u00a0de\u00a0\nimagen.\u00a0La\u00a0media\u00a0de\u00a0fluorescencia \u00a0de\u00a0pHER2\u00a0\n(Integrity \u00a0density/area) \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nseleccionadas \u00a0(\u00fanicamente \u00a0las\u00a0que\u00a0eran\u00a0pan\u2010CK\u00a0\npositivas) \u00a0se\u00a0cuantificaron \u00a0utilizando \u00a0una\u00a0macro\u00a0\npersonalizada \u00a0y\u00a0ejecutada \u00a0en\u00a0el\u00a0software\u00a0gratuito\u00a0\nFIJI\u00a0(ImageJ\u2010Wayne\u00a0Rasband,\u00a0NIH,\u00a0EE.UU.).\u00a0En\u00a0\nresumen, \u00a0la\u00a0macro\u00a0permit\u00eda\u00a0que\u00a0el\u00a0canal\u00a0verde\u00a0\n(representado \u00a0por\u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0pHER2)\u00a0fuera\u00a0\nfiltrado\u00a0con\u00a0un\u00a0radio\u00a01,\u00a0umbralizado \u00a0y\u00a0convertido \u00a0\nen\u00a0una\u00a0imagen\u00a0binaria.\u00a0A\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0aplicaci\u00f3n \u00a0de\u00a0\nla\u00a0operaci\u00f3n \u00a0m\u00ednima\u00a0aritm\u00e9tica \u00a0entre\u00a0el\u00a0canal\u00a0\nverde\u00a0original\u00a0y\u00a0las\u00a0im\u00e1genes \u00a0binarias,\u00a0se\u00a0obtuvo\u00a0la\u00a0\ntinci\u00f3n\u00a0espec\u00edfica \u00a0de\u00a0la\u00a0membrana \u00a0plasm\u00e1tica \u00a0y\u00a0se\u00a0\npudo\u00a0cuantificar \u00a0la\u00a0fluorescencia \u00a0correspondiente \u00a0\nde\u00a0la\u00a0c\u00e9lula\u00a0a\u00a0cuantificar. \u00a0La\u00a0selecci\u00f3n \u00a0de\u00a0cada\u00a0\nc\u00e9lula\u00a0te\u00f1ida\u00a0para\u00a0pHER2\u00a0tambi\u00e9n\u00a0se\u00a0hizo\u00a0en\u00a0base\u00a0\na\u00a0un\u00a0triple\u00a0marcaje\u00a0donde\u00a0adem\u00e1s\u00a0de\u00a0pHER2\u00a0la\u00a0\nc\u00e9lula\u00a0deb\u00eda\u00a0estar\u00a0marcada\u00a0positivamente \u00a0para\u00a0\nDAPI\u00a0(n\u00facleo)\u00a0y\u00a0Alexa\u00a0Fluor\u00a0555\u00a0(pan\u2010CK).\u00a0Los\u00a0\ndatos\u00a0resultantes \u00a0se\u00a0exportaron \u00a0a\u00a0una\u00a0hoja\u00a0de\u00a0\nc\u00e1lculo\u00a0Excel\u00a0y\u00a0se\u00a0normalizaron. \u00a0Por\u00a0cada\u00a0tumor\u00a0se\u00a0\nanaliz\u00f3\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0pHER2\u00a0en\u00a0varias\u00a0c\u00e9lulas\u00a0de\u00a0\ncada\u00a0grupo:\u00a0grupo\u00a0control,\u00a0SP\u00a06\u00a0min\u00a0y\u00a0SP\u00a010\u00a0min,\u00a0\n(m\u00ednimo\u00a020\u00a0c\u00e9lulas\u00a0por\u00a0grupo\u00a0y\u00a0m\u00e1ximo\u00a0275\u00a0\nc\u00e9lulas\u00a0por\u00a0grupo).\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0en\u00a0\nsoblre\u00a0la\u00a0intensidad \u00a0de\u00a0fluorescencia \u00a0de\u00a0pHER2\u00a0se\u00a0\nanalizaron \u00a0mediante \u00a0un\u00a0m\u00e9todo\u00a0basado\u00a0en\u00a0un\u00a0\nmodelo\u00a0mixto489.\u00a0Se\u00a0cre\u00f3\u00a0una\u00a0matriz\u00a0de\u00a0covarianza \u00a0\nno\u00a0estructurada, \u00a0ya\u00a0que\u00a0no\u00a0implicaba \u00a0ninguna\u00a0\nsuposici\u00f3n \u00a0acerca\u00a0de\u00a0la\u00a0variabilidad \u00a0intra\u2010sujeto.\u00a0El\u00a0\nmodelo\u00a0inclu\u00eda\u00a0el\u00a0efecto\u00a0anidado\u00a0de\u00a0cada\u00a0c\u00e9lula\u00a0\ndel\u00a0tumor\u00a0primario\u00a0dentro\u00a0de\u00a0la\u00a0muestra\u00a0del\u00a0\ntumor\u00a0y\u00a0dentro\u00a0de\u00a0los\u00a0distintos\u00a0subtipos\u00a0\ntumorales. \u00a0La\u00a0media\u00a0de\u00a0m\u00ednimos\u00a0cuadrados \u00a0(LSM,\u00a0\ndel\u00a0ingl\u00e9s\u00a0least\u00a0squares\u00a0means )\u00a0y\u00a0un\u00a0intervalo\u00a0de\u00a0\nconfianza \u00a0del\u00a095%\u00a0fueron\u00a0utilizados \u00a0para\u00a0estimar\u00a0\nlos\u00a0efectos\u00a0del\u00a0tratamiento \u00a0SP\u00a0comparado \u00a0con\u00a0el\u00a0\ngrupo\u00a0control.\u00a0El\u00a0an\u00e1lisis\u00a0estad\u00edstico \u00a0se\u00a0realiz\u00f3\u00a0\nutilizando \u00a0el\u00a0software\u00a0SAS\u00a09.2\u00a0(SAS\u00a0Institute\u00a0Inc,\u00a0\nCary,\u00a0NC,\u00a0EE.UU.)\u00a0y\u00a0un\u00a0nivel\u00a0de\u00a00,05\u00a0(dos\u00a0colas)\u00a0fue\u00a0\nconsiderado \u00a0estad\u00edsticamente \u00a0significativo. \u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n108\u00a0\n\u00a05.6.\u00a0Inmunohistoqu\u00edmica \u00a0\n\u00a05.6.1.\u00a0Preparaci\u00f3n \u00a0de\u00a0microarrays \u00a0de\u00a0tejidos\u00a0\n\u00a0\nTrescientos \u00a0dieciocho \u00a0(318)\u00a0casos\u00a0de\u00a0tumores\u00a0de\u00a0\nmama\u00a0invasivos\u00a0fueron\u00a0extra\u00eddos \u00a0de\u00a0forma\u00a0\nconsecutiva \u00a0y\u00a0recogidos \u00a0en\u00a0el\u00a0Seoul\u00a0National\u00a0\nUniversity \u00a0Bundang\u00a0Hospital\u00a0desde\u00a0el\u00a0a\u00f1o\u00a02003\u00a0al\u00a0\na\u00f1o\u00a02006\u00a0de\u00a0acuerdo\u00a0con\u00a0un\u00a0protocolo \u00a0aprobado \u00a0\npor\u00a0la\u00a0Universidad \u00a0Nacional\u00a0de\u00a0Se\u00fal,\u00a0del\u00a0Hospital\u00a0\nBundang. \u00a0Microarrays \u00a0de\u00a0tejidos\u00a0(TMAs)\u00a0se\u00a0\nconstruyeron \u00a0en\u00a0base\u00a0a\u00a0tres\u00a0columnas \u00a0\nrepresentativas \u00a0de\u00a0tejido\u00a0de\u00a0carcinoma \u00a0invasivo\u00a0(2\u00a0\nmm\u00a0de\u00a0di\u00e1metro), \u00a0utilizando \u00a0un\u00a0aparato\u00a0de\u00a0\ntr\u00e9pano\u00a0(Superbiochips \u00a0Laboratories, \u00a0Se\u00fal,\u00a0Corea).\u00a0\nLa\u00a0informaci\u00f3n \u00a0cl\u00ednico\u2010patol\u00f3gica \u00a0se\u00a0obtuvo\u00a0\nmediante \u00a0la\u00a0revisi\u00f3n\u00a0de\u00a0los\u00a0expedientes \u00a0m\u00e9dicos\u00a0y\u00a0\nrevisando \u00a0los\u00a0cortes\u00a0de\u00a0los\u00a0tumores\u00a0te\u00f1idos\u00a0con\u00a0\nhematoxilina \u2010eosina\u00a0(H&E).\u00a0La\u00a0informaci\u00f3n \u00a0histo\u2010\npatol\u00f3gica \u00a0fue\u00a0revisada\u00a0para\u00a0cada\u00a0caso:\u00a0subtipo\u00a0\ntumoral,\u00a0estadio\u00a0T,\u00a0estadio\u00a0N,\u00a0graduaci\u00f3n \u00a0\nhistol\u00f3gica \u00a0de\u00a0Scarff\u2010\u00a0Bloom\u2010Richardson, \u00a0invasi\u00f3n\u00a0\nlinfovascular, \u00a0frente\u00a0de\u00a0invasi\u00f3n\u00a0tumoral\u00a0y\u00a0\npresencia \u00a0o\u00a0ausencia\u00a0de\u00a0componentes \u00a0\ncaracter\u00edsiticos \u00a0de\u00a0un\u00a0CDIS.\u00a0\nLa\u00a0expresi\u00f3n \u00a0de\u00a0biomarcadores \u00a0est\u00e1ndar\u00a0como\u00a0el\u00a0\nRE,\u00a0RP\u00a0y\u00a0HER2\u00a0fue\u00a0evaluada\u00a0en\u00a0secciones \u00a0\ncompletas \u00a0del\u00a0tumor\u00a0o\u00a0en\u00a0secciones \u00a0del\u00a0TMA,\u00a0en\u00a0\naquellos\u00a0casos\u00a0que\u00a0se\u00a0extraviaron \u00a0datos\u00a0durante\u00a0el\u00a0\nestudio.\u00a0La\u00a0expresi\u00f3n \u00a0de\u00a0EGFR\u00a0o\u00a0CK5/6\u00a0fue\u00a0\nevaluada\u00a0utilizando \u00a0los\u00a0TMAs.\u00a0Se\u00a0consideraron \u00a0\npositivos\u00a0los\u00a0marcadores \u00a0de\u00a0RE\u00a0y\u00a0RP\u00a0si\u00a0se\u00a0\nencontraba \u00a0almenos\u00a0un\u00a01%\u00a0de\u00a0positividad \u00a0nuclear,\u00a0\nde\u00a0acuerdo\u00a0con\u00a0las\u00a0directrices \u00a0del\u00a0ASCO/CAP490.\u00a0La\u00a0\npuntuaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0HER2\u00a0se\u00a0clasific\u00f3\u00a0de\u00a0\nla\u00a0siguiente\u00a0manera:\u00a00,\u00a0sin\u00a0tinci\u00f3n;\u00a01+,\u00a0tinci\u00f3n\u00a0\nd\u00e9bil\u00a0e\u00a0incompleta \u00a0de\u00a0la\u00a0membrana \u00a0en\u00a0\u2265\u00a010%\u00a0de\u00a0\nlas\u00a0c\u00e9lulas;\u00a02+,\u00a0tinci\u00f3n\u00a0d\u00e9bil\u00a0o\u00a0moderada \u00a0en\u00a0toda\u00a0la\u00a0\nmembrana \u00a0plasm\u00e1tica \u00a0en\u00a0\u2265 \u00a010%\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\ntumorales; \u00a03+,\u00a0tinci\u00f3n\u00a0fuerte\u00a0de\u00a0toda\u00a0la\u00a0\nmembrana \u00a0completa \u00a0en\u00a0\u2265 \u00a030%\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\ntumorales. \u00a0Cualquier \u00a0tinci\u00f3n\u00a0para\u00a0el\u00a0receptor\u00a0\nEGFR\u00a0fue\u00a0considerada \u00a0como\u00a0positiva,\u00a0y\u00a0una\u00a0\npuntuaci\u00f3n \u00a0de\u00a03+\u00a0en\u00a0las\u00a0muestras \u00a0evaluadas \u00a0por\u00a0\nIHQ\u00a0o\u00a0la\u00a0presencia \u00a0de\u00a0amplificaci\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0HER2\u00a0mediante \u00a0FISH\u00a0se\u00a0consideraron \u00a0positivos\u00a0\npara\u00a0este\u00a0gen.\u00a0Para\u00a0las\u00a0CK5/6,\u00a0los\u00a0casos\u00a0con\u00a0alguna\u00a0\npositividad \u00a0en\u00a0la\u00a0membrana \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nse\u00a0agruparon \u00a0como\u00a0positivos. \u00a0\nLos\u00a0distintos\u00a0subtipos\u00a0de\u00a0CM\u00a0se\u00a0definieron \u00a0tal\u00a0y\u00a0\ncomo\u00a0ya\u00a0estaban\u00a0descritos\u00a0pero\u00a0con\u00a0\nmodificaciones \u00a0menores491.\u00a0Los\u00a0marcadores \u00a0que\u00a0\ndefinen\u00a0los\u00a0subitpos\u00a0tumorales \u00a0utilizados \u00a0en\u00a0este\u00a0\nestudio\u00a0fueron\u00a0los\u00a0siguientes: \u00a0luminal\u00a0A\u00a0(ER+\u00a0y\u00a0/\u00a0o\u00a0\nPR+,\u00a0HER2\u2010),\u00a0luminal\u00a0B\u00a0(ER+\u00a0y\u00a0/\u00a0o\u00a0PR+,\u00a0HER2+),\u00a0\nHER2+\u00a0(ER\u2010,\u00a0PR\u2010,\u00a0HER2+),\u00a0de\u00a0tipo\u00a0Basal\u00a0(ER\u00a0\u2010,\u00a0PR\u2010,\u00a0\nHER2\u2010,\u00a0CK5/6\u00a0+,\u00a0y\u00a0/\u00a0o\u00a0EGFR\u00a0+),\u00a0y\u00a0sin\u00a0clasificar\u00a0\n(negativo \u00a0para\u00a0todos\u00a0los\u00a0marcadores). \u00a0\n5.6.2.\u00a0Preparaci\u00f3n \u00a0de\u00a0bloques\u00a0celulares\u00a0\n\u00a0\nPara\u00a0la\u00a0preparaci\u00f3n \u00a0de\u00a0bloques\u00a0celulares\u00a0se\u00a0\nsembraron \u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0a\u00a0estudiar\u00a0en\u00a0un\u00a0\nflasc\u00f3n\u00a0de\u00a075\u00a0cm2\u00a0de\u00a0superficie \u00a0y\u00a0se\u00a0dejaron\u00a0crecer\u00a0\nhasta\u00a0alcanzar\u00a0el\u00a080%\u00a0de\u00a0su\u00a0confluencia. \u00a0\nSeguidamente \u00a0se\u00a0tripsinizaron, \u00a0se\u00a0centrifugaron \u00a05\u00a0\nmin\u00a0a\u00a01500\u00a0rpm\u00a0y\u00a0se\u00a0hicieron\u00a0dos\u00a0lavados\u00a0con\u00a0PBS.\u00a0\nA\u00a0continuaci\u00f3n \u00a0se\u00a0fijaron\u00a0las\u00a0c\u00e9lulas\u00a0\nresuspendi\u00e9ndolas \u00a0en\u00a01\u00a0ml\u00a0de\u00a0PFA\u00a0al\u00a02%\u00a0durante\u00a0\n30\u201060\u00a0min.\u00a0Una\u00a0vez\u00a0fijadas,\u00a0se\u00a0centrifugaron \u00a0a\u00a0800\u00a0\nrpm\u00a0durante\u00a02\u00a0min\u00a0y\u00a0se\u00a0lavaron\u00a0dos\u00a0veces\u00a0con\u00a01\u00a0ml\u00a0\nde\u00a0PBS,\u00a0resuspendi\u00e9ndolas \u00a0finalmente \u00a0en\u00a010\u201015\u00a0\u00b5l\u00a0\nde\u00a0PBS.\u00a0A\u00a0partir\u00a0de\u00a0aqu\u00ed\u00a0se\u00a0a\u00f1adi\u00f3\u00a0lo\u00a0m\u00e1s\u00a0r\u00e1pido\u00a0\nposible\u00a0100\u00a0\u00b5l\u00a0de\u00a0agar\u00a0al\u00a02%\u00a0(a\u00a0una\u00a0temperatura \u00a0\nno\u00a0mayor\u00a0de\u00a050\u00baC).\u00a0Se\u00a0agitaron\u00a0con\u00a0un\u00a0v\u00f3rtex\u00a0\ndurante\u00a02\u20103\u00a0segundos \u00a0y\u00a0r\u00e1pidamente \u00a0se\u00a0\ncentrifugaron \u00a0a\u00a010000\u00a0rpm\u00a0durante\u00a02\u20103\u00a0min.\u00a0Por\u00a0\n\u00faltimo,\u00a0se\u00a0colocaron \u00a0las\u00a0muestras \u00a0en\u00a0hielo\u00a0unos\u00a020\u00a0\nmin\u00a0hasta\u00a0que\u00a0el\u00a0agar\u00a0solidific\u00f3. \u00a0Con\u00a0una\u00a0jeringa\u00a0\nllena\u00a0de\u00a0PBS\u00a0se\u00a0insert\u00f3\u00a0la\u00a0aguja\u00a0(24G)\u00a0entre\u00a0la\u00a0\npared\u00a0del\u00a0eppendorf \u00a0y\u00a0el\u00a0agar\u00a0solidificado, \u00a0y\u00a0se\u00a0fue\u00a0\ninyectando \u00a0poco\u00a0a\u00a0poco\u00a0el\u00a0PBS\u00a0hasta\u00a0que\u00a0el\u00a0agar\u00a0\nse\u00a0despeg\u00f3.\u00a0Por\u00a0\u00faltimo\u00a0se\u00a0coloc\u00f3\u00a0el\u00a0bloque\u00a0celular\u00a0\nen\u00a0el\u00a0caset\u00a0para\u00a0parafinar\u00a0y\u00a0se\u00a0introdujo \u00a0el\u00a0caset\u00a0\nen\u00a0paraformaldeh\u00eddo \u00a0al\u00a04%\u00a0durante\u00a01\u00a0hora.\u00a0\nFinalmente, \u00a0se\u00a0cambi\u00f3\u00a0el\u00a0caset\u00a0a\u00a0un\u00a0frasco\u00a0con\u00a0\nPBS,\u00a0a\u00a04\u00b0C\u00a0hasta\u00a0su\u00a0procesamiento \u00a0y\u00a0su\u00a0inclusi\u00f3n\u00a0\nen\u00a0parafina.\u00a0\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n109\u00a0\n\u00a05.6.3.\u00a0Procedimiento \u00a0de\u00a0inmunohistoqu\u00edmica \u00a0\n\u00a0\nLos\u00a0cortes\u00a0histol\u00f3gicos \u00a0fueron\u00a0desparafinados \u00a0en\u00a0\nxileno\u00a0(2\u00a0lavados\u00a0de\u00a03\u00a0minutos)\u00a0y\u00a0se\u00a0hidrataron \u00a0en\u00a0\nuna\u00a0serie\u00a0de\u00a0concentraciones \u00a0decrecientes \u00a0de\u00a0\netanol/PBS \u00a0(100,\u00a0100,\u00a070,\u00a0y\u00a050%)\u00a0y\u00a0finalmente \u00a0H2O\u00a0\ndurante\u00a03\u00a0minutos\u00a0cada\u00a0uno.\u00a0Despu\u00e9s\u00a0de\u00a0la\u00a0\nrecuperaci\u00f3n \u00a0de\u00a0ant\u00edgenos \u00a0inducida\u00a0por\u00a0calor\u00a0en\u00a0\ntamp\u00f3n\u00a0de\u00a0citrato\u00a0(pH\u00a06),\u00a0las\u00a0muestras \u00a0fueron\u00a0\nbloqueadas \u00a0con\u00a0suero\u00a0de\u00a0cabra\u00a0y\u00a0se\u00a0incubaron \u00a0\ndurante\u00a01\u00a0hora\u00a0a\u00a0TA\u00a0con\u00a0los\u00a0distintos\u00a0anticuerpos \u00a0\nanti\u00a0NK\u20101R,\u00a0NK\u20102R,\u00a0SP,\u00a0COX2,\u00a0o\u00a0\u03b1 \u2010SMA\u00a0en\u00a0las\u00a0\ndiluciones \u00a0indicadas \u00a0en\u00a0la\u00a0secci\u00f3n\u00a01\u00a0(los\u00a0reactivos\u00a0\nutilizados \u00a0en\u00a0el\u00a0estudio).\u00a0A\u00a0continuaci\u00f3n, \u00a0las\u00a0\nmuestras \u00a0fueron\u00a0incubadas \u00a0con\u00a0un\u00a0anticuerpo \u00a0\nsecundario \u00a0de\u00a0cabra\u00a0anti\u2010rat\u00f3n\u00a0o\u00a0anti\u2010conejo\u00a0IgG\u00a0\nbiotinilado \u00a0a\u00a0una\u00a0diluci\u00f3n\u00a01:100\u00a0durante\u00a030\u00a0min\u00a0a\u00a0\nTA\u00a0seguido\u00a0por\u00a0el\u00a0sistema\u00a0de\u00a0peroxidasa \u00a0ABC\u00a0\n(Vectastain \u00a0ABC\u00a0System\u00a0Vector\u00a0Laboratories). \u00a0El\u00a0\nDAB\u00a0(3,3\u00a0'\u2010diaminodbenzidine) \u00a0se\u00a0utiliz\u00f3\u00a0como\u00a0\nsustrato\u00a0colorim\u00e9trico \u00a0y\u00a0los\u00a0portaobjetos \u00a0se\u00a0contra\u00a0\nti\u00f1eron\u00a0finalmente \u00a0con\u00a0hematoxilina \u00a0o\u00a0verde\u00a0de\u00a0\nmetilo.\u00a0Los\u00a0controles \u00a0negativos \u00a0fueron\u00a0muestras \u00a0\nincubadas \u00a0con\u00a0suero\u00a0de\u00a0cabra\u00a0y\u00a0sin\u00a0el\u00a0anticuerpo \u00a0\nprimario,\u00a0y\u00a0los\u00a0controles \u00a0positivos\u00a0inclu\u00edan\u00a0tejidos\u00a0\nque\u00a0expresaban, \u00a0de\u00a0manera\u00a0conocida, \u00a0cada\u00a0\nprote\u00edna\u00a0a\u00a0estudiar.\u00a0La\u00a0especificidad \u00a0de\u00a0los\u00a0\nanticuerpos \u00a0se\u00a0confirm\u00f3\u00a0adem\u00e1s\u00a0con\u00a0la\u00a0presencia \u00a0\nde\u00a0p\u00e9ptidos\u00a0bloqueantes \u00a0para\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0SP.\u00a0\n5.6.4.\u00a0Evaluaci\u00f3n \u00a0inmunohistoqu\u00edmica \u00a0\n\u00a0\nEl\u00a0an\u00e1lisis\u00a0inmunohistoqu\u00edmico \u00a0de\u00a0los\u00a0TMAs\u00a0se\u00a0\nrealiz\u00f3\u00a0en\u00a0dos\u00a0cortes\u00a0independientes \u00a0de\u00a0muestras \u00a0\npara\u00a0confirmar \u00a0la\u00a0fiabilidad \u00a0de\u00a0la\u00a0tinci\u00f3n.\u00a0La\u00a0\nexpresi\u00f3n \u00a0de\u00a0cada\u00a0marcador \u00a0se\u00a0anot\u00f3\u00a0semi\u2010\ncuantitativamente \u00a0mediante \u00a0la\u00a0puntuaci\u00f3n \u00a0\ninmunorreactiva \u00a0(IRS,\u00a0del\u00a0ingl\u00e9s\u00a0immunoreactive \u00a0\nscore ).\u00a0Esta\u00a0puntuaci\u00f3n \u00a0es\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0dos\u00a0\nvariables, \u00a0el\u00a0porcentaje \u00a0de\u00a0c\u00e9lulas\u00a0positivas\u00a0(PP)\u00a0y\u00a0\nla\u00a0intensidad \u00a0de\u00a0la\u00a0tinci\u00f3n\u00a0(IT).\u00a0La\u00a0IT\u00a0se\u00a0determin\u00f3 \u00a0\ncomo:\u00a00\u00a0si\u00a0no\u00a0hab\u00eda\u00a0tinci\u00f3n;\u00a01\u00a0+\u00a0para\u00a0la\u00a0tinci\u00f3n\u00a0\nd\u00e9bil,\u00a02\u00a0+\u00a0para\u00a0la\u00a0tinci\u00f3n\u00a0moderada, \u00a03\u00a0+\u00a0para\u00a0la\u00a0\ntinci\u00f3n\u00a0fuerte\u00a0y\u00a04\u00a0+\u00a0para\u00a0la\u00a0tinci\u00f3n\u00a0muy\u00a0fuerte.\u00a0Los\u00a0\ncriterios\u00a0para\u00a0la\u00a0IT\u00a0se\u00a0definieron \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0definici\u00f3n \u00a0de\u00a0la\u00a0gama\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0cada\u00a0\nmarcador \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0tumorales, \u00a0estableciendo \u00a0\nla\u00a0intensidad \u00a0m\u00e1s\u00a0baja\u00a0y\u00a0m\u00e1s\u00a0alta\u00a0para\u00a0cada\u00a0\nmarcador \u00a0revisando \u00a0primero\u00a0todas\u00a0las\u00a0muestras. \u00a0\nLa\u00a0variable\u00a0IT\u00a0se\u00a0multiplic\u00f3 \u00a0por\u00a0PP\u00a0y\u00a0se\u00a0obtuvo\u00a0una\u00a0\nvariable\u00a0continua\u00a0para\u00a0definir\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0cada\u00a0\nmarcador. \u00a0Adem\u00e1s,\u00a0los\u00a0valores\u00a0resultantes \u00a0de\u00a0\nexpresi\u00f3n \u00a0tambi\u00e9n\u00a0fueron\u00a0categorizados \u00a0de\u00a0la\u00a0\nsiguiente\u00a0manera:\u00a00\u00a0(tinci\u00f3n\u00a0negativa), \u00a01\u00a0(valor\u00a0de\u00a0\ntinci\u00f3n\u00a0>0\u00a0y\u00a0<100),\u00a02\u00a0(puntuaci\u00f3n \u00a0de\u00a0tinci\u00f3n\u00a0>100\u00a0y\u00a0\n<200),\u00a03\u00a0(valor\u00a0de\u00a0tinci\u00f3n\u00a0>\u00a0200).\u00a0Ambas\u00a0\nevaluaciones, \u00a0tanto\u00a0la\u00a0variable\u00a0continua\u00a0como\u00a0la\u00a0\nvariable\u00a0ordinal\u00a0se\u00a0utilizaron \u00a0para\u00a0investigar \u00a0la\u00a0\nasociaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0con\u00a0las\u00a0caracter\u00edsticas \u00a0\ncl\u00ednico\u2010patol\u00f3gicas \u00a0de\u00a0los\u00a0pacientes. \u00a0\u00a0\nTanto\u00a0para\u00a0la\u00a0variable\u00a0cont\u00ednua\u00a0como\u00a0para\u00a0la\u00a0\nvariable\u00a0oridinal\u00a0el\u00a0an\u00e1lisis\u00a0estad\u00edstico \u00a0de\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0prote\u00edna\u00a0en\u00a0los\u00a0TMAs\u00a0se\u00a0realiz\u00f3\u00a0\nmediante \u00a0la\u00a0prueba\u00a0estad\u00edstica \u00a0de\u00a0Mann\u2010Whitney\u00a0\npara\u00a0dos\u00a0categor\u00edas \u00a0y\u00a0Kruskal\u2010Wallis\u00a0para\u00a0m\u00e1s\u00a0de\u00a0\ndos\u00a0categor\u00edas. \u00a0Cuando\u00a0se\u00a0encontraron \u00a0diferencias \u00a0\nsignificativas \u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0Kruskal\u2010Wallis,\u00a0se\u00a0\nutiliz\u00f3\u00a0una\u00a0ANOVA\u00a0con\u00a0correcci\u00f3n \u00a0de\u00a0Bonferroni. \u00a0\nPara\u00a0el\u00a0an\u00e1lisis\u00a0estad\u00edstico \u00a0se\u00a0utiliz\u00f3\u00a0el\u00a0software\u00a0\nSAS\u00a09.2\u00a0(SAS\u00a0Institute\u00a0Inc,\u00a0Cary,\u00a0NC,\u00a0EE.UU.)\u00a0y\u00a0un\u00a0\nnivel\u00a0de\u00a00,05\u00a0(dos\u00a0colas)\u00a0fue\u00a0considerado \u00a0\nestad\u00edsticamente \u00a0significativo. \u00a0\n5.6.5.\u00a0Evaluaci\u00f3n \u00a0del\u00a0\u00edndice\u00a0mit\u00f3tico\u00a0\n\u00a0\nSe\u00a0evalu\u00f3\u00a0el\u00a0\u00edndice\u00a0mit\u00f3tico\u00a0(IM)\u00a0en\u00a0secciones \u00a0de\u00a0\ntejito\u00a0de\u00a0tumor\u00a0extra\u00eddo\u00a0de\u00a0rat\u00f3n\u00a0y\u00a0te\u00f1idas\u00a0con\u00a0\nH&E.\u00a0El\u00a0IM\u00a0se\u00a0estableci\u00f3 \u00a0mediante \u00a0el\u00a0recuento\u00a0de\u00a0\nlas\u00a0mitosis\u00a0en\u00a010\u00a0campos\u00a0de\u00a0alto\u00a0poder\u00a0(HPF,\u00a0del\u00a0\ningl\u00e9s\u00a0High\u00a0Power\u00a0Field)\u00a0por\u00a0cada\u00a0secci\u00f3n\u00a0del\u00a0\ntumor\u00a0y\u00a0despu\u00e9s\u00a0se\u00a0dividi\u00f3\u00a0el\u00a0promedio \u00a0de\u00a0las\u00a0\nmitosis\u00a0entre\u00a0el\u00a0HPF\u00a0(1,96\u00a0mm2).\u00a0El\u00a0nivel\u00a0de\u00a0\nsignificaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0\nprueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas).\u00a0Los\u00a0valores\u00a0con\u00a0\nuna\u00a0P\u00a0<0,05\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0\nsignificativos. \u00a0\n\u00a0MATERIALES \u00a0Y\u00a0M\u00c9TODOS \u00a0\u00a0\n\u00a0\n110\u00a0\n\u00a05.6.6.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0\nprote\u00edna\u00a0\u03b1\u2010SMA\u00a0\n\u00a0\nSe\u00a0cuantific\u00f3 \u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0\u03b1\u2010SMA\u00a0en\u00a0secciones \u00a0de\u00a0\ntejido\u00a0de\u00a0tumor\u00a0de\u00a0rat\u00f3n\u00a0con\u00a0el\u00a0software\u00a0de\u00a0\nan\u00e1lisis\u00a0de\u00a0imagen\u00a0de\u00a0Olympus, \u00a0Cell^D.\u00a0El\u00a0\nsoftware\u00a0detecta\u00a0autom\u00e1ticamente \u00a0y\u00a0clasifica\u00a0por\u00a0\nseparado \u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0\u03b1\u2010SMA\u00a0y\u00a0la\u00a0zona\u00a0de\u00a0los\u00a0\nn\u00facleos\u00a0pudiendo \u00a0establecer \u00a0de\u00a0esta\u00a0forma\u00a0los\u00a0\ndiferentes \u00a0umbrales \u00a0de\u00a0tinci\u00f3n\u00a0para\u00a0ambos\u00a0\nmarcadores. \u00a0La\u00a0relaci\u00f3n\u00a0entre\u00a0el\u00a0n\u00famero\u00a0de\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0presentes \u00a0en\u00a0la\u00a0secci\u00f3n\u00a0del\u00a0\ntumor\u00a0y\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0\u03b1\u2010SMA\u00a0se\u00a0estableci\u00f3 \u00a0\ndividiendo \u00a0el\u00a0%\u00a0del\u00a0\u00e1rea\u00a0total\u00a0de\u00a0\u03b1 \u2010SMA\u00a0(\u03bcm2)\u00a0\nentre\u00a0%\u00a0de\u00a0la\u00a0superficie \u00a0total\u00a0de\u00a0los\u00a0n\u00facleos\u00a0(\u03bcm2)\u00a0\nen\u00a010\u00a0HPF\u00a0por\u00a0muestra\u00a0de\u00a0tumor.\u00a0El\u00a0nivel\u00a0de\u00a0\nsignificaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0\nprueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas).\u00a0Los\u00a0valores\u00a0con\u00a0\nuna\u00a0P\u00a0<0,05\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0\nsignificativos.\u00a0\n111\u00a0\n\u00a0RESULTADOS \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n113\u00a0\n\u00a01.\u00a0EL\u00a0RECEPTOR \u00a0NK\u20101\u00a0Y\u00a0LA\u00a0SP\u00a0SE\u00a0\nENCUENTRAN \u00a0EXPRESADOS \u00a0EN\u00a0\nTUMORES \u00a0PRIMARIOS \u00a0DE\u00a0C\u00c1NCER\u00a0\nDE\u00a0MAMA\u00a0Y\u00a0SE\u00a0CORRELACIONAN \u00a0\nCON\u00a0EL\u00a0SUBTIPO\u00a0TUMORAL \u00a0HER2+\u00a0\n\u00a0\nEn\u00a0primer\u00a0lugar\u00a0se\u00a0decidi\u00f3\u00a0investigar \u00a0la\u00a0correlaci\u00f3n \u00a0\nentre\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0la\u00a0SP\u00a0con\u00a0\ndiferentes \u00a0caracter\u00edsticas \u00a0clinicopatol\u00f3gicas \u00a0en\u00a0\nc\u00e1ncer\u00a0de\u00a0mama\u00a0humano.\u00a0Para\u00a0ello,\u00a0se\u00a0realiz\u00f3\u00a0\ninmunohistoqu\u00edmica \u00a0para\u00a0esas\u00a0prote\u00ednas \u00a0en\u00a0\nmicromatrices \u00a0de\u00a0tejidos\u00a0o\u00a0microarrays \u00a0que\u00a0\nconten\u00edan \u00a0muestras \u00a0correspondientes \u00a0a\u00a0317\u00a0\npacientes. \u00a0Los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0cada\u00a0\nprote\u00edna\u00a0y\u00a0su\u00a0correlaci\u00f3n \u00a0con\u00a0las\u00a0caracter\u00edsticas \u00a0\nclinicopatol\u00f3gicas \u00a0se\u00a0trataron\u00a0como\u00a0variables\u00a0\ncontinuas \u00a0cuando\u00a0la\u00a0cuantificaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0\nde\u00a0prote\u00edna\u00a0se\u00a0determin\u00f3 \u00a0con\u00a0valores\u00a0de\u00a0entre\u00a00\u00a0y\u00a0\n400\u00a0(Tabla\u00a0anexa\u00a01)\u00a0y\u00a0como\u00a0variables\u00a0ordinales \u00a0\ncuando\u00a0la\u00a0cuantificaci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0se\u00a0\ncategoriz\u00f3 \u00a0en\u00a04\u00a0categor\u00edas \u00a0distintas:\u00a00\u00a0(tinci\u00f3n\u00a0\nnegativa), \u00a01\u00a0(valores\u00a0entre\u00a00\u00a0y\u00a0100),\u00a02\u00a0(valores\u00a0\nentre\u00a0100\u00a0y\u00a0200),\u00a03\u00a0(valores\u00a0por\u00a0encima\u00a0de\u00a0200)\u00a0\n(Tabla\u00a0anexa\u00a02)\u00a0(para\u00a0m\u00e1s\u00a0detalles\u00a0ver\u00a0la\u00a0secci\u00f3n\u00a0\nde\u00a0materiales \u00a0y\u00a0m\u00e9todos). \u00a0Los\u00a0valores\u00a0de\u00a0\nexpresi\u00f3n \u00a0tratados\u00a0tanto\u00a0como\u00a0variable\u00a0continua\u00a0o\u00a0\ncomo\u00a0variable\u00a0ordinal\u00a0mostraron \u00a0correlaciones \u00a0\nsimilares\u00a0tras\u00a0el\u00a0an\u00e1lisis\u00a0estad\u00edstico, \u00a0reforzando \u00a0los\u00a0\nresultados \u00a0obtenidos. \u00a0\nLa\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0NK\u20101\u00a0y\u00a0NK\u20102,\u00a0y\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0SP\u00a0se\u00a0detectaron \u00a0en\u00a0el\u00a094%,\u00a086%\u00a0y\u00a0el\u00a0\n52%\u00a0de\u00a0los\u00a0tumores\u00a0analizados, \u00a0respectivamente \u00a0\n(Fig.\u00a01A\u2010C).\u00a0La\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0de\u00a0la\u00a0\nSP\u00a0se\u00a0asoci\u00f3\u00a0positivamente \u00a0con\u00a0caracter\u00edsticas \u00a0\nhistopatol\u00f3gicas \u00a0tumorales \u00a0relacionadas \u00a0con\u00a0mal\u00a0\npron\u00f3stico. \u00a0Por\u00a0ejemplo,\u00a0los\u00a0niveles\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0se\u00a0correlacionaron \u00a0con\u00a0falta\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0\nRE\u00a0y\u00a0del\u00a0RP,\u00a0y\u00a0con\u00a0sobreexpresi\u00f3n \u00a0de\u00a0p53.\u00a0La\u00a0\nexpresi\u00f3n \u00a0de\u00a0SP\u00a0tambi\u00e9n\u00a0se\u00a0correlacion\u00f3 \u00a0con\u00a0un\u00a0\nalto\u00a0grado\u00a0histol\u00f3gico, \u00a0una\u00a0falta\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0\nRE\u00a0y\u00a0RP,\u00a0y\u00a0una\u00a0expresi\u00f3n \u00a0elevada\u00a0de\u00a0Ki67.\u00a0Por\u00a0el\u00a0\ncontrario, \u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20102\u00a0se\u00a0asoci\u00f3\u00a0con\u00a0un\u00a0bajo\u00a0grado\u00a0histol\u00f3gico, \u00a0positividad \u00a0para\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0los\u00a0RE\u00a0y\u00a0PR,\u00a0y\u00a0con\u00a0ausencia\u00a0de\u00a0\nexpresi\u00f3n \u00a0de\u00a0p53\u00a0(Tabla\u00a0anexa\u00a01\u00a0y\u00a02).\u00a0Seg\u00fan\u00a0los\u00a0\ndatos\u00a0cl\u00ednicos\u00a0recopilados \u00a0clasificamos \u00a0los\u00a0tumores\u00a0\nen\u00a0subtipos\u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0RE,\u00a0PR,\u00a0\nHER2,\u00a0 EGFR\u00a0 y\u00a0 CK\u00a0 5/6\u00a0 mediante \u00a0\ninmunohistoqu\u00edmica, \u00a0tal\u00a0y\u00a0como\u00a0se\u00a0describe\u00a0en\u00a0la\u00a0\nsecci\u00f3n\u00a0de\u00a0materiales \u00a0y\u00a0m\u00e9todos. \u00a0Los\u00a0subtipos\u00a0\ntumorales \u00a0se\u00a0definieron \u00a0como\u00a0luminal\u00a0A,\u00a0luminal\u00a0\nB,\u00a0HER2+,\u00a0basal,\u00a0y\u00a0fenotipo\u00a0indeterminado. \u00a0\nCuriosamente, \u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0y\u00a0de\u00a0SP\u00a0eran\u00a0significativamente \u00a0\nmayores\u00a0en\u00a0los\u00a0tumores\u00a0con\u00a0un\u00a0subtipo\u00a0HER2+,\u00a0\ntanto\u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0considerados \u00a0\ncomo\u00a0variables\u00a0continuas \u00a0como\u00a0en\u00a0los\u00a0\nconsiderados \u00a0como\u00a0variables\u00a0ordinales \u00a0(Fig.\u00a01D\u2010I).\u00a0\nSe\u00a0detect\u00f3\u00a0la\u00a0misma\u00a0asociaci\u00f3n \u00a0positiva\u00a0en\u00a0los\u00a0\ntumores\u00a0que\u00a0presentaban \u00a0una\u00a0amplificaci\u00f3n \u00a0\ng\u00e9nica\u00a0de\u00a0HER2\u00a0(Tabla\u00a0anexa\u00a01\u00a0y\u00a02).\u00a0Por\u00a0el\u00a0\ncontrario, \u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20102\u00a0era\u00a0la\u00a0\nm\u00e1s\u00a0baja\u00a0en\u00a0este\u00a0subtipo\u00a0de\u00a0tumor\u00a0en\u00a0particular \u00a0\n(Fig.\u00a01E\u00a0y\u00a01H).\u00a0\u00a0\n\u00a0\n2.\u00a0LOS\u00a0NIVELES\u00a0CIRCULANTES \u00a0DE\u00a0SP\u00a0\nEST\u00c1N\u00a0AUMENTADOS \u00a0EN\u00a0\nPACIENTES \u00a0CON\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\n\u00a0\nAunque\u00a0la\u00a0SP\u00a0act\u00faa\u00a0principalmente \u00a0como\u00a0un\u00a0\nfactor\u00a0autocrino/paracrino \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0\ncancerosas, \u00a0este\u00a0p\u00e9ptido\u00a0puede\u00a0ser\u00a0detectado \u00a0en\u00a0\nel\u00a0suero\u00a0de\u00a0pacientes \u00a0sanos\u00a0\u00a0y\u00a0tiene\u00a0algunos\u00a0\nefectos\u00a0sist\u00e9micos \u00a0en\u00a0otras\u00a0enfermedades. \u00a0Por\u00a0\nejemplo,\u00a0la\u00a0SP\u00a0puede\u00a0actuar\u00a0sist\u00e9micamente \u00a0como\u00a0\nmensajero \u00a0para\u00a0movilizar\u00a0c\u00e9lulas\u00a0estromales \u00a0\n(CD29+)\u00a0de\u00a0la\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0desde\u00a0la\u00a0periferia\u00a0hasta\u00a0\nlos\u00a0sitios\u00a0lesionados \u00a0y\u00a0promover \u00a0as\u00ed\u00a0la\u00a0curaci\u00f3n\u00a0de\u00a0\ntejido\u00a0da\u00f1ado182.\u00a0\n\u00a0\n\u00a0\n\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n114\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a01.\u00a0Expresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0SP\u00a0en\u00a0tumores\u00a0primarios \u00a0de\u00a0CM.\u00a0Im\u00e1genes \u00a0de\u00a0inmunohistoqu\u00edmica \u00a0representativas \u00a0de\u00a0los\u00a0\ndiferentes \u00a0subtipos\u00a0tumorales \u00a0para\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0(A)\u00a0NK\u20101R,\u00a0(B)\u00a0NK\u20102R\u00a0y\u00a0(C)\n\u00a0SP.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0representa \u00a0100\u00a0\nmicras.\u00a0D\u2010F.\u00a0Los\u00a0gr\u00e1ficos\u00a0de\u00a0barra\u00a0muestran \u00a0el\u00a0porcentaje \u00a0de\u00a0casos\u00a0con\u00a0expresi\u00f3n \u00a0negativa,\u00a0baja,\u00a0media\u00a0y\u00a0alta\u00a0(puntuaci\u00f3n \u00a0de\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a00\u00a0a\u00a03,\u00a0respectivamente, \u00a0evaluada\u00a0como\u00a0variable\u00a0ordinal,\u00a0como\u00a0se\u00a0detalla\u00a0en\u00a0la\u00a0secci\u00f3n\u00a0materiales \u00a0y\u00a0m\u00e9todos) \u00a0de\u00a0NK\u2010\n1R,\u00a0NK\u20102R\u00a0y\u00a0SP\u00a0en\u00a0la\u00a0cada\u00a0subtipo\u00a0tumoral.\u00a0G\u2010I.\u00a0Los\u00a0diagramas \u00a0de\u00a0caja\u00a0muestran \u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0\nSP\u00a0evaluada\u00a0como\u00a0variable\u00a0continua\u00a0en\u00a0cada\u00a0subtipo\u00a0tumoral\u00a0entre\u00a0el\u00a0percentil\u00a05\u201095,\u00a0y\u00a0el\u00a0diamante \u00a0amarillo\u00a0indica\u00a0la\u00a0media\u00a0de\u00a0\nresultados. \u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0calculadas \u00a0mediante \u00a0ANOVA\u00a0se\u00a0indican\u00a0como\u00a0*P<0.05,\u00a0**P<0.01\u00a0y\u00a0***P<0.001.\u00a0LumA,\u00a0\nluminal\u00a0A;\u00a0LumB,\u00a0luminal\u00a0B;\u00a0In,\u00a0indeterminado; \u00a0u.a.\u00a0unidades\u00a0arbitrarias. \u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n115\u00a0\n\u00a0Para\u00a0investigar \u00a0las\u00a0alteraciones \u00a0en\u00a0los\u00a0niveles\u00a0\ns\u00e9ricos\u00a0de\u00a0SP\u00a0circulante \u00a0en\u00a0pacientes \u00a0con\u00a0CM\u00a0y\u00a0su\u00a0\ncorrelaci\u00f3n \u00a0con\u00a0algunas\u00a0caracter\u00edsticas \u00a0cl\u00ednico\u2010\npatol\u00f3gicas, \u00a0se\u00a0determinaron \u00a0mediante \u00a0ELISA\u00a0los\u00a0\nniveles\u00a0s\u00e9ricos\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0139\u00a0pacientes \u00a0con\u00a0CM\u00a0y\u00a0\n92\u00a0controles \u00a0sanos.\u00a0Los\u00a0niveles\u00a0de\u00a0SP\u00a0fueron\u00a0\nsignificativamente \u00a0mayores\u00a0en\u00a0pacientes \u00a0con\u00a0CM\u00a0\nen\u00a0comparaci\u00f3n \u00a0con\u00a0los\u00a0controles \u00a0sanos,\u00a0aunque\u00a0\nno\u00a0se\u00a0observ\u00f3\u00a0ninguna\u00a0correlaci\u00f3n \u00a0con\u00a0un\u00a0subtipo\u00a0\nde\u00a0tumor\u00a0en\u00a0particular \u00a0o\u00a0cualquier \u00a0otra\u00a0\ncaracter\u00edstica \u00a0cl\u00ednico\u2010patol\u00f3gica \u00a0(Fig.\u00a02\u00a0y\u00a0Tabla\u00a0\nanexa\u00a03).\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a02.\u00a0Niveles\u00a0sist\u00e9micos \u00a0de\u00a0SP\u00a0en\u00a0pacientes \u00a0con\u00a0CM\u00a0y\u00a0en\u00a0\npacientes \u00a0sanos .\u00a0Los\u00a0diagramas \u00a0de\u00a0caja\u00a0muestran \u00a0la\u00a0\ndistribuci\u00f3n \u00a0de\u00a0los\u00a0valores\u00a0entre\u00a0el\u00a0percentil\u00a05\u201095,\u00a0y\u00a0el\u00a0\ndiamante \u00a0amarillo\u00a0indica\u00a0la\u00a0media\u00a0de\u00a0resultados. \u00a0Las\u00a0\ndiferencias \u00a0estad\u00edsticas \u00a0se\u00a0calcularon \u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0\nWilcoxon \u00a0para\u00a0dos\u00a0muestras \u00a0y\u00a0se\u00a0indican\u00a0como\u00a0*P<0,05.\u00a0\n\u00a0\n3.\u00a0LAS\u00a0TAQUIQUININAS \u00a0MODULAN \u00a0\nLA\u00a0ACTIVACI\u00d3N \u00a0DE\u00a0LOS\u00a0\nRECEPTORES \u00a0EGFR\u00a0Y\u00a0HER2\u00a0EN\u00a0\nC\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\n3.1\u00a0La\u00a0SP\u00a0transactiva \u00a0HER2\u00a0y\u00a0EGFR\u00a0\nEn\u00a0base\u00a0a\u00a0otras\u00a0publicaciones \u00a0que\u00a0describen \u00a0que\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0mediada\u00a0por\u00a0SP\u00a0\npuede\u00a0transactivar \u00a0a\u00a0EGFR\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0glioblastoma312,\u00a0surgi\u00f3\u00a0la\u00a0hip\u00f3tesis\u00a0de\u00a0que\u00a0la\u00a0alta\u00a0\nexpresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0SP\u00a0en\u00a0los\u00a0tumores\u00a0\nHER2+\u00a0podr\u00eda\u00a0ser\u00a0debida\u00a0a\u00a0la\u00a0existencia \u00a0de\u00a0una\u00a0\ncooperaci\u00f3n \u00a0funcional \u00a0entre\u00a0los\u00a0dos\u00a0sistemas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0(el\u00a0sistema\u00a0de\u00a0taquiquininas \u00a0y\u00a0el\u00a0\nsistema\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0receptores \u00a0\nde\u00a0la\u00a0familia\u00a0ErbB).\u00a0Para\u00a0confirmar \u00a0esta\u00a0hip\u00f3tesis, \u00a0\nse\u00a0exploraron \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0un\u00a0panel\u00a0de\u00a0\nl\u00edneas\u00a0celulares\u00a0de\u00a0CM:\u00a0tres\u00a0l\u00edneas\u00a0con\u00a0\nsobreexpresi\u00f3n \u00a0del\u00a0gen\u00a0ERBB2\u00a0(MDA\u2010MB\u2010453,\u00a0SK\u2010\nBR\u20103\u00a0y\u00a0BT\u2010474),\u00a0dos\u00a0l\u00edneas\u00a0sin\u00a0(MDA\u2010MB\u2010231\u00a0y\u00a0\nMCF7)\u00a0y\u00a0una\u00a0l\u00ednea\u00a0con\u00a0sobreexpresi\u00f3n \u00a0del\u00a0gen\u00a0\nEGFR\u00a0(MDA\u2010MB\u2010468).\u00a0Todas\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0\nCM\u00a0expresaban \u00a0diferentes \u00a0niveles\u00a0de\u00a0los\u00a0tres\u00a0\nprincipales \u00a0receptores \u00a0de\u00a0taquiquininas \u00a0NK\u20101,\u00a0NK\u2010\n2\u00a0y\u00a0NK\u20103\u00a0(Fig.\u00a03).\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nFigura\u00a03.\u00a0Mapa\u00a0de\u00a0intensidades. \u00a0Perfil\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0\nrelativa\u00a0de\u00a0TACR1 ,\u00a0TACR2\u00a0y\u00a0TACR3\u00a0calculados \u00a0mediante \u00a0qPCR\u00a0\nen\u00a0distintas\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0Los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0\ng\u00e9nica\u00a0se\u00a0representan \u00a0como\u00a0log\n10\u00a0de\u00a0los\u00a0valores\u00a0de\u00a02\u2010\u0394\u0394Ct.\u00a0\n\u00a0\n\u00a0\nUna\u00a0vez\u00a0conocida\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0\nde\u00a0taquiquininas \u00a0en\u00a0todas\u00a0las\u00a0l\u00edneas\u00a0celulares, \u00a0se\u00a0\nrealizaron \u00a0estudios\u00a0de\u00a0tiempo\u2010respuesta \u00a0tratando\u00a0\nlas\u00a0l\u00edneas\u00a0con\u00a0SP\u00a0(100\u00a0nM)\u00a0a\u00a00,\u00a01,\u00a02,\u00a04,\u00a06,\u00a08,\u00a010,\u00a015\u00a0y\u00a0\n30\u00a0min.\u00a0Se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0SP\u00a0induc\u00eda\u00a0r\u00e1pidamente \u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0en\u00a0la\u00a0tirosina\u00a01248\u00a0(pHER2\u00a0\nY1248)\u00a0en\u00a0todas\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0HER2+\u00a0dentro\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n116\u00a0\n\u00a0de\u00a0los\u00a0primeros\u00a06\u00a0o\u00a010\u00a0minutos\u00a0(Fig.\u00a04A\u2010B).\u00a0\nAunque\u00a0se\u00a0observ\u00f3\u00a0que\u00a0el\u00a0minuto\u00a0de\u00a0m\u00e1xima\u00a0\nactivaci\u00f3n \u00a0variaba\u00a0entre\u00a0experimentos, \u00a0exist\u00eda\u00a0a\u00a0\nuna\u00a0tendencia \u00a0de\u00a0activaci\u00f3n \u00a0similar\u00a0en\u00a0cada\u00a0\nrepetici\u00f3n \u00a0que\u00a0se\u00a0llev\u00f3\u00a0a\u00a0cabo.\u00a0Interesantemente, \u00a0\nse\u00a0observ\u00f3\u00a0una\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0incluso\u00a0en\u00a0las\u00a0\nl\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010231\u00a0y\u00a0MCF7,\u00a0l\u00edneas\u00a0con\u00a0\nuna\u00a0muy\u00a0baja\u00a0expresi\u00f3n \u00a0del\u00a0receptor, \u00a0y\u00a0sin\u00a0\namplificaci\u00f3n \u00a0o\u00a0sobreexpresi\u00f3n \u00a0del\u00a0gen\u00a0ERBB2492,\u00a0\nlo\u00a0que\u00a0sugiere\u00a0que\u00a0la\u00a0capacidad \u00a0de\u00a0la\u00a0SP\u00a0para\u00a0\nactivar\u00a0receptor\u00a0HER2\u00a0es\u00a0independiente \u00a0de\u00a0los\u00a0\nniveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0este\u00a0receptor. \u00a0Adem\u00e1s\u00a0de\u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2,\u00a0el\u00a0tratamiento \u00a0con\u00a0SP\u00a0\nindujo\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0en\u00a0la\u00a0tirosina\u00a01068\u00a0\n(EGFR\u00a0Y1068),\u00a0tirosina\u00a0que\u00a0se\u00a0activa\u00a0mediante \u00a0la\u00a0\nuni\u00f3n\u00a0de\u00a0ligando245,\u00a0y\u00a0EGFR\u00a0Y845,\u00a0tirosina\u00a0que\u00a0se\u00a0\nactiva\u00a0mediante \u00a0la\u00a0uni\u00f3n\u00a0de\u00a0Src366\u00a0(Fig.\u00a04A\u2010B).\u00a0Por\u00a0\notro\u00a0lado,\u00a0las\u00a0v\u00edas\u00a0de\u00a0p42/44\u00a0MAPK\u00a0y\u00a0Akt\u00a0tambi\u00e9n\u00a0\nse\u00a0activaron \u00a0sustancialmente \u00a0bajo\u00a0el\u00a0est\u00edmulo\u00a0de\u00a0\nla\u00a0SP\u00a0(Fig.\u00a04A\u2010B),\u00a0tal\u00a0y\u00a0como\u00a0se\u00a0describi\u00f3\u00a0\nanteriormente \u00a0en\u00a0otras\u00a0l\u00edneas\u00a0celulares247,313.\u00a0Las\u00a0\ncuantificaciones \u00a0se\u00a0muestran \u00a0como\u00a0\u201cfold\u00a0change\u201d\u00a0\n(n\u00famero\u00a0de\u00a0veces\u00a0que\u00a0se\u00a0expresa\u00a0una\u00a0prote\u00edna\u00a0en\u00a0\nuna\u00a0muestra\u00a0respecto\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0muestra\u00a0\ncontrol).\u00a0\nLa\u00a0activaci\u00f3n \u00a0y\u00a0la\u00a0localizaci\u00f3n \u00a0subcelular \u00a0de\u00a0EGFR\u00a0y\u00a0\nHER2\u00a0bajo\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0SP\u00a0durante\u00a0\ndiferentes \u00a0tiempos\u00a0de\u00a0tratamiento \u00a0tambi\u00e9n\u00a0se\u00a0\nestudiaron \u00a0mediante \u00a0inmunofluorescencia \u00a0y\u00a0\nmicroscop\u00eda \u00a0confocal.\u00a0Se\u00a0observ\u00f3\u00a0un\u00a0incremento \u00a0\nen\u00a0los\u00a0niveles\u00a0de\u00a0pHER2\u00a0Y1248\u00a0en\u00a0la\u00a0membrana \u00a0de\u00a0\nla\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453\u00a0(HER2+)\u00a0y\u00a0un\u00a0\nincremento \u00a0en\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0ves\u00edculas\u00a0\nendoc\u00edticas \u00a0que\u00a0conten\u00edan \u00a0EGFR\u00a0activado\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0(EGFR+).\u00a0Como\u00a0punto\u00a0\nrepresentativo \u00a0solo\u00a0se\u00a0muestran \u00a0im\u00e1genes \u00a0\ncorrespondientes \u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0observada \u00a0a\u00a0los\u00a0\n10\u00a0min\u00a0(Fig.\u00a04C).\u00a03.2\u00a0La\u00a0cin\u00e9tica\u00a0de\u00a0activaci\u00f3n \u00a0del\u00a0\nreceptor\u00a0HER2\u00a0es\u00a0dosis\u2010dependiente \u00a0\nPara\u00a0comprobar \u00a0la\u00a0cin\u00e9tica\u00a0de\u00a0activaci\u00f3n \u00a0del\u00a0\nreceptor\u00a0HER2\u00a0se\u00a0trat\u00f3\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010\n453,\u00a0con\u00a0dosis\u00a0crecientes \u00a0de\u00a0SP\u00a0(100,\u00a0200\u00a0y\u00a0500\u00a0\nnM)\u00a0en\u00a0los\u00a0tiempos\u00a0indicados. \u00a0La\u00a0cin\u00e9tica\u00a0de\u00a0\nactivaci\u00f3n \u00a0del\u00a0receptor\u00a0HER2\u00a0mostr\u00f3\u00a0ser\u00a0dosis\u2010\ndependiente, \u00a0produci\u00e9ndose \u00a0de\u00a0forma\u00a0m\u00e1s\u00a0\ntemprana \u00a0al\u00a0elevarse\u00a0las\u00a0concentraciones \u00a0de\u00a0SP\u00a0\n(Fig.\u00a05A\u2010C).\u00a0\n\u00a0\n3.3\u00a0La\u00a0transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0no\u00a0se\u00a0\nlimita\u00a0a\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0una\u00a0sola\u00a0\ntaquiquinina \u00a0\n\u00a0\nPara\u00a0investigar \u00a0la\u00a0capacidad \u00a0potencial \u00a0de\u00a0otras\u00a0\ntaquiquininas \u00a0para\u00a0activar\u00a0HER2,\u00a0se\u00a0realizaron \u00a0\nestudios\u00a0de\u00a0tiempo\u2010respuesta \u00a0con\u00a0NKA\u00a0y\u00a0NKB\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453,\u00a0la\u00a0cual\u00a0expresa\u00a0los\u00a0tres\u00a0\nreceptores \u00a0de\u00a0taquiquininas \u00a0(NK\u20101,\u00a0NK\u20102\u00a0y\u00a0NK\u20103).\u00a0\nLa\u00a0fosforilaci\u00f3n \u00a0del\u00a0receptor\u00a0HER2\u00a0en\u00a0la\u00a0Tyr1248\u00a0\ntambi\u00e9n\u00a0se\u00a0logr\u00f3\u00a0bajo\u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0NKA\u00a0y\u00a0\nNKB\u00a0(Fig.\u00a06),\u00a0lo\u00a0que\u00a0suger\u00eda\u00a0que\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0HER2\u00a0no\u00a0se\u00a0limitaba\u00a0s\u00f3lo\u00a0a\u00a0la\u00a0SP.\u00a0Sin\u00a0embargo, \u00a0\ndado\u00a0que\u00a0la\u00a0SP\u00a0es\u00a0la\u00a0taquiquinina \u00a0principal\u00a0en\u00a0\nmam\u00edferos, \u00a0se\u00a0decidi\u00f3\u00a0continuar \u00a0las\u00a0\ninvestigaciones \u00a0profundizando \u00a0en\u00a0los\u00a0mecanismos \u00a0\npor\u00a0los\u00a0cuales\u00a0la\u00a0SP\u00a0induc\u00eda\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0\nHER2\u00a0y\u00a0EGFR\u00a0en\u00a0CM.\u00a0\n\u00a0\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n117\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nFigura\u00a04.\u00a0Transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0por\u00a0SP\u00a0en\u00a0l\u00edneas\u00a0\ncelulares\u00a0humanas \u00a0de\u00a0CM.\u00a0A.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0\nWestern\u00a0blot\u00a0que\u00a0muestran \u00a0la\u00a0fosforilaci\u00f3n \u00a0(denotada \u00a0por\u00a0\np\u2010)\u00a0de\u00a0HER2\u00a0(Y1248),\u00a0EGFR\u00a0(Y1048\u00a0y\u00a0Y845),\u00a0p42/44\u2010MAPK\u00a0y\u00a0\nAkt\u00a0despu\u00e9s\u00a0de\u00a0tratar\u00a06\u00a0l\u00edneas\u00a0tumorales \u00a0de\u00a0CM\u00a0con\u00a0SP\u00a0\n(100\u00a0nM)\u00a0a\u00a0los\u00a0tiempos\u00a0indicados. \u00a0La\u00a0tubulina\u00a0(no\u00a0\nmostrada) \u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0\nprote\u00edna.\u00a0B.\u00a0Cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0cada\u00a0\nmembrana \u00a0corregida \u00a0por\u00a0su\u00a0correspondiente \u00a0tubulina.\u00a0Las\u00a0\ncolumnas \u00a0de\u00a0la\u00a0gr\u00e1fica\u00a0corresponden \u00a0a\u00a0los\u00a0puntos\u00a0de\u00a0\ntiempo\u00a00,\u00a01,\u00a02,\u00a04,\u00a06,\u00a08,\u00a010,\u00a015\u00a0y\u00a030\u00a0minutos\u00a0despu\u00e9s\u00a0del\u00a0\ntratamiento \u00a0SP.\u00a0Cada\u00a0imagen\u00a0es\u00a0representativa \u00a0de\u00a0tres\u00a0\nexperimentos \u00a0independientes. \u00a0C.\u00a0Im\u00e1genes \u00a0representativas \u00a0\nde\u00a0la\u00a0Inmunofluorescencia \u00a0de\u00a0pHER2\u00a0y\u00a0EGFR\u00a0tras\u00a0el\u00a0\ntratamiento \u00a0con\u00a0SP\u00a0100\u00a0nM\u00a0durante\u00a010\u00a0minutos\u00a0tomadas\u00a0\nmediante \u00a0microscop\u00eda \u00a0confocal.\u00a0Los\u00a0paneles\u00a0de\u00a0color\u00a0rojo\u00a0y\u00a0\nverde\u00a0resaltan\u00a0las\u00a0c\u00e9lulas\u00a0seleccionadas \u00a0(indicadas \u00a0con\u00a0\nflechas\u00a0blancas)\u00a0para\u00a0mostrar\u00a0la\u00a0ubicaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0EGFR,\u00a0\nrespectivamente. \u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0representa \u00a050\u00a0micras.\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n118\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\nFigura\u00a05.\u00a0Efecto\u00a0dosis\u2010respuesta \u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP.\u00a0La\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453\u00a0se\u00a0trat\u00f3\u00a0con\u00a0A.\u00a0100\u00a0nM,\u00a0\nB.\u00a0200\u00a0nM\u00a0o\u00a0C.\u00a0500\u00a0nM\u00a0de\u00a0SP\u00a0durante\u00a00,\u00a01,\u00a02,\u00a04,\u00a06,\u00a08,\u00a010,\u00a015\u00a0y\u00a030\u00a0minutos,\u00a0\ny\u00a0la\u00a0fosforilaci\u00f3n \u00a0(denotada \u00a0por\u00a0p\u2010)\u00a0de\u00a0HER2\u00a0Y1248\u00a0se\u00a0\ndetect\u00f3\u00a0por\u00a0Western\u00a0blot.\u00a0Como\u00a0control\u00a0end\u00f3geno \u00a0se\u00a0utiliz\u00f3\u00a0la\u00a0tubulina\u00a0para\u00a0asegurar\u00a0una\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna\u00a0en\u00a0cada\u00a0\npunto\u00a0de\u00a0tiempo.\u00a0Los\u00a0gr\u00e1ficos\u00a0representan \u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0pHER2,\u00a0y\u00a0el\u00a0punto\u00a0m\u00e1ximo\u00a0de\u00a0activaci\u00f3n \u00a0se\u00a0indica\u00a0\nen\u00a0rojo.\u00a0\n\u00a0\nFigura\u00a06.\u00a0Las\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0muestran \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0NKA\u00a0(A)\u00a0y\u00a0NKB\u00a0(B)\u00a0a\u00a0100\u00a0nM\u00a0y\u00a01\u00a0\u00b5M\u00a0sobre\u00a0la\u00a0fosforilaci\u00f3n \u00a0\n(denotada \u00a0por\u00a0p\u2010)\u00a0de\u00a0HER2,\u00a0p42/44\u00a0MAPK\u00a0y\u00a0Akt\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453\u00a0para\u00a0los\u00a0tiempos\u00a0indicados. \u00a0Los\u00a0gr\u00e1ficos\u00a0de\u00a0la\u00a0\nderecha\u00a0muestran \u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0cada\u00a0membrana. \u00a0En\u00a0todos\u00a0los\u00a0casos\u00a0se\u00a0utiliz\u00f3\u00a0la\u00a0tubulina\u00a0como\u00a0control\u00a0\nend\u00f3geno \u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00ednas \u00a0para\u00a0cada\u00a0punto\u00a0de\u00a0tiempo.\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n119\u00a0\n\u00a04.\u00a0LA\u00a0SP\u00a0TRANSACTIVA \u00a0HER2\u00a0EN\u00a0\nC\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\nHUMANO \u00a0\nUna\u00a0vez\u00a0demostrado \u00a0in\u00a0vitro\u00a0que\u00a0la\u00a0SP\u00a0\ntransactivaba \u00a0HER2\u00a0en\u00a0l\u00edneas\u00a0celulares, \u00a0se\u00a0decidi\u00f3\u00a0\nconfirmar \u00a0si\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0la\u00a0\nSP\u00a0pod\u00eda\u00a0tener\u00a0una\u00a0relevancia \u00a0cl\u00ednica\u00a0y\u00a0si\u00a0este\u00a0\nfen\u00f3meno \u00a0era\u00a0reproducible \u00a0en\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nderivadas \u00a0de\u00a0pacientes \u00a0con\u00a0CM.\u00a0\u00a0A\u00a0partir\u00a0de\u00a0tejido\u00a0\nfresco\u00a0disgregado \u00a0y\u00a0criopreservado, \u00a0una\u00a0vez\u00a0\ndescongelados \u00a0los\u00a0tejidos,\u00a0se\u00a0prepar\u00f3\u00a0una\u00a0\nsuspensi\u00f3n \u00a0celular\u00a0que\u00a0se\u00a0trat\u00f3\u00a0con\u00a0SP\u00a0(100\u00a0nM)\u00a0\ndurante\u00a06\u00a0y\u00a010\u00a0minutos.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0realiz\u00f3\u00a0\nuna\u00a0inmunofluorescencia \u00a0multicolor \u00a0para\u00a0detectar\u00a0\npHER2\u00a0y\u00a0CKs,\u00a0y\u00a0se\u00a0cuantificaron \u00a0solo\u00a0aquellas\u00a0\nc\u00e9lulas\u00a0CK+\u00a0(de\u00a0origen\u00a0epitelial)\u00a0en\u00a0im\u00e1genes \u00a0\nobtenidas \u00a0a\u00a0partir\u00a0de\u00a0microscop\u00eda \u00a0confocal\u00a0(Fig.\u00a07).\u00a0\nEn\u00a0general,\u00a0se\u00a0analiz\u00f3\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0pHER2\u00a0\nY1248\u00a0en\u00a0un\u00a0total\u00a0de\u00a01896\u00a0c\u00e9lulas\u00a0individuales \u00a0\nobtenidas \u00a0a\u00a0partir\u00a0de\u00a019\u00a0cultivos\u00a0primarios \u00a0de\u00a0\ndistintos\u00a0subtipos\u00a0de\u00a0CM\u00a0definidos \u00a0por\u00a0los\u00a0\nmarcadores \u00a0ER,\u00a0PR\u00a0y\u00a0la\u00a0amplificaci\u00f3n \u00a0de\u00a0HER2\u00a0\n(Tabla\u00a0anexa\u00a04).\u00a0Para\u00a0llevar\u00a0a\u00a0cabo\u00a0este\u00a0estudio\u00a0se\u00a0\nseleccionaron \u00a0por\u00a0IHQ\u00a0tumores\u00a0que\u00a0expresaban \u00a0\nNK\u20101\u00a0y\u00a0diferentes \u00a0niveles\u00a0de\u00a0HER2\u00a0(Fig.\u00a08A\u2010B)\u00a0y\u00a0\nTabla\u00a0anexa\u00a04).\u00a0\u00a0De\u00a0acuerdo\u00a0con\u00a0las\u00a0caracter\u00edsticas \u00a0\nde\u00a0cada\u00a0subtipo\u00a0tumoral,\u00a0se\u00a0detectaron \u00a0niveles\u00a0\nbasales\u00a0de\u00a0pHER2\u00a0Y1248\u00a0m\u00e1s\u00a0elevados\u00a0en\u00a0las\u00a0\nmuestras \u00a0del\u00a0punto\u00a0control\u00a0(0\u00a0min)\u00a0derivadas \u00a0del\u00a0\nsubtipo\u00a0tumoral\u00a0HER2+\u00a0y\u00a0luminal\u00a0B,\u00a0comparados \u00a0\ncon\u00a0el\u00a0luminal\u00a0A\u00a0o\u00a0tumores\u00a0triple\u00a0negativos \u00a0(Fig.\u00a0\n9).\u00a0Despu\u00e9s\u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0todas\u00a0las\u00a0muestras, \u00a0\n\u00fanicamente \u00a0se\u00a0observ\u00f3\u00a0un\u00a0incremento \u00a0\nestad\u00edsticamente \u00a0significativo \u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0\nde\u00a0HER2\u00a0Tyr1248\u00a0mediada\u00a0por\u00a0SP\u00a0en\u00a0aquellas\u00a0\nc\u00e9lulas\u00a0derivadas \u00a0de\u00a0los\u00a0tumores\u00a0HER2+\u00a0y\u00a0triple\u00a0\nnegativo\u00a0(Fig.\u00a010A\u2010B)\u00a0y\u00a0hubo\u00a0algunas\u00a0variaciones \u00a0\nentre\u00a0los\u00a0tumores\u00a0del\u00a0subtipo\u00a0luminal\u00a0A.\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a07.\u00a0Esquema\u00a0del\u00a0dise\u00f1o\u00a0experimental \u00a0utilizado\u00a0para\u00a0los\u00a0\ncultivos\u00a0primarios \u00a0de\u00a0CM\u00a0a\u00a0corto\u00a0plazo\u00a0para\u00a0investigar \u00a0los\u00a0\nefectos\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0en\u00a0los\u00a0tumores\u00a0\nhumanos \u00a0de\u00a0CM.\u00a0\nDe\u00a0hecho,\u00a07\u00a0de\u00a0cada\u00a010\u00a0tumores\u00a0luminal\u00a0A,\u00a0\npresentaban \u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0(de\u00a0acuerdo\u00a0\ncon\u00a0los\u00a0resultados \u00a0obtenidos \u00a0en\u00a0l\u00edneas\u00a0de\u00a0\ncelulares) \u00a0tal\u00a0y\u00a0como\u00a0se\u00a0puede\u00a0apreciar\u00a0en\u00a0los\u00a0\nan\u00e1lisis\u00a0de\u00a0cada\u00a0tumor\u00a0individual \u00a0(Fig.\u00a011A).\u00a0A\u00a0\npesar\u00a0de\u00a0que\u00a0estos\u00a0an\u00e1lisis\u00a0estaban\u00a0limitados \u00a0a\u00a0\ns\u00f3lo\u00a019\u00a0tumores\u00a0primarios \u00a0de\u00a0CM,\u00a0se\u00a0encontr\u00f3\u00a0\nuna\u00a0asociaci\u00f3n \u00a0entre\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0y\u00a0el\u00a0subtipo\u00a0HER2+\u00a0(Fig.\u00a011B)\u00a0o\u00a0la\u00a0\namplificaci\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0HER2\u00a0(Fig.\u00a011C),\u00a0similar\u00a0a\u00a0\nlas\u00a0observaciones \u00a0previas\u00a0en\u00a0los\u00a0TMAs\u00a0(Fig.\u00a01A\u2010D\u2010\nG).\u00a0\u00a0\n\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n120\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a08.\u00a0Im\u00e1genes \u00a0de\u00a0inmunohistoqu\u00edmica \u00a0representativas \u00a0mostrando \u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0los\u00a0tumores\u00a0utilizados \u00a0\npara\u00a0los\u00a0cultivos\u00a0primarios. \u00a0A.\u00a0Las\u00a0diferentes \u00a0im\u00e1genes \u00a0muestran \u00a0los\u00a0patrones\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0detectada \u00a0\nmediante \u00a0IHQ.\u00a0Se\u00a0muestran \u00a0algunos\u00a0ejemplos\u00a0de\u00a0intensidad\n\u00a0muy\u00a0baja\u00a0(1+,\u00a0flecha\u00a0amarilla), \u00a0de\u00a0intensidad \u00a0intermedia \u00a0(2+\u00a0flechas\u00a0\nde\u00a0color\u00a0naranja)\u00a0y\u00a0de\u00a0intensidad \u00a0elevada\u00a0(3+,\u00a0flechas\u00a0rojas).\u00a0Como\u00a0control,\u00a0se\u00a0identificaron \u00a0los\u00a0fibroblastos \u00a0presentes \u00a0en\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0las\u00a0muestras \u00a0analizadas \u00a0y\u00a0que\u00a0presentaban \u00a0una\u00a0alta\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0(estrellas\u00a0negras).\u00a0B.\u00a0Los\u00a0haces\u00a0de\u00a0\nfibras\u00a0nerviosas \u00a0con\u00a0tinci\u00f3n\u00a0positiva\u00a0para\u00a0NK\u20101R\u00a0(flecha\u00a0negra),\u00a0tambi\u00e9n\u00a0se\u00a0utilizaron \u00a0como\u00a0control\u00a0positivo\u00a0para\u00a0el\u00a0marcaje\u00a0del\u00a0\nreceptor\u00a0NK\u20101.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0representa \u00a050\u00a0micras.\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a09.\u00a0Transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP\u00a0en\u00a0cultivos\u00a0primarios \u00a0derivados \u00a0\nde\u00a0muestras \u00a0de\u00a0CM.\u00a0A.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0la\u00a0los\u00a0niveles\u00a0basales\u00a0de\u00a0HER2\u00a0Y1248\u00a0\n(control\u00a0o\u00a00\u00a0min)\u00a0en\u00a0los\u00a0distintos\u00a0subtipos\u00a0de\u00a0tumores.\u00a0Los\u00a0valores\u00a0se\u00a0muestran \u00a0como\u00a0\nmedias\u00a0de\u00a0m\u00ednimos\u00a0cuadrados \u00a0estimadas \u00a0y\u00a0las\u00a0barras\u00a0de\u00a0error\u00a0representan \u00a0el\u00a0\nintervalo\u00a0de\u00a0confianza \u00a0del\u00a095%.\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0se\u00a0indican\u00a0como\u00a0*P<0,05,\u00a0\n**\u00a0P<0,01\u00a0y\u00a0***\u00a0P<0,001.\u00a0TN:\u00a0Triple\u00a0negativo. \u00a0\n\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n121\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0Figura\u00a010.\u00a0Transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP\u00a0en\u00a0cultivos\u00a0primarios \u00a0derivados \u00a0de\u00a0muestras \u00a0de\u00a0CM.\u00a0A.\u00a0Im\u00e1genes \u00a0\nrepresentativas \u00a0de\u00a0inmunofluorescencia \u00a0que\u00a0muestran \u00a0el\u00a0marcaje\u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0pHER2\u00a0Y1248\u00a0(verde)\u00a0y\u00a0pan\u2010CK\u00a0(rojo)\u00a0en\u00a0\nc\u00e9lulas\u00a0humanas\u00a0de\u00a0CM\u00a0de\u00a0diferentes \u00a0subtipos\u00a0de\n\u00a0tumores\u00a0tratados\u00a0con\u00a0SP\u00a0durante\u00a06\u00a0y\u00a010\u00a0minutos.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0representa \u00a0\n20\u00a0micras.\u00a0B.\u00a0Cuantificaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0pHER2.\u00a0Los\u00a0efectos\u00a0de\u00a0la\u00a0SP\u00a0sobre\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0de\u00a0todas\u00a0las\u00a0c\u00e9lulas,\u00a0en\u00a0\ncada\u00a0subgrupo, \u00a0se\u00a0muestran \u00a0como\u00a0control\u00a0(punto\u00a0blanco),\u00a0SP\u00a06\u00a0minutos\u00a0(puntos\u00a0de\u00a0verde\u00a0claro)\u00a0y\u00a0SP\u00a010\u00a0minutos\u00a0(punto\u00a0verde\u00a0\noscuro).\u00a0Los\u00a0valores\u00a0se\u00a0muestran \u00a0como\u00a0medias\u00a0de\u00a0m\u00ednimos\u00a0cuadrados \u00a0estimadas. \u00a0Las\u00a0barras\u00a0de\u00a0error\u00a0representan \u00a0el\u00a0intervalo\u00a0de\u00a0\nconfianza \u00a0del\u00a095%.\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0de\u00a0las\u00a0Medias\u00a0de\u00a0M\u00ednimos\u00a0Cuadrados \u00a0se\u00a0indican\u00a0como\u00a0*P<0,05,\u00a0**\u00a0P<0,01\u00a0y\u00a0***\u00a0\nP<0,001.\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n122\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a011.\u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0en\u00a0cada\u00a0cultivo\u00a0primario\u00a0derivado\u00a0de\u00a0los\u00a0tumores\u00a0primarios \u00a0de\u00a0mama\u00a0y\u00a0niveles\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0en\u00a0los\u00a0distintos\u00a0subtipos. \u00a0A.\u00a0Medias\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0pHER2\u00a0Y1248\u00a0despu\u00e9s\u00a0de\u00a06\u00a0y\u00a010\u00a0minutos\u00a0de\u00a0exposici\u00f3n \u00a0a\u00a0SP\u00a0en\u00a0cada\u00a0\ntumor\u00a0individual. \u00a0B.\u00a0Distribuci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0en\u00a0los\u00a0diferentes \u00a0subtipos\u00a0de\u00a0tumores\u00a0utilizados \u00a0para\u00a0los\u00a0\ncultivos\u00a0primarios. \u00a0C.\u00a0Distribuci\u00f3n \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0dependiendo \u00a0del\u00a0estado\u00a0de\u00a0amplificaci\u00f3n \u00a0de\u00a0HER2.\u00a0u.a.,\u00a0\nunidades\u00a0arbitrarias. \u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n123\u00a0\n\u00a05.\u00a0LA\u00a0SE\u00d1ALIZACI\u00d3N \u00a0\nAUTOCRINA/PARACRINA \u00a0DE\u00a0LA\u00a0SP\u00a0A\u00a0\nTRAV\u00c9S\u00a0DEL\u00a0RECEPTOR \u00a0NK\u20101\u00a0EN\u00a0\nC\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0MAMA\u00a0\nCONTRIBUYE \u00a0A\u00a0LA\u00a0ACTIVACI\u00d3N \u00a0\nBASAL\u00a0DE\u00a0RECEPTORES \u00a0RTKS\u00a0\n5.1.\u00a0La\u00a0sobreexpresi\u00f3n \u00a0del\u00a0receptor\u00a0\nTACR1\u00a0causa\u00a0un\u00a0aumento \u00a0en\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0MAPKs\u00a0\n\u00a0\nYa\u00a0que\u00a0la\u00a0SP\u00a0presenta\u00a0mayor\u00a0afinidad\u00a0de\u00a0uni\u00f3n\u00a0\npara\u00a0receptor\u00a0NK\u20101\u00a0se\u00a0decidi\u00f3\u00a0investigar \u00a0de\u00a0que\u00a0\nmanera\u00a0contribuye \u00a0este\u00a0receptor\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0\nde\u00a0HER2.\u00a0La\u00a0linea\u00a0celular\u00a0MDA\u2010MB\u2010231,\u00a0con\u00a0baja\u00a0\nexpresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0baja\u00a0expresi\u00f3n \u00a0de\u00a0\nHER2,\u00a0se\u00a0transfect\u00f3 \u00a0mediante \u00a0electroporaci\u00f3n \u00a0de\u00a0\nalta\u00a0eficiencia \u00a0con\u00a0un\u00a0pl\u00e1smido\u00a0que\u00a0conten\u00eda\u00a0el\u00a0\ngen\u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0llamado\u00a0TACR1\u00a0\n(pcDNA3.1(+) \u2010TACR1 ),\u00a0y\u00a0el\u00a0vector\u00a0vac\u00edo\u00a0sin\u00a0el\u00a0\ninserto\u00a0como\u00a0control\u00a0(pcDNA3.1(+)). \u00a0Mediante \u00a0\nselecci\u00f3n\u00a0con\u00a0antibi\u00f3tico \u00a0y\u00a0sucesivas \u00a0selecciones \u00a0\npor\u00a0citometr\u00eda \u00a0de\u00a0flujo,\u00a0se\u00a0gener\u00f3\u00a0una\u00a0poblaci\u00f3n \u00a0\ncelular\u00a0con\u00a0alta\u00a0expresion \u00a0de\u00a0NK\u20101\u00a0en\u00a0su\u00a0\nmembrana \u00a0celular\u00a0(Fig.\u00a012).\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nFigura\u00a012.\u00a0Histograma \u00a0representativo \u00a0de\u00a0intensidad \u00a0de\u00a0\nfluerescencia \u00a0para\u00a0el\u00a0receptor\u00a0NK\u20101.\u00a0Depu\u00e9s\u00a0de\u00a0varias\u00a0\nselecciones \u00a0por\u00a0citometria \u00a0de\u00a0flujo\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010\n231\u00a0transfectada \u00a0con\u00a0pcDNA3(+) \u2010TACR1 ,\u00a0presentaba \u00a0una\u00a0\nexpresi\u00f3n \u00a0elevada\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0La\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0en\u00a0estas\u00a0c\u00e9lulas\u00a0tambi\u00e9n\u00a0\nfue\u00a0comprobada \u00a0mediante \u00a0qPCR\u00a0(Fig.\u00a013).\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nFigura\u00a013.\u00a0Sobreexpresi\u00f3n \u00a0del\u00a0gen\u00a0TACR1\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nMDA\u2010MB\u2010231.\u00a0Niveles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0TACR1\u00a0\ndeterminados \u00a0mediante \u00a0qPCR\u00a0y\u00a0el\u00a0m\u00e9todo\u00a02\u2010\u0394\u0394Ct\u00a0en\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0MDA\u2010MB\u2010231\u00a0transfectadas \u00a0con\u00a0pcDNA3.1 \u00a0(+)\u2010TACR1\u00a0\no\u00a0el\u00a0vector\u00a0vac\u00edo.\u00a0Los\u00a0datos\u00a0fueron\u00a0generados \u00a0a\u00a0partir\u00a0de\u00a03\u00a0\nrepeticiones \u00a0y\u00a0estan\u00a0representados \u00a0por\u00a0la\u00a0media+SEM. \u00a0El\u00a0\nnivel\u00a0de\u00a0significaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0\nprueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestra\u00a0como\u00a0\n***P<0,0001.\u00a0\n\u00a0\nUna\u00a0vez\u00a0alcanzado \u00a0un\u00a098%\u00a0de\u00a0poblaci\u00f3n \u00a0celular\u00a0\ncon\u00a0sobreexpresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0se\u00a0trataron\u00a0estas\u00a0\ncelulas\u00a0con\u00a0SP\u00a0(100\u00a0nM)\u00a0durante\u00a06\u00a0y\u00a010\u00a0min.\u00a0En\u00a0las\u00a0\nc\u00e9lulas\u00a0transfectadas \u00a0con\u00a0pcDNA3.1(+) \u2010TACR1\u00a0se\u00a0\nobtubieron \u00a0mayores\u00a0niveles\u00a0de\u00a0pHER2\u00a0Y1248\u00a0bajo\u00a0\nla\u00a0estimulaci\u00f3n \u00a0con\u00a0SP\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0las\u00a0\nc\u00e9lulas\u00a0control\u00a0(Fig.\u00a014),\u00a0lo\u00a0que\u00a0sugeria\u00a0que\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0estaba\u00a0implicado \u00a0en\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP.\u00a0Adem\u00e1s\u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0otras\u00a0prote\u00ednas \u00a0implicadas \u00a0en\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0ambas\u00a0v\u00edas,\u00a0como\u00a0p42/44\u2010MAPK,\u00a0\nfue\u00a0mayor\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0transfectadas \u00a0con\u00a0\npcDNA3.1 \u00a0(+)\u2010TACR1\u00a0bajo\u00a0el\u00a0est\u00edmulo\u00a0de\u00a0SP\u00a0(Fig.\u00a0\n14).\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n124\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a014.\u00a0La\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0induce\u00a0\nla\u00a0activacion \u00a0de\u00a0HER2\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0Im\u00e1genes \u00a0\nrepresentativas \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0\ncorrespondientes \u00a0a\u00a0los\u00a0experimentos \u00a0que\u00a0muestran \u00a0la\u00a0\ncontribuci\u00f3n \u00a0de\u00a0NK\u20101R\u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0(denotada \u00a0por\u00a0p\u2010)\u00a0\nHER2,\u00a0p42/44\n\u2010MAPK\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010231\u00a0\ntransfectada \u00a0con\u00a0pcDNA3.\u00a01(+)\u2010TACR1\u00a0o\u00a0el\u00a0vector\u00a0vac\u00edo\u00a0y\u00a0\ntratada\u00a0durante\u00a06\u00a0y\u00a010\u00a0min\u00a0con\u00a0SP\u00a0100\u00a0nM.\u00a0\n5.2.\u00a0La\u00a0inhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0o\u00a0el\u00a0silenciamiento \u00a0del\u00a0gen\u00a0\nTACR1\u00a0disminuyen \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\nRTKs\u00a0y\u00a0sus\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\n\u00a0\nPara\u00a0investigar \u00a0si\u00a0parte\u00a0de\u00a0la\u00a0adicci\u00f3n\u00a0oncog\u00e9nica \u00a0\nde\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0por\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0\ndepend\u00eda \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0RTKs\u00a0mediada\u00a0por\u00a0\neste\u00a0gen,\u00a0se\u00a0decidi\u00f3\u00a0determinar \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0NK\u20101R\u00a0sobre\u00a0la\u00a0actividad\u00a0basal\u00a0de\u00a0\nHER2\u00a0y\u00a0EGFR\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0Para\u00a0llevar\u00a0\na\u00a0cabo\u00a0estos\u00a0experimentos \u00a0se\u00a0realizaron \u00a0dos\u00a0\naproximaciones \u00a0experimentales: \u00a0por\u00a0un\u00a0lado\u00a0se\u00a0\nsilenci\u00f3\u00a0el\u00a0gen\u00a0TACR1\u00a0mediante \u00a0siRNA\u00a0y\u00a0por\u00a0otro\u00a0\nlado\u00a0se\u00a0inhibi\u00f3\u00a0la\u00a0actividad\u00a0de\u00a0NK\u20101R\u00a0con\u00a0un\u00a0\ninhibidor\u00a0qu\u00edmico\u00a0(L\u2010733,060)\u00a0en\u00a03\u00a0l\u00edneas\u00a0de\u00a0CM,\u00a0\nSKBR3,\u00a0BT\u2010474\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0que\u00a0expresaban \u00a0\ntanto\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0como\u00a0HER2.\u00a0Los\u00a0efectos\u00a0en\u00a0\nla\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0o\u00a0EGFR,\u00a0as\u00ed\u00a0como\u00a0el\u00a0cambio\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0otras\u00a0prote\u00ednas \u00a0se\u00a0\ndetectaron \u00a0mediante \u00a0Western\u00a0blot.\u00a0Seg\u00fan\u00a0la\u00a0\ncuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0el\u00a0\n%\u00a0de\u00a0silenciamento \u00a0conseguido \u00a0para\u00a0TACR1\u00a0en\u00a0las\u00a0\nl\u00edneas\u00a0SK\u2010BR\u20103\u00a0y\u00a0BT\u2010474\u00a0fue\u00a0de\u00a0un\u00a045%\u00a0y\u00a0un\u00a060%,\u00a0\ncon\u00a0un\u00a0nivel\u00a0de\u00a0significaci\u00f3n \u00a0de\u00a0P=\u00a00.0307\u00a0y\u00a0P=\u00a0\n0.0567,\u00a0respectivamente. \u00a0Igualmente, \u00a0este\u00a0\nsilenciamento \u00a0parcial\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0caus\u00f3\u00a0una\u00a0\ndisminuci\u00f3n \u00a0significativa \u00a0en\u00a0los\u00a0niveles\u00a0basales\u00a0de\u00a0\npHER2\u00a0Y1248\u00a0(P=0,0453\u00a0y\u00a0P=0,0057,\u00a0\nrespectivamente \u00a0para\u00a0las\u00a0l\u00edneas\u00a0SK\u2010BR\u20103\u00a0y\u00a0BT\u2010474),\u00a0\nsin\u00a0embargo\u00a0aunque\u00a0se\u00a0consigui\u00f3 \u00a0un\u00a0\nsilenciamiento \u00a0estad\u00edsticamente \u00a0significativo \u00a0del\u00a0\n50%\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453,\u00a0\u00e9ste\u00a0no\u00a0fue\u00a0\nsuficiente \u00a0para\u00a0disminuir \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0\n(Fig.\u00a015A).\u00a0De\u00a0forma\u00a0similar,\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0\nactividad\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0con\u00a0el\u00a0inhibidor\u00a0\nqu\u00edmico\u00a0L\u2010733,060\u00a0caus\u00f3\u00a0una\u00a0reducci\u00f3n \u00a0notable\u00a0\nen\u00a0los\u00a0niveles\u00a0de\u00a0pHER2\u00a0Y1248\u00a0en\u00a0las\u00a0l\u00edneas\u00a0SK\u2010BR\u2010\n3,\u00a0BT\u2010474\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0(P=\u00a00,0212,\u00a0P=\u00a00,0366\u00a0y\u00a0\nP=0,0081,\u00a0respectivamente) \u00a0y\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\nEGFR\u00a0Y1068\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a024h\u00a0\ndespu\u00e9s\u00a0(Fig.\u00a015B).\u00a0Estos\u00a0resultados \u00a0sugier\u00edan\u00a0que\u00a0\nla\u00a0adicci\u00f3n\u00a0oncog\u00e9nica \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0al\u00a0\nreceptor\u00a0NK\u20101\u00a0pod\u00eda\u00a0depender, \u00a0en\u00a0parte,\u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0mediada\u00a0por\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0\nDado\u00a0que\u00a0la\u00a0SP\u00a0tambi\u00e9n\u00a0se\u00a0puede\u00a0unir\u00a0con\u00a0distinta\u00a0\nafinidad\u00a0a\u00a0otros\u00a0receptores \u00a0de\u00a0la\u00a0misma\u00a0familia\u00a0\ncomo\u00a0NK\u20102\u00a0y\u00a0NK\u20103,\u00a0a\u00a0continuaci\u00f3n \u00a0se\u00a0estudiaron \u00a0\nlos\u00a0efectos\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0NK\u2010\n3R\u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0usando\u00a03\u00a0\ninhibidores \u00a0qu\u00edmicos\u00a0espec\u00edficos \u00a0(L\u2010733,060\u00a0para\u00a0\nNK\u20101R,\u00a0MEN\u00a010376\u00a0para\u00a0NK\u20102R\u00a0y\u00a0SB\u00a0218795\u00a0para\u00a0\nNK\u20103R).\u00a0Se\u00a0observ\u00f3\u00a0que\u00a0al\u00a0tratar\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nSKBR3,\u00a0que\u00a0expresa\u00a0los\u00a0tres\u00a0receptores \u00a0NK\u20101,\u00a0NK\u20102\u00a0\ny\u00a0NK\u20103,\u00a0con\u00a0los\u00a0tres\u00a0inhibidores \u00a0conjuntamente, \u00a0se\u00a0\nproduc\u00eda\u00a0casi\u00a0una\u00a0inhibici\u00f3n \u00a0completa \u00a0de\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0(P=0,0027)\u00a0y\u00a0una\u00a0\ndisminuci\u00f3n \u00a0significativa \u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0Akt\u00a0\n(P=\u00a00,0004)\u00a0(Fig.\u00a015C),\u00a0resultados \u00a0que\u00a0confirmaban \u00a0\nla\u00a0implicaci\u00f3n \u00a0del\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0en\u00a0la\u00a0\nmodulaci\u00f3n \u00a0del\u00a0estado\u00a0basal\u00a0de\u00a0activaci\u00f3n \u00a0del\u00a0\nreceptor\u00a0HER2.\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n125\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a015.\u00a0La\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0modula\u00a0la\u00a0actividad \u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0A.\u00a0Efecto\u00a0del\u00a0\nsilenciamiento \u00a0del\u00a0gen\u00a0TACR1\u00a0sobre\u00a0la\u00a0fosforilaci\u00f3n \u00a0basal\u00a0(denotada \u00a0por\u00a0p\u2010)\u00a0de\u00a0HER2.\u00a0Los\u00a0niveles\u00a0proteicos \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0se\n\u00a0\nmuestran \u00a0como\u00a0control\u00a0de\u00a0la\u00a0eficiencia \u00a0del\u00a0siRNA.\u00a0B.\u00a0Efectos\u00a0del\u00a0inhibidor\u00a0L\u2010733,\u00a0060\u00a0en\u00a0SKBR3\u00a0(20\u00a0\u00b5M),\u00a0en\u00a0BT\u2010474\u00a0(20\u00a0\u00b5M)\u00a0y\u00a0en\u00a0\nMDA\u2010MB\u2010453\u00a0(30\u00a0\u00b5M)\u00a0\u00a0sobre\u00a0los\u00a0niveles\u00a0fosforilados \u00a0de\u00a0HER2,\u00a0EGFR,\u00a0p42/44\u2010MAPK\u00a0y\u00a0Akt\u00a0y\u00a0sus\u00a0respectivos \u00a0niveles\u00a0totales.\u00a0C.\u00a0\nEfectos\u00a0de\u00a0la\u00a0triple\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0NK\u20103R\u00a0con\u00a0L\u2010733,060\u00a0(20\u00a0\u00b5M),\u00a0MEN\u00a010376\u00a0(30\u00a0\u00b5M)\u00a0y\u00a0SB\u00a0218795\u00a0(20\u00a0\u00b5M),\u00a0\nrespectivamente, \u00a0sobre\u00a0la\u00a0fosforilaci\u00f3n \u00a0basal\u00a0de\u00a0HER2,\u00a0p42/44\u2010MAPK\u00a0y\u00a0Akt\u00a0y\u00a0sus\u00a0respectivos \u00a0niveles\u00a0de\u00a0prote\u00edna\u00a0total\u00a0de\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0SKBR3.\u00a0Los\u00a0gr\u00e1ficos\u00a0que\u00a0acompa\u00f1an \u00a0a\u00a0cada\u00a0panel\u00a0muestran \u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0\nblot\u00a0relativas\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliza\u00a0como\u00a0control\u00a0end\u00f3geno \u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0Todas\u00a0\nlas\u00a0membranas \u00a0y\u00a0los\u00a0datos\u00a0cuantitativos \u00a0son\u00a0un\u00a0m\u00ednimo\u00a0de\u00a03\u00a0repeticiones \u00a0y\u00a0se\u00a0representan \u00a0como\u00a0media\u00a0\u00b1\u00a0SD.\u00a0El\u00a0nivel\u00a0de\u00a0\nsignificaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0prueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestran \u00a0como\u00a0*P<0,05,\u00a0**P<0,01\u00a0y\u00a0\n***P<0,001.\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n126\u00a0\n\u00a0Estos\u00a0resultados \u00a0podr\u00edan\u00a0tener\u00a0importantes \u00a0\nconsecuencias \u00a0cl\u00ednicas\u00a0en\u00a0las\u00a0terapias\u00a0anti\u2010diana\u00a0y\u00a0\nen\u00a0mecanismos \u00a0de\u00a0quimio\u2010resistencia. \u00a0Adem\u00e1s\u00a0de\u00a0\nla\u00a0funci\u00f3n\u00a0ya\u00a0descrita\u00a0de\u00a0varios\u00a0ligandos\u00a0de\u00a0GPCRs\u00a0\ncomo\u00a0activadores \u00a0de\u00a0EGFR\u00a0y\u00a0HER2\u00a0247,377,493,\u00a0la\u00a0\ncontribuci\u00f3n \u00a0general\u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0v\u00eda\u00a0\nprote\u00ednas \u00a0G\u00a0en\u00a0la\u00a0actividad\u00a0basal\u00a0de\u00a0RTKs\u00a0no\u00a0ha\u00a0\nsido\u00a0del\u00a0todo\u00a0estudiada. \u00a0Por\u00a0este\u00a0motivo,\u00a0se\u00a0quiso\u00a0\ncomprobar \u00a0si\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nGPCRs\u00a0en\u00a0general\u00a0modulaba \u00a0la\u00a0actividad\u00a0basal\u00a0de\u00a0\nHER2\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0Se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0sensibles\u00a0a\u00a0la\u00a0toxina\u00a0pert\u00fasica \u00a0disminu\u00eda \u00a0de\u00a0manera\u00a0considerable \u00a0los\u00a0\nniveles\u00a0basales\u00a0de\u00a0pHER2,\u00a0as\u00ed\u00a0como\u00a0de\u00a0p\u201042/44\u00a0\nMAPK,\u00a0indicando \u00a0que\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nprote\u00ednas \u00a0G\u00a0modula\u00a0directamente \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nHER2\u00a0y\u00a0MAPKs\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0\u00a0(Fig.\u00a016).\u00a0Estos\u00a0\nresultados \u00a0revelan\u00a0un\u00a0nivel\u00a0adicional\u00a0de\u00a0\ncomplejidad \u00a0en\u00a0la\u00a0regulaci\u00f3n \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0\nlos\u00a0receptores \u00a0ErbB\u00a0en\u00a0CM\u00a0y\u00a0podr\u00eda\u00a0tener\u00a0\nconsecuencias \u00a0cl\u00ednicas\u00a0importantes \u00a0en\u00a0el\u00a0uso\u00a0de\u00a0\nterapias\u00a0que\u00a0tienen\u00a0como\u00a0diana\u00a0HER2\u00a0y/o\u00a0EGFR.\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura.\u00a016.\u00a0La\u00a0inhibici\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0G\u00a0sensibles \u00a0a\u00a0toxina\u00a0pert\u00fasica \u00a0modula\u00a0la\u00a0actividad \u00a0de\u00a0HER2\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0Efecto\u00a0que\u00a0\ncausa\u00a0el\u00a0inhibidor\u00a0de\u00a0prote\u00ednas \u00a0G\u00a0toxina\u00a0per\u00fasica\u00a0(PTX)\u00a0a\u00a0100,\u00a0300\u00a0y\u00a0500\u00a0nm\u00a0sobre\u00a0la\u00a0fosforilaci\u00f3n \u00a0basal\u00a0de\u00a0HER2,\n\u00a0p42/44\u2010MAPK\u00a0y\u00a0\nAkt\u00a0en\u00a0distintas\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0Los\u00a0gr\u00e1ficos\u00a0debajo\u00a0de\u00a0las\u00a0membranas \u00a0muestran \u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0\nmembranas \u00a0de\u00a0Western\u00a0blot\u00a0relativas\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0como\u00a0control\u00a0end\u00f3geno \u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0\ncarga\u00a0de\u00a0prote\u00edna.\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n127\u00a0\n\u00a05.3.\u00a0El\u00a0bloqueo\u00a0de\u00a0la\u00a0SP\u00a0con\u00a0\nanticuerpos \u00a0disminuye \u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0RTKs\u00a0y\u00a0sus\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0\nPara\u00a0investigar \u00a0si\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0tambi\u00e9n\u00a0\ninfluenciaba \u00a0los\u00a0niveles\u00a0basales\u00a0de\u00a0HER2,\u00a0se\u00a0\ndecidi\u00f3\u00a0bloquear\u00a0la\u00a0SP\u00a0utilizando \u00a0anticuerpos \u00a0\nespec\u00edficos. \u00a0El\u00a0bloqueo\u00a0de\u00a0la\u00a0SP\u00a0durante\u00a048\u00a0horas\u00a0\ncon\u00a0un\u00a0anticuerpo \u00a0(AB1)\u00a0caus\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0\nsignificativa \u00a0en\u00a0el\u00a0estado\u00a0basal\u00a0de\u00a0activaci\u00f3n \u00a0de\u00a0\nHER2\u00a0y\u00a0EGFR\u00a0en\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010\n453,\u00a0SKBR3,\u00a0B7474\u00a0(sobreexpresi\u00f3n \u00a0de\u00a0HER2)\u00a0y\u00a0\nMDA\u2010MB\u2010468\u00a0(sobreexpresi\u00f3n \u00a0de\u00a0EGFR)\u00a0(Fig.\u00a0\n17A).\u00a0\nBajo\u00a0la\u00a0misma\u00a0dosis\u00a0y\u00a0tiempo\u00a0de\u00a0tratamiento \u00a0el\u00a0\ncontenido \u00a0de\u00a0ARNm\u00a0de\u00a0EGFR,\u00a0HER2\u00a0y\u00a0HER3\u00a0\ntambi\u00e9n\u00a0se\u00a0redujo\u00a0significativamente, \u00a0lo\u00a0que\u00a0\nsuger\u00eda\u00a0que\u00a0un\u00a0bloqueo\u00a0de\u00a0esta\u00a0taquiquinina \u00a0\npod\u00eda\u00a0disminuir \u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0\nde\u00a0estos\u00a0receptores \u00a0en\u00a0algunas\u00a0l\u00edneas\u00a0\u00a0(Fig.\u00a017B).\u00a0\nPor\u00a0lo\u00a0tanto,\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0SP,\u00a0de\u00a0forma\u00a0\nsimilar\u00a0a\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0disminuye \u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0la\u00a0v\u00eda\u00a0MAPKs\u00a0y\u00a0el\u00a0estado\u00a0basal\u00a0de\u00a0\nactivaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0EGFR.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Figura\u00a017.\u00a0El\u00a0bloqueo\u00a0de\u00a0SP\u00a0inhibe\u00a0el\u00a0estado\u00a0de\u00a0activaci\u00f3n \u00a0\nbasal\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0y\u00a0la\u00a0v\u00eda\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0las\u00a0MAPK.\u00a0\nA.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0los\u00a0Western\u00a0blot\u00a0que\u00a0\nmuestran \u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0pHer2\u00a0Y1248,\u00a0pEGFR\u00a0\nY1068\u00a0y\u00a0p\u2010p42/44\u00a0MAPK\u00a0y\u00a0sus\u00a0correspondientes \u00a0\nniveles\u00a0de\u00a0\nprote\u00edna\u00a0total,\u00a0tras\u00a0el\u00a0tratamiento \u00a0con\u00a0SP\u00a0a\u00a0500\u00a0nM\u00a0o\u00a0con\u00a0el\u00a0\nanticuerpo \u00a0AB1\u00a0a\u00a0una\u00a0diluci\u00f3n\u00a01:100.\u00a0La\u00a0expresi\u00f3n \u00a0de\u00a0\ntubulina\u00a0se\u00a0utiliz\u00f3\u00a0como\u00a0control\u00a0end\u00f3geno \u00a0para\u00a0asegurar\u00a0la\u00a0\nmisma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0B.\u00a0Niveles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0\ndeterminados \u00a0por\u00a0qPCR\u00a0de\u00a0las\u00a0diferentes \u00a0l\u00edneas\u00a0celulares\u00a0\ntratadas\u00a0con\u00a0el\u00a0AB1\u00a0(diluci\u00f3n\u00a01/100)\u00a0durante\u00a048\u00a0horas.\u00a0Los\u00a0\nvalores\u00a0de\u00a0expresi\u00f3n \u00a0se\u00a0normalizaron \u00a0respecto\u00a0al\u00a0grupo\u00a0\ncontrol\u00a0de\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0y\u00a0est\u00e1n\u00a0representados \u00a0por\u00a0la\u00a0\nmedia+SD. \u00a0El\u00a0nivel\u00a0de\u00a0significaci\u00f3n \u00a0de\u00a0los\u00a0datos\u00a0se\u00a0analiz\u00f3\u00a0\nmediante \u00a0la\u00a0prueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestra\u00a0\ncomo\u00a0*P<0,05.\u00a0\n\u00a0\n6.\u00a0LA\u00a0TRANSACTIVACI\u00d3N \u00a0DE\u00a0HER2\u00a0\nY\u00a0EGFR\u00a0ES\u00a0UN\u00a0MECANISMO \u00a0\nDEPENDIENTE \u00a0DE\u00a0SRC\u00a0Y\u00a0MMPS\u00a0\n\u00a0\nEstudios\u00a0previos\u00a0han\u00a0demostrado \u00a0que\u00a0el\u00a0\nreceptor\u00a0NK\u20101\u00a0activa\u00a0en\u00a0alg\u00fan\u00a0punto\u00a0de\u00a0su\u00a0ruta\u00a0\nde\u00a0se\u00f1alizaci\u00f3n \u00a0la\u00a0tirosina\u00a0quinasa\u00a0Src224,311,313,\u00a0y\u00a0\nla\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0este\u00a0\nreceptor\u00a0puede\u00a0tambi\u00e9n\u00a0estimular \u00a0la\u00a0sintesis\u00a0de\u00a0\nMMPs\u00a0494.\u00a0Por\u00a0este\u00a0motivo\u00a0se\u00a0decidi\u00f3\u00a0explorar\u00a0la\u00a0\nimplicacion \u00a0de\u00a0las\u00a0MMPs\u00a0y\u00a0Src\u00a0en\u00a0el\u00a0mecanismo \u00a0\nde\u00a0transactivaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0mediado\u00a0por\u00a0\nla\u00a0SP.\u00a0Primero\u00a0se\u00a0decidi\u00f3\u00a0confirmar \u00a0la\u00a0activaci\u00f3n \u00a0\nde\u00a0Src\u00a0por\u00a0SP/NK\u20101R.\u00a0En\u00a0estudios\u00a0de\u00a0tiempo\u2010\nRESULTADOS \u00a0 \u00a0\n\u00a0\n128\u00a0\n\u00a0respuesta \u00a0observamos \u00a0que\u00a0la\u00a0SP\u00a0induc\u00eda\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0Src\u00a0en\u00a0la\u00a0Tyr416\u00a0(pSrc\u00a0Y416),\u00a0\nindicativa \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0esta\u00a0prote\u00edna,\u00a0en\u00a0\nlas\u00a0l\u00edneas\u00a0celulares\u00a0HER2\u00a0negativas \u00a0MDA\u2010MB\u2010\n468,\u00a0MDA\u2010MB\u2010231\u00a0y\u00a0MCF7,\u00a0pero\u00a0no\u00a0se\u00a0encontr\u00f3\u00a0\nninguna\u00a0activaci\u00f3n \u00a0sustancial \u00a0en\u00a0las\u00a0l\u00edneas\u00a0\ncelulares\u00a0HER2+\u00a0SK\u2010BR\u20103,\u00a0BT\u2010474\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0\n(Fig.\u00a018).\u00a0La\u00a0sobreexpresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0en\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0MDA\u2010MB\u2010231\u00a0(Fig.\u00a012\u00a0y\u00a013)\u00a0produjo\u00a0un\u00a0\naumento\u00a0significativo \u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0pSrc\u00a0bajo\u00a0\nla\u00a0estimulaci\u00f3n \u00a0de\u00a0SP\u00a0(Fig.\u00a019A).\u00a0Por\u00a0otro\u00a0lado,\u00a0la\u00a0\ninhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0con\u00a0L\u2010733,\u00a0\n060\u00a0caus\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0dr\u00e1stica\u00a0en\u00a0los\u00a0\nniveles\u00a0de\u00a0pSrc\u00a0Y416\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0SK\u2010BR\u20103\u00a0y\u00a0\nBT\u2010474\u00a0(P=\u00a00,0057,\u00a0P=\u00a00,0001,\u00a0respectivamente), \u00a0\nmientras\u00a0que\u00a0no\u00a0se\u00a0observ\u00f3\u00a0una\u00a0inhibici\u00f3n \u00a0\nsignificativa \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453\u00a0\n(l\u00ednea\u00a0con\u00a0bajos\u00a0niveles\u00a0basales\u00a0de\u00a0Src)\u00a0(Fig.\u00a019B).\u00a0\nAdem\u00e1s,\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0NK\u20103R\u00a0\nen\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0SKBR3\u00a0caus\u00f3\u00a0casi\u00a0una\u00a0\ninhibici\u00f3n \u00a0total\u00a0de\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0Src\u00a0Y416\u00a0\n(P=\u00a00,0005)\u00a0(Fig.\u00a019C)\u00a0reforzando \u00a0la\u00a0idea\u00a0de\u00a0que\u00a0\nSrc\u00a0era\u00a0un\u00a0mediador \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0SP/NK\u2010\n1R\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0\u00a0\nPara\u00a0investigar \u00a0la\u00a0implicaci\u00f3n \u00a0de\u00a0la\u00a0quinasa\u00a0Src\u00a0\nen\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0pHER2\u00a0mediada\u00a0por\u00a0la\u00a0SP378\u00a0\nse\u00a0realiz\u00f3\u00a0un\u00a0ensayo\u00a0de\u00a0tiempo\u2010respuesta \u00a0bajo\u00a0el\u00a0\nest\u00edmulo\u00a0de\u00a0SP\u00a0y\u00a0en\u00a0presencia \u00a0del\u00a0inhibidor\u00a0\nqu\u00edmico\u00a0de\u00a0Src\u00a04\u2010(4\u2032\u2010Phenoxyanilino) \u20106,7\u2010\ndimethoxyquinazoline, \u00a0el\u00a0cual\u00a0compite\u00a0por\u00a0el\u00a0\nATP\u00a0por\u00a0su\u00a0dominio\u00a0catal\u00edtico495.\u00a0La\u00a0inhibici\u00f3n \u00a0de\u00a0\nla\u00a0actividad\u00a0de\u00a0Src\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0SK\u2010BR\u20103\u00a0\nbloque\u00f3\u00a0de\u00a0forma\u00a0significativa \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0\nHER2\u00a0Y1248\u00a0inducida\u00a0por\u00a0la\u00a0SP\u00a0en\u00a0el\u00a0minuto\u00a06,\u00a010\u00a0\ny\u00a015,\u00a0si\u00a0se\u00a0comparaba \u00a0con\u00a0la\u00a0situaci\u00f3n\u00a0control\u00a0\n(ausencia \u00a0de\u00a0inhibidor) \u00a0(Fig.\u00a019D).\u00a0La\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP\u00a0\ntambi\u00e9n\u00a0fue\u00a0sustancialmente \u00a0inhibida\u00a0en\u00a0\npresencia \u00a0del\u00a0inhibidor\u00a0de\u00a0MMPs\u00a01\u201010,\u00a0\nphenantroline \u00a0 monohydrate, \u00a0 y\u00a0 casi\u00a0\ncompletamente \u00a0inhibida\u00a0bajo\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0ambos\u00a0\ninhibidores, \u00a0lo\u00a0que\u00a0suger\u00eda\u00a0que\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0HER2\u00a0mediada\u00a0por\u00a0SP\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0es\u00a0un\u00a0\nproceso\u00a0dependiente \u00a0de\u00a0Src\u00a0y\u00a0MMPs\u00a0(Fig.\u00a019D).\u00a0\nLa\u00a0inhibici\u00f3n \u00a0de\u00a0Src\u00a0y/o\u00a0MMPs\u00a0tambi\u00e9n\u00a0redujo\u00a0los\u00a0niveles\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0p42/44\u00a0MAPK\u00a0en\u00a0\nalgunos\u00a0puntos\u00a0de\u00a0tiempo.\u00a0Esta\u00a0falta\u00a0de\u00a0\ninhibici\u00f3n \u00a0total\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0p42/44\u00a0MAPK\u00a0\nfue\u00a0debida\u00a0en\u00a0parte\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0directa\u00a0de\u00a0la\u00a0\nv\u00eda\u00a0por\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0(Fig.\u00a019D).\u00a0Resultados \u00a0\nsimilares\u00a0se\u00a0observaron \u00a0para\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nMDA\u2010MB\u2010468,\u00a0 donde\u00a0 se\u00a0 redujo\u00a0\nsignificativamente \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0EGFR\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0Src\u00a0y/o\u00a0MMPs,\u00a0tal\u00a0y\u00a0\ncomo\u00a0se\u00a0ha\u00a0descrito\u00a0previamente \u00a0en\u00a0otros\u00a0tipos\u00a0\nde\u00a0tumores313,494\u00a0(Fig.\u00a019E).\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0Figura\u00a018.\u00a0La\u00a0SP\u00a0activa\u00a0Src\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0\nIm\u00e1genes \u00a0representativas \u00a0de\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0\ncorrespondientes \u00a0a\u00a0los\u00a0experimentos \u00a0que\u00a0muestran \u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0Src\u00a0Y416\u00a0a\u00a0los\u00a0tiempos\u00a0indicados \u00a0despu\u00e9s\u00a0\nde\u00a0la\u00a0estimulaci\u00f3n \u00a0SP\u00a0(100\u00a0nM)\u00a0en\u00a0diferentes \u00a0l\u00edneas\u00a0\ncelulares\u00a0de\u00a0CM.\u00a0Todas\u00a0\nlas\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0son\u00a0\nrepresentativas \u00a0de\u00a0tres\u00a0experimentos \u00a0independientes. \u00a0Los\u00a0\ngr\u00e1ficos\u00a0de\u00a0debajo\u00a0muestran \u00a0la\u00a0cuantificaci\u00f3n \u00a0\ndensitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0relativa\u00a0\na\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0asegurar\u00a0la\u00a0\nmisma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0\n\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n129\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0Figura\u00a019.\u00a0Src\u00a0est\u00e1\u00a0implicada \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0membranas \u00a0de\u00a0Western\u00a0\nblot\u00a0correspondientes \u00a0a\u00a0los\u00a0experimentos \u00a0que\u00a0muestran \u00a0(A)\u00a0la\u00a0contribuci\u00f3n \u00a0de\u00a0TACR1\u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0Src\u00a0Y416\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0MDA\u2010\nMB\u2010231\u00a0transfectadas \u00a0con\u00a0pcDNA3.1 \u00a0(+)\u2010TACR1\u00a0o\u00a0el\u00a0vector\u00a0vac\u00edo,\u00a0tratadas\u00a0durante\u00a06\u00a0y\u00a010\u00a0minutos\u00a0con\u00a0SP\u00a0100\u00a0nM;\u00a0(B)\u00a0los\u00a0efectos\u00a0\nde\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0durante\u00a024\u00a0horas\u00a0con\u00a0L\u2010733,\u00a0060\u00a0a\u00a020\u00a0\u00b5M\u00a0(SKBR3),\u00a020\u00a0\u00b5M\u00a0(BT\u2010474),\u00a030\u00a0\u00b5M\u00a0(MDA\u2010MB\u2010453)\u00a0o\u00a0(C)\u00a0\nlos\u00a0tres\u00a0inhibidores \u00a0juntos\u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0NK\u20103R\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0Y416.\u00a0Los\u00a0gr\u00e1ficos\u00a0que\u00a0acompa\u00f1an \u00a0a\u00a0cada\u00a0\npanel\u00a0muestran \u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0relativa\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0\npara\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0Estos\u00a0se\u00a0generaron \u00a0a\u00a0partir\u00a0de\u00a0un\u00a0m\u00ednimo\u00a0de\u00a03\u00a0repeticiones \u00a0y\u00a0se\u00a0presentan \u00a0como\u00a0\nmedia+SD. \u00a0El\u00a0nivel\u00a0de\u00a0significaci\u00f3n \u00a0de\u00a0la\u00a0cuantificaci\u00f3n \u00a0se\u00a0analiz\u00f3\u00a0mediante \u00a0la\u00a0prueba\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestran \u00a0como\u00a0\n*P<0,05,\u00a0**\u00a0P<0,01\u00a0y\u00a0***\u00a0P<0,001.\u00a0(D)\u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0Src\u00a0con\u00a01\u00a0\u00b5M\u00a0de\u00a04\u2010(4\u2032\u2010Phenoxyanilino) \u20106,7\u2010\ndimethoxyquinazoline \u00a0sola\u00a0o\u00a0combinada \u00a0con\u00a07\u00a0\u03bcM\u00a0de\u00a0un\u00a0inhibidor\u00a0gen\u00e9rico\u00a0de\u00a0MMPs\u00a0(1\u201010,\u00a0phenantroline \u00a0monohydrate) \u00a0sobre\u00a0\nla\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0SK\u2010BR\u20103\u00a0o\u00a0(E)\u00a0sobre\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0EGFR\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0tratadas\u00a0con\u00a0SP\u00a0\n(100\u00a0nM)\u00a0durante\u00a06,\u00a010\u00a0y\u00a015\u00a0minutos.\u00a0Todas\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0son\u00a0representativas \u00a0de\u00a0tres\u00a0experimentos \u00a0\nindependientes. \u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n130\u00a0\n\u00a07.\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0CR\u00d3NICA \u00a0DE\u00a0LA\u00a0\nSP\u00a0IN\u00a0VIVO\u00a0TIENE\u00a0ACTIVIDAD \u00a0\nMITOG\u00c9NICA \u00a0Y\u00a0AUMENTA \u00a0LA\u00a0\nACTIVACI\u00d3N \u00a0DE\u00a0HER2\u00a0Y\u00a0EGFR\u00a0EN\u00a0\nUNA\u00a0L\u00cdNEA\u00a0BASAL\u00a0\n\u00a0\nCon\u00a0los\u00a0estudios\u00a0realizados \u00a0hasta\u00a0el\u00a0momento \u00a0se\u00a0\nhab\u00eda\u00a0investigado, \u00a0b\u00e1sicamente, \u00a0los\u00a0efectos\u00a0\nagudos\u00a0de\u00a0la\u00a0SP.\u00a0Sin\u00a0emgargo, \u00a0teniendo\u00a0en\u00a0cuenta\u00a0\nque\u00a0la\u00a0SP\u00a0es\u00a0una\u00a0citoquina \u00a0pro\u2010inflamatoria, \u00a0\ndecidimos \u00a0tambien\u00a0investigar \u00a0los\u00a0efectos\u00a0cr\u00f3nicos\u00a0\nde\u00a0esta\u00a0mol\u00e9cula\u00a0sobre\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0y\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0receptores \u00a0ErbB\u00a0in\u00a0vivo.\u00a0Se\u00a0\ninocularon \u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010231\u00a0en\u00a0el\u00a0\ntejido\u00a0graso\u00a0mamario, \u00a0y\u00a0una\u00a0vez\u00a0desarrollados \u00a0\ntumores\u00a0palables\u00a0se\u00a0implantaron \u00a0por\u00a0v\u00eda\u00a0\nsubcut\u00e1nea \u00a0mini\u2010bombas\u00a0osm\u00f3ticas \u00a0capaces\u00a0de\u00a0\nliberar\u00a0de\u00a0forma\u00a0cont\u00ednua\u00a0y\u00a0controlada \u00a0500\u00a0nM\u00a0de\u00a0\nSP\u00a0durante\u00a027\u00a0d\u00edas.\u00a0Esta\u00a0aproximaci\u00f3n \u00a0\nexperimental \u00a0permiti\u00f3\u00a0investigar \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0\nSP\u00a0en\u00a0una\u00a0l\u00ednea\u00a0celular\u00a0con\u00a0baja\u00a0expresi\u00f3n \u00a0de\u00a0NK\u2010\n1R\u00a0y\u00a0HER2,\u00a0y\u00a0determinar \u00a0de\u00a0este\u00a0modo\u00a0si\u00a0la\u00a0\nexposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0podr\u00eda\u00a0favorecer \u00a0la\u00a0\nselecci\u00f3n\u00a0y\u00a0el\u00a0crecimiento \u00a0de\u00a0c\u00e9lulas\u00a0tumorales \u00a0\ncon\u00a0caracter\u00edsticas \u00a0m\u00e1s\u00a0agresivas. \u00a0El\u00a0tratamiento \u00a0\ncon\u00a0SP\u00a0durante\u00a027\u00a0d\u00edas\u00a0no\u00a0afect\u00f3\u00a0a\u00a0la\u00a0cin\u00e9tica\u00a0de\u00a0\ncrecimiento \u00a0del\u00a0tumor\u00a0ni\u00a0a\u00a0su\u00a0peso\u00a0neto\u00a0final\u00a0(Fig.\u00a0\n20A\u2010B),\u00a0pero\u00a0se\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0significativo \u00a0\nen\u00a0el\u00a0\u00edndice\u00a0mit\u00f3tico\u00a0de\u00a0los\u00a0tumores\u00a0tratados\u00a0con\u00a0\nSP\u00a0(P=\u00a00,0015)\u00a0(Fig.\u00a020C\u2010D).\u00a0Aunque\u00a0por\u00a0\ninmunohistoqu\u00edmica \u00a0no\u00a0se\u00a0observaron \u00a0diferencias \u00a0\nrealmente \u00a0significativas \u00a0en\u00a0la\u00a0expresion \u00a0de\u00a0HER2,\u00a0\nsi\u00a0se\u00a0detect\u00f3\u00a0un\u00a0aumento\u00a0leve\u00a0pero\u00a0consistente \u00a0en\u00a0\nla\u00a0expresi\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0en\u00a0todos\u00a0los\u00a0\ntumores\u00a0analizados \u00a0tratados\u00a0con\u00a0SP\u00a0(Fig.\u00a021A).\u00a0\u00a0\nSin\u00a0embargo, \u00a0los\u00a0an\u00e1lisis\u00a0mediante \u00a0Western\u00a0blot\u00a0\nmostraron \u00a0un\u00a0aumento\u00a0significativo \u00a0en\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0HER2\u00a0(P=\u00a00,0176),\u00a0EGFR\u00a0(P=\u00a00,0079),\u00a0\ny\u00a0p42/44\u2010MAPK\u00a0(P=\u00a00,0214)\u00a0(Fig.\u00a021B)\u00a0en\u00a0los\u00a0tumores\u00a0de\u00a0ratones\u00a0tratados\u00a0con\u00a0SP,\u00a0sugiriendo \u00a0\nque\u00a0la\u00a0presencia \u00a0continua\u00a0de\u00a0SP\u00a0pod\u00eda\u00a0favorecer \u00a0la\u00a0\nexpansi\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0con\u00a0una\u00a0mayor\u00a0\nactivaci\u00f3n \u00a0de\u00a0estas\u00a0v\u00edas.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a020.\u00a0Modulaci\u00f3n \u00a0in\u00a0vivo\u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0\nmediada\u00a0por\u00a0SP.\u00a0A.\u00a0Volumen\u00a0de\u00a0los\u00a0tumores\u00a0ortot\u00f3picos \u00a0de\u00a0\nMDA\u2010MB\u2010231,\u00a0tratados\u00a0con\u00a0soluci\u00f3n\u00a0salina\u00a0o\u00a0SP\u00a0durante\u00a027\u00a0\nd\u00edas\u00a0(media\u00b1SD). \u00a0B.\u00a0Peso\u00a0del\u00a0tumor\n\u00a0a\u00a0los\u00a027\u00a0di\u00e1s.\u00a0Los\u00a0\ndiagramas \u00a0de\u00a0caja\u00a0muestran \u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0los\u00a0valores\u00a0\nentre\u00a0el\u00a0percentil\u00a05\u201095.\u00a0C.\u00a0Im\u00e1genes \u00a0de\u00a0H&E\u00a0representativas \u00a0\nde\u00a0los\u00a0tumores\u00a0del\u00a0grupo\u00a0control\u00a0y\u00a0los\u00a0tratados\u00a0con\u00a0SP\u00a0donde\u00a0\nse\u00a0destaca\u00a0un\u00a0ejemplo\u00a0de\u00a0los\u00a0n\u00facleos\u00a0mit\u00f3ticos. \u00a0La\u00a0barra\u00a0de\u00a0\nescala\u00a0de\u00a0las\u00a0im\u00e1genes \u00a0representa \u00a050\u00a0micras.\u00a0D.\u00a0\u00cdndice\u00a0\nmit\u00f3tico\u00a0calculado \u00a0como\u00a0se\u00a0describe\u00a0en\u00a0la\u00a0secci\u00f3n\u00a0de\u00a0\nmateriales \u00a0y\u00a0m\u00e9todos. \u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0se\u00a0\ncalcularon \u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0de\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0\nmuestran \u00a0como\u00a0**P<0,05\u00a0*P<0,01.\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n131\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a021.\u00a0Modulaci\u00f3n \u00a0in\u00a0vivo\u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0\nde\u00a0HER2\u00a0mediada\u00a0por\u00a0SP.\u00a0A.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0\nIHQ\u00a0\u00a0para\u00a0HER2.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0de\u00a0las\u00a0im\u00e1genes \u00a0\nrepresenta \u00a0100\u00a0micras.\u00a0F.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0\nWestern\u00a0blot\u00a0para\u00a0cada\u00a0grupo\u00a0experimental \u00a0donde\u00a0se\u00a0\nmuestran \u00a0los\u00a0niveles\u00a0de\u00a0expresion \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0HER2,\u00a0\nEGFR\u00a0y\u00a0p42/44\u00a0MAPK.\u00a0El\u00a0gr\u00e1fico\u00a0de\u00a0debajo\u00a0muestra\u00a0la\u00a0\ncuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0\nblot\u00a0relativa\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina.\u00a0Los\u00a0diagramas \u00a0de\u00a0caja\u00a0\nmuestran \u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0los\u00a0valores\u00a0entre\u00a0el\u00a0percentil\u00a05\u2010\n95.\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0se\u00a0calcularon \u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0\nde\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestran \u00a0como\u00a0**P<0,05\u00a0\n*P<0,01.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a08.\u00a0LA\u00a0SP\u00a0END\u00d3GENA \u00a0NO\u00a0AFECTA\u00a0A\u00a0\nLA\u00a0TUMORIG\u00c9NESIS \u00a0O\u00a0EL\u00a0\nCRECIMIENTO \u00a0TUMORAL \u00a0\n\u00a0\nTeniendo \u00a0en\u00a0cuenta\u00a0el\u00a0importante \u00a0papel\u00a0que\u00a0\ndespempe\u00f1a \u00a0la\u00a0SP\u00a0liberada\u00a0por\u00a0una\u00a0variedad\u00a0de\u00a0\ntipos\u00a0celulares\u00a0del\u00a0microambiente \u00a0celular,\u00a0tal\u00a0y\u00a0\ncomo\u00a0hemos\u00a0mencionado \u00a0en\u00a0la\u00a0introducci\u00f3n, \u00a0se\u00a0\ndecidi\u00f3\u00a0investigar \u00a0a\u00a0continuaci\u00f3n, \u00a0la\u00a0implicaci\u00f3n \u00a0\nde\u00a0la\u00a0SP\u00a0endogena \u00a0en\u00a0el\u00a0crecimineto \u00a0tumoral.\u00a0Para\u00a0\npoder\u00a0llevar\u00a0a\u00a0cabo\u00a0este\u00a0estudio\u00a0se\u00a0compar\u00f3\u00a0el\u00a0\ncrecimiento \u00a0de\u00a0la\u00a0l\u00ednea\u00a0tumoral\u00a0sing\u00e9nica \u00a0de\u00a0rat\u00f3n\u00a0\n(EO771),\u00a0TACR1+\u00a0y\u00a0HER2+\u00a0(Fig.\u00a022A),\u00a0inoculada \u00a0en\u00a0\nratones\u00a0homocigotos \u00a0para\u00a0el\u00a0gen\u00a0TAC1tm1Bbm\u00a0\n(\u201cknock\u00a0out\u201d\u00a0o\u00a0K.O)\u00a0y\u00a0en\u00a0ratones\u00a0control\u00a0de\u00a0tipo\u00a0\nsalvaje\u00a0(WT,\u00a0del\u00a0ingl\u00e9s\u00a0wild\u00a0type)\u00a0C57BL/6J\u00a0\nTAC1+/+.\u00a0No\u00a0se\u00a0observaron \u00a0diferencias \u00a0\nsignificativas \u00a0en\u00a0el\u00a0crecimiento \u00a0del\u00a0tumor\u00a030\u00a0d\u00edas\u00a0\ndespu\u00e9s\u00a0de\u00a0la\u00a0inoculaci\u00f3n \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nlo\u00a0que\u00a0suger\u00eda\u00a0que\u00a0en\u00a0las\u00a0primeras\u00a0fases\u00a0del\u00a0\ncrecimiento \u00a0tumoral\u00a0la\u00a0SP\u00a0end\u00f3gena \u00a0no\u00a0parece\u00a0\nfavorecer \u00a0el\u00a0crecimiento \u00a0tumoral,\u00a0pero\u00a0si\u00a0hubo\u00a0un\u00a0\nleve\u00a0incremento \u00a0en\u00a0los\u00a0ratones\u00a0K.O\u00a0para\u00a0el\u00a0gen\u00a0\nTAC1\u00a0en\u00a0los\u00a03\u00a0experimentos \u00a0distintos\u00a0realizados \u00a0\n(Fig.\u00a022B).\u00a0Dado\u00a0que\u00a0la\u00a0l\u00ednea\u00a0tumoral\u00a0de\u00a0rat\u00f3n\u00a0\nEO771\u00a0es\u00a0TACR1+/HER2 \u2010\u00a0tampoco\u00a0se\u00a0pudo\u00a0\ndescartar \u00a0la\u00a0posibilidad \u00a0de\u00a0que\u00a0la\u00a0SP\u00a0end\u00f3gena \u00a0\ntuviera\u00a0otros\u00a0efectos\u00a0potenciales \u00a0en\u00a0un\u00a0modelo\u00a0\nsing\u00e9nico \u00a0de\u00a0CM\u00a0TACR1+/HER2+. \u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0(Contin\u00faa \u00a0en\u00a0la\u00a0p\u00e1gina\u00a0siguiente) \u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n132\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nFigura\u00a022.\u00a0Efectos\u00a0de\u00a0la\u00a0SP\u00a0end\u00f3gena \u00a0sobre\u00a0el\u00a0crecimiento \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0EO771\u00a0inoculadas \u00a0en\u00a0ratones\u00a0C57BL/6J \u00a0\nTAC1\n+/+\u00a0y\u00a0TAC1\u2010/\u2010.\u00a0A.\u00a0Western\u00a0blot\u00a0que\u00a0muestra\u00a0la\u00a0expresi\u00f3n \u00a0\nde\u00a0HER2\u00a0y\u00a0TACR1\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0murina\u00a0EO771\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453.\u00a0La\u00a0expresi\u00f3n \u00a0\nde\u00a0tubulina\u00a0se\u00a0utiliz\u00f3\u00a0como\u00a0control\u00a0end\u00f3geno \u00a0para\u00a0asegurar\u00a0\nla\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0B.\u00a0Curvas\u00a0de\u00a0crecimiento \u00a0de\u00a0los\u00a0\ntumores\u00a0formados \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0murina\u00a0EO771\u00a0\nen\u00a0ratones\u00a0sing\u00e9nicos \u00a0C57BL/6J\u00a0K.O\u00a0o\u00a0WT\u00a0para\u00a0TAC1\u00a0(media\u00a0\u00b1\u00a0\nSEM).\u00a0\n\u00a0\n9.\u00a0LA\u00a0SE\u00d1ALIZACI\u00d3N \u00a0AUTOCRINA \u00a0DE\u00a0\nSP\u00a0A\u00a0TRAV\u00c9S\u00a0DE\u00a0NK\u20101R\u00a0ES\u00a0\nIMPRESCINDIBLE \u00a0PARA\u00a0LA\u00a0\nSUPERVIVENCIA \u00a0DE\u00a0C\u00c9LULAS\u00a0DE\u00a0CM\u00a0\n9.1.\u00a0El\u00a0bloqueo\u00a0del\u00a0sistema\u00a0\ntaquiquin\u00e9rgico \u00a0\u00a0induce\u00a0muerte\u00a0celular\u00a0\nmediada\u00a0por\u00a0apoptosis \u00a0\n\u00a0\nA\u00a0continuacion \u00a0se\u00a0decidi\u00f3\u00a0investigar \u00a0la\u00a0relevancia \u00a0\ndel\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0en\u00a0la\u00a0supervivencia \u00a0\ncelular.\u00a0Debido\u00a0a\u00a0la\u00a0actividad\u00a0reguladora \u00a0que\u00a0\nejerce\u00a0el\u00a0sistema\u00a0taquiquin\u00e9rgico \u00a0sobre\u00a0algunas\u00a0de\u00a0\nlas\u00a0v\u00edas\u00a0que\u00a0tienen\u00a0un\u00a0papel\u00a0importante \u00a0en\u00a0el\u00a0\ndesarrollo \u00a0del\u00a0c\u00e1ncer235,245,496\u00a0se\u00a0consider\u00f3 \u00a0la\u00a0\nposibilidad \u00a0de\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0o\u00a0bien\u00a0de\u00a0SP\u00a0o\u00a0de\u00a0\nNK\u20101R\u00a0podr\u00eda\u00a0ser\u00a0utilizada\u00a0como\u00a0un\u00a0m\u00e9todo\u00a0\nterap\u00e9utico \u00a0e\u00a0inducir\u00a0as\u00ed\u00a0la\u00a0muerte\u00a0de\u00a0c\u00e9lulas\u00a0\ncancerosas. \u00a0Por\u00a0esta\u00a0raz\u00f3n,\u00a0se\u00a0decidi\u00f3\u00a0testar\u00a0si\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0SP\u00a0o\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0podr\u00eda\u00a0inducir\u00a0\napoptosis \u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a09.1.1.\u00a0El\u00a0tratamiento \u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0con\u00a0\nun\u00a0anticuerpo \u00a0anti\u2010SP\u00a0induce\u00a0muerte\u00a0\ncelular\u00a0mediada\u00a0por\u00a0apoptosis \u00a0\n\u00a0\n\u00a0Se\u00a0decidi\u00f3\u00a0utilizar\u00a0un\u00a0anticuerpo \u00a0contra\u00a0SP\u00a0(AB1)\u00a0\ndada\u00a0la\u00a0inexistencia \u00a0de\u00a0compuestos \u00a0qu\u00edmicos\u00a0\ncapaces\u00a0de\u00a0inhibir\u00a0este\u00a0peque\u00f1o\u00a0p\u00e9ptido.\u00a0Se\u00a0\ntrataron\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0y\u00a0c\u00e9lulas\u00a0epiteliales \u00a0de\u00a0\nmama\u00a0no\u00a0tumorales \u00a0con\u00a0el\u00a0anticuerpo \u00a0AB1\u00a0\ndurante\u00a072\u00a0horas\u00a0y\u00a0se\u00a0observ\u00f3\u00a0que\u00a0el\u00a0bloqueo\u00a0de\u00a0\nla\u00a0SP\u00a0causaba\u00a0apoptosis \u00a0de\u00a0una\u00a0forma\u00a0dosis\u2010\ndependiente. \u00a0La\u00a0apoptosis \u00a0se\u00a0midi\u00f3\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nt\u00e9cnicas\u00a0distintas\u00a0pero\u00a0obteniendo \u00a0resultados \u00a0\nsimilares: \u00a0externalizaci\u00f3n \u00a0de\u00a0fosfatidilserina \u00a0\u00a0\n(tinci\u00f3n\u00a0por\u00a0Anexina\u00a0V)\u00a0(Fig.\u00a023A),\u00a0y\u00a0la\u00a0reducci\u00f3n \u00a0\ndel\u00a0potencial \u00a0transmembrana \u00a0mitocondrial \u00a0\n(disminuci\u00f3n \u00a0en\u00a0la\u00a0tinci\u00f3n\u00a0con\u00a0DIOC 6(3))\u00a0(Fig.\u00a023B).\u00a0\nEstos\u00a0resultados \u00a0suger\u00edan\u00a0que\u00a0la\u00a0SP\u00a0podr\u00eda\u00a0estar\u00a0\nactuando \u00a0como\u00a0una\u00a0se\u00f1al\u00a0autocrina \u00a0esencial\u00a0para\u00a0\nla\u00a0supervivencia \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM,\u00a0ya\u00a0que\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0SP\u00a0induc\u00eda\u00a0la\u00a0apoptosis \u00a0celular.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0(Contin\u00faa \u00a0en\u00a0la\u00a0p\u00e1gina\u00a0siguiente) \u00a0\n\u00a0\n\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n133\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a023.\u00a0El\u00a0bloqueo\u00a0de\u00a0la\u00a0SP\u00a0induce\u00a0apoptosis \u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0\nCM.\u00a0A.\u00a0Marcaje\u00a0por\u00a0anexina\u00a0V/IP\u00a0o\u00a0B.\u00a0por\u00a0DIOC 6(3)\u00a0en\u00a0un\u00a0\npanel\u00a0de\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM\u00a0y\u00a0dos\u00a0c\u00e9lulas\u00a0epiteliales \u00a0de\u00a0\nmama\u00a0no\u00a0tumorales \u00a0tratadas\u00a0con\u00a0distintas\u00a0diluciones \u00a0del\u00a0\nanticuerpo \u00a0anti\u2010SP\u00a0(AB1)\u00a0durante\u00a072\u00a0horas,\u00a0y\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0\ntinci\u00f3n\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0mediante \u00a0FACS.\u00a0Las\u00a0cuantificaciones \u00a0se\u00a0\nmuestran \u00a0como\u00a0fold\u00a0change\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0ente\u00a0\nl\u00edneas\u00a0dentro\u00a0de\u00a0cada\u00a0grupo\u00a0se\u00a0muestran \u00a0como\u00a0*P<0,05\u00a0\n(prueba\u00a0t\u00a0de\u00a0Student,\u00a0dos\u00a0colas).\u00a0\n9.1.2.\u00a0La\u00a0inhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0induce\u00a0muerte\u00a0celular\u00a0mediada\u00a0por\u00a0\napoptosis \u00a0\n\u00a0\nEn\u00a0este\u00a0caso,\u00a0se\u00a0trataron\u00a0las\u00a0diferentes \u00a0l\u00edneas\u00a0\ncelulares\u00a0de\u00a0CM\u00a0con\u00a0el\u00a0antagonista \u00a0de\u00a0NK\u20101R,\u00a0L\u2010\n733,060.\u00a0En\u00a0un\u00a0primer\u00a0lugar\u00a0se\u00a0observ\u00f3\u00a0que\u00a0las\u00a0\nc\u00e9lulas\u00a0tratadas\u00a0con\u00a0L\u2010733,060\u00a0disminu\u00edan \u00a0su\u00a0\nproliferaci\u00f3n \u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0en\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0(Fig.\u00a024A\u2010B).\u00a0\nCuriosamente, \u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0estaba\u00a0relacionada \u00a0con\u00a0el\u00a0subtipo\u00a0\ntumoral\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0estudiadas, \u00a0siendo\u00a0mayor\u00a0\nen\u00a0las\u00a0l\u00edneas\u00a0de\u00a0celulares\u00a0luminales \u00a0con\u00a0expresi\u00f3n \u00a0\nde\u00a0HER2\u00a0(SKBR3,\u00a0BT474\u00a0y\u00a0MDA\u2010MD\u2010453)\u00a0que\u00a0en\u00a0\nlas\u00a0l\u00edneas\u00a0de\u00a0celulares\u00a0basales\u00a0con\u00a0menor\u00a0\nexpresi\u00f3n \u00a0de\u00a0HER2\u00a0(MDA\u2010MB\u2010468,\u00a0MDA\u00a0\u2010MB\u2010231,\u00a0\nMCF10A\u00a0y\u00a0MCF12A). \u00a0Por\u00a0otra\u00a0parte,\u00a0el\u00a0efecto\u00a0pro\u2010apopt\u00f3tico \u00a0causado\u00a0por\u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0(a\u00a0juzgar\u00a0por\u00a0la\u00a0positividad \u00a0de\u00a0la\u00a0tinci\u00f3n\u00a0\ncelular\u00a0con\u00a0anexina\u00a0V)\u00a0era\u00a0mayor\u00a0en\u00a0aquellas\u00a0\nc\u00e9lulas\u00a0con\u00a0altos\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0\n(Fig.\u00a024C).\u00a0La\u00a0apoptosis \u00a0causada\u00a0por\u00a0el\u00a0inhibidor\u00a0\nNK\u20101\u00a0en\u00a0todas\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0suger\u00eda\u00a0la\u00a0\nexistencia \u00a0de\u00a0una\u00a0posible\u00a0\"adicci\u00f3n \u00a0oncog\u00e9nica\" \u00a0\nde\u00a0estas\u00a0c\u00e9lulas\u00a0por\u00a0se\u00f1alizar\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0\nNK\u20101.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0(Contin\u00faa \u00a0en\u00a0la\u00a0p\u00e1gina\u00a0siguiente) \u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n134\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a024.\u00a0El\u00a0antagonismo \u00a0de\u00a0NK\u20101\u00a0induce\u00a0apopt\u00f3sis \u00a0en\u00a0\nc\u00e9lulas\u00a0de\u00a0CM.\u00a0A.\u00a0Diferentes \u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM\u00a0fueron\u00a0\ntratadas\u00a0con\u00a0el\u00a0antagonista \u00a0de\u00a0NK\u20101R,\u00a0L\u2010733,\u00a0060\u00a0a\u00a0una\u00a0dosis\u00a0\nde\u00a0entre\u00a00\u00a0y\u00a020\u00a0\u00b5M,\u00a0y\u00a0la\u00a0IC50\u00a0se\u00a0determin\u00f3 \u00a0por\u00a0MTT.\u00a0Se\u00a0\nmuestra\u00a0la\u00a0IC50\u00a0obtenida\u00a0para\u00a0cada\u00a0l\u00ednea\u00a0celular.\u00a0B.\u00a0La\u00a0IC50\u00a0\ndel\u00a0inhibidor\u00a0de\u00a0NK\u20101R\u00a0determinada \u00a0por\u00a0MTT\u00a0correlaciona \u00a0\nnegativamente \u00a0con\u00a0los\u00a0niveles\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0\n(determinado \u00a0por\u00a0Western\u00a0blot)\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0C.\u00a0Los\u00a0\nefectos\u00a0efectos\u00a0del\u00a0antagonista \u00a0NK1\u00a0L\u2010733,060\u00a0sobre\u00a0la\u00a0\nsupervivencia \u00a0en\u00a0l\u00edneas\u00a0de\u00a0CM\u00a0se\u00a0determinaron \u00a0mediante \u00a0\ntinci\u00f3n\u00a0por\u00a0anexina\u00a0V/IP\u00a0y\u00a0los\u00a0resultados \u00a0se\u00a0muestran \u00a0como\u00a0el\u00a0\nfold\u00a0change\u00a0\u00a0del\u00a0grupo\u00a0tratado\u00a0vs\u00a0el\u00a0grupo\u00a0no\u00a0tratado\u00a0en\u00a0cada\u00a0\nl\u00ednea\u00a0celular.\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0ente\u00a0l\u00edneas\u00a0dentro\u00a0\nde\u00a0cada\u00a0dosis\u00a0se\u00a0muestran \u00a0como\u00a0*P<0,05\u00a0(prueba\u00a0t\u00a0de\u00a0\nStudent,\u00a0dos\u00a0colas).\u00a0\n\u00a0\n10.\u00a0EL\u00a0ANTAGONISTA \u00a0DEL\u00a0\nRECEPTOR \u00a0NK\u20101,\u00a0EL\u00a0L\u2010733,060\u00a0\nINHIBE\u00a0EL\u00a0CRECIMIENTO \u00a0TUMORAL \u00a0\nIN\u00a0VIVO\u00a0\n\u00a0\nCon\u00a0los\u00a0experimentos \u00a0anteriores \u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0\nla\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0de\u00a0NK\u20101R\u00a0con\u00a0el\u00a0\ninhibidor\u00a0L\u2010733,\u00a0060\u00a0causaba\u00a0apoptosis \u00a0en\u00a0un\u00a0panel\u00a0de\u00a0l\u00edneas\u00a0c\u00e9lulares\u00a0de\u00a0CM;\u00a0de\u00a0hecho\u00a0NK\u20101R\u00a0\nha\u00a0demostrado \u00a0ser\u00a0una\u00a0diana\u00a0terap\u00e9utica \u00a0\nprometedora \u00a0en\u00a0varios\u00a0tipos\u00a0de\u00a0tumores245,339.\u00a0\nUna\u00a0vez\u00a0demostrada \u00a0su\u00a0efectividad \u00a0in\u00a0vitro,\u00a0se\u00a0\ndecidi\u00f3\u00a0investigar \u00a0como\u00a0afectaba\u00a0el\u00a0mismo\u00a0\ninhibidor\u00a0de\u00a0NK\u20101R\u00a0en\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0de\u00a0\nla\u00a0l\u00ednea\u00a0de\u00a0CM,\u00a0MDA\u2010MB\u2010453\u00a0(HER2+\u00a0NK\u20101R+)\u00a0in\u00a0\nvivo.\u00a0El\u00a0tratamiento \u00a0de\u00a0tumores\u00a0ortot\u00f3picos \u00a0\nderivados \u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0con\u00a0el\u00a0\ninhibidor\u00a0L\u2010733,\u00a0060\u00a0(5\u00a0mg/kg,\u00a0tres\u00a0veces\u00a0por\u00a0\nsemana)\u00a0redujo\u00a0significativamente \u00a0el\u00a0crecimiento \u00a0\ndel\u00a0tumor\u00a0(P<0,0001)\u00a0(Fig.\u00a025A)\u00a0y\u00a0su\u00a0peso\u00a0al\u00a0final\u00a0\nneto\u00a0(P=0,0112)\u00a0(Fig.\u00a025B).\u00a0Los\u00a0efectos\u00a0del\u00a0\ninhibidor\u00a0fueron\u00a0evidentes \u00a0dos\u00a0semanas\u00a0despu\u00e9s\u00a0\ndel\u00a0inicio\u00a0del\u00a0tratamiento \u00a0y\u00a0plenamente \u00a0\nsignificativos \u00a06\u00a0semanas\u00a0despu\u00e9s.\u00a0No\u00a0se\u00a0encontr\u00f3\u00a0\nninguna\u00a0diferencia \u00a0entre\u00a0grupos\u00a0respecto\u00a0a\u00a0la\u00a0\nfrecuencia \u00a0de\u00a0c\u00e9lulas\u00a0HER2+\u00a0identificadas \u00a0despu\u00e9s\u00a0\ndel\u00a0tratamiento \u00a0mediante \u00a0IHQ\u00a0(Fig.\u00a023C),\u00a0pero\u00a0si\u00a0\nse\u00a0observ\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0pHER2\u00a0Y1248\u00a0por\u00a0\nWestern\u00a0blot\u00a0(Fig.\u00a025D).\u00a0Los\u00a0niveles\u00a0totales\u00a0de\u00a0\nHER2\u00a0o\u00a0de\u00a0las\u00a0prote\u00ednas \u00a0Akt\u00a0y\u00a0p42/44\u2010MAPK\u00a0no\u00a0se\u00a0\nvieron\u00a0afectados, \u00a0lo\u00a0que\u00a0suger\u00eda\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0\ndel\u00a0crecimiento \u00a0tumoral\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u2010\n1\u00a0no\u00a0parec\u00eda\u00a0seleccionar \u00a0ninguna\u00a0subpoblaci\u00f3n \u00a0\ncelular\u00a0en\u00a0particular \u00a0(Fig.\u00a025\u00a0C\u2010D).\u00a0\u00a0\nPor\u00a0otro\u00a0lado,\u00a0se\u00a0observ\u00f3\u00a0una\u00a0ligera\u00a0disminuci\u00f3n \u00a0\nen\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0enzima\u00a0COX2\u00a0(mediadora \u00a0de\u00a0\nprocesos\u00a0inflamatorios) \u00a0como\u00a0consecuencia \u00a0de\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0adem\u00e1s\u00a0de\u00a0una\u00a0disminuci\u00f3n \u00a0\nsignificativa \u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0\u03b1\u2010SMA\u00a0\n(\u03b1\u2010actina\u00a0de\u00a0m\u00fasculo\u00a0liso),\u00a0cambios\u00a0que\u00a0\nsuscitaban \u00a0a\u00a0pensar\u00a0que\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0estaba\u00a0\ninvolucrado \u00a0tanto\u00a0en\u00a0la\u00a0modulaci\u00f3n \u00a0de\u00a0\npropiedades \u00a0del\u00a0tumor\u00a0como\u00a0en\u00a0la\u00a0\nreestructuraci\u00f3n \u00a0del\u00a0estroma\u00a0(Fig.\u00a025E\u2010F).\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n135\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a025.\u00a0El\u00a0inhibidor \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0modula\u00a0el\u00a0crecimiento \u00a0tumoral\u00a0in\u00a0vivo.\u00a0A.\u00a0Volumen\u00a0de\u00a0los\u00a0tumores\u00a0ortot\u00f3picos \u00a0\nderivados \u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0tratados\u00a0o\u00a0no\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0NK\u20101R,\u00a0L\u2010733,060\u00a0(media\u00a0\u00b1\n\u00a0SEM).\u00a0B.\u00a0Peso\u00a0del\u00a0tumor\u00a0en\u00a0el\u00a0\n\u00faltimo\u00a0d\u00eda\u00a0de\u00a0experimento. \u00a0C.\u00a0Im\u00e1genes \u00a0representativas \u00a0de\u00a0IHC\u00a0para\u00a0HER2\u00a0para\u00a0cada\u00a0grupo.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0de\u00a0las\u00a0im\u00e1genes \u00a0\nrepresenta \u00a0100\u00a0micras.\u00a0D.\u00a0Membranas \u00a0de\u00a0Western\u00a0blot\u00a0representativas \u00a0para\u00a0cada\u00a0grupo\u00a0de\u00a0tumores\u00a0de\u00a0MDA\u2010MB\u2010453\u00a0tratados\u00a0o\u00a0\nno\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0NK\u20101R\u00a0donde\u00a0se\u00a0muestran \u00a0las\u00a0prote\u00ednas \u00a0pHER2,\u00a0p\u2010p42/44\u00a0MAPK,\u00a0pAkt\u00a0y\u00a0sus\u00a0respectivas \u00a0prote\u00ednas \u00a0totales.\u00a0El\u00a0\ngr\u00e1fico\u00a0de\u00a0debajo\u00a0muestra\u00a0la\u00a0cuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0blot\u00a0relativa\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0\nque\u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0E.\u00a0Expresi\u00f3n \u00a0de\u00a0COX2\u00a0y\u00a0\u03b1\u2010SMA\u00a0en\u00a0los\u00a0tumores\u00a0ortot\u00f3picos \u00a0derivados \u00a0de\u00a0\nla\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0tratados\u00a0o\u00a0no\u00a0con\u00a0el\u00a0inhibidor\u00a0NK\u20101R,\u00a0L\u2010733,\u00a0060.\u00a0F.\u00a0Expresi\u00f3n \u00a0relativa\u00a0de\u00a0c\u00e9lulas\u00a0positivas\u00a0para\u00a0\u03b1\u2010SMA\u00a0en\u00a0\nlos\u00a0tumores\u00a0ortot\u00f3picos \u00a0derivados \u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0tratados\u00a0o\u00a0no\u00a0con\u00a0el\u00a0inhibidor\u00a0NK\u20101R,\u00a0L\u2010733,\u00a0060.\u00a0La\u00a0barra\u00a0de\u00a0escala\u00a0\nrepresenta \u00a050\u00a0micras.\u00a0Los\u00a0diagramas \u00a0de\u00a0caja\u00a0muestran \u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0los\u00a0valores\u00a0entre\u00a0el\u00a0percentil\u00a05\u201095.\u00a0Las\u00a0diferencias \u00a0\nestad\u00edsticas \u00a0de\u00a0cada\u00a0panel\u00a0se\u00a0calcularon \u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0de\u00a0t\u00a0de\u00a0Student\u00a0(dos\u00a0colas)\u00a0y\u00a0se\u00a0muestran \u00a0como\u00a0*\u00a0P<0,05,\u00a0**\u00a0P<0,01\u00a0y\u00a0\n***\u00a0P<0,001.\u00a0El\u00a0canal\u00a0azul\u00a0se\u00a0realz\u00f3\u00a0para\u00a0mejorar\u00a0la\u00a0imagen.\u00a0\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n136\u00a0\n\u00a011.\u00a0LA\u00a0COMBINACI\u00d3N \u00a0DEL\u00a0\nANTAGONISTA \u00a0DE\u00a0NK\u20101R,\u00a0L\u2010733,\u00a0\n060,\u00a0CON\u00a0TERAPIAS \u00a0ANTI\u2010HER2\u00a0\nINHIBE\u00a0SINERG\u00cdSTICAMENTE \u00a0LA\u00a0\nPROLIFERACI\u00d3N \u00a0DE\u00a0C\u00c9LULAS\u00a0DE\u00a0CM\u00a0\n\u00a0\nDespu\u00e9s\u00a0de\u00a0confirmar \u00a0la\u00a0implicaci\u00f3n \u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0en\u00a0la\u00a0supervivencia \u00a0celular\u00a0y\u00a0su\u00a0efecto\u00a0\nmodulador \u00a0de\u00a0la\u00a0actividad\u00a0de\u00a0HER2,\u00a0se\u00a0decidi\u00f3\u00a0\nestudiar\u00a0si\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R\u00a0pod\u00eda\u00a0ser\u00a0\nexplotada \u00a0como\u00a0nueva\u00a0aproximaci\u00f3n \u00a0terap\u00e9utica \u00a0\njunto\u00a0con\u00a0inhibidores \u00a0ErbB,\u00a0\u00a0como\u00a0inhibidores \u00a0de\u00a0\nHER2\u00a0o\u00a0EGFR.\u00a0Para\u00a0este\u00a0estudio\u00a0se\u00a0utiliz\u00f3\u00a0AG825\u00a0\n(inhibidor \u00a0de\u00a0HER2),\u00a0AG1478\u00a0(inhibidor \u00a0de\u00a0EGFR)\u00a0y\u00a0\nLapatinib, \u00a0un\u00a0inhibidor\u00a0dual\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0\nutilizado\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0\nSe\u00a0utilizaron \u00a0ensayos\u00a0MTT\u00a0para\u00a0obtener\u00a0la\u00a0IC50\u00a0de\u00a0\ncada\u00a0f\u00e1rmaco\u00a0por\u00a0separado \u00a0en\u00a0las\u00a02\u00a0l\u00edneas\u00a0\ncelulares\u00a0de\u00a0CM:\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010453\u00a0\n(HER2+)\u00a0y\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0(EGFR+).\u00a0\nUna\u00a0vez\u00a0conocida\u00a0la\u00a0IC50\u00a0se\u00a0aplic\u00f3\u00a0la\u00a0ecuaci\u00f3n\u00a0del\u00a0\nIncide\u00a0de\u00a0combinaci\u00f3n \u00a0(IC)484\u00a0para\u00a0determinar \u00a0si\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0NK\u20101R\u00a0podr\u00eda\u00a0potenciar \u00a0\nlos\u00a0efectos\u00a0de\u00a0los\u00a0inhibidores \u00a0de\u00a0EGFR\u00a0o\u00a0HER2.\u00a0El\u00a0\nIC\u00a0de\u00a0cada\u00a0l\u00ednea\u00a0celular\u00a0ofrece\u00a0resultados \u00a0\ncuantitativos \u00a0para\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0f\u00e1rmacos \u00a0\nque\u00a0permite\u00a0saber\u00a0si\u00a0es\u00a0un\u00a0efecto\u00a0aditivo\u00a0(IC\u00a0=\u00a01),\u00a0\nsin\u00e9rgico\u00a0(IC\u00a0<1),\u00a0o\u00a0antagonista \u00a0(IC>\u00a01).\u00a0El\u00a0\ntratamiento \u00a0con\u00a0L\u2010733,060\u00a0sinergiz\u00f3\u00a0con\u00a0los\u00a0\nefectos\u00a0citot\u00f3xicos \u00a0del\u00a0f\u00e1rmaco\u00a0AG825\u00a0(IC=\u00a0\n0,5686)\u00a0y\u00a0lapatinib\u00a0(IC=\u00a00.653)\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nMDA\u2010MB\u2010453\u00a0(Fig.\u00a026A)\u00a0adem\u00e1s\u00a0el\u00a0L\u2010733,060\u00a0\ntambi\u00e9n\u00a0demostr\u00f3 \u00a0una\u00a0sinergia\u00a0al\u00a0combinarse \u00a0con\u00a0\nLapatinib\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0(IC=\u00a0\n0,4494),\u00a0sin\u00a0embargo\u00a0demostr\u00f3 \u00a0un\u00a0efecto\u00a0\nantagonista \u00a0con\u00a0AG1478\u00a0(IC=\u00a01,7642)\u00a0con\u00a0las\u00a0dosis\u00a0\nutilizadas \u00a0(Fig.\u00a026B).\u00a0Las\u00a0combinaciones \u00a0de\u00a0\nf\u00e1rmacos \u00a0y\u00a0su\u00a0correspondiente \u00a0IC\u00a0para\u00a0ambas\u00a0\nl\u00edneas\u00a0celulares\u00a0se\u00a0muestran \u00a0en\u00a0la\u00a0Tabla\u00a01.\u00a0Estos\u00a0\nresultados \u00a0apoyaban \u00a0la\u00a0idea\u00a0de\u00a0que\u00a0las\u00a0\npropiedades \u00a0moduladoras \u00a0de\u00a0NK\u20101R\u00a0sobre\u00a0los\u00a0\nreceptores \u00a0ErbB\u00a0podr\u00edan\u00a0ser\u00a0explotadas \u00a0para\u00a0aumentar \u00a0la\u00a0eficacia\u00a0de\u00a0las\u00a0terapias\u00a0diana\u00a0dirigidas\u00a0\na\u00a0inhibir\u00a0HER2\u00a0y/o\u00a0EGFR\u00a0en\u00a0CM.\u00a0Esta\u00a0aplicaci\u00f3n \u00a0\npodr\u00eda\u00a0incluso\u00a0ser\u00a0efectiva\u00a0en\u00a0situaciones \u00a0de\u00a0\nquimio\u2010resistencia \u00a0adquirida \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0una\u00a0\nhiperactivaci\u00f3n \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0\nErbB\u00a0ser\u00eda\u00a0m\u00e1s\u00a0efectiva\u00a0la\u00a0inhibici\u00f3n \u00a0concomitante \u00a0\nde\u00a0NK\u20101R\u00a0y\u00a0receptores \u00a0ErbB.\u00a0\n\u00a0\n12.\u00a0UNA\u00a0EXPOSICI\u00d3N \u00a0CONTINUA \u00a0A\u00a0\nLA\u00a0SP\u00a0AUMENTA \u00a0LA\u00a0AGRESIVIDAD \u00a0\nDE\u00a0LAS\u00a0C\u00c9LULAS\u00a0DE\u00a0C\u00c1NCER\u00a0DE\u00a0\nMAMA\u00a0\n12.1.\u00a0La\u00a0exposici\u00f3n \u00a0de\u00a0SP\u00a0durante\u00a05\u00a0\nmeses\u00a0causa\u00a0cambios\u00a0fenot\u00edpicos \u00a0en\u00a0\nl\u00edneas\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0\n\u00a0\nPara\u00a0determinar \u00a0si\u00a0una\u00a0exposici\u00f3n \u00a0de\u00a0SP\u00a0a\u00a0largo\u00a0\u00a0\nplazo\u00a0pod\u00eda\u00a0inducir\u00a0cambios\u00a0en\u00a0las\u00a0propiedades \u00a0\nbiol\u00f3gicas \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0in\u00a0vitro ,\u00a0se\u00a0\ndesarroll\u00f3 \u00a0un\u00a0modelo\u00a0de\u00a0exposici\u00f3n \u00a0a\u00a0SP\u00a0en\u00a0dos\u00a0\nl\u00edneas\u00a0celulares\u00a0de\u00a0CM,\u00a0MDA\u2010MB\u2010453\u00a0(fenotipo \u00a0\nluminal)\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0(fenotipo \u00a0basal),\u00a0l\u00edneas\u00a0\nque\u00a0fueron\u00a0tratadas\u00a0diariamente \u00a0con\u00a0esta\u00a0\ncitoquina \u00a0a\u00a0una\u00a0concentraci\u00f3n \u00a0de\u00a0100\u00a0nM\u00a0durante\u00a0\nm\u00e1s\u00a0de\u00a05\u00a0meses.\u00a0El\u00a0hecho\u00a0de\u00a0utilizar\u00a0cultivos\u00a0\ncelulares, \u00a0a\u00a0diferencia \u00a0del\u00a0estudio\u00a0in\u00a0vivo,\u00a0nos\u00a0\npermiti\u00f3\u00a0tener\u00a0durante\u00a0m\u00e1s\u00a0tiempo\u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0bajo\u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0SP,\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0\nparecida\u00a0a\u00a0una\u00a0inflamaci\u00f3n \u00a0persistente. \u00a0En\u00a0primer\u00a0\nlugar\u00a0se\u00a0caracterizaron \u00a0los\u00a0cambios\u00a0morfol\u00f3gicos, \u00a0\nlas\u00a0 caracter\u00edsticas \u00a0 fenot\u00edpicas \u00a0 (patr\u00f3n\u00a0\nluminal/basal), \u00a0la\u00a0capacidad \u00a0clonog\u00e9nica, \u00a0y\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0algunos\u00a0receptores \u00a0que\u00a0podr\u00edan\u00a0\nestar\u00a0regulados \u00a0por\u00a0la\u00a0SP,\u00a0como\u00a0EGFR\u00a0y\u00a0HER2.\u00a0Para\u00a0\nevitar\u00a0excesivos \u00a0cambios\u00a0clonales\u00a0debidos\u00a0a\u00a0\nm\u00faltiples \u00a0pases\u00a0al\u00a0mantener \u00a0las\u00a0l\u00edneas\u00a0en\u00a0cultivo,\u00a0\nse\u00a0mantuvieron \u00a0siempre\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0\nparentales \u00a0(utilizadas \u00a0como\u00a0control)\u00a0con\u00a0los\u00a0\nmismos\u00a0pases\u00a0que\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0tratadas\u00a0con\u00a0\u00a0\n\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n137\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a026.\u00a0Sensibilidad \u00a0celular\u00a0a\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0inhibidores \u00a0de\u00a0NK\u20101R\u00a0junto\u00a0con\u00a0inhibidores \u00a0de\u00a0EGFR\u00a0y\u00a0HER2 .\u00a0Curvas\u00a0\nsigmoideas \u00a0que\u00a0muestran \u00a0los\u00a0efectos\u00a0de\u00a0(A)\u00a0cada\u00a0tratamiento \u00a0por\u00a0separado \u00a0(AG825,\u00a0Lapatinib \u00a0y\u00a0L\u2010733,060)\u00a0y\u00a0la\u00a0combinaci\u00f3n \u00a0\nentre\u00a0ellos\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\n\u00a0MDA\u2010MB\u2010453\u00a0y\u00a0(B)\u00a0cada\u00a0tratamiento \u00a0por\u00a0separado \u00a0(AG1478, \u00a0Lapatinib\u00a0y\u00a0L\u2010733,060)\u00a0y\u00a0la\u00a0combinaci\u00f3n \u00a0\nentre\u00a0ellos\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468.\u00a0La\u00a0media\u00a0de\u00a0la\u00a0concentraci\u00f3n \u00a0inhibitoria \u00a0m\u00e1xima\u00a0(IC50),\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0ajuste\u00a0de\u00a0curvas\u00a0\ny\u00a0la\u00a0estad\u00edstica \u00a0se\u00a0realiz\u00f3\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0suma\u00a0de\u00a0cuadrados \u00a0extra,\u00a0realizada\u00a0mediante \u00a0el\u00a0estad\u00edstico \u00a0F.\u00a0Los\u00a0valores\u00a0\ncon\u00a0una\u00a0P<0,05\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0C.\u00a0Gr\u00e1fico\u00a0que\u00a0indica\u00a0el\u00a0\u00edndice\u00a0de\u00a0combinaci\u00f3n \u00a0(IC)\u00a0de\u00a0\ninhibidores \u00a0de\u00a0NK\u20101R\u00a0(L\u2010733,\u00a0060)\u00a0junto\u00a0a\u00a0inhibidores \u00a0de\u00a0EGFR\u00a0y\u00a0HER2\u00a0(AG825,\u00a0AG1478\u00a0y\u00a0Lapatinib). \u00a0Los\u00a0diamantes \u00a0representan \u00a0el\u00a0\u00a0\nIC\u00a0de\u00a0las\u00a0combinaciones \u00a0entre\u00a0f\u00e1rmacos. \u00a0Aditividad: \u00a0IC=1;\u00a0Sinergia:\u00a0IC\u00a0<1;\u00a0Antagonismo: \u00a0IC>\u00a01.\u00a0\n\u00a0\n\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n138\u00a0\n\u00a0Tabla\u00a01.\u00a0IC50\u00a0obtenida\u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0respuesta \u00a0a\u00a0drogas\u00a0anti\u2010HER2\u00a0y\u00a0anti\u2010EGFR\u00a0de\u00a0la\u00a0Figura\u00a025.\u00a0\nMDA\u2010MB\u2010453\u00a0\nAG825\u00a0+\u00a0L\u2010733,060\u00a0 IC50\u00a0\n()P\u00a0value\u00a0 Lapatinib \u00a0+\u00a0L\u2010733,060\u00a0 IC50\u00a0\n()P\u00a0value\u00a0\nAG825\u00a0 21.1\u00a0<0.0001Lapatinib \u00a0 0.21\u00a0<0.0001AG825\u00a0+\u00a05\u00a0\u00b5M\u00a0L\u2010733,060\u00a0 11.5\u00a0 Lapatinib \u00a0+\u00a05\u00a0\u00b5M\u00a0L\u2010733,060\u00a0 0.13\u00a0\nL\u2010733,060\u00a0 6.08\u00a0<0.0001L\u2010733,060\u00a0 6.08\u00a0<0.0001L\u2010733,060\u00a0+\u00a025\u00a0\u00b5M\u00a0 0.98\u00a0 L\u2010733,060\u00a0+\u00a00.2\u00a0\u00b5M\u00a0 0.63\u00a0\n\u00cdndice\u00a0de\u00a0combinaci\u00f3n \u00a0 0.5686\u00a0 \u00cdndice\u00a0de\u00a0combinaci\u00f3n \u00a0 0.6353\u00a0\nIC50\u00a0\u00a0e\u00a0IC\u00a0correspondientes \u00a0a\u00a0la\u00a0figura\u00a026C.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nSP,\u00a0y\u00a0en\u00a0ning\u00fan\u00a0caso,\u00a0las\u00a0c\u00e9lulas\u00a0se\u00a0cultivaron \u00a0m\u00e1s\u00a0\nall\u00e1\u00a0de\u00a0un\u00a0pase\u00a030.\u00a0Para\u00a0diferenciar \u00a0las\u00a0c\u00e9lulas\u00a0\nparentales \u00a0de\u00a0las\u00a0tratadas,\u00a0estas\u00a0\u00faltimas\u00a0pasaron\u00a0a\u00a0\ndenominarse \u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0\nEl\u00a0tratamiento \u00a0a\u00a0largo\u00a0plazo\u00a0con\u00a0SP\u00a0indujo\u00a0cambios\u00a0\nfenot\u00edpicos \u00a0m\u00e1s\u00a0evidentes \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010\nMB\u2010468\u00a0SP,\u00a0ya\u00a0que\u00a0parec\u00eda\u00a0mostrar\u00a0un\u00a0fenotipo\u00a0\nm\u00e1s\u00a0epitelial\u00a0que\u00a0la\u00a0l\u00ednea\u00a0parental,\u00a0con\u00a0la\u00a0p\u00e9rdida\u00a0\nde\u00a0morfolog\u00eda \u00a0en\u00a0forma\u00a0fusiforme \u00a0(caracter\u00edstica \u00a0\nde\u00a0l\u00edneas\u00a0celulares\u00a0basales)\u00a0y\u00a0una\u00a0mayor\u00a0tendencia \u00a0\nhacia\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0colonias\u00a0propias\u00a0de\u00a0c\u00e9lulas\u00a0\ncon\u00a0fenotipo\u00a0m\u00e1s\u00a0luminal\u00a0(Fig.\u00a027A).\u00a0Este\u00a0cambio\u00a0\nfenot\u00edpico \u00a0concordaba \u00a0con\u00a0el\u00a0aumento\u00a0de\u00a0\nexpresi\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0CD24+/CD44\u2010\u00a0\u00a0(caracter\u00edsticas \u00a0\nde\u00a0fenotipo\u00a0luminal)\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\n(P=0.001)\u00a0respecto\u00a0a\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0(Fig.\u00a0\n27B)\u00a0analizadas \u00a0mediante \u00a0citometr\u00eda \u00a0de\u00a0flujo,\u00a0y\u00a0\ncon\u00a0un\u00a0aumento\u00a0de\u00a0\u03b1 \u2010Catenina\u00a0(marcador \u00a0de\u00a0\nfenotipo\u00a0epitelial)\u00a0o\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0N\u2010\u00a0\nCadherina \u00a0(P=0.0432)\u00a0o\u00a0Snail\u00a0(P=0.009)\u00a0(ambos\u00a0\nmarcadores \u00a0mesenquimales/basales) \u00a0(Fig.\u00a027C).\u00a0Estos\u00a0resultados \u00a0suger\u00edan\u00a0que\u00a0el\u00a0tratamiento \u00a0con\u00a0\nSP\u00a0promov\u00eda \u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0un\u00a0fenotipo\u00a0m\u00e1s\u00a0\nluminal\u00a0o\u00a0diferenciado \u00a0por\u00a0parte\u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010\nMB\u2010468,\u00a0teniendo\u00a0en\u00a0cuenta\u00a0que\u00a0es\u00a0una\u00a0l\u00ednea\u00a0de\u00a0\nfenotipo\u00a0basal.\u00a0Sin\u00a0embargo\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0\nno\u00a0present\u00f3\u00a0cambios\u00a0significativos \u00a0de\u00a0expresi\u00f3n \u00a0\nde\u00a0marcadores \u00a0CD24/CD44, \u00a0solamente \u00a0un\u00a0\npeque\u00f1o\u00a0aumento\u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0CD24+/CD44\u2010\u00a0\ndel\u00a013%\u00a0(P=0.0015)\u00a0(Fig.\u00a027B),\u00a0pero\u00a0si\u00a0present\u00f3\u00a0\nuna\u00a0disminuci\u00f3n \u00a0en\u00a0los\u00a0marcadores \u00a0epiteliales \u00a0E\u2010\nCaderina\u00a0(P=0.0058)\u00a0y\u00a0\u03b1\u2010Catenina\u00a0(P=0.0003)\u00a0y\u00a0un\u00a0\naumento\u00a0en\u00a0aquellos\u00a0marcadores \u00a0propios\u00a0de\u00a0\nfenotipos \u00a0mesenquimales \u00a0N\u2010Caderina\u00a0y\u00a0Snail\u00a0\n(P=0.0009)\u00a0(Fig.\u00a027C).\u00a0\n\u00a0\n\u00a0\u00a0\u00a0MDA\u2010MB\u2010468\u00a0\nAG1478\u00a0+\u00a0L\u2010733,060\u00a0 IC50\u00a0 P\u00a0value\u00a0\u00a0 Lapatinib \u00a0+\u00a0L\u2010733,060\u00a0 IC50\u00a0 P\u00a0value\u00a0\nAG1478\u00a0 15.80\u00a0 <0.0001 \u00a0Lapatinib \u00a0 1.85\u00a0 <0.0001\nAG1478\u00a0+\u00a04\u00a0\u00b5M\u00a0L\u2010733,060\u00a0 6.83\u00a0 \u00a0Lapatinib \u00a0+\u00a04\u00a0\u00b5M\u00a0L\u2010733,060\u00a0 0.28\u00a0\nL\u2010733,060\u00a0 5.78\u00a0 <0.4720 \u00a0L\u2010733,060\u00a0 5.78\u00a0 <0.0001\nL\u2010733,060\u00a0+\u00a025\u00a0\u00b5M\u00a0 5.38\u00a0 \u00a0L\u2010733,060\u00a0+\u00a02.5\u00a0\u00b5M\u00a0 1.42\u00a0\n\u00cdndice\u00a0de\u00a0combinaci\u00f3n \u00a0 1.7642\u00a0\u00a0\u00cdndice\u00a0de\u00a0combinaci\u00f3n \u00a0 0.4494\u00a0\nIC50\u00a0\u00a0e\u00a0IC\u00a0correspondientes \u00a0a\u00a0la\u00a0figura\u00a026C.\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n139\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a027.\u00a0Desarrollo \u00a0y\u00a0caracterizaci\u00f3n \u00a0de\u00a0un\u00a0modelo\u00a0celular\u00a0con\u00a0sobreexposici\u00f3n \u00a0a\u00a0la\u00a0SP.\u00a0A.\u00a0Im\u00e1genes \u00a0decontraste \u00a0de\u00a0fase\u00a0que\u00a0\nmuestran \u00a0los\u00a0cambios\u00a0morfol\u00f3gicos \u00a0inducidos \u00a0por\u00a0una\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0durante\u00a05\u00a0meses\u00a0en\u00a0c\u00e9lulas\u00a0en\u00a0cultivo.\u00a0\nLa\u00a0barra\u00a0de\u00a0\nescala\u00a0representa \u00a050\u00a0micras.\u00a0B.\u00a0Cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0los\u00a0marcadores \u00a0CD44/CD24 \u00a0en\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0\ntratadas\u00a0continuamente \u00a0con\u00a0SP\u00a0durante\u00a05\u00a0meses.\u00a0C.\u00a0Cambios\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0los\u00a0marcadores \u00a0de\u00a0transici\u00f3n \u00a0epitelio\u2010mesenquima \u00a0\nen\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0tratadas\u00a0continuamente \u00a0con\u00a0SP\u00a0durante\u00a05\u00a0meses.\u00a0Las\u00a0diferencias \u00a0estad\u00edsticas \u00a0\nse\u00a0muestran \u00a0como\u00a0*P<0,05,\u00a0**P<0,01\u00a0y\u00a0***P<0,001\u00a0(prueba\u00a0t\u00a0de\u00a0Student,\u00a0dos\u00a0colas).\u00a0\n\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n140\u00a0\n\u00a012.1.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\naumenta\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0en\u00a0\nl\u00edneas\u00a0de\u00a0CM\u00a0\n\u00a0\nLas\u00a0nuevas\u00a0caracter\u00edsticas \u00a0adquiridas \u00a0bajo\u00a0\ntratamiento \u00a0de\u00a0SP\u00a0tambi\u00e9n\u00a0afectaron \u00a0a\u00a0la\u00a0\ncapacidad \u00a0clonog\u00e9nica \u00a0de\u00a0estas\u00a0l\u00edneas\u00a0celulares. \u00a0\nTanto\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0como\u00a0la\u00a0MDA\u2010MB\u2010\n468\u00a0SP\u00a0mostraron \u00a0una\u00a0mayor\u00a0capacidad \u00a0de\u00a0formar\u00a0\nclones\u00a0despu\u00e9s\u00a0de\u00a03\u00a0semanas\u00a0de\u00a0crecimiento, \u00a0\nsiendo\u00a0a\u00a0su\u00a0vez\u00a0m\u00e1s\u00a0grandes\u00a0y\u00a0numerosos \u00a0que\u00a0las\u00a0\nl\u00edneas\u00a0parentales \u00a0no\u00a0tratadas\u00a0(Fig.\u00a028).\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Figura\u00a028.\u00a0El\u00a0tratamiento \u00a0con\u00a0SP\u00a0de\u00a0forma\u00a0continua\u00a0provoca\u00a0\ncambios\u00a0en\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0de\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0\nCM.\u00a0A.\u00a0Ensayos\u00a0clonog\u00e9nicos \u00a0con\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010\nMB\u2010453\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0tratadas\u00a0o\u00a0no\u00a0cr\u00f3nicamente \u00a0con\u00a0SP.\u00a0\nLas\u00a0im\u00e1genes \u00a0fueron\u00a0tomadas\u00a0despu\u00e9s\u00a0de\u00a03\u00a0semanas\u00a0de\u00a0\ncrecimiento. \u00a012.2\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\naumenta\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0receptores \u00a0\nde\u00a0la\u00a0familia\u00a0ErbB,\u00a0NK\u20101R\u00a0y\u00a0altera\u00a0los\u00a0\nniveles\u00a0de\u00a0IL\u20106\u00a0\n12.2.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\nprovoca\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0genes\u00a0de\u00a0\nla\u00a0familia\u00a0ERBB\u00a0\nUna\u00a0vez\u00a0demostrado \u00a0en\u00a0experimentos \u00a0anteriores \u00a0\nque\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0SP/NK\u20101R\u00a0pod\u00eda\u00a0influir\u00a0en\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0receptores \u00a0ErbB,\u00a0el\u00a0siguiente\u00a0paso\u00a0fue\u00a0\ndeterminar \u00a0si\u00a0el\u00a0tratamiento \u00a0continuo\u00a0con\u00a0SP\u00a0\ncambiaba \u00a0de\u00a0forma\u00a0significativa \u00a0los\u00a0niveles\u00a0de\u00a0\nEGFR,\u00a0HER2,\u00a0HER3\u00a0y\u00a0HER4.\u00a0Se\u00a0tomaron\u00a0varias\u00a0\nmuestras \u00a0de\u00a0las\u00a04\u00a0l\u00edneas\u00a0durante\u00a0los\u00a0dos\u00a0primeros\u00a0\nmeses\u00a0de\u00a0tratamiento \u00a0y\u00a0mediante \u00a0la\u00a0extracci\u00f3n \u00a0de\u00a0\nRNA\u00a0y\u00a0por\u00a0qPCR\u00a0se\u00a0pudieron\u00a0cuantificar \u00a0los\u00a0\nposibles\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0estos\u00a0\nreceptores \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo.\u00a0Teniendo \u00a0en\u00a0\ncuenta\u00a0que\u00a0ambas\u00a0l\u00edneas\u00a0parentales \u00a0ya\u00a0\nsobreexpresan \u00a0los\u00a0receptores \u00a0HER2\u00a0(en\u00a0el\u00a0caso\u00a0de\u00a0\nlas\u00a0MDA\u2010MB\u2010453)\u00a0y\u00a0el\u00a0receptor\u00a0EGFR\u00a0(en\u00a0el\u00a0caso\u00a0\nde\u00a0las\u00a0MDA\u2010MB\u2010468)\u00a0igualmente \u00a0estos\u00a0niveles\u00a0se\u00a0\nvieron\u00a0incrementados \u00a0en\u00a0alg\u00fan\u00a0punto\u00a0del\u00a0\ntratamiento. \u00a0En\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0los\u00a0\nniveles\u00a0de\u00a0RNA\u00a0se\u00a0incrementaron \u00a0unas\u00a02\u00a0veces\u00a0\nm\u00e1s\u00a0para\u00a0EGFR,\u00a0de\u00a02\u00a0a\u00a04\u00a0veces\u00a0m\u00e1s\u00a0para\u00a0HER2,\u00a0de\u00a0\n2\u00a0a\u00a06\u00a0veces\u00a0m\u00e1s\u00a0para\u00a0HER3\u00a0y\u00a0unas\u00a05\u00a0veces\u00a0m\u00e1s\u00a0\npara\u00a0HER4\u00a0comparado \u00a0con\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0las\u00a0\nl\u00edneas\u00a0control\u00a0(Fig.\u00a029A).\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0MDA\u2010\nMB\u2010453\u00a0los\u00a0niveles\u00a0de\u00a0HER2\u00a0y\u00a0HER3\u00a0no\u00a0\naumentaron \u00a0de\u00a0forma\u00a0considerable, \u00a0EGFR\u00a0se\u00a0\nmantuvo\u00a0igual\u00a0o\u00a0disminuy\u00f3 \u00a0y\u00a0los\u00a0niveles\u00a0de\u00a0HER4\u00a0\naumentaron \u00a0unas\u00a03\u00a0veces\u00a0m\u00e1s\u00a0en\u00a0alg\u00fan\u00a0punto\u00a0del\u00a0\ntratamiento \u00a0(Fig.\u00a029A).\u00a0Sin\u00a0embargo, \u00a0los\u00a0niveles\u00a0de\u00a0\nprote\u00edna\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0en\u00a0un\u00a0punto\u00a0final\u00a0del\u00a0\ntratamiento, \u00a0determinados \u00a0tanto\u00a0por\u00a0Western\u00a0\nblot\u00a0(Fig.\u00a029B)\u00a0como\u00a0por\u00a0IHQ\u00a0(Fig.\u00a029C)\u00a0fueron\u00a0\nsignificativamente \u00a0mayores\u00a0en\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0\ntratadas\u00a0con\u00a0SP,\u00a0y\u00a0en\u00a0algunos\u00a0casos\u00a0exist\u00eda\u00a0una\u00a0\nmayor\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0v\u00edas\u00a0p42/44\u2010MAPK\u00a0y\u00a0de\u00a0\nAkt\u00a0(Fig.\u00a029B).\u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n141\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a029.\u00a0Caracterizaci\u00f3n \u00a0de\u00a0un\u00a0modelo\u00a0celular\u00a0con\u00a0sobreexposici\u00f3n \u00a0a\u00a0SP.\u00a0A.\u00a0Niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0genes\u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0en\u00a0\nlas\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0y\u00a0MDA\u2010MB\u00a0453\u00a0SP\u00a0durante\u00a0los\u00a0primeros\u00a02\u00a0meses\u00a0de\u00a0tratamiento. \u00a0Los\u00a0resultados \u00a0de\u00a0expresi\u00f3n \u00a0se\u00a0\nmuestran \u00a0como\u00a0el\u00a0fold\u00a0change\u00a0de\u00a0la\u00a0l\u00ednea\u00a0tratada\u00a0continuamente \u00a0con\u00a0SP\u00a0vs\u00a0la\u00a0l\u00ednea\u00a0parental.\u00a0B.\u00a0Western\u00a0blot\u00a0y\u00a0cuantificaci\u00f3n \u00a0\ndensitom\u00e9trica \u00a0de\u00a0las\u00a0las\u00a0prote\u00ednas \u00a0indicadas \u00a0en\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010453\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0tratadas\u00a0o\u00a0no\u00a0con\u00a0SP\u00a0durante\u00a05\u00a0\nmeses,\u00a0relativas\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0Los\u00a0datos\u00a0fueron\u00a0generados \u00a0a\u00a0\npartir\u00a0de\u00a03\u00a0repeticiones \u00a0y\u00a0se\u00a0presentan \u00a0como\u00a0media\u00b1SD. \u00a0C.\u00a0IHC\u00a0de\u00a0bloques\u00a0celulares\u00a0para\u00a0las\u00a0prote\u00ednas \u00a0indicadas. \u00a0La\u00a0barra\u00a0de\u00a0\nescala\u00a0representa \u00a020\u00a0micras.\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n142\u00a0\n\u00a012.2.2.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0altera\u00a0\nlas\u00a0respuestas \u00a0celulares\u00a0a\u00a0las\u00a0terapias\u00a0\ndirigidas\u00a0contra\u00a0HER2\u00a0y\u00a0EGFR\u00a0\nDado\u00a0que\u00a0la\u00a0hiperactivaci\u00f3n \u00a0de\u00a0receptores \u00a0de\u00a0la\u00a0\nfamilia\u00a0ErbB\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0componentes \u00a0pro\u2010\ninflamatorios \u00a0del\u00a0microambiente \u00a0podr\u00eda\u00a0influir\u00a0en\u00a0\nlas\u00a0respuestas \u00a0celulares\u00a0a\u00a0las\u00a0terapias\u00a0dirigidas\u00a0\ncontra\u00a0estos\u00a0receptores \u00a0(por\u00a0ejemplo,\u00a0los\u00a0\ninhibidores \u00a0de\u00a0EGFR\u00a0o\u00a0HER2),\u00a0el\u00a0siguiente\u00a0paso\u00a0fue\u00a0\ncomprobar \u00a0c\u00f3mo\u00a0afectar\u00edan \u00a0estos\u00a0inhibidores \u00a0a\u00a0la\u00a0\nviabilidad \u00a0celular\u00a0bajo\u00a0los\u00a0efectos\u00a0de\u00a0una\u00a0\nexposici\u00f3n \u00a0de\u00a0SP\u00a0a\u00a0largo\u00a0o\u00a0corto\u00a0plazo.\u00a0Para\u00a0ello\u00a0se\u00a0\ntrataron\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MDA\u2010MB\u2010453,\u00a0MDA\u2010\nMB\u2010453\u00a0SP,\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0con\u00a0\nlos\u00a0inhibidores \u00a0de\u00a0AG825,\u00a0AG1478\u00a0y\u00a0Lapatinib, \u00a0y\u00a0se\u00a0\ndeterminaron \u00a0los\u00a0cambios\u00a0en\u00a0de\u00a0la\u00a0IC50\u00a0para\u00a0cada\u00a0\ninhibidor. \u00a0Una\u00a0breve\u00a0exposici\u00f3n \u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0a\u00a0\nSP\u00a0a\u00a0100\u00a0nM\u00a0o\u00a0500\u00a0nM\u00a0durante\u00a072h\u00a0ten\u00eda\u00a0poco\u00a0o\u00a0\nning\u00fan\u00a0efecto\u00a0sobre\u00a0la\u00a0IC50\u00a0del\u00a0f\u00e1rmaco\u00a0AG825\u00a0en\u00a0\ncualquier \u00a0l\u00ednea\u00a0celular,\u00a0\u00fanicamente \u00a0se\u00a0observ\u00f3\u00a0un\u00a0\naumento\u00a0de\u00a0la\u00a0IC50\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0MDA\u2010MB\u2010453\u00a0a\u00a0\nuna\u00a0dosis\u00a0de\u00a0100\u00a0nM\u00a0(Fig.\u00a030A)\u00a0y\u00a0por\u00a0el\u00a0contrario \u00a0\nun\u00a0descenso \u00a0en\u00a0la\u00a0IC50\u00a0del\u00a0f\u00e1rmaco\u00a0AG1478\u00a0en\u00a0las\u00a0\nc\u00e9lulas\u00a0MDA\u2010MB\u2010468\u00a0expuestas \u00a0a\u00a0una\u00a0dosis\u00a0de\u00a0\n500\u00a0nM\u00a0(Fig.\u00a030B).\u00a0Sin\u00a0embargo, \u00a0el\u00a0tratamiento \u00a0\ncr\u00f3nico\u00a0con\u00a0SP\u00a0durante\u00a05\u00a0meses\u00a0indujo\u00a0un\u00a0\naumento\u00a0significativo \u00a0en\u00a0la\u00a0viabilidad \u00a0de\u00a0las\u00a0l\u00edneas\u00a0\ncelulares\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0o\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\nrespecto\u00a0a\u00a0las\u00a0l\u00edneas\u00a0parentales, \u00a0despu\u00e9s\u00a0de\u00a0haber\u00a0\nsido\u00a0tratadas\u00a0con\u00a0AG1478,\u00a0AG825\u00a0y\u00a0Lapatinib\u00a0(Fig.\u00a0\n30A\u2010B),\u00a0tal\u00a0y\u00a0como\u00a0se\u00a0refleja\u00a0por\u00a0las\u00a0diferencias \u00a0en\u00a0\nlos\u00a0valores\u00a0de\u00a0IC50.\u00a0En\u00a0definitiva, \u00a0estos\u00a0resultados \u00a0\nindican\u00a0que\u00a0una\u00a0exposici\u00f3n \u00a0cr\u00f3nica\u00a0a\u00a0la\u00a0SP\u00a0podr\u00eda\u00a0\ninducir\u00a0cambios\u00a0moleculares \u00a0que\u00a0afectan\u00a0a\u00a0la\u00a0\nrespuesta \u00a0a\u00a0terapias\u00a0dirigidas\u00a0contra\u00a0EGFR\u00a0y\u00a0HER2\u00a0\nya\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0expuestas \u00a0continuamente \u00a0a\u00a0SP\u00a0\npresentan \u00a0una\u00a0mayor\u00a0resistencia \u00a0a\u00a0estos\u00a0\ninhibidores \u00a0respecto\u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0parentales. \u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\nFigura\u00a030.\u00a0Efectos\u00a0de\u00a0la\u00a0SP\u00a0a\u00a0corto\u00a0y\u00a0largo\u00a0plazo\u00a0en\u00a0las\u00a0\nrespuestas \u00a0celulares\u00a0a\u00a0las\u00a0terapias\u00a0anti\u2010HER2\u00a0y\u00a0anti\u2010EGFR.\u00a0\nEnsayos\u00a0de\u00a0MTT\u00a0que\u00a0comparan \u00a0la\u00a0IC50\u00a0para\u00a0de\u00a0cada\u00a0uno\u00a0de\u00a0\nlos\u00a0f\u00e1rmacos \u00a0indicados. \u00a0Los\u00a0c\u00edrculos\u00a0representan \u00a0la\u00a0IC50\u00a0\uf0b1\u00a0el\u00a0\nintervalo\u00a0de\u00a0confianza \u00a0del\u00a095%\u00a0para\u00a0cada\u00a0tratamiento \u00a0en\u00a0(A)\u00a0\nMDA\u2010MB\u2010453\u00a0y\u00a0(B)\u00a0MDA\u2010MB\u2010468\u00a0tras\u00a0la\u00a0exposici\u00f3n \u00a0de\u00a0SP\u00a0\ncorto\u00a0(72h\u00a0una\u00a0dosis\u00a0de\u00a0100\u00a0y\u00a0500\u00a0nM)\u00a0o\u00a0largo\u00a0plazo\u00a0\n(tratamiento \u00a0con\u00a0SP\u00a0100\u00a0nM\u00a0durante\u00a05\u00a0meses).\u00a0El\u00a0an\u00e1lisis\u00a0de\u00a0\najuste\u00a0de\u00a0curvas\u00a0para\u00a0el\u00a0c\u00e1lculo\u00a0de\u00a0la\u00a0IC50\u00a0y\u00a0la\u00a0estad\u00edstica \u00a0se\u00a0\nrealiz\u00f3\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0prueba\u00a0de\u00a0suma\u00a0de\u00a0cuadrados \u00a0\nextra,\u00a0realizada\u00a0mediante \u00a0el\u00a0estad\u00edstico \u00a0F.\u00a0Los\u00a0valores\u00a0con\u00a0una\u00a0\n**P<0,01\u00a0 y\u00a0 ***P<0,001,\u00a0 fueron\u00a0 considerados \u00a0\nestad\u00edsticamente \u00a0significativos. \u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n143\u00a0\n\u00a012.2.3.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\naumenta\u00a0la\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0\nde\u00a0prote\u00ednas \u00a0implicadas \u00a0en\u00a0sus\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0como\u00a0NF\u2010\u03baB\u00a0e\u00a0IL\u20106\u00a0\n\u00a0\nEstudios\u00a0previos\u00a0han\u00a0demostrado \u00a0que\u00a0la\u00a0SP\u00a0puede\u00a0\ncontrolar\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB292,320,\u00a0lo\u00a0que\u00a0sugiere\u00a0que\u00a0\nquiz\u00e1s\u00a0algunos\u00a0de\u00a0los\u00a0efectos\u00a0inducidos \u00a0por\u00a0una\u00a0\nexposici\u00f3n \u00a0continua\u00a0de\u00a0SP\u00a0podr\u00edan\u00a0estar\u00a0\nrelacionados \u00a0con\u00a0la\u00a0sobreexpresi\u00f3n \u00a0del\u00a0receptor\u00a0\nNK\u20101.\u00a0NF\u2010\u03baB\u00a0est\u00e1\u00a0implicada \u00a0en\u00a0m\u00faltiples \u00a0procesos\u00a0\nde\u00a0inflamaci\u00f3n \u00a0y\u00a0c\u00e1ncer.\u00a0En\u00a0nuestras\u00a0l\u00edneas\u00a0\ncelulares\u00a0se\u00a0observ\u00f3\u00a0un\u00a0incremento \u00a0de\u00a0ambas\u00a0\nprote\u00ednas \u00a0respecto\u00a0a\u00a0la\u00a0situaci\u00f3n\u00a0control.\u00a0Mientras\u00a0\nque\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0aument\u00f3\u00a0en\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010\nMB\u2010468\u00a0SP\u00a0y\u00a0MDA\u2010MB\u2010453\u00a0SP,\u00a0la\u00a0prote\u00edna\u00a0\nfosforilada \u00a0NF\u2010\u03baB\u00a0(p\u2010NF\u2010\u03baB)\u00a0aument\u00f3\u00a0levemente \u00a0\nsolamente \u00a0en\u00a0la\u00a0primera\u00a0(Fig.\u00a031A)\u00a0lo\u00a0que\u00a0parec\u00eda\u00a0\nindicar\u00a0una\u00a0regulaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0distinta\u00a0\nen\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0l\u00edneas\u00a0celulares. \u00a0\nPor\u00a0otro\u00a0lado\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0IL\u20106\u00a0tambi\u00e9n\u00a0est\u00e1\u00a0\nregulada\u00a0por\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0de\u00a0manera\u00a0\ndependiente \u00a0o\u00a0independiente \u00a0de\u00a0NF\u2010\u03baB,\u00a0en\u00a0c\u00e9lulas\u00a0\nde\u00a0glioblastoma \u00a0y/o\u00a0de\u00a0CM319,322,497.\u00a0La\u00a0IL\u20106\u00a0es\u00a0otra\u00a0\nmediadora \u00a0de\u00a0la\u00a0inflamaci\u00f3n, \u00a0y\u00a0su\u00a0expresi\u00f3n \u00a0se\u00a0\nregula\u00a0en\u00a0parte\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0\nadem\u00e1s\u00a0de\u00a0ser\u00a0la\u00a0responsable \u00a0de\u00a0activar\u00a0v\u00edas\u00a0de\u00a0\ntransformaci\u00f3n \u00a0celular\u00a0como\u00a0la\u00a0v\u00eda\u00a0de\u00a0STAT3498.\u00a0Se\u00a0\nha\u00a0visto\u00a0en\u00a0la\u00a0Fig.\u00a031A\u00a0que\u00a0el\u00a0tratamiento \u00a0continuo\u00a0\ncon\u00a0SP\u00a0causa\u00a0un\u00a0aumento\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0de\u00a0\nla\u00a0prote\u00edna\u00a0NF\u2010\u03baB\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0SP.\u00a0Por\u00a0\neste\u00a0motivo\u00a0se\u00a0analizaron \u00a0los\u00a0niveles\u00a0de\u00a0IL\u20106\u00a0en\u00a0las\u00a0\n4\u00a0l\u00edneas\u00a0(las\u00a0tratadas\u00a0con\u00a0SP\u00a0y\u00a0sus\u00a0parentales) \u00a0para\u00a0\ncomprobar \u00a0si\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0NK\u20101R\u00a0en\u00a0\nestas\u00a0l\u00edneas\u00a0celulares\u00a0estaba\u00a0relacionada \u00a0con\u00a0la\u00a0\nliberaci\u00f3n \u00a0de\u00a0esta\u00a0citoquina. \u00a0Se\u00a0comprob\u00f3, \u00a0que\u00a0la\u00a0\nIL\u20106\u00a0hab\u00eda\u00a0aumentado \u00a0hasta\u00a04,7\u00a0veces\u00a0m\u00e1s\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0respecto\u00a0a\u00a0la\u00a0l\u00ednea\u00a0\nparental\u00a0no\u00a0tratada\u00a0(Fig.\u00a031B).\u00a0Sin\u00a0embargo, \u00a0no\u00a0se\u00a0\nencontraron \u00a0diferencias \u00a0significativas \u00a0en\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0esta\u00a0interleuquina \u00a0en\u00a0concreto\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0(Fig.\u00a031C).\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0Figura\u00a031.\u00a0Efectos\u00a0de\u00a0la\u00a0SP\u00a0a\u00a0corto\u00a0y\u00a0largo\u00a0plazo\u00a0en\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0reguladoras \u00a0de\u00a0la\u00a0inflamaci\u00f3n. \u00a0A.\u00a0\nWestern\u00a0blot\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0p\u2010NF\u2010\u03baB\u00a0en\u00a0las\u00a0l\u00edneas\u00a0\ntratadas\u00a0con\u00a0SP\u00a0durante\u00a05\u00a0meses\u00a0respecto\u00a0a\u00a0las\u00a0parentales. \u00a0\nLos\n\u00a0paneles\u00a0que\u00a0acompa\u00f1an \u00a0a\u00a0cada\u00a0membrana \u00a0muestran \u00a0la\u00a0\ncuantificaci\u00f3n \u00a0densitom\u00e9trica \u00a0de\u00a0las\u00a0membranas \u00a0de\u00a0Western\u00a0\nblot\u00a0relativa\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0tubulina,\u00a0que\u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0\nasegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna\u00a0(media+SD). \u00a0B.\u00a0Niveles\u00a0\nde\u00a0IL\u20106\u00a0en\u00a0el\u00a0sobrenadante \u00a0de\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010453\u00a0y\u00a0MDA\u2010\nMB\u2010468\u00a0tratadas\u00a048h\u00a0con\u00a0SP\u00a0(100\u00a0nM)\u00a0o\u00a0a\u00a0diario\u00a0durante\u00a05\u00a0\nmeses\u00a0(100\u00a0nm).\u00a0Valores\u00a0con\u00a0una\u00a0**P<0,01\u00a0y\u00a0***P<0,001,\u00a0\nfueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n144\u00a0\n\u00a012.2.4.\u00a0La\u00a0ausencia\u00a0de\u00a0SP\u00a0despu\u00e9s\u00a0de\u00a0una\u00a0\nexposici\u00f3n \u00a0continua\u00a0no\u00a0altera\u00a0los\u00a0niveles\u00a0\nde\u00a0expresi\u00f3n \u00a0de\u00a0EGFR\u00a0o\u00a0HER2\u00a0adquiridos \u00a0\ndurante\u00a0el\u00a0tratamiento \u00a0\n\u00a0\nCuriosamente, \u00a0los\u00a0cambios\u00a0inducidos \u00a0por\u00a0la\u00a0SP\u00a0\npodr\u00edan\u00a0ser\u00a0de\u00a0naturaleza \u00a0epigen\u00e9tica, \u00a0ya\u00a0que\u00a0la\u00a0\neliminaci\u00f3n \u00a0de\u00a0SP\u00a0en\u00a0los\u00a0medios\u00a0de\u00a0cultivo\u00a0de\u00a0la\u00a0\nl\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0durante\u00a0dos\u00a0meses\u00a0no\u00a0\nalter\u00f3\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0EGFR\u00a0o\u00a0HER2\u00a0en\u00a0\nuna\u00a0de\u00a0las\u00a0l\u00edneas\u00a0que\u00a0m\u00e1s\u00a0cambios\u00a0fenot\u00edpicos \u00a0\nhab\u00eda\u00a0sufrido\u00a0(Fig.\u00a032).\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a032.\u00a0Expresi\u00f3n \u00a0de\u00a0los\u00a0receptores \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0tras\u00a0\nla\u00a0deprivaci\u00f3n \u00a0de\u00a0SP\u00a0una\u00a0vez\u00a0establecido \u00a0el\u00a0modelo\u00a0de\u00a0\ntratamiento \u00a0continuo. \u00a0A.\u00a0Valores\u00a0de\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0\nEGFR,\u00a0HER2,\u00a0HER2,\u00a0HER4\u00a0medidos\u00a0por\u00a0qPCR.\u00a0Los\u00a0resultados \u00a0\nde\u00a0expresi\u00f3n \u00a0se\u00a0muestran \u00a0como\u00a0el\u00a0fold\u00a0change\u00a0de\u00a0la\u00a0l\u00ednea\u00a0\ntratada\u00a0continuamente \u00a0con\u00a0SP\u00a0(y\u00a0poteriormente \u00a0deprivada \u00a0de\u00a0\nSP\u00a0durante\u00a02\u00a0meses)\u00a0vs\u00a0la\u00a0l\u00ednea\u00a0parental.\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a013.\u00a0\u00a0EFECTO\u00a0DE\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0\nCONTINUADA \u00a0DE\u00a0LA\u00a0SP\u00a0EN\u00a0LA\u00a0\nEXPRESI\u00d3N \u00a0G\u00c9NICA\u00a0\u00a0\n\u00a0\n\u00a0Para\u00a0determinar \u00a0qu\u00e9\u00a0cambios\u00a0a\u00a0nivel\u00a0de\u00a0expresi\u00f3n \u00a0\ng\u00e9nica\u00a0se\u00a0hab\u00edan\u00a0producido \u00a0en\u00a0las\u00a0l\u00edneas\u00a0tratadas\u00a0\ncontinuamente \u00a0con\u00a0SP\u00a0se\u00a0hizo\u00a0un\u00a0an\u00e1lisis\u00a0\ncomparativo \u00a0del\u00a0perfil\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0de\u00a0las\u00a0\nl\u00edneas\u00a0MDA\u2010MB\u2010453/MDA \u2010MB\u201045\u00a03SP\u00a0y\u00a0MDA\u2010MB\u2010\n468/MDA \u2010MB\u2010468\u00a0SP\u00a0(n=2\u00a0para\u00a0cada\u00a0l\u00ednea\u00a0\ncelular).\u00a0 Se\u00a0 identificaron \u00a0 385\u00a0 genes\u00a0\ndiferencialmente \u00a0 expresados \u00a0 (187\u00a0\nsobreexpresados \u00a0y\u00a0199\u00a0infraexpresados) \u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0(Fig.\u00a033A)\u00a0\u00a0y\u00a0387\u00a0genes\u00a0\ndiferencialmente \u00a0 expresados \u00a0 (193\u00a0\nsobreexpresados \u00a0y\u00a0193\u00a0infraexpresados) \u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0\u00a0(Fig.\u00a033B)\u00a0respecto\u00a0a\u00a0sus\u00a0\nl\u00edneas\u00a0parentales. \u00a0S\u00f3lo\u00a0se\u00a0tuvieron\u00a0en\u00a0cuenta\u00a0las\u00a0\ndiferencias \u00a0con\u00a0un\u00a0P\u00a0valor\u00a0ajustado\u00a0menor\u00a0que\u00a0el\u00a0\n0.1\u00a0(q\u00a0<0.1)\u00a0y\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0o\u00a0\u00a0log 2\u00a0ratio\u00a0\n>1.2\u00a0o\u00a0\u20101.2.\u00a0\u00a0\u00a0\nCon\u00a0tal\u00a0de\u00a0explorar\u00a0los\u00a0datos\u00a0obtenidos \u00a0desde\u00a0una\u00a0\nprespectiva \u00a0global\u00a0se\u00a0utiliz\u00f3\u00a0el\u00a0programa \u00a0Ingenuity \u00a0\nPathways \u00a0Analysis\u00a0(IPA)\u00a0que\u00a0sit\u00faa\u00a0los\u00a0genes\u00a0en\u00a0su\u00a0\ncontexto\u00a0biol\u00f3gico, \u00a0de\u00a0la\u00a0manera\u00a0m\u00e1s\u00a0exhaustiva \u00a0\nposible.\u00a0El\u00a0IPA\u00a0integra\u00a0informaci\u00f3n \u00a0de\u00a0otras\u00a0bases\u00a0\nde\u00a0datos,\u00a0proporciona \u00a0las\u00a0principales \u00a0rutas,\u00a0\nfunciones \u00a0biol\u00f3gicas \u00a0y\u00a0redes\u00a0funcionales \u00a0asociadas \u00a0\na\u00a0los\u00a0genes\u00a0que\u00a0quieres\u00a0estudiar.\u00a0Ofrece\u00a0una\u00a0\npuntuaci\u00f3n \u00a0para\u00a0los\u00a0genes\u00a0m\u00e1s\u00a0relevantes \u00a0\nsobreexpresados \u00a0 o\u00a0 infraexpresados \u00a0\ninterconectados \u00a0entre\u00a0s\u00ed\u00a0y\u00a0otros\u00a0genes\u00a0de\u00a0su\u00a0bases\u00a0\nde\u00a0datos,\u00a0\u00a0 proporcionando \u00a0un\u00a0n\u00famero\u00a0\ndeterminado \u00a0de\u00a0genes\u00a0candidatos. \u00a0El\u00a0an\u00e1lisis\u00a0de\u00a0\nfunci\u00f3n\u00a0gen\u00e9tica\u00a0revel\u00f3\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estos\u00a0\ngenes\u00a0desregulados \u00a0estaban\u00a0involucrados \u00a0en\u00a0ciclo\u00a0\ncelular,\u00a0crecimiento \u00a0y\u00a0proliferaci\u00f3n, \u00a0expresi\u00f3n \u00a0\ng\u00e9nica,\u00a0s\u00edntesis\u00a0de\u00a0prote\u00ednas, \u00a0se\u00f1alizaci\u00f3n \u00a0celular,\u00a0\nrespuesta \u00a0inflamatoria, \u00a0y\u00a0movimiento \u00a0celular\u00a0\n(Tabla\u00a02).\u00a0Estos\u00a0resultados \u00a0se\u00a0obtuvieron \u00a0tambi\u00e9n\u00a0\nde\u00a0forma\u00a0gr\u00e1fica\u00a0y\u00a0est\u00e1n\u00a0representados \u00a0en\u00a0las\u00a0Fig.\u00a0\nanexa\u00a01\u00a0y\u00a02.\u00a0De\u00a0toda\u00a0la\u00a0red\u00a0de\u00a0genes\u00a0generada, \u00a0\nfinalmente \u00a0se\u00a0aceptaron \u00a020\u00a0genes\u00a0candidatos \u00a0para\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n145\u00a0\n\u00a0\ncada\u00a0l\u00ednea\u00a0celular\u00a0(Fig.\u00a034\u00a0A\u2010B).\u00a0Entre\u00a0estas\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0encontramos \u00a0una\u00a0sobre\u00a0regulaci\u00f3n \u00a0de\u00a0\nla\u00a0IL\u20106\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010468,\u00a0de\u00a0acuerdo\u00a0con\u00a0\nlos\u00a0resultados \u00a0analizados \u00a0mediante \u00a0ELISA\u00a0(Fig.\u00a0\nanexa\u00a02,\u00a0red\u00a01).\u00a0\n13.1.\u00a0Genes\u00a0comunes \u00a0alterados \u00a0por\u00a0el\u00a0\ntratamiento \u00a0\u00a0\n\u00a0\nAl\u00a0cruzar\u00a0las\u00a0listas\u00a0de\u00a0genes\u00a0diferencialmente \u00a0\nexpresados \u00a0de\u00a0ambas\u00a0l\u00edneas\u00a0celulares\u00a0se\u00a0pudo\u00a0\nestablecer \u00a0una\u00a0nueva\u00a0lista\u00a0conjunta\u00a0con\u00a0los\u00a0genes\u00a0 comunes\u00a0 sobreexpresados \u00a0 o\u00a0\ninfraexpresados \u00a0en\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0\ncont\u00ednuo\u00a0de\u00a0SP\u00a0(Fig.\u00a035A).\u00a0Fueron\u00a0muy\u00a0pocos\u00a0los\u00a0\ngenes\u00a0comunes\u00a0encontrados, \u00a0en\u00a0total\u00a011\u00a0genes\u00a0(4\u00a0\nsobreexpresados \u00a0y\u00a07\u00a0infraexpresados), \u00a0pero\u00a0no\u00a0era\u00a0\nde\u00a0extra\u00f1ar\u00a0si\u00a0ten\u00edamos \u00a0en\u00a0cuenta\u00a0que\u00a0la\u00a0l\u00ednea\u00a0\nluminal\u00a0MDA\u2010MB\u2010453\u00a0difer\u00eda\u00a0molecularmente \u00a0de\u00a0\nla\u00a0l\u00ednea\u00a0con\u00a0fenotipo\u00a0basal\u00a0MDA\u2010MB\u2010468499\u00a0(Fig.\u00a0\n35B).\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nFigura\u00a033.\u00a0Genes\u00a0principales \u00a0derivados \u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica:\u00a0A.\u00a0Heat\u00a0map\u00a0de\u00a0los\u00a0genes\u00a0diferencialmente \u00a0expresados \u00a0\nen\u00a0las\u00a0l\u00edneas\u00a0(A)\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0(187\u00a0sobreexpresados \u00a0y\u00a0199\u00a0infraexpresados) \u00a0y\u00a0(B)\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0(194\u00a0sobreexpresados \u00a0y\u00a0193\u00a0\ninfraexpresados). \u00a0Se\u00a0utiliz\u00f3\u00a0una\u00a0n=2\u00a0para\u00a0cada\u00a0l\u00ednea\u00a0celular.\u00a0Valores\u00a0expresados \u00a0como\u00a0Log 2ratio\u00a0>\u00a01.2\u00a0y\u00a0un\u00a0valor\u00a0q\u00a0<\u00a00.1.\u00a0Los\u00a0genes\u00a0\nsobreexpresados \u00a0en\u00a0esta\u00a0figura\u00a0se\u00a0muestran \u00a0en\u00a0rojo,\u00a0los\u00a0que\u00a0no\u00a0se\u00a0alteran\u00a0en\u00a0negro,\u00a0mientras\u00a0que\u00a0los\u00a0infraeexpresados \u00a0se\u00a0\nrepresentan \u00a0en\u00a0verde.\u00a0\n\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n146\u00a0\n\u00a0Tabla\u00a02.\u00a0Principales \u00a0genes\u00a0diferencialmente \u00a0expresados \u00a0de\u00a0las\u00a0l\u00edneas\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0involucrados \u00a0en\u00a0las\u00a0\nredes\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0generadas \u00a0por\u00a0el\u00a0IPA.\u00a0\u00a0\nMDA\u2010MB\u2010453\u00a0SP\u00a0\nRED\u00a0 MOL\u00c9CULAS \u00a0DE\u00a0LA\u00a0RED\u00a0 PUNTUACI\u00d3NMOLECULAS \u00a0\nIMPLICADAS \u00a0FUNCIONES \u00a0\nBIOL\u00d3GICAS \u00a0\n1\u00a0ATF5,\u00a0BID,\u00a0C10ORF119, \u00a0CA2,\u00a0CCNE1,\u00a0CCNE2,\u00a0CDC20,\u00a0CDT1,\u00a0\nCyclin\u00a0A,\u00a0Cyclin\u00a0E,\u00a0DHFR,\u00a0DLEU2,\u00a0E2f,\u00a0E2F1,\u00a0HIST1H4H \u00a0\n(includes\u00a0EG:8365), \u00a0Histone\u00a0h3,\u00a0HSPE1,\u00a0ID1,\u00a0ID2,\u00a0ID3,\u00a0IGFBP3,\u00a0\nIGFBP5,\u00a0MCM7,\u00a0MEF2C,\u00a0PCK2,\u00a0PEPCK,\u00a0POLR2L\u00a0(incluye\u00a0\nEG:5441 ),\u00a0Rb,\u00a0RNA\u00a0polymerase \u00a0II,\u00a0SFN,\u00a0SLC3A2,\u00a0SLC7A5,\u00a0\nTCF3,\u00a0TFF1,\u00a0TP63\u00a0\u00a040\u00a0\u00a0 28\u00a0Ciclo\u00a0\ncelular,crecimiento \u00a0\ncelular\u00a0y\u00a0proliferaci\u00f3n \u00a0\ny\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0\n2\u00a0\u00a014\u20103\u20103,\u00a0Akt,\u00a0ASNS,\u00a0ATF3,\u00a0ATF4,\u00a0BAD,\u00a0CEBPB,\u00a0CEBPG,\u00a0Creb,\u00a0\nCYP51A1, \u00a0DUSP2,\u00a0EPHA4,\u00a0GADD45B, \u00a0HERPUD1, \u00a0HNRNPD, \u00a0\nIRS1,\u00a0Jnk,\u00a0LDLR,\u00a0MAP3K5\u00a0(incluye\u00a0EG:4217), \u00a0Mapk,\u00a0MME,\u00a0\nNR4A2,\u00a0P38\u00a0MAPK,\u00a0p85\u00a0(pik3r) ,\u00a0PCBP2,\u00a0PLC\u00a0gamma ,\u00a0PTBP1,\u00a0\nRALGPS1, \u00a0RET,\u00a0SLC7A1,\u00a0TNFRSF12A, \u00a0TRAF3,\u00a0TRIB3,\u00a0TYRO3,\u00a0\nVLDLR\u00a0\u00a038\u00a0\u00a0 27\u00a0Desarrollo \u00a0tisular,\u00a0\ntrastornos \u00a0del\u00a0tejido\u00a0\nconectivo \u00a0y\u00a0\ntrastornos \u00a0\ninmulol\u00f3gicos \u00a0\n3\u00a0\u00a0ABHD3 ,\u00a0ASNS ,\u00a0ATF4 ,\u00a0BCL2A1,\u00a0CA2,\u00a0CA9,\u00a0CA12 ,\u00a0CEBPB ,\u00a0\nEGLN3 ,\u00a0ELF3 ,\u00a0EP300,\u00a0EPO,\u00a0ETS2,\u00a0F7,\u00a0F8,\u00a0F8A1,\u00a0FOSB,\u00a0GRSF1 ,\u00a0\nHIC1,\u00a0HIF1A,\u00a0HIST1H2AD ,\u00a0IER3,\u00a0IL12B,\u00a0LRP8 ,\u00a0NFAT\u00a0(complex), \u00a0\nNUPR1 ,\u00a0SIRT1,\u00a0SLC7A11 ,\u00a0SPHK1 ,\u00a0STC2 ,\u00a0TAC1 ,\u00a0TACR2 ,\u00a0TBP,\u00a0\nTFF1 ,\u00a0VitaminD3 \u2010VDR\u2010RXR\u00a0\u00a021\u00a0\u00a0 18\u00a0Da\u00f1os\u00a0en\u00a0el\u00a0\norganismo, \u00a0\nalteraciones \u00a0\ngen\u00e9ticas \u00a0y\u00a0\nenfermedades \u00a0\nrenales\u00a0y\u00a0urol\u00f3gicas. \u00a0\n4\u00a0\u00a0AARS ,\u00a0AKT2,\u00a0ANG ,\u00a0BTRC,\u00a0CTPS ,\u00a0DEGS1 ,\u00a0EIF1,\u00a0Eif2,\u00a0EIF5,\u00a0\nEIF2B1,\u00a0EIF2S2 ,\u00a0EIF2S3,\u00a0EIF3A,\u00a0EIF4E,\u00a0GATA4,\u00a0Gli,\u00a0GLI1,\u00a0GLI2,\u00a0\nGLI3 ,\u00a0GLRB ,\u00a0GPHN,\u00a0GSK3B,\u00a0IL1R2 ,\u00a0JAG2 ,\u00a0LHX2 ,\u00a0MNX1 ,\u00a0\nMTMR1 ,\u00a0NES,\u00a0PFN1,\u00a0PHLDA2 ,\u00a0PTCH1,\u00a0SOX2,\u00a0SUFU,\u00a0TNC,\u00a0\nYWHAZ\u00a0\u00a017\u00a0\u00a0 16\u00a0S\u00edntesis\u00a0de\u00a0prote\u00ednas, \u00a0\nse\u00f1alizaci\u00f3n \u00a0celular\u00a0y\u00a0\nexpresi\u00f3n \u00a0g\u00e9nica\u00a0\n\u00a0\nMDA\u2010MB\u2010468\u00a0SP\u00a0\nRED\u00a0 MOL\u00c9CULAS \u00a0DE\u00a0LA\u00a0RED\u00a0 PUNTUACI\u00d3NMOLECULAS \u00a0\nIMPLICADAS \u00a0FUNCIONES \u00a0\nBIOL\u00d3GICAS \u00a0\n1\u00a0\u00a0A2M,\u00a0ADAMTS1, \u00a0ATF3,\u00a0BCL3,\u00a0CA9,\u00a0CASP1,\u00a0CXCL10,\u00a0CYP1A1,\u00a0\nFGF2,\u00a0FOXO1,\u00a0GBP2,\u00a0GDF15,\u00a0Histone\u00a0h3,\u00a0ID1,\u00a0IFIT3,\u00a0IL1,\u00a0IL6,\u00a0\nIL1R1,\u00a0IL1RAP,\u00a0IL1RN,\u00a0IRG,\u00a0NCOA1,\u00a0NFkB\u00a0(complex) ,\u00a0OAS1,\u00a0\nPALLD,\u00a0PECAM1, \u00a0PEPCK ,\u00a0PIR,\u00a0PYCARD,\u00a0RNA\u00a0polymerase \u00a0II,\u00a0\nSERPINA3, \u00a0SMYD3,\u00a0STAT ,\u00a0TFPI2,\u00a0TNFSF10\u00a0\u00a039\u00a0\u00a0 28\u00a0Crecimiento \u00a0celular\u00a0y\u00a0\nproliferaci\u00f3n, \u00a0\nmorfolog\u00eda \u00a0tumoral\u00a0y\u00a0\ndesarrollo \u00a0celular\u00a0\u00a0\n2\u00a0\u00a0Actin,\u00a0ADRB2,\u00a0AKAP7,\u00a0Akt,\u00a0Alpha\u00a0Actinin ,\u00a0Alpha\u00a0tubulin,\u00a0\nATP2B4,\u00a0CALD1,\u00a0Calmodulin ,\u00a0CASK,\u00a0CAV1,\u00a0CD99\u00a0(includes\u00a0\nEG:4267), \u00a0CEACAM6 \u00a0(includes\u00a0EG:4680), \u00a0CRIM1,\u00a0CSRP2,\u00a0\nDPYSL2,\u00a0DUSP1,\u00a0EPS8L1,\u00a0ERK1/2 ,\u00a0F\u00a0Actin ,\u00a0GABARAPL1, \u00a0\nGABBR2,\u00a0ICAM1,\u00a0MAGT1,\u00a0MAP1B,\u00a0MYCN,\u00a0Pka,\u00a0PP2A ,\u00a0\nPPAP2B,\u00a0RAC2,\u00a0S100A8,\u00a0S100A9,\u00a0SORBS1,\u00a0TUBA1A,\u00a0Tubulin\u00a0\u00a033\u00a0\u00a0 25\u00a0Respuesta \u00a0\ninflamatoria, \u00a0\nmovimiento \u00a0celular\u00a0y\u00a0\u00a0\nMetabolismo \u00a0lip\u00eddico\u00a0\n3\u00a0\u00a0alcohol\u00a0group\u00a0acceptor\u00a0phosphotransferase, \u00a0ARAF,\u00a0CD14,\u00a0\nCOL18A1, \u00a0Collagen\u00a0type\u00a0IV,\u00a0Collagen(s), \u00a0CTGF,\u00a0CTSL1,\u00a0CTSS,\u00a0\nFGG,\u00a0Fibrinogen, \u00a0FN1,\u00a0GPR37,\u00a0GRK5,\u00a0HBEGF,\u00a0Hsp70 ,\u00a0Hsp90 ,\u00a0\nIgfbp,\u00a0IGFBP2,\u00a0IGFBP5,\u00a0IGFBP7,\u00a0IL7R,\u00a0Integrin ,\u00a0LGALS8,\u00a0LRP,\u00a0\nNOD2,\u00a0NOV,\u00a0OLR1,\u00a0PIM1,\u00a0SGK1,\u00a0STAT5a/b ,\u00a0THBS1,\u00a0Tlr,\u00a0TLR5,\u00a0\nTNC\u00a0\u00a031\u00a0\u00a0 24\u00a0Movimiento \u00a0cellular,\u00a0\ndesarrollo \u00a0y\u00a0funci\u00f3n\u00a0\ndel\u00a0sistema\u00a0muscular\u00a0\ny\u00a0esquel\u00e9tico, \u00a0\ncrecimiento \u00a0celular\u00a0y\u00a0\nproliferaci\u00f3n \u00a0\n4\u00a0\u00a0ADM,\u00a0ANPEP,\u00a0ASAP1,\u00a0BLNK,\u00a0DKK1,\u00a0Focal\u00a0adhesion \u00a0kinase,\u00a0\nFST,\u00a0FYN,\u00a0Gap,\u00a0INHBA,\u00a0IRS1,\u00a0IRS2,\u00a0JAK,\u00a0JAK2,\u00a0Jnk,\u00a0MET,\u00a0MYC,\u00a0\nNCK,\u00a0NRP1,\u00a0P110 ,\u00a0p85\u00a0(pik3r) ,\u00a0Pak,\u00a0Pi3\u2010kinase ,\u00a0PI3K,\u00a0PLC\u00a0\ngamma,\u00a0PLCG2,\u00a0PRKACB,\u00a0PTK2,\u00a0Ras,\u00a0Sos,\u00a0Trk\u00a0Receptor ,\u00a0VAV,\u00a0\nVAV3,\u00a0Vegf,\u00a0WT1\u00a0\u00a022\u00a0\u00a0 19\u00a0Ciclo\u00a0celular,\u00a0\nmovimiento \u00a0y\u00a0\ndesarrollo \u00a0celular\u00a0RESULTADOS \u00a0 \u00a0\n\u00a0\n147\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0Figura\u00a034.\u00a0Genes\u00a0principales \u00a0derivados \u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0con\u00a0el\u00a0IPA:\u00a0A.\u00a010\u00a0genes\u00a0principales \u00a0sobreespresados \u00a0y\u00a010\u00a0infraexpresados \u00a0\nen\u00a0la\u00a0l\u00ednea\u00a0(A)\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0y\u00a0(B)\u00a0MDA\u2010MB\u2010468\u00a0SP.\u00a0Los\u00a0genes\u00a0sobreexpresados \u00a0en\u00a0esta\u00a0figura\u00a0\u00a0se\u00a0muestran \u00a0en\u00a0rojo,\u00a0mientras\u00a0\nque\u00a0los\u00a0infraeexpresados \u00a0se\u00a0representan \u00a0en\n\u00a0verde.\u00a0Los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0cada\u00a0gen\u00a0se\u00a0muestran \u00a0como\u00a0log 2ratio.\u00a0\n\u00a0\u00a0 \u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n148\u00a0\n\u00a0\nLa\u00a0sobreexpresi\u00f3n \u00a0de\u00a0algunos\u00a0de\u00a0estos\u00a0genes\u00a0\ncomo\u00a0el\u00a0ATF3\u00a0(Activating \u00a0transcription \u00a0factor\u00a03),\u00a0\nson\u00a0responsables \u00a0de\u00a0la\u00a0sobreregulaci\u00f3n \u00a0de\u00a0genes\u00a0\ninvolucrados \u00a0en\u00a0la\u00a0met\u00e1stasis \u00a0y\u00a0agresividad \u00a0\ntumoral\u00a0de\u00a0distintos\u00a0tipos\u00a0de\u00a0c\u00e1nceres\u00a0entre\u00a0ellos\u00a0\nel\u00a0CM500.\u00a0Por\u00a0otro\u00a0lado\u00a0el\u00a0aumento\u00a0de\u00a0niveles\u00a0\ncirculantes \u00a0de\u00a0otro\u00a0gen\u00a0sobreexpresado, \u00a0el\u00a0\nGDF15/MIC \u20101\u00a0(growth\u00a0differentiation \u00a0factor\u00a015)\u00a0se\u00a0ha\u00a0asociado\u00a0cl\u00ednicamente \u00a0con\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0CM\u00a0\ny\u00a0con\u00a0la\u00a0resistencia \u00a0a\u00a0la\u00a0quimioterapia \u00a0en\u00a0este\u00a0tipo\u00a0\nde\u00a0c\u00e1ncer,\u00a0pero\u00a0tambi\u00e9n\u00a0en\u00a0pr\u00f3stata,\u00a0ovario\u00a0y\u00a0\nc\u00e1ncer\u00a0colorrectal501\u2010504.\u00a0Adem\u00e1s\u00a0se\u00a0ha\u00a0descrito\u00a0\nanteriormente \u00a0que\u00a0esta\u00a0citoquina \u00a0es\u00a0responsable \u00a0\nde\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0prote\u00edna\u00a0\nSrc\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0c\u00e1ncer\u00a0de\u00a0mama505,506\u00a0\nreduciendo \u00a0la\u00a0sensibilidad \u00a0a\u00a0terapias\u00a0anti\u2010HER2\u00a0\ncomo\u00a0el\u00a0trastuzumab507.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nFigura\u00a035.\u00a0Genes\u00a0principales \u00a0derivados \u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica:\u00a0A.\u00a0Imagen\u00a0representativa \u00a0de\u00a0los\u00a0genes\u00a0expresados \u00a0\nconjuntamente \u00a0por\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0y\u00a0MDA\u2010MB\u2010468\u00a0SP.\u00a0B.\u00a0Heat\u00a0map\u00a0de\u00a0los\u00a011\u00a0genes\u00a0diferencialmente \u00a0expresados \u00a0en\u00a0conjunto\u00a0(4\u00a0\nsobreexpresados \u00a0y\u00a07\u00a0infraexpresados). \u00a0Valores\u00a0expresados \u00a0como\u00a0Log 2ratio\u00a0>\u00a01.2\u00a0y\u00a0un\u00a0valor\u00a0q\u00a0<\u00a00.1.\u00a0Los\u00a0genes\u00a0sobreexpresados \u00a0en\u00a0\nesta\u00a0figura\u00a0se\u00a0muestran \u00a0en\u00a0rojo,\u00a0los\u00a0que\u00a0no\u00a0se\u00a0alteran\u00a0en\u00a0negro,\u00a0mientras\u00a0que\u00a0los\u00a0infraeexpresados \u00a0se\u00a0representan \u00a0en\u00a0verde.\u00a0Se\u00a0\nutiliz\u00f3\u00a0una\u00a0n=2\u00a0para\u00a0cada\u00a0l\u00ednea\u00a0celular.\u00a0\n\u00a0\n\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n149\u00a0\n\u00a014.\u00a0LA\u00a0EXPOSICI\u00d3N \u00a0CONTINUA \u00a0A\u00a0SP\u00a0\nCAUSA\u00a0UNA\u00a0ALTERACI\u00d3N \u00a0EN\u00a0LA\u00a0\nHORMONO \u2010DEPENDENCIA \u00a0DE\u00a0\nC\u00c9LULAS\u00a0RECEPTOR \u00a0DE\u00a0ESTR\u00d3GENO \u00a0\nPOSITIVAS \u00a0\n14.1.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\nprovoca\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0\ngenes\u00a0de\u00a0la\u00a0familia\u00a0ERBB\u00a0y\u00a0aumenta\u00a0la\u00a0\ncapacidad \u00a0clonog\u00e9nica \u00a0en\u00a0presencia \u00a0o\u00a0\nausencia\u00a0de\u00a0hormonas \u00a0en\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0MCF7\u00a0\n\u00a0\nEn\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0las\u00a0pacientes \u00a0con\u00a0receptores \u00a0\nhormonales \u00a0positivos\u00a0que\u00a0muestran \u00a0coexpresi\u00f3n \u00a0\nde\u00a0HER2,\u00a0tienen\u00a0una\u00a0menor\u00a0sensibilidad \u00a0a\u00a0los\u00a0\ntratamientos \u00a0hormonales \u00a0que\u00a0las\u00a0RE+/HER2 \u2010.\u00a0Sin\u00a0\nembargo, \u00a0las\u00a0RE+/HER2 \u2010\u00a0tambi\u00e9n\u00a0presentan \u00a0\nalgunos\u00a0mecanismos \u00a0de\u00a0resistencia \u00a0primaria\u00a0o\u00a0\nadquirida \u00a0a\u00a0los\u00a0tratamientos \u00a0anti\u2010hormonales. \u00a0Hay\u00a0\nmecanismos \u00a0descritos\u00a0como\u00a0la\u00a0fosforilaci\u00f3n \u00a0del\u00a0RE\u00a0\nindependiente \u00a0de\u00a0estr\u00f3geno, \u00a0espec\u00edficamente \u00a0en\u00a0\nla\u00a0Ser167,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0v\u00eda\u00a0PI3K\u2010Akt\u2010mTOR\u00a0que\u00a0\nactiva\u00a0S6K1,\u00a0responsable \u00a0de\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0\nSer167508.\u00a0Conociendo \u00a0de\u00a0antemano \u00a0que\u00a0la\u00a0SP\u00a0\npod\u00eda\u00a0transactivar \u00a0HER2,\u00a0y\u00a0debido\u00a0a\u00a0la\u00a0\ncomunicaci\u00f3n \u00a0existente\u00a0entre\u00a0el\u00a0RE\u00a0y\u00a0receptores \u00a0\nde\u00a0la\u00a0familia\u00a0ErbB\u00a0en\u00a0relaci\u00f3n\u00a0a\u00a0\u00a0mecanismos \u00a0de\u00a0\nresistencia509\u2010511\u00a0primaria\u00a0o\u00a0adquirida \u00a0a\u00a0los\u00a0\ntratamientos \u00a0 anti\u2010hormonales, \u00a0 decidimos \u00a0\ninvestigar \u00a0si\u00a0la\u00a0estimulaci\u00f3n \u00a0con\u00a0SP\u00a0podr\u00eda\u00a0\nfavorecer \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencia \u00a0al\u00a0\ntratamiento \u00a0hormonal. \u00a0\nPor\u00a0este\u00a0motivo\u00a0decidimos \u00a0investigar \u00a0si\u00a0la\u00a0SP,\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0modulacion \u00a0de\u00a0la\u00a0actividad\u00a0de\u00a0HER2,\u00a0\npodria\u00a0contribuir \u00a0a\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0hormono \u2010\nindependencia. \u00a0De\u00a0la\u00a0misma\u00a0manera\u00a0que\u00a0en\u00a0el\u00a0\npunto\u00a012,\u00a0se\u00a0trat\u00f3\u00a0durante\u00a05\u00a0meses\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\nMCF7\u00a0(fenotipo \u00a0luminal\u00a0ER+/HER2 \u2010/EGFR\u2010).\u00a0Una\u00a0\nvez\u00a0conseguido \u00a0el\u00a0modelo\u00a0de\u00a0tratamiento \u00a0cr\u00f3nico\u00a0con\u00a0SP\u00a0la\u00a0l\u00ednea\u00a0obtenida\u00a0se\u00a0denomin\u00f3 \u00a0MCF7\u00a0SP.\u00a0En\u00a0\nprimer\u00a0lugar\u00a0se\u00a0analiz\u00f3\u00a0si\u00a0el\u00a0tratamiento \u00a0continuo\u00a0\ncon\u00a0SP\u00a0cambiaba \u00a0de\u00a0forma\u00a0significativa \u00a0los\u00a0niveles\u00a0\nde\u00a0EGFR,\u00a0HER2,\u00a0HER3\u00a0y\u00a0HER4.\u00a0Se\u00a0tomaron\u00a0varias\u00a0\nmuestras \u00a0de\u00a0las\u00a02\u00a0l\u00edneas\u00a0(tratada\u00a0vs\u00a0parental)\u00a0\ndurante\u00a0los\u00a0dos\u00a0primeros\u00a0meses\u00a0de\u00a0tratamiento \u00a0y\u00a0\nmediante \u00a0qPCR\u00a0se\u00a0cuantificaron \u00a0los\u00a0posibles\u00a0\ncambios\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0estos\u00a0receptores \u00a0a\u00a0lo\u00a0\nlargo\u00a0del\u00a0tiempo.\u00a0No\u00a0se\u00a0apreciaron \u00a0cambios\u00a0\nsignificativos \u00a0en\u00a0ning\u00fan\u00a0receptor, \u00a0solamente \u00a0de\u00a0\nforma\u00a0puntual\u00a0aumentaron \u00a0los\u00a0niveles\u00a0de\u00a0HER2,\u00a0\nHER3\u00a0y\u00a0HER4\u00a0en\u00a0un\u00a0punto\u00a0del\u00a0tratamiento \u00a0(Fig.\u00a0\n36A).\u00a0Sin\u00a0embargo\u00a0si\u00a0aumentaron \u00a0los\u00a0niveles\u00a0\nproteicos \u00a0de\u00a0HER2\u00a0tal\u00a0y\u00a0como\u00a0se\u00a0pudo\u00a0apreciar\u00a0por\u00a0\nWestern\u00a0blot\u00a0(Fig.\u00a036B)\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MCF7\u00a0\nSP,\u00a0y\u00a0en\u00a0algunos\u00a0puntos\u00a0de\u00a0tratamiento \u00a0tambi\u00e9n\u00a0\nse\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0v\u00edas\u00a0\np42/44\u2010MAPK\u00a0y\u00a0de\u00a0Akt\u00a0(Fig.\u00a036B).\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a036.\u00a0Caracterizaci\u00f3n \u00a0de\u00a0un\u00a0modelo\u00a0celular\u00a0ER+/HER2 \u2010\u00a0\ncon\u00a0sobreexposici\u00f3n \u00a0a\u00a0la\u00a0SP.\u00a0A.\u00a0Niveles\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0\nde\u00a0la\u00a0familia\u00a0ErbB\u00a0y\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MCF7\u00a0SP\u00a0durante\u00a0los\u00a0primeros\u00a0\n2\u00a0meses\u00a0de\u00a0tratamiento \u00a0con\u00a0SP\u00a0(69\u00a0d\u00edas\u00a0en\u00a0total).\u00a0Cada\u00a0barra\u00a0\nson\u00a0aproximadamente \u00a09\u00a0d\u00edas\u00a0\nde\u00a0tratamiento. \u00a0Los\u00a0resultados \u00a0\nde\u00a0expresi\u00f3n \u00a0se\u00a0muestran \u00a0como\u00a0el\u00a0fold\u00a0change\u00a0de\u00a0la\u00a0l\u00ednea\u00a0\ntratada\u00a0continuamente \u00a0con\u00a0SP\u00a0vs\u00a0a\u00a0la\u00a0l\u00ednea\u00a0parental.\u00a0B.\u00a0\nWestern\u00a0blot\u00a0de\u00a0pHER2\u00a0Y1248,\u00a0p\u2010p42/44\u00a0MAPK\u00a0y\u00a0p\u2010Akt\u00a0en\u00a0la\u00a0\nl\u00ednea\u00a0MCF7\u00a0tratada\u00a0con\u00a0SP\u00a0durante\u00a02\u00a0meses.\u00a0La\u00a0expresi\u00f3n \u00a0de\u00a0\ntubulina\u00a0se\u00a0utiliz\u00f3\u00a0para\u00a0asegurar\u00a0la\u00a0misma\u00a0carga\u00a0de\u00a0prote\u00edna.\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n150\u00a0\n\u00a0La\u00a0causa\u00a0de\u00a0que\u00a0en\u00a0un\u00a015\u00a0o\u00a020%\u00a0de\u00a0los\u00a0c\u00e1nceres\u00a0\nresistentes \u00a0a\u00a0terapias\u00a0hormonales \u00a0no\u00a0respondan \u00a0\nbien\u00a0estas\u00a0terapias\u00a0endocrinas \u00a0es\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\nexpresi\u00f3n \u00a0del\u00a0RE512.\u00a0Sin\u00a0embargo\u00a0existen\u00a0m\u00fatiples\u00a0\nmecanismos \u00a0distintos\u00a0descritos\u00a0hasta\u00a0el\u00a0momento, \u00a0\nentre\u00a0ellos\u00a0la\u00a0inactivaci\u00f3n \u00a0o\u00a0mutaciones \u00a0en\u00a0la\u00a0\nenzima\u00a0enzima\u00a0CYP2D\u00a0y\u00a0la\u00a0transasctivaci\u00f3n \u00a0de\u00a0\nreceptores \u00a0tirosina\u00a0quinasa\u00a0por\u00a0parte\u00a0de\u00a0los\u00a0RH\u00a0\n508,512.\u00a0Para\u00a0conocer\u00a0si\u00a0el\u00a0tratamiento \u00a0continuo\u00a0\nafectaba\u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0este\u00a0receptor\u00a0se\u00a0\nanalizaron \u00a0sus\u00a0niveles\u00a0mediante \u00a0IHQ\u00a0en\u00a0la\u00a0l\u00ednea\u00a0\nMCF7SP\u00a0y\u00a0MCF7.\u00a0No\u00a0se\u00a0observaron \u00a0cambios\u00a0\nsignificativos \u00a0en\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0RE,\u00a0lo\u00a0\nque\u00a0suger\u00eda\u00a0que\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0contin\u00faa\u00a0a\u00a0trav\u00e9s\u00a0\ndel\u00a0receptor\u00a0NK\u20101\u00a0durante\u00a05\u00a0meses\u00a0no\u00a0contribu\u00eda \u00a0\nen\u00a0el\u00a0cambio\u00a0de\u00a0expresi\u00f3n \u00a0del\u00a0RE,\u00a0al\u00a0menos\u00a0no\u00a0de\u00a0\nmodo\u00a0mayoritario \u00a0(Fig.37) .\u00a0\n14.2.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0\naumenta\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0en\u00a0\nla\u00a0l\u00ednea\u00a0celular\u00a0MCF7\u00a0en\u00a0presencia \u00a0o\u00a0\nausencia\u00a0de\u00a0hormonas \u00a0\nPara\u00a0estudiar\u00a0la\u00a0posible\u00a0relaci\u00f3n\u00a0existente\u00a0entre\u00a0una\u00a0inflamaci\u00f3n \u00a0cr\u00f3nica\u00a0y\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0\nhormono \u2010independencia \u00a0se\u00a0investig\u00f3\u00a0la\u00a0capacidad \u00a0\nde\u00a0proliferaci\u00f3n \u00a0y\u00a0supervivencia \u00a0de\u00a0la\u00a0l\u00ednea\u00a0MCF7\u00a0\nSP\u00a0(RE+)\u00a0en\u00a0un\u00a0medio\u00a0de\u00a0cultivo\u00a0deprivado \u00a0de\u00a0\nhormonas. \u00a0Para\u00a0llevar\u00a0a\u00a0cabo\u00a0este\u00a0estudio\u00a0se\u00a0\nanaliz\u00f3\u00a0a\u00a0su\u00a0vez\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0de\u00a0esta\u00a0\nl\u00ednea\u00a0respecto\u00a0a\u00a0su\u00a0control\u00a0bajo\u00a0condiciones \u00a0de\u00a0\ncrecimiento \u00a0distintas.\u00a0Las\u00a0nuevas\u00a0caracter\u00edsticas \u00a0\nadquiridas \u00a0por\u00a0la\u00a0l\u00ednea\u00a0MCF7\u00a0bajo\u00a0tratamiento \u00a0de\u00a0\nSP\u00a0demostraron \u00a0aumentar \u00a0la\u00a0capacidad \u00a0\nclonog\u00e9nica \u00a0de\u00a0\u00e9stas\u00a0c\u00e9lulas,\u00a0adem\u00e1s\u00a0de\u00a0su\u00a0\ncapacidad \u00a0en\u00a0formar\u00a0colonias\u00a0m\u00e1s\u00a0grandes\u00a0y\u00a0\nnumerosas. \u00a0Y\u00a0adem\u00e1s,\u00a0se\u00a0observ\u00f3\u00a0lo\u00a0que\u00a0parec\u00eda\u00a0\na\u00fan\u00a0m\u00e1s\u00a0importante, \u00a0una\u00a0mayor\u00a0capacidad \u00a0para\u00a0\ncrecer\u00a0en\u00a0un\u00a0medio\u00a0de\u00a0cultivo\u00a0deprivado \u00a0de\u00a0\nhormonas \u00a0(Fig.38A ).\u00a0Por\u00a0tanto,\u00a0el\u00a0hecho\u00a0de\u00a0\nexponer\u00a0a\u00a0esta\u00a0l\u00ednea\u00a0celular\u00a0dependiente \u00a0de\u00a0\nestr\u00f3genos \u00a0a\u00a0una\u00a0contin\u00faa\u00a0activaci\u00f3n \u00a0del\u00a0receptor\u00a0\nNK\u20101,\u00a0facilitaba\u00a0la\u00a0selecci\u00f3n\u00a0de\u00a0clones\u00a0con\u00a0\ncapacidad \u00a0de\u00a0crecer\u00a0en\u00a0ausencia\u00a0de\u00a0hormonas \u00a0\n(Fig.38B ).\u00a0Las\u00a0c\u00e9lulas\u00a0estuvieron \u00a0en\u00a0cultivo\u00a03\u00a0y\u00a05\u00a0\nsemanas, \u00a0para\u00a0poder\u00a0diferenciar \u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0\nclones.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\nFigura\u00a037.\u00a0Caracterizaci\u00f3n \u00a0de\u00a0un\u00a0modelo\u00a0celular\u00a0ER+/HER2 \u2010\u00a0con\u00a0sobreexposici\u00f3n \u00a0a\u00a0la\u00a0SP.\u00a0IHQ\u00a0de\u00a0bloques\u00a0celulares\u00a0que\u00a0permite\u00a0\ncomparar \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0RE\u00a0en\u00a0la\u00a0l\u00ednea\u00a0tratada\u00a0durante\u00a05\u00a0meses\u00a0con\u00a0SP\u00a0(MCF7SP) \u00a0respecto\u00a0a\u00a0la\u00a0l\u00ednea\u00a0parental\u00a0MCF7.\u00a0La\u00a0barra\u00a0de\u00a0\nescala\u00a0representa \u00a050\u00a0micras.\u00a0\n\u00a0\nRESULTADOS \u00a0 \u00a0\n\u00a0\n151\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigura\u00a038.\u00a0El\u00a0tratamiento \u00a0son\u00a0SP\u00a0de\u00a0forma\u00a0continua\u00a0provoca\u00a0cambios\u00a0en\u00a0la\u00a0capacidad \u00a0clonog\u00e9nica \u00a0de\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0hormono \u2010\ndependiente \u00a0MCF7.\u00a0A.\u00a0Ensayos\u00a0clonog\u00e9nicos \u00a0de\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0MCF7\u00a0y\u00a0MCF7\u00a0SP\u00a0en\u00a0presencia \u00a0o\u00a0ausencia\u00a0de\u00a0hormonas \u00a0en\u00a0el\u00a0\nmedio.\u00a0Las\u00a0im\u00e1genes \u00a0fueron\u00a0\ntomadas\u00a0despu\u00e9s\u00a0de\u00a03\u00a0y\u00a05\u00a0semanas\u00a0de\u00a0crecimiento \u00a0para\u00a0permitir\u00a0el\u00a0crecimiento \u00a0de\u00a0los\u00a0peque\u00f1os \u00a0\nclones.\u00a0B.\u00a0Imagen\u00a0en\u00a0contraste \u00a0de\u00a0fase\u00a0de\u00a0aquellas\u00a0colonias\u00a0de\u00a0c\u00e9lulas\u00a0MCF7\u00a0o\u00a0MCF7\u00a0SP\u00a0capaces\u00a0de\u00a0crecer\u00a0pasadas\u00a05\u00a0semanas\u00a0en\u00a0\npresencia \u00a0o\u00a0ausencia\u00a0de\u00a0hormonas \u00a0en\u00a0el\u00a0medio.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\n153\u00a0\n\u00a0ART\u00cdCULO \u00a01\u00a0\n\u00a0 \u00a0\n\u00a0\n155\u00a0\n\u00a0RESUMEN \u00a0ART\u00cdCULO \u00a01\u00a0\u00a0\n\u00a0\nEL\u00a0BLOQUEO \u00a0DE\u00a0LA\u00a0SP\u00a0INDUCE\u00a0MORTALIDAD \u00a0EN\u00a0C\u00c9LULAS\u00a0CANCEROSAS \u00a0Y\u00a0DISMINUYE \u00a0LA\u00a0ACTIVACI\u00d3N \u00a0\nBASAL\u00a0DE\u00a0EGFR\u00a0Y\u00a0HER2\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nNK\u20101\u00a0es\u00a0un\u00a0receptor\u00a0de\u00a0gran\u00a0importancia \u00a0para\u00a0la\u00a0\ntumorog\u00e9nisis \u00a0y\u00a0el\u00a0desarrollo \u00a0de\u00a0procesos\u00a0\nmetast\u00e1sicos \u00a0relacionados \u00a0con\u00a0el\u00a0CM\u00a0y\u00a0otros\u00a0tipos\u00a0\nde\u00a0carcinomas. \u00a0A\u00a0pesar\u00a0de\u00a0los\u00a0considerables \u00a0\nesfuerzos \u00a0realizados \u00a0para\u00a0desarrollar \u00a0y\u00a0mejorar\u00a0\nantagonistas \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0ninguno\u00a0de\u00a0ellos\u00a0\nha\u00a0mostrado \u00a0hasta\u00a0el\u00a0momento \u00a0una\u00a0buena\u00a0\nactividad\u00a0antitumoral \u00a0en\u00a0ensayos\u00a0cl\u00ednicos.\u00a0En\u00a0este\u00a0\ntrabajo\u00a0se\u00a0ha\u00a0analizado \u00a0cual\u00a0es\u00a0el\u00a0resultado \u00a0de\u00a0\ninhibir\u00a0el\u00a0ligando\u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0el\u00a0\nneurop\u00e9ptido \u00a0Sustancia \u00a0P\u00a0(SP),\u00a0plante\u00e1ndolo \u00a0\ncomo\u00a0posible\u00a0enfoque\u00a0terap\u00e9utico \u00a0del\u00a0CM.\u00a0Seg\u00fan\u00a0\nlos\u00a0resultados \u00a0obtenidos \u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0con\u00a0\nanticuerpos \u00a0espec\u00edficos \u00a0contra\u00a0esta\u00a0citoquina \u00a0\ninhib\u00edan\u00a0fuertemente \u00a0el\u00a0crecimiento \u00a0celular\u00a0e\u00a0\ninduc\u00edan\u00a0apoptosis \u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM,\u00a0\ncolon\u00a0y\u00a0pr\u00f3stata.\u00a0Estos\u00a0efectos\u00a0estaban\u00a0\nacompa\u00f1ados \u00a0de\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0las\u00a0v\u00eda\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0activada\u00a0por\u00a0\nmit\u00f3geno \u00a0o\u00a0MAPK.\u00a0\n\u00a0Curiosamente, \u00a0en\u00a0algunas\u00a0l\u00edneas\u00a0celulares, \u00a0el\u00a0\nbloqueo\u00a0de\u00a0la\u00a0SP\u00a0disminu\u00eda, \u00a0adem\u00e1s,\u00a0el\u00a0estado\u00a0\nbasal\u00a0de\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0EGFR,\u00a0sugiriendo \u00a0\nque\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0SP\u00a0era\u00a0\nimportante \u00a0para\u00a0la\u00a0actividad\u00a0basal\u00a0de\u00a0estos\u00a0\nreceptores \u00a0de\u00a0la\u00a0familia\u00a0ErbB.\u00a0Como\u00a0consecuencia \u00a0\ntambi\u00e9n\u00a0se\u00a0observ\u00f3\u00a0un\u00a0bloqueo\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0\ndel\u00a0ciclo\u00a0celular\u00a0y\u00a0de\u00a0varias\u00a0prote\u00ednas \u00a0relacionadas \u00a0\ncon\u00a0el\u00a0ciclo\u00a0celular,\u00a0incluidas\u00a0la\u00a0prote\u00edna\u00a0mTOR.\u00a0La\u00a0\ninhibici\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0tambi\u00e9n\u00a0induc\u00eda\u00a0muerte\u00a0celular\u00a0\nen\u00a0l\u00edneas\u00a0resistentes \u00a0a\u00a0Lapatinib\u00a0y\u00a0Trastuzumab, \u00a0\nl\u00edneas\u00a0que\u00a0presentaban \u00a0altos\u00a0niveles\u00a0de\u00a0HER2,\u00a0\nsugiriendo \u00a0que\u00a0este\u00a0enfoque\u00a0terap\u00e9utico \u00a0podr\u00eda\u00a0\nser\u00a0tambi\u00e9n\u00a0eficaz\u00a0en\u00a0aquellos\u00a0tumores\u00a0que\u00a0\npresentan \u00a0resistencia \u00a0a\u00a0f\u00e1rmacos \u00a0dirigidos\u00a0contra\u00a0\nestos\u00a0receptores \u00a0ErbB.\u00a0Por\u00a0tanto,\u00a0este\u00a0trabajo\u00a0\npropone\u00a0una\u00a0nueva\u00a0estrategia \u00a0terap\u00e9utica \u00a0para\u00a0\naquellos\u00a0tipos\u00a0de\u00a0c\u00e1nceres\u00a0que\u00a0expresan\u00a0\nreceptores \u00a0como\u00a0NK\u20101\u00a0u\u00a0otros\u00a0receptores \u00a0de\u00a0la\u00a0\nfamilia\u00a0de\u00a0las\u00a0taquiquininas, \u00a0bas\u00e1ndose \u00a0en\u00a0el\u00a0\nbloqueo\u00a0inmunol\u00f3gico \u00a0del\u00a0neurop\u00e9ptido \u00a0SP.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0 \u00a0\u00a0Targeting of Substance P\nInduces Cancer Cell Death andDecreases the Steady State ofEGFR and Her2\nCRISTINA MAYORDOMO, SUSANA GARCI \u00b4A-RECIO, ELISABET AMETLLER,\nPATRICIA FERNA \u00b4NDEZ-NOGUEIRA, EVA MARI \u00b4A PASTOR-ARROYO, LAIA VINYALS,\nIGNASI CASAS, PEDRO GASCO \u00b4N, AND VANESSA ALMENDRO *\nDepartment of Medical Oncology, Centro Esther Koplowitz (CEK), Institut d\u2019Investigacions Biome `diques Agust\u0131 \u00b4Pi y Sunyer (IDIBAPS),\nHospital Cl\u0131 \u00b4nic, Medical School, University of Barcelona, Barcelona, Spain\nNK1 is a tachykinin receptor highly relevant to tumorigenesis and metastasis development in breast cancer and other carcinomas. Despite\nthe substantial efforts done to develop potent NK1 receptor antagonists, none of these antagonists had shown good antitumor activity in\nclinical trials. Now, we have tested the effect of inhibition of the neuropeptide Substance P (SP), a NK1 ligand, as a potential therapeutic\napproach in cancer. We found that the inhibition of SP with antibodies strongly inhibit cell growth and induce apoptosis in breast, colon,and prostate cancer cell lines. These effects were accompained by a decrease in the mitogen-activated kinase singaling pathway.\nInterestingly, in some cell lines SP abrogation decreased the steady state of Her2 and EGFR, suggesting that SP-mediated signaling is\nimportant for the basal activity of these ErbB receptors. In consequence, we observed a blockade of the cell cycle progression and the\ninhibition of several cell cycle-related proteins including mTOR. SP inhibition also induced cell death in cell lines resistant to Lapatinib and\nTrastuzumab that have increased levels of active Her2, suggesting that this therapeutic approach could be also effective for those cancers\nresistant to current anti-ErbB therapies. Thus, we propose a new therapeutic strategy for those cancers that express NK1 receptor and/\nor other tachykinin receptors, based in the immuno-blockade of the neuropeptide SP.\nJ. Cell. Physiol. 227: 1358\u20131366, 2012. /C2232011 Wiley Periodicals, Inc.\nThe design of new therapies targeting the tumor\nmicroenvironment has been a focus on intense research over\nthe recent years (Germano et al., 2010; Huang et al., 2010; Liang\net al., 2010). It is becoming progressively clear that tumors\nshould be considered as abnormal tissues tightly connected totheir environment, where each cell type from both the tumor\nand the environment contributes toward tumor maintenance.\nThen, tumor cells as well as components of the tumor\nmicroenvironment should be considered as potentialtherapeutic targets.\nThe cellular component of the tumor microenvironment\nincludes among others, tumor-associated \ufb01broblasts,\nendothelial and neuronal cells, and cells from the immune\nsystem. Tachykinins are small neuropeptides present in the\ntumor microenvironment and synthesized by macrophages,neuronal, endothelial, and epithelial cells (Palma, 2006). Humantachykinins are encoded by the TAC1 ,TAC3 , and TAC4 genes,\nthat express substance P (SP), neurokinin A, and neurokinin B\npeptides that interact with a family of G-protein coupled\nreceptors (GPCRs), the tachykinin receptors NK1, NK2, and\nNK3, respectively (Palma, 2006). SP is an undecapeptide\ninvolved in mediating several physiological processes including\nthe process of wound healing where it facilitates the neurogenic\nin\ufb02ammation (Eglezos et al., 1991; Bost, 2004).\nBoth SP and NK1 receptor are over-expressed in several\ncancers including breast, ovarian, prostate, pancreas, thyroid,\nand glioblastoma, among others (Palma, 2006). In breast cancer,\nthe involvement of SP and its receptor in the acquisition of\noncogenic properties and in facilitation of bone marrow\nmetastasis has been widely described (Singh et al., 2000; Rao\net al., 2004; Castro et al., 2005; Singh et al., 2006). Activation of\nNK1 by SP results in the activation of PI3K, the NF- kB pathway,\nand mitogen-activated kinases (MAPKs). We have also\nobserved that, similarly to other GPCRs in cancers (Almendro\net al., 2010) NK1 can induce signal transduction bytransactivating some receptors with tyrosine kinase activity\nsuch as those belonging to the ErbB family, including EGFR and\nHer2. We observed that exposure to SP enhances the\naggressiveness of breast cancer cells by promoting the activity\nof Her2 and EGFR (unpublished results) an effect that was\npreviously described in other cell types (Castagliuolo et al.,\n2000; Koon et al., 2004; Almendro et al., 2010).\nGiven the relevance of SP-NK1 signaling in cancer,\nsubstantial efforts have been made to develop therapeutic\nAdditional supporting information may be found in the online\nversion of this article.\nContract grant sponsor: Fondo de Investigacio \u00b4n Sanitaria, Instituto\nde Salud Carlos III;\nContract grant number: PI080022.\nContract grant sponsor: Fundacio \u00b4n Cellex.\nContract grant sponsor: Redes Tematicas de Investigacion en\nCancer (RTICC);Contract grant number: RD07/0020/2014.\nContract grant sponsor: Banco de Santander with the collaborationof UB-AVCRI, FBG, IDIBAPS, Hospital Cl\u0131 \u00b4nic and Fundacio \u00b4Cl\u0131\u00b4nic.\nContract grant sponsor: The work was carried out in part at the\nEsther Koplowitz Centre, Barcelona..\n*Correspondence to: Vanessa Almendro, Centro Esther\nKoplowitz (CEK), Institut d\u2019Investigacions Biome `diques Agust\u0131 \u00b4Pi i\nSunyer (IDIBAPS), Laboratori d\u2019Oncologia Molecular i Traslacional\n(ICMHO), Facultat de Medicina, Casanova 143, 08036 Barcelona,\nSpain. E-mail: almendro@clinic.ub.es\nReceived 16 November 2010; Accepted 11 May 2011\nPublished online in Wiley Online Library\n(wileyonlinelibrary.com), 20 May 2011.DOI: 10.1002/jcp.22848ORIGINAL RESEARCH ARTICLE 1358\nJournal ofJournal of\nCellular\nPhysiologyCellular\nPhysiology\n/C2232011 WILEY PERIODICALS, INC.inhibitors against NK1 (Huang and Korlipara, 2010; Munoz\net al., 2011). Despite their promising results in model systems\nnone of them has been shown to have potent antitumor activityin clinical trials (Humphrey, 2003; Hoffmann et al., 2006;\nQuartara and Altamura, 2006). Thus, we decided to target SP\ninstead of its receptor and, given the lack of chemical\ncompounds capable to inhibiting this small peptide, we usedantibodies to address the therapeutic potential of SP inhibition\nin cancer.\nWe have found that the use of antibodies anti-SP induces cell\ndeath in several cancer cell types and that this effect is\naccompanied by a decrease in the signaling through the MAPK\npathway and a decrease in the basal activity and expression of\nHer2 and EGFR. We also found that SP inhibition induced celldeath in breast cancer cells that have developedchemoresistance to anti-Her2 therapies. Based on this\nevidence, we propose to explore a new therapeutic strategy for\nthe treatment of cancers that express NK1, based in the\nimmuno-blockade of SP. Moreover, this therapy may also be\neffective for those cancers that develop resistance to\nchemotherapeutic agents by increasing Her2 or EGFR activity.\nMaterial and Methods\nCell lines\nAll human breast (MDA-MB-231, MDA-MB-468, MDA-MB-\n453, SKBR3, MCF7, BT474), colon (HT29 and HCT 116) and\nprostate (PC-3 and DU-145) cancer cell lines, and normal\nbreast epithelial cells (MCF10A and MCF12A) were purchased\nfrom American Type Culture Collection (Rockville, MD) and\ncultured according to their instructions. Cos-7 cells, derived\nfrom kidney cells of the African green monkey, were a kind gift\nfrom Dr. Engel (School of Medicine, University of Barcelona,\nBarcelona, Spain) and HepG2 cells a gift form Dr. Llovet\n(IDIBAPS, Hospital Clinic, Barcelona, Spain).\nThe different cell lines resistant to Trastuzumab and\nLapatinib have been generated by continuous exposure of theMDA-MB-453, SKBR3, and BT474 cell lines to those drugs,\nfollowing a model previously described (Konecny et al., 2006;\nAlmendro et al., 2009; Liu et al., 2009).\nThe authenticity of all the cell lines used in this study has been\nvalidated by single-locus short tandem repeats typing (Bio-\nSynthesis, Inc, Lewisville, TX).\nReagents\nReagents used for cell culture were rhEGF, from PreProtech,\nRochyHill, NJ and Insulin was from Sigma (St. Louis, MO). SP,\nNeurokinin A, and Neurokinin B were purchased from Sigma,\nSP 1-4 from Genscript USA Inc., NJ, SP 5-11 and FAM-conjugated SP from BioNova Cienti\ufb01ca, Madrid, Spain. NK1\nantagonist L-733,060 was from Tocris, Mossouri.\nGlaxoSmithKline, London, UK generously provided Lapatinib.\nTrastuzumab was obtained from the Pharmacy of our Hospital.All general reagents were purchased from Sigma, BioRad\nLaboratories Inc., California, and Amersham (Piscataway, NJ).\nWestern blot analysis\nWestern blots were done as previously described (Almendro\net al., 2009) with the different antibodies indicated in the Table\nS1. Chemiluminiscence of the bands was detected after ECL\ntreatment (Amersham) of membranes and subsequent analysis\nusing a Fuji\ufb01lm Medical Systems (Tokyo, Japan). Differentintensities of bands were quanti\ufb01ed using Image Gauge\nsoftware, and correct M\nrwas compared with pre-stained\nprotein standards (BioRad). As control group, cells weretreated with rabbit serum, although no effects on the\nexpression of the different proteins analyzed were observed in\ncells treated with rabbit serum or PBS.Quantitative real-time reverse transcription-PCR\nAll the qPCR were performed in cells treated with AB1 at 1/100\ndilution for 48 h. Total RNA was isolated using Qiagen RNeasy\nMini Kit, and 1 mg of RNA was reverse transcribed in a \ufb01nal\nvolume of 100 ml using High Capacity cDNA Reverse\nTranscription Kit (Applied Biosystems, Foster City, CA)according to the instructions of the manufacturer. Quantitative\nPCR analysis was done on the 7900HT Fast Real-Time PCR\nSystem (Applied Biosystems) using Assay-on-demand primersand probes from Applied Biosystems (Hs01076092_m1 for\nEGFR, Hs01001595_m1 for Her2 and Hs00176538_m1 for\nHER3). Transcript levels were normalized to those of beta-actin (Hs99999903_m1) that was used as endogenous control.\nThe levels of EGFR, Her2, and Her3 were analyzed in triplicate\nand calculated using the DCt method.\nDAPI staining\nApoptotic nuclear morphology was evaluated by \ufb02uorescence\nmicroscopy following DAPI staining (1 mg/ml) (Roche\nDiagnostic, Germany). Cells were grown on coverslips and\ntreated for the indicated times with 1/100 dilution of AB1. After\ntreatment, coverslips were \ufb01xed in cold 95% ethanol and\nwashed with PBS, stained with DAPI, and mounted on slides.\nImages were captured by using an inverted epi\ufb02uorescencemicroscope (Leica Microsystems GmbH, Germany). Apoptotic\ncells were identi\ufb01ed by features characteristic of apoptosis (e.g.,\nnuclear condensation, nuclear vacuolization, loss of nuclearmembrane integrity and apoptotic bodies).\nCell proliferation assay\nCell proliferation was assessed with two different methods.\nThe CellTiter 96 Aqueous One Solution Cell ProliferationAssay Kit (MTS; Promega, Wisconsin) was used as previously\ndescribed (Almendro et al., 2009) in subcon\ufb02uent cell cultures\nthat were incubated for 72 h with AB1 or with serial dilutions of\nthe NK1 antagonist L-733,060 (ranging from 0 to 100 mM).\nDifferent doses were assessed in sixtuplicate and every\nexperiment was performed three times. Assay values forcontrols were taken as 100% of viability, and the viability at each\ntreatment point was calculated relative to controls by the\nformula: (Abs 490 nm at every dose/Abs 490 nm at dose\n0)/C2100%. As control group, cells were treated with rabbit\nserum, although no effects on proliferation were observed in\ncells treated with rabbit serum or PBS.\nThe growth curves were performed by counting the total cell\nnumbers obtained after incubating the different cell lines for 24,\n48, and 72 h with AB1.\nAssessment of apoptosis\nFor the analysis of apoptosis induction, cells seeded on six-wellplates and treated with different doses of anti-SP antibodies\n(AB1 or AB2), with AB1 pre-incubated with SP 500 nM for\n30 min at 37 8C (for the rescue experiments), with different\ndoses of NK1 inhibitor L-733,060, with Lapatinib (2.5 mM for\nMDA-MB-453 and SKBR3, and 0.1 mM for BT474) or\nTrastuzumab (200 mg/ml for all the cell lines) for 72 h were\nharvested, and stained for 15 min at room temperature with ananti-Annexin V-FITC antibody and propidium iodide (PI)(human Annexin V Apoptosis Detection Kit, Bender\nMedSystems). To assess the loss of mitochondrial membrane\npotential cells were treated as above and stained for 20 min at\n378C with DIOC\n6(Molecular Probes, Inc., Oregon). Then,\n10,000 cells were analyzed on a FACSCanto II (Becton-\nDickinson, NY) cytometer and the results processed with theFACSDiva Software (Becton-Dickinson). Experiments weredone in duplicate and reproduced at least three times. Rabbit\nserum was used to control for non-speci\ufb01c apoptotic effects,\nJOURNAL OF CELLULAR PHYSIOLOGYSUBSTANCE P AND CANCER CELL SURVIVAL 1359and no effects on apoptosis were observed in cells treated with\nrabbit serum or PBS.\nFACS analysis of NK1\nFor the detection of cell surface NK1 expression, cells werewashed with PBS, resuspended in blocking buffer (BSA 1%-PBS)\nand placed on ice for 15 min. Cells were incubated with the anti-NK1 antibody (Abcam, Cambridge, UK) at 1:100 dilution inblocking buffer for 30 min at 4 8C. Cells were then washed three\ntimes with BSA1%-PBS and stained with Alexa647-conjugated\nanti-mouse IgG antibody (Jackson Immunoresearch\nLaboratories Inc, Westgrove) for 30 min at 4 8C. Control cells\nwithout staining were use to determine the settings of\nauto\ufb02uorescence, and cells stained with secondary antibody\nwere used to ensure the speci\ufb01city of the primary antibodies.\nStained cells were then analyzed on a FACscan \ufb02ow cytometer\nusing FACSCalibur (BDBioscience, NJ) and data processed by\nthe software CellQuest. Ten thousand cells were analyzed for\neach sample, and every experiment was repeated three times.\nBinding assays\nCOS7 cells were transfected with pcDNA3-NK1 (UMR cDNA\nResource Center, University of Missoure-Rolla, MJ) using\nLipofectamine LTX (Invitrogen, CA). Forty-eight hours after\ntransfection the cells were harvested and incubated with a\nblocking solution consisting of PBS-1% BSA-0.05% SodiumAzide for 30 min at room temperature. FAM-conjugated SP(excitation 488 nm, Anaspec, CA) was preincubated with anti-\nSP antibodies AB1 and AB2 in the same blocking solution. Then,\ncells were added to the pre-incubation mixture, leading toa1 0\n/C08M concentration of FAM-SP and a threefold molecular\nratio of the corresponding antibody. This reaction mixture was\nincubated for 30 additional minutes at room temperature and\nthen the cells were washed twice with blocking solution and\ufb01xed in 2% paraformaldehyde. FAM-SP binding to the surface\nNK1 receptor was assessed on a FACSCanto II cytometer\n(Becton-Dickinson).\nAf\ufb01nity assay\nThe af\ufb01nity of AB1 and AB2 to other tachykinins or evenfragments of SP was determined by ELISA. Brie\ufb02y, as capture\npeptides 100 ml of a 3 mg/ml solution of the different peptides\n(full 1-11 aa SP, 1-4 aa SP, 5-11 aa SP, NKA, and NKB) were added\nto each well of 96-well ELISA plate and incubated overnight at\n48C. Then, the plate was incubated with serial dilutions of the\ndifferent anti-SP antibodies for 1 h at room temperature. The\ncapture peptide recognition was detected with a secondary\nHRP-conjugated antibody (GE Healthcare, Little Chalfont, UK)using o-phenylenediamine (0.125% wt/vol; Sigma) as substrate.Absorbance at 450 nm was measured in a Multiskan RC\nMicroplate ELISA reader (Thermo Labsystems, MA).\nStatistical analysis\nData is expressed as means /C6standard deviation. The statistical\nsigni\ufb01cance of the differences was determined using GraphPad\nPrism (Version 5.0) software. Unpaired, two-tailed Student\u2019s t-\ntest and ANOVA were used to compare the means of differenttreatment groups. P-values under 0.05 were considered\nstatistically signi\ufb01cant.\nResults\nTreatment of breast cancer cells with an anti-SPantibody induces cell death\nThe regulatory activity of the SP-controlled pathways in cancer\n(Palma, 2006; Singh et al., 2006; Munoz et al., 2011) led us to\nconsider the possibility that its inhibition could be used as a\ntherapeutic approach to induce cancer cell death. For this\nreason, we \ufb01rst tested if SP inhibition could induce breast\ncancer cell apoptosis. We decided to use an antibody against SP\n(AB1) because the inexistence of chemical compounds was ableto inhibit this small peptide. To investigate the regulatory role ofSP on cell survival we treated a panel of breast cancer cells and\nnon-transformed breast epithelial cells that express different\nlevels of NK1 receptor (Fig. S1A) with AB1 for 72 h and found\nthat SP abrogation induced dose-dependent apoptosis. This was\ndemonstrated by the externalization of phosphatidylserine\n(increase in the Annexin V positive cells) (Fig. 1A and Fig. S2), by\nthe reduction of the mitochondrial transmembrane potential\n(decrease in DIOC\n6(3) positive cells) (Fig. 1B), and by the\nchanges in the nuclei morphology as assessed by DAPI staining\n(Fig. S3). Similar results were obtained when cells were treated\nwith AB1 for 48 h (not shown). These results suggest that SP\ncould act as an autocrine signal essential for breast cancer cell\nsurvival, since SP inhibition induces apoptosis in breast cancer\ncells.\nSP abrogation strongly inhibits the MAPK pathway and\nthe steady state of Her2 and EGFR\nNK1, the high af\ufb01nity receptor for SP, can induce signal\ntransduction by activating the MAPK pathway (Yamaguchi et al.,2005; Almendro et al., 2010). We observed that the blocking of\nSP with AB1 for 48 h decreased the levels of phosphorylated\np42/44-MAPK in all the cell lines tested, indicating an inhibitionof the p42/44 MAPK signaling pathway (Fig. 2A). NK1 receptor\ncan also transduce intracellular signals by the indirect activation\nof Her2 and EGFR (Castagliuolo et al., 2000; Koon et al., 2004;Almendro et al., 2010), that have been demonstrated as\nFig. 1. Blockade of SP induces breast cancer cell apoptosis. A: Annexin V/IP staining and (B) DIOC 6(3) staining and FACS analysis on a panel of\nbreast cancer cell lines and non-transformed breast epithelial cells treated with different dilutions of AB1 for 72 h. Results are indicated as foldchanges relative to the non-treated cells per each cell line. The dots ( *) at the base of each column denote P-values <0.05 (Student t-test).\nJOURNAL OF CELLULAR PHYSIOLOGY1360 MAYORDOMO ET AL.essential for cell survival in some cell types (Faber et al., 2010).\nGiven the relevance of those oncogenes in breast cancer\nprogression, we decided to further explore the cross-talk\nbetween those receptors and the potential role of SP in\ncontrolling the steady state of Her2 and EGFR receptors. The\ninhibition of SP for 48 h also decreased the phosphorylation of\nHer2 (at Tyr1248) and EGFR (at Tyr1068) (Fig. 2A), as\ndemonstrated in three cell lines over-expressing Her2 (MDA-MB-453, SKBR3, and B7474) and in one cell line that over-\nexpresses EGFR (MDA-MB-468) (Fig. S1B). The inhibitory\neffects of SP abrogation on Her2 and p42/44-MAPK\nphosphorylation were time and dose dependent (Fig. S4A) and\npreceded the appearance of annexin V positive cells (Fig. S4B),\nsuggesting that the inhibition of signal transduction might be\nresponsible for the induction of apoptosis. The mRNA contentfor some of these ErbB family members, like EGFR, Her2, and\nHer3, was also signi\ufb01cantly decreased by SP inhibition (Fig. 2B),suggesting that SP abrogation could affect these receptors even\nat the gene expression level. Therefore, SP inhibition decreases\nthe signaling thought the MAPK pathway and the steady state ofHer2 and EGFR, events likely contributing to the induction ofcell death.\nInhibition of SP impairs breast cancer cell proliferation\nSince GPCRs (New and Wong, 2007) and tyrosine kinase\nreceptors (Lenferink et al., 2001; Le et al., 2005) signaling\ninduces mitogenic activity, we hypothesized that SP inhibition\nmight also affect cell proliferation. The treatment with AB1 at 1/\n100 dilution for 48 h decreased the levels of several cell cycle-\nrelated proteins including cyclin D1, Cdk2, and Cdk4 (Fig. 3A).\nTo estimate the proliferation status we used the ratio between\np27 (an inhibitor of Cdk2 and Cdk4) and cyclin D1 (Fredersdorf\net al., 1997). The p27/cyclin D1 ratio was decreased under SP\nFig. 2. BlockadeofSPinhibitstheMAPKsignalingpathwayandthesteadystateofHer2andEGFR.A:Westernblotsshowingtheexpressionlevels\nof the total and active (phosphorylated, indicated by p-) forms of Her2 (at Tyr1248, pHer2-Y1248), EGFR (at Tyr1068; pEGFR-Y1068), and\np42/44MAPKupontreatmentwithSP500 nMorAB1at1/100dilution.Tubulinexpressionwasusedtoensureanequalamountofproteinloadingin\neach of the several blots performed. Representative images of the different Western blots are shown. B: Gene expression levels determined\nby qPCR and the 2/C0DDCtmethod in the different cell lines treated with AB1 (1/100 dilution) for 48 h. The expression values are normalized to the\ncontrol group of each cell line. *denotes P-values <0.05 (Student t-test).\nJOURNAL OF CELLULAR PHYSIOLOGYSUBSTANCE P AND CANCER CELL SURVIVAL 1361treatment and increased upon SP inhibition, indicating an\nincrease and a decrease in the proliferation rate, respectively\n(Fig. 3B). To further con\ufb01rm the effects of SP abrogation on cellproliferation, we measured cell proliferation over 72 h (Fig. 3C)\nand performed MTS proliferation analysis (Fig. 3D). AB1\nsigni\ufb01cantly impaired proliferation of all of the tested cell linesafter 48\u201372 h of treatment, coinciding with G1 arrest as\ndetermined by cell cycle analysis (not shown).\nInterestingly, mTOR, a serine/threonine protein kinase that\nregulates cell growth and proliferation (Fingar et al., 2004), was\nalso decreased by SP inhibition in several breast cancer cell lines\nand in non-transformed breast epithelial cells (Fig. 3F). mTOR is\na useful biomarker for the antiproliferative effect of EGFR\ninhibitors and for the inhibition of multiple pathways, since\nmTOR is needed for the optimal effects of anti-Her2 therapies\n(Miller et al., 2009).\nThe NK1 antagonist L-733,060 induces apoptosis in\nbreast cancer cells\nNK1 is important for the cell survival of different tumor types\n(Palma et al., 2000; Munoz et al., 2004a,b). Based on the effectsof SP inhibition in breast cancer cell survival, we hypothesized\nthat the inhibition of its high af\ufb01nity receptor NK1 will alsoinduce cell death. To con\ufb01rm the implication of NK1 signaling in\nbreast cancer cell survival, we treated the different breast\ncancer cell lines with the potent NK1 antagonist L-733,060. We\nfound that L-733,060 decreased cell proliferation in breast\ncancer cells according to NK1 expression (Fig. S5A and S5B).\nInterestingly, we observed that NK1 expression was related to\ntumor cell subtype, being higher in the luminal cell lines\nexpressing Her2 (SKBR3, BT474, and MDA-MD-453) than in\nthe basal-like cell lines (MDA-MB-468, MDA-MB-231,\nMCF10A, and MCF12A) (Fig. S5A). Moreover, the pro-\napoptotic effect of NK1 inhibition (as judged by annexin Vpositivity) was higher in cells with higher levels of NK1\nexpression (Fig. S5C), suggesting \u2018\u2018oncogenic addiction\u2019\u2019 of\nthese cells to NK1 signaling.\nThe inhibition of SP with AB1 also induces apoptosis in\ncolon and prostate cancer cell lines\nSince NK1 receptor is widely expressed in cancer (Friess et al.,\n2003; Yamaguchi et al., 2005; Rosso et al., 2008; Akazawa et al.,\n2009), we next decided to investigate if the pro-apoptoticeffects of SP inhibition are speci\ufb01c to breast carcinoma. To doso, we \ufb01rst con\ufb01rmed the expression of NK1 in different colon\n(HT29 and HCT116) and prostate (DU154 and PC3) cancer cell\nFig. 3. Effects of SP abrogation on cell proliferation. A: Western blots of cell cycle-related proteins. B: The ratio between the densitometric\nquanti\ufb01cation of p27 and cyclin D1 is shown as an indirect marker of proliferation. C: Growth curves for cells treated with AB1 for 24, 48, and 72 h.\nTotalcellnumbersareshown.D:MeasureofcellproliferationbyMTSassayincellstreatedwithdifferentdosesofAB1for72 h.Resultsareshownasthe percentage of proliferating cells versus the control group. Doses that induced a signi\ufb01cant decrease on cell proliferation by Student t-test\nanalysis are indicated by*P< 0.05 in the base of each column. E: Western blots for mTOR in different cell lines treated with AB1 at the indicated\ndilutions. Tubulin expression wasusedto ensure anequalamount ofprotein loading in eachof theseveral blots performed. Representative images\nof the different Western blots are shown. Values that are different by Student t-test analysis are indicated by*P< 0.05,**P< 0.01,***P< 0.001.\nJOURNAL OF CELLULAR PHYSIOLOGY1362 MAYORDOMO ET AL.lines (Fig. 4A). Then, we determined the effect of the SP\ninhibition on the p42/44 MAPK signaling pathway and on Her2\nactivation, and similar to what we previously observed in breastcancer cells, in different colon and prostate cancer cell lines AB1\nalso decreased the phosphorylated levels of p42/44 MAPK and\nHer2 (on Tyr1248) (Fig. 4B) and the mRNA levels of EGFR,\nHer2, and Her3 (Fig. S6). In consequence, we also observed an\ninduction of apoptosis in all the cell lines tested (Fig. 4C).\nTherefore, our results suggest that the use of anti-SP\nantibodies could have a therapeutic effect in a broad range of\ntumor types expressing NK1.\nSP inhibition effectively induces cell death in breast\ncancer cells refractory to chemotherapy\nBased on the effects of the AB1 on cell survival and on the Her2\nsignaling pathway, we hypothesized that this antibody could be\nalso effective for those cancer cells that have developed\nresistance to therapies against Her2 by over-activating andover-expressing ErbB receptors. To test this hypothesis, we\nused six breast cancer cell lines generated in our laboratory,\nwhich are resistant to Trastuzumab (monoclonal antibody\nagainst Her2) or Lapatinib (dual inhibitor of the tyrosine kinase\ndomains of both Her2 and EGFR) as judged by inhibited\ninduction of apoptosis (Fig. 5A) and improved long-term\nsurvival measured by clonogenic assays (data not shown). These\ncell lines expressed elevated levels of EGFR and Her2 as\ndetermined by Western blot (Fig. 5B) and qPCR (not shown).The treatment with Lapatinib (2.5 mM for MDA-MB-453 and\nSKBR3, and 0.1 mM for BT474) or Trastuzumab (200 mg/ml for\nall the cell lines) induced cell death in the control MDA-MB-453,BT474, and SKBR3 cell lines but not in the derived cell lines\nresistant to each drug (Fig. 5C). Interestingly, AB1 induced cell\ndeath in all the cell lines (Fig. 5C) and decreased Her2\nphosphorylation (at Tyr1248) in both sensitive and resistant celllines (not shown), suggesting that the inhibition of SP could be a\ntherapeutic approach even in cells resistant to Trastuzumab and\nLapatinib. However, the combination of SP inhibition with\nTrastuzumab or Lapatinib did not induce a synergistic effect on\ncell death, suggesting that SP inhibition is not sensitizing the cells\nto neither Trastuzumab nor Lapatinib (Fig. 5C).\nThe antibodies anti-SP effectively block the ability of\nSP to bind NK1\nTo further con\ufb01rm that the effects of AB1 treatment are\nspeci\ufb01c to blocking of SP, we reproduced some of the\nexperiments with another antibody (AB2) and we found that\nthis particular antibody was also able to induce apoptosis\n(Fig. 6A). In addition, we assayed the effect of AB1 and AB2treatment on blocking the binding between SP1 and NK1. We\nfound, that both antibodies were able to block the binding of SP\nto NK1 as determined in the af\ufb01nity assays (Fig. 6B). In\nagreement with this observation, the addition of exogenous SPrescued the apoptotic effects exerted by AB1 (Fig. 6C),\ncorroborating the speci\ufb01city of the treatment. Moreover, in cell\nFig. 4. Blockade of SP induces colon and prostate cancer cell apoptosis. A: Densitometric quanti\ufb01cation of the Western blots for NK1 in\ncolon (HT29 and HCT116) and prostate (PC3 and DU145) cancer cell lines. The MDA-MB-231 cell line is used as positive control. B: Western\nblots for the activated (phosphorylated, indicated by p-) forms of Her2 (at Tyr1248; pHer2-Y1248) and p42/44 MAPK in the indicated cell lines\ntreated with different concentrations of AB1. C: Annexin V/IP staining in colon and prostate cancer cell lines treated with different\nconcentrations of AB1. Results are shown as the fold-induction versus the non-treated group per each cell line. *denotes P-values <0.05\n(Student t-test).\nJOURNAL OF CELLULAR PHYSIOLOGYSUBSTANCE P AND CANCER CELL SURVIVAL 1363lines that do not express NK1, AB1 failed to induce apoptosis\n(Fig. 6D).\nHuman tachykinins share a sequence homology of more than\n40% (Severini et al., 2002). On the other hand, SP can bedegraded by endopeptidases producing fragments of different\nsizes (Matsas et al., 1983; Nieber et al., 1988; Joshi et al., 2001).\nFor these reasons, we \ufb01nally decided to con\ufb01rm that the effects\nof the antibodies used were not the result of its cross-reaction\nwith other tachykinins members. We determined the binding\nability of both antibodies for different fragment of the full nature\nSP, the products of its degradation (the fragments 1\u20134 and 5\u2013\n11), as well as NKA and NKB tachykinins by ELISA. We found\nthat the antibodies used in our experiments were highly speci\ufb01cfor the full-length fragment of SP (1\u201311) although the antibody\nAB2 also recognized to some degree NKA (Fig. 6E). Therefore,\nthe effects of AB1 and AB2 antibodies are likely to be mediated\nspeci\ufb01cally by blocking SP rather than by off-target effects.\nDiscussion\nSince the implication of tachykinins in human diseases\nsubstantial efforts have been invested towards the\ndevelopment of potent antagonists of NK receptors (Huangand Korlipara, 2010). While at the moment the only FDAapproved NK antagonist is Aprepitan, Emend, Merck & Co.\n(prescribed for the treatment of chemotherapy-induced\nFig. 5. The anti-SP treatment is effective in cancer cell lines resistant to different chemotherapeutic agents. A: The percentage of annexin V\npositive cells upon treatment with Trastuzumab (200 mg/ml for all the cell lines) or Lapatinib (2.5 mM for MDA-MB-453 and SKBR3, and 0.1 mM\nfor BT474) was determined byFACS in different cell lines sensitive and resistant to Trastuzumab (TZ) and Lapatinib (LAP). The results are shown\nasmean WSEM.B:Densitometricquanti\ufb01cationofWesternblotsforHer2andp42/44-MAPK. b-actinexpressionwasusedasendogenouscontrol.\nC: Annexin V staining for the indicated cell lines upon treatment with AB1 (1/100 dilution), Trastuzumab (200 mg/ml for all the cell lines), or\nLapatinib (2.5 mM for MDA-MB-453 and SKBR3, and 0.1 mM for BT474), or the combination of them. The results are shown as the fold-induction\nversus the non-treated group per each cell line. The statistical analysis of the results is shown in the Supplementary Table S2.\nJOURNAL OF CELLULAR PHYSIOLOGY1364 MAYORDOMO ET AL.nausea) several NK1 antagonists are currently under clinical\ntrials for the treatment of different diseases (Huang and\nKorlipara, 2010). In addition to the search for NK1 antagonistsadditional efforts have been directed toward \ufb01nding inhibitors\nof SP synthesis (Modly et al., 1986) and blocking activating post-\ntranslational modi\ufb01cations of SP (Jeng et al., 1997).Unfortunately, issues of tissue speci\ufb01city have hampered the\nsuccess of these strategies.\nThe rapid turnover of NK1 in the cell surface limits long-term\nef\ufb01cacy of the NK1 antagonists (Mantyh et al., 1995). Still, given\nthe relevance of the tachykinergic system in cancer progression\n(for instance SP and NK1), the design of targeted therapies\nagainst these molecules continues being an attractive approach\nfor the treatment of cancer (Munoz et al., 2011). To circumvent\nthe caveats of rapid NK1 surface turnover and tissue\nspeci\ufb01cities, we decided to focus on targeting SP. Due to the\nlack of chemical compounds able to inhibit this small peptide, we\ndecided to approach the inhibition of the SP with antibodies. Inaddition to inhibiting activation of NK1, blocking SP could\npotentially target the signal transduction of other tachykinin\nreceptors given the ability of this peptide to bind NK2 and NK3\nalbeit with reduced af\ufb01nity (Palma, 2006).\nWe found that SP blocking antibodies inhibit the MAPK\nsignaling pathway and down-regulate the expression of severalcell cycle-related proteins, likely contributing to the activation\nof apoptosis. Interestingly, SP abrogation also diminishes the\nsteady state of Her2 and EGFR, which are major targets forcurrent oncologic therapies. These receptors stimulate\nproliferation and promote tumor growth and thus, their\ninhibition by anti-SP antibodies further contributes to decreasethe proliferation rate and to induce cell death. Down-regulationof EGFR and Her2 as the result of the inhibition of NK1 signaling\nraises the possibility that NK1 signaling might be important for\nmaintaining the steady states of EGFR and Her2.\nIt is also important to consider that since SP can bind and\nactivate other tachykinin receptors besides NK1 (Palma, 2006),\nblocking SP can have stronger therapeutic outcome than\nblocking NK1 alone. Still, NK1 inhibition remains an attractiveapproach for the treatment of cancer because NK1 expression\nin different tumor types and its inhibition leads to pronounced\nanti-tumor effects both in vitro and in vivo (Munoz et al., 2011).\nIn fact, we observed that similarly to blocking SP, NK1 inhibition\nwith L-733,060, induced cell death in a dose-dependent manner\n(Munoz et al., 2011). Therefore, the SP-NK1 axis is likely to be\nessential for tumor cell survival (Fig. S7). Our \ufb01ndings are\nconsistent with previous evidences showing that the inhibitionofTAC1 expression by small interfering RNA in breast cancer\ncells shows a lack of tumorigenic phenotype and an inhibition of\nFig. 6. Antibodies anti-SP effectively block its binding to NK1. A: Annexin V staining in the SKBR3 cell line treated with the antibodies AB1 and\nAB2. B: AB1 or AB2 treatment blocked the ability of SP-FAM to bind NK1 in Cos7 cells transfected with pcDNA3-NK1 receptor, as determined by\nFACS. C: Annexin V staining for the indicated cell lines treated with the antibody AB1 (1/100 dilution) alone or AB1 plus SP. The fold changes\nversus the control group are shown. D: FACS analysis for NK1 in BT474, HepG2, and Cos7 cell lines (left panel). Annexin V staining for the\nindicated cell lines upon treatment with AB1 (1/100 dilution) for 48 h (right panel). Lapatinib-treated cells were used as control for apoptosis.\nE: Af\ufb01nity of AB1 and AB2 to other tachykinins (NKA and NKB) or SP fragments (SP1-4 and SP5-11) measured by ELISA. Values that are\nsigni\ufb01cantly different between control and treated group by Student t- test analysis are indicated byMP< 0.05,MMP< 0.001.\nJOURNAL OF CELLULAR PHYSIOLOGYSUBSTANCE P AND CANCER CELL SURVIVAL 1365bone marrow metastasis in nude mice (Rao et al., 2004), while\nover-expression of NK1 receptor leads to a transforming\nphenotype (Patel et al., 2005).\nOur data support the utility of inhibiting of the SP-NK1\nsignaling pathway in anti-cancer therapy and suggests that\ntargeting SP might be an alternative pathway in addition to NK1\ninhibition. Given the lack of clear therapeutic effect of NK1inhibition in clinical trials and that targeting SP instead of NK1\nmight potentially overcome the caveats that limit long-term\neffects of NK1 antagonists, we propose a new therapeutic\nstrategy for the treatment of cancers that express NK1\nreceptors, based in the immuno-blockade of SP. Blocking\nantibodies against SP can be potentially administered in\nmonotherapy or in combination with other agents such as NK1inhibitors (Munoz et al., 2011). Moreover, this therapy couldpotentially be effective for cancers that are resistant to current\nanti-ErbB therapies, (such as Trastuzumab and Lapatinib),\noffering another line of defense against refractory tumors.\nAcknowledgments\nThis work has been partially funded by a grant from the Fondode Investigacio \u00b4n Sanitaria, Instituto de Salud Carlos III\n(PI080022), by a grant from the Fundacio \u00b4n Cellex, by Redes\nTema \u00b4ticas de Investigacio \u00b4ne nC a \u00b4ncer (RTICC, RD07/0020/\n2014) and by a grant of Banco de Santander (with the\ncollaboration of UB-AVCRI, FBG, IDIBAPS, Hospital Cl\u0131 \u00b4nic and\nFundacio \u00b4Cl\u0131\u00b4nic). The work was carried out in part at the Esther\nKoplowitz Centre, Barcelona.\nLiterature Cited\nAkazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM.\n2009. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109:1079\u20131086.\nAlmendro V, Ametller E, Garcia-Recio S, Collazo O, Casas I, Auge JM, Maurel J, Gascon P.\n2009. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisitionof chemoresistance to oxaliplatin. PLoS One 4:e4728.\nAlmendro V, Garcia-Recio S, Gascon P. 2010. Tyrosine kinase receptor transactivation\nassociated to G protein-coupled receptors. Curr Drug Targets 11:1169\u20131180.\nBost KL. 2004. Tachykinin-mediated modulation of the immune response. Front Biosci\n9:3331\u20133332.\nCastagliuolo I, Valenick L, Liu J, Pothoulakis C. 2000. Epidermal growth factor receptor\ntransactivation mediates substance P-induced mitogenic responses in U-373 MG cells.J Biol Chem 275:26545\u201326550.\nCastro TA, Cohen MC, Rameshwar P. 2005. The expression of neurokinin-1 and\npreprotachykinin-1 in breast cancer cells depends on the relative degree of invasive andmetastatic potential. Clin Exp Metastasis 22:621\u2013628.\nEglezos A, Andrews PV, Boyd RL, Helme RD. 1991. Modulation of the immune response by\ntachykinins. Immunol Cell Biol 69:285\u2013294.\nFaber AC, Wong KK, Engelman JA. 2010. Differences underlying EGFR and HER2 oncogene\naddiction. Cell Cycle 9:851\u2013852.\nFingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. 2004. mTOR controls cell\ncycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotictranslation initiation factor 4E. Mol Cell Biol 24:200\u2013216.\nFredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA,\nHanby AM, Barnes DM, Shousha S, O\u2019Hare MJ, Lu X. 1997. High level expression ofp27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation betweenthe expression of p27(kip1) and degree of malignancy in human breast and colorectalcancers. Proc Natl Acad Sci USA 94:6380\u20136385.\nFriess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C,\nZimmermann A, Reubi JC, Buchler MW. 2003. Neurokinin-1 receptor expression and itspotential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731\u2013742.\nGermano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F,\nSan\ufb01lippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M,\nGalmarini CM, Tercero JC, Mantovani A, D\u2019Incalci M, Allavena P. 2010. Antitumor and anti-\nin\ufb02ammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res70:2235\u20132244.\nHoffmann T, Bos M, Stadler H, Schnider P, Hunkeler W, Godel T, Galley G, Ballard TM,\nHiggins GA, Poli SM, Sleight AJ. 2006. Design and synthesis of a novel, achiral class of highlypotent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med ChemLett 16:1362\u20131365.\nHuang SC, Korlipara VL. 2010. Neurokinin-1 receptor antagonists: A comprehensive patent\nsurvey. Expert Opin Ther Pat 20:1019\u20131045.Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. 2010.\nSunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth\nof renal cell carcinoma. Cancer Res 70:1053\u20131062.\nHumphrey JM. 2003. Medicinal chemistry of selective neurokinin-1 antagonists. Curr Top\nMed Chem 3:1423\u20131435.\nJeng AY, Fujimoto RA, Chou M, Tan J, Erion MD. 1997. Suppression of substance P\nbiosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potentpeptidylglycine alpha-amidating monooxygenase inhibitors. J Biol Chem 272:14666\u201314671.\nJoshi DD, Dang A, Yadav P, Qian J, Bandari PS, Chen K, Donnelly R, Castro T, Gascon P,\nHaider A, Rameshwar P. 2001. Negative feedback on the effects of stem cell factor onhematopoiesis is partly mediated through neutral endopeptidase activity on substance P: Acombined functional and proteomic study. Blood 98:2697\u20132706.\nKonecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW,\nSpehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. 2006. Activityof the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing andtrastuzumab-treated breast cancer cells. Cancer Res 66:1630\u20131639.\nKoon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. 2004. Metalloproteinases and\ntransforming growth factor-alpha mediate substance P-induced mitogen-activatedprotein kinase activation and proliferation in human colonocytes. J Biol Chem 279:45519\u201345527.\nLe XF, Pruefer F, Bast RC, Jr. 2005. HER2-targeting antibodies modulate the cyclin-dependent\nkinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4:87\u201395.\nLenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. 2001. ErbB2/neu kinase\nmodulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. CancerRes 61:6583\u20136591.\nLiang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S, Yen Y, Lee F, Yu H, Wen W, Jove R.\n2010. Antitumor activity of targeting SRC kinases in endothelial and myeloid cellcompartments of the tumor microenvironment. Clin Cancer Res 16:924\u2013935.\nLiu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer\nTM. 2009. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells:Activation of AXL. Cancer Res 69:6871\u20136878.\nMantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI,\nVigna SR, Maggio JE, et al. 1995. Receptor endocytosis and dendrite reshaping in spinalneurons after somatosensory stimulation. Science 268:1629\u20131632.\nMatsas R, Fulcher IS, Kenny AJ, Turner AJ. 1983. Substance P and [Leu]enkephalin are\nhydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with theendopeptidase of kidney microvilli. Proc Natl Acad Sci USA 80:3111\u20133115.\nMiller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC,\nde Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. 2009.Inhibition of mammalian target of rapamycin is required for optimal antitumor effect ofHER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15:7266\u20137276.\nModly CE, Das M, Don PS, Marcelo CL, Mukhtar H, Bickers DR. 1986. Capsaicin as an in vitro\ninhibitor of benzo(a)pyrene metabolism and its DNA binding in human and murinekeratinocytes. Drug Metab Dispos 14:413\u2013416.\nMunoz M, Perez A, Covenas R, Rosso M, Castro E. 2004a. Antitumoural action of L-733,060\non neuroblastoma and glioma cell lines. Arch Ital Biol 142:105\u2013112.\nMunoz M, Perez A, Rosso M, Zamarriego C, Rosso R. 2004b. Antitumoral action of the\nneurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res14:183\u2013188.\nMun\u02dcoz M, Rosso M, Coven \u02dcas R. 2011. The NK-1 receptor: A new target in cancer therapy.\nCurr Drug Targets 12:909\u2013921.\nNew DC, Wong YH. 2007. Molecular mechanisms mediating the G protein-coupled receptor\nregulation of cell cycle progression. J Mol Signal 2:2.\nNieber K, Oehme P, Arefolov VA, Valdman AV. 1988. Effect of the N-terminal tetrapeptide of\nsubstance P SP (1-4) and tuftsin on the pre- and postsynaptic transmitter out\ufb02ow in rat\nadrenal gland slices. Biomed Biochim Acta 47:663\u2013666.\nPalma C. 2006. Tachykinins and their receptors in human malignancies. Curr Drug Targets\n7:1043\u20131052.\nPalma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. 2000. Anti-tumour activity of\ntachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer82:480\u2013487.\nPatel HJ, Ramkissoon SH, Patel PS, Rameshwar P. 2005. Transformation of breast cells by\ntruncated neurokinin-1 receptor is secondary to activation by preprotachykinin-Apeptides. Proc Natl Acad Sci USA 102:17436\u201317441.\nQuartara L, Altamura M. 2006. Tachykinin receptors antagonists: From research to clinic.\nCurr Drug Targets 7:975\u2013992.\nRao G, Patel PS, Idler SP, Maloof P, Gascon P, Potian JA, Rameshwar P. 2004. Facilitating role\nof preprotachykinin-I gene in the integration of breast cancer cells within the stromalcompartment of the bone marrow: A model of early cancer progression. Cancer Res64:2874\u20132881.\nRosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M. 2008. The NK-1\nreceptor is expressed in human primary gastric and colon adenocarcinomas and is involvedin the antitumor action of L-733,060 and the mitogenic action of substance P on humangastrointestinal cancer cell lines. Tumour Biol 29:245\u2013254.\nSeverini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. 2002. The tachykinin\npeptide family. Pharmacol Rev 54:285\u2013322.\nSingh D, Joshi DD, Hameed M, Qian J, Gascon P, Maloof PB, Mosenthal A, Rameshwar P. 2000.\nIncreased expression of preprotachykinin-I and neurokinin receptors in human breastcancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:388\u2013393.\nSingh AS, Caplan A, Corcoran KE, Fernandez JS, Preziosi M, Rameshwar P. 2006. Oncogenic\nand metastatic properties of preprotachykinin-I and neurokinin-1 genes. Vascul Pharmacol45:235\u2013242.\nYamaguchi K, Kugimiya T, Miyazaki T. 2005. Substance P receptor in U373 MG human\nastrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src. BrainTumor Pathol 22:1\u20138.\nJOURNAL OF CELLULAR PHYSIOLOGY1366 MAYORDOMO ET AL.\u00a0\u00a0\n167\u00a0\n\u00a0DISCUSI\u00d3N \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n169\u00a0\n\u00a0DISCUSI\u00d3N \u00a0\n\u00a0\nVarias\u00a0publicaciones \u00a0han\u00a0abordado \u00a0el\u00a0papel\u00a0de\u00a0la\u00a0\nSP\u00a0como\u00a0factor\u00a0mitog\u00e9nico \u00a0en\u00a0c\u00e9lulas\u00a0no\u00a0\nneopl\u00e1sicas \u00a0y\u00a0neopl\u00e1sicas, \u00a0y\u00a0han\u00a0demostrado \u00a0la\u00a0\ndependencia \u00a0de\u00a0la\u00a0SP\u00a0por\u00a0parte\u00a0de\u00a0otros\u00a0factores\u00a0\nde\u00a0crecimiento \u00a0adicionales \u00a0importantes \u00a0que\u00a0\nactivan\u00a0v\u00edas\u00a0como\u00a0la\u00a0de\u00a0las\u00a0MAPKs494,513.\u00a0En\u00a0esta\u00a0\ntesis\u00a0principalmente \u00a0se\u00a0ha\u00a0demostrado \u00a0c\u00f3mo\u00a0la\u00a0SP\u00a0\ntransactiva \u00a0EGFR\u00a0y\u00a0HER2\u00a0tanto\u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0\nde\u00a0CM\u00a0como\u00a0en\u00a0c\u00e9lulas\u00a0que\u00a0provienen \u00a0de\u00a0tumores\u00a0\nprimarios \u00a0de\u00a0mama\u00a0humanos. \u00a0Adem\u00e1s\u00a0este\u00a0\ntrabajo\u00a0tambi\u00e9n\u00a0describe\u00a0un\u00a0papel\u00a0previamente \u00a0\nno\u00a0identificado \u00a0sobre\u00a0la\u00a0se\u00f1alizaci\u00f3n, \u00a0\nautocrina/paracrina \u00a0y\u00a0de\u00a0forma\u00a0constitutiva, \u00a0de\u00a0la\u00a0\nSP\u00a0como\u00a0moduladora \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0basal\u00a0de\u00a0\nreceptores \u00a0ErbB,\u00a0en\u00a0concreto\u00a0el\u00a0receptor\u00a0HER2.\u00a0\u00a0\nMOL\u00c9CULAS \u00a0IMPLICADAS \u00a0EN\u00a0LA\u00a0\nTRANSACTIVACION \u00a0DE\u00a0RTKs\u00a0A\u00a0TRAV\u00c9S\u00a0\nDEL\u00a0RECEPTOR \u00a0NK1\u00a0E\u00a0IMPLICACIONES \u00a0\nCL\u00cdNICAS\u00a0\n\u00a0\nLa\u00a0capacidad \u00a0de\u00a0la\u00a0SP\u00a0y\u00a0otros\u00a0neurop\u00e9ptidos \u00a0y/o\u00a0\nmediadores \u00a0pro\u2010inflamatorios \u00a0para\u00a0modular\u00a0la\u00a0\nactividad\u00a0de\u00a0los\u00a0RTK\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0es\u00a0de\u00a0\nrelevancia \u00a0cl\u00ednica375,514.\u00a0La\u00a0transmodulaci\u00f3n \u00a0de\u00a0un\u00a0\nRTK\u00a0puede\u00a0servir\u00a0como\u00a0un\u00a0mecanismo \u00a0para\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0estos\u00a0receptores \u00a0de\u00a0una\u00a0manera\u00a0\nindependiente \u00a0del\u00a0ligando247.\u00a0En\u00a0primer\u00a0lugar,\u00a0la\u00a0\nprote\u00edna\u00a0tirosina\u00a0quinasa\u00a0Src\u00a0puede\u00a0directamente \u00a0\ninteraccionar \u00a0y\u00a0fosforilar\u00a0residuos\u00a0Tyr\u00a0del\u00a0dominio\u00a0\nquinasa\u00a0de\u00a0HER2378,380\u00a0y\u00a0de\u00a0la\u00a0cola\u00a0citopl\u00e1smica \u00a0de\u00a0\nreceptores \u00a0de\u00a0su\u00a0misma\u00a0familia\u00a0como\u00a0EGFR364,\u00a0\npermitiendo \u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0homo\u00a0o\u00a0\nheterod\u00edmeros \u00a0estables\u00a0con\u00a0otros\u00a0receptores \u00a0y\u00a0la\u00a0\nuni\u00f3n\u00a0de\u00a0las\u00a0prote\u00ednas \u00a0adaptadoras \u00a0que\u00a0activar\u00e1n \u00a0\nla\u00a0transducci\u00f3n \u00a0de\u00a0se\u00f1ales.\u00a0En\u00a0segundo\u00a0lugar,\u00a0se\u00a0\npuede\u00a0dar\u00a0el\u00a0caso\u00a0que\u00a0una\u00a0vez\u00a0transactivados \u00a0los\u00a0\nRTKs,\u00a0estos\u00a0activen\u00a0a\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0y\u00a0esta\u00a0a\u00a0su\u00a0vez\u00a0\nintervenga \u00a0tanto\u00a0de\u00a0sustrato\u00a0como\u00a0de\u00a0prote\u00edna\u00a0\nactivadora \u00a0de\u00a0los\u00a0RTKs\u00a0creando\u00a0un\u00a0bucle\u00a0regulador \u00a0\npositivo.\u00a0Esta\u00a0sobreactivaci\u00f3n \u00a0contribuye \u00a0en\u00a0la\u00a0persistencia \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0RTKs\u00a0\ny\u00a0en\u00a0el\u00a0mantenimiento \u00a0de\u00a0m\u00faltiples \u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0corriente\u00a0abajo\u00a0del\u00a0receptor363.\u00a0\nDebido\u00a0a\u00a0esto,\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0RTKs\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0mecanismos \u00a0dependientes \u00a0de\u00a0Src\u00a0podr\u00edan\u00a0\ncontribuir \u00a0a\u00a0la\u00a0perdurabilidad \u00a0de\u00a0las\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0por\u00a0parte\u00a0de\u00a0los\u00a0RTKs\u00a0incluso\u00a0en\u00a0\npresencia \u00a0de\u00a0inhibidores \u00a0tirosina\u00a0quinasa\u00a0(Fig.\u00a01).\u00a0\nEn\u00a0los\u00a0c\u00e1nceres\u00a0de\u00a0mama,\u00a0la\u00a0prote\u00edna\u00a0Src\u00a0se\u00a0\nsobreexpresa \u00a0en\u00a0el\u00a070%\u00a0de\u00a0los\u00a0tumores\u00a0y\u00a0en\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0estos\u00a0tumores\u00a0Src\u00a0se\u00a0coexpresa \u00a0al\u00a0\nmenos\u00a0con\u00a0un\u00a0miembro\u00a0de\u00a0la\u00a0familia\u00a0ErbB365.\u00a0El\u00a0\nhecho\u00a0de\u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0\ndependa, \u00a0en\u00a0parte,\u00a0de\u00a0la\u00a0actividad\u00a0de\u00a0otras\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0adicionales \u00a0significa\u00a0que\u00a0estas\u00a0v\u00edas\u00a0\ninstigadoras \u00a0podr\u00edan\u00a0ser\u00a0terap\u00e9uticamente \u00a0\nutilizadas \u00a0para\u00a0desregular \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0los\u00a0\nRTKs.\u00a0De\u00a0hecho\u00a0no\u00a0solo\u00a0la\u00a0sobreexpresi\u00f3n \u00a0de\u00a0\nreceptores \u00a0de\u00a0la\u00a0familia\u00a0ErbB515\u2010517\u00a0u\u00a0otros\u00a0\nreceptores \u00a0como\u00a0IGFR518,519,\u00a0provocan \u00a0resistencia \u00a0\nprimaria\u00a0o\u00a0adquirida \u00a0al\u00a0Trastuzumab \u00a0sino\u00a0que\u00a0\nrecientemente \u00a0se\u00a0ha\u00a0comprobado \u00a0\u00a0que\u00a0pacientes \u00a0\ncon\u00a0altos\u00a0niveles\u00a0de\u00a0la\u00a0prote\u00edna\u00a0fosforilada \u00a0\nSrcY416,\u00a0presentaban \u00a0peores\u00a0respuestas \u00a0a\u00a0\nterapias\u00a0anti\u2010diana\u00a0(como\u00a0el\u00a0Trastuzumab) \u00a0que\u00a0se\u00a0\nve\u00eda\u00a0incrementada \u00a0por\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0PTEN,\u00a0ya\u00a0que\u00a0\nSrc\u00a0es\u00a0sustrato\u00a0directo\u00a0de\u00a0esta\u00a0encima520,521.\u00a0\u00a0Este\u00a0\nhallazgo\u00a0es\u00a0importante \u00a0y\u00a0se\u00a0relaciona\u00a0con\u00a0los\u00a0\nresultados \u00a0obtenidos \u00a0en\u00a0esta\u00a0tesis,\u00a0ya\u00a0que\u00a0la\u00a0\nhiperactivaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src,\u00a0podr\u00eda\u00a0ser\u00a0\ndebida,\u00a0en\u00a0parte,\u00a0a\u00a0otros\u00a0mecanismos \u00a0que\u00a0se\u00a0han\u00a0\nido\u00a0presentando \u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0este\u00a0trabajo.\u00a0Uno\u00a0de\u00a0\nellos\u00a0podr\u00eda\u00a0ser\u00a0la\u00a0sobreexpresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u2010\n1\u00a0o\u00a0su\u00a0hiperactivaci\u00f3n. \u00a0Seg\u00fan\u00a0los\u00a0resultados \u00a0\nobtenidos, \u00a0se\u00a0ha\u00a0demostrado \u00a0por\u00a0primera\u00a0vez,\u00a0que\u00a0\nen\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010231\u00a0transfectada \u00a0y\u00a0que\u00a0\nsobreexpresa \u00a0de\u00a0forma\u00a0estable\u00a0el\u00a0receptor\u00a0NK\u20101,\u00a0\nadem\u00e1s\u00a0de\u00a0causar\u00a0un\u00a0aumento\u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0\nHER2,\u00a0se\u00a0incrementa \u00a0hasta\u00a05\u00a0veces\u00a0la\u00a0fosforilaci\u00f3n \u00a0\nde\u00a0Src\u00a0Y416\u00a0bajo\u00a0el\u00a0est\u00edmulo\u00a0de\u00a0SP.\u00a0En\u00a0estudios\u00a0de\u00a0\ntiempo\u00a0respuesta \u00a0algunas\u00a0l\u00edneas\u00a0respond\u00edan \u00a0al\u00a0\ntratamiento \u00a0de\u00a0SP\u00a0fosforilando \u00a0la\u00a0prote\u00edna\u00a0Src\u00a0en\u00a0\nla\u00a0Tyr\u00a0416.\u00a0Adem\u00e1s\u00a0otras\u00a0estrategias \u00a0\nexperimentales \u00a0 demostraron \u00a0 que\u00a0 la\u00a0\ntransactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0NK\u20101R\u00a0era\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n170\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nFigura\u00a01.\u00a0Propuesta \u00a0de\u00a0modelo\u00a0de\u00a0transactivaci\u00f3n \u00a0de\u00a0EGFR\u00a0y\u00a0HER2\u00a0mediada\u00a0por\u00a0SP.\u00a0NK\u20101R\u00a0induce\u00a0la\u00a0transducci\u00f3n \u00a0de\u00a0se\u00f1ales\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0G.\u00a0Las\u00a0prot\u00e9inas \u00a0G\u00a0heterotrim\u00e9ricas \u00a0se\u00a0componen \u00a0de\u00a0tres\u00a0subunidades \u00a0diferentes: \u00a0la\u00a0\nsubunidad \u00a0G\u03b1\u00a0que\u00a0une\u00a0a\u00a0GDP/GTP \u00a0y\u00a0las\u00a0subunidades \u00a0G\u03b2\u00a0y\u00a0G\u03b3\u00a0que\u00a0forman\u00a0el\u00a0\u00a0complejo \u00a0G\u03b2\u03b3.\u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0NK\u20101R\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0un\u00a0\nagonista\u00a0(en\u00a0este\u00a0caso\u00a0la\u00a0SP)\u00a0estimula\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0prote\u00ednas \u00a0G\u00a0e\u00a0induce\u00a0su\u00a0propia\u00a0cascada\u00a0de\u00a0se\u00f1alizaci\u00f3n, \u00a0como\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0de\u00a0las\u00a0MAPKs,\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0PI3K,\u00a0NF\u2010\u03baB\u00a0y\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0Src.\u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0de\u00a0las\u00a0MAPKs,\u00a0a\u00a0su\u00a0\nvez\u00a0contribuir\u00e1 \u00a0a\u00a0aumentar \u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0MMPs\u00a0al\u00a0exterior\u00a0y\u00a0junto\u00a0a\u00a0las\u00a0activadas \u00a0v\u00eda\u00a0Src,\u00a0clivar\u00e1n\u00a0ligandos\u00a0anclados\u00a0a\u00a0la\u00a0\nmembrana \u00a0plasm\u00e1tica, \u00a0que\u00a0una\u00a0vez\u00a0liberados, \u00a0se\u00a0unir\u00e1n\u00a0a\u00a0receptores \u00a0como\u00a0EGFR.\u00a0Por\u00a0otro\u00a0lado,\u00a0Src\u00a0podr\u00eda\u00a0fosforilar\u00a0\ndirectamente \u00a0las\u00a0colas\u00a0citoplasm\u00e1ticas \u00a0de\u00a0ambos\u00a0receptores \u00a0EGFR\u00a0y\u00a0HER2\u00a0permitiendo \u00a0la\u00a0uni\u00f3n\u00a0de\u00a0prote\u00ednas \u00a0adaptadoras \u00a0que\u00a0\nactivar\u00e1n\u00a0la\u00a0transducci\u00f3n \u00a0de\u00a0se\u00f1ales\u00a0corriente\u00a0abajo.\u00a0En\u00a0base\u00a0a\u00a0nuestros\u00a0resultados, \u00a0proponemos \u00a0que\u00a0esta\u00a0fosforilaci\u00f3n \u00a0directa\u00a0de\u00a0\nlas\u00a0colas\u00a0citoplasm\u00e1ticas \u00a0de\u00a0EGFR\u00a0y\u00a0HER2\u00a0v\u00eda\u00a0Src\u00a0podr\u00eda\u00a0superar\u00a0los\u00a0efectos\u00a0de\u00a0los\u00a0inhibidores \u00a0tirosina\u00a0quinasa,\u00a0ya\u00a0que\u00a0Src\u00a0actuar\u00eda\u00a0\nindependientemente \u00a0de\u00a0la\u00a0actividad\u00a0tyrosina\u00a0quinasa\u00a0de\u00a0EGFR\u00a0y\u00a0HER2.\u00a0\n\u00a0\n\u00a0\ndependiente \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0Src\u00a0y\u00a0de\u00a0\nla\u00a0actividad\u00a0de\u00a0las\u00a0MMPs\u00a0(ya\u00a0que\u00a0la\u00a0inhibci\u00f3n\u00a0de\u00a0\nambas\u00a0prote\u00ednas \u00a0provocaba \u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0\nlos\u00a0niveles\u00a0basales\u00a0de\u00a0HER2\u00a0bajo\u00a0el\u00a0est\u00edmulo\u00a0de\u00a0\nSP).\u00a0La\u00a0prote\u00edna\u00a0Src\u00a0no\u00a0solo\u00a0podr\u00eda\u00a0ser\u00a0clave\u00a0en\u00a0la\u00a0\ntransactivaci\u00f3n \u00a0independiente \u00a0de\u00a0ligando\u00a0de\u00a0los\u00a0\nRTKs,\u00a0si\u00a0no\u00a0que\u00a0probablemente \u00a0tambi\u00e9n\u00a0en\u00a0el\u00a0\nmantenimiento \u00a0o\u00a0activaci\u00f3n \u00a0de\u00a0las\u00a0MMPs\u00a0\ndesencadenando \u00a0el\u00a0clivaje\u00a0de\u00a0ligandos\u00a0unidos\u00a0a\u00a0la\u00a0\nmembrana, \u00a0que\u00a0una\u00a0vez\u00a0liberados, \u00a0se\u00a0unir\u00edan\u00a0a\u00a0\nreceptores \u00a0como\u00a0EGFR373\u00a0(Fig.\u00a01).\u00a0\nBas\u00e1ndonos \u00a0en\u00a0los\u00a0mismos\u00a0estudios\u00a0de\u00a0tiempo\u00a0\nrespuesta, \u00a0en\u00a0todas\u00a0\u00a0las\u00a0l\u00edneas\u00a0estudiadas, \u00a0la\u00a0SP\u00a0\nfosforilaba \u00a0tambi\u00e9n\u00a0prote\u00ednas \u00a0como\u00a0Akt\u00a0y\u00a0p\u201042/44\u00a0MAPK\u00a0ya\u00a0fuera\u00a0directamente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0NK\u20101R\u00a0o\u00a0\nindirectamente \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0transactivaci\u00f3n \u00a0de\u00a0\nRTKs\u00a0(Fig.\u00a01).\u00a0En\u00a0relaci\u00f3n\u00a0a\u00a0este\u00a0incremento \u00a0en\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0prote\u00ednas \u00a0implicadas \u00a0en\u00a0v\u00edas\u00a0de\u00a0\nsupervivencia \u00a0y\u00a0proliferaci\u00f3n \u00a0como\u00a0Akt\u00a0y\u00a0p42/44\u00a0\nMAPK,\u00a0anteriormente \u00a0ya\u00a0se\u00a0hab\u00eda\u00a0observado \u00a0en\u00a0\nc\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0que\u00a0una\u00a0activaci\u00f3n \u00a0\nconstitutiva \u00a0de\u00a0la\u00a0isoforma\u00a0truncada\u00a0del\u00a0receptor\u00a0\nNK\u20101\u00a0conlleva\u00a0a\u00a0un\u00a0incremento \u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0\nde\u00a0Akt\u00a0y\u00a0la\u00a0consecuente \u00a0activaci\u00f3n \u00a0de\u00a0NF\u2010\u03baB.\u00a0\nSeg\u00fan\u00a0su\u00a0modelo\u00a0de\u00a0estudio,\u00a0en\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0\nAkt,\u00a0parecen\u00a0estar\u00a0implicadas \u00a0directamente \u00a0las\u00a0\nprote\u00ednas \u00a0PI3K\u00a0y\u00a0Src,\u00a0y\u00a0en\u00a0cambio\u00a0el\u00a0receptor\u00a0\nEGFR,\u00a0parece\u00a0mediar\u00a0s\u00f3lo\u00a0parcialmente \u00a0su\u00a0\nDISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n171\u00a0\n\u00a0activaci\u00f3n \u00a0ya\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0su\u00a0actividad\u00a0\nmediante \u00a0el\u00a0inhibidor\u00a0qu\u00edmico\u00a0AG1478\u00a0s\u00f3lo\u00a0\nprovoca\u00a0una\u00a0peque\u00f1a\u00a0disminuci\u00f3n \u00a0en\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0Akt335.\u00a0Teniendo \u00a0en\u00a0cuenta\u00a0que\u00a0las\u00a0\nc\u00e9lulas\u00a0de\u00a0glioblastoma \u00a0presentan \u00a0una\u00a0elevada\u00a0\nexpresi\u00f3n \u00a0de\u00a0NK\u20101R335,\u00a0se\u00a0podr\u00eda\u00a0hipotetizar \u00a0que\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0esta\u00a0v\u00eda\u00a0en\u00a0estas\u00a0c\u00e9lulas\u00a0y\u00a0la\u00a0\nconsecuente \u00a0activaci\u00f3n \u00a0de\u00a0v\u00edas\u00a0de\u00a0proliferaci\u00f3n \u00a0y\u00a0\nsupervivencia \u00a0podr\u00edan\u00a0afectar\u00a0a\u00a0la\u00a0respuesta \u00a0\nterap\u00e9utica \u00a0de\u00a0inhibidores \u00a0de\u00a0EGFR.\u00a0De\u00a0hecho,\u00a0en\u00a0\nun\u00a0ensayo\u00a0cl\u00ednico\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0EGFR\u00a0\nErlotinib\u00a0en\u00a0pacientes \u00a0con\u00a0glioblastoma \u00a0se\u00a0observ\u00f3\u00a0\nuna\u00a0falta\u00a0de\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0en\u00a0aquellos\u00a0\ntumores\u00a0que\u00a0presentaban \u00a0unos\u00a0altos\u00a0niveles\u00a0de\u00a0\nfosfo\u2010Akt335.\u00a0Quiz\u00e1s\u00a0con\u00a0un\u00a0bloqueo\u00a0simult\u00e1neo \u00a0de\u00a0\nEGFR\u00a0y\u00a0otras\u00a0v\u00edas\u00a0instigadoras \u00a0de\u00a0la\u00a0v\u00eda\u00a0de\u00a0Akt,\u00a0\ncomo\u00a0NK\u20101R\u00a0podr\u00edan\u00a0mejorar\u00a0las\u00a0respuestas \u00a0a\u00a0\nestos\u00a0tipos\u00a0de\u00a0inhibidores \u00a0en\u00a0pacientes \u00a0con\u00a0\nglioblastoma. \u00a0\u00a0\n\u00a0\nBloqueo\u00a0o\u00a0sobreactivaci\u00f3n \u00a0del\u00a0sistema\u00a0\ntaquiquin\u00e9rgico \u00a0\u00a0\n\u00a0\nCon\u00a0esta\u00a0idea\u00a0en\u00a0mente,\u00a0otro\u00a0de\u00a0los\u00a0objetivos\u00a0\nprincipales \u00a0de\u00a0esta\u00a0tesis\u00a0se\u00a0centr\u00f3\u00a0en\u00a0investigar \u00a0los\u00a0\nefectos\u00a0de\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\nactivadas \u00a0directamente \u00a0por\u00a0NK\u20101R\u00a0y\u00a0v\u00edas\u00a0activadas \u00a0\npor\u00a0receptores \u00a0ErbB,\u00a0para\u00a0determinar \u00a0si\u00a0se\u00a0\npodr\u00edan\u00a0mejorar\u00a0las\u00a0respuestas \u00a0de\u00a0algunas\u00a0\nterapias\u00a0actuales\u00a0dirigidas\u00a0contra\u00a0receptores \u00a0de\u00a0la\u00a0\nfamilia\u00a0ErbB.\u00a0Primero\u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0\nde\u00a0la\u00a0SP\u00a0con\u00a0un\u00a0anticuerpo \u00a0policlonal \u00a0disminu\u00eda \u00a0los\u00a0\nniveles\u00a0de\u00a0activaci\u00f3n \u00a0basal\u00a0de\u00a0EGFR\u00a0y\u00a0HER2\u00a0e\u00a0\ninduc\u00eda\u00a0apoptosis \u00a0celular\u00a0incluso\u00a0en\u00a0l\u00edneas\u00a0\nresistentes \u00a0a\u00a0Lapatinib\u00a0y\u00a0Trastuzumab522.\u00a0\u00c9ste\u00a0\n\u00faltimo\u00a0hallazgo\u00a0era\u00a0importante \u00a0si\u00a0ten\u00edamos \u00a0en\u00a0\ncuenta\u00a0que\u00a0estudios\u00a0hechos\u00a0en\u00a0nuestro\u00a0\nlaboratorio \u00a0demostraban \u00a0que\u00a0estas\u00a0l\u00edneas\u00a0\nresistentes \u00a0a\u00a0inhibidores \u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0ten\u00edan\u00a0\nsobreactivados \u00a0miembros \u00a0de\u00a0la\u00a0familia\u00a0ErbB\u00a0como\u00a0\nuno\u00a0de\u00a0los\u00a0posibles\u00a0mecanismos \u00a0de\u00a0resistencia \u00a0a\u00a0\nestos\u00a0f\u00e1rmacos. \u00a0Por\u00a0lo\u00a0tanto,\u00a0en\u00a0estos\u00a0modelos\u00a0de\u00a0\nquimioresistenica \u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0sistema\u00a0\ntaquiquin\u00e9rgico \u00a0parec\u00eda\u00a0favorecer \u00a0a\u00a0la\u00a0baja\u00a0\nefectividad \u00a0de\u00a0los\u00a0tratamientos \u00a0anti\u2010HER2/EGFR \u00a0en\u00a0las\u00a0l\u00edneas\u00a0resitentes. \u00a0De\u00a0la\u00a0misma\u00a0manera,\u00a0en\u00a0\nesta\u00a0tesis\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0el\u00a0silenciamiento \u00a0\ndel\u00a0receptor\u00a0NK\u20101\u00a0tambi\u00e9n\u00a0disminuye \u00a0\nsignificativamente \u00a0la\u00a0actividad\u00a0de\u00a0HER2\u00a0en\u00a0todas\u00a0\nlas\u00a0l\u00edneas\u00a0celulares\u00a0estudiadas. \u00a0A\u00a0pesar\u00a0de\u00a0que\u00a0s\u00f3lo\u00a0\nse\u00a0consigui\u00f3 \u00a0un\u00a0silenciamiento \u00a0del\u00a050\u201070%,\u00a0fue\u00a0\nsuficiente \u00a0para\u00a0disminuir \u00a0la\u00a0activaci\u00f3n \u00a0basal\u00a0del\u00a0\nreceptor\u00a0HER2\u00a0o\u00a0EGFR.\u00a0Con\u00a0el\u00a0fin\u00a0de\u00a0realizar\u00a0una\u00a0\naproximaci\u00f3n \u00a0m\u00e1s\u00a0terap\u00e9utica, \u00a0la\u00a0inhibici\u00f3n \u00a0del\u00a0\nreceptor\u00a0NK\u20101\u00a0con\u00a0el\u00a0compuesto \u00a0qu\u00edmico\u00a0L\u2010\n733,060\u00a0tambi\u00e9n\u00a0indujo\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0los\u00a0\nniveles\u00a0basales\u00a0de\u00a0HER2,\u00a0y\u00a0caus\u00f3\u00a0muerte\u00a0celular\u00a0\nmediada\u00a0por\u00a0apoptosis \u00a0en\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0\nEstos\u00a0resultados \u00a0induc\u00edan\u00a0a\u00a0pensar\u00a0que\u00a0la\u00a0adicci\u00f3n\u00a0\noncog\u00e9nica \u00a0a\u00a0NK\u20101R,\u00a0por\u00a0parte\u00a0de\u00a0las\u00a0l\u00edneas\u00a0\ncelulares, \u00a0podr\u00eda\u00a0ser\u00a0debida\u00a0a\u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0\nbasal\u00a0de\u00a0HER2\u00a0fuera\u00a0dependiente, \u00a0en\u00a0parte,\u00a0del\u00a0\ncorrecto\u00a0funcionamiento \u00a0del\u00a0receptor\u00a0NK\u20101.\u00a0De\u00a0\nhecho,\u00a0tambi\u00e9n\u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0\nqu\u00edmica\u00a0de\u00a0NK\u20101R,\u00a0sola\u00a0o\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0la\u00a0\ninhibici\u00f3n \u00a0de\u00a0los\u00a0otros\u00a0dos\u00a0receptores \u00a0de\u00a0\ntaquiquininas \u00a0como\u00a0NK\u20102\u00a0y\u00a0NK\u20103,\u00a0disminu\u00edan \u00a0\nsignificativamente \u00a0los\u00a0niveles\u00a0basales\u00a0de\u00a0pHER2\u00a0y\u00a0\nde\u00a0pEGFR\u00a0y\u00a0de\u00a0prote\u00ednas \u00a0implicadas \u00a0en\u00a0su\u00a0\nse\u00f1alizaci\u00f3n, \u00a0como\u00a0MAPKs\u00a0y\u00a0Akt.\u00a0Adem\u00e1s\u00a0la\u00a0\ninhibici\u00f3n \u00a0o\u00a0silenciamiento \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0\ncaus\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0Src\u00a0\nY416\u00a0siendo\u00a0casi\u00a0del\u00a0100%\u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0\ntratada\u00a0con\u00a0los\u00a0tres\u00a0inhibidores \u00a0de\u00a0taquiquininas, \u00a0\nefectos\u00a0que\u00a0se\u00a0correlacionaban \u00a0con\u00a0una\u00a0\ndisminuci\u00f3n \u00a0casi\u00a0total\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0pHER2.\u00a0\u00a0\nExperimentos \u00a0in\u00a0vivo\u00a0reafirmaron \u00a0los\u00a0resultados \u00a0\nobtenidos \u00a0hasta\u00a0el\u00a0momento \u00a0ya\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0\ndel\u00a0receptor\u00a0NK\u20101\u00a0con\u00a0L\u2010733,060\u00a0tambi\u00e9n\u00a0caus\u00f3\u00a0\nuna\u00a0inhibici\u00f3n \u00a0del\u00a0crecimiento \u00a0tumoral\u00a0en\u00a0ratones\u00a0\nSCID.\u00a0Los\u00a0efectos\u00a0del\u00a0inhibidor\u00a0en\u00a0el\u00a0crecimiento \u00a0\ntumoral\u00a0fueron\u00a0evidentes \u00a0dos\u00a0semanas\u00a0despu\u00e9s\u00a0\ndel\u00a0inicio\u00a0del\u00a0tratamiento \u00a0y\u00a0plenamente \u00a0\nsignificativos \u00a0a\u00a0las\u00a06\u00a0semanas. \u00a0Y\u00a0aunque\u00a0en\u00a0este\u00a0\ncaso\u00a0los\u00a0niveles\u00a0totales\u00a0de\u00a0HER2\u00a0no\u00a0parec\u00edan\u00a0\ndisminuir, \u00a0s\u00ed\u00a0que\u00a0se\u00a0observ\u00f3\u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0\nlos\u00a0niveles\u00a0fosforilados \u00a0de\u00a0este\u00a0receptor\u00a0as\u00ed\u00a0como\u00a0\nen\u00a0p\u2010p42/44\u00a0MAPK\u00a0y\u00a0pAkt.\u00a0\u00a0En\u00a0este\u00a0modelo\u00a0\nexperimental \u00a0hab\u00eda\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0el\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n172\u00a0\n\u00a0receptor\u00a0NK\u20101\u00a0no\u00a0s\u00f3lo\u00a0se\u00a0expresa\u00a0en\u00a0c\u00e9lulas\u00a0\ntumorales \u00a0si\u00a0no\u00a0tambi\u00e9n\u00a0en\u00a0c\u00e9lulas\u00a0del\u00a0\nmicroambiente \u00a0como\u00a0los\u00a0miofibroblastos. \u00a0Los\u00a0\nmiofibroblastos \u00a0contribuyen \u00a0en\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0tumorales, \u00a0secretan\u00a0componentes \u00a0de\u00a0la\u00a0\nmatriz\u00a0extracelular \u00a0y\u00a0favorecen \u00a0la\u00a0angiog\u00e9nesis, \u00a0\ninvasi\u00f3n\u00a0y\u00a0met\u00e1stasis \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nSDF\u20101\u00a0o\u00a0SP.\u00a0Adem\u00e1s\u00a0han\u00a0sido\u00a0descritas\u00a0sus\u00a0\nactividades \u00a0pro\u2010tumorales \u00a0en\u00a0modelos\u00a0murinos125.\u00a0\nEstos\u00a0miofibroblastos \u00a0son\u00a0f\u00e1cilmente \u00a0identificables \u00a0\npor\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\u03b1\u2010SMA,\u00a0y\u00a0en\u00a0nuestro\u00a0modelo\u00a0\nmurino,\u00a0se\u00a0observ\u00f3\u00a0que\u00a0en\u00a0aquellos\u00a0ratones\u00a0\ntratados\u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0NK\u20101R\u00a0esta\u00a0prote\u00edna\u00a0\nse\u00a0encontraba \u00a0menos\u00a0expresada \u00a0en\u00a0comparaci\u00f3n \u00a0\ncon\u00a0los\u00a0ratones\u00a0control.\u00a0Adem\u00e1s,\u00a0otra\u00a0prote\u00edna\u00a0del\u00a0\nmicroambiente \u00a0tumoral\u00a0e\u00a0involucrada \u00a0en\u00a0la\u00a0\ns\u00edntesis\u00a0de\u00a0prostaglandinas, \u00a0como\u00a0la\u00a0enzima\u00a0COX\u20102\u00a0\nse\u00a0ve\u00eda\u00a0disminuida \u00a0en\u00a0presencia \u00a0del\u00a0inhibidor. \u00a0Por\u00a0\ntanto,\u00a0los\u00a0cambios\u00a0de\u00a0expresi\u00f3n \u00a0en\u00a0ambas\u00a0\nprote\u00ednas, \u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0pHER2\u00a0\ny\u00a0de\u00a0prote\u00ednas \u00a0implicadas \u00a0en\u00a0su\u00a0ruta\u00a0de\u00a0\nse\u00f1alizaci\u00f3n \u00a0y\u00a0la\u00a0disminuci\u00f3n \u00a0del\u00a0crecimiento \u00a0\ntumoral,\u00a0suscitaban \u00a0a\u00a0pensar\u00a0que\u00a0el\u00a0receptor\u00a0NK\u20101\u00a0\nestaba\u00a0involucrado \u00a0tanto\u00a0en\u00a0la\u00a0modulaci\u00f3n \u00a0de\u00a0\npropiedades \u00a0del\u00a0tumor\u00a0como\u00a0en\u00a0la\u00a0\nreestructuraci\u00f3n \u00a0de\u00a0su\u00a0estroma.\u00a0\nDado\u00a0el\u00a0papel\u00a0tan\u00a0importante \u00a0que\u00a0tiene\u00a0el\u00a0\nmicroambiente \u00a0inflamatorio \u00a0sobre\u00a0el\u00a0inicio\u00a0o\u00a0\ndestino\u00a0de\u00a0una\u00a0lesi\u00f3n\u00a0neopl\u00e1sica \u00a0tambi\u00e9n\u00a0se\u00a0\nestudi\u00f3\u00a0en\u00a0un\u00a0segundo\u00a0modelo\u00a0in\u00a0vivo\u00a0la\u00a0posible\u00a0\nimplicaci\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0ex\u00f3gena\u00a0o\u00a0end\u00f3gena \u00a0en\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral.\u00a0Ratones\u00a0inmunospurimidos \u00a0\ncon\u00a0tumores\u00a0ortot\u00f3picos, \u00a0derivados \u00a0de\u00a0una\u00a0l\u00ednea\u00a0\ncelular\u00a0HER2\u00a0negativa,\u00a0recibieron \u00a0durante\u00a028\u00a0d\u00edas\u00a0\nuna\u00a0dosis\u00a0diaria\u00a0de\u00a0SP,\u00a0y\u00a0aunque\u00a0no\u00a0se\u00a0\nencontraron \u00a0diferencias \u00a0significativas \u00a0en\u00a0el\u00a0\nvolumen\u00a0tumoral\u00a0respecto\u00a0a\u00a0los\u00a0ratones\u00a0tratados\u00a0\ncon\u00a0suero\u00a0salino,\u00a0s\u00ed\u00a0se\u00a0observ\u00f3\u00a0un\u00a0peque\u00f1o\u00a0pero\u00a0\nconsistente \u00a0aumento\u00a0de\u00a0HER2\u00a0en\u00a0todos\u00a0los\u00a0casos,\u00a0\nadem\u00e1s\u00a0de\u00a0un\u00a0aumento\u00a0en\u00a0el\u00a0\u00edndice\u00a0mit\u00f3tico\u00a0de\u00a0\nlas\u00a0mismas\u00a0c\u00e9lulas,\u00a0sugiriendo \u00a0que\u00a0la\u00a0SP\u00a0pod\u00eda\u00a0\nfavorecer \u00a0el\u00a0crecimiento \u00a0de\u00a0clones\u00a0celulares\u00a0con\u00a0\nmayor\u00a0expresi\u00f3n \u00a0de\u00a0HER2.\u00a0Sin\u00a0embargo, \u00a0esta\u00a0\naproximaci\u00f3n \u00a0experimental \u00a0presenta\u00a0ciertas\u00a0\nlimitaciones. \u00a0Por\u00a0una\u00a0parte\u00a0no\u00a0podemos \u00a0descartar \u00a0que\u00a0en\u00a0un\u00a0modelo\u00a0donde\u00a0los\u00a0ratones\u00a0pudieran\u00a0\nrecibir\u00a0SP\u00a0durante\u00a0un\u00a0per\u00edodo\u00a0m\u00e1s\u00a0largo\u00a0de\u00a0tiempo\u00a0\no\u00a0quiz\u00e1s\u00a0partiendo \u00a0de\u00a0un\u00a0tumor\u00a0HER2+,\u00a0se\u00a0\nobtendr\u00edan \u00a0cambios\u00a0m\u00e1s\u00a0dr\u00e1sticos. \u00a0\u00a0\n\u00a0En\u00a0humanos, \u00a0adem\u00e1s\u00a0de\u00a0la\u00a0SP,\u00a0muchas\u00a0otras\u00a0\ncitoquinas \u00a0pro\u2010inflamatorias \u00a0juegan\u00a0un\u00a0papel\u00a0\nimportante \u00a0\nen\u00a0el\u00a0desarrollo \u00a0del\u00a0c\u00e1ncer,\u00a0y\u00a0muchas\u00a0\nde\u00a0estas\u00a0citoquinas \u00a0o\u00a0p\u00e9ptidos\u00a0se\u00f1alizan \u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0GPCRs.\u00a0Dada\u00a0la\u00a0diversidad \u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0\ndistintos\u00a0GPCRs\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0c\u00e1ncer,\u00a0\nhipotetizamos \u00a0que\u00a0los\u00a0resultados \u00a0iniciales\u00a0\nobtenidos \u00a0con\u00a0SP\u00a0y\u00a0NK\u20101R\u00a0podr\u00edan\u00a0extenderse \u00a0a\u00a0\nuna\u00a0gran\u00a0variedad\u00a0de\u00a0receptores \u00a0de\u00a0quimioquinas \u00a0\no\u00a0de\u00a0neurop\u00e9ptidos, \u00a0lo\u00a0que\u00a0implicar\u00eda \u00a0una\u00a0\nconstante \u00a0se\u00f1alizaci\u00f3n \u00a0intracelular \u00a0mediada\u00a0por\u00a0\nprote\u00ednas \u00a0G\u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0cancerosas. \u00a0Para\u00a0probar\u00a0\nesta\u00a0hip\u00f3tesis, \u00a0inhibimos \u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0\npor\u00a0prote\u00ednas \u00a0G\u00a0sensibles\u00a0a\u00a0toxina\u00a0pert\u00fasica, \u00a0y\u00a0\nobservamos \u00a0una\u00a0disminuci\u00f3n \u00a0dr\u00e1stica\u00a0en\u00a0la\u00a0\nactividad\u00a0de\u00a0HER2,\u00a0reforzando \u00a0la\u00a0idea\u00a0de\u00a0que\u00a0la\u00a0\nactivaci\u00f3n \u00a0basal\u00a0de\u00a0HER2\u00a0est\u00e1\u00a0sujeta,\u00a0en\u00a0parte,\u00a0a\u00a0\nmecanismos \u00a0de\u00a0transactivaci\u00f3n \u00a0dependientes \u00a0de\u00a0\nla\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0prote\u00ednas \u00a0G.\u00a0Estos\u00a0\nresultados, \u00a0tambi\u00e9n\u00a0segu\u00edan\u00a0dando\u00a0soporte\u00a0a\u00a0la\u00a0\nidea\u00a0de\u00a0que\u00a0el\u00a0bloqueo\u00a0dual\u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0de\u00a0\nHER2,\u00a0tanto\u00a0de\u00a0las\u00a0v\u00edas\u00a0de\u00a0activaci\u00f3n \u00a0como\u00a0de\u00a0\ntransactivaci\u00f3n, \u00a0podr\u00eda\u00a0mejorar\u00a0la\u00a0respuesta \u00a0\nterap\u00e9utica \u00a0a\u00a0determinadas \u00a0terapias\u00a0dirigidas\u00a0\ncontra\u00a0HER2.\u00a0Esta\u00a0idea\u00a0podr\u00eda\u00a0extenderse \u00a0a\u00a0\nsituaciones \u00a0de\u00a0quimioresistencia, \u00a0donde\u00a0la\u00a0\naparici\u00f3n \u00a0de\u00a0resistencias \u00a0primarias \u00a0o\u00a0adquiridas \u00a0a\u00a0\nterapias\u00a0anti\u2010HER2\u00a0podr\u00eda\u00a0ser\u00a0debida\u00a0en\u00a0parte\u00a0a\u00a0\u00a0\nmecanismos \u00a0alternativos \u00a0de\u00a0transactivaci\u00f3n \u00a0en\u00a0\naquellos\u00a0tumores\u00a0que\u00a0expresan\u00a0NK\u20101R\u00a0o\u00a0que\u00a0\nse\u00f1alizan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0SP\u00a0u\u00a0otra\u00a0taquiquinina. \u00a0\u00a0\nEn\u00a0\u00faltimo\u00a0lugar\u00a0y\u00a0dando\u00a0soporte\u00a0a\u00a0esta\u00a0\u00faltima\u00a0\nhip\u00f3tesis, \u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0NK\u20101R\u00a0\nsinergizaba \u00a0con\u00a0terapias\u00a0anti\u2010EGFR\u00a0y\u00a0anti\u2010HER\u20102\u00a0ya\u00a0\nque\u00a0ambos\u00a0tratamientos \u00a0juntos\u00a0reduc\u00edan\u00a0\nsignificativamente \u00a0la\u00a0supervivencia \u00a0celular\u00a0\ndemostrando \u00a0una\u00a0vez\u00a0m\u00e1s\u00a0la\u00a0dependencia \u00a0\noncog\u00e9nica \u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0por\u00a0ambas\u00a0v\u00edas\u00a0de\u00a0\nse\u00f1alizaci\u00f3n. \u00a0\u00a0\u00a0\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n173\u00a0\n\u00a0LA\u00a0SP\u00a0Y\u00a0NK\u20101R\u00a0EN\u00a0PACIENTES \u00a0CON\u00a0CM\u00a0\n\u00a0\nEl\u00a0CM\u00a0es\u00a0una\u00a0enfermedad \u00a0heterog\u00e9nea, \u00a0integrada \u00a0\npor\u00a0varios\u00a0subtipos\u00a0diferentes, \u00a0con\u00a0distintas\u00a0\ncaracter\u00edsticas \u00a0moleculares \u00a0y\u00a0de\u00a0diferente \u00a0\npron\u00f3stico. \u00a0La\u00a0dependencia \u00a0por\u00a0se\u00f1alizar\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0distintas\u00a0v\u00edas\u00a0de\u00a0supervivencia \u00a0desarrollada \u00a0por\u00a0\nparte\u00a0de\u00a0los\u00a0tumores\u00a0ha\u00a0permitido \u00a0el\u00a0dise\u00f1o\u00a0de\u00a0\nterapias\u00a0espec\u00edficas \u00a0para\u00a0algunos\u00a0de\u00a0estos\u00a0\nsubtipos\u00a0de\u00a0CM.\u00a0Por\u00a0ejemplo,\u00a0el\u00a0descubrimiento \u00a0\ndel\u00a0receptor\u00a0HER2\u00a0y\u00a0el\u00a0dise\u00f1o\u00a0de\u00a0terapias\u00a0\nespec\u00edficas \u00a0dirigidas\u00a0para\u00a0inhibir\u00a0su\u00a0actividad\u00a0han\u00a0\nrevolucionado \u00a0la\u00a0manera\u00a0de\u00a0c\u00f3mo\u00a0tratar\u00a0a\u00a0los\u00a0\ntumores\u00a0HER2+.\u00a0Sin\u00a0embargo, \u00a0a\u00a0pesar\u00a0de\u00a0los\u00a0\nbeneficios \u00a0cl\u00ednicos\u00a0obtenidos \u00a0mediante \u00a0el\u00a0uso\u00a0de\u00a0\ninhibidores \u00a0de\u00a0HER2,\u00a0todav\u00eda\u00a0es\u00a0dif\u00edcil\u00a0lograr\u00a0una\u00a0\nrespuesta \u00a0completa \u00a0en\u00a0estos\u00a0pacientes, \u00a0que\u00a0\npresentan \u00a0mecanismos \u00a0intr\u00ednsecos \u00a0y\u00a0adquiridos \u00a0de\u00a0\nresistencia. \u00a0\nLa\u00a0modulaci\u00f3n \u00a0de\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0los\u00a0RTK\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0NK\u20101R\u00a0refleja\u00a0una\u00a0nueva\u00a0cooperaci\u00f3n \u00a0\noncog\u00e9nica \u00a0entre\u00a0estos\u00a0dos\u00a0tipos\u00a0de\u00a0receptores \u00a0\ndurante\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0tumor.\u00a0Tal\u00a0y\u00a0como\u00a0se\u00a0\nobserv\u00f3\u00a0en\u00a0los\u00a0320\u00a0tumores\u00a0primarios \u00a0de\u00a0mama\u00a0\nhumanos, \u00a0NK\u20101R\u00a0y\u00a0SP\u00a0se\u00a0correlacionaban \u00a0\npositivamente \u00a0con\u00a0aquellos\u00a0tumores\u00a0primarios \u00a0con\u00a0\nfenotipo\u00a0HER2+.\u00a0Adem\u00e1s,\u00a0la\u00a0SP\u00a0era\u00a0capaz\u00a0de\u00a0\nactivar\u00a0HER2\u00a0(independientemente \u00a0de\u00a0sus\u00a0niveles\u00a0\nde\u00a0expresi\u00f3n) \u00a0en\u00a0tumores\u00a0primarios \u00a0de\u00a0mama\u00a0y\u00a0en\u00a0\nl\u00edneas\u00a0celulares\u00a0de\u00a0CM.\u00a0Este\u00a0resultado \u00a0tambi\u00e9n\u00a0es\u00a0\nimportante \u00a0ya\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0con\u00a0anterioridad \u00a0\nque\u00a0antagonistas \u00a0del\u00a0receptor\u00a0NK\u20101\u00a0pueden\u00a0\ntambi\u00e9n\u00a0ser\u00a0efectivos\u00a0en\u00a0c\u00e9lulas\u00a0tumorales \u00a0HER2\u2010\n/ER\u2010339.\u00a0As\u00ed,\u00a0inhibidores \u00a0qu\u00edmicos\u00a0de\u00a0NK\u20101R\u00a0y\u00a0NK\u2010\n2R,\u00a0como\u00a0MEN\u00a011467\u00a0y\u00a0MEN\u00a011420,\u00a0\nrespectivamente, \u00a0inhib\u00edan\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0tanto\u00a0in\u00a0vitro\u00a0como\u00a0in\u00a0vivo,\u00a0\nbloqueando \u00a0el\u00a0efecto\u00a0estimulador \u00a0de\u00a0la\u00a0SP\u00a0y\u00a0\nNKA339.\u00a0Estos\u00a0resultados, \u00a0junto\u00a0con\u00a0los\u00a0\ndemostrados \u00a0en\u00a0la\u00a0presente\u00a0tesis,\u00a0sugieren\u00a0de\u00a0\nnuevo\u00a0que\u00a0tanto\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0SP\u00a0como\u00a0el\u00a0uso\u00a0\nantagonistas \u00a0de\u00a0los\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0\npodr\u00edan\u00a0llegar\u00a0a\u00a0ser\u00a0una\u00a0nueva\u00a0terapia\u00a0incluso\u00a0para\u00a0\ntumores\u00a0con\u00a0fenotipo\u00a0HER2\u2010/ER\u2010.\u00a0Adem\u00e1s\u00a0de\u00a0la\u00a0correlaci\u00f3n \u00a0con\u00a0pacientes \u00a0HER2+,\u00a0se\u00a0\nidentific\u00f3 \u00a0a\u00a0NK\u20101R\u00a0y\u00a0a\u00a0SP\u00a0como\u00a0dos\u00a0nuevos\u00a0\nmarcadores \u00a0asociados \u00a0con\u00a0otras\u00a0caracter\u00edsticas \u00a0\ncl\u00ednicopatol\u00f3gicas \u00a0relacionadas \u00a0con\u00a0un\u00a0mal\u00a0\npron\u00f3stico. \u00a0Por\u00a0ejemplo,\u00a0una\u00a0elevada\u00a0expresi\u00f3n \u00a0\nde\u00a0NK\u20101R\u00a0se\u00a0correlacion\u00f3 \u00a0con\u00a0la\u00a0sobreexpresi\u00f3n \u00a0de\u00a0\np53,\u00a0una\u00a0expresi\u00f3n \u00a0negativa\u00a0de\u00a0RE,\u00a0positividad \u00a0del\u00a0\nfactor\u00a0de\u00a0proliferaci\u00f3n \u00a0Ki67\u00a0y\u00a0un\u00a0alto\u00a0grado\u00a0\nhistol\u00f3gico. \u00a0Por\u00a0otra\u00a0parte,\u00a0la\u00a0elevada\u00a0expresi\u00f3n \u00a0\nde\u00a0SP,\u00a0tambi\u00e9n\u00a0se\u00a0correlacionaba \u00a0con\u00a0un\u00a0alto\u00a0\n\u00edndice\u00a0de\u00a0Ki67\u00a0de\u00a0acuerdo\u00a0con\u00a0el\u00a0papel\u00a0de\u00a0la\u00a0SP\u00a0\ncomo\u00a0mit\u00f3geno \u00a0universal\u00a0en\u00a0c\u00e9lulas\u00a0cancerosas. \u00a0\nAdicionalmente, \u00a0la\u00a0relevancia \u00a0de\u00a0la\u00a0SP\u00a0en\u00a0la\u00a0\nse\u00f1alizaci\u00f3n \u00a0del\u00a0CM\u00a0podr\u00eda\u00a0depender \u00a0del\u00a0\ncontexto. \u00a0Por\u00a0ejemplo,\u00a0la\u00a0co\u2010expresi\u00f3n \u00a0de\u00a0EGFR\u00a0\ny/o\u00a0HER2\u00a0en\u00a0la\u00a0misma\u00a0c\u00e9lula\u00a0cancerosa \u00a0y\u00a0dentro\u00a0\ndel\u00a0mismo\u00a0microdominio \u00a0de\u00a0membrana \u00a0podr\u00eda\u00a0\nproporcionar \u00a0a\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0mediada\u00a0por\u00a0SP,\u00a0\nprote\u00ednas \u00a0adaptadoras \u00a0adicionales \u00a0involucradas \u00a0en\u00a0\nla\u00a0transducci\u00f3n \u00a0de\u00a0se\u00f1ales,\u00a0diversificando \u00a0as\u00ed\u00a0sus\u00a0\nefectos.\u00a0Adem\u00e1s,\u00a0la\u00a0especificidad \u00a0de\u00a0la\u00a0\ntransducci\u00f3n \u00a0de\u00a0se\u00f1ales\u00a0de\u00a0NK\u20101R\u00a0depende\u00a0de\u00a0la\u00a0\nformaci\u00f3n \u00a0de\u00a0complejos \u00a0proteicos \u00a0de\u00a0andamiaje \u00a0\ndespu\u00e9s\u00a0de\u00a0su\u00a0activaci\u00f3n \u00a0y\u00a0posterior\u00a0\ninternalizaci\u00f3n224.\u00a0Asimismo, \u00a0como\u00a0se\u00a0muestra\u00a0en\u00a0\neste\u00a0trabajo,\u00a0no\u00a0todos\u00a0los\u00a0receptores \u00a0de\u00a0la\u00a0SP\u00a0\nest\u00e1n\u00a0relacionados \u00a0con\u00a0los\u00a0mismos\u00a0mecanismos \u00a0de\u00a0\npromoci\u00f3n \u00a0tumoral.\u00a0Por\u00a0ejemplo\u00a0el\u00a0receptor\u00a0NK\u20102\u00a0\nmostr\u00f3\u00a0una\u00a0correlaci\u00f3n \u00a0con\u00a0tumores\u00a0RE\u00a0y\u00a0RP\u00a0\npositivos, \u00a0un\u00a0bajo\u00a0grado\u00a0histol\u00f3gico, \u00a0\ninfraexpresi\u00f3n \u00a0de\u00a0p53\u00a0y\u00a0un\u00a0bajo\u00a0nivel\u00a0de\u00a0Ki67\u00a0as\u00ed\u00a0\ncomo\u00a0una\u00a0correlaci\u00f3n \u00a0positiva\u00a0con\u00a0el\u00a0fenotipo\u00a0\nLuminal\u00a0A\u00a0(tumores\u00a0m\u00e1s\u00a0diferenciados \u00a0y\u00a0de\u00a0mejor\u00a0\npron\u00f3stico). \u00a0\u00a0\nPor\u00a0tanto,\u00a0esta\u00a0asociaci\u00f3n \u00a0positiva\u00a0entre\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0NK\u20101R\u00a0y\u00a0SP\u00a0y\u00a0los\u00a0tumores\u00a0con\u00a0\nfenotipo\u00a0HER2+,\u00a0as\u00ed\u00a0como\u00a0caracter\u00edsticas \u00a0\nasociadas \u00a0a\u00a0un\u00a0peor\u00a0pron\u00f3stico, \u00a0y\u00a0la\u00a0dependencia \u00a0\nongog\u00e9nica \u00a0que\u00a0muestran \u00a0las\u00a0l\u00edneas\u00a0de\u00a0CM\u00a0por\u00a0la\u00a0\nmodulaci\u00f3n \u00a0de\u00a0HER2\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0\nnos\u00a0da\u00a0la\u00a0oportunidad \u00a0de\u00a0plantear\u00a0y\u00a0desarrollar \u00a0\nnuevas\u00a0estrategias \u00a0experimentales \u00a0y\u00a0terap\u00e9uticas \u00a0\nque\u00a0puedan\u00a0frenar\u00a0el\u00a0CM.\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n174\u00a0\n\u00a0EFECTOS\u00a0CR\u00d3NICOS \u00a0DE\u00a0LA\u00a0SP\u00a0\n\u00a0\nAdem\u00e1s\u00a0de\u00a0los\u00a0efectos\u00a0agudos\u00a0y\u00a0a\u00a0corto\u00a0plazo\u00a0de\u00a0la\u00a0\nSP,\u00a0tambi\u00e9n\u00a0se\u00a0investigaron \u00a0los\u00a0efectos\u00a0cr\u00f3nicos\u00a0\nde\u00a0esta\u00a0citoquina \u00a0sobre\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0\nEGFR\u00a0en\u00a0l\u00edneas\u00a0de\u00a0CM.\u00a0Fue\u00a0interesante \u00a0observar\u00a0\nque\u00a0la\u00a0exposici\u00f3n \u00a0a\u00a0SP\u00a0durante\u00a0m\u00e1s\u00a0de\u00a05\u00a0meses\u00a0\ncausaba\u00a0cambios\u00a0morfol\u00f3gicos \u00a0y\u00a0biol\u00f3gicos \u00a0en\u00a0\nc\u00e9lulas\u00a0HER2\u00a0o\u00a0EGFR\u00a0positivas. \u00a0De\u00a0hecho,\u00a0una\u00a0\nexposici\u00f3n \u00a0prolongada \u00a0a\u00a0esta\u00a0citoquina \u00a0provoc\u00f3\u00a0\ncambios\u00a0dr\u00e1sticos\u00a0en\u00a0la\u00a0\u00a0respuesta \u00a0a\u00a0terapias\u00a0anti\u2010\nHER2\u00a0y\u00a0anti\u00a0EGFR,\u00a0como\u00a0el\u00a0AG825,\u00a0Lapatinip\u00a0o\u00a0\nAG1478,\u00a0sugiriendo \u00a0que\u00a0una\u00a0situaci\u00f3n\u00a0de\u00a0\ninflamaci\u00f3n \u00a0cr\u00f3nica\u00a0con\u00a0presencia \u00a0de\u00a0elevados\u00a0\nniveles\u00a0de\u00a0SP\u00a0podr\u00eda\u00a0contribuir \u00a0a\u00a0la\u00a0generaci\u00f3n \u00a0de\u00a0\ntumores\u00a0m\u00e1s\u00a0resistentes \u00a0a\u00a0estas\u00a0terapias.\u00a0Cuando\u00a0\nanalizamos \u00a0el\u00a0fenotipo\u00a0CD24/CD44 \u00a0y\u00a0ciertos\u00a0\nmarcadores \u00a0de\u00a0EMT\u00a0que\u00a0se\u00a0han\u00a0relacionado \u00a0con\u00a0\nadquisici\u00f3n \u00a0de\u00a0quimioresistencia \u00a0se\u00a0observ\u00f3\u00a0que\u00a0el\u00a0\ntratamiento \u00a0continuo\u00a0con\u00a0SP\u00a0contribu\u00eda \u00a0a\u00a0la\u00a0\nadquisici\u00f3n \u00a0de\u00a0caracter\u00edsticas \u00a0fenot\u00edpicas \u00a0propias\u00a0\nde\u00a0un\u00a0fenotipo\u00a0luminal/epitelial \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0la\u00a0\nl\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0y\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0\nMDA\u2010MB\u2010453\u00a0contribu\u00eda \u00a0a\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\nmarcadores \u00a0propios\u00a0de\u00a0un\u00a0fenotipo\u00a0m\u00e1s\u00a0\nmesenquimal \u00a0como\u00a0Snail\u00a0a\u00a0la\u00a0vez\u00a0que\u00a0perd\u00edan\u00a0\notros\u00a0propios\u00a0de\u00a0un\u00a0fenotipo\u00a0epitelial\u00a0como\u00a0la\u00a0E\u2010\ncadherina \u00a0o\u00a0\u03b1\u2010catenina.\u00a0Independientemente \u00a0de\u00a0\nestos\u00a0cambios\u00a0en\u00a0el\u00a0fenotipo,\u00a0se\u00a0observ\u00f3\u00a0en\u00a0\nambos\u00a0casos\u00a0una\u00a0mayor\u00a0capacidad \u00a0de\u00a0formar\u00a0\nclones,\u00a0indicativo \u00a0de\u00a0una\u00a0mayor\u00a0agresividad \u00a0\nadquirida \u00a0por\u00a0sobreexposici\u00f3n \u00a0a\u00a0la\u00a0SP.\u00a0\nEst\u00e1\u00a0demostrado \u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0varios\u00a0\nreceptores \u00a0oncog\u00e9nicos, \u00a0incluyendo \u00a0HER2,\u00a0puede\u00a0\ncontribuir \u00a0a\u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0v\u00edas\u00a0inflamatorias \u00a0\nintr\u00ednsecas \u00a0en\u00a0c\u00e9lulas\u00a0cancerosas129,523,\u00a0y\u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0TAC1\u00a0y\u00a0TACR1\u00a0puede\u00a0estar\u00a0modulada \u00a0\na\u00a0trav\u00e9s\u00a0de\u00a0NF\u2010\u03baB\u00a0y\u00a0se\u00f1ales\u00a0pro\u2010\ninflamatorias292,294,319,322,497.\u00a0Por\u00a0lo\u00a0tanto,\u00a0otro\u00a0de\u00a0\nlos\u00a0objetivos\u00a0de\u00a0esta\u00a0tesis\u00a0fue\u00a0comprobar \u00a0si\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0SP\u00a0pod\u00eda\u00a0adem\u00e1s\u00a0\naumentar \u00a0la\u00a0activaci\u00f3n \u00a0de\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\ninflamatorias \u00a0creando,\u00a0de\u00a0este\u00a0modo,\u00a0un\u00a0bucle\u00a0\npositivo.\u00a0De\u00a0hecho,\u00a0observamos \u00a0que\u00a0la\u00a0exposici\u00f3n \u00a0cr\u00f3nica\u00a0de\u00a0SP\u00a0en\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM\u00a0caus\u00f3\u00a0\nun\u00a0aumento\u00a0en\u00a0la\u00a0actividad\u00a0de\u00a0HER2\u00a0y\u00a0EGFR\u00a0y\u00a0un\u00a0\naumento\u00a0en\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0a\u00a0trav\u00e9s\u00a0\nprobablemente \u00a0de\u00a0la\u00a0v\u00eda\u00a0intr\u00ednseca \u00a0inflamatoria \u00a0\nmediada\u00a0por\u00a0NF\u2010\u03baB,\u00a0Src\u00a0y\u00a0MMPs.\u00a0De\u00a0acuerdo\u00a0con\u00a0\nestos\u00a0resultados \u00a0los\u00a0niveles\u00a0de\u00a0citoquinas \u00a0pro\u2010\ninlfamatorias \u00a0reguladas \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0NK\u20101R\u00a0y/o\u00a0NF\u2010\n\u03baB\u00a0como\u00a0la\u00a0IL\u20106\u00a0se\u00a0hab\u00edan\u00a0incrementado \u00a0hasta\u00a05\u00a0\nveces\u00a0en\u00a0el\u00a0medio\u00a0extracelular \u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010\nMB\u2010468\u00a0tratada\u00a0continuamente \u00a0con\u00a0SP\u00a0y\u00a0no\u00a0hubo\u00a0\ncambios\u00a0en\u00a0la\u00a0l\u00ednea\u00a0de\u00a0menor\u00a0expresi\u00f3n \u00a0de\u00a0NF\u2010kB,\u00a0\nMDA\u2010MB\u2010453.\u00a0Aunque\u00a0ser\u00edan\u00a0necesarias \u00a0m\u00e1s\u00a0\nevidencias \u00a0experimentales, \u00a0estos\u00a0resultados \u00a0\nsugieren\u00a0que\u00a0bajo\u00a0la\u00a0presencia \u00a0de\u00a0SP,\u00a0la\u00a0activaci\u00f3n \u00a0\nde\u00a0HER2\u00a0iniciar\u00eda\u00a0una\u00a0cascada\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0\ninflamatoria \u00a0que\u00a0podr\u00eda\u00a0estimular \u00a0finalmente \u00a0la\u00a0\nexpresi\u00f3n \u00a0de\u00a0TAC1\u00a0y\u00a0TACR1 .\u00a0\nPara\u00a0identificar \u00a0de\u00a0forma\u00a0global\u00a0cambios\u00a0en\u00a0el\u00a0\npatr\u00f3n\u00a0molecular \u00a0de\u00a0estas\u00a0l\u00edneas\u00a0expuestas \u00a0a\u00a0SP,\u00a0\nse\u00a0realizaron \u00a0estudios\u00a0de\u00a0expresi\u00f3n \u00a0g\u00e9nica\u00a0con\u00a0\nmicroarrays .\u00a0Se\u00a0observ\u00f3\u00a0que\u00a0exist\u00edan\u00a0genes\u00a0\ndiferencialmente \u00a0expresados \u00a0en\u00a0las\u00a0l\u00edneas\u00a0tratadas\u00a0\ncontinuamente \u00a0con\u00a0SP\u00a0respecto\u00a0a\u00a0las\u00a0l\u00edneas\u00a0\ncontrol,\u00a0aunque\u00a0se\u00a0identificaron \u00a0pocos\u00a0genes\u00a0\ncom\u00fanmente \u00a0desregulados \u00a0en\u00a0las\u00a02\u00a0l\u00edneas\u00a0\nprobablemente \u00a0debido\u00a0a\u00a0la\u00a0distinta\u00a0naturaleza \u00a0\n(luminal/basal) \u00a0de\u00a0ambas.\u00a0En\u00a0total\u00a0hab\u00eda\u00a011\u00a0genes\u00a0\ncomunes\u00a0desregulados \u00a0bajo\u00a0el\u00a0tratamiento \u00a0con\u00a0SP.\u00a0\nEntre\u00a0ellos,\u00a0identificamos \u00a0una\u00a0sobreexpresion \u00a0de\u00a0\ngenes\u00a0involucrados \u00a0en\u00a0la\u00a0met\u00e1stasis \u00a0y\u00a0agresividad \u00a0\ntumoral\u00a0de\u00a0distintos\u00a0tipos\u00a0de\u00a0c\u00e1nceres, \u00a0como\u00a0el\u00a0\nfactor\u00a0de\u00a0transcripci\u00f3n \u00a0ATF3500\u00a0o\u00a0el\u00a0gen\u00a0GDF15\u00a0\n(tambi\u00e9n\u00a0conocido\u00a0como\u00a0MIC\u20101)\u00a0asociado\u00a0\ncl\u00ednicamente \u00a0a\u00a0la\u00a0progresi\u00f3n \u00a0del\u00a0CM\u00a0y\u00a0al\u00a0desarrollo \u00a0\nde\u00a0mecanismos \u00a0de\u00a0resistencia \u00a0a\u00a0quimioterapia. \u00a0\nUno\u00a0de\u00a0los\u00a0mecanismos \u00a0descritos\u00a0por\u00a0los\u00a0cuales\u00a0el\u00a0\nfactor\u00a0GDF15\u00a0reduce\u00a0la\u00a0sensibilidad \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nde\u00a0CM\u00a0a\u00a0terapias\u00a0anti\u2010HER2\u00a0es\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0HER2\u00a0mediada\u00a0por\u00a0la\u00a0prote\u00edna\u00a0\nSrc505,506.\u00a0Se\u00a0ha\u00a0propuesto \u00a0que\u00a0debido\u00a0a\u00a0la\u00a0similitud\u00a0\nde\u00a0este\u00a0factor\u00a0con\u00a0TGF\u2010\uf062,\u00a0GDF15\u00a0podr\u00eda\u00a0se\u00f1alizar\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0su\u00a0receptor, \u00a0activar\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0\nSrc\u00a0y\u00a0esta\u00a0a\u00a0su\u00a0vez\u00a0activar\u00eda\u00a0HER2,\u00a0magnificando \u00a0\nas\u00ed\u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0p\u201042\u201044\u00a0MAPK\u00a0\ny\u00a0Akt.\u00a0Por\u00a0tanto,\u00a0podr\u00eda\u00a0ser\u00a0que\u00a0el\u00a0sistema\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n175\u00a0\n\u00a0taquiquin\u00e9rgico \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0secreci\u00f3n \u00a0de\u00a0GDF15\u00a0\nestuviera \u00a0favoreciendo \u00a0a\u00fan\u00a0m\u00e1s\u00a0la\u00a0transactivaci\u00f3n \u00a0\nde\u00a0v\u00edas\u00a0caracter\u00edsticas \u00a0de\u00a0receptores \u00a0de\u00a0la\u00a0familia\u00a0\nErbB.\u00a0\nAnalizadas \u00a0de\u00a0forma\u00a0individual, \u00a0en\u00a0cada\u00a0l\u00ednea\u00a0\ncelular\u00a0tratada\u00a0continuamente \u00a0con\u00a0SP,\u00a0se\u00a0\nobservaron \u00a0varios\u00a0genes\u00a0diferencialmente \u00a0\nexpresados \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0su\u00a0l\u00ednea\u00a0parental.\u00a0\nEntre\u00a0ellos\u00a0se\u00a0encontraban \u00a0por\u00a0ejemplo\u00a0ADAMST1 \u00a0\ny\u00a0IGBP5\u00a0en\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010MB\u2010468\u00a0SP.\u00a0ADAMST1 \u00a0es\u00a0\nuna\u00a0metalloproteasa \u00a0involucrada \u00a0en\u00a0procesos\u00a0de\u00a0\nmet\u00e1stasis \u00a0e\u00a0invasi\u00f3n\u00a0de\u00a0varios\u00a0tipos\u00a0de\u00a0tumores\u00a0\nentre\u00a0ellos\u00a0el\u00a0CM524,525.\u00a0Esta\u00a0metaloproteasa \u00a0est\u00e1\u00a0\nimplicada \u00a0en\u00a0procesos\u00a0de\u00a0transactivaci\u00f3n \u00a0ya\u00a0que\u00a0\ncliva\u00a0ligandos\u00a0anclados\u00a0a\u00a0la\u00a0membrana \u00a0capaces\u00a0de\u00a0\nunirse\u00a0a\u00a0receptores \u00a0tirosina\u00a0quinasa\u00a0como\u00a0EGFR,\u00a0\nadem\u00e1s\u00a0de\u00a0remodelar \u00a0la\u00a0matriz\u00a0extracelular \u00a0\npermitiendo \u00a0as\u00ed\u00a0la\u00a0migraci\u00f3n \u00a0o\u00a0implantaci\u00f3n \u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0tumorales \u00a0en\u00a0m\u00e9dula\u00a0\u00f3sea526.\u00a0En\u00a0cambio,\u00a0\u00a0\nIGFBP5\u00a0(del\u00a0ingl\u00e9s\u00a0insulin\u2010like\u00a0growth\u00a0factor\u00a0\nbinding\u00a0protein\u00a05),\u00a0es\u00a0una\u00a0prote\u00edna\u00a0que\u00a0puede\u00a0\njugar\u00a0un\u00a0papel\u00a0dual,\u00a0y\u00a0su\u00a0papel\u00a0en\u00a0CM\u00a0parece\u00a0ser\u00a0\nbastante\u00a0complejo. \u00a0IGFBP5\u00a0est\u00e1\u00a0involucrado \u00a0en\u00a0la\u00a0\nregulaci\u00f3n \u00a0del\u00a0factor\u00a0inductor\u00a0del\u00a0receptor\u00a0de\u00a0la\u00a0\ninsulina\u00a0(IGF,\u00a0del\u00a0ingl\u00e9s\u00a0insulin\u00a0growth\u00a0factor ),\u00a0\u00a0\nligando\u00a0de\u00a0IGFR.\u00a0Este\u00a0receptor\u00a0est\u00e1\u00a0involucrado \u00a0en\u00a0\nv\u00edas\u00a0de\u00a0proliferaci\u00f3n \u00a0y\u00a0supervivencia \u00a0tumoral.\u00a0La\u00a0\nuni\u00f3n\u00a0de\u00a0IGFBP5\u00a0a\u00a0IGF,\u00a0provoca\u00a0que\u00a0este\u00a0factor\u00a0no\u00a0\npueda\u00a0unirse\u00a0a\u00a0su\u00a0receptor\u00a0y\u00a0se\u00f1alizar\u00a0\ncorrectamente. \u00a0Esta\u00a0prote\u00edna\u00a0se\u00a0encuentra \u00a0\nexpresada \u00a0en\u00a0c\u00e1ncer\u00a0de\u00a0mama527\u00a0y\u00a0se\u00a0ha\u00a0\nrelacionado \u00a0con\u00a0un\u00a0peor\u00a0pron\u00f3stico \u00a0de\u00a0la\u00a0\nenfermedad528.\u00a0Incluso\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0adem\u00e1s\u00a0\nde\u00a0su\u00a0papel\u00a0uni\u00e9ndose \u00a0a\u00a0IGF,\u00a0podr\u00eda\u00a0actuar\u00a0por\u00a0\nuna\u00a0v\u00eda\u00a0independiente \u00a0de\u00a0IGFR\u00a0y\u00a0mediante \u00a0otros\u00a0\nreceptores \u00a0internalizarse \u00a0y\u00a0se\u00f1alizar\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\notras\u00a0prote\u00ednas \u00a0relacionadas \u00a0con\u00a0met\u00e1stasis529.\u00a0\nEsta\u00a0prote\u00edna,\u00a0por\u00a0otro\u00a0lado,\u00a0tambi\u00e9n\u00a0puede\u00a0\ninhibir\u00a0la\u00a0proliferaci\u00f3n \u00a0celular\u00a0y\u00a0activar\u00a0la\u00a0\napoptosis530.\u00a0Existen\u00a0otros\u00a0estudios\u00a0que\u00a0\ncorrelacionan \u00a0negativamente \u00a0los\u00a0niveles\u00a0de\u00a0\nIGFBP5\u00a0con\u00a0la\u00a0sobreexpresi\u00f3n \u00a0de\u00a0HER2\u00a0en\u00a0\npacientes \u00a0con\u00a0CM531.\u00a0Esto\u00a0podr\u00eda\u00a0explicar\u00a0el\u00a0hecho\u00a0\nque\u00a0al\u00a0contrario \u00a0que\u00a0las\u00a0MDA\u2010MB\u2010468,\u00a0las\u00a0MDA\u2010\nMB\u2010453\u00a0tengan\u00a0disminuida \u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0esta\u00a0prote\u00edna,\u00a0quiz\u00e1s\u00a0como\u00a0respuesta \u00a0para\u00a0alterar\u00a0v\u00edas\u00a0\nanti\u2010apopt\u00f3ticas. \u00a0Adem\u00e1s\u00a0de\u00a0este\u00a0gen,\u00a0la\u00a0l\u00ednea\u00a0\ncelular\u00a0 MDA\u2010MB\u2010453\u00a0 presentaba \u00a0 una\u00a0\nsobreexpresi\u00f3n \u00a0del\u00a0gen\u00a0SLC7A11 .\u00a0SLC7A11\u00a0es\u00a0una\u00a0\nsubunidad \u00a0del\u00a0sistema\u00a0de\u00a0transporte \u00a0de\u00a0\namino\u00e1cidos \u00a0XC\u2010\u00a0que\u00a0media\u00a0la\u00a0entrada\u00a0de\u00a0cistina\u00a0\ndentro\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0a\u00a0cambio\u00a0de\u00a0la\u00a0salida\u00a0de\u00a0\nglutamato. \u00a0Su\u00a0expresi\u00f3n \u00a0es\u00a0m\u00e1s\u00a0elevada\u00a0en\u00a0c\u00e9lulas\u00a0\ny\u00a0pacientes \u00a0de\u00a0CM\u00a0que\u00a0en\u00a0tejido\u00a0no\u00a0tumoral\u00a0y\u00a0su\u00a0\nsobreexpresi\u00f3n \u00a0est\u00e1\u00a0implicada \u00a0en\u00a0v\u00edas\u00a0anti\u2010\napopt\u00f3ticas532.\u00a0\nA\u00a0trav\u00e9s\u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0relaciones \u00a0funcionales \u00a0\nasociadas \u00a0a\u00a0los\u00a0genes\u00a0diferencialmente \u00a0\nexpresados, \u00a0generadas \u00a0por\u00a0el\u00a0IPA,\u00a0se\u00a0obtuvieron \u00a0\nvarias\u00a0redes\u00a0de\u00a0se\u00f1alizaci\u00f3n \u00a0distintas.\u00a0La\u00a0red\u00a01\u00a0de\u00a0\nla\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010MB\u2010468\u00a0se\u00a0centr\u00f3,\u00a0entre\u00a0\notros\u00a0genes,\u00a0en\u00a0la\u00a0IL\u20106,\u00a0FOXO1\u00a0y\u00a0GDF15\u00a0todos\u00a0ellos\u00a0\nrelacionados \u00a0con\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0otros\u00a0genes\u00a0o\u00a0\nfactores\u00a0de\u00a0transcripci\u00f3n \u00a0que\u00a0interact\u00faan \u00a0\ndirectamente \u00a0con\u00a0un\u00a0importante \u00a0complejo \u00a0\nrelacionado \u00a0con\u00a0la\u00a0supervivencia \u00a0y\u00a0proliferaci\u00f3n \u00a0\ncelular\u00a0como\u00a0NF\u2010\u03baB.\u00a0En\u00a0la\u00a0red\u00a01\u00a0de\u00a0la\u00a0l\u00ednea\u00a0MDA\u2010\nMB\u2010453\u00a0una\u00a0lista\u00a0de\u00a0genes\u00a0como\u00a0CCNE2 ,\u00a0CCNE1 ,\u00a0\nMCM7 ,\u00a0BID\u00a0(todos\u00a0ellos\u00a0involucrados \u00a0en\u00a0la\u00a0\nregulaci\u00f3n \u00a0de\u00a0ciclo\u00a0celular,\u00a0divisi\u00f3n\u00a0celular\u00a0y\u00a0\nreplicaci\u00f3n \u00a0del\u00a0DNA\u00a0menos\u00a0BID,\u00a0\u00a0responsable \u00a0\u00a0de\u00a0\nla\u00a0regulaci\u00f3n \u00a0de\u00a0la\u00a0apoptosis) \u00a0converg\u00edan \u00a0e\u00a0\ninteractuaban \u00a0directamente \u00a0con\u00a0el\u00a0gen\u00a0E2F1 ,\u00a0gen\u00a0\nque\u00a0se\u00a0une\u00a0a\u00a0la\u00a0regi\u00f3n\u00a0promotora \u00a0de\u00a0un\u00a0n\u00famero\u00a0\nelevado\u00a0de\u00a0genes\u00a0cuyos\u00a0productos \u00a0est\u00e1n\u00a0\ninvolucrados \u00a0en\u00a0la\u00a0regulaci\u00f3n \u00a0del\u00a0ciclo\u00a0celular,\u00a0\napoptosis, \u00a0transcripci\u00f3n \u00a0o\u00a0en\u00a0la\u00a0replicaci\u00f3n \u00a0del\u00a0\nADN.\u00a0E2F1\u00a0puede\u00a0mediar\u00a0tambi\u00e9n\u00a0tanto\u00a0la\u00a0\nproliferaci\u00f3n \u00a0celular\u00a0como\u00a0la\u00a0apoptosis \u00a0\ndependiente \u00a0de\u00a0p53533,534.\u00a0Por\u00a0tanto\u00a0parece\u00a0ser\u00a0\nque\u00a0el\u00a0software\u00a0IPA\u00a0en\u00a0este\u00a0caso\u00a0relacionaba \u00a0un\u00a0\nn\u00famero\u00a0considerable \u00a0de\u00a0genes,\u00a0todos\u00a0ellos,\u00a0\nresponsables \u00a0de\u00a0regular\u00a0la\u00a0maquinaria \u00a0de\u00a0divisi\u00f3n\u00a0\ny\u00a0supervivencia \u00a0celular.\u00a0\n\u00a0Y\u00a0en\u00a0\u00faltimo\u00a0lugar,\u00a0aunque\u00a0son\u00a0todav\u00eda\u00a0resultados \u00a0\npreliminares, \u00a0se\u00a0quiso\u00a0estudiar\u00a0si\u00a0exist\u00eda\u00a0alguna\u00a0\nrelaci\u00f3n\u00a0entre\u00a0la\u00a0exposici\u00f3n \u00a0a\u00a0largo\n\u00a0plazo\u00a0de\u00a0la\u00a0SP\u00a0\ncon\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0una\u00a0hormono \u2010independencia \u00a0\npor\u00a0parte\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0RE+/HER2 \u2010.\u00a0La\u00a0l\u00ednea\u00a0DISCUSI\u00d3N \u00a0\u00a0\n\u00a0\n176\u00a0\n\u00a0celular\u00a0MCF7\u00a0SP\u00a0mostr\u00f3\u00a0una\u00a0mayor\u00a0capacidad \u00a0de\u00a0\ngenerar\u00a0clones\u00a0que\u00a0su\u00a0l\u00ednea\u00a0parental.\u00a0Y\u00a0a\u00fan\u00a0m\u00e1s\u00a0\nimportante, \u00a0esta\u00a0l\u00ednea\u00a0fue\u00a0capaz\u00a0de\u00a0generar\u00a0clones\u00a0\nen\u00a0ausencia\u00a0de\u00a0hormonas \u00a0a\u00a0diferencia \u00a0de\u00a0la\u00a0l\u00ednea\u00a0\nparental\u00a0MCF7\u00a0que\u00a0en\u00a0ausencia\u00a0de\u00a0hormonas \u00a0era\u00a0\nincapaz\u00a0de\u00a0sobrevivir. \u00a0Este\u00a0fue\u00a0un\u00a0descubrimiento \u00a0\nimportante \u00a0que\u00a0nos\u00a0hizo\u00a0plantear\u00a0varias\u00a0hip\u00f3tesis: \u00a0\n(1)\u00a0la\u00a0exposici\u00f3n \u00a0a\u00a0largo\u00a0plazo\u00a0de\u00a0la\u00a0citoquina \u00a0pro\u2010\ninflamatoria \u00a0SP\u00a0parec\u00eda\u00a0seleccionar \u00a0a\u00a0una\u00a0peque\u00f1a\u00a0\npoblaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0dentro\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0total,\u00a0\ncapaces\u00a0de\u00a0crecer\u00a0en\u00a0ausencia\u00a0de\u00a0hormonas, \u00a0y\u00a0(2)\u00a0\nla\u00a0exposici\u00f3n \u00a0cont\u00ednua\u00a0a\u00a0SP\u00a0generaba \u00a0cambios\u00a0\nfenot\u00edpicos \u00a0o\u00a0genot\u00edpicos \u00a0en\u00a0las\u00a0c\u00e9lulas\u00a0tumorales \u00a0\nconfiri\u00e9ndoles \u00a0una\u00a0capacidad \u00a0distinta\u00a0para\u00a0\nsobrevivir \u00a0en\u00a0ausencia\u00a0de\u00a0hormonas. \u00a0Adem\u00e1s,\u00a0no\u00a0\nse\u00a0observaron \u00a0cambios\u00a0significativos \u00a0en\u00a0los\u00a0niveles\u00a0\nde\u00a0expresi\u00f3n \u00a0del\u00a0RE\u00a0en\u00a0las\u00a0l\u00edneas\u00a0tratadas\u00a0vs\u00a0las\u00a0\nparentales, \u00a0pero\u00a0s\u00ed\u00a0que\u00a0algunos\u00a0genes\u00a0de\u00a0la\u00a0familia\u00a0\nErbB\u00a0parec\u00edan\u00a0aumentar \u00a0en\u00a0peque\u00f1a\u00a0medida\u00a0su\u00a0\nexpresi\u00f3n. \u00a0Experimentos \u00a0futuros\u00a0sobre\u00a0este\u00a0\ntrabajo\u00a0revelar\u00e1n \u00a0datos\u00a0m\u00e1s\u00a0esclarecedores \u00a0sobre\u00a0\nla\u00a0capacidad \u00a0de\u00a0la\u00a0SP\u00a0en\u00a0generar\u00a0hormono \u2010\nindependencia \u00a0en\u00a0esta\u00a0l\u00ednea\u00a0celular,\u00a0y\u00a0si\u00a0\u00e9sta\u00a0\nhormono \u2010independencia \u00a0est\u00e1\u00a0sujeta,\u00a0por\u00a0ejemplo,\u00a0\na\u00a0la\u00a0sobreexpresi\u00f3n \u00a0de\u00a0HER2\u00a0y\u00a0NK1\u00a0o\u00a0a\u00a0la\u00a0\ninfraexpresi\u00f3n \u00a0del\u00a0RE\u00a0en\u00a0aquellos\u00a0clones\u00a0hormono \u2010\nindependientes. \u00a0\n\u00a0\u00a0\nEn\u00a0conclusi\u00f3n, \u00a0los\u00a0resultados \u00a0presentados \u00a0en\u00a0la\u00a0\npresente\u00a0tesis\u00a0muestran \u00a0otro\u00a0mecanismo \u00a0por\u00a0el\u00a0\ncual\u00a0la\u00a0inflamaci\u00f3n, \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0SP,\u00a0modula\u00a0la\u00a0\nprogresi\u00f3n \u00a0tumoral\u00a0y\u00a0la\u00a0adquisici\u00f3n \u00a0de\u00a0\ncaracter\u00edsticas \u00a0 fenot\u00edpicas/genot\u00edpicas \u00a0 que\u00a0\naportan\u00a0nuevos\u00a0mecanismos \u00a0de\u00a0supervivencia \u00a0\n(MCF7\u00a0SP)\u00a0o\u00a0agresividad \u00a0(MDA\u2010MB\u2010468,\u00a0MDA\u2010MB\u2010\n453)\u00a0a\u00a0las\u00a0l\u00edneas\u00a0celulares. \u00a0Por\u00a0otra\u00a0parte,\u00a0la\u00a0\ninteracci\u00f3n \u00a0entre\u00a0m\u00faltiples \u00a0v\u00edas\u00a0de\u00a0se\u00f1alizaci\u00f3n, \u00a0\ntales\u00a0como\u00a0las\u00a0que\u00a0se\u00a0desencadenan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nactivaci\u00f3n \u00a0de\u00a0NK\u20101R\u00a0y\u00a0receptores \u00a0HER2\u00a0\nidentificadas \u00a0en\u00a0este\u00a0trabajo,\u00a0implica\u00a0que\u00a0para\u00a0\nlograr\u00a0una\u00a0respuesta \u00a0terap\u00e9utica \u00a0completa \u00a0con\u00a0\nterapias\u00a0dirigidas\u00a0contra\u00a0los\u00a0receptores \u00a0tirosina\u00a0\nquinasa,\u00a0como\u00a0por\u00a0ejemplo\u00a0HER2,\u00a0ambos\u00a0\nmecanismos \u00a0(activaci\u00f3n \u00a0y\u00a0transactivaci\u00f3n) \u00a0\ndeber\u00edan\u00a0de\u00a0ser\u00a0inhibidos. \u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n177\u00a0\n\u00a0CONCLUSIONES \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0CONCLUSIONES \u00a0\u00a0\n\u00a0\n179\u00a0\n\u00a0CONCLUSIONES \u00a0\n\u00a0\n1.\u00a0El\u00a0receptor\u00a0NK\u20101\u00a0y\u00a0la\u00a0SP\u00a0se\u00a0encuentran \u00a0altamente \u00a0expresados \u00a0en\u00a0tumores\u00a0primarios \u00a0de\u00a0mama\u00a0y\u00a0sus\u00a0\nniveles\u00a0se\u00a0correlacionan \u00a0con\u00a0tumores\u00a0del\u00a0subtipo\u00a0HER2+\u00a0y\u00a0con\u00a0factores\u00a0de\u00a0mal\u00a0pronostico. \u00a0\u00a0\n2.\u00a0La\u00a0expresi\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20102\u00a0se\u00a0correlaciona \u00a0con\u00a0factores\u00a0de\u00a0mejor\u00a0pron\u00f3stico \u00a0y\u00a0con\u00a0tumores\u00a0del\u00a0\nsubtipo\u00a0luminal\u00a0A.\u00a0\n3.\u00a0Los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0la\u00a0SP\u00a0son\u00a0significativamente \u00a0mayores\u00a0en\u00a0\u00a0pacientes \u00a0con\u00a0CM\u00a0que\u00a0en\u00a0controles \u00a0\nsanos.\u00a0\n4.\u00a0La\u00a0SP\u00a0transactiva \u00a0el\u00a0receptor\u00a0HER2\u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM\u00a0obtenidas \u00a0de\u00a0tumores\u00a0primarios \u00a0as\u00ed\u00a0como\u00a0en\u00a0l\u00edneas\u00a0\ncelulares. \u00a0\n5.\u00a0La\u00a0transactivaci\u00f3n \u00a0del\u00a0receptor\u00a0HER2\u00a0bajo\u00a0el\u00a0est\u00edmulo\u00a0de\u00a0SP\u00a0est\u00e1\u00a0mediada\u00a0por\u00a0MMPs\u00a0y\u00a0la\u00a0prote\u00edna\u00a0\nquinasa\u00a0no\u00a0receptora \u00a0Src.\u00a0\n6.\u00a0El\u00a0bloqueo\u00a0de\u00a0la\u00a0SP\u00a0con\u00a0anticuerpos \u00a0y\u00a0la\u00a0inhibici\u00f3n \u00a0qu\u00edmica\u00a0del\u00a0receptor\u00a0NK\u20101\u00a0provoca\u00a0muerte\u00a0celular\u00a0\nmediada\u00a0por\u00a0apoptosis \u00a0en\u00a0c\u00e9lulas\u00a0de\u00a0CM.\u00a0\n7.\u00a0La\u00a0activaci\u00f3n \u00a0basal\u00a0del\u00a0receptor\u00a0HER2\u00a0en\u00a0CM\u00a0depende\u00a0parcialmente \u00a0de\u00a0la\u00a0se\u00f1alizaci\u00f3n \u00a0\nautocrina/paracrina \u00a0mediada\u00a0por\u00a0la\u00a0citoquina \u00a0pro\u2010inflamatoria/neurop\u00e9ptido \u00a0SP.\u00a0\n8.\u00a0La\u00a0inhibici\u00f3n \u00a0de\u00a0los\u00a03\u00a0receptores \u00a0de\u00a0taquiquininas \u00a0NK\u20101,\u00a0NK\u20102,\u00a0NK\u20103,\u00a0inhibe\u00a0casi\u00a0completamente \u00a0la\u00a0\nactivaci\u00f3n \u00a0basal\u00a0de\u00a0HER2,\u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Src,\u00a0p\u201042/44\u00a0MAPK\u00a0y\u00a0Akt.\u00a0\n9.\u00a0El\u00a0antagonista \u00a0de\u00a0NK\u20101\u00a0L\u2010733,060\u00a0inhibe\u00a0el\u00a0crecimiento \u00a0de\u00a0tumores\u00a0otrot\u00f3picos \u00a0de\u00a0mama\u00a0con\u00a0fenotipo\u00a0\nHER2+\u00a0en\u00a0ratones\u00a0SCID,\u00a0y\u00a0disminuye \u00a0la\u00a0fosforilaci\u00f3n \u00a0de\u00a0HER2,\u00a0p\u201042/44,\u00a0Akt\u00a0y\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0\u03b1\u2010SMA\u00a0y\u00a0\nCOX2.\u00a0\n10.\u00a0Tratamientos \u00a0anti\u2010HER2\u00a0como\u00a0el\u00a0Lapatinib \u00a0o\u00a0AG825\u00a0sinergizan \u00a0con\u00a0el\u00a0inhibidor\u00a0de\u00a0NK\u20101\u00a0(L\u2010733,060)\u00a0\ndisminuyendo \u00a0la\u00a0supervivencia \u00a0celular.\u00a0\n11.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0causa\u00a0cambios\u00a0fenot\u00edpicos \u00a0en\u00a0las\u00a0l\u00edneas\u00a0celulares\u00a0de\u00a0CM,\u00a0MDA\u2010MB\u2010453\u00a0y\u00a0\nMDA\u2010MB\u2010468\u00a0aumentando \u00a0la\u00a0agresividad \u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0y\u00a0provocando \u00a0una\u00a0disminuci\u00f3n \u00a0en\u00a0la\u00a0sensibilidad \u00a0a\u00a0\nf\u00e1rmacos \u00a0anti\u2010HER2\u00a0y\u00a0anti\u2010EGFR.\u00a0\n12.\u00a0La\u00a0exposici\u00f3n \u00a0cont\u00ednua\u00a0a\u00a0SP\u00a0altera\u00a0la\u00a0expresi\u00f3n \u00a0de\u00a0genes\u00a0responsables \u00a0de\u00a0ciclo\u00a0celular,\u00a0crecimiento \u00a0y\u00a0\nproliferaci\u00f3n, \u00a0expresi\u00f3n \u00a0g\u00e9nica,\u00a0s\u00edntesis\u00a0proteica,\u00a0se\u00f1alizaci\u00f3n \u00a0celular,\u00a0respuesta \u00a0inflamatoria, \u00a0y\u00a0\nmovimiento \u00a0celular\u00a0en\u00a0las\u00a0l\u00edneas\u00a0tratadas\u00a0continuamente \u00a0con\u00a0SP\u00a0respecto\u00a0a\u00a0las\u00a0l\u00edneas\u00a0parentales. \u00a0\n13.\u00a0La\u00a0exposici\u00f3n \u00a0continua\u00a0a\u00a0SP\u00a0es\u00a0capaz\u00a0de\u00a0causar\u00a0hormono \u2010independencia \u00a0in\u00a0vitro .\u00a0\n\u00a0\u00a0\n181\u00a0\n\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n183\u00a0\n\u00a0Tabla\u00a0anexa\u00a01.\u00a0An\u00e1lisis\u00a0estad\u00edstico \u00a0de\u00a0la\u00a0correlaci\u00f3n \u00a0de\u00a0NK\u20101R,\u00a0NK\u20102R\u00a0y\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0SP\u00a0(tratados\u00a0como\u00a0\nvariables\u00a0continuas) \u00a0con\u00a0las\u00a0caracter\u00edsticas \u00a0cl\u00ednico\u2010patol\u00f3gicas \u00a0de\u00a0los\u00a0pacientes. \u00a0N\u00a0indica\u00a0el\u00a0n\u00famero\u00a0de\u00a0muestras \u00a0\nanalizadas \u00a0para\u00a0cada\u00a0caracter\u00edstica \u00a0cl\u00ednico\u2010patol\u00f3gica. \u00a0\u00a0\nCaracter\u00edsticas \u00a0clinico\u00a0\npatol\u00f3gicas \u00a0NK\u20101R\u00a0 NK\u20102R\u00a0 SP\u00a0\nN\u00a0Media\u00a0\n(SD)\u00a0Mediana\u00a0(25\u00a0\nPctl\u201075\u00a0Pctl)\u00a0P\u00a0valor N\u00a0Media\u00a0\n(SD)\u00a0Mediana (25\u00a0\nPctl\u201075\u00a0Pctl)\u00a0P\u00a0valor\u00a0N\u00a0Media\u00a0\n(SD)\u00a0Mediana (25\u00a0\nPctl\u201075\u00a0Pctl)\u00a0P\u00a0valor\u00a0\nQuimioterapia \u00a0\nNeoadyuvante \u00a0No\u00a0 292\u00a0143\u00a0(85)\u00a0140\u00a0(100\u2010200)\u00a00.7094\u00a0293\u00a0104\u00a0(81)\u00a0100\u00a0(25\u2010150)\u00a00.5233\u00a0289\u00a041\u00a0(59)\u00a0 5\u00a0(0\u201070)\u00a00.0895\u00a0\nS\u00ed\u00a0 25\u00a0137\u00a0(85)\u00a0120\u00a0(85\u2010200)\u00a0 25\u00a0107\u00a0(65)\u00a0120\u00a0(50\u2010140)\u00a0 24\u00a066\u00a0(72)\u00a037.5\u00a0(0\u2010120)\u00a0\nEstadio\u00a0T\u00a01\u00a0 156\u00a0147\u00a0(87)\u00a0125\u00a0(100\u2010210)\u00a0\n0.9229\u00a0156\u00a0109\u00a0(75)\u00a0100\u00a0(50\u2010150)\u00a0\n0.0364\u00a0154\u00a042\u00a0(62)\u00a0 2.5\u00a0(0\u201070)\u00a0\n0.3702\u00a02\u00a0 142\u00a0139\u00a0(82)\u00a0130\u00a0(100\u2010200)\u00a0 143\u00a094\u00a0(82)\u00a0 100\u00a0(5\u2010150)\u00a0 141\u00a045\u00a0(58)\u00a0 20\u00a0(0\u201090)\u00a0\n3\u00a0 9\u00a0154\u00a0(98)\u00a0120\u00a0(100\u2010200)\u00a0 9\u00a0155\u00a0(83)\u00a0140\u00a0(120\u2010200) 9\u00a071\u00a0(85)\u00a025\u00a0(0\u2010150)\u00a0\n4\u00a0 10\u00a0128\u00a0(74)\u00a0160\u00a0(50\u2010200)\u00a0 10\u00a0132\u00a0(89)\u00a0122\u00a0(100\u2010200) 9\u00a019\u00a0(37)\u00a0 0\u00a0(0\u20105)\u00a0\nEstadio\u00a0N\u00a00\u00a0 157\u00a0146\u00a0(86)\u00a0140\u00a0(100\u2010200)\u00a0\n0.6831\u00a0158\u00a0101\u00a0(77)\u00a0100\u00a0(25\u2010150)\u00a0\n0.4673\u00a0156\u00a049\u00a0(64)\u00a010\u00a0(0\u2010100)\u00a0\n0.0321\u00a01\u00a0 91\u00a0132\u00a0(84)\u00a0120\u00a0(100\u2010200)\u00a0 91\u00a0106\u00a0(86)\u00a0100\u00a0(25\u2010150)\u00a0 89\u00a027\u00a0(46)\u00a0 0\u00a0(0\u201040)\u00a0\n2\u00a0 39\u00a0152\u00a0(93)\u00a0150\u00a0(100\u2010200)\u00a0 39\u00a0121\u00a0(78)\u00a0125\u00a0(50\u2010150)\u00a0 38\u00a063\u00a0(68)\u00a050\u00a0(0\u2010100)\u00a0\n3\u00a0 30\u00a0147\u00a0(67)\u00a0135\u00a0(100\u2010200)\u00a0 30\u00a091\u00a0(76)\u00a0105\u00a0(10\u2010130)\u00a0 30\u00a037\u00a0(58)\u00a0 2.5\u00a0(0\u201050)\u00a0\nGrado\u00a0\nhistol\u00f3gico \u00a01\u00a0 59\u00a0142\u00a0(82)\u00a0115\u00a0(100\u2010200)\u00a0\n0.9465\u00a059\u00a0142\u00a0(78)\u00a0130\u00a0(100\u2010200)\n<0.0001\u00a058\u00a028\u00a0(54)\u00a0 0\u00a0(0\u201025)\u00a0\n0.0158\u00a0 2\u00a0 106\u00a0146\u00a0(81)\u00a0120\u00a0(100\u2010200)\u00a0 106\u00a0106\u00a0(75)\u00a0110\u00a0(50\u2010150)\u00a0 103\u00a047\u00a0(67)\u00a0 10\u00a0(0\u201070)\u00a0\n3\u00a0 136\u00a0142\u00a0(89)\u00a0150\u00a0(64\u2010200)\u00a0 137\u00a081\u00a0(77)\u00a0 80\u00a0(5\u2010120)\u00a0 136\u00a050\u00a0(59)\u00a025\u00a0(0\u2010100)\u00a0\nInvasi\u00f3n\u00a0\nvenosa\u00a0No\u00a0 299\u00a0143\u00a0(85)\u00a0130\u00a0(100\u2010200)\u00a00.6575\u00a0300\u00a0104\u00a0(79)\u00a0100\u00a0(30\u2010150)\u00a00.8146\u00a0295\u00a044\u00a0(61)\u00a0 5\u00a0(0\u201080)\u00a00.9501\u00a0\nS\u00ed\u00a0 18\u00a0134\u00a0(82)\u00a0120\u00a0(100\u2010175)\u00a0 18\u00a0108\u00a0(94)\u00a0110\u00a0(25\u2010150)\u00a0 18\u00a032\u00a0(39)\u00a0 15\u00a0(0\u201050)\u00a0\nInvasi\u00f3n\u00a0\nlinf\u00e0tica\u00a0No\u00a0 173\u00a0147\u00a0(80)\u00a0150\u00a0(100\u2010200)\u00a00.1993\u00a0173\u00a0111\u00a0(79)\u00a0100\u00a0(50\u2010150)\u00a00.1623\u00a0171\u00a049\u00a0(65)\u00a010\u00a0(0\u2010100)\u00a00.0874\u00a0\nS\u00ed\u00a0 144\u00a0137\u00a0(90)\u00a0120\u00a0(77\u2010200)\u00a0 145\u00a096\u00a0(80)\u00a0100\u00a0(20\u2010150)\u00a0 142\u00a035\u00a0(54)\u00a0 0\u00a0(0\u201050)\u00a0\nBorde\u00a0del\u00a0\ntumor\u00a0Infiltrativo \u00a0 226\u00a0145\u00a0(84)\u00a0135\u00a0(100\u2010200)\u00a00.5521\u00a0227\u00a0112\u00a0(76)\u00a0120\u00a0(50\u2010150)\u00a00.0006\u00a0223\u00a036\u00a0(57)\u00a0 0\u00a0(0\u201050)\u00a00.0001\u00a0pushing\u00a0 91\u00a0138\u00a0(87)\u00a0120\u00a0(60\u2010200)\u00a0 91\u00a085\u00a0(85)\u00a0 100\u00a0(5\u2010120)\u00a0 90\u00a061\u00a0(65)\u00a050\u00a0(0\u2010100)\u00a0\nSubtipo\u00a0Lum\u00a0A\u00a0 201\u00a0132\u00a0(79)\u00a0120\u00a0(100\u2010200)\u00a0\n0.0002\u00a0201\u00a0116\u00a0(81)\u00a0120\u00a0(50\u2010150)\u00a0\n0.0007\u00a0197\u00a035\u00a0(57)\u00a0 0\u00a0(0\u201050)\u00a0\n0.0053\u00a0Lum\u00a0B\u00a0 26\u00a0127\u00a0(89)\u00a0120\u00a0(50\u2010200)\u00a0 26\u00a0102\u00a0(74)\u00a0100\u00a0(50\u2010140)\u00a0 26\u00a043\u00a0(65)\u00a012.5\u00a0(0\u201080)\u00a0\nHER2+\u00a0 33\u00a0199\u00a0(92)\u00a0210\u00a0(120\u2010250)\u00a0 34\u00a079\u00a0(69)\u00a0 90\u00a0(20\u2010120)\u00a0 33\u00a078\u00a0(79)\u00a080\u00a0(0\u2010130)\u00a0\nBasal\u00a0 36\u00a0134\u00a0(80)\u00a0145\u00a0(64\u2010173)\u00a0 36\u00a064\u00a0(64)\u00a0 50\u00a0(3\u2010100)\u00a0 36\u00a045\u00a0(50)\u00a012.5(0\u2010100)\u00a0\nInd.\u00a0 21\u00a0187\u00a0(89)\u00a0150\u00a0(120.250) \u00a0 21\u00a098\u00a0(83)\u00a0100\u00a0(10\u2010160)\u00a0 21\u00a058\u00a0(52)\u00a050\u00a0(10\u2010100)\u00a0\nRE\u00a0Neg\u00a0(<1%)\u00a0 98\u00a0165\u00a0(92)\u00a0150\u00a0(100\u2010245)\u00a00.0029\u00a099\u00a079\u00a0(70)\u00a0 100\u00a0(5\u2010120)\u00a00.0001\u00a098\u00a058\u00a0(65)\u00a045\u00a0(0\u2010100)\u00a00.0011\u00a0Pos\u00a0(\u22651%)\u00a0 219\u00a0132\u00a0(80)\u00a0120\u00a0(100\u2010200)\u00a0 219\u00a0115\u00a0(81)\u00a0120\u00a0(50\u2010150)\u00a0 215\u00a036\u00a0(57)\u00a0 0\u00a0(0\u201050)\u00a0\nRP\u00a0Neg\u00a0(<1%)\u00a0 136\u00a0150\u00a0(87)\u00a0150\u00a0(100\u2010200)\u00a00.2233\u00a0137\u00a083\u00a0(75)\u00a0100\u00a0(10\u2010125)\u00a0<0.0001\u00a0136\u00a055\u00a0(66)\u00a025\u00a0(0\u2010100)\u00a00.002\u00a0Pos\u00a0(\u22651%)\u00a0 181\u00a0137\u00a0(83)\u00a0120\u00a0(100\u2010200)\u00a0 181\u00a0120\u00a0(79)\u00a0120\u00a0(70\u2010160)\u00a0 177\u00a034\u00a0(54)\u00a0 0\u00a0(0\u201050)\u00a0\nHER2\u00a0negativo\u00a0 46\u00a0132\u00a0(81)\u00a0120\u00a0(50\u2010170)\u00a0\n0.0007\u00a046\u00a091\u00a0(81)\u00a0100\u00a0(10\u2010130)\u00a0\n0.0328\u00a046\u00a040\u00a0(53)\u00a0 10\u00a0(0\u201070)\u00a0\n0.0308\u00a01+\u00a0 114\u00a0122\u00a0(83)\u00a0112\u00a0(50\u2010170)\u00a0 114\u00a0101\u00a0(82)\u00a0100\u00a0(10\u2010150)\u00a0 112\u00a033\u00a0(55)\u00a0 0\u00a0(0\u201050)\u00a0\n2+\u00a0 107\u00a0154\u00a0(79)\u00a0140\u00a0(100\u2010200)\u00a0 107\u00a0120\u00a0(77)\u00a0120\u00a0(50\u2010160)\u00a0 106\u00a043\u00a0(56)\u00a022.5\u00a0(0\u201070)\u00a0\n3+\u00a0 50\u00a0177\u00a0(91)\u00a0200\u00a0(100\u2010250)\u00a0 51\u00a091\u00a0(74)\u00a0100\u00a0(20\u2010125)\u00a0 49\u00a069\u00a0(78)\u00a050\u00a0(0\u2010110)\u00a0\np53\u00a0Neg\u00a0(\u226410%)\u00a0245\u00a0134\u00a0(82)\u00a0120\u00a0(100\u2010200)\u00a00.001\u00a0245\u00a0113\u00a0(81)\u00a0110\u00a0(50\u2010150)\u00a00.0002\u00a0242\u00a040\u00a0(60)\u00a0 0\u00a0(0\u201070)\u00a00.0323\u00a0Pos\u00a0(>10%)\u00a0 72\u00a0173\u00a0(86)\u00a0150\u00a0(100\u2010248)\u00a0 73\u00a073\u00a0(66)\u00a0 70\u00a0(5\u2010120)\u00a0 71\u00a053\u00a0(61)\u00a035\u00a0(0\u2010100)\u00a0\nKi67\u00a0Bajo\u00a0(\u226410%)\u00a0185\u00a0137\u00a0(82)\u00a0115\u00a0(100\u2010200)\u00a00.1266\u00a0185\u00a0120\u00a0(78)\u00a0120\u00a0(70\u2010160)\u00a0<0.0001\u00a0181\u00a038\u00a0(58)\u00a0 0\u00a0(0\u201050)\u00a00.0215\u00a0Alto\u00a0(>10%)\u00a0132\u00a0150\u00a0(89)\u00a0150\u00a0(100\u2010200)\u00a0 133\u00a082\u00a0(76)\u00a0 80\u00a0(5\u2010125)\u00a0 132\u00a050\u00a0(63)\u00a025\u00a0(0\u2010100)\u00a0\nRecurrencia \u00a0No\u00a0 277\u00a0145\u00a0(84)\u00a0140\u00a0(100\u2010200)\u00a00.2401\u00a0278\u00a0107\u00a0(79)\u00a0100\u00a0(50\u2010150)\u00a00.1233\u00a0273\u00a044\u00a0(61)\u00a0 10\u00a0(0\u201080)\u00a00.641\u00a0\nS\u00ed\u00a0 40\u00a0128\u00a0(90)\u00a0120\u00a0(50\u2010200)\u00a0 40\u00a085\u00a0(80)\u00a0 100\u00a0(5\u2010140)\u00a0 40\u00a038\u00a0(56)\u00a0 2.5\u00a0(0\u201070)\u00a0\nMet\u00e1stasis \u00a0a\u00a0\ndist\u00e0ncia\u00a0No\u00a0 284\u00a0145\u00a0(85)\u00a0135\u00a0(100\u2010200)\u00a00.2903\u00a0285\u00a0106\u00a0(79)\u00a0100\u00a0(45\u2010150)\u00a00.2256\u00a0280\u00a044\u00a0(61)\u00a0 10\u00a0(0\u201080)\u00a00.7618\u00a0\nS\u00ed\u00a0 33\u00a0126\u00a0(80)\u00a0120\u00a0(50\u2010200)\u00a0 33\u00a088\u00a0(83)\u00a0 100\u00a0(5\u2010140)\u00a0 33\u00a039\u00a0(59)\u00a0 5\u00a0(0\u201050)\u00a0\n\u00a0\nAn\u00e1lisis\u00a0estad\u00edstico \u00a0realizado\u00a0con\u00a0la\u00a0prueba\u00a0U\u00a0de\u00a0Mann\u2010Whitney\u00a0(2\u00a0categor\u00edas), \u00a0Kruskal\u2010Wallis\u00a0(m\u00e1s\u00a0de\u00a02\u00a0categor\u00edas). \u00a0Valores\u00a0con\u00a0\nuna\u00a0P<0,05,\u00a0resaltados \u00a0en\u00a0negrita,\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0\n\u00a0\n\u00a0\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n184\u00a0\n\u00a0Tabla\u00a0anexa\u00a02.\u00a0An\u00e1lisis\u00a0estad\u00edstico \u00a0de\u00a0la\u00a0correlaci\u00f3n \u00a0del\u00a0receptor\u00a0NK\u20101,\u00a0NK\u20102\u00a0y\u00a0los\u00a0niveles\u00a0de\u00a0expresi\u00f3n \u00a0de\u00a0SP\u00a0\n(tratados\u00a0como\u00a0variables\u00a0ordinales) \u00a0con\u00a0las\u00a0caracter\u00edsticas \u00a0cl\u00ednicopatol\u00f3gicas \u00a0de\u00a0los\u00a0pacientes. \u00a0Cada\u00a0valor\u00a0indica\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0muestras \u00a0para\u00a0cada\u00a0categor\u00eda \u00a0de\u00a0expresi\u00f3n \u00a0(columnas) \u00a0de\u00a0las\u00a0caracter\u00edsticas \u00a0cl\u00ednico\u2010patol\u00f3gicas \u00a0indicadas \u00a0\n(fila).\u00a0Los\u00a0n\u00fameros\u00a0entre\u00a0par\u00e9ntesis \u00a0indican\u00a0el\u00a0porcentaje \u00a0de\u00a0muestras \u00a0para\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0caracter\u00edsticas \u00a0cl\u00ednico\u2010\npatol\u00f3gicas \u00a0(fila).\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\n\u00a0Caracter\u00edsticas \u00a0clinicopatol\u00f3gicas \u00a0NK\u20101R\u00a0\n0\u00a0 1\u00a0 2\u00a0 3\u00a0 P\u00a0valor\u00a0\nQuimioterapia \u00a0\nNeoadyuvante \u00a0No\u00a0 17\u00a0(5.8%)\u00a0 99\u00a0(33.9%)\u00a0 116\u00a0(39.7%)\u00a0 60\u00a0(20.5%)\u00a00.5531\u00a0\nS\u00ed\u00a0 2\u00a0(8.0%)\u00a0 9\u00a0(36.0%)\u00a0 10\u00a0(40.0%)\u00a0 4\u00a0(16.0%)\u00a0\nEstadio\u00a0T\u00a01\u00a0 8\u00a0(5.1%)\u00a0 56\u00a0(35.9%)\u00a0 53\u00a0(34.0%)\u00a0 39\u00a0(25.0%)\u00a0\n0.749\u00a02\u00a0 9\u00a0(6.3%)\u00a0 47\u00a0(33.1%)\u00a0 63\u00a0(44.4%)\u00a0 23\u00a0(16.2%)\u00a0\n3\u00a0 1\u00a0(11.1%)\u00a0 2\u00a0(22.2%)\u00a0 4\u00a0(44.4%)\u00a0 2\u00a0(22.2%)\u00a0\n4\u00a0 1\u00a0(10.0%)\u00a0 3\u00a0(30.0%)\u00a0 6\u00a0(60.0%)\u00a0 0\u00a0(0.0%)\u00a0\nEstadio\u00a0N\u00a00\u00a0 8\u00a0(5.1%)\u00a0 55\u00a0(35.0%)\u00a0 60\u00a0(38.2%)\u00a0 34\u00a0(21.7%)\u00a0\n0.751\u00a01\u00a0 10\u00a0(11.0%)\u00a0 29\u00a0(31.9%)\u00a0 35\u00a0(38.5%)\u00a0 17\u00a0(18.7%)\u00a0\n2\u00a0 1\u00a0(2.6%)\u00a0 14\u00a0(35.9%)\u00a0 16\u00a0(41.0%)\u00a0 8\u00a0(20.5%)\u00a0\n3\u00a0 0\u00a0(0.0%)\u00a0 10\u00a0(33.3%)\u00a0 15\u00a0(50.0%)\u00a0 5\u00a0(16.7%)\u00a0\nGrado\u00a0histol\u00f3gico \u00a01\u00a0 2\u00a0(3.4%)\u00a0 23\u00a0(39.0%)\u00a0 22\u00a0(37.3%)\u00a0 12\u00a0(20.3%)\u00a0\n0.9117\u00a0 2\u00a0 6\u00a0(5.7%)\u00a0 33\u00a0(31.1%)\u00a0 45\u00a0(42.5%)\u00a0 22\u00a0(20.8%)\u00a0\n3\u00a0 10\u00a0(7.4%)\u00a0 43\u00a0(31.6%)\u00a0 55\u00a0(40.4%)\u00a0 28\u00a0(20.6%)\u00a0\nInvasi\u00f3n\u00a0venosa\u00a0No\u00a0 18\u00a0(6.0%)\u00a0 101\u00a0(33.8%)\u00a0 119\u00a0(39.8%)\u00a0 61\u00a0(20.4%)\u00a00.6798\u00a0\nS\u00ed\u00a0 1\u00a0(5.6%)\u00a0 7\u00a0(38.9%)\u00a0 7\u00a0(38.9%)\u00a0 3\u00a0(16.7%)\u00a0\nInvasi\u00f3n\u00a0linf\u00e0tica\u00a0No\u00a0 7\u00a0(4.0%)\u00a0 56\u00a0(32.4%)\u00a0 72\u00a0(41.6%)\u00a0 38\u00a0(22.0%)\u00a00.1046\u00a0\nS\u00ed\u00a0 12\u00a0(8.3%)\u00a0 52\u00a0(36.1%)\u00a0 54\u00a0(37.5%)\u00a0 26\u00a0(18.1%)\u00a0\nBorde\u00a0del\u00a0tumor\u00a0Infiltrativo \u00a0 14\u00a0(6.2%)\u00a0 77\u00a0(34.1%)\u00a0 88\u00a0(38.9%)\u00a0 47\u00a0(20.8%)\u00a00.9456\u00a0pushing\u00a0 5\u00a0(5.5%)\u00a0 31\u00a0(34.1%)\u00a0 38\u00a0(41.8%)\u00a0 17\u00a0(18.7%)\u00a0\nSubtipo\u00a0Lum\u00a0A\u00a0 14\u00a0(7.0%)\u00a0 75\u00a0(37.3%)\u00a0 82\u00a0(40.8%)\u00a0 30\u00a0(14.9%)\u00a0\n0.0001\u00a0Lum\u00a0B\u00a0 2\u00a0(7.7%)\u00a0 10\u00a0(38.5%)\u00a0 10\u00a0(38.5%)\u00a0 4\u00a0(15.4%)\u00a0\nHER2+\u00a0 1\u00a0(3.0%)\u00a0 5\u00a0(15.2%)\u00a0 10\u00a0(30.3%)\u00a0 17\u00a0(51.5%)\u00a0\nBasal\u00a0 2\u00a0(5.6%)\u00a0 14\u00a0(38.9%)\u00a0 14\u00a0(38.9%)\u00a0 6\u00a0(16.7%)\u00a0\nInd.\u00a0 0\u00a0(0.0%)\u00a0 4\u00a0(19.0%)\u00a0 10\u00a0(47.6%)\u00a0 7\u00a0(33.3%)\u00a0\nRE\u00a0Neg\u00a0(<1%)\u00a0 5\u00a0(5.1%)\u00a0 24\u00a0(24.5%)\u00a0 39\u00a0(39.8%)\u00a0 30\u00a0(30.6%)\u00a00.0017\u00a0Pos\u00a0(\u22651%)\u00a0 14\u00a0(6.4%)\u00a0 84\u00a0(38.4%)\u00a0 87\u00a0(39.7%)\u00a0 34\u00a0(15.5%)\u00a0\nRP\u00a0Neg\u00a0(<1%)\u00a0 5\u00a0(3.7%)\u00a0 44\u00a0(32.4%)\u00a0 54\u00a0(39.7%)\u00a0 33\u00a0(24.3%)\u00a00.0725\u00a0Pos\u00a0(\u22651%)\u00a0 14\u00a0(7.7%)\u00a0 64\u00a0(35.4%)\u00a0 72\u00a0(39.8%)\u00a0 31\u00a0(17.1%)\u00a0\nHER2\u00a0negativo\u00a0 1\u00a0(2.2%)\u00a0 17\u00a0(37.0%)\u00a0 21\u00a0(45.7%)\u00a0 7\u00a0(15.2%)\u00a0\n0.0029\u00a01+\u00a0 15\u00a0(13.2%)\u00a0 41\u00a0(36.0%)\u00a0 41\u00a0(36.0%)\u00a0 17\u00a0(14.9%)\u00a0\n2+\u00a0 1\u00a0(0.9%)\u00a0 39\u00a0(36.4%)\u00a0 45\u00a0(42.1%)\u00a0 22\u00a0(20.6%)\u00a0\n3+\u00a0 2\u00a0(4.0%)\u00a0 11\u00a0(22.0%)\u00a0 19\u00a0(38.0%)\u00a0 18\u00a0(36.0%)\u00a0\np53\u00a0Neg\u00a0(\u226410%)\u00a0 18\u00a0(7.3%)\u00a0 90\u00a0(36.7%)\u00a0 96\u00a0(39.2%)\u00a0 41\u00a0(16.7%)\u00a00.0008\u00a0Pos(>10%)\u00a0 1\u00a0(1.4%)\u00a0 18\u00a0(25.0%)\u00a0 30\u00a0(41.7%)\u00a0 23\u00a0(31.9%)\u00a0\nKi67\u00a0Bajo\u00a0(\u226410%)\u00a0 11\u00a0(57.9%)\u00a0 71\u00a0(65.7%)\u00a0 70\u00a0(55.6%)\u00a0 33\u00a0(51.6%)\u00a00.0797\u00a0Alto\u00a0(>10%)\u00a0 8\u00a0(42.1%)\u00a0 37\u00a0(34.3%)\u00a0 56\u00a0(44.4%)\u00a0 31\u00a0(48.4%)\u00a0\nRecurrencia \u00a0No\u00a0 16\u00a0(5.8%)\u00a0 93\u00a0(33.6%)\u00a0 111\u00a0(40.1%)\u00a0 57\u00a0(20.6%)\u00a00.4678\u00a0\nS\u00ed\u00a0 3\u00a0(7.5%)\u00a0 15\u00a0(37.5%)\u00a0 15\u00a0(37.5%)\u00a0 7\u00a0(17.5%)\u00a0\nMet\u00e1stasis \u00a0a\u00a0\ndist\u00e0ncia\u00a0No\u00a0 17\u00a0(6.0%)\u00a0 95\u00a0(33.5%)\u00a0 113\u00a0(39.8%)\u00a0 59\u00a0(20.8%)\u00a00.4348\u00a0\nS\u00ed\u00a0 2\u00a0(6.1%)\u00a0 13\u00a0(39.4%)\u00a0 13\u00a0(39.4%)\u00a0 5\u00a0(15.2%)\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n185\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\n\u00a0Caracter\u00edsticas \u00a0clinicopatol\u00f3gicas \u00a0NK\u20102R\u00a0\n0\u00a0 1\u00a0 2\u00a0 3\u00a0 P\u00a0valor\u00a0\nQuimioterapia \u00a0\nNeoadyuvante \u00a0No\u00a0 43\u00a0(14.7%)\u00a0 117\u00a0(39.9%)\u00a0 100\u00a0(34.1%)\u00a0 33\u00a0(11.3%)\u00a00.3974\u00a0\nS\u00ed\u00a0 0\u00a0(0.0%)\u00a0 12\u00a0(48.0%)\u00a0 12\u00a0(48.0%)\u00a0 1\u00a0(4.0%)\u00a0\nEstadio\u00a0T\u00a01\u00a0 16\u00a0(10.3%)\u00a0 66\u00a0(42.3%)\u00a0 59\u00a0(37.8%)\u00a0 15\u00a0(9.6%)\u00a0\n0.0432\u00a02\u00a0 27\u00a0(18.9%)\u00a0 57\u00a0(39.9%)\u00a0 44\u00a0(30.8%)\u00a0 15\u00a0(10.5%)\u00a0\n3\u00a0 0\u00a0(0.0%)\u00a0 2\u00a0(22.2%)\u00a0 5\u00a0(55.6%)\u00a0 2\u00a0(22.2%)\u00a0\n4\u00a0 0\u00a0(0.0%)\u00a0 4\u00a0(40.0%)\u00a0 4\u00a0(40.0%)\u00a0 2\u00a0(20.0%)\u00a0\nEstadio\u00a0N\u00a00\u00a0 25\u00a0(15.8%)\u00a0 65\u00a0(41.1%)\u00a0 54\u00a0(34.2%)\u00a0 14\u00a0(8.9%)\u00a0\n0.4457\u00a01\u00a0 10\u00a0(11.0%)\u00a0 40\u00a0(44.0%)\u00a0 28\u00a0(30.8%)\u00a0 13\u00a0(14.3%)\u00a0\n2\u00a0 4\u00a0(10.3%)\u00a0 13\u00a0(33.3%)\u00a0 17\u00a0(43.6%)\u00a0 5\u00a0(12.8%)\u00a0\n3\u00a0 4\u00a0(13.3%)\u00a0 11\u00a0(36.7%)\u00a0 13\u00a0(43.3%)\u00a0 2\u00a0(6.7%)\u00a0\nGrado\u00a0histol\u00f3gico \u00a01\u00a0 5\u00a0(8.5%)\u00a0 16\u00a0(27.1%)\u00a0 27\u00a0(45.8%)\u00a0 11\u00a0(18.6%)\u00a0\n<0.0001\u00a0 2\u00a0 11\u00a0(10.4%)\u00a0 40\u00a0(37.7%)\u00a0 47\u00a0(44.3%)\u00a0 8\u00a0(7.5%)\u00a0\n3\u00a0 26\u00a0(19.0%)\u00a0 70\u00a0(51.1%)\u00a0 28\u00a0(20.4%)\u00a0 13\u00a0(9.5%)\u00a0\nInvasi\u00f3n\u00a0venosa\u00a0No\u00a0 41\u00a0(13.7%)\u00a0 122\u00a0(40.7%)\u00a0 106\u00a0(35.3%)\u00a0 31\u00a0(10.3%)\u00a00.5673\u00a0\nS\u00ed\u00a0 2\u00a0(11.1%)\u00a0 7\u00a0(38.9%)\u00a0 6\u00a0(33.3%)\u00a0 3\u00a0(16.7%)\u00a0\nInvasi\u00f3n\u00a0linf\u00e0tica\u00a0No\u00a0 21\u00a0(12.1%)\u00a0 72\u00a0(41.6%)\u00a0 59\u00a0(34.1%)\u00a0 21\u00a0(12.1%)\u00a00.5521\u00a0\nS\u00ed\u00a0 22\u00a0(15.2%)\u00a0 57\u00a0(39.3%)\u00a0 53\u00a0(36.6%)\u00a0 13\u00a0(9.0%)\u00a0\nBorde\u00a0del\u00a0tumor\u00a0Infiltrativo \u00a0 22\u00a0(9.7%)\u00a0 85\u00a0(37.4%)\u00a0 96\u00a0(42.3%)\u00a0 24\u00a0(10.6%)\u00a00.0002\u00a0pushing\u00a0 21\u00a0(23.1%)\u00a0 44\u00a0(48.4%)\u00a0 16\u00a0(17.6%)\u00a0 10\u00a0(11.0%)\u00a0\nSubtipo\u00a0Lum\u00a0A\u00a0 23\u00a0(11.4%)\u00a0 67\u00a0(33.3%)\u00a0 85\u00a0(42.3%)\u00a0 26\u00a0(12.9%)\u00a0\n0.0006\u00a0Lum\u00a0B\u00a0 3\u00a0(11.5%)\u00a0 13\u00a0(50.0%)\u00a0 7\u00a0(26.9%)\u00a0 3\u00a0(11.5%)\u00a0\nHER2+\u00a0 4\u00a0(11.8%)\u00a0 19\u00a0(55.9%)\u00a0 9\u00a0(26.5%)\u00a0 2\u00a0(5.9%)\u00a0\nBasal\u00a0 8\u00a0(22.2%)\u00a0 22\u00a0(61.1%)\u00a0 5\u00a0(13.9%)\u00a0 1\u00a0(2.8%)\u00a0\nInd.\u00a0 5\u00a0(23.8%)\u00a0 8\u00a0(38.1%)\u00a0 6\u00a0(28.6%)\u00a0 2\u00a0(9.5%)\u00a0\nRE\u00a0Neg\u00a0(<1%)\u00a0 17\u00a0(17.2%)\u00a0 54\u00a0(54.5%)\u00a0 23\u00a0(23.2%)\u00a0 5\u00a0(5.1%)\u00a0<0.0001\u00a0Pos\u00a0(\u22651%)\u00a0 26\u00a0(11.9%)\u00a0 75\u00a0(34.2%)\u00a0 89\u00a0(40.6%)\u00a0 29\u00a0(13.2%)\u00a0\nRP\u00a0Neg\u00a0(<1%)\u00a0 25\u00a0(18.2%)\u00a0 69\u00a0(50.4%)\u00a0 33\u00a0(24.1%)\u00a0 10\u00a0(7.3%)\u00a0<0.0001\u00a0Pos\u00a0(\u22651%)\u00a0 18\u00a0(9.9%)\u00a0 60\u00a0(33.1%)\u00a0 79\u00a0(43.6%)\u00a0 24\u00a0(13.3%)\u00a0\nHER2\u00a0negativo\u00a0 7\u00a0(15.2%)\u00a0 24\u00a0(52.2%)\u00a0 10\u00a0(21.7%)\u00a0 5\u00a0(10.9%)\u00a0\n0.118\u00a01+\u00a0 20\u00a0(17.5%)\u00a0 42\u00a0(36.8%)\u00a0 41\u00a0(36.0%)\u00a0 11\u00a0(9.6%)\u00a0\n2+\u00a0 9\u00a0(8.4%)\u00a0 40\u00a0(37.4%)\u00a0 45\u00a0(42.1%)\u00a0 13\u00a0(12.1%)\u00a0\n3+\u00a0 7\u00a0(13.7%)\u00a0 23\u00a0(45.1%)\u00a0 16\u00a0(31.4%)\u00a0 5\u00a0(9.8%)\u00a0\np53\u00a0Neg\u00a0(\u226410%)\u00a0 31\u00a0(12.7%)\u00a0 89\u00a0(36.3%)\u00a0 94\u00a0(38.4%)\u00a0 31\u00a0(12.7%)\u00a00.0017\u00a0Pos\u00a0(>10%)\u00a0 12\u00a0(16.4%)\u00a0 40\u00a0(54.8%)\u00a0 18\u00a0(24.7%)\u00a0 3\u00a0(4.1%)\u00a0\nKi67\u00a0Bajo\u00a0(\u226410%)\u00a0 17\u00a0(9.2%)\u00a0 64\u00a0(34.6%)\u00a0 81\u00a0(43.8%)\u00a0 23\u00a0(12.4%)\u00a0<0.0001\u00a0Alto\u00a0(>10%)\u00a0 26\u00a0(19.5%)\u00a0 65\u00a0(48.9%)\u00a0 31\u00a0(23.3%)\u00a0 11\u00a0(8.3%)\u00a0\nRecurrencia \u00a0No\u00a0 35\u00a0(12.6%)\u00a0 113\u00a0(40.6%)\u00a0 99\u00a0(35.6%)\u00a0 31\u00a0(11.2%)\u00a00.2406\u00a0\nS\u00ed\u00a0 8\u00a0(20.0%)\u00a0 16\u00a0(40.0%)\u00a0 13\u00a0(32.5%)\u00a0 3\u00a0(7.5%)\u00a0\nMet\u00e1stasis \u00a0a\u00a0dist\u00e0nciaNo\u00a0 37\u00a0(13.0%)\u00a0 115\u00a0(40.4%)\u00a0 102\u00a0(35.8%)\u00a0 31\u00a0(10.9%)\u00a00.3614\u00a0\nS\u00ed\u00a0 6\u00a0(18.2%)\u00a0 14\u00a0(42.4%)\u00a0 10\u00a0(30.3%)\u00a0 3\u00a0(9.1%)\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n186\u00a0\n\u00a0\u00a0\nCaracter\u00edsticas \u00a0clinicopatol\u00f3gicas \u00a0SP\u00a0\n0\u00a0 1\u00a0 2\u00a0 3\u00a0 P\u00a0valor\u00a0\nQuimioterapia \u00a0\nNeoadyuvante \u00a0No\u00a0 141\u00a0(48.8%)\u00a0107\u00a0(37.0%)\u00a0 34\u00a0(11.8%)\u00a0 7\u00a0(2.4%)\u00a00.0778\u00a0\nSi\u00a0 9\u00a0(37.5%)\u00a0 7\u00a0(29.2%)\u00a0 6\u00a0(25.0%)\u00a0 2\u00a0(8.3%)\u00a0\nEstadio\u00a0T\u00a01\u00a0 77\u00a0(50.0%)\u00a0 55\u00a0(35.7%)\u00a0 18\u00a0(11.7%)\u00a0 4\u00a0(2.6%)\u00a0\n0.3489\u00a02\u00a0 63\u00a0(44.7%)\u00a0 54\u00a0(38.3%)\u00a0 20\u00a0(14.2%)\u00a0 4\u00a0(2.8%)\u00a0\n3\u00a0 4\u00a0(44.4%)\u00a0 2\u00a0(22.2%)\u00a0 2\u00a0(22.2%)\u00a0 1\u00a0(11.1%)\u00a0\n4\u00a0 6\u00a0(66.7%)\u00a0 3\u00a0(33.3%)\u00a0 0\u00a0(0.0%)\u00a0 0\u00a0(0.0%)\u00a0\nEstadio\u00a0N\u00a00\u00a0 73\u00a0(46.8%)\u00a0 53\u00a0(34.0%)\u00a0 24\u00a0(15.4%)\u00a0 6\u00a0(3.8%)\u00a0\n0.1156\u00a01\u00a0 48\u00a0(53.9%)\u00a0 34\u00a0(38.2%)\u00a0 6\u00a0(6.7%)\u00a0 1\u00a0(1.1%)\u00a0\n2\u00a0 14\u00a0(36.8%)\u00a0 15\u00a0(39.5%)\u00a0 7\u00a0(18.4%)\u00a0 2\u00a0(5.3%)\u00a0\n3\u00a0 15\u00a0(50.0%)\u00a0 12\u00a0(40.0%)\u00a0 3\u00a0(10.0%)\u00a0 0\u00a0(0.0%)\u00a0\nGrado\u00a0histol\u00f3gico \u00a01\u00a0 37\u00a0(63.8%)\u00a0 16\u00a0(27.6%)\u00a0 4\u00a0(6.9%)\u00a0 1\u00a0(1.7%)\u00a0\n0.0123\u00a0 2\u00a0 47\u00a0(45.6%)\u00a0 37\u00a0(35.9%)\u00a0 15\u00a0(14.6%)\u00a0 4\u00a0(3.9%)\u00a0\n3\u00a0 55\u00a0(40.4%)\u00a0 57\u00a0(41.9%)\u00a0 20\u00a0(14.7%)\u00a0 4\u00a0(2.9%)\u00a0\nInvasi\u00f3n\u00a0venosa\u00a0No\u00a0 143\u00a0(48.5%)\u00a0103\u00a0(34.9%)\u00a0 40\u00a0(13.6%)\u00a0 9\u00a0(3.1%)\u00a00.9661\u00a0\nSi\u00a0 7\u00a0(38.9%)\u00a0 11\u00a0(61.1%)\u00a0 0\u00a0(0.0%)\u00a0 0\u00a0(0.0%)\u00a0\nInvasi\u00f3n\u00a0linf\u00e0tica\u00a0No\u00a0 77\u00a0(45.0%)\u00a0 64\u00a0(37.4%)\u00a0 23\u00a0(13.5%)\u00a0 7\u00a0(4.1%)\u00a00.1922\u00a0\nSi\u00a0 73\u00a0(51.4%)\u00a0 50\u00a0(35.2%)\u00a0 17\u00a0(12.0%)\u00a0 2\u00a0(1.4%)\u00a0\nBorde\u00a0del\u00a0tumor\u00a0Infiltrativo \u00a0 122\u00a0(54.7%)\u00a0 73\u00a0(32.7%)\u00a0 23\u00a0(10.3%)\u00a0 5\u00a0(2.2%)\u00a00.0001\u00a0pushing\u00a0 28\u00a0(31.1%)\u00a0 41\u00a0(45.6%)\u00a0 17\u00a0(18.9%)\u00a0 4\u00a0(4.4%)\u00a0\nSubtipo\u00a0Lum\u00a0A\u00a0 107\u00a0(54.3%)\u00a0 68\u00a0(34.5%)\u00a0 17\u00a0(8.6%)\u00a0 5\u00a0(2.5%)\u00a0\n0.013\u00a0Lum\u00a0B\u00a0 11\u00a0(42.3%)\u00a0 10\u00a0(38.5%)\u00a0 4\u00a0(15.4%)\u00a0 1\u00a0(3.8%)\u00a0\nHER2+\u00a0 13\u00a0(39.4%)\u00a0 7\u00a0(21.2%)\u00a0 10\u00a0(30.3%)\u00a0 3\u00a0(9.1%)\u00a0\nBasal\u00a0 14\u00a0(38.9%)\u00a0 16\u00a0(44.4%)\u00a0 6\u00a0(16.7%)\u00a0 0\u00a0(0.0%)\u00a0\nInd.\u00a0 5\u00a0(23.8%)\u00a0 13\u00a0(61.9%)\u00a0 3\u00a0(14.3%)\u00a0 0\u00a0(0.0%)\u00a0\nRE\u00a0Neg\u00a0(<1%)\u00a0 36\u00a0(36.7%)\u00a0 39\u00a0(39.8%)\u00a0 19\u00a0(19.4%)\u00a0 4\u00a0(4.1%)\u00a00.0024\u00a0Pos\u00a0(\u22651%)\u00a0 114\u00a0(53.0%)\u00a0 75\u00a0(34.9%)\u00a0 21\u00a0(9.8%)\u00a0 5\u00a0(2.3%)\u00a0\nRP\u00a0Neg\u00a0(<1%)\u00a0 54\u00a0(39.7%)\u00a0 52\u00a0(38.2%)\u00a0 24\u00a0(17.6%)\u00a0 6\u00a0(4.4%)\u00a00.0025\u00a0Pos\u00a0(\u22651%)\u00a0 96\u00a0(54.2%)\u00a0 62\u00a0(35.0%)\u00a0 16\u00a0(9.0%)\u00a0 3\u00a0(1.7%)\u00a0\nHER2\u00a0negativo\u00a0 19\u00a0(41.3%)\u00a0 21\u00a0(45.7%)\u00a0 6\u00a0(13.0%)\u00a0 0\u00a0(0.0%)\u00a0\n0.0476\u00a01+\u00a0 63\u00a0(56.3%)\u00a0 37\u00a0(33.0%)\u00a0 9\u00a0(8.0%)\u00a0 3\u00a0(2.7%)\u00a0\n2+\u00a0 48\u00a0(45.3%)\u00a0 43\u00a0(40.6%)\u00a0 13\u00a0(12.3%)\u00a0 2\u00a0(1.9%)\u00a0\n3+\u00a0 20\u00a0(40.8%)\u00a0 13\u00a0(26.5%)\u00a0 12\u00a0(24.5%)\u00a0 4\u00a0(8.2%)\u00a0\np53\u00a0Neg\u00a0(\u226410%)\u00a0 124\u00a0(51.2%)\u00a0 81\u00a0(33.5%)\u00a0 31\u00a0(12.8%)\u00a0 6\u00a0(2.5%)\u00a00.0611\u00a0Pos\u00a0(>10%)\u00a0 26\u00a0(36.6%)\u00a0 33\u00a0(46.5%)\u00a0 9\u00a0(12.7%)\u00a0 3\u00a0(4.2%)\u00a0\nKi67\u00a0Bajo\u00a0(\u226410%)\u00a0 98\u00a0(54.1%)\u00a0 57\u00a0(31.5%)\u00a0 24\u00a0(13.3%)\u00a0 2\u00a0(1.1%)\u00a00.0161\u00a0Alto\u00a0(>10%)\u00a0 52\u00a0(39.4%)\u00a0 57\u00a0(43.2%)\u00a0 16\u00a0(12.1%)\u00a0 7\u00a0(5.3%)\u00a0\nRecurrencia \u00a0No\u00a0 130\u00a0(47.6%)\u00a0 99\u00a0(36.3%)\u00a0 36\u00a0(13.2%)\u00a0 8\u00a0(2.9%)\u00a00.6681\u00a0\nSi\u00a0 20\u00a0(50.0%)\u00a0 15\u00a0(37.5%)\u00a0 4\u00a0(10.0%)\u00a0 1\u00a0(2.5%)\u00a0\nMet\u00e1stasis \u00a0a\u00a0dist\u00e0nciaNo\u00a0 134\u00a0(47.9%)\u00a0102\u00a0(36.4%)\u00a0 36\u00a0(12.9%)\u00a0 8\u00a0(2.9%)\u00a00.9372\u00a0\nSi\u00a0 16\u00a0(48.5%)\u00a0 12\u00a0(36.4%)\u00a0 4\u00a0(12.1%)\u00a0 1\u00a0(3.0%)\u00a0\n\u00a0\nAn\u00e1lisis\u00a0estad\u00edstico \u00a0realizado\u00a0con\u00a0la\u00a0prueba\u00a0U\u00a0de\u00a0Mann\u2010Whitney\u00a0(2\u00a0categor\u00edas), \u00a0Kruskal\u2010Wallis\u00a0(m\u00e1s\u00a0de\u00a02\u00a0categor\u00edas). \u00a0Valores\u00a0con\u00a0\nuna\u00a0P<0,05,\u00a0resaltados \u00a0en\u00a0negrita,\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n187\u00a0\n\u00a0Tabla\u00a0anexa\u00a03.\u00a0Informaci\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0la\u00a0cohorte\u00a0utilizada\u00a0para\u00a0investigar \u00a0los\u00a0niveles\u00a0circulantes \u00a0de\u00a0SP\u00a0en\u00a0los\u00a0en\u00a0\npacientes \u00a0con\u00a0CM\u00a0respecto\u00a0a\u00a0los\u00a0donantes \u00a0sanos.\u00a0\n\u00a0\nAn\u00e1lisis\u00a0estad\u00edstico \u00a0realizado\u00a0con\u00a0la\u00a0prueba\u00a0U\u00a0de\u00a0Mann\u2010Whitney\u00a0(2\u00a0categor\u00edas), \u00a0Kruskal\u2010Wallis\u00a0(m\u00e1s\u00a0de\u00a02\u00a0categor\u00edas). \u00a0Valores\u00a0con\u00a0\nuna\u00a0P<0,05,\u00a0resaltados \u00a0en\u00a0negrita,\u00a0fueron\u00a0considerados \u00a0estad\u00edsticamente \u00a0significativos. \u00a0\n*An\u00e1lisis\u00a0estad\u00edstico \u00a0con\u00a0una\u00a0ANOVA\u00a0de\u00a0\u00a0rangos.\u00a0Las\u00a0comparaciones \u00a0entre\u00a0los\u00a0grupos:\u00a0S\u00ed\u00a0vs\u00a0No\u00a0(P=\u00a00,0652);\u00a0S\u00ed\u00a0vs\u00a0Desconocido \u00a0(P=\u00a0\n0.8747)\u00a0y\u00a0no\u00a0frente\u00a0a\u00a0desconocidos \u00a0(P=\u00a00,0371).\u00a0Caracter\u00edsticas \u00a0histopatol\u00f3gicas \u00a0de\u00a0\nlos\u00a0pacientes \u00a0con\u00a0CM\u00a0\u00a0 Variable\u00a0de\u00a0an\u00e1lisis:\u00a0SP\u00a0(ng/ml)\u00a0P\u00a0\nvalor\u00a0N\u00a0 Media\u00a0SD\u00a0Minimo\u00a0Mediana\u00a0Maximo\u00a025th\u00a0\nPctl\u00a075th\u00a0\nPctl\u00a0\nEdad\u00a0<50\u00a0 36\u00a0 908\u00a0 372\u00a0 244\u00a0 813\u00a0 1703\u00a0 683\u00a0 1098\u00a00.0601\u00a0>=50\u00a0 103\u00a0 1163\u00a0752\u00a0 192\u00a0 928\u00a0 6082\u00a0 736\u00a0 1456\u00a0\n\u00cdndice\u00a0de\u00a0masa\u00a0\ncorporal\u00a0(IMC)\u00a0<18,5\u00a0 11\u00a0 1057\u00a0359\u00a0 606\u00a0 964\u00a0 1688\u00a0 731\u00a0 1247\u00a0\n0.3472\u00a018,5\u201025\u00a0 53\u00a0 989\u00a0 555\u00a0 244\u00a0 851\u00a0 3561\u00a0 702\u00a0 1098\u00a0\n25\u201030\u00a0 47\u00a0 1150\u00a0853\u00a0 192\u00a0 926\u00a0 6082\u00a0 788\u00a0 1346\u00a0\n>30\u00a0 28\u00a0 1227\u00a0673\u00a0 264\u00a0 1037\u00a0 2812\u00a0 724\u00a0 1575\u00a0\nCA\u2010153\u00a0(U/ml)\u00a0<\u00a040\u00a0 135\u00a0 1093\u00a0684\u00a0 192\u00a0 900\u00a0 6082\u00a0 721\u00a0 1346\u00a00.6547\u00a0>=40\u00a0 4\u00a0 1227\u00a0719\u00a0 781\u00a0 912\u00a0 2301\u00a0 829\u00a0 1624\u00a0\nCEA\u00a0(ng/ml)\u00a0<5\u00a0 120\u00a0 1087\u00a0702\u00a0 192\u00a0 908\u00a0 6082\u00a0 735\u00a0 1330\u00a00.6567\u00a0>=5\u00a0 19\u00a0 1159\u00a0555\u00a0 512\u00a0 883\u00a0 2301\u00a0 721\u00a0 1688\u00a0\nRE\u00a0Neg\u00a0(<10%)\u00a0 27\u00a0 1282\u00a01133\u00a0 514\u00a0 944\u00a0 6082\u00a0 785\u00a0 1302\u00a00.5109\u00a0Pos\u00a0(>=10%)\u00a0 111\u00a0 1044\u00a0514\u00a0 192\u00a0 889\u00a0 2812\u00a0 709\u00a0 1346\u00a0\nRP\u00a0Neg\u00a0(<10%)\u00a0 55\u00a0 1159\u00a0863\u00a0 411\u00a0 889\u00a0 6082\u00a0 772\u00a0 1337\u00a00.7724\u00a0Pos\u00a0(\u226510%)\u00a0 83\u00a0 1046\u00a0530\u00a0 192\u00a0 900\u00a0 2812\u00a0 713\u00a0 1346\u00a0\nHER2\u00a0Neg\u00a0 13\u00a0 1142\u00a0893\u00a0 208\u00a0 802\u00a0 3561\u00a0 713\u00a0 1341\u00a0\n0.3695\u00a01+\u00a0 77\u00a0 1126\u00a0752\u00a0 192\u00a0 947\u00a0 6082\u00a0 733\u00a0 1369\u00a0\n2+\u00a0 11\u00a0 1129\u00a0524\u00a0 411\u00a0 899\u00a0 2315\u00a0 849\u00a0 1480\u00a0\n3+\u00a0 18\u00a0 923\u00a0 550\u00a0 244\u00a0 793\u00a0 2619\u00a0 702\u00a0 954\u00a0\nSubtipo\u00a0tumoral\u00a0Lum\u00a0A\u00a0 83\u00a0 1054\u00a0521\u00a0 192\u00a0 889\u00a0 2812\u00a0 702\u00a0 1369\u00a0\n0.353\u00a0Lum\u00a0B\u00a0 11\u00a0 986\u00a0 677\u00a0 244\u00a0 814\u00a0 2619\u00a0 702\u00a0 1098\u00a0\nHER2\u00a0 7\u00a0 823\u00a0 276\u00a0 514\u00a0 772\u00a0 1367\u00a0 606\u00a0 917\u00a0\nTN\u00a0 15\u00a0 1559\u00a01449\u00a0 626\u00a0 975\u00a0 6082\u00a0 811\u00a0 1688\u00a0\nIN\u00a0 2\u00a0 886\u00a0 105\u00a0 811\u00a0 886\u00a0 960\u00a0 811\u00a0 960\u00a0\nPatolog\u00eda \u00a0CDIS\u00a0 26\u00a0 1067\u00a0389\u00a0 423\u00a0 949\u00a0 1883\u00a0 808\u00a0 1281\u00a0\n0.7440\u00a0CDI\u00a0 99\u00a0 1113\u00a0765\u00a0 192\u00a0 889\u00a0 6082\u00a0 709\u00a0 1346\u00a0\nCDI/CDIS\u00a0 1\u00a0 626\u00a0 .\u00a0 626\u00a0 626\u00a0 626\u00a0 626\u00a0 626\u00a0\nCLI\u00a0 10\u00a0 1144\u00a0537\u00a0 417\u00a0 1027\u00a0 2134\u00a0 721\u00a0 1465\u00a0\nGrado\u00a0nuclear\u00a0GH\u00a0I\u00a0 17\u00a0 940\u00a0 476\u00a0 192\u00a0 802\u00a0 2301\u00a0 733\u00a0 996\u00a0\n0.3614\u00a0 GH\u00a0II\u00a0 63\u00a0 994\u00a0 468\u00a0 208\u00a0 899\u00a0 2315\u00a0 647\u00a0 1341\u00a0\nGH\u00a0III\u00a0 34\u00a0 1138\u00a0550\u00a0 512\u00a0 903\u00a0 2812\u00a0 811\u00a0 1415\u00a0\nGrado\u00a0histol\u00f3gico \u00a01\u00a0 28\u00a0 944\u00a0 543\u00a0 192\u00a0 824\u00a0 2315\u00a0 590\u00a0 1211\u00a0\n0.0927\u00a0 2\u00a0 39\u00a0 1289\u00a0947\u00a0 264\u00a0 1031\u00a0 6082\u00a0 709\u00a0 1531\u00a0\n3\u00a0 19\u00a0 972\u00a0 231\u00a0 606\u00a0 882\u00a0 1367\u00a0 814\u00a0 1281\u00a0\nTama\u00f1o\u00a0tumoral\u00a0<\u00a02\u00a0cm\u00a0 86\u00a0 1074\u00a0574\u00a0 208\u00a0 883\u00a0 3561\u00a0 709\u00a0 1369\u00a0\n0.7193\u00a0 2\u20105\u00a0cm\u00a0 42\u00a0 1069\u00a0493\u00a0 192\u00a0 941\u00a0 2619\u00a0 811\u00a0 1341\u00a0\n>\u00a05\u00a0cm\u00a0 8\u00a0 1447\u00a01889\u00a0 411\u00a0 875\u00a0 6082\u00a0 628\u00a0 1038\u00a0\nN\u00f3dulos\u00a0linf\u00e1ticos\u00a0Afectados \u00a0 94\u00a0 1043\u00a0692\u00a0 192\u00a0 881\u00a0 6082\u00a0 726\u00a0 1247\u00a00.0914\u00a0No\u00a0afectados \u00a0 45\u00a0 1208\u00a0655\u00a0 264\u00a0 1031\u00a0 3561\u00a0 785\u00a0 1507\u00a0\nTratamiento \u00a0Neoadyuvancia \u00a0 24\u00a0 1227\u00a01140\u00a0 288\u00a0 1010\u00a0 6082\u00a0 818\u00a0 1211\u00a00.5869\u00a0Cirug\u00eda\u00a0 115\u00a0 1069\u00a0546\u00a0 192\u00a0 883\u00a0 3561\u00a0 721\u00a0 1369\u00a0\nMedicaci\u00f3n \u00a0con\u00a0\nantiinflamatorios \u00a0S\u00ed*\u00a0 17\u00a0 1235\u00a0594\u00a0 423\u00a0 1098\u00a0 2812\u00a0 755\u00a0 1478\u00a0\n0.0399*\u00a0 No*\u00a0 91\u00a0 1005\u00a0552\u00a0 192\u00a0 852\u00a0 3561\u00a0 704\u00a0 1226\u00a0\nDesconocido* \u00a0 30\u00a0 1301\u00a0998\u00a0 430\u00a0 1070\u00a0 6082\u00a0 811\u00a0 1456\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n188\u00a0\n\u00a0Tabla\u00a0anexa\u00a04.\u00a0Informaci\u00f3n \u00a0histopatol\u00f3gica \u00a0de\u00a0las\u00a0muestras \u00a0utilizadas \u00a0para\u00a0determinar \u00a0los\u00a0efectos\u00a0de\u00a0la\u00a0SP\u00a0en\u00a0\ntumores\u00a0primarios \u00a0humanos \u00a0de\u00a0mama\u00a0y\u00a0el\u00a0valor\u00a0de\u00a0la\u00a0fluorescencia \u00a0media\u00a0para\u00a0la\u00a0expresi\u00f3n \u00a0pHER2\u00a0Y1248 .\u00a0Se\u00a0\nmuestra\u00a0la\u00a0intensidad \u00a0media\u00a0de\u00a0fluorescencia \u00a0de\u00a0pHER2\u00a0Y1248\u00a0para\u00a0cada\u00a0grupo\u00a0de\u00a0tratamiento. \u00a0La\u00a0activaci\u00f3n \u00a0de\u00a0\nHER2\u00a0se\u00a0consider\u00f3 \u00a0positiva\u00a0cuando\u00a0la\u00a0intensidad \u00a0media\u00a0de\u00a0fluorescencia \u00a0fue\u00a0superior\u00a0a\u00a0la\u00a0del\u00a0control\u00a0despu\u00e9s\u00a0de\u00a06\u00a0o\u00a0\n10\u00a0minutos\u00a0de\u00a0tratamiento \u00a0con\u00a0SP.\u00a0\n\u00a0\nND:\u00a0No\u00a0determinado \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0Muestra\u00a0\u00a0Caracter\u00edsticas \u00a0histopatol\u00f3gicas \u00a0Intensidad \u00a0de\u00a0fluorescencia \u00a0\nmedia\u00a0\u00a0 Activaci\u00f3n\nHER2\u00a0\u00a0Edad\u00a0NK\u20101R\u00a0RE\u00a0PR\u00a0HER2\u00a0\nIHC\u00a0HER2\u00a0\nFISH\u00a0SubtipoGrado\u00a0\nhistol\u00f3gicoTipo\u00a0 0\u00a0min\u00a0 6\u00a0min\u00a010\u00a0min\u00a0\nBT8\u00a0 87\u00a0 110\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A 2 IDC 687\u00a0 756\u00a0 517\u00a0 si\nBT41\u00a0 74\u00a0 100\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A 2 IDC 756\u00a0 805\u00a0 977\u00a0 si\u00a0\nBT91\u00a0 64\u00a0 105\u00a0+\u00a0+\u00a0 ++\u00a0\u2010 \u00a0 Lum\u00a0A 2 IDC 465\u00a0 857\u00a0 973\u00a0 si\u00a0\nBT93\u00a0 63\u00a0 180\u00a0+\u00a0\u2010 \u00a0 ++\u00a0\u2010 \u00a0 Lum\u00a0A 2 IDC 1192\u00a0 1266\u00a0 1987\u00a0 si\u00a0\nBT100\u00a0 65\u00a0 200\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A 1 IDC 897\u00a0 848\u00a0 1029\u00a0 si\u00a0\nBT115\u00a0 60\u00a0 100\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A ND ILC\u00a0 456\u00a0 492\u00a0 539\u00a0 si\u00a0\nBT116\u00a0 50\u00a0 100\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A 1 IDC 499\u00a0 781\u00a0 703\u00a0 si\u00a0\nBT123\u00a0 52\u00a0 200\u00a0+\u00a0+\u00a0 ++\u00a0\u2010 \u00a0 Lum\u00a0A 2 IDC 596\u00a0 397\u00a0 494\u00a0 no\nBT130\u00a0 54\u00a0 120\u00a0+\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A 1 IDC 486\u00a0 353\u00a0 279\u00a0 no\nBT135\u00a0 81\u00a0 20\u00a0 +\u00a0+\u00a0 +\u00a0 ND Lum\u00a0A ND IDC 1107\u00a0 951\u00a0 829\u00a0 no\nBT88\u00a0 32\u00a0 110\u00a0+\u00a0\u2010 \u00a0 ++\u00a0 +\u00a0 Lum\u00a0B 3 IDC 1113\u00a0 864\u00a0 1005\u00a0 no\nBT95\u00a0 43\u00a0 200\u00a0+\u00a0+\u00a0 ++\u00a0 +\u00a0 Lum\u00a0B 2 IDC 657\u00a0 539\u00a0 610\u00a0 no\nBT109\u00a0 48\u00a0 200\u00a0+\u00a0\u2010\u00a0 +++\u00a0ND Lum\u00a0B 2 IDC 789\u00a0 455\u00a0 786\u00a0 no\nBT137\u00a0 67\u00a0 260\u00a0+\u00a0\u2010 \u00a0 +++\u00a0ND Lum\u00a0B ND LCIS 1152\u00a0 776\u00a0 1242\u00a0 no\nBT1\u00a0 52\u00a0 140\u00a0\u2010 \u00a0 \u2010\u00a0 +++\u00a0ND HER2 3 IDC 823\u00a0 1016\u00a0 838\u00a0 si\u00a0\nBT24\u00a0 78\u00a0 190\u00a0\u2010 \u00a0 \u2010\u00a0 +++\u00a0ND HER2 3 IDC 1242\u00a0 1769\u00a0 1864\u00a0 si\u00a0\nBT142\u00a0 63\u00a0 180\u00a0\u2010 \u00a0\u2010 \u00a0 +++\u00a0ND HER2 2 IDC 691\u00a0 962\u00a0 1077\u00a0 si\u00a0\nBT56\u00a0 88\u00a0 200\u00a0\u2010 \u00a0\u2010 \u00a0 +\u00a0 ND TN 3 IDC 173\u00a0 605\u00a0 178\u00a0 si\u00a0\nBT126\u00a0 34\u00a0 200\u00a0\u2010 \u00a0\u2010 \u00a0 +\u00a0 ND TN 3 IDC 522\u00a0 582\u00a0 465\u00a0 si\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n189\u00a0\n\u00a0Tabla\u00a0anexa\u00a05.\u00a0IC50\u00a0obtenida\u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0respuesta \u00a0a\u00a0drogas\u00a0anti\u2010HER2\u00a0y\u00a0anti\u2010EGFR\u00a0de\u00a0la\u00a0Fig.\u00a030.\u00a0\n\u00a0\n\u00a0 MDA\u2010MB\u2010453\u00a0 MDA\u2010MB\u2010468\u00a0\n\u00a0IC50\u00a0\nAG1478\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG825\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nLapatinib \u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG1478\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG825\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nLapatinib \u00a0\n(\u00b5M)\u00a0\nControl\u00a0 5.66\u00a0 20.\u00a054\u00a0 0.224\u00a0 34.41\u00a0 36.34\u00a0 2.32\u00a0\nSP\u00a0100\u00a0nM\u00a0 5.41\u00a0 33.06\u00a0 0.233\u00a0 31.50\u00a0 35.78\u00a0 2.89\u00a0\nSP\u00a0500\u00a0nM\u00a0 5.38\u00a0 22.98\u00a0 0.259\u00a0 27.89\u00a0 35.80\u00a0 2.52\u00a0\nP\u00a0valor\u00a0SP\u00a0100\u00a0nM\u00a0 n.s.\u00a0 <0.0001\u00a0 n.s.\u00a0 n.s.\u00a0 n.s.\u00a0 n.s.\u00a0\nP\u00a0valor\u00a0SP\u00a0500\u00a0nM\u00a0 n.s.\u00a0 n.s.\u00a0 n.s.\u00a0 0.049\u00a0 n.s.\u00a0 n.s.\u00a0\nIC50\u00a0correspondientes \u00a0a\u00a0la\u00a0Figura\u00a030.\u00a0n.s.,\u00a0no\u00a0significativo. \u00a0\n\u00a0\n\u00a0 MDA\u2010MB\u2010453\u00a0 MDA\u2010MB\u2010468\u00a0\n\u00a0IC50\u00a0\nAG1478\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG825\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nLapatinib \u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG1478\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nAG825\u00a0\n(\u00b5M)\u00a0IC50\u00a0\nLapatinib \u00a0\n(\u00b5M)\u00a0\nControl\u00a0 5.66\u00a0 28.62\u00a0 0.22\u00a0 12.56\u00a0 30.97\u00a0 3.11\u00a0\nSobreexposici\u00f3n \u00a0a\u00a0SP\u00a0 12.95\u00a0 38.93\u00a0 1.46\u00a0 75.23\u00a0 36.59\u00a0 3.55\u00a0\nP\u00a0valor\u00a0 <0.0001\u00a0 0.03\u00a0 <0.0001\u00a0 <0.0001\u00a0 <0.0001\u00a0 n.s.\u00a0\nIC50\u00a0correspondientes \u00a0a\u00a0la\u00a0Figura\u00a030.\u00a0n.s.,\u00a0no\u00a0significativo. \u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n190\u00a0\n\u00a0Tabla\u00a0anexa\u00a06.\u00a0Nuevos\u00a0enfoques \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0CM\u00a0HER2+*.\u00a0Modificada \u00a0de455.\u00a0\u00a0\nESTRATEGIAS \u00a0Y\u00a0F\u00c1RMACOS \u00a0 ESTADO\u00a0REFERENCIAS \u00a0O\u00a0ENSAYOS \u00a0CL\u00cdNICOS \u00a0\nIDENTIFICADOS \u00a0\nOptimizaci\u00f3n \u00a0de\u00a0la\u00a0estructura \u00a0del\u00a0trastuzumab \u00a0\nErtumaxomab \u00a0(trifuncional,mAb \u00a0\u00a0bispec\u00edfico \u00a0anti\u2010HER2\u00a0y\u00a0\nCD3\u00a0Fase\u00a0II\u00a0(terminada) \u00a0\u00a0 \u00a0535\u2010537\u00a0\u00a0\nConjugaci\u00f3n \u00a0de\u00a0mol\u00e9culas \u00a0anti\u2010HER2\u00a0enlazado \u00a0con\u00a0un\u00a0agente\u00a0citot\u00f3xico \u00a0\nTrastuzumab\u2013DM1 \u00a0(trastuzumab \u00a0conjugado \u00a0con\u00a0un\u00a0\nderivado\u00a0de\u00a0la\u00a0maitansina \u00a0(DM1)\u00a0Fase\u00a0III\u00a0\u00a0538\u00a0\nTerapias\u00a0EGFR\u00a0\u00a0\nPelitinib\u00a0(Inhibidor \u00a0TK\u00a0irreversible) \u00a0\u00a0Fase\u00a0I\u2013II\u00a0\n(suspendido) \u00a0\u00a0539\u00a0\nTerapias\u00a0HER3\u00a0\nMM\u2010121\u00a0(mAb\u00a0\u00a0anti\u2010HER3)\u00a0\u00a0 Fase\u00a0I\u2013II\u00a0\u00a0540,\u00a0\u00a0NCT01097460, \u00a0NCT00911898 \u00a0\u00a0\nMM\u2010111\u00a0(anticuerpo \u00a0biespec\u00edfico \u00a0HER2/HER3) \u00a0\u00a0 Fase\u00a0I\u2013II\u00a0\u00a0541,\u00a0\u00a0NCT00911898, \u00a0NCT01097460 \u00a0\u00a0\nTerapias\u00a0HER2\u00a0\nPertuzumab \u00a0(mAb\u00a0\u00a0que\u00a0inhibe\u00a0la\u00a0dimerizaci\u00f3n \u00a0de\u00a0HER2)\u00a0\u00a0 Fase\u00a0III\u00a0\u00a0542\u00a0\nITKs\u00a0de\u00a0amplio\u00a0espectro\u00a0\nNeratinib \u00a0(ITK\u00a0irreversible \u00a0HER1/HER2) \u00a0\u00a0 Fase\u00a0III\u2021\u00a0\u00a0543\u00a0\nBIBW\u20102992\u00a0(ITK\u00a0irreversible \u00a0HER1/HER2) \u00a0\u00a0 Fase\u00a0II\u00a0\u00a0544\u00a0\nInhibici\u00f3n \u00a0de\u00a0la\u00a0PI3K\u00a0(clase\u00a0I)\u00a0\u00a0\nXL147\u00a0(Inhibidor \u00a0panPI3K\u00a0[todas\u00a0las\u00a0clases\u00a0de\u00a0la\u00a0\nisoforma\u00a0I])\u00a0\u00a0Fase\u00a0I\u2013II\u00a0\u00a0545,\u00a0NCT01042925, \u00a0NCT01082068 \u00a0\u00a0\nBGT226\u00a0(Inhibidor \u00a0selectivo\u00a0de\u00a0p110\u03b1\u00a0PI3K)\u00a0\u00a0 Fase I\u2013II\u00a0\u00a0 NCT00600275, \u00a0NCT00742105 \u00a0\u00a0\nInhibici\u00f3n \u00a0de\u00a0mTOR\u00a0\u00a0\nEverolimus \u00a0\u00a0 Fase\u00a0III\u00a0\u00a0546,\u00a0547\u00a0\nInhibici\u00f3n \u00a0de\u00a0la\u00a0v\u00eda\u00a0de\u00a0IGFR\u00a0\nFigitumumab \u00a0(mAb\u00a0anti\u00a0IGF\u20101R)\u00a0\u00a0 Fase\u00a0II\u00a0\u00a0548,\u00a0NCT00635245 \u00a0\u00a0\nCixutumumab \u00a0(mAb\u00a0anti\u00a0IGF\u20101R)\u00a0\u00a0 Fase\u00a0II\u00a0\u00a0\u00a0549,\u00a0NCT00699491, \u00a0NCT00728949 \u00a0\u00a0\nAVE1642\u00a0(mAb\u00a0anti\u00a0IGF\u20101R)\u00a0\u00a0Fase\u00a0II\u00a0(terminado \u00a0\npor\u00a0decisi\u00f3n\u00a0de\u00a0la\u00a0\ncompa\u00f1\u00eda) \u00a0NCT0074878 \u00a0\u00a0\nDalotuzumab \u00a0(mAb\u00a0anti\u00a0IGF\u20101R)\u00a0\u00a0Fase\u00a0I\u2013II\u00a0\n(completado) \u00a0\u00a0NCT00759785 \u00a0\u00a0\u00a0\nAMG479\u00a0(mAb\u00a0anti\u00a0IGF\u20101R)\u00a0\u00a0 Fase\u00a0II\u00a0\u00a0 NCT00626106 \u00a0\u00a0\nOSI\u2010906\u00a0(Inhibidor \u00a0IGF\u20101R\u00a0)\u00a0\u00a0 Fase I\u2013II\u00a0\u00a0 NCT01013506 \u00a0\u00a0\nInhibici\u00f3n \u00a0de\u00a0HSP90\u00a0\u00a0\nAlvespimycin \u00a0\u00a0Fase\u00a0I\u2013II\u00a0(fase\u00a0II\u00a0en\u00a0\nHER2+\u00a0CM\u00a0\ncompletado) \u00a0\u00a0550\u00a0\nRetaspimycin \u00a0\u00a0 Fase II\u00a0\u00a0551,\u00a0NCT00817362 \u00a0\u00a0\nBIIB021\u00a0\u00a0 Fase\u00a0I\u2013II\u00a0\u00a0552,\u00a0NCT00412412 \u00a0\u00a0\nAUY922\u00a0\u00a0 Fase\u00a0I\u2013II\u00a0\u00a0 NCT00526045 \u00a0\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\n\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n191\u00a0\n\u00a0ESTRATEGIAS \u00a0Y\u00a0F\u00c1RMACOS \u00a0 ESTADO\u00a0REFERENCIAS \u00a0O\u00a0ENSAYOS \u00a0CL\u00cdNICOS \u00a0\nIDENTIFICADOS \u00a0\u00a0\nVacunas\u00a0e\u00a0Inmunoterapia \u00a0\nE75\u00a0(vacuna\u00a0pept\u00eddica \u00a0basada\u00a0en\u00a0el\u00a0dominio\u00a0\nextracelular \u00a0de\u00a0HER2)\u00a0\u00a0Fase\u00a0II\u00a0\u00a0549,\u00a0553,\u00a0554\u00a0\u00a0\nGP2\u00a0(vacuna\u00a0pept\u00eddica \u00a0basada\u00a0en\u00a0el\u00a0dominio\u00a0\ntransmembrana \u00a0de\u00a0HER2)\u00a0Fase\u00a0II\u00a0555\u00a0\nAE37\u00a0(vacuna\u00a0pept\u00eddica, \u00a0h\u00edbrido\u00a0de\u00a0li\u2010key\u00a0)\u00a0\u00a0 Fase II\u00a0\u00a0556\u00a0\nVacuna\u00a0pept\u00eddica \u00a0del\u00a0dominio\u00a0intracelular \u00a0de\u00a0HER2\u00a0 Fase\u00a0I\u2013II\u00a0\u00a0 NCT00343109, \u00a0NCT00791037, \u00a0NCT00363012 \u00a0\u00a0\nHER2\u00a0AUTOVAC \u00a0(PX104.1.6) \u00a0\u00a0Fase\u00a0I\u2013II\u00a0\n(discontinuo) \u00a0\u00a0NCT00068614 \u00a0\u00a0\ndHER2\u00a0(prote\u00edna \u00a0modificada \u00a0de\u00a0HER2)\u00a0con\u00a0AS15\u00a0\nadyuvante \u00a0Fase\u00a0I\u2013II\u00a0\u00a0 NCT00058526, \u00a0NCT00952692 \u00a0\u00a0\nAllogeneic \u00a0GM\u2010CSFsecreting \u00a0wholecell \u00a0breastcancer \u00a0\nvaccine\u00a0\u00a0Fase\u00a0II\u00a0\u00a0NCT00399529, \u00a0NCT00095862, \u00a0NCT00847171, \u00a0\nNCT00971737, \u00a0NCT00397371 \u00a0\u00a0\nVacunas\u00a0aut\u00f3logas \u00a0de\u00a0c\u00e9lulas\u00a0dendtriticas \u00a0(c\u00e9lulas\u00a0\ndendtriticas \u00a0que\u00a0contienen \u00a0p\u00e8ptidos\u00a0HER2\u00a0o\u00a0que\u00a0estan\u00a0\ngen\u00e9ticamente \u00a0manipuladas \u00a0para\u00a0sobreexpesar \u00a0HER2)\u00a0\u00a0Fase\u00a0I\u2013II\u00a0\u00a0557,\u00a0NCT00266110, \u00a0NCT00228358 \u00a0\u00a0\nPG134D5 \u2010D12\u00a0(CAR\u00a0antiHER2\u00a0;\u00a0linfocitos\u00a0aut\u00f3logos \u00a0de\u00a0\nsangre\u00a0perif\u00e9rica \u00a0\u00a0transducidos \u00a0con\u00a0un\u00a0vector\u00a0retroviral) \u00a0\u00a0Fase\u00a0I\u2013II\u00a0\u00a0 NCT00924287 \u00a0\u00a0\nQuinasas \u00a0multidiana \u00a0e\u00a0inhibidores \u00a0de\u00a0la\u00a0angiog\u00e9nesis \u00a0\u00a0\nBevacizumab \u00a0(mAb\u00a0anti\u00a0VEGF\u2010A)\u00a0\u00a0 Fase\u00a0III\u2021\u00a0\u00a0558\u00a0\nPazopanib \u00a0(Inhibidor \u00a0de\u00a0VEGFR,\u00a0PDGFR\u00a0y\u00a0c\u2010kit;\u00a0Inhibe\u00a0la\u00a0\nrelaci\u00f3n\u00a0de\u00a0v\u00edas\u00a0entre\u00a0HER2\u00a0y\u00a0VEGFR)\u00a0\u00a0Fase\u00a0II\u00a0\u00a0559\u00a0\nSunitinib\u00a0(Inhibidor \u00a0de\u00a0VEGFR,\u00a0PDGFR,\u00a0c\u2010Kit,\u00a0RET,\u00a0FLT3,\u00a0\nand\u00a0CSF1R)\u00a0\u00a0Fase\u00a0II\u00a7\u00a0\u00a0560\u00a0\n\u00a0*En\u00a0ensayos\u00a0cl\u00ednicos\u00a0de\u00a0fase\u00a0I\u2013II\u00a0o\u00a0mas\u00a0avanzados. \u00a0\u2021Como\u00a0adyuvancia \u00a0y\u00a0para\u00a0pacientes \u00a0con\u00a0un\u00a0etadio\u00a0avanzado \u00a0de\u00a0la\u00a0enfermedad. \u00a0\u00a7Dos\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0negativos \u00a0fase\u00a0III\u00a0trials\u00a0en\u00a0enfermos \u00a0HER\u00a0negativos. \u00a0Abreviaturas: \u00a0AS15,\u00a0Inmunoterapia \u00a0espec\u00edfica \u00a0anti\u2010cancer;\u00a0CAR,\u00a0\u00a0receptor\u00a0de\u00a0\nadenovirus \u00a0coxsackievirusy \u00a0;\u00a0CSF1R,\u00a0Receptor\u00a0del\u00a0factor\u00a01\u00a0estimulador \u00a0de\u00a0colonias\u00a0;\u00a0FLT3,\u00a0Tirosina\u00a0quinasa\u00a03\u00a0Fms\u2010like;\u00a0GM\u2010CSF,\u00a0factor\u00a0estimulante \u00a0\nde\u00a0colonias\u00a0de\u00a0granulocitos \u2010macr\u00f3fagos; \u00a0HSP90,\u00a0prote\u00edna\u00a0de\u00a0shock\u00a0t\u00e9rmico\u00a090;\u00a0IGF\u20101R,\u00a0receptor\u00a0del\u00a0factor\u00a0de\u00a0crecimiento \u00a0insul\u00ednico \u00a0tipo\u00a01;\u00a0mAb,\u00a0\nanticuerpo \u00a0monoclonal; \u00a0ITK,\u00a0inhibidor\u00a0tirosina\u00a0quinasa.\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0ANEXOS\u00a0\u00a0\n\u00a0\n192\u00a0\n\u00a0\nFigura\u00a0anexa\u00a01.\u00a0Representaci\u00f3n \u00a0esquem\u00e1tica \u00a0de\u00a0los\u00a0genes\u00a0diferencialmente \u00a0expresados \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010\nMB\u2010453\u00a0SP\u00a0interconectados. \u00a0El\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0v\u00edas\u00a0se\u00a0realiz\u00f3\u00a0con\u00a0el\u00a0software\u00a0IPA.\u00a0Los\u00a0genes\u00a0sobreexpresados \u00a0en\u00a0este\u00a0\ngrupo\u00a0se\u00a0muestran \u00a0en\u00a0rojo,\u00a0mientras\u00a0que\u00a0los\u00a0infraeexpresados \u00a0se\u00a0representan \u00a0en\u00a0verde.\u00a0\u00a0\nRed\u00a01.\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n193\u00a0\n\u00a0\nRed\u00a02.\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n194\u00a0\n\u00a0Red\u00a03.\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n195\u00a0\n\u00a0\nRed\u00a04.\u00a0MDA\u2010MB\u2010453\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n196\u00a0\n\u00a0\nFigura\u00a0anexa\u00a02.\u00a0Representaci\u00f3n \u00a0esquem\u00e1tica \u00a0de\u00a0los\u00a0genes\u00a0diferencialmente \u00a0expresados \u00a0en\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0MDA\u2010\nMB\u2010468\u00a0SP\u00a0interconectados. \u00a0El\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0v\u00edas\u00a0se\u00a0realiz\u00f3\u00a0con\u00a0el\u00a0software\u00a0IPA.\u00a0Los\u00a0genes\u00a0sobreexpresados \u00a0en\u00a0este\u00a0\ngrupo\u00a0se\u00a0muestran \u00a0en\u00a0rojo,\u00a0mientras\u00a0que\u00a0los\u00a0infraeexpresados \u00a0se\u00a0representan \u00a0en\u00a0verde.\u00a0El\u00a0c\u00edrculo\u00a0rojo\u00a0resalta\u00a0la\u00a0IL\u20106\u00a0\nsobreexpreada \u00a0en\u00a0esta\u00a0l\u00ednea\u00a0celular\u00a0e\u00a0interconectada \u00a0con\u00a0ATF\u20103\u00a0y\u00a0NF\u2010\u03baB.\u00a0\nRed\u00a01.\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n197\u00a0\n\u00a0\nRed\u00a02.\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n198\u00a0\n\u00a0\nRed\u00a03.\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n(Contin\u00faa \u00a0en\u00a0la\u00a0siguiente\u00a0p\u00e1gina)\u00a0\nANEXOS\u00a0\u00a0\n\u00a0\n199\u00a0\n\u00a0Red\u00a04.\u00a0MDA\u2010MB\u2010468\u00a0SP\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\nOTROS\u00a0ART\u00cdCULOS \u00a0PUBLICADOS \u00a0DURANTE \u00a0EL\u00a0PERIODO \u00a0DE\u00a0TESIS\u00a0DOCOTRAL \u00a0\n\u00a0\n\u00a0\n201\u00a0\n\u00a0PUBLICACIONES \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n1.\u00a0Almendro \u00a0V,\u00a0Ametller\u00a0E,\u00a0Garcia\u2010Recio\u00a0S,\u00a0Collazo\u00a0O,\u00a0Casas\u00a0I,\u00a0Aug\u00e9\u00a0JM,\u00a0Maurel\u00a0J,\u00a0\u00a0Gasc\u00f3n\u00a0P.\u00a0\nIncreased \u00a0MMP\u20107\u00a0expression \u00a0and\u00a0loss\u00a0of\u00a0Fas\u00a0receptor\u00a0functionality \u00a0in\u00a0colorectal \u00a0cancer:\u00a0a\u00a0potential\u00a0\nmechanism \u00a0of\u00a0acquired\u00a0chemoresistance .\u00a0PLoS\u00a0One.\u00a02009.\u00a0Vol.\u00a04.\u00a0\n2.\u00a0Elisabet\u00a0Ametller, \u00a0Susana\u00a0Garcia\u2010Recio ,\u00a0Domizziana \u00a0Costamagna, \u00a0Cristina\u00a0Mayordomo \u2010Tella,\u00a0\nPatricia\u00a0Fern\u00e1ndez \u2010Nogueira, \u00a0Neus\u00a0Carb\u00f3,\u00a0Eva\u00a0Mar\u00eda\u00a0Pastor\u2010Arroyo,\u00a0Pedro\u00a0Gasc\u00f3n,\u00a0Vanessa\u00a0\nAlmendro. \u00a0Tumor\u00a0promoting \u00a0effects\u00a0of\u00a0CD95\u00a0signalling \u00a0in\u00a0chemoresistant \u00a0cells.\u00a0Molecular \u00a0Cancer.\u00a0\n2010.\u00a0Vol.\u00a09.\u00a0\u00a0\n3.\u00a0Elisabet\u00a0Ametller, \u00a0Susana\u00a0Garcia\u2010Recio ,\u00a0Gerard\u00a0Callejo,\u00a0Neus\u00a0Carb\u00f3,\u00a0Pedro\u00a0Gasc\u00f3n,\u00a0Vanessa\u00a0\nAlmendro. \u00a0Differential \u00a0regulation \u00a0of\u00a0MMP7\u00a0in\u00a0colon\u00a0cancer\u00a0cells\u00a0resistant\u00a0and\u00a0sensitive\u00a0to\u00a0\noxaliplatin \u2010induced\u00a0cell\u00a0death.\u00a0Cancer\u00a0Biology\u00a0&\u00a0Therapy .\u00a02011.\u00a0Vol.\u00a011.\u00a0\n4.\u00a0Cristina\u00a0Mayordomo, \u00a0Susana\u00a0Garc\u00eda\u2010Recio ,\u00a0Elisabet\u00a0Ametller, \u00a0Patricia\u00a0Fern\u00e1ndez \u2010Nogueira, \u00a0\nIgnasi\u00a0Casas,\u00a0Eva\u00a0Mar\u00eda\u00a0Pastor\u2010Arroyo,\u00a0Pedro\u00a0Gasc\u00f3n,\u00a0Vanessa\u00a0Almendro*.\u00a0Targeting \u00a0of\u00a0Substance \u00a0\nP\u00a0induces\u00a0cancer\u00a0cell\u00a0death\u00a0and\u00a0decreases \u00a0the\u00a0steady\u00a0state\u00a0of\u00a0EGFR\u00a0and\u00a0Her2.\u00a0J\u00a0Cell\u00a0Physiol.\u00a02012.\u00a0\nVol\u00a0227.\u00a0\n5.\u00a0Susana\u00a0Garcia\u2010Recio,\u00a0Gemma\u00a0Fuster,\u00a0Patricia\u00a0Fernandez \u2010Nogueira, \u00a0Eva.M\u00a0Pastor\u2010Arroyo,\u00a0So\u00a0\nYeong\u00a0Park,\u00a0Cristina\u00a0Mayordomo, \u00a0Elisabet\u00a0Ametller, \u00a0Mario\u00a0Mancino, \u00a0Xavier\u00a0Gonzalez\u2010Farre,\u00a0Hege\u00a0\nRussnes,\u00a0Pablo\u00a0Engel,\u00a0Domiziana \u00a0Costamagna, \u00a0Pedro\u00a0L.\u00a0Fernandez, \u00a0Pedro\u00a0Gasc\u00f3n,\u00a0Vanessa\u00a0\nAlmendro .\u00a0Substance \u00a0P\u00a0autocrine \u00a0signaling\u00a0contributes \u00a0to\u00a0persistent \u00a0HER2\u00a0activation \u00a0that\u00a0drives\u00a0\nmalignant \u00a0progression \u00a0and\u00a0drug\u00a0resistance \u00a0in\u00a0breast\u00a0cancer.\u00a02013.\u00a0Cancer\u00a0Research\u00a0(potentially \u00a0\nacceptable \u00a0for\u00a0publication). \u00a0\u00a0\n\u00a0\nREVISIONES \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n1. Almendro \u00a0V,\u00a0Garcia\u2010Recio\u00a0S,\u00a0Gasc\u00f3n\u00a0P.\u00a0Tyrosine\u00a0kinase\u00a0receptor\u00a0transactivation \u00a0associated \u00a0to\u00a0\nGprotein\u2010coupled\u00a0receptors. \u00a0Curr\u00a0Drug\u00a0Targets.\u00a011:1169\u201080\u00a0(2010).\u00a0\n\u00a0\nCAP\u00cdTULOS \u00a0DE\u00a0LIBRO\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n1.\u00a0Almendro \u00a0V,\u00a0Garcia\u2010Recio\u00a0S,\u00a0Ametller\u00a0E,\u00a0Gasc\u00f3n\u00a0P.\u00a0Papel\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0madre\u00a0tumorales \u00a0en\u00a0el\u00a0\ndesarrollo \u00a0de\u00a0met\u00e1stasis. \u00a0Monograf\u00edas \u00a0sobre\u00a0el\u00a0c\u00e1ncer\u00a0de\u00a0mama\u00a0metast\u00e1sico, \u00a0biblioteca \u00a0Merk\u2010\nSerono.\u00a0Ed.\u00a0Dr.\u00a0Antonio\u00a0Ant\u00f3n\u00a0Torres\u00a0(in\u00a0press,\u00a02010).\u00a0ISBN:\u00a0978\u201084\u2010693\u20102431\u20108.\u00a0\n\u00a0\u00a0\n\u00a0\n203\u00a0\n\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nBIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n205\u00a0\n\u00a0BIBLIOGRAF\u00cdA \u00a0\n\u00a0\u00a0\n\u00a0\n1.\u00a0 Skarin,\u00a0A.T.\u00a0Atlas\u00a0of\u00a0Diagnostic \u00a0Oncology ,\u00a0\n(Mosby,\u00a02000).\u00a0\n2.\u00a0 Parmar,\u00a0H.\u00a0&\u00a0Cunha,\u00a0G.R.\u00a0Epithelial \u2010\nstromal\u00a0interactions \u00a0in\u00a0the\u00a0mouse\u00a0and\u00a0\nhuman\u00a0mammary \u00a0gland\u00a0in\u00a0vivo.\u00a0Endocr\u00a0\nRelat\u00a0Cancer\u00a011,\u00a0437\u2010458\u00a0(2004).\u00a0\n3.\u00a0 Russo,\u00a0J.\u00a0&\u00a0Russo,\u00a0I.H.\u00a0Development \u00a0of\u00a0the\u00a0\nhuman\u00a0breast.\u00a0Maturitas \u00a049,\u00a02\u201015\u00a0(2004).\u00a0\n4.\u00a0 Osborne,\u00a0M.P.\u00a0Breast\u00a0development \u00a0and\u00a0\nanatomy. \u00a0In:\u00a0Diseases\u00a0of\u00a0the\u00a0Breast\u00a0\u00a0\n(Lippincott \u2010Raven,\u00a0Philadelphia, \u00a02004).\u00a0\n5.\u00a0 Elston,\u00a0C.W.\u00a0&\u00a0Ellis,\u00a0I.O.\u00a0Normal\u00a0structure\u00a0\nand\u00a0developmental \u00a0abnormalities. \u00a0In:\u00a0The\u00a0\nbreast:\u00a0systemic\u00a0pathology. \u00a0,\u00a0(Churchill \u00a0\nLivingstone, \u00a01998).\u00a0\n6.\u00a0 Dickson,\u00a0R.B.\u00a0Biochemical \u00a0control\u00a0of\u00a0breast\u00a0\ndevelopment. \u00a0In:\u00a0Diseases\u00a0of\u00a0the\u00a0Breast ,\u00a0\n(Lippincott \u2010Raven,\u00a0Philadelphia, \u00a02004).\u00a0\n7.\u00a0 Ruiz,\u00a0E.\u00a0Recuerdo \u00a0anat\u00f3mico \u00a0e\u00a0histol\u00f3gico \u00a0\nde\u00a0la\u00a0mama.\u00a0A:\u00a0Manual\u00a0de\u00a0patolog\u00eda \u00a0\nmamaria. \u00a01\u201013\u00a0(JIMS,\u00a01993).\u00a0\n8.\u00a0 Jolicoeur, \u00a0F.\u00a0Intrauterine \u00a0breast\u00a0\ndevelopment \u00a0and\u00a0the\u00a0mammary \u00a0\nmyoepithelial \u00a0lineage.\u00a0J\u00a0Mammary \u00a0Gland\u00a0\nBiol\u00a0Neoplasia \u00a010,\u00a0199\u2010210\u00a0(2005).\u00a0\n9.\u00a0 Gyorki,\u00a0D.E.,\u00a0Asselin\u2010Labat,\u00a0M.L.,\u00a0van\u00a0\nRooijen,\u00a0N.,\u00a0Lindeman, \u00a0G.J.\u00a0&\u00a0Visvader,\u00a0J.E.\u00a0\nResident\u00a0macrophages \u00a0influence \u00a0stem\u00a0cell\u00a0\nactivity\u00a0in\u00a0the\u00a0mammary \u00a0gland.\u00a0Breast\u00a0\nCancer\u00a0Res\u00a011,\u00a0R62\u00a0(2009).\u00a0\n10.\u00a0 Bertos,\u00a0N.R.\u00a0&\u00a0Park,\u00a0M.\u00a0Breast\u00a0cancer\u00a0\u2010\u00a0\none\u00a0term,\u00a0many\u00a0entities?\u00a0J\u00a0Clin\u00a0Invest\u00a0121,\u00a0\n3789\u20103796\u00a0(2011).\u00a0\n11.\u00a0 Lakhani,\u00a0S.R.\u00a0&\u00a0O'Hare,\u00a0M.J.\u00a0The\u00a0mammary \u00a0\nmyoepithelial \u00a0cell\u2010\u2010Cinderella \u00a0or\u00a0ugly\u00a0\nsister?\u00a0Breast\u00a0Cancer\u00a0Res\u00a03,\u00a01\u20104\u00a0(2001).\u00a0\n12.\u00a0 Deugnier, \u00a0M.A.,\u00a0Teuliere,\u00a0J.,\u00a0Faraldo,\u00a0\nM.M.,\u00a0Thiery,\u00a0J.P.\u00a0&\u00a0Glukhova, \u00a0M.A.\u00a0The\u00a0\nimportance \u00a0of\u00a0being\u00a0a\u00a0myoepithelial \u00a0cell.\u00a0\nBreast\u00a0Cancer\u00a0Res\u00a04,\u00a0224\u2010230\u00a0(2002).\u00a013.\u00a0 Gudjonsson, \u00a0T.,\u00a0et\u00a0al.\u00a0Normal\u00a0and\u00a0tumor\u2010\nderived\u00a0myoepithelial \u00a0cells\u00a0differ\u00a0in\u00a0their\u00a0\nability\u00a0to\u00a0interact\u00a0with\u00a0luminal\u00a0breast\u00a0\nepithelial \u00a0cells\u00a0for\u00a0polarity\u00a0and\u00a0basement \u00a0\nmembrane \u00a0deposition. \u00a0J\u00a0Cell\u00a0Sci\u00a0115,\u00a039\u2010\n50\u00a0(2002).\u00a0\n14.\u00a0 Suzuki,\u00a0R.,\u00a0et\u00a0al.\u00a0Proliferation \u00a0and\u00a0\ndifferentiation \u00a0in\u00a0the\u00a0human\u00a0breast\u00a0during\u00a0\npregnancy. \u00a0Differentiation \u00a066,\u00a0106\u2010115\u00a0\n(2000).\u00a0\n15.\u00a0 Bankfalvi, \u00a0A.,\u00a0et\u00a0al.\u00a0Different\u00a0proliferative \u00a0\nactivity\u00a0of\u00a0the\u00a0glandular \u00a0and\u00a0myoepithelial \u00a0\nlineages\u00a0in\u00a0benign\u00a0proliferative \u00a0and\u00a0early\u00a0\nmalignant \u00a0breast\u00a0diseases.\u00a0Mod\u00a0Pathol\u00a017,\u00a0\n1051\u20101061\u00a0(2004).\u00a0\n16.\u00a0 Hansen,\u00a0R.K.\u00a0&\u00a0Bissell,\u00a0M.J.\u00a0Tissue\u00a0\narchitecture \u00a0and\u00a0breast\u00a0cancer:\u00a0the\u00a0role\u00a0of\u00a0\nextracellular \u00a0matrix\u00a0and\u00a0steroid\u00a0\nhormones. \u00a0Endocr\u00a0Relat\u00a0Cancer\u00a07,\u00a095\u2010113\u00a0\n(2000).\u00a0\n17.\u00a0 Russo,\u00a0I.H.\u00a0&\u00a0Russo,\u00a0J.\u00a0Role\u00a0of\u00a0hormones \u00a0in\u00a0\nmammary \u00a0 cancer\u00a0 initiation\u00a0 and\u00a0\nprogression. \u00a0J\u00a0Mammary \u00a0Gland\u00a0Biol\u00a0\nNeoplasia \u00a03,\u00a049\u201061\u00a0(1998).\u00a0\n18.\u00a0 Rosfjord,\u00a0E.C.\u00a0&\u00a0Dickson,\u00a0R.B.\u00a0Growth\u00a0\nfactors,\u00a0apoptosis, \u00a0and\u00a0survival\u00a0of\u00a0\nmammary \u00a0epithelial \u00a0cells.\u00a0J\u00a0Mammary \u00a0\nGland\u00a0Biol\u00a0Neoplasia \u00a04,\u00a0229\u2010237\u00a0(1999).\u00a0\n19.\u00a0 Bajo,\u00a0J.M.,\u00a0Lailla,\u00a0J.M.\u00a0&\u00a0Xercavins, \u00a0J.\u00a0\nFundamentos \u00a0 de\u00a0 Ginecolog\u00eda \u00a0\n(Panamericana, \u00a02009).\u00a0\n20.\u00a0 Howard,\u00a0B.A.\u00a0&\u00a0Gusterson, \u00a0B.A.\u00a0Human\u00a0\nbreast\u00a0development. \u00a0J\u00a0Mammary \u00a0Gland\u00a0\nBiol\u00a0Neoplasia \u00a05,\u00a0119\u2010137\u00a0(2000).\u00a0\n21.\u00a0 Giani,\u00a0C.,\u00a0et\u00a0al.\u00a0Estrogen\u00a0and\u00a0progesterone \u00a0\nreceptors \u00a0in\u00a0benign\u00a0breast\u00a0tumors\u00a0and\u00a0\nlesions:\u00a0relationship \u00a0with\u00a0histological \u00a0and\u00a0\ncytological \u00a0features.\u00a0Int\u00a0J\u00a0Cancer\u00a037,\u00a07\u201010\u00a0\n(1986).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n206\u00a0\n\u00a022.\u00a0 Gillett,\u00a0C.,\u00a0et\u00a0al.\u00a0Cyclin\u00a0D1\u00a0and\u00a0prognosis \u00a0in\u00a0\nhuman\u00a0breast\u00a0cancer.\u00a0Int\u00a0J\u00a0Cancer\u00a069,\u00a092\u2010\n99\u00a0(1996).\u00a0\n23.\u00a0 Osin,\u00a0P.P.,\u00a0Anbazhagan, \u00a0R.,\u00a0Bartkova, \u00a0J.,\u00a0\nNathan,\u00a0B.\u00a0&\u00a0Gusterson, \u00a0B.A.\u00a0Breast\u00a0\ndevelopment \u00a0gives\u00a0insights\u00a0into\u00a0breast\u00a0\ndisease.\u00a0Histopathology \u00a033,\u00a0275\u2010283\u00a0\n(1998).\u00a0\n24.\u00a0 Tavassoli, \u00a0F.A.\u00a0&\u00a0Devilee,\u00a0P.\u00a0World\u00a0Health\u00a0\nOrganization \u00a0Classification \u00a0of\u00a0Tumours. \u00a0\nPathology \u00a0and\u00a0Genetics\u00a0of\u00a0Tumours\u00a0of\u00a0the\u00a0\nBreast\u00a0and\u00a0Female\u00a0Genital\u00a0Organs ,\u00a0(IARC\u00a0\nPress,\u00a0Lyon,\u00a02003\u00a0).\u00a0\n25.\u00a0 Ruiz,\u00a0E.\u00a0Patolog\u00eda \u00a0maligna.\u00a0A:\u00a0Manual\u00a0de\u00a0\npatolog\u00eda \u00a0mamaria ,\u00a0(JIMS,\u00a01993).\u00a0\n26.\u00a0 Powell,\u00a0D.E.\u00a0&\u00a0Stelling,\u00a0C.B.\u00a0Carcinoma \u00a0de\u00a0\nmama.\u00a0In:\u00a0Enfermedades \u00a0de\u00a0la\u00a0mama:\u00a0\ndiagn\u00f3stico \u00a0y\u00a0detecci\u00f3n. ,\u00a0(DE\u00a0Powell\u00a0and\u00a0\nCB\u00a0Stelling.\u00a0Mosby/Doyma \u00a0Libros,\u00a01995).\u00a0\n27.\u00a0 Burstein,\u00a0H.J.,\u00a0Polyak,\u00a0K.,\u00a0Wong,\u00a0J.S.,\u00a0\nLester,\u00a0S.C.\u00a0&\u00a0Kaelin,\u00a0C.M.\u00a0Ductal\u00a0\ncarcinoma \u00a0in\u00a0situ\u00a0of\u00a0the\u00a0breast.\u00a0N\u00a0Engl\u00a0J\u00a0\nMed\u00a0350,\u00a01430\u20101441\u00a0(2004).\u00a0\n28.\u00a0 Breastcancer.org. \u00a0\nhttp://www.breastcancer.org/ .\u00a0(2012).\u00a0\n29.\u00a0 Meenakshi \u00a0Singh,\u00a0M.\u00a0Digital\u00a0Atlas\u00a0of\u00a0\nBreast\u00a0 Pathology. \u00a0\nhttp://www.hsc.stonybrook.edu/breast \u2010\natlas/ .\u00a0\n30.\u00a0 Foote,\u00a0F.W.\u00a0&\u00a0Stewart,\u00a0F.W.\u00a0Lobular\u00a0\ncarcinoma \u00a0in\u00a0situ:\u00a0A\u00a0rare\u00a0form\u00a0of\u00a0\nmammary \u00a0cancer.\u00a0Am\u00a0J\u00a0Pathol\u00a017,\u00a0491\u2010\n496\u00a0493\u00a0(1941).\u00a0\n31.\u00a0 Page,\u00a0D.L.,\u00a0Dupont,\u00a0W.D.,\u00a0Rogers,\u00a0L.W.\u00a0&\u00a0\nRados,\u00a0M.S.\u00a0Atypical\u00a0hyperplastic \u00a0lesions\u00a0\nof\u00a0the\u00a0female\u00a0breast.\u00a0A\u00a0long\u2010term\u00a0follow\u2010\nup\u00a0study.\u00a0Cancer\u00a055,\u00a02698\u20102708\u00a0(1985).\u00a0\n32.\u00a0 Lakhani,\u00a0S.R.,\u00a0et\u00a0al.\u00a0The\u00a0management \u00a0of\u00a0\nlobular\u00a0carcinoma \u00a0in\u00a0situ\u00a0(LCIS).\u00a0Is\u00a0LCIS\u00a0the\u00a0\nsame\u00a0as\u00a0ductal\u00a0carcinoma \u00a0in\u00a0situ\u00a0(DCIS)?\u00a0\nEur\u00a0J\u00a0Cancer\u00a042,\u00a02205\u20102211\u00a0(2006).\u00a0\n33.\u00a0 Kilbride,\u00a0K.E.\u00a0&\u00a0Newman, \u00a0L.A.\u00a0Lobular\u00a0\nCarcinoma \u00a0In\u00a0Situ:\u00a0Clinical\u00a0Management. \u00a0\nIn:\u00a0Diseases\u00a0of\u00a0the\u00a0Breast ,\u00a0(Lippincott \u00a0\nWilliams\u00a0&\u00a0Wilkins,\u00a02010).\u00a034.\u00a0 Simpson,\u00a0P.T.,\u00a0Reis\u2010Filho,\u00a0J.S.\u00a0&\u00a0Lakhani,\u00a0\nS.R.\u00a0Lobular\u00a0Carcinoma \u00a0In\u00a0Situ:\u00a0Biology\u00a0\nand\u00a0Pathology. \u00a0In:\u00a0Diseases\u00a0of\u00a0the\u00a0Breast ,\u00a0\n(Lippincott \u00a0Williams\u00a0&\u00a0Wilkins,\u00a02010).\u00a0\n35.\u00a0 Afonso,\u00a0N.\u00a0&\u00a0Bouwman, \u00a0D.\u00a0Lobular\u00a0\ncarcinoma \u00a0in\u00a0situ.\u00a0Eur\u00a0J\u00a0Cancer\u00a0Prev\u00a017,\u00a0\n312\u2010316\u00a0(2008).\u00a0\n36.\u00a0 Page,\u00a0D.L.\u00a0Special\u00a0types\u00a0of\u00a0invasive\u00a0breast\u00a0\ncancer,\u00a0with\u00a0clinical\u00a0implications. \u00a0Am\u00a0J\u00a0\nSurg\u00a0Pathol\u00a027,\u00a0832\u2010835\u00a0(2003).\u00a0\n37.\u00a0 Schnitt,\u00a0S.J.\u00a0&\u00a0Guidi,\u00a0A.J.\u00a0Pathology \u00a0of\u00a0\ninvasive\u00a0breast\u00a0cancer.\u00a0In\u00a0Diseases\u00a0of\u00a0the\u00a0\nBreast ,\u00a0(Lippincott \u00a0Williams\u00a0&\u00a0Wilkins,\u00a0\nPhiladelphia, \u00a02004).\u00a0\n38.\u00a0 Weigelt,\u00a0B.,\u00a0et\u00a0al.\u00a0Refinement \u00a0of\u00a0breast\u00a0\ncancer\u00a0classification \u00a0by\u00a0molecular \u00a0\ncharacterization \u00a0of\u00a0histological \u00a0special\u00a0\ntypes.\u00a0J\u00a0Pathol\u00a0216,\u00a0141\u2010150\u00a0(2008).\u00a0\n39.\u00a0 McClenathan, \u00a0J.H.\u00a0&\u00a0de\u00a0la\u00a0Roza,\u00a0G.\u00a0\nAdenoid\u00a0cystic\u00a0breast\u00a0cancer.\u00a0Am\u00a0J\u00a0Surg\u00a0\n183,\u00a0646\u2010649\u00a0(2002).\u00a0\n40.\u00a0 Tavassoli, \u00a0F.A.\u00a0Classification \u00a0of\u00a0metaplastic \u00a0\ncarcinomas \u00a0of\u00a0the\u00a0breast.\u00a0Pathol\u00a0Annu\u00a027\u00a0\nPt\u00a02,\u00a089\u2010119\u00a0(1992).\u00a0\n41.\u00a0 Elston,\u00a0C.W.\u00a0&\u00a0Ellis,\u00a0I.O.\u00a0The\u00a0Breast\u00a0\n(Churchill \u00a0Livingstone, \u00a0Edinburg, \u00a01998).\u00a0\n42.\u00a0 Bae,\u00a0S.Y.,\u00a0et\u00a0al.\u00a0The\u00a0prognoses \u00a0of\u00a0\nmetaplastic \u00a0breast\u00a0cancer\u00a0patients\u00a0\ncompared \u00a0to\u00a0those\u00a0of\u00a0triple\u2010negative\u00a0\nbreast\u00a0cancer\u00a0patients.\u00a0Breast\u00a0Cancer\u00a0Res\u00a0\nTreat\u00a0126,\u00a0471\u2010478\u00a0(2011).\u00a0\n43.\u00a0 Eusebi,\u00a0V.,\u00a0Millis,\u00a0R.R.,\u00a0Cattani,\u00a0M.G.,\u00a0\nBussolati, \u00a0G.\u00a0&\u00a0Azzopardi, \u00a0J.G.\u00a0Apocrine\u00a0\ncarcinoma \u00a0of\u00a0the\u00a0breast.\u00a0A\u00a0morphologic \u00a0\nand\u00a0immunocytochemical \u00a0study.\u00a0Am\u00a0J\u00a0\nPathol\u00a0123,\u00a0532\u2010541\u00a0(1986).\u00a0\n44.\u00a0 Singletary, \u00a0S.E.,\u00a0Patel\u2010Parekh,\u00a0L.\u00a0&\u00a0Bland,\u00a0\nK.I.\u00a0Treatment \u00a0trends\u00a0in\u00a0early\u2010stage\u00a0\ninvasive\u00a0lobular\u00a0carcinoma: \u00a0a\u00a0report\u00a0from\u00a0\nthe\u00a0National\u00a0Cancer\u00a0Data\u00a0Base.\u00a0Ann\u00a0Surg\u00a0\n242,\u00a0281\u2010289\u00a0(2005).\u00a0\n45.\u00a0 Ramnani, \u00a0D.M.\u00a0http://WebPathology.com \u00a0\n(2012).\u00a0\n46.\u00a0 Merajver, \u00a0S.D.,\u00a0Iniesta,\u00a0M.D.\u00a0&\u00a0Sabel,\u00a0M.S.\u00a0\nInflammatory \u00a0Breast\u00a0Cancer.\u00a0In:\u00a0Diseases\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n207\u00a0\n\u00a0of\u00a0the\u00a0Breast. ,\u00a0(Lippincott \u00a0Williams\u00a0&\u00a0\nWilkins,\u00a02010).\u00a0\n47.\u00a0 Bloom,\u00a0H.J.\u00a0&\u00a0Richardson, \u00a0W.W.\u00a0\nHistological \u00a0grading\u00a0and\u00a0prognosis \u00a0in\u00a0\nbreast\u00a0cancer;\u00a0a\u00a0study\u00a0of\u00a01409\u00a0cases\u00a0of\u00a0\nwhich\u00a0359\u00a0have\u00a0been\u00a0followed\u00a0for\u00a015\u00a0\nyears.\u00a0Br\u00a0J\u00a0Cancer\u00a011,\u00a0359\u2010377\u00a0(1957).\u00a0\n48.\u00a0 Elston,\u00a0C.W.\u00a0&\u00a0Ellis,\u00a0I.O.\u00a0Assessment \u00a0of\u00a0\nhistological \u00a0grade.\u00a0In:\u00a0The\u00a0breast ,\u00a0\n(Churchill \u00a0Livingstone, \u00a0Edinburgh, \u00a0New\u00a0\nYork,\u00a01998).\u00a0\n49.\u00a0 Balslev,\u00a0I.,\u00a0et\u00a0al.\u00a0The\u00a0Nottingham \u00a0\nPrognostic \u00a0Index\u00a0applied\u00a0to\u00a09,149\u00a0patients\u00a0\nfrom\u00a0the\u00a0studies\u00a0of\u00a0the\u00a0Danish\u00a0Breast\u00a0\nCancer\u00a0Cooperative \u00a0Group\u00a0(DBCG).\u00a0Breast\u00a0\nCancer\u00a0Res\u00a0Treat\u00a032,\u00a0281\u2010290\u00a0(1994).\u00a0\n50.\u00a0 Sobin,\u00a0L.H.,\u00a0Hermanek, \u00a0P.\u00a0&\u00a0Hutter,\u00a0R.V.\u00a0\nTNM\u00a0classification \u00a0of\u00a0malignant \u00a0tumors.\u00a0A\u00a0\ncomparison \u00a0between\u00a0the\u00a0new\u00a0(1987)\u00a0and\u00a0\nthe\u00a0old\u00a0editions.\u00a0Cancer\u00a061,\u00a02310\u20102314\u00a0\n(1988).\u00a0\n51.\u00a0 Sobin,\u00a0L.H.,\u00a0Gospodarowicz, \u00a0M.K.\u00a0&\u00a0\nWittekind, \u00a0C.\u00a0TNM\u00a0Classification \u00a0of\u00a0\nMalignant \u00a0Tumours. \u00a0Members \u00a0of\u00a0UICC\u00a0\nCommittees \u00a0Associated \u00a0with\u00a0the\u00a0TNM\u00a0\nSystem ,\u00a0(Wiley\u2010Blackwell, \u00a02010).\u00a0\n52.\u00a0 Edge,\u00a0S.B.,\u00a0et\u00a0al.\u00a0AJCC\u00a0Cancer\u00a0Staging\u00a0\nManual ,\u00a0(Springer, \u00a0New\u00a0York,\u00a0NY:\u00a0,\u00a02010).\u00a0\n53.\u00a0 GLOBOCAN, \u00a0World\u00a0Health\u00a0Organisation \u00a0\n(WHO)\u00a0&\u00a0International \u00a0Agency\u00a0for\u00a0\nResearch\u00a0on\u00a0Cancer\u00a0\u00a0 (IACR).\u00a0\nCANCERMondial. \u00a0\u00a0(2008).\u00a0\n54.\u00a0 Th\u00fcmmler, \u00a0K.,\u00a0Bristton,\u00a0A.\u00a0&\u00a0Kirc,\u00a0W.\u00a0Data\u00a0\nand\u00a0Information \u00a0on\u00a0Women\u00b4s \u00a0Healt\u00a0in\u00a0the\u00a0\nEuropean \u00a0Union.\u00a0Directorate \u00a0General\u00a0for\u00a0\nElath\u00a0and\u00a0Consumers ,\u00a0(Drenden, \u00a0Germany, \u00a0\n2009).\u00a0\n55.\u00a0 Lopez\u2010Avente,\u00a0G.,\u00a0Pollan,\u00a0M.,\u00a0Aragones, \u00a0N.\u00a0\n&\u00a0Hern\u00e1ndez, \u00a0V.\u00a0\u00c1rea\u00a0de\u00a0Epidemiolog\u00eda \u00a0\nAmbiental \u00a0y\u00a0C\u00e1ncer.\u00a0Centro\u00a0Nacional\u00a0de\u00a0\nEpidemiolog\u00eda. \u00a0Instituto\u00a0de\u00a0Salud\u00a0Carlos\u00a0III,\u00a0\n(Ministerio \u00a0de\u00a0Sanidad\u00a0y\u00a0Consumo. \u00a0,\u00a0\n2009).\u00a056.\u00a0 Pollan,\u00a0M.,\u00a0et\u00a0al.\u00a0Recent\u00a0changes\u00a0in\u00a0breast\u00a0\ncancer\u00a0incidence \u00a0in\u00a0Spain,\u00a01980\u20102004.\u00a0J\u00a0\nNatl\u00a0Cancer\u00a0Inst\u00a0101,\u00a01584\u20101591\u00a0(2009).\u00a0\n57.\u00a0 Borras,\u00a0J.M.,\u00a0Borras,\u00a0J.,\u00a0Izquierdo, \u00a0A.\u00a0&\u00a0\nGispert,\u00a0R.\u00a0El\u00a0impacto\u00a0del\u00a0c\u00e1ncer\u00a0en\u00a0\nCatalu\u00f1a. \u00a0Med\u00a0Clin\u00a0Vol\u00a0131(2008).\u00a0\n58.\u00a0 Singletary, \u00a0S.E.\u00a0Rating\u00a0the\u00a0risk\u00a0factors\u00a0for\u00a0\nbreast\u00a0cancer.\u00a0Ann\u00a0Surg\u00a0237,\u00a0474\u2010482\u00a0\n(2003).\u00a0\n59.\u00a0 Willett,\u00a0W.C.\u00a0Diet\u00a0and\u00a0cancer.\u00a0Oncologist \u00a0\n5,\u00a0393\u2010404\u00a0(2000).\u00a0\n60.\u00a0 Cruz,\u00a0J.J.\u00a0&\u00a0Rodriguez, \u00a0C.A.\u00a0Oncolog\u00eda \u00a0\nCl\u00ednica.\u00a0C\u00e1ncer\u00a0de\u00a0mama.\u00a0Rodriguez, \u00a0C.A\u00a0;\u00a0\nG\u00f3mez,\u00a0A.\u00a0,\u00a0(Nova\u2010sidonia\u00a0Madrid,\u00a02008).\u00a0\n61.\u00a0 Burstein,\u00a0H.J.,\u00a0Harris,\u00a0J.R.\u00a0&\u00a0Morrow,\u00a0M.\u00a0\nMalignant \u00a0Tumors\u00a0on\u00a0the\u00a0breast.\u00a0\u00a0Cancer:\u00a0\nPrinciples \u00a0&\u00a0Practice\u00a0of\u00a0Oncology ,\u00a0\n(Lippincott \u2010Williams., \u00a0Philadelphia, \u00a02008).\u00a0\n62.\u00a0 Land,\u00a0C.E.,\u00a0Boice,\u00a0J.D.,\u00a0Jr.,\u00a0Shore,\u00a0R.E.,\u00a0\nNorman,\u00a0J.E.\u00a0&\u00a0Tokunaga, \u00a0M.\u00a0Breast\u00a0\ncancer\u00a0risk\u00a0from\u00a0low\u2010dose\u00a0exposures \u00a0to\u00a0\nionizing\u00a0radiation: \u00a0results\u00a0of\u00a0parallel\u00a0\nanalysis\u00a0of\u00a0three\u00a0exposed\u00a0populations \u00a0of\u00a0\nwomen.\u00a0J\u00a0Natl\u00a0Cancer\u00a0Inst\u00a065,\u00a0353\u2010376\u00a0\n(1980).\u00a0\n63.\u00a0 Boice,\u00a0J.D.,\u00a0Jr.,\u00a0Preston,\u00a0D.,\u00a0Davis,\u00a0F.G.\u00a0&\u00a0\nMonson,\u00a0R.R.\u00a0Frequent\u00a0chest\u00a0X\u2010ray\u00a0\nfluoroscopy \u00a0and\u00a0breast\u00a0cancer\u00a0incidence \u00a0\namong\u00a0 tuberculosis \u00a0 patients\u00a0 in\u00a0\nMassachusetts. \u00a0Radiat\u00a0Res\u00a0125,\u00a0214\u2010222\u00a0\n(1991).\u00a0\n64.\u00a0 Clemons, \u00a0M.,\u00a0Loijens,\u00a0L.\u00a0&\u00a0Goss,\u00a0P.\u00a0Breast\u00a0\ncancer\u00a0risk\u00a0following \u00a0irradiation \u00a0for\u00a0\nHodgkin's \u00a0disease.\u00a0Cancer\u00a0Treat\u00a0Rev\u00a026,\u00a0\n291\u2010302\u00a0(2000).\u00a0\n65.\u00a0 American \u00a0 cancer\u00a0 society.\u00a0\nhttp://www.cancer.org/ .\u00a0(2012).\u00a0\n66.\u00a0 Dumitrescu, \u00a0R.G.\u00a0&\u00a0Cotarla,\u00a0I.\u00a0\nUnderstanding \u00a0breast\u00a0cancer\u00a0risk\u00a0\u2010\u2010\u00a0where\u00a0\ndo\u00a0we\u00a0stand\u00a0in\u00a02005?\u00a0J\u00a0Cell\u00a0Mol\u00a0Med\u00a09,\u00a0\n208\u2010221\u00a0(2005).\u00a0\n67.\u00a0 Dupont,\u00a0W.D. ,\u00a0et\u00a0al.\u00a0Breast\u00a0cancer\u00a0risk\u00a0\nassociated \u00a0with\u00a0proliferative \u00a0breast\u00a0\ndisease\u00a0and\u00a0atypical\u00a0hyperplasia. \u00a0Cancer\u00a0\n71,\u00a01258\u20101265\u00a0(1993).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n208\u00a0\n\u00a068.\u00a0 Page,\u00a0D.L.,\u00a0Dupont,\u00a0W.D.,\u00a0Rogers,\u00a0L.W.\u00a0&\u00a0\nLandenberger, \u00a0M.\u00a0Intraductal \u00a0carcinoma \u00a0\nof\u00a0the\u00a0breast:\u00a0follow\u2010up\u00a0after\u00a0biopsy\u00a0only.\u00a0\nCancer\u00a049,\u00a0751\u2010758\u00a0(1982).\u00a0\n69.\u00a0 Narod,\u00a0S.A.\u00a0&\u00a0Foulkes,\u00a0W.D.\u00a0BRCA1\u00a0and\u00a0\nBRCA2:\u00a01994\u00a0and\u00a0beyond.\u00a0Nat\u00a0Rev\u00a0Cancer\u00a0\n4,\u00a0665\u2010676\u00a0(2004).\u00a0\n70.\u00a0 Antoniou, \u00a0A.,\u00a0et\u00a0al.\u00a0Average\u00a0risks\u00a0of\u00a0breast\u00a0\nand\u00a0ovarian\u00a0cancer\u00a0associated \u00a0with\u00a0BRCA1\u00a0\nor\u00a0BRCA2\u00a0mutations \u00a0detected\u00a0in\u00a0case\u00a0\nSeries\u00a0unselected \u00a0for\u00a0family\u00a0history:\u00a0a\u00a0\ncombined \u00a0analysis\u00a0of\u00a022\u00a0studies.\u00a0Am\u00a0J\u00a0\nHum\u00a0Genet\u00a072,\u00a01117\u20101130\u00a0(2003).\u00a0\n71.\u00a0 Morgan,\u00a0D.,\u00a0Sylvester, \u00a0H.,\u00a0Lucas,\u00a0F.L.\u00a0&\u00a0\nMiesfeldt, \u00a0S.\u00a0Cancer\u00a0prevention \u00a0and\u00a0\nscreening \u00a0practices\u00a0among\u00a0women\u00a0at\u00a0risk\u00a0\nfor\u00a0hereditary \u00a0breast\u00a0and\u00a0ovarian\u00a0cancer\u00a0\nafter\u00a0genetic\u00a0counseling \u00a0in\u00a0the\u00a0community \u00a0\nsetting.\u00a0Fam\u00a0Cancer\u00a08,\u00a0277\u2010287\u00a0(2009).\u00a0\n72.\u00a0 Ford,\u00a0D.,\u00a0et\u00a0al.\u00a0Genetic\u00a0heterogeneity \u00a0and\u00a0\npenetrance \u00a0analysis\u00a0of\u00a0the\u00a0BRCA1\u00a0and\u00a0\nBRCA2\u00a0genes\u00a0in\u00a0breast\u00a0cancer\u00a0families.\u00a0\nThe\u00a0Breast\u00a0Cancer\u00a0Linkage\u00a0Consortium. \u00a0\nAm\u00a0J\u00a0Hum\u00a0Genet\u00a062,\u00a0676\u2010689\u00a0(1998).\u00a0\n73.\u00a0 Easton,\u00a0D.F.,\u00a0et\u00a0al.\u00a0Cancer\u00a0risks\u00a0in\u00a0two\u00a0\nlarge\u00a0breast\u00a0cancer\u00a0families\u00a0linked\u00a0to\u00a0\nBRCA2\u00a0on\u00a0chromosome \u00a013q12\u201013.\u00a0Am\u00a0J\u00a0\nHum\u00a0Genet\u00a061,\u00a0120\u2010128\u00a0(1997).\u00a0\n74.\u00a0 Brose,\u00a0M.S. ,\u00a0et\u00a0al.\u00a0Cancer\u00a0risk\u00a0estimates \u00a0\nfor\u00a0BRCA1\u00a0mutation \u00a0carriers\u00a0identified \u00a0in\u00a0a\u00a0\nrisk\u00a0evaluation \u00a0program. \u00a0J\u00a0Natl\u00a0Cancer\u00a0Inst\u00a0\n94,\u00a01365\u20101372\u00a0(2002).\u00a0\n75.\u00a0 Chen,\u00a0S.\u00a0&\u00a0Parmigiani, \u00a0G.\u00a0Meta\u2010analysis\u00a0of\u00a0\nBRCA1\u00a0and\u00a0BRCA2\u00a0penetrance. \u00a0J\u00a0Clin\u00a0\nOncol\u00a025,\u00a01329\u20101333\u00a0(2007).\u00a0\n76.\u00a0 Balmain,\u00a0A.,\u00a0Gray,\u00a0J.\u00a0&\u00a0Ponder,\u00a0B.\u00a0The\u00a0\ngenetics\u00a0and\u00a0genomics \u00a0of\u00a0cancer.\u00a0Nat\u00a0\nGenet\u00a033\u00a0Suppl ,\u00a0238\u2010244\u00a0(2003).\u00a0\n77.\u00a0 Marusyk, \u00a0A.\u00a0&\u00a0Polyak,\u00a0K.\u00a0Tumor\u00a0\nheterogeneity: \u00a0causes\u00a0and\u00a0consequences. \u00a0\nBiochim\u00a0Biophys\u00a0Acta\u00a01805 ,\u00a0105\u2010117\u00a0\n(2009).\u00a0\n78.\u00a0 Perez,\u00a0E.A.\u00a0Breast\u00a0cancer\u00a0management: \u00a0\nopportunities \u00a0and\u00a0barriers\u00a0to\u00a0an\u00a0individualized \u00a0approach. \u00a0Oncologist \u00a016\u00a0\nSuppl\u00a01,\u00a020\u201022\u00a0(2011).\u00a0\n79.\u00a0 Visvader,\u00a0J.E.\u00a0Cells\u00a0of\u00a0origin\u00a0in\u00a0cancer.\u00a0\nNature\u00a0469,\u00a0314\u2010322\u00a0(2011).\u00a0\n80.\u00a0 Campbell, \u00a0L.L.\u00a0&\u00a0Polyak,\u00a0K.\u00a0Breast\u00a0tumor\u00a0\nheterogeneity: \u00a0cancer\u00a0stem\u00a0cells\u00a0or\u00a0clonal\u00a0\nevolution? \u00a0Cell\u00a0Cycle\u00a06,\u00a02332\u20102338\u00a0(2007).\u00a0\n81.\u00a0 Shipitsin,\u00a0M.,\u00a0et\u00a0al.\u00a0Molecular \u00a0definition \u00a0of\u00a0\nbreast\u00a0tumor\u00a0heterogeneity. \u00a0Cancer\u00a0Cell\u00a0\n11,\u00a0259\u2010273\u00a0(2007).\u00a0\n82.\u00a0 Sorlie,\u00a0T.,\u00a0et\u00a0al.\u00a0Gene\u00a0expression \u00a0patterns\u00a0\nof\u00a0breast\u00a0carcinomas \u00a0distinguish \u00a0tumor\u00a0\nsubclasses \u00a0with\u00a0clinical\u00a0implications. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a098,\u00a010869\u201010874\u00a0\n(2001).\u00a0\n83.\u00a0 Perou,\u00a0C.M. ,\u00a0et\u00a0al.\u00a0Molecular \u00a0portraits\u00a0of\u00a0\nhuman\u00a0breast\u00a0tumours.\u00a0Nature\u00a0406,\u00a0747\u2010\n752\u00a0(2000).\u00a0\n84.\u00a0 Herschkowitz, \u00a0J.I.,\u00a0et\u00a0al.\u00a0Identification \u00a0of\u00a0\nconserved \u00a0gene\u00a0expression \u00a0features\u00a0\nbetween\u00a0murine\u00a0mammary \u00a0carcinoma \u00a0\nmodels\u00a0and\u00a0human\u00a0breast\u00a0tumors.\u00a0\nGenome\u00a0Biol\u00a08,\u00a0R76\u00a0(2007).\u00a0\n85.\u00a0 Hennessy, \u00a0B.T.,\u00a0et\u00a0al.\u00a0Characterization \u00a0of\u00a0a\u00a0\nnaturally\u00a0occurring \u00a0breast\u00a0cancer\u00a0subset\u00a0\nenriched\u00a0in\u00a0epithelial \u2010to\u2010mesenchymal \u00a0\ntransition \u00a0and\u00a0stem\u00a0cell\u00a0characteristics. \u00a0\nCancer\u00a0Res\u00a069,\u00a04116\u20104124\u00a0(2009).\u00a0\n86.\u00a0 Prat,\u00a0A.\u00a0&\u00a0Perou,\u00a0C.M.\u00a0Mammary \u00a0\ndevelopment \u00a0meets\u00a0cancer\u00a0genomics. \u00a0Nat\u00a0\nMed\u00a015,\u00a0842\u2010844\u00a0(2009).\u00a0\n87.\u00a0 Prat,\u00a0A.,\u00a0et\u00a0al.\u00a0Phenotypic \u00a0and\u00a0molecular \u00a0\ncharacterization \u00a0of\u00a0the\u00a0claudin\u2010low\u00a0\nintrinsic\u00a0subtype\u00a0of\u00a0breast\u00a0cancer.\u00a0Breast\u00a0\nCancer\u00a0Res\u00a012,\u00a0R68\u00a0(2010).\u00a0\n88.\u00a0 Wagner,\u00a0K.U.,\u00a0et\u00a0al.\u00a0An\u00a0adjunct\u00a0mammary \u00a0\nepithelial \u00a0cell\u00a0population \u00a0in\u00a0parous\u00a0\nfemales:\u00a0its\u00a0role\u00a0in\u00a0functional \u00a0adaptation \u00a0\nand\u00a0tissue\u00a0renewal.\u00a0Development \u00a0129,\u00a0\n1377\u20101386\u00a0(2002).\u00a0\n89.\u00a0 Shackleton, \u00a0M.,\u00a0et\u00a0al.\u00a0Generation \u00a0of\u00a0a\u00a0\nfunctional \u00a0mammary \u00a0gland\u00a0from\u00a0a\u00a0single\u00a0\nstem\u00a0cell.\u00a0Nature\u00a0439,\u00a084\u201088\u00a0(2006).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n209\u00a0\n\u00a090.\u00a0 Stingl,\u00a0J.,\u00a0et\u00a0al.\u00a0Purification \u00a0and\u00a0unique\u00a0\nproperties \u00a0of\u00a0mammary \u00a0epithelial \u00a0stem\u00a0\ncells.\u00a0Nature\u00a0439,\u00a0993\u2010997\u00a0(2006).\u00a0\n91.\u00a0 Polyak,\u00a0K.\u00a0Breast\u00a0cancer:\u00a0origins\u00a0and\u00a0\nevolution. \u00a0J\u00a0Clin\u00a0Invest\u00a0117,\u00a03155\u20103163\u00a0\n(2007).\u00a0\n92.\u00a0 Almendro, \u00a0V.\u00a0&\u00a0Fuster,\u00a0G.\u00a0Heterogeneity \u00a0\nof\u00a0breast\u00a0cancer:\u00a0etiology\u00a0and\u00a0clinical\u00a0\nrelevance. \u00a0Clin\u00a0Transl\u00a0Oncol\u00a013,\u00a0767\u2010773\u00a0\n(2011).\u00a0\n93.\u00a0 Lim,\u00a0E.,\u00a0et\u00a0al.\u00a0Aberrant\u00a0luminal\u00a0progenitors \u00a0\nas\u00a0the\u00a0candidate \u00a0target\u00a0population \u00a0for\u00a0\nbasal\u00a0tumor\u00a0development \u00a0in\u00a0BRCA1\u00a0\nmutation \u00a0carriers.\u00a0Nat\u00a0Med\u00a015,\u00a0907\u2010913\u00a0\n(2009).\u00a0\n94.\u00a0 Gusterson, \u00a0B.A.,\u00a0Ross,\u00a0D.T.,\u00a0Heath,\u00a0V.J.\u00a0&\u00a0\nStein,\u00a0T.\u00a0Basal\u00a0cytokeratins \u00a0and\u00a0their\u00a0\nrelationship \u00a0to\u00a0the\u00a0cellular\u00a0origin\u00a0and\u00a0\nfunctional \u00a0classification \u00a0of\u00a0breast\u00a0cancer.\u00a0\nBreast\u00a0Cancer\u00a0Res\u00a07,\u00a0143\u2010148\u00a0(2005).\u00a0\n95.\u00a0 Visvader,\u00a0J.E.\u00a0Keeping\u00a0abreast\u00a0of\u00a0the\u00a0\nmammary \u00a0epithelial \u00a0hierarchy \u00a0and\u00a0breast\u00a0\ntumorigenesis. \u00a0Genes\u00a0Dev\u00a023,\u00a02563\u20102577\u00a0\n(2009).\u00a0\n96.\u00a0 Clarke,\u00a0R.B.\u00a0Isolation\u00a0and\u00a0characterization \u00a0\nof\u00a0human\u00a0mammary \u00a0stem\u00a0cells.\u00a0Cell\u00a0Prolif\u00a0\n38,\u00a0375\u2010386\u00a0(2005).\u00a0\n97.\u00a0 Molyneux, \u00a0G.,\u00a0et\u00a0al.\u00a0BRCA1\u00a0basal\u2010like\u00a0\nbreast\u00a0cancers\u00a0originate\u00a0from\u00a0luminal\u00a0\nepithelial \u00a0progenitors \u00a0and\u00a0not\u00a0from\u00a0basal\u00a0\nstem\u00a0cells.\u00a0Cell\u00a0Stem\u00a0Cell\u00a07,\u00a0403\u2010417\u00a0\n(2010).\u00a0\n98.\u00a0 Proia,\u00a0T.A.,\u00a0et\u00a0al.\u00a0Genetic\u00a0predisposition \u00a0\ndirects\u00a0breast\u00a0cancer\u00a0phenotype \u00a0by\u00a0\ndictating\u00a0progenitor \u00a0cell\u00a0fate.\u00a0Cell\u00a0Stem\u00a0\nCell\u00a08,\u00a0149\u2010163\u00a0(2011).\u00a0\n99.\u00a0 Liu,\u00a0S.,\u00a0et\u00a0al.\u00a0BRCA1\u00a0regulates \u00a0human\u00a0\nmammary \u00a0stem/progenitor \u00a0cell\u00a0fate.\u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0105,\u00a01680\u20101685\u00a0\n(2008).\u00a0\n100.\u00a0Callagy,\u00a0G.,\u00a0et\u00a0al.\u00a0Molecular \u00a0classification \u00a0\nof\u00a0breast\u00a0carcinomas \u00a0using\u00a0tissue\u00a0\nmicroarrays. \u00a0Diagn\u00a0Mol\u00a0Pathol\u00a012,\u00a027\u201034\u00a0\n(2003).\u00a0101.\u00a0Nielsen,\u00a0T.O.,\u00a0et\u00a0al.\u00a0Immunohistochemical \u00a0\nand\u00a0clinical\u00a0characterization \u00a0of\u00a0the\u00a0basal\u2010\nlike\u00a0subtype\u00a0of\u00a0invasive\u00a0breast\u00a0carcinoma. \u00a0\nClin\u00a0Cancer\u00a0Res\u00a010,\u00a05367\u20105374\u00a0(2004).\u00a0\n102.\u00a0Rakha,\u00a0E.A.,\u00a0et\u00a0al.\u00a0Prognostic \u00a0markers\u00a0in\u00a0\ntriple\u2010negative\u00a0breast\u00a0cancer.\u00a0Cancer\u00a0109,\u00a0\n25\u201032\u00a0(2007).\u00a0\n103.\u00a0Bertucci,\u00a0F.,\u00a0et\u00a0al.\u00a0How\u00a0basal\u00a0are\u00a0triple\u2010\nnegative\u00a0breast\u00a0cancers?\u00a0Int\u00a0J\u00a0Cancer\u00a0123,\u00a0\n236\u2010240\u00a0(2008).\u00a0\n104.\u00a0Tischkowitz, \u00a0M.,\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0\nimmunohistochemical \u00a0markers\u00a0can\u00a0refine\u00a0\nprognosis \u00a0in\u00a0triple\u00a0negative\u00a0breast\u00a0cancer.\u00a0\nBMC\u00a0Cancer\u00a07,\u00a0134\u00a0(2007).\u00a0\n105.\u00a0Bidard,\u00a0F.C.,\u00a0et\u00a0al.\u00a0Does\u00a0triple\u2010negative\u00a0\nphenotype \u00a0accurately \u00a0identify\u00a0basal\u2010like\u00a0\ntumour?\u00a0 An\u00a0 immunohistochemical \u00a0\nanalysis\u00a0based\u00a0on\u00a0143\u00a0'triple\u2010negative'\u00a0\nbreast\u00a0cancers.\u00a0Ann\u00a0Oncol\u00a018,\u00a01285\u20101286\u00a0\n(2007).\u00a0\n106.\u00a0Bhargava, \u00a0R.\u00a0&\u00a0Dabbs,\u00a0D.J.\u00a0Luminal\u00a0B\u00a0\nbreast\u00a0tumors\u00a0are\u00a0not\u00a0HER2\u00a0positive.\u00a0\nBreast\u00a0Cancer\u00a0Res\u00a010,\u00a0404;\u00a0author\u00a0reply\u00a0\n405\u00a0(2008).\u00a0\n107.\u00a0Cheang,\u00a0M.C. ,\u00a0et\u00a0al.\u00a0Ki67\u00a0index,\u00a0HER2\u00a0\nstatus,\u00a0and\u00a0prognosis \u00a0of\u00a0patients\u00a0with\u00a0\nluminal\u00a0B\u00a0breast\u00a0cancer.\u00a0J\u00a0Natl\u00a0Cancer\u00a0Inst\u00a0\n101,\u00a0736\u2010750\u00a0(2009).\u00a0\n108.\u00a0Sotiriou,\u00a0C.\u00a0&\u00a0Pusztai,\u00a0L.\u00a0Gene\u2010expression \u00a0\nsignatures \u00a0in\u00a0breast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n360,\u00a0790\u2010800\u00a0(2009).\u00a0\n109.\u00a0Prat,\u00a0A.\u00a0&\u00a0Perou,\u00a0C.M.\u00a0Deconstructing \u00a0the\u00a0\nmolecular \u00a0portraits\u00a0of\u00a0breast\u00a0cancer.\u00a0Mol\u00a0\nOncol\u00a05,\u00a05\u201023\u00a0(2011).\u00a0\n110.\u00a0Farmer,\u00a0P.,\u00a0et\u00a0al.\u00a0Identification \u00a0of\u00a0\nmolecular \u00a0apocrine\u00a0breast\u00a0tumours\u00a0by\u00a0\nmicroarray \u00a0analysis.\u00a0Oncogene \u00a024,\u00a04660\u2010\n4671\u00a0(2005).\u00a0\n111.\u00a0Makino,\u00a0S.\u00a0Further\u00a0evidence\u00a0favoring\u00a0the\u00a0\nconcept\u00a0of\u00a0the\u00a0stem\u00a0cell\u00a0in\u00a0ascites\u00a0tumors\u00a0\nof\u00a0rats.\u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci\u00a063,\u00a0818\u2010830\u00a0\n(1956).\u00a0\n112.\u00a0Michor,\u00a0F.\u00a0&\u00a0Polyak,\u00a0K.\u00a0The\u00a0origins\u00a0and\u00a0\nimplications \u00a0of\u00a0intratumor \u00a0heterogeneity. \u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n210\u00a0\n\u00a0Cancer\u00a0Prev\u00a0Res\u00a0(Phila)\u00a03,\u00a01361\u20101364\u00a0\n(2010).\u00a0\n113.\u00a0Jamieson, \u00a0C.H.,\u00a0et\u00a0al.\u00a0Granulocyte \u2010\nmacrophage \u00a0progenitors \u00a0as\u00a0candidate \u00a0\nleukemic\u00a0stem\u00a0cells\u00a0in\u00a0blast\u2010crisis\u00a0CML.\u00a0N\u00a0\nEngl\u00a0J\u00a0Med\u00a0351,\u00a0657\u2010667\u00a0(2004).\u00a0\n114.\u00a0Al\u2010Hajj,\u00a0M.,\u00a0Wicha,\u00a0M.S.,\u00a0Benito\u2010\nHernandez, \u00a0A.,\u00a0Morrison, \u00a0S.J.\u00a0&\u00a0Clarke,\u00a0\nM.F.\u00a0Prospective \u00a0identification \u00a0of\u00a0\ntumorigenic \u00a0breast\u00a0cancer\u00a0cells.\u00a0Proc\u00a0Natl\u00a0\nAcad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0100,\u00a03983\u20103988\u00a0(2003).\u00a0\n115.\u00a0Sheridan, \u00a0C.,\u00a0et\u00a0al.\u00a0CD44+/CD24 \u2010\u00a0breast\u00a0\ncancer\u00a0cells\u00a0exhibit\u00a0enhanced \u00a0invasive\u00a0\nproperties: \u00a0an\u00a0early\u00a0step\u00a0necessary \u00a0for\u00a0\nmetastasis. \u00a0Breast\u00a0Cancer\u00a0Res\u00a08,\u00a0R59\u00a0\n(2006).\u00a0\n116.\u00a0Pece,\u00a0S.,\u00a0et\u00a0al.\u00a0Biological \u00a0and\u00a0molecular \u00a0\nheterogeneity \u00a0of\u00a0breast\u00a0cancers\u00a0correlates \u00a0\nwith\u00a0their\u00a0cancer\u00a0stem\u00a0cell\u00a0content.\u00a0Cell\u00a0\n140,\u00a062\u201073\u00a0(2010).\u00a0\n117.\u00a0Villadsen, \u00a0R.,\u00a0et\u00a0al.\u00a0Evidence\u00a0for\u00a0a\u00a0stem\u00a0cell\u00a0\nhierarchy \u00a0in\u00a0the\u00a0adult\u00a0human\u00a0breast.\u00a0J\u00a0Cell\u00a0\nBiol\u00a0177,\u00a087\u2010101\u00a0(2007).\u00a0\n118.\u00a0Clayton,\u00a0H.,\u00a0Titley,\u00a0I.\u00a0&\u00a0Vivanco,\u00a0M.\u00a0\nGrowth\u00a0 and\u00a0 differentiation \u00a0 of\u00a0\nprogenitor/stem \u00a0cells\u00a0derived\u00a0from\u00a0the\u00a0\nhuman\u00a0mammary \u00a0gland.\u00a0Exp\u00a0Cell\u00a0Res\u00a0297,\u00a0\n444\u2010460\u00a0(2004).\u00a0\n119.\u00a0Meyer,\u00a0 M.J.,\u00a0 et\u00a0 al.\u00a0\nCD44posCD49fhiCD133/2hi \u00a0 defines\u00a0\nxenograft \u2010initiating\u00a0cells\u00a0in\u00a0estrogen\u00a0\nreceptor\u2010negative\u00a0breast\u00a0cancer.\u00a0Cancer\u00a0\nRes\u00a070,\u00a04624\u20104633\u00a0(2010).\u00a0\n120.\u00a0Ginestier, \u00a0C.,\u00a0et\u00a0al.\u00a0ALDH1\u00a0is\u00a0a\u00a0marker\u00a0of\u00a0\nnormal\u00a0and\u00a0malignant \u00a0human\u00a0mammary \u00a0\nstem\u00a0cells\u00a0and\u00a0a\u00a0predictor \u00a0of\u00a0poor\u00a0clinical\u00a0\noutcome. \u00a0Cell\u00a0Stem\u00a0Cell\u00a01,\u00a0555\u2010567\u00a0(2007).\u00a0\n121.\u00a0Quintana, \u00a0E.,\u00a0et\u00a0al.\u00a0Efficient\u00a0tumour\u00a0\nformation \u00a0by\u00a0single\u00a0human\u00a0melanoma \u00a0\ncells.\u00a0Nature\u00a0456,\u00a0593\u2010598\u00a0(2008).\u00a0\n122.\u00a0Iliopoulos, \u00a0D.,\u00a0Hirsch,\u00a0H.A.,\u00a0Wang,\u00a0G.\u00a0&\u00a0\nStruhl,\u00a0K.\u00a0Inducible\u00a0formation \u00a0of\u00a0breast\u00a0\ncancer\u00a0stem\u00a0cells\u00a0and\u00a0their\u00a0dynamic\u00a0\nequilibrium \u00a0with\u00a0non\u2010stem\u00a0cancer\u00a0cells\u00a0via\u00a0IL6\u00a0secretion. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0108,\u00a0\n1397\u20101402\u00a0(2011).\u00a0\n123.\u00a0Marotta,\u00a0L.L.,\u00a0et\u00a0al.\u00a0The\u00a0JAK2/STAT3 \u00a0\nsignaling\u00a0pathway\u00a0is\u00a0required\u00a0for\u00a0growth\u00a0\nof\u00a0CD44(+)CD24( \u2010)\u00a0stem\u00a0cell\u2010like\u00a0breast\u00a0\ncancer\u00a0cells\u00a0in\u00a0human\u00a0tumors.\u00a0J\u00a0Clin\u00a0Invest\u00a0\n121,\u00a02723\u20102735.\u00a0\n124.\u00a0Louie,\u00a0E.,\u00a0et\u00a0al.\u00a0Identification \u00a0of\u00a0a\u00a0stem\u2010like\u00a0\ncell\u00a0population \u00a0by\u00a0exposing\u00a0metastatic \u00a0\nbreast\u00a0cancer\u00a0cell\u00a0lines\u00a0to\u00a0repetitive \u00a0cycles\u00a0\nof\u00a0hypoxia\u00a0and\u00a0reoxygenation. \u00a0Breast\u00a0\nCancer\u00a0Res\u00a012,\u00a0R94\u00a0(2010).\u00a0\n125.\u00a0Hanahan, \u00a0D.\u00a0&\u00a0Weinberg, \u00a0R.A.\u00a0Hallmarks \u00a0\nof\u00a0cancer:\u00a0the\u00a0next\u00a0generation. \u00a0Cell\u00a0144,\u00a0\n646\u2010674\u00a0(2011).\u00a0\n126.\u00a0Virchow,\u00a0R.\u00a0Aetiologie \u00a0der\u00a0neoplastischen \u00a0\nGeschwulste/Pathogenie \u00a0 der\u00a0\nneoplastischen \u00a0 Geschwulste. \u00a0 In:\u00a0\nHirschwald \u00a0VvA,\u00a0(Ed.\u00a0Die\u00a0Krankhaften \u00a0\nGeschwustle, \u00a0Berlin,\u00a0Germany, \u00a01863).\u00a0\n127.\u00a0Balkwill,\u00a0F.\u00a0&\u00a0Mantovani, \u00a0A.\u00a0Inflammation \u00a0\nand\u00a0cancer:\u00a0back\u00a0to\u00a0Virchow? \u00a0Lancet\u00a0357,\u00a0\n539\u2010545\u00a0(2001).\u00a0\n128.\u00a0Dvorak,\u00a0H.F.\u00a0Tumors:\u00a0wounds\u00a0that\u00a0do\u00a0not\u00a0\nheal.\u00a0Similarities \u00a0between\u00a0tumor\u00a0stroma\u00a0\ngeneration \u00a0and\u00a0wound\u00a0healing.\u00a0N\u00a0Engl\u00a0J\u00a0\nMed\u00a0315,\u00a01650\u20101659\u00a0(1986).\u00a0\n129.\u00a0Mantovani, \u00a0A.,\u00a0Allavena,\u00a0P.,\u00a0Sica,\u00a0A.\u00a0&\u00a0\nBalkwill,\u00a0F.\u00a0Cancer\u2010related\u00a0inflammation. \u00a0\nNature\u00a0454,\u00a0436\u2010444\u00a0(2008).\u00a0\n130.\u00a0Aggarwal, \u00a0B.B.,\u00a0Vijayalekshmi, \u00a0R.V.\u00a0&\u00a0\nSung,\u00a0B.\u00a0Targeting \u00a0inflammatory \u00a0pathways \u00a0\nfor\u00a0prevention \u00a0and\u00a0therapy\u00a0of\u00a0cancer:\u00a0\nshort\u2010term\u00a0friend,\u00a0long\u2010term\u00a0foe.\u00a0Clin\u00a0\nCancer\u00a0Res\u00a015,\u00a0425\u2010430\u00a0(2009).\u00a0\n131.\u00a0Hussain,\u00a0S.P.,\u00a0Hofseth,\u00a0L.J.\u00a0&\u00a0Harris,\u00a0C.C.\u00a0\nRadical\u00a0causes\u00a0of\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0Cancer\u00a0\n3,\u00a0276\u2010285\u00a0(2003).\u00a0\n132.\u00a0Yamanishi, \u00a0Y.,\u00a0et\u00a0al.\u00a0Regional\u00a0analysis\u00a0of\u00a0\np53\u00a0mutations \u00a0in\u00a0rheumatoid \u00a0arthritis\u00a0\nsynovium. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a099,\u00a0\n10025\u201010030\u00a0(2002).\u00a0\n133.\u00a0Grivennikov, \u00a0S.I.,\u00a0Greten,\u00a0F.R.\u00a0&\u00a0Karin,\u00a0M.\u00a0\nImmunity, \u00a0inflammation, \u00a0and\u00a0cancer.\u00a0Cell\u00a0\n140,\u00a0883\u2010899\u00a0(2010).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n211\u00a0\n\u00a0134.\u00a0Coussens, \u00a0L.M.\u00a0&\u00a0Werb,\u00a0Z.\u00a0Inflammation \u00a0\nand\u00a0cancer.\u00a0Nature\u00a0420,\u00a0860\u2010867\u00a0(2002).\u00a0\n135.\u00a0Nickoloff, \u00a0B.J.,\u00a0Ben\u2010Neriah,\u00a0Y.\u00a0&\u00a0Pikarsky,\u00a0\nE.\u00a0Inflammation \u00a0and\u00a0cancer:\u00a0is\u00a0the\u00a0link\u00a0as\u00a0\nsimple\u00a0as\u00a0we\u00a0think?\u00a0J\u00a0Invest\u00a0Dermatol \u00a0124,\u00a0\nx\u2010xiv\u00a0(2005).\u00a0\n136.\u00a0Coley,\u00a0W.B.\u00a0The\u00a0treatment \u00a0of\u00a0malignant \u00a0\ntumors\u00a0by\u00a0repeated\u00a0inoculations \u00a0of\u00a0\nerysipelas. \u00a0With\u00a0a\u00a0report\u00a0of\u00a0ten\u00a0original\u00a0\ncases.\u00a01893.\u00a0Clin\u00a0Orthop\u00a0Relat\u00a0Res,\u00a03\u201011\u00a0\n(1991).\u00a0\n137.\u00a0Burnet,\u00a0M.\u00a0Immunological \u00a0Factors\u00a0in\u00a0the\u00a0\nProcess\u00a0of\u00a0Carcinogenesis. \u00a0Br\u00a0Med\u00a0Bull\u00a020,\u00a0\n154\u2010158\u00a0(1964).\u00a0\n138.\u00a0Burnet,\u00a0M.\u00a0Cancer:\u00a0a\u00a0biological \u00a0approach. \u00a0\nIII.\u00a0Viruses\u00a0associated \u00a0with\u00a0neoplastic \u00a0\nconditions. \u00a0IV.\u00a0Practical\u00a0applications. \u00a0Br\u00a0\nMed\u00a0J\u00a01,\u00a0841\u2010847\u00a0(1957).\u00a0\n139.\u00a0Burnet,\u00a0F.M.\u00a0The\u00a0concept\u00a0of\u00a0\nimmunological \u00a0surveillance. \u00a0Prog\u00a0Exp\u00a0\nTumor\u00a0Res\u00a013,\u00a01\u201027\u00a0(1970).\u00a0\n140.\u00a0Dunn,\u00a0G.P.,\u00a0Bruce,\u00a0A.T.,\u00a0Ikeda,\u00a0H.,\u00a0Old,\u00a0L.J.\u00a0\n&\u00a0Schreiber, \u00a0R.D.\u00a0Cancer\u00a0immunoediting: \u00a0\nfrom\u00a0immunosurveillance \u00a0to\u00a0tumor\u00a0\nescape.\u00a0Nat\u00a0Immunol\u00a03,\u00a0991\u2010998\u00a0(2002).\u00a0\n141.\u00a0Dunn,\u00a0G.P.,\u00a0Old,\u00a0L.J.\u00a0&\u00a0Schreiber, \u00a0R.D.\u00a0The\u00a0\nimmunobiology \u00a0 of\u00a0 cancer\u00a0\nimmunosurveillance \u00a0and\u00a0immunoediting. \u00a0\nImmunity \u00a021,\u00a0137\u2010148\u00a0(2004).\u00a0\n142.\u00a0Dunn,\u00a0G.P.,\u00a0Old,\u00a0L.J.\u00a0&\u00a0Schreiber, \u00a0R.D.\u00a0The\u00a0\nthree\u00a0Es\u00a0of\u00a0cancer\u00a0immunoediting. \u00a0Annu\u00a0\nRev\u00a0Immunol\u00a022,\u00a0329\u2010360\u00a0(2004).\u00a0\n143.\u00a0Smyth,\u00a0M.J.,\u00a0Dunn,\u00a0G.P.\u00a0&\u00a0Schreiber, \u00a0R.D.\u00a0\nCancer\u00a0 immunosurveillance \u00a0 and\u00a0\nimmunoediting: \u00a0the\u00a0roles\u00a0of\u00a0immunity \u00a0in\u00a0\nsuppressing \u00a0tumor\u00a0development \u00a0and\u00a0\nshaping\u00a0tumor\u00a0immunogenicity. \u00a0Adv\u00a0\nImmunol\u00a090,\u00a01\u201050\u00a0(2006).\u00a0\n144.\u00a0Mantovani, \u00a0A.,\u00a0Bottazzi,\u00a0B.,\u00a0Colotta,\u00a0F.,\u00a0\nSozzani,\u00a0S.\u00a0&\u00a0Ruco,\u00a0L.\u00a0The\u00a0origin\u00a0and\u00a0\nfunction\u00a0 of\u00a0 tumor\u2010associated \u00a0\nmacrophages. \u00a0Immunol\u00a0Today\u00a013,\u00a0265\u2010270\u00a0\n(1992).\u00a0\n145.\u00a0Hagemann, \u00a0T.,\u00a0et\u00a0al.\u00a0\"Re\u2010educating\" \u00a0\ntumor\u2010associated \u00a0 macrophages \u00a0 by\u00a0targeting\u00a0NF\u2010kappaB.\u00a0J\u00a0Exp\u00a0Med\u00a0205,\u00a0\n1261\u20101268\u00a0(2008).\u00a0\n146.\u00a0Koebel,\u00a0C.M. ,\u00a0et\u00a0al.\u00a0Adaptive\u00a0immunity \u00a0\nmaintains \u00a0occult\u00a0cancer\u00a0in\u00a0an\u00a0equilibrium \u00a0\nstate.\u00a0Nature\u00a0450,\u00a0903\u2010907\u00a0(2007).\u00a0\n147.\u00a0Bui,\u00a0J.D.\u00a0&\u00a0Schreiber, \u00a0R.D.\u00a0Cancer\u00a0\nimmunosurveillance, \u00a0immunoediting \u00a0and\u00a0\ninflammation: \u00a0 independent \u00a0 or\u00a0\ninterdependent \u00a0processes? \u00a0Curr\u00a0Opin\u00a0\nImmunol\u00a019,\u00a0203\u2010208\u00a0(2007).\u00a0\n148.\u00a0Murdoch, \u00a0C.,\u00a0Muthana, \u00a0M.,\u00a0Coffelt,\u00a0S.B.\u00a0&\u00a0\nLewis,\u00a0C.E.\u00a0The\u00a0role\u00a0of\u00a0myeloid\u00a0cells\u00a0in\u00a0the\u00a0\npromotion \u00a0of\u00a0tumour\u00a0angiogenesis. \u00a0Nat\u00a0\nRev\u00a0Cancer\u00a08,\u00a0618\u2010631\u00a0(2008).\u00a0\n149.\u00a0Duncan,\u00a0L.M.,\u00a0Richards,\u00a0L.A.\u00a0&\u00a0Mihm,\u00a0\nM.C.,\u00a0Jr.\u00a0Increased \u00a0mast\u00a0cell\u00a0density\u00a0in\u00a0\ninvasive\u00a0melanoma. \u00a0J\u00a0Cutan\u00a0Pathol\u00a025,\u00a011\u2010\n15\u00a0(1998).\u00a0\n150.\u00a0Lin,\u00a0E.Y.,\u00a0Nguyen,\u00a0A.V.,\u00a0Russell,\u00a0R.G.\u00a0&\u00a0\nPollard,\u00a0J.W.\u00a0Colony\u2010stimulating \u00a0factor\u00a01\u00a0\npromotes \u00a0progression \u00a0of\u00a0mammary \u00a0\ntumors\u00a0to\u00a0malignancy. \u00a0J\u00a0Exp\u00a0Med\u00a0193,\u00a0\n727\u2010740\u00a0(2001).\u00a0\n151.\u00a0DeNardo, \u00a0D.G.,\u00a0et\u00a0al.\u00a0CD4(+)\u00a0T\u00a0cells\u00a0\nregulate\u00a0pulmonary \u00a0metastasis \u00a0of\u00a0\nmammary \u00a0carcinomas \u00a0by\u00a0enhancing \u00a0\nprotumor \u00a0properties \u00a0of\u00a0macrophages. \u00a0\nCancer\u00a0Cell\u00a016,\u00a091\u2010102\u00a0(2009).\u00a0\n152.\u00a0De\u00a0Palma,\u00a0M.,\u00a0et\u00a0al.\u00a0Tie2\u00a0identifies \u00a0a\u00a0\nhematopoietic \u00a0lineage\u00a0of\u00a0proangiogenic \u00a0\nmonocytes \u00a0required\u00a0for\u00a0tumor\u00a0vessel\u00a0\nformation \u00a0and\u00a0a\u00a0mesenchymal \u00a0population \u00a0\nof\u00a0pericyte\u00a0progenitors. \u00a0Cancer\u00a0Cell\u00a08,\u00a0211\u2010\n226\u00a0(2005).\u00a0\n153.\u00a0Mantovani, \u00a0A.,\u00a0Sozzani,\u00a0S.,\u00a0Locati,\u00a0M.,\u00a0\nAllavena,\u00a0P.\u00a0&\u00a0Sica,\u00a0A.\u00a0Macrophage \u00a0\npolarization: \u00a0 tumor\u2010associated \u00a0\nmacrophages \u00a0as\u00a0a\u00a0paradigm \u00a0for\u00a0polarized \u00a0\nM2\u00a0mononuclear \u00a0phagocytes. \u00a0Trends\u00a0\nImmunol\u00a023,\u00a0549\u2010555\u00a0(2002).\u00a0\n154.\u00a0Hagemann, \u00a0T.,\u00a0et\u00a0al.\u00a0Ovarian\u00a0cancer\u00a0cells\u00a0\npolarize\u00a0macrophages \u00a0toward\u00a0a\u00a0tumor\u2010\nassociated \u00a0phenotype. \u00a0J\u00a0Immunol\u00a0176,\u00a0\n5023\u20105032\u00a0(2006).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n212\u00a0\n\u00a0155.\u00a0Biswas,\u00a0S.K.\u00a0&\u00a0Mantovani, \u00a0A.\u00a0Macrophage \u00a0\nplasticity\u00a0and\u00a0interaction \u00a0with\u00a0lymphocyte \u00a0\nsubsets:\u00a0cancer\u00a0as\u00a0a\u00a0paradigm. \u00a0Nat\u00a0\nImmunol\u00a011,\u00a0889\u2010896\u00a0(2010).\u00a0\n156.\u00a0Menetrier \u2010Caux,\u00a0C.,\u00a0et\u00a0al.\u00a0Inhibition \u00a0of\u00a0the\u00a0\ndifferentiation \u00a0of\u00a0dendritic\u00a0cells\u00a0from\u00a0\nCD34(+)\u00a0progenitors \u00a0by\u00a0tumor\u00a0cells:\u00a0role\u00a0of\u00a0\ninterleukin \u20106\u00a0and\u00a0macrophage \u00a0colony\u2010\nstimulating \u00a0factor.\u00a0Blood\u00a092,\u00a04778\u20104791\u00a0\n(1998).\u00a0\n157.\u00a0Karin,\u00a0M.\u00a0Nuclear\u00a0factor\u2010kappaB\u00a0in\u00a0cancer\u00a0\ndevelopment \u00a0and\u00a0progression. \u00a0Nature\u00a0\n441,\u00a0431\u2010436\u00a0(2006).\u00a0\n158.\u00a0Yu,\u00a0H.,\u00a0Kortylewski, \u00a0M.\u00a0&\u00a0Pardoll,\u00a0D.\u00a0\nCrosstalk\u00a0between\u00a0cancer\u00a0and\u00a0immune\u00a0\ncells:\u00a0role\u00a0of\u00a0STAT3\u00a0in\u00a0the\u00a0tumour\u00a0\nmicroenvironment. \u00a0Nat\u00a0Rev\u00a0Immunol\u00a07,\u00a0\n41\u201051\u00a0(2007).\u00a0\n159.\u00a0Swann,\u00a0J.B.,\u00a0et\u00a0al.\u00a0Demonstration \u00a0of\u00a0\ninflammation \u2010induced\u00a0cancer\u00a0and\u00a0cancer\u00a0\nimmunoediting \u00a0 during\u00a0 primary\u00a0\ntumorigenesis. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0\n105,\u00a0652\u2010656\u00a0(2008).\u00a0\n160.\u00a0Pollard,\u00a0 J.W.\u00a0 Tumour\u2010educated \u00a0\nmacrophages \u00a0 promote\u00a0 tumour\u00a0\nprogression \u00a0and\u00a0metastasis. \u00a0Nat\u00a0Rev\u00a0\nCancer\u00a04,\u00a071\u201078\u00a0(2004).\u00a0\n161.\u00a0Voronov,\u00a0E.,\u00a0et\u00a0al.\u00a0IL\u20101\u00a0is\u00a0required\u00a0for\u00a0\ntumor\u00a0invasiveness \u00a0and\u00a0angiogenesis. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0100,\u00a02645\u20102650\u00a0\n(2003).\u00a0\n162.\u00a0Weinreich, \u00a0D.M. ,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0\ninterleukin \u00a01\u00a0receptor\u00a0antagonist \u00a0gene\u00a0\ntransduction \u00a0on\u00a0human\u00a0melanoma \u00a0\nxenografts \u00a0in\u00a0nude\u00a0mice.\u00a0Cancer\u00a0Res\u00a063,\u00a0\n5957\u20105961\u00a0(2003).\u00a0\n163.\u00a0Mantovani, \u00a0A.,\u00a0et\u00a0al.\u00a0The\u00a0chemokine \u00a0\nsystem\u00a0in\u00a0cancer\u00a0biology\u00a0and\u00a0therapy.\u00a0\nCytokine\u00a0Growth\u00a0Factor\u00a0Rev\u00a021,\u00a027\u201039\u00a0\n(2010).\u00a0\n164.\u00a0Bonecchi, \u00a0R.,\u00a0Locati,\u00a0M.\u00a0&\u00a0Mantovani, \u00a0A.\u00a0\nChemokines \u00a0and\u00a0cancer:\u00a0a\u00a0fatal\u00a0attraction. \u00a0\nCancer\u00a0Cell\u00a019,\u00a0434\u2010435\u00a0(2011).\u00a0165.\u00a0US,\u00a0V.E.\u00a0&\u00a0Gaddum,\u00a0J.H.\u00a0An\u00a0unidentified \u00a0\ndepressor \u00a0substance \u00a0in\u00a0certain\u00a0tissue\u00a0\nextracts.\u00a0J\u00a0Physiol\u00a072,\u00a074\u201087\u00a0(1931).\u00a0\n166.\u00a0Khawaja,\u00a0A.M.\u00a0&\u00a0Rogers,\u00a0D.F.\u00a0Tachykinins: \u00a0\nreceptor\u00a0to\u00a0effector.\u00a0Int\u00a0J\u00a0Biochem\u00a0Cell\u00a0Biol\u00a0\n28,\u00a0721\u2010738\u00a0(1996).\u00a0\n167.\u00a0Chang,\u00a0M.M.\u00a0&\u00a0Leeman,\u00a0S.E.\u00a0Isolation\u00a0of\u00a0a\u00a0\nsialogogic \u00a0 peptide\u00a0 from\u00a0 bovine\u00a0\nhypothalamic \u00a0 tissue\u00a0 and\u00a0 its\u00a0\ncharacterization \u00a0as\u00a0substance \u00a0P.\u00a0J\u00a0Biol\u00a0\nChem\u00a0245,\u00a04784\u20104790\u00a0(1970).\u00a0\n168.\u00a0Otsuka,\u00a0 M.\u00a0 &\u00a0 Yoshioka, \u00a0 K.\u00a0\nNeurotransmitter \u00a0functions \u00a0of\u00a0mammalian \u00a0\ntachykinins. \u00a0Physiol\u00a0Rev\u00a073,\u00a0229\u2010308\u00a0\n(1993).\u00a0\n169.\u00a0Holmgren, \u00a0S.\u00a0&\u00a0Jensen,\u00a0J.\u00a0Evolution \u00a0of\u00a0\nvertebrate \u00a0neuropeptides. \u00a0Brain\u00a0Res\u00a0Bull\u00a0\n55,\u00a0723\u2010735\u00a0(2001).\u00a0\n170.\u00a0Patacchini, \u00a0R.,\u00a0Lecci,\u00a0A.,\u00a0Holzer,\u00a0P.\u00a0&\u00a0\nMaggi,\u00a0C.A.\u00a0Newly\u00a0discovered \u00a0tachykinins \u00a0\nraise\u00a0new\u00a0questions \u00a0about\u00a0their\u00a0peripheral \u00a0\nroles\u00a0and\u00a0the\u00a0tachykinin \u00a0nomenclature. \u00a0\nTrends\u00a0Pharmacol \u00a0Sci\u00a025,\u00a01\u20103\u00a0(2004).\u00a0\n171.\u00a0Nelson,\u00a0D.A.,\u00a0Marriott,\u00a0I.\u00a0&\u00a0Bost,\u00a0K.L.\u00a0\nExpression \u00a0of\u00a0hemokinin \u00a01\u00a0mRNA\u00a0by\u00a0\nmurine\u00a0dendritic\u00a0cells.\u00a0J\u00a0Neuroimmunol \u00a0\n155,\u00a094\u2010102\u00a0(2004).\u00a0\n172.\u00a0Zhang,\u00a0Y.,\u00a0Lu,\u00a0L.,\u00a0Furlonger, \u00a0C.,\u00a0Wu,\u00a0G.E.\u00a0&\u00a0\nPaige,\u00a0C.J.\u00a0Hemokinin \u00a0is\u00a0a\u00a0hematopoietic \u2010\nspecific\u00a0tachykinin \u00a0that\u00a0regulates \u00a0B\u00a0\nlymphopoiesis. \u00a0Nat\u00a0Immunol\u00a01,\u00a0392\u2010397\u00a0\n(2000).\u00a0\n173.\u00a0Sternini,\u00a0C.\u00a0Tachykinin \u00a0and\u00a0calcitonin \u00a0\ngene\u2010related\u00a0peptide\u00a0immunoreactivities \u00a0\nand\u00a0mRNAs\u00a0in\u00a0the\u00a0mammalian \u00a0enteric\u00a0\nnervous\u00a0system\u00a0and\u00a0sensory\u00a0ganglia.\u00a0Adv\u00a0\nExp\u00a0Med\u00a0Biol\u00a0298,\u00a039\u201051\u00a0(1991).\u00a0\n174.\u00a0Douglas,\u00a0S.D.\u00a0&\u00a0Leeman,\u00a0S.E.\u00a0Neurokinin \u20101\u00a0\nreceptor: \u00a0functional \u00a0significance \u00a0in\u00a0the\u00a0\nimmune\u00a0system\u00a0in\u00a0reference \u00a0to\u00a0selected\u00a0\ninfections \u00a0and\u00a0inflammation. \u00a0Ann\u00a0N\u00a0Y\u00a0\nAcad\u00a0Sci\u00a01217 ,\u00a083\u201095\u00a0(2010).\u00a0\n175.\u00a0Koon,\u00a0H.W.\u00a0&\u00a0Pothoulakis, \u00a0C.\u00a0\nImmunomodulatory \u00a0 properties \u00a0 of\u00a0\nsubstance \u00a0P:\u00a0the\u00a0gastrointestinal \u00a0system\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n213\u00a0\n\u00a0as\u00a0a\u00a0model.\u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci\u00a01088 ,\u00a023\u201040\u00a0\n(2006).\u00a0\n176.\u00a0Douglas,\u00a0S.D.,\u00a0et\u00a0al.\u00a0Elevated\u00a0substance \u00a0P\u00a0\nlevels\u00a0in\u00a0HIV\u2010infected\u00a0men.\u00a0AIDS\u00a015,\u00a02043\u2010\n2045\u00a0(2001).\u00a0\n177.\u00a0Douglas,\u00a0S.D.,\u00a0et\u00a0al.\u00a0Elevated\u00a0substance \u00a0P\u00a0\nlevels\u00a0in\u00a0HIV\u2010infected\u00a0women\u00a0in\u00a0\ncomparison \u00a0to\u00a0HIV\u2010negative\u00a0women.\u00a0AIDS\u00a0\nRes\u00a0Hum\u00a0Retroviruses \u00a024,\u00a0375\u2010378\u00a0(2008).\u00a0\n178.\u00a0Ho,\u00a0W.Z. ,\u00a0et\u00a0al.\u00a0Substance \u00a0P\u00a0modulates \u00a0\nhuman\u00a0 immunodeficiency \u00a0 virus\u00a0\nreplication \u00a0in\u00a0human\u00a0peripheral \u00a0blood\u00a0\nmonocyte \u2010derived\u00a0macrophages. \u00a0AIDS\u00a0Res\u00a0\nHum\u00a0Retroviruses \u00a012,\u00a0195\u2010198\u00a0(1996).\u00a0\n179.\u00a0Lai,\u00a0J.P.,\u00a0et\u00a0al.\u00a0Substance \u00a0P\u00a0antagonist \u00a0(CP\u2010\n96,345)\u00a0inhibits\u00a0HIV\u20101\u00a0replication \u00a0in\u00a0\nhuman\u00a0mononuclear \u00a0phagocytes. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a098,\u00a03970\u20103975\u00a0(2001).\u00a0\n180.\u00a0Wang,\u00a0X.,\u00a0et\u00a0al.\u00a0Neurokinin \u20101\u00a0receptor\u00a0\nantagonist \u00a0(aprepitant) \u00a0inhibits\u00a0drug\u2010\nresistant\u00a0HIV\u20101\u00a0infection\u00a0of\u00a0macrophages \u00a0\nin\u00a0vitro.\u00a0J\u00a0Neuroimmune \u00a0Pharmacol \u00a02,\u00a042\u2010\n48\u00a0(2007).\u00a0\n181.\u00a0O'Connor, \u00a0T.M. ,\u00a0et\u00a0al.\u00a0The\u00a0role\u00a0of\u00a0\nsubstance \u00a0P\u00a0in\u00a0inflammatory \u00a0disease.\u00a0J\u00a0Cell\u00a0\nPhysiol\u00a0201,\u00a0167\u2010180\u00a0(2004).\u00a0\n182.\u00a0Hong,\u00a0H.S.,\u00a0et\u00a0al.\u00a0A\u00a0new\u00a0role\u00a0of\u00a0substance \u00a0\nP\u00a0as\u00a0an\u00a0injury\u2010inducible\u00a0messenger \u00a0for\u00a0\nmobilization \u00a0of\u00a0CD29(+)\u00a0stromal\u2010like\u00a0cells.\u00a0\nNat\u00a0Med\u00a015,\u00a0425\u2010435\u00a0(2009).\u00a0\n183.\u00a0Page,\u00a0N.M.\u00a0New\u00a0challenges \u00a0in\u00a0the\u00a0study\u00a0of\u00a0\nthe\u00a0mammalian \u00a0tachykinins. \u00a0Peptides\u00a026,\u00a0\n1356\u20101368\u00a0(2005).\u00a0\n184.\u00a0Pennefather, \u00a0J.N.,\u00a0et\u00a0al.\u00a0Tachykinins \u00a0and\u00a0\ntachykinin \u00a0receptors: \u00a0a\u00a0growing\u00a0family.\u00a0\nLife\u00a0Sci\u00a074,\u00a01445\u20101463\u00a0(2004).\u00a0\n185.\u00a0Bost,\u00a0 K.L.\u00a0 Tachykinin \u2010mediated \u00a0\nmodulation \u00a0of\u00a0the\u00a0immune\u00a0response. \u00a0\nFront\u00a0Biosci\u00a09,\u00a03331\u20103332\u00a0(2004).\u00a0\n186.\u00a0Ho,\u00a0W.Z.,\u00a0Lai,\u00a0J.P.,\u00a0Zhu,\u00a0X.H.,\u00a0Uvaydova, \u00a0M.\u00a0\n&\u00a0Douglas,\u00a0S.D.\u00a0Human\u00a0monocytes \u00a0and\u00a0\nmacrophages \u00a0express\u00a0substance \u00a0P\u00a0and\u00a0\nneurokinin \u20101\u00a0receptor. \u00a0J\u00a0Immunol\u00a0159,\u00a0\n5654\u20105660\u00a0(1997).\u00a0187.\u00a0Satake,\u00a0H.\u00a0&\u00a0Kawada,\u00a0T.\u00a0Overview \u00a0of\u00a0the\u00a0\nprimary\u00a0structure, \u00a0tissue\u2010distribution, \u00a0and\u00a0\nfunctions \u00a0of\u00a0tachykinins \u00a0and\u00a0their\u00a0\nreceptors. \u00a0Curr\u00a0Drug\u00a0Targets\u00a07,\u00a0963\u2010974\u00a0\n(2006).\u00a0\n188.\u00a0Maggi,\u00a0C.A.\u00a0The\u00a0effects\u00a0of\u00a0tachykinins \u00a0on\u00a0\ninflammatory \u00a0and\u00a0immune\u00a0cells.\u00a0Regul\u00a0\nPept\u00a070,\u00a075\u201090\u00a0(1997).\u00a0\n189.\u00a0Holzer,\u00a0P.\u00a0&\u00a0Holzer\u2010Petsche,\u00a0U.\u00a0\nTachykinins \u00a0in\u00a0the\u00a0gut.\u00a0Part\u00a0II.\u00a0Roles\u00a0in\u00a0\nneural\u00a0excitation, \u00a0secretion \u00a0and\u00a0\ninflammation. \u00a0Pharmacol \u00a0Ther\u00a073,\u00a0219\u2010\n263\u00a0(1997).\u00a0\n190.\u00a0Weihe,\u00a0E.,\u00a0et\u00a0al.\u00a0Molecular \u00a0anatomy\u00a0of\u00a0the\u00a0\nneuro\u2010immune\u00a0connection. \u00a0Int\u00a0J\u00a0Neurosci\u00a0\n59,\u00a01\u201023\u00a0(1991).\u00a0\n191.\u00a0Rameshwar, \u00a0P.,\u00a0Ganea,\u00a0D.\u00a0&\u00a0Gascon,\u00a0P.\u00a0In\u00a0\nvitro\u00a0stimulatory \u00a0effect\u00a0of\u00a0substance \u00a0P\u00a0on\u00a0\nhematopoiesis. \u00a0Blood\u00a081,\u00a0391\u2010398\u00a0(1993).\u00a0\n192.\u00a0Rameshwar, \u00a0P.\u00a0&\u00a0Gascon,\u00a0P.\u00a0Substance \u00a0P\u00a0\n(SP)\u00a0mediates \u00a0production \u00a0of\u00a0stem\u00a0cell\u00a0\nfactor\u00a0and\u00a0interleukin \u20101\u00a0in\u00a0bone\u00a0marrow\u00a0\nstroma:\u00a0potential\u00a0autoregulatory \u00a0role\u00a0for\u00a0\nthese\u00a0cytokines \u00a0in\u00a0SP\u00a0receptor\u00a0expression \u00a0\nand\u00a0induction. \u00a0Blood\u00a086,\u00a0482\u2010490\u00a0(1995).\u00a0\n193.\u00a0Rameshwar, \u00a0P.,\u00a0Poddar,\u00a0A.\u00a0&\u00a0Gascon,\u00a0P.\u00a0\nHematopoietic \u00a0regulation \u00a0mediated \u00a0by\u00a0\ninteractions \u00a0among\u00a0the\u00a0neurokinins \u00a0and\u00a0\ncytokines. \u00a0Leuk\u00a0Lymphoma \u00a028,\u00a01\u201010\u00a0\n(1997).\u00a0\n194.\u00a0Nilsson,\u00a0J.,\u00a0von\u00a0Euler,\u00a0A.M.\u00a0&\u00a0Dalsgaard, \u00a0\nC.J.\u00a0Stimulation \u00a0of\u00a0connective \u00a0tissue\u00a0cell\u00a0\ngrowth\u00a0by\u00a0substance \u00a0P\u00a0and\u00a0substance \u00a0K.\u00a0\nNature\u00a0315,\u00a061\u201063\u00a0(1985).\u00a0\n195.\u00a0Payan,\u00a0D.G.,\u00a0Brewster, \u00a0D.R.\u00a0&\u00a0Goetzl,\u00a0E.J.\u00a0\nSpecific\u00a0stimulation \u00a0of\u00a0human\u00a0T\u00a0\nlymphocytes \u00a0by\u00a0substance \u00a0P.\u00a0J\u00a0Immunol\u00a0\n131,\u00a01613\u20101615\u00a0(1983).\u00a0\n196.\u00a0Nakamura, \u00a0M.,\u00a0et\u00a0al.\u00a0Synergistic \u00a0effect\u00a0of\u00a0\nsubstance \u00a0P\u00a0with\u00a0epidermal \u00a0growth\u00a0factor\u00a0\non\u00a0epithelial \u00a0migration \u00a0in\u00a0rabbit\u00a0cornea.\u00a0\nExp\u00a0Eye\u00a0Res\u00a065,\u00a0321\u2010329\u00a0(1997).\u00a0\n197.\u00a0Castagliuolo, \u00a0I.,\u00a0et\u00a0al.\u00a0Protective \u00a0effects\u00a0of\u00a0\nneurokinin \u20101\u00a0receptor\u00a0during\u00a0colitis\u00a0in\u00a0\nmice:\u00a0role\u00a0of\u00a0the\u00a0epidermal \u00a0growth\u00a0factor\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n214\u00a0\n\u00a0receptor. \u00a0Br\u00a0J\u00a0Pharmacol \u00a0136,\u00a0271\u2010279\u00a0\n(2002).\u00a0\n198.\u00a0Koon,\u00a0H.W.,\u00a0Zhao,\u00a0D.,\u00a0Zhan,\u00a0Y.,\u00a0Moyer,\u00a0\nM.P.\u00a0&\u00a0Pothoulakis, \u00a0C.\u00a0Substance \u00a0P\u00a0\nmediates \u00a0antiapoptotic \u00a0responses \u00a0in\u00a0\nhuman\u00a0colonocytes \u00a0by\u00a0Akt\u00a0activation. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0104,\u00a02013\u20102018\u00a0\n(2007).\u00a0\n199.\u00a0Castagliuolo, \u00a0I.,\u00a0et\u00a0al.\u00a0Increased \u00a0substance \u00a0\nP\u00a0responses \u00a0in\u00a0dorsal\u00a0root\u00a0ganglia\u00a0and\u00a0\nintestinal \u00a0macrophages \u00a0during\u00a0Clostridium \u00a0\ndifficile\u00a0toxin\u00a0A\u00a0enteritis\u00a0in\u00a0rats.\u00a0Proc\u00a0Natl\u00a0\nAcad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a094,\u00a04788\u20104793\u00a0(1997).\u00a0\n200.\u00a0Bhatia,\u00a0M.,\u00a0et\u00a0al.\u00a0Role\u00a0of\u00a0substance \u00a0P\u00a0and\u00a0\nthe\u00a0neurokinin \u00a01\u00a0receptor\u00a0in\u00a0acute\u00a0\npancreatitis \u00a0and\u00a0pancreatitis \u2010associated \u00a0\nlung\u00a0injury.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a095,\u00a0\n4760\u20104765\u00a0(1998).\u00a0\n201.\u00a0Grady,\u00a0E.F.,\u00a0et\u00a0al.\u00a0Substance \u00a0P\u00a0mediates \u00a0\ninflammatory \u00a0 oedema\u00a0 in\u00a0 acute\u00a0\npancreatitis \u00a0via\u00a0activation \u00a0of\u00a0the\u00a0\nneurokinin \u20101\u00a0receptor\u00a0in\u00a0rats\u00a0and\u00a0mice.\u00a0Br\u00a0\nJ\u00a0Pharmacol \u00a0130,\u00a0505\u2010512\u00a0(2000).\u00a0\n202.\u00a0Shrikhande, \u00a0S.V.,\u00a0et\u00a0al.\u00a0NK\u20101\u00a0receptor\u00a0gene\u00a0\nexpression \u00a0is\u00a0related\u00a0to\u00a0pain\u00a0in\u00a0chronic\u00a0\npancreatitis. \u00a0Pain\u00a091,\u00a0209\u2010217\u00a0(2001).\u00a0\n203.\u00a0Veronesi, \u00a0B.,\u00a0Carter,\u00a0J.D.,\u00a0Devlin,\u00a0R.B.,\u00a0\nSimon,\u00a0S.A.\u00a0&\u00a0Oortgiesen, \u00a0M.\u00a0\nNeuropeptides \u00a0and\u00a0capsaicin\u00a0stimulate \u00a0\nthe\u00a0release\u00a0of\u00a0inflammatory \u00a0cytokines \u00a0in\u00a0a\u00a0\nhuman\u00a0bronchial \u00a0epithelial \u00a0cell\u00a0line.\u00a0\nNeuropeptides \u00a033,\u00a0447\u2010456\u00a0(1999).\u00a0\n204.\u00a0Sio,\u00a0S.W.,\u00a0Puthia,\u00a0M.K.,\u00a0Lu,\u00a0J.,\u00a0Moochhala, \u00a0\nS.\u00a0&\u00a0Bhatia,\u00a0M.\u00a0The\u00a0neuropeptide \u00a0\nsubstance \u00a0P\u00a0is\u00a0a\u00a0critical\u00a0mediator\u00a0of\u00a0burn\u2010\ninduced\u00a0acute\u00a0lung\u00a0injury.\u00a0J\u00a0Immunol\u00a0180,\u00a0\n8333\u20108341\u00a0(2008).\u00a0\n205.\u00a0Harrison,\u00a0S.\u00a0&\u00a0Geppetti, \u00a0P.\u00a0Substance \u00a0p.\u00a0Int\u00a0\nJ\u00a0Biochem\u00a0Cell\u00a0Biol\u00a033,\u00a0555\u2010576\u00a0(2001).\u00a0\n206.\u00a0Joos,\u00a0G.F.,\u00a0Germonpre, \u00a0P.R.\u00a0&\u00a0Pauwels,\u00a0\nR.A.\u00a0Role\u00a0of\u00a0tachykinins \u00a0in\u00a0asthma.\u00a0Allergy\u00a0\n55,\u00a0321\u2010337\u00a0(2000).\u00a0\n207.\u00a0Sturiale,\u00a0S.,\u00a0et\u00a0al.\u00a0Neutral\u00a0endopeptidase \u00a0\n(EC\u00a03.4.24.11) \u00a0terminates \u00a0colitis\u00a0by\u00a0degrading \u00a0substance \u00a0P.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0\nU\u00a0S\u00a0A\u00a096,\u00a011653\u201011658\u00a0(1999).\u00a0\n208.\u00a0Scholzen, \u00a0T.E.,\u00a0et\u00a0al.\u00a0Neutral\u00a0\nendopeptidase \u00a0terminates \u00a0substance \u00a0P\u2010\ninduced\u00a0inflammation \u00a0in\u00a0allergic\u00a0contact\u00a0\ndermatitis. \u00a0J\u00a0Immunol\u00a0166,\u00a01285\u20101291\u00a0\n(2001).\u00a0\n209.\u00a0Joshi,\u00a0D.D.,\u00a0et\u00a0al.\u00a0Negative\u00a0feedback\u00a0on\u00a0\nthe\u00a0effects\u00a0of\u00a0stem\u00a0cell\u00a0factor\u00a0on\u00a0\nhematopoiesis \u00a0is\u00a0partly\u00a0mediated \u00a0through\u00a0\nneutral\u00a0endopeptidase \u00a0activity\u00a0on\u00a0\nsubstance \u00a0P:\u00a0a\u00a0combined \u00a0functional \u00a0and\u00a0\nproteomic \u00a0study.\u00a0Blood\u00a098,\u00a02697\u20102706\u00a0\n(2001).\u00a0\n210.\u00a0Gascon,\u00a0P.,\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0\npreprotachykinin \u2010I\u00a0 peptides\u00a0 on\u00a0\nhematopoietic \u00a0homeostasis. \u00a0A\u00a0role\u00a0for\u00a0\nbone\u00a0marrow\u00a0endopeptidases. \u00a0Ann\u00a0N\u00a0Y\u00a0\nAcad\u00a0Sci\u00a0917,\u00a0416\u2010423\u00a0(2000).\u00a0\n211.\u00a0Albrecht,\u00a0M.,\u00a0et\u00a0al.\u00a0Expression \u00a0and\u00a0\nimmunolocalisation \u00a0 of\u00a0 neutral\u00a0\nendopeptidase \u00a0in\u00a0prostate\u00a0cancer.\u00a0Eur\u00a0\nUrol\u00a044,\u00a0415\u2010422\u00a0(2003).\u00a0\n212.\u00a0Dai,\u00a0J.,\u00a0et\u00a0al.\u00a0Tumor\u2010suppressive \u00a0effects\u00a0of\u00a0\nneutral\u00a0endopeptidase \u00a0in\u00a0androgen \u2010\nindependent \u00a0prostate\u00a0cancer\u00a0cells.\u00a0Clin\u00a0\nCancer\u00a0Res\u00a07,\u00a01370\u20101377\u00a0(2001).\u00a0\n213.\u00a0Werge,\u00a0T.\u00a0The\u00a0tachykinin \u00a0tale:\u00a0molecular \u00a0\nrecognition \u00a0in\u00a0a\u00a0historical\u00a0perspective. \u00a0J\u00a0\nMol\u00a0Recognit\u00a020,\u00a0145\u2010153\u00a0(2007).\u00a0\n214.\u00a0Page,\u00a0N.M.\u00a0Brain\u00a0tachykinins. \u00a0Chapter\u00a0105\u00a0\nin:\u00a0The\u00a0Handbook \u00a0of\u00a0Biologically \u00a0Active\u00a0\nPeptides ,\u00a0(Elservier, \u00a02006).\u00a0\n215.\u00a0Gerard,\u00a0N.P.,\u00a0et\u00a0al.\u00a0Human\u00a0substance \u00a0P\u00a0\nreceptor\u00a0(NK\u20101):\u00a0organization \u00a0of\u00a0the\u00a0gene,\u00a0\nchromosome \u00a0localization, \u00a0and\u00a0functional \u00a0\nexpression \u00a0of\u00a0cDNA\u00a0clones.\u00a0Biochemistry \u00a0\n30,\u00a010640\u201010646\u00a0(1991).\u00a0\n216.\u00a0Metz,\u00a0R.L.,\u00a0Patel,\u00a0P.S.,\u00a0Hameed,\u00a0M.,\u00a0Bryan,\u00a0\nM.\u00a0&\u00a0Rameshwar, \u00a0P.\u00a0Role\u00a0of\u00a0human\u00a0\nHGFIN/nmb \u00a0in\u00a0breast\u00a0cancer.\u00a0Breast\u00a0\nCancer\u00a0Res\u00a09,\u00a0R58\u00a0(2007).\u00a0\n217.\u00a0Rameshwar, \u00a0P.\u00a0Implication \u00a0of\u00a0possible\u00a0\ntherapies \u00a0targeted\u00a0for\u00a0the\u00a0tachykinergic \u00a0\nsystem\u00a0with\u00a0the\u00a0biology\u00a0of\u00a0neurokinin \u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n215\u00a0\n\u00a0receptors \u00a0and\u00a0emerging \u00a0related\u00a0proteins.\u00a0\nRecent\u00a0Pat\u00a0CNS\u00a0Drug\u00a0Discov\u00a02,\u00a079\u201084\u00a0\n(2007).\u00a0\n218.\u00a0Maggi,\u00a0C.A.\u00a0The\u00a0mammalian \u00a0tachykinin \u00a0\nreceptors. \u00a0Gen\u00a0Pharmacol \u00a026,\u00a0911\u2010944\u00a0\n(1995).\u00a0\n219.\u00a0Hopkins,\u00a0B.,\u00a0Powell,\u00a0S.J.,\u00a0Danks,\u00a0P.,\u00a0Briggs,\u00a0\nI.\u00a0&\u00a0Graham,\u00a0A.\u00a0Isolation\u00a0and\u00a0\ncharacterisation \u00a0of\u00a0the\u00a0human\u00a0lung\u00a0NK\u20101\u00a0\nreceptor\u00a0cDNA.\u00a0Biochem\u00a0Biophys\u00a0Res\u00a0\nCommun\u00a0180,\u00a01110\u20101117\u00a0(1991).\u00a0\n220.\u00a0Fong,\u00a0T.M.,\u00a0Anderson, \u00a0S.A.,\u00a0Yu,\u00a0H.,\u00a0Huang,\u00a0\nR.R.\u00a0&\u00a0Strader,\u00a0C.D.\u00a0Differential \u00a0activation \u00a0\nof\u00a0intracellular \u00a0effector\u00a0by\u00a0two\u00a0isoforms\u00a0of\u00a0\nhuman\u00a0neurokinin \u20101\u00a0receptor. \u00a0Mol\u00a0\nPharmacol \u00a041,\u00a024\u201030\u00a0(1992).\u00a0\n221.\u00a0Mantyh,\u00a0P.W. ,\u00a0et\u00a0al.\u00a0Differential \u00a0\nexpression \u00a0of\u00a0two\u00a0isoforms\u00a0of\u00a0the\u00a0\nneurokinin \u20101\u00a0(substance \u00a0P)\u00a0receptor\u00a0in\u00a0\nvivo.\u00a0Brain\u00a0Res\u00a0719,\u00a08\u201013\u00a0(1996).\u00a0\n222.\u00a0Caberlotto, \u00a0L.,\u00a0et\u00a0al.\u00a0Neurokinin \u00a01\u00a0receptor\u00a0\nand\u00a0relative\u00a0abundance \u00a0of\u00a0the\u00a0short\u00a0and\u00a0\nlong\u00a0isoforms\u00a0in\u00a0the\u00a0human\u00a0brain.\u00a0Eur\u00a0J\u00a0\nNeurosci\u00a017,\u00a01736\u20101746\u00a0(2003).\u00a0\n223.\u00a0Lai,\u00a0J.P.,\u00a0et\u00a0al.\u00a0Differences \u00a0in\u00a0the\u00a0length\u00a0of\u00a0\nthe\u00a0carboxyl\u00a0terminus\u00a0mediate\u00a0functional \u00a0\nproperties \u00a0of\u00a0neurokinin \u20101\u00a0receptor. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0105,\u00a012605\u201012610\u00a0\n(2008).\u00a0\n224.\u00a0DeFea,\u00a0K.A.,\u00a0et\u00a0al.\u00a0The\u00a0proliferative \u00a0and\u00a0\nantiapoptotic \u00a0effects\u00a0of\u00a0substance \u00a0P\u00a0are\u00a0\nfacilitated \u00a0by\u00a0formation \u00a0of\u00a0a\u00a0beta\u00a0\u2010\narrestin\u2010dependent \u00a0scaffolding \u00a0complex.\u00a0\nProc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a097,\u00a011086\u201011091\u00a0\n(2000).\u00a0\n225.\u00a0Garland,\u00a0A.M.,\u00a0Grady,\u00a0E.F.,\u00a0Payan,\u00a0D.G.,\u00a0\nVigna,\u00a0S.R.\u00a0&\u00a0Bunnett,\u00a0N.W.\u00a0Agonist\u2010\ninduced\u00a0internalization \u00a0of\u00a0the\u00a0substance \u00a0P\u00a0\n(NK1)\u00a0receptor\u00a0expressed \u00a0in\u00a0epithelial \u00a0\ncells.\u00a0Biochem\u00a0J\u00a0303\u00a0(\u00a0Pt\u00a01),\u00a0177\u2010186\u00a0\n(1994).\u00a0\n226.\u00a0Tansky,\u00a0M.F.,\u00a0Pothoulakis, \u00a0C.\u00a0&\u00a0Leeman,\u00a0\nS.E.\u00a0Functional \u00a0consequences \u00a0of\u00a0alteration \u00a0\nof\u00a0N\u2010linked\u00a0glycosylation \u00a0sites\u00a0on\u00a0the\u00a0neurokinin \u00a01\u00a0receptor. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0\nU\u00a0S\u00a0A\u00a0104,\u00a010691\u201010696\u00a0(2007).\u00a0\n227.\u00a0McGillis,\u00a0J.P.,\u00a0Mitsuhashi, \u00a0M.\u00a0&\u00a0Payan,\u00a0\nD.G.\u00a0Immunomodulation \u00a0by\u00a0tachykinin \u00a0\nneuropeptides. \u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci\u00a0594,\u00a085\u2010\n94\u00a0(1990).\u00a0\n228.\u00a0Organist,\u00a0M.L.,\u00a0Harvey,\u00a0J.P.,\u00a0McGillis,\u00a0J.P.\u00a0&\u00a0\nPayan,\u00a0D.G.\u00a0Processing \u00a0of\u00a0the\u00a0human\u00a0IM\u20109\u00a0\nlymphoblast \u00a0substance \u00a0P\u00a0receptor. \u00a0\nBiosynthetic \u00a0and\u00a0degradation \u00a0studies\u00a0\nusing\u00a0a\u00a0monoclonal \u00a0anti\u2010receptor\u00a0\nantibody. \u00a0Biochem\u00a0Biophys\u00a0Res\u00a0Commun\u00a0\n151,\u00a0535\u2010541\u00a0(1988).\u00a0\n229.\u00a0Munoz,\u00a0M.,\u00a0et\u00a0al.\u00a0Antitumoral \u00a0action\u00a0of\u00a0\nthe\u00a0neurokinin \u20101\u2010receptor\u00a0antagonist \u00a0L\u2010\n733,060\u00a0and\u00a0mitogenic \u00a0action\u00a0of\u00a0\nsubstance \u00a0P\u00a0on\u00a0human\u00a0retinoblastoma \u00a0cell\u00a0\nlines.\u00a0Invest\u00a0Ophthalmol \u00a0Vis\u00a0Sci\u00a046,\u00a02567\u2010\n2570\u00a0(2005).\u00a0\n230.\u00a0Friess,\u00a0H.,\u00a0et\u00a0al.\u00a0Neurokinin \u20101\u00a0receptor\u00a0\nexpression \u00a0and\u00a0its\u00a0potential\u00a0effects\u00a0on\u00a0\ntumor\u00a0growth\u00a0in\u00a0human\u00a0pancreatic \u00a0\ncancer.\u00a0Lab\u00a0Invest\u00a083,\u00a0731\u2010742\u00a0(2003).\u00a0\n231.\u00a0Kage,\u00a0R.,\u00a0Leeman,\u00a0S.E.\u00a0&\u00a0Boyd,\u00a0N.D.\u00a0\nBiochemical \u00a0characterization \u00a0of\u00a0two\u00a0\ndifferent\u00a0forms\u00a0of\u00a0the\u00a0substance \u00a0P\u00a0\nreceptor\u00a0in\u00a0rat\u00a0submaxillary \u00a0gland.\u00a0J\u00a0\nNeurochem \u00a060,\u00a0347\u2010351\u00a0(1993).\u00a0\n232.\u00a0Li,\u00a0H.,\u00a0et\u00a0al.\u00a0A\u00a0substance \u00a0P\u00a0(neurokinin \u20101)\u00a0\nreceptor\u00a0mutant\u00a0carboxyl\u2010terminally \u00a0\ntruncated \u00a0to\u00a0resemble \u00a0a\u00a0naturally\u00a0\noccurring \u00a0receptor\u00a0isoform\u00a0displays\u00a0\nenhanced \u00a0responsiveness \u00a0and\u00a0resistance \u00a0\nto\u00a0desensitization. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0\nA\u00a094,\u00a09475\u20109480\u00a0(1997).\u00a0\n233.\u00a0Beaujouan, \u00a0J.C.,\u00a0Saffroy,\u00a0M.,\u00a0Torrens,\u00a0Y.,\u00a0\nSagan,\u00a0S.\u00a0&\u00a0Glowinski, \u00a0J.\u00a0Pharmacological \u00a0\ncharacterization \u00a0of\u00a0tachykinin \u00a0septide\u2010\nsensitive\u00a0binding\u00a0sites\u00a0in\u00a0the\u00a0rat\u00a0\nsubmaxillary \u00a0gland.\u00a0Peptides\u00a020,\u00a01347\u2010\n1352\u00a0(1999).\u00a0\n234.\u00a0Beaujouan, \u00a0J.C.,\u00a0Saffroy,\u00a0M.,\u00a0Torrens,\u00a0Y.\u00a0&\u00a0\nGlowinski, \u00a0J.\u00a0Different\u00a0subtypes\u00a0of\u00a0\ntachykinin \u00a0NK(1)\u00a0receptor\u00a0binding\u00a0sites\u00a0are\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n216\u00a0\n\u00a0present\u00a0in\u00a0the\u00a0rat\u00a0brain.\u00a0J\u00a0Neurochem \u00a075,\u00a0\n1015\u20101026\u00a0(2000).\u00a0\n235.\u00a0Palma,\u00a0C.\u00a0Tachykinins \u00a0and\u00a0their\u00a0receptors \u00a0\nin\u00a0human\u00a0malignancies. \u00a0Curr\u00a0Drug\u00a0Targets\u00a0\n7,\u00a01043\u20101052\u00a0(2006).\u00a0\n236.\u00a0Almeida,\u00a0T.A.,\u00a0et\u00a0al.\u00a0Tachykinins \u00a0and\u00a0\ntachykinin \u00a0receptors: \u00a0structure\u00a0and\u00a0\nactivity\u00a0relationships. \u00a0Curr\u00a0Med\u00a0Chem\u00a011,\u00a0\n2045\u20102081\u00a0(2004).\u00a0\n237.\u00a0Pinto,\u00a0F.M. ,\u00a0et\u00a0al.\u00a0mRNA\u00a0expression \u00a0of\u00a0\ntachykinins \u00a0and\u00a0tachykinin \u00a0receptors \u00a0in\u00a0\ndifferent\u00a0human\u00a0tissues.\u00a0Eur\u00a0J\u00a0Pharmacol \u00a0\n494,\u00a0233\u2010239\u00a0(2004).\u00a0\n238.\u00a0Bandari,\u00a0P.S.,\u00a0et\u00a0al.\u00a0Crosstalk\u00a0between\u00a0\nneurokinin \u00a0receptors \u00a0is\u00a0relevant\u00a0to\u00a0\nhematopoietic \u00a0regulation: \u00a0cloning\u00a0and\u00a0\ncharacterization \u00a0 of\u00a0 neurokinin \u20102\u00a0\npromoter. \u00a0J\u00a0Neuroimmunol \u00a0138,\u00a065\u201075\u00a0\n(2003).\u00a0\n239.\u00a0Ricardo,\u00a0M.,\u00a0Trzaska,\u00a0K.A.\u00a0&\u00a0Rameshwar, \u00a0\nP.\u00a0Neurokinin \u2010A\u00a0inhibits\u00a0cell\u00a0cycle\u00a0\nactivators \u00a0in\u00a0K562\u00a0cells\u00a0and\u00a0activates\u00a0Smad\u00a0\n4\u00a0through\u00a0a\u00a0non\u2010canonical \u00a0pathway: \u00a0a\u00a0\nnovel\u00a0method\u00a0in\u00a0neural\u2010hematopoietic \u00a0\naxis.\u00a0J\u00a0Neuroimmunol \u00a0204,\u00a085\u201091\u00a0(2008).\u00a0\n240.\u00a0Bang,\u00a0R.,\u00a0et\u00a0al.\u00a0Neurokinin \u20101\u00a0receptor\u00a0\nantagonists \u00a0CP\u201096,345\u00a0and\u00a0L\u2010733,060\u00a0\nprotect\u00a0mice\u00a0from\u00a0cytokine\u2010mediated \u00a0liver\u00a0\ninjury.\u00a0J\u00a0Pharmacol \u00a0Exp\u00a0Ther\u00a0305,\u00a031\u201039\u00a0\n(2003).\u00a0\n241.\u00a0Goode,\u00a0T.,\u00a0et\u00a0al.\u00a0Neurokinin \u20101\u00a0receptor\u00a0\nexpression \u00a0in\u00a0inflammatory \u00a0bowel\u00a0disease:\u00a0\nmolecular \u00a0quantitation \u00a0and\u00a0localisation. \u00a0\nGut\u00a047,\u00a0387\u2010396\u00a0(2000).\u00a0\n242.\u00a0Renzi,\u00a0D.,\u00a0Pellegrini, \u00a0B.,\u00a0Tonelli,\u00a0F.,\u00a0\nSurrenti,\u00a0C.\u00a0&\u00a0Calabro,\u00a0A.\u00a0Substance \u00a0P\u00a0\n(neurokinin \u20101)\u00a0and\u00a0neurokinin \u00a0A\u00a0\n(neurokinin \u20102)\u00a0receptor\u00a0gene\u00a0and\u00a0protein\u00a0\nexpression \u00a0in\u00a0the\u00a0healthy\u00a0and\u00a0inflamed\u00a0\nhuman\u00a0intestine. \u00a0Am\u00a0J\u00a0Pathol\u00a0157,\u00a01511\u2010\n1522\u00a0(2000).\u00a0\n243.\u00a0ter\u00a0Beek,\u00a0W.P.,\u00a0Biemond, \u00a0I.,\u00a0Muller,\u00a0E.S.,\u00a0\nvan\u00a0den\u00a0Berg,\u00a0M.\u00a0&\u00a0Lamers,\u00a0C.B.\u00a0\nSubstance \u00a0P\u00a0receptor\u00a0expression \u00a0in\u00a0\npatients\u00a0with\u00a0inflammatory \u00a0bowel\u00a0disease.\u00a0Determination \u00a0by\u00a0three\u00a0different\u00a0\ntechniques, \u00a0i.e.,\u00a0storage\u00a0phosphor \u00a0\nautoradiography, \u00a0 RT\u2010PCR\u00a0 and\u00a0\nimmunohistochemistry. \u00a0Neuropeptides \u00a041,\u00a0\n301\u2010306\u00a0(2007).\u00a0\n244.\u00a0Koon,\u00a0H.W. ,\u00a0et\u00a0al.\u00a0Substance \u00a0P\u2010stimulated \u00a0\ninterleukin \u20108\u00a0expression \u00a0in\u00a0human\u00a0colonic\u00a0\nepithelial \u00a0cells\u00a0involves\u00a0protein\u00a0kinase\u00a0\nCdelta\u00a0activation. \u00a0J\u00a0Pharmacol \u00a0Exp\u00a0Ther\u00a0\n314,\u00a01393\u20101400\u00a0(2005).\u00a0\n245.\u00a0Munoz,\u00a0M.,\u00a0Rosso,\u00a0M.\u00a0&\u00a0Covenas,\u00a0R.\u00a0The\u00a0\nNK\u20101\u00a0Receptor: \u00a0A\u00a0New\u00a0Target\u00a0in\u00a0Cancer\u00a0\nTherapy.\u00a0Curr\u00a0Drug\u00a0Targets\u00a0(2011).\u00a0\n246.\u00a0Dorsam,\u00a0R.T.\u00a0&\u00a0Gutkind,\u00a0J.S.\u00a0G\u2010protein\u2010\ncoupled\u00a0receptors \u00a0and\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0\nCancer\u00a07,\u00a079\u201094\u00a0(2007).\u00a0\n247.\u00a0Almendro, \u00a0V.,\u00a0Garcia\u2010Recio,\u00a0S.\u00a0&\u00a0Gascon,\u00a0\nP.\u00a0Tyrosine\u00a0kinase\u00a0receptor\u00a0transactivation \u00a0\nassociated \u00a0to\u00a0G\u00a0protein\u2010coupled\u00a0\nreceptors. \u00a0Curr\u00a0Drug\u00a0Targets\u00a011,\u00a01169\u2010\n1180\u00a0(2010).\u00a0\n248.\u00a0Neer,\u00a0E.J.\u00a0Heterotrimeric \u00a0G\u00a0proteins:\u00a0\norganizers \u00a0of\u00a0transmembrane \u00a0signals.\u00a0Cell\u00a0\n80,\u00a0249\u2010257\u00a0(1995).\u00a0\n249.\u00a0Lowes,\u00a0V.L.,\u00a0Ip,\u00a0N.Y.\u00a0&\u00a0Wong,\u00a0Y.H.\u00a0\nIntegration \u00a0of\u00a0signals\u00a0from\u00a0receptor\u00a0\ntyrosine\u00a0kinases\u00a0and\u00a0g\u00a0protein\u2010coupled\u00a0\nreceptors. \u00a0Neurosignals \u00a011,\u00a05\u201019\u00a0(2002).\u00a0\n250.\u00a0Neer,\u00a0E.J.\u00a0G\u00a0proteins:\u00a0critical\u00a0control\u00a0points\u00a0\nfor\u00a0transmembrane \u00a0signals.\u00a0Protein\u00a0Sci\u00a03,\u00a0\n3\u201014\u00a0(1994).\u00a0\n251.\u00a0Smotrys,\u00a0J.E.\u00a0&\u00a0Linder,\u00a0M.E.\u00a0Palmitoylation \u00a0\nof\u00a0intracellular \u00a0signaling\u00a0proteins:\u00a0\nregulation \u00a0and\u00a0function.\u00a0Annu\u00a0Rev\u00a0\nBiochem\u00a073,\u00a0559\u2010587\u00a0(2004).\u00a0\n252.\u00a0Malbon,\u00a0C.C.\u00a0G\u00a0proteins\u00a0in\u00a0development. \u00a0\nNat\u00a0Rev\u00a0Mol\u00a0Cell\u00a0Biol\u00a06,\u00a0689\u2010701\u00a0(2005).\u00a0\n253.\u00a0Nakajima, \u00a0Y.,\u00a0Tsuchida, \u00a0K.,\u00a0Negishi,\u00a0M.,\u00a0Ito,\u00a0\nS.\u00a0&\u00a0Nakanishi, \u00a0S.\u00a0Direct\u00a0linkage\u00a0of\u00a0three\u00a0\ntachykinin \u00a0receptors \u00a0to\u00a0stimulation \u00a0of\u00a0\nboth\u00a0phosphatidylinositol \u00a0hydrolysis \u00a0and\u00a0\ncyclic\u00a0AMP\u00a0cascades\u00a0in\u00a0transfected \u00a0\nChinese\u00a0hamster\u00a0ovary\u00a0cells.\u00a0J\u00a0Biol\u00a0Chem\u00a0\n267,\u00a02437\u20102442\u00a0(1992).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n217\u00a0\n\u00a0254.\u00a0Laniyonu, \u00a0A.,\u00a0Sliwinski\u2010Lis,\u00a0E.\u00a0&\u00a0Fleming,\u00a0N.\u00a0\nDifferent\u00a0tachykinin \u00a0receptor\u00a0subtypes\u00a0are\u00a0\ncoupled\u00a0to\u00a0the\u00a0phosphoinositide \u00a0or\u00a0cyclic\u00a0\nAMP\u00a0signal\u00a0transduction \u00a0pathways \u00a0in\u00a0rat\u00a0\nsubmandibular \u00a0cells.\u00a0FEBS\u00a0Lett\u00a0240,\u00a0186\u2010\n190\u00a0(1988).\u00a0\n255.\u00a0Macdonald, \u00a0S.G.,\u00a0Dumas,\u00a0J.J.\u00a0&\u00a0Boyd,\u00a0N.D.\u00a0\nChemical\u00a0cross\u2010linking\u00a0of\u00a0the\u00a0substance \u00a0P\u00a0\n(NK\u20101)\u00a0receptor\u00a0to\u00a0the\u00a0alpha\u00a0subunits\u00a0of\u00a0\nthe\u00a0G\u00a0proteins\u00a0Gq\u00a0and\u00a0G11.\u00a0Biochemistry \u00a0\n35,\u00a02909\u20102916\u00a0(1996).\u00a0\n256.\u00a0Ye,\u00a0R.D.\u00a0Regulation \u00a0of\u00a0nuclear\u00a0factor\u00a0\nkappaB\u00a0activation \u00a0by\u00a0G\u2010protein\u2010coupled\u00a0\nreceptors. \u00a0J\u00a0Leukoc\u00a0Biol\u00a070,\u00a0839\u2010848\u00a0\n(2001).\u00a0\n257.\u00a0Wettschureck, \u00a0N.\u00a0&\u00a0Offermanns, \u00a0S.\u00a0\nMammalian \u00a0G\u00a0proteins\u00a0and\u00a0their\u00a0cell\u00a0type\u00a0\nspecific\u00a0functions. \u00a0Physiol\u00a0Rev\u00a085,\u00a01159\u2010\n1204\u00a0(2005).\u00a0\n258.\u00a0Meshki,\u00a0J.,\u00a0et\u00a0al.\u00a0Neurokinin \u00a01\u00a0receptor\u00a0\nmediates \u00a0membrane \u00a0blebbing\u00a0in\u00a0HEK293\u00a0\ncells\u00a0through\u00a0a\u00a0Rho/Rho\u2010associated \u00a0coiled\u2010\ncoil\u00a0kinase\u2010dependent \u00a0mechanism. \u00a0J\u00a0Biol\u00a0\nChem\u00a0284,\u00a09280\u20109289\u00a0(2009).\u00a0\n259.\u00a0Nishimura, \u00a0K.,\u00a0Frederick, \u00a0J.\u00a0&\u00a0Kwatra,\u00a0\nM.M.\u00a0Human\u00a0substance \u00a0P\u00a0receptor\u00a0\nexpressed \u00a0in\u00a0Sf9\u00a0cells\u00a0couples\u00a0with\u00a0\nmultiple\u00a0endogenous \u00a0G\u00a0proteins.\u00a0J\u00a0Recept\u00a0\nSignal\u00a0Transduct \u00a0Res\u00a018,\u00a051\u201065\u00a0(1998).\u00a0\n260.\u00a0Williams,\u00a0R.,\u00a0Zou,\u00a0X.\u00a0&\u00a0Hoyle,\u00a0G.W.\u00a0\nTachykinin \u20101\u00a0 receptor\u00a0 stimulates \u00a0\nproinflammatory \u00a0gene\u00a0expression \u00a0in\u00a0lung\u00a0\nepithelial \u00a0cells\u00a0through\u00a0activation \u00a0of\u00a0NF\u2010\nkappaB\u00a0via\u00a0a\u00a0G(q)\u2010dependent \u00a0pathway. \u00a0\nAm\u00a0J\u00a0Physiol\u00a0Lung\u00a0Cell\u00a0Mol\u00a0Physiol\u00a0292,\u00a0\nL430\u2010437\u00a0(2007).\u00a0\n261.\u00a0Kavelaars, \u00a0A.,\u00a0et\u00a0al.\u00a0Activation \u00a0of\u00a0human\u00a0\nmonocytes \u00a0via\u00a0a\u00a0non\u2010neurokinin \u00a0\nsubstance \u00a0P\u00a0receptor\u00a0that\u00a0is\u00a0coupled\u00a0to\u00a0Gi\u00a0\nprotein,\u00a0calcium,\u00a0phospholipase \u00a0D,\u00a0MAP\u00a0\nkinase,\u00a0and\u00a0IL\u20106\u00a0production. \u00a0J\u00a0Immunol\u00a0\n153,\u00a03691\u20103699\u00a0(1994).\u00a0\n262.\u00a0Ziche,\u00a0M.,\u00a0et\u00a0al.\u00a0Substance \u00a0P\u00a0stimulates \u00a0\nneovascularization \u00a0 in\u00a0 vivo\u00a0 and\u00a0proliferation \u00a0of\u00a0cultured\u00a0endothelial \u00a0cells.\u00a0\nMicrovasc \u00a0Res\u00a040,\u00a0264\u2010278\u00a0(1990).\u00a0\n263.\u00a0Hennig,\u00a0I.M.,\u00a0Laissue,\u00a0J.A.,\u00a0Horisberger, \u00a0U.\u00a0\n&\u00a0Reubi,\u00a0J.C.\u00a0Substance \u2010P\u00a0receptors \u00a0in\u00a0\nhuman\u00a0primary\u00a0neoplasms: \u00a0tumoral\u00a0and\u00a0\nvascular\u00a0localization. \u00a0Int\u00a0J\u00a0Cancer\u00a061,\u00a0786\u2010\n792\u00a0(1995).\u00a0\n264.\u00a0Reubi,\u00a0J.C.,\u00a0Mazzucchelli, \u00a0L.,\u00a0Hennig,\u00a0I.\u00a0&\u00a0\nLaissue,\u00a0J.A.\u00a0Local\u00a0up\u2010regulation \u00a0of\u00a0\nneuropeptide \u00a0receptors \u00a0in\u00a0host\u00a0blood\u00a0\nvessels\u00a0around\u00a0human\u00a0colorectal \u00a0cancers.\u00a0\nGastroenterology \u00a0110,\u00a01719\u20101726\u00a0(1996).\u00a0\n265.\u00a0Reubi,\u00a0J.C.\u00a0Regulatory \u00a0peptide\u00a0receptors \u00a0\nas\u00a0molecular \u00a0targets\u00a0for\u00a0cancer\u00a0diagnosis \u00a0\nand\u00a0therapy.\u00a0Q\u00a0J\u00a0Nucl\u00a0Med\u00a041,\u00a063\u201070\u00a0\n(1997).\u00a0\n266.\u00a0Reubi,\u00a0J.C.,\u00a0et\u00a0al.\u00a0Regulatory \u00a0peptide\u00a0\nreceptors \u00a0in\u00a0human\u00a0hepatocellular \u00a0\ncarcinomas. \u00a0Gut\u00a045,\u00a0766\u2010774\u00a0(1999).\u00a0\n267.\u00a0Gillespie,\u00a0E.,\u00a0et\u00a0al.\u00a0Truncated \u00a0neurokinin \u20101\u00a0\nreceptor\u00a0is\u00a0increased \u00a0in\u00a0colonic\u00a0epithelial \u00a0\ncells\u00a0from\u00a0patients\u00a0with\u00a0colitis\u2010associated \u00a0\ncancer.\u00a0Proceedings \u00a0of\u00a0the\u00a0National\u00a0\nAcademy\u00a0of\u00a0Sciences\u00a0108,\u00a017420\u201017425\u00a0\n(2011).\u00a0\n268.\u00a0Schaffer,\u00a0M.,\u00a0Beiter,\u00a0T.,\u00a0Becker,\u00a0H.D.\u00a0&\u00a0\nHunt,\u00a0T.K.\u00a0Neuropeptides: \u00a0mediators \u00a0of\u00a0\ninflammation \u00a0and\u00a0tissue\u00a0repair?\u00a0Arch\u00a0Surg\u00a0\n133,\u00a01107\u20101116\u00a0(1998).\u00a0\n269.\u00a0Munford, \u00a0R.S.\u00a0&\u00a0Pugin,\u00a0J.\u00a0Normal\u00a0\nresponses \u00a0to\u00a0injury\u00a0prevent\u00a0systemic\u00a0\ninflammation \u00a0 and\u00a0 can\u00a0 be\u00a0\nimmunosuppressive. \u00a0Am\u00a0J\u00a0Respir\u00a0Crit\u00a0Care\u00a0\nMed\u00a0163,\u00a0316\u2010321\u00a0(2001).\u00a0\n270.\u00a0Mantyh,\u00a0P.W.\u00a0Neurobiology \u00a0of\u00a0substance \u00a0\nP\u00a0and\u00a0the\u00a0NK1\u00a0receptor. \u00a0J\u00a0Clin\u00a0Psychiatry \u00a0\n63\u00a0Suppl\u00a011,\u00a06\u201010\u00a0(2002).\u00a0\n271.\u00a0Mu\u00f1oz,\u00a0M.,\u00a0Rosso,\u00a0M.\u00a0&\u00a0Cove\u00f1as,\u00a0R.\u00a0\nNeurokinin \u20101\u00a0receptor\u00a0antagonists \u00a0and\u00a0\ncancer.\u00a0In:\u00a0Focus\u00a0on\u00a0Neuropeptide \u00a0\nResearch\u00a0(Ed.\u00a0Transworld \u00a0Research\u00a0\nNetwork., \u00a02007).\u00a0\n272.\u00a0Munoz,\u00a0M.,\u00a0Rosso,\u00a0M.\u00a0&\u00a0Covenas,\u00a0R.\u00a0A\u00a0\nnew\u00a0frontier\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0cancer:\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n218\u00a0\n\u00a0NK\u20101\u00a0receptor\u00a0antagonists. \u00a0Curr\u00a0Med\u00a0\nChem\u00a017,\u00a0504\u2010516.\u00a0\n273.\u00a0Hilakivi\u2010Clarke,\u00a0L.,\u00a0Rowland, \u00a0J.,\u00a0Clarke,\u00a0R.\u00a0&\u00a0\nLippman, \u00a0M.E.\u00a0Psychosocial \u00a0factors\u00a0in\u00a0the\u00a0\ndevelopment \u00a0and\u00a0progression \u00a0of\u00a0breast\u00a0\ncancer.\u00a0Breast\u00a0Cancer\u00a0Res\u00a0Treat\u00a029,\u00a0141\u2010\n160\u00a0(1994).\u00a0\n274.\u00a0Okamura, \u00a0M.,\u00a0Yamawaki, \u00a0S.,\u00a0Akechi,\u00a0T.,\u00a0\nTaniguchi, \u00a0K.\u00a0&\u00a0Uchitomi, \u00a0Y.\u00a0Psychiatric \u00a0\ndisorders \u00a0following \u00a0first\u00a0breast\u00a0cancer\u00a0\nrecurrence: \u00a0prevalence, \u00a0associated \u00a0factors\u00a0\nand\u00a0relationship \u00a0to\u00a0quality\u00a0of\u00a0life.\u00a0Jpn\u00a0J\u00a0Clin\u00a0\nOncol\u00a035,\u00a0302\u2010309\u00a0(2005).\u00a0\n275.\u00a0Kramer,\u00a0M.S. ,\u00a0et\u00a0al.\u00a0Distinct\u00a0mechanism \u00a0\nfor\u00a0antidepressant \u00a0activity\u00a0by\u00a0blockade\u00a0of\u00a0\ncentral\u00a0substance \u00a0P\u00a0receptors. \u00a0Science\u00a0\n281,\u00a01640\u20101645\u00a0(1998).\u00a0\n276.\u00a0Sivam,\u00a0S.P.,\u00a0et\u00a0al.\u00a0Lithium\u00a0increases \u00a0rat\u00a0\nstriatal\u00a0 beta\u2010\u00a0 and\u00a0 gamma\u2010\npreprotachykinin \u00a0messenger \u00a0RNAs.\u00a0J\u00a0\nPharmacol \u00a0Exp\u00a0Ther\u00a0248,\u00a01297\u20101301\u00a0\n(1989).\u00a0\n277.\u00a0Shibata,\u00a0K.,\u00a0Haverstick, \u00a0D.M.\u00a0&\u00a0Bannon,\u00a0\nM.J.\u00a0Tachykinin \u00a0gene\u00a0expression \u00a0in\u00a0rat\u00a0\nlimbic\u00a0nuclei:\u00a0modulation \u00a0by\u00a0dopamine \u00a0\nantagonists. \u00a0J\u00a0Pharmacol \u00a0Exp\u00a0Ther\u00a0255,\u00a0\n388\u2010392\u00a0(1990).\u00a0\n278.\u00a0Maier,\u00a0S.F.\u00a0&\u00a0Watkins,\u00a0L.R.\u00a0Immune\u2010to\u2010\ncentral\u00a0nervous\u00a0system\u00a0communication \u00a0\nand\u00a0its\u00a0role\u00a0in\u00a0modulating \u00a0pain\u00a0and\u00a0\ncognition: \u00a0Implications \u00a0for\u00a0cancer\u00a0and\u00a0\ncancer\u00a0treatment. \u00a0Brain\u00a0Behav\u00a0Immun\u00a017\u00a0\nSuppl\u00a01,\u00a0S125\u2010131\u00a0(2003).\u00a0\n279.\u00a0Munoz,\u00a0M.,\u00a0Rosso,\u00a0M.,\u00a0Casinello, \u00a0F.\u00a0&\u00a0\nCovenas,\u00a0R.\u00a0Paravertebral \u00a0anesthesia: \u00a0how\u00a0\nsubstance \u00a0P\u00a0and\u00a0the\u00a0NK\u20101\u00a0receptor\u00a0could\u00a0\nbe\u00a0involved\u00a0in\u00a0regional\u00a0block\u00a0and\u00a0breast\u00a0\ncancer\u00a0recurrence. \u00a0Breast\u00a0Cancer\u00a0Res\u00a0\nTreat\u00a0122,\u00a0601\u2010603\u00a0(2010).\u00a0\n280.\u00a0Kato,\u00a0H.,\u00a0Shichiri,\u00a0M.,\u00a0Marumo, \u00a0F.\u00a0&\u00a0Hirata,\u00a0\nY.\u00a0 Adrenomedullin \u00a0 as\u00a0 an\u00a0\nautocrine/paracrine \u00a0apoptosis \u00a0survival\u00a0\nfactor\u00a0for\u00a0rat\u00a0endothelial \u00a0cells.\u00a0\nEndocrinology \u00a0138,\u00a02615\u20102620\u00a0(1997).\u00a0281.\u00a0Guha,\u00a0S.,\u00a0et\u00a0al.\u00a0Broad\u2010spectrum \u00a0G\u00a0protein\u2010\ncoupled\u00a0receptor\u00a0antagonist, \u00a0[D\u2010Arg1,D\u2010\nTrp5,7,9,Leu11]SP: \u00a0a\u00a0dual\u00a0inhibitor\u00a0of\u00a0\ngrowth\u00a0and\u00a0angiogenesis \u00a0in\u00a0pancreatic \u00a0\ncancer.\u00a0Cancer\u00a0Res\u00a065,\u00a02738\u20102745\u00a0(2005).\u00a0\n282.\u00a0Everard,\u00a0M.J.,\u00a0Macaulay, \u00a0V.M.,\u00a0Millar,\u00a0J.L.\u00a0\n&\u00a0Smith,\u00a0I.E.\u00a0[D\u2010Arg1,\u00a0D\u2010Phe5,\u00a0D\u2010Trp7,9,\u00a0\nLeu11]\u00a0substance \u00a0P\u00a0inhibits\u00a0the\u00a0growth\u00a0of\u00a0\nhuman\u00a0small\u00a0cell\u00a0lung\u00a0cancer\u00a0xenografts \u00a0in\u00a0\nvivo.\u00a0Eur\u00a0J\u00a0Cancer\u00a029A,\u00a01450\u20101453\u00a0(1993).\u00a0\n283.\u00a0Lang,\u00a0K.,\u00a0et\u00a0al.\u00a0Induction \u00a0of\u00a0a\u00a0\nmetastatogenic \u00a0tumor\u00a0cell\u00a0type\u00a0by\u00a0\nneurotransmitters \u00a0and\u00a0its\u00a0pharmacological \u00a0\ninhibition \u00a0by\u00a0established \u00a0drugs.\u00a0Int\u00a0J\u00a0\nCancer\u00a0112,\u00a0231\u2010238\u00a0(2004).\u00a0\n284.\u00a0Bleul,\u00a0C.C.,\u00a0Fuhlbrigge, \u00a0R.C.,\u00a0Casasnovas, \u00a0\nJ.M.,\u00a0Aiuti,\u00a0A.\u00a0&\u00a0Springer,\u00a0T.A.\u00a0A\u00a0highly\u00a0\nefficacious \u00a0lymphocyte \u00a0chemoattractant, \u00a0\nstromal\u00a0cell\u2010derived\u00a0factor\u00a01\u00a0(SDF\u20101).\u00a0J\u00a0Exp\u00a0\nMed\u00a0184,\u00a01101\u20101109\u00a0(1996).\u00a0\n285.\u00a0Zheng,\u00a0H.,\u00a0Fu,\u00a0G.,\u00a0Dai,\u00a0T.\u00a0&\u00a0Huang,\u00a0H.\u00a0\nMigration \u00a0of\u00a0endothelial \u00a0progenitor \u00a0cells\u00a0\nmediated \u00a0by\u00a0stromal\u00a0cell\u2010derived\u00a0factor\u2010\n1alpha/CXCR4 \u00a0via\u00a0PI3K/Akt/eNOS \u00a0signal\u00a0\ntransduction \u00a0pathway. \u00a0J\u00a0Cardiovasc \u00a0\nPharmacol \u00a050,\u00a0274\u2010280\u00a0(2007).\u00a0\n286.\u00a0Kryczek,\u00a0I.,\u00a0Wei,\u00a0S.,\u00a0Keller,\u00a0E.,\u00a0Liu,\u00a0R.\u00a0&\u00a0Zou,\u00a0\nW.\u00a0Stroma\u2010derived\u00a0factor\u00a0(SDF\u20101/CXCL12) \u00a0\nand\u00a0human\u00a0tumor\u00a0pathogenesis. \u00a0Am\u00a0J\u00a0\nPhysiol\u00a0Cell\u00a0Physiol\u00a0292,\u00a0C987\u2010995\u00a0(2007).\u00a0\n287.\u00a0Patel,\u00a0S.A.,\u00a0et\u00a0al.\u00a0Breast\u00a0cancer\u00a0biology:\u00a0\nthe\u00a0multifaceted \u00a0roles\u00a0of\u00a0mesenchymal \u00a0\nstem\u00a0cells.\u00a0J\u00a0Oncol\u00a02008 ,\u00a0425895\u00a0(2008).\u00a0\n288.\u00a0Muller,\u00a0A.,\u00a0et\u00a0al.\u00a0Involvement \u00a0of\u00a0\nchemokine \u00a0receptors \u00a0in\u00a0breast\u00a0cancer\u00a0\nmetastasis. \u00a0Nature\u00a0410,\u00a050\u201056\u00a0(2001).\u00a0\n289.\u00a0Moharita, \u00a0A.L.,\u00a0et\u00a0al.\u00a0SDF\u20101{alpha}\u00a0\nregulation \u00a0in\u00a0breast\u00a0cancer\u00a0cells\u00a0\ncontacting \u00a0bone\u00a0marrow\u00a0stroma\u00a0is\u00a0critical\u00a0\nfor\u00a0normal\u00a0hematopoiesis. \u00a0Blood\u00a0108,\u00a0\n3245\u20103252\u00a0(2006).\u00a0\n290.\u00a0Corcoran, \u00a0K.E.,\u00a0et\u00a0al.\u00a0Mesenchymal \u00a0stem\u00a0\ncells\u00a0in\u00a0early\u00a0entry\u00a0of\u00a0breast\u00a0cancer\u00a0into\u00a0\nbone\u00a0marrow.\u00a0PLoS\u00a0One\u00a03,\u00a0e2563\u00a0(2008).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n219\u00a0\n\u00a0291.\u00a0Corcoran, \u00a0K.E.\u00a0&\u00a0Rameshwar, \u00a0P.\u00a0Nuclear\u00a0\nfactor\u2010kappaB\u00a0accounts\u00a0for\u00a0the\u00a0repressor \u00a0\neffects\u00a0of\u00a0high\u00a0stromal\u00a0cell\u2010derived\u00a0factor\u2010\n1alpha\u00a0levels\u00a0on\u00a0Tac1\u00a0expression \u00a0in\u00a0\nnontumorigenic \u00a0breast\u00a0cells.\u00a0Mol\u00a0Cancer\u00a0\nRes\u00a05,\u00a0373\u2010381\u00a0(2007).\u00a0\n292.\u00a0Ramkissoon, \u00a0S.H.,\u00a0Patel,\u00a0P.S.,\u00a0Taborga,\u00a0M.\u00a0\n&\u00a0Rameshwar, \u00a0P.\u00a0Nuclear\u00a0Factor\u2010{kappa}B\u00a0\nIs\u00a0Central\u00a0to\u00a0the\u00a0Expression \u00a0of\u00a0Truncated \u00a0\nNeurokinin \u20101\u00a0Receptor\u00a0in\u00a0Breast\u00a0Cancer:\u00a0\nImplication \u00a0for\u00a0Breast\u00a0Cancer\u00a0Cell\u00a0\nQuiescence \u00a0within\u00a0Bone\u00a0Marrow\u00a0Stroma.\u00a0\nCancer\u00a0Res\u00a067,\u00a01653\u20101659\u00a0(2007).\u00a0\n293.\u00a0Rao,\u00a0G.,\u00a0et\u00a0al.\u00a0Facilitating \u00a0role\u00a0of\u00a0\npreprotachykinin \u2010I\u00a0gene\u00a0in\u00a0the\u00a0integration \u00a0\nof\u00a0breast\u00a0cancer\u00a0cells\u00a0within\u00a0the\u00a0stromal\u00a0\ncompartment \u00a0of\u00a0the\u00a0bone\u00a0marrow:\u00a0a\u00a0\nmodel\u00a0of\u00a0early\u00a0cancer\u00a0progression. \u00a0Cancer\u00a0\nRes\u00a064,\u00a02874\u20102881\u00a0(2004).\u00a0\n294.\u00a0Oh,\u00a0H.S.,\u00a0et\u00a0al.\u00a0Bone\u00a0marrow\u00a0stroma\u00a0\ninfluences \u00a0transforming \u00a0growth\u00a0factor\u2010\nbeta\u00a0production \u00a0in\u00a0breast\u00a0cancer\u00a0cells\u00a0to\u00a0\nregulate\u00a0c\u2010myc\u00a0activation \u00a0of\u00a0the\u00a0\npreprotachykinin \u2010I\u00a0gene\u00a0in\u00a0breast\u00a0cancer\u00a0\ncells.\u00a0Cancer\u00a0Res\u00a064,\u00a06327\u20106336\u00a0(2004).\u00a0\n295.\u00a0Payan,\u00a0D.G.,\u00a0McGillis,\u00a0J.P.\u00a0&\u00a0Organist,\u00a0M.L.\u00a0\nBinding\u00a0characteristics \u00a0and\u00a0affinity\u00a0\nlabeling\u00a0of\u00a0protein\u00a0constituents \u00a0of\u00a0the\u00a0\nhuman\u00a0IM\u20109\u00a0lymphoblast \u00a0receptor\u00a0for\u00a0\nsubstance \u00a0P.\u00a0J\u00a0Biol\u00a0Chem\u00a0261,\u00a014321\u2010\n14329\u00a0(1986).\u00a0\n296.\u00a0Fowler,\u00a0C.J.\u00a0&\u00a0Brannstrom, \u00a0G.\u00a0Substance \u00a0P\u00a0\nenhances \u00a0forskolin\u2010stimulated \u00a0cyclic\u00a0AMP\u00a0\nproduction \u00a0 in\u00a0 human\u00a0 UC11MG\u00a0\nastrocytoma \u00a0cells.\u00a0Methods\u00a0Find\u00a0Exp\u00a0Clin\u00a0\nPharmacol \u00a016,\u00a021\u201028\u00a0(1994).\u00a0\n297.\u00a0Palma,\u00a0C.,\u00a0Nardelli,\u00a0F.,\u00a0Manzini,\u00a0S.\u00a0&\u00a0\nMaggi,\u00a0C.A.\u00a0Substance \u00a0P\u00a0activates\u00a0\nresponses \u00a0correlated \u00a0with\u00a0tumour\u00a0growth\u00a0\nin\u00a0human\u00a0glioma\u00a0cell\u00a0lines\u00a0bearing\u00a0\ntachykinin \u00a0NK1\u00a0receptors. \u00a0Br\u00a0J\u00a0Cancer\u00a079,\u00a0\n236\u2010243\u00a0(1999).\u00a0\n298.\u00a0Mukerji,\u00a0I.,\u00a0Ramkissoon, \u00a0S.H.,\u00a0Reddy,\u00a0K.K.\u00a0\n&\u00a0Rameshwar, \u00a0P.\u00a0Autocrine \u00a0proliferation \u00a0\nof\u00a0neuroblastoma \u00a0cells\u00a0is\u00a0partly\u00a0mediated \u00a0through\u00a0neurokinin \u00a0receptors: \u00a0relevance \u00a0\nto\u00a0bone\u00a0marrow\u00a0metastasis. \u00a0J\u00a0Neurooncol \u00a0\n71,\u00a091\u201098\u00a0(2005).\u00a0\n299.\u00a0Clive,\u00a0S.,\u00a0et\u00a0al.\u00a0Forearm\u00a0blood\u00a0flow\u00a0and\u00a0\nlocal\u00a0responses \u00a0to\u00a0peptide\u00a0vasodilators: \u00a0a\u00a0\nnovel\u00a0pharmacodynamic \u00a0measure\u00a0in\u00a0the\u00a0\nphase\u00a0I\u00a0trial\u00a0of\u00a0antagonist \u00a0G,\u00a0a\u00a0\nneuropeptide \u00a0growth\u00a0factor\u00a0antagonist. \u00a0\nClin\u00a0Cancer\u00a0Res\u00a07,\u00a03071\u20103078\u00a0(2001).\u00a0\n300.\u00a0Munoz,\u00a0M.,\u00a0et\u00a0al.\u00a0The\u00a0NK1\u00a0receptor\u00a0is\u00a0\ninvolved\u00a0in\u00a0the\u00a0antitumoural \u00a0action\u00a0of\u00a0L\u2010\n733,060\u00a0and\u00a0in\u00a0the\u00a0mitogenic \u00a0action\u00a0of\u00a0\nsubstance \u00a0P\u00a0on\u00a0neuroblastoma \u00a0and\u00a0glioma\u00a0\ncell\u00a0lines.\u00a0Neuropeptides \u00a039,\u00a0427\u2010432\u00a0\n(2005).\u00a0\n301.\u00a0Munoz,\u00a0M.,\u00a0Perez,\u00a0A.,\u00a0Covenas,\u00a0R.,\u00a0Rosso,\u00a0\nM.\u00a0&\u00a0Castro,\u00a0E.\u00a0Antitumoural \u00a0action\u00a0of\u00a0L\u2010\n733,060\u00a0on\u00a0neuroblastoma \u00a0and\u00a0glioma\u00a0cell\u00a0\nlines.\u00a0Arch\u00a0Ital\u00a0Biol\u00a0142,\u00a0105\u2010112\u00a0(2004).\u00a0\n302.\u00a0Munoz,\u00a0M.,\u00a0et\u00a0al.\u00a0NK\u20101\u00a0receptor\u00a0\nantagonists \u00a0induce\u00a0apoptosis \u00a0and\u00a0\ncounteract \u00a0 substance \u00a0 P\u2010related\u00a0\nmitogenesis \u00a0in\u00a0human\u00a0laryngeal\u00a0cancer\u00a0\ncell\u00a0line\u00a0HEp\u20102.\u00a0Invest\u00a0New\u00a0Drugs\u00a026,\u00a0111\u2010\n118\u00a0(2008).\u00a0\n303.\u00a0Palma,\u00a0C.,\u00a0et\u00a0al.\u00a0Anti\u2010tumour\u00a0activity\u00a0of\u00a0\ntachykinin \u00a0NK1\u00a0receptor\u00a0antagonists \u00a0on\u00a0\nhuman\u00a0glioma\u00a0U373\u00a0MG\u00a0xenograft. \u00a0Br\u00a0J\u00a0\nCancer\u00a082,\u00a0480\u2010487\u00a0(2000).\u00a0\n304.\u00a0Brener,\u00a0S.,\u00a0et\u00a0al.\u00a0A\u00a0role\u00a0for\u00a0the\u00a0substance \u00a0\nP/NK\u20101\u00a0receptor\u00a0complex\u00a0in\u00a0cell\u00a0\nproliferation \u00a0in\u00a0oral\u00a0squamous \u00a0cell\u00a0\ncarcinoma. \u00a0Anticancer \u00a0Res\u00a029,\u00a02323\u20102329\u00a0\n(2009).\u00a0\n305.\u00a0Esteban,\u00a0F.,\u00a0Munoz,\u00a0M.,\u00a0Gonzalez\u2010Moles,\u00a0\nM.A.\u00a0&\u00a0Rosso,\u00a0M.\u00a0A\u00a0role\u00a0for\u00a0substance \u00a0P\u00a0in\u00a0\ncancer\u00a0promotion \u00a0and\u00a0progression: \u00a0a\u00a0\nmechanism \u00a0to\u00a0counteract \u00a0intracellular \u00a0\ndeath\u00a0signals\u00a0following \u00a0oncogene \u00a0\nactivation \u00a0or\u00a0DNA\u00a0damage.\u00a0Cancer\u00a0\nMetastasis \u00a0Rev\u00a025,\u00a0137\u2010145\u00a0(2006).\u00a0\n306.\u00a0Gonzalez\u00a0Moles,\u00a0M.A. ,\u00a0et\u00a0al.\u00a0Cell\u00a0\nproliferation \u00a0associated \u00a0with\u00a0actions\u00a0of\u00a0\nthe\u00a0substance \u00a0P/NK\u20101\u00a0receptor\u00a0complex\u00a0in\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n220\u00a0\n\u00a0keratocystic \u00a0odontogenic \u00a0tumours.\u00a0Oral\u00a0\nOncol\u00a044,\u00a01127\u20101133\u00a0(2008).\u00a0\n307.\u00a0Singh,\u00a0D.,\u00a0et\u00a0al.\u00a0Increased \u00a0expression \u00a0of\u00a0\npreprotachykinin \u2010I\u00a0 and\u00a0 neurokinin \u00a0\nreceptors \u00a0in\u00a0human\u00a0breast\u00a0cancer\u00a0cells:\u00a0\nimplications \u00a0for\u00a0bone\u00a0marrow\u00a0metastasis. \u00a0\nProc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a097,\u00a0388\u2010393\u00a0\n(2000).\u00a0\n308.\u00a0Luo,\u00a0W.,\u00a0Sharif,\u00a0T.R.\u00a0&\u00a0Sharif,\u00a0M.\u00a0\nSubstance \u00a0P\u2010induced\u00a0mitogenesis \u00a0in\u00a0\nhuman\u00a0astrocytoma \u00a0cells\u00a0correlates \u00a0with\u00a0\nactivation \u00a0of\u00a0the\u00a0mitogen\u2010activated \u00a0\nprotein\u00a0kinase\u00a0signaling\u00a0pathway. \u00a0Cancer\u00a0\nRes\u00a056,\u00a04983\u20104991\u00a0(1996).\u00a0\n309.\u00a0Munoz,\u00a0M.,\u00a0Perez,\u00a0A.,\u00a0Rosso,\u00a0M.,\u00a0\nZamarriego, \u00a0C.\u00a0&\u00a0Rosso,\u00a0R.\u00a0Antitumoral \u00a0\naction\u00a0of\u00a0the\u00a0neurokinin \u20101\u00a0receptor\u00a0\nantagonist \u00a0L\u2010733\u00a0060\u00a0on\u00a0human\u00a0\nmelanoma \u00a0cell\u00a0lines.\u00a0Melanoma \u00a0Res\u00a014,\u00a0\n183\u2010188\u00a0(2004).\u00a0\n310.\u00a0Munoz,\u00a0M.,\u00a0et\u00a0al.\u00a0Antitumoral \u00a0Action\u00a0of\u00a0\nthe\u00a0Neurokinin \u20101\u2010Receptor\u00a0Antagonist \u00a0L\u2010\n733,060\u00a0and\u00a0Mitogenic \u00a0Action\u00a0of\u00a0\nSubstance \u00a0P\u00a0on\u00a0Human\u00a0Retinoblastoma \u00a0\nCell\u00a0Lines.\u00a0Invest.\u00a0Ophthalmol. \u00a0Vis.\u00a0Sci.\u00a046,\u00a0\n2567\u20102570\u00a0(2005).\u00a0\n311.\u00a0Yamaguchi, \u00a0K.,\u00a0Richardson, \u00a0M.D.,\u00a0Bigner,\u00a0\nD.D.\u00a0&\u00a0Kwatra,\u00a0M.M.\u00a0Signal\u00a0transduction \u00a0\nthrough\u00a0substance \u00a0P\u00a0receptor\u00a0in\u00a0human\u00a0\nglioblastoma \u00a0cells:\u00a0roles\u00a0for\u00a0Src\u00a0and\u00a0\nPKCdelta. \u00a0Cancer\u00a0Chemother \u00a0Pharmacol \u00a0\n56,\u00a0585\u2010593\u00a0(2005).\u00a0\n312.\u00a0Castagliuolo, \u00a0I.,\u00a0Valenick,\u00a0L.,\u00a0Liu,\u00a0J.\u00a0&\u00a0\nPothoulakis, \u00a0C.\u00a0Epidermal \u00a0growth\u00a0factor\u00a0\nreceptor\u00a0 transactivation \u00a0 mediates \u00a0\nsubstance \u00a0P\u2010induced\u00a0mitogenic \u00a0responses \u00a0\nin\u00a0U\u2010373\u00a0MG\u00a0cells.\u00a0J\u00a0Biol\u00a0Chem\u00a0275,\u00a026545\u2010\n26550\u00a0(2000).\u00a0\n313.\u00a0Yamaguchi, \u00a0K.,\u00a0Kugimiya, \u00a0T.\u00a0&\u00a0Miyazaki, \u00a0T.\u00a0\nSubstance \u00a0P\u00a0receptor\u00a0in\u00a0U373\u00a0MG\u00a0human\u00a0\nastrocytoma \u00a0cells\u00a0activates\u00a0mitogen\u2010\nactivated \u00a0protein\u00a0kinases\u00a0ERK1/2\u00a0through\u00a0\nSrc.\u00a0Brain\u00a0Tumor\u00a0Pathol\u00a022,\u00a01\u20108\u00a0(2005).\u00a0\n314.\u00a0Della\u00a0Rocca,\u00a0G.J.,\u00a0et\u00a0al.\u00a0Ras\u2010dependent \u00a0\nmitogen\u2010activated \u00a0 protein\u00a0 kinase\u00a0activation \u00a0by\u00a0G\u00a0protein\u2010coupled\u00a0receptors. \u00a0\nConvergence \u00a0of\u00a0Gi\u2010\u00a0and\u00a0Gq\u2010mediated \u00a0\npathways \u00a0on\u00a0calcium/calmodulin, \u00a0Pyk2,\u00a0\nand\u00a0Src\u00a0kinase.\u00a0J\u00a0Biol\u00a0Chem\u00a0272,\u00a019125\u2010\n19132\u00a0(1997).\u00a0\n315.\u00a0DeFea,\u00a0K.A.,\u00a0et\u00a0al.\u00a0beta\u2010arrestin\u2010\ndependent \u00a0endocytosis \u00a0of\u00a0proteinase \u2010\nactivated \u00a0receptor\u00a02\u00a0is\u00a0required\u00a0for\u00a0\nintracellular \u00a0targeting\u00a0of\u00a0activated \u00a0ERK1/2.\u00a0\nJ\u00a0Cell\u00a0Biol\u00a0148,\u00a01267\u20101281\u00a0(2000).\u00a0\n316.\u00a0Luttrell,\u00a0L.M.,\u00a0et\u00a0al.\u00a0Beta\u2010arrestin\u2010\ndependent \u00a0formation \u00a0of\u00a0beta2\u00a0adrenergic \u00a0\nreceptor\u2010Src\u00a0protein\u00a0kinase\u00a0complexes. \u00a0\nScience\u00a0283,\u00a0655\u2010661\u00a0(1999).\u00a0\n317.\u00a0Patel,\u00a0H.J.,\u00a0Ramkissoon, \u00a0S.H.,\u00a0Patel,\u00a0P.S.\u00a0&\u00a0\nRameshwar, \u00a0P.\u00a0Transformation \u00a0of\u00a0breast\u00a0\ncells\u00a0by\u00a0truncated \u00a0neurokinin \u20101\u00a0receptor\u00a0is\u00a0\nsecondary \u00a0 to\u00a0 activation \u00a0 by\u00a0\npreprotachykinin \u2010A\u00a0peptides. \u00a0Proc\u00a0Natl\u00a0\nAcad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0102,\u00a017436\u201017441\u00a0(2005).\u00a0\n318.\u00a0Grady,\u00a0E.F.,\u00a0et\u00a0al.\u00a0Delineation \u00a0of\u00a0the\u00a0\nendocytic \u00a0pathway\u00a0of\u00a0substance \u00a0P\u00a0and\u00a0its\u00a0\nseven\u2010transmembrane \u00a0domain\u00a0NK1\u00a0\nreceptor. \u00a0Mol\u00a0Biol\u00a0Cell\u00a06,\u00a0509\u2010524\u00a0(1995).\u00a0\n319.\u00a0Lazarczyk, \u00a0M.,\u00a0Matyja,\u00a0E.\u00a0&\u00a0Lipkowski, \u00a0A.\u00a0\nSubstance \u00a0P\u00a0and\u00a0its\u00a0receptors \u00a0 \u2010\u2010\u00a0 a\u00a0\npotential\u00a0target\u00a0for\u00a0novel\u00a0medicines \u00a0in\u00a0\nmalignant \u00a0brain\u00a0tumour\u00a0therapies \u00a0(mini\u2010\nreview).\u00a0Folia\u00a0Neuropathol \u00a045,\u00a099\u2010107\u00a0\n(2007).\u00a0\n320.\u00a0Lieb,\u00a0K.,\u00a0Fiebich,\u00a0B.L.,\u00a0Berger,\u00a0M.,\u00a0Bauer,\u00a0J.\u00a0\n&\u00a0Schulze\u2010Osthoff,\u00a0K.\u00a0The\u00a0neuropeptide \u00a0\nsubstance \u00a0P\u00a0activates\u00a0transcription \u00a0factor\u00a0\nNF\u2010kappa\u00a0B\u00a0and\u00a0kappa\u00a0B\u2010dependent \u00a0gene\u00a0\nexpression \u00a0in\u00a0human\u00a0astrocytoma \u00a0cells.\u00a0J\u00a0\nImmunol\u00a0159,\u00a04952\u20104958\u00a0(1997).\u00a0\n321.\u00a0Lai,\u00a0J.P.,\u00a0Douglas,\u00a0S.D.,\u00a0Wang,\u00a0Y.J.\u00a0&\u00a0Ho,\u00a0\nW.Z.\u00a0Real\u2010time\u00a0reverse\u00a0transcription \u2010PCR\u00a0\nquantitation \u00a0of\u00a0substance \u00a0P\u00a0receptor\u00a0(NK\u2010\n1R)\u00a0mRNA.\u00a0Clin\u00a0Diagn\u00a0Lab\u00a0Immunol\u00a012,\u00a0\n537\u2010541\u00a0(2005).\u00a0\n322.\u00a0Fiebich,\u00a0B.L.,\u00a0Schleicher, \u00a0S.,\u00a0Butcher,\u00a0R.D.,\u00a0\nCraig,\u00a0A.\u00a0&\u00a0Lieb,\u00a0K.\u00a0The\u00a0neuropeptide \u00a0\nsubstance \u00a0P\u00a0activates\u00a0p38\u00a0mitogen\u2010\nactivated \u00a0protein\u00a0kinase\u00a0resulting\u00a0in\u00a0IL\u20106\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n221\u00a0\n\u00a0expression \u00a0independently \u00a0from\u00a0NF\u2010kappa\u00a0\nB.\u00a0J\u00a0Immunol\u00a0165,\u00a05606\u20105611\u00a0(2000).\u00a0\n323.\u00a0Chang,\u00a0C.Y.,\u00a0et\u00a0al.\u00a0Prognostic \u00a0and\u00a0clinical\u00a0\nimplication \u00a0of\u00a0IL\u20106\u00a0expression \u00a0in\u00a0\nglioblastoma \u00a0multiforme. \u00a0J\u00a0Clin\u00a0Neurosci\u00a0\n12,\u00a0930\u2010933\u00a0(2005).\u00a0\n324.\u00a0Marriott,\u00a0I.,\u00a0Mason,\u00a0M.J.,\u00a0Elhofy,\u00a0A.\u00a0&\u00a0Bost,\u00a0\nK.L.\u00a0Substance \u00a0P\u00a0activates\u00a0NF\u2010kappaB\u00a0\nindependent \u00a0of\u00a0elevations \u00a0in\u00a0intracellular \u00a0\ncalcium\u00a0in\u00a0murine\u00a0macrophages \u00a0and\u00a0\ndendritic\u00a0cells.\u00a0J\u00a0Neuroimmunol \u00a0102,\u00a0163\u2010\n171\u00a0(2000).\u00a0\n325.\u00a0Azzolina,\u00a0A.,\u00a0Bongiovanni, \u00a0A.\u00a0&\u00a0Lampiasi, \u00a0\nN.\u00a0Substance \u00a0P\u00a0induces\u00a0TNF\u2010alpha\u00a0and\u00a0IL\u20106\u00a0\nproduction \u00a0through\u00a0NF\u00a0kappa\u00a0B\u00a0in\u00a0\nperitoneal \u00a0mast\u00a0cells.\u00a0Biochim\u00a0Biophys\u00a0\nActa\u00a01643 ,\u00a075\u201083\u00a0(2003).\u00a0\n326.\u00a0Guo,\u00a0C.J.,\u00a0Lai,\u00a0J.P.,\u00a0Luo,\u00a0H.M.,\u00a0Douglas,\u00a0S.D.\u00a0\n&\u00a0Ho,\u00a0W.Z.\u00a0Substance \u00a0P\u00a0up\u2010regulates \u00a0\nmacrophage \u00a0inflammatory \u00a0protein\u20101beta\u00a0\nexpression \u00a0in\u00a0human\u00a0T\u00a0lymphocytes. \u00a0J\u00a0\nNeuroimmunol \u00a0131,\u00a0160\u2010167\u00a0(2002).\u00a0\n327.\u00a0Chen,\u00a0B.C.,\u00a0et\u00a0al.\u00a0Bradykinin \u00a0B2\u00a0receptor\u00a0\nmediates \u00a0NF\u2010kappaB\u00a0activation \u00a0and\u00a0\ncyclooxygenase \u20102\u00a0expression \u00a0via\u00a0the\u00a0\nRas/Raf\u20101/ERK\u00a0pathway\u00a0in\u00a0human\u00a0airway\u00a0\nepithelial \u00a0cells.\u00a0J\u00a0Immunol\u00a0173,\u00a05219\u20105228\u00a0\n(2004).\u00a0\n328.\u00a0Wang,\u00a0T.,\u00a0et\u00a0al.\u00a0Co\u2010activation \u00a0of\u00a0ERK,\u00a0NF\u2010\nkappaB,\u00a0and\u00a0GADD45beta \u00a0in\u00a0response\u00a0to\u00a0\nionizing\u00a0radiation. \u00a0J\u00a0Biol\u00a0Chem\u00a0280,\u00a012593\u2010\n12601\u00a0(2005).\u00a0\n329.\u00a0Wang,\u00a0C.Y.,\u00a0Cusack,\u00a0J.C.,\u00a0Jr.,\u00a0Liu,\u00a0R.\u00a0&\u00a0\nBaldwin,\u00a0A.S.,\u00a0Jr.\u00a0Control\u00a0of\u00a0inducible\u00a0\nchemoresistance: \u00a0enhanced \u00a0anti\u2010tumor\u00a0\ntherapy\u00a0through\u00a0increased \u00a0apoptosis \u00a0by\u00a0\ninhibition \u00a0of\u00a0NF\u2010kappaB.\u00a0Nat\u00a0Med\u00a05,\u00a0412\u2010\n417\u00a0(1999).\u00a0\n330.\u00a0Lee,\u00a0C.H.,\u00a0Jeon,\u00a0Y.T.,\u00a0Kim,\u00a0S.H.\u00a0&\u00a0Song,\u00a0Y.S.\u00a0\nNF\u2010kappaB\u00a0as\u00a0a\u00a0potential\u00a0molecular \u00a0target\u00a0\nfor\u00a0cancer\u00a0therapy.\u00a0Biofactors \u00a029,\u00a019\u201035\u00a0\n(2007).\u00a0\n331.\u00a0Vivanco,\u00a0I.\u00a0&\u00a0Sawyers,\u00a0C.L.\u00a0The\u00a0\nphosphatidylinositol \u00a0 3\u2010Kinase\u00a0 AKT\u00a0pathway\u00a0in\u00a0human\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0Cancer\u00a0\n2,\u00a0489\u2010501\u00a0(2002).\u00a0\n332.\u00a0Paez,\u00a0J.\u00a0&\u00a0Sellers,\u00a0W.R.\u00a0PI3K/PTEN/AKT \u00a0\npathway. \u00a0A\u00a0critical\u00a0mediator \u00a0of\u00a0oncogenic \u00a0\nsignaling. \u00a0Cancer\u00a0Treat\u00a0Res\u00a0115,\u00a0145\u2010167\u00a0\n(2003).\u00a0\n333.\u00a0Borlado,\u00a0L.R.,\u00a0et\u00a0al.\u00a0Increased \u00a0\nphosphoinositide \u00a03\u2010kinase\u00a0activity\u00a0induces\u00a0\na\u00a0lymphoproliferative \u00a0disorder\u00a0and\u00a0\ncontributes \u00a0to\u00a0tumor\u00a0generation \u00a0in\u00a0vivo.\u00a0\nFASEB\u00a0J\u00a014,\u00a0895\u2010903\u00a0(2000).\u00a0\n334.\u00a0Schwindinger, \u00a0W.F.\u00a0&\u00a0Robishaw, \u00a0J.D.\u00a0\nHeterotrimeric \u00a0G\u2010protein\u00a0betagamma \u2010\ndimers\u00a0in\u00a0growth\u00a0and\u00a0differentiation. \u00a0\nOncogene \u00a020,\u00a01653\u20101660\u00a0(2001).\u00a0\n335.\u00a0Akazawa, \u00a0T.,\u00a0et\u00a0al.\u00a0A\u00a0constitutively \u00a0active\u00a0\nform\u00a0of\u00a0neurokinin \u00a01\u00a0receptor\u00a0and\u00a0\nneurokinin \u00a01\u00a0receptor\u2010mediated \u00a0apoptosis \u00a0\nin\u00a0glioblastomas. \u00a0J\u00a0Neurochem \u00a0109,\u00a01079\u2010\n1086\u00a0(2009).\u00a0\n336.\u00a0Snider,\u00a0R.M. ,\u00a0et\u00a0al.\u00a0A\u00a0potent\u00a0nonpeptide \u00a0\nantagonist \u00a0of\u00a0the\u00a0substance \u00a0P\u00a0(NK1)\u00a0\nreceptor. \u00a0Science\u00a0251,\u00a0435\u2010437\u00a0(1991).\u00a0\n337.\u00a0Huang,\u00a0S.C.\u00a0&\u00a0Korlipara, \u00a0V.L.\u00a0Neurokinin \u20101\u00a0\nreceptor\u00a0antagonists: \u00a0a\u00a0comprehensive \u00a0\npatent\u00a0survey.\u00a0Expert\u00a0Opin\u00a0Ther\u00a0Pat\u00a020,\u00a0\n1019\u20101045\u00a0(2010).\u00a0\n338.\u00a0Seabrook, \u00a0G.R.,\u00a0et\u00a0al.\u00a0L\u2010733,060,\u00a0a\u00a0novel\u00a0\ntachykinin \u00a0NK1\u00a0receptor\u00a0antagonist; \u00a0\neffects\u00a0 in\u00a0 [Ca2+]i\u00a0 mobilisation, \u00a0\ncardiovascular \u00a0and\u00a0dural\u00a0extravasation \u00a0\nassays.\u00a0Eur\u00a0J\u00a0Pharmacol \u00a0317,\u00a0129\u2010135\u00a0\n(1996).\u00a0\n339.\u00a0Bigioni,\u00a0M.,\u00a0Benzo,\u00a0A.,\u00a0Irrissuto,\u00a0C.,\u00a0Maggi,\u00a0\nC.A.\u00a0&\u00a0Goso,\u00a0C.\u00a0Role\u00a0of\u00a0NK\u20101\u00a0and\u00a0NK\u20102\u00a0\ntachykinin \u00a0receptor\u00a0antagonism \u00a0on\u00a0the\u00a0\ngrowth\u00a0of\u00a0human\u00a0breast\u00a0carcinoma \u00a0cell\u00a0\nline\u00a0MDA\u2010MB\u2010231.\u00a0Anticancer \u00a0Drugs\u00a016,\u00a0\n1083\u20101089\u00a0(2005).\u00a0\n340.\u00a0Munoz,\u00a0M.,\u00a0et\u00a0al.\u00a0Neurokinin \u20101\u00a0receptors \u00a0\nlocated\u00a0in\u00a0human\u00a0retinoblastoma \u00a0cell\u00a0\nlines:\u00a0antitumor \u00a0action\u00a0of\u00a0its\u00a0antagonist, \u00a0L\u2010\n732,138.\u00a0Invest\u00a0Ophthalmol \u00a0Vis\u00a0Sci\u00a048,\u00a0\n2775\u20102781\u00a0(2007).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n222\u00a0\n\u00a0341.\u00a0\u201cDrug\u00a0Aproval\u00a0Package:\u00a0EMEND\u00a0\n(Aprepitant) \u00a0 NDA\u00a0 #21\u2010549\u201d.\u00a0\nhttp://www.accessdata. fda.gov/drugsatfd\na_docs/nda/2003/21 \u2010549_Emend.cfm .\u00a0\n342.\u00a0U\u00a0S\u00a0Food\u00a0and\u00a0Drug\u00a0Administration. \u00a0\u00a0\n(http://www.fda.gov/ohrms/dockets/ac/0\n3/briefing/3928B1_01_Merck%20Backgro\nunder.pdf) .\u00a0\n343.\u00a0Munoz,\u00a0M.\u00a0&\u00a0Rosso,\u00a0M.\u00a0The\u00a0NK\u20101\u00a0receptor\u00a0\nantagonist \u00a0aprepitant \u00a0as\u00a0a\u00a0broad\u00a0spectrum \u00a0\nantitumor \u00a0drug.\u00a0Invest\u00a0New\u00a0Drugs\u00a028,\u00a0187\u2010\n193\u00a0(2010).\u00a0\n344.\u00a0Kast,\u00a0R.E.\u00a0Why\u00a0cerebellar \u00a0glioblastoma \u00a0is\u00a0\nrare\u00a0and\u00a0how\u00a0that\u00a0indicates\u00a0adjunctive \u00a0use\u00a0\nof\u00a0the\u00a0FDA\u2010approved \u00a0anti\u2010emetic\u00a0\naprepitant \u00a0might\u00a0retard\u00a0cerebral\u00a0\nglioblastoma \u00a0growth:\u00a0a\u00a0new\u00a0hypothesis \u00a0to\u00a0\nan\u00a0old\u00a0question. \u00a0Clin\u00a0Transl\u00a0Oncol\u00a011,\u00a0408\u2010\n410\u00a0(2009).\u00a0\n345.\u00a0Langdon,\u00a0S.,\u00a0et\u00a0al.\u00a0Broad\u00a0spectrum \u00a0\nneuropeptide \u00a0antagonists \u00a0inhibit\u00a0the\u00a0\ngrowth\u00a0of\u00a0small\u00a0cell\u00a0lung\u00a0cancer\u00a0in\u00a0vivo.\u00a0\nCancer\u00a0Res\u00a052,\u00a04554\u20104557\u00a0(1992).\u00a0\n346.\u00a0Reeve,\u00a0J.G.\u00a0&\u00a0Bleehen,\u00a0N.M.\u00a0[D\u2010Arg1,\u00a0D\u2010\nPhe5,\u00a0D\u2010Trp7,9,\u00a0Leu11]\u00a0substance \u00a0P\u00a0\ninduces\u00a0apoptosis \u00a0in\u00a0lung\u00a0cancer\u00a0cell\u00a0lines\u00a0\nin\u00a0vitro.\u00a0Biochem\u00a0Biophys\u00a0Res\u00a0Commun\u00a0\n199,\u00a01313\u20101319\u00a0(1994).\u00a0\n347.\u00a0Mayordomo, \u00a0C.,\u00a0et\u00a0al.\u00a0Targeting \u00a0of\u00a0\nsubstance \u00a0P\u00a0induces\u00a0cancer\u00a0cell\u00a0death\u00a0and\u00a0\ndecreases \u00a0the\u00a0steady\u00a0state\u00a0of\u00a0EGFR\u00a0and\u00a0\nHer2.\u00a0J\u00a0Cell\u00a0Physiol\u00a0227,\u00a01358\u20101366.\u00a0\n348.\u00a0Arthur,\u00a0D.B.,\u00a0Akassoglou, \u00a0K.\u00a0&\u00a0Insel,\u00a0P.A.\u00a0\nP2Y2\u00a0and\u00a0TrkA\u00a0receptors \u00a0interact\u00a0with\u00a0Src\u00a0\nfamily\u00a0kinase\u00a0for\u00a0neuronal\u00a0differentiation. \u00a0\nBiochem\u00a0Biophys\u00a0Res\u00a0Commun\u00a0347,\u00a0678\u2010\n682\u00a0(2006).\u00a0\n349.\u00a0Hsieh,\u00a0M.,\u00a0et\u00a0al.\u00a0Luteinizing \u00a0hormone \u2010\ndependent \u00a0activation \u00a0of\u00a0the\u00a0epidermal \u00a0\ngrowth\u00a0factor\u00a0network\u00a0is\u00a0essential\u00a0for\u00a0\novulation. \u00a0Mol\u00a0Cell\u00a0Biol\u00a027,\u00a01914\u20101924\u00a0\n(2007).\u00a0\n350.\u00a0Lappano,\u00a0R.\u00a0&\u00a0Maggiolini, \u00a0M.\u00a0G\u00a0protein\u2010\ncoupled\u00a0receptors: \u00a0novel\u00a0targets\u00a0for\u00a0drug\u00a0discovery \u00a0in\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0Drug\u00a0Discov\u00a0\n10,\u00a047\u201060.\u00a0\n351.\u00a0Piiper,\u00a0A.\u00a0&\u00a0Zeuzem,\u00a0S.\u00a0Receptor\u00a0tyrosine\u00a0\nkinases\u00a0are\u00a0signaling\u00a0intermediates \u00a0of\u00a0G\u00a0\nprotein\u2010coupled\u00a0receptors. \u00a0Curr\u00a0Pharm\u00a0\nDes\u00a010,\u00a03539\u20103545\u00a0(2004).\u00a0\n352.\u00a0Negro,\u00a0A.,\u00a0et\u00a0al.\u00a0erbB2\u00a0is\u00a0required\u00a0for\u00a0G\u00a0\nprotein\u2010coupled\u00a0receptor\u00a0signaling\u00a0in\u00a0the\u00a0\nheart.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0103,\u00a0\n15889\u201015893\u00a0(2006).\u00a0\n353.\u00a0Saito,\u00a0Y.,\u00a0Haendeler, \u00a0J.,\u00a0Hojo,\u00a0Y.,\u00a0\nYamamoto, \u00a0K.\u00a0&\u00a0Berk,\u00a0B.C.\u00a0Receptor\u00a0\nheterodimerization: \u00a0essential\u00a0mechanism \u00a0\nfor\u00a0platelet\u2010derived\u00a0growth\u00a0factor\u2010induced\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ntransactivation. \u00a0Mol\u00a0Cell\u00a0Biol\u00a021,\u00a06387\u2010\n6394\u00a0(2001).\u00a0\n354.\u00a0Meng,\u00a0D.,\u00a0Shi,\u00a0X.,\u00a0Jiang,\u00a0B.H.\u00a0&\u00a0Fang,\u00a0J.\u00a0\nInsulin\u2010like\u00a0growth\u00a0factor\u2010I\u00a0(IGF\u2010I)\u00a0induces\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ntransactivation \u00a0and\u00a0cell\u00a0proliferation \u00a0\nthrough\u00a0reactive\u00a0oxygen\u00a0species.\u00a0Free\u00a0\nRadic\u00a0Biol\u00a0Med\u00a042,\u00a01651\u20101660\u00a0(2007).\u00a0\n355.\u00a0Caja,\u00a0L.,\u00a0et\u00a0al.\u00a0Differential \u00a0intracellular \u00a0\nsignalling \u00a0induced\u00a0by\u00a0TGF\u2010beta\u00a0in\u00a0rat\u00a0adult\u00a0\nhepatocytes \u00a0and\u00a0hepatoma \u00a0cells:\u00a0\nimplications \u00a0in\u00a0liver\u00a0carcinogenesis. \u00a0Cell\u00a0\nSignal\u00a019,\u00a0683\u2010694\u00a0(2007).\u00a0\n356.\u00a0Hirota,\u00a0K.,\u00a0Murata,\u00a0M.,\u00a0Itoh,\u00a0T.,\u00a0Yodoi,\u00a0J.\u00a0&\u00a0\nFukuda,\u00a0K.\u00a0Redox\u2010sensitive\u00a0transactivation \u00a0\nof\u00a0epidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0by\u00a0\ntumor\u00a0necrosis\u00a0factor\u00a0confers\u00a0the\u00a0NF\u2010\nkappa\u00a0B\u00a0activation. \u00a0J\u00a0Biol\u00a0Chem\u00a0276,\u00a0\n25953\u201025958\u00a0(2001).\u00a0\n357.\u00a0Dajani,\u00a0O.F.,\u00a0et\u00a0al.\u00a0Prostaglandin \u00a0E2\u00a0\nupregulates \u00a0EGF\u2010stimulated \u00a0signaling\u00a0in\u00a0\nmitogenic \u00a0pathways \u00a0involving\u00a0Akt\u00a0and\u00a0ERK\u00a0\nin\u00a0hepatocytes. \u00a0J\u00a0Cell\u00a0Physiol\u00a0214,\u00a0371\u2010380\u00a0\n(2008).\u00a0\n358.\u00a0Natarajan, \u00a0K.\u00a0&\u00a0Berk,\u00a0B.C.\u00a0Crosstalk\u00a0\ncoregulation \u00a0mechanisms \u00a0of\u00a0G\u00a0protein\u2010\ncoupled\u00a0receptors \u00a0and\u00a0receptor\u00a0tyrosine\u00a0\nkinases.\u00a0Methods\u00a0Mol\u00a0Biol\u00a0332,\u00a051\u201077\u00a0\n(2006).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n223\u00a0\n\u00a0359.\u00a0Pyne,\u00a0N.J.,\u00a0et\u00a0al.\u00a0Experimental \u00a0systems\u00a0for\u00a0\nstudying\u00a0the\u00a0role\u00a0of\u00a0G\u2010protein\u2010coupled\u00a0\nreceptors \u00a0in\u00a0receptor\u00a0tyrosine\u00a0kinase\u00a0\nsignal\u00a0transduction. \u00a0Methods\u00a0Enzymol\u00a0\n390,\u00a0451\u2010475\u00a0(2004).\u00a0\n360.\u00a0Dhanasekaran, \u00a0D.N.\u00a0Transducing \u00a0the\u00a0\nsignals:\u00a0a\u00a0G\u00a0protein\u00a0takes\u00a0a\u00a0new\u00a0identity.\u00a0\nSci\u00a0STKE\u00a02006 ,\u00a0pe31\u00a0(2006).\u00a0\n361.\u00a0McCole,\u00a0D.F.,\u00a0Truong,\u00a0A.,\u00a0Bunz,\u00a0M.\u00a0&\u00a0\nBarrett,\u00a0K.E.\u00a0Consequences \u00a0of\u00a0direct\u00a0\nversus\u00a0indirect\u00a0activation \u00a0of\u00a0epidermal \u00a0\ngrowth\u00a0factor\u00a0receptor\u00a0in\u00a0intestinal \u00a0\nepithelial \u00a0cells\u00a0are\u00a0dictated\u00a0by\u00a0protein\u2010\ntyrosine\u00a0phosphatase \u00a01B.\u00a0J\u00a0Biol\u00a0Chem\u00a0282,\u00a0\n13303\u201013315\u00a0(2007).\u00a0\n362.\u00a0Guarino,\u00a0M.\u00a0Src\u00a0signaling\u00a0in\u00a0cancer\u00a0\ninvasion.\u00a0J\u00a0Cell\u00a0Physiol\u00a0223,\u00a014\u201026.\u00a0\n363.\u00a0Bromann, \u00a0P.A.,\u00a0Korkaya,\u00a0H.\u00a0&\u00a0Courtneidge, \u00a0\nS.A.\u00a0The\u00a0interplay\u00a0between\u00a0Src\u00a0family\u00a0\nkinases\u00a0and\u00a0receptor\u00a0tyrosine\u00a0kinases.\u00a0\nOncogene \u00a023,\u00a07957\u20107968\u00a0(2004).\u00a0\n364.\u00a0Biscardi,\u00a0J.S.,\u00a0et\u00a0al.\u00a0c\u2010Src\u2010mediated \u00a0\nphosphorylation \u00a0of\u00a0the\u00a0epidermal \u00a0growth\u00a0\nfactor\u00a0receptor\u00a0on\u00a0Tyr845\u00a0and\u00a0Tyr1101\u00a0is\u00a0\nassociated \u00a0with\u00a0modulation \u00a0of\u00a0receptor\u00a0\nfunction.\u00a0J\u00a0Biol\u00a0Chem\u00a0274,\u00a08335\u20108343\u00a0\n(1999).\u00a0\n365.\u00a0Biscardi,\u00a0J.S.,\u00a0Ishizawar, \u00a0R.C.,\u00a0Silva,\u00a0C.M.\u00a0&\u00a0\nParsons,\u00a0S.J.\u00a0Tyrosine\u00a0kinase\u00a0signalling \u00a0in\u00a0\nbreast\u00a0cancer:\u00a0epidermal \u00a0growth\u00a0factor\u00a0\nreceptor\u00a0and\u00a0c\u2010Src\u00a0interactions \u00a0in\u00a0breast\u00a0\ncancer.\u00a0Breast\u00a0Cancer\u00a0Res\u00a02,\u00a0203\u2010210\u00a0\n(2000).\u00a0\n366.\u00a0Tice,\u00a0D.A.,\u00a0Biscardi,\u00a0J.S.,\u00a0Nickles,\u00a0A.L.\u00a0&\u00a0\nParsons,\u00a0S.J.\u00a0Mechanism \u00a0of\u00a0biological \u00a0\nsynergy\u00a0between\u00a0cellular\u00a0Src\u00a0and\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0Proc\u00a0\nNatl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a096,\u00a01415\u20101420\u00a0(1999).\u00a0\n367.\u00a0Ishizawar, \u00a0R.\u00a0&\u00a0Parsons,\u00a0S.J.\u00a0c\u2010Src\u00a0and\u00a0\ncooperating \u00a0partners\u00a0in\u00a0human\u00a0cancer.\u00a0\nCancer\u00a0Cell\u00a06,\u00a0209\u2010214\u00a0(2004).\u00a0\n368.\u00a0Stover,\u00a0D.R.,\u00a0Becker,\u00a0M.,\u00a0Liebetanz, \u00a0J.\u00a0&\u00a0\nLydon,\u00a0N.B.\u00a0Src\u00a0phosphorylation \u00a0of\u00a0the\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0at\u00a0novel\u00a0\nsites\u00a0mediates \u00a0receptor\u00a0interaction \u00a0with\u00a0Src\u00a0and\u00a0P85\u00a0alpha.\u00a0J\u00a0Biol\u00a0Chem\u00a0270,\u00a015591\u2010\n15597\u00a0(1995).\u00a0\n369.\u00a0Ahn,\u00a0S.,\u00a0et\u00a0al.\u00a0Src\u2010dependent \u00a0tyrosine\u00a0\nphosphorylation \u00a0regulates \u00a0dynamin\u00a0self\u2010\nassembly \u00a0and\u00a0ligand\u2010induced\u00a0endocytosis \u00a0\nof\u00a0the\u00a0epidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0J\u00a0\nBiol\u00a0Chem\u00a0277,\u00a026642\u201026651\u00a0(2002).\u00a0\n370.\u00a0Vieira,\u00a0A.V.,\u00a0Lamaze,\u00a0C.\u00a0&\u00a0Schmid,\u00a0S.L.\u00a0\nControl\u00a0of\u00a0EGF\u00a0receptor\u00a0signaling\u00a0by\u00a0\nclathrin\u2010mediated \u00a0endocytosis. \u00a0Science\u00a0\n274,\u00a02086\u20102089\u00a0(1996).\u00a0\n371.\u00a0Chow,\u00a0J.C.,\u00a0Condorelli, \u00a0G.\u00a0&\u00a0Smith,\u00a0R.J.\u00a0\nInsulin\u2010like\u00a0growth\u00a0factor\u2010I\u00a0receptor\u00a0\ninternalization \u00a0regulates \u00a0signaling\u00a0via\u00a0the\u00a0\nShc/mitogen \u2010activated \u00a0protein\u00a0kinase\u00a0\npathway, \u00a0but\u00a0not\u00a0the\u00a0insulin\u00a0receptor\u00a0\nsubstrate \u20101\u00a0pathway. \u00a0J\u00a0Biol\u00a0Chem\u00a0273,\u00a0\n4672\u20104680\u00a0(1998).\u00a0\n372.\u00a0Maudsley, \u00a0S.,\u00a0et\u00a0al.\u00a0The\u00a0beta(2)\u2010adrenergic \u00a0\nreceptor\u00a0mediates \u00a0extracellular \u00a0signal\u2010\nregulated \u00a0kinase\u00a0activation \u00a0via\u00a0assembly \u00a0\nof\u00a0a\u00a0multi\u2010receptor\u00a0complex\u00a0with\u00a0the\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0J\u00a0Biol\u00a0\nChem\u00a0275,\u00a09572\u20109580\u00a0(2000).\u00a0\n373.\u00a0Pierce,\u00a0K.L.,\u00a0et\u00a0al.\u00a0Epidermal \u00a0growth\u00a0factor\u00a0\n(EGF)\u00a0receptor\u2010dependent \u00a0ERK\u00a0activation \u00a0\nby\u00a0G\u00a0protein\u2010coupled\u00a0receptors: \u00a0a\u00a0co\u2010\nculture\u00a0 system\u00a0 for\u00a0 identifying \u00a0\nintermediates \u00a0upstream \u00a0and\u00a0downstream \u00a0\nof\u00a0heparin\u2010binding\u00a0EGF\u00a0shedding. \u00a0J\u00a0Biol\u00a0\nChem\u00a0276,\u00a023155\u201023160\u00a0(2001).\u00a0\n374.\u00a0Shida,\u00a0D.,\u00a0et\u00a0al.\u00a0Lysophospholipids \u00a0\ntransactivate \u00a0HER2/neu \u00a0(erbB\u20102)\u00a0in\u00a0human\u00a0\ngastric\u00a0cancer\u00a0cells.\u00a0Biochem\u00a0Biophys\u00a0Res\u00a0\nCommun\u00a0327,\u00a0907\u2010914\u00a0(2005).\u00a0\n375.\u00a0Cabioglu, \u00a0N.,\u00a0et\u00a0al.\u00a0CXCL\u201012/stromal \u00a0cell\u2010\nderived\u00a0factor\u20101alpha\u00a0transactivates \u00a0\nHER2\u2010neu\u00a0in\u00a0breast\u00a0cancer\u00a0cells\u00a0by\u00a0a\u00a0novel\u00a0\npathway\u00a0involving\u00a0Src\u00a0kinase\u00a0activation. \u00a0\nCancer\u00a0Res\u00a065,\u00a06493\u20106497\u00a0(2005).\u00a0\n376.\u00a0Li,\u00a0Y.M. ,\u00a0et\u00a0al.\u00a0Upregulation \u00a0of\u00a0CXCR4\u00a0is\u00a0\nessential\u00a0for\u00a0HER2\u2010mediated \u00a0tumor\u00a0\nmetastasis. \u00a0Cancer\u00a0Cell\u00a06,\u00a0459\u2010469\u00a0(2004).\u00a0\n377.\u00a0Arora,\u00a0P.,\u00a0Cuevas,\u00a0B.D.,\u00a0Russo,\u00a0A.,\u00a0Johnson,\u00a0\nG.L.\u00a0&\u00a0Trejo,\u00a0J.\u00a0Persistent \u00a0transactivation \u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n224\u00a0\n\u00a0of\u00a0EGFR\u00a0and\u00a0ErbB2/HER2 \u00a0by\u00a0protease\u2010\nactivated \u00a0receptor\u20101\u00a0promotes \u00a0breast\u00a0\ncarcinoma \u00a0cell\u00a0invasion.\u00a0Oncogene \u00a027,\u00a0\n4434\u20104445\u00a0(2008).\u00a0\n378.\u00a0Belsches\u2010Jablonski, \u00a0A.P.,\u00a0et\u00a0al.\u00a0Src\u00a0family\u00a0\nkinases\u00a0and\u00a0HER2\u00a0interactions \u00a0in\u00a0human\u00a0\nbreast\u00a0cancer\u00a0cell\u00a0growth\u00a0and\u00a0survival.\u00a0\nOncogene \u00a020,\u00a01465\u20101475\u00a0(2001).\u00a0\n379.\u00a0Kim,\u00a0H.,\u00a0et\u00a0al.\u00a0The\u00a0c\u2010Src\u00a0tyrosine\u00a0kinase\u00a0\nassociates \u00a0with\u00a0the\u00a0catalytic\u00a0domain\u00a0of\u00a0\nErbB\u20102:\u00a0implications \u00a0for\u00a0ErbB\u20102\u00a0mediated \u00a0\nsignaling\u00a0and\u00a0transformation. \u00a0Oncogene \u00a0\n24,\u00a07599\u20107607\u00a0(2005).\u00a0\n380.\u00a0Ishizawar, \u00a0R.C.,\u00a0Miyake,\u00a0T.\u00a0&\u00a0Parsons,\u00a0S.J.\u00a0\nc\u2010Src\u00a0modulates \u00a0ErbB2\u00a0and\u00a0ErbB3\u00a0\nheterocomplex \u00a0formation \u00a0and\u00a0function.\u00a0\nOncogene \u00a026,\u00a03503\u20103510\u00a0(2007).\u00a0\n381.\u00a0Luttrell,\u00a0L.M.,\u00a0Della\u00a0Rocca,\u00a0G.J.,\u00a0van\u00a0\nBiesen,\u00a0T.,\u00a0Luttrell,\u00a0D.K.\u00a0&\u00a0Lefkowitz, \u00a0R.J.\u00a0\nGbetagamma \u00a0subunits\u00a0mediate\u00a0Src\u2010\ndependent \u00a0phosphorylation \u00a0of\u00a0the\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0A\u00a0\nscaffold\u00a0for\u00a0G\u00a0protein\u2010coupled\u00a0receptor\u2010\nmediated \u00a0Ras\u00a0activation. \u00a0J\u00a0Biol\u00a0Chem\u00a0272,\u00a0\n4637\u20104644\u00a0(1997).\u00a0\n382.\u00a0Hawes,\u00a0B.E.,\u00a0van\u00a0Biesen,\u00a0T.,\u00a0Koch,\u00a0W.J.,\u00a0\nLuttrell,\u00a0L.M.\u00a0&\u00a0Lefkowitz, \u00a0R.J.\u00a0Distinct\u00a0\npathways \u00a0of\u00a0Gi\u2010\u00a0and\u00a0Gq\u2010mediated \u00a0\nmitogen\u2010activated \u00a0 protein\u00a0 kinase\u00a0\nactivation. \u00a0J\u00a0Biol\u00a0Chem\u00a0270,\u00a017148\u201017153\u00a0\n(1995).\u00a0\n383.\u00a0Tsai,\u00a0W.,\u00a0Morielli,\u00a0A.D.\u00a0&\u00a0Peralta,\u00a0E.G.\u00a0The\u00a0\nm1\u00a0muscarinic \u00a0acetylcholine \u00a0receptor\u00a0\ntransactivates \u00a0the\u00a0EGF\u00a0receptor\u00a0to\u00a0\nmodulate \u00a0ion\u00a0channel\u00a0activity.\u00a0EMBO\u00a0J\u00a016,\u00a0\n4597\u20104605\u00a0(1997).\u00a0\n384.\u00a0Prenzel,\u00a0N.,\u00a0et\u00a0al.\u00a0EGF\u00a0receptor\u00a0\ntransactivation \u00a0by\u00a0G\u2010protein\u2010coupled\u00a0\nreceptors \u00a0requires\u00a0metalloproteinase \u00a0\ncleavage\u00a0of\u00a0proHB\u2010EGF.\u00a0Nature\u00a0402,\u00a0884\u2010\n888\u00a0(1999).\u00a0\n385.\u00a0Chen,\u00a0C.H.,\u00a0et\u00a0al.\u00a0Reactive\u00a0oxygen\u00a0species\u00a0\ngeneration \u00a0is\u00a0involved\u00a0in\u00a0epidermal \u00a0\ngrowth\u00a0factor\u00a0receptor\u00a0transactivation \u00a0\nthrough\u00a0the\u00a0transient\u00a0oxidization \u00a0of\u00a0Src\u00a0homology \u00a0 2\u2010containing \u00a0 tyrosine\u00a0\nphosphatase \u00a0in\u00a0endothelin \u20101\u00a0signaling\u00a0\npathway\u00a0in\u00a0rat\u00a0cardiac\u00a0fibroblasts. \u00a0Mol\u00a0\nPharmacol \u00a069,\u00a01347\u20101355\u00a0(2006).\u00a0\n386.\u00a0Ohtsu,\u00a0H.,\u00a0Dempsey, \u00a0P.J.\u00a0&\u00a0Eguchi,\u00a0S.\u00a0\nADAMs\u00a0as\u00a0mediators \u00a0of\u00a0EGF\u00a0receptor\u00a0\ntransactivation \u00a0by\u00a0G\u00a0protein\u2010coupled\u00a0\nreceptors. \u00a0Am\u00a0J\u00a0Physiol\u00a0Cell\u00a0Physiol\u00a0291,\u00a0\nC1\u201010\u00a0(2006).\u00a0\n387.\u00a0Hynes,\u00a0N.E.\u00a0&\u00a0Schlange, \u00a0T.\u00a0Targeting \u00a0\nADAMS\u00a0and\u00a0ERBBs\u00a0in\u00a0lung\u00a0cancer.\u00a0Cancer\u00a0\nCell\u00a010,\u00a07\u201011\u00a0(2006).\u00a0\n388.\u00a0Schulze,\u00a0A.,\u00a0Nicke,\u00a0B.,\u00a0Warne,\u00a0P.H.,\u00a0\nTomlinson, \u00a0S.\u00a0&\u00a0Downward, \u00a0J.\u00a0The\u00a0\ntranscriptional \u00a0response\u00a0to\u00a0Raf\u00a0activation \u00a0\nis\u00a0almost\u00a0completely \u00a0dependent \u00a0on\u00a0\nMitogen\u2010activated \u00a0Protein\u00a0Kinase\u00a0Kinase\u00a0\nactivity\u00a0and\u00a0shows\u00a0a\u00a0major\u00a0autocrine \u00a0\ncomponent. \u00a0Mol\u00a0Biol\u00a0Cell\u00a015,\u00a03450\u20103463\u00a0\n(2004).\u00a0\n389.\u00a0Shilo,\u00a0B.Z.\u00a0Regulating \u00a0the\u00a0dynamics \u00a0of\u00a0EGF\u00a0\nreceptor\u00a0signaling\u00a0in\u00a0space\u00a0and\u00a0time.\u00a0\nDevelopment \u00a0132,\u00a04017\u20104027\u00a0(2005).\u00a0\n390.\u00a0S\u00e1nchez\u2010Lemus,\u00a0E.\u00a0&\u00a0Arias\u2010Monta\u00f1o, \u00a0J.A.\u00a0\nTransactivaci\u00f3n \u00a0de\u00a0receptores \u00a0con\u00a0\nactividad\u00a0de\u00a0cinasa\u00a0de\u00a0tirosina\u00a0(RTK\u2019s)\u00a0por\u00a0\nreceptores \u00a0acoplados \u00a0a\u00a0prote\u00ednas \u00a0G.\u00a0\nRevista\u00a0Biom\u00e9dica \u00a015,\u00a033\u201048\u00a0(2004).\u00a0\n391.\u00a0Tanida,\u00a0S.,\u00a0et\u00a0al.\u00a0The\u00a0mechanism \u00a0of\u00a0\ncleavage\u00a0of\u00a0EGFR\u00a0ligands\u00a0induced\u00a0by\u00a0\ninflammatory \u00a0cytokines \u00a0in\u00a0gastric\u00a0cancer\u00a0\ncells.\u00a0Gastroenterology \u00a0127,\u00a0559\u2010569\u00a0\n(2004).\u00a0\n392.\u00a0Schafer,\u00a0B.,\u00a0Gschwind, \u00a0A.\u00a0&\u00a0Ullrich,\u00a0A.\u00a0\nMultiple\u00a0G\u2010protein\u2010coupled\u00a0receptor\u00a0\nsignals\u00a0converge\u00a0on\u00a0the\u00a0epidermal \u00a0growth\u00a0\nfactor\u00a0receptor\u00a0to\u00a0promote\u00a0migration \u00a0and\u00a0\ninvasion.\u00a0Oncogene \u00a023,\u00a0991\u2010999\u00a0(2004).\u00a0\n393.\u00a0Yan,\u00a0Y.,\u00a0Shirakabe, \u00a0K.\u00a0&\u00a0Werb,\u00a0Z.\u00a0The\u00a0\nmetalloprotease \u00a0Kuzbanian \u00a0(ADAM10) \u00a0\nmediates \u00a0the\u00a0transactivation \u00a0of\u00a0EGF\u00a0\nreceptor\u00a0by\u00a0G\u00a0protein\u2010coupled\u00a0receptors. \u00a0J\u00a0\nCell\u00a0Biol\u00a0158,\u00a0221\u2010226\u00a0(2002).\u00a0\n394.\u00a0Asakura,\u00a0M.,\u00a0et\u00a0al.\u00a0Cardiac\u00a0hypertrophy \u00a0is\u00a0\ninhibited\u00a0by\u00a0antagonism \u00a0of\u00a0ADAM12\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n225\u00a0\n\u00a0processing \u00a0of\u00a0HB\u2010EGF:\u00a0metalloproteinase \u00a0\ninhibitors \u00a0as\u00a0a\u00a0new\u00a0therapy.\u00a0Nat\u00a0Med\u00a08,\u00a0\n35\u201040\u00a0(2002).\u00a0\n395.\u00a0Gooz,\u00a0M.,\u00a0Gooz,\u00a0P.,\u00a0Luttrell,\u00a0L.M.\u00a0&\u00a0\nRaymond, \u00a0J.R.\u00a05\u2010HT2A\u00a0receptor\u00a0induces\u00a0\nERK\u00a0phosphorylation \u00a0and\u00a0proliferation \u00a0\nthrough\u00a0ADAM\u201017\u00a0tumor\u00a0necrosis\u00a0factor\u2010\nalpha\u2010converting \u00a0 enzyme\u00a0 (TACE)\u00a0\nactivation \u00a0and\u00a0heparin\u2010bound\u00a0epidermal \u00a0\ngrowth\u00a0factor\u2010like\u00a0growth\u00a0factor\u00a0(HB\u2010EGF)\u00a0\nshedding\u00a0in\u00a0mesangial \u00a0cells.\u00a0J\u00a0Biol\u00a0Chem\u00a0\n281,\u00a021004\u201021012\u00a0(2006).\u00a0\n396.\u00a0Ohtsu,\u00a0H.,\u00a0et\u00a0al.\u00a0ADAM17\u00a0mediates \u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ntransactivation \u00a0and\u00a0vascular\u00a0smooth\u00a0\nmuscle\u00a0cell\u00a0hypertrophy \u00a0induced\u00a0by\u00a0\nangiotensin \u00a0II.\u00a0Arterioscler \u00a0Thromb\u00a0Vasc\u00a0\nBiol\u00a026,\u00a0e133\u2010137\u00a0(2006).\u00a0\n397.\u00a0Schafer,\u00a0B.,\u00a0Marg,\u00a0B.,\u00a0Gschwind, \u00a0A.\u00a0&\u00a0\nUllrich,\u00a0 A.\u00a0 Distinct\u00a0 ADAM\u00a0\nmetalloproteinases \u00a0regulate\u00a0G\u00a0protein\u2010\ncoupled\u00a0 receptor\u2010induced\u00a0 cell\u00a0\nproliferation \u00a0and\u00a0survival.\u00a0J\u00a0Biol\u00a0Chem\u00a0279,\u00a0\n47929\u201047938\u00a0(2004).\u00a0\n398.\u00a0Ancha,\u00a0H.R.,\u00a0et\u00a0al.\u00a0Histamine \u00a0stimulation \u00a0\nof\u00a0MMP\u20101(collagenase \u20101)\u00a0secretion \u00a0and\u00a0\ngene\u00a0expression \u00a0in\u00a0gastric\u00a0epithelial \u00a0cells:\u00a0\nrole\u00a0of\u00a0EGFR\u00a0transactivation \u00a0and\u00a0the\u00a0MAP\u00a0\nkinase\u00a0pathway. \u00a0Int\u00a0J\u00a0Biochem\u00a0Cell\u00a0Biol\u00a039,\u00a0\n2143\u20102152\u00a0(2007).\u00a0\n399.\u00a0Roelle,\u00a0S.,\u00a0et\u00a0al.\u00a0Matrix\u00a0metalloproteinases \u00a0\n2\u00a0and\u00a09\u00a0mediate\u00a0epidermal \u00a0growth\u00a0factor\u00a0\nreceptor\u00a0transactivation \u00a0by\u00a0gonadotropin \u2010\nreleasing\u00a0hormone. \u00a0J\u00a0Biol\u00a0Chem\u00a0278,\u00a0\n47307\u201047318\u00a0(2003).\u00a0\n400.\u00a0Razandi,\u00a0M.,\u00a0Pedram,\u00a0A.,\u00a0Park,\u00a0S.T.\u00a0&\u00a0\nLevin,\u00a0E.R.\u00a0Proximal\u00a0events\u00a0in\u00a0signaling\u00a0by\u00a0\nplasma\u00a0membrane \u00a0estrogen\u00a0receptors. \u00a0J\u00a0\nBiol\u00a0Chem\u00a0278,\u00a02701\u20102712\u00a0(2003).\u00a0\n401.\u00a0Hao,\u00a0L.,\u00a0Du,\u00a0M.,\u00a0Lopez\u2010Campistrous, \u00a0A.\u00a0&\u00a0\nFernandez \u2010Patron,\u00a0C.\u00a0Agonist\u2010induced\u00a0\nactivation \u00a0of\u00a0matrix\u00a0metalloproteinase \u20107\u00a0\npromotes \u00a0vasoconstriction \u00a0through\u00a0the\u00a0\nepidermal \u00a0 growth\u00a0 factor\u2010receptor\u00a0\npathway. \u00a0Circ\u00a0Res\u00a094,\u00a068\u201076\u00a0(2004).\u00a0402.\u00a0Mukhin,\u00a0Y.V.,\u00a0Gooz,\u00a0M.,\u00a0Raymond, \u00a0J.R.\u00a0&\u00a0\nGarnovskaya, \u00a0M.N.\u00a0Collagenase \u20102\u00a0and\u00a0\u20103\u00a0\nmediate\u00a0epidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ntransactivation \u00a0by\u00a0bradykinin \u00a0B2\u00a0receptor\u00a0\nin\u00a0kidney\u00a0cells.\u00a0J\u00a0Pharmacol \u00a0Exp\u00a0Ther\u00a0318,\u00a0\n1033\u20101043\u00a0(2006).\u00a0\n403.\u00a0Eguchi,\u00a0S.,\u00a0et\u00a0al.\u00a0Calcium\u2010dependent \u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ntransactivation \u00a0mediates \u00a0the\u00a0angiotensin \u00a0\nII\u2010induced\u00a0mitogen\u2010activated \u00a0protein\u00a0\nkinase\u00a0activation \u00a0in\u00a0vascular\u00a0smooth\u00a0\nmuscle\u00a0cells.\u00a0J\u00a0Biol\u00a0Chem\u00a0273,\u00a08890\u20108896\u00a0\n(1998).\u00a0\n404.\u00a0Hackel,\u00a0P.O.,\u00a0Zwick,\u00a0E.,\u00a0Prenzel,\u00a0N.\u00a0&\u00a0\nUllrich,\u00a0A.\u00a0Epidermal \u00a0growth\u00a0factor\u00a0\nreceptors: \u00a0critical\u00a0mediators \u00a0of\u00a0multiple\u00a0\nreceptor\u00a0pathways. \u00a0Curr\u00a0Opin\u00a0Cell\u00a0Biol\u00a011,\u00a0\n184\u2010189\u00a0(1999).\u00a0\n405.\u00a0Prenzel,\u00a0N.,\u00a0Zwick,\u00a0E.,\u00a0Leserer,\u00a0M.\u00a0&\u00a0\nUllrich,\u00a0A.\u00a0Tyrosine\u00a0kinase\u00a0signalling \u00a0in\u00a0\nbreast\u00a0cancer.\u00a0Epidermal \u00a0growth\u00a0factor\u00a0\nreceptor: \u00a0convergence \u00a0point\u00a0for\u00a0signal\u00a0\nintegration \u00a0and\u00a0diversification. \u00a0Breast\u00a0\nCancer\u00a0Res\u00a02,\u00a0184\u2010190\u00a0(2000).\u00a0\n406.\u00a0Hynes,\u00a0N.E.\u00a0&\u00a0Lane,\u00a0H.A.\u00a0ERBB\u00a0receptors \u00a0\nand\u00a0cancer:\u00a0the\u00a0complexity \u00a0of\u00a0targeted\u00a0\ninhibitors. \u00a0Nat\u00a0Rev\u00a0Cancer\u00a05,\u00a0341\u2010354\u00a0\n(2005).\u00a0\n407.\u00a0Miettinen, \u00a0P.J.,\u00a0et\u00a0al.\u00a0Epithelial \u00a0immaturity \u00a0\nand\u00a0multiorgan \u00a0failure\u00a0in\u00a0mice\u00a0lacking\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0Nature\u00a0\n376,\u00a0337\u2010341\u00a0(1995).\u00a0\n408.\u00a0Sibilia,\u00a0M.\u00a0&\u00a0Wagner,\u00a0E.F.\u00a0Strain\u2010\ndependent \u00a0epithelial \u00a0defects\u00a0in\u00a0mice\u00a0\nlacking\u00a0the\u00a0EGF\u00a0receptor. \u00a0Science\u00a0269,\u00a0\n234\u2010238\u00a0(1995).\u00a0\n409.\u00a0Threadgill, \u00a0D.W. ,\u00a0et\u00a0al.\u00a0Targeted\u00a0disruption \u00a0\nof\u00a0mouse\u00a0EGF\u00a0receptor: \u00a0effect\u00a0of\u00a0genetic\u00a0\nbackground \u00a0on\u00a0mutant\u00a0phenotype. \u00a0\nScience\u00a0269,\u00a0230\u2010234\u00a0(1995).\u00a0\n410.\u00a0Lee,\u00a0K.F.,\u00a0et\u00a0al.\u00a0Requirement \u00a0for\u00a0\nneuregulin \u00a0receptor\u00a0erbB2\u00a0in\u00a0neural\u00a0and\u00a0\ncardiac\u00a0development. \u00a0Nature\u00a0378,\u00a0394\u2010\n398\u00a0(1995).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n226\u00a0\n\u00a0411.\u00a0Crone,\u00a0S.A.,\u00a0et\u00a0al.\u00a0ErbB2\u00a0is\u00a0essential\u00a0in\u00a0the\u00a0\nprevention \u00a0of\u00a0dilated\u00a0cardiomyopathy. \u00a0\nNat\u00a0Med\u00a08,\u00a0459\u2010465\u00a0(2002).\u00a0\n412.\u00a0Yarden,\u00a0Y.\u00a0&\u00a0Sliwkowski, \u00a0M.X.\u00a0Untangling \u00a0\nthe\u00a0ErbB\u00a0signalling \u00a0network.\u00a0Nat\u00a0Rev\u00a0Mol\u00a0\nCell\u00a0Biol\u00a02,\u00a0127\u2010137\u00a0(2001).\u00a0\n413.\u00a0Schlessinger, \u00a0J.\u00a0Ligand\u2010induced,\u00a0receptor\u2010\nmediated \u00a0dimerization \u00a0and\u00a0activation \u00a0of\u00a0\nEGF\u00a0receptor. \u00a0Cell\u00a0110,\u00a0669\u2010672\u00a0(2002).\u00a0\n414.\u00a0Burgess,\u00a0A.W. ,\u00a0et\u00a0al.\u00a0An\u00a0open\u2010and\u2010shut\u00a0\ncase?\u00a0Recent\u00a0insights\u00a0into\u00a0the\u00a0activation \u00a0\nof\u00a0EGF/ErbB \u00a0receptors. \u00a0Mol\u00a0Cell\u00a012,\u00a0541\u2010\n552\u00a0(2003).\u00a0\n415.\u00a0Ogiso,\u00a0H.,\u00a0et\u00a0al.\u00a0Crystal\u00a0structure\u00a0of\u00a0the\u00a0\ncomplex\u00a0of\u00a0human\u00a0epidermal \u00a0growth\u00a0\nfactor\u00a0and\u00a0receptor\u00a0extracellular \u00a0domains.\u00a0\nCell\u00a0110,\u00a0775\u2010787\u00a0(2002).\u00a0\n416.\u00a0Garrett,\u00a0T.P.,\u00a0et\u00a0al.\u00a0Crystal\u00a0structure\u00a0of\u00a0a\u00a0\ntruncated \u00a0epidermal \u00a0growth\u00a0factor\u00a0\nreceptor\u00a0extracellular \u00a0domain\u00a0bound\u00a0to\u00a0\ntransforming \u00a0growth\u00a0factor\u00a0alpha.\u00a0Cell\u00a0\n110,\u00a0763\u2010773\u00a0(2002).\u00a0\n417.\u00a0Zhang,\u00a0X.,\u00a0Gureasko, \u00a0J.,\u00a0Shen,\u00a0K.,\u00a0Cole,\u00a0P.A.\u00a0\n&\u00a0Kuriyan,\u00a0J.\u00a0An\u00a0allosteric\u00a0mechanism \u00a0for\u00a0\nactivation \u00a0of\u00a0the\u00a0kinase\u00a0domain\u00a0of\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor. \u00a0Cell\u00a0\n125,\u00a01137\u20101149\u00a0(2006).\u00a0\n418.\u00a0Garrett,\u00a0T.P.,\u00a0et\u00a0al.\u00a0The\u00a0crystal\u00a0structure\u00a0of\u00a0\na\u00a0truncated \u00a0ErbB2\u00a0ectodomain \u00a0reveals\u00a0an\u00a0\nactive\u00a0conformation, \u00a0poised\u00a0to\u00a0interact\u00a0\nwith\u00a0other\u00a0ErbB\u00a0receptors. \u00a0Mol\u00a0Cell\u00a011,\u00a0\n495\u2010505\u00a0(2003).\u00a0\n419.\u00a0Cho,\u00a0H.S.,\u00a0et\u00a0al.\u00a0Structure \u00a0of\u00a0the\u00a0\nextracellular \u00a0region\u00a0of\u00a0HER2\u00a0alone\u00a0and\u00a0in\u00a0\ncomplex\u00a0with\u00a0the\u00a0Herceptin \u00a0Fab.\u00a0Nature\u00a0\n421,\u00a0756\u2010760\u00a0(2003).\u00a0\n420.\u00a0Franklin,\u00a0M.C. ,\u00a0et\u00a0al.\u00a0Insights\u00a0into\u00a0ErbB\u00a0\nsignaling\u00a0from\u00a0the\u00a0structure\u00a0of\u00a0the\u00a0ErbB2\u2010\npertuzumab \u00a0complex.\u00a0Cancer\u00a0Cell\u00a05,\u00a0317\u2010\n328\u00a0(2004).\u00a0\n421.\u00a0Bose,\u00a0R.\u00a0&\u00a0Zhang,\u00a0X.\u00a0The\u00a0ErbB\u00a0kinase\u00a0\ndomain:\u00a0structural \u00a0perspectives \u00a0into\u00a0\nkinase\u00a0activation \u00a0and\u00a0inhibition. \u00a0Exp\u00a0Cell\u00a0\nRes\u00a0315,\u00a0649\u2010658\u00a0(2009).\u00a0422.\u00a0Soltoff,\u00a0S.P.\u00a0&\u00a0Cantley,\u00a0L.C.\u00a0p120cbl\u00a0is\u00a0a\u00a0\ncytosolic\u00a0adapter\u00a0protein\u00a0that\u00a0associates \u00a0\nwith\u00a0phosphoinositide \u00a03\u2010kinase\u00a0in\u00a0\nresponse\u00a0to\u00a0epidermal \u00a0growth\u00a0factor\u00a0in\u00a0\nPC12\u00a0and\u00a0other\u00a0cells.\u00a0J\u00a0Biol\u00a0Chem\u00a0271,\u00a0\n563\u2010567\u00a0(1996).\u00a0\n423.\u00a0Alimandi, \u00a0M.,\u00a0et\u00a0al.\u00a0Cooperative \u00a0signaling\u00a0\nof\u00a0ErbB3\u00a0and\u00a0ErbB2\u00a0in\u00a0neoplastic \u00a0\ntransformation \u00a0and\u00a0human\u00a0mammary \u00a0\ncarcinomas. \u00a0Oncogene \u00a010,\u00a01813\u20101821\u00a0\n(1995).\u00a0\n424.\u00a0Pinkas\u2010Kramarski, \u00a0R.,\u00a0et\u00a0al.\u00a0Diversification \u00a0\nof\u00a0Neu\u00a0differentiation \u00a0factor\u00a0and\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0signaling\u00a0by\u00a0\ncombinatorial \u00a0receptor\u00a0interactions. \u00a0\nEMBO\u00a0J\u00a015,\u00a02452\u20102467\u00a0(1996).\u00a0\n425.\u00a0Chausovsky, \u00a0A.,\u00a0et\u00a0al.\u00a0Molecular \u00a0\nrequirements \u00a0for\u00a0the\u00a0effect\u00a0of\u00a0neuregulin \u00a0\non\u00a0cell\u00a0spreading, \u00a0motility\u00a0and\u00a0colony\u00a0\norganization. \u00a0Oncogene \u00a019,\u00a0878\u2010888\u00a0\n(2000).\u00a0\n426.\u00a0Cohen,\u00a0S.,\u00a0Ushiro,\u00a0H.,\u00a0Stoscheck, \u00a0C.\u00a0&\u00a0\nChinkers, \u00a0M.\u00a0A\u00a0native\u00a0170,000\u00a0epidermal \u00a0\ngrowth\u00a0factor\u00a0receptor\u2010kinase\u00a0complex\u00a0\nfrom\u00a0shed\u00a0plasma\u00a0membrane \u00a0vesicles.\u00a0J\u00a0\nBiol\u00a0Chem\u00a0257,\u00a01523\u20101531\u00a0(1982).\u00a0\n427.\u00a0Barros,\u00a0F.F.,\u00a0Powe,\u00a0D.G.,\u00a0Ellis,\u00a0I.O.\u00a0&\u00a0Green,\u00a0\nA.R.\u00a0Understanding \u00a0the\u00a0HER\u00a0family\u00a0in\u00a0\nbreast\u00a0cancer:\u00a0interaction \u00a0with\u00a0ligands,\u00a0\ndimerization \u00a0 and\u00a0 treatments. \u00a0\nHistopathology \u00a056,\u00a0560\u2010572\u00a0(2010).\u00a0\n428.\u00a0Roepstorff, \u00a0K.,\u00a0Grovdal,\u00a0L.,\u00a0Grandal,\u00a0M.,\u00a0\nLerdrup,\u00a0M.\u00a0&\u00a0van\u00a0Deurs,\u00a0B.\u00a0Endocytic \u00a0\ndownregulation \u00a0of\u00a0ErbB\u00a0receptors: \u00a0\nmechanisms \u00a0and\u00a0relevance \u00a0in\u00a0cancer.\u00a0\nHistochem \u00a0Cell\u00a0Biol\u00a0129,\u00a0563\u2010578\u00a0(2008).\u00a0\n429.\u00a0Domagala, \u00a0T.,\u00a0et\u00a0al.\u00a0Stoichiometry, \u00a0kinetic\u00a0\nand\u00a0binding\u00a0analysis\u00a0of\u00a0the\u00a0interaction \u00a0\nbetween\u00a0epidermal \u00a0growth\u00a0factor\u00a0(EGF)\u00a0\nand\u00a0the\u00a0extracellular \u00a0domain\u00a0of\u00a0the\u00a0EGF\u00a0\nreceptor. \u00a0Growth\u00a0Factors\u00a018,\u00a011\u201029\u00a0\n(2000).\u00a0\n430.\u00a0Wosikowski, \u00a0K.,\u00a0Schuurhuis, \u00a0D.,\u00a0Kops,\u00a0G.J.,\u00a0\nSaceda,\u00a0M.\u00a0&\u00a0Bates,\u00a0S.E.\u00a0Altered\u00a0gene\u00a0\nexpression \u00a0in\u00a0drug\u2010resistant\u00a0human\u00a0breast\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n227\u00a0\n\u00a0cancer\u00a0cells.\u00a0Clin\u00a0Cancer\u00a0Res\u00a03,\u00a02405\u20102414\u00a0\n(1997).\u00a0\n431.\u00a0Noonberg, \u00a0S.B.\u00a0&\u00a0Benz,\u00a0C.C.\u00a0Tyrosine\u00a0\nkinase\u00a0inhibitors \u00a0targeted\u00a0to\u00a0the\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\nsubfamily: \u00a0role\u00a0as\u00a0anticancer \u00a0agents.\u00a0\nDrugs\u00a059,\u00a0753\u2010767\u00a0(2000).\u00a0\n432.\u00a0Coussens, \u00a0L.,\u00a0et\u00a0al.\u00a0Tyrosine\u00a0kinase\u00a0\nreceptor\u00a0with\u00a0extensive \u00a0homology \u00a0to\u00a0EGF\u00a0\nreceptor\u00a0shares\u00a0chromosomal \u00a0location\u00a0\nwith\u00a0neu\u00a0oncogene. \u00a0Science\u00a0230,\u00a01132\u2010\n1139\u00a0(1985).\u00a0\n433.\u00a0Yaziji,\u00a0H.,\u00a0et\u00a0al.\u00a0HER\u20102\u00a0testing\u00a0in\u00a0breast\u00a0\ncancer\u00a0using\u00a0parallel\u00a0tissue\u2010based\u00a0\nmethods. \u00a0JAMA\u00a0291,\u00a01972\u20101977\u00a0(2004).\u00a0\n434.\u00a0Owens,\u00a0M.A.,\u00a0Horten,\u00a0B.C.\u00a0&\u00a0Da\u00a0Silva,\u00a0\nM.M.\u00a0HER2\u00a0amplification \u00a0ratios\u00a0by\u00a0\nfluorescence \u00a0in\u00a0situ\u00a0hybridization \u00a0and\u00a0\ncorrelation \u00a0with\u00a0immunohistochemistry \u00a0in\u00a0\na\u00a0cohort\u00a0of\u00a06556\u00a0breast\u00a0cancer\u00a0tissues.\u00a0\nClin\u00a0Breast\u00a0Cancer\u00a05,\u00a063\u201069\u00a0(2004).\u00a0\n435.\u00a0Ricci,\u00a0A.,\u00a0et\u00a0al.\u00a0Analysis\u00a0of\u00a0protein\u2010protein\u00a0\ninteractions \u00a0involved\u00a0in\u00a0the\u00a0activation \u00a0of\u00a0\nthe\u00a0Shc/Grb\u20102\u00a0pathway\u00a0by\u00a0the\u00a0ErbB\u20102\u00a0\nkinase.\u00a0Oncogene \u00a011,\u00a01519\u20101529\u00a0(1995).\u00a0\n436.\u00a0Bentires\u2010Alj,\u00a0M.,\u00a0et\u00a0al.\u00a0A\u00a0role\u00a0for\u00a0the\u00a0\nscaffolding \u00a0adapter\u00a0GAB2\u00a0in\u00a0breast\u00a0cancer.\u00a0\nNat\u00a0Med\u00a012,\u00a0114\u2010121\u00a0(2006).\u00a0\n437.\u00a0Prigent,\u00a0S.A.\u00a0&\u00a0Gullick,\u00a0W.J.\u00a0Identification \u00a0\nof\u00a0c\u2010erbB\u20103\u00a0binding\u00a0sites\u00a0for\u00a0\nphosphatidylinositol \u00a03'\u2010kinase\u00a0and\u00a0SHC\u00a0\nusing\u00a0an\u00a0EGF\u00a0receptor/c \u2010erbB\u20103\u00a0chimera.\u00a0\nEMBO\u00a0J\u00a013,\u00a02831\u20102841\u00a0(1994).\u00a0\n438.\u00a0Tan,\u00a0M.,\u00a0Yao,\u00a0J.\u00a0&\u00a0Yu,\u00a0D.\u00a0Overexpression \u00a0of\u00a0\nthe\u00a0c\u2010erbB\u20102\u00a0gene\u00a0enhanced \u00a0intrinsic\u00a0\nmetastasis \u00a0potential\u00a0in\u00a0human\u00a0breast\u00a0\ncancer\u00a0cells\u00a0without\u00a0increasing \u00a0their\u00a0\ntransformation \u00a0abilities.\u00a0Cancer\u00a0Res\u00a057,\u00a0\n1199\u20101205\u00a0(1997).\u00a0\n439.\u00a0Citri,\u00a0A.\u00a0&\u00a0Yarden,\u00a0Y.\u00a0EGF\u2010ERBB\u00a0signalling: \u00a0\ntowards\u00a0the\u00a0systems\u00a0level.\u00a0Nat\u00a0Rev\u00a0Mol\u00a0\nCell\u00a0Biol\u00a07,\u00a0505\u2010516\u00a0(2006).\u00a0\n440.\u00a0Olayioye, \u00a0M.A.,\u00a0Neve,\u00a0R.M.,\u00a0Lane,\u00a0H.A.\u00a0&\u00a0\nHynes,\u00a0N.E.\u00a0The\u00a0ErbB\u00a0signaling\u00a0network:\u00a0\nreceptor\u00a0 heterodimerization \u00a0 in\u00a0development \u00a0and\u00a0cancer.\u00a0EMBO\u00a0J\u00a019,\u00a0\n3159\u20103167\u00a0(2000).\u00a0\n441.\u00a0Gorgoulis, \u00a0V.,\u00a0et\u00a0al.\u00a0Expression \u00a0of\u00a0EGF,\u00a0\nTGF\u2010alpha\u00a0and\u00a0EGFR\u00a0in\u00a0squamous \u00a0cell\u00a0lung\u00a0\ncarcinomas. \u00a0Anticancer \u00a0Res\u00a012,\u00a01183\u20101187\u00a0\n(1992).\u00a0\n442.\u00a0Issing,\u00a0W.J.,\u00a0Wustrow, \u00a0T.P.\u00a0&\u00a0Heppt,\u00a0W.J.\u00a0\nOncogenes \u00a0related\u00a0to\u00a0head\u00a0and\u00a0neck\u00a0\ncancer.\u00a0Anticancer \u00a0Res\u00a013,\u00a02541\u20102551\u00a0\n(1993).\u00a0\n443.\u00a0Wong,\u00a0A.J.,\u00a0et\u00a0al.\u00a0Structural \u00a0alterations \u00a0of\u00a0\nthe\u00a0epidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0\ngene\u00a0in\u00a0human\u00a0gliomas.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0\nU\u00a0S\u00a0A\u00a089,\u00a02965\u20102969\u00a0(1992).\u00a0\n444.\u00a0Moscatello, \u00a0D.K.,\u00a0et\u00a0al.\u00a0Frequent\u00a0\nexpression \u00a0of\u00a0a\u00a0mutant\u00a0epidermal \u00a0growth\u00a0\nfactor\u00a0receptor\u00a0in\u00a0multiple\u00a0human\u00a0tumors.\u00a0\nCancer\u00a0Res\u00a055,\u00a05536\u20105539\u00a0(1995).\u00a0\n445.\u00a0Ross,\u00a0J.S.\u00a0&\u00a0Fletcher,\u00a0J.A.\u00a0The\u00a0HER\u20102/neu\u00a0\noncogene \u00a0in\u00a0breast\u00a0cancer:\u00a0prognostic \u00a0\nfactor,\u00a0predictive \u00a0factor,\u00a0and\u00a0target\u00a0for\u00a0\ntherapy.\u00a0Stem\u00a0Cells\u00a016,\u00a0413\u2010428\u00a0(1998).\u00a0\n446.\u00a0Xia,\u00a0W.,\u00a0et\u00a0al.\u00a0Combination \u00a0of\u00a0EGFR,\u00a0HER\u2010\n2/neu,\u00a0and\u00a0HER\u20103\u00a0is\u00a0a\u00a0stronger\u00a0predictor \u00a0\nfor\u00a0the\u00a0outcome\u00a0of\u00a0oral\u00a0squamous \u00a0cell\u00a0\ncarcinoma \u00a0than\u00a0any\u00a0individual \u00a0family\u00a0\nmembers. \u00a0Clin\u00a0Cancer\u00a0Res\u00a05,\u00a04164\u20104174\u00a0\n(1999).\u00a0\n447.\u00a0Lyne,\u00a0J.C.,\u00a0et\u00a0al.\u00a0Tissue\u00a0expression \u00a0of\u00a0neu\u00a0\ndifferentiation \u00a0factor/heregulin \u00a0and\u00a0its\u00a0\nreceptor\u00a0complex\u00a0in\u00a0prostate\u00a0cancer\u00a0and\u00a0\nits\u00a0biologic\u00a0effects\u00a0on\u00a0prostate\u00a0cancer\u00a0cells\u00a0\nin\u00a0vitro.\u00a0Cancer\u00a0J\u00a0Sci\u00a0Am\u00a03,\u00a021\u201030\u00a0(1997).\u00a0\n448.\u00a0Shintani,\u00a0S.,\u00a0Funayama, \u00a0T.,\u00a0Yoshihama, \u00a0Y.,\u00a0\nAlcalde,\u00a0R.E.\u00a0&\u00a0Matsumura, \u00a0T.\u00a0Prognostic \u00a0\nsignificance \u00a0of\u00a0ERBB3\u00a0overexpression \u00a0in\u00a0\noral\u00a0squamous \u00a0cell\u00a0carcinoma. \u00a0Cancer\u00a0Lett\u00a0\n95,\u00a079\u201083\u00a0(1995).\u00a0\n449.\u00a0Kew,\u00a0T.Y.,\u00a0et\u00a0al.\u00a0c\u2010erbB\u20104\u00a0protein\u00a0\nexpression \u00a0in\u00a0human\u00a0breast\u00a0cancer.\u00a0Br\u00a0J\u00a0\nCancer\u00a082,\u00a01163\u20101170\u00a0(2000).\u00a0\n450.\u00a0Gilbertson, \u00a0R.J.,\u00a0Perry,\u00a0R.H.,\u00a0Kelly,\u00a0P.J.,\u00a0\nPearson,\u00a0A.D.\u00a0&\u00a0Lunec,\u00a0J.\u00a0Prognostic \u00a0\nsignificance \u00a0of\u00a0HER2\u00a0and\u00a0HER4\u00a0\ncoexpression \u00a0 in\u00a0 childhood \u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n228\u00a0\n\u00a0medulloblastoma. \u00a0Cancer\u00a0Res\u00a057,\u00a03272\u2010\n3280\u00a0(1997).\u00a0\n451.\u00a0Daniele,\u00a0L.\u00a0&\u00a0Sapino,\u00a0A.\u00a0Anti\u2010HER2\u00a0\ntreatment \u00a0and\u00a0breast\u00a0cancer:\u00a0state\u00a0of\u00a0the\u00a0\nart,\u00a0recent\u00a0patents,\u00a0and\u00a0new\u00a0strategies. \u00a0\nRecent\u00a0Pat\u00a0Anticancer \u00a0Drug\u00a0Discov\u00a04,\u00a09\u201018\u00a0\n(2009).\u00a0\n452.\u00a0Mohsin,\u00a0S.K.,\u00a0et\u00a0al.\u00a0Neoadjuvant \u00a0\ntrastuzumab \u00a0induces\u00a0apoptosis \u00a0in\u00a0primary\u00a0\nbreast\u00a0cancers.\u00a0J\u00a0Clin\u00a0Oncol\u00a023,\u00a02460\u20102468\u00a0\n(2005).\u00a0\n453.\u00a0NCCN\u00a0Practice\u00a0Guidelines \u00a0in\u00a0Oncology. \u00a0\nNational\u00a0Comprehensive \u00a0Cancer\u00a0Network\u00a0\n[online],\u00a0\nhttp://www.nccn.org/p rofessionals/physic\nian_gls/PDF/breast.pdf \u00a0(2011).\u00a0\n454.\u00a0Goldhirsch, \u00a0A.,\u00a0et\u00a0al.\u00a0Strategies \u00a0for\u00a0\nsubtypes\u2010\u2010dealing\u00a0with\u00a0the\u00a0diversity\u00a0of\u00a0\nbreast\u00a0cancer:\u00a0highlights \u00a0of\u00a0the\u00a0St.\u00a0Gallen\u00a0\nInternational \u00a0Expert\u00a0Consensus \u00a0on\u00a0the\u00a0\nPrimary\u00a0Therapy\u00a0of\u00a0Early\u00a0Breast\u00a0Cancer\u00a0\n2011.\u00a0Ann\u00a0Oncol\u00a022,\u00a01736\u20101747.\u00a0\n455.\u00a0Arteaga,\u00a0C.L.,\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0HER2\u2010\npositive\u00a0breast\u00a0cancer:\u00a0current\u00a0status\u00a0and\u00a0\nfuture\u00a0perspectives. \u00a0Nat\u00a0Rev\u00a0Clin\u00a0Oncol\u00a09,\u00a0\n16\u201032\u00a0(2011).\u00a0\n456.\u00a0Piccart\u2010Gebhart,\u00a0M.J.,\u00a0et\u00a0al.\u00a0Trastuzumab \u00a0\nafter\u00a0adjuvant\u00a0chemotherapy \u00a0in\u00a0HER2\u2010\npositive\u00a0breast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0353,\u00a0\n1659\u20101672\u00a0(2005).\u00a0\n457.\u00a0Gianni,\u00a0L.,\u00a0et\u00a0al.\u00a0Treatment \u00a0with\u00a0\ntrastuzumab \u00a0for\u00a01\u00a0year\u00a0after\u00a0adjuvant\u00a0\nchemotherapy \u00a0in\u00a0patients\u00a0with\u00a0HER2\u2010\npositive\u00a0early\u00a0breast\u00a0cancer:\u00a0a\u00a04\u2010year\u00a0\nfollow\u2010up\u00a0of\u00a0a\u00a0randomised \u00a0controlled \u00a0trial.\u00a0\nLancet\u00a0Oncol\u00a012,\u00a0236\u2010244.\u00a0\n458.\u00a0Smith,\u00a0I.,\u00a0et\u00a0al.\u00a02\u2010year\u00a0follow\u2010up\u00a0of\u00a0\ntrastuzumab \u00a0after\u00a0adjuvant\u00a0chemotherapy \u00a0\nin\u00a0HER2\u2010positive\u00a0breast\u00a0cancer:\u00a0a\u00a0\nrandomised \u00a0controlled \u00a0trial.\u00a0Lancet\u00a0369,\u00a0\n29\u201036\u00a0(2007).\u00a0\n459.\u00a0Romond,\u00a0E.H.,\u00a0et\u00a0al.\u00a0Trastuzumab \u00a0plus\u00a0\nadjuvant\u00a0chemotherapy \u00a0for\u00a0operable\u00a0\nHER2\u2010positive\u00a0breast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n353,\u00a01673\u20101684\u00a0(2005).\u00a0460.\u00a0Perez,\u00a0E.A.\u00a0Updated\u00a0results\u00a0of\u00a0the\u00a0\ncombined \u00a0analysis\u00a0of\u00a0NCCTG\u00a0N9831\u00a0and\u00a0\nNSABP\u00a0B\u201131\u00a0adjuvant\u00a0chemotherapy \u00a0\nwith/without \u00a0trastuzumab \u00a0in\u00a0patients\u00a0with\u00a0\nHER2\u2010positive\u00a0breast\u00a0cancer\u00a0[abstract]. \u00a0.\u00a0J.\u00a0\nClin.\u00a0Oncol.\u00a025\u00a0(Suppl.\u00a018),\u00a0a512\u00a0(2007).\u00a0\n461.\u00a0Perez,\u00a0E.A.,\u00a0et\u00a0al.\u00a0Four\u2010year\u00a0follow\u2010up\u00a0of\u00a0\ntrastuzumab \u00a0plus\u00a0adjuvant\u00a0chemotherapy \u00a0\nfor\u00a0operable\u00a0human\u00a0epidermal \u00a0growth\u00a0\nfactor\u00a0receptor\u00a02\u2010positive\u00a0breast\u00a0cancer:\u00a0\njoint\u00a0analysis\u00a0of\u00a0data\u00a0from\u00a0NCCTG\u00a0N9831\u00a0\nand\u00a0NSABP\u00a0B\u201031.\u00a0J\u00a0Clin\u00a0Oncol\u00a029,\u00a03366\u2010\n3373\u00a0(2011).\u00a0\n462.\u00a0Slamon,\u00a0D.,\u00a0et\u00a0al.\u00a0Adjuvant\u00a0trastuzumab \u00a0in\u00a0\nHER2\u2010positive\u00a0breast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n365,\u00a01273\u20101283.\u00a0\n463.\u00a0Slamon,\u00a0D.J.\u00a0Phase\u00a0III\u00a0randomized \u00a0trial\u00a0\ncomparing \u00a0 doxorubicin \u00a0 and\u00a0\ncyclophosphamide \u00a0followed\u00a0by\u00a0docetaxel \u00a0\n(AC\u00a0T)\u00a0with\u00a0doxorubicin \u00a0and\u00a0\ncyclophosphamide \u00a0followed\u00a0by\u00a0docetaxel \u00a0\nand\u00a0trastuzumab \u00a0(ACTH)\u00a0with\u00a0docetaxel, \u00a0\ncarboplatin \u00a0and\u00a0trastuzumab \u00a0(TCH)\u00a0in\u00a0\nHER2/neu \u00a0positive\u00a0early\u00a0breast\u00a0cancer\u00a0\npatients:\u00a0BCIRG\u00a0006\u00a0Study\u00a0[abstract]. \u00a0.\u00a0\nBreast\u00a0Cancer\u00a0Res.\u00a0Treat.\u00a094\u00a0(Suppl.\u00a01),\u00a0S5\u00a0\n(2005).\u00a0\n464.\u00a0Sledge,\u00a0G.\u00a0Pilot\u00a0trial\u00a0of\u00a0paclitaxel \u2010\nHerceptin \u00a0adjuvant\u00a0therapy\u00a0for\u00a0early\u00a0stage\u00a0\nbreast\u00a0cancer\u00a0(E2198)\u00a0[abstract]. \u00a0.\u00a0Breast\u00a0\nCancer\u00a0Res.\u00a0Treat.\u00a069\u00a0a209\u00a0(2001).\u00a0\n465.\u00a0Sledge,\u00a0G.\u00a0Adjuvant\u00a0trastuzumab: \u00a0long\u2010\nterm\u00a0results\u00a0of\u00a0E2198\u00a0[abstract]. \u00a0.\u00a0Breast\u00a0\nCancer\u00a0Res.\u00a0Treat.\u00a0100\u00a0(Suppl.\u00a01),\u00a0S106\u00a0\n(2006).\u00a0\n466.\u00a0Joensuu,\u00a0H.,\u00a0et\u00a0al.\u00a0Adjuvant\u00a0docetaxel \u00a0or\u00a0\nvinorelbine \u00a0with\u00a0or\u00a0without\u00a0trastuzumab \u00a0\nfor\u00a0breast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0354,\u00a0809\u2010\n820\u00a0(2006).\u00a0\n467.\u00a0Joensuu,\u00a0H.,\u00a0et\u00a0al.\u00a0Fluorouracil, \u00a0epirubicin, \u00a0\nand\u00a0cyclophosphamide \u00a0with\u00a0either\u00a0\ndocetaxel \u00a0or\u00a0vinorelbine, \u00a0with\u00a0or\u00a0without\u00a0\ntrastuzumab, \u00a0as\u00a0adjuvant\u00a0treatments \u00a0of\u00a0\nbreast\u00a0cancer:\u00a0final\u00a0results\u00a0of\u00a0the\u00a0FinHer\u00a0\nTrial.\u00a0J\u00a0Clin\u00a0Oncol\u00a027,\u00a05685\u20105692\u00a0(2009).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n229\u00a0\n\u00a0468.\u00a0Ryan,\u00a0Q.,\u00a0et\u00a0al.\u00a0FDA\u00a0drug\u00a0approval\u00a0\nsummary: \u00a0lapatinib\u00a0in\u00a0combination \u00a0with\u00a0\ncapecitabine \u00a0for\u00a0previously \u00a0treated\u00a0\nmetastatic \u00a0 breast\u00a0 cancer\u00a0 that\u00a0\noverexpresses \u00a0HER\u20102.\u00a0Oncologist \u00a013,\u00a01114\u2010\n1119\u00a0(2008).\u00a0\n469.\u00a0Spector,\u00a0N.L.,\u00a0et\u00a0al.\u00a0Study\u00a0of\u00a0the\u00a0biologic\u00a0\neffects\u00a0of\u00a0lapatinib, \u00a0a\u00a0reversible \u00a0inhibitor\u00a0\nof\u00a0ErbB1\u00a0and\u00a0ErbB2\u00a0tyrosine\u00a0kinases,\u00a0on\u00a0\ntumor\u00a0growth\u00a0and\u00a0survival\u00a0pathways \u00a0in\u00a0\npatients\u00a0with\u00a0advanced \u00a0malignancies. \u00a0J\u00a0\nClin\u00a0Oncol\u00a023,\u00a02502\u20102512\u00a0(2005).\u00a0\n470.\u00a0Xia,\u00a0W.,\u00a0et\u00a0al.\u00a0Anti\u2010tumor\u00a0activity\u00a0of\u00a0\nGW572016: \u00a0a\u00a0dual\u00a0tyrosine\u00a0kinase\u00a0\ninhibitor\u00a0blocks\u00a0EGF\u00a0activation \u00a0of\u00a0\nEGFR/erbB2 \u00a0and\u00a0downstream \u00a0Erk1/2\u00a0and\u00a0\nAKT\u00a0pathways. \u00a0Oncogene \u00a021,\u00a06255\u20106263\u00a0\n(2002).\u00a0\n471.\u00a0Konecny,\u00a0G.E.,\u00a0et\u00a0al.\u00a0Activity\u00a0of\u00a0the\u00a0dual\u00a0\nkinase\u00a0inhibitor\u00a0lapatinib\u00a0(GW572016) \u00a0\nagainst\u00a0 HER\u20102\u2010overexpressing \u00a0 and\u00a0\ntrastuzumab \u2010treated\u00a0breast\u00a0cancer\u00a0cells.\u00a0\nCancer\u00a0Res\u00a066,\u00a01630\u20101639\u00a0(2006).\u00a0\n472.\u00a0Xia,\u00a0W.,\u00a0et\u00a0al.\u00a0Combining \u00a0lapatinib\u00a0\n(GW572016), \u00a0a\u00a0small\u00a0molecule\u00a0inhibitor\u00a0of\u00a0\nErbB1\u00a0and\u00a0ErbB2\u00a0tyrosine\u00a0kinases,\u00a0with\u00a0\ntherapeutic \u00a0 anti\u2010ErbB2\u00a0 antibodies \u00a0\nenhances \u00a0 apoptosis \u00a0 of\u00a0 ErbB2\u2010\noverexpressing \u00a0breast\u00a0cancer\u00a0cells.\u00a0\nOncogene \u00a024,\u00a06213\u20106221\u00a0(2005).\u00a0\n473.\u00a0Anido,\u00a0J.,\u00a0et\u00a0al.\u00a0Biosynthesis \u00a0of\u00a0\ntumorigenic \u00a0HER2\u00a0C\u2010terminal\u00a0fragments \u00a0\nby\u00a0alternative \u00a0initiation\u00a0of\u00a0translation. \u00a0\nEMBO\u00a0J\u00a025,\u00a03234\u20103244\u00a0(2006).\u00a0\n474.\u00a0Blackwell, \u00a0K.L.,\u00a0et\u00a0al.\u00a0Single\u2010agent\u00a0lapatinib\u00a0\nfor\u00a0HER2\u2010overexpressing \u00a0advanced \u00a0or\u00a0\nmetastatic \u00a0breast\u00a0cancer\u00a0that\u00a0progressed \u00a0\non\u00a0first\u2010\u00a0or\u00a0second\u2010line\u00a0trastuzumab \u2010\ncontaining \u00a0regimens. \u00a0Ann\u00a0Oncol\u00a020,\u00a01026\u2010\n1031\u00a0(2009).\u00a0\n475.\u00a0Geyer,\u00a0C.E.,\u00a0et\u00a0al.\u00a0Lapatinib\u00a0plus\u00a0\ncapecitabine \u00a0for\u00a0HER2\u2010positive\u00a0advanced \u00a0\nbreast\u00a0cancer.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0355,\u00a02733\u2010\n2743\u00a0(2006).\u00a0476.\u00a0Cameron, \u00a0D.,\u00a0et\u00a0al.\u00a0A\u00a0phase\u00a0III\u00a0randomized \u00a0\ncomparison \u00a0of\u00a0lapatinib\u00a0plus\u00a0capecitabine \u00a0\nversus\u00a0capecitabine \u00a0alone\u00a0in\u00a0women\u00a0with\u00a0\nadvanced \u00a0breast\u00a0cancer\u00a0that\u00a0has\u00a0\nprogressed \u00a0on\u00a0trastuzumab: \u00a0updated\u00a0\nefficacy\u00a0and\u00a0biomarker \u00a0analyses.\u00a0Breast\u00a0\nCancer\u00a0Res\u00a0Treat\u00a0112,\u00a0533\u2010543\u00a0(2008).\u00a0\n477.\u00a0Tomasello, \u00a0G.,\u00a0de\u00a0Azambuja, \u00a0E.,\u00a0Dinh,\u00a0P.,\u00a0\nSnoj,\u00a0N.\u00a0&\u00a0Piccart\u2010Gebhart,\u00a0M.\u00a0Jumping\u00a0\nhigher:\u00a0is\u00a0it\u00a0still\u00a0possible? \u00a0The\u00a0ALTTO\u00a0trial\u00a0\nchallenge. \u00a0Expert\u00a0Rev\u00a0Anticancer \u00a0Ther\u00a08,\u00a0\n1883\u20101890\u00a0(2008).\u00a0\n478.\u00a0Di\u00a0Leo,\u00a0A.,\u00a0et\u00a0al.\u00a0Phase\u00a0III,\u00a0double\u2010blind,\u00a0\nrandomized \u00a0study\u00a0comparing \u00a0lapatinib\u00a0\nplus\u00a0paclitaxel \u00a0with\u00a0placebo\u00a0plus\u00a0paclitaxel \u00a0\nas\u00a0first\u2010line\u00a0treatment \u00a0for\u00a0metastatic \u00a0\nbreast\u00a0cancer.\u00a0J\u00a0Clin\u00a0Oncol\u00a026,\u00a05544\u20105552\u00a0\n(2008).\u00a0\n479.\u00a0Johnston, \u00a0S.,\u00a0et\u00a0al.\u00a0Lapatinib\u00a0combined \u00a0\nwith\u00a0letrozole\u00a0versus\u00a0letrozole\u00a0and\u00a0\nplacebo\u00a0as\u00a0first\u2010line\u00a0therapy\u00a0for\u00a0\npostmenopausal \u00a0hormone \u00a0receptor\u2010\npositive\u00a0metastatic \u00a0breast\u00a0cancer.\u00a0J\u00a0Clin\u00a0\nOncol\u00a027,\u00a05538\u20105546\u00a0(2009).\u00a0\n480.\u00a0Blackwell, \u00a0K.L.,\u00a0et\u00a0al.\u00a0Randomized \u00a0study\u00a0of\u00a0\nLapatinib\u00a0alone\u00a0or\u00a0in\u00a0combination \u00a0with\u00a0\ntrastuzumab \u00a0in\u00a0women\u00a0with\u00a0ErbB2\u2010\npositive,\u00a0 trastuzumab \u2010refractory \u00a0\nmetastatic \u00a0breast\u00a0cancer.\u00a0J\u00a0Clin\u00a0Oncol\u00a028,\u00a0\n1124\u20101130\u00a0(2010).\u00a0\n481.\u00a0Baselga,\u00a0J.\u00a0et\u00a0al.\u00a0First\u00a0results\u00a0of\u00a0the\u00a0\nNeoALTTO \u00a0trial\u00a0(BIG\u00a001\u201306\u00a0/\u00a0EGF\u00a0106903):\u00a0\na\u00a0phase\u00a0III,\u00a0randomized, \u00a0open\u00a0label,\u00a0\nneoadjuvant \u00a0 study\u00a0 of\u00a0 lapatinib, \u00a0\ntrastuzumab, \u00a0and\u00a0their\u00a0combination \u00a0plus\u00a0\npaclitaxel \u00a0in\u00a0women\u00a0with\u00a0HER2\u2010positive\u00a0\nprimary\u00a0breast\u00a0cancer\u00a0[abstract\u00a0S3\u20103].\u00a0.\u00a0\nCancer\u00a0Res.\u00a070\u00a0(Suppl.\u00a024),,\u00a082s\u00a0(2010).\u00a0\n482.\u00a0Untch,\u00a0M.\u00a0et\u00a0al.\u00a0Lapatinib \u00a0vs\u00a0trastuzumab \u00a0\nin\u00a0combination \u00a0with\u00a0neo\u2010adjuvant\u00a0\nanthracycline \u2010taxane\u2010based\u00a0\nchemotherapy: \u00a0Primary\u00a0efficacy\u00a0endpoint\u00a0\nanalysis\u00a0of\u00a0the\u00a0GEPARQUINTO \u00a0STUDY\u00a0\n(GBG\u00a044)\u00a0[abstract\u00a0S3\u20101].\u00a0.\u00a0Cancer\u00a0Res.\u00a070\u00a0\n(Suppl.\u00a024),\u00a0,\u00a081s\u00a0(2010).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n230\u00a0\n\u00a0483.\u00a0Chan,\u00a0A.,\u00a0et\u00a0al.\u00a0Vinorelbine \u00a0plus\u00a0\ntrastuzumab \u00a0combination \u00a0as\u00a0first\u2010line\u00a0\ntherapy\u00a0for\u00a0HER\u00a02\u2010positive\u00a0metastatic \u00a0\nbreast\u00a0cancer\u00a0patients:\u00a0an\u00a0international \u00a0\nphase\u00a0II\u00a0trial.\u00a0Br\u00a0J\u00a0Cancer\u00a095,\u00a0788\u2010793\u00a0\n(2006).\u00a0\n484.\u00a0Chou,\u00a0T.C.\u00a0&\u00a0Talalay,\u00a0P.\u00a0Quantitative \u00a0\nanalysis\u00a0of\u00a0dose\u2010effect\u00a0relationships: \u00a0the\u00a0\ncombined \u00a0effects\u00a0of\u00a0multiple\u00a0drugs\u00a0or\u00a0\nenzyme\u00a0inhibitors. \u00a0Adv\u00a0Enzyme\u00a0Regul\u00a022,\u00a0\n27\u201055\u00a0(1984).\u00a0\n485.\u00a0Pfaffl,\u00a0M.W.\u00a0A\u00a0new\u00a0mathematical \u00a0model\u00a0\nfor\u00a0relative\u00a0quantification \u00a0in\u00a0real\u2010time\u00a0RT\u2010\nPCR.\u00a0Nucleic\u00a0Acids\u00a0Res\u00a029,\u00a0e45\u00a0(2001).\u00a0\n486.\u00a0Irizarry,\u00a0R.A.,\u00a0et\u00a0al.\u00a0Summaries \u00a0of\u00a0\nAffymetrix \u00a0GeneChip \u00a0probe\u00a0level\u00a0data.\u00a0\nNucleic\u00a0Acids\u00a0Res\u00a031,\u00a0e15\u00a0(2003).\u00a0\n487.\u00a0Gentleman, \u00a0R.C.,\u00a0et\u00a0al.\u00a0Bioconductor: \u00a0\nopen\u00a0software\u00a0development \u00a0for\u00a0\ncomputational \u00a0biology\u00a0and\u00a0bioinformatics. \u00a0\nGenome\u00a0Biol\u00a05,\u00a0R80\u00a0(2004).\u00a0\n488.\u00a0Hong,\u00a0F.,\u00a0et\u00a0al.\u00a0RankProd: \u00a0a\u00a0bioconductor \u00a0\npackage\u00a0for\u00a0detecting \u00a0differentially \u00a0\nexpressed \u00a0genes\u00a0in\u00a0meta\u2010analysis.\u00a0\nBioinformatics \u00a022,\u00a02825\u20102827\u00a0(2006).\u00a0\n489.\u00a0Verbeke,\u00a0G.\u00a0&\u00a0Molenberghs, \u00a0G.\u00a0Linear\u00a0\nMixed\u00a0Models\u00a0for\u00a0longitudinal \u00a0Data. ,\u00a0\n(Springer\u2010Verlag,\u00a0New\u00a0York,\u00a02000).\u00a0\n490.\u00a0Hammond, \u00a0M.E. ,\u00a0et\u00a0al.\u00a0American \u00a0Society\u00a0\nof\u00a0Clinical\u00a0Oncology/College \u00a0Of\u00a0American \u00a0\nPathologists \u00a0guideline\u00a0recommendations \u00a0\nfor\u00a0immunohistochemical \u00a0testing\u00a0of\u00a0\nestrogen\u00a0and\u00a0progesterone \u00a0receptors \u00a0in\u00a0\nbreast\u00a0cancer.\u00a0J\u00a0Clin\u00a0Oncol\u00a028,\u00a02784\u20102795\u00a0\n(2010).\u00a0\n491.\u00a0Carey,\u00a0L.A.,\u00a0et\u00a0al.\u00a0Race,\u00a0breast\u00a0cancer\u00a0\nsubtypes, \u00a0and\u00a0survival\u00a0in\u00a0the\u00a0Carolina\u00a0\nBreast\u00a0Cancer\u00a0Study.\u00a0JAMA\u00a0295,\u00a02492\u2010\n2502\u00a0(2006).\u00a0\n492.\u00a0Kury,\u00a0F.D.,\u00a0et\u00a0al.\u00a0Determination \u00a0of\u00a0HER\u2010\n2/neu\u00a0amplification \u00a0and\u00a0expression \u00a0in\u00a0\ntumor\u00a0tissue\u00a0and\u00a0cultured\u00a0cells\u00a0using\u00a0a\u00a0\nsimple,\u00a0phenol\u00a0free\u00a0method\u00a0for\u00a0nucleic\u00a0\nacid\u00a0isolation.\u00a0Oncogene \u00a05,\u00a01403\u20101408\u00a0\n(1990).\u00a0493.\u00a0Daub,\u00a0H.,\u00a0Weiss,\u00a0F.U.,\u00a0Wallasch, \u00a0C.\u00a0&\u00a0\nUllrich,\u00a0A.\u00a0Role\u00a0of\u00a0transactivation \u00a0of\u00a0the\u00a0\nEGF\u00a0receptor\u00a0in\u00a0signalling \u00a0by\u00a0G\u2010protein\u2010\ncoupled\u00a0receptors. \u00a0Nature\u00a0379,\u00a0557\u2010560\u00a0\n(1996).\u00a0\n494.\u00a0Koon,\u00a0H.W.,\u00a0Zhao,\u00a0D.,\u00a0Na,\u00a0X.,\u00a0Moyer,\u00a0M.P.\u00a0\n&\u00a0Pothoulakis, \u00a0C.\u00a0Metalloproteinases \u00a0and\u00a0\ntransforming \u00a0growth\u00a0factor\u2010alpha\u00a0mediate\u00a0\nsubstance \u00a0P\u2010induced\u00a0mitogen\u2010activated \u00a0\nprotein\u00a0kinase\u00a0activation \u00a0and\u00a0proliferation \u00a0\nin\u00a0human\u00a0colonocytes. \u00a0J\u00a0Biol\u00a0Chem\u00a0279,\u00a0\n45519\u201045527\u00a0(2004).\u00a0\n495.\u00a0Tian,\u00a0G.,\u00a0Cory,\u00a0M.,\u00a0Smith,\u00a0A.A.\u00a0&\u00a0Knight,\u00a0\nW.B.\u00a0Structural \u00a0determinants \u00a0for\u00a0potent,\u00a0\nselective\u00a0dual\u00a0site\u00a0inhibition \u00a0of\u00a0human\u00a0\npp60c\u2010src\u00a0by\u00a04\u2010anilinoquinazolines. \u00a0\nBiochemistry \u00a040,\u00a07084\u20107091\u00a0(2001).\u00a0\n496.\u00a0Singh,\u00a0A.S.,\u00a0et\u00a0al.\u00a0Oncogenic \u00a0and\u00a0\nmetastatic \u00a0properties \u00a0of\u00a0preprotachykinin \u2010\nI\u00a0and\u00a0neurokinin \u20101\u00a0genes.\u00a0Vascul\u00a0\nPharmacol \u00a045,\u00a0235\u2010242\u00a0(2006).\u00a0\n497.\u00a0Iliopoulos, \u00a0D.,\u00a0Hirsch,\u00a0H.A.\u00a0&\u00a0Struhl,\u00a0K.\u00a0An\u00a0\nepigenetic \u00a0switch\u00a0involving\u00a0NF\u2010kappaB,\u00a0\nLin28,\u00a0Let\u20107\u00a0MicroRNA, \u00a0and\u00a0IL6\u00a0links\u00a0\ninflammation \u00a0to\u00a0cell\u00a0transformation. \u00a0Cell\u00a0\n139,\u00a0693\u2010706\u00a0(2009).\u00a0\n498.\u00a0Marotta,\u00a0L.L.,\u00a0et\u00a0al.\u00a0The\u00a0JAK2/STAT3 \u00a0\nsignaling\u00a0pathway\u00a0is\u00a0required\u00a0for\u00a0growth\u00a0\nof\u00a0CD44+CD24 \u2010\u00a0stem\u00a0cell\u2010like\u00a0breast\u00a0\ncancer\u00a0cells\u00a0in\u00a0human\u00a0tumors.\u00a0J\u00a0Clin\u00a0Invest\u00a0\n121(2011).\u00a0\n499.\u00a0Neve,\u00a0R.M. ,\u00a0et\u00a0al.\u00a0A\u00a0collection \u00a0of\u00a0breast\u00a0\ncancer\u00a0cell\u00a0lines\u00a0for\u00a0the\u00a0study\u00a0of\u00a0\nfunctionally \u00a0distinct\u00a0cancer\u00a0subtypes. \u00a0\nCancer\u00a0Cell\u00a010,\u00a0515\u2010527\u00a0(2006).\u00a0\n500.\u00a0Yin,\u00a0X.,\u00a0Dewille,\u00a0J.W.\u00a0&\u00a0Hai,\u00a0T.\u00a0A\u00a0potential\u00a0\ndichotomous \u00a0role\u00a0of\u00a0ATF3,\u00a0an\u00a0adaptive\u2010\nresponse\u00a0gene,\u00a0in\u00a0cancer\u00a0development. \u00a0\nOncogene \u00a027,\u00a02118\u20102127\u00a0(2008).\u00a0\n501.\u00a0Staff,\u00a0A.C.,\u00a0et\u00a0al.\u00a0Growth\u00a0differentiation \u00a0\nfactor\u201015\u00a0as\u00a0a\u00a0prognostic \u00a0biomarker \u00a0in\u00a0\novarian\u00a0cancer.\u00a0Gynecol\u00a0Oncol\u00a0118,\u00a0237\u2010\n243.\u00a0\n502.\u00a0Welsh,\u00a0J.B.,\u00a0et\u00a0al.\u00a0Large\u2010scale\u00a0delineation \u00a0\nof\u00a0 secreted\u00a0 protein\u00a0 biomarkers \u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n231\u00a0\n\u00a0overexpressed \u00a0in\u00a0cancer\u00a0tissue\u00a0and\u00a0serum.\u00a0\nProc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a0100,\u00a03410\u20103415\u00a0\n(2003).\u00a0\n503.\u00a0Brown,\u00a0D.A.,\u00a0et\u00a0al.\u00a0MIC\u20101\u00a0serum\u00a0level\u00a0and\u00a0\ngenotype: \u00a0associations \u00a0with\u00a0progress\u00a0and\u00a0\nprognosis \u00a0of\u00a0colorectal \u00a0carcinoma. \u00a0Clin\u00a0\nCancer\u00a0Res\u00a09,\u00a02642\u20102650\u00a0(2003).\u00a0\n504.\u00a0Mimeault, \u00a0M.\u00a0&\u00a0Batra,\u00a0S.K.\u00a0Divergent \u00a0\nmolecular \u00a0mechanisms \u00a0underlying \u00a0the\u00a0\npleiotropic \u00a0functions \u00a0of\u00a0macrophage \u00a0\ninhibitory \u00a0cytokine\u20101\u00a0in\u00a0cancer.\u00a0J\u00a0Cell\u00a0\nPhysiol\u00a0224,\u00a0626\u2010635.\u00a0\n505.\u00a0Kim,\u00a0K.K.,\u00a0Lee,\u00a0J.J.,\u00a0Yang,\u00a0Y.,\u00a0You,\u00a0K.H.\u00a0&\u00a0\nLee,\u00a0J.H.\u00a0Macrophage \u00a0inhibitory \u00a0cytokine\u20101\u00a0\nactivates\u00a0AKT\u00a0and\u00a0ERK\u20101/2\u00a0via\u00a0the\u00a0\ntransactivation \u00a0of\u00a0ErbB2\u00a0in\u00a0human\u00a0breast\u00a0\nand\u00a0gastric\u00a0cancer\u00a0cells.\u00a0Carcinogenesis \u00a0\n29,\u00a0704\u2010712\u00a0(2008).\u00a0\n506.\u00a0Park,\u00a0Y.J.,\u00a0Lee,\u00a0H.\u00a0&\u00a0Lee,\u00a0J.H.\u00a0Macrophage \u00a0\ninhibitory \u00a0cytokine\u20101\u00a0transactivates \u00a0ErbB\u00a0\nfamily\u00a0receptors \u00a0via\u00a0the\u00a0activation \u00a0of\u00a0Src\u00a0in\u00a0\nSK\u2010BR\u20103\u00a0human\u00a0breast\u00a0cancer\u00a0cells.\u00a0BMB\u00a0\nRep\u00a043,\u00a091\u201096.\u00a0\n507.\u00a0Joshi,\u00a0J.P.,\u00a0Brown,\u00a0N.E.,\u00a0Griner,\u00a0S.E.\u00a0&\u00a0\nNahta,\u00a0R.\u00a0Growth\u00a0differentiation \u00a0factor\u00a015\u00a0\n(GDF15)\u2010mediated \u00a0HER2\u00a0phosphorylation \u00a0\nreduces\u00a0trastuzumab \u00a0sensitivity \u00a0of\u00a0HER2\u2010\noverexpressing \u00a0breast\u00a0cancer\u00a0cells.\u00a0\nBiochem\u00a0Pharmacol \u00a082,\u00a01090\u20101099.\u00a0\n508.\u00a0Yamnik,\u00a0R.L.\u00a0&\u00a0Holz,\u00a0M.K.\u00a0mTOR/S6K1 \u00a0and\u00a0\nMAPK/RSK \u00a0 signaling\u00a0 pathways \u00a0\ncoordinately \u00a0regulate\u00a0estrogen\u00a0receptor\u00a0\nalpha\u00a0serine\u00a0167\u00a0phosphorylation. \u00a0FEBS\u00a0\nLett\u00a0584,\u00a0124\u2010128.\u00a0\n509.\u00a0Arpino,\u00a0G.,\u00a0Wiechmann, \u00a0L.,\u00a0Osborne,\u00a0C.K.\u00a0\n&\u00a0Schiff,\u00a0R.\u00a0Crosstalk\u00a0between\u00a0the\u00a0\nestrogen\u00a0receptor\u00a0and\u00a0the\u00a0HER\u00a0tyrosine\u00a0\nkinase\u00a0receptor\u00a0family:\u00a0molecular \u00a0\nmechanism \u00a0and\u00a0clinical\u00a0implications \u00a0for\u00a0\nendocrine \u00a0therapy\u00a0resistance. \u00a0Endocr\u00a0Rev\u00a0\n29,\u00a0217\u2010233\u00a0(2008).\u00a0\n510.\u00a0Hutcheson, \u00a0I.R.,\u00a0et\u00a0al.\u00a0Oestrogen \u00a0receptor\u2010\nmediated \u00a0modulation \u00a0of\u00a0the\u00a0EGFR/MAPK \u00a0\npathway\u00a0in\u00a0tamoxifen \u2010resistant\u00a0MCF\u20107\u00a0cells.\u00a0Breast\u00a0Cancer\u00a0Res\u00a0Treat\u00a081,\u00a081\u201093\u00a0\n(2003).\u00a0\n511.\u00a0Knowlden, \u00a0J.M.,\u00a0et\u00a0al.\u00a0Elevated\u00a0levels\u00a0of\u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor/c \u2010erbB2\u00a0\nheterodimers \u00a0mediate\u00a0an\u00a0autocrine \u00a0\ngrowth\u00a0regulatory \u00a0pathway\u00a0in\u00a0tamoxifen \u2010\nresistant\u00a0MCF\u20107\u00a0cells.\u00a0Endocrinology \u00a0144,\u00a0\n1032\u20101044\u00a0(2003).\u00a0\n512.\u00a0Musgrove, \u00a0E.A.\u00a0&\u00a0Sutherland, \u00a0R.L.\u00a0\nBiological \u00a0determinants \u00a0of\u00a0endocrine \u00a0\nresistance \u00a0in\u00a0breast\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0\nCancer\u00a09,\u00a0631\u2010643\u00a0(2009).\u00a0\n513.\u00a0Seckl,\u00a0M.J.\u00a0&\u00a0Rozengurt, \u00a0E.\u00a0Effect\u00a0of\u00a0\ntyrphostin \u00a0combined \u00a0with\u00a0a\u00a0substance \u00a0P\u00a0\nrelated\u00a0antagonist \u00a0on\u00a0small\u00a0cell\u00a0lung\u00a0\ncancer\u00a0cell\u00a0growth\u00a0in\u00a0vitro.\u00a0Eur\u00a0J\u00a0Cancer\u00a0\n32A,\u00a0342\u2010345\u00a0(1996).\u00a0\n514.\u00a0Rivas,\u00a0M.A. ,\u00a0et\u00a0al.\u00a0Transactivation \u00a0of\u00a0ErbB\u2010\n2\u00a0induced\u00a0by\u00a0tumor\u00a0necrosis\u00a0factor\u00a0alpha\u00a0\npromotes \u00a0NF\u2010kappaB\u00a0activation \u00a0and\u00a0\nbreast\u00a0cancer\u00a0cell\u00a0proliferation. \u00a0Breast\u00a0\nCancer\u00a0Res\u00a0Treat\u00a0122,\u00a0111\u2010124.\u00a0\n515.\u00a0Moulder, \u00a0S.L.,\u00a0et\u00a0al.\u00a0Epidermal \u00a0growth\u00a0\nfactor\u00a0receptor\u00a0(HER1)\u00a0tyrosine\u00a0kinase\u00a0\ninhibitor\u00a0ZD1839\u00a0(Iressa)\u00a0inhibits\u00a0\nHER2/neu \u00a0(erbB2)\u2010overexpressing \u00a0breast\u00a0\ncancer\u00a0cells\u00a0in\u00a0vitro\u00a0and\u00a0in\u00a0vivo.\u00a0Cancer\u00a0Res\u00a0\n61,\u00a08887\u20108895\u00a0(2001).\u00a0\n516.\u00a0Dua,\u00a0R.,\u00a0et\u00a0al.\u00a0EGFR\u00a0over\u2010expression \u00a0and\u00a0\nactivation \u00a0in\u00a0high\u00a0HER2,\u00a0ER\u00a0negative\u00a0\nbreast\u00a0cancer\u00a0cell\u00a0line\u00a0induces\u00a0\ntrastuzumab \u00a0resistance. \u00a0Breast\u00a0Cancer\u00a0Res\u00a0\nTreat\u00a0122,\u00a0685\u2010697.\u00a0\n517.\u00a0Ritter,\u00a0C.A.,\u00a0et\u00a0al.\u00a0Human\u00a0breast\u00a0cancer\u00a0\ncells\u00a0selected\u00a0for\u00a0resistance \u00a0to\u00a0\ntrastuzumab \u00a0in\u00a0vivo\u00a0overexpress \u00a0\nepidermal \u00a0growth\u00a0factor\u00a0receptor\u00a0and\u00a0\nErbB\u00a0ligands\u00a0and\u00a0remain\u00a0dependent \u00a0on\u00a0\nthe\u00a0ErbB\u00a0receptor\u00a0network.\u00a0Clin\u00a0Cancer\u00a0\nRes\u00a013,\u00a04909\u20104919\u00a0(2007).\u00a0\n518.\u00a0Albanell,\u00a0J.\u00a0&\u00a0Baselga,\u00a0J.\u00a0Unraveling \u00a0\nresistance \u00a0to\u00a0trastuzumab \u00a0(Herceptin): \u00a0\ninsulin\u2010like\u00a0growth\u00a0factor\u2010I\u00a0receptor, \u00a0a\u00a0\nnew\u00a0suspect.\u00a0J\u00a0Natl\u00a0Cancer\u00a0Inst\u00a093,\u00a01830\u2010\n1832\u00a0(2001).\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n232\u00a0\n\u00a0519.\u00a0Lu,\u00a0Y.,\u00a0Zi,\u00a0X.,\u00a0Zhao,\u00a0Y.,\u00a0Mascarenhas, \u00a0D.\u00a0&\u00a0\nPollak,\u00a0M.\u00a0Insulin\u2010like\u00a0growth\u00a0factor\u2010I\u00a0\nreceptor\u00a0signaling\u00a0and\u00a0resistance \u00a0to\u00a0\ntrastuzumab \u00a0(Herceptin). \u00a0J\u00a0Natl\u00a0Cancer\u00a0\nInst\u00a093,\u00a01852\u20101857\u00a0(2001).\u00a0\n520.\u00a0Zhang,\u00a0S.,\u00a0et\u00a0al.\u00a0Combating \u00a0trastuzumab \u00a0\nresistance \u00a0by\u00a0targeting\u00a0SRC,\u00a0a\u00a0common\u00a0\nnode\u00a0downstream \u00a0of\u00a0multiple\u00a0resistance \u00a0\npathways. \u00a0Nat\u00a0Med\u00a017,\u00a0461\u2010469\u00a0(2011).\u00a0\n521.\u00a0Burgess,\u00a0D.J.\u00a0Breast\u00a0cancer:\u00a0SRC\u00a0hits\u00a0the\u00a0\nmark.\u00a0Nat\u00a0Rev\u00a0Cancer\u00a011,\u00a0314\u2010315\u00a0(2011).\u00a0\n522.\u00a0Mayordomo, \u00a0C.,\u00a0et\u00a0al.\u00a0Targeting \u00a0of\u00a0\nSubstance \u00a0P\u00a0induces\u00a0cancer\u00a0cell\u00a0death\u00a0and\u00a0\ndecreases \u00a0the\u00a0steady\u00a0state\u00a0of\u00a0EGFR\u00a0and\u00a0\nHer2.\u00a0J\u00a0Cell\u00a0Physiol\u00a0227,\u00a01358\u20101366\u00a0(2012).\u00a0\n523.\u00a0Hartman, \u00a0Z.C.,\u00a0et\u00a0al.\u00a0HER2\u00a0overexpression \u00a0\nelicits\u00a0a\u00a0proinflammatory \u00a0IL\u20106\u00a0autocrine \u00a0\nsignaling\u00a0loop\u00a0that\u00a0is\u00a0critical\u00a0for\u00a0\ntumorigenesis. \u00a0Cancer\u00a0Res\u00a071,\u00a04380\u20104391\u00a0\n(2011).\u00a0\n524.\u00a0Minn,\u00a0A.J.,\u00a0et\u00a0al.\u00a0Distinct\u00a0organ\u2010specific\u00a0\nmetastatic \u00a0potential\u00a0of\u00a0individual \u00a0breast\u00a0\ncancer\u00a0cells\u00a0and\u00a0primary\u00a0tumors.\u00a0J\u00a0Clin\u00a0\nInvest\u00a0115,\u00a044\u201055\u00a0(2005).\u00a0\n525.\u00a0Mochizuki, \u00a0S.\u00a0&\u00a0Okada,\u00a0Y.\u00a0ADAMs\u00a0in\u00a0\ncancer\u00a0cell\u00a0proliferation \u00a0and\u00a0progression. \u00a0\nCancer\u00a0Sci\u00a098,\u00a0621\u2010628\u00a0(2007).\u00a0\n526.\u00a0Lu,\u00a0X.,\u00a0et\u00a0al.\u00a0ADAMTS1 \u00a0and\u00a0MMP1\u00a0\nproteolytically \u00a0engage\u00a0EGF\u2010like\u00a0ligands\u00a0in\u00a0\nan\u00a0osteolytic \u00a0signaling\u00a0cascade\u00a0for\u00a0bone\u00a0\nmetastasis. \u00a0Genes\u00a0Dev\u00a023,\u00a01882\u20101894\u00a0\n(2009).\u00a0\n527.\u00a0McGuire, \u00a0S.E.,\u00a0Hilsenbeck, \u00a0S.G.,\u00a0Figueroa, \u00a0\nJ.A.,\u00a0Jackson,\u00a0J.G.\u00a0&\u00a0Yee,\u00a0D.\u00a0Detection \u00a0of\u00a0\ninsulin\u2010like\u00a0growth\u00a0factor\u00a0binding\u00a0proteins\u00a0\n(IGFBPs)\u00a0by\u00a0ligand\u00a0blotting\u00a0in\u00a0breast\u00a0\ncancer\u00a0tissues.\u00a0Cancer\u00a0Lett\u00a077,\u00a025\u201032\u00a0\n(1994).\u00a0\n528.\u00a0Becker,\u00a0M.A. ,\u00a0et\u00a0al.\u00a0IGFBP\u00a0ratio\u00a0confers\u00a0\nresistance \u00a0to\u00a0IGF\u00a0targeting\u00a0and\u00a0correlates \u00a0\nwith\u00a0increased \u00a0invasion\u00a0and\u00a0poor\u00a0outcome\u00a0\nin\u00a0breast\u00a0tumors.\u00a0Clin\u00a0Cancer\u00a0Res\u00a018,\u00a0\n1808\u20101817.\u00a0\n529.\u00a0Akkiprik,\u00a0M.,\u00a0et\u00a0al.\u00a0Multifunctional \u00a0roles\u00a0of\u00a0\ninsulin\u2010like\u00a0growth\u00a0factor\u00a0binding\u00a0protein\u00a05\u00a0in\u00a0breast\u00a0cancer.\u00a0Breast\u00a0Cancer\u00a0Res\u00a010,\u00a0\n212\u00a0(2008).\u00a0\n530.\u00a0Butt,\u00a0A.J.,\u00a0Dickson,\u00a0K.A.,\u00a0McDougall, \u00a0F.\u00a0&\u00a0\nBaxter,\u00a0R.C.\u00a0Insulin\u2010like\u00a0growth\u00a0factor\u2010\nbinding\u00a0protein\u20105\u00a0inhibits\u00a0the\u00a0growth\u00a0of\u00a0\nhuman\u00a0breast\u00a0cancer\u00a0cells\u00a0in\u00a0vitro\u00a0and\u00a0in\u00a0\nvivo.\u00a0J\u00a0Biol\u00a0Chem\u00a0278,\u00a029676\u201029685\u00a0\n(2003).\u00a0\n531.\u00a0Mita,\u00a0K.,\u00a0et\u00a0al.\u00a0Prognostic \u00a0significance \u00a0of\u00a0\ninsulin\u2010like\u00a0growth\u00a0factor\u00a0binding\u00a0protein\u00a0\n(IGFBP)\u20104\u00a0and\u00a0IGFBP\u20105\u00a0expression \u00a0in\u00a0\nbreast\u00a0cancer.\u00a0Jpn\u00a0J\u00a0Clin\u00a0Oncol\u00a037,\u00a0575\u2010582\u00a0\n(2007).\u00a0\n532.\u00a0Liu,\u00a0X.X.,\u00a0et\u00a0al.\u00a0MicroRNA \u201026b\u00a0is\u00a0\nunderexpressed \u00a0in\u00a0human\u00a0breast\u00a0cancer\u00a0\nand\u00a0induces\u00a0cell\u00a0apoptosis \u00a0by\u00a0targeting\u00a0\nSLC7A11. \u00a0FEBS\u00a0Lett\u00a0585,\u00a01363\u20101367\u00a0\n(2011).\u00a0\n533.\u00a0Wu,\u00a0X.\u00a0&\u00a0Levine,\u00a0A.J.\u00a0p53\u00a0and\u00a0E2F\u20101\u00a0\ncooperate \u00a0to\u00a0mediate\u00a0apoptosis. \u00a0Proc\u00a0Natl\u00a0\nAcad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a091,\u00a03602\u20103606\u00a0(1994).\u00a0\n534.\u00a0Martinez\u2010Balbas,\u00a0M.A.,\u00a0Bauer,\u00a0U.M.,\u00a0\nNielsen,\u00a0S.J.,\u00a0Brehm,\u00a0A.\u00a0&\u00a0Kouzarides, \u00a0T.\u00a0\nRegulation \u00a0of\u00a0E2F1\u00a0activity\u00a0by\u00a0acetylation. \u00a0\nEMBO\u00a0J\u00a019,\u00a0662\u2010671\u00a0(2000).\u00a0\n535.\u00a0Kiewe,\u00a0P.\u00a0&\u00a0Thiel,\u00a0E.\u00a0Ertumaxomab: \u00a0a\u00a0\ntrifunctional \u00a0antibody\u00a0for\u00a0breast\u00a0cancer\u00a0\ntreatment. \u00a0Expert\u00a0Opin\u00a0Investig\u00a0Drugs\u00a017,\u00a0\n1553\u20101558\u00a0(2008).\u00a0\n536.\u00a0Jager,\u00a0M.,\u00a0Schoberth, \u00a0A.,\u00a0Ruf,\u00a0P.,\u00a0Hess,\u00a0J.\u00a0&\u00a0\nLindhofer, \u00a0H.\u00a0The\u00a0trifunctional \u00a0antibody\u00a0\nertumaxomab \u00a0destroys\u00a0tumor\u00a0cells\u00a0that\u00a0\nexpress\u00a0low\u00a0levels\u00a0of\u00a0human\u00a0epidermal \u00a0\ngrowth\u00a0factor\u00a0receptor\u00a02.\u00a0Cancer\u00a0Res\u00a069,\u00a0\n4270\u20104276\u00a0(2009).\u00a0\n537.\u00a0Kiewe,\u00a0P.,\u00a0et\u00a0al.\u00a0Phase\u00a0I\u00a0trial\u00a0of\u00a0the\u00a0\ntrifunctional \u00a0anti\u2010HER2\u00a0x\u00a0anti\u2010CD3\u00a0\nantibody\u00a0ertumaxomab \u00a0in\u00a0metastatic \u00a0\nbreast\u00a0cancer.\u00a0Clin\u00a0Cancer\u00a0Res\u00a012,\u00a03085\u2010\n3091\u00a0(2006).\u00a0\n538.\u00a0LoRusso,\u00a0P.\u00a0Quantitative \u00a0assessment \u00a0of\u00a0\ndiagnostic \u00a0markers\u00a0and\u00a0correlations \u00a0with\u00a0\nefficacy\u00a0in\u00a0two\u00a0phase\u00a0II\u00a0studies\u00a0of\u00a0\ntrastuzumab \u2010DM1\u00a0(T\u2010DM1)\u00a0for\u00a0patients\u00a0\n(pts)\u00a0with\u00a0metastatic \u00a0breast\u00a0cancer\u00a0(MBC)\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n233\u00a0\n\u00a0who\u00a0had\u00a0progressed \u00a0on\u00a0prior\u00a0HER2\u2010\ndirected\u00a0therapy.\u00a0(Abstract). \u00a0Jounal\u00a0of\u00a0\nClinical\u00a0Oncology \u00a028,\u00a015s\u00a0(2010).\u00a0\n539.\u00a0Ocana,\u00a0A.\u00a0&\u00a0Amir,\u00a0E.\u00a0Irreversible \u00a0pan\u2010ErbB\u00a0\ntyrosine\u00a0kinase\u00a0inhibitors \u00a0and\u00a0breast\u00a0\ncancer:\u00a0current\u00a0status\u00a0and\u00a0future\u00a0\ndirections. \u00a0Cancer\u00a0Treat\u00a0Rev\u00a035,\u00a0685\u2010691\u00a0\n(2009).\u00a0\n540.\u00a0Schoeberl, \u00a0B.,\u00a0et\u00a0al.\u00a0An\u00a0ErbB3\u00a0antibody, \u00a0\nMM\u2010121,\u00a0is\u00a0active\u00a0in\u00a0cancers\u00a0with\u00a0ligand\u2010\ndependent \u00a0activation. \u00a0Cancer\u00a0Res\u00a070,\u00a0\n2485\u20102494.\u00a0\n541.\u00a0Huhalov,\u00a0A.\u00a0MM\u2010111,\u00a0an\u00a0ErbB2/ErbB3 \u00a0\nbispecific \u00a0antibody\u00a0with\u00a0potent\u00a0activity\u00a0in\u00a0\nErbB2\u2010overexpressing \u00a0cells,\u00a0positively \u00a0\ncombines \u00a0with\u00a0trastuzumab \u00a0to\u00a0inhibit\u00a0\ngrowth\u00a0of\u00a0breast\u00a0cancer\u00a0cells\u00a0driven\u00a0by\u00a0the\u00a0\nErbB2/ErbB3 \u00a0oncogenic \u00a0unit\u00a0[abstract\u00a0\n3485].\u00a0Proc.\u00a0of\u00a0the\u00a0AACR\u00a0(Washington \u00a0DC,\u00a0\nUSA)\u00a0(\u00a02010).\u00a0\n542.\u00a0Baselga,\u00a0J.,\u00a0et\u00a0al.\u00a0Phase\u00a0II\u00a0trial\u00a0of\u00a0\npertuzumab \u00a0and\u00a0trastuzumab \u00a0in\u00a0patients\u00a0\nwith\u00a0human\u00a0epidermal \u00a0growth\u00a0factor\u00a0\nreceptor\u00a02\u2010positive\u00a0metastatic \u00a0breast\u00a0\ncancer\u00a0that\u00a0progressed \u00a0during\u00a0prior\u00a0\ntrastuzumab \u00a0therapy.\u00a0J\u00a0Clin\u00a0Oncol\u00a028,\u00a0\n1138\u20101144\u00a0(2010).\u00a0\n543.\u00a0Burstein,\u00a0H.J.,\u00a0et\u00a0al.\u00a0Neratinib, \u00a0an\u00a0\nirreversible \u00a0ErbB\u00a0receptor\u00a0tyrosine\u00a0kinase\u00a0\ninhibitor,\u00a0in\u00a0patients\u00a0with\u00a0advanced \u00a0\nErbB2\u2010positive\u00a0breast\u00a0cancer.\u00a0J\u00a0Clin\u00a0Oncol\u00a0\n28,\u00a01301\u20101307.\u00a0\n544.\u00a0Hickish,\u00a0T.\u00a0Use\u00a0of\u00a0BIBW\u00a0a\u00a0novel\u00a0\nirreversible \u00a0EGFR/HER2 \u00a0tyrosine\u00a0kinase\u00a0\ninhibitor\u00a0(TKI),\u00a0to\u00a0treat\u00a0patients\u00a0with\u00a0\nHER2\u2010positive\u00a0metastatic \u00a0breast\u00a0cancer\u00a0\nafter\u00a0failure\u00a0of\u00a0treatment \u00a0with\u00a0\ntrastuzumab \u00a0[abstract]. \u00a0J.\u00a0Clin.\u00a0Oncol.\u00a0\u00a027\u00a0\n(Suppl.\u00a015),\u00a0a1023\u00a0((2009).). \u00a0\n545.\u00a0Shapiro,\u00a0G.\u00a0Phase\u00a0I\u00a0dose\u2010escalation \u00a0study\u00a0\nof\u00a0XL147,\u00a0a\u00a0PI3K\u00a0inhibitor\u00a0administered \u00a0\norally\u00a0to\u00a0patients\u00a0with\u00a0solid\u00a0tumors\u00a0\n[abstract]. \u00a0.\u00a0J.\u00a0Clin.\u00a0Oncol.\u00a027\u00a0(Suppl.\u00a015),\u00a0\na3500\u00a0(2009).\u00a0546.\u00a0Ellard,\u00a0S.L.,\u00a0et\u00a0al.\u00a0Randomized \u00a0phase\u00a0II\u00a0\nstudy\u00a0comparing \u00a0two\u00a0schedules \u00a0of\u00a0\neverolimus \u00a0 in\u00a0 patients\u00a0 with\u00a0\nrecurrent/metastatic \u00a0breast\u00a0cancer:\u00a0NCIC\u00a0\nClinical\u00a0Trials\u00a0Group\u00a0IND.163.\u00a0J\u00a0Clin\u00a0Oncol\u00a0\n27,\u00a04536\u20104541\u00a0(2009).\u00a0\n547.\u00a0Baselga,\u00a0J.,\u00a0et\u00a0al.\u00a0Phase\u00a0II\u00a0randomized \u00a0\nstudy\u00a0of\u00a0neoadjuvant \u00a0everolimus \u00a0plus\u00a0\nletrozole\u00a0compared \u00a0with\u00a0placebo\u00a0plus\u00a0\nletrozole\u00a0in\u00a0patients\u00a0with\u00a0estrogen\u00a0\nreceptor\u2010positive\u00a0breast\u00a0cancer.\u00a0J\u00a0Clin\u00a0\nOncol\u00a027,\u00a02630\u20102637\u00a0(2009).\u00a0\n548.\u00a0Gualberto, \u00a0A.\u00a0Figitumumab \u00a0(CP\u2010751,871)\u00a0\nfor\u00a0cancer\u00a0therapy.\u00a0Expert\u00a0Opin\u00a0Biol\u00a0Ther\u00a0\n10,\u00a0575\u2010585.\u00a0\n549.\u00a0McKian,\u00a0K.P.\u00a0&\u00a0Haluska,\u00a0P.\u00a0Cixutumumab. \u00a0\nExpert\u00a0Opin\u00a0Investig\u00a0Drugs\u00a018,\u00a01025\u20101033\u00a0\n(2009).\u00a0\n550.\u00a0Miller,\u00a0K.\u00a0Phase\u00a0I\u00a0trial\u00a0of\u00a0alvespimycin \u00a0\n(KOS\u20101022;\u00a017\u2010DMAG)\u00a0and\u00a0trastuzumab \u00a0\n(T)\u00a0[abstract]. \u00a0J.\u00a0Clin.\u00a0Oncol.\u00a0Suppl.\u00a018,\u00a0\na1115\u00a0(2007).\u00a0\n551.\u00a0Hanson,\u00a0B.E.\u00a0&\u00a0Vesole,\u00a0D.H.\u00a0Retaspimycin \u00a0\nhydrochloride \u00a0(IPI\u2010504):\u00a0a\u00a0novel\u00a0heat\u00a0\nshock\u00a0protein\u00a0inhibitor\u00a0as\u00a0an\u00a0anticancer \u00a0\nagent.\u00a0Expert\u00a0Opin\u00a0Investig\u00a0Drugs\u00a018,\u00a0\n1375\u20101383\u00a0(2009).\u00a0\n552.\u00a0Lundgren, \u00a0K.,\u00a0et\u00a0al.\u00a0BIIB021,\u00a0an\u00a0orally\u00a0\navailable, \u00a0fully\u00a0synthetic\u00a0small\u2010molecule\u00a0\ninhibitor\u00a0of\u00a0the\u00a0heat\u00a0shock\u00a0protein\u00a0Hsp90.\u00a0\nMol\u00a0Cancer\u00a0Ther\u00a08,\u00a0921\u2010929\u00a0(2009).\u00a0\n553.\u00a0Mittendorf, \u00a0E.A.,\u00a0Holmes,\u00a0J.P.,\u00a0Ponniah,\u00a0S.\u00a0\n&\u00a0Peoples,\u00a0G.E.\u00a0The\u00a0E75\u00a0HER2/neu \u00a0peptide\u00a0\nvaccine.\u00a0Cancer\u00a0Immunol\u00a0Immunother \u00a057,\u00a0\n1511\u20101521\u00a0(2008).\u00a0\n554.\u00a0Patil,\u00a0R.,\u00a0et\u00a0al.\u00a0Clinical\u00a0and\u00a0immunologic \u00a0\nresponses \u00a0of\u00a0HLA\u2010A3+\u00a0breast\u00a0cancer\u00a0\npatients\u00a0vaccinated \u00a0with\u00a0the\u00a0HER2/neu \u2010\nderived\u00a0peptide\u00a0vaccine,\u00a0E75,\u00a0in\u00a0a\u00a0phase\u00a0\nI/II\u00a0clinical\u00a0trial.\u00a0J\u00a0Am\u00a0Coll\u00a0Surg\u00a0210,\u00a0140\u2010\n147.\u00a0\n555.\u00a0Carmichael, \u00a0M.G. ,\u00a0et\u00a0al.\u00a0Results\u00a0of\u00a0the\u00a0first\u00a0\nphase\u00a01\u00a0clinical\u00a0trial\u00a0of\u00a0the\u00a0HER\u20102/neu\u00a0\npeptide\u00a0(GP2)\u00a0vaccine\u00a0in\u00a0disease\u2010free\u00a0\nbreast\u00a0cancer\u00a0patients:\u00a0United\u00a0States\u00a0BIBLIOGRAF\u00cdA \u00a0\u00a0\n\u00a0\n234\u00a0\n\u00a0Military\u00a0Cancer\u00a0Institute\u00a0Clinical\u00a0Trials\u00a0\nGroup\u00a0Study\u00a0I\u201004.\u00a0Cancer\u00a0116,\u00a0292\u2010301.\u00a0\n556.\u00a0Holmes,\u00a0J.P.,\u00a0et\u00a0al.\u00a0Results\u00a0of\u00a0the\u00a0first\u00a0\nphase\u00a0I\u00a0clinical\u00a0trial\u00a0of\u00a0the\u00a0novel\u00a0II\u2010key\u00a0\nhybrid\u00a0preventive \u00a0HER\u20102/neu\u00a0peptide\u00a0\n(AE37)\u00a0vaccine.\u00a0J\u00a0Clin\u00a0Oncol\u00a026,\u00a03426\u20103433\u00a0\n(2008).\u00a0\n557.\u00a0Morse,\u00a0M.A. ,\u00a0et\u00a0al.\u00a0Long\u00a0term\u00a0disease\u2010free\u00a0\nsurvival\u00a0and\u00a0T\u00a0cell\u00a0and\u00a0antibody\u00a0responses \u00a0\nin\u00a0women\u00a0with\u00a0high\u2010risk\u00a0Her2+\u00a0breast\u00a0\ncancer\u00a0following \u00a0vaccination \u00a0against\u00a0Her2.\u00a0\nJ\u00a0Transl\u00a0Med\u00a05,\u00a042\u00a0(2007).\u00a0\n558.\u00a0Pegram,\u00a0M.,\u00a0Chan,\u00a0D.\u00a0&\u00a0Dichmann, \u00a0R.A.\u00a0\nPhase\u00a0II\u00a0combined \u00a0biological \u00a0therapy\u00a0\ntargeting\u00a0the\u00a0HER2\u00a0proto\u2010oncogene \u00a0and\u00a0\nthe\u00a0vascular\u00a0endothelial \u00a0growth\u00a0factor\u00a0\nusing\u00a0trastuzumab \u00a0(T)\u00a0and\u00a0bevacizumab \u00a0\n(B)\u00a0as\u00a0first\u00a0line\u00a0treatment \u00a0of\u00a0HER2\u2010\namplified \u00a0breast\u00a0cancer\u00a0[abstract\u00a0301].\u00a0.\u00a0\nBreast\u00a0Cancer\u00a0Res.\u00a0Treat.\u00a0100\u00a0(Suppl.\u00a01),\u00a0\nS28\u00a0(2006).\u00a0\n559.\u00a0Slamon,\u00a0D.J.\u00a0Randomized \u00a0study\u00a0of\u00a0\npazopanib+lapatinib \u00a0vs.\u00a0lapatinib\u00a0alone\u00a0in\u00a0\npatients\u00a0with\u00a0HER2\u2010positive\u00a0advanced \u00a0or\u00a0\nmetastatic \u00a0breast\u00a0cancer\u00a0[abstract]. \u00a0J.\u00a0Clin.\u00a0\nOncol.\u00a026\u00a0(Suppl.\u00a015),\u00a0a1016\u00a0(2008).\u00a0\n560.\u00a0Burstein,\u00a0H.J.,\u00a0et\u00a0al.\u00a0Phase\u00a0II\u00a0study\u00a0of\u00a0\nsunitinib\u00a0malate,\u00a0an\u00a0oral\u00a0multitargeted \u00a0\ntyrosine\u00a0kinase\u00a0inhibitor,\u00a0in\u00a0patients\u00a0with\u00a0\nmetastatic \u00a0breast\u00a0cancer\u00a0previously \u00a0\ntreated\u00a0with\u00a0an\u00a0anthracycline \u00a0and\u00a0a\u00a0\ntaxane.\u00a0J\u00a0Clin\u00a0Oncol\u00a026,\u00a01810\u20101816\u00a0(2008).\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0La SP es una citoquina pro-inflamatoria/neurop\u00e9ptido que pertenece a la familia de las \nt\na\nq\nu\ni\nq\nu\ni\nn\ni\nn\na\ns\n \ny\n \ns\ne\n\u00f1\na\nl\ni\nz\na\n \na\n \nt\nr\na\nv\n\u00e9\ns\n \nd\ne\n \ns\nu\n \nr\ne\nc\ne\np\nt\no\nr\n \nd\ne\n \nm\na\ny\no\nr\n \na\nf\ni\nn\ni\nd\na\nd\n,\n \ne\nl\n \nr\ne\nc\ne\np\nt\no\nr\n \nN\nK\n-\n1\n.\n \nN\nK\n-\n1\nR\n \ne\ns\n \nu\nn\n \nr\ne\nc\ne\np\nt\no\nr\n \na\nc\no\np\nl\na\nd\no\n \na\n \np\nr\no\nt\ne\n\u00ed\nn\na\ns\n \nG\n \nq\nu\ne\n \ns\ne\n \ns\no\nb\nr\ne\ne\nx\np\nr\ne\ns\na\n \ne\nn\n \nc\n\u00e9\nl\nu\nl\na\ns\n \nd\ne\n \nc\n\u00e1\nn\nc\ne\nr\n \nd\ne\n \nm\na\nm\na\n.\n \n \nE\nl\n \nh\ne\nc\nh\no\n \nq\nu\ne\n \nl\na\n \nS\nP\n \na\nc\nt\n\u00fa\ne\n \nc\no\nm\no\n \nn\ne\nu\nr\no\nt\nr\na\nn\ns\nm\ni\ns\no\nr\n,\n \ns\ne\n\u00f1\na\nl\ni\nc\ne\n \na\n \nt\nr\na\nv\n\u00e9\ns\n \nd\ne\nl\n \ns\ni\ns\nt\ne\nm\na\n \nn\ne\nr\nv\ni\no\ns\no\n \ny\n \na\nc\nt\n\u00fa\ne\n \nc\no\nm\no\n \nc\ni\nt\no\nq\nu\ni\nn\na\n \np\nr\no\n-\ni\nn\nf\nl\na\nm\na\nt\no\nr\ni\na\n \nr\ne\ng\nu\nl\na\nn\nd\no\n \nl\na\n \nr\ne\ns\np\nu\ne\ns\nt\na\n \ni\nn\nm\nu\nn\ne\n,\n \np\ne\nr\nm\ni\nt\ne\n \nq\nu\ne\n \ne\ns\nt\ne\n \np\n\u00e9\np\nt\ni\nd\no\n \ne\ns\nt\n\u00e9\n \np\nr\ne\ns\ne\nn\nt\ne\n \ne\nn\n \nm\n\u00fa\nl\nt\ni\np\nl\ne\ns\n \ns\ni\ns\nt\ne\nm\na\ns\n \nr\ne\ng\nu\nl\n\u00e1\nn\nd\no\nl\no\ns\n \nd\ne\n \nf\no\nr\nm\na\n \np\no\ns\ni\nt\ni\nv\na\n \no\n \nn\ne\ng\na\nt\ni\nv\na\n \ns\ne\ng\n\u00fa\nn\n \ne\nl\n \nc\no\nn\nt\ne\nx\nt\no\n.\n \nE\ns\nt\na\nE\ns\nt\na\n \nt\ne\ns\ni\ns\n \ns\ne\n \nh\na\n \nc\ne\nn\nt\nr\na\nd\no\n \ne\nn\n \ne\ns\nt\nu\nd\ni\na\nr\n \ne\nl\n \np\na\np\ne\nl\n \nd\ne\n \nl\na\n \nS\nP\n \ne\nn\n \nl\na\n \np\nr\no\ng\nr\ne\ns\ni\n\u00f3\nn\n \nt\nu\nm\no\nr\na\nl\n \nd\ne\n \nc\n\u00e9\nl\nu\nl\na\ns\n \nd\ne\n \nc\n\u00e1\nn\nc\ne\nr\n \nd\ne\n \nm\na\nm\na\n.\n \nD\na\nd\no\n \nq\nu\ne\n \nl\na\n \nS\nP\n \ns\ne\n\u00f1\na\nl\ni\nz\na\n \na\n \nt\nr\na\nv\n\u00e9\ns\n \nd\ne\n \nr\ne\nc\ne\np\nt\no\nr\ne\ns\n \nu\nn\ni\nd\no\ns\n \na\n \np\nr\no\nt\ne\n\u00ed\nn\na\ns\n \nG\n,\n \ny\n \nd\ne\nb\ni\nd\no\n \na\nl\n \nc\nr\ne\nc\ni\ne\nn\nt\ne\n \ni\nn\nt\ne\nr\n\u00e9\ns\n \ns\no\nb\nr\ne\n \nl\na\n \nt\nr\na\nn\ns\na\nc\nt\ni\nv\na\nc\ni\n\u00f3\nn\n \nd\ne\n \nr\ne\nc\ne\np\nt\no\nr\ne\ns\n \nt\ni\nr\no\ns\ni\nn\na\n \nq\nu\ni\nn\na\ns\na\n \np\no\nr\n \np\na\nr\nt\ne\n \nd\ne\n \nG\nP\nC\nR\ns\n,\n \ns\ne\n \nd\ne\nc\ni\nd\ni\n\u00f3\n \ni\nn\nv\ne\ns\nt\ni\ng\na\nr\n \nl\na\n \np\no\ns\ni\nb\nl\ne\n \nc\no\no\np\ne\nr\na\nc\ni\n\u00f3\nn\n \no\nn\nc\no\ng\n\u00e9\nn\ni\nc\na\n \ne\nn\nt\nr\ne\n \ne\nl\n \nr\ne\nc\ne\np\nt\no\nr\n \nt\ni\nr\no\ns\ni\nn\na\n \nq\nu\ni\nn\na\ns\na\n \nH\nE\nR\n2\n,\n \ni\nm\np\no\nr\nt\na\nn\nt\ne\n \np\na\nr\na\n \ne\nl\n \nd\ni\na\ng\nn\n\u00f3\ns\nt\ni\nc\no\n \ny\n \ne\nv\no\nl\nu\nc\ni\n\u00f3\nn\n \nd\ne\n \nl\na\n \ne\nn\nf\ne\nr\nm\ne\nd\na\nd\n,\n \ny\n \ne\nl\n \nr\ne\nc\ne\np\nt\no\nr\n \nd\ne\n \nt\na\nq\nu\ni\nq\nu\ni\nn\ni\nn\na\ns\n \nN\nK\n-\n1\nR\n.\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}